PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Tomei, KL; Doe, C; Prestigiacomo, CJ; Gandhi, CD				Tomei, Krystal L.; Doe, Christopher; Prestigiacomo, Charles J.; Gandhi, Chirag D.			Comparative analysis of state-level concussion legislation and review of current practices in concussion	NEUROSURGICAL FOCUS			English	Article						concussion legislation; sports injury; concussion; injury prevention	SPORT-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; INJURY SURVEILLANCE SYSTEM; TO-PLAY GUIDELINES; BASE-LINE VALUES; DESCRIPTIVE EPIDEMIOLOGY; UNITED-STATES; ICE HOCKEY; LACROSSE INJURIES; HEAD-INJURIES	Object. Forty-two states and the District of Columbia have passed legislation based on the Lystedt law of Washington state, enacted in 2009 to protect young athletes who have sustained a concussion. The aim of this study was to note the several similarities and differences among the various laws. Methods. Concussion legislation was compared for 50 states and the District of Columbia. Evaluation parameters of this study included stipulations of concussion education, criteria for removal from play, requirements for evaluation and return to play after concussion, and individuals required to assess young athletes. Other parameters that were not consistent across states were also noted. Results. Forty-three states and the District of Columbia have passed concussion legislation, and an additional 4 states have pending legislation. All states with existing legislation support concussion education for coaches; however, only 48% require coaches to undergo formal education. Athletes must be educated on concussion in 86% of states and parents in 88.7%. Suspicion of concussion is a criterion for removal from play in 75% of states; signs and symptoms of concussion are criteria for removal from play in 16% of states. The individuals allowed to evaluate and clear an athlete for return to play differ greatly among states. Conclusions. Injury prevention legislation holds historical precedent, and given the increasing attention to long-term sequelae of repeated head trauma and concussion, concussion legislation has been rapidly passed in 43 states and the District of Columbia. Although the exact stipulations of these laws vary among states, the overall theme is to increase recognition of concussion in young athletes and ensure that they are appropriately cleared for return to play after concussion. (http://thejns.org/doi/abs/10.3171/2012.9.FOCUS12280)	[Tomei, Krystal L.; Doe, Christopher; Prestigiacomo, Charles J.; Gandhi, Chirag D.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07101 USA		Tomei, KL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, 90 Bergen St,Suite 8100,POB 1709, Newark, NJ 07101 USA.	tomeikr@umdnj.edu	Prestigiacomo, Charles J/B-3911-2018; Michiels, Jan/F-1601-2010	Prestigiacomo, Charles J/0000-0002-5979-2378; Michiels, Jan/0000-0001-5829-0897			Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; Adler RH, 2011, PHYS MED REH CLIN N, V22, P721, DOI 10.1016/j.pmr.2011.08.010; Ahmed OH, 2012, BRIT J SPORT MED, V46, P675, DOI 10.1136/bjsm.2010.081620; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Beck L. F., 2011, Morbidity and Mortality Weekly Report, V59, P1681; Boffano P, 2011, J CRANIOFAC SURG, V22, P2053, DOI 10.1097/SCS.0b013e318231988d; Borglund S T, 1999, J Emerg Nurs, V25, P496, DOI 10.1016/S0099-1767(99)70013-9; Brixey SN, 2011, INJURY PREV, V17, P233, DOI 10.1136/ip.2010.029835; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Cloudburst Group, 2010, POL EV STAT YOUTH SP; Conner KA, 2010, J SAFETY RES, V41, P17, DOI 10.1016/j.jsr.2009.10.005; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P255; Dick R, 2007, J ATHL TRAINING, V42, P211; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; Emery CA, 2011, BRIT J SPORT MED, V45, P1289, DOI 10.1136/bjsports-2011-090538; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Foreman Megan, 2010, State Legis, V36, P28; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Giebel S, 2011, J EMERG MED, V41, P649, DOI 10.1016/j.jemermed.2011.03.021; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Herbert David L, 2007, Curr Sports Med Rep, V6, P20, DOI 10.1007/s11932-007-0007-x; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Ji M, 2006, ACCIDENT ANAL PREV, V38, P128, DOI 10.1016/j.aap.2005.08.002; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Laker SR, 2011, PHYS MED REH CLIN N, V22, P619, DOI 10.1016/j.pmr.2011.08.004; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Macias Alexis, 2011, Bull Am Coll Surg, V96, P51; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Masiakos Peter T, 2011, Bull Am Coll Surg, V96, P31; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McLellan TL, 2011, BRIT J SPORT MED, V45, P993, DOI 10.1136/bjsm.2011.083618; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Putukian M, 2011, PM&R, V3, pS425, DOI 10.1016/j.pmrj.2011.08.003; Rivara FP, 1999, AM J PREV MED, V16, P30, DOI 10.1016/S0749-3797(98)00113-5; Rogers SC, 2011, J TRAUMA, V71, pS527, DOI 10.1097/TA.0b013e31823a4ba2; Sabini RC, 2011, PHYSICIAN SPORTSMED, V39, P23, DOI 10.3810/psm.2011.09.1917; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Theye Fred, 2004, Clin Med Res, V2, P165; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	69	35	35	1	23	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E11	10.3171/2012.9.FOCUS12280			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500012	23199423	Bronze			2022-02-06	
J	Lin, Y; Pan, YH; Wang, ML; Huang, XJ; Yin, YH; Wang, Y; Jia, F; Xiong, WH; Zhang, N; Jiang, JY				Lin, Yong; Pan, Yaohua; Wang, Mingliang; Huang, Xianjian; Yin, Yuhua; Wang, Yu; Jia, Feng; Xiong, Wenhao; Zhang, Nu; Jiang, Ji-yao			Blood-brain barrier permeability is positively correlated with cerebral microvascular perfusion in the early fluid percussion-injured brain of the rat	LABORATORY INVESTIGATION			English	Article						blood brain barrier; MRI; rat; traumatic brain injury; vascular reactivity	CAPILLARY PERFUSION; EDEMA FORMATION; HEAD TRAUMA; CORTICAL CONTUSION; SMALL MOLECULES; TIME-COURSE; MODEL; MATRIX-METALLOPROTEINASE-9; PATHOPHYSIOLOGY; EPIDEMIOLOGY	The blood-brain barrier (BBB) opening following traumatic brain injury (TBI) provides a chance for therapeutic agents to cross the barrier, yet the reduction of the cerebral microvascular perfusion after TBI may limit the intervention. Meanwhile, optimizing the cerebral capillary perfusion by the strategies such as fluid administration may cause brain edema due to the BBB opening post trauma. To guide the TBI therapy, we characterized the relationship between the changes in the cerebral capillary perfusion and BBB permeability after TBI. First, we observed the changes of the cerebral capillary perfusion by the intracardiac perfusion of Evans Blue and the BBB disruption with magnetic resonance imaging (MRI) in the rat subjected to lateral fluid percussion (FP) brain injury. The correlation between two variables was next evaluated with the correlation analysis. Since related to BBB breakdown, matrix metalloproteinase-9 (MMP-9) activity was finally detected by gelatin zymography. We found that the ratios of the perfused microvessel numbers in the lesioned cortices were significantly reduced at 0 and 1 h post trauma compared with that in the normal cortex, which then dramatically recovered at 4 and 24 h after injury, and that the BBB permeability was greatly augmented in the ipsilateral parts at 4, 12, and 24h, and in the contralateral area at 24h after injury compared with that in the uninjured brain. The correlation analysis showed that the BBB permeability increase was related to the restoration of the cerebral capillary perfusion over a 24-h period post trauma. Moreover, the gelatin zymography analysis indicated that the MMP-9 activity in the injured brain increased at 4h and significantly elevated at 12 and 24h as compared to that at 0 or 1 h after TBI. Our findings demonstrate that the 4h post trauma is a critical turning point during the development of TBI, and, importantly, the correlation analysis may guide us how to treat TBI. Laboratory Investigation (2012) 92, 1623-1634; doi:10.1038/labinvest.2012.118; published online 10 September 2012	[Lin, Yong; Pan, Yaohua; Huang, Xianjian; Yin, Yuhua; Wang, Yu; Jia, Feng; Xiong, Wenhao; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, Shanghai 200127, Peoples R China; [Wang, Mingliang] Shanghai Jiao Tong Univ, Dept Radiol, Ruijin Hosp, Sch Med, Shanghai 200127, Peoples R China; [Zhang, Nu] Wenzhou Med Univ, Dept Neurol Surg, Peoples Hosp 2, Wenzhou, Zhejiang, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiangjyb@online.sh.cn			National Science and Nature Committee of China [30973086]; National Health Ministry of China [200802093]; Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1409800]; Program for Shanghai Outstanding Medical Academic Leader	This work was supported by the Grants of National Science and Nature Committee of China (No. 30973086), National Health Ministry of China (No. 200802093), Shanghai Science and Technology Committee (No. 10JC1409800), and Program for Shanghai Outstanding Medical Academic Leader.	Baethmann A, 1998, Curr Opin Anaesthesiol, V11, P193, DOI 10.1097/00001503-199804000-00013; BARTH KNM, 1992, NEUROSURGERY, V30, P138, DOI 10.1227/00006123-199201000-00028; Beaumont A, 2002, ACT NEUR S, V81, P217; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Dawson DA, 1997, BRAIN RES, V749, P200, DOI 10.1016/S0006-8993(96)01166-3; del Valle J, 2008, J NEUROSCI METH, V174, P42, DOI 10.1016/j.jneumeth.2008.06.025; Dewey CW, 2000, VET CLIN N AM-SMALL, V30, P207, DOI 10.1016/S0195-5616(00)50010-2; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Ford JC, 1997, ACAD RADIOL, V4, P115, DOI 10.1016/S1076-6332(97)80010-4; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOBEL U, 1990, CIRC RES, V66, P271, DOI 10.1161/01.RES.66.2.271; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hawkins BT, 2006, J NEUROSCI METH, V151, P262, DOI 10.1016/j.jneumeth.2005.08.006; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Maikos JT, 2007, J NEUROTRAUM, V24, P492, DOI 10.1089/neu.2006.0149; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; McGoron Anthony J, 2008, BMC Med Imaging, V8, P4, DOI 10.1186/1471-2342-8-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Smith MJ, 2008, CRIT CARE MED, V36, P2703, DOI 10.1097/CCM.0b013e3181843e9a; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Wang-Fischer Y, 2009, MANUAL STROKE MODELS, P193; WEISS HR, 1988, MICROVASC RES, V36, P172, DOI 10.1016/0026-2862(88)90017-9; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Zoccoli G, 1996, J CEREBR BLOOD F MET, V16, P1312, DOI 10.1097/00004647-199611000-00028	47	35	40	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	NOV	2012	92	11					1623	1634		10.1038/labinvest.2012.118			12	Medicine, Research & Experimental; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pathology	032ZL	WOS:000310761800010	22964852	Bronze			2022-02-06	
J	Prichep, LS; Jacquin, A; Filipenko, J; Dastidar, SG; Zabele, S; Vodencarevic, A; Rothman, NS				Prichep, Leslie S.; Jacquin, Arnaud; Filipenko, Julie; Dastidar, Samanwoy Ghosh; Zabele, Stephen; Vodencarevic, Asmir; Rothman, Neil S.			Classification of Traumatic Brain Injury Severity Using Informed Data Reduction in a Series of Binary Classifier Algorithms	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Genetic algorithms (GAs); informed data reduction; multiclass classification; quantitative electroencephalography (QEEG); traumatic brain injury (TBI)	CT HEAD RULE; GENETIC ALGORITHMS; EEG; SPECTROSCOPY; CONCUSSION; DURATION; TOOL; MRI	Assessment of medical disorders is often aided by objective diagnostic tests which can lead to early intervention and appropriate treatment. In the case of brain dysfunction caused by head injury, there is an urgent need for quantitative evaluation methods to aid in acute triage of those subjects who have sustained traumatic brain injury (TBI). Current clinical tools to detect mild TBI (mTBI/concussion) are limited to subjective reports of symptoms and short neurocognitive batteries, offering little objective evidence for clinical decisions; or computed tomography (CT) scans, with radiation-risk, that are most often negative in mTBI. This paper describes a novel methodology for the development of algorithms to provide multi-class classification in a substantial population of brain injured subjects, across a broad age range and representative subpopulations. The method is based on age-regressed quantitative features (linear and nonlinear) extracted from brain electrical activity recorded from a limited montage of scalp electrodes. These features are used as input to a unique "informed data reduction" method, maximizing confidence of prospective validation and minimizing over-fitting. A training set for supervised learning was used, including: "normal control," "concussed," and " structural injury/CT positive (CT+)." The classifier function separating CT+ from the other groups demonstrated a sensitivity of 96% and specificity of 78%; the classifier separating " normal controls" from the other groups demonstrated a sensitivity of 81% and specificity of 74%, suggesting high utility of such classifiers in acute clinical settings. The use of a sequence of classifiers where the desired risk can be stratified further supports clinical utility.	[Prichep, Leslie S.] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY 10016 USA; [Jacquin, Arnaud; Filipenko, Julie; Dastidar, Samanwoy Ghosh; Rothman, Neil S.] BrainScope Inc, Bethesda, MD 20814 USA; [Zabele, Stephen] BBN, Raytheon, Cambridge, MA 02138 USA; [Vodencarevic, Asmir] Int Grad Sch Dynam Intelligent Syst, D-33102 Paderborn, Germany		Prichep, LS (corresponding author), NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY 10016 USA.	leslie.prichep@nyumc.org; arnaud.jacquin@brain-scope.com; julie.filipenko@brainscope.com; sam.dastidar@brainscope.com; szabele@bbn.com; asmirv@gmail.com; neil.rothman@brainscope.com			BrainScope, Inc., Bethesda, MD, USA	This work was supported by BrainScope, Inc., Bethesda, MD, USA.	Aviyente S, 2011, HUM BRAIN MAPP, V32, P80, DOI 10.1002/hbm.21000; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; DUDA OR, 2001, PATTERN CLASSIFICATI; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faul M, 2010, TRAUMATIC BRAIN INJU; Fisch B. J., 1999, FISCH SPEHLMANNS EEG, P3; GASSER T, 1982, ELECTROEN CLIN NEURO, V53, P119, DOI 10.1016/0013-4694(82)90112-2; Ghalenoui H, 2008, PREHOSP DISASTER MED, V23, P558, DOI 10.1017/S1049023X00006415; Harper Paul R, 2005, Health Policy, V71, P315, DOI 10.1016/j.healthpol.2004.05.002; He BYJ, 2010, NEURON, V66, P353, DOI 10.1016/j.neuron.2010.04.020; HIGUCHI T, 1988, PHYSICA D, V31, P277, DOI 10.1016/0167-2789(88)90081-4; Isenhart R., 2012, COMP MED BIOL UNPUB; Jacquin A, 2007, P ANN INT IEEE EMBS, P1928, DOI 10.1109/IEMBS.2007.4352694; John E.R., 1987, HDB ELECTROENCEPHALO, P449; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1980, SCIENCE, V210, P1255, DOI 10.1126/science.7434026; Kahraman S., 2006, J TRAUMA ACUTE CARE, V61; Kalafut MA, 2000, STROKE, V31, P1667, DOI 10.1161/01.STR.31.7.1667; Kessel B, 2007, INJURY, V38, P1065, DOI 10.1016/j.injury.2007.05.009; Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; Langlois J.A., 2006, J HEAD TRAUMA REHABI, V21; Lehmann D, 2005, PSYCHIAT RES-NEUROIM, V138, P141, DOI 10.1016/j.pscychresns.2004.05.007; Leon-Carrion J, 2010, BRAIN INJURY, V24, P1193, DOI 10.3109/02699052.2010.506636; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Li JL, 2008, BIOSTATISTICS, V9, P566, DOI 10.1093/biostatistics/kxm050; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malloy, 1998, Semin Clin Neuropsychiatry, V3, P186; Mitchell M., 1996, INTRO GENETIC ALGORI; Norman RG, 2000, SLEEP, V23, P901; Oh IS, 2004, IEEE T PATTERN ANAL, V26, P1424, DOI 10.1109/TPAMI.2004.105; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Prichep LS, 2006, NEUROBIOL AGING, V27, P471, DOI 10.1016/j.neurobiolaging.2005.07.021; Rabinoff M, 2011, Open Med Inform J, V5, P1, DOI 10.2174/1874431101105010001; Raghavendra B. S., 2005, PHYSIOL MEAS, V30, P795; RAUDYS SJ, 1991, IEEE T PATTERN ANAL, V13, P252, DOI 10.1109/34.75512; Raymer ML, 2000, IEEE T EVOLUT COMPUT, V4, P164, DOI 10.1109/4235.850656; Rosso OA, 2001, J NEUROSCI METH, V105, P65, DOI 10.1016/S0165-0270(00)00356-3; Sakkalis V, 2011, COMPUT BIOL MED, V41, P1110, DOI 10.1016/j.compbiomed.2011.06.020; Selesnick I. W., 2002, NEW COMPLEX DIRECTIO, P573; SIEDLECKI W, 1989, PATTERN RECOGN LETT, V10, P335, DOI 10.1016/0167-8655(89)90037-8; Somorjai RL, 2011, J BIOMED INFORM, V44, P775, DOI 10.1016/j.jbi.2011.04.004; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Suffin SC, 2007, J AM PHYS SURG, V12, P104; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tax DMJ, 2002, INT C PATT RECOG, P124, DOI 10.1109/ICPR.2002.1048253; TEASDALE G, 1974, LANCET, V2, P81; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2005, CLIN NEUROPHYSIOL, V116, P2129, DOI 10.1016/j.clinph.2005.04.026; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; WEINER JM, 1966, BIOMETRICS, V22, P268, DOI 10.2307/2528518; Whithain EM, 2007, CLIN NEUROPHYSIOL, V118, P1877, DOI 10.1016/j.clinph.2007.04.027; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yang JH, 1998, IEEE INTELL SYST APP, V13, P44, DOI 10.1109/5254.671091	63	35	35	0	12	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	NOV	2012	20	6					806	822		10.1109/TNSRE.2012.2206609			17	Engineering, Biomedical; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Rehabilitation	040WW	WOS:000311357400008	22855231				2022-02-06	
J	Braden, CA; Cuthbert, JP; Brenner, L; Hawley, L; Morey, C; Newman, J; Staniszewski, K; Harrison-Felix, C				Braden, Cynthia A.; Cuthbert, Jeffrey P.; Brenner, Lisa; Hawley, Lenore; Morey, Clare; Newman, Jody; Staniszewski, Kristi; Harrison-Felix, Cynthia			Health and wellness characteristics of persons with traumatic brain injury	BRAIN INJURY			English	Article						Health promotion; wellness; traumatic brain injury; community dwelling	QUALITY-OF-LIFE; COMMUNITY INTEGRATION; PARTICIPATION ASSESSMENT; HEAD-INJURY; REHABILITATION; SATISFACTION; DISABILITY; OUTCOMES; INDIVIDUALS; RELIABILITY	Objective: To describe health and wellness characteristics of persons with TBI living in the community, compare to other disability populations and evaluate the associations between health-related constructs. Design: Observational. Setting: Outpatient rehabilitation hospital and a Veterans Affairs Medical Centre. Participants: Seventy-four community-dwelling adults with moderate-to-severe TBI. Interventions: None. Main measures: Health Promoting Lifestyle Profile II (HPLP-II), Self Rated Abilities Health Practices Scale (SRAHP), Barriers to Health Promoting Activities for Disabled Scale (BHPAD), Medical Outcomes Study 12-Item Health Status Survey Short Form (SF-12), Personal Resource Questionnaire-adapted (PRQ-a), Perceived Wellness Survey (PWS), Diener Satisfaction with Life Scale (SWLS) and Participation Assessment with Recombined Tools-Objective (PART-O). Results: Health-promoting behaviours, self-efficacy and barriers to health were comparable to other disability populations. Perceived health status, participation and life satisfaction were decreased. Measures of health promotion and self-efficacy were positively associated with perceived mental health status, life satisfaction and participation. Barriers to healthy activities were negatively associated with health promotion, self-efficacy and perceived mental health status. Conclusions: Health and wellness status was below desired levels for the study cohort, and comparable to other disability populations. Better understanding of associations among health-related constructs is needed. Continued research on conceptually-based health and wellness interventions for persons with TBI is recommended.	[Braden, Cynthia A.; Cuthbert, Jeffrey P.; Hawley, Lenore; Morey, Clare; Newman, Jody; Staniszewski, Kristi; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Brenner, Lisa] Mental Illness Res,Educ & Clin Ctr, Vet Integrated Serv Network 19, Denver, CO USA		Braden, CA (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	cbraden@craighospital.org	Brenner, Lisa A./AAG-2442-2019		US Department of Education, Office of Special Education and Rehabilitation Services, National Institute on Disability and Rehabilitation Research [H133A070022]	This research was supported by an award from the US Department of Education, Office of Special Education and Rehabilitation Services, National Institute on Disability and Rehabilitation Research to the Rocky Mountain Regional Brain Injury System (H133A070022). The opinions expressed in this manuscript are those of the authors and do not necessarily reflect the views of the Department of Education or the Department of Veterans Affairs.	Adams T, 1997, AM J HEALTH PROMOT, V11, P208, DOI 10.4278/0890-1171-11.3.208; Ali R, 2002, ADDICTION, V97, P1183; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Becker H, 1991, Am J Health Promot, V5, P449; BECKER H, 1993, SELF RATED ABILITIES, V17, P42; Becker MH, 1974, HLTH BELIEF MODEL PE; Benedict, 2001, HOPKINS VERBAL LEARN; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Centers for Disease Control and Prevention, 2010, OV OB COL; Centers for Disease Control and Prevention, GET STATS TRAUM BRAI; Centers for Disease Control and Prevention and Department of Health and Human Services, 2006, BMI BOD MASS IND; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Correa J.C.R., 2011, J HEAD TRAUMA REHAB, P1; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2003, PROBLEMATIC SUBSTANC; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Faul M, 2010, TRAUMATIC BRAIN INJU; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finkelstein E., 2006, INCIDENCE EC BURDEN; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Golden CJ., 2002, STROOP COLOR WORD TE; Hagen C, 1974, RANCHO LOS AMIGOS SC; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hillier SL, 1997, BRAIN INJURY, V11, P661; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kwon BK, 2010, J NEUROTRAUM, V27, P21, DOI 10.1089/neu.2009.1048; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lynch WJ, 2002, J HEAD TRAUMA REHAB, V17, P66, DOI 10.1097/00001199-200202000-00009; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCullagh S, 2005, TXB TRAUMATIC BRAIN, P321; National Institute of Neurological Disorders and Stroke, 2002, TRAUM BRAIN INJ HOP; Nieuwenhuijsen ER, 2006, DISABIL REHABIL, V28, P245, DOI 10.1080/09638280500197743; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Office of Applied Studies Department of HHS, 2010, AD TABL STAT EST SUB; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Putnam M, 2003, J REHABIL, V69, P37; Reitan R. M., 1993, HALSTED REITAN NEURO; Rimmer JH., 2001, CTR HLTH PROMOTION R; RRTC Health & Wellness Consortium, 2004, HLTH LIF EV BAS CURR; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuifbergen A K, 1995, Sch Inq Nurs Pract, V9, P31; Stuifbergen AK, 2000, NURS RES, V49, P122, DOI 10.1097/00006199-200005000-00002; STUIFBERGEN AK, 1994, RES NURS HEALTH, V17, P3, DOI 10.1002/nur.4770170103; Stuifbergen AK, 1995, SCHOLARLY INQUIRY NU, V9, P51; Stuifbergen Alexa K, 2004, J Holist Nurs, V22, P12; Stuijbergen AK, 2003, ARCH PHYS MED REHAB, V84, P467, DOI 10.1053/apmr.2003.50028; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; The Traumatic Brain Injury Model Systems National Data and Statistical Center, POL 101A ID SUBJ; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; U. S. Department of Health and Human Services, 2010, HLTH PEOPL 2020 DIS; Uniform Data System for Medical Rehabilitation, 1993, GUID UN DAT SET MED; Walker S.N., 1996, PSYCOMETRIC EV UNPUB, V13, P120; Ware J, 1994, SF 36 PHYS MENTAL SU; Weinert C, 1987, West J Nurs Res, V9, P589; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P957, DOI 10.1097/01.PHM.0000098504.78524.E2	72	35	35	1	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2012	26	11					1315	1327		10.3109/02699052.2012.706351			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	005AQ	WOS:000308723100005	22876980				2022-02-06	
J	Johansson, B; Carlsson, A; Carlsson, ML; Karlsson, M; Nilsson, MK; Nordquist-Brandt, E; Ronnback, L				Johansson, Birgitta; Carlsson, Arvid; Carlsson, Maria L.; Karlsson, Magdalena; Nilsson, Marie K. L.; Nordquist-Brandt, Elisabeth; Ronnback, Lars			Placebo-controlled cross-over study of the monoaminergic stabiliser (-)-OSU6162 in mental fatigue following stroke or traumatic brain injury	ACTA NEUROPSYCHIATRICA			English	Article						brain injuries; drug therapy; mental fatigue; stroke	5-HT2A SEROTONIN; (+)-OSU6162; DISORDERS	Objective Mental fatigue occurring after a stroke or traumatic brain injury (TBI) often results in difficulties returning to work and pursuing social activities. No effective treatment of this condition is available today. In this study, we have tested a novel pharmacological strategy using the monoaminergic stabiliser (-)-OSU6162. Methods (-)-OSU6162 was given orally for 4 weeks in doses increasing from 15 to 45 mg b.i.d. to 12 patients suffering from mental fatigue, following upon stroke (n?=?6) or TBI (n?=?6). (-)-OSU6162 was compared with placebo using a double-blind, randomised cross-over design. Patients included were well rehabilitated physically with no gross impairment in cognitive functions other than those related to the mental fatigue. Results (-)-OSU6162 caused a remarkable improvement in mental stamina, as evaluated by a self-assessment scale on mental fatigue. Statistical significance was reached on the primary endpoint (Mental Fatigue Scale). There was a trend towards improvement in the secondary endpoints processing speed and attention. Principal component analysis showed an overall positive treatment effect in 7 of 12 patients. Beneficial responses were seen already during the first few days of active drug treatment. Increasing dosage caused no further improvement. Adverse reactions consisted of short-lasting mild nausea and attenuated appetite. These side effects disappeared upon dose reduction. Conclusion The monoaminergic stabiliser (-)-OSU6162 offers promise as a candidate for treatment of mental fatigue after a stroke or TBI.	[Johansson, Birgitta] Univ Gothenburg, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden		Johansson, B (corresponding author), Univ Gothenburg, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, Sahlgrenska Acad, Dubbsgatan 14,1Tr, SE-41345 Gothenburg, Sweden.	birgitta.johansson@neuro.gu.se		, Birgitta/0000-0003-0240-1142	Arvid Carlsson Foundation; Foundation for Neuropharmacological Research and Education	This research was supported by the Arvid Carlsson Foundation and the Foundation for Neuropharmacological Research and Education.	ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azmitia EC, 1999, NEUROPSYCHOPHARMACOL, V21, pS33; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Brennan AR, 2008, ANN NY ACAD SCI, V1129, P236, DOI 10.1196/annals.1417.007; Burstein ES, 2011, J NEURAL TRANSM, V118, P1523, DOI 10.1007/s00702-011-0701-y; Carlsson ML, 2011, J NEURAL TRANSM, V118, P1511, DOI 10.1007/s00702-011-0704-8; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; DeLuca J, 2005, ISS CLIN COGN NEUROP, P1; Ekesbo A, 1997, NEUROREPORT, V8, P2567, DOI 10.1097/00001756-199707280-00029; Ellis DC, 2001, DELIS KAPLAN EXECUTI; Gefvert O, 2000, NORD J PSYCHIAT, V54, P93; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Johansson B, 2013, BRAIN INJURY, V23, P1027; Johansson B., 2012, BRAIN INJURY FUNCTIO, V1, P3, DOI [10.5772/27042, DOI 10.5772/27042]; Johansson Birgitta, 2012, ISRN Psychiatry, V2012, P686425, DOI 10.5402/2012/686425; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Lahti RA, 2007, J NEURAL TRANSM, V114, P1143, DOI 10.1007/s00702-007-0784-7; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundberg T, 2002, NORD J PSYCHIAT, V56, P24; Madison S., 2003, LASDIAGNOS; Posner MI, 2007, ANNU REV PSYCHOL, V58, P1, DOI 10.1146/annurev.psych.58.110405.085516; Reitan R, 1985, HALSTEAD REITAN NEUR; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Rodriguez CA, 2004, J CLIN PHARMACOL, V44, P276, DOI 10.1177/0091270003262792; Ronnback L, 2012, LONG LASTING MENTAL; Ronnback L, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-22; Rung JP, 2008, J NEURAL TRANSM, V115, P899, DOI 10.1007/s00702-008-0038-3; Senn S., 2002, CROSS OVER TRIALS CL, V2nd ed.; Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Tedroff J, 1999, NEUROLOGY, V53, P1605, DOI 10.1212/WNL.53.7.1605; Tedroff J, 2000, CLIN EFFECTS OSU6162; Wechsler D., 2003, WECHSLER ADULT INTEL; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139	36	35	35	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1601-5215			ACTA NEUROPSYCHIATR	Acta Neuropsychiatr.	OCT	2012	24	5					266	274		10.1111/j.1601-5215.2012.00678.x			9	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	007IP	WOS:000308882300004	25286991				2022-02-06	
J	Chow, JW; Yablon, SA; Stokic, DS				Chow, John W.; Yablon, Stuart A.; Stokic, Dobrivoje S.			Coactivation of ankle muscles during stance phase of gait in patients with lower limb hypertonia after acquired brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						Coactivation; Co-contraction; Stroke; Traumatic brain injury	DISTURBED MOTOR CONTROL; CEREBRAL-PALSY; SPASTIC GAIT; STROKE; COCONTRACTION; CHILDREN; WALKING; JOINT; KINEMATICS; MOVEMENTS	Objective: Examine (1) coactivation between tibialis anterior (TA) and medial gastrocnemius (MG) muscles during stance phase of gait in patients with moderate-to-severe resting hypertonia after stroke or traumatic brain injury (TBI) and (2) the relationship between coactivation and stretch velocity-dependent increase in MG activity. Methods: Gait and surface EMG were recorded from patients with stroke or TBI (11 each) and corresponding healthy controls (n = 11) to determine the magnitude and duration of TA-MG coactivation. The frequency and gain of positive (>0) and significant positive (p < 0.05) EMG-lengthening velocity (EMG-LV) slope in MG were related to coactivation parameters. Results: The magnitude of coactivation was increased on the more-affected (MA) side, whereas the duration was prolonged on the less-affected (LA) side of both stroke and TBI patients. The difference reached significance during the initial and late double support. The magnitude of coactivation positively correlated with the gain of significant positive EMG-LV slope in TBI patients. Conclusions: Increased coactivation between TA and MG during initial and late double support is a unique feature of gait in stroke and TBI patients with muscle hypertonia. Significance: Increased coactivation may represent an adaptation to compensate for impaired stability during step transition after stroke and TBI. (C) 2012 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Chow, John W.; Yablon, Stuart A.; Stokic, Dobrivoje S.] Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS 39216 USA		Chow, JW (corresponding author), Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.	jchow@mmrcrehab.org		Stokic, Dobrivoje/0000-0002-1891-5730	Wilson Research Foundation, Jackson, MS, USA	We are grateful to Mark Hemleben and Terry Horn for their assistance with this study. This work was supported in part by the Wilson Research Foundation, Jackson, MS, USA.	Achache V, 2010, CLIN NEUROPHYSIOL, V121, P930, DOI 10.1016/j.clinph.2009.12.037; Arene N, 2009, TOP STROKE REHABIL, V16, P346, DOI 10.1310/tsr1605-346; BALMASEDA MT, 1988, ARCH PHYS MED REHAB, V69, P1009; BERGER W, 1982, ELECTROEN CLIN NEURO, V53, P538, DOI 10.1016/0013-4694(82)90066-9; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Chow JW, 2010, BRAIN INJURY, V24, P1575, DOI 10.3109/02699052.2010.523053; Chow JW, 2009, NEUR M PLANN; Crenna P, 1998, NEUROSCI BIOBEHAV R, V22, P571, DOI 10.1016/S0149-7634(97)00046-8; Damiano DL, 2000, ARCH PHYS MED REHAB, V81, P895, DOI 10.1053/apmr.2000.5579; Den Otter AR, 2007, GAIT POSTURE, V25, P342, DOI 10.1016/j.gaitpost.2006.04.007; Falconer K, 1985, Electromyogr Clin Neurophysiol, V25, P135; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Granata KP, 2000, J BONE JOINT SURG AM, V82A, P174, DOI 10.2106/00004623-200002000-00003; HAWKINS D, 1990, J BIOMECH, V23, P487, DOI 10.1016/0021-9290(90)90304-L; Holz JH, 1998, INTRO SURFACE ELECTR; Ishikawa M, 2005, J APPL PHYSIOL, V99, P603, DOI 10.1152/japplphysiol.00189.2005; KADABA MP, 1990, J ORTHOP RES, V8, P383, DOI 10.1002/jor.1100080310; KNUTSSON E, 1979, BRAIN, V102, P405, DOI 10.1093/brain/102.2.405; Lamontagne A, 2000, J ELECTROMYOGR KINES, V10, P407, DOI 10.1016/S1050-6411(00)00028-6; Lamontagne A, 2002, GAIT POSTURE, V15, P244, DOI 10.1016/S0966-6362(01)00190-4; Lamontagne A, 2001, ARCH PHYS MED REHAB, V82, P1696, DOI 10.1053/apmr.2001.26810; Lance J.W., 1980, SPASTICITY DISORDERE, P485; Lin PY, 2006, ARCH PHYS MED REHAB, V87, P562, DOI 10.1016/j.apmr.2005.12.042; Manganotti P, 2007, J REHABIL MED, V39, P115, DOI 10.2340/16501977-0036; MARKS M, 1958, ANN NY ACAD SCI, V74, P59, DOI 10.1111/j.1749-6632.1958.tb39532.x; NIELSEN J, 1994, EXP BRAIN RES, V102, P350; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Pierce SR, 2007, CLIN BIOMECH, V22, P1045, DOI 10.1016/j.clinbiomech.2007.08.003; Shiavi R, 1987, J Rehabil Res Dev, V24, P24; Stokic DS, 2009, NEUR M PLANN; Unnithan V B, 1996, Electromyogr Clin Neurophysiol, V36, P487; van Hedel HJA, 2006, GAIT POSTURE, V24, P35, DOI 10.1016/j.gaitpost.2005.06.015; YANG JF, 1984, ARCH PHYS MED REHAB, V65, P517	33	35	38	1	23	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	AUG	2012	123	8					1599	1605		10.1016/j.clinph.2012.01.006			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	970DJ	WOS:000306108000019	22325644				2022-02-06	
J	Hemerka, JN; Wu, XR; Dixon, CE; Garman, RH; Exo, JL; Shellington, DK; Blasiole, B; Vagni, VA; Janesko-Feldman, K; Xu, M; Wisniewski, SR; Bayir, H; Jenkins, LW; Clark, RSB; Tisherman, SA; Kochanek, PM				Hemerka, Joseph N.; Wu, Xianren; Dixon, C. Edward; Garman, Robert H.; Exo, Jennifer L.; Shellington, David K.; Blasiole, Brian; Vagni, Vincent A.; Janesko-Feldman, Keri; Xu, Mu; Wisniewski, Stephen R.; Bayir, Huelya; Jenkins, Larry W.; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.			Severe Brief Pressure-Controlled Hemorrhagic Shock after Traumatic Brain Injury Exacerbates Functional Deficits and Long-Term Neuropathological Damage in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; controlled cortical impact; head injury; head trauma; Morris water maze; polytrauma; secondary insult	CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; HIPPOCAMPAL NEUROGENESIS; SECONDARY ISCHEMIA; MOTOR DEFICITS; RESUSCITATION; HYPOTENSION; MODEL; ISOFLURANE	Hypotension after traumatic brain injury (TBI) worsens outcome. We published the first report of TBI plus hemorrhagic shock (HS) in mice using a volume-controlled approach and noted increased neuronal death. To rigorously control blood pressure during HS, a pressure-controlled HS model is required. Our hypothesis was that a brief, severe period of pressure-controlled HS after TBI in mice will exacerbate functional deficits and neuropathology versus TBI or HS alone. C57BL6 male mice were randomized into four groups (n = 10/group): sham, HS, controlled cortical impact (CCI), and CCI + HS. We used a pressure-controlled shock phase (mean arterial pressure [MAP] = 25-27 ram Hg for 35 min) and its treatment after mild to moderate CCI including, a 90 min pre-hospital phase, during which lactated Ringer's solution was given to maintain MAP > 70 mm Hg, and a hospital phase, when the shed blood was re-infused. On days 14-20, the mice were evaluated in the Morris water maze (MWM, hidden platform paradigm). On day 21, the lesion and hemispheric volumes were quantified. Neuropathology and hippocampal neuron counts (hematoxylin and eosin [H&E], Fluoro-Jade B, and NeuN) were evaluated in the mice (n=60) at 24 h, 7 days, or 21 days (n = 5/group/time point). HS reduced MAP during the shock phase in the HS and CCI+HS groups (p < 0.05). Fluid requirements during the pre-hospital phase were greatest in the CCI + HS group (p < 0.05), and were increased in HS versus sham and CCI animals (p < 0.05). MWM latency was increased on days 14 and 15 after CCI + HS (p < 0.05). Swim speed and visible platform latency were impaired in the CCI + HS group (p < 0.05). CCI+HS animals had increased contusion volume versus the CCI group ( p < 0.05). Hemispheric volume loss was increased 33.3% in the CCI + HS versus CCI group (p < 0.05). CA1 cell loss was seen in CCI + HS and CCI animals at 24 h and 7 days (p < 0.05). CA3 cell loss was seen after CCI+HS (p < 0.05 at 24h and 7 days). CA1 cell loss at 21 days was seen only in CCI+HS animals (p < 0.05). Brief, severe, pressure-controlled HS after CCI produces robust functional deficits and exacerbates neuropathology versus CCI or HS alone.	[Hemerka, Joseph N.; Wu, Xianren; Dixon, C. Edward; Garman, Robert H.; Exo, Jennifer L.; Shellington, David K.; Blasiole, Brian; Vagni, Vincent A.; Janesko-Feldman, Keri; Xu, Mu; Bayir, Huelya; Jenkins, Larry W.; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Wu, Xianren; Blasiole, Brian; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Exo, Jennifer L.; Shellington, David K.; Vagni, Vincent A.; Janesko-Feldman, Keri; Xu, Mu; Bayir, Huelya; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Dixon, C. Edward; Jenkins, Larry W.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Garman, Robert H.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Exo, Jennifer L.; Shellington, David K.; Bayir, Huelya; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Tisherman, Samuel A.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Tisherman, Samuel A./AAK-9377-2020; Kochanek, Patrick M/D-2371-2015	Tisherman, Samuel A./0000-0003-3810-3729; Kochanek, Patrick M/0000-0002-2627-913X; Shellington, David/0000-0001-6708-6978; Wisniewski, Stephen/0000-0002-3877-9860	Defense Advanced Research Projects Agency (DARPA) Prevent ProgramUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-10-C2124]; United States ArmyUnited States Department of Defense [W81XWH-06-1-0247, W81XWH-09-2-0187, T32 HD040686, NS 30218, NS30318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS030218, P20NS030318, P01NS030318] Funding Source: NIH RePORTER	We thank the Defense Advanced Research Projects Agency (DARPA) Prevent Program (N66001-10-C2124 to P.M.K.), the United States Army (W81XWH-06-1-0247 and W81XWH-09-2-0187 to P.M.K.; T32 HD040686 to J.L.E.; NS 30218 and NS30318 to C.E.D.) for support. The views, opinions, and findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of DARPA or the U.S. Department of Defense.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Carrillo P, 1998, J TRAUMA, V45, P239, DOI 10.1097/00005373-199808000-00007; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; Dennis AM, 2006, CRIT CARE MED, V34, pA5, DOI 10.1097/00003246-200612002-00017; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Dong HX, 2003, J NEUROSCI, V23, P1742; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Garner J, 2010, ANN SURG, V251, P1131, DOI 10.1097/SLA.0b013e3181e00fcb; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; Luo CX, 2007, J NEUROCHEM, V103, P1872, DOI 10.1111/j.1471-4159.2007.04915.x; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; RICHES AC, 1973, J PHYSIOL-LONDON, V228, P279, DOI 10.1113/jphysiol.1973.sp010086; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Teranishi K, 2012, INJURY, V43, P585, DOI 10.1016/j.injury.2010.09.042; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	57	35	35	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2192	2208		10.1089/neu.2011.2303			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900007	22738159	Green Published			2022-02-06	
J	Puentedura, EJ; Louw, A				Puentedura, Emilio J.; Louw, Adriaan			A neuroscience approach to managing athletes with low back pain	PHYSICAL THERAPY IN SPORT			English	Article						Athlete; Chronic; Low back pain; Musculoskeletal; Neuroscience education; Pain	FEAR-AVOIDANCE BELIEFS; CHRONIC MUSCULOSKELETAL PAIN; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PREDICTION RULE; CHRONIC-FATIGUE-SYNDROME; TRAUMATIC BRAIN-INJURY; SPINAL MANIPULATION; CENTRAL SENSITIZATION; PHYSICAL-THERAPISTS; DISC DEGENERATION	Low back pain (LBP) is a common complaint within the athletic population and is commonly managed through a biomedical approach. The injured or damaged structure causing the LBP is identified and treated, and complete recovery from the episode is expected. Clinical experience shows us that often, athletes with LBP will not recover from their episode and may continue their sports participation despite persistent pain, or they may limit participation. Recent neuroscience research into the biology of pain suggests that clinicians involved in the management of athletes with LBP should embrace a biopsychosocial approach by engaging the brain and nervous system. This manuscript provides an overview of such a biopsychosocial approach, and presents information on the neurobiology of the athlete's pain experience. (C) 2011 Elsevier Ltd. All rights reserved.	[Puentedura, Emilio J.] Univ Nevada, Sch Allied Hlth Sci, Dept Phys Therapy, Las Vegas, NV 89154 USA; [Puentedura, Emilio J.; Louw, Adriaan] Int Spine & Pain Inst, Story City, IA USA		Puentedura, EJ (corresponding author), Univ Nevada, Sch Allied Hlth Sci, Dept Phys Therapy, 4505 Maryland Pkwy,Box 453029, Las Vegas, NV 89154 USA.	louie.puentedura@unlv.edu	Puentedura, Emilio J./AAG-7118-2020	Puentedura, Emilio J./0000-0003-4771-4732			Acerra NE, 2005, NEUROLOGY, V65, P751, DOI 10.1212/01.wnl.0000178745.11996.8c; Alyas F, 2007, BRIT J SPORT MED, V41, P836, DOI 10.1136/bjsm.2007.037747; ARNTZ A, 1995, BEHAV RES THER, V33, P49, DOI 10.1016/0005-7967(94)E0017-D; Autio RA, 2006, SPINE, V31, P1247, DOI 10.1097/01.brs.0000217681.83524.4a; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Baron R, 2004, PROG PAIN RES MANAG, V31, P193; BAYER TL, 1991, PAIN, V44, P45, DOI 10.1016/0304-3959(91)90145-N; Bayer TL, 1998, PAIN, V74, P327, DOI 10.1016/S0304-3959(97)00196-6; Ben Ounis O, 2011, ANN ENDOCRINOL-PARIS, V72, P34, DOI 10.1016/j.ando.2010.04.002; Bischof JE, 2010, GAIT POSTURE, V31, P502, DOI 10.1016/j.gaitpost.2010.02.010; Bono CM, 2004, J BONE JOINT SURG AM, V86A, P382, DOI 10.2106/00004623-200402000-00027; Boyd BS, 2009, J ORTHOP SPORT PHYS, V39, P780, DOI 10.2519/jospt.2009.3002; Butler DS, 2003, EXPLAIN PAIN; Butler DS, 2000, SENSITIVE NERVOUS SY; Childs JD, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-32; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Childs JD, 2007, MIL MED, V172, P440, DOI 10.7205/MILMED.172.4.440; Cibulka MT, 1999, J ORTHOP SPORT PHYS, V29, P595, DOI 10.2519/jospt.1999.29.10.595; Clarke CL, 2011, MANUAL THER, V16, P544, DOI 10.1016/j.math.2011.05.003; COOK AJ, 1987, NATURE, V325, P151, DOI 10.1038/325151a0; Cook JL, 2002, MANUAL THER, V7, P121, DOI 10.1054/math.2002.0458; Coppieters MW, 2006, ARCH PHYS MED REHAB, V87, P1412, DOI 10.1016/j.apmr.2006.06.012; Coppieters MW, 2006, J ORTHOP RES, V24, P1883, DOI 10.1002/jor.20210; Crewther BT, 2011, J STRENGTH COND RES, V25, P10, DOI 10.1519/JSC.0b013e3181fb47f5; Critchley DJ, 2007, SPINE, V32, P1474, DOI 10.1097/BRS.0b013e318067dc26; d'Hemecourt PA, 2000, CLIN SPORT MED, V19, P663, DOI 10.1016/S0278-5919(05)70231-3; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fernandez-De-Las-Penas C, 2007, J ORTHOP SPORT PHYS, V37, P325, DOI 10.2519/jospt.2007.2542; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; Flor H, 2000, Prog Brain Res, V129, P313; Flor H, 2003, ANN SCI M PAIN SOC B; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Foster NE, 2011, PHYS THER, V91, P790, DOI 10.2522/ptj.20100326; Fritz JM, 2002, PHYS THER, V82, P973, DOI 10.1093/ptj/82.10.973; Fritz JM, 2001, PAIN, V94, P7, DOI 10.1016/S0304-3959(01)00333-5; George SZ, 2007, CLIN J PAIN, V23, P76, DOI 10.1097/01.ajp.0000210949.19429.34; George SZ, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-68; George SZ, 2006, J OCCUP REHABIL, V16, P95, DOI 10.1007/s10926-005-9007-y; George SZ, 2006, CLIN J PAIN, V22, P197, DOI 10.1097/01.ajp.0000148627.92498.54; George SZ, 2004, PHYS THER, V84, P538, DOI 10.1093/ptj/84.6.538; George SZ, 2003, SPINE, V28, P2551, DOI 10.1097/01.BRS.0000096677.84605.A2; George SZ, 2002, CLIN SPORT MED, V21, P105, DOI 10.1016/S0278-5919(03)00060-7; George SZ, 2001, SPINE, V26, P2139, DOI 10.1097/00007632-200110010-00019; Geraci Michael C Jr, 2005, Phys Med Rehabil Clin N Am, V16, P711, DOI 10.1016/j.pmr.2005.02.004; Gifford L., 1998, PHYSIOTHERAPY, V84, P27; Gifford L S, 1997, J Hand Ther, V10, P86; Girault JA, 2004, ARCH NEUROL-CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641; Goldby LJ, 2006, SPINE, V31, P1083, DOI 10.1097/01.brs.0000216464.37504.64; GROSS J, 1996, MUSCULOSKELETAL EXAM; HALDEMAN S, 1990, SPINE, V15, P718, DOI 10.1097/00007632-199007000-00019; Hangai M, 2009, AM J SPORT MED, V37, P149, DOI 10.1177/0363546508323252; Harrison DE, 1997, J MANIP PHYSIOL THER, V20, P607; HIDES JA, 1994, SPINE, V19, P165, DOI 10.1097/00007632-199401001-00009; Hides J, 2008, J ORTHOP SPORT PHYS, V38, P101, DOI 10.2519/jospt.2008.2658; Hind K, 2006, BONE, V39, P880, DOI 10.1016/j.bone.2006.03.012; Hodges PW, 2003, J ELECTROMYOGR KINES, V13, P361, DOI 10.1016/S1050-6411(03)00042-7; Holm LW, 2007, J RHEUMATOL, V34, P193; Iwamoto J, 2004, SCAND J MED SCI SPOR, V14, P346, DOI 10.1111/j.1600-0838.2004.00379.x; Janig W., 2006, P 11 WORLD C PAIN, P331; JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7; Jull G, 2009, MANUAL THER, V14, P117, DOI 10.1016/j.math.2009.01.004; Kraft DE, 2002, PEDIATR CLIN N AM, V49, P643, DOI 10.1016/S0031-3955(02)00007-X; LARSSON SE, 1995, EUR J APPL PHYSIOL, V70, P451, DOI 10.1007/BF00618497; Linton SJ, 2011, PHYS THER, V91, P700, DOI 10.2522/ptj.20100330; Loeser J. D., 1999, EVALUATION TREATMENT; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Louw A, 2011, ARCH PHYS MED REHAB, V92, P2041, DOI 10.1016/j.apmr.2011.07.198; Louw Adriaan, 2012, Physiotherapy Theory and Practice, V28, P50, DOI 10.3109/09593985.2011.562602; Louw QA, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.035360; Lundin O, 2001, SCAND J MED SCI SPOR, V11, P103, DOI 10.1034/j.1600-0838.2001.011002103.x; MacDonald DA, 2006, MANUAL THER, V11, P254, DOI 10.1016/j.math.2006.02.004; Malick A, 2000, FUNCT NEUROL, V15, P28; Marras WS, 2007, SPINE, V32, P2387, DOI 10.1097/BRS.0b013e3181557be9; Masui T, 2005, J SPINAL DISORD TECH, V18, P121, DOI 10.1097/01.bsd.0000154452.13579.b2; Melzack, 2005, TXB PAIN; Melzack R, 2001, J Dent Educ, V65, P1378; Melzack R, 1999, PAIN, pS121, DOI 10.1016/S0304-3959(99)00145-1; Merskey H, 1994, CLASSIFICATION CHRON; Moseley GL, 2007, PHYS THER REV, V12, P169, DOI 10.1179/108331907X223010; Moseley GL, 2007, PAIN, V133, P64, DOI 10.1016/j.pain.2007.03.002; Moseley G Lorimer, 2002, Spine (Phila Pa 1976), V27, pE29, DOI 10.1097/00007632-200201150-00013; Moseley GL, 2005, AUST J PHYSIOTHER, V51, P49; Moseley GL, 2004, CLIN J PAIN, V20, P324, DOI 10.1097/00002508-200409000-00007; Moseley GL, 2004, EUR J PAIN, V8, P39, DOI 10.1016/S1090-3801(03)00063-6; Moseley GL, 2003, AUST J PHYSIOTHER, V49, P263, DOI 10.1016/S0004-9514(14)60142-2; Moseley GL, 2003, MANUAL THER, V8, P130, DOI 10.1016/S1356-689X(03)00051-1; Moseley GL, 2004, BRAIN, V127, P2339, DOI 10.1093/brain/awh248; Moseley GL., 2003, J MAN MANIP THERAP, V11, P88, DOI [DOI 10.1179/106698103790826383, 10.1179/106698103790826383]; Moseley L, 2002, AUST J PHYSIOTHER, V48, P297, DOI 10.1016/S0004-9514(14)60169-0; Nadler SF, 2002, ARCH PHYS MED REHAB, V83, P1753, DOI 10.1053/apmr.2002.35659; Nadler SF, 2002, MED SCI SPORT EXER, V34, P9, DOI 10.1097/00005768-200201000-00003; Nadler SF, 2002, CLIN J SPORT MED, V12, P73, DOI 10.1097/00042752-200203000-00002; Ness R. M., 2000, ENCY STRESS; Nielsen JB, 2008, J PHYSIOL-LONDON, V586, P65, DOI 10.1113/jphysiol.2007.142661; Nijs J, 2011, MANUAL THER, V16, P413, DOI 10.1016/j.math.2011.04.005; Nijs J, 2010, MANUAL THER, V15, P135, DOI 10.1016/j.math.2009.12.001; Oliveira A, 2006, SPINE, V31, P1652, DOI 10.1097/01.brs.0000224172.45828.e3; Ong A, 2003, BRIT J SPORT MED, V37, P263, DOI 10.1136/bjsm.37.3.263; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Puentedura EJ, 2010, J ORTHOP SPORT PHYS, V40, P214, DOI 10.2519/jospt.2010.3115; Raney NH, 2007, J ORTHOP SPORT PHYS, V37, P472, DOI 10.2519/jospt.2007.2523; Richardson C A, 1995, Man Ther, V1, P2, DOI 10.1054/math.1995.0243; Richardson CA, 2002, SPINE, V27, P399, DOI 10.1097/00007632-200202150-00015; Richardson CA, 2004, THERAPEUTIC EXERCISE; Segal TY, 2005, J PEDIATR ENDOCR MET, V18, P295; Simotas AC, 2005, ARCH PHYS MED REHAB, V86, P693, DOI 10.1016/j.apmr.2004.11.003; Standaert Christopher J, 2004, Curr Sports Med Rep, V3, P35; Sterling M, 2001, J PAIN, V2, P135, DOI 10.1054/jpai.2001.19951; Takemitsu M, 2006, SPINE, V31, P909, DOI 10.1097/01.brs.0000209308.19642.96; Tanskanen MM, 2011, J STRENGTH COND RES, V25, P787, DOI 10.1519/JSC.0b013e3181c1fa5d; Trainor TJ, 2002, CLIN SPORT MED, V21, P93, DOI 10.1016/S0278-5919(03)00059-0; Van Houdenhove B, 2009, MED HYPOTHESES, V72, P701, DOI 10.1016/j.mehy.2008.11.044; Vernon-Roberts B, 2007, SPINE, V32, P2797, DOI 10.1097/BRS.0b013e31815b64d2; Vukelic S, 2011, J BIOL CHEM, V286, P10265, DOI 10.1074/jbc.M110.188268; Waddell G., 2004, BACK PAIN REVOLUTION; Walsh J, 2009, MANUAL THER, V14, P623, DOI 10.1016/j.math.2008.12.007; Walsh J, 2009, J MANIP PHYSIOL THER, V32, P184, DOI 10.1016/j.jmpt.2009.02.006; Waris E, 2007, SPINE, V32, P681, DOI 10.1097/01.brs.0000257523.38337.96; Watkins LR, 2003, PROG PAIN RES MANAG, V24, P369; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Weiner BK, 2008, SPINE, V33, P219, DOI 10.1097/BRS.0b013e3181604572; Wong RA, 2007, PHYS THER, V87, P986, DOI 10.2522/ptj.20050392; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; WOOLF CJ, 1994, TXB PAIN; WOOLF CJ, 2005, WALL MELZACKS TXB PA, P91; Woolf CJ, 2007, ANESTHESIOLOGY, V106, P864, DOI 10.1097/01.anes.0000264769.87038.55; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1; Zhong X, 2005, J APPL PHYSIOL, V98, P2024, DOI 10.1152/japplphysiol.00620.2004	128	35	36	2	41	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1466-853X			PHYS THER SPORT	Phys. Ther. Sport	AUG	2012	13	3					123	133		10.1016/j.ptsp.2011.12.001			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	991EB	WOS:000307683200002	22814445				2022-02-06	
J	Masino, SA; Kawamura, M; Ruskin, DN; Geiger, JD; Boison, D				Masino, S. A.; Kawamura, M., Jr.; Ruskin, D. N.; Geiger, J. D.; Boison, D.			Purines and neuronal excitability: Links to the ketogenic diet	EPILEPSY RESEARCH			English	Article						Adenosine; ATP; Epilepsy; Hemichannel; Hippocampus; Long-term potentiation; Metabolism; Seizure; Transgenic mouse	LONG-TERM POTENTIATION; POLYUNSATURATED FATTY-ACIDS; ADENOSINE KINASE INHIBITOR; CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN-INJURY; ANTIINFLAMMATORY PROPERTIES; HIPPOCAMPAL SLICES; MICE; ATP; CHILDREN	ATP and adenosine are purines that play dual roles in cell metabolism and neuronal signaling. Acting at the A(1) receptor (A(1)R) subtype, adenosine acts directly on neurons to inhibit excitability and is a powerful endogenous neuroprotective and anticonvulsant molecule. Previous research showed an increase in ATP and other cell energy parameters when an animal is administered a ketogenic diet, an established metabolic therapy to reduce epileptic seizures, but the relationship among purines, neuronal excitability and the ketogenic diet was unclear. Recent work in vivo and in vitro tested the specific hypothesis that adenosine acting at A(1)Rs is a key mechanism underlying the success of ketogenic diet therapy and yielded direct evidence linking A(1)Rs to the antiepileptic effects of a ketogenic diet. Specifically, an in vitro mimic of a ketogenic diet revealed an A(1)R-dependent metabolic autocrine hyperpolarization of hippocampal neurons. In parallel, applying the ketogenic diet in vivo to transgenic mouse models with spontaneous electrographic seizures revealed that intact A(1)Rs are necessary for the seizure-suppressing effects of the diet. This is the first direct in vivo evidence linking A(1)Rs to the antiepileptic effects of a ketogenic diet. Other predictions of the relationship between purines and the ketogenic diet are discussed. Taken together, recent research on the role of purines may offer new opportunities for metabolic therapy and insight into its underlying mechanisms. (c) 2011 Elsevier B.V. All rights reserved.	[Masino, S. A.; Ruskin, D. N.] Trinity Coll, Neurosci Program, Hartford, CT 06106 USA; [Masino, S. A.; Ruskin, D. N.] Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; [Kawamura, M., Jr.] Jikei Univ, Sch Med, Dept Pharmacol, Tokyo, Japan; [Geiger, J. D.] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58203 USA; [Boison, D.] Legacy Res Inst, Robert Stone Dow Neurobiol Labs, Portland, OR 97232 USA		Masino, SA (corresponding author), Trinity Coll, Neurosci Program, Hartford, CT 06106 USA.	susan.masino@trincoll.edu	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781	National Institutes of Health NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065957, R15NS066392, R15 065446, 2P20RR017699]; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); CHDI; National Science FoundationNational Science Foundation (NSF) [IOS-0843585]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR017699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065957, R15NS066392, R15NS065446, R15NS061290] Funding Source: NIH RePORTER	We acknowledge the support of National Institutes of Health NINDS R01NS065957, R15NS066392, R15 065446 and 2P20RR017699 from the NCRR (a component of the NIH), CHDI, and National Science Foundation IOS-0843585.	AKIMITSU T, 1995, AM J PHYSIOL-HEART C, V269, pH1743, DOI 10.1152/ajpheart.1995.269.5.H1743; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; ARAI A, 1990, NEUROSCI LETT, V119, P41, DOI 10.1016/0304-3940(90)90750-4; BELFRAGE M, 1995, ANESTH ANALG, V81, P713, DOI 10.1097/00000539-199510000-00010; Boison D, 2011, EXPERT OPIN DRUG DIS, V6, P713, DOI 10.1517/17460441.2011.575777; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Cheng BH, 2009, BRAIN RES, V1286, P25, DOI 10.1016/j.brainres.2009.06.060; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DEVIVO DC, 1978, ANN NEUROL, V3, P331, DOI 10.1002/ana.410030410; DOLPHIN AC, 1983, NEUROSCI LETT, V39, P83, DOI 10.1016/0304-3940(83)90169-6; Dulla CG, 2005, NEURON, V48, P1011, DOI 10.1016/j.neuron.2005.11.009; Dulla CG, 2009, J NEUROPHYSIOL, V102, P1984, DOI 10.1152/jn.90695.2008; EVANS MC, 1987, NEUROSCI LETT, V83, P287, DOI 10.1016/0304-3940(87)90101-7; Fenoglio-Simeone KA, 2009, EPILEPSIA, V50, P2027, DOI 10.1111/j.1528-1167.2009.02163.x; Freeman JM, 2007, PEDIATRICS, V119, P535, DOI 10.1542/peds.2006-2447; Fuxe K, 2007, PHYSIOL BEHAV, V92, P210, DOI 10.1016/j.physbeh.2007.05.034; Gabriel A, 1998, NEUROSCIENCE, V86, P67, DOI 10.1016/S0306-4522(98)00011-6; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; GOLDBERG MP, 1988, NEUROSCI LETT, V89, P323, DOI 10.1016/0304-3940(88)90547-2; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Gomes CV, 2011, BBA-BIOMEMBRANES, V1808, P1380, DOI 10.1016/j.bbamem.2010.12.001; Gourine AV, 2005, NATURE, V436, P108, DOI 10.1038/nature03690; Greene AE, 2001, EPILEPSIA, V42, P1371, DOI 10.1046/j.1528-1157.2001.17601.x; HAAS HL, 1984, PFLUG ARCH EUR J PHY, V402, P244, DOI 10.1007/BF00585506; Hallbook T, 2007, EPILEPSIA, V48, P59, DOI 10.1111/j.1528-1167.2006.00834.x; Hemingway C, 2001, PEDIATRICS, V108, P898, DOI 10.1542/peds.108.4.898; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Huang ZL, 2007, CURR OPIN PHARMACOL, V7, P33, DOI 10.1016/j.coph.2006.09.004; HUTTENLOCHER PR, 1976, PEDIATR RES, V10, P536, DOI 10.1203/00006450-197605000-00006; Jarvis MF, 2000, J PHARMACOL EXP THER, V295, P1156; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002; KARLSTEN R, 1992, Pharmacology and Toxicology, V70, P434; Kawamura M, 2010, J NEUROSCI, V30, P3886, DOI 10.1523/JNEUROSCI.0055-10.2010; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Koranda JL, 2011, J NEUROPHYSIOL, V106, P662, DOI 10.1152/jn.00001.2011; Kossoff EH, 2009, J CHILD NEUROL, V24, P979, DOI 10.1177/0883073809337162; Kukley M, 2005, J NEUROSCI, V25, P2832, DOI 10.1523/JNEUROSCI.4260-04.2005; Lara DR, 2010, J ALZHEIMERS DIS, V20, pS239, DOI 10.3233/JAD-2010-1378; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Li TF, 2007, NEURON GLIA BIOL, V3, P353, DOI 10.1017/S1740925X0800015X; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2008, NEURON GLIA BIOL, V4, P91, DOI 10.1017/S1740925X09990135; Ma WY, 2007, J NEUROSCI, V27, P3618, DOI 10.1523/JNEUROSCI.0132-07.2007; Mantis John G, 2004, Nutr Metab (Lond), V1, P11, DOI 10.1186/1743-7075-1-11; Masino SA, 2009, CURR NEUROPHARMACOL, V7, P257, DOI 10.2174/157015909789152164; Masino SA, 1999, J NEUROSCI, V19, P1932; Masino SA, 2008, TRENDS NEUROSCI, V31, P273, DOI 10.1016/j.tins.2008.02.009; Masino SA, 2011, J CLIN INVEST, V121, P2679, DOI 10.1172/JCI57813; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; MITCHELL JB, 1993, HIPPOCAMPUS, V3, P77, DOI 10.1002/hipo.450030108; Moore KA, 2003, P NATL ACAD SCI USA, V100, P14397, DOI 10.1073/pnas.1835831100; Muzykewicz DA, 2009, EPILEPSIA, V50, P1118, DOI 10.1111/j.1528-1167.2008.01959.x; NAKAZAWA M, 1983, BRAIN DEV-JPN, V5, P375, DOI 10.1016/S0387-7604(83)80042-4; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Newby A C, 1985, Adv Myocardiol, V6, P273; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; Nylen K, 2009, BBA-GEN SUBJECTS, V1790, P208, DOI 10.1016/j.bbagen.2008.12.005; ORO J, 1961, ARCH BIOCHEM BIOPHYS, V94, P217, DOI 10.1016/0003-9861(61)90033-9; Pan JW, 1999, EPILEPSIA, V40, P703, DOI 10.1111/j.1528-1157.1999.tb00766.x; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Panico LR, 2000, REV NEUROLOGIA, V30, P8, DOI 10.33588/rn.3001.99521; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Pignataro G, 2007, J CEREBR BLOOD F MET, V27, P1, DOI 10.1038/sj.jcbfm.9600334; Poon A, 1999, EUR J PHARMACOL, V384, P123, DOI 10.1016/S0014-2999(99)00626-3; Porkka-Heiskanen T, 1999, ANN MED, V31, P125, DOI 10.3109/07853899908998788; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Rho JM, 2010, EPILEPSY CURR, V10, P159, DOI 10.1111/j.1535-7511.2010.01387.x; RIBEIRO JA, 1979, BIOCHEM PHARMACOL, V28, P1297, DOI 10.1016/0006-2952(79)90428-3; Ribeiro JA, 2010, J ALZHEIMERS DIS, V20, pS3, DOI 10.3233/JAD-2010-1379; Ruskin D.N., 2010, SOC NEUROSCI, V375, P4; Ruskin DN, 2011, PHYSIOL BEHAV, V103, P501, DOI 10.1016/j.physbeh.2011.04.001; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Samoilova M, 2010, J NEUROCHEM, V113, P826, DOI 10.1111/j.1471-4159.2010.06645.x; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Schmidt AP, 2009, BRIT J PHARMACOL, V156, P163, DOI 10.1111/j.1476-5381.2008.00025.x; Sitkovsky MV, 2005, TRENDS IMMUNOL, V26, P299, DOI 10.1016/j.it.2005.04.004; Sorkin LS, 2003, EXP NEUROL, V184, P162, DOI 10.1016/S0014-4886(03)00102-X; Studer FE, 2006, NEUROSCIENCE, V142, P125, DOI 10.1016/j.neuroscience.2006.06.016; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Tai KK, 2008, J NEURAL TRANSM, V115, P1011, DOI 10.1007/s00702-008-0050-7; Tekkok S, 1999, J NEUROPHYSIOL, V81, P174, DOI 10.1152/jn.1999.81.1.174; Tendler D, 2007, DIGEST DIS SCI, V52, P589, DOI 10.1007/s10620-006-9433-5; Thio LL, 2010, EPILEPSIA, V51, P1619, DOI 10.1111/j.1528-1167.2009.02515.x; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Van der Auwera Ingrid, 2005, Nutr Metab (Lond), V2, P28, DOI 10.1186/1743-7075-2-28; Vanotti A, 2007, CNS DRUGS, V21, P3, DOI 10.2165/00023210-200721001-00002; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Wilder RM., 1921, MAYO CLIN B, V2, P307; Xu XP, 2008, EPILEPSY RES, V80, P57, DOI 10.1016/j.eplepsyres.2008.03.013; Yamada KA, 2005, NEUROSCI LETT, V385, P210, DOI 10.1016/j.neulet.2005.05.038; Yang XX, 2010, J MOL NEUROSCI, V42, P145, DOI 10.1007/s12031-010-9336-y; YARBROUGH GG, 1981, EUR J PHARMACOL, V76, P137, DOI 10.1016/0014-2999(81)90495-7; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	97	35	36	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUL	2012	100	3			SI		229	238		10.1016/j.eplepsyres.2011.07.014			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	988ZQ	WOS:000307530400006	21880467	Green Accepted			2022-02-06	
J	Olsen, AS; Sozda, CN; Cheng, JP; Hoffman, AN; Kline, AE				Olsen, Adam S.; Sozda, Christopher N.; Cheng, Jeffrey P.; Hoffman, Ann N.; Kline, Anthony E.			Traumatic Brain Injury-Induced Cognitive and Histological Deficits Are Attenuated by Delayed and Chronic Treatment with the 5-HT1A-Receptor Agonist Buspirone	JOURNAL OF NEUROTRAUMA			English	Article						behavioral outcome; controlled cortical impact; functional recovery; 5-HT1A-receptor agonist; hippocampus; learning and memory; Morris water maze; traumatic brain injury	5-HT1A RECEPTOR AGONIST; BAY X 3702; NEUROBEHAVIORAL BENEFIT; BEHAVIORAL RECOVERY; TREATMENT REGIMEN; UNITED-STATES; HALOPERIDOL; HIPPOCAMPAL; PERFORMANCE; 8-OH-DPAT	The aim of this study was to evaluate the potential efficacy of the serotonin(1A) (5-HT1A) receptor agonist bus-pirone (BUS) on behavioral and histological outcome after traumatic brain injury (TBI). Ninety-six isoflurane-anesthetized adult male rats were randomized to receive either a controlled cortical impact or sham injury, and then assigned to six TBI and six sham groups receiving one of five doses of BUS (0.01, 0.05, 0.1, 0.3, or 0.5 mg/kg) or saline vehicle (VEH, 1.0 mL/kg). Treatments began 24 h after surgery and were administered intraperitoneally once daily for 3 weeks. Motor function (beam-balance/beam-walk tests) and spatial learning/memory (Morris water maze) were assessed on post-operative days 1-5 and 14-19, respectively. Morphologically intact CA1/CA3 cells and cortical lesion volume were quantified at 3 weeks. No differences were observed among the BUS and VEH sham groups in any end-point measure and thus the data were pooled. Regarding the TBI groups, repeated-measures ANOVAs revealed that the 0.3 mg/kg dose of BUS enhanced cognitive performance relative to VEH and the other BUS doses (p < 0.05), but did not significantly impact motor function. Moreover, the same dose conferred selective histological protection as evidenced by smaller cortical lesions, but not greater CA1/CA3 cell survival. No significant behavioral or histological differences were observed among the other BUS doses versus VEH. These data indicate that BUS has a narrow therapeutic dose response, and that 0.3 mg/kg is optimal for enhancing spatial learning and memory in this model of TBI. BUS may have potential as a novel pharmacotherapy for clinical TBI.	[Olsen, Adam S.; Sozda, Christopher N.; Cheng, Jeffrey P.; Hoffman, Ann N.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207; Olsen, Adam/0000-0003-0957-9867	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700, R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health grants HD043851, HD046700, and NS060005 (to A.E.K.).	Albert PR, 2004, NEUROSCIENTIST, V10, P575, DOI 10.1177/1073858404267382; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Banos JH, 2010, J HEAD TRAUMA REHAB, V25, P357, DOI 10.1097/HTR.0b013e3181d6c715; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; COOP CF, 1991, NEUROSCIENCE, V40, P169, DOI 10.1016/0306-4522(91)90182-N; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Faul M, 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Koen Nastassja, 2011, Dialogues Clin Neurosci, V13, P423; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; KREISS DS, 1992, NEUROPHARMACOLOGY, V31, P1073, DOI 10.1016/0028-3908(92)90110-B; Luttgen M, 2005, NEUROPHARMACOLOGY, V48, P830, DOI 10.1016/j.neuropharm.2005.01.007; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCMILLEN BA, 1983, J NEUROSCI, V3, P733; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 2007, BEHAV BRAIN RES, V184, P81, DOI 10.1016/j.bbr.2007.06.026; Meneses A, 2007, NEUROSCI BIOBEHAV R, V31, P705, DOI 10.1016/j.neubiorev.2007.02.001; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009	63	35	38	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1898	1907		10.1089/neu.2012.2358			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400394	22416854	Green Published			2022-02-06	
J	Weaver, LK; Cifu, D; Hart, B; Wolf, G; Miller, RS				Weaver, Lindell K.; Cifu, David; Hart, Brett; Wolf, George; Miller, R. Scott			Hyperbaric oxygen for post-concussion syndrome: Design of Department of Defense clinical trials	UNDERSEA AND HYPERBARIC MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY	The current wars in the Middle East have resulted in between 10-20% of U.S. service members with mild traumatic brain injury (mTBI). While anecdotal reports have associated hyperbaric oxygen (HBO2) with improved outcomes after mTBI, controlled research is lacking. The Department of Defense (DoD), in collaboration with the Department of Veterans Affairs (DVA), has a comprehensive program examining this issue. The DoD's four randomized controlled trials will enroll a total of 242 service members with post-concussion syndrome and expose them to a range of control, sham and HBO2 conditions for 40 sessions over a period of eight to 11 weeks. Compression pressures will range from 1.2 atm abs (sham) to 2.4 atm abs, and oxygen concentration will range from room air (sham and control) to 100%. Outcomes measures include both subjective and objective measures performed at baseline, at exposure completion, and at three to 12 months' follow-up. This integrated program of clinical trials investigating the efficacy of HBO2 in service members with persistent symptoms following mTBI exposure will be important to define practice guidelines and, if needed, for the development of definitive clinical trials in this population.	[Weaver, Lindell K.] Intermt LDS Hosp, Salt Lake City, UT USA; [Weaver, Lindell K.] Intermt Med Ctr, Murray, UT USA; [Weaver, Lindell K.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Cifu, David] Stat 4PM& R Program Off, Dept Vet Affairs, Washington, DC USA; [Cifu, David] Virginia Commonwealth Univ, Dept PM & R, Richmond, VA USA; [Hart, Brett] Naval Operat Med Inst NOMI, Detachment Naval Aerosp Med Inst NAMI, Pensacola, FL USA; [Wolf, George] USAF, Sch Aerosp Med, Hyperbar Med Dept, Lackland AFB, TX USA; [Miller, R. Scott] US Army Med Mat Dev Act USAMMDA, Ft Detrick, MD USA		Weaver, LK (corresponding author), Intermt LDS Hosp, Salt Lake City, UT USA.	lindell.weaver@imail.org		Cifu, David/0000-0003-1600-9387	Intermountain Healthcare [W911QY-11-C-0062]; U.S. Army Medical Material Development Command/U.S. Army Medical Research and Material Command (USAMMDA/USAMRMC) [W911QY-11-C-0062]; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-09-2-206]	Dr. Weaver's efforts were supported, in part, through a contact between Intermountain Healthcare and the U.S. Army Medical Material Development Command/U.S. Army Medical Research and Material Command (USAMMDA/USAMRMC) (W911QY-11-C-0062).; Dr. Cifu's efforts were supported, in part, through a Defense Advanced Research Projects Agency grant (N66001-09-2-206).	American Psychiatric Association, 2000, DIAGN STAT MAN METN; [Anonymous], 2008, US NAV DIV MAN REV 6; Centers for Medicare and Medicaid Services, 2006, CTR MED MED SERV PUB, V100-3; Cifu DX, 2011, OVERCOMING POST DEPL; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Day SJ, 2000, BRIT MED J, V321, P504, DOI 10.1136/bmj.321.7259.504; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Gesell L.B., 2008, HYPERBARIC OXYGEN TH; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harch PG, 2002, P 2 INT S HYP OX CER; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jansen T, 2009, UNDERSEA HYPERBAR M, V36, P347; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McDonagh MS, 2003, AHRQ PUBLICATION, P59; Neubauer RA, 1992, UNDERSEA BIOMED RES, V19, P66; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Undersea and Hyperbaric Medical Society, 2003, HYP OX THER CHRON BR; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Weaver LK, 2011, UNDERSEA HYPERBAR M, V38, P462; Weaver LK, 1997, UNDERSEA HYPERB ME S, V24, P36; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391	25	35	37	0	6	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	JUL-AUG	2012	39	4					807	814					8	Marine & Freshwater Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Marine & Freshwater Biology; Research & Experimental Medicine	250BP	WOS:000326825400005	22908837				2022-02-06	
J	Frassanito, P; Massimi, L; Caldarelli, M; Tamburrini, G; Di Rocco, C				Frassanito, Paolo; Massimi, Luca; Caldarelli, Massimo; Tamburrini, Gianpiero; Di Rocco, Concezio			Complications of delayed cranial repair after decompressive craniectomy in children less than 1 year old	ACTA NEUROCHIRURGICA			English	Article						Paediatric head injury; Infants; Postoperative subdural effusion; Enlarging duraplasty; Autologous cranial bone replacement	DURA-MATER; SUBDURAL COLLECTIONS; CEREBROSPINAL-FLUID; BONE-GRAFTS; CRANIOPLASTY; BRAIN; ADOLESCENTS; HEMATOMA; IMMATURE; HYGROMA	Decompressive craniectomy is an effective treatment option in case of refractory intracranial hypertension after severe head injury. The incidence of complications following cranial repair after decompressive craniectomy for traumatic brain injury is not negligible, particularly in infants and young toddlers. However, only a few dedicated papers can be found in the literature. We describe the complications observed in two boys and one girl under 1 year of age that were treated in the last decade by hemicranial decompressive craniotomy and enlarging hemispheric duraplasty, and subsequent cranial repair by means of autologous bone-flap replacement. Despite good clinical and neurological outcome, the postoperative clinical course was complicated in all cases by early or late evidence of subdural fluid collections associated to the occurrence of hydrocephalus and causing recurrent dislocation and progressive resorption of the autologous bone flap. Infants less than 1 year old, undergoing decompressive craniectomy after traumatic brain injury, experience a high rate of complications following subsequent cranial repair. Subdural collections and resorption of the autologous bone flap are to be considered as extremely common complications.	[Frassanito, Paolo] Catholic Med Sch, Pediat Neurosurg Unit, I-00168 Rome, Italy; [Frassanito, Paolo; Massimi, Luca; Caldarelli, Massimo; Tamburrini, Gianpiero; Di Rocco, Concezio] Catholic Med Sch, Policlin A Gemelli, I-00168 Rome, Italy		Frassanito, P (corresponding author), Catholic Med Sch, Pediat Neurosurg Unit, Largo Agostino Gemelli 8, I-00168 Rome, Italy.	paolo.frassanito@gmail.com	FRASSANITO, Paolo/K-4099-2018	FRASSANITO, Paolo/0000-0003-0071-3126			Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Di Rocco C, 2000, PEDIATR NEUROSURG, V33, P198, DOI 10.1159/000055953; Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6; Fox RJ, 1996, NEUROSURGERY, V39, P84, DOI 10.1097/00006123-199607000-00017; FRIEDE RL, 1978, AM J PATHOL, V92, P69; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Greenwald JA, 2000, PLAST RECONSTR SURG, V105, P1382, DOI 10.1097/00006534-200004040-00018; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hannah JA, 1936, J NERV MENT DIS, V84, P169, DOI 10.1097/00005053-193608000-00005; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jannathan J, 2007, J NEUROSURG S, V106, P268; Kristof RA, 2008, J NEUROSURG, V108, P275, DOI 10.3171/JNS/2008/108/2/0275; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; MARKOWITZ S, 1987, J NEUROSCI, V7, P4129, DOI 10.1523/jneurosci.07-12-04129.1987; Miranda P, 2004, NEUROCIRUGIA, V15, P67; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; POSNICK JC, 1993, NEUROSURGERY, V32, P785, DOI 10.1227/00006123-199305000-00011; PROLO DJ, 1991, CLIN ORTHOP RELAT R, P270; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Valenca MM, 2010, J NEUROSURG, V113, P982, DOI 10.3171/2009.11.JNS09674; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512	26	35	35	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAY	2012	154	5					927	933		10.1007/s00701-011-1253-5			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	934PG	WOS:000303455800023	22198327				2022-02-06	
J	Jones, TA; Liput, DJ; Maresh, EL; Donlan, N; Parikh, TJ; Marlowe, D; Kozlowski, DA				Jones, Theresa A.; Liput, Daniel J.; Maresh, Erin L.; Donlan, Nicole; Parikh, Toral J.; Marlowe, Dana; Kozlowski, Dorothy A.			Use-Dependent Dendritic Regrowth Is Limited after Unilateral Controlled Cortical Impact to the Forelimb Sensorimotor Cortex	JOURNAL OF NEUROTRAUMA			English	Article						dendritic arborization; forelimb deficits; forelimb sensorimotor cortex; synaptic density; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NOGO-A EXPRESSION; LESS-AFFECTED FORELIMB; MOTOR CORTEX; NEURAL PLASTICITY; SYNAPTIC PROTEINS; PYRAMIDAL NEURONS; OXIDATIVE STRESS; ISCHEMIC-STROKE; ADULT-RATS	Compensatory neural plasticity occurs in both hemispheres following unilateral cortical damage incurred by seizures, stroke, and focal lesions. Plasticity is thought to play a role in recovery of function, and is important for the utility of rehabilitation strategies. Such effects have not been well described in models of traumatic brain injury (TBI). We examined changes in immunoreactivity for neural structural and plasticity-relevant proteins in the area surrounding a controlled cortical impact (CCI) to the forelimb sensorimotor cortex (FL-SMC), and in the contralateral homotopic cortex over time (3-28 days). CCI resulted in considerable motor deficits in the forelimb contralateral to injury, and increased reliance on the ipsilateral forelimb. The density of dendritic processes, visualized with immunostaining for microtubule-associated protein-2 (MAP-2), were bilaterally decreased at all time points. Synaptophysin (SYN) immunoreactivity increased transiently in the injured hemisphere, but this reflected an atypical labeling pattern, and it was unchanged in the contralateral hemisphere compared to uninjured controls. The lack of compensatory neuronal structural plasticity in the contralateral homotopic cortex, despite behavioral asymmetries, is in contrast to previous findings in stroke models. In the cortex surrounding the injury (but not the contralateral cortex), decreases in dendrites were accompanied by neurodegeneration, as indicated by Fluoro-Jade B (FJB) staining, and increased expression of the growth-inhibitory protein Nogo-A. These studies indicate that, following unilateral CCI, the cortex undergoes neuronal structural degradation in both hemispheres out to 28 days post-injury, which may be indicative of compromised compensatory plasticity. This is likely to be an important consideration in designing therapeutic strategies aimed at enhancing plasticity following TBI.	[Liput, Daniel J.; Marlowe, Dana; Kozlowski, Dorothy A.] De Paul Univ, Dept Biol Sci, Chicago, IL 60614 USA; [Jones, Theresa A.; Maresh, Erin L.; Donlan, Nicole; Parikh, Toral J.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Jones, Theresa A.; Maresh, Erin L.; Donlan, Nicole; Parikh, Toral J.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA		Kozlowski, DA (corresponding author), De Paul Univ, Dept Biol Sci, 2325 N Clifton, Chicago, IL 60614 USA.	dkozlows@depaul.edu	Jones, Theresa A/F-1182-2010	Jones, Theresa A/0000-0003-0906-6439; Liput, Daniel/0000-0002-8418-3494	DePaul University Research Council; College of Liberal Arts and Sciences; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056839] Funding Source: NIH RePORTER	Support for this work was provided by DePaul University Research Council and College of Liberal Arts and Sciences Undergraduate Grants to D. A. K. We thank Dr. R. P. Allred for help with statistical analyses.	Adkins DL, 2006, EXP NEUROL, V200, P356, DOI 10.1016/j.expneurol.2006.02.131; Adkins DL, 2004, NEUROSCIENCE, V128, P473, DOI 10.1016/j.neuroscience.2004.07.019; Allred RP, 2008, FUTUR NEUROL, V3, P189, DOI 10.2217/14796708.3.2.189; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Brown CE, 2008, NEUROSCIENTIST, V14, P139, DOI 10.1177/1073858407309854; Campbell J.N., 2011, J NEUROTRAUMA; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Cheatwood JL, 2008, STROKE, V39, P2091, DOI 10.1161/STROKEAHA.107.507426; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chu CJ, 2000, EXP NEUROL, V166, P403, DOI 10.1006/exnr.2000.7509; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; Donoghue JP, 1986, SENSORY MOTOR AREAS, P243; Ferrer I, 2002, Cerebellum, V1, P213, DOI 10.1080/14734220260418448; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Funahashi S, 2008, J COMP NEUROL, V506, P141, DOI 10.1002/cne.21541; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hovda D.A., 1996, NEUROTRAUMA, P1459; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; Hsu JE, 2005, EUR J NEUROSCI, V22, P2069, DOI 10.1111/j.1460-9568.2005.04370.x; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Jones TA, 1999, J COMP NEUROL, V414, P57; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Jones TA, 1996, BRAIN RES, V733, P142, DOI 10.1016/S0006-8993(96)00792-5; Jones TA, 2009, STROKE, V40, pS136, DOI 10.1161/STROKEAHA.108.533653; Jortner BS, 1997, NEUROTOXICOLOGY, V18, P161; Josephson A, 2001, EXP NEUROL, V169, P319, DOI 10.1006/exnr.2001.7659; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lehr RP, 2010, TRAUMATIC BRAIN INJURY: REHABILITATION, TREATMENT, AND CASE MANAGEMENT, 3RD EDITION, P455; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Liu HP, 2002, NEUROSCI LETT, V328, P257, DOI 10.1016/S0304-3940(02)00528-1; Luke LM, 2004, SYNAPSE, V54, P187, DOI 10.1002/syn.20080; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Mir HM, 2004, BRAIN RES, V1002, P28, DOI 10.1016/j.brainres.2003.12.006; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; R Development Core Team, 2010, R LANG ENV STAT COMP; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; Schallert T., 1997, BRAIN PLASTICITY ADV, P73; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shin JW, 2006, NEUROSCI LETT, V394, P117, DOI 10.1016/j.neulet.2005.10.032; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Voorhies AC, 2002, BEHAV BRAIN RES, V133, P237, DOI 10.1016/S0166-4328(02)00029-3; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Zorner B, 2010, ANN NY ACAD SCI, V1198, pE22, DOI 10.1111/j.1749-6632.2010.05566.x; [No title captured]; [No title captured]; [No title captured]	73	35	35	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1455	1468		10.1089/neu.2011.2207			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600018	22352953	Green Published			2022-02-06	
J	Shiroma, EJ; Ferguson, PL; Pickelsimer, EE				Shiroma, Eric J.; Ferguson, Pamela L.; Pickelsimer, E. Elisabeth			Prevalence of Traumatic Brain Injury in an Offender Population: A Meta-Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; inmates; prevalence; head injury; correctional health care	HEAD-INJURY; SEXUAL OFFENSES; HISTORY; HOSPITALIZATION; DELINQUENTS; EPILEPSY; ABUSE; RISK; TBI	Traumatic brain injury (TBI) can create challenges to managing offenders and to their successful community reentry upon release. In this study, the researchers reviewed relevant articles in Pubmed, PsycInfo, Medline, and EmBase (1983 to 2009) and communicated with other researchers to identify 20 epidemiologic studies that met preestablished inclusion criteria. Random-effects meta-and subgroup analyses were conducted to calculate the prevalence of TBI and the effects of gender, offender type, and definition and method of identifying TBI. The estimated prevalence of TBI in the overall offender population was 60.25 (95% confidence interval: 48.08 to 72.41). A truer estimate of TBI prevalence in offending populations could lead to more appropriate resource allocation, screening, and management of offenders.	[Shiroma, Eric J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Shiroma, Eric J.; Ferguson, Pamela L.; Pickelsimer, E. Elisabeth] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA		Shiroma, EJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave,Kresge Bldg, Boston, MA 02115 USA.	eshiroma@hsph.harvard.edu	Shiroma, Eric/AAV-5487-2021	Shiroma, Eric/0000-0003-4920-2642			Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bax L, 2008, MIX COMPREHENSIVE FR; Bax Leon, 2006, BMC Med Res Methodol, V6, P50, DOI 10.1186/1471-2288-6-50; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Brain Injury Association of Wyoming, 2008, STUD UND BRAIN UNPUB; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; Bureau of Justice Statistics, 2008, 221944 NCJ US DEP JU; Carswell K, 2004, J ADOLESCENCE, V27, P415, DOI 10.1016/j.adolescence.2004.04.003; Corrigan JD, 2008, FINAL PROGRAMMATIC R; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; DelBello MP, 1999, PSYCHIAT RES, V89, P281, DOI 10.1016/S0165-1781(99)00112-2; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Finkelstein E., 2006, INCIDENCE EC BURDEN; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; GOODMAN LA, 1970, J AM STAT ASSOC, V65, P226, DOI 10.2307/2283589; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Langevin R, 2006, BRAIN COGNITION, V60, P206; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEWIS DO, 1987, J AM ACAD CHILD PSY, V26, P744, DOI 10.1097/00004583-198709000-00022; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Merbitz C., 1995, J OFFENDER REHABILIT, V22, P11, DOI DOI 10.1300/J076V22N03_02; Minnesota Department of Corrections, 2008, ANN C MINN BRAIN INJ; Miura H, 2005, PSYCHIAT CLIN NEUROS, V59, P661, DOI 10.1111/j.1440-1819.2005.01434.x; Morrell R.F., 1998, J OFFENDER REHABIL, V27, P1, DOI [DOI 10.1300/J076V27N03_01, https://doi.org/10.1300/J076v27n03_01]; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089	41	35	35	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					E1	E10		10.1097/HTR.0b013e3182571c14			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500001	22573043				2022-02-06	
J	Turner, EL; Perel, P; Clayton, T; Edwards, P; Hernandez, AV; Roberts, I; Shakur, H; Steyerberg, EW				Turner, Elizabeth L.; Perel, Pablo; Clayton, Tim; Edwards, Phil; Hernandez, Adrian V.; Roberts, Ian; Shakur, Haleema; Steyerberg, Ewout W.		CRASH Trial Collaborators	Covariate adjustment increased power in randomized controlled trials: an example in traumatic brain injury	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Covariate adjustment; Prognostic targeting; Strict selection; Relative sample size; Power in clinical trials; Traumatic brain injury	CLINICAL-TRIALS; STATISTICAL POWER; NEUROPROTECTIVE AGENTS; HEAD-INJURY; SIZE	Objective: We aimed to determine to what extent covariate adjustment could affect power in a randomized controlled trial (RCT) of a heterogeneous population with traumatic brain injury (TBI). Study Design and Setting: We analyzed 14-day mortality in 9,497 participants in the Corticosteroid Randomization After Significant Head Injury (CRASH) RCT of corticosteroid vs. placebo. Adjustment was made using logistic regression for baseline covariates of two validated risk models derived from external data (International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury [IMPACT]) and from the CRASH data. The relative sample size (RESS) measure, defined as the ratio of the sample size required by an adjusted analysis to attain the same power as the unadjusted reference analysis, was used to assess the impact of adjustment. Results: Corticosteroid was associated with higher mortality compared with placebo (odds ratio = 1.25, 95% confidence interval = 1.13-1.39). RESS of 0.79 and 0.73 were obtained by adjustment using the IMPACT and CRASH models, respectively, which, for example, implies an increase from 80% to 88% and 91% power, respectively. Conclusion: Moderate gains in power may be obtained using covariate adjustment from logistic regression in heterogeneous conditions such as TBI. Although analyses of RCTs might consider covariate adjustment to improve power, we caution against this approach in the planning of RCTs. (c) 2012 Elsevier Inc. All rights reserved.	[Turner, Elizabeth L.; Perel, Pablo; Clayton, Tim; Edwards, Phil; Roberts, Ian; Shakur, Haleema] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; [Hernandez, Adrian V.] Cleveland Clin, Lerner Res Inst, Dept Quantitat Hlth Sci, Hlth Outcomes & Clin Epidemiol Sect, Cleveland, OH 44195 USA; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands		Turner, EL (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	elizabeth.tumer@lshtm.ac.uk	Steyerberg, Ewout W/C-1509-2018; Hernandez, Adrian V./ABD-4616-2021; Gallardo, Angel Jesus Lacerda/AAZ-9478-2020	Steyerberg, Ewout W/0000-0002-7787-0122; Hernandez, Adrian V./0000-0002-9999-4003; Gallardo, Angel Jesus Lacerda/0000-0001-9171-2000; Clayton, Tim/0000-0002-1266-3288; Edwards, Phil/0000-0003-4431-8822; /0000-0002-2342-301X; Shakur-Still, Haleema/0000-0002-6511-109X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-42691]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	The authors wish to thank all CRASH collaborators for their involvement in the trial. Professor Chris Frost provided many helpful comments and advice on an earlier manuscript and the methods. Two reviewers provided helpful comments and references, which greatly improved the final version. Financial support (E.W.S.) was provided by National Institute of Health (NS-42691).	Aberegg Scott K, 2010, Crit Care, V14, pR77, DOI 10.1186/cc8990; Altman DG, 2001, BIOSTATISTICS CLIN T, P122; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P142, DOI 10.1016/j.jclinepi.2009.06.002; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Davison A. C., 2006, CAMBRIDGE SERIES STA; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Ford I, 2002, STAT MED, V21, P2899, DOI 10.1002/sim.1294; GAIL MH, 1984, BIOMETRIKA, V71, P431; Groenwold RHH, 2011, CONTEMP CLIN TRIALS, V32, P399, DOI 10.1016/j.cct.2010.12.011; Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358; Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 2007, J NEUROTRAUM, V24, P232; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pocock S, 1984, CLIN TRIALS PRACTICA; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Roozenbeek B, 2010, CRIT CARE, V14, DOI 10.1186/cc9021; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Steyerberg ETW, 2004, MED DECIS MAKING, V24, P102, DOI 10.1177/0272989X03262285; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Weir CJ, 2004, STROKE, V35, P2111, DOI 10.1161/01.STR.0000136556.34438.b3; Zhang PG, 2010, COMMUN STAT-SIMUL C, V39, P1305, DOI 10.1080/03610918.2010.491170	29	35	35	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	MAY	2012	65	5					474	481		10.1016/j.jclinepi.2011.08.012			8	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; Public, Environmental & Occupational Health	920ZJ	WOS:000302447500003	22169080	Green Accepted			2022-02-06	
J	Won, SJ; Choi, Y; Yoo, BH; Sohn, M; Ying, WH; Swanson, RA; Suh, SW				Won, Seok Joon; Choi, Young; Yoo, Byung Hoon; Sohn, Min; Ying, Weihai; Swanson, Raymond A.; Suh, Sang Won			Prevention of Traumatic Brain Injury-Induced Neuron Death by Intranasal Delivery of Nicotinamide Adenine Dinucleotide	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; intranasal; microglia; nicotinamide adenine dinucleotide; poly(ADP-ribose) polymerase-1; superoxide; traumatic brain injury	POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; TRANSIENT FOCAL ISCHEMIA; FLUID PERCUSSION INJURY; NAD(+) DEPLETION; MICROGLIAL ACTIVATION; CELL-DEATH; NEUTROPHIL ACCUMULATION; CEREBRAL-ISCHEMIA; GLOBAL-ISCHEMIA; NITRIC-OXIDE	Traumatic brain injury (TBI) is one of the most devastating injuries experienced by military personnel, as well as the general population, and can result in acute and chronic complications such as cognitive impairments. Since there are currently no effective tools for the treatment of TBI, it is of great importance to determine the mechanisms of neuronal death that characterize this insult. Several studies have indicated that TBI-induced neuronal death arises in part due to excessive activation of poly(ADP-ribose) polymerase-1 (PARP-1), which results in nicotinamide adenine dinucleotide (NAD(+)) depletion and subsequent energy failure. In this study, we investigated whether intranasal administration of NAD(+) could reduce neuronal death after TBI. Rats were subjected to a weight-drop TBI model that induces cortical and hippocampal neuronal death. The intranasal administration of NAD(+) (20 mg/kg) immediately after TBI protected neurons in CA1, CA3, and dentate gyrus of the hippocampus, but not in the cortex. In addition, delayed microglial activation normally seen after TBI was reduced by NAD(+) treatment at 7 days after insult. Neuronal superoxide production and PARP-1 accumulation after TBI were not inhibited by NAD+ treatment, indicating that reactive oxygen species (ROS) production and PARP-1 activation are events that occur upstream of NAD(+) depletion. This study suggests that intranasal delivery of NAD(+) represents a novel, inexpensive, and non-toxic intervention for preventing TBI-induced neuronal death.	[Choi, Young; Suh, Sang Won] Hallym Univ, Dept Physiol, Coll Med, Chunchon 200702, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Chunchon, South Korea; [Won, Seok Joon; Yoo, Byung Hoon; Swanson, Raymond A.; Suh, Sang Won] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Yoo, Byung Hoon] Inje Univ, Sch Med, Sanggye Paik Hosp, Dept Anesthesiol, Seoul, South Korea; [Ying, Weihai] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Neurol, Shanghai 200030, Peoples R China		Suh, SW (corresponding author), Hallym Univ, Dept Physiol, Coll Med, 1 Okcheon Dong, Chunchon 200702, South Korea.	swsuh@hallym.ac.kr		Swanson, Raymond/0000-0002-3664-5359; Choi, Bo Young/0000-0002-9579-3503; SOHN, MIN/0000-0003-4021-2051	U.S. Department of Veterans AffairsUS Department of Veterans Affairs; U.S. Department of DefenseUnited States Department of Defense [W81XWH-05-2-0094]; Hallym University [HRF-2010-033]; Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A100687]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421] Funding Source: NIH RePORTER	This work was supported by the U.S. Department of Veterans Affairs and by the U.S. Department of Defense under contract number W81XWH-05-2-0094, and by the Hallym University (HRF-2010-033), and the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100687).	Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Murakami K, 1998, BRAIN RES, V780, P304, DOI 10.1016/S0006-8993(97)01217-1; Plaschke K, 2000, NEUROSCI LETT, V284, P109, DOI 10.1016/S0304-3940(00)00988-5; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Sheline CT, 2003, EUR J NEUROSCI, V18, P1402, DOI 10.1046/j.1460-9568.2003.02865.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Singh P, 2003, NEUROL INDIA, V51, P215; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tsuchiyama R, 2009, NEUROL RES, V31, P179, DOI 10.1179/174313209X393609; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Yenari MA, 2006, NEUROCHEM INT, V49, P164, DOI 10.1016/j.neuint.2006.03.016; Ying WJ, 2007, FRONT BIOSCI-LANDMRK, V12, P2728, DOI 10.2741/2267; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Zhu KQ, 2005, NEUROREPORT, V16, P1209, DOI 10.1097/00001756-200508010-00015	43	35	36	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1401	1409		10.1089/neu.2011.2228			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600014	22352983	Green Published			2022-02-06	
J	Weber, JT; Lamont, M; Chibrikova, L; Fekkes, D; Vlug, AS; Lorenz, P; Kreutzmann, P; Slemmer, JE				Weber, John T.; Lamont, Matthew; Chibrikova, Lyudmila; Fekkes, Durk; Vlug, Angela S.; Lorenz, Peter; Kreutzmann, Peter; Slemmer, Jennifer E.			Potential neuroprotective effects of oxyresveratrol against traumatic injury	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Gliosis; Glutamate; In vitro; Neuron; Oxyresveratrol; Trauma	FOCAL CEREBRAL-ISCHEMIA; SMILACIS-CHINAE RHIZOME; FREE-RADICAL SCAVENGERS; BRAIN-INJURY; CELL-DEATH; NORMOBARIC HYPEROXIA; HIPPOCAMPAL CELLS; OXIDATIVE STRESS; RESVERATROL; DAMAGE	Oxyresveratrol is a potent antioxidant and free-radical scavenger found in mulberry wood (Morus alba L.) with demonstrated protective effects against cerebral ischemia. We analyzed the neuroprotective ability of oxyresveratrol using an in vitro model of stretch-induced trauma in co-cultures of neurons and glia, or by exposing cultures to high levels of glutamate. Cultures were treated with 25 mu M, 50 mu M or 100 mu M oxyresveratrol at the time of injury. Trauma produced marked neuronal death when measured 24 h post-injury, and oxyresveratrol significantly inhibited this death. Microscopic examination of glia suggested signs of toxicity in cultures treated with 100 mu M oxyresveratrol, as demonstrated by elevated S-100B protein release and a high proportion of cells with condensed nuclei. Cultures exposed to glutamate (100 mu M) for 24 h exhibited similar to 37% neuronal loss, which was not inhibited by oxyresveratrol. These results show that the two pathologies of high glutamate exposure and trauma are differentially affected by oxyresveratrol treatment in vitro. Further studies using oxyresveratrol in trauma models are warranted, as toxicity to glia could be beneficial by inhibiting reactive gliosis, which often occurs after trauma. Crown Copyright (C) 2012 Published by Elsevier B. V. All rights reserved.	[Weber, John T.; Chibrikova, Lyudmila] Mem Univ Newfoundland, Sch Pharm, Hlth Sci Ctr, St John, NF A1B 3V6, Canada; [Weber, John T.; Lamont, Matthew] Mem Univ Newfoundland, Hlth Sci Ctr, Fac Med, Div Biomed Sci, St John, NF A1B 3V6, Canada; [Weber, John T.; Fekkes, Durk; Slemmer, Jennifer E.] Erasmus MC, Dept Neurosci, NL-3015 GE Rotterdam, Netherlands; [Fekkes, Durk] Erasmus MC, Dept Psychiat, NL-3015 GE Rotterdam, Netherlands; [Vlug, Angela S.; Lorenz, Peter; Kreutzmann, Peter] Univ Magdeburg, Inst Med Neurobiol, D-39120 Magdeburg, Germany; [Slemmer, Jennifer E.] Univ Prince Edward Isl, Dept Biol, Charlottetown, PE C1A 4P3, Canada		Weber, JT (corresponding author), Mem Univ Newfoundland, Sch Pharm, Hlth Sci Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.	jweber@mun.ca; mgl080@mun.ca; lc3147@mun.ca; d.fekkes@erasmusmc.nl; Angela.Vlug@sanofi-aventis.com; Peter.Lorenz@wala.de; Peter.Kreutzmann@med.ovgu.de; jeslemmer@hollandcollege.com		Lamont, Matthew/0000-0003-4365-9078	Research Council for Earth and Life Sciences (ALW)Netherlands Organization for Scientific Research (NWO); Research Council for Medical Sciences (MW); Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO); Hersenstichting Nederland; Natural Sciences and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Erasmus Medical Centre	Work conducted at the Erasmus Medical Centre was supported by grants from the Research Council for Earth and Life Sciences (ALW) and Research Council for Medical Sciences (MW) with financial aid from the Netherlands Organization for Scientific Research (NWO), a Breedtestrategie subsidie from Erasmus Medical Centre, and funding from Hersenstichting Nederland. The authors thank Robert De Jonge, Doortje Engel and Ans Voskuilen-Kooijman for their technical assistance with lactate, pyurvate and glucose measurements. Work conducted at Memorial University was supported by grants from the Natural Sciences and Engineering Research Council (NSERC) and the Canada Foundation for Innovation. We thank Erica Kelly, Stephanie Hewitt, Catherine Orr and Breanna Skye Fisher for assistance with dissections, immunohistochemistry and cell counting.	Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Andrabi SA, 2004, BRAIN RES, V1017, P98, DOI 10.1016/j.brainres.2004.05.038; Ban JY, 2008, J PHARMACOL SCI, V106, P68, DOI 10.1254/jphs.FP0071206; Ban JY, 2006, BIOL PHARM BULL, V29, P2419, DOI 10.1248/bpb.29.2419; Breuer C, 2006, NEUROSCI LETT, V393, P113, DOI 10.1016/j.neulet.2005.09.081; Chao JF, 2008, FREE RADICAL BIO MED, V45, P1019, DOI 10.1016/j.freeradbiomed.2008.07.002; Dore S, 2005, NEUROSIGNALS, V14, P61, DOI 10.1159/000085386; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FEKKES D, 1995, J CHROMATOGR B, V669, P177, DOI 10.1016/0378-4347(95)00111-U; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Huang SS, 2001, LIFE SCI, V69, P1057, DOI 10.1016/S0024-3205(01)01195-X; Inoue H, 2003, NEUROSCI LETT, V352, P203, DOI 10.1016/j.neulet.2003.09.001; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Lorenz P, 2003, NITRIC OXIDE-BIOL CH, V9, P64, DOI 10.1016/j.niox.2003.09.005; Lyons MM, 2003, J AGR FOOD CHEM, V51, P5867, DOI 10.1021/jf034150f; Rimando AM, 2004, J AGR FOOD CHEM, V52, P4713, DOI 10.1021/jf040095e; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	32	35	38	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	APR 5	2012	680	1-3					55	62		10.1016/j.ejphar.2012.01.036			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	901SE	WOS:000300986300009	22489319				2022-02-06	
J	Eakin, K; Miller, JP				Eakin, Katharine; Miller, Jonathan P.			Mild Traumatic Brain Injury Is Associated with Impaired Hippocampal Spatiotemporal Representation in the Absence of Histological Changes	JOURNAL OF NEUROTRAUMA			English	Article						electrophysiology; hippocampus; mild traumatic brain injury; place cells; task-specific cells	FLUID PERCUSSION INJURY; ENTORHINAL CORTEX; MEMORY IMPAIRMENT; RAT; PERFORMANCE; NEURONS	Mild traumatic brain injury (mTBI) accounts for the majority of head trauma cases. Despite some lasting cognitive, emotional, and behavioral deficits, there are frequently no overt morphological defects, suggesting that changes may result from alterations in the physiology of individual neurons. We investigated hippocampal neural activity in rats during a working memory task to determine the effect of mTBI on cellular physiology. Male Sprague-Dawley rats (300-350 g) underwent mTBI via lateral fluid percussion (1.5 atm), and were compared with sham-operated rats. The rats then underwent bilateral implantation of electrodes into the CA1 and CA3 hippocampal subfields and were trained to perform in a delayed nonmatch-to-place swim T-maze. Single-neuron activity was analyzed during task performance 30-90 days after trauma. There were no histological differences between control and mTBI rats. Stereological analysis demonstrated no neuronal loss. Nevertheless, rats subjected to mTBI demonstrated significantly poorer performance on the task with increasing delay. Examination of single-neuron spiking activity revealed no significant difference in firing rates or spike characteristics, but rats exposed to mTBI were found to have significantly fewer cells with activity spatiotemporally correlated with location in the maze ("task-specific cells,'' p < 0.05 by Fisher's exact test). Memory deficits, including disorganized patterns of hippocampal neural activity after mTBI, were seen in rats. Because it is seen in the absence of clear morphological defects, these data suggest that functional impairment after mTBI may result from alterations in the activity of individual neurons.	[Eakin, Katharine; Miller, Jonathan P.] Case Western Reserve Univ, Dept Neurol Surg, Cleveland, OH 44106 USA		Miller, JP (corresponding author), Case Western Reserve Univ, Dept Neurol Surg, 10900 Euclid Ave, Cleveland, OH 44106 USA.	Jonathan.Miller@UHhospitals.org		Miller, Jonathan/0000-0001-5441-1751	Case Western Reserve School of Medicine; Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons	We thank Osmond Wu, B.A., and Thomas Ostergard, B.S., for assistance with the experiments. Financial support has been provided by Case Western Reserve School of Medicine and the Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons.	Ahmed OJ, 2009, TRENDS NEUROSCI, V32, P329, DOI 10.1016/j.tins.2009.01.009; Barnes CA, 1997, NATURE, V388, P272, DOI 10.1038/40859; Berger TW, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046017; Clark RE, 2000, J NEUROSCI, V20, P8853; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M, 2010, TRAUMATIC BRAIN INJU; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hampson RE, 1996, P NATL ACAD SCI USA, V93, P13487, DOI 10.1073/pnas.93.24.13487; Hampson RE, 1999, NATURE, V402, P610, DOI 10.1038/45154; HAMPSON RE, 1993, BEHAV NEUROSCI, V107, P715, DOI 10.1037/0735-7044.107.5.715; Hollup SA, 2001, EUR J NEUROSCI, V13, P1197, DOI 10.1046/j.0953-816x.2001.01487.x; Lipton PA, 2007, J NEUROSCI, V27, P5787, DOI 10.1523/JNEUROSCI.1063-07.2007; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MILLER VM, 1980, BRAIN RES, V194, P311, DOI 10.1016/0006-8993(80)91214-7; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whiting MD, 2006, J NEUROTRAUM, V23, P1529, DOI 10.1089/neu.2006.23.1529; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	24	35	35	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1180	1187		10.1089/neu.2011.2192			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100018	22229460				2022-02-06	
J	Larson, MJ; Clayson, PE; Farrer, TJ				Larson, Michael J.; Clayson, Peter E.; Farrer, Thomas J.			Performance Monitoring and Cognitive Control in Individuals with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive control; Performance monitoring; Traumatic brain injury; Concussion; Stroop; ERN	EVENT-RELATED POTENTIALS; MAJOR DEPRESSIVE DISORDER; ERROR-DETECTION; CONFLICT ADAPTATION; ANTERIOR CINGULATE; ERP COMPONENTS; STROOP TASK; ELECTROENCEPHALOGRAPHIC RECORDINGS; FUNCTIONAL-SIGNIFICANCE; RELEVANT INFORMATION	Literature suggests that individuals with mild traumatic brain injury (mTBI) show subtle abnormalities in the cognitive control process of performance monitoring. The neural bases of performance monitoring can be measured using the error-related negaitivity (ERN) and post-error positivity (Pe) components of the scalp-recorded event-related potential (ERP). Thirty-six individuals with mTBI and 46 demographically similar controls completed a modified color-naming Stroop task while ERPs were recorded. Separate repeated-measures analyses of variance were used to examine the behavioral (response times [RT] and error rates) and ERP (ERN and Pe amplitudes) indices of performance monitoring. Both groups showed slower RTs and increased error rates on incongruent trials relative to congruent trials. Likewise, both groups showed more negative ERN and more positive Pe amplitude to error trials relative to correct trials. Notably, there were no significant main effects or interactions of group for behavioral and ERP measures. Subgroup and correlational analyses with post-concussive symptoms and indices of injury severity were also not significant. Findings suggest comparable performance to non-injured individuals in some aspects of cognitive control in this sample. Neuropsychological implications and comparison with other cognitive control component processes in individuals with TBI are provided. (JINS, 2012, 18, 323-333)	[Larson, Michael J.; Clayson, Peter E.; Farrer, Thomas J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Clayson, Peter E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA		Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	Clayson, Peter/AAC-9207-2019; Clayson, Peter/AAC-4028-2022; Larson, Michael J/C-8543-2012; Clayson, Peter E/F-5438-2011	Clayson, Peter/0000-0003-4437-6598; Larson, Michael J/0000-0002-8199-8065; Clayson, Peter E/0000-0003-4437-6598; Farrer, Thomas J./0000-0001-8092-6214	Brigham Young University College of Family, Home, and Social Sciences	This study has not been published or submitted elsewhere and was supported by funds from the Brigham Young University College of Family, Home, and Social Sciences. The authors report no conflicts of interest.	Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Benton A., 1976, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Carroll JFX., 2001, MENTAL HLTH SCREENIN; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Chiu PH, 2007, AM J PSYCHIAT, V164, P608, DOI 10.1176/appi.ajp.164.4.608; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Cohen JD, 2000, NAT NEUROSCI, V3, P421, DOI 10.1038/74783; Compton RJ, 2008, EMOTION, V8, P58, DOI 10.1037/1528-3542.8.1.58; Compton RJ, 2007, BRAIN COGNITION, V64, P247, DOI 10.1016/j.bandc.2007.03.006; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Dien J, 2005, CLIN NEUROPHYSIOL, V116, P1808, DOI 10.1016/j.clinph.2004.11.025; Dien J, 2004, PSYCHOPHYSIOLOGY, V41, P665, DOI 10.1111/j.1469-8986.2004.00193.x; Dien J., 2005, EVENT RELATED POTENT; Dien J, 2007, HUM BRAIN MAPP, V28, P742, DOI 10.1002/hbm.20304; Dien J, 2010, BRAIN RES, V1355, P126, DOI 10.1016/j.brainres.2010.07.099; Dien J, 2010, J NEUROSCI METH, V187, P138, DOI 10.1016/j.jneumeth.2009.12.009; Dien J, 2010, PSYCHOPHYSIOLOGY, V47, P170, DOI 10.1111/j.1469-8986.2009.00885.x; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Egner T, 2005, NAT NEUROSCI, V8, P1784, DOI 10.1038/nn1594; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Foti D, 2011, HUM BRAIN MAPP, V32, P2207, DOI 10.1002/hbm.21182; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Hanslmayr S, 2008, J COGNITIVE NEUROSCI, V20, P215, DOI 10.1162/jocn.2008.20020; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; Holmes AJ, 2008, ARCH GEN PSYCHIAT, V65, P179, DOI 10.1001/archgenpsychiatry.2007.19; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Jung TP, 2000, CLIN NEUROPHYSIOL, V111, P1745, DOI 10.1016/S1388-2457(00)00386-2; Jung TP, 2000, PSYCHOPHYSIOLOGY, V37, P163, DOI 10.1017/S0048577200980259; Jung TP, 1998, ADV NEUR IN, V10, P894; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim MS, 2006, PSYCHIAT CLIN NEUROS, V60, P303, DOI 10.1111/j.1440-1819.2006.01506.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lagerlund TD, 1997, J CLIN NEUROPHYSIOL, V14, P73, DOI 10.1097/00004691-199701000-00007; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Luck S.J., 2005, INTRO EVENT RELATED, V1st ed.; Morris SE, 2006, J ABNORM PSYCHOL, V115, P239, DOI 10.1037/0021-843X.115.2.239; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Olvet DM, 2009, PSYCHOPHYSIOLOGY, V46, P957, DOI 10.1111/j.1469-8986.2009.00848.x; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Rainer G, 1998, NATURE, V393, P577, DOI 10.1038/31235; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A., 1964, EXAMEN CLIN PSYCHOL; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Speilberger CD., 1970, MANUAL STATE TRAIT A, DOI DOI 10.1017/S0033291701005141; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	75	35	36	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2012	18	2					323	333		10.1017/S1355617711001779			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	899DI	WOS:000300794600016	22272692				2022-02-06	
J	Schwandt, M; Harris, JE; Thomas, S; Keightley, M; Snaiderman, A; Colantonio, A				Schwandt, Marika; Harris, Jocelyn E.; Thomas, Scott; Keightley, Michelle; Snaiderman, Abe; Colantonio, Angela			Feasibility and Effect of Aerobic Exercise for Lowering Depressive Symptoms Among Individuals With Traumatic Brain Injury: A Pilot Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aerobic exercise; community; depression; traumatic brain injury	PHYSICAL-ACTIVITY; CARDIAC REHABILITATION; RATING-SCALE; ENDURANCE; BENEFITS; EFFICACY; PROGRAM; ANXIETY; STROKE	Purpose: To establish the feasibility and effect of an aerobic exercise intervention on symptoms of depression among individuals with traumatic brain injury. Design: A pre-post single group. Participants: Four community dwelling participants (>11 months postinjury) with residual physical impairment recruited from an outpatient clinic. Intervention: 12-week aerobic exercise program. Outcome Measures: The Hamilton Rating Scale for Depression; aerobic capacity (cycle ergometer, heart rate at reference resistance, perceived exertion); Rosenberg Self-Esteem Scale and program perception (survey). Analysis: Descriptive statistics to depict change in outcome measure scores. Answers from the survey were collated and presented as summary statements. Results: All participants had fewer symptoms of depression, improved aerobic capacity and higher self esteem after the intervention. High satisfaction with the program was reported with no adverse effects. Conclusion: The aerobic exercise program was feasible and effective for individuals with traumatic brain injury, leading to improved mood, cardiovascular fitness, and self-esteem. Future research is needed to determine the intensity, frequency, and duration required to reach and maintain improvement.	[Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Schwandt, Marika] Univ Toronto, Grad Program Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Thomas, Scott] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5G 1V7, Canada; [Snaiderman, Abe] Toronto Rehabil Inst, Dept Psychiat, Toronto, ON, Canada; [Snaiderman, Abe] Toronto Rehabil Inst, Dept Med PMR, Toronto, ON, Canada		Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Thomas, Scott G/G-4522-2012; Harris, Jocelyn Ellen/ABE-7420-2021	Thomas, Scott G/0000-0002-5564-4271; Harris, Jocelyn Ellen/0000-0002-3293-1833; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP]; Toronto Rehabilitation InstituteUniversity of Toronto; Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Women's College Research InstituteUniversity of Toronto; Strategic Training Fellowship in Health Care, Technology and Place [FRN: STP 53911]	Funding for this study for AC was obtained from the Canadian Institutes for Health Research (200903MOP), The Toronto Rehabilitation Institute, and a grant from the Ministry of Health and Long Term Care. Support for this study was given to MS from the Toronto Rehabilitation Institute and a Fellowship from the Women's College Research Institute and to JEH in a CIHR Fellowship Award and a Strategic Training Fellowship in Health Care, Technology and Place (FRN: STP 53911). Authors do not have any conflicts to disclose.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Ballesteros J, 2007, J AFFECT DISORDERS, V102, P93, DOI 10.1016/j.jad.2006.12.015; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Brenes GA, 2007, AGING MENT HEALTH, V11, P61, DOI 10.1080/13607860600736372; Brown C, 2005, MED CARE, V43, P1203, DOI 10.1097/01.mlr.0000185733.30697.f6; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Eng JJ, 2004, ARCH PHYS MED REHAB, V85, P113, DOI 10.1016/S0003-9993(03)00436-2; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hellweg S, 2008, BRAIN INJURY, V22, P365, DOI 10.1080/02699050801998250; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Knapen J, 2005, PSYCHOTHER PSYCHOSOM, V74, P353, DOI 10.1159/000087782; Lai SM, 2006, J AM GERIATR SOC, V54, P240, DOI 10.1111/j.1532-5415.2006.00573.x; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; Rosenberg M., 1965, SOC ADOLESCENT SELF; Sabapathy NM, 2011, CLIN REHABIL, V25, P14, DOI 10.1177/0269215510375908; Scholz U, 2006, SOC SCI MED, V62, P3109, DOI 10.1016/j.socscimed.2005.11.035; Stroud NM, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-68; Stuart M, 2009, NEUROREHAB NEURAL RE, V23, P726, DOI 10.1177/1545968309332734; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Yohannes AM, 2010, J CLIN NURS, V19, P2806, DOI 10.1111/j.1365-2702.2010.03313.x; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	28	35	38	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2012	27	2					99	103		10.1097/HTR.0b013e31820e6858			5	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	912LI	WOS:000301799100002	21386712				2022-02-06	
J	Xavier, AM; Serafim, KGG; Higashi, DT; Vanat, N; Flaiban, KKMD; Siqueira, CPCM; Venancio, EJ; Ramos, SD				Xavier, A. M.; Serafim, K. G. G.; Higashi, D. T.; Vanat, N.; Flaiban, K. K. M. da C.; Siqueira, C. P. C. M.; Venancio, E. J.; Ramos, S. de P.			Simvastatin improves morphological and functional recovery of sciatic nerve injury in Wistar rats	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Simvastatin; Sciatic nerve; Immunomodulation; Nervous regeneration	TRAUMATIC BRAIN-INJURY; MONOCYTE CHEMOATTRACTANT PROTEIN-1; WALLERIAN DEGENERATION; PERIPHERAL-NERVE; IN-VIVO; MACROPHAGE RECRUITMENT; ISCHEMIC-STROKE; CELL-ACTIVATION; NEURONAL CELLS; SCHWANN-CELLS	Aim: The purpose of this work is to investigate the effects of simvastatin on sciatic nerve regeneration in male Wistar Rats. Materials and methods: Forty animals were allocated into four groups: (1) control (C); (2) control + simvastatin (CS); (3) lesioned animals + sterile PBS (LC) and (4) lesioned animals + simvastatin (LS). Lesioned animals were submitted to crushing lesion of right sciatic nerve. Simvastatin (20 mg/kg/day, i.p.) was administered for five days. Footprints were obtained weekly for evaluation of functional locomotor recovery by means of the Sciatic Function Index (SFI). Blood samples were obtained weekly for quantifying circulating leukocytes. Animals were sacrificed after 21 days for histological analyses of sciatic nerve and spleen. Results: LS Animals presented increased SFI scores, decreased areas of oedema and mononuclear cell infiltration during Wallerian degeneration and nerve regeneration (7,14 and 21 days; P < 0.05). Spleen weight and white pulp areas was increased in LC animals after 21 days. Increased numbers of circulating neutrophils were observed in simvastatin treated animals (CS e LS) at seven, 14 and 21 days, compared to non-treated groups (C and LC). Conclusion: The study suggests that simvastatin accelerates the morphological and functional recovery process of the peripheral nervous system interfering with innate and acquired immunity. (C) 2011 Elsevier Ltd. All rights reserved.	[Ramos, S. de P.] Univ Estadual Londrina, Dept Histol, BR-86051990 Londrina, PR, Brazil; [Vanat, N.; Flaiban, K. K. M. da C.] Univ Estadual Londrina, Vet Hosp, BR-86051990 Londrina, PR, Brazil; [Siqueira, C. P. C. M.] Univ Estadual Londrina, Dept Physiotherapy, BR-86051990 Londrina, PR, Brazil; [Venancio, E. J.] Univ Estadual Londrina, Dept Pathol Sci, BR-86051990 Londrina, PR, Brazil		Ramos, SD (corresponding author), Univ Estadual Londrina, Dept Histol, Rodovia Celso Garcia Cid PR 445,Km 380, BR-86051990 Londrina, PR, Brazil.	ramossolange@yahoo.com	Flaiban, Karina/AAJ-9441-2021; Venancio, Emerson Jose/F-6767-2012	Flaiban, Karina/0000-0001-6461-6961; Venancio, Emerson/0000-0002-3735-9207			Al-Bishri A, 2008, BRIT J ORAL MAX SURG, V46, P455, DOI 10.1016/j.bjoms.2008.01.020; Avellino AM, 2004, EXP NEUROL, V187, P430, DOI 10.1016/j.expneurol.2004.02.004; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Colivicchi F, 2007, STROKE, V38, P2652, DOI 10.1161/STROKEAHA.107.487017; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Dunn SE, 2006, J EXP MED, V203, P401, DOI 10.1084/jem.20051129; Dunzendorfer S, 1997, CIRC RES, V81, P963; Eccles KA, 2008, ATHEROSCLEROSIS, V200, P69, DOI 10.1016/j.atherosclerosis.2007.12.018; Gholami MR, 2008, EUR J PHARMACOL, V590, P111, DOI 10.1016/j.ejphar.2008.05.050; Gholami Mohammad Reza, 2007, Pak J Biol Sci, V10, P4256, DOI 10.3923/pjbs.2007.4256.4260; Golz G, 2006, EUR J NEUROSCI, V24, P2721, DOI 10.1111/j.1460-9568.2006.05155.x; Guasti L, 2006, J HYPERTENS, V24, P2423, DOI 10.1097/01.hjh.0000251903.62804.77; Hakamada-Taguchi R, 2003, CIRC RES, V93, P948, DOI 10.1161/01.RES.0000101298.76864.14; Han KH, 2005, CIRCULATION, V111, P1439, DOI 10.1161/01.CIR.0000158484.18024.1F; Hayashi T, 2005, BRAIN RES, V1037, P52, DOI 10.1016/j.brainres.2004.12.051; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Jander S, 2001, BRAIN PATHOL, V11, P27; Karanth S, 2006, EXP NEUROL, V202, P161, DOI 10.1016/j.expneurol.2006.05.024; Klopfleisch S, 2008, J NEUROSCI, V28, P13609, DOI 10.1523/JNEUROSCI.2765-08.2008; Lee H, 2006, BIOCHEM BIOPH RES CO, V350, P742, DOI 10.1016/j.bbrc.2006.09.108; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lilje O, 2002, CELL MOL LIFE SCI, V59, P2191, DOI 10.1007/s000180200018; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Maher BM, 2009, J LEUKOCYTE BIOL, V85, P186, DOI 10.1189/jlb.0608382; Martini R, 2008, GLIA, V56, P1566, DOI 10.1002/glia.20766; Montaner J, 2008, EUR J NEUROL, V15, P82, DOI 10.1111/j.1468-1331.2007.02015.x; Nakamichi K, 2006, NEUROSCI LETT, V407, P205, DOI 10.1016/j.neulet.2006.08.044; Nezic L, 2009, BASIC CLIN PHARMACOL, V104, P185, DOI 10.1111/j.1742-7843.2008.00302.x; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Park DS, 2009, ACTA OTO-LARYNGOL, V129, P166, DOI 10.1080/00016480802163358; Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407; Pienaar IS, 2009, J NEURAL TRANSM, V116, P791, DOI 10.1007/s00702-009-0247-4; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Rallidis LS, 2008, INT J CARDIOL, V124, P271, DOI 10.1016/j.ijcard.2006.12.059; Ruohonen S, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-26; Schramm R, 2007, IMMUNOLOGY, V120, P315, DOI 10.1111/j.1365-2567.2006.02505.x; Shaw SK, 2008, EXP NEUROL, V210, P286, DOI 10.1016/j.expneurol.2007.11.024; Siebert H, 2000, J NEUROIMMUNOL, V110, P177, DOI 10.1016/S0165-5728(00)00343-X; Ulivieri C, 2008, EUR J IMMUNOL, V38, P2832, DOI 10.1002/eji.200838278; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Wang YP, 2008, J NEUROL SCI, V267, P107, DOI 10.1016/j.jns.2007.10.004; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xin JP, 2008, BRAIN BEHAV IMMUN, V22, P528, DOI 10.1016/j.bbi.2007.10.006; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang X, 2008, IMMUNOL RES, V41, P165, DOI 10.1007/s12026-008-8019-z; Zhang X, 2008, J IMMUNOL, V180, P6988, DOI 10.4049/jimmunol.180.10.6988; Zhang ZR, 2008, ACTA NEUROPATHOL, V115, P335, DOI 10.1007/s00401-007-0301-y	51	35	38	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAR	2012	43	3					284	289		10.1016/j.injury.2011.05.036			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	897HU	WOS:000300640000007	21684542				2022-02-06	
J	Dizdarevic, K; Hamdan, A; Omerhodzic, I; Kominlija-Smajic, E				Dizdarevic, Kemal; Hamdan, Alhafidz; Omerhodzic, Ibrahim; Kominlija-Smajic, Elvedina			Modified Lund concept versus cerebral perfusion pressure-targeted therapy: A randomised controlled study in patients with secondary brain ischaemia	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Microdialysis; Lund concept; Cerebral perfusion pressure; Secondary brain ischaemia; Traumatic brain injury; Subarachnoid haemorrhage	ANEURYSMAL SUBARACHNOID HEMORRHAGE; RUPTURED INTRACRANIAL ANEURYSMS; INTRACEREBRAL MICRODIALYSIS; ENDOVASCULAR COILING; PROTOCOL; INJURY; TRIAL; ISAT	Purpose: Secondary brain ischaemia (SBI) usually develops after aneurysmal subarachnoid haemorrhage (SAH) and severe traumatic brain injury (TB!). Current approaches to managing these conditions are based either on intracranial pressure-targeted therapy (ICP-targeted) with cerebral microdialysis (CM) monitoring according to the modified Lund concept or cerebral perfusion pressure-targeted therapy (CPP-targeted). We present a prospective, randomised controlled study comparing relative effectiveness of the two management strategies. Methods: Sixty comatose operated patients with SBI following aneurysmal SAH and severe TBI were randomised into ICP-targeted therapy with CM monitoring and CPP-targeted therapy groups. Mortality rates in both groups were calculated and tissue biochemical signs of cerebral ischaemia were analysed using CM. Measured CM data were related to outcome (Glasgow Outcome Scale [GOS] score 1,2 and 3 for poor outcome or GOS score 4 and 5 for good outcome). Results: Patients treated with ICP-targeted therapy with CM monitoring had significantly lower mortality rate as compared with those treated with CPP-targeted therapy (P=0.03). Patients monitored with CM who had poor outcome had lower mean values of glucose and higher mean values of glycerol and lactate/pyruvate ratio as compared with those who had good outcome (glucose: P=0.003; glycerol: P=0.02; lactate/pyruvate ratio: P=0.01). There was no difference in the mortality outcome between aneurysmal SAH and severe TBI in the two groups (P=0.28 for ICP-targeted therapy with CM monitoring, P=0.36 for CPP-targeted therapy). Also, there were no differences in the CM values between patients with aneurysmal SAH and severe TBI who underwent ICP-targeted therapy (glucose: P=0.23; glycerol: P=0.41; lactate/pyruvate ratio: P=0.40). Conclusion: The modified Lund concept, directed at bedside real-time monitoring of brain biochemistry by CM showed better results compared to CPP-targeted therapy in the treatment of comatose patients sustaining SBI after aneurysmal SAH and severe TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Dizdarevic, Kemal; Omerhodzic, Ibrahim] Univ Sarajevo, Ctr Clin, Dept Neurosurg, Sarajevo 71000, Bosnia & Herceg; [Hamdan, Alhafidz] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Kominlija-Smajic, Elvedina] Univ Sarajevo, Ctr Clin, Dept Anaethesiol, Sarajevo 71000, Bosnia & Herceg		Dizdarevic, K (corresponding author), Univ Sarajevo, Ctr Clin, Dept Neurosurg, Bolnika 25, Sarajevo 71000, Bosnia & Herceg.	kemaldiz@bih.net.ba	Omerhodzic, Ibrahim/AAL-7976-2020	Omerhodzic, Ibrahim/0000-0001-5143-8801; Hamdan, Alhafidz/0000-0002-0794-5504			American Association of Neurological Surgeon, 2004, NEUROTRAUMA CRIT SPR, p:3; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; *BRAIN TRAUM FDN, 2000, GUID MAN TRAUM BRAIN; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; Dizdairevic K, 2007, PROCEEDINGS OF THE 13TH EUROPEAN CONGRESS OF NEUROSURGERY, P505; Dizdarevic K, 2006, 2 BOSN C NEUR, P345; Dizdarevic Kemal, 2004, Med Arh, V58, P301; Dizdarevic Kemal, 2006, Med Arh, V60, P13; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, pS42; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Hamada J, 2004, NEUROSURGERY, V54, P31, DOI 10.1227/01.NEU.0000097196.55204.0B; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Huang SJ, 2006, J CLIN NEUROSCI, V13, P818, DOI 10.1016/j.jocn.2005.11.034; K Dizdarevic, 2011, ANEURYSMAL SUBARACHN, P161; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Nordstrom CH, 2008, CRIT CARE, V12, DOI 10.1186/cc6826; Oddo Mauro, 2009, Rev Med Suisse, V5, P2506; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rusnak M, 2006, ACTA INFORM MED, V14, P10; Rusnak M, 2005, EUPHA C; Ryttlefors M, 2010, ACTA NEUROCHIR, V152, P241, DOI 10.1007/s00701-009-0496-x; Sarrafzadeh AS, 2007, ANAESTHESIST, V56, P957, DOI 10.1007/s00101-007-1244-3; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stocchetti N, 1991, Minerva Anestesiol, V57, P327; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109	36	35	38	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	FEB	2012	114	2					142	148		10.1016/j.clineuro.2011.10.005			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	900WJ	WOS:000300922100008	22036839				2022-02-06	
J	Cohen, SP; Plunkett, AR; Wilkinson, I; Nguyen, C; Kurihara, C; Flagg, A; Morlando, B; Stone, C; White, RL; Anderson-Barnes, VC; Galvagno, SM				Cohen, Steven P.; Plunkett, Anthony R.; Wilkinson, Indy; Conner Nguyen; Kurihara, Connie; Flagg, Artemus, II; Morlando, Benny; Stone, Christina; White, Ronald L.; Anderson-Barnes, Victoria C.; Galvagno, Samuel M., Jr.			Headaches during war: Analysis of presentation, treatment, and factors associated with outcome	CEPHALALGIA			English	Article						Epidemiology; headache; soldier; war	BACK-PAIN; PREVALENCE; IMPACT; EPIDEMIOLOGY; MIGRAINE; INJURY	Background: Headache is often associated with physical trauma and psychological stress. The aim of this study is to evaluate the impact of headache on personnel deployed in war zones and to identify factors associated with return to duty (RTD). Methods: Outcome data were prospectively collected on 985 personnel medically evacuated out of Operations Iraqi and Enduring Freedom for a primary diagnosis of headache between 2004 and 2009. Electronic medical records were reviewed to examine clinical and treatment patterns and the effect that myriad factors had on RTD. Results: 33.6% of evacuees returned to duty. The most common headaches were post-concussion (34.1%) and migraine (30.0%). Headaches typically associated with trauma such as post-concussion (18.7%), occipital neuralgia (23.1%), and cervicogenic headache (29.7%) had the lowest RTD rates, whereas tension headache (49.6%) was associated with the best outcome. Other variables associated with negative outcome included presence of aura (OR 0.51, 95% CI 0.30-0.88; p 0.02), traumatic brain injury (OR 0.50, 95% CI 0.29-0.87; p = 0.01), opioid (OR 0.41, 95% CI 0.26-0.63; p < 0.001), and beta-blocker (OR 0.26, 95% CI 0.12-0.61; p = 0.002) use, and co-existing psychopathology (p < 0.001 in univariable analysis). Conclusion: Headaches represent a significant cause of unit attrition in personnel deployed in military operations, with physical trauma and co-existing psychopathology associated with poorer outcomes.	[Cohen, Steven P.; Flagg, Artemus, II; Galvagno, Samuel M., Jr.] Johns Hopkins Sch Med, Baltimore, MD USA; [Cohen, Steven P.; Plunkett, Anthony R.; Wilkinson, Indy; Kurihara, Connie; Morlando, Benny; Anderson-Barnes, Victoria C.] Walter Reed Army Med Ctr, Silver Spring, MD USA; [Cohen, Steven P.; Plunkett, Anthony R.; Wilkinson, Indy; White, Ronald L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Conner Nguyen; Stone, Christina; White, Ronald L.] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Galvagno, Samuel M., Jr.] Bloomberg Sch Publ Hlth, Baltimore, MD USA		Cohen, SP (corresponding author), 550 N Broadway,Suite 301, Baltimore, MD 21029 USA.	scohen40@jhmi.edu		Galvagno, Samuel/0000-0001-5563-4092; Merritt, Victoria/0000-0001-5683-4168	John P Murtha Neuroscience and Pain Institute; US ArmyUnited States Department of Defense; Army Regional Anesthesia and Pain Medicine Initiative	This work was supported in part by a Congressional Grant from the John P Murtha Neuroscience and Pain Institute, the US Army, and the Army Regional Anesthesia and Pain Medicine Initiative.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Andrychowski J, 1998, Neurol Neurochir Pol, V32, P871; APRILL C, 1992, SPINE, V17, P744, DOI 10.1097/00007632-199207000-00003; Belasco A, TROOP LEVELS AFGHAN; Bigal Marcelo E, 2004, Curr Neurol Neurosci Rep, V4, P98, DOI 10.1007/s11910-004-0022-8; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Chibnall JT, 2009, PAIN MED, V10, P1378, DOI 10.1111/j.1526-4637.2009.00738.x; Cohen SP, 2011, CAN MED ASSOC J, V183, pE289, DOI 10.1503/cmaj.100244; Cohen SP, 2011, CLIN J PAIN, V27, P19, DOI 10.1097/AJP.0b013e3181f06b06; Cohen SP, 2010, SPINE, V35, P758, DOI 10.1097/BRS.0b013e3181bb11a8; Cohen SP, 2010, LANCET, V375, P301, DOI 10.1016/S0140-6736(09)61797-9; Cohen SP, 2009, ARCH INTERN MED, V169, P1916, DOI 10.1001/archinternmed.2009.380; Gallagher R Michael, 2007, Expert Rev Neurother, V7, P1279, DOI 10.1586/14737175.7.10.1279; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Helseth EK, 2008, HEADACHE, V48, P883, DOI 10.1111/j.1526-4610.2007.00962.x; HOEFFLER DF, 1981, MIL MED, V146, P776; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jensen R, 2008, LANCET NEUROL, V7, P354, DOI 10.1016/S1474-4422(08)70062-0; Pop PHM, 2002, EUR J NEUROL, V9, P171, DOI 10.1046/j.1468-1331.2002.00355.x; Robbins MS, 2010, SEMIN NEUROL, V30, P107, DOI 10.1055/s-0030-1249220; Russell MB, 2006, EUR J EPIDEMIOL, V21, P153, DOI 10.1007/s10654-005-6031-3; Saper JR, 2008, HEADACHE, V48, P838, DOI 10.1111/j.1526-4610.2008.01153.x; Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Torelli P, 2010, NEUROL SCI, V31, P145, DOI 10.1007/s10072-010-0311-8; US Centers for Disease Control and Prevention, INT CLASS DIS; Vincent MB, 2008, CEPHALALGIA, V28, P32, DOI 10.1111/j.1468-2982.2008.01616.x; Weeks R, 2006, HEADACHE, V46, pS110, DOI 10.1111/j.1526-4610.2006.00562.x; WEINER L P, 1969, Headache, V9, P162, DOI 10.1111/j.1526-4610.1969.hed0903162.x; Winsvold BS, 2011, EUR J NEUROL, V18, P504, DOI 10.1111/j.1468-1331.2010.03199.x; Winter AC, 2011, J HEADACHE PAIN, V12, P147, DOI 10.1007/s10194-010-0286-0; Wober Christian, 2010, Handb Clin Neurol, V97, P161, DOI 10.1016/S0072-9752(10)97012-7	34	35	36	1	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	JAN	2012	32	2					94	108		10.1177/0333102411422382			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	880SX	WOS:000299428600002	21994113				2022-02-06	
J	Falconer, C; Antonucci, SM				Falconer, Carolyn; Antonucci, Sharon M.			Use of semantic feature analysis in group discourse treatment for aphasia: Extension and expansion	APHASIOLOGY			English	Article						Stroke rehabilitation; Lexical retrieval; Connected speech; Discourse; Therapy	CONNECTED SPEECH; WORD RETRIEVAL; ADULTS; THERAPY; STABILITY; SAMPLE	Background: Semantic feature analysis (SFA) is a treatment for lexical retrieval impairment in which participants are cued to provide semantic information about concepts they have difficulty naming, in an effort to facilitate accurate lexical retrieval (Boyle, 2004a). Previous work has provided preliminary evidence that persons with aphasia who participated in SFA-focused group aphasia treatment demonstrate improved lexical retrieval in discourse, with additional improvements observed in either general communication informativeness or efficiency (Antonucci, 2009). Furthermore, results suggested that individuals with differing mechanisms of anomia could derive benefits from participation in SFA-focused group treatment. Aims: The aim of the current study was to investigate further training of SFA in connected speech during group aphasia treatment. This study expanded and extended previous work (Antonucci, 2009), through the addition of participants with more varied aetiologies and severities of aphasia, and through the introduction of home practice. It was hypothesised that lexical retrieval during discourse would improve, as would overall communicative informativeness and/or efficiency. Methods & Procedures: Four individuals with aphasia participated in biweekly group treatment during which SFA was trained through connected speech tasks. Three participants presented with stroke aphasia, while one demonstrated aphasia consequent to traumatic brain injury. Discourse measures included those for overall communicative informativeness and efficiency (Nicholas & Brookshire, 1993) and for word-class-specific lexical retrieval (Mayer & Murray, 2003). Effect sizes were calculated for all discourse measures. Pre-and post-treatment performance on the spontaneous speech portion of theWestern Aphasia Battery-Revised was also analysed relative to discourse measures, to corroborate findings from more frequently repeated probes. Outcomes & Results: All four participants demonstrated improvement to communicative informativeness and/or efficiency in connected speech tasks. Conclusions: Results provide additional support for the hypothesis that SFA administered during group aphasia treatment can be used successfully to facilitate improvement of communicative effectiveness. These results also support previous findings that individuals with differing aetiologies and natures of word retrieval impairment may benefit from participation in the same SFA-focused group aphasia treatment. Future work proceeding from this study may be directed towards differentiating which aspects of the treatment are most effective across participants with varied naming impairment, what is the optimal group composition and size, and towards discerning the most effective methods for facilitating and monitoring home practice.	[Falconer, Carolyn; Antonucci, Sharon M.] NYU, Dept Commun Sci & Disorders, New York, NY 10012 USA		Antonucci, SM (corresponding author), NYU, Dept Commun Sci & Disorders, 665 Broadway,9th Floor, New York, NY 10012 USA.	sma208@nyu.edu	Falconer, Carolyn/AAI-2237-2020				Adair Ewing S, 2007, GROUP TREATMENT NEUR, P11; Antonucci SM, 2009, APHASIOLOGY, V23, P854, DOI 10.1080/02687030802634405; Beeson P. M., 2008, METAANALYSES APHASIA; Beeson P. M., 2007, GROUP TREATMENT NEUR, P148; Bernstein-Ellis E, 2007, GROUP TREATMENT NEUR, P71; Boyle M, 2004, AM J SPEECH-LANG PAT, V13, P236, DOI 10.1044/1058-0360(2004/025); Boyle M., 2001, PERSPECT NEUROPHYSIO, V11, P23, DOI [10.1044/nnsld11.2.23, DOI 10.1044/NNSLD11.2.23]; Boyle M., 2004, DISCOURSE TREATMENT; Boyle M., 1995, AM J SPEECH-LANG PAT, P94, DOI DOI 10.1044/1058-0360.0404.94; BROOKSHIRE RH, 1994, J SPEECH HEAR RES, V37, P399, DOI 10.1044/jshr.3702.399; Busk P. L., 1992, SINGLE CASE RES DESI; Clausen NS, 2003, APHASIOLOGY, V17, P625, DOI 10.1080/02687030344000003; Coelho CA, 2000, APHASIOLOGY, V14, P133, DOI 10.1080/026870300401513; Davis GA, 2005, APHASIOLOGY, V19, P21, DOI 10.1080/02687030444000598; Helm-Estabrooks N., 2003, NARRATIVE STORY CARD; Helm-Estabrooks N., 1989, MELODIC INTONATION T; Holland, 1995, AM J SPEECH-LANG PAT, V4, P109, DOI [https://doi.org/10.1044/1058-0360.0404.109, DOI 10.1044/1058-0360.0404.109]; Howard D, 1992, PYRAMIDS PALM TREES; Kaplan E, 1983, BOSTON NAMING TEST; Katz RC, 1997, J SPEECH LANG HEAR R, V40, P493, DOI 10.1044/jslhr.4003.493; Kertesz A., 2006, W APHASIA BATTERY RE; Larfeuil C, 1997, APHASIOLOGY, V11, P783, DOI 10.1080/02687039708250456; Mason C, 2011, APHASIOLOGY, V25, P245, DOI 10.1080/02687038.2010.489258; MASSARO M, 1994, CLIN APHASIOL, V22, P245; Mayer JF, 2003, APHASIOLOGY, V17, P481, DOI 10.1080/02687030344000148; MEASSO G, 1993, ACTA NEUROL SCAND, V88, P70; Meinzer M, 2005, STROKE, V36, P1462, DOI 10.1161/01.STR.0000169941.29831.2a; Miller J, 1985, SYSTEMATIC ANAL LANG; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Peach RK, 2010, APHASIOLOGY, V24, P971, DOI 10.1080/02687030903058629; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Raven J., 1998, COLOURED PROGRESSIVE; Rider JD, 2008, AM J SPEECH-LANG PAT, V17, P161, DOI 10.1044/1058-0360(2008/016); Simmons-Mackie N, 2007, TOP LANG DISORD, V27, P5, DOI 10.1097/00011363-200701000-00003; Wambaugh JL, 2007, J REHABIL RES DEV, V44, P381, DOI 10.1682/JRRD.2006.05.0038	35	35	35	0	32	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology		2012	26	1					64	82		10.1080/02687038.2011.602390			19	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	910OI	WOS:000301648700004					2022-02-06	
J	Gallun, FJ; Lewis, MS; Folmer, RL; Diedesch, AC; Kubli, LR; McDermott, DJ; Walden, TC; Fausti, SA; Lew, HL; Leek, MR				Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Diedesch, Anna C.; Kubli, Lina R.; McDermott, Daniel J.; Walden, Therese C.; Fausti, Stephen A.; Lew, Henry L.; Leek, Marjorie R.			Implications of blast exposure for central auditory function: A review	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory dysfunction; auditory processing disorder; blast; central auditory dysfunction; central auditory processing; central auditory system; hearing loss; rehabilitation; traumatic brain injury; veteran	TRAUMATIC BRAIN-INJURY; HEARING-LOSS; SPEECH IDENTIFICATION; PROCESSING DISORDER; SPATIAL SEPARATION; RECEPTIVE-FIELDS; GLOBAL WAR; CORTEX; REHABILITATION; DYSFUNCTION	Auditory system functions, from peripheral sensitivity to central processing capacities, are all at risk from a blast event. Accurate encoding of auditory patterns in time, frequency, and space are required for a clear understanding of speech and accurate localization of sound sources in environments with background noise, multiple sound sources, and/or reverberation. Further work is needed to refine the battery of clinical tests sensitive to the sorts of central auditory dysfunction observed in individuals with blast exposure. Treatment options include low-gain hearing aids, remote-microphone technology, and auditory-training regimens, but clinical evidence does not yet exist for recommending one or more of these options. As this population ages, the natural aging process and other potential brain injuries (such as stroke and blunt trauma) may combine with blast-related brain changes to produce a population for which the current clinical diagnostic and treatment tools may prove inadequate. It is important to maintain an updated understanding of the scope of the issues present in this population and to continue to identify those solutions that can provide measurable improvements in the lives of Veterans who have been exposed to high-intensity blasts during the course of their military service.	[Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Diedesch, Anna C.; McDermott, Daniel J.; Fausti, Stephen A.; Leek, Marjorie R.] Portland VA Med Ctr, Dept Vet Affairs VA Rehabil Res & Dev Natl Ctr Re, Portland, OR USA; [Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Fausti, Stephen A.; Leek, Marjorie R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Kubli, Lina R.; Walden, Therese C.] WRNMMC, Audiol & Speech Ctr, Bethesda, MD USA; [Lew, Henry L.] DVBIC, Richmond, VA USA		Gallun, FJ (corresponding author), VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	Frederick.Gallun@va.gov	Folmer, Robert L/E-3105-2010; Gallun, Frederick J./G-3792-2012	Gallun, Frederick J./0000-0002-4145-2199	VA RR&D Merit Review Award [01807]; VA RR&D Career Development II Awards [C4963-W, C7067-W]; VA RR&D Senior Research Career Scientist Award [C4042-L]; VA RR&D National Center for Rehabilitative Auditory Research; Veterans AffairsUS Department of Veterans Affairs [I01RX000536] Funding Source: NIH RePORTER	This material was based on work supported by VA RR&D Merit Review Award (grant 01807: PIs Leek, Fausti), VA RR&D Career Development II Awards (grant C4963-W: PI Gallun; and grant C7067-W: PI Lewis), VA RR&D Senior Research Career Scientist Award (grant C4042-L: PI Leek), and the VA RR&D National Center for Rehabilitative Auditory Research.	American Academy of Audiology (AAA), 2010, AM AC AUD CLIN PRACT; American Speech-Language-Hearing Association (ASHA), 2005, CENTR AUD PROC DIS W; Bamiou DE, 2006, NEUROLOGY, V67, P614, DOI 10.1212/01.wnl.0000230197.40410.db; Bregman A.S., 1990, AUDITORY SCENE ANAL; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; CHANDLER D, 2006, ASHA LEADER, P8; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Cherney LR, 2010, J HEAD TRAUMA REHAB, V25, P219, DOI 10.1097/HTR.0b013e3181dc82c1; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; Colburn H.S., 1978, HDB PERCEPT, V4, P467; CUSACK R, 2004, ECOLOGICAL PSYCHOACO, P16; Darwin Christopher J., 2008, V29, P215; DEMANY L, 2008, AUDITORY PERCEPTION, P115; *DEP VET AFF OFF P, 2011, TBI COMPR EV SUMM; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dowling W.J., 1986, MUSIC COGNITION, V1st ed.; Elhilali M, 2007, J NEUROSCI, V27, P10372, DOI 10.1523/JNEUROSCI.1462-07.2007; Elhilali M, 2008, J ACOUST SOC AM, V124, P3751, DOI 10.1121/1.3001672; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Folmer RL, 2011, INT J PSYCHOPHYSIOL, V82, P4, DOI 10.1016/j.ijpsycho.2011.03.005; Fritz J, 2003, NAT NEUROSCI, V6, P1216, DOI 10.1038/nn1141; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Griffiths TD, 2004, NAT REV NEUROSCI, V5, P887, DOI 10.1038/nrn1538; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Johnston KN, 2009, INT J AUDIOL, V48, P371, DOI 10.1080/14992020802687516; Joris PX, 2004, PHYSIOL REV, V84, P541, DOI 10.1152/physrev.00029.2003; Kandel E.R., 1991, PRINCIPLES NEURAL SC, V3rd ed.; Katz J., 1998, SSW TEST MANUAL, Vfifth; Kidd G, 2005, J ACOUST SOC AM, V118, P3804, DOI 10.1121/1.2109187; Kidd G, 2005, ACTA ACUST UNITED AC, V91, P526; Kidd Gerald Jr., 2008, V29, P143; Kohler W., 1947, GESTALT PSYCHOL, V2nd; Kuk F, 2008, J AM ACAD AUDIOL, V19, P465, DOI 10.3766/jaaa.19.6.3; Leaver AM, 2010, J NEUROSCI, V30, P7604, DOI 10.1523/JNEUROSCI.0296-10.2010; Leek MR, 2001, J ACOUST SOC AM, V109, P2944, DOI 10.1121/1.1371761; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lewis MS, 2010, VOLTA REV, V110, P31, DOI 10.17955/tvr.110.1.617; LOUI P, 2010, P 159 M AC SOC AM NO, V9, DOI DOI 10.1121/1.3431713; Loui P, 2008, CURR BIOL, V18, pR331, DOI 10.1016/j.cub.2008.02.045; Marrone N, 2008, J ACOUST SOC AM, V124, P3064, DOI 10.1121/1.2980441; Marrone N, 2008, J ACOUST SOC AM, V124, P1146, DOI 10.1121/1.2945710; Moore B.C., 2007, COCHLEAR HEARING LOS; MOORE BCJ, 1992, J ACOUST SOC AM, V91, P2881, DOI 10.1121/1.402925; Musiek FE, 2005, EAR HEARING, V26, P608, DOI 10.1097/01.aud.0000188069.80699.41; MUSIEK FE, 1983, EAR HEARING, V4, P79, DOI 10.1097/00003446-198303000-00002; MUSIEK FE, 1987, AUDIOLOGY, V26, P79; Nelken I, 2003, BIOL CYBERN, V89, P397, DOI 10.1007/s00422-003-0445-3; Noble W, 2006, INT J AUDIOL, V45, P172, DOI 10.1080/14992020500376933; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oxenham AJ, 2009, J ACOUST SOC AM, V125, P2189, DOI 10.1121/1.3089220; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; Petkov CI, 2008, NAT NEUROSCI, V11, P367, DOI 10.1038/nn2043; Petkov CI, 2006, PLOS BIOL, V4, P1213, DOI 10.1371/journal.pbio.0040215; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Saunders GH, 2012, J REHABIL RES DEV, V49, P1043, DOI 10.1682/JRRD.2010.08.0157; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scott SK, 2003, TRENDS NEUROSCI, V26, P100, DOI 10.1016/S0166-2236(02)00037-1; Shinn-Cunningham Barbara G, 2008, Trends Amplif, V12, P283, DOI 10.1177/1084713808325306; Smart Jennifer L., 2007, Australian and New Zealand Journal of Audiology, V29, P53, DOI 10.1375/audi.29.1.53; STECKER C, 2012, TRANSLATIONAL PERSPE; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tervaniemi M, 2003, BRAIN RES REV, V43, P231, DOI 10.1016/j.brainresrev.2003.08.004; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6; Wang D., 2006, COMPUTATIONAL AUDITO; Wilson Richard H, 2005, J Am Acad Audiol, V16, P367, DOI 10.3766/jaaa.16.6.5; Winer JA, 2007, HEARING RES, V229, P3, DOI 10.1016/j.heares.2007.01.017; Yost WA, 2009, ATTEN PERCEPT PSYCHO, V71, P1701, DOI 10.3758/APP.71.8.1701; Zatorre RJ, 2007, HEARING RES, V229, P24, DOI 10.1016/j.heares.2007.01.018	76	35	37	0	16	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					1059	1074		10.1682/JRRD.2010.09.0166			16	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	149EZ	WOS:000319303100009	23341279	Bronze			2022-02-06	
J	Lehan, T; Arango-Lasprilla, JC; Reyes, CJDL; Quijano, MC				Lehan, Tara; Arango-Lasprilla, Juan Carlos; Reyes, Carlos Jose de los; Quijano, Maria Cristina			The ties that bind: The relationship between caregiver burden and the neuropsychological functioning of TBI survivors	NEUROREHABILITATION			English	Article						Caregivers; burden; traumatic brain injury; neuropsychological functioning; family system	TRAUMATIC BRAIN-INJURY; FAMILY MEMBERS; REHABILITATION; IMPACT; DEPRESSION; HEALTH; ADULTS; SCALE; NEEDS	Advances in medical and assistive technology have increased the likelihood of survival following a traumatic brain injury (TBI). Consequently, families frequently must provide care to individuals with TBI. Because they are rarely prepared for the associated demanding medical needs and financial burden, family caregivers are at risk for physical and emotional problems, which can negatively influence their individual and family functioning. Whereas scholars have examined the influence of survivor functioning on caregiver burden, few have explicitly recognized that caregiver burden also influences survivor functioning. Results of a multivariate linear regression suggest that, in a sample of 51 pairs of TBI survivors and their caregivers living in Colombia, survivors receiving care from a family member who reported a higher level of burden had poorer objective neuropsychological functioning than those receiving care from a family member who reported a lower level of burden, after controlling for survivor education and history of occupational therapy. Therefore, a family-focused approach might maximize intervention effectiveness, especially for Latin American and Hispanic families, which tend to be characterized by a strong sense of familism. The emphasis on family can create problems in a healthcare system that views the individual as the primary unit.	[Lehan, Tara] Northcent Univ, Prescott Valley, AZ USA; [Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Reyes, Carlos Jose de los] Univ Norte, Dept Psychol, Barranquilla, Colombia; [Quijano, Maria Cristina] Pontificia Univ Javeriana Cali, Dept Social Sci, Cali, Colombia		Lehan, T (corresponding author), POB 4503, Richmond, VA 23220 USA.	tlehan@ncu.edu	Lehan, Tara/AAO-4793-2020	Quijano Martinez, Maria Cristina/0000-0003-3548-1628			Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Baca Zinn Maxine, 1982, HUMBOLDT J SOCIAL RE, V10, P224, DOI DOI 10.1086/493962; Borrell-Carrio F, 2004, ANN FAM MED, V2, P576, DOI 10.1370/afm.245; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Buhse M, 2008, J NEUROSCI NURS, V40, P25, DOI 10.1097/01376517-200802000-00005; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Carr D, 2010, J MARRIAGE FAM, V72, P743, DOI 10.1111/j.1741-3737.2010.00728.x; Cavallo M.M., 2011, TXB TRAUMATIC BRAIN, P483; Chou K., 2003, AM J MED SCI, V23, P73; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Dixon T. M., 2005, MED ASPECTS DISABILI, P119; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Family Caregiver Alliance, 1998, SEL TRAUM BRAIN INJ; Frosch S, 1997, BRAIN INJURY, V11, P891; Galanti Geri-Ann, 2003, J Transcult Nurs, V14, P180, DOI 10.1177/1043659603014003004; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gil M, 1996, BRAIN INJURY, V10, P39, DOI 10.1080/026990596124700; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; Harris JKJ, 2001, BRAIN INJURY, V15, P223; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T, P297; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS., 1982, NEUROBEHAVIORAL CONS; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LIEBERMAN MA, 1995, GERONTOLOGIST, V35, P94, DOI 10.1093/geront/35.1.94; Luna I, 1996, WESTERN J NURS RES, V18, P267, DOI 10.1177/019394599601800304; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Magone C. A., 1993, DEMENTIA, V4, P287; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199504000-00003; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Martin M., 1996, REV GERONTOLOGIA, V6, P338; Martin-Carrasco M, 2010, AGING MENT HEALTH, V14, P705, DOI 10.1080/13607860903586094; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; MILLER B, 1991, J HEALTH SOC BEHAV, V32, P165, DOI 10.2307/2137150; MILLER L, 1993, AM J FAM THER, V21, P111, DOI 10.1080/01926189308250910; Mittelman M, 2005, CURR OPIN PSYCHIATR, V18, P633, DOI 10.1097/01.yco.0000184416.21458.40; MONTGOMERY RJV, 1985, RES AGING, V7, P137, DOI 10.1177/0164027585007001007; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Ostrosky-Solis F, 1997, NEUROPSI EVALUACION; REINHARD SC, 1995, J MARRIAGE FAM, V57, P741, DOI 10.2307/353928; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Riviere S, 2002, INT J GERIATR PSYCH, V17, P950, DOI 10.1002/gps.724; Rolland JS, 1994, FAMILIES ILLNESS DIS; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Weihs K, 2002, FAM SYST HEALTH, V20, P7, DOI [10.1037/h0089481, DOI 10.1037/H0089481]; Zarit SH., 1985, HIDDEN VICTIMS ALZHE; [No title captured], DOI DOI 10.1097/00001199-198812000-00004	59	35	37	0	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2012	30	1					87	95		10.3233/NRE-2011-0730			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	904ZT	WOS:000301240900010	22349845				2022-02-06	
J	Lannsjo, M; Borg, J; Bjorklund, G; af Geijerstam, JL; Lundgren-Nilsson, A				Lannsjo, Marianne; Borg, Jorgen; Bjorklund, Gunilla; af Geijerstam, Jean-Luc; Lundgren-Nilsson, Asa			INTERNAL CONSTRUCT VALIDITY OF THE RIVERMEAD POST-CONCUSSION SYMPTOMS QUESTIONNAIRE	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; Rivermead Post-Concussion Symptoms Questionnaire; Rasch analysis	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURIES; RASCH ANALYSIS; MILD; MODERATE; RELIABILITY; PREDICTION; SEQUELAE; COHORT; SCALE	Objective: To investigate the internal construct validity of the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) by Rasch analysis of data from a national cohort of patients with mild traumatic brain injury. Methods: Data collected at 3 months after mild traumatic brain injury from 2,523 patients were analysed using the partial credit model, describing rating scale structure, local dependency, age and gender differential functioning, dimensionality and model fit. Results: Categories did not work in a consistent manner; however, collapsing of Categories 1 and 2 yielded ordered thresholds. Local dependency of items was present and 2 item pairs were combined. There was no differential item functioning by gender or age. The Rasch factor explained 47.7% of the variance and the first contrast explained 12.4% of the unexplained variance (eigenvalue 1.9). Further analysis indicated 3 or more dimensions. Person measure had a mean of -2.16, showing poor targeting of persons to items. Person reliability was 0.71 and person separation index was 1.56. Conclusion: According to this Rasch analysis of data from a representative sample of mild traumatic brain injury, the RPQ may not be optimal for this population. Even after reducing the number of categories and collapsing items with local dependency, unidimensionality was not reached, which argues against summation of a total score. However, the scale is unbiased for gender and age.	[Lannsjo, Marianne] Uppsala Univ, Dept Rehabil Med, Inst Neurosci, Uppsala, Sweden; [Borg, Jorgen] Karolinska Inst, Dept Rehabil Med, Inst Clin Sci, Stockholm, Sweden; [Bjorklund, Gunilla] Karolinska Inst, Dept Publ Hlth Sci, Div Publ Hlth Epidemiol, Stockholm, Sweden; [af Geijerstam, Jean-Luc] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden; [Lundgren-Nilsson, Asa] Univ Gothenburg, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, Gothenburg, Sweden		Lannsjo, M (corresponding author), Sandviken Hosp, SE-81189 Sandviken, Sweden.	marianne.lannsjo@lg.se		Borg, Jorgen/0000-0002-2372-7478; Lannsjo, Marianne/0000-0001-8792-3796	Swedish insurance company AFA; Centre for Research and Development, Uppsala University/County Council of Gavleborg	This study was supported by grants from the Swedish insurance company AFA and the Centre for Research and Development, Uppsala University/County Council of Gavleborg. Special thanks to Dr Mike Linacre for his kind support and statistical advice.	af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Angoff WH, 1993, DIFFERENTIAL ITEM FU; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Bond T. G., 2007, APPL RASCH MODEL FUN, V2; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Harrison D, 1986, MULTIVARIATE BEHAV R, V19, P49; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Holland PW, 1993, DIFFERENTIAL ITEM FU; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Linacre J M, 1999, J Outcome Meas, V3, P103; Linacre JM, 2008, WINSTEPS VERSION 3 6; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rasch G, 1960, POBABILISTIC MODELS; Reckase M.D., 1979, J EDUC BEHAV STAT, V4, P207, DOI DOI 10.3102/10769986004003207; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R M, 1998, J Outcome Meas, V2, P66; SMITH RM, 1994, OBJECTIVE MEASUREMEN, V2; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Tennant A., 2006, RASCH MEAS T, V20, P1048; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO	45	35	36	0	9	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV	2011	43	11					997	1002		10.2340/16501977-0875			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	856QN	WOS:000297658600006	22031345	gold			2022-02-06	
J	Dockree, PM; Robertson, IH				Dockree, Paul M.; Robertson, Ian H.			Electrophysiological markers of cognitive deficits in traumatic brain injury: A review	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Traumatic brain injury; ERP; Spectral EEG; Cognitive impairment	CLOSED-HEAD-INJURY; ANTERIOR CINGULATE CORTEX; INFORMATION-PROCESSING DEFICITS; DIFFUSE AXONAL INJURY; SUSTAINED ATTENTION; RESPONSE-INHIBITION; EXECUTIVE FUNCTIONS; ERP COMPONENTS; SEVERE TBI; AWARENESS	Event-related potentials (ERPs) and oscillatory activity from the human electroencephalogram (EEG) provides a rich source of data that helps elucidate specific processing impairments in TBI patients. This review will focus on some of the central and disabling cognitive deficits in TBI and how broadband ERP markers and the spectral content of the EEG can help explain abnormalities in brain function that impact upon processing speed, sustained attention, performance monitoring, inhibitory control and cognitive flexibility. Physiological signals also provide useful outcome markers in cognitive intervention studies in conjunction with behavioural endpoints. Potential rehabilitation approaches utilising electrophysiological markers of recovery are also discussed. Progress has been made in recent years in defining key pathophysiological mechanisms in the context of sensitive laboratory paradigms. However, aberrant physiological signals need to be understood more clearly in future studies in terms of the neuroanatomical impact of injury, particularly in relation to the most common type of damage in TBI, disrupting extended white matter fibres. (C) 2011 Elsevier B.V. All rights reserved.	[Dockree, Paul M.] Trinity Coll Dublin, Sch Psychol, Dublin, Ireland; Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dublin, Ireland		Dockree, PM (corresponding author), Trinity Coll Dublin, Sch Psychol, Dublin, Ireland.	dockreep@tcd.ie		Robertson, Ian H/0000-0001-8637-561X	Health Research Board, Ireland	This work was supported by a grant from the Health Research Board, Ireland.	Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Boksem MAS, 2008, BIOL PSYCHOL, V79, P185, DOI 10.1016/j.biopsycho.2008.04.010; CAMPBELL KB, 1990, ELECTROEN CLIN NEURO, P202; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Damasio A.R, 1998, PREFRONTAL CORTEX EX, P103; de Bruijn ERA, 2004, PSYCHOPHARMACOLOGY, V177, P151, DOI 10.1007/s00213-004-1915-6; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; Dockree PM, 2006, BRAIN, V129, P128, DOI 10.1093/brain/awh664; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fassbender C, 2009, EUR J NEUROSCI, V29, P181, DOI 10.1111/j.1460-9568.2008.06557.x; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Frank MJ, 2007, COGN AFFECT BEHAV NE, V7, P297, DOI 10.3758/CABN.7.4.297; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI 10.1016/j.biopsycho.2006.11.003; Gaetz M, 2000, BRAIN INJURY, V14, P815; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Holroyd CB, 2008, CORTEX, V44, P548, DOI 10.1016/j.cortex.2007.08.013; Iznak EV, 2010, ZH NEVROL PSIKHIATR, V110, P27; Jiang Q, 2010, STROKE, V41, pS112, DOI 10.1161/STROKEAHA.110.595629; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lew HL, 2009, AM J PHYS MED REHAB, V88, P1, DOI 10.1097/PHM.0b013e3181911102; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lutz A, 2009, J NEUROSCI, V29, P13418, DOI 10.1523/JNEUROSCI.1614-09.2009; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Marquez de la Plata C.D., 2010, J INT NEUROPSYCH SOC, P1; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Morton N, 2010, J INT NEUROPSYCH SOC, V16, P1089, DOI 10.1017/S1355617710000925; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; O'Connell B.C., 2010, 20 ANN ROTM RES I C; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, J NEUROSCI, V29, P8604, DOI 10.1523/JNEUROSCI.5967-08.2009; O'Connell RG, 2004, NEUROREPORT, V15, P2535, DOI 10.1097/00001756-200411150-00021; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Prigatano G., 1986, COGNITIVE DYSFUNCTIO; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Rule RR, 2002, COGN AFFECT BEHAV NE, V2, P264, DOI 10.3758/CABN.2.3.264; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Smallwood J, 2008, J COGNITIVE NEUROSCI, V20, P458, DOI 10.1162/jocn.2008.20037; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977	92	35	36	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		53	60		10.1016/j.ijpsycho.2011.01.004			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600006	21238506				2022-02-06	
J	Schneider, EB; Efron, DT; MacKenzie, EJ; Rivara, FP; Nathens, AB; Jurkovich, GJ				Schneider, Eric B.; Efron, David T.; MacKenzie, Ellen J.; Rivara, Frederick P.; Nathens, Avery B.; Jurkovich, Gregory J.			Premorbid Statin Use Is Associated With Improved Survival and Functional Outcomes in Older Head-Injured Individuals	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Statins; Head trauma; Survival; Functional outcomes	MORTALITY; TRAUMA; SEPSIS; SCALE; ONSET; BRAIN; RISK	Objective: To determine whether preinjury statin use is associated with survival and functional recovery in older adult victims of moderate/severe head trauma. Methods: Using the National Study of Costs and Outcomes of Trauma dataset compiled from 69 US hospitals, the effect of preinjury statin use was assessed for in-hospital mortality and functional outcome in patients aged >= 65 with head injury Abbreviated Injury Score (AIS) >= 3. Individuals dying within 24 hours of admission or presenting with fixed dilated pupils were excluded. The Extended Glasgow Outcome Scale, dichotomized at the ability to return to premorbid major activity, was used to measure functional outcome. Multivariate regression modeled statin use and outcomes controlling for demographic, comorbidity, and injury characteristics. Results: Of 523 eligible individuals, 117 (22%) used statins at the time of injury. Statin use was associated with a 76% lower adjusted risk of in-hospital death (relative risk[RR] = 0.24; 95% confidence interval [CI], 0.08-0.69). Of 395 individuals discharged alive, 303 survived 1 year and 264 had complete Extended Glasgow Outcome Scale scores. Statin users and nonusers demonstrated similar risk of good recovery at 3 months (RR = 0.83; 95% CI, 0.46-1.49). At 12 months postinjury, statin users had 13% higher likelihood of good recovery (RR = 1.13; 95% CI, 1.01-1.26). The presence of cardiovascular comorbidities abrogated this effect. Conclusion: Preinjury statin use in older adult traumatic brain injury victims is associated with reduced risk of death and improved functional recovery at 12 months postinjury. Individuals with cardiovascular comorbidities lose this benefit of premorbid statin use. Statins, as possible protective agents in head trauma, warrant further study.	[Schneider, Eric B.] Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21218 USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Jurkovich, Gregory J.] Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA; [Nathens, Avery B.] St Michaels Hosp, Dept Surg, Toronto, ON M5B 1W8, Canada; [Efron, David T.] Johns Hopkins Sch Med, Div Acute Care Surg & Adult Trauma Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21218 USA		Schneider, EB (corresponding author), Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, 600 N Wolfe St,Harvey 611, Baltimore, MD 21218 USA.	eschnei1@jhmi.edu					Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1; *BRAIN INJ ASS, 2006, FACTS TRAUM BRAIN IN; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; Cimino M, 2007, NEUROSCIENTIST, V13, P208, DOI 10.1177/1073858406297121; Dormuth CR, 2009, CIRCULATION, V119, P2051, DOI 10.1161/CIRCULATIONAHA.108.824151; Efron DT, 2008, J TRAUMA, V64, P66, DOI 10.1097/TA.0b013e31815b842a; Elkind MSV, 2005, NEUROLOGY, V65, P253, DOI 10.1212/01.WNL.0000171746.63844.6a; Galley HF, 1996, BRIT J ANAESTH, V77, P11, DOI 10.1093/bja/77.1.11; Hackam DG, 2006, LANCET, V367, P413, DOI 10.1016/S0140-6736(06)68041-0; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MACKENZIE EJ, 1986, AM ASS AUT MED P 30; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; McGirt MJ, 2006, NEUROSURGERY, V58, P945, DOI 10.1227/01.NEU.0000210262.67628.7E; Neal MD, 2009, J TRAUMA, V67, P476, DOI 10.1097/TA.0b013e3181ad66bb; OSLER T, 1997, J TRAUMA, V43, P992; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13	21	35	38	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					815	819		10.1097/TA.0b013e3182319de5			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	833ZT	WOS:000295925700013	21986733				2022-02-06	
J	Ziebell, JM; Bye, N; Semple, BD; Kossmann, T; Morganti-Kossmann, MC				Ziebell, Jenna M.; Bye, Nicole; Semple, Bridgette D.; Kossmann, Thomas; Morganti-Kossmann, Maria Cristina			Attenuated neurological deficit, cell death and lesion volume in Fas-mutant mice is associated with altered neuroinflammation following traumatic brain injury	BRAIN RESEARCH			English	Article						Cell death; Caspase; Cytokine; Fas; Neuroinflammation; Traumatic brain injury	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; TNF-ALPHA; NEUTROPHIL INFILTRATION; MONOCLONAL-ANTIBODY; EXPRESSION; APOPTOSIS; LIGAND; RAT	Progressive neurodegeneration following traumatic brain injury (TBI) involves the Fas and TNF-receptor1 protein systems which have been implicated in mediating delayed cell death. In this study, we used two approaches to assess whether inhibition of these pathways reduced secondary brain damage and neurological deficits after TBI. Firstly, we investigated whether the expression of non-functional Fas in lpr mice subjected to TBI altered tissue damage and neurological outcome. Compared to wild-type, lpr mice showed improved neurological deficit (p=0.0009), decreased lesion volume (p=0.017), number of TUNEL+cells (p=0.011) and caspase-3+ cells (p=0.007). Changes in cellular inflammation and cytokine production were also compared between mouse strains. Accumulation of macrophages/microglia occurred earlier in lpr mice, likely due to enhanced production of the chemotactic mediators IL-12(p40) and MCP-1 (p<0.05). Cortical production of IL-1 alpha and IL-6 increased after injury to a similar extent regardless of strain (p<0.05), while TNT and G-CSF were significantly higher in lpr animals (p<0.05). Secondly, we assessed whether therapeutic inhibition of FasL and TNF via intravenous injection of neutralizing antibodies in wild-type mice post-TBI could reproduce the beneficial effects observed in lpr animals. No differences were found with this approach in animals treated with anti-FasL and anti-TNF antibodies alone or the combination of both. Altogether, reduced neurological deficits and lesion volume in lpr mice was associated with altered cellular and humoral inflammation, possibly contributing to neuroprotection, whereas neutralization of FasL and TNF had no effect. In future studies, the lpr mouse strain may be utilized as a model to further characterize molecular and cellular mechanisms protecting against secondary brain damage after TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Ziebell, Jenna M.; Bye, Nicole; Semple, Bridgette D.; Morganti-Kossmann, Maria Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ziebell, Jenna M.; Bye, Nicole; Semple, Bridgette D.; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Kossmann, Thomas] EpworthHealth, Melbourne, Vic, Australia		Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu	Ziebell, Jenna/Y-4496-2019	Ziebell, Jenna/0000-0003-2497-4347; Morganti-Kossmann, Cristina/0000-0002-0807-2063	Victorian Neurotrauma Initiative (VNI); Transport Accident Commission (TAC); Bethlehem Griffiths Research Foundation; L.E.W. Carty Charitable Fund	The authors would like to thank Dr Ian Musgrave for his advice on nonparametric data analysis. This study was supported by the Victorian Neurotrauma Initiative (VNI) program grant and Senior research Fellowship to CM-K, Transport Accident Commission (TAC), Bethlehem Griffiths Research Foundation and L.E.W. Carty Charitable Fund.	Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conti AC, 1998, J NEUROSCI, V18, P5663; Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fujikawa DG, 2002, J NEUROCHEM, V83, P229, DOI 10.1046/j.1471-4159.2002.01152.x; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Letellier E, 2010, IMMUNITY, V32, P240, DOI 10.1016/j.immuni.2010.01.011; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Mehmet H, 2001, CELL DEATH DIFFER, V8, P659, DOI 10.1038/sj.cdd.4400899; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Qiu JH, 2002, J NEUROSCI, V22, P3504; Sabelko KA, 1997, J IMMUNOL, V159, P3096; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Schroeter M, 2003, MOL BRAIN RES, V117, P1, DOI 10.1016/S0169-328X(03)00255-9; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yoshimoto T, 1998, J IMMUNOL, V160, P588; Yoshino O, 2004, SPINE, V29, P1394, DOI 10.1097/01.BRS.0000129894.34550.48; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	35	37	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 26	2011	1414						94	105		10.1016/j.brainres.2011.07.056			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	830MI	WOS:000295660700011	21871613				2022-02-06	
J	Li, Y; Zhang, LY; Kallakuri, S; Zhou, RZ; Cavanaugh, JM				Li, Yan; Zhang, Liying; Kallakuri, Srinivasu; Zhou, Runzhou; Cavanaugh, John M.			Quantitative Relationship between Axonal Injury and Mechanical Response in a Rodent Head Impact Acceleration Model	JOURNAL OF NEUROTRAUMA			English	Article						corpus callosum; head impact acceleration model; linear and angular head motion; rat; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; INTRAAXONAL NEUROFILAMENT COMPACTION; CONTROLLED CORTICAL IMPACT; OPTIC-NERVE; RAT MODEL; AXOLEMMAL PERMEABILITY; DIFFUSE; DAMAGE; BIOMECHANICS; EXPRESSION	A modified Marmarou impact acceleration model was developed to study the mechanical responses induced by this model and their correlation to traumatic axonal injury (TAI). Traumatic brain injury (TBI) was induced in 31 anesthetized male Sprague-Dawley rats (392 +/- 13 g) by a custom-made 450-g impactor from heights of 1.25 m or 2.25 m. An accelerometer and angular rate sensor measured the linear and angular responses of the head, while the impact event was captured by a high-speed video camera. TAI distribution along the rostro-caudal direction, as well as across the left and right hemispheres, was determined using beta-amyloid precursor protein (beta-APP) immunocytochemistry, and detailed TAI injury maps were constructed for the entire corpus callosum. Peak linear acceleration 1.25 m and 2.25 m impacts were 666 +/- 165 g and 907 +/- 501 g, respectively. Peak angular velocities were 95 +/- 24 rad/sec and 124 +/- 48 rad/sec, respectively. Compared to the 2.25-m group, the observed TAI counts in the 1.25-m impact group were significantly lower. Average linear acceleration, peak angular velocity, average angular acceleration, and surface righting time were also significantly different between the two groups. A positive correlation was observed between normalized total TAI counts and average linear acceleration (R-2=0.612, p < 0.05), and time to surface right (R-2=0.545, p < 0.05). Our study suggested that a 2.25-m drop in the Marmarou model may not always result in a severe injury, and TAI level is related to the linear and angular acceleration response of the rat head during impact, not necessarily the drop height.	[Li, Yan; Zhang, Liying; Kallakuri, Srinivasu; Zhou, Runzhou; Cavanaugh, John M.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA		Zhang, LY (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock St, Detroit, MI 48201 USA.	lzhang@wayne.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EB006508]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB006508] Funding Source: NIH RePORTER	The work was supported by National Institutes of Health grant R01 EB006508.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Blumbergs PC, 1997, HEAD INJURY PATHOPHY, P39; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Czeiter E, 2008, J NEUROTRAUM, V25, P205, DOI 10.1089/neu.2007.0331; Dieterich DC, 2002, NEUROSCI LETT, V317, P29, DOI 10.1016/S0304-3940(01)02418-1; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fei Z, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-96; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist MD, 2004, STRAIN, V40, P180, DOI 10.1111/j.1475-1305.2004.00168.x; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Kallakuri S, 2007, NEUROL RES, V29, P362, DOI 10.1179/016164107X204675; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; King A. I., 2003, IRCOBI C LISB PORT; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1993, CRASHWORTHINESS OCCU, V169, P169; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; PRASAD P, 1985, 851246 SAE; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Rhodes JKJ, 2002, NEUROSCI LETT, V335, P1, DOI 10.1016/S0304-3940(02)00811-X; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Sawauchi S, 2004, J NEUROTRAUM, V21, P563, DOI 10.1089/089771504774129892; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Sengul G, 2008, J CLIN NEUROSCI, V15, P1125, DOI 10.1016/j.jocn.2007.11.005; Shafieian M, 2009, J BIOMECH, V42, P2136, DOI 10.1016/j.jbiomech.2009.05.041; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Ueda T, 2001, MOL BRAIN RES, V86, P63, DOI 10.1016/S0169-328X(00)00261-8; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071; Wang HC, 2010, J CLIN NEUROSCI, V17, P157, DOI 10.1016/j.jocn.2009.07.099; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zhang L, 2001, Stapp Car Crash J, V45, P369; ZHANG L, 2010, P IBIA 8 WORLD C BRA; ZHANG L, 2010, J NEUROTRAUM, V26, pA18; ZHANG L, 2005, P ASME BIOENG C 5480; ZHANG L, 2011, J NEUROTRAUMA, V28, pA26; Zhang LY, 2011, J NEUROSCI METH, V198, P93, DOI 10.1016/j.jneumeth.2011.03.024; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	87	35	36	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1767	1782		10.1089/neu.2010.1687			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000010	21895482	Green Published			2022-02-06	
J	Ma, HY; Yu, B; Kong, L; Zhang, YY; Shi, YX				Ma, Haiying; Yu, Bo; Kong, Li; Zhang, Yuanyuan; Shi, Yuxiu			Transplantation of neural stem cells enhances expression of synaptic protein and promotes functional recovery in a rat model of traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						neural stem cell; transplantation; traumatic brain injury; synaptogenesis	FLUID PERCUSSION INJURY; SPINAL-CORD; BEHAVIORAL RECOVERY; ADULT-RAT; GAP-43; MICE; HIPPOCAMPUS; NEURONS; CORTEX; MOUSE	Transplantion of neural stem cells (NSCs) has shown promise for the treatment of traumatic brain injury (TBI). Although the functional mechanisms underlying transplant-mediated recovery following TBI have yet to be determined, previous studies demonstrated that transplanted NSCs may respond to the release of specific neurotransmitters, and/or the production of factors that promote neuronal growth. Therefore, we hypothesize that the direct transplantation of NSCs into the injured brain enhanced the expression of synaptic protein and regeneration-associated protein, which may be responsible for promoting functional recovery in a rat model of TBI. Our results showed that NSC transplant significantly improved neurological motor function in selected behavioral tests compared to saline control rats. Our data showed that the number of surviving cells engrafted into the rats was 4.1 +/- 0.9% of engrafted cells at 8 weeks post-transplantation, with 11.4 +/- 1.6% beta III-tubulin-immunopositive cells of these cells. RT-PCR and Western blot analysis demonstrated that the expression of synaptophysin (SYP) and regeneration-associated protein (GAP43) in the injured brain of NSC-transplanted rats was significantly increased compared to the saline control rats during the experimental period. These data suggest that NSCs transplanted directly into the injured brain are capable of surviving, differentiating into neurons and promoting functional recovery in a rat model of TBI. Engrafted NSCs increase the expression of SYP and GAP43 in the injured brain of NSC-transplanted rats, which is suggested as one of the mechanisms underlying the improved functional recovery on motor behavior due to the transplantation of NSCs following TBI.	[Ma, Haiying; Kong, Li; Shi, Yuxiu] China Med Univ, Dept Histol & Embryol, Inst Pathol & Pathophysiol, Shenyang 110001, Peoples R China; [Yu, Bo] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110004, Peoples R China; [Ma, Haiying; Kong, Li; Zhang, Yuanyuan] Dalian Med Univ, Dept Histol & Embryol, Liaoning 116044, Peoples R China; [Zhang, Yuanyuan] Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA		Shi, YX (corresponding author), China Med Univ, Dept Histol & Embryol, Inst Pathol & Pathophysiol, 92 Beima Rd, Shenyang 110001, Peoples R China.	yuxiushi@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30850001]; Education Bureau, Liaoning Province, China [2008779, 2008851]	This study was supported by grants from the National Natural Science Foundation of China (No. 30850001) and the S&T Research Project of the Education Bureau, Liaoning Province, China (No. 2008779 and 2008851). We thank Professor Xuehu Ma and Associate Professor Shui Guan from the Stem Cell and Tissue Engineering Laboratory of Dalian University of Technology for their support in culturing NSCs.	AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Benninger Y, 2000, BRAIN PATHOL, V10, P330; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Buffo A, 2003, EUR J NEUROSCI, V18, P2146, DOI 10.1046/j.1460-9568.2003.02940.x; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Fauza DO, 2008, SURGERY, V144, P367, DOI 10.1016/j.surg.2008.05.009; Fournier AE, 1997, J NEUROSCI RES, V47, P561, DOI 10.1002/(SICI)1097-4547(19970315)47:6<561::AID-JNR1>3.0.CO;2-B; Fricker-Gates RA, 2001, RESTOR NEUROL NEUROS, V19, P119; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hughes-Davis EJ, 2005, NEUROSCIENCE, V135, P1231, DOI 10.1016/j.neuroscience.2005.07.017; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; JACOBS KM, 1993, J COMP NEUROL, V336, P151, DOI 10.1002/cne.903360112; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Kong L, 2010, NEUROBIOL DIS, V38, P446, DOI 10.1016/j.nbd.2010.03.005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liebau S, 2007, STEM CELLS, V25, P1720, DOI 10.1634/stemcells.2006-0823; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Ma XH, 2010, CRYOBIOLOGY, V60, P184, DOI 10.1016/j.cryobiol.2009.10.013; MASLIAH E, 1994, ACTA NEUROPATHOL, V87, P135; Modo M, 2002, STROKE, V33, P2270, DOI 10.1161/01.STR.0000027693.50675.C5; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	32	35	39	1	9	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997			MOL MED REP	Mol. Med. Rep.	SEP-OCT	2011	4	5					849	856		10.3892/mmr.2011.510			8	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	801JQ	WOS:000293435300013	21687946	Bronze			2022-02-06	
J	Picard, C; Pasquier, F; Martinaud, O; Hannequin, D; Godefroy, O				Picard, Candice; Pasquier, Florence; Martinaud, Olivier; Hannequin, Didier; Godefroy, Olivier			Early Onset Dementia Characteristics in a Large Cohort From Academic Memory Clinics	ALZHEIMER DISEASE & ASSOCIATED DISORDERS			English	Article						dementia; Alzheimer's disease; frontotemporal lobar degeneration; lewy body dementia; alcoholic dementia	DIAGNOSTIC-CRITERIA; INTERNATIONAL WORKSHOP; PREVALENCE; FREQUENCY; CONSENSUS; DISEASE	Aim: To describe the characteristics of early-onset dementia (EOD) in a cohort from 3 memory clinics. Methods: We assessed all patients with dementia referred to the Academic Memory Clinics at Amiens, Lille, and Rouen University Medical Centers between 2005 and 2007. Patients aged less than 65 years at the time of onset of symptom were included in the EOD group, whereas older patients were included in the late-onset dementia (LOD) group. Results: Three thousand four hundred and seventy-three patients (including 1932 women) were included and 811 (23.4%) were classified as EOD. The sex ratio was 1.12, whereas women were overrepresented in LOD (P = 0.001). Patients with EOD were more frequently (P = 0.001) living at home (87.3%), they had a lower educational level than the general population (P = 0.0001) but were more educated (P = 0.001). The current Mini Mental State Examination did not differ (P = 0.3) between EOD (18.6 +/- 7.6) and LOD (18.9 +/- 6). The most common causes of EOD were Alzheimer's (22.3%) and vascular (15.9%) diseases and 4 pathologies that were significantly more frequent (P = 0.001) than in the LOD group: frontotemporal dementia (9.7%), alcohol-related dementia (9.4%), traumatic brain injury (3.8%), and Huntington's disease (3%). Conclusions: EOD is characterized by specific features and different causes although Alzheimer's and vascular dementias remain the main causes of dementia in EOD.	[Picard, Candice; Godefroy, Olivier] Univ Hosp Amiens, Dept Neurol, Amiens, France; [Martinaud, Olivier; Hannequin, Didier] Lille Nord France, UDSL EA 1046, Lille, France; [Martinaud, Olivier; Hannequin, Didier] INSERM, F-75654 Paris 13, France; [Martinaud, Olivier; Hannequin, Didier] Rouen CNR MAJ, Rouen, France		Picard, C (corresponding author), Hop Nord Amiens, Picard Serv Neurol, F-80054 Amiens, France.	picard.candice@chu-amiens.fr	Martinaud, Olivier/AAS-9307-2020; Pasquier, Florence/F-1527-2017; Godefroy, Olivier/D-6117-2012	Pasquier, Florence/0000-0001-9880-9788; Godefroy, Olivier/0000-0001-6789-6620			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Emre M, 2007, MOVEMENT DISORD, V22, P1689, DOI 10.1002/mds.21507; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; *HAS, 2008, DIAGN TREATM; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P736, DOI 10.1093/ije/20.3.736; Ikejima C, 2009, STROKE, V40, P2709, DOI 10.1161/STROKEAHA.108.542308; Kelley BJ, 2008, ARCH NEUROL-CHICAGO, V65, P1502, DOI 10.1001/archneur.65.11.1502; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McMurtray A, 2006, DEMENT GERIATR COGN, V21, P59, DOI 10.1159/000089546; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Oslin D, 1998, INT J GERIATR PSYCH, V13, P203, DOI 10.1002/(SICI)1099-1166(199804)13:4<203::AID-GPS734>3.0.CO;2-B; Panegyres Peter K, 2007, Am J Alzheimers Dis Other Demen, V22, P48, DOI 10.1177/1533317506295887; Papageorgiou SG, 2009, ALZ DIS ASSOC DIS, V23, P347, DOI 10.1097/WAD.0b013e31819e6b28; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Shinagawa S, 2007, DEMENT GERIATR COGN, V24, P42, DOI 10.1159/000102596; Yokota O, 2005, EUR J NEUROL, V12, P782, DOI 10.1111/j.1468-1331.2005.01072.x	18	35	37	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0893-0341			ALZ DIS ASSOC DIS	Alzheimer Dis. Assoc. Dis.	JUL-SEP	2011	25	3					203	205		10.1097/WAD.0b013e3182056be7			3	Clinical Neurology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	811JW	WOS:000294206600003	21192236				2022-02-06	
J	Abdel-Salam, OME				Abdel-Salam, Omar M. E.			Stem Cell Therapy for Alzheimer's Disease	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimer's disease; stem cells; neurogenesis; hippocampus	AMYLOID PRECURSOR PROTEIN; MARROW STROMAL CELLS; ADULT HIPPOCAMPAL NEUROGENESIS; TRANSGENIC MOUSE MODEL; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; MICROTUBULE-ASSOCIATED PROTEIN; PROMOTES FUNCTIONAL RECOVERY; NEURONAL PROGENITOR CELLS; IN-VITRO DIFFERENTIATION	Alzheimer's disease (AD) is a progressive neurodegenerative disorder which impairs the memory and intellectual abilities of the affected individuals. Loss of episodic as well as semantic memory is an early and principal feature. The basal forebrain cholinergic system is the population of neurons most affected by the neurodegenerative process. Extracellular as well as intracellular deposition of beta-amyloid or Abeta (A beta) protein, intracellular formation of neurofibrillary tangles and neuronal loss are the neuropathological hallmarks of AD. In the last few years, hopes were raised that cell replacement therapy would provide cure by compensating the lost neuronal systems. Stem cells obtained from embryonic as well as adult tissue and grafted into the intact brain of mice or rats were mostly followed by their incorporation into the host parenchyma and differentiation into functional neural lineages. In the lesioned brain, stem cells exhibited targeted migration towards the damaged regions of the brain, where they engrafted, proliferated and matured into functional neurones. Neural precursor cells can be intravenously administered and yet migrate into brain damaged areas and induce functional recovery. Observations in animal models of AD have provided evidence that transplanted stem cells or neural precursor cells (NPCs) survive, migrate, and differentiate into cholinergic neurons, astrocytes, and oligodendrocytes with amelioration of the learning/memory deficits. Besides replacement of lost or damaged cells, stem cells stimulate endogenous neural precursors, enhance structural neuroplasticity, and down regulate proinflammatory cytokines and neuronal apoptotic death. Stem cells could also be genetically modified to express growth factors into the brain. In the last years, evidence indicated that the adult brain of mammals preserves the capacity to generate new neurons from neural stem/progenitor cells. Inefficient adult neurogenesis may contribute to the pathogenesis of AD and other neurodegenerative disorders. An attempt at mobilizing this endogenous pool of resident stem-like cells provides another attractive approach for the treatment of AD. Studies in patients with AD indicated decreased hippocampal volume derived by neurodegeneration. Intriguingly, many drugs including antidepressants, lithium, acetyl cholinesterase inhibitors, and ginkgo biloba, were able to enhance the impaired neurogenesis in this disease process. This paved the way towards exploring the possible pharmacological manipulation of neurogenesis which would offer an alternative approach for the treatment of AD.	[Abdel-Salam, Omar M. E.] Natl Res Ctr, Dept Pharmacol, Cairo, Egypt; [Abdel-Salam, Omar M. E.] Natl Res Ctr, Dept Toxicol & Narcot, Cairo, Egypt		Abdel-Salam, OME (corresponding author), Natl Res Ctr, Dept Pharmacol, Cairo, Egypt.	omasalam@hotmail.com	Abdel-Salam, Omar M.E./L-1296-2017	Abdel-Salam, Omar M.E./0000-0002-4450-1582			Abdipranoto A, 2008, CNS NEUROL DISORD-DR, V7, P187, DOI 10.2174/187152708784083858; Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Aizenstein HJ, 2008, ARCH NEUROL-CHICAGO, V65, P1509, DOI 10.1001/archneur.65.11.1509; ALEKSANDROVA MA, 2003, RUSS J DEV BIOL, V34, P131; Alexanian AR, 2008, STEM CELLS DEV, V17, P1123, DOI 10.1089/scd.2007.0212; Alley GM, 2010, J NEUROSCI RES, V88, P143, DOI 10.1002/jnr.22172; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Amaral DG, 1999, HIPPOCAMPUS, V9, P1; Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Ando K, 1999, J NEUROSCI, V19, P4421; Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108; Ashford JW, 2002, J ALZHEIMERS DIS, V4, P169, DOI 10.3233/JAD-2002-4307; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Baddeley A, 2001, PHILOS T R SOC B, V356, P1345, DOI 10.1098/rstb.2001.0957; Baharvand H, 2007, INT J DEV BIOL, V51, P371, DOI 10.1387/ijdb.072280hb; BALIN B, 2006, ALZHEIMERS DEMENT, V2, pS431; BALL MJ, 1977, ACTA NEUROPATHOL, V37, P111, DOI 10.1007/BF00692056; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Baron R, 2008, FASEB J, V22, P2843, DOI 10.1096/fj.08-105866; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Becker M, 2007, P NATL ACAD SCI USA, V104, P1691, DOI 10.1073/pnas.0610180104; Bell-McGinty S, 2002, AM J PSYCHIAT, V159, P1424, DOI 10.1176/appi.ajp.159.8.1424; Bentz K, 2007, J NEUROSCI RES, V85, P1057, DOI 10.1002/jnr.21219; Bithell A, 2005, CLIN SCI, V108, P13, DOI 10.1042/CS20040276; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Boekhoorn K, 2006, J NEUROSCI, V26, P3514, DOI 10.1523/JNEUROSCI.5425-05.2006; Boekhoorn K, 2006, NEUROBIOL DIS, V24, P1, DOI 10.1016/j.nbd.2006.04.017; Boldrini M, 2009, NEUROPSYCHOPHARMACOL, V34, P2376, DOI 10.1038/npp.2009.75; Bondolfi L, 2002, J NEUROSCI, V22, P515, DOI 10.1523/JNEUROSCI.22-02-00515.2002; Bonnet E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003487; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Brera B, 2000, NEUROBIOL DIS, V7, P395, DOI 10.1006/nbdi.2000.0313; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Bueller JA, 2006, BIOL PSYCHIAT, V59, P812, DOI 10.1016/j.biopsych.2005.09.022; Bussiere T, 2004, AM J PATHOL, V165, P987, DOI 10.1016/S0002-9440(10)63360-3; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Calingasan NY, 2008, NEUROSCIENCE, V153, P986, DOI 10.1016/j.neuroscience.2008.02.071; Casalbore P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004434; Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X; Celsi F, 2007, NEUROBIOL DIS, V26, P342, DOI 10.1016/j.nbd.2006.12.022; Chen HH, 2007, NEUROBIOL AGING, V28, P1148, DOI 10.1016/j.neurobiolaging.2006.05.036; Chen Q, 2008, NEUROBIOL DIS, V29, P316, DOI 10.1016/j.nbd.2007.09.005; Chen X, 2006, IUBMB LIFE, V58, P686, DOI 10.1080/15216540601047767; Chen Y, 2009, CELL DEATH DIFFER, V16, P386, DOI 10.1038/cdd.2008.94; Chevallier NL, 2005, AM J PATHOL, V167, P151, DOI 10.1016/S0002-9440(10)62962-8; Choi SH, 2008, NEURON, V59, P568, DOI 10.1016/j.neuron.2008.07.033; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; CLARE L, 2004, ESSENTIAL HDB MEMORY, P255; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3; COOKE JA, 2007, CULTURE HUMAN STEM C, P23; Cotel MC, 2008, BRAIN RES, V1222, P207, DOI 10.1016/j.brainres.2008.05.052; Covacu R, 2006, STEM CELLS, V24, P2792, DOI 10.1634/stemcells.2005-0640; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Cummings JL, 2002, AM FAM PHYSICIAN, V65, P2525; Czeh B, 2007, NEUROPSYCHOPHARMACOL, V32, P1490, DOI 10.1038/sj.npp.1301275; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; De Rosa R, 2005, P NATL ACAD SCI USA, V102, P3811, DOI 10.1073/pnas.0500195102; De Strooper B, 2000, J CELL SCI, V113, P1857; DeKosky ST, 1996, NEURODEGENERATION, V5, P417, DOI 10.1006/neur.1996.0056; DEMARS MP, 2008, ALZHEIMERS DEMENT S1, V4, pT633; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dodart JC, 2005, P NATL ACAD SCI USA, V102, P1211, DOI 10.1073/pnas.0409072102; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Doody RS, 2003, J CLIN PSYCHIAT, V64, P11; DOODY RS, 1995, J NEUROPSYCH CLIN N, V7, P54; Dorningues A, 2007, NEUROCHEM INT, V50, P872, DOI 10.1016/j.neuint.2007.03.001; Driscoll I, 2009, NEUROLOGY, V72, P1906, DOI 10.1212/WNL.0b013e3181a82634; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Du AT, 2007, BRAIN, V130, P1159, DOI 10.1093/brain/awm016; Du H, 2010, BBA-MOL BASIS DIS, V1802, P198, DOI 10.1016/j.bbadis.2009.07.005; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Eckert A, 2008, NEURODEGENER DIS, V5, P157, DOI 10.1159/000113689; Eder-Colli L, 2009, BRAIN RES BULL, V80, P296, DOI 10.1016/j.brainresbull.2009.06.007; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Einstein O, 2007, ANN NEUROL, V61, P209, DOI 10.1002/ana.21033; El Seady R, 2008, BIOCHEM BIOPH RES CO, V376, P358, DOI 10.1016/j.bbrc.2008.08.166; Engler H, 2006, BRAIN, V129, P2856, DOI 10.1093/brain/awl178; Erceg S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002122; Ermini FV, 2008, AM J PATHOL, V172, P1520, DOI 10.2353/ajpath.2008.060520; Erten-Lyons D, 2009, NEUROLOGY, V72, P354, DOI 10.1212/01.wnl.0000341273.18141.64; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Eucher JN, 2007, EXP NEUROL, V203, P486, DOI 10.1016/j.expneurol.2006.09.021; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; Falke E, 2003, AM J PATHOL, V163, P1615, DOI 10.1016/S0002-9440(10)63518-3; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Fleischman DA, 1999, CURR OPIN NEUROBIOL, V9, P240, DOI 10.1016/S0959-4388(99)80034-8; Fletcher PC, 1995, EXPERIENTIA, V51, P1197, DOI 10.1007/BF01944737; Folin M, 2003, INT J MOL MED, V11, P267; Francis PT, 1999, J NEUROL NEUROSUR PS, V67, P558; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V88, P8362, DOI 10.1073/pnas.88.19.8362; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Frodl T, 2008, J PSYCHIATR NEUROSCI, V33, P423; Galvan Veronica, 2007, CNS & Neurological Disorders-Drug Targets, V6, P303, DOI 10.2174/187152707783220938; Galvin KA, 2006, NEUROREHABILITATION, V21, P255; Gan L, 2008, NEUROBIOL DIS, V29, P71, DOI 10.1016/j.nbd.2007.08.002; Garbuzova-Davis S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002494; Garzon DJ, 2007, J NEUROSCI, V27, P2628, DOI 10.1523/JNEUROSCI.5053-06.2007; GELINAS D, 2006, ALZHEIMERS DEMENT S1, V2, pS476; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Glover J. C., 2008, STEM CELLS HUMAN EMB, P55; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Gonul AS, 2005, EUR ARCH PSY CLIN N, V255, P381, DOI 10.1007/s00406-005-0578-6; Guerin D, 2009, NEUROBIOL AGING, V30, P272, DOI 10.1016/j.neurobiolaging.2007.05.020; Guzman R, 2007, P NATL ACAD SCI USA, V104, P10211, DOI 10.1073/pnas.0608519104; Habisch HJ, 2010, STEM CELLS DEV, V19, P629, DOI 10.1089/scd.2009.0045; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Hao HN, 2003, J HEMATOTH STEM CELL, V12, P23, DOI 10.1089/152581603321210109; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Hartl D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002759; Hattiangady B, 2008, NEUROBIOL AGING, V29, P129, DOI 10.1016/j.neurobiolaging.2006.09.015; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; He P, 2009, J NEUROSCI, V29, P6545, DOI 10.1523/JNEUROSCI.0421-09.2009; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; Heng BC, 2004, CELL TISSUE RES, V315, P291, DOI 10.1007/s00441-003-0847-5; Henneman WJP, 2009, NEUROLOGY, V72, P999, DOI 10.1212/01.wnl.0000344568.09360.31; Heo C, 2007, J NEUROCHEM, V102, P493, DOI 10.1111/j.1471-4159.2007.04499.x; Herring A, 2009, EXP NEUROL, V216, P184, DOI 10.1016/j.expneurol.2008.11.027; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Holsinger RMD, 2000, MOL BRAIN RES, V76, P347, DOI 10.1016/S0169-328X(00)00023-1; Honig LS, 2005, NEUROLOGY, V64, P494, DOI 10.1212/01.WNL.0000150886.50187.30; Hou JF, 2009, NEUROSCI LETT, V462, P294, DOI 10.1016/j.neulet.2009.07.031; Hu M, 2007, BRAIN RES, V1151, P227, DOI 10.1016/j.brainres.2007.03.051; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Ikonomovic MD, 2003, J ALZHEIMERS DIS, V5, P39, DOI 10.3233/JAD-2003-5106; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Irons H, 2004, CELL TRANSPLANT, V13, P283, DOI 10.3727/000000004783983990; Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062; Janicki SM, 2000, NEUROBIOL AGING, V21, P829, DOI 10.1016/S0197-4580(00)00222-0; Jayatissa MN, 2008, NEUROPHARMACOLOGY, V54, P530, DOI 10.1016/j.neuropharm.2007.11.009; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Jin K, 2006, BRAIN RES, V1085, P183, DOI 10.1016/j.brainres.2006.02.081; Kaneko N, 2006, GENES CELLS, V11, P1145, DOI 10.1111/j.1365-2443.2006.01010.x; Karbanova Jana, 2004, Biomedical Papers (Olomouc), V148, P217; Keller J, 2008, AM J PSYCHIAT, V165, P872, DOI 10.1176/appi.ajp.2008.07081257; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KIHLSTROM JF, 1987, SCIENCE, V237, P1445, DOI 10.1126/science.3629249; Kim DE, 2006, RADIOLOGY, V241, P822, DOI 10.1148/radiol.2413050466; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kim JM, 2007, BRAIN RES, V1183, P43, DOI 10.1016/j.brainres.2007.09.005; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Koketsu D, 2006, EXP NEUROL, V199, P92, DOI 10.1016/j.expneurol.2006.03.012; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Kolecki R, 2008, ACTA NEUROPATHOL, V116, P419, DOI 10.1007/s00401-008-0380-4; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; Kotani S, 2008, CHEM-BIOL INTERACT, V175, P227, DOI 10.1016/j.cbi.2008.04.004; Kronmuller KT, 2008, J AFFECT DISORDERS, V110, P241, DOI 10.1016/j.jad.2008.01.022; Kruman II, 2005, NEUROREPORT, V16, P1055, DOI 10.1097/00001756-200507130-00005; Kwak YD, 2006, STEM CELLS DEV, V15, P381, DOI 10.1089/scd.2006.15.381; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Laske C, 2008, J ALZHEIMERS DIS, V15, P451; Laske C, 2007, J PSYCHIATR RES, V41, P387, DOI 10.1016/j.jpsychires.2006.01.014; Laske C, 2009, J ALZHEIMERS DIS, V17, P115, DOI 10.3233/JAD-2009-1017; Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611; Lee HJ, 2007, STEM CELLS, V25, P1204, DOI 10.1634/stemcells.2006-0409; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; Lerch JP, 2005, CEREB CORTEX, V15, P995, DOI 10.1093/cercor/bhh200; Letenneur L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003637; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Leung E, 2011, NEUROBIOL AGING, V32, P387, DOI 10.1016/j.neurobiolaging.2009.02.025; Levesque MF, 2009, OPEN STEM CELL J, V1, P20; Leyhe T, 2008, EUR ARCH PSY CLIN N, V258, P124, DOI 10.1007/s00406-007-0764-9; LEYHE T, 2009, INT J NEUROPSYCHOPH, V7, P1; Li B, 2008, J NEUROPATH EXP NEUR, V67, P78, DOI 10.1097/nen.0b013e318160c5db; Li G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005424; Li LY, 2008, J MOL NEUROSCI, V34, P157, DOI 10.1007/s12031-007-9022-x; Lie DC, 2002, J NEUROSCI, V22, P6639; Liebau S, 2007, STEM CELLS, V25, P1720, DOI 10.1634/stemcells.2006-0823; Ling DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004201; Little CS, 2004, NEUROBIOL AGING, V25, P419, DOI 10.1016/S0197-4580(03)00127-1; Liu Jinping, 2008, Neuroembryology and Aging, V5, P134, DOI 10.1159/000193851; Liu Y, 2008, J NEUROSCI, V28, P13805, DOI 10.1523/JNEUROSCI.4218-08.2008; Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091; Lopez-Toledano MA, 2004, J NEUROSCI, V24, P5439, DOI 10.1523/JNEUROSCI.0974-04.2004; Lopez-Toledano MA, 2007, J ALZHEIMERS DIS, V12, P229; Lovell MA, 2006, NEUROBIOL AGING, V27, P909, DOI 10.1016/j.neurobiolaging.2005.05.004; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Luo XG, 2009, NEUROIMMUNOMODULAT, V16, P28, DOI 10.1159/000179664; Lyons A, 2007, J NEUROCHEM, V101, P771, DOI 10.1111/j.1471-4159.2006.04370.x; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Maekawa M, 2009, NEUROSCI RES, V63, P259, DOI 10.1016/j.neures.2008.12.006; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mann DMA, 2001, AM J PATHOL, V158, P2165, DOI 10.1016/S0002-9440(10)64688-3; Marchesi VT, 2005, P NATL ACAD SCI USA, V102, P9093, DOI 10.1073/pnas.0503181102; Marutle A, 2007, P NATL ACAD SCI USA, V104, P12506, DOI 10.1073/pnas.0705346104; MASAYUKI F, 2000, CEREBROVASC DIS, V10, P2; Mazur-Kolecka B, 2006, NEUROBIOL AGING, V27, P1181, DOI 10.1016/j.neurobiolaging.2005.07.006; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Mega MS, 2002, PSYCHOSOM MED, V64, P487, DOI 10.1097/00006842-200205000-00013; Menendez M, 2005, BRAIN DEV-JPN, V27, P246, DOI 10.1016/j.braindev.2004.07.008; Michalski B, 2003, MOL BRAIN RES, V111, P148, DOI 10.1016/S0169-328X(03)00003-2; Miklossy J, 2006, NEUROBIOL AGING, V27, P228, DOI 10.1016/j.neurobiolaging.2005.01.018; Millet P, 2005, NEUROBIOL DIS, V19, P57, DOI 10.1016/j.nbd.2004.11.006; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mirochnic S, 2009, HIPPOCAMPUS, V19, P1008, DOI 10.1002/hipo.20560; Mishkin M, 1998, HIPPOCAMPUS, V8, P212; Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x; Mizoguchi H, 2009, J PHARMACOL EXP THER, V331, P14, DOI 10.1124/jpet.109.154724; Mizuno M, 2000, J NEUROSCI, V20, P7116, DOI 10.1523/JNEUROSCI.20-18-07116.2000; Mohapel P, 2004, NEUROBIOL DIS, V15, P196, DOI 10.1016/j.nbd.2003.11.010; Moreno H, 2009, P NATL ACAD SCI USA, V106, P5901, DOI 10.1073/pnas.0900944106; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morgan D, 2007, EXP NEUROL, V205, P330, DOI 10.1016/j.expneurol.2007.03.006; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Morizane A, 2008, CELL TISSUE RES, V331, P323, DOI 10.1007/s00441-007-0541-0; Mortimer JA, 1998, NEUROBIOL AGING, V19, P615; Mosconi L, 2006, J NUCL MED, V47, P1778; Mowla A, 2007, J CLIN PSYCHOPHARM, V27, P484, DOI 10.1097/jcp.0b013e31814b98c1; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; Muotri AR, 2005, P NATL ACAD SCI USA, V102, P18644, DOI 10.1073/pnas.0509315102; Murray IVJ, 2007, J BIOL CHEM, V282, P9335, DOI 10.1074/jbc.M608589200; Murrell W, 2005, DEV DYNAM, V233, P496, DOI 10.1002/dvdy.20360; Narr KL, 2004, NEUROIMAGE, V21, P1563, DOI 10.1016/j.neuroimage.2003.11.011; Naumann N, 2010, HIPPOCAMPUS, V20, P971, DOI 10.1002/hipo.20693; Niidome T, 2008, NEUROREPORT, V19, P1361, DOI 10.1097/WNR.0b013e32830e6dd6; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Pajak B, 2009, FOLIA NEUROPATHOL, V47, P252; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Parodi J, 2010, J BIOL CHEM, V285, P2506, DOI 10.1074/jbc.M109.030023; Patterson D, 2009, HUM GENET, V126, P195, DOI 10.1007/s00439-009-0696-8; Pekcec A, 2008, AGING CELL, V7, P368, DOI 10.1111/j.1474-9726.2008.00392.x; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Peters F, 2009, BRAIN, V132, P1833, DOI 10.1093/brain/awp075; Petersen RC, 2000, NEUROLOGY, V54, P581, DOI 10.1212/WNL.54.3.581; PETERSEN RC, 1994, NEUROLOGY, V44, P867, DOI 10.1212/WNL.44.5.867; Pham K, 2003, EUR J NEUROSCI, V17, P879, DOI 10.1046/j.1460-9568.2003.02513.x; Picone P, 2009, BIOPHYS J, V96, P4200, DOI 10.1016/j.bpj.2008.11.056; Pike KE, 2007, BRAIN, V130, P2837, DOI 10.1093/brain/awm238; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Pluchino S, 2008, BRAIN, V131, P2564, DOI 10.1093/brain/awn198; Politi LS, 2007, STEM CELLS, V25, P2583, DOI 10.1634/stemcells.2007-0037; Popa-Wagner A, 2006, CURR NEUROVASC RES, V3, P3, DOI 10.2174/156720206775541732; Porayette P, 2009, J BIOL CHEM, V284, P23806, DOI 10.1074/jbc.M109.026328; Probst A, 1991, BRAIN PATHOL, V1, P229, DOI 10.1111/j.1750-3639.1991.tb00666.x; Ramsay Michael A E, 2002, Proc (Bayl Univ Med Cent), V15, P135; Rao MS, 2006, AGING CELL, V5, P545, DOI 10.1111/j.1474-9726.2006.00243.x; Rapp MA, 2006, ARCH GEN PSYCHIAT, V63, P161, DOI 10.1001/archpsyc.63.2.161; Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140; Redwine JM, 2003, P NATL ACAD SCI USA, V100, P1381, DOI 10.1073/pnas.242746599; Rees Tina M., 2005, Current Alzheimer Research, V2, P291, DOI 10.2174/1567205054367847; Reif A, 2006, MOL PSYCHIATR, V11, P514, DOI 10.1038/sj.mp.4001791; Reiman EM, 2009, P NATL ACAD SCI USA, V106, P6820, DOI 10.1073/pnas.0900345106; Resende R, 2007, BRAIN RES, V1143, P11, DOI 10.1016/j.brainres.2007.01.071; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Rizk P, 2006, NEUROPSYCHOPHARMACOL, V31, P1146, DOI 10.1038/sj.npp.1300954; RIZOS EN, 2008, WORLD J BIOL PSYCHIA, V10, P1; Rockenstein E, 2007, ACTA NEUROPATHOL, V113, P265, DOI 10.1007/s00401-006-0166-5; Rodriguez JJ, 2009, NEUROREPORT, V20, P907, DOI 10.1097/WNR.0b013e32832be77d; Rodriguez JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002935; Roisen FJ, 2001, BRAIN RES, V890, P11, DOI 10.1016/S0006-8993(00)03016-X; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Rossato JI, 2007, LEARN MEMORY, V14, P36, DOI 10.1101/lm.422607; Rosser AE, 2007, CURR OPIN NEUROL, V20, P688, DOI 10.1097/WCO.0b013e3282f132fc; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SANDHUL JK, 2004, P INT SOC MAG RESON, P11; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schliebs R, 2006, J NEURAL TRANSM, V113, P1625, DOI 10.1007/s00702-006-0579-2; Schliebs R, 2005, NEUROCHEM RES, V30, P895, DOI 10.1007/s11064-005-6962-9; Schuff N, 2009, BRAIN, V132, P1067, DOI 10.1093/brain/awp007; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shah SB, 2009, NEUROBIOL DIS, V36, P11, DOI 10.1016/j.nbd.2009.05.016; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Sheline YI, 1999, J NEUROSCI, V19, P5034; Shen CY, 2008, J BIOL CHEM, V283, P17721, DOI 10.1074/jbc.M800013200; Shetty AK, 2008, J NEUROSCI RES, V86, P3062, DOI 10.1002/jnr.21764; Shi F, 2009, HIPPOCAMPUS, V19, P1055, DOI 10.1002/hipo.20573; Shiino A, 2006, NEUROIMAGE, V33, P17, DOI 10.1016/j.neuroimage.2006.06.010; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Siman R, 2000, J NEUROSCI, V20, P8717; Siwak-Tapp CT, 2007, NEUROBIOL LEARN MEM, V88, P249, DOI 10.1016/j.nlm.2007.05.001; Sluimer JD, 2008, NEUROLOGY, V70, P1836, DOI 10.1212/01.wnl.0000311446.61861.e3; Small DH, 2009, J ALZHEIMERS DIS, V16, P225, DOI 10.3233/JAD-2009-0951; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; Smith MM, 2009, CLIN HEMORHEOL MICRO, V41, P229, DOI 10.3233/CH-2009-1174; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Srivastava AS, 2006, STEM CELLS, V24, P1689, DOI 10.1634/stemcells.2005-0531; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Stackman RW, 2003, EXP NEUROL, V184, P510, DOI 10.1016/S0014-4886(03)00399-6; Standridge John B., 2006, Current Alzheimer Research, V3, P95, DOI 10.2174/156720506776383068; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Stopford CL, 2007, CORTEX, V43, P846, DOI 10.1016/S0010-9452(08)70684-1; Sugaya K, 2006, PANMINERVA MED, V48, P87; Sugaya K, 2008, NEURODEGENER DIS, V5, P170, DOI 10.1159/000113693; Sugiura S, 2005, STROKE, V36, P859, DOI 10.1161/01.STR.0000158905.22871.95; SULLIVAN S, 2007, HUMAN EMBRYONIC STEM, P35; Suzuki H, 2004, BIOCHEM BIOPH RES CO, V322, P918, DOI 10.1016/j.bbrc.2004.07.201; Swijnenburg RJ, 2005, CIRCULATION, V112, pI166, DOI 10.1161/CIRCULATIONAHA.104.525824; Tackenberg C, 2009, J NEUROSCI, V29, P14439, DOI 10.1523/JNEUROSCI.3590-09.2009; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takeuchi A, 2000, AM J PATHOL, V157, P331, DOI 10.1016/S0002-9440(10)64544-0; Takeuchi H, 2007, NEUROSCI LETT, V426, P69, DOI 10.1016/j.neulet.2007.08.048; Tang J, 2008, NEUROSCI RES, V62, P86, DOI 10.1016/j.neures.2008.06.005; Tang Jun, 2007, Neurosci Bull, V23, P263, DOI 10.1007/s12264-007-0039-5; Taniuchi N, 2007, NEUROREPORT, V18, P1801, DOI 10.1097/WNR.0b013e3282f1c9e9; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Taupin P, 2009, EXPERT OPIN THER PAT, V19, P373, DOI 10.1517/13543770802681649; Taupin P, 2009, EXPERT OPIN THER PAT, V19, P715, DOI 10.1517/13543770902721295; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Tchantchou F, 2009, J ALZHEIMERS DIS, V18, P787, DOI 10.3233/JAD-2009-1189; Terry AV, 2003, J PHARMACOL EXP THER, V306, P821, DOI 10.1124/jpet.102.041616; Thomas ED, 1999, BRIT J HAEMATOL, V105, P330, DOI 10.1111/j.1365-2141.1999.01337.x; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Tonchev AB, 2006, EXP NEUROL, V198, P101, DOI 10.1016/j.expneurol.2005.11.022; Tsai KJ, 2007, J EXP MED, V204, P1273, DOI 10.1084/jem.20062481; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; TULVING E, 1988, BRAIN COGNITION, V8, P3, DOI 10.1016/0278-2626(88)90035-8; Tulving E., 1983, ELEMENTS EPISODIC ME; Tulving Endel, 1995, P839; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Uylings H. B. M., 2000, NEURODEGENERATIVE DE, P61; Vakili K, 2000, BIOL PSYCHIAT, V47, P1087, DOI 10.1016/S0006-3223(99)00296-6; Valente T, 2009, J ALZHEIMERS DIS, V18, P849, DOI 10.3233/JAD-2009-1188; Van Vickle GD, 2008, MOL MED, V14, P184, DOI [10.2119/2007-00094.Van Vickle, 10.2119/2007-00094.VanVickle]; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; Verret L, 2007, J NEUROSCI, V27, P6771, DOI 10.1523/JNEUROSCI.5564-06.2007; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Visser PJ, 2002, J NEUROL NEUROSUR PS, V72, P491; Vogel A, 2005, DEMENT GERIATR COGN, V19, P75, DOI 10.1159/000082352; Vogel A, 2004, DEMENT GERIATR COGN, V17, P181, DOI 10.1159/000076354; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; von Gunten A, 2006, BRAIN RES REV, V51, P176, DOI 10.1016/j.brainresrev.2005.11.003; Vythilingam M, 2004, BIOL PSYCHIAT, V56, P101, DOI 10.1016/j.biopsych.2004.04.002; Waldau B, 2008, CELL MOL LIFE SCI, V65, P2372, DOI 10.1007/s00018-008-8053-y; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Wang PN, 2009, PSYCHIAT RES-NEUROIM, V171, P221, DOI 10.1016/j.pscychresns.2008.05.002; Wang QH, 2006, J MED INVESTIG, V53, P61, DOI 10.2152/jmi.53.61; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Watson DJ, 2006, HUM GENE THER, V17, P693, DOI 10.1089/hum.2006.17.693; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Weiner HL, 2000, ANN NEUROL, V48, P567, DOI 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.3.CO;2-N; Wen PH, 2004, EXP NEUROL, V188, P224, DOI 10.1016/j.expneurol.2004.04.002; Wen PH, 2002, NEUROBIOL DIS, V10, P8, DOI 10.1006/nbdi.2002.0490; Wengenack TM, 2000, NAT BIOTECHNOL, V18, P868, DOI 10.1038/78482; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Wianny F, 2008, STEM CELLS, V26, P1444, DOI 10.1634/stemcells.2007-0953; Winkler J, 1998, J MOL MED-JMM, V76, P555, DOI 10.1007/s001090050250; Winstead W, 2005, AM J RHINOL, V19, P83, DOI 10.1177/194589240501900115; Wisniewski HM, 1996, NEUROPATH APPL NEURO, V22, P3, DOI 10.1111/j.1365-2990.1996.tb00839.x; Wisniewski T, 1997, AM J PATHOL, V151, P601; Wolf SA, 2006, BIOL PSYCHIAT, V60, P1314, DOI 10.1016/j.biopsych.2006.04.004; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; WU EX, 2004, P INT SOC MAG RESON, V11, P1432; Wu L, 2008, J CELL MOL MED, V12, P1611, DOI 10.1111/j.1582-4934.2007.00203.x; Wu S, 2008, PATHOBIOLOGY, V75, P186, DOI 10.1159/000124979; Xiao M, 2005, EXP NEUROL, V194, P12, DOI 10.1016/j.expneurol.2005.01.021; Xiu MH, 2009, PROG NEURO-PSYCHOPH, V33, P1508, DOI 10.1016/j.pnpbp.2009.08.011; Xuan AG, 2008, NEUROSCI LETT, V440, P331, DOI 10.1016/j.neulet.2008.05.107; Xuan AG, 2009, NEUROSCI LETT, V450, P167, DOI 10.1016/j.neulet.2008.12.001; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Yasutake C, 2006, EUR ARCH PSY CLIN N, V256, P402, DOI [10.1007/s00406-006-0652-8, 10.1007/s00406-006-0702-2]; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yu YX, 2009, HIPPOCAMPUS, V19, P1247, DOI 10.1002/hipo.20587; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhang ZH, 2008, NEUROSCI LETT, V444, P227, DOI 10.1016/j.neulet.2008.08.049; Zhao GY, 2007, STEM CELLS DEV, V16, P429, DOI 10.1089/scd.2006.0092; Zheng XS, 2007, BRAIN INJURY, V21, P275, DOI 10.1080/02699050701225754; ZHIFEI W, 2006, PHARM BIOCH BEHAV, V83, P603; Zhu JH, 2006, NEW ENGL J MED, V355, P2376, DOI 10.1056/NEJMc055304; Ziabreva I, 2006, J PSYCHOSOM RES, V61, P311, DOI 10.1016/j.jpsychores.2006.07.017; Zuba-Surma EK, 2008, J MOL CELL CARDIOL, V44, P865, DOI 10.1016/j.yjmcc.2008.02.279; Zwart I, 2009, EXP NEUROL, V216, P439, DOI 10.1016/j.expneurol.2008.12.028	403	35	43	1	58	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	JUN	2011	10	4					459	485					27	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy	777PG	WOS:000291634700007	21495961				2022-02-06	
J	Dong, XQ; Yu, WH; Hu, YY; Zhang, ZY; Huang, M				Dong, Xiao-Qiao; Yu, Wen-Hua; Hu, Yue-Yu; Zhang, Zu-Yong; Huang, Man			Oxymatrine reduces neuronal cell apoptosis by inhibiting Toll-like receptor 4/nuclear factor kappa-B-dependent inflammatory responses in traumatic rat brain injury	INFLAMMATION RESEARCH			English	Article						Traumatic brain injury; Oxymatrine; Toll-like receptor 4; Nuclear factor kappa-B; Inflammatory cytokine; Neuronal cell apoptosis	INNATE; MECHANISMS	Objective To investigate the influence of oxymatrine (OMT) on Toll-like receptor 4 (TLR-4)/nuclear factor kappa-B (NF-kappa B)-dependent inflammatory responses and neuronal cell apoptosis after traumatic brain injury (TBI). Materials and methods Wistar rats were given an intraperitoneal injection of 60 or 120 mg/kg OMT after TBI once a day till day 5. Rats were killed by decapitation at hours 2, 6 and 12, and days 1, 2, 3 and 5 after TBI. Gene expressions of TLR-4 and NF-kappa B, concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1 beta) and interleukin-6 (IL-6) as well as the number of apoptotic neuronal cells in traumatic rat brain tissues were determined. Results The administration of 120 mg/kg OMT could significantly suppress gene expressions of TLR-4 and NF-kappa B, lessen concentrations of TNF-alpha, IL-1 beta and IL-6, and reduce the number of apoptotic neuronal cells in traumatic rat brain tissues by the Mann-Whitney U test (P < 0.05), but the administration of 60 mg/kg OMT could not (P > 0.05). Conclusion OMT may inhibit TLR4/NF-kappa B-dependent inflammatory responses, and furthermore lessen neuronal cell apoptosis after TBI.	[Dong, Xiao-Qiao; Yu, Wen-Hua; Zhang, Zu-Yong] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, Hangzhou 310000, Zhejiang, Peoples R China; [Hu, Yue-Yu; Huang, Man] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Intens Care Unit, Coll Med, Hangzhou 310000, Zhejiang, Peoples R China		Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310000, Zhejiang, Peoples R China.	dxqhyy@163.com			Traditional Chinese Medicine Department of Zhejiang Province [2010ZA101]	This work is financially supported by the Traditional Chinese Medicine Department of Zhejiang Province, No. 2010ZA101.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Cui LL, 2011, NEUROL RES, V33, P319, DOI 10.1179/016164110X12759951866876; Fan HG, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/704706; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hong-Li S, 2008, PHYTOTHER RES, V22, P985, DOI 10.1002/ptr.2452; Liu Y, 2009, BRAIN RES, V1268, P174, DOI 10.1016/j.brainres.2009.02.069; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Xiang XX, 2002, CHINESE MED J-PEKING, V115, P593; Zeng Z., 1999, J GASTROEN HEPATOL, V14, P5295; Zhao JP, 2008, SURG TODAY, V38, P931, DOI 10.1007/s00595-008-3785-8	22	35	42	0	10	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	JUN	2011	60	6					533	539		10.1007/s00011-010-0300-7			7	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	765BS	WOS:000290679000004	21190123				2022-02-06	
J	Tate, RL; Simpson, GK; Soo, CA; Lane-Brown, AT				Tate, Robyn L.; Simpson, Grahame K.; Soo, Cheryl A.; Lane-Brown, Amanda T.			PARTICIPATION AFTER ACQUIRED BRAIN INJURY: CLINICAL AND PSYCHOMETRIC CONSIDERATIONS OF THE SYDNEY PSYCHOSOCIAL REINTEGRATION SCALE (SPRS)	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain injuries; participation; community integration; assessment; psychometric properties	INTERNATIONAL CLASSIFICATION; REHABILITATION; DISABILITY; RECOVERY; OUTCOMES; HEALTH; QUESTIONNAIRE; ICF	Objective: To examine the psychometric qualities and develop the clinical utility of the Sydney Psychosocial Reintegration Scale (SPRS) as a measure of participation in people with traumatic brain injury. Design: Data generated from previous prospective studies. Subjects/patients: Convenience samples of healthy community-based volunteers (n=105) and people with severe brain injury (n=510). Methods: (i) The equivalence of a new 5-point version of the SPRS was determined vs the original 7-point version; (ii) construct validity was tested using Rasch analyses; (iii) normative and comparative data tables were produced, and data examined for floor/ceiling effects; (iv) a reliable change index score was generated. Results: Patterns of psychometric properties for the 5- and 7-point versions were almost identical (e.g. total scores r(s) =0.98). Rasch analyses on Forms A and B found good fit to the model, for person (3.36 and 3.03, respectively) and item (7.78 and 7.25, respectively) separation; reliability coefficients were high (all >= 0.90). Mean infit statistics met standard criteria (between 0.7 and 1.3). No floor/ceiling effects were detected. The reliable change index value was calculated for the total score for Form A using logit scores, and a conversion table provided. Conclusion: The 5-point version of the SPRS demonstrates strong psychometric qualities as a measure of participation after traumatic brain injury.	[Tate, Robyn L.; Simpson, Grahame K.; Soo, Cheryl A.; Lane-Brown, Amanda T.] Univ Sydney, Sydney Med Sch, No Clin Sch, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Tate, Robyn L.] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [Simpson, Grahame K.] Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Soo, Cheryl A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Tate, RL (corresponding author), Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060	Motor Accidents Authority of New South Wales, Australia	We are grateful to Dr Mike Linacre for helpful advice on the Rasch analyses conducted for this paper. Acknowledgement is also made of the researchers who contributed data on the SPRS. Some of the studies on which this paper is based were supported by the Motor Accidents Authority of New South Wales, Australia.	Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; DeLisa J., 1998, REHABILITATION MED P, P3; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Kervick RB, 2005, BRAIN INJURY, V19, P881, DOI 10.1080/02699050400025273; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Ley P., 1972, QUANTITATIVE ASPECTS; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Magasi S, 2010, ARCH PHYS MED REHAB, V91, pS17, DOI 10.1016/j.apmr.2010.07.011; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Malec J. F., 2003, MANUAL MAYO PORTLAND; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Norman, 2003, HLTH MEASUREMENT SCA; PERDICES M, 2005, BRAIN IMPAIRMENT, V0006, P00219; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Post MWM, 2008, J REHABIL MED, V40, P620, DOI 10.2340/16501977-0223; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Resnik L, 2009, ARCH PHYS MED REHAB, V90, P856, DOI 10.1016/j.apmr.2008.11.010; SIMPSON G, 2004, BRAIN IMPAIR, V5, DOI DOI 10.1375/BRIM.5.1.67.35401; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate R, TRAUMATIC B IN PRESS; Tate R.L., 2006, BRAIN IMPAIR, V7, P1, DOI DOI 10.1375/brim.7.1.1; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; Tate RL, 2010, COMPENDIUM TESTS SCA; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Whiteneck GG, 1992, CRAIG HANDICAP ASSES; *WHO, 2000, DIS ASS SCHED; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILSON BA, 1999, EXTENDED RIVERMEAD B; World Health Organization, 2007, INT CLASS FUNCT DIS	34	35	35	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JUN	2011	43	7					609	618		10.2340/16501977-0829			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	787IF	WOS:000292369100006	21667008	gold, Green Submitted			2022-02-06	
J	Lavinio, A; Menon, DK				Lavinio, Andrea; Menon, David K.			Intracranial pressure: why we monitor it, how to monitor it, what to do with the number and what's the future?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						intracranial pressure; monitoring; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; VENTRICULAR DRAINAGE CATHETERS; CEREBROSPINAL-FLUID; CLINICAL ARTICLE; BLOOD-FLOW; RETROSPECTIVE ANALYSIS; INTENSIVE-CARE; EFFICACY	Purpose of review The review touches upon the current physiopathological concepts relating to the field of intracranial pressure (ICP) monitoring and offers an up-to-date overview of the ICP monitoring technologies and of the signal-analysis techniques relevant to clinical practice. Recent findings Improved ICP probes, antibiotic-impregnated ventricular catheters and multimodality, computerized systems allow ICP monitoring and individualized optimization of brain physiology. Noninvasive technologies for ICP and cerebral perfusion pressure assessment are being tested in the clinical arena. Computerized morphological analysis of the ICP pulse-waveform can provide an indicator of global cerebral perfusion. Summary Current recommendations for the management of traumatic brain injury indicate ICP monitoring in patients who remain comatose after resuscitation if the admission computed tomography scan reveals intracranial abnormalities such as haematomas, contusions and cerebral oedema. The most reliable methods of ICP monitoring are ventricular catheters and intraparenchymal systems. A growing number of these devices are being safely placed by neurointensivists. The consensus is to treat ICP exceeding the 20 mmHg threshold, and to target cerebral perfusion pressure between 50 and 70 mmHg. Recent evidence suggests that such thresholds should be optimized based on multimodality monitoring and individual brain physiology. Noninvasive ICP estimation using transcranial Doppler can have a role as a screening tool in patients with low to intermediate risk of developing intracranial hypertension. However, the technology remains insufficiently accurate and too cumbersome for continuous ICP monitoring.	[Lavinio, Andrea; Menon, David K.] Cambridge Univ Hosp Fdn Trust, Univ Div Anaesthesia, Cambridge, England		Lavinio, A (corresponding author), Addenbrookes Hosp, Dept Anaesthesia, BOX 93,Hills Rd, Cambridge CB2 0QQ, England.	a.lavinio@addenbrookes.nhs.uk	Lavinio, Andrea/M-1778-2016		Royal College of Anaesthetists; Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health ResearchNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: researchfish	D. K. M. is funded by the BOC Professorship of the Royal College of Anaesthetists, the Medical Research Council (UK), and by the National Institute for Health Research.	Al-Tamimi YZ, 2009, NEUROSURGERY, V64, P94, DOI 10.1227/01.NEU.0000328392.98602.5A; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BAUER DF, 2010, J TRAUMA; Beer R, 2008, J NEUROL, V255, P1617, DOI 10.1007/s00415-008-0059-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Birch AA, 2006, NEUROCRIT CARE, V5, P51, DOI 10.1385/NCC:5:1:51; Brady KM, 2010, STROKE, V41, P1957, DOI 10.1161/STROKEAHA.109.575167; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Brandi G, 2010, ACTA NEUROCHIR, V152, P965, DOI 10.1007/s00701-010-0643-4; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bremmer R, 2010, NEUROCRIT CARE, V12, P362, DOI 10.1007/s12028-009-9329-2; Citerio G, 2008, NEUROSURGERY, V63, P1152, DOI 10.1227/01.NEU.0000335148.87042.D7; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dahlqvist Mats B, 2010, J Med Case Rep, V4, P297, DOI 10.1186/1752-1947-4-297; DAVSON H, 1973, BRAIN, V96, P329, DOI 10.1093/brain/96.2.329; Ehtisham A, 2009, NEUROCRIT CARE, V10, P241, DOI 10.1007/s12028-008-9097-4; Fichtner J, 2010, J NEUROSURG, V112, P840, DOI 10.3171/2009.8.JNS091297; FIZ JA, 1993, CHEST, V104, P1203, DOI 10.1378/chest.104.4.1203; Flibotte JJ, 2004, NEUROCRIT CARE, V1, P61, DOI 10.1385/NCC:1:1:61; Forsyth RJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002043.pub2; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Geeraerts T, 2009, BIOMARK MED, V3, P129, DOI 10.2217/BMM.09.6; Georgiadis D, 2001, STROKE, V32, P2088, DOI 10.1161/hs0901.095406; Hetem DJ, 2010, J NEUROSURG, V113, P1309, DOI 10.3171/2010.6.JNS10258; Hu X, 2010, PHYSIOL MEAS, V31, P679, DOI 10.1088/0967-3334/31/5/006; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Lavinio A, 2008, EUR J ANAESTH, V25, P137, DOI 10.1017/S0265021507003298; Leverstein-van Hall MA, 2010, J NEUROSURG, V112, P345, DOI 10.3171/2009.6.JNS09223; Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378; Lozier AP, 2008, NEUROSURGERY, V62, P688, DOI [10.1227/01.neu.0000316273.35833.7c, 10.1227/01.NEU.0000017465.78245.6C]; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Matevosyan K, 2011, J NEUROSURG, V114, P3, DOI 10.3171/2010.7.JNS091699; Muttaiyah S, 2010, J CLIN NEUROSCI, V17, P296, DOI 10.1016/j.jocn.2009.06.016; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; O'Neill BR, 2008, SURG NEUROL, V70, P268, DOI 10.1016/j.surneu.2007.05.007; Petkus V, 2002, ULTRASONICS, V40, P829, DOI 10.1016/S0041-624X(02)00216-0; Piek J, 1996, NEUROSURGERY, V38, P216, DOI 10.1097/00006123-199601000-00051; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; Schmidt B, 2008, ACTA NEUROCHIR SUPPL, V102, P49, DOI 10.1007/978-3-211-85578-2_10; Schmidt Bernhard, 2002, Eur J Ultrasound, V16, P37, DOI 10.1016/S0929-8266(02)00044-7; Schmidt EA, 2005, ACTA NEUROCHIR SUPPL, V95, P253; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shimbles S, 2005, ACTA NEUROCHIR SUPPL, V95, P197; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	57	35	43	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2011	24	2					117	123		10.1097/ACO.0b013e32834458c5			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	732AS	WOS:000288154100001	21293261				2022-02-06	
J	Crompton, JG; Bone, C; Oyetunji, T; Pollack, KM; Bolorunduro, O; Villegas, C; Stevens, K; Cornwell, EE; Efron, DT; Haut, ER; Haider, AH				Crompton, Joseph G.; Bone, Curt; Oyetunji, Tolulope; Pollack, Keshia M.; Bolorunduro, Oluwaseyi; Villegas, Cassandra; Stevens, Kent; Cornwell, Edward E., III; Efron, David T.; Haut, Elliott R.; Haider, Adil H.			Motorcycle Helmets Associated with Lower Risk of Cervical Spine Injury: Debunking the Myth	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRAUMA DATA-BANK; DEVELOPING-COUNTRY; HEAD-INJURIES; USE-LAW; MORTALITY; COMPLICATIONS; FATALITIES; SEVERITY; SAFETY; BURDEN	BACKGROUND: There has been a repeal of the universal helmet law in several states despite definitive evidence that helmets reduce mortality, traumatic brain injury, and hospital expenditures. Opponents of the universal helmet law have successfully claimed that helmets should not be required because of greater torque on the neck, which is thought to increase the likelihood of a cervical spine injury. There is currently insufficient evidence to counter claims that helmets do not increase the risk of cervical spine injury after a motorcycle collision. The objective of this study was to determine the impact of motorcycle helmets on the likelihood of developing a cervical spine injury after a motorcycle collision. STUDY DESIGN: We reviewed cases in the National Trauma Databank (NTDB) v7.0 involving motorcycle collisions. Multiple logistic regression was used to analyze the independent effect of helmets on cervical spine injury. Cases were adjusted for age, race, sex, insurance status, anatomic (Injury Severity Score) and physiologic injury severity (systolic blood pressure < 90 mmHg), and head injury (Abbreviated Injury Score > 3). RESULTS: Between 2002 and 2006, 62,840 cases of motorcycle collision were entered into the NTDB; 40,588 had complete data and were included in the adjusted analysis. Helmeted riders had a lower adjusted odds (0.80 [CI 0.72 to 0.90]) and a lower proportion of cervical spine injury (3.5% vs 4.4%, p < 0.05) compared with nonhelmeted riders. CONCLUSIONS: Helmeted motorcyclists are less likely to suffer a cervical spine injury after a motorcycle collision. This finding challenges a long-standing objection to mandatory helmet use that claims helmets are associated with cervical spine injury. Re-enactment of the universal helmet law should be considered in states where it has been repealed. (J Am Coll Surg 2011;212:295-300. (c) 2011 by the American College of Surgeons)	[Crompton, Joseph G.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA USA; [Bone, Curt; Villegas, Cassandra; Stevens, Kent; Efron, David T.; Haut, Elliott R.; Haider, Adil H.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Oyetunji, Tolulope; Bolorunduro, Oluwaseyi; Cornwell, Edward E., III] Howard Univ, Coll Med, Washington, DC USA; [Pollack, Keshia M.] Ctr Injury Res & Policy, Dept Hlth Policy & Management, Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA		Crompton, JG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Surg, 75 Westwood Blvd, Los Angeles, CA USA.	jcrompton@mednet.ucla.edu	Haut, Elliott R./J-3948-2019; Oyetunji, Tolulope A/D-1447-2011	Oyetunji, Tolulope/0000-0003-3039-7195; Haut, Elliott/0000-0001-7075-771X			*AM COLL SURG COMM, 2008, NTDB VERS 7; BARANCIK JI, 1981, J TRAUMA, V21, P627, DOI 10.1097/00005373-198108000-00006; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; Croce MA, 2009, ANN SURG, V250, P390, DOI 10.1097/SLA.0b013e3181b365a2; Deitch EA, 2007, ANN SURG, V246, P447, DOI 10.1097/SLA.0b013e318148566; GOLDSTEIN JP, 1986, EVALUATION REV, V10, P355, DOI 10.1177/0193841X8601000306; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2009, SURGERY, V146, P308, DOI 10.1016/j.surg.2009.05.006; Houston DJ, 2007, AM J PUBLIC HEALTH, V97, P2063, DOI 10.2105/AJPH.2006.094615; Jones MM, 2007, AM J PUBLIC HEALTH, V97, P208, DOI 10.2105/AJPH.2005.083204; Kardooni S, 2008, J TRAUMA, V64, P273, DOI 10.1097/TA.0b013e31816335ae; Keng SH, 2005, ACCIDENT ANAL PREV, V37, P349, DOI 10.1016/j.aap.2004.09.006; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LAWRENCE BA, COSTS INJURIES RESUL; Li LP, 2008, ACCIDENT ANAL PREV, V40, P1937, DOI 10.1016/j.aap.2008.06.019; LIU BC, 2009, COCHRANE LIB; LUNA GK, 1981, WESTERN J MED, V135, P89; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; *NAT HIGHW SAF ADM, 1996, CRASH OUTC DAT EV SY; *NAT HIGHW TRAFF S, 2006, REC TRENDS FAT MOT C; National Highway Traffic Safety Administration, 2008, MOT HELM US LAWS; Norvell DC, 2002, AM J EPIDEMIOL, V156, P483, DOI 10.1093/aje/kwf081; O'Connor Peter J, 2005, Traffic Inj Prev, V6, P60, DOI 10.1080/15389580590903195; ORSAY E, 1996, ANN INJURY MED, V27, P389; Pervin A, 2009, B WORLD HEALTH ORGAN, V87, P369, DOI 10.2471/BLT.08.057109; Rubin D.B., 1987, MULTIPLE IMPUTATION; SARKAR S, 1995, J TRAUMA, V38, P242, DOI 10.1097/00005373-199502000-00017; Solagberu BA, 2006, INJURY PREV, V12, P266, DOI 10.1136/ip.2005.011221; StataCorp, 2007, STAT STAT SOFTW REL; Vaca F, 2006, ANN EMERG MED, V47, P203, DOI 10.1016/j.annemergmed.2005.12.008; *WHO, WHO HELM IN US	32	35	37	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	MAR	2011	212	3					295	300		10.1016/j.jamcollsurg.2010.09.032			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Surgery	748XW	WOS:000289427400004	21227720				2022-02-06	
J	Thomas, DG; Collins, MW; Saladino, RA; Frank, V; Raab, J; Zuckerbraun, NS				Thomas, Danny G.; Collins, Michael W.; Saladino, Richard A.; Frank, Virginia; Raab, Jenny; Zuckerbraun, Noel S.			Identifying Neurocognitive Deficits in Adolescents Following Concussion	ACADEMIC EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; COLLEGE FOOTBALL PLAYERS; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; HEAD-INJURIES; IMPACT; RECOVERY; PERFORMANCE; SYMPTOMS	P>Objectives: This study of concussed adolescents sought to determine if a computer-based neurocognitive assessment (Immediate Postconcussion Assessment and Cognitive Test [ImPACT]) performed on patients who present to the emergency department (ED) immediately following head injury would correlate with assessments performed 3 to 10 days postinjury and if ED neurocognitive testing would detect differences in concussion severity that clinical grading scales could not. Methods: A prospective cohort sample of patients 11 to 17 years of age presenting to the ED within 12 hours of a head injury were evaluated using two traditional concussion grading scales and neurocognitive testing. ED neurocognitive scores were compared to follow-up scores obtained at least 3 days postinjury. Postconcussive symptoms, outcomes, and complications were assessed via telephone follow-up for all subjects. Results: Sixty patients completed phone follow-up. Thirty-six patients (60%) completed follow-up testing a median of 6 days postinjury. Traditional concussion grading did not correlate with neurocognitive deficits detected in the ED or at follow-up. For the neurocognitive domains of verbal memory, processing speed, and reaction time, there was a significant correlation between ED and follow-up scores trending toward clinical improvement. By 2 weeks postinjury, 23 patients (41%) had not returned to normal activity. At 6 weeks, six patients (10%) still had not returned to normal activity. Conclusions: Immediate assessment in the ED can predict neurocognitive deficits seen in follow-up and may be potentially useful to individualize management or test therapeutic interventions. Neurocognitive assessment in the ED detected deficits that clinical grading could not and correlated with deficits at follow-up.	[Thomas, Danny G.; Saladino, Richard A.; Frank, Virginia; Raab, Jenny; Zuckerbraun, Noel S.] Univ Pittsburgh, Med Ctr, Dept Pediat, Emergency Med Div, Pittsburgh, PA 15260 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Ctr Sports Med, Dept Orthoped Surg,Sports Concuss Program, Pittsburgh, PA USA		Thomas, DG (corresponding author), Univ Pittsburgh, Med Ctr, Dept Pediat, Emergency Med Div, Pittsburgh, PA 15260 USA.	dthomas@mcw.edu	Thomas, Danny G/C-8314-2014	Thomas, Danny/0000-0002-7470-9835	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5-T32-NS07495]; Pittsburgh Emergency Medicine Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007495] Funding Source: NIH RePORTER	Disclosures: NIH 5-T32-NS07495. Source of funding: NIH National Research Service Award Training Grant in Pediatrics.; Role: Trainee (P. I.: Ira Bergman MD, PhD); Pittsburgh Emergency Medicine Foundation Research Grant.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Collins Michael W, 2002, Curr Sports Med Rep, V1, P12; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GIOIA G, 2007, GALV TX GALV BRAIN I; GIOIA G, 2007, ANN M INT NEUR SOC P; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P744; IVERSON GL, 2003, DALL TX NAT AC NEUR; JACOBS ES, 2010, VANC BC PED AC SOC A; Langlois J., HEADS BRAIN INJURY Y; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOVELL M, NORMATIVE DATA IMPAC; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Paniak C, 2000, BRAIN INJURY, V14, P219; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5	45	35	35	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAR	2011	18	3					246	254		10.1111/j.1553-2712.2011.01015.x			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	734YM	WOS:000288379600007	21401786	Green Accepted			2022-02-06	
J	Tomura, S; Nawashiro, H; Otani, N; Uozumi, Y; Toyooka, T; Ohsumi, A; Shima, K				Tomura, Satoshi; Nawashiro, Hiroshi; Otani, Naoki; Uozumi, Yoichi; Toyooka, Terushige; Ohsumi, Atsushi; Shima, Katsuji			Effect of Decompressive Craniectomy on Aquaporin-4 Expression after Lateral Fluid Percussion Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin-4; brain edema; decompressive craniectomy; lateral fluid percussion; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; EDEMA; EPIDEMIOLOGY; HYPERTENSION; DAMAGE; MODEL	Decompressive craniectomy is one therapeutic option for severe traumatic brain injury (TBI), and it has long been used for the treatment of patients with malignant post-traumatic brain edema. A lack of definitive evidence, however, prevents physicians from drawing any conclusions about the effects of decompressive craniectomy for the treatment of TBI. Therefore, the aim of the present study was to investigate the influence of decompressive craniectomy on post-traumatic brain edema formation. The aquaporin-4 (AQP4) water channel is predominantly expressed in astrocytes, and it plays an important role in the regulation of brain water homeostasis. In the present study, we investigated the time course of AQP4 expression and the water content of traumatized cortex following decompressive craniectomy after TBI. Adult male Sprague-Dawley rats (300-400 g) were subjected to lateral fluid percussion injury using the Dragonfly device. The effect of decompressive craniectomy was studied in traumatized rats without craniectomy (closed skull, DC-), and in rats craniectomized immediately after trauma (DC+). AQP4 expression was investigated with a Western blot analysis and immunohistochemistry. Brain edema was measured using the wet weight/dry weight method. At 48 h after TBI, AQP4 expression of the DC- group was significantly increased compared with the DC+ group (p<0.01). In addition, the cortical water content of the DC- group was significantly increased compared to the DC+ group at the same time point (p<0.05). The present results suggest that decompressive craniectomy may affect AQP4 expression and reduce brain edema formation after TBI.	[Tomura, Satoshi; Nawashiro, Hiroshi; Otani, Naoki; Uozumi, Yoichi; Toyooka, Terushige; Ohsumi, Atsushi; Shima, Katsuji] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan		Tomura, S (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	tomura@ndmc.ac.jp		Uozumi, Yoichi/0000-0002-5985-2764			AGRE P, 1993, AM J PHYSIOL, V265, pF463; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Barzo P, 1997, ACT NEUR S, V70, P119; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; HATASHITA S, 1985, STROKE, V16, P661, DOI 10.1161/01.STR.16.4.661; Heitsch H, 2000, DRUG NEWS PERSPECT, V13, P213; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Nielsen S, 1997, J NEUROSCI, V17, P171; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shima K, 2003, ACT NEUR S, V86, P17; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Umezawa Hitoshi, 1993, Neurologia Medico-Chirurgica, V33, P139, DOI 10.2176/nmc.33.139; Unterberg A, 1990, Adv Neurol, V52, P355; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	35	38	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					237	243		10.1089/neu.2010.1443			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700007	21083433				2022-02-06	
J	McDonald, S; Li, S; De Sousa, A; Rushby, J; Dimoska, A; James, C; Tate, RL				McDonald, Skye; Li, Sophie; De Sousa, Arielle; Rushby, Jacqueline; Dimoska, Aneta; James, Charlotte; Tate, Robyn L.			Impaired mimicry response to angry faces following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Emotion; Emotion perception; Electromyography; Traumatic brain injury; Mimicry	EMOTIONAL FACIAL EXPRESSIONS; PERCEPTION DEFICITS; SOCIAL-PERCEPTION; RECOGNITION; BEHAVIOR; AMYGDALA; IMPAIRMENTS; EXPERIENCE; RESONANCE; SADNESS	This study examined whether severe traumatic brain injuries (TBIs) interfere with normal facial mimicry when observing facial expressions. A total of 21 adults with severe TBI and 20 control participants viewed angry and happy facial expressions taken from the Ekman and Friesen (1976) series while facial movement of the corrugator supercilii (brow) and zygomaticus major (cheek) was monitored. Faces were presented both statically and dynamically (gradually morphing from neutral to the final expression). The control group showed increased brow activity to angry expressions and increased cheek activity to happy expressions. This activity was evident as early as 500 ms, consistent with previous research suggesting that facial mimicry commences as an automatic process. The TBI group showed similar activity to happy expressions but no clear response to angry expressions, either early (500-1,000 ms) or over the entire 6-s duration of the displayed image. This was the case for both static and dynamic displays. There was no relationship between facial mimicry and accuracy in identifying (matching) facial expressions for either the TBI or control participants. These results are consistent with the view that ventral frontal structures mediate early responses to angry expressions and that these are frequently compromised as a result of severe TBI. The results did not support the view that simulation (mimicry) facilitates emotion recognition.	[McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn L.] Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Rushby, Jacqueline/D-1820-2010	McDonald, Skye/0000-0003-0723-6094; Rushby, Jacqueline/0000-0002-5018-638X; Li, Sophie/0000-0002-4762-6911	National Health & Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	This research was funded with grants from the National Health & Medical Research Council of Australia. We are grateful to the Sydney metropolitan brain injury units-Royal Rehabilitation Centre, Westmead Brain Injury Unit, and Liverpool Brain Injury Unit-who assisted with recruitment. We are particularly grateful to the people with traumatic brain injuries and our control participants who gave willingly of their time to assist this research.	Achaibou A, 2008, NEUROPSYCHOLOGIA, V46, P1104, DOI 10.1016/j.neuropsychologia.2007.10.019; ADELMANN PK, 1989, ANNU REV PSYCHOL, V40, P249, DOI 10.1146/annurev.ps.40.020189.001341; Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2004, J COGNITIVE NEUROSCI, V16, P453, DOI 10.1162/089892904322926782; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 1999, PSYCHOL SCI, V10, P167, DOI 10.1111/1467-9280.00126; Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Bailey PE, 2009, PSYCHOL AGING, V24, P224, DOI 10.1037/a0014112; Bavelas J. B., 1986, J PERS SOC PSYCHOL, V51, P1173; Biele C, 2006, EXP BRAIN RES, V171, P1, DOI 10.1007/s00221-005-0254-0; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; Blairy S, 1999, J NONVERBAL BEHAV, V23, P5, DOI 10.1023/A:1021370825283; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Buchanan TW, 2004, BEHAV NEUROSCI, V118, P429, DOI 10.1037/0735-7044.118.2.429; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Courville C. B., 1945, PATHOLOGY NERVOUS SY; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Damasio AR, 1998, BRAIN RES REV, V26, P83, DOI 10.1016/S0165-0173(97)00064-7; de Wied M, 2006, J PSYCHIAT RES, V40, P112, DOI 10.1016/j.jpsychires.2005.08.003; Decety J, 2008, DEV PSYCHOPATHOL, V20, P1053, DOI 10.1017/S0954579408000503; Dimberg U, 2000, PSYCHOL SCI, V11, P86, DOI 10.1111/1467-9280.00221; Dimberg U, 2000, PSYCHOPHYSIOLOGY, V37, P693, DOI 10.1017/S0048577200990759; Dimberg U, 1998, SCAND J PSYCHOL, V39, P39, DOI 10.1111/1467-9450.00054; DIMBERG U, 1990, BIOL PSYCHOL, V30, P151, DOI 10.1016/0301-0511(90)90024-Q; Dimberg U, 2007, SCAND J PSYCHOL, V48, P321, DOI 10.1111/j.1467-9450.2007.00586.x; Ekman P., 1976, PICTURES FACIAL AFFE; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608, DOI 10.1152/jn.1995.73.6.2608; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; FRIDLUND AJ, 1986, PSYCHOPHYSIOLOGY, V23, P567, DOI 10.1111/j.1469-8986.1986.tb00676.x; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Goldman AI, 2005, COGNITION, V94, P193, DOI 10.1016/j.cognition.2004.01.005; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; HADLEY DM, 1988, CLIN RADIOL, V39, P131; Harmer CJ, 2001, NAT NEUROSCI, V4, P17, DOI 10.1038/82854; HAVILAND JM, 1987, DEV PSYCHOL, V23, P97, DOI 10.1037/0012-1649.23.1.97; Hermans EJ, 2009, BIOL PSYCHOL, V80, P348, DOI 10.1016/j.biopsycho.2008.12.002; Hermans EJ, 2006, PSYCHONEUROENDOCRINO, V31, P859, DOI 10.1016/j.psyneuen.2006.04.002; Hess U, 1998, COGNITION EMOTION, V12, P509, DOI 10.1080/026999398379547; Hess U, 2001, INT J PSYCHOPHYSIOL, V40, P129, DOI 10.1016/S0167-8760(00)00161-6; Hoffman M. L., 1984, EMOTIONS COGNITION B, P103; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kilts CD, 2003, NEUROIMAGE, V18, P156, DOI 10.1006/nimg.2002.1323; LEVENSON RW, 1990, PSYCHOPHYSIOLOGY, V27, P363, DOI 10.1111/j.1469-8986.1990.tb02330.x; LOVIBOND PF, 1995, MANUAL DEPRESSION AN; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S., 2004, NEUROPSYCHOL REHABIL, V14, P205; McHugo GJ, 1996, MOTIV EMOTION, V20, P85, DOI 10.1007/BF02253867; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Moody EJ, 2007, EMOTION, V7, P447, DOI 10.1037/1528-3542.7.2.447; Niedenthal PM, 2001, COGNITION EMOTION, V15, P853, DOI 10.1080/02699930143000194; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; Penn DL, 2000, SCHIZOPHR RES, V46, P217, DOI 10.1016/S0920-9964(00)00005-0; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; Smith CA, 1996, MOTIV EMOTION, V20, P237, DOI 10.1007/BF02251888; Sonnby-Borgstrom M, 2002, SCAND J PSYCHOL, V43, P433, DOI 10.1111/1467-9450.00312; Sonnby-Borgstrom M, 2003, J NONVERBAL BEHAV, V27, P3, DOI 10.1023/A:1023608506243; Soussignan R, 2005, NEUROCASE, V11, P114, DOI 10.1080/13554790590922513; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Tabachnick B. G., 1989, USING MULTIVARIATE S; Tassinary Louis G, 2000, HDB PSYCHOPHYSIOLOGY; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; Weyers P, 2006, PSYCHOPHYSIOLOGY, V43, P450, DOI 10.1111/j.1469-8986.2006.00451.x; Williams JHG, 2006, NEUROPSYCHOLOGIA, V44, P610, DOI 10.1016/j.neuropsychologia.2005.06.010; [No title captured]	74	35	35	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	1					17	29	PII 922748270	10.1080/13803391003761967			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	714QK	WOS:000286823900003	20526931				2022-02-06	
J	Salottolo, K; Offner, P; Levy, AS; Mains, CW; Slone, DS; Bar-Or, D				Salottolo, Kristin; Offner, Patrick; Levy, A. Stewart; Mains, Charles W.; Slone, Denetta S.; Bar-Or, David			Interrupted Pharmocologic Thromboprophylaxis Increases Venous Thromboembolism in Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Pharmacologic thromboprophylaxis; Traumatic brain injury; Thromboembolism; Coagulation	MOLECULAR-WEIGHT HEPARIN; DVT HOSPITAL PRACTICE; FACTORS-AN ANALYSIS; DATA-BANK NTDB; MAJOR TRAUMA; 1602 EPISODES; PROPHYLAXIS; PATIENT; COAGULOPATHY; PREDICTORS	Background: Pharmacologic thromboprophylaxis (PTP) is frequently withheld, begun late, or interrupted in patients with traumatic brain injury (TBI). The purpose of this study was to analyze whether late or interrupted PTP increases the risk of venous thromboembolism (VTE) after TBI. Methods: We retrospectively studied patients with blunt TBI and stable head computed tomography (CT) scans who were admitted to two Level I trauma centers. PTP use was analyzed as an independent risk factor for VTE using separate logistic regression models for each definition of PTP use: (1) administration of PTP; (2) timing of PTP (early [<72 hours] vs. late [>= 72 hours]); and (3) continuous versus interrupted use of PTP. Results: Four hundred eighty patients with TBI were identified. VTE occurred in 15 patients (3.13%). VTE developed in six patients despite early PTP (5.56%), four patients with late PTP (2.72%), and five with no PTP (2.22%). Neither administration of PTP nor timing of PTP was independent predictor of developing a VTE (PTP vs. none: odds ratio [OR] = 0.36, p = 0.18; early PTP vs. late PTP: OR = 2.00, p = 0.41). PTP was administered continuously in 188 patients (73.7%). Patients with interrupted PTP had a significant increased odds of developing VTE compared with patients with continuous PTP (OR = 7.07, p = 0.04). Walking before discharge significantly decreased the odds of developing a VTE (OR = 0.19, p = 0.02). Conclusions: Interrupted administration of PTP in patients with TBI is associated with significantly increased risk of VTE. These findings underscore the importance of continuous PTP administration, and every effort should be made to avoid interruption if possible.	[Salottolo, Kristin; Bar-Or, David] Swedish Med Ctr, Trauma Res Dept, Englewood, CO 80113 USA; [Salottolo, Kristin; Offner, Patrick; Mains, Charles W.; Bar-Or, David] St Anthony Cent Hosp, Trauma Res Dept, Denver, CO USA; [Offner, Patrick; Mains, Charles W.] St Anthony Cent Hosp, Trauma Serv Dept, Denver, CO USA; [Levy, A. Stewart] St Anthony Cent Hosp, Div Neurosurg, Denver, CO USA; [Slone, Denetta S.] Swedish Med Ctr, Trauma Serv Dept, Englewood, CO 80113 USA; [Offner, Patrick; Mains, Charles W.; Bar-Or, David] Rocky Vista Univ, Parker, CO 80134 USA		Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave Room 4-454, Englewood, CO 80113 USA.	dbaror@dmibio.com	Bar-Or, David/AAE-9328-2020				Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Datta Indraneel, 2010, J Trauma Manag Outcomes, V4, P1, DOI 10.1186/1752-2897-4-1; Depew AJ, 2008, AM SURGEON, V74, P906; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; Eppsteiner RW, 2010, WORLD J SURG, V34, P10, DOI 10.1007/s00268-009-0284-z; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts William H, 2006, Hematology Am Soc Hematol Educ Program, P462; Haut ER, 2009, J TRAUMA, V66, P994, DOI 10.1097/TA.0b013e3181991adc; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Lozance K, 1998, J CLIN NEUROSCI, V5, P394, DOI 10.1016/S0967-5868(98)90269-7; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers SO, 2007, J TRAUMA, V62, P562; Scales DC, 2010, CRIT CARE, V14, DOI 10.1186/cc8980; Shackford SR, 2004, ANN SURG, V240, P496; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021; Vergouwen MDI, 2008, CURR OPIN CRIT CARE, V14, P149, DOI 10.1097/MCC.0b013e3282f57540	23	35	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2011	70	1					19	26		10.1097/TA.0b013e318207c54d			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	707WD	WOS:000286320300007	21217476				2022-02-06	
J	Chisholm, KM; Harruff, RC				Chisholm, Karen M.; Harruff, Richard C.			Elderly Deaths Due to Ground-Level Falls	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						ground-level falls in the elderly; head injuries; warfarin anticoagulation	TRAUMATIC BRAIN-INJURY; PREINJURY WARFARIN USE; SEVERE HEAD-INJURIES; INTRACRANIAL HEMORRHAGE; OLDER-ADULTS; ATRIAL-FIBRILLATION; RISK-FACTORS; ADVANCED AGE; ANTICOAGULATION; COMPLICATIONS	This study analyzed 237 fatal ground-level falls occurring in decedents aged 65 years or older reported to the Seattle-King County Medical Examiner's Office during the year 2007. Head injuries accounted for 109 (46%) of the deaths, and nonhead injuries accounted for 128 (54%) of the deaths. Falls occurred in similar locations in both groups. Compared with those of nonhead injuries, decedents of head injuries were younger (82 vs 87.5 years), were more often male (58% vs 45%), died sooner after their injury (9 days vs 23 days), and were more likely treated with anticoagulants, especially warfarin (48% vs 16%). Subdural hematoma was the most common specific traumatic lesion, occurring in 86% of the decedents of head injury; skull fractures occurred in 13%. Decedents of head injury who were treated with anticoagulants, on average, sustained less severe head injury than those who were not treated with anticoagulants.	[Chisholm, Karen M.] Univ Washington, Dept Pathol, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [Harruff, Richard C.] King Cty Med Examiners Off, Seattle, WA USA		Harruff, RC (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.	richard.harruff@kingcounty.gov		Chisholm, Karen/0000-0002-1898-1252	National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, through the Division of Medical Genetics, Department of Medicine, University of WashingtonUniversity of WashingtonUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [F30 ES13069]; Department of Pathology, University of WashingtonUniversity of Washington [NIGMS GM07266]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [F30ES013069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007266] Funding Source: NIH RePORTER	K.M.C. was supported by grant F30 ES13069 from the National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, through the Division of Medical Genetics, Department of Medicine, University of Washington. K.M.C. was also a recipient of the Medical Scientist Training Program grant NIGMS GM07266, through the Department of Pathology, University of Washington.	Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Fang MC, 2004, ANN INTERN MED, V141, P745, DOI 10.7326/0003-4819-141-10-200411160-00005; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Hartshorne NJ, 1997, AM J FOREN MED PATH, V18, P258, DOI 10.1097/00000433-199709000-00006; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kannus P, 2005, AM J PUBLIC HEALTH, V95, P422, DOI 10.2105/AJPH.2004.047779; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; MATHIESEN T, 1995, ACTA NEUROL SCAND, V91, P208; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Oakley A, 1996, QUAL HEALTH CARE, V5, P243, DOI 10.1136/qshc.5.4.243; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Rivara FP, 1997, NEW ENGL J MED, V337, P613, DOI 10.1056/NEJM199708283370907; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Saab M, 1996, J ACCID EMERG MED, V13, P208; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055	26	35	35	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2010	31	4					350	354		10.1097/PAF.0b013e3181f69c87			5	Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine; Pathology	688BQ	WOS:000284824700017	20938326				2022-02-06	
J	Lee, HC; Chuang, HC; Cho, DY; Cheng, KF; Lin, PH; Chen, CC				Lee, Han-Chung; Chuang, Hao-Che; Cho, Der-Yang; Cheng, Kuang-Fu; Lin, Pao-Hsuan; Chen, Chun-Chung			Applying Cerebral Hypothermia and Brain Oxygen Monitoring in Treating Severe Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Brain tissue oxygen; Cerebral perfusion pressure; Glasgow Outcome Scale; Hypothermia; Intracranial pressure; Traumatic brain injury; Treatment process capability	SEVERE HEAD-INJURY; PROMISING TREATMENT MODALITY; THERAPEUTIC HYPOTHERMIA; PERFUSION-PRESSURE; TISSUE OXYGEN; INTRACRANIAL-PRESSURE; METABOLISM; OPPORTUNITIES; TEMPERATURE; MANAGEMENT	BACKGROUND: Severe traumatic brain injury (TBI) was to be one of the major health problems encountered in modern medicine and had an incalculable socioeconomic impact. The initial cerebral damage after acute brain injury is often exacerbated by postischemic hyperthermia and worsens the outcome. Hypothermia is one of the current therapies designed to combat this deleterious effect. The brain tissue oxygen (PtiO2)-guided cerebral perfusion pressure (CPP) management was successfully reduced because of cerebral hypoxic episodes following TBI. MATERIALS AND METHODS: Forty-five patients with severe TBI whose Glasgow Coma Scale (GCS) score ranged between 4 and 8 during September 2006 and August 2007 were enrolled in China Medical University Hospital, Taichung, Taiwan. One patient with a GCS score of 3 was excluded for poor outcome. These patients were randomized into three groups. Group A (16 patients) was intracranial pressure/cerebral perfusion pressure (ICP/CPP)-guided management only, Group B (15 patients) was ICP/CPP guided with mild hypothermia, and Group C (14 patients) was combined mild hypothermia and PtiO2 guided with CPP management on patients with severe TBI. All patients were treated with ICP/CPP management (ICP <20 mm Hg, CPP >60 mm Hg). However, the group with PtiO2 monitoring was required to raise the PtiO2 above 20 mm Hg. Length of intensive care unit stay, ICP, PtiO2, Glasgow Outcome Scale (GOS) score, mortality, and complications were analyzed. RESULTS: The ICP values progressively increased in the first 3 days but showed smaller changes in hypothermia groups (Groups B and C) and were significantly lower than those of the normothermia group (Group A) at the same time point. We also found out that the averaged ICP were significantly related to days and the daily variations [measured as (daily observation - daily group mean)(2)] of ICP were shown to the significantly different among three treatment groups after the third posttraumatic day. The values of PtiO2 in Group C tended to rise when the ICP decreased were also observed. A favorable outcome is divided by the result of GOS scores. The percentage of favorable neurologic outcome was 50% in the normothermia group, 60% in the hypothermia-only group, and 71.4% in the PtiO2 group, with statistical significance. The percentage of mortality was 12.5% in the normothermia group, 6.7% in the hypothermia-only group, and 8.5% in the PtiO2 group, without statistical significance in three groups. Complications included pulmonary infections, peptic ulcer, and leukocytopenia (43.8% in the normothermia group, 55.6% in the hypothermia-only group, and 50% in the PtiO2 group). CONCLUSIONS: Therapeutic mild hypothermia combined with PtiO2-guided CPP/ICP management allows reducing elevated ICP before 24 hours after injury, and daily variations of ICP were shown to be significantly different among the three treatment groups after the third posttraumatic day. It means that the hypothermia groups may reduce the ICP earlier and inhibit the elicitation of acute inflammation after cerebral contusion. Our data also provided evidence that early treatment that lowers PtiO2 may improve the outcome and seems the best medical treatment method in these three groups. We concluded that therapeutic mild hypothermia combined with PtiO2-guided CPP/ICP management provides beneficial effects when treating TBI, and a multicenter randomized trial needs to be undertaken.	[Lee, Han-Chung; Chuang, Hao-Che; Cho, Der-Yang; Chen, Chun-Chung] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; [Cheng, Kuang-Fu; Lin, Pao-Hsuan] China Med Univ, Ctr Biostat, Taichung, Taiwan		Chen, CC (corresponding author), China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan.	braintumorgbm@yahoo.com.tw			China Medical University Hospital, Taichung, Taiwan, Republic of China [DMR 96 IRB55]	This study was supported by grant DMR 96 IRB55 from the China Medical University Hospital, Taichung, Taiwan, Republic of China. The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.	CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiu WT, 2003, J TRAUMA, V55, P391, DOI 10.1097/01.TA.0000079368.15678.6D; Cho DY, 2006, NEUROSURGERY, V58, P866, DOI 10.1227/01.NEU.0000209892.42585.9B; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Huang SJ, 2006, J CLIN NEUROSCI, V13, P818, DOI 10.1016/j.jocn.2005.11.034; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; Patterson Jessica, 2005, J Neurosci Nurs, V37, P236; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sakurai A, 2003, ACTA NEUROCHIR SUPPL, V86, P251; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272	28	35	40	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	DEC	2010	74	6					654	660		10.1016/j.wneu.2010.06.019			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	793IP	WOS:000292814100025	21492636				2022-02-06	
J	Wood, RLL; Williams, C; Lewis, R				Wood, Rodger L. L.; Williams, Claire; Lewis, Ruth			Role of alexithymia in suicide ideation after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injuries; Emotions; Affective symptoms; Depression; Hopelessness; Worthlessness	DEPRESSION; SCALE; RISK	A high frequency of suicide ideation (SI) has been reported following traumatic brain injury (TBI) (Simpson & Tate 2002 Teasdale & Engberg 2001) This study examined the frequency of SI following TBI and its relationship to alexithymia, and depression plus two components of depression-hopelessness and worthlessness One hundred and five TBI patients and 74 demographically matched controls completed the Toronto Alexithymia Scale-20 (TAS-20) and the Beck Depression Inventory (BDI-II) Ratings of SI hopelessness and worthlessness were extracted from the BDI-II Results confirm a high frequency of SI (33%) and alexithymia (61%) after TBI compared with healthy controls (1 4% and 6 5% respectively) A high frequency of alexithymia was also found in a sub-group of moderate severely depressed TBI patients (70 68%) compared with two non-TBI depressed samples (53 92% and 44 8%) A significant association was found between SI and alexithymia in the TBI group with the SI group reporting significantly higher TAS-20 total scores However, logistic regression analysis found that worthlessness was the strongest predictor of SI after TBI The results of this study suggest that increased attention should be directed toward emotional change after TBI, as alexithymia may mediate the development of worthlessness and in turn, increase the risk of SI (JINS 2010 16 1108-1114)	[Wood, Rodger L. L.; Williams, Claire; Lewis, Ruth] Swansea Univ, Sch Human & Hlth Sci, Dept Psychol, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales		Wood, RLL (corresponding author), Swansea Univ, Sch Human Sci, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.			Williams, Claire/0000-0002-0791-744X			BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Beck A. T., 1996, MANUAL BECK DEPRESSI, VII; BECK AT, 1985, AM J PSYCHIAT, V142, P559; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; DIEKSTRA RFW, 1995, SUICIDE LIFE-THREAT, V25, P36; Hall RCW, 1999, PSYCHOSOMATICS, V40, P18, DOI 10.1016/S0033-3182(99)71267-3; Hintikka J, 2004, COMPR PSYCHIAT, V45, P340, DOI 10.1016/j.comppsych.2004.06.008; Hirsch N, 2001, ENCEPHALE, V27, P61; Honkalampi K, 2000, J PSYCHOSOM RES, V48, P99, DOI 10.1016/S0022-3999(99)00083-5; Honkalampi K, 2001, PSYCHOTHER PSYCHOSOM, V70, P247, DOI 10.1159/000056262; Iancu I, 2001, COMPR PSYCHIAT, V42, P477, DOI 10.1053/comp.2001.27893; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kaltiala-Heino R, 1999, BRIT MED J, V319, P348, DOI 10.1136/bmj.319.7206.348; Kauhanen J, 1996, J PSYCHOSOM RES, V41, P541, DOI 10.1016/S0022-3999(96)00226-7; Kuhner C., 2007, RESPONSE STYLES QUES; Larsson B, 1998, EUR CHILD ADOLES PSY, V7, P201, DOI 10.1007/s007870050068; SCHOTTE DE, 1982, J CONSULT CLIN PSYCH, V50, P690, DOI 10.1037/0022-006X.50.5.690; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Steer RA, 1998, J PSYCHOPATHOL BEHAV, V20, P127, DOI 10.1023/A:1023091529735; Taiminen TJ, 1996, ACTA PSYCHIAT SCAND, V93, P195, DOI 10.1111/j.1600-0447.1996.tb10631.x; Taylor G J, 1997, DISORDERS FECT REGUL; TAYLOR GJ, 1992, PSYCHOTHER PSYCHOSOM, V57, P34, DOI 10.1159/000288571; Teasdale T W, 2006, EVIDENCE BASED MENTA, V6, P11; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; WechslerD, 2001, WECHSLER TEST ADULT; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	29	35	35	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2010	16	6					1108	1114		10.1017/S1355617710001013			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	690RL	WOS:000285023200018	20875201				2022-02-06	
J	Toklu, HZ; Hakan, T; Celik, H; Biber, N; Erzik, C; Ogunc, AV; Akakin, D; Cikler, E; Cetinel, S; Ersahin, M; Sener, G				Toklu, Hale Z.; Hakan, Tayfun; Celik, Hasan; Biber, Necat; Erzik, Can; Ogunc, Ayliz V.; Akakin, Dilek; Cikler, Esra; Cetinel, Sule; Ersahin, Mehmet; Sener, Goksel			Neuroprotective Effects of Alpha-Lipoic Acid in Experimental Spinal Cord Injury in Rats	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Alpha-lipoic acid; Antioxidants; Spinal cord injuries; Trauma; Neuroprotection; Lipid Peroxidation; Glutathione, Myeloperoxidase; DNA damage	ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; DIHYDROLIPOIC ACID; ANTIOXIDANT; METHYLPREDNISOLONE; GLUTATHIONE; PROTECTS	Background: Oxidative stress is a mediator of secondary injury to the spinal cord following trauma. Objective: To investigate the putative neuroprotective effect of a-lipoic acid (LA), a powerful antioxidant, in a rat model of spinal cord injury (SCI). Methods: Wistar albino rats were divided as control, vehicle-treated SCI, and LA-treated SCI groups. To induce SCI, a standard weight-drop method that induced a moderately severe injury (100 g/cm force) at T10 was used. Injured animals were given either 50 mg/kg LA or saline at 30 minutes postinjury by intraperitoneal injection. At 7 days postinjury, neurologic examination was performed, and rats were decapitated. Spinal cord samples were taken for histologic examination or determination of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and DNA fragmentation. Formation of reactive oxygen species in spinal cord tissue samples was monitored by using a chemiluminescence (CL) technique. Results: SCI caused a significant decrease in spinal cord GSH content, which was accompanied with significant increases in luminol CL and MDA levels, MPO activity, and DNA damage. Furthermore, LA treatment reversed all these biochemical parameters as well as SO-induced histopathologic alterations. Conversely, impairment of the neurologic function caused by SCI remained unchanged. Conclusion: The present study suggests that LA reduces SCI-induced oxidative stress and exerts neuroprotection by inhibiting lipid peroxidation, glutathione depletion, and DNA fragmentation.	[Toklu, Hale Z.; Hakan, Tayfun; Celik, Hasan; Biber, Necat; Erzik, Can; Ogunc, Ayliz V.; Akakin, Dilek; Cikler, Esra; Cetinel, Sule; Ersahin, Mehmet; Sener, Goksel] Marmara Univ Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey		Toklu, HZ (corresponding author), Marmara Univ Sch Pharm, Dept Pharmacol, Tibbiye Cad 49, TR-34668 Istanbul, Turkey.	haletoklu@yahoo.com	Sener, Goksel/AAN-4461-2021; cetinel, sule/AAB-8510-2022; Hakan, Tayfun/O-9979-2019; Erzik, Can/AAZ-5485-2021; Toklu, Hale/AAR-2330-2020; Hakan, Tayfun/P-8626-2015	Sener, Goksel/0000-0001-7444-6193; Hakan, Tayfun/0000-0003-1444-7076; Erzik, Can/0000-0002-7914-1169; Toklu, Hale/0000-0002-9797-3591; Hakan, Tayfun/0000-0003-1444-7076			Adibhatla RM, 2008, BMB REP, V41, P560, DOI 10.5483/BMBRep.2008.41.8.560; ALLEN AR, 1911, SURGERY */* JAMA, V57, P878; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bernards CM, 2006, SPINAL CORD, V44, P594, DOI 10.1038/sj.sc.3101891; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Biewenga GP, 1997, DRUG METAB REV, V29, P1025, DOI 10.3109/03602539709002242; Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0; Bilska A, 2005, PHARMACOL REP, V57, P570; Buege J A, 1978, Methods Enzymol, V52, P302; Burton K, 1967, METHODS ENZ, VXII, P163; DAVIES GR, 1992, GUT, V33, P1467, DOI 10.1136/gut.33.11.1467; Dulundu E, 2007, PHARMACOLOGY, V79, P163, DOI 10.1159/000098953; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Ersahin M, 2010, NEUROCHEM RES, V35, P418, DOI 10.1007/s11064-009-0072-z; Foster TS, 2007, DIABETES EDUCATOR, V33, P111, DOI 10.1177/0145721706297450; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Glantzounis GK, 2006, CURR PHARM DESIGN, V12, P2891, DOI 10.2174/138161206777947641; GNS D, 2008, Exp Neural, V211, P259; Haklar G, 1998, MARMARA MED J, V11, P55; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Jia ZQ, 2009, MOL CELL BIOCHEM, V323, P131, DOI 10.1007/s11010-008-9971-6; KAGAN VE, 1992, BIOCHEM PHARMACOL, V44, P1637, DOI 10.1016/0006-2952(92)90482-X; Kolgazi M, 2007, J GASTROEN HEPATOL, V22, P1859, DOI 10.1111/j.1440-1746.2006.04504.x; Maczurek A, 2008, ADV DRUG DELIVER REV, V60, P1463, DOI 10.1016/j.addr.2008.04.015; Manda K, 2007, BEHAV BRAIN RES, V177, P7, DOI 10.1016/j.bbr.2006.11.013; Moini H, 2002, TOXICOL APPL PHARM, V182, P84, DOI 10.1006/taap.2002.9437; NOSEWORTHY IH, 2000, MULTIPLE SCLEROSIS *, V343, P938; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Roy S, 1998, BIOFACTORS, V8, P17, DOI 10.1002/biof.5520080104; Salinthone Sonemany, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P132, DOI 10.2174/187153008784534303; Sehirli O, 2008, CLIN EXP PHARMACOL P, V35, P249, DOI 10.1111/j.1440-1681.2007.04810.x; Sehirli O, 2008, PHARMACOLOGY, V81, P173, DOI 10.1159/000111145; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; SUZUKI YJ, 1993, FREE RADICAL RES COM, V18, P115, DOI 10.3109/10715769309147348; Taoka Y, 2001, J NEUROTRAUM, V18, P533, DOI 10.1089/089771501300227332; Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; Zhang WJ, 2007, P NATL ACAD SCI USA, V104, P4077, DOI 10.1073/pnas.0700305104	42	35	37	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	OCT	2010	33	4					401	409		10.1080/10790268.2010.11689719			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	674AJ	WOS:000283705200010	21061900	Green Published			2022-02-06	
J	Brown, KV; Dharm-Datta, S; Potter, BK; Etherington, J; Mistlin, A; Hsu, JR; Clasper, JC				Brown, Kate V.; Dharm-Datta, Shresth; Potter, B. Kyle; Etherington, John; Mistlin, Alan; Hsu, Joseph R.; Clasper, Jon C.			Comparison of Development of Heterotopic Ossification in Injured US and UK Armed Services Personnel With Combat-Related Amputations: Preliminary Findings and Hypotheses Regarding Causality	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Heterotopic ossification; Risk factors; Amputation level; Blast; Patient exposure	TRAUMATIC BRAIN-INJURY; STAPHYLOCOCCUS-AUREUS; HUMAN OSTEOBLASTS; BONE-FORMATION; RISK-FACTORS; EXPRESSION; EXPERIENCE; MANAGEMENT; SEVERITY; MOUSE	Background: Recent reports have documented the rate of heterotopic ossification (HO) formation in the residual limbs of combat-related amputees from the US Armed Forces injured in Operations Iraqi and Enduring Freedom. Final amputation level within the zone of injury and blast as the mechanism of injury were identified as possible risk factors for the occurrence and grade of HO. There has been no previous description of HO in combat-related amputees from the UK service personnel. The purpose of this study was to examine potential differences in the prevalence of HO between UK and US Allied Forces, with particular attention to these risk factors, patient exposures, and any treatment differences between these two groups. Methods: We reviewed the medical records and radiographs of 35 combat-related amputations from the UK and contrasted them with 213 previously reported amputations in US military personnel. We evaluated prevalence and severity of residual limb HO, Injury Severity Score (ISS), the mechanism and zone of injury, type and level of amputation, number of debridements, method of wound irrigation, presence of severe head injury and/or burns injury, use of topical negative pressure therapy and pulse lavage, number of days until wound closure, type of closure, and subsequent infections. All patients had a minimum of 2-month posthospital discharge radiographic follow-up. Comparisons were made using Fisher's exact, one-way analysis of variance, and chi(2) analyses. Results: There was no significant difference in either the overall prevalence of HO or the prevalence of moderate to severe HO in the two populations. Twenty of 35 (57.1%) limbs in the UK amputations developed HO compared with 134 of 213 (63%) in the US amputations (p > 0.05). The UK amputations had 12 cases (34.3%) of moderate to severe HO compared with 72 cases (33.8%) in the US amputations (p > 0.05). However, there was a significant difference in the number of UK amputations 0 of 20 (0%) versus the number of US amputations 25 of 134 (12%; p = 0.04), which required excision of symptomatic lesions. There was a significant association in the development of HO in UK personnel with the use of topical negative pressure treatment (p = 0.05) and increasing ISS scores (p = 0.04) and in the development of moderate to severe HO with increasing ISS (p = 0.006) and severe HI (p = 0.04). Unlike in the previous report, no significant association was found in UK personnel between any of the remaining hypothesized risk factors and either the presence or grade of HO. Conclusions: Although no difference was identified in the overall prevalence of HO, there are inconsistencies in the possible underlying causes of HO between the two cohorts. Further research is required in an ongoing effort to determine a causal relationship between treatment and subsequent HO formation.	[Brown, Kate V.] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA; [Dharm-Datta, Shresth; Etherington, John; Mistlin, Alan] Def Med Rehabil Ctr, Epsom, Surrey, England; [Potter, B. Kyle] Walter Reed Army Med Ctr, Amputee Patient Care Program, Integrated Dept Orthopaed & Rehabil, Washington, DC 20307 USA; [Potter, B. Kyle] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA; [Hsu, Joseph R.] Brooke Army Med Ctr, Dept Trauma & Orthopaed, Ft Sam Houston, TX 78234 USA; [Clasper, Jon C.] Acad Dept Mil Surg & Trauma, Birmingham, W Midlands, England		Brown, KV (corresponding author), USA, Inst Surg Res, 3400 Rawley E Chambers, Ft Sam Houston, TX 78234 USA.	kate.brown2@amedd.army.mil	Potter, Benjamin/U-1769-2019	Potter, MD, Benjamin K./0000-0002-8771-0317			Alexander EH, 2001, INFECT IMMUN, V69, P1581, DOI 10.1128/IAI.69.3.1581-1586.2001; Barrack RL, 2002, CLIN ORTHOP RELAT R, P208, DOI 10.1097/01.blo.0000030497.43495.3f; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bost KL, 2000, INFECT IMMUN, V68, P5075, DOI 10.1128/IAI.68.9.5075-5083.2000; BRACKETT EG, 1927, MED DEP US ARMY WO 1, V2, P713; Brown KV, 2009, J TRAUMA, V66, pS93, DOI 10.1097/TA.0b013e31819cdcb0; Chen XQ, 2007, J ORTHOP TRAUMA, V21, P693, DOI 10.1097/BOT.0b013e31815a7e91; Ebinger T, 2000, J TRAUMA, V48, P1058, DOI 10.1097/00005373-200006000-00010; EVANS EB, 1991, CLIN ORTHOP RELAT R, P94; GUSTILO RB, 1990, J BONE JOINT SURG AM, V72A, P299, DOI 10.2106/00004623-199072020-00023; HANSEN MO, 1994, MIL MED, V159, P376, DOI 10.1093/milmed/159.5.376; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hunt JL, 2006, J BURN CARE RES, V27, P535, DOI 10.1097/01.BCR.0000226023.58438.14; Islinger RB, 2000, MIL MED, V165, P463, DOI 10.1093/milmed/165.6.463; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Marriott I, 2004, AM J PATHOL, V164, P1399, DOI 10.1016/S0002-9440(10)63226-9; McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256-005-0958-z; Otis G, 1883, MED SURG HIST CIVI 3, V2, P880; Owens BD, 2007, J ORTHOP TRAUMA, V21, P254, DOI 10.1097/BOT.0b013e31802f78fb; Pape HC, 2004, J BONE JOINT SURG BR, V86B, P783, DOI 10.1302/0301-620X.86B6.15356; PETERSON SL, 1989, J TRAUMA, V29, P365, DOI 10.1097/00005373-198903000-00015; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS191; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; REDDI AH, 1995, CLIN ORTHOP RELAT R, P115; Richards AM, 1997, BURNS, V23, P64, DOI 10.1016/S0305-4179(96)00074-5; Rush RM, 2007, MIL MED, V172, P777; SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; VENIER L H, 1971, Archives of Physical Medicine and Rehabilitation, V52, P475	29	35	35	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2010	69			1			S116	S122		10.1097/TA.0b013e3181e44cc7			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	627AC	WOS:000280009000018	20622605				2022-02-06	
J	Salgado, AJ; Fraga, JS; Mesquita, AR; Neves, NM; Reis, RL; Sousa, N				Salgado, Antonio J.; Fraga, Joana S.; Mesquita, Ana R.; Neves, Nuno M.; Reis, Rui L.; Sousa, Nuno			Role of Human Umbilical Cord Mesenchymal Progenitors Conditioned Media in Neuronal/Glial Cell Densities, Viability, and Proliferation	STEM CELLS AND DEVELOPMENT			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS; IN-VITRO; STROMAL CELLS; NEUROLOGICAL DEFICITS; MAMMALIAN FOREBRAIN; MATRIX CELLS; RAT-BRAIN; TRANSPLANTATION; DIFFERENTIATION	It has been recently reported that mesenchymal progenitor/stem cells isolated from the Wharton's Jelly (WJ) of umbilical cords (UC) ameliorate the condition of animals suffering from central nervous system (CNS)-related conditions. However, little is known on the mechanisms that regulate these actions. Therefore, the objective of the present work was to determine how the conditioned media (CM) of a population of mesenchymal progenitors present in the UC WJ, known as human umbilical cord perivascular cells (HUCPVCs), regulate processes such as cell viability, survival, and proliferation of postnatal hippocampal neurons and glial cells. For this purpose primary hippocampal and cortical cultures of neurons and glial cells, respectively, were incubated with CM from HUCPVCs. Results revealed that HUCPVCs CM increase glial cell viability and proliferation. Furthermore, it was observed that glial cell cultures exhibited higher numbers of GFAP-positive cells (astrocytes) and O4-positive cells (oligodendrocytes) when incubated with the CM. Additionally, it was also observed that the growth factors presents in the CM did not induce an increase on the microglial cells number. For hippocampal neurons similar results were obtained, as cultures exposed to HUCPVCs CM disclosed higher numbers of MAP-2-positive cells. Moreover it was also observed that the cell viability and proliferation in this primary hippocampal cell culture system was also higher, when compared to control cultures. From these results it was possible to conclude that HUCPVCs release neuroregulatory factors that have a direct impact on the densities, viability, and proliferation of glial cells and hippocampal primary cultures.	[Salgado, Antonio J.; Fraga, Joana S.; Mesquita, Ana R.; Sousa, Nuno] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal; [Neves, Nuno M.; Reis, Rui L.] Univ Minho, Res Grp Biomat Biodegradables & Biomimet 3Bs, Headquarters European Inst Excellence Tissue Engn, Taipas, Guimaraes, Portugal; [Neves, Nuno M.; Reis, Rui L.] PT Govt Associated Lab, Inst Biotechnol & Bioengn, Guimaraes, Portugal		Sousa, N (corresponding author), Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Campus Gualtar, P-4710057 Braga, Portugal.	njcsousa@ecsaude.uminho.pt	Fraga, Joana S. M./K-3509-2013; Salgado, Antonio/J-4129-2013; Salgado, Antonio J/T-6500-2018; Neves, Nuno M/B-4685-2008; Sousa, Nuno JC/N-9137-2017; Sousa, Nuno/C-2782-2009; Reis, Rui L./A-8938-2008	Fraga, Joana S. M./0000-0003-3234-0600; Salgado, Antonio/0000-0003-3806-9823; Salgado, Antonio J/0000-0003-3806-9823; Neves, Nuno M/0000-0003-3041-0687; Sousa, Nuno JC/0000-0002-8755-5126; Reis, Rui L./0000-0002-4295-6129; UMinho, 3B's Research Group/0000-0002-5195-3456; Mesquita, Ana/0000-0002-9635-2355	Portuguese Foundation for Science and TechnologyPortuguese Foundation for Science and Technology [Salgado-SFRH/BPD/17595/2004]; Funda ao Calouste de Gulbenkian	Portuguese Foundation for Science and Technology through funds from POCTI and/or FEDER programs (funding to ICVS, 3B's Research Group and post doctoral fellowship to A.J. Salgado-SFRH/BPD/17595/2004); funding from Funda ao Calouste de Gulbenkian. The authors would also like to acknowledge Prof. J.E. Davies from the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, Canada, for kindly providing some of the HUCPVCs lots used in the present work. This work was performed following the terms of the cooperation agreement signed between the 3B's Research Group of the University of Minho and the Hospital de Sao Marcos in Braga and approved by its ethical committee.	Akiyama Y, 2002, J NEUROSCI, V22, P6623; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Emsley JG, 2003, EXP NEUROL, V183, P298, DOI 10.1016/S0014-4886(03)00129-8; Ennis J, 2008, CYTOTHERAPY, V10, P174, DOI 10.1080/14653240801891667; Fiore M, 2002, PHYSIOL BEHAV, V77, P437, DOI 10.1016/S0031-9384(02)00875-2; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Hirko AC, 2008, STEM CELLS, V26, P2893, DOI 10.1634/stemcells.2008-0075; Kang SK, 2003, EXP NEUROL, V183, P355, DOI 10.1016/S0014-4886(03)00089-X; Kang SK, 2007, BRAIN PATHOL, V17, P263, DOI 10.1111/j.1750-3639.2007.00070.x; Kang SK, 2006, STEM CELLS DEV, V15, P583, DOI 10.1089/scd.2006.15.583; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu J, 2005, DEVELOPMENT, V132, P3231, DOI 10.1242/dev.01893; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Medicetty S, 2004, EXP NEUROL, V190, P32, DOI 10.1016/j.expneurol.2004.06.023; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; MUNOZ RM, 2005, PNAS, V37, P18171; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Salih V, 2000, J MATER SCI-MATER M, V11, P615, DOI 10.1023/A:1008901612674; Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004-0166; Scarisbrick IA, 2000, DEV BRAIN RES, V123, P87, DOI 10.1016/S0165-3806(00)00077-8; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Silva GA, 2003, J MATER SCI-MATER M, V14, P1055, DOI 10.1023/B:JMSM.0000004002.11278.30; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Weiss ML, 2003, EXP NEUROL, V182, P288, DOI 10.1016/S0014-4886(03)00128-6; Wislet-Gendebien S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-33; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	37	35	38	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUL	2010	19	7					1067	1074		10.1089/scd.2009.0279			8	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	626PC	WOS:000279976900012	19705968	Green Submitted			2022-02-06	
J	Chuang, PY; Conley, YP; Poloyac, SM; Okonkwo, DO; Ren, DX; Sherwood, PR; Hravnak, M; Alexander, SA				Chuang, Pei-Ying; Conley, Yvette P.; Poloyac, Samuel M.; Okonkwo, David O.; Ren, Dianxu; Sherwood, Paula R.; Hravnak, Marilyn; Alexander, Sheila A.			Neuroglobin Genetic Polymorphisms and Their Relationship to Functional Outcomes after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional outcomes; neuroglobin; single nucleotide polymorphisms; traumatic brain injury	RATING-SCALE; HEAD-INJURY; BINDING-PROPERTIES; MOUSE NEUROGLOBIN; HEME ENVIRONMENT; NITRIC-OXIDE; IN-VITRO; PROTEIN; OXYGEN; CYTOGLOBIN	Neuroglobin has shown rich neuroprotective effects against cerebral hypoxia, and therefore has the potential to impact outcomes after traumatic brain injury (TBI). However, to date an association between genetic variation within the human neuroglobin (NGB) gene and recovery post-TBI has not been reported. The purpose of this study was to explore the relationship between NGB genotypes and outcomes (as assessed by the Glasgow Outcome Scale [GOS], the Disability Rating Scale [DRS], and the Neurobehavioral Rating Scale-Revised [NRS-R]) after severe TBI. Genotyping using TaqMan allele discrimination for two tagging single nucleotide polymorphisms (tSNPs) that represent the two haplotype blocks for NGB (rs3783988 and rs10133981) was completed on DNA obtained from 196 Caucasian patients recovering from severe TBI. Patients were dichotomized based on the presence of the variant allele for each tSNP. Chi-square and Fisher's exact tests were used to compare characteristics between groups. Multivariate linear regression was used to examine NGB tSNPs and recovery from severe TBI. Subjects with the TT genotype (wild-type) for rs3783988 were more likely to have better GOS and DRS scores at 3, 6, 12, and 24 months, while rs10133981 genotype was not significantly related to functional outcome. After controlling for age, gender, and Glasgow Coma Scale (GCS) score, those subjects with the rs3783988 TT genotype had more than a 2.65-times greater likelihood of better functional outcomes than individuals with genotypes harboring a variant allele. Data suggest that the haplotype block represented by rs3783988 in NGB appears to influence recovery after severe TBI. Represented within this haplotype block of NGB is the region that codes for the oxygen-binding portion of NGB.	[Chuang, Pei-Ying; Conley, Yvette P.; Sherwood, Paula R.; Hravnak, Marilyn; Alexander, Sheila A.] Univ Pittsburgh, Sch Nursing, Acute Tertiary Care Dept, Pittsburgh, PA 15261 USA		Chuang, PY (corresponding author), Univ Pittsburgh, Sch Nursing, Acute Tertiary Care Dept, 3500 Victoria St,312 Victoria Bldg, Pittsburgh, PA 15261 USA.	peiyingc@yahoo.com			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR04801, R01NR008424, P50NS30318]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL074316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004801, R01NR004339, R01NR008424] Funding Source: NIH RePORTER	We sincerely thank Dr. Mary E. Kerr, Deputy Director of the National Institute of Nursing Research, National Institutes of Health, for introducing us to this topic and for guiding us in our research. Support for the project was provided by grants from the National Institutes of Health (R01NR04801, R01NR008424, and P50NS30318).	*APPL BIOS, 2006, TAQMAN SNP GEN ASS; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Cullen NK, 2009, PM&R, V1, P1069, DOI 10.1016/j.pmrj.2009.09.013; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Duong TTH, 2009, J NEUROCHEM, V108, P1143, DOI 10.1111/j.1471-4159.2008.05846.x; Fordel E, 2004, IUBMB LIFE, V56, P681, DOI 10.1080/15216540500037406; Garry DJ, 2003, LANCET, V362, P342, DOI 10.1016/S0140-6736(03)14055-X; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Hamdane D, 2004, MICRON, V35, P59, DOI 10.1016/j.micron.2003.10.019; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Herold S, 2005, COMP BIOCHEM PHYS A, V142, P124, DOI 10.1016/j.cbpb.2005.06.009; Hundahl C, 2006, BRAIN RES, V1085, P19, DOI 10.1016/j.brainres.2006.02.040; *INT HAPMAP PROJ, 2009, HAPMAP GEN BROWS PHA; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Khan AA, 2007, P NATL ACAD SCI USA, V104, P19114, DOI 10.1073/pnas.0706167104; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lardinois OM, 2008, BIOCHEMISTRY-US, V47, P10440, DOI 10.1021/bi800771k; Lin Y, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-110; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Miller SA, 1988, NUCLEIC ACIDS RES, V16, P883, DOI [DOI 10.1093/NAR/16.3.1215, 10.1093/nar/16.3.1215]; Moens L, 2000, NATURE, V407, P461, DOI 10.1038/35035181; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; *NAT I NEUR DIS ST, 2009, PUBL NINDS; Peroni D, 2007, NEUROSCI LETT, V421, P110, DOI 10.1016/j.neulet.2007.05.046; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, ACTA CRYSTALLOGR D, V58, P1848, DOI 10.1107/S090744490201260X; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Povlishock JT, 2000, J NEUROTRAUM, V17, pVII, DOI 10.1089/neu.2000.17.vii; Povlishock JT, 2004, J NEUROTRAUM, V21, pIII; *QIAG CORP, 2007, SAMPL 7 ASS TECHN; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Smagghe BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002039; *SPSS INC, 2008, SPSS BAS 15 0 WIND U; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Doorslaer S, 2003, J BIOL CHEM, V278, P4919, DOI 10.1074/jbc.M210617200; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vinck E, 2006, J BIOL INORG CHEM, V11, P467, DOI 10.1007/s00775-006-0100-2; Wakasugi K, 2005, ANN NY ACAD SCI, V1053, P220, DOI 10.1196/annals.1344.020; Wakasugi K, 2005, BIOCHEMISTRY-US, V44, P2943, DOI 10.1021/bi0477539; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Walker FA, 2006, J BIOL INORG CHEM, V11, P391, DOI 10.1007/s00775-006-0095-8; Wang XY, 2008, STROKE, V39, P1869, DOI 10.1161/STROKEAHA.107.506022; Wright J, 2000, GLASGOW OUTCOME SCAL; Xu J, 2009, J INORG BIOCHEM, V103, P1693, DOI 10.1016/j.jinorgbio.2009.09.016	55	35	36	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					999	1006		10.1089/neu.2009.1129			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300004	20345238	Green Published			2022-02-06	
J	Cox, DJ; Davis, M; Singh, H; Barbour, B; Nidiffer, FD; Trude, T; Mourant, R; Moncrief, R				Cox, Daniel J.; Davis, Margaret; Singh, Harsimran; Barbour, Brent; Nidiffer, F. Don; Trude, Tina; Mourant, Ronald; Moncrief, Rick			Driving Rehabilitation for Military Personnel Recovering From Traumatic Brain Injury Using Virtual Reality Driving Simulation: A Feasibility Study	MILITARY MEDICINE			English	Article							ACUSTIMULATION; ONDANSETRON	Objective: To investigate the feasibility of virtual reality drying simulation rehabilitation training (VRDSRT) with military personnel recovering from traumatic brain injury (TBI). Methods: Eleven men with TBI were randomly assigned as controls (n = 5) receiving residential rehabilitation only or the VRDSRT group (n = 6) receiving residential rehabilitation and VRDSRT. All subjects underwent pre- and postassessments including simulator driving, and completing road rage and risky driving questionnaires. Between assessments, VRDSRT subjects received 4-6, 60- to 90-min rehabilitation training sessions involving practicing progressively more complex driving skills (lane position, speed control, etc.) through progressively more demanding traffic. Results: VRDSRT was well received, considered realistic and effective, with no reported simulation sickness. Driving performance improved significantly in the VRDSRT group only (p < 0.01). They also demonstrated a reduction in road rage ( p = 0.01) and risky driving ( p = 0.04) at post-assessment. Conclusion: VRDSRT showed promising results with respect to retraining driving performance and behavior among military personnel recovering from TBI.	[Cox, Daniel J.; Davis, Margaret; Singh, Harsimran; Barbour, Brent] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA; [Nidiffer, F. Don; Trude, Tina] Virginia NeuroCare, Def & Vet Brain Injury Ctr, Charlottesville, VA 22902 USA; [Mourant, Ronald] Northeastern Univ, Snell Engn Ctr 334, Dept Mech & Ind Engn, Boston, MA 02115 USA; [Moncrief, Rick] MBFARR LLC, San Jose, CA 95140 USA		Cox, DJ (corresponding author), Univ Virginia Hlth Syst, Box 800223, Charlottesville, VA 22908 USA.				DARPA (Defense Advanced Research Projects Agency)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK028288] Funding Source: NIH RePORTER	The authors gratefully acknowledge the support offered by Dr. Jeffery Barth (director of research), Mr. Gary Levine (speech therapist), and Ms. Kate Bennett (case manager) all at Lakeview Virginia, NeuroCare, Charlottesville, Virginia 22902. The study was supported by a grant from DARPA (Defense Advanced Research Projects Agency) through a Phase I SBIR (Small Business Innovation Research) Program.	Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; *ARM FORC HLTH SUR, 2008, MSMR, V15, P2; Coloma M, 2002, ANESTHESIOLOGY, V97, P1387, DOI 10.1097/00000542-200212000-00009; Cox CV, 2009, CHRONICLE DRIVER ED, V57, P9; Cox DJ, 2008, ARCH PEDIAT ADOL MED, V162, P793, DOI 10.1001/archpedi.162.8.793; DePasquale JP, 2001, J SAFETY RES, V32, P1, DOI 10.1016/S0022-4375(00)00050-5; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; HU SQ, 1992, GASTROENTEROLOGY, V102, P1854, DOI 10.1016/0016-5085(92)90305-I; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; RIKE P, INT TRAFF MED ASS AN; Rizzo A, 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI 10.1162/1054746053967094; ROCCHIO C, 2007, DRIVING BRAIN INJURY; SINGH H, 2010, HDB DRIVING IN PRESS; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; White PF, 2005, ANESTH ANALG, V100, P367, DOI 10.1213/01.ANE.0000144425.16116.0A; Zoroya G., 2009, 360000 VETERANS MAY	19	35	37	0	10	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	JUN	2010	175	6					411	416		10.7205/MILMED-D-09-00081			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	607FS	WOS:000278485100008	20572473	Bronze			2022-02-06	
J	Jia, F; Pan, YH; Mao, Q; Liang, YM; Jiang, JY				Jia, Feng; Pan, Yao-hua; Mao, Qing; Liang, Yu-min; Jiang, Ji-yao			Matrix Metalloproteinase-9 Expression and Protein Levels after Fluid Percussion Injury in Rats: The Effect of Injury Severity and Brain Temperature	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; matrix metalloproteinase-9; mild hypothermia; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; INTRACEREBRAL HEMORRHAGE; POSTTRAUMATIC HYPOTHERMIA; MATRIX METALLOPROTEINASES; THERAPEUTIC HYPOTHERMIA; HOUSEKEEPING GENES; MILD HYPOTHERMIA; NEURONAL DEATH; CELL-DEATH; MECHANISMS	The temporal and regional expression profiles of matrix metalloproteinase-9 (MMP-9), after moderate or severe traumatic brain injury (TBI) were measured to investigate the effects of post-traumatic hypothermia (33 degrees C) or hyperthermia (39 degrees C). In the first phase of this study, adult male Sprague-Dawley rats were randomly assigned to groups of moderate TBI (1.8-2.2 atm), severe TBI (2.4-2.7 atm), and sham-injured control. The rats were killed at 4, 6, 12, 24, 48, and 72 h, or 1 week after TBI, for mRNA and protein analysis. In the second phase, rats underwent moderate fluid percussion brain injury, followed immediately by 4 h of post-traumatic normothermia (37 degrees C), hyperthermia (39 degrees C), or hypothermia (32 degrees C). The rats were killed at 12 and 48 h after TBI for mRNA expression analyses, or killed at 24 and 72 h after TBI for protein expression analyses. Brain samples, including the cerebral cortex and hippocampus (both ipsilateral and contralateral hemispheres of each group), were assayed using RT-PCR and Western blot techniques. MMP-9 levels in both the ipsilateral and contralateral hemispheres were significantly increased after TBI compared with those of sham injured animals (p < 0.01). Two expression peaks of MMP-9 were observed in the ipsilateral cortex and hippocampus. An increase in injury severity was associated with an increase in mRNA (12 and 48 h), and protein (24 and 72 h) levels of MMP-9. Posttraumatic hypothermia attenuated the increase in both the mRNA and protein levels of MMP-9, compared with normothermia and hyperthermia (p < 0.01). In contrast, hyperthermia had no significant effect on mRNA (at 12 h) and protein levels (at 24 h) of MMP-9, compared with normothermic values (p > 0.05), but resulted in a significant increase in the levels of MMP-9 mRNA and protein at 24 and 72 h, respectively (p < 0.01). Increases in MMP-9 mRNA and protein after TBI were proportional to injury severity in this model. The effects of post-traumatic hypothermia on the expression of MMP-9 may partially explain the observed effects of post-traumatic temperature on secondary injury after TBI.	[Jia, Feng; Pan, Yao-hua; Mao, Qing; Liang, Yu-min; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Jia, Feng] Jiangsu Univ, Affiliated Hosp, Yixing Peoples Hosp, Dept Neurosurg, Yixing City, Jiangsu, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China.	jiangjyb@online.sh.cn					Aswal APS, 2008, ANIM REPROD SCI, V103, P164, DOI 10.1016/j.anireprosci.2007.04.012; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Burk J, 2008, BRAIN RES, V1226, P248, DOI 10.1016/j.brainres.2008.06.015; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Celik SE, 2006, J NEUROTRAUM, V23, P1355, DOI 10.1089/neu.2006.23.1355; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Jia F, 2009, J NEUROTRAUMA; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; JIANG C, 2009, INFLAMM RES     0409; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOHANSEN KS, 1983, ACTA PATH MICRO IM C, V91, P355; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203, DOI 10.1152/ajpregu.1998.274.5.R1203; Noble LJ, 2002, J NEUROSCI, V22, P7526; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; UTOH J, 1992, ARTIF ORGANS, V16, P377; Vink R, 2002, EXPERT OPIN INV DRUG, V11, P1375, DOI 10.1517/13543784.11.10.1375; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wallace JA, 2002, J CEREBR BLOOD F MET, V22, P1303, DOI 10.1097/01.WCB.0000040943.89393.c1; Wang J, 2005, NEUROCRIT CARE, V3, P77, DOI 10.1385/NCC:3:1:077; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Whalen MJ, 1997, ACT NEUR S, V70, P260; Yamashita A, 2007, ARCH HISTOL CYTOL, V70, P197, DOI 10.1679/aohc.70.197; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	52	35	37	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1059	1068		10.1089/neu.2009.1067			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300009	20233042				2022-02-06	
J	Ong, WY; Kim, JH; He, X; Chen, P; Farooqui, AA; Jenner, AM				Ong, Wei-Yi; Kim, Ji-Hyun; He, Xin; Chen, Peng; Farooqui, Akhlaq A.; Jenner, Andrew M.			Changes in Brain Cholesterol Metabolome After Excitotoxicity	MOLECULAR NEUROBIOLOGY			English	Article						Cholesterol; Oxysterols; Cholesterol oxidation products; Brain injury; Kainate; Excitotoxicity	INDUCED NEURONAL INJURY; LIVER-X-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; CYTOPLASMIC PHOSPHOLIPASE A(2); APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; RAT HIPPOCAMPUS; STRESS RESISTANCE; KAINATE INJURY; GLIAL-CELLS	Excitotoxicity due to excess stimulation of glutamate receptors in neurons is accompanied by increased Ca2+ influx, stimulation of Ca2+-dependent enzymes, ATP depletion, increase in lipid peroxidation products, and loss of glutathione. These changes resemble neurochemical alterations in acute neuronal injury (stroke, spinal cord injury, and traumatic brain injury) and chronic neurodegenerative diseases such as Alzheimer's disease. Intracerebroventricular injection of the potent glutamate analog kainate in rats results in increased cholesterol concentration in the hippocampus at short to medium time intervals, i.e., 3 days-1 week post-injection, as detected by gas chromatography-mass spectrometry in the lesioned hippocampus. This is accompanied by an early increase in levels of cholesterol biosynthetic precursors and increases in both enzymatically derived oxysterols such as 24-hydroxycholesterol and cholesterol oxidation products (COPs) generated by reactive oxygen species, including cholesterol epoxides and 7-ketocholesterol. In contrast to COPs, no change in concentration of the neurosteroid pregnenolone was found after KA injury. Cholesterol and COPs significantly increase exocytosis in cultured PC12 cells and neurons, and both oxysterols and COPs are able to induce cytotoxic and apoptotic injuries in different cell types, including neurons. Together, the findings suggest that increased cholesterol and COPs after KA excitotoxicity could themselves lead to disturbed neuronal ion homeostasis, increased neurotransmitter release, and propagation of excitotoxicity.	[Ong, Wei-Yi; Kim, Ji-Hyun] Natl Univ Singapore, Dept Anat, Singapore 119260, Singapore; [Ong, Wei-Yi; Jenner, Andrew M.] Natl Univ Singapore, Aging Neurobiol Res Programme, Singapore 119260, Singapore; [He, Xin] Beijing Univ Chinese Med, Dept Anat, Beijing, Peoples R China; [Chen, Peng] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore, Singapore; [Farooqui, Akhlaq A.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Jenner, Andrew M.] Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore		Ong, WY (corresponding author), Natl Univ Singapore, Dept Anat, Singapore 119260, Singapore.	antongwy@nus.edu.sg; bchjam@nus.edu.sg	Chen, Peng/G-6202-2010; Chen, Peng/D-3993-2009; jenner, andrew M/H-4791-2016	Chen, Peng/0000-0003-3730-1846; jenner, andrew M/0000-0003-1767-2033	National Medical Research Council of SingaporeNational Medical Research Council, Singapore [NMRC/EDG/0012/2007, NMRC/EDG/0060/2009]	This work was supported by grants from the National Medical Research Council of Singapore (NMRC/EDG/0012/2007 and NMRC/EDG/0060/2009).	Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200; Alexandrov P, 2005, NEUROREPORT, V16, P909, DOI 10.1097/00001756-200506210-00007; Berthier A, 2005, FEBS J, V272, P3093, DOI 10.1111/j.1742-4658.2005.04723.x; Biagini G, 2009, EPILEPSIA, V50, P53, DOI 10.1111/j.1528-1167.2008.01971.x; Bjorkhem I, 2006, ACTA NEUROL SCAND, V114, P43, DOI 10.1111/j.1600-0404.2006.00684.x; Bjorkhem I, 1998, J LIPID RES, V39, P1594; BOTOLOTTO ZA, 2003, PHILOS T R SOC B, V358, P657; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cartagena CM, 2008, J NEUROTRAUM, V25, P1087, DOI 10.1089/neu.2007.0444; Chang JY, 2009, BIOPHYS J, V96, P1839, DOI 10.1016/j.bpj.2008.11.033; Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656; Chia WJ, 2008, EXP BRAIN RES, V186, P143, DOI 10.1007/s00221-007-1209-4; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; DeBose-Boyd RA, 2008, CELL RES, V18, P609, DOI 10.1038/cr.2008.61; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Eckert GP, 2007, NEUROSCI LETT, V423, P47, DOI 10.1016/j.neulet.2007.05.063; Farooqui A.A., 2008, NEUROCHEMICAL ASPECT; Farooqui AA, 2001, BRAIN RES REV, V38, P61, DOI 10.1016/S0169-328X(01)00214-5; Farooqui AA, 2007, GLYCEROPHOSPHOLIPIDS; Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268; Farooqui Akhlaq A, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P85, DOI 10.2174/1568006043481239; Fernandez A, 2009, J NEUROSCI, V29, P6394, DOI 10.1523/JNEUROSCI.4909-08.2009; Frank C, 2008, EXP NEUROL, V212, P407, DOI 10.1016/j.expneurol.2008.04.019; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Ganfornina MD, 2008, AGING CELL, V7, P506, DOI 10.1111/j.1474-9726.2008.00395.x; Gong JS, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-9; Gosselet F, 2009, BRAIN RES, V1249, P34, DOI 10.1016/j.brainres.2008.10.036; Guan XL, 2006, FASEB J, V20, P1152, DOI 10.1096/fj.05-5362com; Guirland C, 2007, ADV EXP MED BIOL, V621, P144, DOI 10.1007/978-0-387-76715-4_11; Han JH, 2007, BRAIN RES, V1137, P11, DOI 10.1016/j.brainres.2006.12.041; He X, 2007, J NEUROSCI RES, V85, P423, DOI 10.1002/jnr.21107; He X, 2006, J NEUROPATH EXP NEUR, V65, P652, DOI 10.1097/01.jnen.0000225906.82428.69; He X, 2009, NEUROSCI LETT, V455, P183, DOI 10.1016/j.neulet.2009.03.038; Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200; Hirsch-Reinshagen V, 2009, J LIPID RES, V50, P885, DOI 10.1194/jlr.M800584-JLR200; Hu CY, 2000, J NEUROCYTOL, V29, P765, DOI 10.1023/A:1010942521671; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Infante RE, 2008, J BIOL CHEM, V283, P1064, DOI 10.1074/jbc.M707944200; Iuliano L, 2003, ANAL BIOCHEM, V312, P217, DOI 10.1016/S0003-2697(02)00467-0; Jenner A, 2007, FREE RADICAL BIO MED, V42, P559, DOI 10.1016/j.freeradbiomed.2006.11.024; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; Karasinska JM, 2009, J NEUROSCI, V29, P3579, DOI 10.1523/JNEUROSCI.4741-08.2009; Kim JH, 2010, J NEUROCHEM, V112, P34, DOI 10.1111/j.1471-4159.2009.06449.x; Kim JH, 2009, J CHEM NEUROANAT, V37, P71, DOI 10.1016/j.jchemneu.2008.12.004; Kohchi C, 1998, BRAIN RES, V801, P233, DOI 10.1016/S0006-8993(98)00585-X; Kojima M, 2004, TOXICOL LETT, V154, P35, DOI 10.1016/j.toxlet.2004.06.010; Korade Z, 2007, NEUROBIOL AGING, V28, P1522, DOI 10.1016/j.neurobiolaging.2006.06.026; Koyrakh L, 2005, J NEUROSCI, V25, P11468, DOI 10.1523/JNEUROSCI.3484-05.2005; Lee CYJ, 2008, FREE RADICAL BIO MED, V44, P1314, DOI 10.1016/j.freeradbiomed.2007.12.026; Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2; Leoni V, 2005, J LIPID RES, V46, P191, DOI 10.1194/jlr.C400005-JLR200; Levi O, 2005, J NEUROCHEM, V95, P987, DOI 10.1111/j.1471-4159.2005.03441.x; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Liou HL, 2006, J BIOL CHEM, V281, P36710, DOI 10.1074/jbc.M608743200; Lizard G, 2000, FREE RADICAL BIO MED, V28, P743, DOI 10.1016/S0891-5849(00)00163-5; Lu XR, 2001, FREE RADICAL BIO MED, V30, P1263, DOI 10.1016/S0891-5849(01)00528-7; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Luthra S, 2008, MICROVASC RES, V75, P343, DOI 10.1016/j.mvr.2007.10.003; Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MacDonald John F., 2006, Critical Reviews in Neurobiology, V18, P71; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Massey JB, 2006, CURR OPIN LIPIDOL, V17, P296, DOI 10.1097/01.mol.0000226123.17629.ab; Meaney S, 2007, J LIPID RES, V48, P944, DOI 10.1194/jlr.M600529-JLR200; Mishra S, 2007, J NEUROCHEM, V103, P135, DOI 10.1111/j.1471-4159.2007.04720.x; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Morello F, 2009, ATHEROSCLEROSIS, V207, P38, DOI 10.1016/j.atherosclerosis.2009.04.001; Muffat J, 2008, P NATL ACAD SCI USA, V105, P7088, DOI 10.1073/pnas.0800896105; Nieweg K, 2009, J NEUROCHEM, V109, P125, DOI 10.1111/j.1471-4159.2009.05917.x; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2; Ong WY, 2000, NEUROSCIENCE, V97, P143, DOI 10.1016/S0306-4522(00)00031-2; Ong WY, 2004, NEUROSCIENCE, V128, P561, DOI 10.1016/j.neuroscience.2004.07.001; Ong WY, 2003, BRAIN PATHOL, V13, P250; Ong WY, 2003, EXP BRAIN RES, V148, P521, DOI 10.1007/s00221-002-1315-2; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Pendse AA, 2009, J LIPID RES, V50, pS178, DOI 10.1194/jlr.R800070-JLR200; Perez-Otano I, 2004, NEUROSIGNALS, V13, P175, DOI 10.1159/000077524; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Recuero M, 2009, AGING CELL, V8, P128, DOI 10.1111/j.1474-9726.2009.00457.x; Reid CA, 2000, TRENDS PHARMACOL SCI, V21, P159, DOI 10.1016/S0165-6147(00)01479-6; Rickhag M, 2008, J CEREBR BLOOD F MET, V28, P551, DOI 10.1038/sj.jcbfm.9600552; Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008; Rise P, 2004, PROSTAG LEUKOTR ESS, V71, P79, DOI 10.1016/j.plefa.2003.12.005; Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859; Ryan L, 2006, INT J TOXICOL, V25, P35, DOI 10.1080/10915810500488387; Ryan L, 2004, CELL BIOL TOXICOL, V20, P313, DOI 10.1007/s10565-004-5066-7; SAITO M, 1987, J NEUROSCI RES, V18, P319, DOI 10.1002/jnr.490180208; Sanchez D, 2006, CURR BIOL, V16, P680, DOI 10.1016/j.cub.2006.03.024; Sandhya TL, 1998, BRAIN RES, V788, P223, DOI 10.1016/S0006-8993(97)01552-7; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Stefani M, 2009, CURR ALZHEIMER RES, V6, P15, DOI 10.2174/156720509787313899; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Suzuki S, 2007, J NEUROSCI, V27, P6417, DOI 10.1523/JNEUROSCI.0690-07.2007; TANG Y, 2010, CLIN EXP PH IN PRESS; Tarr PT, 2008, J LIPID RES, V49, P169, DOI 10.1194/jlr.M700364-JLR200; Thelen KM, 2006, NEUROSCI LETT, V403, P15, DOI 10.1016/j.neulet.2006.04.034; Thwin MM, 2003, EXP BRAIN RES, V150, P427, DOI 10.1007/s00221-003-1476-7; Trousson A, 2009, J NEUROCHEM, V109, P945, DOI 10.1111/j.1471-4159.2009.06009.x; Vaya J, 2007, J NEUROCHEM, V102, P1727, DOI 10.1111/j.1471-4159.2007.04689.x; Walker DW, 2006, CURR BIOL, V16, P674, DOI 10.1016/j.cub.2006.01.057; Walkley SU, 2004, BBA-MOL CELL BIOL L, V1685, P48, DOI 10.1016/j.bbalip.2004.08.011; Wang H, 2002, MOL CELL BIOL, V22, P8478, DOI 10.1128/MCB.22.24.8478-8490.2002; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Wang YQ, 2008, J PROTEOME RES, V7, P1606, DOI 10.1021/pr7006076; Yu ZF, 2002, NEUROBIOL DIS, V11, P199, DOI 10.1006/nbdi.2002.0530; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175; Zhang J, 2009, BIOPHYS J, V97, P1371, DOI 10.1016/j.bpj.2009.06.025	113	35	36	0	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUN	2010	41	2-3			SI		299	313		10.1007/s12035-010-8099-3			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	601WI	WOS:000278095800025	20140539				2022-02-06	
J	Sroufe, NS; Fuller, DS; West, BT; Singal, BM; Warschausky, SA; Maio, RF				Sroufe, Nicole S.; Fuller, Douglas S.; West, Brady T.; Singal, Bonita M.; Warschausky, Seth A.; Maio, Ronald F.			Postconcussive Symptoms and Neurocognitive Function After Mild Traumatic Brain Injury in Children	PEDIATRICS			English	Article						traumatic brain injury; postconcussive symptoms; prospective study; longitudinal study	POST-CONCUSSIVE SYNDROME; HEAD-INJURY; UNITED-STATES; EPIDEMIOLOGY; PERFORMANCE; SEVERITY	OBJECTIVES: We describe children's postconcussive symptoms (PCSs), neurocognitive function, and recovery during 4 to 5 weeks after mild traumatic brain injury (MTBI) and compare performance and recovery with those of injured control group participants without MTBIs. METHODS: A prospective, longitudinal, observational study was performed with a convenience sample from a tertiary care, pediatric emergency department. Participants were children 10 to 17 years of age who were treated in the emergency department and discharged. The MTBI group included patients with blunt head trauma, Glasgow Coma Scale scores of 13 to 15, loss of consciousness for <= 30 minutes, posttraumatic amnesia of <= 24 hours, altered mental status, or focal neurologic deficits, and no intracranial abnormalities. The control group included patients with injuries excluding the head. The Post-Concussion Symptom Questionnaire and domain-specific neurocognitive tests were completed at baseline and at 1 and 4 to 5 weeks after injury. RESULTS: Twenty-eight MTBI group participants and 45 control group participants were compared. There were no significant differences in demographic features. Control group participants reported some PCSs; however, MTBI group participants reported significantly more PCSs at all times. Among MTBI group participants, PCSs persisted for 5 weeks after injury, decreasing significantly between 1 and 4 to 5 weeks. Patterns of recovery on the Trail-Making Test Part B differed significantly between groups; performance on other neurocognitive measures did not differ. CONCLUSIONS: In children 10 to 17 years of age, self-reported PCSs were not exclusive to patients with MTBIs. However, PCSs and recovery patterns for the Trail-Making Test Part B differed significantly between the groups. Pediatrics 2010; 125: e1331-e1339	[Sroufe, Nicole S.; Maio, Ronald F.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Warschausky, Seth A.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Sroufe, Nicole S.; Maio, Ronald F.] Univ Michigan, Injury Res Ctr, Ann Arbor, MI 48109 USA; [Fuller, Douglas S.; West, Brady T.] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA; [Singal, Bonita M.] St Joseph Mercy Hosp, Dept Clin Res, Ann Arbor, MI 48104 USA; [Maio, Ronald F.] Univ Michigan, Off Vice President Res Univ, Ann Arbor, MI 48109 USA		Sroufe, NS (corresponding author), 1500 E Med Ctr Dr,Room TC B1 380, Ann Arbor, MI 48109 USA.	nicolel@med.umich.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE00284-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000284] Funding Source: NIH RePORTER	This work was funded by the Centers for Disease Control and Prevention (grant R49CE00284-01).	ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BIJUR PE, 1990, PEDIATRICS, V86, P337; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Diggle P., 2002, ANAL LONGITUDINAL DA; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Molenberghs G., 2005, MODELS DISCRETE LONG; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; Pinkston JB, 2000, BRAIN COGNITION, V44, P74; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Reitan RM, 1985, HALSTEADREITAN NEURO; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Rutter M, 1996, J DEV BEHAV PEDIATR, V17, P183; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schmidt M., 1996, REY AUDITORY VERBAL; Schootman M, 2000, BRAIN INJURY, V14, P373; Smith A., 2002, SYMBOL DIGIT MODALIT; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; THOMSON JB, 2000, NEUROPSYCHOLOGICAL M, P233; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; TWISK JWR, 2003, APPL LONGITUDINAL DA, P280; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	49	35	35	0	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2010	125	6					E1331	E1339		10.1542/peds.2008-2364			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	604GX	WOS:000278268600036	20478946				2022-02-06	
J	Air, EL; Yuan, WH; Holland, SK; Jones, BV; Bierbrauer, K; Altaye, M; Mangano, FT				Air, Ellen L.; Yuan, Weihong; Holland, Scott K.; Jones, Blaise V.; Bierbrauer, Karin; Altaye, Mekibib; Mangano, Francesco T.			Longitudinal comparison of pre- and postoperative diffusion tensor imaging parameters in young children with hydrocephalus Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						pediatric hydrocephalus; diffusion tensor imaging; fractional anisotropy; mean diffusivity; axial diffusivity; radial diffusivity; cerebrospinal fluid shunt insertion	TRAUMATIC BRAIN-INJURY; WHITE-MATTER MATURATION; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; WATER DIFFUSION; EARLY-CHILDHOOD; SPINA-BIFIDA; ANISOTROPY; DTI; ABNORMALITIES	Object. The goal in this study was to compare the integrity of white matter before and after ventriculoperitoneal (VP) shunt insertion by evaluating the an isotropic diffusion properties with the aid of diffusion tensor (DT) imaging in young children with hydrocephalus. Methods. The authors retrospectively identified 10 children with hydrocephalus who underwent both pre- and postoperative DT imaging studies. The DT imaging parameters (fractional anisotropy [FA], mean diffusivity, axial diffusivity, and radial diffusivity) were computed and compared longitudinally in the splenium and genu of the corpus callosum (gCC) and in the anterior and posterior limbs of the internal capsule (PLIC). The patients' values on DT imaging at the pre- and postshunt stages were compared with the corresponding age-matched controls as well as with a large cohort of healthy children in the database. Results. In the gCC, 7 of 10 children had abnormally low preoperative FA values, 6 of which normalized postoperatively. All 3 of the 10 children who had normal preoperative FA values had normal FA values postoperatively as well. In the PUG, 7 of 10 children had abnormally high FA values, 6 of which normalized postoperatively, whereas the other one had abnormally low postoperative FA. Of the remaining 3 children, 2 had abnormally low preoperative FA values in the PLIC; this normalized in 1 patient after surgery. The other child had a normal preoperative FA value that became abnormally low postoperatively. When comparing the presurgery frequency of abnormally low, normal, and abnormally high FA values to those postsurgery, there. was a statistically significant longitudinal difference in both gCC (p = 0.02) and MAC (p = 0.002). Conclusions. In this first longitudinal DT imaging study of young children with hydrocephalus. DT imaging anisotropy yielded abnormal results in several white matter regions of the brain, and trended toward normalization following VP shunt placement. (DOI: 10.3171/2009.11.PEDS09343)	[Mangano, Francesco T.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Neurosurg,Dept Pediat Neurosurg, Cincinnati, OH 44529 USA; [Yuan, Weihong; Holland, Scott K.] Cincinnati Childrens Hosp, Dept Radiol, Pediat Neuroimaging Res Consortium, Med Ctr, Cincinnati, OH USA; [Jones, Blaise V.] Cincinnati Childrens Hosp, Med Ctr, Dept Neuroradiol, Cincinnati, OH USA; [Altaye, Mekibib] Cincinnati Childrens Hosp, Med Ctr, Dept Biostat & Epidemiol, Cincinnati, OH USA; [Air, Ellen L.; Bierbrauer, Karin; Mangano, Francesco T.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 44529 USA		Mangano, FT (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Neurosurg,Dept Pediat Neurosurg, MLC 2016,3333 Burnet Ave, Cincinnati, OH 44529 USA.	francesco.mangano@cchmc.org	Altaye, Mekibib/N-5274-2015	Holland, Scott/0000-0003-3719-0875	CCHMC [SPR103674]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS066932] Funding Source: NIH RePORTER	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This study was supported in part by the Robert L. McLaurin, M.D., Faculty Development Scholarship in Neurosurgery at CCHMC, and by a CCHMC Trustee Grant (SPR103674).	Assaf Y, 2006, AM J NEURORADIOL, V27, P1717; Bammer R, 2000, MAGNET RESON MED, V44, P583, DOI 10.1002/1522-2594(200010)44:4<583::AID-MRM12>3.0.CO;2-O; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Cascio CJ, 2007, J AM ACAD CHILD PSY, V46, P213, DOI 10.1097/01.chi.0000246064.93200.e8; Del Bigio MR, 2003, ANN NEUROL, V53, P337, DOI 10.1002/ana.10453; DELBIGIO MR, 1994, CAN J NEUROL SCI, V21, P299, DOI 10.1017/S0317167100040865; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; Ding XQ, 2008, AM J NEURORADIOL, V29, P1261, DOI 10.3174/ajnr.A1097; Dreha-Kulaczewski S, 2006, NEURORADIOLOGY, V48, P893, DOI 10.1007/s00234-006-0148-2; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; Gao W, 2009, AM J NEURORADIOL, V30, P290, DOI 10.3174/ajnr.A1363; Gilmore JH, 2007, AM J NEURORADIOL, V28, P1789, DOI 10.3174/ajnr.A0751; Hasan KM, 2008, J NEUROSURG-PEDIATR, V2, P75, DOI 10.3171/PED/2008/2/7/075; Hasan KM, 2008, J MAGN RESON IMAGING, V27, P700, DOI 10.1002/jmri.21297; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Herweh C, 2009, NEUROIMAGE, V44, P306, DOI 10.1016/j.neuroimage.2008.09.006; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Khong PL, 2006, J CLIN ONCOL, V24, P884, DOI 10.1200/JCO.2005.02.4505; Leliefeld PH, 2009, J NEUROSURG-PEDIATR, V4, P56, DOI 10.3171/2009.3.PEDS08337; Mataro M, 2001, NEUROPSYCHOL REV, V11, P169, DOI 10.1023/A:1012904907249; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Qiu DQ, 2008, NEUROIMAGE, V41, P223, DOI 10.1016/j.neuroimage.2008.02.023; Rose J, 2007, DEV MED CHILD NEUROL, V49, P745, DOI 10.1111/j.1469-8749.2007.00745.x; Saksena S, 2008, CEREBELLUM, V7, P392, DOI 10.1007/s12311-008-0041-0; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; van Engelen SJPM, 2008, AM J NEURORADIOL, V29, P816, DOI 10.3174/ajnr.A0921; Werring DJ, 2000, J NEUROL NEUROSUR PS, V69, P269, DOI 10.1136/jnnp.69.2.269; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yuan W, 2009, AM J NEURORADIOL, V30, P1792, DOI 10.3174/ajnr.A1663; Yuan W, 2008, J NEUROSURG-PEDIATR, V1, P263, DOI 10.3171/PED/2008/1/4/263; Yung A, 2007, PEDIATR RES, V61, P732, DOI 10.1203/pdr.0b013e31805365db; Zelaya F, 1999, MAGN RESON IMAGING, V17, P331, DOI 10.1016/S0730-725X(98)00192-1	37	35	35	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	APR	2010	5	4					385	391		10.3171/2009.11.PEDS09343			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	574AB	WOS:000275959700013	20367345				2022-02-06	
J	Purins, K; Enblad, P; Sandhagen, B; Lewen, A				Purins, Karlis; Enblad, Per; Sandhagen, Bo; Lewen, Anders			Brain tissue oxygen monitoring: a study of in vitro accuracy and stability of Neurovent-PTO and Licox sensors	ACTA NEUROCHIRURGICA			English	Article						Licox; Neurovent-PTO; Brain tissue oxygenation; Accuracy; Neurointensive care; Traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL OXYGENATION; PARTIAL-PRESSURE; INSPIRED OXYGEN; SATURATION; PO2; EXPERIENCE; TENSION; LACTATE	Periods of brain tissue ischemia are common after severe head injury, and their occurrence and duration are negatively correlated with outcome. Accurate and reliable measurement of brain tissue oxygenation (B-ti pO(2)) may be a key to improve patient outcome after severe head injury. Knowledge of stability and accuracy of the B-ti pO(2) systems is crucial. We have therefore conducted a bench test study of new Neurovent-PTOA (R) (NV) and LicoxA (R) (LX) oxygen tension catheters to evaluate the sensor accuracy, response time to different oxygen tensions, response to temperature changes and long-term stability. For all experiments five new fluorescent NV sensors and five new electrochemical LX sensors were used. The catheter probes were placed into a container filled with a buffer solution. The solution was equilibrated with five high precision calibration gases. The accuracy of the probes was recorded after an equilibration period of 20 min in O-2 concentrations of 5, 10, 20, 30 and 40 mmHg at 37.0 +/- 0.2A degrees C. The probe response to an increase in temperature from 37.0A degrees C to 38.5A degrees C to 40.0A degrees C in two different gases with O-2 concentrations of 10 and 20 mmHg were analysed. We also recorded the time for reaching 90% of a new oxygen concentration level when switching from one concentration to another. Finally, to test if there was a time-dependant drift in pO(2) recordings, all sensors were left in 10 mmHg O-2 solution for 10 days, and recordings were taken every 24 h. In all gas concentrations, NV and LX sensors measured pO(2) with high accuracy and stability in vitro (mean differences from calculated values were for NV 0.76-1.6 mmHg and for LX -0.46-0.26 mmHg). Both sensors showed a shorter response time to pO(2) increase (for NV 56 +/- 22 s and for LX 78 +/- 21 s) compared to pO(2) decrease (for NV 131 +/- 42 s and for LX 215 +/- 63 s). NV pO(2) values were more stable for changes in temperature, while LX sensors showed larger standard deviations with increasing temperature (the difference from the calculated values in 19.7 mmHg O-2 at 40A degrees C were for NV probes between 0.5 and 1.7 mmHg and LX between -2.3 and 1.9 mmHg). Both sensors gave stable results with low standard deviations during long-term (10 days) use, but with a slight elevation of measured pO(2) levels by time. Both NV and LX were accurate in detecting different oxygen tensions, and they did not deviate over longer recording times. However, LX needed a significantly longer time to detect changes in pO(2) levels compared to NV. Furthermore, LX probes showed an increased standard deviation with higher temperatures.	[Purins, Karlis; Enblad, Per; Lewen, Anders] Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden; [Sandhagen, Bo] Univ Uppsala Hosp, Dept Med Sci, Sect Clin Physiol, S-75185 Uppsala, Sweden		Enblad, P (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.	per.enblad@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	Swedish Research CouncilSwedish Research CouncilEuropean Commission	The study was supported by The Swedish Research Council. We would like to acknowledge Lars Berglund, Ph. D., Uppsala Clinical Research Center, Uppsala University for statistical advice.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Fandino J, 1999, ACTA NEUROCHIR, V141, P825, DOI 10.1007/s007010050383; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Haitsma IK, 2007, PROG BRAIN RES, V161, P207, DOI 10.1016/S0079-6123(06)61014-5; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 2003, BRIT J NEUROSURG, V17, P311, DOI 10.1080/02688690310001601199; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stocchetti N, 2005, J NEUROL NEUROSUR PS, V76, P1135, DOI 10.1136/jnnp.2004.041269; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	23	35	35	0	8	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	APR	2010	152	4					681	688		10.1007/s00701-009-0532-x			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	573WI	WOS:000275945600017	19826757				2022-02-06	
J	Flierl, MA; Stoneback, JW; Beauchamp, KM; Hak, DJ; Morgan, SJ; Smith, WR; Stahel, PF				Flierl, Michael A.; Stoneback, Jason W.; Beauchamp, Kathryn M.; Hak, David J.; Morgan, Steven J.; Smith, Wade R.; Stahel, Philip F.			Femur Shaft Fracture Fixation in Head-Injured Patients: When Is the Right Time?	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						Traumatic brain injury; femur fracture; intramedullary nail fixation; damage control; external fixation	TRAUMATIC BRAIN-INJURY; COMA SCALE SCORE; FEMORAL FRACTURES; MULTIPLE TRAUMA; EXTERNAL FIXATION; MAJOR FRACTURES; STABILIZATION; POLYTRAUMA; STRATEGIES; MANAGEMENT	The ideal timing and modality of femur shaft fracture fixation in head-injured patients remains a topic of debate. Several groups advocate the immediate definitive fixation Of femur fractures ("early total care"), whereas others support the concept of "damage control orthopaedics" with temporary fracture fixation by means of external fixation and staged, planned conversion to internal fixation. The present review was designed to address this unresolved controversy by outlining the underlying immunopathophysiology of traumatic brain injury and providing clinical recommendations on the timing of femur shaft fracture fixation in patients with severe head injuries.	[Flierl, Michael A.; Stoneback, Jason W.; Hak, David J.; Morgan, Steven J.; Smith, Wade R.; Stahel, Philip F.] Univ Colorado, Dept Orthopaed Surg, Denver Hlth Med Ctr, Sch Med, Denver, CO 80204 USA; [Beauchamp, Kathryn M.; Stahel, Philip F.] Univ Colorado, Dept Neurosurg, Denver Hlth Med Ctr, Sch Med, Denver, CO 80204 USA		Stahel, PF (corresponding author), Univ Colorado, Dept Orthopaed Surg, Denver Hlth Med Ctr, Sch Med, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org					Anglen JO, 2003, J TRAUMA, V54, P1166, DOI 10.1097/01.TA.0000057232.66613.AC; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bhandari M, 2003, CLIN ORTHOP RELAT R, P187, DOI 10.1097/01.blo.0000043051.62337.bd; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; Bose D, 2006, INJURY, V37, P20, DOI 10.1016/j.injury.2005.06.054; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS45; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Brundage SI, 2002, J TRAUMA, V52, P299, DOI 10.1097/00005373-200202000-00016; CHARASH WE, 1994, J TRAUMA, V37, P667, DOI 10.1097/00005373-199410000-00023; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Edwards P, 2005, LANCET, V365, P1957; Elf K, 2003, EUR J TRAUMA, V29, P74; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Forteza AM, 1999, STROKE, V30, P2687, DOI 10.1161/01.STR.30.12.2687; Garg R, 2006, STROKE, V37, P267, DOI 10.1161/01.STR.0000195175.29487.30; Gebhard F, 2008, LANGENBECK ARCH SURG, V393, P825, DOI 10.1007/s00423-008-0334-2; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Giannoudis PV, 1999, J BONE JOINT SURG BR, V81B, P356, DOI 10.1302/0301-620X.81B2.8988; Giannoudis PV, 2002, CLIN ORTHOP RELAT R, P378, DOI 10.1097/01.blo.00000236813.17269.24; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; Glenn JN, 2004, CLIN ORTHOP RELAT R, P142, DOI 10.1097/01.blo.0000131644.61246.c4; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Gray AC, 2009, J ORTHOP TRAUMA, V23, P90, DOI 10.1097/BOT.0b013e31819194c6; Grotz MRW, 2004, INJURY, V35, P1077, DOI 10.1016/j.injury.2004.05.025; Harwood PJ, 2005, J TRAUMA, V58, P446, DOI 10.1097/01.TA.0000153942.28015.77; HOFMAN PAM, 1991, J TRAUMA, V31, P261, DOI 10.1097/00005373-199131020-00020; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Holcomb JB, 2007, J TRAUMA, V62, pS36, DOI 10.1097/TA.0b013e3180654134; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; Kalb DC, 1998, SURGERY, V124, P739, DOI 10.1067/msy.1998.91395; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; KOTWICA Z, 1990, ACTA NEUROCHIR, V102, P19, DOI 10.1007/BF01402180; Lehmann U, 2001, UNFALLCHIRURG, V104, P196, DOI 10.1007/s001130050715; LEHMANN U, 1995, UNFALLCHIRURG, V98, P437; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morshed S, 2009, J BONE JOINT SURG AM, V91A, P3, DOI 10.2106/JBJS.H.00338; Mousavi M, 2001, INJURY, V32, P679, DOI 10.1016/S0020-1383(01)00048-1; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nau T, 2003, ANZ J SURG, V73, P1018, DOI 10.1046/j.1445-2197.2003.t01-19-.x; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; Nowotarski PJ, 2000, J BONE JOINT SURG AM, V82A, P781, DOI 10.2106/00004623-200006000-00004; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Pape HC, 2008, J ORTHOP RES, V26, P1478, DOI 10.1002/jor.20697; Pape HC, 2007, ANN SURG, V246, P491, DOI 10.1097/SLA.0b013e3181485750; Pape Hans-Christoph, 2005, J Orthop Trauma, V19, P551, DOI 10.1097/01.bot.0000161712.87129.80; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921, DOI 10.1302/0301-620X.75B6.8245083; POOLE GV, 1992, J TRAUMA, V32, P654, DOI 10.1097/00005373-199205000-00019; Ransohoff RM, 2002, ANN NY ACAD SCI, V961, P346, DOI 10.1111/j.1749-6632.2002.tb03120.x; Ransohoff RM, 2002, J INFECT DIS, V186, pS152, DOI 10.1086/344266; Reed AR, 2002, SAMJ S AFR MED J, V92, P221; REYNOLDS MA, 1995, ANN SURG, V222, P470; Rixen D, 2005, J TRAUMA, V59, P1375, DOI 10.1097/01.ta.0000198364.50334.39; Roberts Craig S, 2005, Instr Course Lect, V54, P447; Rose S, 1998, LANGENBECK ARCH SURG, V383, P199, DOI 10.1007/s004230050119; Sagraves Scott G, 2006, J Intensive Care Med, V21, P5, DOI 10.1177/0885066605282790; Scalea TM, 2008, J TRAUMA, V65, P253, DOI 10.1097/TA.0b013e31817fa475; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; Spahn DR, 2007, CRIT CARE, V11, DOI 10.1186/cc5686; Spinella PC, 2007, J TRAUMA, V62, pS82, DOI 10.1097/TA.0b013e318065b21f; Stahel PF, 2005, ORTHOPADE, V34, P852, DOI 10.1007/s00132-005-0844-3; Stahel PF, 2005, ORTHOPADE, V34, P823, DOI 10.1007/s00132-005-0842-5; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; STAHEL PF, 2009, GEN SURG PRINCIPLES, P131; STAHEL PF, 2005, EUR J TRAUMA, V31, P200; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Stahel PF, 2007, INJURY, V38, P1409, DOI 10.1016/j.injury.2007.09.023; Stahel PF, 2009, CURR OPIN ANESTHESIO, V22, P289, DOI 10.1097/ACO.0b013e32832678ed; Starr AJ, 1998, J TRAUMA, V45, P980, DOI 10.1097/00005373-199811000-00026; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Taeger G, 2005, J TRAUMA, V59, P408, DOI 10.1097/01.ta.0000175088.29170.3e; Townsend RN, 1998, J TRAUMA, V44, P977, DOI 10.1097/00005373-199806000-00008; Tracey KJ, 2001, FASEB J, V15, P1575, DOI 10.1096/fj.01-0148hyp; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Velmahos GC, 1998, AM J SURG, V176, P324, DOI 10.1016/S0002-9610(98)00208-6; Wang MC, 2007, J TRAUMA, V62, P1250, DOI 10.1097/01.ta.0000215581.50234.56; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Wu Xue-Hai, 2003, Chin J Traumatol, V6, P114; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	95	35	37	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	FEB	2010	24	2					107	114		10.1097/BOT.0b013e3181b6bdfc			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	549RV	WOS:000274072700007	20101135				2022-02-06	
J	Chang, MC; Kim, SH; Kim, OL; Bai, DS; Jang, SH				Chang, Min Cheol; Kim, Seong Ho; Kim, Oh Lyong; Bai, Dai Seg; Jang, Sung Ho			The relation between fornix injury and memory impairment in patients with diffuse axonal injury: A diffusion tensor imaging study	NEUROREHABILITATION			English	Article						Diffuse axonal injury; memory; diffuse tensor imaging; fornix; brain injury	CLOSED-HEAD TRAUMA; CORTICOSPINAL TRACT; FIBER TRACKING; TRACTOGRAPHY; LESIONS; BRAIN; INFARCTION; INTEGRITY; RECOVERY; FEATURES	Little is known about the relation between fornix injury and memory impairment in diffuse axonal injury (DAD. In the current study, we attempted to investigate fornix injury in patients with memory impairment following DAI, using diffusion tensor imaging (DTI). Nine patients with DAI and nine age-and sex-matched control subjects were recruited. The DTIs were acquired using a sensitivity-encoding head coil on a 1.5 T. Five regions of interest (ROI) were drawn manually on a color fractional anisotropy (FA) map: two ROIs for each column, one ROI for the body, and two ROIs for each crus. The FA and apparent diffusion coefficient (ADC) were measured in each of the ROIs. Cognitive function was evaluated using the Memory Assessment Scale, Wechsler Intelligence Scale, and Mini-Mental State Exam. In the DAI group, the FA value in the fornix body was significantly decreased compared with that of the control group. In contrast, we did not find significant differences in the column and crus of the fornix. Among all of the cognitive function scales, only the Memory Assessment Scale scores were significantly correlated with the FA values of the fornix body in the DAI group. We found that memory impairment in patients with DAI is closely related to neuronal injury of the fornix body among the three fornix regions that we assessed. DTI could be useful in the evaluation of patients with memory impairment following DAI.	[Chang, Min Cheol; Jang, Sung Ho] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea; [Kim, Seong Ho; Kim, Oh Lyong] Yeungnam Univ, Coll Med, Dept Neurosurg, Taegu 705717, South Korea; [Bai, Dai Seg] Yeungnam Univ, Coll Med, Dept Psychiat, Taegu 705717, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADEL KA, 2005, FUNCTIONAL NEUROANAT, P271; Aggleton JP, 2000, BRAIN, V123, P800, DOI 10.1093/brain/123.4.800; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Concha L, 2005, AM J NEURORADIOL, V26, P2267; DESPOSITO M, 1995, NEUROLOGY, V45, P1546, DOI 10.1212/WNL.45.8.1546; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAFMAN J, 1985, ARCH NEUROL-CHICAGO, V42, P1162, DOI 10.1001/archneur.1985.04060110044014; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P104; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hattingen E, 2007, J NEUROL NEUROSUR PS, V78, P655, DOI 10.1136/jnnp.2006.109801; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Kuroki N, 2006, BIOL PSYCHIAT, V60, P22, DOI 10.1016/j.biopsych.2005.09.021; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Park SA, 2000, NEUROLOGY, V54, P1379, DOI 10.1212/WNL.54.6.1379; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Takei K, 2008, SCHIZOPHR RES, V103, P52, DOI 10.1016/j.schres.2008.03.008; Tsivilis D, 2008, NAT NEUROSCI, V11, P834, DOI 10.1038/nn.2149; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler, 1997, WECHSLER ADULT INTEL; WILLIAMS JM, 1991, MEMORY ASSESSMENT SC; Zahr NM, 2009, NEUROIMAGE, V44, P1050, DOI 10.1016/j.neuroimage.2008.09.046	34	35	36	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	4					347	353		10.3233/NRE-2010-0572			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	632NE	WOS:000280430600008	20555158				2022-02-06	
J	Kumar, R; Saksena, S; Husain, M; Srivastava, A; Rathore, RKS; Agarwal, S; Gupta, RK				Kumar, Raj; Saksena, Sona; Husain, Mazhar; Srivastava, Arti; Rathore, Ram K. S.; Agarwal, Shruti; Gupta, Rakesh K.			Serial Changes in Diffusion Tensor Imaging Metrics of Corpus Callosum in Moderate Traumatic Brain Injury Patients and Their Correlation With Neuropsychometric Tests: A 2-Year Follow-up Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						corpus callosum; diffuse axonal injury; diffusion tensor imaging; fractional anisotropy; neuropsychological test; radial diffusivity; traumatic brain injury	AXONAL INJURY; WHITE-MATTER; HEAD-INJURY; MILD; MR; DEGENERATION; PERFORMANCE; RECOVERY; ATROPHY; STATE	Objective: To assess longitudinally the severity of diffuse axonal injury in the corpus callosum, in patients with moderate traumatic brain injury (TBI) through quantitative diffusion tensor imaging and to correlate these changes with neuropsychometric tests (NPT) at 6 and 24 months after injury. Design: Prospective longitudinal study. Participants: Sixteen patients with TBI and 17 age/sex-matched healthy controls. Methods: Patients underwent magnetic resonance imaging at 3 time points: within 2 weeks (range = 5-14 days), 6 months, and 24 months after injury. NPT could be performed only at 6 and 24 months. Results: In patients with TBI, a significant increase in fractional anisotropy (FA) values in genu as well as an insignificant decrease in radial diffusivity (RD) and mean diffusivity values in genu and splenium were observed over time, respectively. FA, RD, and mean diffusivity values continued to be abnormal in patients compared with controls at the end of 2 years. Although some NPT scores improved over time in these patients, these were still significantly impaired compared with controls. Conclusions: FA and RD indices appear to be surrogate markers of microstructural alterations in patients over time and correlate significantly with some of the NPT scores. The recovery in these indices associated with recovery in neurocognitive deficits suggests that these indices may be used as an objective marker for residual injury in these patients.	[Saksena, Sona; Srivastava, Arti; Gupta, Rakesh K.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India; [Kumar, Raj; Husain, Mazhar] Chhatrapati Shahuji Maharaj Med Univ, Dept Neurosurg, Lucknow, Uttar Pradesh, India; [Rathore, Ram K. S.; Agarwal, Shruti] Indian Inst Technol, Dept Math & Stat, Kanpur 208016, Uttar Pradesh, India		Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India.	rgupta@sgpgi.ac.in		Agarwal, Shruti/0000-0003-0902-5354	Indian Council of Medical Research, New Delhi, IndiaIndian Council of Medical Research (ICMR) [5/4-5/13/Neuro/2004-NCD-1]	Part of the study was supported by Indian Council of Medical Research (grant 5/4-5/13/Neuro/2004-NCD-1). Raj Kumar and Sona Saksena thank the Indian Council of Medical Research, New Delhi, India, for the financial assistance.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Batchelor PG, 2003, MAGN RESON MED, V49, P1143, DOI 10.1002/mrm.10491; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DHIMAN RK, 1995, J GASTROEN HEPATOL, V10, P14, DOI 10.1111/j.1440-1746.1995.tb01041.x; Dougherty RF, 2005, P NATL ACAD SCI USA, V102, P7350, DOI 10.1073/pnas.0500003102; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; FRENCHMAN KA, 2005, J CLIN EXP NEUROPSYC, V27, P324; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Graham D.I., 2002, GREENFIELDS NEUROPAT; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jover R, 2003, AM J GASTROENTEROL, V98, P1599, DOI 10.1016/S0002-9270(03)00310-1; KATZ D, 1997, NEUROLOGICAL REHABIL; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar M, 2008, NMR BIOMED, V21, P581, DOI 10.1002/nbm.1228; LAMPERT PW, 1966, AM J PATHOL, V49, P1139; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARR AL, 2001, CENTRAL NERVOUS SYST; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ramalingaswamy P, 1974, MANUAL INDIAN ADAPTA; Ramnani N, 2004, BIOL PSYCHIAT, V56, P613, DOI 10.1016/j.biopsych.2004.02.004; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; RAPPORT M, 2008, J NEUROPSYCHIATRY CL, V20, P68; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schiff ND, 2006, J HEAD TRAUMA REHAB, V21, P388, DOI 10.1097/00001199-200609000-00003; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stewart CA, 2007, NAT CLIN PRACT GASTR, V4, P677, DOI 10.1038/ncpgasthep0999; Thomalla G, 2005, J NEUROL NEUROSUR PS, V76, P266, DOI 10.1136/jnnp.2004.046375; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wechsler, 1997, WECHSLER ADULT INTEL; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wolfson, 1993, HALSTEAD REITAN NEUR	51	35	38	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					31	42		10.1097/HTR.0b013e3181bff331			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800005	20051898				2022-02-06	
J	Livingston, LA; Kennedy, RE; Marwitz, JH; Arango-Lasprilla, JC; Rapport, LJ; Bushnik, T; Gary, KW				Livingston, Lee A.; Kennedy, Richard E.; Marwitz, Jennifer H.; Arango-Lasprilla, Juan C.; Rapport, Lisa J.; Bushnik, Tamara; Gary, Kelli W.			Predictors of family caregivers' life satisfaction after traumatic brain injury at one and two years post-injury: A longitudinal multi-center investigation	NEUROREHABILITATION			English	Article						Traumatic brain injury; caregivers; life satisfaction; family functioning	DISABILITY RATING-SCALE; GALVESTON ORIENTATION; AMNESIA TEST; SOCIAL SUPPORT; UNITED-STATES; MISSING-DATA; HEAD-INJURY; REHABILITATION; RELIABILITY; MEDICINE	Objective: To determine predictors of family caregiver life satisfaction at one and two years after traumatic brain injury (TBI). Methods: Prospective collaborative longitudinal study of 336 family members caring for individuals with TBI participating in the National Institute on Disability and Rehabilitation Research (NIDRR) designated TBI Model Systems of Care (TBIMS). Survivors' medical and demographic information was obtained from the TBIMS database. Follow-up interviews were completed with both survivors and family caregivers at 1 year and 2 years post injury. The primary outcome variable, caregiver life satisfaction, was measured with the Satisfaction with Life Scale (SWLS). Results: Repeated measures ordinal logistic regression showed that survivors' functional status at discharge, drug use, and neurobehavioral problems were significant predictors of family caregivers' life satisfaction at 1 and 2 years post injury. Conclusions: Family members of individuals with TBI often experience reduced life satisfaction in the first 2 years following their relatives' TBI. Psychiatric and neurobehavioral problems, such as drug use and depression, as well as motor dysfunction in survivors may be important contributors to decreased life satisfaction among their caregivers.	[Marwitz, Jennifer H.; Arango-Lasprilla, Juan C.; Gary, Kelli W.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Livingston, Lee A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Kennedy, Richard E.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA; [Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Bushnik, Tamara] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; [Bushnik, Tamara] Rusk Inst Rehabil Med, San Jose, CA USA		Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	jhmarwit@vcu.edu	Kennedy, Richard/K-1525-2018	Kennedy, Richard/0000-0003-4638-126X; Rapport, Lisa/0000-0001-8014-9523			Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; [Anonymous], 1997, GUID UN DAT SET MED; Arango-Lasprilla JC, 2009, NEUROREHABILITATION, V24, P5, DOI 10.3233/NRE-2009-0449; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; *CRAIG HOSP NAT DA, 2006, TRAUM BRAIN INJ MOD; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Enders CK, 2006, PSYCHOSOM MED, V68, P427, DOI 10.1097/01.psy.0000221275.75056.d8; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1994, ARCH PHYSICAL MED RE, V75, P10; HALLAHAN DP, 1997, ADV LEARN BEHAV DISA, V11, P27; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALHOTRA NK, 1987, J MARKETING RES, V24, P74, DOI 10.2307/3151755; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; R Development Core Team, 2008, R LANG ENV STAT COMP; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAYMOND MR, 1987, EDUC PSYCHOL MEAS, V47, P13, DOI 10.1177/0013164487471002; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; Roche V, 2009, AM J MED SCI, V337, P199, DOI 10.1097/MAJ.0b013e31818b114d; ROTH PL, 1994, PERS PSYCHOL, V47, P537, DOI 10.1111/j.1744-6570.1994.tb01736.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; *SAS I INC, 1999, SAS; Schafer JL, 1997, ANAL INCOMPLETE MULT; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Stumpf S.A, 1978, J MANAGE, V4, P65; VANBUUREN S, 2009, R PACK VERS 1 21; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	46	35	35	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2010	27	1					73	81		10.3233/NRE-2010-0582			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000007	20634602				2022-02-06	
J	Norup, A; Siert, L; Mortensen, EL				Norup, Anne; Siert, Lars; Mortensen, Erik Lykke			Emotional distress and quality of life in relatives of patients with severe brain injury: The first month after injury	BRAIN INJURY			English	Article						Relatives; severe brain injury; anxiety; depression; quality of life; emotional distress	SEVERE HEAD-INJURY; FOLLOW-UP; REHABILITATION; POPULATION; PREDICTORS; CARERS; HEALTH; ADULTS; SCALE	Primary objective: To investigate emotional distress and quality of life in a sample of Danish relatives of patients with severe brain injury at admission to intensive rehabilitation in the sub-acute phase. Research design: Clinical convenience sample. Methods and procedures: Participants included 31 primary relatives of patients with severe brain injury. The participants were recruited at admission to Traumatic Brain Injury Unit, Copenhagen University Hospital, Glostrup. All relatives completed the depression and anxiety scales from SCL-90-R (Symptom Checklist) and the Role Emotional, Social Function, Mental Health and Vitality scale of the SF-36 similar to 36 days after injury. Data concerning severity of injury, the patients' level of consciousness and function was also collected. Main outcome and results: The participants had significantly lower scores on all quality of life scales (p<50.01) and significantly more symptoms of anxiety (p<0.01) and depression (p<0.01) than normal reference populations. Correlations were found between the patients' condition and the level of anxiety and depression in relatives. Conclusions: The majority of relatives had severely impaired quality of life and symptoms of anxiety and depression at the time of admission. Future research should focus on developing and evaluating interventions in the acute phase.	[Mortensen, Erik Lykke] Univ Copenhagen, Inst Publ Hlth, Copenhagen, Denmark; [Mortensen, Erik Lykke] Univ Copenhagen, Ctr Healthy Aging, Copenhagen, Denmark; [Norup, Anne; Siert, Lars] Copenhagen Univ Hosp, Dept Neurorehabil, Traumat Brain Injury Unit, Glostrup, Denmark		Norup, A (corresponding author), Copenhagen Univ Hosp, Dept Neurorehabil, Traumat Brain Injury Unit, Kettegard 30, DK-2650 Hvidovre, Denmark.	anne.norup@hvh.regionh.dk		Norup, Anne/0000-0002-5598-6116; Mortensen, Erik Lykke/0000-0002-6985-451X	The Ludvig and Sara Elsass Foundation; Aase and Ejnar Danielsens Foundation; Ostifterne Association	The authors would like to thank all participants in the study and additionally acknowledge the support of the staff at Department of Neurorehabilitation, Traumatic Brain Injury Unit, Copenhagen University Hospital, Glostrup, Denmark as well as MD, PhD Karen-Lise Welling, Neuro Intensive Care Unit, Department of Neuroanaesthesiology, Rigshospitalet, Copenhagen University Hospital and MD Vagn Eskesen, Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital. The study was funded by grants from The Ludvig and Sara Elsass Foundation, Ostifterne Association and Aase and Ejnar Danielsens Foundation	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECH P, 2006, SCL 90 R VEJLEDNING; Beck AT, 1987, BECK DEPRESSION INVE; BjOrner JB., 1997, DANSK MANUAL SF 36 S; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; *COP HOSP CORP, 2000, TRAUM BRAIN INJ UN; Derogatis LR, 1994, SCL 90 R SYMPTOM CHE; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P199; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P204; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Florian V, 1991, Int Disabil Stud, V13, P150; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Hagen C., 1972, LEVELS COGNITIVE FUN; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Heck G, 2000, NEUROL REHABIL, V6, P125; Hickey AM, 1997, PSYCHOL HEALTH, V12, P827, DOI 10.1080/08870449708406743; HICKEY AM, 1992, IRISH MED J, V84, P109; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leathem J, 1996, BRAIN INJURY, V10, P27; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Moules S, 1999, BRAIN INJURY, V13, P983; *NAT BOARD HLTH, 1997, TREATM TRAUM NONTR B; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, B BRIT PSYCHOL SOC, V31, P183; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1985, J CLIN EXP NEUROPSYC, V7, P165; Olsen LR, 2006, ACTA PSYCHIAT SCAND, V113, P477, DOI 10.1111/j.1600-0447.2005.00743.x; Panting A, 1972, REHABILITATION, V38, P33; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1983, FOLIA PHONIATR, V35, P179	42	35	36	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	2					81	88		10.3109/02699050903508200			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500003	20085445				2022-02-06	
J	Prigatano, GP				Prigatano, George P.			Anosognosia: clinical and ethical considerations	CURRENT OPINION IN NEUROLOGY			English	Article						anosognosia; causes; ethical issues; impaired self-awareness; treatment	TRAUMATIC BRAIN-INJURY; IMPAIRED AWARENESS; ANTONS-SYNDROME; FRONTOTEMPORAL DEMENTIA; COGNITIVE IMPAIRMENT; CORTICAL BLINDNESS; RIGHT-HEMISPHERE; HEMIPLEGIA; STROKE; DISEASE	Purpose of review This review considers recent findings on classical forms of anosognosia and less dramatic disturbances in self-awareness observed in various brain disorders. It also addresses issues of clinical management and ethical treatment. Recent findings The study of anosognosia for hemiplegia, Anton's syndrome, and less dramatic disturbances in self-awareness in conditions such as Alzheimer's disease, mild cognitive impairment, and severe traumatic brain injury suggests its 'multifactorial' nature. Lesions in various regions of the brain may contribute to different forms of anosognosia. Animal and human studies suggest that the insular cortex plays an important role in subjective awareness of feeling states, and may be implicated in various forms of anosognosia. Also, right frontal lobe lesions have been implicated, but typically in patients who have bilateral cerebral dysfunction. These patients require careful clinical management in light of their reduced awareness of their neurological and neuropsychological functions that impact daily activities. Summary The study of anosognosia and disorders of self-awareness has expanded greatly over the past 20 years. Various patient groups may show different levels of impaired awareness or anosognosia. Guidelines for the clinical management and ethical treatment of these patients are needed, but beginning efforts have been made.	[Prigatano, George P.] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA; [Prigatano, George P.] Maricopa Cty Gen Hosp, Phoenix, AZ USA		Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 222 W Thomas Rd,Suite 315, Phoenix, AZ 85013 USA.	george.prigatano@chw.edu			Newsome Foundation	The author thanks Jennifer Gray, PhD, and Bruce White, DO, for their help in reviewing earlier drafts of this manuscript and making helpful suggestions for improving it. The author also wishes to acknowledge the Newsome Foundation for providing economic support for the time to prepare this article. Special thanks to Mary Henry for her expert secretarial help.	Abutalebi J, 2007, BEHAV NEUROL, V18, P183, DOI 10.1155/2007/306075; Anderson MC, 2004, SCIENCE, V303, P232, DOI 10.1126/science.1089504; Anton G., 1898, WIEN KLIN WOCHENSCHR, V11, P227; Argenta PA, 1998, OBSTET GYNECOL, V91, P810, DOI 10.1016/S0029-7844(97)00718-7; Babinski J, 1914, REV NEUROL, V27, P845; Berti A, 2005, SCIENCE, V309, P488, DOI 10.1126/science.1110625; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; BOTTINI G, STUDY ANOSO IN PRESS; BREIER JI, 1995, NEUROLOGY, V45, P65, DOI 10.1212/WNL.45.1.65; Cocchini G, 2002, NEUROPSYCHOLOGIA, V40, P2030, DOI 10.1016/S0028-3932(02)00054-4; Craig A., 2008, HDB EMOTIONS; CRAIG AD, STUDY ANOSO IN PRESS; Cramer SC, 2008, CURR OPIN NEUROL, V21, P76, DOI 10.1097/WCO.0b013e3282f36cb6; Della Sala S, 1988, Schweiz Arch Neurol Psychiatr (1985), V139, P5; FORSTL H, 1993, NEUROPSY NEUROPSY BE, V6, P1; Fotopoulou A, 2009, NEUROPSYCHOLOGIA, V47, P1256, DOI 10.1016/j.neuropsychologia.2009.01.018; Gialanella B, 2005, STROKE, V36, P2687, DOI 10.1161/01.STR.0000189627.27562.c0; Hoth KF, 2007, J CLIN EXP NEUROPSYC, V29, P365, DOI 10.1080/13803390600718958; Jehkonen M, 2000, ACTA NEUROL SCAND, V102, P378, DOI 10.1034/j.1600-0404.2000.102006378.x; Jehkonen M, 2006, ACTA NEUROL SCAND, V114, P293, DOI 10.1111/j.1600-0404.2006.00723.x; Karnath HO, 2005, J NEUROSCI, V25, P7134, DOI 10.1523/JNEUROSCI.1590-05.2005; KARNATH HO, STUDY ANOSO IN PRESS; Kertesz A, 2000, J INT NEUROPSYCH SOC, V6, P460, DOI 10.1017/S1355617700644041; LEBRUN Y, 1987, CORTEX, V23, P251, DOI 10.1016/S0010-9452(87)80035-7; Misra M, 1989, Indian J Ophthalmol, V37, P196; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; Orfei MD, 2007, BRAIN, V130, P3075, DOI 10.1093/brain/awm106; Pedersen PM, 1996, J NEUROL REHABIL, V10, P243; Prigatano G., 2008, COGNITIVE NEUROREHAB, P218; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, AWARENESS DEFICIT BR, P111; PRIGATANO GP, STUDY ANOSOGNOSIA; PRIGATANO GP, STUDY ANOSO IN PRESS; RAMACHANDRAN VS, 1994, INT REV NEUROBIOL, V37, P291; Ries ML, 2007, J INT NEUROPSYCH SOC, V13, P450, DOI 10.1017/S1355617707070488; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROOS KL, 1990, CLIN ELECTROENCEPHAL, V21, P104, DOI 10.1177/155005949002100212; RUBENS AB, 1990, AWARENESS DEFICIT BR, P40; Salmon E, 2006, HUM BRAIN MAPP, V27, P588, DOI 10.1002/hbm.20203; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schneider CE, 1998, PRACTICE AUTONOMY PA; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SIEGLER M, 2002, CLIN ETHICS; Snowden JS, 1998, ARCH NEUROL-CHICAGO, V55, P801, DOI 10.1001/archneur.55.6.801; STARKSTEIN SE, STUDY ANOSO IN PRESS; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; Trifiletti RR, 2007, EUR J NEUROL, V14, pE11, DOI 10.1111/j.1468-1331.2006.01581.x; VOCAT R, STUDY ANOSO IN PRESS; Vuilleumier P, 2001, BRAIN, V124, P1077, DOI 10.1093/brain/124.6.1077; Weinstein EA, 1955, DENIAL ILLNESS; White B., 2007, DRUGS ETHICS QUALITY; Yilmazlar S, 2003, PEDIATR NEUROSURG, V38, P156, DOI 10.1159/000068813	55	35	37	2	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2009	22	6					606	611		10.1097/WCO.0b013e328332a1e7			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	529UK	WOS:000272544100008	19809315				2022-02-06	
J	Imer, M; Omay, B; Uzunkol, A; Erdem, T; Sabanci, PA; Karasu, A; Albayrak, SB; Sencer, A; Hepgul, K; Kaya, M				Imer, Murat; Omay, Bulent; Uzunkol, Ajlan; Erdem, Tulin; Sabanci, Pulat Akin; Karasu, Aykut; Albayrak, Serdar Baki; Sencer, Altay; Hepgul, Kemal; Kaya, Mehmet			Effect of magnesium, MK-801 and combination of magnesium and MK-801 on blood-brain barrier permeability and brain edema after experimental traumatic diffuse brain injury	NEUROLOGICAL RESEARCH			English	Article						Diffuse brain injury; blood-brain barrier; brain edema; magnesium; MK-801	FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL HEAD TRAUMA; ACUTE SUBDURAL-HEMATOMA; D-ASPARTATE ANTAGONISTS; RATS; THERAPY; INFARCTION; SULFATE; MODEL; REDUCTION	Objective: Glutamate antagonists are very attractive drugs in laboratory works to protect neural tissue against ischemia. In this work, the effects of magnesium, MK-801 and combination of magnesium and MK-801 on blood-brain barrier (BBB) and brain edema after experimentally induced traumatic brain injury are evaluated. Methods: A standard closed head injury was induced on the rats by a controlled impact device using a 450-g free falling mass from a height of 2 m onto a metallic disc fixed to the intact skull. One of the following was injected to animals intraperitoneally 30 minutes after injury: saline, magnesium, MK-801 and magnesium plus MK-801. To quantify the brain edema, the specific gravity of the brain tissue was determined. To demonstrate the alteration of the BBB permeability, Evans blue dye was used as a tracer. Results: In all treatment groups, the specific gravity of brain tissue values was significantly higher compared with the control group. Evans blue dye content in the brain tissue was significantly reduced in all three treatment groups with respect to the control group. There was no significant difference of effect between the groups of magnesium alone and MK-801 alone when compared with each other and when compared with their combination. Conclusion: The present data demonstrate that treatment with magnesium, MK-801 and combination of magnesium and MK-801 can reduce formation of brain edema and can help restore BBB permeability after experimental diffuse brain injury. [Neurol Res 2009; 31: 977-981]	[Sabanci, Pulat Akin] Istanbul Univ, Istanbul Fac Med, Dept Neurosurg, Istanbul, Turkey		Sabanci, PA (corresponding author), Istanbul Univ, Istanbul Fac Med, Dept Neurosurg, Istanbul, Turkey.	sabanci.akin@gmail.com	Sencer, Altay/AAD-8002-2020; SABANCI, PULAT AKIN/AAT-1325-2020; Hepgul, Kemal Tanju/AAV-1510-2020				Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CHI OZ, 1991, CIRC RES, V69, P414, DOI 10.1161/01.RES.69.2.414; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Davis M, 1997, ACT NEUR S, V70, P30; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Gorgulu A, 2000, ACTA NEUROCHIR, V142, P1287, DOI 10.1007/s007010070027; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Kaya M, 2001, CAN J PHYSIOL PHARM, V79, P793, DOI 10.1139/cjpp-79-9-793; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; Schmid-Elsaesser R, 1999, NEUROSURGERY, V44, P163, DOI 10.1097/00006123-199901000-00100; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; YANG GY, 1994, NEUROSURGERY, V34, P339, DOI 10.1227/00006123-199402000-00018	29	35	36	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	NOV	2009	31	9					977	981		10.1179/174313209X385617			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	530XQ	WOS:000272626700015	19215660				2022-02-06	
J	Wright, JK; Zant, E; Groom, K; Schlegel, RE; Gilliland, K				Wright, James K.; Zant, Eddie; Groom, Kevin; Schlegel, Robert E.; Gilliland, Kirby			Case report: Treatment of mild traumatic brain injury with hyperbaric oxygen	UNDERSEA AND HYPERBARIC MEDICINE			English	Article							NEUROPSYCHOLOGICAL ASSESSMENT METRICS; NEURAL STEM-CELLS; COGNITIVE RECOVERY; THERAPY; SPORTS; DAMAGE; RATS	Two United States Air Force Airmen were injured in a roadside improvised explosive device (IED) blast in Iraq in January 2008. Both airmen suffered concussive injuries and developed irritability, sleep disturbances, headaches, memory difficulties and cognitive difficulties as symptoms of mild traumatic brain injury (mTBI). Six months after injury, repeat Automated Neuropsychological Assessment Metrics (ANAM) testing showed deterioration, when compared to pre-injury baseline ANAM assessment, in all measured areas (simple reaction time, procedural reaction time, code substitution learning, code substitution delayed, mathematical processing, and matching to sample). The airmen were treated with hyperbaric oxygen in treatments of 100% oxygen for one hour at 1.5 atmospheres absolute, resulting in rapid improvement of headaches and sleep disturbances, improvement in all symptoms and resolution of most symptoms. Repeat ANAM testing after completion of the hyperbaric treatments - nine months after initial injury - showed improvement in all areas, with most measures improving to pre-injury baseline levels. The airmen received no other treatment besides medical monitoring. Repeat neuropsychologic testing confirmed the improvement. We conclude that the improvement in symptoms and ANAM performance is most likely attributable to HBO treatment.	[Wright, James K.] 720th Special Tact Grp, Hurlburt Field, FL USA; [Zant, Eddie] Hyperbar Med Inc, Ft Walton Beach, FL USA; [Groom, Kevin] Anchor Clin, Destin, FL USA; [Schlegel, Robert E.; Gilliland, Kirby] Univ Oklahoma, Ctr Study Human Operator Performance, Norman, OK 73019 USA		Wright, JK (corresponding author), 720th Special Tact Grp, Hurlburt Field, FL USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Andersson EE, 2006, J REHABIL MED, V38, P26, DOI 10.1080/16501970500310564; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; *ASS SECR DEF HLTH, 2007, TRAUM BRAIN INJ DEF; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; *DEP VET AFF, 2004, VET HLTH IN TRAUM BR; Gamboa AM, 2006, NEUROREHABILITATION, V21, P327; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Harch Paul G, 2009, Cases J, V2, P6538, DOI 10.4076/1757-1626-2-6538; Kelly JP, 1997, NEUROLOGY, V48, P581; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Peng ZY, 2008, BRAIN RES, V1212, P71, DOI 10.1016/j.brainres.2008.03.027; Randolph C., 1998, REPEATABLE BATTERY A; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Shi Xiao-yan, 2003, Chin J Traumatol, V6, P346; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Wang XL, 2008, BRAIN RES, V1222, P87, DOI 10.1016/j.brainres.2008.05.016; Wang XL, 2007, NEUROREPORT, V18, P1753, DOI 10.1097/WNR.0b013e3282f0ec09; Yang YJ, 2008, UNDERSEA HYPERBAR M, V35, P113; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	30	35	38	1	10	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	NOV-DEC	2009	36	6					391	399					9	Marine & Freshwater Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Marine & Freshwater Biology; Research & Experimental Medicine	541IB	WOS:000273407400001	20112530				2022-02-06	
J	Castellani, G; Zweifel, C; Kim, DJ; Carrera, E; Radolovich, DK; Smielewski, P; Hutchinson, PJ; Pickard, JD; Czosnyka, M				Castellani, Gianluca; Zweifel, Christian; Kim, Dong-Joo; Carrera, Emmanuel; Radolovich, Danila K.; Smielewski, Piotr; Hutchinson, Peter J.; Pickard, John D.; Czosnyka, Marek			Plateau Waves in Head Injured Patients Requiring Neurocritical Care	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Cerebral perfusion pressure; Traumatic brain injury; Cerebral autoregulation; Plateau waves; TBI outcome	CEREBROVASCULAR PRESSURE TRANSMISSION; CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; ONLINE ANALYSIS; SOFTWARE; MODEL	Plateau waves often develop in neurointensive care patients. They are sudden increases in intracranial pressure (ICP) that lead to dramatic decreases of cerebral perfusion pressure (CPP) and can therefore contribute to ischemic secondary brain insult. The aim of this study was to analyze the occurrence of plateau waves in head injured patients requiring neurocritical care, their relation with cerebral autoregulation and impact on outcome. Data were analyzed retrospectively in 444 head injured patients admitted to Neuroscience Critical Care Unit of Addenbrooke's Hospital in Cambridge, UK. Arterial blood pressure (ABP), intracranial pressure (ICP), heart rate (HR) were digitally recorded and derived indices calculated. Primary monitoring data, autoregulation indices, outcome of patients, initial CT findings (in a subgroup of patients), brain tissue monitoring data (in a subgroup) were compared between patients who developed plateau waves and those who did not. Plateau waves were observed in 109/444 patients (24.5%). They were significantly more frequent in younger patients. Impaired cerebrovascular pressure reactivity and depleted compensatory reserve were associated with vasodilatation on the top of the wave. Plateau waves were not associated with poorer outcome unless the episodes lasted for a long time (longer than 30-40 min). Plateau waves were more frequently seen in patients with lesser midline shift, lower volume of contusion on CT scan, absence of skull fractures, and lower brain tissue concentration of carbon dioxide. Plateau waves are frequent phenomenon. They are not associated with worse outcome unless they lead to sustained intracranial hypertension.	[Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Cambridge CB2 2QQ, England; [Castellani, Gianluca; Zweifel, Christian; Kim, Dong-Joo; Carrera, Emmanuel; Radolovich, Danila K.; Smielewski, Piotr; Hutchinson, Peter J.; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; [Castellani, Gianluca] Univ Pavia, Anaesthesia & Intens Care Sch, I-27100 Pavia, Italy; [Kim, Dong-Joo] Univ Cambridge, Dept Engn, Cambridge CB2 2QQ, England; [Radolovich, Danila K.] Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy		Czosnyka, M (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Level 4,A Ward,Box 167, Cambridge CB2 2QQ, England.	g.l.castellani@tiscali.it; mc141@medschl.cam.ac.uk		Carrera, Emmanuel/0000-0003-0045-5382; Smielewski, Peter/0000-0001-5096-3938	National institute of Health Research Biomedical Research centerNational Institute for Health Research (NIHR); Cambridge University Hospital Foundation Trust-Neurosciences Theme; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBBSP3-125550, PASSMP3-124262]; SICPA Foundation, Lausanne, Switzerland.; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0601025, G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0601025, G0001237, G9439390] Funding Source: UKRI	The authors are in debt to all the team participating in data collection: Mrs. Pippa Al-Rawi, Mrs. Helen Seley, Mrs. Carole Turner, Dr. Marcella Balestreri, Dr. Magda Hiler, Dr. Luzius Steiner, Dr. Eric Schmidt, Dr. Stefan Piechnik, Dr. Andreas Raabe, Mr. Eric Guazzo, Dr. David Menon, Dr. Arun Gupta, Dr. Basil Matta, Mr. Peter Kirkpatrick, Mr. Ivan Timofyeyev, Mr. Pwawanjit Minhas, Mr. Rodney Laing, and all nursing and research staff of NCCU and Wolfson Brain Imaging Centre. The project was supported by National institute of Health Research Biomedical Research center, Cambridge University Hospital Foundation Trust-Neurosciences Theme. Further support was achieved from the Swiss National Science Foundation (PBBSP3-125550 to CZ and PASSMP3-124262 to EC), Bern, Switzerland. EC was additionally supported by the SICPA Foundation, Lausanne, Switzerland.	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Daley ML, 2006, ACTA NEUROCHIR SUPPL, V96, P103; Daley ML, 2005, ACT NEUR S, V95, P327; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; HAYASHI M, 1991, BRAIN, V114, P2693, DOI 10.1093/brain/114.6.2693; HAYASHI M, 1987, J NEUROSURG, V67, P97, DOI 10.3171/jns.1987.67.1.0097; HAYASHI M, 1991, BRAIN, V114, P2681, DOI 10.1093/brain/114.6.2681; HAYASHI M, 1984, J NEUROSURG, V61, P30, DOI 10.3171/jns.1984.61.1.0030; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Imberti R, 2005, J NEUROSURG, V102, P455, DOI 10.3171/jns.2005.102.3.0455; Lundberg N., 1960, ACTA PSYCHIAT NEUROL, V149, P158; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; RENIER D, 1982, J NEUROSURG, V57, P370, DOI 10.3171/jns.1982.57.3.0370; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Schmidt B, 1999, J CEREBR BLOOD F MET, V19, P990, DOI 10.1097/00004647-199909000-00006; Smielewski P, 2005, ACT NEUR S, V95, P43; Stevens SA, 2008, IEEE T BIO-MED ENG, V55, P388, DOI 10.1109/TBME.2007.900552; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	21	35	38	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2009	11	2					143	150		10.1007/s12028-009-9235-7			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	495OG	WOS:000269902300003	19565359				2022-02-06	
J	Richmond, TS; Amsterdam, JD; Guo, W; Ackerson, T; Gracias, V; Robinson, KM; Hollander, JE				Richmond, T. S.; Amsterdam, J. D.; Guo, W.; Ackerson, T.; Gracias, V.; Robinson, K. M.; Hollander, J. E.			The effect of post-injury depression on return to pre-injury function: a prospective cohort study	PSYCHOLOGICAL MEDICINE			English	Article						Depression; function; injury; psychiatric disorders; work	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; STATUS QUESTIONNAIRE; MULTIPLE INJURIES; SEVERITY SCORE; OLDER PERSONS; IMPACT; DISABILITY; SYMPTOMS	Background. Millions of people seek emergency department (ED) care for injuries each year, the majority for minor injuries. Little is known about the effect of psychiatric co-morbid disorders that emerge after minor injury on functional recovery. This Study examined the effect of post-injury depression on return to pre-injury levels of function. Method. This was a longitudinal cohort study with follow-up at 3, 6 and 12 months post-injury: 275 adult were randomly selected from those presenting to the ED with minor injury; 248 were retained over the post-injury year. Function was measured with the Functional Status Questionnaire (FSQ). Psychiatric disorders were diagnosed using the Structured Clinical Interview for DSM-IV-TR disorders (SCID). Results. During the post-injury year, 18.1 % [95% confidence interval (CI) 13.3-22.9] were diagnosed with depression. Adjusting for clinical and demographic covariates, the depressed group was less likely to return to pre-injury levels of activities of daily living [odds ratio (OR) 8.37, 95% CI 3.78-18.53] and instrumental activities of daily living (OR 3.25, 95%, CI 1.44-7.31), less likely to return to pre-injury work status (OR 2.37, 95% CI 1.04-5.38), and more likely to spend days in bed because of health (OR 2.41, 95% CI 1.15-5.07). Conclusions. Depression was the most frequent psychiatric diagnosis in the year after minor injury requiring emergency care. Individuals with depression did not return to pre-injury levels of function during the post-injury year.	[Richmond, T. S.] Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Philadelphia, PA 19104 USA; [Amsterdam, J. D.] Univ Penn, Sch Med, Dept Psychiat, Depress Res Unit, Philadelphia, PA 19104 USA; [Guo, W.] Univ Penn, Sch Med, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Gracias, V.] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; [Robinson, K. M.] Univ Penn, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA; [Hollander, J. E.] Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA		Richmond, TS (corresponding author), Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA.	terryr@nursing.upenn.edu		Hollander, Judd/0000-0002-1318-2785	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ROIMH63818]; NIH/NCCAMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine; Lilly Research LaboratoriesEli Lilly; Novartis Inc.; Sanofi-Aventis Inc.Sanofi-Aventis; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH063818] Funding Source: NIH RePORTER	This study was funded by the National Institute of Mental Health (NIMH) grant ROIMH63818 (to T.S.R.).; J.D.A. is currently receiving research grant support from the NIMH, NIH/NCCAM, Lilly Research Laboratories, Novartis Inc., and Sanofi-Aventis Inc. He is on the speaker's bureau of Wyeth and Bristol-Myers-Squibb.	Akfaffiong M, 1999, INT J GERIATR PSYCH, V14, P845, DOI 10.1002/(SICI)1099-1166(199910)14:10<845::AID-GPS34>3.0.CO;2-H; Aklin WM, 2006, PSYCHOTHERAPY, V43, P50, DOI 10.1037/0033-3204.43.1.50; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Arinzon Z, 2007, DISABIL REHABIL, V29, P651, DOI 10.1080/09638280600926470; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bisson JI, 2004, BRIT J PSYCHIAT, V184, P63, DOI 10.1192/bjp.184.1.63; Carty J, 2006, J AFFECT DISORDERS, V90, P257, DOI 10.1016/j.jad.2005.11.011; *CDC, 2005, CDC PROT HLTH LIF ST; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Cleary PD, 2000, QUAL LIFE RES, V9, P747, DOI 10.1023/A:1008977923785; Committee on the Future of Emergency Care in the United States Health System Institute of Medicine, 2007, HOSP BAS EM CAR BREA; Davis RG, 2008, J TRAUMA STRESS, V21, P218, DOI 10.1002/jts.20313; De Jonge P, 2006, PSYCHOSOMATICS, V47, P33, DOI 10.1176/appi.psy.47.1.33; Elashoff JD., 1999, NQUERY ADVISOR VERSI; Elklit A, 2002, J INTERPERS VIOLENCE, V17, P872, DOI 10.1177/0886260502017008005; First M.B., 1994, STRUCTURED CLIN INTE; Fishbain DA, 2003, PAIN MED, V4, P51, DOI 10.1046/j.1526-4637.2003.03008.x; FLASKERUD JH, 2001, ISSUES MENTAL HLTH N, V21, P5; Hepp U, 2005, PSYCHOTHER PSYCHOSOM, V74, P379, DOI 10.1159/000087786; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Hollander JE, 2004, ACAD EMERG MED, V11, P200, DOI 10.1197/j.aem.2003.07.023; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; KELLER MB, 1987, ARCH GEN PSYCHIAT, V44, P540; Kempen GIJM, 2003, INT J GERIATR PSYCH, V18, P14, DOI 10.1002/gps.768; Kessing LV, 2007, ACTA PSYCHIAT SCAND, V115, P85, DOI 10.1111/j.1600-0447.2007.00966.x; Kilgo PD, 2006, J TRAUMA, V60, P1002, DOI 10.1097/01.ta.0000215827.54546.01; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; Mason S, 2002, EMERG MED J, V19, P400, DOI 10.1136/emj.19.5.400; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Murphy N, 1998, J NEUROL NEUROSUR PS, V65, P460, DOI 10.1136/jnnp.65.4.460; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2005, J TRAUMA STRESS, V18, P557, DOI 10.1002/jts.20064; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Richmond TS, 1997, NURS RES, V46, P262, DOI 10.1097/00006199-199709000-00004; Richmond TS, 2000, J TRAUMA STRESS, V13, P681, DOI 10.1023/A:1007866318207; Rosenthal DA, 1999, REHABIL COUNS BULL, V42, P243; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; Scaf-Klomp W, 2003, AGE AGEING, V32, P88, DOI 10.1093/ageing/32.1.88; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; *STATACORP, 1999, STATA STAT SOFTW REL; Stein MB, 2006, PSYCHOL MED, V36, P587, DOI 10.1017/S0033291706007239; van Gool CH, 2005, SOC SCI MED, V60, P25, DOI 10.1016/j.socscimed.2004.04.021; WHO, 2007, PREV INJ VIOL GUID M; Zatzick DF, 2001, GEN HOSP PSYCHIAT, V23, P114, DOI 10.1016/S0163-8343(01)00140-2; ZIMMERMAN M, 1986, ARCH GEN PSYCHIAT, V43, P234	51	35	35	3	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	OCT	2009	39	10					1709	1720		10.1017/S0033291709005376			12	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	499XQ	WOS:000270260500015	19250582	Green Accepted, Green Submitted			2022-02-06	
J	Sharma, HS; Patnaik, R; Sharma, A; Sjoqujst, PO; Lafuente, JV				Sharma, Hari Shanker; Patnaik, Ranjana; Sharma, Aruna; Sjoqujst, Per-Ove; Lafuente, Jose V.			Silicon Dioxide Nanoparticles (SiO(2), 40-50 nm) Exacerbate Pathophysiology of Traumatic Spinal Cord Injury and Deteriorate Functional Outcome in the Rat. An Experimental Study Using Pharmacological and Morphological Approaches	JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY			English	Article						Nanoparticles; Spinal Cord Injury; Silicon Dioxide; Motor Function; Blood-Spinal Cord Barrier; Spinal Cord Edema; Neuronal Injury; Antioxidants; H-290/51; Oxidative Stress	BLOOD-BRAIN-BARRIER; ANTIOXIDANT COMPOUND H-290/51; NITRIC-OXIDE SYNTHASE; EDEMA FORMATION; MICROVASCULAR PERMEABILITY; PARA-CHLOROPHENYLALANINE; ELECTRON-MICROSCOPY; OXIDATIVE DAMAGE; SEROTONIN LEVELS; STRESS	Silicon (SiO(2)) nanoparticles or silica dust is quite common form of exposure to soldiers engaged in gulf war that may influence their health and brain function. It is quite likely that traumatic injuries to the CNS may be influenced by exposure to these nanoparticles. However, the details of silicon nanoparticles on human health functions are still unknown. In this investigation we examined the effects of chronic silicon dioxide nanoparticles (SiO(2), 40-50 nm) exposure on spinal cord injury (SCI) induced alterations on the functional outcome and the cord pathology in a rat model. Since nanciparticles induce oxidative stress, the influence of an antioxidant compound H-290/51 was also examined in these nanoparticles treated injured rats as well. Rats treated with SiO(2) for 7 days did not show any significant alteration in behaviour on rota rod performances or on capacity angle tests. However, subjection of these nanciparticles exposed rats to SCI resulted in a profound deterioration in motor functions compared to normal rats with SCI. The magnitude of blood-spinal cord barrier (BSCB) disruption to Evans blue and radioiodine tracers and edema formation was much more aggravated following SCI in nanoparticles treated animals compared to untreated traumatized rats. Pretreatment with H-290/51 (50 mg/kg, p.o.) 30 min before SCI in nanoparticle treated rats did not alter spinal cord pathology or functional outcome, however, this dose of the compound was very effective in reducing pathophysiology of SCI in normal animals. These observations are the first to suggest that exposure of nanoparticles enhances the sensitivity of CNS to injuries and alter the effect of neuroprotective drugs.	[Sharma, Hari Shanker; Sharma, Aruna] Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, SE-75185 Uppsala, Sweden; [Patnaik, Ranjana] Banaras Hindu Univ, Sch Biomed Engn, Inst Technol, Dept Biomat, Varanasi 221005, Uttar Pradesh, India; [Sjoqujst, Per-Ove] Astra Zeneca, Integrat Pharmacol, SE-43183 Molndal, Sweden; [Lafuente, Jose V.] Univ Basque Country, Lab Clin & Expt Neurosci LaCEN, Dept Neurosci, Bilbao 48080, Spain		Sharma, HS (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, SE-75185 Uppsala, Sweden.		Sharma, Aruna/D-4430-2011; Patnaik, Ranjana/AAZ-4440-2020; Lafuente, Jose-Vicente/O-6395-2014	Patnaik, Ranjana/0000-0002-8131-177X; Lafuente, Jose-Vicente/0000-0001-7246-0987			ALESSANDRINI F, 2009, AM J RESP CRIT CARE, V5; Apopa PL, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-1; Bao F, 2008, EXP NEUROL, V214, P160, DOI 10.1016/j.expneurol.2008.09.006; Bartunkova J, 2006, AM J IND MED, V49, P569, DOI 10.1002/ajim.20327; Bennett WD, 2002, AM J RESP CRIT CARE, V165, P1671, DOI 10.1164/rccm145; Brooking J, 2001, J DRUG TARGET, V9, P267, DOI 10.3109/10611860108997935; Chen Z, 2008, ENVIRON SCI TECHNOL, V42, P8985, DOI 10.1021/es800975u; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DRISCOLL KE, 1990, AM J RESP CELL MOL, V2, P381, DOI 10.1165/ajrcmb/2.4.381; FLORENCE AT, 1995, J DRUG TARGET, V3, P65, DOI 10.3109/10611869509015936; FUBINI B, 1990, TOXICOL IND HEALTH, V6, P571; Gao KP, 2006, INT J PHARMACEUT, V310, P213, DOI 10.1016/j.ijpharm.2005.11.040; Ichinose T, 2008, INHAL TOXICOL, V20, P685, DOI [10.1080/08958370801935133, 10.1080/08958370801935133 ]; Jia HY, 2009, J AM CHEM SOC, V131, P40, DOI 10.1021/ja808033w; Neretti N, 2009, P NATL ACAD SCI USA, V106, P2277, DOI 10.1073/pnas.0812484106; NICOLINI C, 1995, BIOSENS BIOELECTRON, V10, P723, DOI 10.1016/0956-5663(95)96963-Y; Oberlin O, 1996, ANN ONCOL, V7, P73; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; Ostraat ML, 2008, J OCCUP ENVIRON HYG, V5, P390, DOI 10.1080/15459620802071646; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1929; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5014, DOI 10.1166/jnn.2009.GR04; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5055, DOI 10.1166/jnn.2009.GR09; Sharma HS, 2009, J CHEM NEUROANAT, V37, P18, DOI 10.1016/j.jchemneu.2008.08.002; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI 10.1517/14656566.9.16.2773 ; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P197, DOI 10.1196/annals.1403.014; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P95, DOI 10.1196/annals.1403.007; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5073, DOI 10.1166/jnn.2009.GR10; SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 2006, J NEURAL TRANSM, V113, P521, DOI 10.1007/s00702-005-0405-2; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 2003, ACT NEUR S, V86, P415; Sharma HS, 2002, AMINO ACIDS, V23, P261, DOI 10.1007/s00726-001-0137-z; Sharma HS, 1998, AMINO ACIDS, V14, P121, DOI 10.1007/BF01345252; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1992, NEUROSCIENCE, V50, P445, DOI 10.1016/0306-4522(92)90436-6; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Wang Z. G., 1994, Journal of Environmental Pathology Toxicology and Oncology, V13, P205; Xia T, 2008, ACS NANO, V2, P2592; Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Zhang Wen-Chang, 1997, Biomedical and Environmental Sciences, V10, P377	46	35	36	1	16	AMER SCIENTIFIC PUBLISHERS	STEVENSON RANCH	25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA	1533-4880			J NANOSCI NANOTECHNO	J. Nanosci. Nanotechnol.	AUG	2009	9	8					4970	4980		10.1166/jnn.2009.1717			11	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	470QO	WOS:000267994100061	19928175				2022-02-06	
J	Fann, JR; Jones, AL; Dikmen, SS; Temkin, NR; Esselman, PC; Bombardier, CH				Fann, Jesse R.; Jones, Audrey L.; Dikmen, Sureyya S.; Temkin, Nancy R.; Esselman, Peter C.; Bombardier, Charles H.			Depression Treatment Preferences After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; depression; patient satisfaction; therapeutics	PRIMARY-CARE PATIENTS; COLLABORATIVE CARE; MAJOR DEPRESSION; EXERCISE TREATMENT; PRIME-MD; MANAGEMENT; INTERNET; UTILITY; PEOPLE; WOMEN	Objective: To determine preferences for depression treatment modalities and settings among persons with traumatic brain injury (TBI). Design: Telephone survey. Depression status was determined using the Patient Health Questionnaire-9. Setting: Harborview Medical Center, Seattle, Washington, the level I trauma center serving Washington, Idaho, Montana, and Alaska. Participants: One hundred forty-five adults, English-speaking consecutive patients admitted with complicated mild to severe TBI. Main Outcome Measures: Telephone survey within 12 months post-TBI ascertaining preferences for depression treatment modalities and settings. Results: More patients favored physical exercise or counseling as a depression treatment than other treatment modalities. Group therapy was the least favored modality. Patients favored speaking with a clinician in the clinic or over the telephone and were less likely to communicate with a clinician over the Internet. Subjects with probable major depression or a history of antidepressant use or outpatient mental health treatment were more likely to express a preference for antidepressants for treatment of depression. Conclusions: This study underscores the importance of understanding patient preferences and providing patient education in selecting a treatment for depression after TBI. Future studies should examine psychotherapy and alternative treatment modalities and delivery models for the management of depression in this vulnerable population.	[Fann, Jesse R.; Dikmen, Sureyya S.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA; [Fann, Jesse R.; Jones, Audrey L.; Dikmen, Sureyya S.; Esselman, Peter C.; Bombardier, Charles H.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA; [Dikmen, Sureyya S.; Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Sch Med, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA; [Fann, Jesse R.] Univ Washington, Dept Epidemiol, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA		Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Sch Med, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA.	fann@u.washington.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283; Jones, Audrey/0000-0003-1533-7469	National Center for Medical Rehabilitation Research [R-01 HD39415]; National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER	This study was supported by grant R-01 HD39415 from the National Center for Medical Rehabilitation Research, National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH). The authors thank Erika Pelzer Meghan Keough, and Holly Rau for their assistance with data collection, and Jason Barber for his assistance with data analysis.	Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Backenstrass M, 2006, GEN HOSP PSYCHIAT, V28, P178, DOI 10.1016/j.genhosppsych.2005.10.001; Bedi N, 2000, BRIT J PSYCHIAT, V177, P312, DOI 10.1192/bjp.177.4.312; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Christensen H, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.1.e3; Ciechanowski P, 2004, JAMA-J AM MED ASSOC, V291, P1569, DOI 10.1001/jama.291.13.1569; Clarke G, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e16; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Dobscha SK, 2007, PSYCHOSOMATICS, V48, P482, DOI 10.1176/appi.psy.48.6.482; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Dwight-Johnson M, 2004, PSYCHIAT SERV, V55, P934, DOI 10.1176/appi.ps.55.8.934; Dwight-Johnson M, 2000, J GEN INTERN MED, V15, P527, DOI 10.1046/j.1525-1497.2000.08035.x; Elkin I, 1999, PSYCHOTHER RES, V9, P437, DOI 10.1093/ptr/9.4.437; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Gum AM, 2006, GERONTOLOGIST, V46, P14, DOI 10.1093/geront/46.1.14; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Katon W, 2002, J GEN INTERN MED, V17, P741, DOI 10.1046/j.1525-1497.2002.11051.x; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lin P, 2005, ANN BEHAV MED, V30, P164, DOI 10.1207/s15324796abm3002_9; Loh A, 2006, PATIENT EDUC COUNS, V63, P314, DOI 10.1016/j.pec.2006.04.006; Lowe B, 2006, J GEN INTERN MED, V21, P39, DOI 10.1111/j.1525-1497.2005.0266.x; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; Scholle Sarah Hudson, 2003, Matern Child Health J, V7, P95, DOI 10.1023/A:1023864810207; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2000, AM J OBSTET GYNECOL, V183, P759, DOI 10.1067/mob.2000.106580; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tutty S, 2000, Eff Clin Pract, V3, P170; Ugarriza DN, 2006, J PSYCHOSOC NURS, V44, P37, DOI 10.3928/02793695-20060101-08; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; van Schaik DJF, 2004, GEN HOSP PSYCHIAT, V26, P184, DOI 10.1016/j.genhosppsych.2003.12.001; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	46	35	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					272	278		10.1097/HTR.0b013e3181a66342			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000006	19625866				2022-02-06	
J	Caulfield, EV; Dutton, RP; Floccare, DJ; Stansbury, LG; Scalea, TM; Esposito, TJ				Caulfield, Eileen V.; Dutton, Richard P.; Floccare, Douglas J.; Stansbury, Lynn G.; Scalea, Thomas M.; Esposito, Thomas J.			Prehospital Hypocapnia and Poor Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; TBI; ETCO2; End-tidal capnometry	CEREBRAL-BLOOD-FLOW; CARBON-DIOXIDE; HEAD-INJURY; HYPERVENTILATION; SCORE; HUMANS; VOLUME; SCALE	Background: The Brain Trauma Foundation (BTF) Guidelines for prehospital management of traumatic brain injury (TBI) recommend a goal end-tidal carbon dioxide of 30 min Hg to 35 mm Hg in patients without signs of herniation. Methods: We examined prehospital concordance with BTF Guidelines, selected demographic and physiologic variables and outcomes for 100 consecutive admissions to a well-established Level I regional trauma center. All patients had blunt TBI with Glasgow Coma Score <= 8 without signs of herniation. All were transported by helicopter by flight paramedics experienced with BTF Guidelines and the continuous wave form capnometer. Patients, resumed spontaneous ventilation after intubation. Results: Concordance (prehospital endtidal carbon dioxide >29 nun Hg) was achieved in 65 of 100 cases. Mortality was 29% (19 of 65) among those in whom guideline levels were achieved prehospital and 46% (16 of 35) in those in whom guideline levels were not achieved prehospital (odds ratio, 0.49; p = 0.10). The "achieved" group was younger (p = 0.02), with higher calculated probability of survival (p = 0.01). Intracranial pressure was maintained under intensive care within acceptable limits in the hospital in both groups but was significantly higher in the "not achieved" group (p = 0.05). Conclusions. Our data, though not statistically significant, suggest that patients who are harder to keep Aithin the guidelines in the field are more likely to die, because of more severe TBI or complication by other factors such as age or injury severity. Whether increased awareness of this phenomenon can improve outcomes is unknown but suggests an approach to future education and research.	[Caulfield, Eileen V.; Dutton, Richard P.; Floccare, Douglas J.; Stansbury, Lynn G.; Scalea, Thomas M.] Univ Maryland Med Syst, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Esposito, Thomas J.] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA		Stansbury, LG (corresponding author), Univ Maryland Med Syst, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.	lynn.stansbury@gmail.com					*AANS CNS AANS CNS, 2007, GUID MAN SEV TRAU S1; Bader M K, 2000, Crit Care Nurs Clin North Am, V12, P413; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 2000, GUID PREH MAN TRAUM; *CDCP, 2006, FACTS TRAUM BRAIN IN; Chamberlain D J, 1998, Aust Crit Care, V11, P123, DOI 10.1016/S1036-7314(98)70499-0; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; FORTUNE JB, 1995, J TRAUMA, V39, P463; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; Heath D L, 1999, J Neurosci Nurs, V31, P97; Henzler D, 2007, CRIT CARE MED, V35, P1027, DOI 10.1097/01.CCM.0000259526.45894.08; JENNETT B, 1975, LANCET, V1, P480; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; Lal Dave, 2003, Prehosp Disaster Med, V18, P20; Lee Lorri A, 2002, Int Anesthesiol Clin, V40, P31; Mazzeo AT, 2006, J NEUROSURG ANESTH, V18, P170, DOI 10.1097/01.ana.0000210999.18033.f6; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OSWALD V, 1999, J EMERG NURS, V25, P455; PERSSON A, 1988, PHYS REV B, V38, P5568, DOI 10.1103/PhysRevB.38.5568; RUTA TS, 1993, ANESTHESIOLOGY, V78, P134, DOI 10.1097/00000542-199301000-00019; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Soubani AO, 2001, AM J EMERG MED, V19, P141, DOI 10.1053/ajem.2001.21353; SPAITE DW, 1993, ANN EMERG MED, V22, P1310, DOI 10.1016/S0196-0644(05)80113-1; St John Robert E, 2003, Crit Care Nurse, V23, P83; TEASDALE C, 1974, LANCET, V304, P81; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1997, ANESTH ANALG, V85, P55, DOI 10.1097/00000539-199707000-00010; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S	35	35	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1577	1583		10.1097/TA.0b013e3181a3931d			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	457PN	WOS:000266944500010	19509617				2022-02-06	
J	Kharatishvili, I; Sierra, A; Immonen, RJ; Grohn, OHJ; Pitkanen, A				Kharatishvili, Irina; Sierra, Alejandra; Immonen, Riikka J.; Grohn, Olli H. J.; Pitkanen, Asla			Quantitative T2 mapping as a potential marker for the initial assessment of the severity of damage after traumatic brain injury in rat	EXPERIMENTAL NEUROLOGY			English	Article						Behavioral tests; Fluid percussion model; Histopathology; Lesion volume; Quantitative MRI; Traumatic brain injury	CLOSED-HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; POSTTRAUMATIC EPILEPSY; TIME-COURSE; SEIZURES; PREDICTION; DIFFUSION; MILD; MRI; CT	Severity of traumatic brain injury (TBI) positively correlates with the risk of post-traumatic epilepsy (PTE). Studies on post-traumatic epileptogenesis would greatly benefit from markers that at acute phase would reliably predict the extent and severity of histologic brain damage caused by TBI in individual subjects. Currently in experimental models, severity of TBI is determined by the pressure of applied load that does not directly reflect the extent of inflicted brain injury, mortality within experimental population, or impairment in behavioral tests that are laborious to perform. We aimed to compare MRI markers measured at acute post-injury phase to previously used indicators of injury severity in the ability to predict the extent of histologically determined post-traumatic tissue damage. We used lateral fluid-percussion injury model in rat that is a clinically relevant model of closed head injury in humans, and results in PTE in severe cases. Rats (48 injured, 12 controls) were divided into moderate (mTBI) and severe (sTBI) groups according to impact strength. MRI data (T2, T2*, lesion volume) were acquired 3 days post-injury. Motor deficits were analysed using neuroscore (NS) and beam balance (BB) tests 2 and 3 days post-injury, respectively. Histological evaluation of lesion volume (Fluoro-jade B) was used as the reference outcome measure, and was performed 2 weeks after TBI. From MRI parameters studied, quantitative T2 values of cortical lesion not only correlated with histologic lesion volume (P<0.001, r=0.6, N=34), as well as NS (P<0.01, r=-0.5, N=34) and BB (P<0.01, r=-0.5. N=34) results, but also successfully differentiated animals with mTBI from those with sTBI 70.6 +/- 6.2 6.2 ms vs. 75.9 +/- 2.6 ms, P<0.001). Quantitative T2 of the lesion early after TBI can serve as an indicator of the severity of post-traumatic cortical damage and neuro-motor impairment, and has a potential as a clinical marker for identification of individuals with elevated risk of PTE. (C) 2009 Elsevier Inc. All rights reserved.	[Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Sierra, Alejandra; Immonen, Riikka J.; Grohn, Olli H. J.] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Biomed NMR Res Grp,Biomed Imaging Unit, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.	Asla.Pitkanen@uku.fi		Sierra Lopez, Alejandra/0000-0001-5399-2056	Academy of FinlandAcademy of FinlandEuropean Commission; Emil Aaltonen Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; Orion Pharma; Finnish Epilepsy Research Foundation; Finnish Cultural FoundationFinnish Cultural FoundationFinnish IT center for science	This work was supported by the Academy of Finland, the Emil Aaltonen Foundation, the Sigrid Juselius Foundation, Orion Pharma, the Finnish Epilepsy Research Foundation, and the Finnish Cultural Foundation. We thank Mrs. Merja Lukkari, and Mr. Jarmo Hartikainen for their excellent technical assistance.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DALESSANDRO R, 1983, ARCH NEUROL-CHICAGO, V40, P831, DOI 10.1001/archneur.1983.04050120081022; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; FRENCH BN, 1977, SURG NEUROL, V7, P171; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 2005, HEAD INJURY PATHOPHY, P441; JENNETT B, 1975, EPILEPSY NONMISSILE; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KURTZKE JF, 1987, CLIN NEUROLOGY, P1; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42	52	35	35	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2009	217	1					154	164		10.1016/j.expneurol.2009.01.026			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	442RT	WOS:000265859000018	19416663				2022-02-06	
J	Putukian, M; Aubry, M; McCrory, P				Putukian, M.; Aubry, M.; McCrory, P.			Return to play after sports concussion in elite and non-elite athletes?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; MANAGEMENT; STATEMENT; DIAGNOSIS; RECOVERY; INJURIES; GAME	Objective: To examine the published literature relating to the difference in concussion management strategies between elite and non-elite athletes. Design: Systematic literature review of concussion management. Intervention: Pubmed, Medline, Psych Info, Cochrane Library and Sport Discus databases were reviewed using the MeSH keywords brain concussion and mild traumatic brain injury, combined with athletic injuries. Each were then refined by adding the keyword "return to play" (RTP). English language and human studies only were assessed. Results: For the Medline search, using "brain concussion" as a keyword, 4319 articles were found; this was decreased to 111 when RTP was used to refine the search. When "mild traumatic brain injury" was used, 2509 articles were found; this decreased to 39 when RTP was used to refine the search. Following initial review, these articles form the basis of the discussion below. Conclusions: The non-elite athlete may not have the same resources available as the elite athlete (such as the presence of trained medical staff during practice and competition, a concussion programme as part of sideline preparedness, the benefit of neuropsychological or postural testing, as well as consultants with expertise in concussion readily available) and as a result will generally be managed more conservatively. Younger athletes often have a greater incidence of concussion with longer recovery time frames; however, they are often managed with less expertise and with limited resources.	[Putukian, M.] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08540 USA; [McCrory, P.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic, Australia		Putukian, M (corresponding author), Princeton Univ, Univ Hlth Serv, Washington Rd, Princeton, NJ 08540 USA.	putukian@princeton.edu	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Braham R, 2004, J SCI MED SPORT, V7, P451, DOI 10.1016/S1440-2440(04)80263-9; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HERRING S, 2006, MED SCI SPORTS EXERC, V38, P395, DOI DOI 10.1249/01.MSS.0000202025.48774.31; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	29	35	35	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I28	I31		10.1136/bjsm.2009.058230			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100005	19433421				2022-02-06	
J	Levin, AV				Levin, Alex V.			Retinal Hemorrhages: Advances in Understanding	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article						Retinal hemorrhage; Child abuse; Shaken baby syndrome; Abusive head trauma; Retinoschisis	TRAUMATIC AXONAL INJURY; SUSPECTED CHILD-ABUSE; HEAD-INJURY; CARDIOPULMONARY-RESUSCITATION; OPTIC-NERVE; INFANT; MODEL; FOLDS; CONVULSIONS; RETINOPATHY	Retinal hemorrhage is a cardinal manifestation of abusive head injury characterized by repetitive acceleration-deceleration with or without blunt head impact. Detailed description of the hemorrhages and documentation are critical to diagnosis. Vitreoretinal traction appears to be the major causative factor. Outcome is largely dependent on brain and optic nerve injury.	Wills Eye Inst, Philadelphia, PA 19107 USA		Levin, AV (corresponding author), Wills Eye Inst, 840 Walnut St,12th Floor, Philadelphia, PA 19107 USA.	alevin@willseye.org					Agrawal A, 2006, SURV OPHTHALMOL, V51, P129, DOI 10.1016/j.survophthal.2005.12.003; Agrawal A, 2007, BRIT J OPHTHALMOL, V91, P1456, DOI 10.1136/bjo.2007.117408; Altinok D, 2009, PEDIATR RADIOL, V39, P290, DOI 10.1007/s00247-008-1086-4; Amberg R, 2001, FORENSIC SCI INT, V124, P157, DOI 10.1016/S0379-0738(01)00582-5; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; BHOLA R, 2005, INVEST OPHTH VIS SCI, V46, pE4090; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; BRAY GL, 1987, AM J DIS CHILD, V141, P1215, DOI 10.1001/archpedi.1987.04460110085030; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; Emadi-Konjin P, 2005, CLIN BIOCHEM, V38, P450, DOI 10.1016/j.clinbiochem.2005.01.018; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; FACKLER JC, 1992, AM J DIS CHILD, V146, P1294, DOI 10.1001/archpedi.1992.02160230052014; Fenton S, 1999, ARCH OPHTHALMOL-CHIC, V117, P1432; Forbes BJ, 2008, J AAPOS, V12, P177, DOI 10.1016/j.jaapos.2007.07.009; Forbes BJ, 2007, J AAPOS, V11, P179, DOI 10.1016/j.jaapos.2006.08.006; GANGEMI M, 1987, NEUROCHIRURGIA, V30, P53; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Gilliland MGF, 2007, AM J FOREN MED PATH, V28, P323, DOI 10.1097/PAF.0b013e31815b4c00; GILLILAND MGF, 1992, FORENSIC SCI INT, V56, P77, DOI 10.1016/0379-0738(92)90149-Q; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; GOETTING MG, 1990, PEDIATRICS, V85, P585; Goldman M, 2006, J PEDIATR-US, V148, P835, DOI 10.1016/j.jpeds.2005.12.052; GONZALEZ VI, 1995, EUR J OPHTHALMOL, V5, P247; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HANSEN HC, 1994, NEURO-OPHTHALMOLOGY, V14, P345, DOI 10.3109/01658109409024061; Herr S, 2004, PEDIATRICS, V113, P1658, DOI 10.1542/peds.113.6.1658; HOFFMAN R, 2006, OPHTHALMOLOGY PHOTOG, P151; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Johnston CS, 1996, J AM COLL NUTR, V15, P586, DOI 10.1080/07315724.1996.10718634; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; Kivlin JD, 2008, ARCH OPHTHALMOL-CHIC, V126, P800, DOI 10.1001/archopht.126.6.800; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Lantz PE, 2005, J FORENSIC SCI, V50, P1450; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Levin AV, 2006, ARCH OPHTHALMOL-CHIC, V124, P1773, DOI 10.1001/archopht.124.12.1773; Levin AV, 2001, AM J FOREN MED PATH, V22, P417, DOI 10.1097/00000433-200112000-00019; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; LEVIN AV, 2007, HOSP SICK CHILDRENS, P133; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MATSCHKE J, 2008, INT J LEGAL MED; Matthews GP, 1996, J PEDIATR OPHTHALMOL, V33, P260, DOI 10.3928/0191-3913-19960701-13; Mei-Zahav M, 2002, ARCH DIS CHILD, V86, P334, DOI 10.1136/adc.86.5.334; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Nagaoka T, 2002, INVEST OPHTH VIS SCI, V43, P3037; Nolte KB, 1997, J FORENSIC SCI, V42, P935; OBI E, 2007, J AAPOS, V11, P99, DOI DOI 10.1016/J.JAAPOS.2007.01.031; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; Ozbay D, 2004, CAN J OPHTHALMOL, V39, P727, DOI 10.1016/S0008-4182(04)80066-8; Parsons MA, 2001, J CLIN PATHOL, V54, P417, DOI 10.1136/jcp.54.6.417; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; RANGARAJAN N, J AAPOS IN PRESS; Richards PG, 2006, ARCH DIS CHILD, V91, P205, DOI 10.1136/adc.2005.090761; Sandramouli S, 1997, ARCH DIS CHILD, V76, P449, DOI 10.1136/adc.76.5.449; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2; SCHOENFELD A, 1985, ARCH OPHTHALMOL-CHIC, V103, P932; Scott AW, 2009, AM J OPHTHALMOL, V147, P364, DOI 10.1016/j.ajo.2008.08.010; Serbanescu I, 2008, EYE, V22, P715, DOI 10.1038/eye.2008.6; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STURM V, 2008, EYE; TOMASI L, 1986, AM J DIS CHILD, V93, P1335; Tyagi AK, 1998, BRIT J OPHTHALMOL, V82, P659, DOI 10.1136/bjo.82.6.659; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; Wygnanski-Jaffe T, 2007, EYE, V21, P83, DOI 10.1038/sj.eye.6702163; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	72	35	35	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	APR	2009	56	2					333	+		10.1016/j.pcl.2009.02.003			13	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	441CA	WOS:000265745700003	19358919				2022-02-06	
J	Arango-Lasprilla, JC; Ketchum, JM; Gary, KW; Kreutzer, JS; O'Neil-Pirozzi, TM; Wehman, P; de la Plata, CM; Jha, A				Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Gary, Kelli W.; Kreutzer, Jeffrey S.; O'Neil-Pirozzi, Therese M.; Wehman, Paul; de la Plata, Carlos Marquez; Jha, Amitabh			The Influence of Minority Status on Job Stability After Traumatic Brain Injury	PM&R			English	Article								Objective: To determine the influence of minority status on job stability after traumatic brain injury (TBI). Setting: TBI Model Systems Centers. Participants: 633 individuals (414 Caucasians vs. 219 Minorities) with primarily moderate to severe TBI hospitalized at one of the TBI Model Systems Centers between 1988 and 2001 with 3 years of continuous follow up employment data after discharge. Main Outcome Measures: Job stability was defined as "stable" (competitively employed at all three follow-up visits), "unemployed" (not competitively employed at all three visits), and "unstable" (any other mixture of competitively employed and not competitively employed over the three follow-up visits). Methods: A multinomial logistic regression model was used to model the effect of ethnicity on job stability post TBI after adjusting for injury and demographic characteristics. Results: Compared to Caucasians, the adjusted odds for minorities were 3.587 times greater for being unemployed versus being stably employed (95% CI = 1.930, 6.668), 1.911 times greater for being unstably employed versus being stably employed (95% Cl = 1.006, 3.628), and 1.878 times more greater for being unemployed versus being unstably employed (95% Cl = 1.157, 3.046) after adjusting for preinjury employment status, age, marital status, education, cause of injury, total length of stay in acute and rehabilitation hospitals, and DRS at discharge. Conclusions: Minority status is an independent predictor of short-term job stability after TBI. Minority TBI survivors were more likely than Caucasians to be unemployed or unstably employed. Rehabilitation professionals should develop employment interventions that will address the specific needs of these racial/ethnic groups and facilitate optimal employment outcomes for minority TBI survivors.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ Rehabil Psychol & Neur, VCU W Hosp, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Gary, Kelli W.; Kreutzer, Jeffrey S.; Wehman, Paul] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; [de la Plata, Carlos Marquez] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Jha, Amitabh] Univ Colorado, Sch Med, Craig Hosp, Dept Phys Med & Rehabil, Englewood, CO USA		Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ Rehabil Psychol & Neur, VCU W Hosp, Dept Phys Med & Rehabil, 3rd Floor,Room 3-102,1200 E Broad St, Richmond, VA 23298 USA.	jcarangolasp@vcu.edu	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A070036, H133P040006]	This research was supported by grants H133A070036 and H133P040006 from the National Institute on Disability and Rehabilitation Research, United States Department of Education.	Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Botuck S, 1998, J REHABIL, V64, P42; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85, DOI 10.1097/01.HTR.0000265096.44683.6b; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake RE, 1996, J CONSULT CLIN PSYCH, V64, P391, DOI 10.1037/0022-006X.64.2.391; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; James P., 2002, HUM RESOUR MANAG J, V12, P82; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kregel J, 1994, NeuroRehabilitation, V4, P1, DOI 10.3233/NRE-1994-4103; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leff HS, 2005, PSYCHIAT SERV, V56, P1237, DOI 10.1176/appi.ps.56.10.1237; Lehman AF, 2002, ARCH GEN PSYCHIAT, V59, P165, DOI 10.1001/archpsyc.59.2.165; Lemeshow S, 2000, APPL LOGISTIC REGRES; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; McLeod A, 2004, OCCUP ENVIRON MED, V61, P414, DOI 10.1136/oem.2003.007336; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pierce K, 2003, RES DEV DISABIL, V24, P369, DOI 10.1016/S0891-4222(03)00057-X; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Possl O, 2001, BRAIN INJURY, V15, P15; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schopp LH, 2006, J HEAD TRAUMA REHAB, V21, P213, DOI 10.1097/00001199-200605000-00002; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802	39	35	35	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	JAN	2009	1	1					41	49		10.1016/j.pmrj.2008.07.001			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V24LD	WOS:000208411000007	19627871				2022-02-06	
J	Beijer, U; Andreasson, S				Beijer, Ulla; Andreasson, Sven			Physical diseases among homeless people: Gender differences and comparisons with the general population	SCANDINAVIAN JOURNAL OF PUBLIC HEALTH			English	Article						Homeless people; gender; physical health; hospital care	NEW-YORK-CITY; PATTERNS; ADULTS	Aim: To study morbidity amongst homeless men and women by comparing prevalence of hospital care for somatic diseases and injuries with a control group of men and women from the general population. Methods: A cohort of 1,364 men and 340 women were documented as homeless in 1996. Comparisons are made concerning hospital care for somatic diseases and injuries (1996-2002) among 3,750 men and 1,250 women from the general population. Results: The relative risk (RR) for homeless men and women of being hospitalised was double that of the men and women in the controls (1.93 and 1.96 respectively). Homeless women had a slightly, not significant, increased risk compared to homeless men (RR 1.10). Younger homeless women had a significant higher risk. Among diagnostic categories, the highest prevalence was found among homeless men in the diagnosis group injury/poisoning (22%). The highest risk was found for skin diseases (RR 36.96) and concerned homeless women. There were a number of gender specific diagnoses, where risks were considerably elevated, such as diseases of the genital organs, viral hepatitis, and poisoning for homeless women, and cerebrovascular diseases, diseases of the liver, and concussion for homeless men. Conclusions: Homeless people had twice the risk of being hospitalised for physical diseases compared to the general population. Younger women were particularly at risk compared to homeless men and to women in the controls. There were a number of gender specific diagnoses that are important to take into account when planning services for homeless people.	[Beijer, Ulla; Andreasson, Sven] Karolinska Inst, Dept Publ Hlth Sci, Div Social Med, Stockholm, Sweden; [Andreasson, Sven] Swedish Natl Inst Publ Hlth, Stockholm, Sweden		Beijer, U (corresponding author), Beroendecentrum, M4-02 Karolinska Solna, S-17176 Stockholm, Sweden.	u.beijer@telia.com		Beijer, Ulla/0000-0002-4274-6607	Swedish National Institute of Public Health, Stockholm	This study was supported by a grant from the Swedish National Institute of Public Health, Stockholm. The authors would also like to thank Stefan Borg, Karolinska Institutet, Stockholm, Sweden, for his support, and Anders Leifman for his statistical contribution.	AGREN G, 1994, HEMLOSA STOCKHOLM, P18; AGREN G, 1997, HEMLOSA STOCKHOLM 19, P9; Beijer U, 2007, NORD J PSYCHIAT, V61, P363, DOI 10.1080/08039480701644637; BEIJER U, 1997, PSYKISKT STORDA HEML, P10; Beijer U, 1998, HEMLOSA KVINNOR STOC, V1998, P7; Burstrom B., 2007, HALSA LIVSVILLKOR BL; Culhane DP, 2001, J EPIDEMIOL COMMUN H, V55, P515, DOI 10.1136/jech.55.7.515; Epele ME, 2002, CULT MED PSYCHIAT, V26, P33, DOI 10.1023/A:1015237130328; FINNE E, 2003, STAT SUBSTANCE ABUSE, P6; Finney A, 2002, BR J NURS S6, V11, P17; GELBERG L, 1993, MED CARE, V31, P757, DOI 10.1097/00005650-199309000-00001; HALLDIN J, 2001, KLINISK PILOTSTUDIE; Lim YW, 2002, MED CARE, V40, P510; Nyamathi AM, 2002, J GEN INTERN MED, V17, P134, DOI 10.1046/j.1525-1497.2002.10415.x; PADGETT DK, 1995, SOC SCI MED, V41, P547, DOI 10.1016/0277-9536(94)00364-Y; PEDERSEN PV, 2008, SUSY UDSAT HLTH PROF; Pitz S, 2005, OPHTHALMOLOGICA, V219, P345, DOI 10.1159/000088376; Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; STADIG I, 1987, VART HAR KVINNORNA F, P58; STATIGOS AJ, 2003, MED CUTANEOUS DISORD, V2, P168; Takano T, 1999, J URBAN HEALTH, V76, P73, DOI 10.1007/BF02344463; Wamala SP, 2002, GENDER SOCIAL INEQUI; WIECHA JL, 1991, PUBLIC HEALTH REP, V106, P364	24	35	35	1	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1403-4948			SCAND J PUBLIC HEALT	Scand. J. Public Health	JAN	2009	37	1					93	100		10.1177/1403494808099972			8	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	403BU	WOS:000263057600013	19141558				2022-02-06	
J	Derwall, M; Stoppe, C; Brucken, D; Rossaint, R; Fries, M				Derwall, Matthias; Stoppe, Christian; Bruecken, David; Rossaint, Rolf; Fries, Michael			Changes in S-100 protein serum levels in survivors of out-of-hospital cardiac arrest treated with mild therapeutic hypothermia: a prospective, observational study	CRITICAL CARE			English	Article							NEURON-SPECIFIC ENOLASE; HYPOXIC BRAIN-DAMAGE; CARDIOPULMONARY-RESUSCITATION; REGAINING CONSCIOUSNESS; PREDICTION; MARKERS; STROKE; INJURY; BLOOD; S100B	Introduction Knowledge about the influence of current neuroprotective interventions on prognostic markers after survival from cardiac arrest is lacking. This study aimed to investigate the effects of mild therapeutic hypothermia on the release of the astroglial protein S-100 after cardiopulmonary resuscitation (CPR) in survivors of out-of-hospital cardiac arrest. Methods This was a prospective, observational study performed during a two-year period, involving medical emergency services and five collaborating hospitals at the city of Aachen, Germany. Sixty-eight subjects were enrolled by the emergency physician on duty by taking blood samples after successful attempts at resuscitation with return of spontaneous circulation (ROSC), followed by samples at 6, 12, 24, 72 and 120 hours post ROSC by the appropriate intensive care unit staff. Depending on the decision of the attending physician, subjects were cooled down to 33 degrees C (n = 37) for 24 hours or were held at 37 degrees C (n = 31). Patients were tracked for estimating mortality and gross neurological outcome for 14 days. Results S-100 levels in patients not receiving mild therapeutic hypothermia (normothermia (NT)) showed equivalent numbers as compared with cooled patients (mild therapeutic hypothermia (MTH)) on baseline (NT = 1.38 mu g/l versus MTH = 1.30 mu g/l; P = 0.886). S-100 levels on baseline were significantly lower in patients with a good neurological outcome at 14 days after the event in comparison to their peers with adverse outcome (P = 0.014). Although the difference in S-100 levels of MTH patients with adverse or favourable neurological outcome reached statistical significance, it did not in NT patients. Conclusions Although the predictive power of S-100 levels were best on admission but not at later time points, MTH had no influence on S-100 serum levels in survivors of non-traumatic out-of-hospital cardiac arrest in the particular setting of this investigation.	[Derwall, Matthias; Stoppe, Christian; Bruecken, David; Rossaint, Rolf; Fries, Michael] Univ Hosp RWTH Aachen, Dept Anaesthesiol, D-52074 Aachen, Germany; [Derwall, Matthias] Univ Hosp RWTH Aachen, Inst Neuropathol, D-52074 Aachen, Germany		Derwall, M (corresponding author), Univ Hosp RWTH Aachen, Dept Anaesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mderwall@ukaachen.de			Laerdal Foundation for Acute Medicine, Stavanger, Norway	Parts of the study were supported by the Laerdal Foundation for Acute Medicine, Stavanger, Norway. The sponsor had no involvement in the study design, or in the collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication.	Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; BARGER SW, 1992, J BIOL CHEM, V267, P9689; Becker L, 2008, RESUSCITATION, V79, P22, DOI 10.1016/j.resuscitation.2008.06.019; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bottiger BW, 2001, CIRCULATION, V103, P2694; de Latorre F, 2001, RESUSCITATION, V48, P211, DOI 10.1016/S0300-9572(00)00379-8; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ekmektzoglou KA, 2007, RESUSCITATION, V75, P219, DOI 10.1016/j.resuscitation.2007.03.016; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Fries M, 2004, ANAESTHESIST, V53, P959, DOI 10.1007/s00101-004-0743-8; Fries M, 2003, RESUSCITATION, V59, P105, DOI 10.1016/S0300-9572(03)00164-3; Grasner JT, 2008, ANASTH INTENSIV NOTF, V43, P706, DOI 10.1055/s-0028-1102989; Grubb NR, 2007, HEART, V93, P1268, DOI 10.1136/hrt.2006.091314; Hachimi-Idrissi S, 2005, RESUSCITATION, V64, P187, DOI 10.1016/j.resuscitation.2004.08.008; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hsu AA, 2008, PEDIATR CRIT CARE ME, V9, P245, DOI 10.1097/PCC.0b013e3181727b22; Jonsson H, 2001, ANN THORAC SURG, V71, P1433, DOI 10.1016/S0003-4975(00)02612-6; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KARPIAK SE, 1976, BRAIN RES, V102, P313, DOI 10.1016/0006-8993(76)90885-4; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mussack T, 2001, WORLD J SURG, V25, P539, DOI 10.1007/s002680020082; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Safar P, 1981, BRAIN FAILURE RESUSC, P155; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; van Alem AP, 2004, AM HEART J, V148, P416, DOI 10.1016/j.ahj.2004.01.031	35	35	36	1	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	2							R58	10.1186/cc7785			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	453UN	WOS:000266638500030	19368739	Green Published, gold			2022-02-06	
J	Greve, KW; Etherton, JL; Ord, J; Bianchini, KJ; Curtis, KL				Greve, Kevin W.; Etherton, Joseph L.; Ord, Jonathan; Bianchini, Kevin J.; Curtis, Kelly L.			Detecting Malingered Pain-Related Disability: Classification Accuracy of the Test of Memory Malingering	CLINICAL NEUROPSYCHOLOGIST			English	Article						Chronic pain; Cognition; Malingering; Criterion groups validation; Symptom validity test; Response bias; Test of Memory Malingering	LABORATORY-INDUCED PAIN; TRAUMATIC BRAIN-INJURY; MMPI-2 VALIDITY SCALES; NEUROCOGNITIVE DYSFUNCTION; COGNITIVELY INTACT; NORMATIVE DATA; DIGIT SPAN; DEPRESSION; INDICATORS; TOMM	This study used criterion groups validation to determine the accuracy of the Test of Memory Malingering (TOMM) in detecting malingered pain-related disability (MPRD) across a range of cutoffs in chronic pain patients undergoing psychological evaluation (n = 604). Data from patients with traumatic brain injury (n = 45) and dementia (n = 59) are presented for comparison. TOMM scores decreased and failure rates increased as a function of greater external evidence of intentional under-performance. The TOMM detected from 37.5% to 60.2% of MPRD patients, depending on the cutoff. False positive (FP) error rates ranged from 0% to 5.1%. Accuracy data for Trial 1 are also reported. In chronic pain the original cutoffs produced no FP errors but were associated with high false negative error rates. Higher cutoffs increased sensitivity without adversely affecting specificity. The relevance of these findings to research and clinical practice is discussed.	[Greve, Kevin W.; Ord, Jonathan; Bianchini, Kevin J.; Curtis, Kelly L.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Etherton, Joseph L.; Bianchini, Kevin J.; Curtis, Kelly L.] Jefferson Neurobehav Grp, Metairie, LA USA; [Etherton, Joseph L.] Texas State Univ, San Marcos, TX USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Frederick RI, 2007, ASSESSMENT, V14, P3, DOI 10.1177/1073191106292009; GERVAIS RO, 2001, J FORENSIC NEUROPSYC, V2, DOI DOI 10.1300/J151V02N02_01; Green P., 2005, GREENS WORD MEMORY T, Vrev. ed.; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; GREVE KW, ASSESSMENT IN PRESS; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; IVERSON GL, 2001, J FORENSIC NEUROPSYC, V2, P19, DOI DOI 10.1300/J151v02n01_02; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; Larrabee GJ, 2007, ASSESSMENT MALINGERE, P44; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds CR, 1998, CRIT ISS NE, P261; Rogers R., 1997, CLIN ASSESSMENT MALI; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002	51	35	35	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	7					1250	1271	PII 914408817	10.1080/13854040902828272			22	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	497WI	WOS:000270094200008	19728222				2022-02-06	
J	Xiong, YQ; Singh, IN; Hall, ED				Xiong, Yiqin; Singh, Indrapal N.; Hall, Edward D.			Tempol protection of spinal cord mitochondria from peroxynitrite-induced oxidative damage	FREE RADICAL RESEARCH			English	Article						Tempol; spinal cord; mitochondria; nitrotyrosine; lipid peroxidation; oxidative damage	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; CYTOCHROME-C; LIPID-PEROXIDATION; MOUSE MODEL; PERMEABILITY TRANSITION; NITROXIDE ANTIOXIDANT; ELECTRON-TRANSPORT; TYROSINE NITRATION; HEAD-INJURY	Peroxynitrite (PN)-mediated mitochondrial dysfunction has been implicated in the secondary injury process after traumatic spinal cord injury (SCI). This study investigated the detrimental effects of the PN donor SIN-1(3-morpholinosydnonimine) on isolated healthy spinal cord mitochondria and the protective effects of tempol, a catalytic scavenger of PN-derived radicals. A 5 min exposure of the mitochondria to SIN-1 caused a dose-dependent decrease in the respiratory control ratio (RCR) that was accompanied by significant increases in complex I-driven states II and IV respiration rates and decreases in states III and V. These impairments occurred together with an increase in mitochondrial protein 3-nitrotyrosine (3-NT), but not in lipid peroxidation (LP)-related 4-hydroxynonenal (4-HNE). Tempol significantly antagonized the respiratory effects of SIN-1 in parallel with an attenuation of 3-NT levels. These results show that the exogenous PN donor, SIN-1, rapidly causes mitochondrial oxidative damage and complex I dysfunction identical to traumatic spinal cord mitochondrial impairment and that this is mainly due to tyrosine nitration. Consistent with that, the protection of mitochondrial respiratory function by tempol is associated with a decrease in 3-NT levels in mitochondrial proteins also similar to the previously reported antioxidant actions of tempol in traumatically-injured spinal cord mitochondria.	[Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Xiong, Yiqin/H-1710-2012; Hall, Edward D/F-8930-2013		Kentucky Spinal Cord & Head Injury Research Trust6-5; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS046566] Funding Source: NIH RePORTER	Support for this study was provided by a grant from the Kentucky Spinal Cord & Head Injury Research Trust ( KSCHIRT # 6-5).	Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Batthyany C, 2005, BIOCHEMISTRY-US, V44, P8038, DOI 10.1021/bi0474620; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Brookes PS, 1998, J NEUROCHEM, V70, P2195; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Genovese T, 2007, FREE RADICAL BIO MED, V43, P763, DOI 10.1016/j.freeradbiomed.2007.05.012; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Murray J, 2003, J BIOL CHEM, V278, P37223, DOI 10.1074/jbc.M305694200; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025	50	35	38	1	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.		2009	43	6					604	612		10.1080/10715760902977432			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	457ZR	WOS:000266979100010	19513907	Green Accepted			2022-02-06	
J	Dickin, DC; Doan, JB				Dickin, D. C.; Doan, J. B.			Postural stability in altered and unaltered sensory environments following fatiguing exercise of lower extremity joints	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						recovery; sensory perturbation; sway-referenced support; posturography	MUSCLE FATIGUE; BALANCE; CONTRACTIONS; CONCUSSION; SWAY; PROPRIOCEPTION; POSITION; DEFICITS; SCORES; INJURY	Investigations of postural recovery following controlled external perturbations have provided models for healthy and pathological balance behavior. Less work, however, has investigated postural responses related to internal perturbations of the balance system. In this study, lower extremity joint (knee, or ankle) and overall fatigue of the dominant leg provided the internal perturbations to the balance system. Postural sway was examined during unilateral dominant leg standing before and immediately following fatiguing exercise, as well as at 10, 20, and 30 min post-fatigue activity. Sway was measured in both firm and sway-referenced support surface (external perturbation) conditions. Both joint-localized fatigue and overall fatigue were found to induce impairments in postural control, which were further exacerbated by external postural perturbations. Follow-up pairwise comparisons indicated that these impairments persisted at 10 and 30 min post-fatigue. No differences in postural sway were found between fatigue locations or across any interactions between sway and fatigue location. The results indicated that muscular fatigue imposed a prolonged internal perturbation to postural control, regardless of any individual or combined joint fatigue localization. This global effect, combined with the prolonged impairment in postural response, provides support for critical contributions from a central mechanism to postural deficits due to fatigue.	[Dickin, D. C.] Univ Idaho, Dept Hlth Phys Educ Recreat & Dance, Moscow, ID 83844 USA; [Doan, J. B.] Univ Lethbridge, Dept Kinesiol, Lethbridge, AB T1K 3M4, Canada		Dickin, DC (corresponding author), Univ Idaho, Dept Hlth Phys Educ Recreat & Dance, POB 442401, Moscow, ID 83844 USA.	cdickin@uidaho.edu	Dickin, D. Clark/A-8303-2009	Dickin, D. Clark/0000-0002-3104-4167			Baechle TR, 2000, ESSENTIALS STRENGTH; BOTTAS R, 2001, EUR J APPL PHYSL, V94, P62; Brown LA, 2006, PARKINSONISM RELAT D, V12, P376, DOI 10.1016/j.parkreldis.2006.03.004; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Condron JE, 2002, J AM GERIATR SOC, V50, P157, DOI 10.1046/j.1532-5415.2002.50022.x; DAVIDSON BS, 2001, EUR J APPL PHYSL, V93, P183; Dickin D, 2004, EXP AGING RES, V30, P373, DOI 10.1080/03610730490484416; DUNCAN PW, 1990, PHYS THER, V70, P88, DOI 10.1093/ptj/70.2.88; Enoka RM, 1996, J APPL PHYSIOL, V81, P2339, DOI 10.1152/jappl.1996.81.6.2339; Fu ASN, 2005, AM J SPORT MED, V33, P1174, DOI 10.1177/0363546504271976; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; Goerlick M, 2003, APPL ERGON, V34, P317, DOI 10.1016/S0003-6870(03)00039-5; Gribble PA, 2004, ARCH PHYS MED REHAB, V85, P589, DOI 10.1016/j.apmr.2003.06.031; Grindstaff TL, 2006, PERCEPT MOTOR SKILL, V102, P379; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Johnson B, 1998, BANK MARKETING, V30, P12; Karlsson A, 1997, COMPUT METH PROG BIO, V52, P165, DOI 10.1016/S0169-2607(96)01794-4; Ledin T, 2004, GAIT POSTURE, V19, P184, DOI 10.1016/S0966-6362(03)00061-4; Lysholm M, 1998, SCAND J MED SCI SPOR, V8, P432; Mair SD, 1996, AM J SPORT MED, V24, P137, DOI 10.1177/036354659602400203; MARKS R, 1993, PERCEPT MOTOR SKILL, V77, P1195, DOI 10.2466/pms.1993.77.3f.1195; Melnyk M, 2007, KNEE SURG SPORT TR A, V15, P525, DOI 10.1007/s00167-006-0226-3; MILLER PK, 1976, PERCEPT MOTOR SKILL, V42, P135, DOI 10.2466/pms.1976.42.1.135; Miura K, 2004, ARTHROSCOPY, V20, P414, DOI 10.1016/j.arthro.2004.01.007; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; NASHNER LM, 1990, P APTA FOR NASHV TEN, P5; Paasuke M, 1999, ACTA PHYSIOL SCAND, V166, P319; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pline KM, 2006, ERGONOMICS, V49, P1639, DOI 10.1080/00140130600901678; Rose DJ, 2000, J AM GERIATR SOC, V48, P275, DOI 10.1111/j.1532-5415.2000.tb02646.x; Schieppati M, 2003, NEUROSCIENCE, V121, P277, DOI 10.1016/S0306-4522(03)00439-1; Smith ICH, 2007, J APPL PHYSIOL, V102, P207, DOI 10.1152/japplphysiol.00571.2006; Stauber WT, 2004, J ELECTROMYOGR KINES, V14, P61, DOI 10.1016/j.jelekin.2003.09.010; Vuillerme N, 2007, INT J SPORTS MED, V28, P243, DOI 10.1055/s-2006-924292; Vuillerme N, 2003, ARCH PHYS MED REHAB, V84, P1560, DOI 10.1016/S0003-9993(03)00235-1; Vuillerme N, 2002, NEUROSCI LETT, V333, P131, DOI 10.1016/S0304-3940(02)00999-0; Walsh LD, 2004, J PHYSIOL-LONDON, V558, P705, DOI 10.1113/jphysiol.2004.062703; Yaggie JA, 2002, ARCH PHYS MED REHAB, V83, P224, DOI 10.1053/apmr.2002.28032	38	35	36	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	DEC	2008	18	6					765	772		10.1111/j.1600-0838.2007.00760.x			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	376US	WOS:000261209100013	18248536				2022-02-06	
J	Mahmood, A; Goussev, A; Lu, DY; Qu, CS; Xiong, Y; Kazmi, H; Chopp, M				Mahmood, Asim; Goussev, Anton; Lu, Dunyue; Qu, Changsheng; Xiong, Ye; Kazmi, Humaira; Chopp, Michael			Long-Lasting Benefits after Treatment of Traumatic Brain Injury (TBI) in Rats with Combination Therapy of Marrow Stromal Cells (MSCs) and Simvastatin	JOURNAL OF NEUROTRAUMA			English	Article						combination therapy; marrow stromal cells (MSCs); simvastatin; traumatic brain injury (TBI)	ADULT RATS; TRANSPLANTATION; ATORVASTATIN; NEUROGENESIS; RECOVERY; MODEL	This study was designed to investigate the beneficial effects of combination therapy of simvastatin and marrow stromal cells (MSCs) in improving functional outcome after traumatic brain injury (TBI) in rats. Adult female Wistar rats (n = 72 and 8, per group) were injured with controlled cortical impact and treated either with monotherapy of MSCs or simvastatin or a combination therapy of these two agents. Different combination doses were tested, and nine groups of animals were studied. Neurological function was evaluated using Modified Neurological Severity Score (MNSS), and animals were sacrificed 3 months after injury. Coronal brain sections were stained with standard hematoxylin and eosin immunohistochemistry. Our results showed that, though functional improvement was seen with monotherapies of MSCs and simvastatin, the combination therapy when used in optimal doses was significantly better in improving functional outcome. This improvement was long lasting and persisted until the end of the trial (3 months). The optimum combination dose was 0.5mg of simvastatin combined with 2 x 10(6) MSCS. post mortem analysis showed the presence of donor MSCs within the injured cortex. Endogenous cellular proliferation induced by the neurorestorative treatments was also observed in the lesion boundary zone. Our data show that MSCs and simvastatin have a synergistic effect in improving functional outcome after TBI.	[Mahmood, Asim; Goussev, Anton; Qu, Changsheng; Xiong, Ye; Kazmi, Humaira] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Lu, Dunyue] SUNY Brooklyn, Dept Psychiat, Brooklyn, NY USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Mahmood, A (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052280-02, R01 NS052280-04] Funding Source: Medline		Ballantyne CM, 2004, AM J CARDIOL, V93, P1487, DOI 10.1016/j.amjcard.2004.02.060; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011; Zacco A, 2003, J NEUROSCI, V23, P11104	23	35	38	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1441	1447		10.1089/neu.2007.0495			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500005	19072586	Green Published, Green Accepted			2022-02-06	
J	Jin, GZ; Cho, SJ; Choi, EG; Lee, YS; Yu, XF; Choi, KS; Yee, ST; Jeon, JT; Kim, MO; Kong, IK				Jin, Guang-Zhen; Cho, Su-Jin; Choi, Eu-Gene; Lee, Young-S.; Yu, Xian-Feng; Choi, Kap-Seong; Yee, Sung-Tae; Jeon, Jin-Tae; Kim, Myeong-Ok; Kong, Il-Keun			Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro	CELL BIOLOGY INTERNATIONAL			English	Article						Co-culture; Dopamine; Mesenchymal stem cells; Tyrosine hydroxylase; Ventral mesencephalic cells	MARROW STROMAL CELLS; NERVE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; FUNCTIONAL RECOVERY; PC12 CELLS; BONE; DIFFERENTIATION; TRANSPLANTATION; NEURONS	Mesenchymal stem cells (MSCs) are pluripotent adult stem cells. It has been shown that MSCs secrete neurotrophic factors involving nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Also, these neurotrophic factors can upregulate tyrosine hydroxylase (TH) gene expression in PC12 cells and neural stem cells. Here, we investigated the effect of co-culturing rat E13.5 ventral mesencephalic cells (VMCs) with MSCs from rat bone marrow on TH expression and dopamine (DA) content. The study consisted of 3 groups: MSC, VMC and a combined MSC + VMC group. All groups were cultured in serum-free neuro-basal medium for 3 days. Thereafter, each group was analyzed by RT-PCR, western blotting, and HPLC. The co-culture group showed a higher expression at TH and DA than the VMC group. However, TH and DA were not present in the MSC group. These observations suggest that MSCs could be an alternative source for treating neurodegenerative diseases such as Parkinson's disease (PD). Crown Copyright (C) 2008 Published by Elsevier Ltd on behalf of International Federation for Cell Biology. All rights reserved.	[Jin, Guang-Zhen; Cho, Su-Jin; Choi, Eu-Gene; Lee, Young-S.; Jeon, Jin-Tae; Kim, Myeong-Ok; Kong, Il-Keun] Gyeongsang Natl Univ, Grad Sch, Inst Agr & Life Sci, Div Appl Life Sci BK21, Jinju 660701, Gyeongnam Prov, South Korea; [Yu, Xian-Feng] Sunchon Natl Univ, Dept Anim Sci & Technol, Sunchon 540742, South Korea; [Choi, Kap-Seong] Sunchon Natl Univ, Dept Food Sci & Technol, Sunchon 540742, South Korea; [Yee, Sung-Tae] Sunchon Natl Univ, Dept Biol, Sunchon 540742, South Korea		Kong, IK (corresponding author), Gyeongsang Natl Univ, Grad Sch, Inst Agr & Life Sci, Div Appl Life Sci BK21, Jinju 660701, Gyeongnam Prov, South Korea.	ikong@gnu.kr	Kim, Myeong Ok/AAS-1488-2021	Kim, Myeong Ok/0000-0003-4317-1072; Choi, Eugene/0000-0002-0964-7615	Korea Science and Engineering Foundation (KOSEF)Korea Science and Engineering Foundation [M10525010001-05N2501-00110]; Korean government (MOEST)Ministry of Education, Science and Technology, Republic of KoreaKorean Government; Post BK21 ProgramMinistry of Education & Human Resources Development (MOEHRD), Republic of Korea	This work was supported by a grant from the Korea Science and Engineering Foundation (KOSEF; #M10525010001-05N2501-00110) and funding from the Korean government (MOEST). Guang-Zhen Jin, Eugene Choi, Young-S Lee, and Su-Jin Cho were supported by scholarships from the Post BK21 Program.	Chaturvedi RK, 2006, NEUROBIOL DIS, V22, P421, DOI 10.1016/j.nbd.2005.12.008; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Jin GZ, 2007, J VET SCI, V8, P377, DOI 10.4142/jvs.2007.8.4.377; Kan I, 2007, NEUROSCI LETT, V419, P28, DOI 10.1016/j.neulet.2007.03.070; Kim TE, 2003, BIOCHEM BIOPH RES CO, V305, P1040, DOI 10.1016/S0006-291X(03)00879-9; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Li XM, 1997, J NEUROSCI RES, V47, P449; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lu LL, 2005, BRAIN RES PROTOC, V15, P46, DOI 10.1016/j.brainresprot.2005.03.002; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; O'Byrne MB, 2000, ADV EXP MED BIOL, V483, P369; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Tao H, 2005, DEV GROWTH DIFFER, V47, P423; ZHOU JW, 1994, DEV BRAIN RES, V81, P318, DOI 10.1016/0165-3806(94)90318-2; Zhou JW, 1998, NEUROSCI LETT, V252, P215, DOI 10.1016/S0304-3940(98)00577-1	24	35	45	0	2	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	1065-6995			CELL BIOL INT	Cell Biol. Int.	NOV	2008	32	11					1433	1438		10.1016/j.cellbi.2008.08.014			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	369CU	WOS:000260671900012	18778785				2022-02-06	
J	Larsen, A; Kolind, K; Pedersen, DS; Doering, P; Pedersen, MO; Danscher, G; Penkowa, M; Stoltenberg, M				Larsen, Agnete; Kolind, Kristian; Pedersen, Dan Sonne; Doering, Peter; Pedersen, Mie Ostergaard; Danscher, Gorm; Penkowa, Milena; Stoltenberg, Meredin			Gold ions bio-released from metallic gold particles reduce inflammation and apoptosis and increase the regenerative responses in focal brain injury	HISTOCHEMISTRY AND CELL BIOLOGY			English	Article						apoptosis; autometallography (AMG); dissolucytosis; gold; immunosuppression; microglia; neuroregeneration; stem cells	NEURAL STEM-CELLS; OXIDATIVE STRESS; REACTIVE ASTROCYTES; INTERLEUKIN-6-DEFICIENT MICE; SODIUM THIOMALATE; TITANIUM IMPLANTS; TISSUE-RESPONSE; IFN-GAMMA; IN-VITRO; NEUROGENESIS	Traumatic brain injury results in loss of neurons caused as much by the resulting neuroinflammation as by the injury. Gold salts are known to be immunosuppressive, but their use are limited by nephrotoxicity. However, as we have proven that implants of pure metallic gold release gold ions which do not spread in the body, but are taken up by cells near the implant, we hypothesize that metallic gold could reduce local neuroinflammation in a safe way. Bio-liberation, or dissolucytosis, of gold ions from metallic gold surfaces requires the presence of disolycytes i.e. macrophages and the process is limited by their number and activity. We injected 20-45 mu m gold particles into the neocortex of mice before generating a cryo-injury. Comparing gold-treated and untreated cryolesions, the release of gold reduced microgliosis and neuronal apoptosis accompanied by a transient astrogliosis and an increased neural stem cell response. We conclude that bio-liberated gold ions possess pronounced anti-inflammatory and neuron-protective capacities in the brain and suggest that metallic gold has clinical potentials. Intra-cerebral application of metallic gold as a pharmaceutical source of gold ions represents a completely new medical concept that bypasses the blood-brain-barrier and allows direct drug delivery to inflamed brain tissue.	[Larsen, Agnete; Doering, Peter; Danscher, Gorm; Stoltenberg, Meredin] Univ Aarhus, Dept Neurobiol, Inst Anat, DK-8000 Aarhus C, Denmark; [Kolind, Kristian; Pedersen, Dan Sonne; Pedersen, Mie Ostergaard; Penkowa, Milena] Univ Copenhagen, Panum Inst, Sect Neuroprotect, DK-2200 Copenhagen, Denmark		Larsen, A (corresponding author), Univ Aarhus, Dept Neurobiol, Inst Anat, DK-8000 Aarhus C, Denmark.	al@neuro.au.dk		Larsen, Agnete/0000-0001-8765-8443			ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Aschner M, 2002, BRAIN PATHOL, V12, P475; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bondeson J, 1995, BIOCHEM PHARMACOL, V50, P1753, DOI 10.1016/0006-2952(95)02030-6; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Cai JL, 2002, DEV BIOL, V251, P221, DOI 10.1006/dbio.2002.0828; CHANG DM, 1990, J RHEUMATOL, V17, P1148; Danscher G, 2002, HISTOCHEM CELL BIOL, V117, P447, DOI 10.1007/s00418-002-0400-8; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; FELSON DT, 1990, ARTHRITIS RHEUM, V34, P1342; Ferre N, 2006, MINI-REV MED CHEM, V6, P1321, DOI 10.2174/138955706778993049; Futami T, 2000, J PERIODONTOL, V71, P287, DOI 10.1902/jop.2000.71.2.287; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Ihrie RA, 2008, CELL TISSUE RES, V331, P179, DOI 10.1007/s00441-007-0461-z; Kang MK, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-15; KOIKE R, 1994, MOL PHARMACOL, V46, P599; Larsen A, 2007, HISTOCHEM CELL BIOL, V128, P1, DOI 10.1007/s00418-007-0295-5; Mhatre M, 2004, J ALZHEIMERS DIS, V6, P147; MOGILNICKA EM, 1982, CHEM-BIOL INTERACT, V40, P247, DOI 10.1016/0009-2797(82)90104-1; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morshead CM, 2003, EUR J NEUROSCI, V18, P76, DOI 10.1046/j.1460-9568.2003.02727.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Okano H, 2007, J NEUROCHEM, V102, P1459, DOI 10.1111/j.1471-4159.2007.04674.x; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 2004, J NEUROSCI RES, V77, P35, DOI 10.1002/jnr.20154; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 1999, GLIA, V25, P343; PERSELLIN RH, 1966, ARTHRITIS RHEUM-US, V9, P57, DOI 10.1002/art.1780090107; Potashkin JA, 2006, ANTIOXID REDOX SIGN, V8, P144, DOI 10.1089/ars.2006.8.144; Roach P, 2007, J MATER SCI-MATER M, V18, P1263, DOI 10.1007/s10856-006-0064-3; Santos E, 2008, DEV NEUROBIOL, V68, P31, DOI 10.1002/dneu.20566; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; SENNERBY L, 1993, J MATER SCI-MATER M, V4, P494, DOI 10.1007/BF00120129; SHARMA RP, 1981, CLIN EXP PHARMACOL P, V8, P591, DOI 10.1111/j.1440-1681.1981.tb00771.x; Simard AR, 2004, NEUROREPORT, V15, P2305, DOI 10.1097/00001756-200410250-00001; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; TOZMAN ECS, 1987, MED TOXICOL ADV DRUG, V2, P177, DOI 10.1007/BF03259863; Turrin NP, 2006, MOL NEUROBIOL, V34, P221, DOI 10.1385/MN:34:3:221; Vaccarino FM, 2007, NEUROSCIENTIST, V13, P173, DOI 10.1177/1073858406298336; Van Raay TJ, 2001, DEV GENES EVOL, V211, P453, DOI 10.1007/s004270100174; Walton NM, 2006, GLIA, V54, P815, DOI 10.1002/glia.20419; YANNI G, 1994, ANN RHEUM DIS, V53, P315, DOI 10.1136/ard.53.5.315; Zhang RL, 2005, NEUROSCIENTIST, V11, P408, DOI 10.1177/1073858405278865	57	35	35	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0948-6143	1432-119X		HISTOCHEM CELL BIOL	Histochem. Cell Biol.	OCT	2008	130	4					681	692		10.1007/s00418-008-0448-1			12	Cell Biology; Microscopy	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Microscopy	344BT	WOS:000258901000006	18542984				2022-02-06	
J	Williams, TM; Sadjadi, J; Harken, AH; Victorino, GP				Williams, Trevor M.; Sadjadi, Javid; Harken, Alden H.; Victorino, Gregory P.			The Necessity to Assess Anticoagulation Status in Elderly Injured Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Anticoagulation; Warfarin; Elderly; Trauma; Mortality or outcome	PREINJURY WARFARIN USE; TRAUMA PATIENTS; IMPACT; MANAGEMENT; REHABILITATION; ADULTS	Background: The trauma literature is inconsistent in its conclusions and recommendations concerning the influence of oral anticoagulation on outcomes after injury. Some report worse outcomes, whereas others showed no effect. We approached this problem by using the patients' admission international normalized ratio (INR) values to document anticoagulation and hypothesized that warfarin anticoagulation is associated with increased mortality after trauma in the elderly. We further questioned the cost-effectiveness of admission INR testing. MethodS: We conducted a retrospective review of 3,242 trauma patients aged 50 and older. INR data were used as a surrogate for warfarin anticoagulation and was related to age, sex, and Injury Severity Scale score (ISS) to analyze effects on mortality. Logistic regression was used to perform multivariate analyses. INR costs were summed from all laboratory department costs. Results: Of the 3,242 elderly injured patients, admission INR was obtained in 1,251 patients. One hundred and two patients had an "elevated" JNR of >1.5. Mortality for those with an INR >1.5 was 22.6%, versus 8.2% for those with an INR <1.5 (p < 0.0001). The logistic regression gave an age and ISS adjusted odds of death of 30% for a one unit increase in INR (OR 1.3, 95% CI 1.1-1.5; p value 0.002). This correlates to an age and injury score adjusted odds of death of 2.5 for an INR > 1.5 (95% Cl 1.2-4.2; p value 0.014). INR cost was estimated at $5 per blood draw. Conclusion: After adjusting for age, gender, and ISS, anticoagulation was associated with increased overall mortality. Elderly patients are commonly anticoagulated and anticoagulation is a therapeutically reversible risk factor. Considering the increasing number of indications for and prevalence of anticoagulation, the low cost of an INR and the potential reduction in costs associated with traumatic brain injury, these data support the recommendation to assess a coagulation profile in elderly trauma patients to identify earlier those in need of closer monitoring and a more aggressive reversal of their anticoagulation.	[Williams, Trevor M.; Sadjadi, Javid; Harken, Alden H.; Victorino, Gregory P.] UCSF E Bay, Dept Surg, Alameda Cty Med Ctr, Oakland, CA 94602 USA		Victorino, GP (corresponding author), UCSF E Bay, Dept Surg, Alameda Cty Med Ctr, 1411 E 31st St, Oakland, CA 94602 USA.	victorinog@surgery.ucsf.edu					Chu UB, 1996, AM J SURG, V172, P558, DOI 10.1016/S0002-9610(96)00234-6; CHU UB, 1996, AM J SURG, V172, P562; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Heit JA, 2001, J THROMB THROMBOLYS, V12, P81, DOI 10.1023/A:1012746729537; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sachdev GP, 1999, AM J HEALTH-SYST PH, V56, P1505, DOI 10.1093/ajhp/56.15.1505; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; Scalea TM, 1990, J TRAUMA, V30, P134; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4; *US BUR CENS, 2000, INT PROJ; Wahl WL, 2001, J TRAUMA, V51, P1151; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	17	35	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2008	65	4					772	777		10.1097/TA.0b013e3181877ff7			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	361JS	WOS:000260124500006	18849789				2022-02-06	
J	Bikle, DD				Bikle, D. D.			Integrins, insulin like growth factors, and the skeletal response to load	OSTEOPOROSIS INTERNATIONAL			English	Article						bone; IGF; integrin; mechanical load; osteoblast; osteoclast	I IGF-I; UNLOADING INDUCES RESISTANCE; MESENCHYMAL STEM-CELLS; FOCAL ADHESION KINASE; SMOOTH-MUSCLE-CELLS; BONE-FORMATION; SIMULATED WEIGHTLESSNESS; ALPHA-V-BETA-3 INTEGRIN; PARATHYROID-HORMONE; OSTEOBLASTIC CELLS	Bone loss during skeletal unloading, whether due to neurotrauma resulting in paralysis or prolonged immobilization due to a variety of medical illnesses, accelerates bone loss. In this review the evidence that skeletal unloading leads to bone loss, at least in part, due to disrupted insulin like growth factor (IGF) signaling, resulting in reduced osteoblast proliferation and differentiation, will be examined. The mechanism underlying this disruption in IGF signaling appears to involve integrins, the expression of which is reduced during skeletal unloading. Integrins play an important, albeit not well defined, role in facilitating signaling not only by IGF but also by other growth factors. However, the interaction between selected integrins such as alpha upsilon beta 3 and beta 1 integrins and the IGF receptor are of especial importance with respect to the ability of bone to respond to mechanical load. Disruption of this interaction blocks IGF signaling and results in bone loss.	[Bikle, D. D.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Bikle, D. D.] Vet Affairs Med Ctr, Special Diagnost & Treatment Ctr, San Francisco, CA 94121 USA		Bikle, DD (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	Daniel.bikle@ucsf.edu			NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR055924] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK054793, R01 DK54793] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR055924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK054793] Funding Source: NIH RePORTER		ABRAM AC, 1988, J BIOMECH, V21, P755, DOI 10.1016/0021-9290(88)90284-9; Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021-9290(00)00231-1; Bikle D, 2001, J BONE MINER RES, V16, P2320, DOI 10.1359/jbmr.2001.16.12.2320; BIKLE DD, 1987, ENDOCRINOLOGY, V120, P678, DOI 10.1210/endo-120-2-678; BIKLE DD, 1994, AM J PHYSIOL-ENDOC M, V267, pE822, DOI 10.1152/ajpendo.1994.267.6.E822; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Boudignon BM, 2007, J APPL PHYSIOL, V103, P125, DOI 10.1152/japplphysiol.00111.2007; Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200; CANALIS E, 1985, CLIN ORTHOP RELAT R, P246; Carvalho RS, 2002, J CELL BIOCHEM, V84, P497; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; Cowles EA, 2000, J BIOMED MATER RES, V52, P725, DOI 10.1002/1097-4636(20001215)52:4<725::AID-JBM18>3.0.CO;2-O; Dufour C, 2007, EXP CELL RES, V313, P394, DOI 10.1016/j.yexcr.2006.10.021; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Fujihara S, 2006, J BONE MINER RES, V21, P956, DOI 10.1359/JBMR.060315; GARETTO LP, 1990, FASEB J, V4, P24, DOI 10.1096/fasebj.4.1.2295374; Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GLOBUS RK, 1984, ENDOCRINOLOGY, V114, P2264, DOI 10.1210/endo-114-6-2264; Globus RK, 1998, J CELL SCI, V111, P1385; GLOBUS RK, 1986, ENDOCRINOLOGY, V118, P733, DOI 10.1210/endo-118-2-733; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756-3282(00)00424-5; HALLORAN BP, 1986, ENDOCRINOLOGY, V118, P948, DOI 10.1210/endo-118-3-948; HALLORAN BP, 1988, AM J PHYSIOL, V255, pE875, DOI 10.1152/ajpendo.1988.255.6.E875; Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105-2896.2005.00335.x; Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661; Iwaniec UT, 2005, J APPL PHYSIOL, V98, P690, DOI 10.1152/japplphysiol.00689.2004; JEE WSS, 1983, AM J PHYSIOL, V244, pR310, DOI 10.1152/ajpregu.1983.244.3.R310; Jiang J, 2006, BONE, V39, P494, DOI 10.1016/j.bone.2006.02.068; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; Kaiser E, 2001, J CELL BIOCHEM, V83, P617, DOI 10.1002/jcb.1256; Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200; KIDDER LS, 1990, BONE MINER, V11, P305, DOI 10.1016/0169-6009(90)90027-D; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kostenuik PJ, 1999, J BONE MINER RES, V14, P21, DOI 10.1359/jbmr.1999.14.1.21; Kostenuik PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE1133; Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017; LANYON LE, 1984, J BIOMECH, V17, P897, DOI 10.1016/0021-9290(84)90003-4; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; LEBLANC A, 1985, J APPL PHYSIOL, V58, P1669, DOI 10.1152/jappl.1985.58.5.1669; Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002-220821; Liedert A, 2006, BIOCHEM BIOPH RES CO, V349, P1, DOI 10.1016/j.bbrc.2006.07.214; Long RK, 2005, J BONE MINER RES, V20, pS250; MACHWATE M, 1993, AM J PHYSIOL, V264, pE790, DOI 10.1152/ajpendo.1993.264.5.E790; Maile LA, 2006, MOL ENDOCRINOL, V20, P405, DOI 10.1210/me.2005-0241; Maile LA, 2001, J CELL SCI, V114, P1417; Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611; Meyers VE, 2004, J CELL BIOCHEM, V93, P697, DOI 10.1002/jcb.20229; Miura Y, 2005, P NATL ACAD SCI USA, V102, P14022, DOI 10.1073/pnas.0409397102; Mizuno M, 2000, J CELL PHYSIOL, V184, P207, DOI 10.1002/1097-4652(200008)184:2<207::AID-JCP8>3.0.CO;2-U; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706; Moursi AM, 1997, J CELL SCI, V110, P2187; Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004-2126; OGANOV VS, 1991, ACTA ASTRONAUT, V23, P129, DOI 10.1016/0094-5765(91)90109-I; PATTERSONBUCKENDAHL P, 1989, AM J PHYSIOL, V257, pR1103; Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284; Pistone M, 1996, CELL BIOL INT, V20, P471, DOI 10.1006/cbir.1996.0062; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756-3282(96)00260-8; Reijnders CMA, 2007, J ENDOCRINOL, V192, P131, DOI 10.1677/joe.1.06880; Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545; Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721; Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105-2896.2005.00331.x; Sakata T, 2004, J BONE MINER RES, V19, P436, DOI 10.1359/JBMR.0301241; Sakata T, 2003, BONE, V32, P669, DOI 10.1016/S8756-3282(03)00088-7; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; SHAW SR, 1987, J BIOMECH, V20, P225, DOI 10.1016/0021-9290(87)90289-2; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; TURNER CH, 1995, AM J PHYSIOL-ENDOC M, V269, pE438, DOI 10.1152/ajpendo.1995.269.3.E438; TURNER RT, 1995, AVIAT SPACE ENVIR MD, V66, P770; VICO L, 1988, AM J PHYSIOL, V255, pR243, DOI 10.1152/ajpregu.1988.255.2.R243; VICO L, 1992, J BONE MINER RES, V7, pS445, DOI 10.1002/jbmr.5650071415; VICO L, 1991, AVIAT SPACE ENVIR MD, V62, P26; Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104; Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517; Wang YM, 2006, J BONE MINER RES, V21, P1350, DOI 10.1359/JBMR.060610; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; WRONSKI TJ, 1983, AM J PHYSIOL, V244, pR305, DOI 10.1152/ajpregu.1983.244.3.R305; YAGODOVSKY VS, 1976, AVIAT SPACE ENVIR MD, V47, P734; Zerath E, 1991, Physiologist, V34, pS194; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633; Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083	96	35	38	0	5	SPRINGER LONDON LTD	ARTINGTON	ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP, GUILDFORD, ENGLAND	0937-941X			OSTEOPOROSIS INT	Osteoporosis Int.	SEP	2008	19	9					1237	1246		10.1007/s00198-008-0597-z			10	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	336XX	WOS:000258401200003	18373051				2022-02-06	
J	Fleming, J; Riley, L; Gill, H; Gullo, MJ; Strong, J; Shum, D				Fleming, Jennifer; Riley, Lee; Gill, Hannah; Gullo, Matthew J.; Strong, Jenny; Shum, David			Predictors of prospective memory in adults with traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						memory deficits; intention; neuropsychological tests; chronic brain injury; rehabilitation; outpatients	CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; SELF-AWARENESS; NORMATIVE DATA; PERFORMANCE; REHABILITATION; DEFICITS; REMEDIATION; RELIABILITY; PROGRAM	Previous studies have established that prospective memory is commonly affected following traumatic brain injury (TBI). This study examines whether demographic factors, injury severity and site, executive function, and metacognitive factors predict prospective memory performance in adults with TBI, using a cross-sectional multivariate correlational model. Prospective memory of 44 adults (mean age = 30 years) with severe TBI was measured by the Cambridge Prospective Memory Test (CAMPROMPT) time-based and event-based scores. Using stepwise multiple regression, the time-based score was predicted by the Controlled Oral Word Association Test (COWAT) Animals subtest score, length of post-traumatic amnesia (PTA) and use of note-taking on the CAMPROMPT. The event-based score was predicted by length of PTA and COWAT Animals score. Therefore, patients with longer periods of PTA and executive function impairment may be expected to display poorer prospective memory. Note-taking was associated with improved performance on time-based prospective memory tasks.	[Fleming, Jennifer; Riley, Lee; Gill, Hannah; Strong, Jenny] Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Gill, Hannah; Gullo, Matthew J.; Shum, David] Griffith Univ, Appl Cognit Neurosci Res Ctr, Brisbane, Qld 4111, Australia; [Gullo, Matthew J.; Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia		Fleming, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia.	j.fleming@uq.edu.au	Fleming, Jennifer M/B-4436-2011; Strong, Jenny/F-1211-2010; Gullo, Matthew/C-3850-2008; Gullo, Hannah/C-5011-2008; Shum, David/A-3914-2008	Strong, Jenny/0000-0002-9367-8755; Gullo, Matthew/0000-0003-3657-5191; Shum, David/0000-0002-4810-9262; GULLO, Hannah/0000-0003-4238-4033	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [288002]	This research was funded by a National Health and Medical Research Council (NHMRC) Project grant (ID No. 288002).	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; GEFFEN G, 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Levine B., 2002, PRINCIPLES FRONTAL L, P51; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Neulinger K., 2002, BRAIN IMPAIR, V3, P1, DOI [10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Otani H, 1997, MEMORY, V5, P343, DOI 10.1080/741941393; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Palmer HM, 2000, BRAIN COGNITION, V44, P103; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wechsler D., 2011, WECHSLER ABBREVIATED; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; Wilson B., 2005, CAMBRIDGE PROSPECTIV	46	35	37	1	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2008	14	5					823	831		10.1017/S1355617708080971			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	354DZ	WOS:000259620400012	18764977	Green Published, Bronze			2022-02-06	
J	Falo, MC; Reeves, TM; Phillips, LL				Falo, M. Cristina; Reeves, Thomas M.; Phillips, Linda L.			Agrin expression during synaptogenesis induced by traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						extracellular matrix; neuroplasticity; traumatic brain injury	HEPARAN-SULFATE PROTEOGLYCAN; CULTURED HIPPOCAMPAL-NEURONS; ADULT-RAT BRAIN; EXTRACELLULAR-MATRIX; SYNAPTIC PLASTICITY; ACETYLCHOLINE-RECEPTORS; ORGANIZING PROTEIN; NERVOUS-SYSTEM; DEFICIENT MICE; MESSENGER-RNA	Interaction between extracellular matrix proteins and regulatory proteinases can mediate synaptic integrity. Previously, we documented that matrix metalloproteinase 3 (MMP-3) expression and activity increase following traumatic brain injury (TBI). We now report protein and mRNA analysis of agrin, a MMP- 3 substrate, over the time course of trauma-induced synaptogenesis. Agrin expression during the successful synaptic reorganization of unilateral entorhinal cortical lesion (UEC) was compared with expression when normal synaptogenesis fails (combined fluid percussion TBI and bilateral entorhinal lesion [BEC]). We observed that agrin protein was increased in both models at 2 and 7 days postinjury, and immuohistochemical (IHC) co-localization suggested reactive astrocytes contribute to that increase. Agrin formed defined boundaries for sprouting axons along deafferented dendrites in the UEC, but failed to do so after combined insult. Similarly, Western blot analysis revealed greater increase in UEC agrin protein relative to the combined TBI + BEC model. Both models showed increased agrin transcription at 7 days postinjury and mRNA normalization by 15 days. Attenuation of synaptic pathology with the NMDA antagonist MK-801 reduced 7-day UEC agrin transcript to a level not different from unlesioned controls. By contrast, MK-801 in the combined insult failed to significantly change 7-day agrin transcript, mRNA levels remaining elevated over uninjured sham cases. Together, these results suggest that agrin plays an important role in the sprouting phase of reactive synaptogenesis, and that both its expression and distribution are correlated with extent of successful recovery after TBI. Further, when pathogenic conditions which induce synaptic plasticity are reduced, increase in agrin mRNA is attenuated.	[Falo, M. Cristina; Reeves, Thomas M.; Phillips, Linda L.] Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Phillips, LL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	llphilli@vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS044372, R56NS044372] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS-047463, NS-44372, R01 NS044372] Funding Source: Medline		Bergstrom RA, 2007, NEUROSCIENCE, V149, P527, DOI 10.1016/j.neuroscience.2007.08.017; Bose CM, 2000, J NEUROSCI, V20, P9086; BRINES ML, 1993, BRAIN RES, V631, P1, DOI 10.1016/0006-8993(93)91179-V; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; Burgess RW, 2000, J CELL BIOL, V151, P41, DOI 10.1083/jcb.151.1.41; Cohen-Cory S, 2002, SCIENCE, V298, P770, DOI 10.1126/science.1075510; Cotman SL, 1999, EXP CELL RES, V249, P54, DOI 10.1006/excr.1999.4463; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Ferreira A, 1999, J CELL SCI, V112, P4729; Frotscher M, 2006, CELL TISSUE RES, V326, P361, DOI 10.1007/s00441-006-0269-2; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; Halfter W, 1997, J COMP NEUROL, V383, P1; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; Hilgenberg LGW, 2002, MOL CELL NEUROSCI, V19, P97, DOI 10.1006/mcne.2001.1056; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim MJ, 2003, J NEUROBIOL, V55, P261, DOI 10.1002/neu.10213; Koulen P, 1999, EUR J NEUROSCI, V11, P4188, DOI 10.1046/j.1460-9568.1999.00848.x; Kroger S, 2002, NEWS PHYSIOL SCI, V17, P207, DOI 10.1152/01390.2002; Kroger S, 1996, EUR J NEUROSCI, V8, P500, DOI 10.1111/j.1460-9568.1996.tb01234.x; Lesuisse C, 2000, MOL BRAIN RES, V81, P92, DOI 10.1016/S0169-328X(00)00161-3; Li Z, 1999, J NEUROBIOL, V39, P547, DOI 10.1002/(SICI)1097-4695(19990615)39:4<547::AID-NEU8>3.0.CO;2-C; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; Mantych KB, 2001, J NEUROSCI, V21, P6802, DOI 10.1523/JNEUROSCI.21-17-06802.2001; McCroskery S, 2006, MOL CELL NEUROSCI, V33, P15, DOI 10.1016/j.mcn.2006.06.004; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; OCONNOR LT, 1995, MOL BRAIN RES, V33, P277, DOI 10.1016/0169-328X(95)00147-K; OCONNOR LT, 1994, J NEUROSCI, V14, P1141, DOI 10.1523/JNEUROSCI.14-03-01141.1994; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Povlishock John T., 1995, P504; Reif R, 2007, FASEB J, V21, P3468, DOI 10.1096/fj.07-8800com; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Serpinskaya AS, 1999, DEV BIOL, V205, P65, DOI 10.1006/dbio.1998.9112; Smith MA, 2002, NEUROREPORT, V13, P1485, DOI 10.1097/00001756-200208270-00001; Sole S, 2004, J NEUROPATH EXP NEUR, V63, P338, DOI 10.1093/jnen/63.4.338; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; SZKLARCZYK A, 2002, J NEUROSCI, V267, P203; THOMAS WS, 1993, DEV BIOL, V158, P523, DOI 10.1006/dbio.1993.1210; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tournell CE, 2006, NEUROSCIENCE, V141, P1327, DOI 10.1016/j.neuroscience.2006.05.004; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; Yang JF, 2001, J NEUROSCI, V21, P9572, DOI 10.1523/JNEUROSCI.21-24-09572.2001; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618	55	35	35	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					769	783		10.1089/neu.2008.0511			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000005	18627255	Green Published			2022-02-06	
J	Colantonio, A; Kontos, PC; Gilbert, JE; Rossiter, K; Gray, J; Keightley, ML				Colantonio, Angela; Kontos, Pia C.; Gilbert, Julie E.; Rossiter, Kate; Gray, Julia; Keightley, Michelle L.			After the crash: Research-based theater for knowledge transfer	JOURNAL OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS			English	Article						education; continuing; brain injury theater; knowledge transfer; professional education; evaluation	TRAUMATIC BRAIN-INJURY; BREAST-CANCER; REFLECTIONS; FAMILY; STAGE	Introduction: The aim of this project was to develop and evaluate a research-based dramatic production for the purpose of transferring knowledge about traumatic brain injury (TBI) to health care professionals, managers, and decision makers. Methods: Using results drawn from six focus group discussions with key stakeholders (consumers, informal care-givers, and health care practitioners experienced in the field of TBI) and relevant scientific literature, a 50-minute play was produced for the purpose of conveying the experiences of TBI survivors, informal care providers, and health practitioners and best practice for TBI care. A self-administered postperformance survey was distributed to audience members at the end of four performances in Ontario, Canada, to evaluate the play's efficacy. Two hundred ninety-one questionnaires were completed. The questionnaire had five questions scored on a 5-item Likert scale with space for open-ended comments. Results: Consistently high mean scores from the questionnaires indicate that theater is a highly efficacious and engaging method of knowledge transfer, particularly for complex material that deals with human emotion and interpersonal relationships. Discussion: Responses supported the effectiveness of drama as a knowledge translation strategy and identified its potential to impact practice positively.	[Colantonio, Angela; Kontos, Pia C.] Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Kontos, Pia C.] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; [Gilbert, Julie E.] Univ Toronto, Canc Care Ontario, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada		Colantonio, A (corresponding author), Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765; Kontos, Pia/0000-0002-8893-2544	Health Care, Technology, and Place (HCTP); Canadian Institutes for Health Research [CIHR]Canadian Institutes of Health Research (CIHR); Strategic Alliance Fund; Ontario Rehabilitation Research Network; Toronto Rehabilitation InstituteUniversity of Toronto; Ontario Work Study Program; Ministry of Health and Long-Term Care in OntarioMinistry of Health and Long-Term Care, Ontario	We Would like to acknowledge and thank these institutions for financial support for this project: Health Care, Technology, and Place (HCTP): An Interdisciplinary Capacity Enhancement Team (Institute of Health Services and Policy Research-Canadian Institutes for Health Research [CIHR]), Strategic Alliance Fund (The Change Foundation and HCTP), the Ontario Rehabilitation Research Network, the Toronto Rehabilitation Institute, and the Ontario Work Study Program. Toronto Rehabilitation Institute receives funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long-Term Care in Ontario. We wish to thank all the many participants. organizations, and artistic team who contributed to this project.	BATES B, 1988, WAY ACTOR PATH KNOWL; COLANTONIO A, 2006, WORLD FED OCC THER C; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; Crisp R., 1993, DISABIL HANDICAP SOC, V8, P393, DOI DOI 10.1080/02674649366780371; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; GRAY J, 2006, CRASH PLAY BRA UNPUB; GRAY R, 2002, STANDING OVATION; Gray RE, 2003, J CANCER EDUC, V18, P223, DOI 10.1207/s15430154jce1804_10; Gray RE, 2002, ETHNOGR ALT BOOK SER, V9, P57; Gray RE, 2003, QUAL INQ, V9, P254, DOI 10.1177/1077800402250957; Gray RE, 2001, HEALTH, V5, P233, DOI 10.1177/136345930100500205; Gray Ross, 2000, Health Expect, V3, P137, DOI 10.1046/j.1369-6513.2000.00071.x; Gray Ross, 2003, QUALITATIVE RES, V3, P284; Hagen U., 1973, RESPECT ACTING; Hobson S. J. G., 1999, CLIENT CTR PRACTICE, P51; Jackson A, 2005, J AESTHET EDUC, V39, P104; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; KONTOS R, 2006, QUAL RES, V6, P301; Levy J, 2005, J AESTHET EDUC, V39, P20, DOI 10.1353/jae.2005.0042; Lorenz KA, 2004, ACAD MED, V79, P481, DOI 10.1097/00001888-200405000-00020; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Mienczakowski J, 1999, STUD EDUC ETHNOG, V2, P145; Mienczakowski J., 1995, QUALITATIVE INQUIRY, V1, P360, DOI DOI 10.1177/107780049500100306; Mienczakowski Jim., 2001, HDB ETHNOGRAPHY, P468, DOI 10.4135/9781848608337.n32; Mitchell GJ, 2006, NURS SCI QUART, V19, P198, DOI 10.1177/0894318406289878; Morgan DL., 1998, FOCUS GROUP KIT; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Rosenbaum ME, 2005, MED EDUC, V39, P622, DOI 10.1111/j.1365-2929.2005.02181.x; Rossiter K, 2008, SOC SCI MED, V66, P130, DOI 10.1016/j.socscimed.2007.07.021; Rossiter K, 2008, J HEALTH PSYCHOL, V13, P277, DOI 10.1177/1359105307086707; Saldana J, 2003, QUAL INQ, V9, P218, DOI 10.1177/1077800402250932; Saldana J., 1998, RES DRAMA ED, V3, P181, DOI [10.1080/1356978980030205, DOI 10.1080/1356978980030205]; Salverson J, 2001, THEATER, V31, P118; Sinding C, 2002, QUAL HEALTH RES, V12, P61, DOI 10.1177/104973230201200105; Strauss A., 1994, HDB QUALITATIVE RES, V17, P273, DOI DOI 10.1007/BF00988593; Sumsion T, 1999, CLIENT CTR PRACTICE, P1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TURK M, 2006, BRAIN INJURY MED PRI, P227; Wilkins S, 2001, Can J Occup Ther, V68, P70	40	35	36	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-1912	1554-558X		J CONTIN EDUC HEALTH	J. Contin. Educ. Health Prof.	SUM	2008	28	3					180	185		10.1002/chp.177			6	Education, Scientific Disciplines; Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Education & Educational Research; Health Care Sciences & Services	348VP	WOS:000259238500009	18712795				2022-02-06	
J	Lu, J; Murray, GD; Steyerberg, EW; Butcher, I; Mchugh, GS; Lingsma, H; Mushkudiani, N; Choi, S; Maas, AIR; Marmarou, A				Lu, Juan; Murray, Gordon D.; Steyerberg, Ewout W.; Butcher, Isabella; Mchugh, Gillian S.; Lingsma, Hester; Mushkudiani, Nino; Choi, Sung; Maas, Andrew I. R.; Marmarou, Anthony			Effects of Glasgow Outcome Scale misclassification on traumatic brain injury clinical trials	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; Glasgow Outcome Scale; misclassifications; observer variation; power; traumatic brain injury	SEVERE HEAD-INJURY; STRUCTURED INTERVIEWS; RELIABILITY; EXPERIENCE; MULTICENTER; GUIDELINES; MANAGEMENT	The Glasgow Outcome Scale (GOS) is the primary endpoint for efficacy analysis of clinical trials in traumatic brain injury (TBI). Accurate and consistent assessment of outcome after TBI is essential to the evaluation of treatment results, particularly in the context of multicenter studies and trials. The inconsistent measurement or interobserver variation on GOS outcome, or for that matter, on any outcome scales, may adversely affect the sensitivity to detect treatment effects in clinical trial. The objective of this study is to examine effects of nondifferential misclassification of the widely used five-category GOS outcome scale and in particular to assess the impact of this misclassification on detecting a treatment effect and statistical power. We followed two approaches. First, outcome differences were analyzed before and after correction for misclassification using a dataset of 860 patients with severe brain injury randomly sampled from two TBI trials with known differences in outcome. Second, the effects of misclassification on outcome distribution and statistical power were analyzed in simulation studies on a hypothetical 800-patient dataset. Three potential patterns of nondifferential misclassification (random, upward and downward) on the dichotomous GOS outcome were analyzed, and the power of finding treatments differences was investigated in detail. All three patterns of misclassification reduce the power of detecting the true treatment effect and therefore lead to a reduced estimation of the true efficacy. The magnitude of such influence not only depends on the size of the misclassification, but also on the magnitude of the treatment effect. In conclusion, nondifferential misclassification directly reduces the power of finding the true treatment effect. An awareness of this procedural error and methods to reduce misclassification should be incorporated in TBI clinical trials.	[Lu, Juan; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Choi, Sung] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Steyerberg, Ewout W.; Lingsma, Hester; Mushkudiani, Nino] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands; [Murray, Gordon D.; Butcher, Isabella; Mchugh, Gillian S.] Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium		Marmarou, A (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980508, Richmond, VA 23298 USA.	marmarou@vcu.edu	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Lu, Juan/0000-0002-5389-7603; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 019235-21, NS 042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691, R01NS019235, R56NS019235] Funding Source: NIH RePORTER		Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BULLOCK MR, 2002, FOCUS, V13, pECP1; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Marmarou A., 2001, HEAD TRAUMA BASIC PR; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	20	35	35	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					641	651		10.1089/neu.2007.0510			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900007	18578634	Green Submitted, Green Published			2022-02-06	
J	Tata, DA; Yamamoto, BK				Tata, Despina A.; Yamamoto, Bryan K.			Chronic stress enhances methamphetamine-induced extracellular glutamate and excitotoxicity in the rat striatum	SYNAPSE			English	Article						spectrin proteolysis; glucocorticoids; metyrapone; dopamine transporter; serotonin transporter	EXCITATORY AMINO-ACIDS; COCAINE-INDUCED LOCOMOTION; NUCLEUS-ACCUMBENS SHELL; TRAUMATIC BRAIN-INJURY; CHRONIC MILD STRESS; ALPHA-II-SPECTRIN; LONG-TERM; INDUCED NEUROTOXICITY; CORTICOSTERONE SYNTHESIS; MONOAMINE DEPLETIONS	Striking parallels exist between the neurochemical and toxic effects of stress and methamphetamine. Despite these similarities, no studies have examined how stress may promote the toxic effects of methamphetamine (METH). The current study tested the hypothesis that chronic stress enhances METH toxicity by augmenting glutamate (GLU) release and excitotoxicity in response to METH administration. Adult male Sprague-Dawley rats were exposed to 10 days of unpredictable stress and then received either saline or METH (7.5 mg/kg, i.p., once every 2 h x four injections). Prior exposure to unpredictable stress acutely enhanced the striatal extracellular GLU concentrations in response to METH, and eventually caused proteolysis of the cytoskeleton protein spectrin. Administration of the corticosterone synthesis inhibitor, metyrapone (25 mg/kg, i.p., prior to each stressor), during unpredictable stress attenuated the enhanced striatal GLU release in response to METH, blocked spectrin proteolysis, and attenuated METH-associated toxicity measured by long-term depletions in the dopamine and serotonin tissue content as well as depletions in dopamine and serotonin transporter immunoreactivity of the striatum. In summary, prior exposure to unpredictable stress enhances METH-induced elevations of GLU in the striatum, resulting in long-term excitotoxic damage and an augmentation of damage to dopamine and serotonin terminals. These studies provide a neurochemical basis for how stress contributes to the deleterious effects of METH abuse.	[Tata, Despina A.; Yamamoto, Bryan K.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Neurochem Lab, Boston, MA 02118 USA		Yamamoto, BK (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Neurochem Lab, L-613,715 Albany St, Boston, MA 02118 USA.	bkyam@bu.edu	Tata, Despina A./AAH-5300-2020; Yamamoto, Bryan/Z-1050-2019	Tata, Despina A./0000-0001-5563-4017; 	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA16866, DA07606, R01 DA016866, R01 DA007606] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA007606, R01DA016866] Funding Source: NIH RePORTER		ABEKAWA T, 1994, BRAIN RES, V643, P276, DOI 10.1016/0006-8993(94)90033-7; Araujo APN, 2003, BEHAV BRAIN RES, V139, P75, DOI 10.1016/S0166-4328(02)00088-8; ARMANINI MP, 1990, BRAIN RES, V532, P7, DOI 10.1016/0006-8993(90)91734-X; BAKHIT C, 1981, NEUROSCI LETT, V23, P99, DOI 10.1016/0304-3940(81)90194-4; Bielajew C, 2002, BEHAV BRAIN RES, V136, P583, DOI 10.1016/S0166-4328(02)00222-X; BIRON D, 1992, NEUROENDOCRINOLOGY, V55, P468, DOI 10.1159/000126158; Broom SL, 2005, PSYCHOPHARMACOLOGY, V181, P467, DOI 10.1007/s00213-005-0007-6; Brown PJ, 1998, J SUBST ABUSE TREAT, V15, P445, DOI 10.1016/S0740-5472(97)00286-9; Burrows KB, 1999, NEUROSCIENCE, V90, P833, DOI 10.1016/S0306-4522(98)00506-5; Calvo N, 1998, BRAIN RES, V800, P227, DOI 10.1016/S0006-8993(98)00515-0; Clemens KJ, 2005, NEUROPHARMACOLOGY, V49, P195, DOI 10.1016/j.neuropharm.2005.03.002; Cordero MI, 2002, STRESS, V5, P71, DOI 10.1080/102538902900124404; Czyrak A, 1997, NEUROSCIENCE, V79, P489, DOI 10.1016/S0306-4522(96)00649-5; Daberkow DP, 2005, PHARMACOL BIOCHEM BE, V81, P198, DOI 10.1016/j.pbb.2005.03.010; Dal-Zotto S, 2003, PSYCHONEUROENDOCRINO, V28, P992, DOI 10.1016/S0306-4530(02)00120-8; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; Deng XL, 2007, BIOL PSYCHIAT, V61, P1235, DOI 10.1016/j.biopsych.2006.09.010; Deng XL, 2002, NEUROPHARMACOLOGY, V42, P837, DOI 10.1016/S0028-3908(02)00034-5; Der-Avakian A, 2006, PSYCHONEUROENDOCRINO, V31, P653, DOI 10.1016/j.psyneuen.2006.02.004; Dziedzicka-Wasylewska M, 1997, BEHAV PHARMACOL, V8, P607, DOI 10.1097/00008877-199711000-00017; Eyerman DJ, 2005, J PHARMACOL EXP THER, V312, P160, DOI 10.1124/jpet.104.072264; Friedman SD, 1998, PHARMACOL BIOCHEM BE, V61, P35, DOI 10.1016/S0091-3057(98)00066-5; HERMAN JP, 1995, NEUROENDOCRINOLOGY, V61, P180, DOI 10.1159/000126839; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; Kita T, 2003, J PHARMACOL SCI, V92, P178; Liu L, 1999, BRAIN RES, V821, P134, DOI 10.1016/S0006-8993(99)01085-9; LOWY MT, 1993, J NEUROCHEM, V61, P1957, DOI 10.1111/j.1471-4159.1993.tb09839.x; LOWY MT, 1995, J NEUROCHEM, V65, P268; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P89, DOI 10.1016/0306-4522(95)00259-L; Marinelli M, 1996, BRAIN RES, V724, P251, DOI 10.1016/0006-8993(96)00309-5; Mark KA, 2004, J NEUROSCI, V24, P11449, DOI 10.1523/JNEUROSCI.3597-04.2004; Matuszewich L, 2004, NEUROSCIENCE, V124, P637, DOI 10.1016/j.neuroscience.2003.12.007; MOGHADDAM B, 1994, BRAIN RES, V655, P251, DOI 10.1016/0006-8993(94)91622-5; MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x; NASH JF, 1992, BRAIN RES, V581, P237, DOI 10.1016/0006-8993(92)90713-J; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; PIAZZA PV, 1994, BRAIN RES, V658, P259, DOI 10.1016/S0006-8993(09)90034-8; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Quinton MS, 2006, AAPS J, V8, pE337, DOI 10.1208/aapsj080238; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; SAMANTARAY S, 2006, ANN NY ACAD SCI, V74, P349; SIMAN R, 1989, J NEUROSCI, V9, P1579; Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917; Soderpalm A, 2003, PSYCHOPHARMACOLOGY, V170, P188, DOI 10.1007/s00213-003-1536-5; SONINO N, 1982, HORMONE ANTAGONISTS, P419; Sonsalla PK, 1996, BRAIN RES, V738, P172, DOI 10.1016/0006-8993(96)00995-X; SONSALLA PK, 1989, SCIENCE, V243, P398, DOI 10.1126/science.2563176; Staszewski RD, 2006, J NEUROCHEM, V96, P1267, DOI 10.1111/j.1471-4159.2005.03618.x; STEINBEHRENS B, 1994, J NEUROSCI, V14, P5373; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; STEINBEHRENS BA, 1992, J NEUROCHEM, V58, P1730, DOI 10.1111/j.1471-4159.1992.tb10047.x; STEPHANS SE, 1994, SYNAPSE, V17, P203, DOI 10.1002/syn.890170310; Straiko MMW, 2007, NEUROSCIENCE, V144, P223, DOI 10.1016/j.neuroscience.2006.08.073; TATA DA, 2005, CHRONIS STRESS ENHAN; Thiriet N, 2005, J NEUROSCI, V25, P5273, DOI 10.1523/JNEUROSCI.4893-04.2005; Venero C, 1999, EUR J NEUROSCI, V11, P2465, DOI 10.1046/j.1460-9568.1999.00668.x; WAGNER GC, 1980, BRAIN RES, V181, P151, DOI 10.1016/0006-8993(80)91265-2; Wallace TL, 2001, SYNAPSE, V39, P1, DOI 10.1002/1098-2396(20010101)39:1<1::AID-SYN1>3.0.CO;2-7; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; YAMAMOTO BK, 1990, BRAIN RES, V506, P236, DOI 10.1016/0006-8993(90)91256-G; Yu J, 2004, BRAIN RES, V1007, P124, DOI 10.1016/j.brainres.2004.01.077; Zhu JPQ, 2006, NEUROSCIENCE, V140, P607, DOI 10.1016/j.neuroscience.2006.02.055	65	35	38	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	MAY	2008	62	5					325	336		10.1002/syn.20497			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	284CA	WOS:000254681600002	18288648	Green Accepted			2022-02-06	
J	Utagawa, A; Bramlett, HM; Daniels, L; Lotocki, G; Dekaban, GA; Weaver, LC; Dietrich, WD				Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dekaban, Gregory A.; Weaver, Lynne C.; Dietrich, W. Dalton			Transient blockage of the CD11d/CD18 integrin reduces contusion volume and macrophage infiltration after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; microglia/macrophages; CD11d/CD18 integrin; adhesion molecules; inflammation; histopathology	INTERCELLULAR-ADHESION MOLECULE-1; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; FLUID-PERCUSSION INJURY; TNF-ALPHA; INFLAMMATORY RESPONSE; BARRIER DYSFUNCTION; IMPROVED RECOVERY; MICE DEFICIENT; CELL-DEATH	The early inflammatory response to traumatic brain injury (TBI) may result in secondary damage. The purpose of this study was to evaluate the effects of a transient treatment employing a blocking monoclonal antibody (mAb) to the CD11d/CD18 integrin on histopathological outcome and macrophage infiltration following TBI. A parasagittal fluid percussion (FP) brain injury (1.8-2.1 atm) was induced in male Sprague-Dawley rats. Rats were randomized into two trauma groups, treated (N = 7) and nontreated (N = 8) animals. In the treated group, a mAb to the CD11d subunit of the CD11d/CD18 integrin was administered 30 min, 24 and 48 h after brain injury. Control animals received an isotype-matched irrelevant mAb using the same dose and treatment regimen. At 3 days after TBI, animals were perfusion-fixed for histopathological and immunocytochemical analysis. The anti-CD11d mAb treatment reduced contusion areas as well as overall contusion volume compared to vehicle treated animals. For example, overall contusion volume was reduced from 2.7 +/- 0.5 mm(3) (mean +/- SEM) to 1.4 +/- 0.4 with treatment (p < 0.05). Immunocytochemical studies identifying CD68 immunoreactive macrophages showed that treatment caused significant attenuation of leukocyte infiltration into the contused cortical areas. These data emphasize the beneficial effects of blocking inflammatory cell recruitment into the injured brain on histopathological outcome following traumatic brain injury. (C) 2008 Elsevier B.V. All rights reserved.	[Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Neurotrauma Res Ctr, Miami, FL 33136 USA; [Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Dekaban, Gregory A.; Weaver, Lynne C.] Univ Western Ontario, Robarts Res Inst, Spinal Cord Injury Team, Biotherapeut Res Grp, London, ON, Canada		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu	Weaver, Lynne C/K-8491-2013; Dekaban, Gregory/L-1987-2013	Dekaban, Gregory/0000-0002-3087-4660	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042133, R01 NS042133, NS056072, R01 NS042133-05, P50 NS030291-15, R01 NS056072, NS030291, P50 NS030291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS056072, P50NS030291] Funding Source: NIH RePORTER		Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Becker Kyra J, 2002, Curr Med Res Opin, V18 Suppl 2, ps18, DOI 10.1185/030079902125000688; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Faxon DP, 2002, J AM COLL CARDIOL, V40, P1199, DOI 10.1016/S0735-1097(02)02136-8; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Grayson MH, 1999, INT ARCH ALLERGY IMM, V118, P263, DOI 10.1159/000024094; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamada Y, 1996, J NEUROCHEM, V66, P1525; LODDICK SA, 2002, IMMUN INFLAMM DIS, P90; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Shanley TP, 1998, J IMMUNOL, V160, P1014; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH CW, 1993, SEMIN HEMATOL, V30, P45; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Van der Vieren M, 1999, J IMMUNOL, V163, P1984; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Zausinger S, 2002, BRAIN RES PROTOC, V9, P112, DOI 10.1016/S1385-299X(02)00138-1; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZILLES L, 1985, CORTEX RAT STEREOTAX	54	35	35	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 1	2008	1207						155	163		10.1016/j.brainres.2008.02.057			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	299AW	WOS:000255729200016	18374312	Green Accepted			2022-02-06	
J	Carey, JC; Wade, SL; Wolfe, CR				Carey, Joanne C.; Wade, Shari L.; Wolfe, Christopher R.			Lessons learned: The effect of prior technology use on web-based interventions	CYBERPSYCHOLOGY & BEHAVIOR			English	Article							TRAUMATIC BRAIN-INJURY; PROBLEM-SOLVING INTERVENTION; COMPUTER ANXIETY; EFFICACY BELIEFS; CHILDREN; FAMILIES	This study examined the role of regular prior technology use in treatment response to an online family problem-solving (OFPS) intervention and an Internet resource intervention (IRI) for pediatric traumatic brain injury (TBI). Participants were 150 individuals in 40 families of children with TBI randomly assigned to OFPS intervention or an IRI. All families received free computers and Internet access to TBI resources. OFPS families received Web-based sessions and therapist-guided synchronous videoconferences focusing on problem solving, communication skills, and behavior management. All participants completed measures of depression, anxiety, and computer usage. OFPS participants rated treatment satisfaction, therapeutic alliance, and Web site and technology comfort. With the OFPS intervention, depression and anxiety improved significantly more among technology using parents (n = 14) than nontechnology users (n = 6). Technology users reported increasing comfort with technology over time, and this change was predictive of depression at followup. Satisfaction and ease-of-use ratings did not differ by technology usage. Lack of regular prior home computer usage and nonadherence were predictive of anxiety at followup. The IRI was not globally effective. However, controlling for prior depression, age, and technology at work, there was a significant effect of technology at home for depression. Families with technology experience at home (n = 11) reported significantly greater improvements in depression than families without prior technology experience at home (n = 8). Although Web-based OFPS was effective in improving caregiver functioning, individuals with limited computer experience may benefit less from an online intervention due to increased nonadherence.	[Carey, Joanne C.; Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat Rehabiliatat, Cincinnati, OH 45229 USA; [Wolfe, Christopher R.] Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA		Wade, SL (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Dept Pediat Rehabiliatat, 3333 Burnett Ave,MLC 4009, Cincinnati, OH 45229 USA.	Shari.Wade@cchmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD040942, HD40942-02] Funding Source: Medline		A Henry Suzanne Ball Ruth M Williams Lucy, 1998, J Ment Health, V7, P411, DOI 10.1080/09638239818012; Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; Brodie M, 2000, HEALTH AFFAIR, V19, P255, DOI 10.1377/hlthaff.19.6.255; Chua SL, 1999, COMPUT HUM BEHAV, V15, P609, DOI 10.1016/S0747-5632(99)00039-4; GLUECKAUF RL, 1997, AUDIOVISUAL EQUIPMEN; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Potosky D, 2002, COMPUT HUM BEHAV, V18, P241, DOI 10.1016/S0747-5632(01)00050-4; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Speilberger CD., 1983, STATE TRAIT ANXIETY; Stepankova O, 2006, METHOD INFORM MED, V45, P300; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; Wilfong JD, 2006, COMPUT HUM BEHAV, V22, P1001, DOI 10.1016/j.chb.2004.03.020; [No title captured], DOI DOI 10.1177/014662167700100306	20	35	37	0	18	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	APR	2008	11	2					188	195		10.1089/cpb.2007.0025			8	Communication; Psychology, Applied	Social Science Citation Index (SSCI)	Communication; Psychology	294SH	WOS:000255425300010	18422412	Green Accepted			2022-02-06	
J	Hu, X; Xu, P; Lee, DJ; Vespa, P; Baldwin, K; Bergsneider, M				Hu, Xiao; Xu, Peng; Lee, Darrin J.; Vespa, Paul; Baldwin, Kevin; Bergsneider, Marvin			An algorithm for extracting intracranial pressure latency relative to electrocardiogram R wave	PHYSIOLOGICAL MEASUREMENT			English	Article						intracranial pressure; pulse wave velocity; cerebrovascular resistance; cerebral blood flow autoregulation	ARTERIAL STIFFNESS; VELOCITY; DISEASE; ECG	Intracranial pressure ( ICP) latency is defined as the time interval between the peak of the QRS complex of the electrocardiogram ( ECG) and the corresponding onset of intracranial pressure ( ICP) pulse. Due to its inherent relationship with arterial pulse wave velocity, ICP latency may allow continuous monitoring of pathophysiological changes in the cerebrovasculature. The objective of the present work was to develop and validate a computerized algorithm for extracting ICP latency in a beat-by-beat fashion. The proposed ICP latency extraction algorithm exploits the mature technique of ECG QRS detection and includes a new adaptive peak detection methodology. The results were validated by comparing the performance of two human observers versus the algorithm in terms of locating the onset points of ICP pulses for 59 recordings extracted from 25 adult patients. The average ICP latency was 72.6 +/- 19.5 ms ( range 40.0-159.8). The ICP pulse detection algorithm demonstrated a baseline sensitivity of 0.97 and a positive predictivity of 0.88. No difference was found in the mean location errors from comparing the results obtained by the two observers and those from comparing the results from the algorithm to those from the two observers. Further investigation is needed to demonstrate the role of ICP latency in characterizing dynamic cerebral vascular pathophysiological changes in clinical states such as subarachnoid hemorrhage and traumatic brain injury.	[Hu, Xiao; Xu, Peng; Lee, Darrin J.; Vespa, Paul; Baldwin, Kevin; Bergsneider, Marvin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90095 USA; [Hu, Xiao; Bergsneider, Marvin] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Biomed Engn Grad Program, Los Angeles, CA USA; [Xu, Peng] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu 610054, Peoples R China		Hu, X (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS055045, R01NS054881, R21NS055998, R21NS059797] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21-NS054881, R21 NS059797, R21 NS055045, R01 NS054881, R21-NS055045, R21-NS055998, R21 NS055998-02, R21 NS055998, R01 NS054881-02, R21 NS055045-02, R21 NS059797-01A1] Funding Source: Medline		Aboy M, 2005, IEEE T BIO-MED ENG, V52, P1662, DOI 10.1109/TBME.2005.855725; Afonso VX, 1999, IEEE T BIO-MED ENG, V46, P192, DOI 10.1109/10.740882; Chang HK, 2006, ANN RHEUM DIS, V65, P415, DOI 10.1136/ard.2005.043430; CHIU YC, 1991, AM HEART J, V121, P1460, DOI 10.1016/0002-8703(91)90153-9; DALEY ML, 1982, NEUROSURGERY, V11, P617, DOI 10.1227/00006123-198211000-00005; Davies JI, 2003, J HYPERTENS, V21, P463, DOI 10.1097/00004872-200303000-00004; de Isla LP, 2006, J AM SOC ECHOCARDIOG, V19, P1338, DOI 10.1016/j.echo.2006.05.015; GILLER CA, 1994, ULTRASOUND MED BIOL, V20, P101, DOI 10.1016/0301-5629(94)90074-4; Hansen TW, 2006, CIRCULATION, V113, P664, DOI 10.1161/CIRCULATIONAHA.105.579342; Harrod CG, 2005, NEUROSURGERY, V56, P633, DOI 10.1227/01.NEU.0000156644.45384.92; Jadhav Uday M, 2005, Indian Heart J, V57, P226; Kohler BU, 2002, IEEE ENG MED BIOL, V21, P42, DOI 10.1109/51.993193; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; Nichols W. W., 2005, MCDONALDS BLOOD FLOW; Nichols WW, 2002, CURR OPIN CARDIOL, V17, P543, DOI 10.1097/00001573-200209000-00016; NYGARDS ME, 1983, MED BIOL ENG COMPUT, V21, P538, DOI 10.1007/BF02442378; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P3384, DOI 10.1161/CIRCULATIONAHA.104.483628	18	35	35	0	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0967-3334	1361-6579		PHYSIOL MEAS	Physiol. Meas.	APR	2008	29	4					459	471		10.1088/0967-3334/29/4/004			13	Biophysics; Engineering, Biomedical; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering; Physiology	285VJ	WOS:000254804000004	18354246	Green Accepted			2022-02-06	
J	Medved, MI; Brockmeier, J				Medved, Maria I.; Brockmeier, Jens			Continuity amid chaos: Neurotrauma, loss of memory, and sense of self	QUALITATIVE HEALTH RESEARCH			English	Article						neurotrauma; narrative; self; memory loss; brain injury	TRAUMATIC BRAIN-INJURY; AWARENESS; PEOPLE	In serious illness or disability, individuals commonly say that their sense of self has dramatically changed. One might expect that the experience of a radically altered sense of self would be even more profound in individuals after neuro-trauma because it is the brain itself that suddenly, and often literally, becomes "strange." The aim of this study was to investigate how people left with autobiographical memory impairments - impairments that also affect the capacity to organize complex linguistic productions such as autobiographical narratives - experience themselves and, specifically, their sense of self. Seven adults who had primarily anterograde memory impairments for 1 year were interviewed. Regardless of the profound changes in their everyday functioning and lives, the stories the participants told evoke a surprising sense of a continuous self. Employing several narrative and discursive techniques, they emphasized sameness and an unbroken connection between their pre- and post- morbid lives. We believe that most individuals felt they did not have to recover their former sense of self because they subjectively seemed to have never lost it.	[Medved, Maria I.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada; [Brockmeier, Jens] Free Univ Berlin, D-1000 Berlin, Germany; [Brockmeier, Jens] Univ E London, London E15 4LZ, England		Medved, MI (corresponding author), Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada.	medved@cc.umanitoba.ca					ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; Brockmeier J., 2001, NARRATIVE IDENTITY S, P39; Brockmeier Jens, 2001, NARRATIVE IDENTITY S, P25, DOI DOI 10.1075/SIN.1.03BRU; Croft SE, 1999, WESTERN J COMM, V63, P329, DOI 10.1080/10570319909374645; Eakin P.J., 1999, OUR LIVES BECOME STO; Frank, 1995, WOUNDED STORYTELLER; Goldstein K, 1995, ORGANISM HOLISTIC AP; Gregory R J, 1998, J Psychosoc Nurs Ment Health Serv, V36, P28; Hill H, 1999, BRAIN INJURY, V13, P839, DOI 10.1080/026990599121043; Leduc M, 1999, BRAIN COGNITION, V40, P174; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Medved Maria I, 2007, Psychol Health Med, V12, P603, DOI 10.1080/13548500601164404; Medved MI, 2006, MEMORY, V14, P276, DOI 10.1080/09658210500233524; Medved MI, 2004, QUAL HEALTH RES, V14, P741, DOI 10.1177/1049732304265972; MEDVED MI, 2008, CULTURE HLTH ILLNESS; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; POLLACK R, 1994, ED DIMENSIONS ACQUIR, V303, P371; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 2000, ARCH CLIN NEUROPSYCH, V15, P71, DOI 10.1016/S0887-6177(99)00021-9; PRIGATANO GP, 1997, DEPRESSION PHYS ILLN, P341; ROBINSON RG, 1987, STROKE, V17, P1102; Sabat, 2001, EXPERIENCE ALZHEIMER; SCHAFER R, 1992, RETELLING LIFE NARRA; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002	25	35	36	2	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323			QUAL HEALTH RES	Qual. Health Res.	APR	2008	18	4					469	479		10.1177/1049732308315731			11	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	279AH	WOS:000254326900004	18354046				2022-02-06	
J	Willemse-Van Son, AHP; Ribbers, GM; Hop, WCJ; van Duijn, CM; Stam, HJ				Willemse-van Son, A. H. P.; Ribbers, G. M.; Hop, W. C. J.; van Duijn, C. M.; Stam, H. J.			Association between apolipoprotein-epsilon 4 and long-term outcome after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; SHORT GENERIC VERSION; E POLYMORPHISM; GENOTYPE PREDICTS; APOE GENOTYPE; E EPSILON-4; NEUROGENESIS; GUIDELINES; RECOVERY; E4	Objectives: To investigate the effect of carrying the apolipoprotein epsilon 4 (APOE-epsilon 4) allele on global functional outcome, on activity limitations and participation restrictions, and on community integration at 3, 6, 12, 18, 24 and 36 months after traumatic brain injury. Method: The Glasgow Outcome Scale (GOS), the Sickness Impact Profile-68 (SIP-68) and the Community Integration Questionnaire (CIQ) were assessed in 79 moderate and severe traumatic brain injury patients at 3, 6, 12, 18, 24 and 36 months post injury. Repeated measures analyses of variance were performed with APOE-epsilon 4 status and time of measurement as independent variables and the GOS, SIP-68 and CIQ as dependent variables. Analyses were adjusted for baseline age, gender and Glasgow Coma Scale. Results: Patients with the APOE-epsilon 4 allele had a significantly better global functional outcome on the GOS than patients without the APOE-epsilon 4 allele. No significant associations were found between APOE-epsilon 4 status and the SIP-68 and CIQ. Discussion: In contrast to other studies, we found that carrying the APOE-epsilon 4 allele had a protective influence on outcome. Multiple mechanisms, and in some cases competitive mechanisms, may explain the variable relation between the APOE-epsilon 4 allele and outcome after traumatic brain injury.	[Willemse-van Son, A. H. P.; Ribbers, G. M.; Stam, H. J.] Erasmus MC, Dept Rehabil Med, Rotterdam, Netherlands; [Ribbers, G. M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Hop, W. C. J.; van Duijn, C. M.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands		Willemse-Van Son, AHP (corresponding author), Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.vanson-willemse@erasmusmc.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Chiang MF, 2003, ACTA NEUROCHIR WIEN, V145, P53; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P863, DOI 10.1016/0895-4356(94)90189-9; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levi O, 2007, J NEUROCHEM, V100, P202, DOI 10.1111/j.1471-4159.2006.04189.x; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SING CF, 1985, AM J HUM GENET, V37, P268; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WHO, 2002, INT CLASS FUNCT DIS; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE	45	35	36	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2008	79	4					426	430		10.1136/jnnp.2007.129460			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	275AP	WOS:000254044600018	17971433				2022-02-06	
J	Kobeissy, FH; Jeung, JA; Warren, MW; Geier, JE; Gold, MS				Kobeissy, Firas H.; Jeung, Jennifer A.; Warren, Matthew W.; Geier, Jacqueline E.; Gold, Mark S.			Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats	ADDICTION BIOLOGY			English	Article						ghrelin; growth hormone; leptin; MDMA; methamphetamine; neuropeptide-Y	TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; APPETITE SUPPRESSION; INDUCED NEUROTOXICITY; ARCUATE NUCLEUS; GENE-EXPRESSION; MESSENGER-RNA; SERUM LEPTIN; ECSTASY	Club drug abuse is a growing problem in the United States. Beyond addiction and toxicity are endocrine effects which are not well characterized. Specifically, the changes in appetite following exposure to drugs of abuse are an interesting but poorly understood phenomenon. Serum hormones such as leptin, ghrelin, growth hormone (GH), and neuropeptide-Y (NP-Y) are known to affect appetite, but have not been studied extensively with drugs of abuse. In this work, we examine the effects of club drugs 3,4-methylenedioxymethamphetamine (MDMA) (ecstasy) and methamphetamine (METH) (doses of 5, 20 and 40 mg/kg) on serum concentrations of these hormones in adult male Sprague-Dawley rats 6, 12, 24 and 48 hours after drug administration. In a dose-dependent manner, MDMA was shown to cause transient significant decreases in serum leptin and GH followed by a base line recovery after 24 hours. Conversely, serum ghrelin increased and normalized after 24 hours. Interestingly, serum NP-Y showed a steady decrease in both treatment of MDMA and METH at different time points and dosages. In humans, abuse of these drugs reduces eating. As evident from these data, acute administration of METH and MDMA had significant effects on different serum hormone levels involved in appetite regulation. Future studies should be performed to see how chronic, low dose drug administration would affect hormone levels and try to answer questions about the physiological mechanisms involved in the anorexic paradigm observed in drug use.	[Kobeissy, Firas H.; Jeung, Jennifer A.; Warren, Matthew W.; Geier, Jacqueline E.; Gold, Mark S.] Univ Florida, Coll Med, Gainesville, FL 32610 USA; [Kobeissy, Firas H.; Gold, Mark S.] Univ Florida, Dept Psychiat, Div Addict Med, Gainesville, FL 32611 USA; [Gold, Mark S.] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA		Kobeissy, FH (corresponding author), Univ Florida, Coll Med, PO Box 100215, Gainesville, FL 32610 USA.	firasko@ufl.edu; msgold@ufl.edu	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T 35 HL07489] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T35HL007489] Funding Source: NIH RePORTER		BATTAGLIA G, 1987, J PHARMACOL EXP THER, V242, P911; Baucum AJ, 2004, J NEUROSCI, V24, P3436, DOI 10.1523/JNEUROSCI.0387-04.2004; Baumann MH, 2007, PSYCHOPHARMACOLOGY, V189, P407, DOI 10.1007/s00213-006-0322-6; Chan YY, 1996, ENDOCRINOLOGY, V137, P1319, DOI 10.1210/en.137.4.1319; Cho AK, 2001, SYNAPSE, V39, P161, DOI 10.1002/1098-2396(200102)39:2<161::AID-SYN7>3.0.CO;2-E; CRANE C, 2007, J HISTOCHEM CYTOCHEM; Crowley WR, 2005, NEUROSCIENCE, V132, P167, DOI 10.1016/j.neuroscience.2004.11.037; Curzon G, 1997, TRENDS PHARMACOL SCI, V18, P21, DOI 10.1016/S0165-6147(96)01003-6; Daberkow DP, 2005, PHARMACOL BIOCHEM BE, V81, P198, DOI 10.1016/j.pbb.2005.03.010; DAFTERS RI, 1995, PHYSIOL BEHAV, V58, P877, DOI 10.1016/0031-9384(95)00136-7; Davidson C, 2005, NEUROCHEM INT, V46, P189, DOI 10.1016/j.neuint.2004.11.004; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; Deng XL, 1999, J NEUROSCI, V19, P10107; DeSouza I, 1997, PHARMACOL TOXICOL, V80, P207; DUBE MG, 1992, BRAIN RES BULL, V29, P865, DOI 10.1016/0361-9230(92)90157-S; Egecioglu E, 2006, AM J PHYSIOL-ENDOC M, V290, pE317, DOI 10.1152/ajpendo.00181.2005; Faria R, 2006, ANN NY ACAD SCI, V1074, P643, DOI 10.1196/annals.1369.062; Federici M, 2007, BIOL PSYCHIAT, V62, P680, DOI 10.1016/j.biopsych.2006.11.019; Gayle DA, 2006, LIFE SCI, V79, P1531, DOI 10.1016/j.lfs.2006.04.015; Gerra G, 2002, BEHAV BRAIN RES, V134, P403, DOI 10.1016/S0166-4328(02)00052-9; Ginawi OT, 2005, REGUL TOXICOL PHARM, V41, P122, DOI 10.1016/j.yrtph.2004.10.005; Ginawi OT, 2005, PHARMACOL RES, V51, P255, DOI 10.1016/j.phrs.2004.09.002; GUY J, 1988, PEPTIDES, V9, P567, DOI 10.1016/0196-9781(88)90165-9; Halford J C, 2000, Prog Drug Res, V54, P25; Hegadoren KM, 1999, NEUROSCI BIOBEHAV R, V23, P539, DOI 10.1016/S0149-7634(98)00046-3; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; Hosoda Hiroshi, 2002, Mol Interv, V2, P494, DOI 10.1124/mi.2.8.494; Hsieh YS, 2006, TOXICOL APPL PHARM, V212, P99, DOI 10.1016/j.taap.2005.07.006; Islam SKN, 2002, BRIT J NUTR, V88, P507, DOI 10.1079/BJN2002702; Jaehne EJ, 2005, PHARMACOL BIOCHEM BE, V81, P485, DOI 10.1016/j.pbb.2005.04.005; JONAS JM, 1986, LANCET, V1, P390; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kalra SP, 2004, J ADDICT DIS, V23, P5, DOI 10.1300/J069v23n03_02; Kleiner KD, 2004, J ADDICT DIS, V23, P105, DOI 10.1300/J069v23n03_08; Malpass A, 1999, PHARMACOL BIOCHEM BE, V64, P29, DOI 10.1016/S0091-3057(99)00116-1; Mas M, 1999, J PHARMACOL EXP THER, V290, P136; Morley KC, 2001, EUR J PHARMACOL, V433, P91, DOI 10.1016/S0014-2999(01)01512-6; Nogueiras R, 2004, DIABETES, V53, P2552, DOI 10.2337/diabetes.53.10.2552; PAUL SM, 1982, SCIENCE, V218, P487, DOI 10.1126/science.7123250; PELLETIER G, 1991, NEUROSCI LETT, V127, P96, DOI 10.1016/0304-3940(91)90903-7; SALISBURY JJ, 1985, BEHAV NEUROSCI, V99, P1153, DOI 10.1037/0735-7044.99.6.1153; SAMANIN R, 1993, PHARMACOL TOXICOL, V73, P63, DOI 10.1111/j.1600-0773.1993.tb01537.x; Sanchez J, 2004, PFLUG ARCH EUR J PHY, V448, P500, DOI 10.1007/s00424-004-1283-4; Santolaria F, 2003, ALCOHOL ALCOHOLISM, V38, P60, DOI 10.1093/alcalc/agg015; Staszewski RD, 2006, J NEUROCHEM, V96, P1267, DOI 10.1111/j.1471-4159.2005.03618.x; Stephenson CP, 1999, NEUROSCIENCE, V92, P1011, DOI 10.1016/S0306-4522(99)00049-4; Thiriet N, 2005, J NEUROSCI, V25, P5273, DOI 10.1523/JNEUROSCI.4893-04.2005; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; Wang XY, 2005, J PHARMACOL EXP THER, V314, P1002, DOI 10.1124/jpet.105.088476; Warren MW, 2007, INT J NEUROPSYCHOPH, V10, P479, DOI 10.1017/S1461145706007061; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; Yu J, 2004, BRAIN RES, V1007, P124, DOI 10.1016/j.brainres.2004.01.077	53	35	35	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-6215	1369-1600		ADDICT BIOL	Addict. Biol.	MAR	2008	13	1					15	25		10.1111/j.1369-1600.2007.00083.x			11	Biochemistry & Molecular Biology; Substance Abuse	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Substance Abuse	259GN	WOS:000252927900002	17910739				2022-02-06	
J	Mckay, C; Wertheimer, JC; Fichtenberg, NL; Casey, JE				McKay, Cherisse; Wertheimer, Jeffrey C.; Fichtenberg, Norman L.; Casey, Joseph E.			The repeatable battery for the assessment of neuropsychological status (rbans): Clinical utility in a traumatic brain injury sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						psychometrics; RBANS; TBI	IMPAIRMENT	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS, Randolph, 1998), a neuropsychological screening measure initially designed to assess the cognitive deficits associated with dementia, has since been clinically implemented with other neurological populations including traumatic brain injury ( TBI). This study evaluated the clinical utility ofthe RBANS in a TBIpopulation by comparing the profiles of 51 TBI cases and 34 non-head-injured controls. A cross RBANS' Index Scores, the TBI group performed at a significantly lower level than the controls; sensitivity to TBI and likelihood ratios ranged from modest to strong; and specificity was high. Particularly efficacious was the clinical efficiency exhibited by the Total Scale Index (summary score) of the RBANS.	[McKay, Cherisse; Casey, Joseph E.] Univ Windsor, Windsor, ON N9B 3P4, Canada; [Wertheimer, Jeffrey C.; Fichtenberg, Norman L.] Wayne State Univ, Detroit, MI 48202 USA		Mckay, C (corresponding author), Univ Windsor, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	cherissemckay@hotmail.com					Aupperle RL, 2002, MULT SCLER J, V8, P382, DOI 10.1191/1352458502ms832oa; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Beatty WW, 2004, ARCH CLIN NEUROPSYCH, V19, P825, DOI 10.1016/j.acn.2003.12.001; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; Carone D.A., 2004, 32 M INT NEUR SOC BA; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hamilton BB, 1987, REHABILITATION OUTCO, P137; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Larson EB, 2005, J CLIN EXP NEUROPSYC, V27, P16, DOI 10.1080/138033990513564; Larson Eric B, 2003, Top Stroke Rehabil, V9, P10; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Randolph C., 1998, REPEATABLE BATTERY A; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P531, DOI 10.1076/clin.17.4.531.27938; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; SILVERBERG N, 1974, IN PRESS CLIN NEUROP; TERRYBERRYSPOHR L, 2000, ANN M NAT AC NEUR OR; Tombaugh T.N., 1996, TEST MEMORY MALINGER	25	35	37	1	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAR	2008	22	2					228	241		10.1080/13854040701260370			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	279ZA	WOS:000254393500004	17853143				2022-02-06	
J	Samah, B; Porcheray, F; Gras, G				Samah, B.; Porcheray, F.; Gras, G.			Neurotrophins modulate monocyte chemotaxis without affecting macrophage function	CLINICAL AND EXPERIMENTAL IMMUNOLOGY			English	Article						chemotaxis; macrophage; monocyte; neurotrophin; SDF-1	NERVE GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; CHEMOKINE RECEPTOR CXCR4; TRAUMATIC BRAIN-INJURY; CELL-DERIVED FACTOR-1-ALPHA; TRK PROTOONCOGENE; RAT HIPPOCAMPUS; ALPHA-CHEMOKINE; IN-VITRO; GLUCOCORTICOIDS MODULATE	Neurotrophins nerve growth factor (NGF), brain-derived growth factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) and their high-affinity tyrosine protein kinase receptor (Trk) family, TrkA, TrkB, TrkC, and low-affinity p75(NTR) receptor, are key molecules implicated in the development of the central nervous system. Increasing evidence suggests that they also have physiological and pathological roles outside the nervous system. In this study we examined the expression of neurotrophins and their receptors in human activated macrophages and to what extent neurotrophins themselves modulate macrophage activation, in a model of primary adult monocyte-derived macrophage. Our data indicate that macrophages express neurotrophin and neurotrophin receptor genes differentially, and respond to cell stimulation by specific inductions. Neurotrophins did not modify the antigen-presenting capacities of macrophages or their production of proinflammatory cytokines, but somehow skewed their activation phenotype. In contrast, NGF clearly increased CXCR-4 expression in macrophage and their chemotactic response to low CXCL-12 concentration. The differential effect of specific macrophage stimuli on neurotrophin expression, in particular NGF and NT-3, and the specific enhancement of CXCR-4 expression suggest that neurotrophins might participate in tissue-healing mechanisms that should be investigated further in vivo.	[Samah, B.; Porcheray, F.; Gras, G.] Univ Paris Sud, Serv Immunovirol, IFR13 Inst Paris Cytokines, CEA,DSV,iMETI,SIV,UMR E 01, F-92265 Fontenay Aux Roses, France		Gras, G (corresponding author), Univ Paris Sud, Serv Immunovirol, IFR13 Inst Paris Cytokines, CEA,DSV,iMETI,SIV,UMR E 01, 18 Route Panorama, F-92265 Fontenay Aux Roses, France.	gabriel.gras@cea.fr					Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Asami T, 2006, BIOCHEM BIOPH RES CO, V344, P941, DOI 10.1016/j.bbrc.2006.03.228; Badr G, 2005, INT IMMUNOL, V17, P459, DOI 10.1093/intimm/dxh227; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Barouch R, 2001, J LEUKOCYTE BIOL, V69, P1019; Barouch R, 2001, J NEUROIMMUNOL, V112, P72, DOI 10.1016/S0165-5728(00)00408-2; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; Bonini P, 2001, JOP, V2, P105; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.ne.18.030195.001255; BRODIE C, 1992, J IMMUNOL, V148, P3492; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Chang CN, 2005, J CLIN NEUROSCI, V12, P680, DOI 10.1016/j.jocn.2005.05.004; Chen S, 2005, IMMUNOLOGY, V114, P565, DOI 10.1111/j.1365-2567.2004.02110.x; De Simone R, 2004, MOL NEUROBIOL, V29, P197, DOI 10.1385/MN:29:2:197; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Felszeghy K, 2004, NEUROIMMUNOMODULAT, V11, P404, DOI 10.1159/000080151; FIGDOR CG, 1983, CELL BIOPHYS, V5, P105, DOI 10.1007/BF02796137; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Garaci E, 1999, P NATL ACAD SCI USA, V96, P14013, DOI 10.1073/pnas.96.24.14013; Garcia-Suarez O, 1998, IMMUNOLOGY, V94, P235, DOI 10.1046/j.1365-2567.1998.00505.x; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; Hattori K, 2003, LEUKEMIA LYMPHOMA, V44, P575, DOI 10.1080/1042819021000037985; Hess DC, 2004, EXP NEUROL, V186, P134, DOI 10.1016/j.expneurol.2003.11.005; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; HOLLOWELL JP, 1990, EXP NEUROL, V110, P45, DOI 10.1016/0014-4886(90)90050-3; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kayali AG, 2003, J CELL BIOL, V163, P859, DOI 10.1083/jcb.200304153; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; Kobayashi H, 2001, NEUROSCI LETT, V305, P157, DOI 10.1016/S0304-3940(01)01854-7; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; la Sala A, 2000, J LEUKOCYTE BIOL, V68, P104; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAURENZI MA, 1994, EUR J BIOCHEM, V223, P733, DOI 10.1111/j.1432-1033.1994.tb19047.x; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Montaner LJ, 1999, J IMMUNOL, V162, P4606; Morrissette Naomi, 1999, Trends in Cell Biology, V9, P199, DOI 10.1016/S0962-8924(99)01540-8; MUES B, 1989, IMMUNOLOGY, V67, P303; Nakajima K, 1998, GLIA, V24, P272, DOI 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; Perez-Perez M, 1999, CELL TISSUE RES, V298, P75, DOI 10.1007/s004419900089; Porcheray F, 2005, CLIN EXP IMMUNOL, V142, P481, DOI 10.1111/j.1365-2249.2005.02934.x; Porcheray F, 2006, AM J PHYSIOL-CELL PH, V291, pC618, DOI 10.1152/ajpcell.00021.2006; Porcheray F, 2006, VIROLOGY, V349, P112, DOI 10.1016/j.virol.2006.02.031; Ricci A, 2004, AM J RESP CELL MOL, V30, P12, DOI 10.1165/rcmb.2002-0110OC; Rozen S, 2000, Methods Mol Biol, V132, P365; Schebesch C, 1997, IMMUNOLOGY, V92, P478, DOI 10.1046/j.1365-2567.1997.00371.x; Shamovsky IL, 1999, PROTEIN SCI, V8, P2223; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Susaki Y, 1996, BLOOD, V88, P4630, DOI 10.1182/blood.V88.12.4630.bloodjournal88124630; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; THORPE LW, 1987, J NEUROSCI RES, V18, P134, DOI 10.1002/jnr.490180120; UNANUE ER, 1987, HOSP PRACT, V22, P87, DOI 10.1080/21548331.1987.11707695; UNANUE ER, 1987, HOSP PRACT OFF, V22, P102; Vega JA, 2003, J ANAT, V203, P1, DOI 10.1046/j.1469-7580.2003.00203.x; Yang JT, 2005, EXP NEUROL, V192, P437, DOI 10.1016/j.expneurol.2004.12.023; Yang JT, 1998, NEUROREPORT, V9, P3477, DOI 10.1097/00001756-199810260-00026; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	75	35	36	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0009-9104			CLIN EXP IMMUNOL	Clin. Exp. Immunol.	MAR	2008	151	3					476	486		10.1111/j.1365-2249.2007.03578.x			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	256EW	WOS:000252711500014	18190610	Green Published			2022-02-06	
J	Chang, MW; Young, MS; Lin, MT				Chang, Ming-Wen; Young, Ming-Shing; Lin, Mao-Tsun			An inclined plane system with microcontroller to determine limb motor function of laboratory animals	JOURNAL OF NEUROSCIENCE METHODS			English	Article						animal model; laboratory animal; inclined plane; motor function; neurologic examination	OPEN-FIELD ACTIVITY; FLUID PERCUSSION; BRAIN-INJURY; ISCHEMIA; DEFICITS; WEIGHT; RATS	This study describes a high-accuracy inclined plane test system for quantitative measurement of the limb motor function of laboratory rats. The system is built around a microcontroller and uses a stepping motor to drive a ball screw, which changes the angle of the inclined plane. Any of the seven inclination speeds can be selected by the user. Two infrared (IR) LED/detector, pairs function as interrupt sensors for objective determination of the moment that the rat loses its grip on the textured flooring of the starting area and slips down the plane. Inclination angle at the moment of IR interrupt (i.e. rat slip) is recorded. A liquid crystal display module shows the inclination speed and the inclination angle. The system can function as a standalone device but a RS232 port allows connection to a personal computer (PC), so data can be sent directly to hard disk for storage and analysis. Experiments can be controlled by a local keypad or by the connected PC. Advantages of the presented system include easy operation, high accuracy, non-dependence on human observation for determination of slip angle, stand-alone capability, low cost and easy modification of the controlling software for different types of experiments. A fully functional prototype of the system is described. The prototype was used experimentally by a-hospital group testing traumatic brain injury experiments, and some of their results are presented for system verification. It is found that the system is stable, accurate and easily used by investigators. (c) 2007 Elsevier B.V. All rights reserved.	[Lin, Mao-Tsun] ChiMei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Chang, Ming-Wen; Young, Ming-Shing] Natl Cheng Kung Univ, Dept Elect Engn, Tainan 701, Taiwan		Lin, MT (corresponding author), ChiMei Med Ctr, Dept Med Res, Tainan 710, Taiwan.	891201@mail.chimei.org.tw					BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Carter CS, 2002, J GERONTOL A-BIOL, V57, pB193, DOI 10.1093/gerona/57.5.B193; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GIULIAN D, 1975, PHYSIOL BEHAV, V14, P109, DOI 10.1016/0031-9384(75)90150-X; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; KAO CH, IN PRESS SHOCK; Koob AO, 2006, J NEUROSCI METH, V157, P330, DOI 10.1016/j.jneumeth.2006.04.020; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; REIS DJ, 1974, PROG CARDIOVASC DIS, V17, P51, DOI 10.1016/0033-0620(74)90038-3; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RYCK MD, 1989, STROKE, V20, P1383; Spangenberg EMF, 2005, LAB ANIM-UK, V39, P45, DOI 10.1258/0023677052886457; Wang Y, 1997, J NEUROSCI, V17, P4341; Whishaw IQ, 1999, MODERN TECHNIQUES NE, P1243; Yonemori F, 2000, J CEREBR BLOOD F MET, V20, P74, DOI 10.1097/00004647-200001000-00011	17	35	38	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	FEB 15	2008	168	1					186	194		10.1016/j.jneumeth.2007.09.013			9	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	261EQ	WOS:000253062300026	17953994				2022-02-06	
J	Butt, MF; Dhar, SA; ul Gani, N; Farooq, M; Mir, MR; Halwai, MA; Kangu, KA; Mir, BA; Kawoosa, AA				Butt, Mohammad Farooq; Dhar, Shabir A.; ul Gani, Naseem; Farooq, Munir; Mir, M. R.; Halwai, M. A.; Kangu, K. A.; Mir, B. A.; Kawoosa, A. A.			Delayed fixation of displaced femoral neck fractures in younger adults	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						fracture neck of femur; delayed fixation; avascular necrosis; non-union	INTERNAL-FIXATION; INTRACAPSULAR FRACTURES; HEAD; NECROSIS; REDUCTION; FEMUR; AGES; HIP	We report the results of 52 patients aged 20-55 years with displaced femoral neck fractures, in whom delayed closed reduction and internal fixation was performed. Seven patients developed avascular necrosis (AVN) and non-union was seen in five patients. Whereas most patients with non-union were subjected to repeat procedures, none of the patients with AVN required surgery. The follow-up averaged 40 months (range 22-64 months). Three patients were lost to follow-up. Functional outcome was defined by Judet's system. Good to excellent functional outcome was achieved in 45 cases. The study demonstrated that delayed closed reduction and internal fixation of displaced fractures in young adults which, we believe, is the prevalent form of treatment of these injuries in the developing world results in high rate of fracture union and good functional outcome. The rate of AVN, however, may be a concern if the patients are followed for a longer period. (c) 2007 Elsevier Ltd. All rights reserved.	[Butt, Mohammad Farooq; Dhar, Shabir A.; ul Gani, Naseem; Farooq, Munir; Mir, M. R.; Halwai, M. A.; Kangu, K. A.; Mir, B. A.; Kawoosa, A. A.] Govt Hosp Bone & Joint Surg, Srinagar 190005, Jammu & Kashmir, India		Butt, MF (corresponding author), Govt Hosp Bone & Joint Surg, Srinagar 190005, Jammu & Kashmir, India.	mfbutt72@yahoo.co.in		Ahmad Kawoosa, Altaf/0000-0002-1092-9775			ARNOLDI CC, 1972, CLIN ORTHOP RELAT R, P116; ARNOLDI CC, 1977, CLIN ORTHOP RELAT R, P217; ASNIS SE, 1994, J BONE JOINT SURG AM, V76A, P1793, DOI 10.2106/00004623-199412000-00005; BRAY TJ, 1988, CLIN ORTHOP RELAT R, P127; CLAFFEY TJ, 1960, J BONE JOINT SURG BR, V42, P802, DOI 10.1302/0301-620X.42B4.802; DRAKE JK, 1984, CLIN ORTHOP RELAT R, P172; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301-620X.67B1.3155745; GARDEN R S, 1971, Journal of Bone and Joint Surgery British Volume, V53, P183; Haidukewych GJ, 2004, J BONE JOINT SURG AM, V86A, P1711, DOI 10.2106/00004623-200408000-00015; Jain R, 2002, J BONE JOINT SURG AM, V84A, P1605, DOI 10.2106/00004623-200209000-00013; Jakob M, 1999, Swiss Surg, V5, P257, DOI 10.1024/1023-9332.5.6.257; LINDEQUIST S, 1995, J ORTHOP TRAUMA, V9, P215, DOI 10.1097/00005131-199506000-00006; LUYAO GL, 1994, J BONE JOINT SURG AM, V76A, P15, DOI 10.2106/00004623-199401000-00003; MANNINGER J, 1989, INJURY, V20, P101, DOI 10.1016/0020-1383(89)90152-6; PARKER MJ, 1992, J BONE JOINT SURG BR, V74, P203, DOI 10.1302/0301-620X.74B2.1544952; PROTZMAN RR, 1976, J BONE JOINT SURG AM, V58, P689, DOI 10.2106/00004623-197658050-00020; STINCHFIELD FE, 1957, J BONE JOINT SURG AM, V39, P1043, DOI 10.2106/00004623-195739050-00005; SWIONTKOWSKI MF, 1994, J BONE JOINT SURG AM, V76A, P129, DOI 10.2106/00004623-199401000-00019; SWIONTKOWSKI MF, 1987, J ORTHOPAED RES, V5, P433, DOI 10.1002/jor.1100050316; SWIONTKOWSKI MF, 1984, J BONE JOINT SURG AM, V66A, P837, DOI 10.2106/00004623-198466060-00003; SWIONTKOWSKI MF, 1993, ACTA ORTHOP SCAND, V64, P196, DOI 10.3109/17453679308994570; Upadhyay A, 2004, J BONE JOINT SURG BR, V86B, P1035, DOI 10.1302/0301-620X.86B7.15047; Whitman R., 1933, AM J SURG, V21, P335; ZETTERBERG CH, 1982, ACTA ORTHOP SCAND, V53, P427, DOI 10.3109/17453678208992237	24	35	42	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	FEB	2008	39	2					238	243		10.1016/j.injury.2007.09.002			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	268UV	WOS:000253606200015	18241865				2022-02-06	
J	Gutierrez-Gonzalez, R; Boto, GR; Rivero-Garvia, M; Perez-Zamarron, A; Gomez, G				Gutierrez-Gonzalez, Raquel; Boto, Gregorio R.; Rivero-Garvia, Monica; Perez-Zamarron, Alvaro; Gomez, Gustavo			Penetrating brain injury by drill bit	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						head injury; non-missile; penetrating brain injury; self-inflicted	TRANSCRANIAL STAB WOUNDS; CRANIOCEREBRAL INJURIES; POWER DRILL; NAIL-GUN; ANGIOGRAPHY	Non-missile low velocity penetrating brain injuries are unusual among civilian population. They show specific characteristics different from missile wounds. In this paper we describe a rare case of self-inflicted penetrating head trauma by electric drill. We document neuroimaging studies and review the management concerning this pathology. To our knowledge, this is the first case of intracranial retained drill bit with such radiological findings reported in the literature. An 80-year-old male with no previous psychiatric disorder presented at our hospital after suffering an accident while working with an electric drill. Physical examination revealed right lower extremity plegia and three penetrating scalp wounds to the left parasagittal region. Skull Xray and computed tomography demonstrated an intracranial metallic foreign body located in the left parietal lobe and an intraparenchymal hematoma with no mass effect close to the foreign body. The patient was taken to the operating room to remove the drill bit fragment. Antibiotic and antiseizure prophylaxis were administered. Postoperative computed tomography confirmed no residual metallic fragments and functional recovery was excellent. After psychiatric assessment, suicide attempt was confirmed and antidepressive therapy was then started. On follow-up, no complication was documented. It is essential to exclude penetrating brain trauma whenever a scalp wound is noticed in order to provide proper treatment and prevention care. The permanent neurological deficit in low velocity injuries is related to the degree and location of the primary injury. It also depends on an early diagnosis and treatment and the absence of delayed complications. (C) 2007 Elsevier B.V. All rights reserved.	[Gutierrez-Gonzalez, Raquel; Boto, Gregorio R.; Rivero-Garvia, Monica; Gomez, Gustavo] Hosp Clin San Carlos, Dept Neurosurg, Madrid 28040, Spain; [Perez-Zamarron, Alvaro] Hosp Univ La Paz, Dept Neurosurg, Madrid 28046, Spain		Gutierrez-Gonzalez, R (corresponding author), Hosp Clin San Carlos, Dept Neurosurg, Prof Martin Lagos S-N, Madrid 28040, Spain.	rgutierrezgonzalez@yahoo.es	Rodriguez-Boto, Gregorio/AAR-9035-2021; IBIS, NEUROCIENCIA APLICAD/C-2516-2016; Rivero-Garvia, Monica MRG/F-1567-2015	Rodriguez-Boto, Gregorio/0000-0001-6361-5713; Rivero-Garvia, Monica MRG/0000-0001-5125-6151; Gutierrez-Gonzalez, Raquel/0000-0003-1489-4247			[Anonymous], 2001, J TRAUMA S2, V51, pS41; [Anonymous], 2001, J TRAUMA S2, V51, pS34; Carey ME, 2004, YOUMANS NEUROLOGICAL, V4, P5223; Chibbaro S, 2006, ACTA NEUROCHIR, V148, P937, DOI 10.1007/s00701-006-0794-5; COSTANTINIDES F, 1982, AM J FOREN MED PATH, V3, P241, DOI 10.1097/00000433-198209000-00009; CZASTKA H, 1997, NEUROL NEUROCHIR POL, V11, P395; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; Karabatsou K, 2005, AM J FOREN MED PATH, V26, P174, DOI 10.1097/01.paf.0000163823.55149.60; KELLY AJ, 1992, SURG NEUROL, V38, P471, DOI 10.1016/0090-3019(92)90118-7; KHALIL N, 1991, SURG NEUROL, V35, P294, DOI 10.1016/0090-3019(91)90008-W; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Litvack ZN, 2006, J NEUROSURG, V104, P828, DOI 10.3171/jns.2006.104.5.828; Nathoo N, 2000, NEUROSURGERY, V47, P1117, DOI 10.1097/00006123-200011000-00018; Navarro Celma J A, 1989, Acta Med Leg Soc (Liege), V39, P247; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; Schmeling Andreas, 2003, Archiv fuer Kriminologie, V211, P65; Zazpe I, 2006, NEUROCIRUGIA, V17, P544; 2001, J TRAUMA S2, V51, pS26; 2001, J TRAUMA S2, V51, pS44; 2001, J TRAUMA S2, V51, pS7	22	35	37	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	FEB	2008	110	2					207	210		10.1016/j.clineuro.2007.09.014			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	266CE	WOS:000253408100019	17983703				2022-02-06	
J	Moore, TM; Callaway, CW; Hostler, D				Moore, Tracy M.; Callaway, Clifton W.; Hostler, David			Core temperature cooling in healthy volunteers after rapid intravenous infusion of cold and room temperature saline solution	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Scientific Assembly of the American-College-of-Emergency-Physicians	SEP 26-29, 2005	Washington, DC	Amer Coll Emergency Phys			CARDIAC-ARREST; HYPOTHERMIA; HUMANS; MEPERIDINE; INDUCTION; CLONIDINE; URAPIDIL; FLUID	Study objective: Studies have suggested that inducing mild hypothermia improves neurologic outcomes after traumatic brain injury, major stroke, traumatic hemorrhage, and cardiac arrest. Although infusion of cold normal saline solution is a simple and inexpensive method for initiating hypothermia, human cold-defense mechanisms potentially make this route stressful or ineffective. We hypothesize that rapid infusion of 30 mL/kg of cold (4 degrees C, 39.2 degrees F) 0.9% saline solution during 30 minutes to healthy subjects (aged 27 [standard deviation (SD) 4] years) will reduce core body temperature to the therapeutic range of 33 degrees C to 35 degrees C (91.4 degrees F to 95 degrees F). Methods: Sixteen subjects were randomly assigned to receive either cold (4 degrees C, 39.2 degrees F) or room temperature (23 degrees C, 73.4 degrees F) normal saline solution. Subjects were not informed of their assignment, but blinding was not possible after initiation of the infusion. Core temperature, skin temperature, and vital signs were recorded every 2 minutes. Subjects indicated global discomfort during the infusion on a 100-mm visual analog scale at 5-minute intervals. Results: Core temperature decreased in both the cold saline solution (1.0 degrees C [SD 0.4 degrees C]/1.8 degrees F [0.7 degrees F]) and room temperature saline solution (0.5 degrees C [SD 0.1 degrees C]/0.9 degrees F [0.2 degrees F]) groups, whereas skin temperature was unchanged. Slopes calculated from the core temperature cooling curves indicate that the majority of cooling occurred during the first half of the infusion. Examination of the core temperature cooling curves revealed a 2-phase temporal pattern in 30-minute cooling curves. The early phase, spanning 0 to 14 minutes, demonstrated rapid cooling in both groups, with a larger effect observed in subjects receiving cold saline solution. Conclusion: In this pilot study of healthy volunteers, rapid administration of cold saline solution to awake normothermic volunteers resulted in 1 degrees C (1.8 degrees F) cooling but did not induce a therapeutic plane of hypothermia. This change in core temperature was not accompanied by significant changes in skin temperature. These data suggest that a reduction in core temperature of about 1 degrees C (1.8 degrees F) can be achieved in healthy humans before a thermoregulatory response is triggered and that rapid infusion of cold intravenous fluids is insufficient by itself to overcome this response. The clinically relevant control arm of room temperature saline solution also resulted in mild core cooling.	[Moore, Tracy M.; Callaway, Clifton W.; Hostler, David] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15213 USA; [Hostler, David] Univ Pittsburgh, Emergency Responder Human Performance Lab, Pittsburgh, PA 15213 USA		Hostler, D (corresponding author), Univ Pittsburgh, Dept Emergency Med, 230 McKee Pl,Suite 400, Pittsburgh, PA 15213 USA.	hostlerdp@upmc.edu		Callaway, Clifton/0000-0002-3309-1573; Hostler, David/0000-0002-7711-4001			Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; *CARD ARR STUD GRO, 2002, J AM COLL CARDIOL, V346, P549; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Frank SM, 2000, AM J PHYSIOL-REG I, V279, pR349, DOI 10.1152/ajpregu.2000.279.1.R349; Frank SM, 2003, CLIN SCI, V104, P503, DOI 10.1042/CS20020256; Frank SM, 1997, AM J PHYSIOL-REG I, V272, pR557, DOI 10.1152/ajpregu.1997.272.2.R557; Giuliano K K, 2000, Am J Crit Care, V9, P254; Kliegel A, 2007, RESUSCITATION, V73, P46, DOI 10.1016/j.resuscitation.2006.08.023; Logue ES, 2007, ACAD EMERG MED, V14, P293, DOI 10.1197/j.aem.2006.10.097; O'Brien C, 1998, MED SCI SPORT EXER, V30, P468, DOI 10.1097/00005768-199803000-00020; Piper SN, 2000, ANESTH ANALG, V90, P954, DOI 10.1213/00000539-200004000-00033; Rajek A, 2000, ANESTHESIOLOGY, V93, P629, DOI 10.1097/00000542-200009000-00010; Schwarzkopf KRG, 2001, ANESTH ANALG, V92, P257; Silbergleit R, 1998, ANN EMERG MED, V31, P339, DOI 10.1016/S0196-0644(98)70344-0; Sramek P, 2000, EUR J APPL PHYSIOL, V81, P436, DOI 10.1007/s004210050065; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X	18	35	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	FEB	2008	51	2					153	159		10.1016/j.annemergmed.2007.07.012			7	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	256JO	WOS:000252725000007	18045737				2022-02-06	
J	Yao, XL; Liu, J; McCabe, JT				Yao, Xianglan; Liu, Jiong; McCabe, Joseph T.			Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; cerebral cortex; hippocampus; PA28 alpha; quantitative real-time PCR; beta-proteasome subunits	INTERFERON-GAMMA; GENE-EXPRESSION; OXIDATIVE STRESS; UBIQUITIN IMMUNOREACTIVITY; GENOMIC ORGANIZATION; ANTIGEN PRESENTATION; HYBRID PROTEASOMES; OXIDIZED PROTEINS; TISSUE EXPRESSION; 20S PROTEASOMES	Following cellular stress or tissue injury, the proteasome plays a critical role in protein degradation and signal transduction. The present study examined the beta-subunit expression of constitutive proteasomes (beta 1, beta 2, and beta 5), immunoproteasomes (beta 1i, beta 2i, and beta 5i) and the 11S proteasome activator, PA28 alpha, in the rat CNS after traumatic brain injury (TBI). Concomitant measures assessed changes in proteasome activities. Quantitative real time PCR results indicated that beta 1 and beta 2 mRNA levels were not changed, while beta 5 mRNA levels were significantly decreased in injured CNS following TBI. However, beta 1i, beta 2i, beta 5i, and PA28 alpha mRNA levels were significantly increased in the injured CNS. Western blotting studies found that beta 1, beta 2, beta 5, beta 2i, and beta 5i subunit protein levels remained unchanged in the injured CNS, but beta 1i and PA28 alpha protein levels were significantly elevated in ipsilateral cerebral cortex and hippocampus. Proteasome activity assays found that peptidyl glutamyl peptide hydrolase-like and chymotrypsin-like activity were significantly reduced in the CNS after TBI, and that trypsin-like proteasome activity was increased in the injured cerebral cortex. Our results demonstrated that both proteasome composition and function in the CNS were affected by trauma. Treatments that preserve proteasome function following CNS injury may be beneficial as an approach to cerebral neuroprotection.	[Yao, Xianglan; Liu, Jiong; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Yao, XL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	xyao@usuhs.mil	McCabe, Joseph T/J-6293-2014	McCabe, Joseph T/0000-0002-1159-7442			Adori C, 2006, J HISTOCHEM CYTOCHEM, V54, P263, DOI 10.1369/jhc.5B6752.2005; Adori C, 2005, NEUROBIOL DIS, V19, P427, DOI 10.1016/j.nbd.2005.01.015; Ahtoniemi T, 2007, MOL PHARMACOL, V71, P30, DOI 10.1124/mol.106.028415; Anselmi B, 1998, J GERONTOL A-BIOL, V53, pB173, DOI 10.1093/gerona/53A.3.B173; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; Bader N, 2006, BIOL CHEM, V387, P1351, DOI 10.1515/BC.2006.169; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Ceremuga TE, 2001, ENDOCR RES, V27, P433, DOI 10.1081/ERC-100107867; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Ding QX, 2007, TRENDS NEUROSCI, V30, P31, DOI 10.1016/j.tins.2006.11.003; Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824; Farout L, 2000, ARCH BIOCHEM BIOPHYS, V374, P207, DOI 10.1006/abbi.1999.1585; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gozal D, 2003, J NEUROCHEM, V86, P1545, DOI 10.1046/j.1471-4159.2003.01973.x; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; Groettrup M, 2001, BIOCHIMIE, V83, P367, DOI 10.1016/S0300-9084(01)01251-2; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Grune T, 2005, FREE RADICAL BIO MED, V39, P1208, DOI 10.1016/j.freeradbiomed.2005.06.009; Halliwell B, 2002, ANN NY ACAD SCI, V962, P182, DOI 10.1111/j.1749-6632.2002.tb04067.x; HARRIS JR, 1968, BIOCHIM BIOPHYS ACTA, V150, P534, DOI 10.1016/0005-2736(68)90157-0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Heink S, 2005, P NATL ACAD SCI USA, V102, P9241, DOI 10.1073/pnas.0501711102; Henninger N, 2006, NEUROSCI LETT, V398, P300, DOI 10.1016/j.neulet.2006.01.015; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ide T, 1999, J CEREBR BLOOD F MET, V19, P750, DOI 10.1097/00004647-199907000-00004; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 2004, INT J BIOCHEM CELL B, V36, P2376, DOI 10.1016/j.biocel.2004.05.003; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kopp F, 2001, J MOL BIOL, V313, P465, DOI 10.1006/jmbi.2001.5063; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee CS, 2004, J NEUROCHEM, V91, P996, DOI 10.1111/j.1471-4159.2004.02813.x; Li J, 2001, BIOCHIMIE, V83, P373, DOI 10.1016/S0300-9084(01)01236-6; Li ZM, 2004, J NEUROCHEM, V90, P19, DOI 10.1111/j.1471-4159.2004.02456.x; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Martin S, 2004, NEUROSCI LETT, V357, P76, DOI 10.1016/j.neulet.2003.10.085; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; Mendonca DMF, 2006, NEUROSCI LETT, V404, P315, DOI 10.1016/j.neulet.2006.06.009; Mengual E, 1996, J NEUROSCI, V16, P6331; Minami Y, 2000, J BIOL CHEM, V275, P9055, DOI 10.1074/jbc.275.12.9055; Mishto M, 2006, NEUROBIOL AGING, V27, P54, DOI 10.1016/j.neurobiolaging.2004.12.004; Mizukami K, 2002, ACTA NEUROPATHOL, V103, P453, DOI 10.1007/s00401-001-0489-1; MORI H, 1996, RECENT ADV GASTROENT, V1, P249; Murata S, 2001, EMBO J, V20, P5898, DOI 10.1093/emboj/20.21.5898; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; Noda C, 2000, BIOCHEM BIOPH RES CO, V277, P348, DOI 10.1006/bbrc.2000.3676; Ordway GA, 2000, J APPL PHYSIOL, V88, P1134, DOI 10.1152/jappl.2000.88.3.1134; Piccinini M, 2003, J NEUROIMMUNOL, V135, P135, DOI 10.1016/S0165-5728(02)00439-3; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Puttaparthi K, 2005, EXP NEUROL, V196, P441, DOI 10.1016/j.expneurol.2005.08.027; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schwarz K, 2000, EUR J IMMUNOL, V30, P3672, DOI 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weih M, 2001, J CEREBR BLOOD F MET, V21, P1090, DOI 10.1097/00004647-200109000-00006; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Yamano T, 2002, J EXP MED, V196, P185, DOI 10.1084/jem.20011922; Yang Y, 2006, BRAIN RES, V1075, P1, DOI 10.1016/j.brainres.2005.12.060; YAO X, 2007, IN PRESS BRAIN RES; Yao XL, 2006, NEUROSCI LETT, V409, P65, DOI 10.1016/j.neulet.2006.09.015; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yewdell JW, 2005, P NATL ACAD SCI USA, V102, P9089, DOI 10.1073/pnas.0504018102; ZANELLI E, 1993, IMMUNOGENETICS, V38, P400, DOI 10.1007/BF00184520; Zhang L, 2006, THROMB HAEMOSTASIS, V95, P166, DOI 10.1160/TH05-07-0477; ZHOU P, 1993, GENOMICS, V16, P664, DOI 10.1006/geno.1993.1245	74	35	35	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2008	104	2					353	363		10.1111/j.1471-4159.2007.04970.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	242ZX	WOS:000251765800007	17944870				2022-02-06	
J	Shintani, A; Nakao, N; Kakishita, K; Itakura, T				Shintani, Aki; Nakao, Naoyuki; Kakishita, Koji; Itakura, Toru			Protection of dopamine neurons by bone marrow stromal cells	BRAIN RESEARCH			English	Article						neurotrophic factor; dopamine neuron; cell therapy	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; PARKINSONS-DISEASE; RAT MODEL; NEUROTROPHIC FACTOR; MESENCEPHALIC TISSUE; FUNCTIONAL RECOVERY; LAZAROIDS IMPROVE; STEM-CELLS; ADULT RATS	Transplantation of bone marrow stromal cells (BMSC) has recently been demonstrated to provide neuroprotection in animal models of brain injuries such as ischemia and trauma. The present study was undertaken to explore whether BMSC can promote the survival of dopamine (DA) neurons in neuronal insult models in vitro. We also examined whether BMSC can increase the survival rate of embryonic DA neurons grafted into the striatum of a rat model of Parkinson's disease (PD). Treatment with conditioned media derived from BMSC cultures was found to significantly prevent the death of DA neurons in in vitro cell injury models such as serum deprivation and exposure to the neurotoxin 6-OHDA. In a transplantation study, we also found that the survival of grafted DA cells was significantly enhanced by treating donor cells with the conditioned media at the steps of both cell dissociation and implantation. The results suggest that BMSC may secrete diffusible factors able to protect DA neurons against neuronal injuries. Indeed, BMSC expressed mRNA encoding brain-derived neurotrophic factor, fibroblast growth factor-2 and glial cell line-derived neurotrophic factor, all of which have previously been shown to exhibit potent neurotrophic effects on DA cells. Enzyme-linked immunosorbent assay revealed that the cells release these growth factors into culture media. The present data indicate that BMSC may be a potential donor source of cell-based regenerative therapy for PD where the progressive loss of the midbrain DA neurons takes place. (c) 2007 Elsevier B.V. All rights reserved.	[Shintani, Aki; Nakao, Naoyuki; Kakishita, Koji; Itakura, Toru] Wakayama Med Univ, Dept Neurol Surg, Wakayama 6410012, Japan		Nakao, N (corresponding author), Wakayama Med Univ, Dept Neurol Surg, Wakayama 6410012, Japan.	nnakao@wakayama-med.ac.jp					ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Brundin P, 2000, BRAIN, V123, P1380, DOI 10.1093/brain/123.7.1380; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2002, J NEUROL SCI, V199, P17, DOI 10.1016/S0022-510X(02)00075-8; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; FRODL EM, 1994, NEUROREPORT, V5, P2393, DOI 10.1097/00001756-199411000-00045; Hagell P, 1999, BRAIN, V122, P1121, DOI 10.1093/brain/122.6.1121; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Horwitz EM, 2001, BLOOD, V97, P1227, DOI 10.1182/blood.V97.5.1227; HYMAN C, 1994, J NEUROSCI, V14, P335; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Kakishita K, 2003, BRAIN RES, V980, P48, DOI 10.1016/S0006-8993(03)02875-0; Kinnaird T, 2004, CIRC RES, V95, P354, DOI 10.1161/01.RES.0000137878.26174.66; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MAYER E, 1993, NEUROSCIENCE, V56, P379, DOI 10.1016/0306-4522(93)90339-H; McKay BS, 2006, EXP NEUROL, V201, P234, DOI 10.1016/j.expneurol.2006.04.016; Nakao N, 1998, J NEUROSCI, V18, P1806; Nakao N, 2004, EXP NEUROL, V188, P65, DOI 10.1016/j.expneurol.2004.03.004; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; Nakao N, 1997, BRAIN RES, V777, P202, DOI 10.1016/S0006-8993(97)01116-5; Nakao N, 2000, J NEUROSURG, V92, P659, DOI 10.3171/jns.2000.92.4.0659; NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; OTTO D, 1993, J NEUROSCI RES, V34, P382, DOI 10.1002/jnr.490340403; PESCHANSKI M, 1994, BRAIN, V117, P487, DOI 10.1093/brain/117.3.487; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Rosenzweig A, 2006, NEW ENGL J MED, V355, P1274, DOI 10.1056/NEJMe068172; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Toledo-Aral JJ, 2003, J NEUROSCI, V23, P141; UNGERSTEDT U, 1970, BRAIN RES, V24, P486; Villadiego J, 2005, J NEUROSCI, V25, P4091, DOI 10.1523/JNEUROSCI.4312-04.2005; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587	55	35	37	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 19	2007	1186						48	55		10.1016/j.brainres.2007.09.086			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	249BJ	WOS:000252201500006	17996227				2022-02-06	
J	Griesemer, D; Mautes, AM				Griesemer, Desiree; Mautes, Angelika M.			Closed head injury causes hyperexcitability in rat hippocampal CA1 but not in CA3 pyramidal cells	JOURNAL OF NEUROTRAUMA			English	Article						CA1/CA3 pyramidal cell; closed head injury; epilepsy; hyperexcitability	TRAUMATIC BRAIN-INJURY; SELECTIVE VULNERABILITY; REGIONAL DIFFERENCES; MECHANISMS; PATHOPHYSIOLOGY; INTERNEURONS; HOMEOSTASIS; POTASSIUM; EPILEPSY; NEURONS	Traumatic brain injury frequently elicits epileptic seizures hours or days after the impact. The mechanisms on cellular level are poorly understood. Because posttraumatic epilepsy appears in many cases as a temporal-lobe epilepsy which originated the hippocampus, we studied trauma-induced hyperexcitability on the cellular level in this brain area. We used the model of closed head injury to analyse the electrophysiological changes in CA1 and CA3 pyramidal cells and in interneurones of the CA1 field, which is extremely sensitive to ischemia. We found that morphologically closed head injury (CHI) led to a gradual progressive, cell type specific time course in neuronal degeneration. To analyse electrophysiological impairment we measured resting membrane potential, recorded spontaneous action potentials and induced action potentials by current pulses at different times after CHI. We found a dramatic increase in the frequency of spontaneous action potentials of CA1 but not of CA3 pyramidal cells after CHI. This hyperexcitability was maximal at 2 h (4.5-fold higher than sham), was also observed at 24 h after CHI and disappeared after 3 days. We found that CA1 interneurones responded by a much weaker increase of AP frequency after CHI. We conclude that the strong hyperexcitability after CHI is cell-type specific and transient. The understanding of the complex neuronal interactions probably offers a promising possibility for pharmacological intervention to prevent posttraumatic epilepsy.	[Griesemer, Desiree] Univ Saarland, Dept Physiol, D-66421 Homburg, Germany; [Mautes, Angelika M.] Univ Saarland, Neurosurg Res Lab, D-6650 Homburg, Germany		Griesemer, D (corresponding author), Univ Saarland, Dept Physiol, Bldg 58, D-66421 Homburg, Germany.	desiree.griesemer@uniklinik-saarland.de	Griesemer, Desiree/A-9152-2018	Griesemer, Desiree/0000-0002-0551-038X			AMARAL DG, 1978, J COMP NEUROL, V182, P851, DOI 10.1002/cne.901820508; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; BUZSAKI G, 1983, BRAIN RES, V266, P334, DOI 10.1016/0006-8993(83)90665-0; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CREPEL V, 1992, NEUROSCIENCE, V47, P579, DOI 10.1016/0306-4522(92)90167-Z; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Engel J, 2003, EPILEPSIA, V44, P60, DOI 10.1111/j.0013-9580.2003.12002.x; FEENEY DM, 1979, BRAIN RES, V178, P329, DOI 10.1016/0006-8993(79)90697-8; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Griesemer W, 2002, EUR BIOPHYS J BIOPHY, V31, P467, DOI 10.1007/s00249-002-0241-3; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; JOHANSEN FF, 1983, ACTA NEUROPATHOL, V61, P135, DOI 10.1007/BF00697393; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Kreisman NR, 2000, J NEUROPHYSIOL, V83, P1031, DOI 10.1152/jn.2000.83.2.1031; KROBERT KA, 1992, J NEUROTRAUM, V9, P64; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; NEWMAN GC, 1995, J NEUROSCI METH, V61, P33, DOI 10.1016/0165-0270(95)00020-U; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PEREZPINON MA, 1995, J NEUROPHYSIOL, V74, P565, DOI 10.1152/jn.1995.74.2.565; Raza M, 2007, NEUROSCI LETT, V418, P77, DOI 10.1016/j.neulet.2007.03.005; SANTHAKUMAR V, 2000, HYPOTHESIS J PHYSL, P117; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Temkin N R, 1995, New Horiz, V3, P518; TSUBOKAWA H, 1992, NEUROSCIENCE, V49, P807, DOI 10.1016/0306-4522(92)90358-9; Villanueva V, 2005, EPILEPTIC DISORD, V7, P83	43	35	36	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1823	1832		10.1089/neu.2006.0237			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000005	18159994				2022-02-06	
J	Jantzen, JPAH				Jantzen, Jan-Peter A. H.			Prevention and treatment of intracranial hypertension	BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY			English	Article						intracranial pressure; ICP; intracranial hypertension; hydrocephalus; ICP treatment; intracranial hypertension; ICP measurement; ICP monitoring; ICP etiology; ICP treatment; intracranial hypertension; Lund; CPP; intracranial osmolarity; cerebral edema; vasogenic cerebral edema; cerebral edema treatment; cerebrum; cerebrum blood flow; cerebrum blood volume; cerebral blood flow; cerebral circulation; cerebral vessels; CO2 reactivity		Intracranial pressure (ICP) is the pressure exerted by cranial contents on the dural envelope. It comprises the partial pressures of brain, blood and cerebrospinal fluid (CSF). Normal intracranial pressure is somewhere below 10 mmHg; it may increase as a result of traumatic brain injury, stroke, neoplasm, Reye's syndrome, hepatic coma, or other pathologies. When ICP increases above 20 mmHg it may damage neurons and jeopardize cerebral perfusion. If such a condition persists, treatment is indicated. Control of ICP requires measurement, which can only be performed invasively. Standard techniques include direct ventricular manometry or measurement in the parenchyma with electronic or fiberoptic devices. Displaying the time course of pressure (high-resolution ICP tonoscopy) allows assessment of the validity of the signal and identification of specific pathological findings, such as A-, B- and C-waves. When ICP is pathologically elevated at or above 20-25 mmHg - it needs to be lowered. A range of treatment modalities is available and should be applied with consideration of the underlying cause. When intracranial hypertension is caused by hematoma, contusion, tumor, hygroma, hydrocephalus or pneumatocephalus, surgical treatment is indicated. In the absence of a surgically treatable condition, ICP may be controlled by correcting the patient's position, temperature, ventilation or hemodynamics. If intracranial hypertension persists, drainage of CSF via external drainage is most effective. Other first-tier options include induced hypocapnea (hyperventilation; paCO(2) < 35 mmHg), hyperosmolar therapy (mannitol, hypertonic saline) and induced arterial hypertension (CPP concept). When autoregulation of cerebral blood flow is compromised, hyperoncotic treatment aimed at reducing vasogenic edema and intracranial blood volume may be applied. When intracranial hypertension persists, second-tier treatments may be indicated. These include 'forced hyperventilation' (paCO(2) < 25 mmHg), barbiturate coma or experimental protocols such as tris buffer, indomethacin or induced hypothermia. The last resort is emergent bilateral decompressive craniectomy; once taken into consideration, it should be performed without undue delay.	[Jantzen, Jan-Peter A. H.] Johannes Gutenberg Univ Mainz, Med Sch, Mainz, Germany; [Jantzen, Jan-Peter A. H.] Univ Texas Dallas, Southwestern Med Sch, Dallas, TX 75083 USA; [Jantzen, Jan-Peter A. H.] Acad Teaching Hosp Hannover Nordstadt, Dept Anaesthesiol, Intens Care & Pain Management, Haltenhoffstr 41, D-30167 Hannover, Germany		Jantzen, JPAH (corresponding author), Acad Teaching Hosp Hannover Nordstadt, Dept Anaesthesiol, Intens Care & Pain Management, Haltenhoffstr 41, D-30167 Hannover, Germany.	jan-peter@jantzen.net					ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS55, DOI DOI 10.1089/NEU.2007.9988; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS45; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Czosnyka Marek, 1800, Neurosurg Focus, V22, pE10; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; DUTHIE SE, 1994, J NEUROSURG ANESTH, V6, P201; Gupta VL, 1996, ACTA ANAESTH SCAND, V40, P389, DOI 10.1111/j.1399-6576.1996.tb04453.x; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jantzen J-P, 2007, J NEUROSURGICAL ANES, V19, P346; Jantzen J-P, 1992, EUR J ANAESTH, V9, P269; LIN ES, 1991, BRIT J ANAESTH, V66, P476, DOI 10.1093/bja/66.4.476; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; MILHORAT TH, 1987, NEUROSURGERY, V20, P15, DOI 10.1227/00006123-198701000-00004; MINDERMANN T, 1992, ACTA NEUROCHIR, V116, P60, DOI 10.1007/BF01541255; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; PFENNINGER E, 1989, ANAESTHESIST, V38, P189; Rasmussen M, 2005, ACTA ANAESTH SCAND, V49, P341, DOI 10.1111/j.1399-6576.2005.00647.x; REASONER DK, 1994, ANESTHESIOLOGY, V80, P1008, DOI 10.1097/00000542-199405000-00009; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026	26	35	44	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1521-6896	1878-1608		BEST PRACT RES-CLIN	Best Pract. Res.-Clin Anaesth.	DEC	2007	21	4					517	538		10.1016/j.bpa.2007.09.001			22	Anesthesiology	Emerging Sources Citation Index (ESCI)	Anesthesiology	V27TF	WOS:000215381400007	18286835				2022-02-06	
J	Mathias, JL; Bowden, SC; Bigler, ED; Rosenfeld, JV				Mathias, J. L.; Bowden, S. C.; Bigler, E. D.; Rosenfeld, J. V.			Is performance on the Wechsler test of adult reading affected by traumatic brain injury?	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							PREMORBID INTELLIGENCE; VALIDITY	Objectives. The validity of the National Adult Reading Test (NART) as a predictor of premorbid IQ when used with patients who have sustained a traumatic brain injury (TBI) has been questioned in recent years. This study examined whether performance on the Wechsler Test of Adult Reading (WTAR) is similarly affected by TBI in the first year after an injury. Design and Method. The WTAR scores of participants who had sustained a mild TBI (N = 82), moderate TBI (N = 73), severe TBI (N = 61) or an orthopaedic injury (N = 95) were compared (cross-sectional study). A subset of 21 mild TBI, 31 moderate TBI, 26 severe TBI and 21 control group participants were additionally reassessed 6 months later to assess the impact of recovery on WTAR scores (longitudinal study). Results. The severe TBI group had significantly lower scores on the WTAR than the mild TBI, moderate TBI and control groups in the cross-sectional study, despite being matched demographically. The findings from the longitudinal study revealed a significant group difference and a small improvement in performance over time but the interaction between group and time was not significant, suggesting that the improvements in WTAR performance over time were not restricted to more severely injured individuals whose performance was temporarily suppressed. Conclusions. These findings suggest that reading performance may be affected by severe TBI and that the WTAR may underestimate premorbid IQ when used in this context, which may cause clinicians to underestimate the cognitive deficits experienced by these patients.	Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; Univ Melbourne, Sch Behav Sci, Dept Psychol, Melbourne, Vic, Australia; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia		Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013; Rosenfeld, Jeffrey V/B-7249-2011	Mathias, Jane/0000-0001-8957-8594			Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CRAWFORD JR, 1990, BRIT J CLIN PSYCHOL, V29, P435, DOI 10.1111/j.2044-8260.1990.tb00908.x; Franzen MD, 1997, ARCH CLIN NEUROPSYCH, V12, P711, DOI 10.1016/S0887-6177(97)00046-2; Freeman J, 2000, BRIT J CLIN PSYCHOL, V39, P95, DOI 10.1348/014466500163130; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; WILLSHIRE D, 1991, J CLIN EXP NEUROPSYC, V13, P204, DOI 10.1080/01688639108401038	20	35	35	0	4	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	NOV	2007	46		4				457	466		10.1348/014466507X190197			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	234KS	WOS:000251163600007	17535531				2022-02-06	
J	Heitger, MH; Jones, RD; Frampton, CM; Ardagh, MW; Anderson, TJ				Heitger, Marcus H.; Jones, Richard D.; Frampton, Chris M.; Ardagh, Michael W.; Anderson, Tim J.			Recovery in the first year after mild head injury: Divergence of symptom status and self-perceived quality of life	JOURNAL OF REHABILITATION MEDICINE			English	Article						head injury; recovery; IQ; rehabilitation; health status	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYMPTOMS; FOLLOW-UP; POSTCONCUSSION SYNDROME; PREDICTIVE-VALUE; ADULTS; QUESTIONNAIRE; POPULATION; DISABILITY; COMPLAINTS	Objective: To examine self-perceived health status during the first year following mild closed head injury. Methods: At 1 week, and at 3, 6 and 12 months post-injury, 37 patients with mild closed head injury completed written versions of the Rivermead Post-Concussion Symptoms Questionnaire (RPSQ), the Rivermead Head-Injury Followup Questionnaire (RHIFQ) and the SF-36 Health Survey. Thirty-seven controls provided baselines for the SF-36 and the RPSQ. Results: The 3 questionnaires conveyed differing impressions of recovery. On the RPSQ, the patients exhibited ongoing symptomatic complaints and higher scores compared with controls. The RHIFQ conveyed a better recovery in terms of everyday function. The SF-36 showed the best recovery, with the mild closed head injury group achieving normal scores at 3, 6 and 12 months. Regression analyses indicated an influence of IQ, but not of age, education, or clinical measures of injury severity, on long-term health status. Conclusion: Recovery after mild closed head injury can involve a dichotomy of persistent post-concussional symptoms but relatively normal functionality and quality of life. In addition to indicating an influence of IQ on perception of recovery in mild closed head injury, our findings demonstrate that the nature of self-report questionnaires considerably influences the picture of recovery. This emphasizes the importance of methods unaffected by IQ and self-evaluative accuracy in the assessment of mild closed head injury.	Van Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Univ Otago, Dept Med, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand		Heitger, MH (corresponding author), Van Veer Inst Parkinsons & Brain Res, POB 2682, Christchurch, New Zealand.	marcus.heitger@chmeds.ac.nz		Jones, Richard/0000-0003-2287-3358			Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X	40	35	35	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2007	39	8					612	621		10.2340/16501977-0100			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	225UK	WOS:000250543400005	17896052	Green Submitted, Green Published, gold			2022-02-06	
J	Hickey, RW; Adelson, PD; Johnnides, MJ; Davis, DS; Yu, Z; Rose, ME; Chang, YF; Graham, SH				Hickey, Robert W.; Adelson, P. David; Johnnides, Michael J.; Davis, Dwight S.; Yu, Zhisheng; Rose, Marie E.; Chang, Yue-Fang; Graham, Steven H.			Cyclooxygenase-2 activity following traumatic brain injury in the developing rat	PEDIATRIC RESEARCH			English	Article							NITRIC-OXIDE SYNTHASE; NEURONAL CELL-DEATH; CEREBRAL-ISCHEMIA; INHIBITION; EXPRESSION; APOPTOSIS; MODEL; NEUROTOXICITY; INFLAMMATION; METABOLISM	Cyclooxygenase (COX) is the rate-limiting enzyme in the production of prostaglandins. COX-2, the predominant COX isoform in brain, is induced by synaptic activity. COX-2-generated prostaglandins are important regulators for a range of activities under physiologic conditions. However, under pathologic conditions, COX-2 activity can produce reactive oxygen species and toxic prostaglandin metabolites that can exacerbate brain injury. In this study, we examine the developmental production of COX-2 and test the ability of a COX-2 inhibitor, SC58125, to attenuate traumatic brain injury in developing rats. We show that constitutive COX-2 concentration is low (0.5-fold adult concentration) during the first postnatal week and then increases to 3-fold of adult levels between days 14-60. Controlled cortical impact (CCI) at postnatal day (PND) 17, but not PND 7, caused an additional 3-fold increase in COX-2 content and was associated with an increase in the COX-2 product PGE(2). Treatment with the COX-2 inhibitor SC58125 in PND17 rats exposed to CCI attenuated the rise in PGE, but did not attenuate lesion volume or improve performance in the Morris water	Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; VA Pittsburg Healthcare Syst, Ctr Clin, Pittsburgh, PA 15206 USA		Hickey, RW (corresponding author), Childrens Hosp Pittsburgh, Div Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	robert.hickely@chp.edu	Adelson, David/W-2083-2019		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [KO8 HD40848, K08 HD040848] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS42298, R01 NS037459, R01 NS037459-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037459, R01NS042298] Funding Source: NIH RePORTER		Andreasson KI, 2001, J NEUROSCI, V21, P8198; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; CEMAK I, 2001, CLIN EXP PHARM PHYSL, V28, P922; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Graham SH, 2003, ARCH NEUROL-CHICAGO, V60, P628, DOI 10.1001/archneur.60.4.628; Jiang JF, 2004, J NEUROCHEM, V90, P1036, DOI 10.1111/j.1471-4159.2004.02577.x; Kaufmann WE, 1997, BRAIN DEV-JPN, V19, P25, DOI 10.1016/S0387-7604(96)00047-2; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kim EJ, 2002, J NEUROSCI RES, V70, P97, DOI 10.1002/jnr.10373; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Li ZM, 2004, BIOCHEM BIOPH RES CO, V319, P1171, DOI 10.1016/j.bbrc.2004.05.098; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Moochhala SM, 2005, J TRAUMA, V59, P448, DOI 10.1097/01.ta.0000174858.79847.6d; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Takamatsu H, 2002, BRAIN RES, V925, P176, DOI 10.1016/S0006-8993(01)03280-2; Teather LA, 2002, LEARN MEMORY, V9, P41, DOI 10.1101/lm.43602; Tocco G, 1997, EXP NEUROL, V144, P339, DOI 10.1006/exnr.1997.6429; Towfighi J, 1997, DEV BRAIN RES, V100, P149, DOI 10.1016/S0165-3806(97)00036-9; UENO R, 1985, J NEUROCHEM, V45, P483, DOI 10.1111/j.1471-4159.1985.tb04014.x; Yagami T, 2002, J NEUROCHEM, V81, P449, DOI 10.1046/j.1471-4159.2002.00800.x	30	35	35	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	SEP	2007	62	3					271	276		10.1203/PDR.0b013e3180db2902			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	203KJ	WOS:000248973200008	17622965	Bronze			2022-02-06	
J	Yilmaz, N; Dulger, H; Kiymaz, N; Yilmaz, C; Gudu, BO; Demir, I				Yilmaz, Nebi; Dulger, Haluk; Kiymaz, Nejmi; Yilmaz, Cahide; Gudu, Burhan O.; Demir, Ismail			Activity of mannitol and hypertonic saline therapy on the oxidant and antioxidant system during the acute term after traumatic brain injury in the rats	BRAIN RESEARCH			English	Article						mannitol; hypertonic saline; malondialdehyde; antioxidant enzyme; brain injury	ELEVATED INTRACRANIAL-PRESSURE; ACID-REACTIVE SUBSTANCES; CATALASE ACTIVITY; MODEL; PATHOPHYSIOLOGY; DEXTRAN-70; INCREASES; SERUM	In this study, our objective is to investigate the effects of mannitol and 7.5% hypertonic saline (HS) therapy on the levels of malondialdehyde (MDA), catalase and glutathione peroxidase (GSH-Px) in the early stages of experimental head traumas in rats. Rats included in the study were divided into four groups: Group I Control, Group II Trauma, Group III Mannitol, and Group IV 7.5% Hypertonic Saline. Rats in Group 11 were subject to head trauma only. Mannitol was injected intraperitoneally to rats in Group III after head trauma and 7.5% HS was injected intraperitoneally to rats in Group IV after head trauma. Rats were sacrificed 4 h after administration of mannitol. or 7.5% HS, and the levels of MDA catalase and GSH-Px in brain tissues extracted from rats were determined. MDA levels in the trauma group were significantly increased compared with the control group (p<0.01), whereas there was a reduction in catalase and GSH-Px levels, although these differences were not significant. By contrast, in the mannitol group, MDA, catalase and GSH-Px levels were lower than the levels in the trauma group, and these reductions were statistically significant (p<0.05). The MDA, catalase and GSH-Px levels of the 7.5% HS group were lower than those of the trauma group; however, this reduction was not statistically significant. It was concluded that mannitol and 7.5% HS therapies that are used to reduce intracranial pressure and to increase the use of catalase, an antioxidant enzyme, and GSH-Px, are likely to reduce cellular damage by reducing the formation of MDA, the levels of which are known to be indicative of cellular level oxidant damage. (c) 2007 Elsevier B.V. All rights reserved.	Yuzuncu Yil Univ, Sch Med, Dept Neurosurg, Van, Turkey; Yuzuncu Yil Univ, Sch Med, Dept Biochem, Van, Turkey; Yuzuncu Yil Univ, Sch Med, Dept Pediat Neurol, Van, Turkey		Yilmaz, N (corresponding author), Yuzuncu Yil Univ, Sch Med, Dept Neurosurg, Van, Turkey.	yilmaznebi@yahoo.com	GUDU, BURHAN/ABC-1595-2021	GUDU, BURHAN/0000-0002-5011-815X			Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; CAO LZ, 2000, HUNAN YIKE DAXUE XUE, V28, P109; Choi SH, 2006, EMERG MED J, V23, P119, DOI 10.1136/emj.2004.020651; Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOTH L, 1991, CLIN CHIM ACTA, V196, P143, DOI 10.1016/0009-8981(91)90067-M; HALL ED, 1993, RES P ARNMD, V71, P81; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Orlic T, 2002, AM J PHYSIOL-CELL PH, V282, pC1261, DOI 10.1152/ajpcell.00479.2001; PLEBAN PA, 1982, CLIN CHEM, V28, P311; Povlishock J T, 1992, Hum Cell, V5, P345; Santos A, 2005, NEUROCHEM RES, V30, P625, DOI 10.1007/s11064-005-2750-9; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WASOWICZ W, 1993, CLIN CHEM, V39, P2522	22	35	37	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	2007	1164						132	135		10.1016/j.brainres.2007.06.017			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	208LX	WOS:000249321900014	17651707				2022-02-06	
J	De Oliveira, CO; Reimer, AG; Da Rocha, AB; Grivicich, I; Schneider, RF; Roisenberg, I; Regner, A; Simon, D				De Oliveira, Clarissa Oliveira; Reimer, Alexandre Gard; Da Rocha, Adriana Brondani; Grivicich, Ivana; Schneider, Rogerio Fett; Roisenberg, Israel; Regner, Andrea; Simon, Daniel			Plasma von Willebrand factor levels correlate with clinical outcome of severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; biomarkers; outcome measures; traumatic brain injury; von Willebrand factor	SEVERE HEAD-INJURY; PROTEIN CONCENTRATIONS; EARLY PREDICTOR; SERUM S-100B; MARKER; S100B; HEMORRHAGE; CHILDREN; STROKE; DAMAGE	Biochemical markers of cellular stress/injury have been proposed to indicate outcome after head injury. The aim of the present study was to determine whether plasma von Willebrand factor (VWF) levels correlate with primary outcome and with clinical variables in severe traumatic brain injury (TBI). Forty-four male patients, victims of severe TBI, were analyzed. Clinical outcome variables of severe TBI comprised survival and neurological assessment using the Glasgow Outcome Scale (GOS) at intensive care unit (ICU) discharge. Computerized tomography (CT) scans were analyzed according to Marshall CT classification. Three consecutive venous blood samples were taken: first sample (11.4 +/- 5.2 h after trauma, mean +/- SD), and 24 h and 7 days later. The result of mean plasma VWF concentration was significantly higher in the TBI group (273 U/dL) than in the control group (107 U/dL; p < 0.001). Severe TBI was associated with a 50% mortality rate. Nonsurvivors presented significantly higher APACHE II scores than survivors (nonsurvivors mean, 18.8; survivors mean, 12.7; p < 0.001), and also presented higher scores in Marshall CT classification ( nonsurvivors mean, 4.6; survivors mean, 2.7; p < 0.05). There was a significant positive correlation between plasma levels at second plasma sampling and scores in Marshall CT classification (p < 0.05). The sensitivity of plasma VWF concentration in predicting mortality according to the cut-off of 234 U/dL was 64%, with a specificity of 68%. Therefore, VWF increases following severe TBI may be a marker of unfavorable outcome.	Univ Luterana Brasil, PPG Diagnost Genet & Mol, BR-92425900 Canoas, RS, Brazil; Univ Fed Rio Grande do Sul, PPG Genet & Biol Mol, Porto Alegre, RS, Brazil; Hosp Municipal Pronto Socorro, SAMU, Porto Alegre, RS, Brazil		Regner, A (corresponding author), Univ Luterana Brasil, PPG Diagnost Genet & Mol, Av Farroupilha 8001,Predio 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br	Simon, Daniel/A-9087-2011; Regner, Andrea/M-2596-2014; Grivicich, Ivana/A-6777-2013	Simon, Daniel/0000-0003-1122-8468; Regner, Andrea/0000-0002-6657-7991; Grivicich, Ivana/0000-0001-9820-5730			Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BLANN AD, 1993, MED HYPOTHESES, V41, P419, DOI 10.1016/0306-9877(93)90118-A; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fischer RR, 1996, BRAZ J MED BIOL RES, V29, P1641; Garcia-Fernandez N, 2000, THROMB RES, V100, P19, DOI 10.1016/S0049-3848(00)00306-6; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015, DOI 10.1152/ajpheart.2000.279.3.H1015; KESSLER CM, 2004, CECIL TXB MED, P1069; Kraus J, 1996, NEUROTRAUMA, P13; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; MEISSNER RV, 1992, BRAZ J GENET, V15, P935; Mendolicchio GL, 2005, SEMIN HEMATOL, V42, P5, DOI 10.1053/j.seminhematol.2004.09.006; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Pelsers MMAL, 2005, CLIN CHEM LAB MED, V43, P802, DOI 10.1515/CCLM.2005.135; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Siemiatkowski A, 2000, HAEMOSTASIS, V30, P189; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; ZAGARA G, 1992, J NEUROSURG SCI, V35, P77	32	35	36	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1331	1338		10.1089/neu.2006.0159			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500004	17711394				2022-02-06	
J	Bhang, SH; Lee, YE; Cho, SW; Shim, JW; Lee, SH; Choi, CY; Chang, JW; Kim, BS				Bhang, Suk Ho; Lee, Young Eun; Cho, Seung-Woo; Shim, Jae-Won; Lee, Sang-Hun; Choi, Cha Yong; Chang, Jin Woo; Kim, Byung-Soo			Basic fibroblast growth factor promotes bone marrow stromal cell transplantation-mediated neural regeneration in traumatic brain injury	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						basic fibroblast growth factors; bone marrow stromal cell; brain trauma injury; fibrin gel	RAT MODEL; ISCHEMIA; MICE; NEUROGENESIS; RELEASE; HEPARIN	The current study was designed to evaluate the effects of basic fibroblast growth factor (bFGF) on human BMSC (hBMSC) transplantation-mediated neural regeneration in traumatic brain injury (TBI). Fibrin gel was used as a delivery vehicle to release bFGF locally in the TBI sites in a controlled manner. To test this hypothesis, hBMSCs suspended in fibrin gel containing bFGF were transplanted to rat TBI sites. Transplantation of hBMSCs suspended in fibrin gel without bFGF served as a control. hBMSC transplantation and bFGF treatment showed enhanced neural tissue regeneration than that of the control. The infarction volume and apoptotic activity of the transplanted hBMSCs were significantly decreased, and functional outcomes were significantly improved in the hBMSC transplantation and bFGF treatment group than in the control group. This study demonstrates that bFGF significantly enhances histological and functional recovery when used in hBMSC transplantation therapy in TBI. (C) 2007 Elsevier Inc. All rights reserved.	Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea; Seoul Natl Univ, Sch Chem & Biol Engn, Seoul 151742, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Neurosurg, Seoul 120752, South Korea; Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 133791, South Korea; Hanyang Univ, Inst Mental Hlth, Seoul 133791, South Korea		Chang, JW (corresponding author), Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.	jchang@yumc.yonsei.ac.kr; bskim@hanyang.ac.kr	Cho, Seung-Woo/AAU-1214-2021; lee, sang hun/Q-4650-2019; Byung-Soo, Kim/O-2352-2013	Cho, Seung-Woo/0000-0001-8058-332X; lee, sang hun/0000-0002-9005-5966; Byung-Soo, Kim/0000-0001-5210-7430; Chang, Jin Woo/0000-0002-2717-0101			Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Hile DD, 2000, J CONTROL RELEASE, V66, P177, DOI 10.1016/S0168-3659(99)00268-0; Jeon O, 2005, J CONTROL RELEASE, V105, P249, DOI 10.1016/j.jconrel.2005.03.023; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kilic E, 2004, NEUROSCIENCE, V128, P359, DOI 10.1016/j.neuroscience.2004.06.064; Li Q, 2002, EXP NEUROL, V177, P531, DOI 10.1006/exnr.2002.7994; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; OLSSON M, 1995, J NEUROSCI, V15, P3863; Ourednik J, 2004, CELL TRANSPLANT, V13, P307, DOI 10.3727/000000004783983963; Ramirez JJ, 1999, NEUROREPORT, V10, P1201, DOI 10.1097/00001756-199904260-00008; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Rozas G, 1997, BRAIN RES PROTOC, V2, P75, DOI 10.1016/S1385-299X(97)00034-2; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V65, P389, DOI 10.1016/S0168-3659(99)00221-7; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Tabata Y, 1998, BIOMATERIALS, V19, P807, DOI 10.1016/S0142-9612(98)00233-6; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yulug B, 2004, BRAIN RES, V996, P76, DOI 10.1016/j.brainres.2003.10.012	31	35	52	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	JUL 20	2007	359	1					40	45		10.1016/j.bbrc.2007.05.046			6	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	178YZ	WOS:000247257600007	17531197				2022-02-06	
J	Liu-Snyder, P; Logan, MP; Shi, R; Smith, DT; Ben Borgens, R				Liu-Snyder, Peishan; Logan, Melissa Peasley; Shi, Riyi; Smith, Daniel T.; Ben Borgens, Richard			Neuroprotection from secondary injury by polyethylene glycol requires its internalization	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						PEG; secondary injury; acrolein; endogenous toxins; CNS	SPINAL-CORD-INJURY; AXONAL MEMBRANE DISRUPTION; MOLECULAR REPAIR; NERVE MEMBRANES; CONDUCTION LOSS; WHITE-MATTER; BRAIN-INJURY; ACROLEIN; CELLS; RECOVERY	Polyethylene glycol ( PEG) is well known to both fuse and repair cell membranes. This capability has been exploited for such diverse usages as the construction of hybridomas and as a reparative agent following neurotrauma. The latter development has proceeded through preclinical testing in cases of naturally induced paraplegia in dogs. The mechanisms of action of polymer-mediated neurorepair/neuroprotection are still under investigation. It is likely that the unique interaction of hydrophilic polymers with the mechanical properties of cell membranes in concert with an ability to interfere with mechanisms of secondary injury such as the production of highly reactive oxygen species (ROS or 'free radicals') is the basis for neuroprotection by polymers. Here we provide further evidence that the ability of PEG to reduce or limit secondary injury and/or lipid peroxidation (LPO) of membranes requires entry of PEG into the cytosol, further suggesting a physical interaction with the membranes of organelles such as mitochondria as the initial event leading to neurorepair/neuroprotection. We have evaluated this relationship in vitro using acrolein, a potent endogenous toxin that is a product of LPO. Acrolein can pass through cell membranes with ease, inducing progressive LPO in 'bystander' cells, and the production of even more acrolein by inducing its own production. Immediate application of PEG (10 mmol l(-1), 2000 Da) to poisoned neurons in vitro was unable to rescue them from necrosis and death. Furthermore, three-dimensional confocal microscopy of fluorescently decorated PEG shows that it does not enter these cells for up to 2 h after application. By this time the mechanisms of necrosis are likely irreversible. Additionally, severe oxygen and or glucose deprivation of spinal cord white matter in vitro also initiates LPO. Addition of potent free radical scavengers such as ascorbic acid or superoxide dismutase (SOD) is able to interfere with this process, but PEG is not. Taken together, these data are consistent with the hypothesis that PEG is able to rescue mechanically damaged cells, based on a restructuring of the damaged plasmalemma. Furthermore, in compromised cells with an intact cell membrane, PEG must first gain access to the cytosol where this same capability may be useful in restoring the integrity of cellular organelles such as mitochondria, though the intracellular concentration of the polymer must be significant relative to the concentration of toxins produced by LPO in order to rescue the cell.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA		Ben Borgens, R (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	cpr@purdue.edu					Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 2003, ADV ANATOMY EMBRYOLO, V171; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; Georgiev G, 2004, EUR BIOPHYS J BIOPHY, V33, P742, DOI 10.1007/s00249-004-0421-4; Georgiev GA, 2006, EUR BIOPHYS J BIOPHY, V35, P352, DOI 10.1007/S00249-006-0043-0; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Peasley MA, 2003, J NEUROL SCI, V216, P23, DOI 10.1016/S0022-510X(03)00201-6; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572, DOI 10.1152/jn.1996.76.3.1572; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Working PK, 1997, ACS SYM SER, V680, P45; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844	37	35	35	0	9	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	APR 15	2007	210	8					1455	1462		10.1242/jeb.02756			8	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	152HX	WOS:000245353700020	17401128	Green Submitted, Bronze			2022-02-06	
J	Wagner, AK; Ren, DX; Conley, YP; Ma, XC; Kerr, ME; Zafonte, RD; Puccio, AM; Marion, DW; Dixon, CE				Wagner, Amy K.; Ren, Dianxu; Conley, Yvette P.; Ma, Xiecheng; Kerr, Mary E.; Zafonte, Ross D.; Puccio, Ava M.; Marion, Donald W.; Dixon, C. Edward			Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebrospinal fluid; dopamine; homovanillic acid; dihydroxyphenylacetic acid; sex-based difference; genetic polymorphism	WATER MAZE PERFORMANCE; GENDER-DIFFERENCES; METHYLPHENIDATE TREATMENT; TRANSPORTER AVAILABILITY; HOMOVANILLIC-ACID; DOWN-REGULATION; AMINO-ACIDS; IN-VIVO; ESTROGEN; HEALTHY	Object. Dopamine (DA) pathways have been implicated in cognitive deficits after traumatic brain injury (TBI). Both sex and the dopamine transporter (DAT) 3' variable number of tandem repeat polymorphism have been associated with differences in DAT protein density, and DAT protein affects both presynaptic DA release, through reverse transport, and DA reuptake. Catecholamines and associated metabolites are subject to autooxidation, resulting in the formation of reactive oxygen species that may contribute to subsequent oxidative injury. The purpose of this study was to determine associations between factors that affect DAT expression and cerebrospinal fluid (CSF) DA and metabolite levels after severe TBI. Methods. Sixty-three patients with severe TBI (Glasgow Coma Scale score : 8) were evaluated. The patients' genotypes were obtained using previously banked samples of CSF, and serial CSF samples (416 samples) were used to evaluate DA and metabolite levels. High-performance liquid chromatography was used to determine CSF levels of DA, 3,4-dihydroxyphenyl acetic acid (DOPAC), and homovanillic acid (HVA) during the first 5 days after injury. Mixed-effects multivariate regression modeling revealed that patients with the DAT 10/10 genotype had higher CSF DA levels than patients with either the DAT 9/9 or DAT 9/10 genotypes (p = 0.009). Females with the DAT 10/10 genotype had higher CSF DA levels than females with the DAT 9/9 or DAT 9/10 genotypes, and sex was associated with higher DOPAC levels (p = 0.004). Inotrope administration also contributed to higher DA levels (p = 0.002). Conclusions. In addition to systemic administration of DA, inherent factors such as sex and DAT genotype affect post-TBI CSF DA and DA metabolite levels, a phenomenon that may modulate susceptibility to DA-mediated oxidative injury.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Marion, Donald/AAR-5749-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS30318] Funding Source: Medline		AGNATI LF, 1995, MED RES REV, V15, P33, DOI 10.1002/med.2610150104; Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9; Borland LM, 2004, J NEUROCHEM, V91, P220, DOI 10.1111/j.1471-4159.2004.02708.x; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COOK EH, 1995, AM J HUM GENET, V56, P993; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dluzen DE, 2000, J NEUROCYTOL, V29, P387, DOI 10.1023/A:1007117424491; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DOUCETTESTAMM LA, 1995, GENET EPIDEMIOL, V12, P303, DOI 10.1002/gepi.1370120307; Engelborghs S, 2003, NEUROCHEM RES, V28, P1145, DOI 10.1023/A:1024255208563; Gardiner SA, 2004, AM J GERIAT PSYCHIAT, V12, P621, DOI 10.1176/appi.ajgp.12.6.621; GARRIS PA, 1994, J NEUROSCI, V14, P6084; Gerevich Z, 2001, NEUROSCIENCE, V104, P761, DOI 10.1016/S0306-4522(01)00102-6; Gerlach M, 2001, J NEURAL TRANSM, V108, P189, DOI 10.1007/s007020170087; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gulley JM, 2003, EUR J PHARMACOL, V479, P139, DOI 10.1016/j.ejphar.2003.08.064; Hastings TG, 1996, ADV EXP MED BIOL, V387, P97; Heinz A, 2000, NEUROPSYCHOPHARMACOL, V22, P133, DOI 10.1016/S0893-133X(99)00099-8; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Jiang H, 2003, NEUROPHARMACOLOGY, V45, P1011, DOI 10.1016/S0028-3908(03)00286-7; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Jonsson EG, 2000, J PSYCHIAT RES, V34, P239, DOI 10.1016/S0022-3956(00)00013-3; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; Khoshbouei H, 2003, J BIOL CHEM, V278, P12070, DOI 10.1074/jbc.M212815200; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Krause KH, 2000, NEUROSCI LETT, V285, P107, DOI 10.1016/S0304-3940(00)01040-5; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Lambert G, 2002, BRAIN RES BULL, V58, P77, DOI 10.1016/S0361-9230(02)00762-1; Laranjinha J, 2002, J NEUROCHEM, V81, P892, DOI 10.1046/j.1471-4159.2002.00900.x; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Michelhaugh SK, 2001, J NEUROCHEM, V79, P1033, DOI 10.1046/j.1471-4159.2001.00647.x; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; Newcorn J H, 2001, Curr Psychiatry Rep, V3, P87, DOI 10.1007/s11920-001-0004-3; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; Oechsner M, 2002, J NEURAL TRANSM, V109, P69, DOI 10.1007/s702-002-8237-z; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Raiteri M, 1978, Ann Ist Super Sanita, V14, P97; RIVEST R, 1995, BRAIN RES, V692, P269, DOI 10.1016/0006-8993(95)00611-S; Sesack SR, 1998, J NEUROSCI, V18, P2697; SMITH TS, 1994, NEUROREPORT, V5, P1009, DOI 10.1097/00001756-199404000-00039; Swanson JM, 2000, NEUROSCI BIOBEHAV R, V24, P21, DOI 10.1016/S0149-7634(99)00062-7; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Xie T, 1999, MOL PHARMACOL, V56, P31, DOI 10.1124/mol.56.1.31; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; YATES CM, 1979, J NEUROL NEUROSUR PS, V42, P887, DOI 10.1136/jnnp.42.10.887; Youdim MBH, 2004, NEUROLOGY, V63, pS32, DOI 10.1212/WNL.63.7_suppl_2.S32; Zhang H, 2003, J CHROMATOGR B, V784, P131, DOI 10.1016/S1570-0232(02)00788-2	59	35	35	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2007	106	4					538	547		10.3171/jns.2007.106.4.538			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	155OJ	WOS:000245586900005	17432702				2022-02-06	
J	Bulger, EM; Nathens, AB; Rivara, FP; MacKenzie, E; Sabath, DR; Jurkovich, GJ				Bulger, Eileen M.; Nathens, Avery B.; Rivara, Frederick P.; MacKenzie, Ellen; Sabath, Daniel R.; Jurkovich, Gregory J.			National variability in out-of-hospital treatment after traumatic injury	ANNALS OF EMERGENCY MEDICINE			English	Article							CARDIAC-ARREST; BRAIN-INJURY; ENDOTRACHEAL INTUBATION; CARE; EMS; RESUSCITATION	Study objective: The optimal out-of-hospital treatment for trauma patients remains a subject of national debate. Researchers designing future studies to address these issues must understand the variability in treatment that exists across the United States. We define the variability in the out-of-hospital treatment provided to trauma patients in the United States. Methods: This was a retrospective analysis of prospectively collected data for a cohort study of trauma outcomes. The study was conducted at 15 urban or suburban regions across the United States, 18 Level I trauma centers and 51 nontrauma centers. We used a weighted population sample based on data from all hospital trauma deaths and a sample of patients discharged between January 2001 and December 2002. Entry criteria included at least 1 body region with an Abbreviated Injury Score greater than 3 and age between 18 and 84 years. Exclusion criteria were patient age greater than 65 years and isolated hip fractures and patients with burns. Results: Complete out-of-hospital data were available for 3,357 patients, representing a weighted population sample of 9,929 patients. Out-of-hospital treatment varied substantially among the regions, including out-of-hospital intubation (5% to 48%), use of neuromuscular blocking agents or sedatives to facilitate intubation (0% to 100%), surgical airway access (0.1% to 3.5%), peripheral and central intravenous access (22% to 95%), and needle thoracentesis (0% to 5%). Conclusion: There is considerable national variability in out-of-hospital procedures performed for trauma patients.	Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Johns Hopkins Sch Publ Hlth, Baltimore, MD USA		Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Box 359796,325 9th Ave, Seattle, WA 98104 USA.	ebulger@u.washington.edu					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; COBB LA, 1993, ARCH INTERN MED, V153, P1165, DOI 10.1001/archinte.153.10.1165; Cornwell EE, 2000, ARCH SURG-CHICAGO, V135, P315, DOI 10.1001/archsurg.135.3.315; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS R, 2003, US TODAY        0728, pA7; DAVIS R, 2003, US TODAY        0728, pA1; DAVIS R, 2003, US TODAY        0728, pA6; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; FILDES JJ, 2004, NATL TRAUMA DATABANK; Fortune JB, 1997, J TRAUMA, V42, P832, DOI 10.1097/00005373-199705000-00013; Frankel H, 1997, AM J EMERG MED, V15, P630, DOI 10.1016/S0735-6757(97)90174-1; Fredriksson M, 2003, AM J EMERG MED, V21, P276, DOI 10.1016/S0735-6757(03)00082-2; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Li J, 1999, AM J EMERG MED, V17, P141, DOI 10.1016/S0735-6757(99)90046-3; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Raghunathan T.E., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	26	35	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAR	2007	49	3					293	301		10.1016/j.annemergmed.2006.06.038			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	142GI	WOS:000244637000008	16978737				2022-02-06	
J	Redell, JB; Dash, PK				Redell, John B.; Dash, Pramod K.			Traumatic brain injury stimulates hippocampal catechol-O-methyl transferase expression in microglia	NEUROSCIENCE LETTERS			English	Article						protein array; microarray; proteomics; dopamine; COMT; TBI	RAT FRONTAL-CORTEX; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CONTROLLED CORTICAL IMPACT; DOPAMINE TRANSPORTER; PROTEIN EXPRESSION; PREFRONTAL CORTEX; WORKING-MEMORY; METHYLTRANSFERASE; TECHNOLOGY; GENOTYPE	Outcome following traumatic brain injury (TBI) is in large part determined by the combined action of multiple processes. In order to better understand the response of the central nervous system to injury, we utilized an antibody array to simultaneously screen 507 proteins for altered expression in the injured hippocampus, a structure critical for memory formation. Array analysis indicated 41 candidate proteins have altered expression levels 24h after TBI. Of particular interest was catechol-O-methyl transferase (COMT), an enzyme involved in metabolizing catecholamines released following neuronal activity. Altered catecholamine signaling has been observed after brain injury, and may contribute to the cognitive dysfunctions and behavioral deficits often experienced after TBI. Our data shows that COMT expression in the injured ipsilateral hippocampus was elevated for at least 14 d after controlled cortical impact injury. We found strong co-localization of COMT immunoreactivity with the microglia marker lbal near the injury site. Since dopamine transporter expression has been reported to be down-regulated after brain injury, COMT-mediated catecholamine metabolism may play a more prominent role in terminating catecholamine signaling in injured areas. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Univ Texas, Sch Med, Dept Neurobiol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH072933, R01 MH072933] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, NS049160, R01 NS035457, R01 NS049160] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS049160] Funding Source: NIH RePORTER		Akil M, 2003, J NEUROSCI, V23, P2008; Anderson K, 2003, BRAIN, V126, P2052, DOI 10.1093/brain/awg208; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Farber K, 2005, MOL CELL NEUROSCI, V29, P128, DOI 10.1016/j.mcn.2005.01.003; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jiang YJ, 2002, J CEREBR BLOOD F MET, V22, P689, DOI 10.1097/00004647-200206000-00007; KAROUM F, 1994, J NEUROCHEM, V63, P972, DOI 10.1046/j.1471-4159.1994.63030972.x; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; LUNDSTROM K, 1995, BBA-PROTEIN STRUCT M, V1251, P1, DOI 10.1016/0167-4838(95)00071-2; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Redell JB, 2003, EXP BIOL MED, V228, P261, DOI 10.1177/153537020322800304; Sesack SR, 1998, J NEUROSCI, V18, P2697; Srivastava M, 2006, MOL GENET METAB, V87, P303, DOI 10.1016/j.ymgme.2005.10.021; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	30	35	38	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	FEB 8	2007	413	1					36	41		10.1016/j.neulet.2006.11.060			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	141JO	WOS:000244574800008	17240060	Green Accepted			2022-02-06	
J	Mauritz, W; Janciak, I; Wilbacher, I; Rusnak, M				Mauritz, Walter; Janciak, Ivan; Wilbacher, Ingrid; Rusnak, Martin		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria IV: Intensive care management	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; monitoring; intracranial pressure; cerebral perfusion pressure; hyperventilation; hypertonic saline; glucose levels; outcome	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; HYPOTHERMIA; HYPERGLYCEMIA; SALINE; EPIDEMIOLOGY; HYPERTENSION; GUIDELINES; MANNITOL	OBJECTIVES: The goal of this paper is to describe the ICU management of severe traumatic brain injury (TBI) in Austria. PATIENTS AND METHODS: Data sets from 415 patients included by 5 Austrian hospitals were available. The analysis focused on complications and outcomes of intensive care, monitoring of intracranial pressure (ICP), efficacy of interventions to control ICP, management of hemodynamics and cerebral perfusion pressure (CPP), ventilation, and effects of hyperglycaemia. RESULTS: Overall ICU mortality was 30.8%; 90-day mortality was 35.7%. Final outcome was favorable in 33%, unfavorable in 51%, and in 16% the final outcome was unknown. An ICP monitoring device was used in 64%; most patients received intraparenchymal sensors (77%). Events associated with mortality > 50% were CPP < 50 mm Hg for > 12 hours/day, ICP > 25 mm Hg for > 12 hours/day, and MAP < 70 mm Hg for > 18 hours/day. The use of ICP monitoring was associated with significantly reduced ICU mortality. Interventions that may have improved the outcome included the use of barbiturates (short-term), hypertonic saline, moderate hyperventilation (33 < pCO(2) < 37; p < 0.001 vs. aggressive hyperand normoventilation), and normothermia. Hyperglycaemia was associated with poor outcome. CONCLUSIONS: Our study showed that ICU management of patients with severe TBI mostly follows international guidelines, and that outcome was comparable to or even better than that reported by other authors. Low CPP was associated with poor outcome, and was more often due to low MAP than to elevated ICP. The use of barbiturates and hypertonic saline was more common than expected. CPP should be maintained > 50 mm Hg, the use of catecholamines, fluid loading, barbiturates (short-term), moderate hyperventilation, hypertonic saline, and insulin may improve outcome after severe TBI.	INRO, Med Advisory Board, A-1080 Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anesthesia & Crit Care Med, Vienna, Austria		Mauritz, W (corresponding author), INRO, Med Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016	Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P457; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Citerio Giuseppe, 2003, Curr Opin Crit Care, V9, P120, DOI 10.1097/00075198-200304000-00007; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Firsching R, 2001, WORLD J SURG, V25, P1221; Forster Nicole, 2004, Curr Opin Anaesthesiol, V17, P371, DOI 10.1097/00001503-200410000-00004; Guyot LL, 1998, ACT NEUR S, V71, P47; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Hartl R, 1997, ACT NEUR S, V70, P126; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Lane PL, 2000, CAN J SURG, V43, P442; Lang E W, 1995, New Horiz, V3, P400; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Procaccio F, 2000, J Neurosurg Sci, V44, P1; ROBERTS I, 2000, COCHRANE DB SYST REV, V2; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	39	35	35	0	10	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					46	55		10.1007/s00508-006-0763-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142GQ	WOS:000244637800010	17318750				2022-02-06	
J	Rusnak, M; Janciak, I; Majdan, M; Wilbacher, I; Mauritz, W				Rusnak, Martin; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Mauritz, Walter		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria I: Introduction to the study	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; treatment; guidelines; epidemiology	GLASGOW OUTCOME SCALE; CLINICAL-TRIALS; CARE; GUIDELINES	OBJECTIVES: The goals of the Austrian Severe Traumatic Brain Injury Study were to investigate the current management of patients with severe traumatic brain injury in Austria and to assess the effects of introducing guidelines for the management of severe traumatic brain injury upon the outcome of these patients. The purpose of this paper is to give a detailed description of the goals, methods, and overall results of the study, and to provide an introduction to a series of papers where the results of the study will be presented and discussed. STUDY DESIGN: The study included patients with severe traumatic brain injury from five centers in Austria. Data on accident, pre-hospital treatment, hospital treatment, and patient status were collected prospectively. Patient data was entered daily for the first 10 days in hospital and then up to a year after discharge from intensive care. All data was entered into an internet-based database. The data was evaluated to describe epidemiology, pre-hospital treatment, medical management, and surgical management; the evaluation also assessed the effects of guideline-based management on traumatic brain injury patients. RESULTS: The data set comprises a total of 492 patient records from the 5 participating hospitals; this data was collected over a 3-year period. Data quality is considered good; the number of missing data items is low. ICU mortality was 31.6%. Final outcome: 23% of the patients had a good recovery, 10% had moderate disabilities, 8% had severe disabilities, 6% were persistent vegetative, and 38% died. Final outcome was unknown in 16% of patients. CONCLUSIONS: This study proved that an internetbased database may be a valuable tool for prospective multicenter studies if many variables have to be collected for a high number of patients. The results of our study provide enough evidence to initiate further research on many aspects of the management of traumatic brain injury patients.	INRO, Med Advisory Board, A-1080 Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, Vienna, Austria		Mauritz, W (corresponding author), INRO, Med Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016; Majdan, Marek/K-5017-2012	Rusnak, Martin/0000-0003-3321-1042; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712			*ADD INC, XLSTAT VERS; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Drobetz H, 2000, ANASTH INTENSIV NOTF, V35, P630, DOI 10.1055/s-2000-7365; Erly WK, 2002, AM J NEURORADIOL, V23, P103; Eysenbach G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e13; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Lallas CD, 2004, J UROLOGY, V171, P1880, DOI 10.1097/01.ju.0000120221.39184.3c; Laupland KB, 2004, CRIT CARE, V8, pR431, DOI 10.1186/cc2947; Marks RG, 2004, CONTROL CLIN TRIALS, V25, P437, DOI 10.1016/j.cct.2004.07.001; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Nathanson AT, 1999, WILD ENVIRON MED, V10, P218, DOI 10.1580/1080-6032(1999)010[0218:WIROAP]2.3.CO;2; *OST STAT ZENTR, 2000, KAPITEL, V3, P11; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; *US DEP HHS CDCP N, 1999, TRAUM BRAIN INJ US R; Wade D T, 1987, Int Rehabil Med, V8, P129; Wei SJ, 2004, J CLIN ONCOL, V22, P4730, DOI 10.1200/JCO.2004.07.103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wyatt JC, 2000, J AM MED INFORM ASSN, V7, P426, DOI 10.1136/jamia.2000.0070426	22	35	35	0	8	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					23	28		10.1007/s00508-006-0760-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142GQ	WOS:000244637800007	17318747				2022-02-06	
J	Zhang, L; Zhang, WP; Chen, KD; Qian, XD; Fang, SH; Wei, EQ				Zhang, Lei; Zhang, Wei-Ping; Chen, Ke-Da; Qian, Xiao-Dong; Fang, San-Hua; Wei, Er-Qing			Caffeic acid attenuates neuronal damage, astrogliosis and glial scar formation in mouse brain with cryoinjury	LIFE SCIENCES			English	Article						caffeic acid; traumatic brain injury; cryoinjury; neuroprotection; astrogliosis; glial scar	PHENETHYL ESTER; COLD-INJURY; ANTIOXIDANT ACTIVITY; CEREBRAL-ISCHEMIA; CHLOROGENIC ACID; EXPRESSION; 5-LIPOXYGENASE; ASTROCYTES; RECEPTOR; OXYGEN	Traumatic brain injury induces neuron damage in early phase, and astrogliosis and the formation of the glial scar in late phase. Caffeic acid (3, 4-dihydroxycinnamic acid), one of the natural phenolic compounds, exerts neuroprotective effects against ischemic brain injuries with anti-oxidant and anti-inflammatory properties, and by scavenging reactive species. However, whether caffeic acid has protective effects against traumatic brain injury is unknown. Therefore, we determined the effect of caffeic acid on the lesion in the early (1 day) and late phases (7 to 28 days) of cryoinjury in mice. We found that caffeic acid (10 and 50 mg/kg, i.p., for 7 days after cryoinjury) reduced the lesion area and attenuated the neuron loss around the lesion core 1 to 28 days, but attenuated the neuron loss in the lesion core only 1 day after cryoinjury. Moreover, caffeic acid attenuated astrocyte proliferation, glial scar wall formation and glial fibrillary acidic protein (GFAP) protein expression in the late phase of cryoinjury (7 to 28 days). Caffeic acid also inhibited the reduction of superoxide dismutase activity and the increase in malondialdehyde content in the brain 1 day after cryoinjury. These results indicate that caffeic acid exerts a protective effect in traumatic brain injury, especially on glial scar formation in the late phase, which at least is associated with its anti-oxidant ability. (c) 2006 Elsevier Inc. All rights reserved.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310058, Peoples R China		Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, 388 Yu Hang Tang Rd, Hangzhou 310058, Peoples R China.	weieq200l@yahoo.com	Zhang, Lei/F-2603-2011				Aladag MA, 2006, INT J DEV NEUROSCI, V24, P9, DOI 10.1016/j.ijdevneu.2005.12.002; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; CASTELLUCCIO C, 1995, FEBS LETT, V368, P188, DOI 10.1016/0014-5793(95)00639-Q; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Flentjar NJ, 2002, EXP NEUROL, V177, P9, DOI 10.1006/exnr.2002.7927; Ge QF, 2006, J NEUROCHEM, V97, P992, DOI 10.1111/j.1471-4159.2006.03828.x; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Gulcin I, 2006, TOXICOLOGY, V217, P213, DOI 10.1016/j.tox.2005.09.011; Hazell AS, 2002, NEUROCHEM INT, V41, P271, DOI 10.1016/S0197-0186(02)00013-X; Hermann DM, 2004, NEUROSCIENCE, V123, P371, DOI 10.1016/j.neuroscience.2003.09.032; Hirano S, 2004, BIOCHEM BIOPH RES CO, V317, P437, DOI 10.1016/j.bbrc.2004.03.049; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; Irmak MK, 2003, CELL BIOCHEM FUNCT, V21, P283, DOI 10.1002/cbf.1024; Keller JN, 1999, BRAIN RES, V830, P10, DOI 10.1016/S0006-8993(99)01272-X; Kikuzaki H, 2002, J AGR FOOD CHEM, V50, P2161, DOI 10.1021/jf011348w; Kim JA, 1998, ARCH PHARM RES, V21, P664, DOI 10.1007/BF02976754; Kim SR, 2000, PHYTOCHEMISTRY, V54, P503, DOI 10.1016/S0031-9422(00)00110-2; Kono Y, 1997, BBA-GEN SUBJECTS, V1335, P335, DOI 10.1016/S0304-4165(96)00151-1; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; Lee SY, 2006, NEUROSCI RES, V56, P204, DOI 10.1016/j.neures.2006.06.005; Li PG, 2005, HYPERTENS RES, V28, P369, DOI 10.1291/hypres.28.369; Logan A, 2002, ADV EXP MED BIOL, V513, P115; Montpied P, 2003, MOL BRAIN RES, V115, P111, DOI 10.1016/S0169-328X(03)00178-5; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Nardini M, 2001, FREE RADICAL BIO MED, V30, P722, DOI 10.1016/S0891-5849(00)00515-3; Nardini M, 2000, BBA-GEN SUBJECTS, V1474, P219, DOI 10.1016/S0304-4165(00)00009-X; Penkowa M, 2003, J NEUROSCI RES, V73, P481, DOI 10.1002/jnr.10681; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; SONDHEIMER E, 1958, ARCH BIOCHEM BIOPHYS, V74, P131, DOI 10.1016/0003-9861(58)90207-8; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Stewart LR, 2001, J NEUROSCI RES, V65, P565, DOI 10.1002/jnr.1186; Tada T, 2004, NEUROCHEM INT, V45, P23, DOI 10.1016/j.neuint.2004.01.002; Tsai SK, 2006, LIFE SCI, V78, P2758, DOI 10.1016/j.lfs.2005.10.017; Turkoglu OF, 2005, SURG NEUROL, V64, P11, DOI 10.1016/j.surneu.2005.07.041; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Wei X, 2004, BRAIN, V127, P2629, DOI 10.1093/brain/awh316; Yasuoka N, 2004, DEV BRAIN RES, V151, P129, DOI 10.1016/j.devbrainres.2004.04.006; Yoshida H, 2006, CNS DRUG REV, V12, P9, DOI 10.1111/j.1527-3458.2006.00009.x; Zhang L, 2006, NEUROPATHOLOGY, V26, P99, DOI 10.1111/j.1440-1789.2006.00658.x; Zhou Y, 2006, ACTA PHARMACOL SIN, V27, P1103, DOI 10.1111/j.1745-7254.2006.00406.x	47	35	42	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	JAN 16	2007	80	6					530	537		10.1016/j.lfs.2006.09.039			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	131IX	WOS:000243863600004	17074364				2022-02-06	
J	Davis, DP; Fakhry, SM; Wang, HE; Bulger, EM; Domeier, RM; Trask, AL; Bochicchio, GV; Hauda, WE; Robinson, L				Davis, Daniel P.; Fakhry, Samir M.; Wang, Henry E.; Bulger, Eileen M.; Domeier, Robert M.; Trask, Arthur L.; Bochicchio, Grant V.; Hauda, William E.; Robinson, Linda			Paramedic rapid sequence intubation for severe traumatic brain injury: Perspectives from an expert panel	PREHOSPITAL EMERGENCY CARE			English	Article						paramedic; rapid sequence intubation; traumatic brain injury; intubation; prehospital; airway management; neuromuscular blockade	COMA SCALE SCORE; PREHOSPITAL ENDOTRACHEAL INTUBATION; HEAD-INJURY; TRACHEAL INTUBATION; GAG REFLEX; SURVIVAL; FIELD; VENTILATION; MODERATE; DAMAGE	Although early intubation has become standard practice in the prehospital management of severe traumatic brain injury (TBI), many patients cannot be intubated without neuromuscular blockade. Several emergency medical services (EMS) systems have implemented paramedic rapid sequence intubation (RSI) protocols, with published reports documenting apparently conflicting outcomes effects. In response, the Brain Trauma Foundation assembled a panel of experts to interpret the existing literature regarding paramedic RSI for severe TBI and offer guidance for EMS systems considering adding this skill to the paramedic scope of practice. The interpretation of this panel can be summarized as follows: (1) the existing literature regarding paramedic RSI is inconclusive, and apparent differences in outcome can be explained by use of different methodologies and variability in comparison groups; (2) the use of Glasgow Coma Scale score alone to identify TBI patients requiring RSI is limited, with additional research needed to refine our screening criteria; (3) suboptimal RSI technique as well as subsequent hyperventilation may account for some of the mortality increase reported with the procedure; (4) initial and ongoing training as well as experience with RSI appear to affect performance; and (5) the success of a paramedic RSI program is dependent on particular EMS and trauma system characteristics.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Inova Fairfax Hosp, Inova Reg Trauma Ctr, Trauma Serv, Falls Church, VA USA; Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA; Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Michigan, St Joseph Mercy Hosp Emergency Med, Ann Arbor, MI 48109 USA; R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Fairfax Cty Police, Helicopter Div, Fairfax, VA USA		Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net		Hauda II, William/0000-0003-1425-7715			Addington WR, 1999, ARCH PHYS MED REHAB, V80, P150, DOI 10.1016/S0003-9993(99)90112-0; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Baker CC, 2005, J TRAUMA, V58, P723; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christensen EF, 2003, BRIT MED J, V327, P533, DOI 10.1136/bmj.327.7414.533; Combes X, 2006, ACAD EMERG MED, V13, P828, DOI 10.1197/j.aem.2006.02.016; DAVIES AE, 1995, LANCET, V345, P487, DOI 10.1016/S0140-6736(95)90584-7; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2006, AM J EMERG MED, V24, P752, DOI 10.1016/j.ajem.2006.02.014; Davis D, 2004, ARCHAEOLOGY, V57, P8; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Deschamp C, 2001, Air Med J, V20, P38, DOI 10.1016/S1067-991X(01)70059-4; Domeier RM, 2005, PREHOSP EMERG CARE, V9, P114; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Dutton RP, 2002, J TRAUMA, V53, P857, DOI 10.1097/00005373-200211000-00009; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; FLOCCARE DJ, 2005, PREHOSP EMERG CARE, V9, P108; FORSSTROM JJ, 1995, ANN MED, V27, P509, DOI 10.3109/07853899509002462; GABRIEL EJ, 2000, GUIDELINES PREHOSPIT, P39; Garrison HG, 2002, ANN EMERG MED, V40, P81, DOI 10.1067/mem.2002.124758; Garza AG, 2003, J EMERG MED, V25, P251, DOI 10.1016/S0736-4679(03)00198-7; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Haug E, 2004, ACAD EMERG MED, V11, P349, DOI 10.1197/j.aem.2003.12.015; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Leder SB, 1996, HEAD NECK-J SCI SPEC, V18, P138, DOI 10.1002/(SICI)1097-0347(199603/04)18:2<138::AID-HED5>3.0.CO;2-2; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; MACIVER IN, 1958, LANCET, V1, P390; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MATEER JR, 1993, ANN EMERG MED, V22, P675, DOI 10.1016/S0196-0644(05)81846-3; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Sibbritt David, 2004, Health Care Manag Sci, V7, P163, DOI 10.1023/B:HCMS.0000039379.32963.9e; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Smith S B, 1991, J Air Med Transp, V10, P11; Spaite DW, 2001, ANN EMERG MED, V37, P657, DOI 10.1067/mem.2001.115215; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Teramoto S, 2000, ARCH PHYS MED REHAB, V81, P1517, DOI 10.1053/apmr.2000.9171; Vadeboncoeur TF, 2006, J EMERG MED, V30, P131, DOI 10.1016/j.jemermed.2005.04.019; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang H E, 2000, Prehosp Emerg Care, V4, P14, DOI 10.1080/10903120090941560; Wang HE, 2005, RESUSCITATION, V67, P69, DOI 10.1016/j.resuscitation.2005.05.008; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang Henry E, 2005, Prehosp Emerg Care, V9, P156; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	72	35	36	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care		2007	11	1					1	8		10.1080/10903120601021093			8	Emergency Medicine; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Public, Environmental & Occupational Health	156CV	WOS:000245626600001	17169868				2022-02-06	
S	Sharma, HS; Johanson, CE		Slikker, W; Andrew, RJ; Trembly, B		Sharma, Hari Shanker; Johanson, Conrad E.			Intracerebroventricularly administered neurotrophins attenuate - Blood-cerebrospinal fluid barrier breakdown and brain pathology following whole-body hyperthermia - An experimental study in the rat using biochemical and morphological approaches	NEUROPROTECTIVE AGENTS: EIGHTH INTERNATIONAL NEUROPROTECTION SOCIETY MEETING	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	8th International Conference on Neuroprotective Agents	SEP 18-20, 2006	Mackinac Isl, MI	Int Neuroprotect Soc		whole-body hyperthermia; heat stress; body temperature; blood-brain barrier; CSF barrier; brain edema; neurotrophins; BDNF; GDNF; IGF-1; cell injury; ependyma; choroid plexus	GROWTH-FACTOR-I; INJURY FOLLOWING TRAUMA; CHOROID-PLEXUS; SPINAL-CORD; UP-REGULATION; PERMEABILITY; EXPRESSION; TRANSPORT; RECEPTORS; SYSTEM	Previous studies from our laboratory show that apart from blood-brain barrier (BBB) disruption, the blood-cerebrospinal fluid (CSF) barrier (BCSFB) for proteins is also broken down following wholebody hyperthermia (WBH) in a rat model. Breakdown of the BCSFB alters brain homeostasis and adversely affects the structure and function of the central nervous system (CNS). Since neurotrophins and growth factors (e.g., brain-derived growth factor [BDNF], glial cell line-derived neurotrophic factor [GDNF], and insulin-like growth factor 1 [IGF-1]) are known neuroprotective agents in traumatic and ischemic brain injuries, a possibility exists that these neurotrophins will also attenuate neuronal and choroidal injury in WBH. Subjection of adult rats to 4 h of WBH at 38 degrees C in a biological oxygen demand (BOD) incubator exhibited a profound increase in BCSFB permeability to Evans blue and radioiodine. Degeneration of choroidal epithelial cells and underlying ependyma, dilatation of the lateral ventricular space, and degenerative changes in the adjacent neuropil were frequent. The hippocampus, caudate nucleus, thalamus, and hypothalamus showed profound BBB disruption and brain edema formation. Intracerebroventricular (i.c.v.) administration of BDNF, GDNF, and IGF-1 into the right lateral cerebral ventricle (1, 2, or 5 mu g in 30 mu L, 24 h before WBH) significantly reduced the BCSFB and BBB breakdown, brain edema formation, and cellular/tissue injuries. These beneficial effects were most pronounced in GDNF- or IGF-1-pretreated animals. These novel observations suggest that neurotrophins administered into ventricular CSF can attenuate BCSFB and BBB damage following WBH and thereby confer neuroprotection. Stabilization of BCSFB function is thus one of the crucial factors in achieving neuroprotection in WBH.	[Sharma, Hari Shanker] Uppsala Univ, Inst Surg Sci, Dept Anaesthesiol & Intens Care, Lab Cerebrovasc Res, Uppsala, Sweden; [Johanson, Conrad E.] Rhode Isl Hosp, Brown Med Sch, Dept Neurosurg, Providence, RI USA		Sharma, HS (corresponding author), Frodingsgatan 12 28, SE-75421 Uppsala, Sweden.	sharma@surgsci.uu.se		Johanson, Conrad/0000-0002-1297-5484	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027910] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG27910] Funding Source: Medline		Al-Sarraf H, 2007, J VASC RES, V44, P99, DOI 10.1159/000098260; Armstrong CS, 2000, J NEUROSCI RES, V59, P649, DOI 10.1002/(SICI)1097-4547(20000301)59:5<649::AID-JNR8>3.0.CO;2-W; Borlongan CV, 2004, STROKE, V35, P2206, DOI 10.1161/01.STR.0000138954.25825.0b; Carro E, 2006, NEUROBIOL AGING, V27, P1250, DOI 10.1016/j.neurobiolaging.2005.06.015; Chiaretti A, 2004, ACTA PAEDIATR, V93, P1178, DOI 10.1080/08035250410031314; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; DEKEYSER J, 1994, SYNAPSE, V17, P196, DOI 10.1002/syn.890170309; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Ghersi-Egea JF, 2006, J CEREBR BLOOD F MET, V26, P1165, DOI 10.1038/sj.jcbfm.9600267; Ikeda T, 1999, INT J DEV NEUROSCI, V17, P681, DOI 10.1016/S0736-5748(99)00057-X; JOHANSON C, 2005, INT J NEUROPROTECTIO, V1, P77; Johanson CE, 2005, BLOOD-CEREBROSPINAL FLUID BARRIER, P311; Johanson CE, 2005, PHARM RES-DORDR, V22, P1011, DOI 10.1007/s11095-005-6039-0; Johanson CE, 2000, CELL MOL NEUROBIOL, V20, P197, DOI 10.1023/A:1007097622590; JOHANSON CE, 2003, NEUROSCIENCE MED, P165; JOHANSON CE, 2004, BLOOD SPINAL CORD BR, P361; Johanson Conrad, 2004, Cerebrospinal Fluid Res, V1, P3, DOI 10.1186/1743-8454-1-3; Koo H, 2001, INT J DEV NEUROSCI, V19, P549, DOI 10.1016/S0736-5748(01)00042-9; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; MURPHY VA, 1985, J CEREBR BLOOD F MET, V5, P401, DOI 10.1038/jcbfm.1985.55; RAPOPORT SI, 1976, BLOOD BRAIN BARRIER, P1; Redzic ZB, 2005, CURR TOP DEV BIOL, V71, P1, DOI 10.1016/S0070-2153(05)71001-2; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; Saura J, 1999, NEUROREPORT, V10, P161, DOI 10.1097/00001756-199901180-00031; Segal MB, 2001, MICROSC RES TECHNIQ, V52, P38, DOI 10.1002/1097-0029(20010101)52:1<38::AID-JEMT6>3.3.CO;2-A; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P426; SHARMA H S, 1984, Indian Journal of Physiology and Pharmacology, V28, P259; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P231; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Sharma HS, 2007, PROG BRAIN RES, V162, P295, DOI 10.1016/S0079-6123(06)62015-3; Sharma HS, 2007, PROG BRAIN RES, V162, P459, DOI 10.1016/S0079-6123(06)62023-2; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P407, DOI 10.1196/annals.1344.036; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, INDIAN J MED RES, V121, P621; Sharma HS, 2003, ACT NEUR S, V86, P383; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; Sharma HS, 1998, AMINO ACIDS, V14, P121, DOI 10.1007/BF01345252; Sharma HS, 2000, AMINO ACIDS, V19, P351, DOI 10.1007/s007260070066; SHARMA HS, 1990, ACT NEUR S, V51, P383; SHARMA HS, 2006, ACTA NEUROCHIR SUPP, P329; Sharma HS, 1999, ACTA U UPSAL, V830, P1; Sharma HS, 1982, THESIS BANARAS HINDU, P1; Smith DE, 2004, ADV DRUG DELIVER REV, V56, P1765, DOI 10.1016/j.addr.2004.07.008; Spector R, 2007, J NEUROCHEM, V103, P425, DOI 10.1111/j.1471-4159.2007.04773.x; Spector R, 2006, PHARM RES-DORDR, V23, P2515, DOI 10.1007/s11095-006-9091-5; TIMMUSK T, 1995, NEUROREPORT, V6, P1997, DOI 10.1097/00001756-199510010-00011; Weaver C. E., 2003, ADV MOL CEL, V31, P269	50	35	39	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-685-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2007	1122						112	129		10.1196/annals.1403.008			18	Multidisciplinary Sciences; Neurosciences; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BHD20	WOS:000252267100008	18077568				2022-02-06	
J	Nitch, S; Boone, KB; Wen, J; Arnold, G; Alfano, K				Nitch, Stephen; Boone, Kyle Brauer; Wen, Johnny; Arnold, Ginger; Alfano, Kimberly			The utility of the Rey Word Recognition Test in the detection of suspect effort	CLINICAL NEUROPSYCHOLOGIST			English	Article							FORCED-CHOICE METHOD; PERFORMANCE; VALIDATION; SENSITIVITY; VALIDITY	The Rey Word Recognition Test potentially represents an underutilized tool for clinicians to use in the detection of suspect effort. The present study examined the predictive accuracy of the test by examining the performance of three groups of participants: (a) 92 noncredible patients (as determined by failed psychometric and behavioral criteria and external motive to feign), (b) 51 general clinical patients with no motive to feign, and (c) 31 learning disabled college students. Results demonstrated gender differences in performance that necessitated separate cutoff scores for men and women. Use of a cutoff score of <= 7 words correctly recognized identified 80.5% of noncredible female patients while maintaining specificity of > 90%. However, to achieve this level of specificity in male noncredible patients, the cutoff score had to be lowered to <= 5, with resultant sensitivity of only 62.7%. A combination variable (recognition correct minus false positive errors + number of words recognized from the first 8 words) showed enhanced sensitivity in identifying suspect effort in a subset of the noncredible sample who were claiming cognitive symptoms secondary to traumatic brain injury (i.e., cutoff score of <= 9= 81.6% sensitivity with 90% specificity). Results indicate that the Rey Word Recognition Test is an accurate and cost-effective method for the detection of noncredible cognitive performance.	Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA; Patton State Hosp, Patton, CA USA; Kaiser Permanente, Los Angeles, CA USA; Inst Rehabil, Santa Barbara, CA USA		Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, Box 495,1000 W Carson St,Bldg F-9, Torrance, CA 90509 USA.	kboone@labiomed.org					ARNOLD G, 2004, CLIN NEUROPSYCHOL, V18, P1; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Baker R, 2000, Appl Neuropsychol, V7, P111, DOI 10.1207/S15324826AN0702_8; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Boone K., 2002, B TEST MANUAL; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Frederick R. I., 1997, VALIDITY INDICATOR P; Frederick R.I., 2003, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n03_01, DOI 10.1300/J151V02N03_01, https://doi.org/10.1300/J151v02n03_01]; Frederick RI, 2000, J CLIN EXP NEUROPSYC, V22, P720, DOI 10.1076/jcen.22.6.720.951; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; WARNERCHACON KR, 1994, THESIS CALIFORNIA SC	26	35	35	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2006	20	4					873	887		10.1080/13854040590967603			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	085IE	WOS:000240597000020	16980268				2022-02-06	
J	Pickelsimer, EE; Selassie, AW; Gu, JK; Langlois, JA				Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.; Gu, Ja Kook; Langlois, Jean A.			A population-based outcomes study of persons hospitalized with traumatic brain injury - Operations of the South Carolina traumatic brain injury follow-up registry	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						follow-up registry methods; outcomes study; population surveillance; traumatic brain injury	QUALITY-OF-LIFE; HEAD-INJURY; SF-36; NEEDS; QUESTIONNAIRE; HANDICAP; VALIDITY; PROXIES; DESIGN; IMPACT	Objective: To describe the design and operations of the South Carolina Traumatic Brain Injury (TBI) Follow-up Registry. Design: Statewide prospective cohort study. Setting: State of South Carolina. Participants: 2118 persons discharged from acute care hospitals after experiencing TBI. Intervention: Telephone interviews. Main Outcome Measures: Service needs, alcohol and drug use, psychosocial health, health-related quality of life, functional status, symptoms of TBI, employment, global life satisfaction, and death. Results: Selected initial and 1-year follow-up findings concerning demographic, insurance status, income, and employment factors. Conclusions: Population-based outcome studies that describe longer term problems associated with TBI, the need for services, and estimated disability could be useful to inform public policy.	Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA USA		Pickelsimer, EE (corresponding author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, POB 250835,135 Cannon St,Suite 303, Charleston, SC 29425 USA.	pickelse@musc.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BARRERA M, 1983, AM J COMMUN PSYCHOL, V11, P133; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; *CDCP, 1999, REP REC TRAUM BRAIN; *CDCP, 1998, GRANT M MAY 4 ATL; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; CHESNUT RM, 1999, 2 AG HLTH CAR POL RE; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; *CTR INJ RES POL J, 1997, ICMAP 90 SOFTW; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; DAVIS K, 1995, INQUIRY-J HEALTH CAR, V32, P196; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; *DIV INJ VIOL PREV, 1999, TBI SURV SYST DAT EV; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GERBER WD, 1995, FUNCT NEUROL, V10, P27; GFROERER J, 1992, BRIT J ADDICT, V87, P1345; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jones M L, 1992, J Insur Med, V24, P186; KATZ D, 1995, ARCH NEUROL-CHICAGO, V51, P661; *L HARR ASS INC, 1994, HARR POLL DIS AM, P101; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LAWRENCE RH, 1995, J AGING HEALTH, V7, P74, DOI 10.1177/089826439500700104; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; MCDOWELL AJ, 1971, HEALTH SERV REP, V86, P592, DOI 10.2307/4594235; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT SE 193, V193; *NAT CTR INJ PREV, 2001, INJ FACT BOOK 2001 2; National Center for Health Statistics, INT CLASS DIS; Novack TA, 2000, BRAIN INJURY, V14, P987; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; ROTHMAN ML, 1991, MED CARE, V29, P115, DOI 10.1097/00005650-199102000-00004; *S CAR DEP HLTH EN, 2003 BRFSS ALC CONS; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; SELASSIE AW, 2006, S CAROLINA TRAUMATIC, P236; SZKLO M, 2000, EPIDEMIOLOGY BASICS, P343; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thurman DJ., 1995, GUIDELINES SURVEILLA; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VICKREY BG, 1992, MED CARE, V30, P299, DOI 10.1097/00005650-199204000-00002; VOGLESBURG R, 1990, VOCATIONAL REHABILIT; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WIEDERHOLT WC, 1989, NEUROLOGY, V39, P96, DOI 10.1212/WNL.39.1.96; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	64	35	35	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					491	504		10.1097/00001199-200611000-00004			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400004	17122680				2022-02-06	
J	Ates, O; Cayli, S; Gurses, I; Yucel, N; Iraz, M; Altinoz, E; Kocak, A; Yologlu, S				Ates, Ozkan; Cayli, Suleyman; Gurses, Iclal; Yucel, Neslihan; Iraz, Mustafa; Altinoz, Eyup; Kocak, Ayhan; Yologlu, Saim			Effect of pinealectomy and. melatonin replacement on morphological and biochemical recovery after traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						antioxidant; melatonin; oxidative stress; pinealectomy; traumatic brain injury	XANTHINE-OXIDASE ACTIVITY; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; FREE-RADICALS; NITRIC-OXIDE; RAT-BRAIN; NEUROHORMONE MELATONIN; LIPID-PEROXIDATION; MOLECULAR DAMAGE; HEAD TRAUMA	Numerous studies showed that melatonin, a free radical scavenger, is neuroprotective. In this study, we investigated the effect of pinealectomy and administration of exogenous melatonin on oxidative stress and morphological changes after experimental brain injury. The animals were divided into six groups, each having 12 rats. Group I underwent craniotomy alone. Group 2 underwent craniotomy followed by brain trauma and received no medication. Group 3 underwent craniotomy followed by brain trauma and received melatonin. Group 4 underwent pinealectomy and craniotomy alone. Group 5 underwent pinealectomy and craniotomy followed by brain injury and received no medication. Group 6 underwent pinealectomy and craniotomy followed by brain trauma and received melatonin. Melatonin (100 mg/kg) was given intraperitoneally immediately after trauma to the rats in Groups 3 and 6. Pinealectomy caused a significant increase in the malondialdehyde (MDA), nitric oxide (NO), glutathione (GSH), and xanthine oxidase (XO) levels, and a decrease in GSH levels as compared to the control group. Trauma to pinealectomized rats causes significantly higher oxidative stress. Exogeneous melatonin administration significantly reduced MDA, XO and NO levels, increased GSH levels, and attenuated tissue lesion area. These findings suggest that reduction in endogenous melatonin after pinealectomy makes the rats more vulnerable to trauma, and exogenous melatonin administration has an important neuroprotective effect. (c) 2006 ISDN. Published by Elsevier Ltd. All rights reserved.	Inonu Univ, Dept Neurosurg, Sch Med, Turgut Ozal Med Ctr, TR-44069 Malatya, Turkey; Inonu Univ, Dept Pathol, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Emergency Med, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Pharmacol, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Biochem, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Biostat, Sch Med, TR-44069 Malatya, Turkey		Ates, O (corresponding author), Inonu Univ, Dept Neurosurg, Sch Med, Turgut Ozal Med Ctr, TR-44069 Malatya, Turkey.	atesozkan@hotmail.com	Yologlu, Saim/ABI-8014-2020; Gurses, Iclal/AAH-8552-2021; Yucel, Neslihan/ABI-3412-2020	Yologlu, Saim/0000-0002-9619-3462; Yucel, Neslihan/0000-0001-5845-2614; Altinoz, Eyup/0000-0002-3991-9773			ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; Bonnefont-Rousselot D, 2000, DIABETES METAB, V26, P163; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; De Butte M, 2002, NEUROBIOL AGING, V23, P309, DOI 10.1016/S0197-4580(01)00277-9; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; Dundar K, 2005, CLIN EXP PHARMACOL P, V32, P926, DOI 10.1111/j.1440-1681.2005.04286.x; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HARDELAND R, 1995, J PINEAL RES, V18, P104, DOI 10.1111/j.1600-079X.1995.tb00147.x; HOFFMAN RA, 1965, ANAT REC, V153, P19, DOI 10.1002/ar.1091530103; Horakova L, 2000, GEN PHYSIOL BIOPHYS, V19, P195; IKEDA Y, 1990, NEUROSURGERY, V27, P1; ITOH T, 1986, STROKE, V17, P1284, DOI 10.1161/01.STR.17.6.1284; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; KANEMITSU H, 1989, BRAIN RES, V499, P367, DOI 10.1016/0006-8993(89)90786-5; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Marklund N., 1997, NEUROREPORT, V717, P109; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Noda Y, 1999, J PINEAL RES, V27, P159, DOI 10.1111/j.1600-079X.1999.tb00611.x; Ozbek E, 2000, EUR UROL, V37, P172, DOI 10.1159/000020135; PANG SF, 1990, J PINEAL RES, V8, P179, DOI 10.1111/j.1600-079X.1990.tb00678.x; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; PRAJDA N, 1975, FEBS LETT, V59, P245, DOI 10.1016/0014-5793(75)80385-1; REITER RJ, 1993, BRAZ J MED BIOL RES, V26, P1141; Reiter RJ, 1998, ANN NY ACAD SCI, V854, P410, DOI 10.1111/j.1749-6632.1998.tb09920.x; Reiter RJ, 1998, NUTRITION, V14, P691, DOI 10.1016/S0899-9007(98)00064-1; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; SKENE DJ, 1990, BRAIN RES, V528, P170, DOI 10.1016/0006-8993(90)90214-V; Sofic E, 2005, J NEURAL TRANSM, V112, P349, DOI 10.1007/s00702-004-0270-4; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; Vural H, 2001, J PINEAL RES, V31, P193, DOI 10.1034/j.1600-079X.2001.310301.x; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1602/neurorx.1.1.5; Yeleswaram K, 1997, J PINEAL RES, V22, P45, DOI 10.1111/j.1600-079X.1997.tb00302.x; ZANG LY, 1998, BIOCHIM BIOPHYS ACTA, V27, P469; Zhou JN, 2003, J PINEAL RES, V35, P125, DOI 10.1034/j.1600-079X.2003.00065.x	51	35	37	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	OCT	2006	24	6					357	363		10.1016/j.ijdevneu.2006.08.003			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	092ZZ	WOS:000241138200002	16959465				2022-02-06	
J	Carnevale, GJ; Anselmi, V; Johnston, MV; Busichio, K; Walsh, V				Carnevale, George J.; Anselmi, Vera; Johnston, Mark V.; Busichio, Kim; Walsh, Vanessa			A natural setting behavior management program for persons with acquired brain injury: A randomized controlled trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						behavior therapy; brain injuries; burden of illness; caregivers; rehabilitation; stress; psychological	INDIVIDUALS; DISTRESS	Objective: To investigate the efficacy of a behavior management program delivered in the natural community setting for persons with brain injury and their caregivers. Design: Three-group randomized controlled trial. Setting: Homes and other community settings. Participants: Thirty-seven persons with traumatic and other acquired brain injury and their caregivers. Interventions: Natural Setting Behavior Management (NSBM) involving education and individualized behavior modification program versus education only versus control group. Main Outcome Measures: Changes in frequency of targeted problematic behaviors. Subscale in Questionnaire on Resources and Stress, Maslach Burnout Inventory, and the Neurobehavioral Functioning Inventory. Results: While no significant effects were detected at termination of education only (P<.075) or of NSBM (P<.56), significant treatment effects were found at the main outcome point 3 months after termination of services (P<.002). Rates of disruptive or aggressive behaviors declined significantly in the NSBM group. Differences in caregiver-rated stress, burden, and aggression were not statistically significant. Conclusions: A program of caregiver education and individualized behavior management in natural settings can decrease the frequency of disruptive behavioral challenges. Larger studies are needed to clarify the duration and intensity of education and individualized treatment required to diminish behavioral challenges and to understand relationships with general stress and burden experienced by caregivers.	Rehabil Specialists, Clin Serv Dev, N Haledon, NJ 07508 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Kessler Med Rehabil Res & Educ Corp, Nat Setting Behav Management, W Orange, NJ USA; Kessler Med Rehabil Res & Educ Corp, Outcomes Res, W Orange, NJ USA		Carnevale, GJ (corresponding author), Rehabil Specialists, Clin Serv Dev, 33 Sisomac Rd, N Haledon, NJ 07508 USA.	gcarnevale@rehab-specialists.com	Janson, Patrick/AAC-7581-2022				Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Backman CL, 1999, AM J PHYS MED REHAB, V78, P170, DOI 10.1097/00002060-199903000-00022; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; EDLUND W, 2004, AM ACAD NEUROLOGY CL; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Holroyd J., 1987, MANUAL QUESTIONNAIRE; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAUSAR R, 1996, CLIN REHABIL, V10, P159; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LETHBRIDGECEJKU M, 2004, VITAL HLTH STAT 10, V222, P1; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; Maslach C., 1996, MBI MASLACH BURNOUT; Moher David, 2003, Clin Oral Investig, V7, P2; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROSENTHAL M, 2000, TRAUMATIC BRAIN INJU; Senn S, 2000, STAT MED, V19, P861, DOI 10.1002/(SICI)1097-0258(20000330)19:6<861::AID-SIM407>3.0.CO;2-F; Smith LM, 1995, FAMILY SUPPORT PROGR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Winer B. J., 1991, STAT PRINCIPLES EXPT, V3rd; [No title captured]	29	35	36	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2006	87	10					1289	1297		10.1016/j.apmr.2006.06.010			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	095OA	WOS:000241316000001	17023236				2022-02-06	
J	Nolin, P; Villemure, R; Heroux, L				Nolin, P.; Villemure, R.; Heroux, L.			Determining long-term symptoms following mild traumatic brain injury: Method of interview affects self-report	BRAIN INJURY			English	Article						mild traumatic brain injury; subjective symptoms; assessment	POST-CONCUSSIONAL SYNDROME; MINOR HEAD-INJURY; POSTCONCUSSIONAL DISORDER; CHRONIC PAIN; MEMORY PERFORMANCE; MAJOR DEPRESSION; UNITED-STATES; RISK-FACTORS; STRESS; COMPENSATION	Primary objective: To examine the role played by two interviewing methods used ( spontaneous response and suggested response) in the evaluation of long- term subjective post- mild traumatic brain injury ( mTBI) symptoms. Research design: Cohort study. Method and procedures: One hundred and eight adult participants were contacted for a follow- up telephone interview 12 - 36 months after their mTBI. The participants had to firstly spontaneously indicate symptoms that were still present following their mTBI ( spontaneous response). Secondly, a list of symptoms was read to the participants and they had to say whether or not they were afflicted by each symptom ( suggested response). Paired t- tests were performed to compare the means obtained using the two methods. The percentage of symptoms reported with the two interviewing methods were used to analyse symptom types. Experimental intervention: None. Main outcomes and results: Results show that participants reported significantly more symptoms and a given symptom when a list was read to the participants. Furthermore, neither the number of symptoms nor the type of symptoms reported is identical for the two interviewing methods. Conclusion: The interviewing method used influences the number and type of long- term post- mTBI symptoms reported by participants.	Univ Quebec Trois Rivieres, Child & Family Dev Res Unit, Dept Psychol, Trois Rivieres, PQ G9A 5H7, Canada		Nolin, P (corresponding author), Univ Quebec Trois Rivieres, Child & Family Dev Res Unit, Dept Psychol, POB 500, Trois Rivieres, PQ G9A 5H7, Canada.	pierre.nolin@uqtr.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Brand N, 1997, INT J PSYCHOPHYSIOL, V25, P17, DOI 10.1016/S0167-8760(97)85373-1; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CAVANAUGH JC, 1986, EDUC GERONTOL, V12, P385, DOI 10.1080/0380127860120413; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DUBORD S, 2000, B PSYCHOL, V53, P185; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; EYSENCK MW, 1991, PERSPECTIVES COGNITI, P314; Fabiano RJ, 1998, J REHABIL, V64, P9; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Horan WP, 1997, ARCH CLIN NEUROPSYCH, V12, P575, DOI 10.1016/S0887-6177(97)00012-7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LOWDON IMR, 1989, INJURY, V20, P193, DOI 10.1016/0020-1383(89)90109-5; MARCOTTE AC, 2005, CADRE REFERENCE CLIN, P1; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; NOLIN P, 1996, UNPUB QUESTIONNAIRE; NOLIN P, 1997, REPERE ESSAIS ED, V18, P93; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Teasdale TW, 1997, BRIT MED J, V315, P569; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trepanier S, 1997, CAN J AGING, V16, P84, DOI 10.1017/S0714980800014173; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; WEST RL, 1984, EXP AGING RES, V10, P197, DOI 10.1080/03610738408258464; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	64	35	35	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1147	1154		10.1080/02699050601049247			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600005	17123931				2022-02-06	
J	Isoniemi, H; Kurki, T; Tenovuo, O; Kairisto, V; Portin, R				Isoniemi, H.; Kurki, T.; Tenovuo, O.; Kairisto, V.; Portin, R.			Hippocampal volume, brain atrophy, and APOE genotype after traumatic brain injury	NEUROLOGY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; HEAD-INJURY; ALZHEIMERS-DISEASE; PSYCHIATRIC-DISORDERS; E DEFICIENCY; RISK; ASSOCIATION; POPULATION; PREDICTS; MUTATION	Objective: To examine the association between hippocampal volumes, general brain atrophy, and apolipoprotein E (APOE) polymorphism in patients with a remote traumatic brain injury (TBI). Methods: MRI-based volumetric analyses of the hippocampus and lateral ventricles were performed in 58 patients with TBI of varying severity on average 31.3 years after the trauma. The APOE genotype was determined using standard methods and correlated with the MRI volumetric measurements. Results: Hippocampal or lateral ventricle volumes did not differ significantly in those patients with the APOE-epsilon 4 allele (APOE4) vs those without this allele. Conclusions: The APOE-epsilon 4 allele was not associated with the development of hippocampal or ventricular atrophy after traumatic brain injury. If the APOE-epsilon 4 allele is associated with an unfavorable outcome after traumatic brain injury as proposed, this association may involve mechanisms other than those responsible for the development of brain atrophy.	Turku Univ, Cent Hosp, Dept Radiol, Turku, Finland; Turku Univ, Cent Hosp, Dept Clin Chem, Turku, Finland; Turku Univ, Cent Hosp, Dept Neurol, Turku, Finland		Tenovuo, O (corresponding author), Turku Univ, Dept Neurol, Kiinamyllynkatu 4-8, Turku 20520, Finland.	olli.tenovuo@tyks.fi		Kurki, Timo/0000-0001-5532-3534			Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Champagne D, 2005, EXP NEUROL, V194, P31, DOI 10.1016/j.expneurol.2005.01.016; DELEON MJ, 1993, AM J NEURORADIOL, V14, P897; den Heijer T, 2002, NEUROLOGY, V59, P746, DOI 10.1212/WNL.59.5.746; Donohoe GG, 2000, CLIN CHEM, V46, P1540; Donohoe GG, 1999, CLIN CHEM, V45, P143; EHNHOLM C, 1986, J LIPID RES, V27, P227; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GREENWOOD R, 2002, J NEUROL NEUROSUR PS, V73, P8; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kleifeld O, 1998, INT J DEV NEUROSCI, V16, P755, DOI 10.1016/S0736-5748(98)00084-7; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newcombe F, 1996, J CLIN EXP NEUROPSYC, V18, P1, DOI 10.1080/01688639608408258; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L	33	35	37	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 12	2006	67	5					756	760		10.1212/01.wnl.0000234140.64954.12			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	083EC	WOS:000240437700006	16966535				2022-02-06	
J	Ross, AP; Christian, SL; Zhao, HWW; Drew, KL				Ross, Austin P.; Christian, Sherri L.; Zhao, Huiwen W.; Drew, Kelly L.			Persistent tolerance to oxygen and nutrient deprivation and N-methyl-D-aspartate in cultured hippocampal slices from hibernating Arctic ground squirrel	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						channel arrest; excitotoxicity; hibernation; ischemia; Na+K+ ATPase; neuroprotection	ANOXIC TURTLE BRAIN; INTRACELLULAR CALCIUM; ISCHEMIA-REPERFUSION; IN-VITRO; HYPOXIA; NEURONS; INJURY; RECEPTORS; PROTEIN; NEUROPROTECTION	Hibernating Arctic ground squirrel (hAGS), Spermophilus parryii, survive profound decreases in cerebral perfusion during torpor and return to normal blood flow during intermittent rewarming periods without neurologic damage. Hibernating AGS tolerate traumatic brain injury in vivo, and acute hippocampal slices from hibernating animals tolerate oxygen and glucose deprivation. It remains unclear, however, if neuroprotection results from intrinsic tissue properties or from differences in response to acute trauma associated with slice preparation. The goal of this work was therefore to determine whether an intrinsic tissue tolerance persists in chronic culture of AGS hippocampal slices at 37 degrees C. A second goal was to address N-methyl-D-aspartate (NMDA) receptor involvement and channel arrest as potential mechanisms of intrinsic tissue tolerance. Baseline neuronal survival and tolerance to oxygen and nutrient deprivation (OND), an in vitro model of ischemia-reperfusion, were assessed in the CA1 region of hippocampal slices from juvenile, hAGS and interbout euthermic AGS (ibeAGS). Early in culture (insult onset at 3 h), slices from both hAGS and ibeAGS tolerate OND (4 h deprivation followed by 20 h recovery) and 500 mu mol/L NMDA plus 20mmol/L KCI. Later in culture (insult onset at 24 h), tolerance persists in slices from hAGS but not in slices from ibeAGS. Ouabain (Na+ K+ ATPase inhibitor) administered 24 h in culture enhances survival of slices from hAGS (assessed 24 h later). Thus, tolerance to OND in slices from hAGS is due to intrinsic tissue properties likely involving NMDA receptors and ion channel arrest.	Univ Alaska Fairbanks, Alaskan Basic Neurosci Program, Inst Arctic Biol, Fairbanks, AK 99775 USA		Drew, KL (corresponding author), Univ Alaska Fairbanks, Alaskan Basic Neurosci Program, Inst Arctic Biol, POB 757000, Fairbanks, AK 99775 USA.	ffkld@uaf.edu	Drew, Kelly L/B-7995-2013	Christian, Sherri/0000-0002-4289-4386	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54NS041069] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1P20RR16466, 2P20RR16466] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NIH-NS41069] Funding Source: Medline		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Arora S, 2005, STROKE, V36, P1232, DOI 10.1161/01.STR.0000165902.18021.5b; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Bickler PE, 2004, NEUROSCIENCE, V127, P673, DOI 10.1016/j.neuroscience.2004.05.035; Bickler PE, 2000, J NEUROSCI, V20, P3522, DOI 10.1523/JNEUROSCI.20-10-03522.2000; Bickler PE, 2003, NEUROSCIENCE, V118, P25, DOI 10.1016/S0306-4522(02)00763-7; BICKLER PE, 1992, AM J PHYSIOL, V263, pR1298, DOI 10.1152/ajpregu.1992.263.6.R1298; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bonde C, 2003, NEUROCHEM INT, V43, P381, DOI 10.1016/S0197-0186(03)00025-1; Bonde C, 2003, NEUROCHEM INT, V43, P371, DOI 10.1016/S0197-0186(03)00024-X; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; CHIH CP, 1989, AM J PHYSIOL, V257, pR854, DOI 10.1152/ajpregu.1989.257.4.R854; DAVE KR, 2005, IN PRESS STROKE; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; DOLL CJ, 1993, AM J PHYSIOL, V265, pR929, DOI 10.1152/ajpregu.1993.265.4.R929; Drew KL, 2001, FREE RADICAL BIO MED, V31, P563, DOI 10.1016/S0891-5849(01)00628-1; EDWARDS RA, 1989, AM J PHYSIOL, V257, pR1354; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; Frerichs KU, 1998, J CEREBR BLOOD F MET, V18, P168, DOI 10.1097/00004647-199802000-00007; Gentile NT, 1996, NEUROCHEM RES, V21, P947, DOI 10.1007/BF02532345; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; IGELMUND P, 1996, ADAPTATIONS COLD; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kleindorfer D, 2004, STROKE, V35, pE27, DOI 10.1161/01.STR.0000109767.11426.17; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Lindell SL, 2005, AM J PHYSIOL-GASTR L, V288, pG473, DOI 10.1152/ajpgi.00223.2004; Lipton Stuart A, 2004, NeuroRx, V1, P101, DOI 10.1602/neurorx.1.1.101; LYMAN CP, 1948, J EXP ZOOL, V109, P55, DOI 10.1002/jez.1401090105; Ma YL, 2005, AM J PHYSIOL-REG I, V289, pR1297, DOI 10.1152/ajpregu.00260.2005; MacDonald JA, 1999, BIOCHEM BIOPH RES CO, V254, P424, DOI 10.1006/bbrc.1998.9960; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Pek M, 1997, J EXP BIOL, V200, P1913; PENGELLEY ET, 1961, CAN J ZOOL, V39, P98; PEREZPINZON MA, 1992, AM J PHYSIOL, V262, pR712, DOI 10.1152/ajpregu.1992.262.4.R712; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; STRASSER U, 1995, J NEUROSCI METH, V57, P177, DOI 10.1016/0165-0270(94)00147-9; WALLIS RA, 1995, BRAIN RES, V674, P75, DOI 10.1016/0006-8993(94)01438-N; WILLIS JS, 1971, COMP BIOCHEM PHYSIOL, V39, P437, DOI 10.1016/0300-9629(71)90307-0; Zhang L, 1997, J NEUROCHEM, V69, P1983; Zhou F, 2001, AM J PATHOL, V158, P2145, DOI 10.1016/S0002-9440(10)64686-X	41	35	36	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2006	26	9					1148	1156		10.1038/sj.jcbfm.9600271			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	077FX	WOS:000240015300006	16395285	Bronze			2022-02-06	
J	Kyung, KS; Gon, JH; Geun, KY; Sup, JJ; Suk, WJ; Ho, KJ				Kyung, Kang Soo; Gon, Jeon Hyo; Geun, Kim Yong; Sup, Jung Jin; Suk, Woo Jae; Ho, Kim Jae			6-Shogaol, a natural product, reduces cell death and restores motor function in rat spinal cord injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptotic cell death; function recovery; inflammation; myelination; neuroprotection; spinal cord injury	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM INJURY; ACTIVATION; PATHOPHYSIOLOGY; DEGENERATION; INFLAMMATION; MACROPHAGES; APOPTOSIS; AXONS; PEROXYNITRITE	Spinal cord injury (SCI) results in progressive waves of secondary injuries, which via the activation of a barrage of noxious pathological mechanisms exacerbate the injury to the spinal cord. Secondary injuries are associated with edema, inflammation, excitotoxicity, excessive cytokine release, caspase activation and cell apoptosis. This study was aimed at investigating the possible neuroprotective effects of 6-shogaol purified from Zingiber officinale by comparing an experimental SCI rat group with SCI control rats. Shogaol attenuated apoptotic cell death, including poly(ADP-ribose) polymerase activity, and reduced astrogliosis and hypomyelination which occurs in areas of active cell death in the spinal cords of SCI rats. The foremost protective effect of shogaol in SCI would therefore be manifested in the suppression of the acute secondary apoptotic cell death. However, it does not attenuate active microglia and macrophage infiltration. This finding is supported by a lack of histopathological changes in the areas of the lesion in the shogaol-treated SCI rats. Moreover, shogaol-mediated neuroprotection has been linked with shogaol's attenuation of p38 mitogen-activated protein kinase, p-SAPK/JNK and signal transducer, and with transcription-3 activation. Our results demonstrate that shogaol administrated immediately after SCI significantly diminishes functional deficits. The shogaol-treated group recovered hindlimb reflexes more rapidly and a higher percentage of these rats regained responses compared with the untreated injured rats. The overall hindlimb functional improvement of hindlimbs, as measured by the Basso, Beattie and Bresnahan scale, was significantly enhanced in the shogaol-treated group relative to the SCI control rats. Our data show that the therapeutic outcome of shogaol probably results from its comprehensive effects of blocking apoptotic cell death, resulting in the protection of white matter, oligodendrocytes and neurons, and inhibiting astrogliosis. Our finding that the administration of shogaol prevents secondary pathological events in traumatic SCIs and promotes recovery of motor functions in an animal model raises the issue of whether shogaol could be used therapeutically in humans after SCI.	Pusan Natl Univ, Sch Med, Dept Physiol, Pusan 602739, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon, South Korea		Kyung, KS (corresponding author), Pusan Natl Univ, Sch Med, Dept Physiol, 1-10 Ami Dong, Pusan 602739, South Korea.	skkang@pusan.ac.kr	Mat Zain, Mazatulikhma/B-2025-2010				ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Blight AR, 2002, NAT NEUROSCI, V5, P1051, DOI 10.1038/nn939; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRUCK W, 1990, ACTA NEUROPATHOL, V80, P415; BRUCK W, 1991, J NEUROL SCI, V103, P182, DOI 10.1016/0022-510X(91)90162-Z; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; HOLSTEGE G, 1991, PROG BRAIN RES, V87, P307; Honmou O, 1996, J NEUROSCI, V16, P3199; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; Jander S, 2001, BRAIN PATHOL, V11, P27; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; KANG SK, 2006, STEM CELLS DEV, V15; Kiefer R, 2001, PROG NEUROBIOL, V64, P109, DOI 10.1016/S0301-0082(00)00060-5; Kim DSHL, 2004, BIOORG MED CHEM LETT, V14, P1287, DOI 10.1016/j.bmcl.2003.12.041; Kim DSHL, 2002, PLANTA MED, V68, P375, DOI 10.1055/s-2002-26757; Kobrine A I, 1975, Surg Neurol, V3, P261; Lai MD, 2005, INT J MOL MED, V15, P725; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liao CH, 2005, BIOCHEM BIOPH RES CO, V329, P1306, DOI 10.1016/j.bbrc.2005.02.110; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MCTIGUE DM, 2002, PROG BRAIN RES, V128, P3; Omura T, 2005, BRAIN RES, V1057, P29, DOI 10.1016/j.brainres.2005.07.008; POPVICH PG, 1997, J COMP NEUROL, V377, P443; Ruemmele FM, 1999, BIOCHEM BIOPH RES CO, V260, P159, DOI 10.1006/bbrc.1999.0734; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Teng YD, 1997, J NEUROSCI, V17, P4359; TETZLAFF W, 1994, PROG BRAIN RES, V103, P271; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Whalen MJ, 2000, ACT NEUR S, V76, P61; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	53	35	36	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2006	24	4					1042	1052		10.1111/j.1460-9568.2006.04908.x			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	076TE	WOS:000239979800009	16930431				2022-02-06	
J	Oda, J; Sakamoto, J; Sakano, K				Oda, Juhachi; Sakamoto, Jiro; Sakano, Kenichi			Mechanical evaluation of the skeletal structure and tissue of the woodpecker and its shock absorbing system	JSME INTERNATIONAL JOURNAL SERIES A-SOLID MECHANICS AND MATERIAL ENGINEERING			English	Article						impact strength; framed structure; biomechanics; woodpecker		A woodpecker strikes its beak toward a tree repeatedly. But, the damage of brain or the brain concussion doesn't occur by this action. Human cannot strike strongly the head without the damage of a brain. Therefore, it is predicted that the brain of a woodpecker is protected from the shock by some methods and that the woodpecker has the original mechanism to absorb a shock. In this study, the endoskeltal structure, especially head part structure of woodpecker is dissected and the impact-proof system is analyzed by FEM and model experiment. From the results, it is obvious that the woodpecker has the original impact-proof system as the unique states of hyoid bone, skull, tissue and brain. Moreover it is considered that woodpecker has the advanced impact-proof system relating with not only the head part but also with the whole body.	Kanazawa Univ, Dept Human & Mech Syst Engn, Bion Design Lab, Kanazawa, Ishikawa 9201192, Japan; Toyota Motor Co Ltd, Chassis Prod Engn Div, FR Chassis Planning & Engn Dept, Toyota, Aichi 4718572, Japan		Oda, J (corresponding author), Kanazawa Univ, Dept Human & Mech Syst Engn, Bion Design Lab, Kanazawa, Ishikawa 9201192, Japan.	oda18@t.kanazawa-u.ac.jp	SAKAMOTO, Jiro/E-7095-2015	SAKAMOTO, Jiro/0000-0002-1511-9958			AIDA T, 2000, STUDY HUMAN HEAD IMP, P12; MAY PRA, 1976, LANCET, P454; NISHIMOTO T, 1996, T JAPAN SOC MECH E A, V62, P2109; OGASAWARA K, 1998, WORLD BLACK WOODPECK; ZHANG L, 2001, P BIOENG C, P831	5	35	39	8	56	JAPAN SOC MECHANICAL ENGINEERS	TOKYO	SHINANOMACHI-RENGAKAN BLDG, SHINANOMACHI 35, SHINJUKU-KU, TOKYO, 160-0016, JAPAN	1344-7912			JSME INT J A-SOLID M	JSME Int. J. Ser. A-Solid Mech. Mat. Eng.	JUL	2006	49	3					390	396		10.1299/jsmea.49.390			7	Engineering, Mechanical; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	080RK	WOS:000240265500015		gold			2022-02-06	
J	Patel, MB; Feinstein, AJ; Saenz, AD; Majetschak, M; Proctor, KG				Patel, Mayur B.; Feinstein, Ara J.; Saenz, Alvaro D.; Majetschak, Matthias; Proctor, Kenneth G.			Prehospital HBOC-201 after traumatic brain injury and hemorrhagic shock in swine	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	19th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 10-14, 2006	Orlando, FL	Eastern Assco Surg Trauma		brain injury; swine; blood substitute; HBOC; hemoglobin based oxygen carrier	CEREBRAL PERFUSION-PRESSURE; TUMOR-NECROSIS-FACTOR; BOVINE POLYMERIZED HEMOGLOBIN; SMALL-VOLUME RESUSCITATION; CROSS-LINKED HEMOGLOBIN; TISSUE OXYGEN-TENSION; SEVERE HEAD-INJURY; BLOOD SUBSTITUTES; SUBARACHNOID HEMORRHAGE; ARGININE-VASOPRESSIN	Background. Data are limited on the actions of hemoglobin based oxygen carriers (HBOCs) after traumatic brain injury (TBI). This study evaluates neurotoxicity, vasoactivity, cardiac toxicity, and inflammatory activity of HBOC-201 (Biopure, Cambridge, Mass.) resuscitation in a TBI model. Methods: Swine received TBI and hemorrhage. After 30 minutes, resuscitation was initiated with 10 mL/kg normal saline (NS), followed by either HBOC-201 (6 mL/kg, n = 10) or NS control (n = 10). Supplemental NS was administered to both groups to maintain mean arterial pressure (MAP) > 60 mm Hg until 60 minutes, and to maintain cerebral perfusion pressure (CPP) > 70 mm Hg from 60 to 300 minutes. The control group received mannitol (1 g/kg) and blood (10 mL/kg) at 90 minutes and half (n = 5) received CPP directed phenylephrine (PE) therapy after 120 minutes. Serum cytokines; were measured with ELISA and coagulation was evaluated with thromboelastography. Brains were harvested for neuropathology. Results. With HBOC administration, MAP, CPP, and brain tissue PO2 were restored within 30 minutes and maintained until 300 minutes. Clot strength and fibrin formation were maintained and 9/10 successfully extubated. In contrast, with control, MAP and brain tissue PO2 did not correct until 120 minutes, after mannitol, transfusion and 40% more crystalloid. Furthermore, without PE, CPP did not reach target and 0/5 could be extubated. Lactate, heart rate, cardiac output, mixed venous oxygenation, muscle oxygenation, serum cytokines, and histology did not differ between groups. Conclusions. After TBI, a single HBOC-201 bolus with minimal supplements provided rapid resuscitation, while maintaining CPP and improving brain oxygenation, without causing cardiac dysfunction, coagulopathy, cytokine release, or brain structural changes.	Univ Miami, Sch Med, Ryder Trauma Ctr, Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Div Surg Crit Care, Miami, FL USA; Univ Miami, Miller Sch Med, DeWitt Daughtry Familt Dept Surg, Miami, FL USA; Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL USA		Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr, Div Trauma, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Proctor, Kenneth/AAA-2199-2022; Patel, Mayur/K-2363-2013	Proctor, Kenneth/0000-0003-1326-6628; Feinstein, Ara/0000-0001-6214-5334	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008749] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-01] Funding Source: Medline		Arnaud F, 2005, SHOCK, V24, P145, DOI 10.1097/01.shk.0000170354.18437.2f; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAUM; Carrillo EH, 2002, J TRAUMA, V52, P449, DOI 10.1097/00005373-200203000-00006; Cole DJ, 1998, J NEUROSURG ANESTH, V10, P153, DOI 10.1097/00008506-199807000-00005; Cole DJ, 1999, CRIT CARE MED, V27, P972, DOI 10.1097/00003246-199905000-00038; Crookes BA, 2004, SURGERY, V135, P662, DOI 10.1016/j.surg.2003.11.017; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dong F, 2006, SHOCK, V25, P50, DOI 10.1097/01.shk.0000187982.56030.94; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Fitzpatrick CM, 2004, J AM COLL SURGEONS, V199, P693, DOI 10.1016/j.jamcollsurg.2004.07.025; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Greenburg AG, 2004, CRIT CARE, V8, pS61, DOI 10.1186/cc2455; Hamilton RG, 2001, TRANSFUSION, V41, P219, DOI 10.1046/j.1537-2995.2001.41020219.x; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; Jahr Jonathan S, 2002, Am J Ther, V9, P431, DOI 10.1097/00045391-200209000-00011; James MF, 2004, ANESTH ANALG, V99, P1593, DOI 10.1213/01.ANE.0000136477.46472.EB; Johnson JL, 2001, J TRAUMA, V50, P449, DOI 10.1097/00005373-200103000-00008; Johnson JL, 2003, J TRAUMA, V54, P133, DOI 10.1097/00005373-200301000-00016; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Lee SK, 2002, ACAD EMERG MED, V9, P969; Levy JH, 2003, EXPERT OPIN BIOL TH, V3, P509, DOI 10.1517/14712598.3.3.509; Loke KE, 2000, J CARDIOVASC PHARM, V35, P84, DOI 10.1097/00005344-200001000-00011; Malhotra AK, 2004, J TRAUMA, V56, P1049, DOI 10.1097/01.TA.0000127765.75643.66; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Manley GT, 2003, ADV EXP MED BIOL, V530, P311; Marret E, 2004, ANESTH ANALG, V98, P604, DOI 10.1213/01.ANE.0000099366.73625.DD; Maxwell RA, 2000, J TRAUMA, V49, P200, DOI 10.1097/00005373-200008000-00005; MCFAUL SJ, 1994, BLOOD, V84, P3175, DOI 10.1182/blood.V84.9.3175.bloodjournal8493175; Moore EE, 2003, J AM COLL SURGEONS, V196, P1, DOI 10.1016/S1072-7515(02)01704-0; Moore EE, 2005, SHOCK, V24, P197, DOI 10.1097/01.shk.0000180075.76766.fe; Moreira PL, 1997, CLIN CHEM, V43, P1792; Ortegon DP, 2003, J TRAUMA, V55, P755, DOI 10.1097/01.TA.0000085722.52921.6D; Piper IR, 1998, BRIT J ANAESTH, V80, P639, DOI 10.1093/bja/80.5.639; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; Reid TJ, 2003, TRANSFUSION, V43, P280, DOI 10.1046/j.1537-2995.2003.00314.x; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; Saxena R, 1999, STROKE, V30, P993, DOI 10.1161/01.STR.30.5.993; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sheppard FR, 2004, J TRAUMA, V57, P720, DOI 10.1097/01.TA.0000140479.65350.28; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Torres IP, 2005, ANESTH ANALG, V100, P912, DOI 10.1213/01.ANE.0000146960.79532.DB; *US DEP HHS FDA CT, 2005, CRIT SAF EFF EV OX T; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Wahr Joyce A, 2003, Anesthesiol Clin North Am, V21, P553, DOI 10.1016/S0889-8537(03)00044-0	49	35	35	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2006	61	1					46	56		10.1097/01.ta.0000219730.71206.3a			11	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	065TV	WOS:000239183600012	16832248				2022-02-06	
J	Rinne, MB; Pasanen, ME; Vartiainen, MV; Lehto, TM; Sarajuuri, JM; Alaranta, HT				Rinne, Marjo B.; Pasanen, Matti E.; Vartiainen, Matti V.; Lehto, Tommi M.; Sarajuuri, Jaana M.; Alaranta, Hannu T.			Motor performance in physically well-recovered men with traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article; Proceedings Paper	5th World Congress on Traumatic Brain Injury	MAY, 2003	STOCKHOLM, SWEDEN			brain injury; motor skills; psychomotor performance; rehabilitation	INTERRATER RELIABILITY; TEST BATTERY; IDENTIFICATION; POPULATION; MODERATE; ADULTS; MILD	Objective: The primary aim of this study was to compare the motor performance of physically well-recovered men with traumatic brain injury with that of healthy men. Design: Cross-sectional study in a national rehabilitation centre. Methods: Static and dynamic balance, agility and rhythm co-ordination of men with traumatic brain injury ( n = 34) and healthy controls ( n = 36) were assessed. Between-group differences in dynamic balance and agility were analysed by analysis of covariance and differences in static balance and rhythm co-ordination by logistic regression analysis. Cut-off points for clinical screening were determined by receiver operating characteristics analyses. Results: Men with traumatic brain injury had impaired balance and agility compared with healthy men and in a rhythm co-ordination test they had difficulties in starting and sustaining simultaneous rhythmical movements of hands and feet. In receiver operating characteristics analyses a running figure-of-eight test ( agility), tandem walking forwards ( dynamic balance) and rhythm co-ordination test with fast tempo were found the most sensitive and specific for distinguishing between men with traumatic brain injury and the healthy men. Conclusions: The impairments in motor performance of physically well-recovered patients with traumatic brain injury were obvious. The results of this study extend the knowledge of problems in motor performance among patients with traumatic brain injury and provide further information for clinical rehabilitation.	UKK Inst Hlth Promot Res, FI-33501 Tampere, Finland; Kapyla Rehabil Ctr, Helsinki, Finland		Rinne, MB (corresponding author), UKK Inst Hlth Promot Res, POB 30, FI-33501 Tampere, Finland.	marjo.rinne@uta.fi	Sarajuuri, Jaana/AAD-8665-2019	Sarajuuri, Jaana/0000-0002-6432-0295			Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hillier SL, 1997, BRAIN INJURY, V11, P649; Laukkanen R, 1993, MED SCI; Masanic CA, 1998, ARCH PHYS MED REHAB, V79, P811, DOI 10.1016/S0003-9993(98)90361-6; MCGUIRE SA, 1995, NEUROLOGY, V45, pA328; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; PELOSO PM, 1987, J REHAB MED S, V43, P22; Quinn B, 2000, BRAIN INJURY, V14, P1063; Rinne MB, 2001, INT J SPORTS MED, V22, P192, DOI 10.1055/s-2001-16384; RMITAGE P, 2002, STAT METHODS MED RES; Sosin DM, 1996, BRAIN INJURY, V10, P47; Suni JH, 1998, PHYS THER, V78, P134, DOI 10.1093/ptj/78.2.134; TEGNER Y, 1986, AM J SPORT MED, V14, P156, DOI 10.1177/036354658601400212	20	35	35	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JUL	2006	38	4					224	229		10.1080/16501970600582989			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	057QK	WOS:000238610100004	16801204	gold			2022-02-06	
J	Plurad, D; Demetriades, D; Gruzinski, G; Preston, C; Chan, L; Gaspard, D; Margulies, D; Cryer, HG				Plurad, D; Demetriades, D; Gruzinski, G; Preston, C; Chan, L; Gaspard, D; Margulies, D; Cryer, HG			Pedestrian injuries: The association of alcohol consumption with the type and severity of injuries and outcomes	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRAUMATIC BRAIN-INJURY; HEMORRHAGIC-SHOCK; EXPERIMENTAL-MODEL; ETHANOL; INTOXICATION; PREVALENCE; RESUSCITATION	BACKGROUND: Literature on the effect of alcohol ingestion on short-term outcomes for trauma patients shows conflicting results. We performed this study to investigate the prevalence of positive alcohol screens and the effect of alcohol level on injury patterns, injury severity, and outcomes in pedestrians and bicyclists involved in a collision with an automobile. STUDY DESIGN: The study population included all pedestrians and bicyclists older than 10 years, treated in any of the 13 trauma centers in the Los Angeles County Emergency Services System during the calendar year 2003, who were involved in a collision with an automobile and had a blood alcohol level measured. The alcohol negative group was defined as those patients with a blood alcohol level <= 0.05 g/dL. Low and high alcohol groups were defined as those having blood alcohol levels > 0.05 g/dL to < 0.08 g/dL and >= 0.08 g/dL, respectively. We compared the three study groups with respect to demographics, injury patterns, injury severity, complications, and outcomes. Logistic regression was used to determine if alcohol had an independent association with any outcomes. RESULTS: There were 1,042 patients who met study criteria. Overall, 606 patients (58%) had a negative alcohol screen, 84 (8%) had low alcohol levels, and 352 (34%) had high alcohol levels. Alcohol level was not notably associated with severity of injury, admission hypotension, ICU length of stay, major complications, and injury pattern (head, chest, abdomen, or extremity Area Injury Score). Mortality was similar in the three alcohol level groups, but the overall complication rate and hospital length of stay were markedly higher in the high alcohol level group than they were in the negative alcohol level group. CONCLUSIONS: In pedestrians and bicyclists involved in a collision with an automobile, a high alcohol level is not associated with body area severity of injury, overall severity of injury, and hospital mortality. But high alcohol level is notably associated with higher overall complication rate and longer hospital length of stay.	Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Los Angeles, CA 90033 USA; Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA; Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; Huntington Mem Hosp, Dept Surg, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Surg, Los Angeles, CA USA		Demetriades, D (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Rm 1105,1200 N State St, Los Angeles, CA 90033 USA.						BOTTOMS GD, 1990, ALCOHOL CLIN EXP RES, V14, P776, DOI 10.1111/j.1530-0277.1990.tb01245.x; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Chen SC, 1999, J TRAUMA, V47, P881, DOI 10.1097/00005373-199911000-00011; Cornwell EE, 1998, AM SURGEON, V64, P461; DAUGHTERS K, 1995, AM SURGEON, V61, P896; Delgado-Rodriguez M, 2003, BRIT J SURG, V90, P1287, DOI 10.1002/bjs.4186; Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017; Fabian MJ, 2002, J TRAUMA, V53, P864, DOI 10.1097/00005373-200211000-00010; Field CA, 2001, J TRAUMA, V50, P13, DOI 10.1097/00005373-200101000-00002; Girasek DC, 2002, ANN EMERG MED, V39, P622, DOI 10.1067/mem.2002.122864; Hewitt PM, 1999, J TRAUMA, V47, P346, DOI 10.1097/00005373-199908000-00022; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Madan AK, 1999, J TRAUMA, V47, P568, DOI 10.1097/00005373-199909000-00026; McDonough KH, 2002, J TRAUMA, V53, P541, DOI 10.1097/00005373-200209000-00024; Molina PE, 2003, ALCOHOL CLIN EXP RES, V27, P563, DOI 10.1097/01.ALC.0000057946.57330.F7; Phelan H, 2002, J TRAUMA, V52, P675, DOI 10.1097/00005373-200204000-00010; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	21	35	36	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	JUN	2006	202	6					919	927		10.1016/j.jamcollsurg.2006.02.024			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	050EW	WOS:000238071300009	16735206				2022-02-06	
J	Fujimura, K; Segami, N; Kobayashi, S				Fujimura, K; Segami, N; Kobayashi, S			Anatomical study of the complications of intraoral vertico-sagittal ramus osteotomy	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article								Purpose: The present study was performed to determine the variations in anatomical features of the ramus and the course of the maxillary artery to reduce the risk of injury during intraoral vertico-sagittal ramus osteotomy (IVSRO). Materials and Methods: The locations and sizes of anatomical features of the medial aspect of mandibular rami were measured in 94 bilateral sides of 47 dry mandibles as a control group, and the results were compared with 3-dimensional computed tomography images of 44 sides of 22 patients with prognathism. We also dissected 12 sides of 6 mandibles from cadavers in a simulated IVSRO procedure to determine the course of the maxillary artery near the medial aspect of the ramus. Results: In the dry mandibles and patients with prognathism, the mandibular foramen was located slightly posterior to the center of the width of the mandibular ramus, and the lingula tip was located about one third the distance from the sigmoid notch to the inferior border of the ramus. The distance from the lateral margin of the mandibular foramen to the lateral surface of the mandibular ramus ranged from 3.1 to 4.4 mm. However, these distances showed various ranges. In the mandibles from Asian cadavers, the maxillary artery approached close to the ramus and passed lateral to the lower head of the lateral pterygoid muscle. Conclusions: The position of the mandibular foramen in rami varies among individuals and, therefore, should be confirmed preoperatively on axial CT images. In addition, the maxillary artery approaches close to the medial aspect of the sigmoid notch in many cases. Therefore, the medial aspect from the sigmoid notch should be exposed carefully in the IVSRO procedure to avoid damaging the maxillary artery. (c) 2006 American Association of Oral and Maxillofacial Surgeons.	Kanazawa Med Univ, Dept Oral & Maxillofacial Surg, Kahoku, Ishikawa 9200293, Japan		Fujimura, K (corresponding author), Kanazawa Med Univ, Dept Oral & Maxillofacial Surg, 1-1 Uchinada, Kahoku, Ishikawa 9200293, Japan.	1-kkk@kanazawa-med.ac.jp					CHOUNG PH, 1992, J CRANIO MAXILL SURG, V20, P153, DOI 10.1016/S1010-5182(05)80390-7; da Fontoura RA, 2002, J ORAL MAXIL SURG, V60, P660, DOI 10.1053/joms.2002.33115; Fujimura K, 2004, J ORAL MAXIL SURG, V62, P1246, DOI 10.1016/j.joms.2004.01.026; Hall HD, 1992, MODERN PRACTICE ORTH, P2111; KAMIJOU Y, 1967, ORAL ANATOMY, V3, P494; Kim Hee-Jin, 1997, Yonsei Medical Journal, V38, P19; LOVESTEDT SA, 1961, ANATOMY SURGEONS, V1, P340; SMITH BR, 1991, J ORAL MAXIL SURG, V49, P112, DOI 10.1016/0278-2391(91)90095-4; Westermark A, 1998, BRIT J ORAL MAX SURG, V36, P425, DOI 10.1016/S0266-4356(98)90457-0	9	35	38	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	MAR	2006	64	3					384	389		10.1016/j.joms.2005.11.009			6	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	018TD	WOS:000235786800006	16487798				2022-02-06	
J	Akca, O				Akca, Ozan			Optimizing the intraoperative management of carbon dioxide concentration	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						carbon dioxide; cardiac output; hypercapnia; hypocapnia; ischemia; oxygen; perfusion; reperfusion; tissue oxygenation		Purpose of review This review assesses whether there is a carbon dioxide concentration range that provides optimum benefit to the patient intraoperatively. It includes the physiological effects of carbon dioxide on various organ systems in awake and anesthetized individuals and its clinical effects in the ischemia/reperfusion setting. This review will present views on end-tidal or arterial carbon dioxide tension management in the perioperative period. Recent findings Hypocapnia reduces intracranial pressure and is used by clinicians during acute traumatic brain injury, acute intracranial hemorrhage, and acutely growing brain tumors. There is mounting evidence, however, that hypercapnia improves tissue perfusion and oxygenation. Therefore, clinicians may want to induce mild-to-moderate hypercapnia during reperfusion states such as major vascular surgery, organ transplantation, tissue-graft surgery, and cases managed with low mean arterial pressures to control bleeding. As hypercapnia preserves cerebral blood flow even under relatively low perfusion pressures, it may be beneficial during global reperfusion scenarios. This hypothesis needs to be tested extensively before being considered for clinical applications. From a different perspective, current American Heart Association Guidelines recommend 12-15 breaths/min during cardiopulmonary resuscitation and stress the potential negative role of inadvertent hyperventilation on survival outcome. The importance of this concept is discussed briefly. Summary Overall, the benefits of managing carbon dioxide concentration intraoperatively for the maintenance of cardiac output, tissue oxygenation, perfusion, intracranial pressure, and cerebrovascular reactivity are well defined.	[Akca, Ozan] Univ Louisville, Dept Anesthesiol & Perioperat Med, Outcomes Res Inst, Louisville, KY 40292 USA; [Akca, Ozan] Univ Louisville, Neurosci & Anesthesia Intens Care Unit, Louisville, KY 40292 USA		Akca, O (corresponding author), 501 East Broadway,Suite 210, Louisville, KY 40202 USA.	ozan.akca@louisville.edu	Akca, Ozan/I-8856-2019	Akca, Ozan/0000-0002-7275-1060	NIH (Bethesda, MD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM 61655, DE 14879-01A1]; Joseph Drown Foundation (Los Angeles, CA); Gheens Foundation (Louisville, KY); Commonwealth of Kentucky Research Challenge Trust Fund (Louisville, KY); Foundation for Anesthesia Education and Research; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM061655] Funding Source: NIH RePORTER	This work was supported by NIH Grants GM 61655 and DE 14879-01A1 (Bethesda, MD), the Joseph Drown Foundation (Los Angeles, CA), the Gheens Foundation (Louisville, KY), and the Commonwealth of Kentucky Research Challenge Trust Fund (Louisville, KY). Dr Akca is the recipient of a Research Training Grant from the Foundation for Anesthesia Education and Research. The author appreciates the editorial assistance of Nancy Alsip, PhD.	Akca O, 2003, ANAESTHESIA, V58, P536, DOI 10.1046/j.1365-2044.2003.03193.x; Akca O, 1999, LANCET, V354, P41, DOI 10.1016/S0140-6736(99)00874-0; Akca O, 2002, ANESTHESIOLOGY, V97, P801, DOI 10.1097/00000542-200210000-00009; Akca O, 2004, AMERICAN SOCIETY OF; ALBERTI E, 1975, BRIT J ANAESTH, V47, P941, DOI 10.1093/bja/47.9.941; Ali S, 2003, AMERICAN SOCIETY OF, pA; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ANDERSEN MN, 1966, ANN SURG, V163, P161, DOI 10.1097/00000658-196602000-00001; [Anonymous], 2000, CIRCULATION SUPPL, V102, pI1; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BLACKBURN JP, 1970, BRIT J ANAESTH, V42, P559; BLACKBURN JP, 1972, ANESTHESIOLOGY, V37, P268, DOI 10.1097/00000542-197209000-00002; BOIX JH, 1994, REV ESP FISIOL, V50, P19; BONIFACE KJ, 1953, AM J PHYSIOL, V172, P752, DOI 10.1152/ajplegacy.1953.172.3.752; Cottrell J., 2004, AM SOC ANESTHESIOLOG, V2004, P145; CULLEN DJ, 1969, ANESTHESIOLOGY, V31, P407; Duong TQ, 2001, MAGN RESON MED, V45, P61, DOI 10.1002/1522-2594(200101)45:1<61::AID-MRM1010>3.0.CO;2-8; Gelb A, 2004, AM SOC ANESTHESIOLOG, V2004, P377; GLEASON CA, 1989, J PEDIATR-US, V115, P309, DOI 10.1016/S0022-3476(89)80091-5; GOSAIN A, 1991, SURGERY, V109, P523; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1995, ACTA ANAESTH SCAND, V39, P201, DOI 10.1111/j.1399-6576.1995.tb04359.x; Huttunen J, 1999, EXP BRAIN RES, V125, P248, DOI 10.1007/s002210050680; Ikeda T, 1998, AM J SURG, V175, P33, DOI 10.1016/S0002-9610(97)00237-7; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Karsli C, 2004, ANESTH ANALG, V99, P1049, DOI 10.1213/01.ane.0000132778.84943.8d; Karsli C, 2003, PAEDIATR ANAESTH, V13, P26, DOI 10.1046/j.1460-9592.2003.01017.x; Karsli C, 2003, ANESTH ANALG, V97, P694, DOI 10.1213/01.ANE.0000074235.81165.AF; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P2287, DOI 10.1164/ajrccm.162.6.2003066; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P399, DOI 10.1164/ajrccm.162.2.9911026; Laffey JG, 2000, INTENS CARE MED, V26, P133, DOI 10.1007/s001340050027; Laffey JG, 1999, LANCET, V354, P1283, DOI 10.1016/S0140-6736(99)02388-0; LEON JE, 1991, CAN J ANAESTH, V38, P817, DOI 10.1007/BF03036954; MANLEY ES, 1964, AM J PHYSIOL, V207, P634, DOI 10.1152/ajplegacy.1964.207.3.634; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Mas A, 2000, CRIT CARE MED, V28, P360, DOI 10.1097/00003246-200002000-00012; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; MATTA BF, 1995, ANESTHESIOLOGY, V83, P980, DOI 10.1097/00000542-199511000-00011; Mirzai H, 2004, J NEUROSURG ANESTH, V16, P1, DOI 10.1097/00008506-200401000-00001; MONROE RG, 1960, AM J PHYSIOL, V199, P1121, DOI 10.1152/ajplegacy.1960.199.6.1121; Nagase K, 2001, J CLIN ANESTH, V13, P551, DOI 10.1016/S0952-8180(01)00328-2; NG ML, 1967, AM J PHYSIOL, V213, P115, DOI 10.1152/ajplegacy.1967.213.1.115; Nishiyama T, 1999, ANESTH ANALG, V89, P1437, DOI 10.1097/00000539-199912000-00021; NOBLE MIM, 1967, J APPL PHYSIOL, V22, P147, DOI 10.1152/jappl.1967.22.1.147; NOBLE WH, 1981, CAN ANAESTH SOC J, V28, P422, DOI 10.1007/BF03010350; NOMURA F, 1994, CIRCULATION, V90, P321; Plattner O, 2000, ARCH SURG-CHICAGO, V135, P818, DOI 10.1001/archsurg.135.7.818; Ragheb J, 2004, BRIT J ANAESTH, V92, P464, DOI 10.1093/bja/aeh090; RICHARDSON DW, 1972, AM J PHYSIOL, V223, P1308, DOI 10.1152/ajplegacy.1972.223.6.1308; Rosenblum WI, 2001, EUR J PHARMACOL, V417, P203, DOI 10.1016/S0014-2999(01)00899-8; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Shibata K, 1998, AM J RESP CRIT CARE, V158, P1578, DOI 10.1164/ajrccm.158.5.9804039; SHOEMAKER WC, 1991, CRIT CARE MED, V19, P672, DOI 10.1097/00003246-199105000-00014; STREBEL S, 1993, BRIT J ANAESTH, V71, P272, DOI 10.1093/bja/71.2.272; Vannucci RC, 1997, PEDIATR RES, V42, P24, DOI 10.1203/00006450-199707000-00005; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S; Wei EP, 1999, STROKE, V30, P851, DOI 10.1161/01.STR.30.4.851; Wilson-Smith E, 2003, BRIT J ANAESTH, V91, P190, DOI 10.1093/bja/aeg171; Wolley K, 1990, CIRC RES, V100, P102; YOUNG WL, 1991, ANESTH ANALG, V73, P416	63	35	41	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	FEB	2006	19	1					19	25					7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	V42RV	WOS:000209631800004	16547429				2022-02-06	
J	Kim, H; Colantonio, A; Chipman, M				Kim, Hwan; Colantonio, Angela; Chipman, Mary			Traumatic brain injury occurring at work	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			brain injury; occupational; epidemiology; Ontario Trauma Registry	CONSTRUCTION-INDUSTRY; HEAD-INJURIES; OUTCOMES	Introduction: Traumatic brain injury (TBI) occurring in the workplace carries major economic repercussions such as lost wages and hospital costs. Little is known about the profile of risk factors for work-related traumatic brain injury. Aims: This study describes the pre-injury demographic characteristics, injury- related characteristics and outcomes of work-related TBI and compares them with those of non work-related TBI. This study aims to provide profiles of work-related TBI to improve our understanding and awareness of TBI in the workplace and to better inform prevention efforts. Methods: Cross-sectional study using the Comprehensive Data Set (CDS) of Ontario (Canada) Trauma Registry (OTR) from 1993 to 2001. Cases with the ICD-9-CM codes for head injury were included in the database of serious injuries from lead trauma hospitals. Results: The study identified 950 (7.3%) people with work-related TBI. Pre-injury demographics and injury-related characteristics of work-related TBI were significantly different from non work-related TBI such as age, gender, mechanisms of injury, Injury Severity Score, length of stay and in-hospital death. Discussion: This research provides the first comprehensive overview of work-related TBI based on Canadian data. It identifies high risk profiles to better target prevention.	Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Grad Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada		Kim, H (corresponding author), Grad Dept Rehabil Sci, 500 Univ Ave,Room 962, Toronto, ON M5G 1V7, Canada.	hwan.kim@utoronto.ca					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; *CIHI, 2001, ONT TRAUM REG 2001 R; *CIHI, 2002, ONT TRAUM REG B WORK; *CIHI, 2004, ONT TRAUM REG B MAJ; COLEMAN VP, 1986, J OCCUP ACCID, V8, P161, DOI 10.1016/0376-6349(86)90002-7; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Garber BG, 1996, J TRAUMA, V40, P733, DOI 10.1097/00005373-199605000-00008; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Hsiao H, 2001, ERGONOMICS, V44, P537, DOI 10.1080/00140130110034480; Janicak CA, 1998, J OCCUP ENVIRON MED, V40, P347, DOI 10.1097/00043764-199804000-00009; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KISNER SM, 1994, J OCCUP ENVIRON MED, V36, P137, DOI 10.1097/00043764-199402000-00008; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; Lane PL, 1997, ACCIDENT ANAL PREV, V29, P53, DOI 10.1016/S0001-4575(96)00061-9; Langlois JA., 2004, TRAUMATIC BRAIN INJU; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Peele PB, 2005, J OCCUP ENVIRON MED, V47, P424, DOI 10.1097/01.jom.0000158700.50594.0f; Pickett William, 2004, Chronic Dis Can, V25, P32; *STAT CAN, 2003, LAB FORC HIST REV; Tricco AC, 2006, BRAIN INJURY, V20, P719, DOI 10.1080/02699050600664640; Woo BH., 2000, REHABILITATION PEOPL; *WSIB, 2004, STAT S 2004 ANN REP	25	35	35	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2006	21	4					269	278					10	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700002	17361044				2022-02-06	
J	Marsh, NV; Martinovich, WM				Marsh, NV; Martinovich, WM			Executive dysfunction and domestic violence	BRAIN INJURY			English	Article						traumatic brain injury; domestic violence; executive dysfunction	HEAD-INJURY; AGGRESSION; BEHAVIOR; DEFICITS	Primary objective: To replicate previous studies which have reported a high prevalence of traumatic brain injury (TBI) in partner-abusive men and to extend research in this area by determining the prevalence of executive dysfunctions, which have been linked with both TBI and violent behaviour. Research design: Thirty-eight men with criminal convictions for violence and who were receiving treatment for abusing their partners were assessed. Methods and procedures: Subjects with a self-reported history of TBI (n = 22) were compared to the non-TBI group (n = 16) on various psychological measures. Main outcomes and results: The two groups were not significantly different on the variables of age, pre-morbid IQ, self-esteem and alcohol use. The TBI group scored more poorly than the non-TBI group on a measure of current IQ and two of the three measures of executive functioning. Conclusion: The presence of executive dysfunction has implications for the design of successful intervention programmes with this sub-group of batterers.	Univ New England, Sch Psychol, Armidale, NSW 2351, Australia; Univ Waikato, Dept Psychol, Hamilton, New Zealand		Marsh, NV (corresponding author), Univ New England, Sch Psychol, Armidale, NSW 2351, Australia.	nigel.marsh@une.edu.au	Marsh, Nigel/ABA-3609-2021; Marsh, Nigel V./F-5433-2019	Marsh, Nigel/0000-0002-4060-6432; Marsh, Nigel V./0000-0002-4060-6432			ANDERSON RM, 1994, PRACTITIONERS GUIDE; BOLL TJ, 1994, DIAGNOSTIC INTERVIEW, P46; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P.W., 1997, HAYLING BRIXTON TEST; Cohen R A, 1999, Violence Vict, V14, P397; Cohen RA, 2003, J INT NEUROPSYCH SOC, V9, P760, DOI 10.1017/S1355617703950090; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Ehrensaft MK, 2003, J CONSULT CLIN PSYCH, V71, P741, DOI 10.1037/0022-006X.71.4.741; Felson RB, 2000, SOC PSYCHOL QUART, V63, P86, DOI 10.2307/2695883; Filley CM, 2001, NEUROPSY NEUROPSY BE, V14, P1; Golden CJ, 1996, AGGRESS VIOLENT BEH, V1, P3, DOI 10.1016/1359-1789(95)00002-X; Holtzworth-Munroe A, 2000, COGNITIVE THER RES, V24, P135, DOI 10.1023/A:1005489807454; Jelicic M, 2001, INT J NEUROSCI, V110, P73, DOI 10.3109/00207450108994222; Krakowski M, 2003, J NEUROPSYCH CLIN N, V15, P294, DOI 10.1176/appi.neuropsych.15.3.294; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; MORSE PA, 1992, CLIN SYNDROMES ADULT, P84; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Paschall MJ, 2002, AGGRESS VIOLENT BEH, V7, P215, DOI 10.1016/S1359-1789(00)00044-6; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; Rosenberg M., 1965, SOC ADOLESCENT SELF; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SHEPARD M, 1992, J FAM VIOLENCE, V7, P167, DOI 10.1007/BF00979025; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STATISTICS NEW ZEALAND, 1997, NZ SOC EC IND OCC ST; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; White R, 1992, CLIN SYNDROMES ADULT; [No title captured]	29	35	37	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					61	66		10.1080/02699050500110645			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000007	16403701				2022-02-06	
J	Tasker, RC				Tasker, Robert C.			Changes in white matter late after severe traumatic brain injury in childhood	DEVELOPMENTAL NEUROSCIENCE			English	Article						magnetic resonance imaging; traumatic axonal injury; traumatic brain injury; white matter	CLOSED-HEAD-INJURY; CORPUS-CALLOSUM GROWTH; HIPPOCAMPAL PATHOLOGY; INTRACRANIAL-PRESSURE; QUANTITATIVE-ANALYSIS; CLINICAL-FEATURES; VASCULAR PATTERN; CHILDREN; ATROPHY; MRI	Severe traumatic brain injury in childhood, particularly that complicated by raised intracranial pressure, has significant long-term effects on the brain. Since magnetic resonance imaging provides a means of visualizing neuroanatomic structure in exquisite detail, the scope of this review is to revisit the pathology of traumatic brain injury described in recent clinical imaging studies. Acute imaging provides insight into the acute mechanism of focal and diffuse injury. There is some reduction in threshold for white matter pathology in the hemisphere ipsilateral to injury. After injury, there may be long-term effects on white matter architecture and the potential for brain growth. In this context, the pattern of hippocampal rather than parahippocampal gyrus tissue loss provides insight into the likely cause of white matter injury being cerebral hypoperfusion. Copyright (c) 2006 S. Karger AG, Basel.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Paediat, Cambridge CB2 2QQ, England		Tasker, RC (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Paediat, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113			ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DEREUCK J, 1971, EUR NEUROL, V5, P321; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENARELLI TA, 1982, ANN NEUROL, V12, P564; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JOHNSON SC, 1994, NEUROPSYCHOLOGY, V8, P1; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LINDENBERG R, 1955, AM J PATHOL, V31, P297; Lo T Y M, 2003, Pediatr Rehabil, V6, P47, DOI 10.1080/1363849031000109516; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; Nakagawa H, 1998, AM J NEURORADIOL, V19, P1129; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; ONUMA T, 1995, J NEUROSURG, V82, P995, DOI 10.3171/jns.1995.82.6.0995; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; PRAYER L, 1993, ACTA RADIOL, V34, P593; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Rajapakse JC, 1996, BRAIN DEV-JPN, V18, P379, DOI 10.1016/0387-7604(96)00034-4; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TASKER RC, 2001, DEV MED CHILD NEUROL, V86, pS6; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomita H, 1990, Adv Neurol, V52, P553; VANDENBE.R, 1969, ANGIOLOGY, V20, P88, DOI 10.1177/000331976902000205; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; Verger K, 2001, BRAIN INJURY, V15, P211; Vinjamuri S, 2000, NUCL MED COMMUN, V21, P645, DOI 10.1097/00006231-200007000-00008; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333	63	35	35	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					302	308		10.1159/000094156			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600007	16943653				2022-02-06	
J	Parton, A; Coulthard, E; Husain, M				Parton, A; Coulthard, E; Husain, M			Neuropharmacological modulation of cognitive deficits after brain damage	CURRENT OPINION IN NEUROLOGY			English	Article						cognitive function; neuropharmacology; stroke; traumatic brain injury	ACUTE ISCHEMIC-STROKE; HEAD-INJURY; DOSE-ESCALATION; CAFFEINOL; NEUROPROTECTION; ANTAGONIST; DONEPEZIL; MEMORY; METHYLPHENIDATE; REHABILITATION	Purpose of review This review discusses recent studies that have implications for potential neuropharmacological interventions which target cognitive deficits resulting from traumatic brain injury or stroke. Recent findings An important new study concerning the activity of N-methyl-D-aspartate (NMDA) receptors after brain injury reveals that previous influential hypotheses about an increase in glutamate triggering neuronal death may need to be revised. Furthermore, the study suggests that cognitive function may be best preserved by stimulation of NMDA receptors with agonists rather than by the use of antagonists, as previously believed. Investigations of animal models of stroke and traumatic brain injury have further demonstrated the possibility of intervening in the acute and sub-acute stages to protect specific brain systems, such as preservation of the cholinergic system (via cholinesterase inhibitors) and hippocampal neurons (via a D2 agonist). Clinical trials in humans indicate it is also possible to target these neurotransmitter systems to enhance cognitive performance in patients with chronic deficits. In particular, recent studies demonstrated that it is possible to ameliorate the effects of two common cognitive syndromes, visual neglect and aphasia. Summary Cognitive deficits are an extremely common consequence of either traumatic brain injury or stroke. Recent studies demonstrate the potential for using neuropharmacological intervention after acquired brain injury to prevent or ameliorate the effects of cognitive impairments. These treatments, however, are still in their preliminary stages and further research is required to identify the most effective compounds.	Univ London Imperial Coll Sci & Technol, Div Neurosci & Mental Hlth, Charing Cross Hosp, London W6 8RF, England; UCL, Inst Cognit Neurosci, London WC1E 7HU, England		Parton, A (corresponding author), Univ London Imperial Coll Sci & Technol, Div Neurosci & Mental Hlth, Charing Cross Hosp, London W6 8RF, England.	a.parton@imperial.ac.uk	Parton, Andrew/J-8174-2012; Husain, Masud/C-2074-2008	Husain, Masud/0000-0002-6850-9255; Parton, Andrew/0000-0003-0633-7846; coulthard, elizabeth/0000-0002-0017-9595			Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; Albers GW, 1999, STROKE, V30, P508, DOI 10.1161/01.STR.30.3.508; APHASIA BT, 2005, ADV CLIN NEUROSCIENC, V5, P30; Aronowski J, 2003, STROKE, V34, P1246, DOI 10.1161/01.STR.0000068170.80517.B3; Belayev L, 2004, BRAIN RES, V1008, P278, DOI 10.1016/j.brainres.2004.02.039; Berthier ML, 2003, NEUROLOGY, V60, P1218, DOI 10.1212/01.WNL.0000055871.82308.41; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; Borlongan CV, 2005, BRAIN RES, V1038, P50, DOI 10.1016/j.brainres.2005.01.028; Breitenstein C, 2004, NEUROPSYCHOPHARMACOL, V29, P1704, DOI 10.1038/sj.npp.1300464; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Cooper JR, 1997, PRINCIPLES NEUROPSYC; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; EGELKO S, 1989, ARCH PHYS MED REHAB, V70, P297; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Knecht S, 2004, ANN NEUROL, V56, P20, DOI 10.1002/ana.20125; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; MALHOTRA PA, IN PRESS ANN NEUROL; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Nys GMS, 2005, NEUROLOGY, V64, P821, DOI 10.1212/01.WNL.0000152984.28420.5A; Parton A, 2004, J NEUROL NEUROSUR PS, V75, P13; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P1719, DOI 10.1001/jama.285.13.1719; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Walker W, 2004, BRAIN INJURY, V18, P739, DOI 10.1080/02699050310001646224; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zhao CS, 2005, BEHAV BRAIN RES, V156, P85, DOI 10.1016/j.bbr.2004.05.011; Zhao XR, 2005, STROKE, V36, P129, DOI 10.1161/01.STR.0000149624.87661.18	39	35	38	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2005	18	6					675	680		10.1097/01.wco.0000189872.54245.13			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989MT	WOS:000233678800009	16280679				2022-02-06	
J	Young, MJ				Young, MJ			Stem cells in the mammalian eye: a tool for retinal repair	APMIS			English	Article						stem cells; retina; regeneration; development	FIBROBLAST-GROWTH-FACTOR; ROD PHOTORECEPTOR DIFFERENTIATION; FIBRILLARY ACIDIC PROTEIN; NEURAL PROGENITOR CELLS; RAT RETINA; DOPAMINERGIC-NEURONS; FATE DETERMINATION; POLYMER SCAFFOLDS; ROYAL-COLLEGE; ANIMAL-MODEL	Degenerative diseases and traumatic injuries of the central nervous system (CNS) are major causes of long-term disability, whether such insults impact the brain, retina, or spinal cord. Substantial tissue destruction can be sustained by these complex structures without loss of life, while the lack of effective CNS regeneration frequently results in a marked degradation in quality of life. Only recently has it become clear that an enormous potential for regeneration is present within the mammalian CNS. The challenge now presented to researchers is to harness this potential to treat disease. Recent studies showing that stem and progenitor cells can be isolated from the mammalian retina have prompted many researchers to develop strategies aimed at restoring function to the diseased retina. This review summarizes a number of issues related to this goal, including retinal development, transplantation immunology, tissue engineering, and large animal studies. The application of these divergent disciplines to stem cell technology is vital to the development of the novel strategies needed to make retinal transplantation a clinical success.	Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA		Young, MJ (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	mikey@vision.eri.harvard.edu					Ahmad I, 1997, DEV BIOL, V185, P92, DOI 10.1006/dbio.1997.8546; Alexiades MR, 1997, DEVELOPMENT, V124, P1119; Atala A, 2000, WORLD J UROL, V18, P364, DOI 10.1007/s003450000152; Bhattacharya S, 2003, INVEST OPHTH VIS SCI, V44, P2764, DOI 10.1167/iovs.02-0899; Brundin P, 2001, NAT MED, V7, P512, DOI 10.1038/87796; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Cai JL, 2002, DEV BIOL, V251, P221, DOI 10.1006/dbio.2002.0828; Cao W, 1997, INVEST OPHTH VIS SCI, V38, P1358; Carrier RL, 1999, BIOTECHNOL BIOENG, V64, P580, DOI 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X; Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534; CASTILLO BV, 1995, CURR EYE RES, V14, P677, DOI 10.3109/02713689508998495; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chu Y, 1998, AUST NZ J OPHTHALMOL, V26, P87, DOI 10.1111/j.1442-9071.1998.tb01447.x; Colthurst MJ, 2000, BIOMATERIALS, V21, P649, DOI 10.1016/S0142-9612(99)00220-3; Cook AD, 1997, J BIOMED MATER RES, V35, P513; Davis AA, 2000, MOL CELL NEUROSCI, V15, P11, DOI 10.1006/mcne.1999.0806; deRaad S, 1996, OPHTHALMIC RES, V28, P99, DOI 10.1159/000267881; DOWLING JE, 1970, INVEST OPHTH VISUAL, V9, P655; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Emgard M, 2002, NEUROSCIENCE, V115, P1177, DOI 10.1016/S0306-4522(02)00480-3; Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Hadlock T, 1998, ARCH OTOLARYNGOL, V124, P1081, DOI 10.1001/archotol.124.10.1081; HICKS D, 1992, J NEUROSCI, V12, P2022; Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100; Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298; Inoue T, 2002, DEVELOPMENT, V129, P831; Karlsson J, 2002, BRAIN RES, V955, P268, DOI 10.1016/S0006-8993(02)03601-6; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; Kelley MW, 1999, NEUROREPORT, V10, P2389, DOI 10.1097/00001756-199908020-00031; Klassen H, 2004, PROG RETIN EYE RES, V23, P149, DOI 10.1016/j.preteyeres.2004.01.002; KLASSEN H, 1987, P NATL ACAD SCI USA, V84, P6958, DOI 10.1073/pnas.84.19.6958; Klassen H, 2001, NEUROSCI LETT, V312, P180, DOI 10.1016/S0304-3940(01)02215-7; Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511; Lai LX, 2002, MOL REPROD DEV, V62, P300, DOI 10.1002/mrd.10146; Langer R, 2000, ACCOUNTS CHEM RES, V33, P94, DOI 10.1021/ar9800993; Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022; Lavik EB, 2001, J BIOMED MATER RES, V58, P291, DOI 10.1002/1097-4636(2001)58:3<291::AID-JBM1019>3.0.CO;2-N; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levine EM, 1997, J NEUROSCI, V17, P6277; Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808; Libby RT, 1996, INVEST OPHTH VIS SCI, V37, P1651; Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642; Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204; Love RM, 2002, CELL TRANSPLANT, V11, P653, DOI 10.3727/000000002783985431; LUND R, 2000, NERVOUS CONTROL EYE; Lund RD, 1997, OPHTHALMIC RES, V29, P305, DOI 10.1159/000268029; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142-9612(96)85756-5; Morrow EM, 1999, DEVELOPMENT, V126, P23; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Park KW, 2001, ANIM BIOTECHNOL, V12, P173, DOI 10.1081/ABIO-100108344; Petters RM, 1997, NAT BIOTECHNOL, V15, P965, DOI 10.1038/nbt1097-965; Pittack C, 1997, DEVELOPMENT, V124, P805; Pomahac B, 1998, CRIT REV ORAL BIOL M, V9, P333, DOI 10.1177/10454411980090030601; Rapaport DH, 1998, SEMIN CELL DEV BIOL, V9, P241, DOI 10.1006/scdb.1998.0232; REH TA, 1994, PERSPECT DEV NEUROBI, V2, P183; Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.3.CO;2-4; Rothermel A, 2003, INVEST OPHTH VIS SCI, V44, P2221, DOI 10.1167/iovs.02-0915; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; STENKAMP DL, 1993, INVEST OPHTH VIS SCI, V34, P2425; Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721; Temenoff JS, 2000, BIOMATERIALS, V21, P431, DOI 10.1016/S0142-9612(99)00213-6; Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Warfvinge K, 2005, ARCH OPHTHALMOL-CHIC, V123, P1385, DOI 10.1001/archopht.123.10.1385; Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142-9612(96)85762-0; Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	78	35	37	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0903-4641	1600-0463		APMIS	APMIS	NOV	2005	113	11-12					845	857		10.1111/j.1600-0463.2005.apm_334.x			13	Immunology; Microbiology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Microbiology; Pathology	012QG	WOS:000235353500011	16480454	Bronze			2022-02-06	
J	Koob, AO; Duerstock, BS; Babbs, CF; Sun, YL; Borgens, RB				Koob, AO; Duerstock, BS; Babbs, CF; Sun, YL; Borgens, RB			Intravenous polyethylene glycol inhibits the loss of cerebral cells after brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; degeneration; ethidium bromide; neuroprotection; polyethylene glycol (PEG)	SPINAL-CORD-INJURY; AXONAL INJURY; NEURONAL APOPTOSIS; MOLECULAR REPAIR; NERVE MEMBRANES; MODEL; RAT; RECOVERY; FUSION; RECONNECTION	We have tested the effectiveness of polyethylene glycol (PEG) to restore the integrity of neuronal membranes after mechanical damage secondary to severe traumatic brain injury (TBI) produced by a standardized head injury model in rats. We provide additional detail on the standardization of this model, particularly the use and storage of foam bedding that serves to both support the animal during the impact procedure-and as a dampener to the acceleration of the brass weight. Further, we employed a dye exclusion technique using ethidium bromide (EB; quantitative evaluation) and horseradish peroxidase (HRP; qualitative evaluation). Both have been successfully used previously to evaluate neural injury in the spinal cord since they enter cells when their plasma membranes are damaged. We quantified EB labeling (90 mu M in 110 mu L of sterile saline) after injection into the left lateral ventricle of the rat brain 2 h after injury. At six h after injection and 8 h after injury, the animals were sacrificed and the brains were analyzed. In the injured rat brain, EB entered cells lining and medial to the ventricles, particularly the axons of the corpus callosum. There was minimal EB labeling in uninjured control brains, limited to cells lining the luminal surfaces of the ventricles. Intravenous injections of PEG (1 cc of saline, 30% by volume, 2000 MW) immediately after severe TBI resulted in significantly decreased EB uptake compared with injured control animals. A similar result was achieved using the larger marker, HRP. PEG-treated brains closely resembled those of uninjured animals.	Purdue Univ, Ctr Paralysis Res, Dept Biol Sci, Neurosci Program, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Comp Sci, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Dept Biomed Engn, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Ctr Paralysis Res, Dept Biol Sci, Neurosci Program, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu					AESCHBACHER M, 1986, CELL BIOL TOXICOL, V2, P247, DOI 10.1007/BF00122693; AHKONG QF, 1987, J CELL SCI, V88, P389; Bajaj CL, 1997, VISUALIZATION '97 - PROCEEDINGS, P167, DOI 10.1109/VISUAL.1997.663875; BITTNER GD, 1986, BRAIN RES, V367, P351, DOI 10.1016/0006-8993(86)91617-3; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 2003, ADV ANAT EMBRYOLOGY, P1; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DEY CS, 1988, BIOCHEM INT, V17, P367; Donaldson J, 2002, NEUROSURGERY, V50, P147, DOI 10.1097/00006123-200201000-00023; Duerstock BS, 2000, COMPUT MED IMAG GRAP, V24, P389, DOI 10.1016/S0895-6111(00)00034-3; Duerstock BS, 2003, J MICROSC-OXFORD, V210, P138, DOI 10.1046/j.1365-2818.2003.01130.x; Feng YZ, 2003, EUR J PHARMACOL, V481, P169, DOI 10.1016/j.ejphar.2003.09.016; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Koenig E, 1999, NEUROSCIENCE, V89, P5, DOI 10.1016/S0306-4522(98)00282-6; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KRAUSE TL, 1991, BRAIN RES, V561, P350, DOI 10.1016/0006-8993(91)91615-8; KRAUSE TL, 1990, P NATL ACAD SCI USA, V87, P1471, DOI 10.1073/pnas.87.4.1471; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; Piper M, 2004, ANNU REV CELL DEV BI, V20, P505, DOI 10.1146/annurev.cellbio.20.010403.111746; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roy M, 1999, TRENDS NEUROSCI, V22, P419, DOI 10.1016/S0166-2236(99)01435-6; SHAPIRA Y, 1989, Neurological Research, V11, P169; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; SUNKYUNG L, 1995, J CELL SCI, V116, P4467; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Versace J, 1971, REV SEVERITY INDEX; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Working PK, 1997, ACS SYM SER, V680, P45; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	55	35	35	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1092	1111		10.1089/neu.2005.22.1092			20	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600006	16238486	Green Submitted			2022-02-06	
J	Tsai, SJ				Tsai, SJ			Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia	MEDICAL SCIENCE MONITOR			English	Article						N-acetylaspartate; N-acetyl aspartylglutamate; schizophrenia; glutamate; type 3 metabotropic glutamate receptor; N-methyl-D-aspartate receptor; glutamate carboxypeptidase II	PROTON-MAGNETIC-RESONANCE; METABOTROPIC GLUTAMATE-RECEPTOR; LINKED ACIDIC DIPEPTIDASE; TRAUMATIC BRAIN-INJURY; L-ASPARTIC ACID; PREFRONTAL CORTEX; GENE-EXPRESSION; FRONTAL-LOBE; RAT-BRAIN; MITOCHONDRIAL DYSFUNCTION	The "glutamate hypothesis" of schizophrenia has emerged from the finding that phencyclidine (PCP) induces psychotic-like behaviors in rodents, possibly by blocking the N-methyl-D-aspartate (NMDA) subtype of glutainate receptor, thereby causing increased glutamate release. N-acetyl aspartylglutamate (NAAG), an endogenous peptide abundant in mammalian nervous systems, is localized in certain brain cells, including cortical and hippocampal pyramidal neurons. NAAG is synthesized from N-acetylaspartate (NAA) and glutamate, and NAA availability may limit the rate of NAAG synthesis. Although NAAG is known to have some neurotransmitter-like functions, NAA does not. NAAG is a highly selective agonist of the type 3 metabotropic glutamate receptor (mGluR3, a presynaptic autoreceptor) and can inhibit glutamate release. In addition, at low levels, NAAG is an NMDA receptor antagonist, and blocking of NMDA receptors may increase glutamatc release. Taken together, low central NAAG levels may antagonize the effect of glutamate at NMDA receptors and decrease its agonistic effect on presynaptic rnGluR3; both activities could increase glutamate release, similar to the increase demonstrated in the PCP model of schizophrenia. In this report, it is suggested that the central NAAG deficit, possibly through decreased synthesis or increased degradation of NAAG, may play a role in the pathogenesis of schizophrenia. Evidence is presented and discussed from magnetic resonance, postmortem, animal model, schizophrenia treatment, and genetic studies. The central NAAG deficit model of schizophrenia could explain the disease process, from the perspectives of both neurodevelopment and neurodegeneration, and may point to potential treatments for schizophrenia.	Taipei Vet Gen Hosp, Dept Psychiat, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Div Psychiat, Taipei 112, Taiwan		Tsai, SJ (corresponding author), Taipei Vet Gen Hosp, Dept Psychiat, 201,Shihpai Rd,Sec 2, Taipei 11217, Taiwan.	sjtsai@vghtpe.gov.tw	Tsai, Shih-Jen/AAK-7944-2020	Tsai, Shih-Jen/0000-0002-9987-022X			Arciniegas DB, 2003, INT REV PSYCHIATR, V15, P328, DOI 10.1080/09540260310001606719; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Ben-Shachar D, 2002, J NEUROCHEM, V83, P1241, DOI 10.1046/j.1471-4159.2002.01263.x; Bertolino A, 2001, BIOL PSYCHIAT, V49, P39, DOI 10.1016/S0006-3223(00)00997-5; Bertolino A, 2002, CEREB CORTEX, V12, P983, DOI 10.1093/cercor/12.9.983; Bertolino A, 1998, BIOL PSYCHIAT, V43, P641, DOI 10.1016/S0006-3223(97)00555-6; Black K, 2001, SCHIZOPHR RES, V47, P215, DOI 10.1016/S0920-9964(00)00144-4; Braus DF, 2001, PHARMACOPSYCHIATRY, V34, P251, DOI 10.1055/s-2001-18037; Brooks WM, 1998, BIOL PSYCHIAT, V43, P263, DOI 10.1016/S0006-3223(97)00462-9; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Callicott JH, 2000, AM J PSYCHIAT, V157, P1646, DOI 10.1176/appi.ajp.157.10.1646; Callicott JH, 1998, BIOL PSYCHIAT, V44, P941, DOI 10.1016/S0006-3223(98)00264-9; Cartmell J, 1999, J PHARMACOL EXP THER, V291, P161; Chavez-Noriega LE, 2002, CNS NEUROL DISORD-DR, V1, P261, DOI 10.2174/1568007023339337; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Coyle JT, 2004, PSYCHOPHARMACOLOGY, V174, P32, DOI 10.1007/s00213-003-1709-2; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; CUMMINGS JL, 1988, PSYCHOSOMATICS, V29, P16, DOI 10.1016/S0033-3182(88)72418-4; Deicken RF, 1999, SCHIZOPHR RES, V37, P217, DOI 10.1016/S0920-9964(98)00173-X; Deicken RF, 2003, AM J PSYCHIAT, V160, P873, DOI 10.1176/appi.ajp.160.5.873; Deicken RF, 2000, REV NEUROSCIENCE, V11, P147; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Ende G, 2000, SCHIZOPHR RES, V41, P389, DOI 10.1016/S0920-9964(99)00089-4; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Farber NB, 1995, BIOL PSYCHIAT, V38, P788, DOI 10.1016/0006-3223(95)00046-1; Flores C, 2003, NEUROPSYCHOPHARMACOL, V28, P1227, DOI 10.1038/sj.npp.1300129; Fukuzako H, 1995, PSYCHIAT RES-NEUROIM, V61, P193, DOI 10.1016/0925-4927(95)02622-5; Gehl LM, 2004, J NEUROCHEM, V90, P989, DOI 10.1111/j.1471-4159.2004.02578.x; Ghose S, 2004, NEUROPSYCHOPHARMACOL, V29, P117, DOI 10.1038/sj.npp.1300304; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Haas GL, 1998, J PSYCHIAT RES, V32, P151, DOI 10.1016/S0022-3956(98)00008-9; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harte MK, 2004, BIOL PSYCHIAT, V56, P296, DOI 10.1016/j.biopsych.2004.06.009; Heimberg C, 1998, PSYCHIAT RES-NEUROIM, V83, P105, DOI 10.1016/S0925-4927(98)00034-1; Ho BC, 2003, ARCH GEN PSYCHIAT, V60, P585, DOI 10.1001/archpsyc.60.6.585; JAKOBS C, 1991, J INHERIT METAB DIS, V14, P653, DOI 10.1007/BF01799929; JENKINS BG, 1993, NEUROLOGY, V43, P2689, DOI 10.1212/WNL.43.12.2689; Keshavan MS, 2003, SCHIZOPHRENIA BULL, V29, P757, DOI 10.1093/oxfordjournals.schbul.a007045; Kilbride J, 1998, EUR J PHARMACOL, V356, P149, DOI 10.1016/S0014-2999(98)00526-3; Kodsi MH, 1997, NEUROSCI LETT, V231, P103, DOI 10.1016/S0304-3940(97)00482-5; Konradi C, 2003, PHARMACOL THERAPEUT, V97, P153, DOI 10.1016/S0163-7258(02)00328-5; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; KRYSTAL JH, IN PRESS PSYCHOPHARM; LAUTENSCHLAGER NT, 2001, CURR PSYCHIAT REP, V3, P3219; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; MacKay S, 1996, RADIOLOGY, V198, P537, DOI 10.1148/radiology.198.2.8596863; Mathew SJ, 2003, BIOL PSYCHIAT, V54, P727, DOI 10.1016/S0006-3223(03)00004-0; MEYERHOFF JL, 1989, BRAIN RES, V505, P130, DOI 10.1016/0006-8993(89)90123-6; MEYERHOFF JL, 1985, BRAIN RES, V346, P392, DOI 10.1016/0006-8993(85)90877-7; Michael N, 2003, NEUROPSYCHOPHARMACOL, V28, P720, DOI 10.1038/sj.npp.1300085; Middleton FA, 2002, J NEUROSCI, V22, P2718, DOI 10.1523/JNEUROSCI.22-07-02718.2002; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; MIYAKE M, 1982, CLIN CHIM ACTA, V120, P119; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; Molina V, 2005, SCHIZOPHR RES, V73, P209, DOI 10.1016/j.schres.2004.02.001; Moreno A, 2001, J NEUROCHEM, V77, P347, DOI 10.1046/j.1471-4159.2001.00282.x; Nudmamud S, 2003, BIOL PSYCHIAT, V53, P1138, DOI 10.1016/S0006-3223(02)01742-0; Ohrmann P, 2005, SCHIZOPHR RES, V73, P153, DOI 10.1016/j.schres.2004.08.021; Okamura N, 2003, BRAIN RES, V992, P114, DOI 10.1016/j.brainres.2003.08.045; Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; Poland RE, 1999, J PSYCHIATR RES, V33, P41, DOI 10.1016/S0022-3956(98)00043-0; Reneman L, 2002, AM J NEURORADIOL, V23, P231; Reynolds LM, 2005, SCHIZOPHR RES, V73, P147, DOI 10.1016/j.schres.2004.02.003; Sawa A, 2003, MOL MED, V9, P3, DOI 10.1007/BF03402101; Schoepp Darryle D., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P215, DOI 10.2174/1568007024606177; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Schweinsburg BC, 2001, ALCOHOL CLIN EXP RES, V25, P924, DOI 10.1097/00000374-200106000-00019; Sigmundsson T, 2003, SCHIZOPHR RES, V64, P63, DOI 10.1016/S0920-9964(02)00533-9; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Stanley JA, 2000, BIOL PSYCHIAT, V48, P357, DOI 10.1016/S0006-3223(00)00949-5; STANLEY JA, 1995, MAGNET RESON MED, V34, P17, DOI 10.1002/mrm.1910340105; STAUCH BL, 1989, NEUROSCI LETT, V100, P295, DOI 10.1016/0304-3940(89)90702-7; Thomas AG, 2000, J PHARMACOL EXP THER, V295, P16; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; Tsai SJ, 2005, SCHIZOPHR RES, V76, P359, DOI 10.1016/j.schres.2004.12.018; Tsuang M, 2000, BIOL PSYCHIAT, V47, P210, DOI 10.1016/S0006-3223(99)00289-9; Tyson RL, 1998, NEUROSCI LETT, V251, P181, DOI 10.1016/S0304-3940(98)00527-8; WESTBROOK GL, 1986, J NEUROSCI, V6, P3385; Wroblewska B, 1997, J NEUROCHEM, V69, P174; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x	83	35	35	0	6	INT SCIENTIFIC LITERATURE, INC	ALBERTSON	1125 WILLIS AVE, ALBERTSON, NY 11507 USA	1234-1010			MED SCI MONITOR	Med. Sci. Monitor	SEP	2005	11	9					HY39	HY45					7	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Research & Experimental Medicine	965CV	WOS:000231928500001	16127367				2022-02-06	
J	Arbogast, KB; Margulies, SS; Christian, CW				Arbogast, KB; Margulies, SS; Christian, CW			Initial neurologic presentation in young children sustaining inflicted and unintentional fatal head injuries	PEDIATRICS			English	Article						abuse; accidents; falls; head injuries; lucid interval	TRAUMATIC BRAIN-INJURY; SHAKEN BABY SYNDROME; COMA SCALE; INFANT; FALLS; TIME	Background. It remains unclear if fatal brain injuries in young children are characterized by immediate rapid deterioration or can present after an initial period of lucidity. This issue has legal implications in child abuse, for which understanding the clinical course affects perpetrator identification. Objective. To determine patterns of neurologic presentation on hospital admission in infants and toddlers who die of inflicted and unintentional injury. Design/Methods. Data on children < 48 months of age who sustained a fatal head injury from 1986-2002 were extracted from the Pennsylvania Trauma Outcomes Study. Only those with external-causes-of-injury codes for inflicted injury, falls, and motor vehicle crashes (MVCs) with a recorded Glasgow Coma Scale (GCS) on admission were included. The GCS was compared across mechanisms and age groups (0-11, 12-23, 24-35, and 36-47 months). Results. Of the 314 fatally injured children, 37% sustained inflicted injury, 13% sustained a fall, and 49% sustained an MVC. At admission, 6.8% of all children had a GCS score of > 7, and 1.9% presented with a GCS score of > 12 ( lucid). The incidence of admission a GCS score of > 7 varied by mechanism. Overall, children with inflicted injury were 3 times more likely to present with a GCS score of > 7 than those injured in MVCs ( odds ratio [OR]: 3.6; 95% confidence interval [CI]: 1.2-10.3), but incidence of a GCS score of > 7 did not differ between inflicted injuries and falls. Similarly, when considering only those children >= 24 months old, a GCS score of > 7 did not differ by mechanism. In contrast, in those < 24 months old, children who died as a result of inflicted injury were > 10 times more likely to have a GCS score of > 7 than those who died as a result of a MVC (OR: 9.36; 95% CI: 1.3-80.9). Conclusions. The data suggest an age- and mechanism-dependent presentation of neurologic status in children with fatal head injury. Although infrequent, young victims of fatal head trauma may present as lucid (GCS score: > 12) before death. Furthermore, children < 48 months old sustaining inflicted injury are 3 times more likely to be assessed with a moderate GCS score 7) than those in MVCs. This effect is amplified in the youngest children (< 24 months old): those with inflicted injury were 10 times more likely to present with moderate GCS scores than those in MVCs. In addition, this youngest age group seems to be overrepresented in those who present as lucid (GCS score: > 12 [5 of 6]). It is unclear whether these differences are the result of inadequate tests to evaluate consciousness in younger children or differences in biomechanical mechanisms of inflicted trauma.	Childrens Hosp Philadelphia, TraumaLink Interdisciplinary Pediat Injury Contro, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Div Emergency Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Div Gen Pediat, Philadelphia, PA 19104 USA		Arbogast, KB (corresponding author), Childrens Hosp Philadelphia, TraumaLink Interdisciplinary Pediat Injury Contro, 34th St & Civ Ctr Blvd,3535 TraumaLink,10th Floor, Philadelphia, PA 19104 USA.	arbogast@email.chop.edu		Arbogast, Kristy/0000-0002-1694-4562			Denton S, 2003, AM J FOREN MED PATH, V24, P371, DOI 10.1097/01.paf.0000097851.18478.16; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Nance ML, 2003, J TRAUMA, V55, P631, DOI 10.1097/01.TA.0000035090.99483.0A; NASHELSKY MB, 1995, AM J FOREN MED PATH, V16, P154, DOI 10.1097/00000433-199506000-00016; Page RB, 2004, NEUROSURGERY, V54, P143, DOI 10.1227/01.NEU.0000097514.60813.1B; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SIMPSON D, 1982, LANCET, V2, P450; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9	17	35	36	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2005	116	1					180	184		10.1542/peds.2004-2671			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	941IC	WOS:000230207500050	15995050				2022-02-06	
J	Kaplan, S; Gokyar, A; Unal, B; Tunc, AT; Bahadir, A; Aslan, H				Kaplan, S; Gokyar, A; Unal, B; Tunc, AT; Bahadir, A; Aslan, H			A simple technique for localizing consecutive fields for disector pairs in light microscopy: Application to neuron counting in rabbit spinal cord following spinal cord injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						physical fractionator; stereology; injury; spinal cord; hypothermia; methylprednisolone	TRAUMATIC BRAIN-INJURY; METHYLPREDNISOLONE TREATMENT; ARBITRARY PARTICLES; UNBIASED ESTIMATION; ISCHEMIC-STROKE; CYCLOSPORINE-A; STEREOLOGY; RAT; HYPOTHERMIA; NUMBER	Locating the same microscopic fields in consecutive sections is important in stereological analysis. The tools for achieving this requirement have limited number in practice. This paper presents a simple and inexpensive technique for localizing the same fields on disector pairs in conventional light microscopes equipped with widely available dial indicators. It is partly a modification of equipment previously described. The presented procedure requires two light microscopes equipped with dial indicators and modified slide clips. An application of the present system was shown in a model of spinal cord injury (SCI). A midthoracic laminectomy was performed leaving the dura intact. A contusion was done at the level of midthoracic spinal cord segments (T7-T8) by dropping a 10-g mass from a height of 30cm. The subjects were randomly divided into three groups (10 animals in each): hypothermia group, methylprednisolone group, and traumatic spinal cord injury alone group. Present result show that treatment with hypothermia after spinal cord trauma has a neuroprotective effect on cell damage but not in the methylprednisolone treatment group. (c) 2005 Elsevier B.V. All rights reserved.	Ondokuz Mayis Univ, Sch Med, Dept Histol & Embryol, TR-55139 Kurupelit, Turkey; Hosp Social Insurance Fdn, Neurosurg Clin, TR-55305 Samsun, Turkey; Ataturk Univ, Sch Med, Dept Histol & Embryol, TR-25100 Erzurum, Turkey; Gaziosmanpasa Univ, Sch Med, Dept Histol & Embryol, TR-60100 Tokat, Turkey		Kaplan, S (corresponding author), Ondokuz Mayis Univ, Sch Med, Dept Histol & Embryol, TR-55139 Kurupelit, Turkey.	skaplan@omu.edu.tr	Turkkani, Ayten/AAW-4897-2021; Aslan, Huseyin/K-4602-2012; Gokyar, Ahmet/N-9877-2018; Kaplan, Suleyman/A-5396-2008	Gokyar, Ahmet/0000-0003-1942-587X; Kaplan, Suleyman/0000-0003-1477-5002			Battiston B, 2000, MICROSURG, V20, P37, DOI 10.1002/(SICI)1098-2752(2000)20:1<37::AID-MICR7>3.0.CO;2-5; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; BRADBURY S, 1990, MICROSC ANAL, V17, P7; BRAENDGAARD H, 1986, J NEUROSCI METH, V18, P39, DOI 10.1016/0165-0270(86)90112-3; DELATTRE JY, 1989, J NEUROSURG, V70, P920, DOI 10.3171/jns.1989.70.6.0920; Glaser JR, 2000, J CHEM NEUROANAT, V20, P115, DOI 10.1016/S0891-0618(00)00073-9; Gok A, 2002, ACTA NEUROCHIR, V144, P817, DOI 10.1007/s00701-002-0964-z; Gong QY, 1999, BRIT J RADIOL, V72, P1177, DOI 10.1259/bjr.72.864.10703475; Graves MJ, 2000, BRIT J RADIOL, V73, P825, DOI 10.1259/bjr.73.872.11026856; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; GUNTINASLICHIUS O, 1993, J MICROSC-OXFORD, V172, P177, DOI 10.1111/j.1365-2818.1993.tb03409.x; Hof PR, 2001, TRENDS NEUROSCI, V24, P377, DOI 10.1016/S0166-2236(00)01834-8; HOWARD CV, 1998, 3 DIMENSIONAL MEASUR, P187; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Kaplan S, 2001, J MICROSC-OXFORD, V203, P321, DOI 10.1046/j.1365-2818.2001.00931.x; KIM D, 2002, SPINE J S, V2, P34; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Larsen JO, 1998, J NEUROSCI METH, V85, P107, DOI 10.1016/S0165-0270(98)00129-0; Mackay CE, 1999, ACTA STEREOL, V18, P149; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McCutcheon EP, 2004, J TRAUMA, V56, P1076, DOI 10.1097/01.TA.0000082312.71894.D4; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; Merola A, 2002, J ORTHOP TRAUMA, V16, P155, DOI 10.1097/00005131-200203000-00003; MOLLER A, 1990, J MICROSC-OXFORD, V159, P61, DOI 10.1111/j.1365-2818.1990.tb03019.x; Ohm TG, 1997, NEUROBIOL AGING, V18, P393, DOI 10.1016/S0197-4580(97)00034-1; POVER CM, 1991, ANAT REC, V231, P573, DOI 10.1002/ar.1092310419; Sharma Alok, 2004, Indian Journal of Experimental Biology, V42, P476; Sonmez OF, 2002, ACTA NEUROCHIR, V144, P921, DOI 10.1007/s00701-002-0971-0; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Tos P, 2000, MICROSURG, V20, P65, DOI 10.1002/(SICI)1098-2752(2000)20:2<65::AID-MICR4>3.3.CO;2-W; TUCKER JH, 1994, J MICROSC-OXFORD, V176, P75, DOI 10.1111/j.1365-2818.1994.tb03501.x; VANICKY I, 1993, J NEUROSURG, V79, P736, DOI 10.3171/jns.1993.79.5.0736; WEIRICH SD, 1990, SPINE, V15, P630, DOI 10.1097/00007632-199007000-00004; White RJ, 2001, J NEUROSURG, V94, P183; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206; Zeidman SM, 1996, J SPINAL DISORD, V9, P367	44	35	38	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 30	2005	145	1-2					277	284		10.1016/j.jneumeth.2005.02.012			8	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	936OY	WOS:000229866500024	15922043				2022-02-06	
J	Rocchi, G; Caroli, E; Belli, E; Salvati, M; Cimatti, M; Delfini, R				Rocchi, G; Caroli, E; Belli, E; Salvati, M; Cimatti, M; Delfini, R			Severe craniofacial fractures with frontobasal involvement and cerebrospinal fluid fistula: indications for surgical repair	SURGICAL NEUROLOGY			English	Article						cerebrospinal fluid fistula; fracture; head injury; management; meningitis; rhinorrhea; surgical repair	CT CISTERNOGRAPHY; RHINORRHEA; LOCALIZATION; DIAGNOSIS; MANAGEMENT; COMPLICATIONS; TOMOGRAPHY; SELECTION; LEAKAGE	Background: The management of posttraumatic cerebrospinal fluid (CSF) fistulae is a controversial topic. Although recent literature shows that endoscopic repair of CSF fistula is efficacious and minimally invasive, in specific conditions open operative approach remains imperative. Methods: A series of 36 patients underwent surgery for posttraumatic CSF fistula according to specific selection criteria. These criteria included: bone displacement more than I cm (5 cases), location of fracture in proximity to the midline (6 cases), involvement of cribriform plate (12 cases), presence of encephalocele (3 cases), and failure of the conservative treatment (10 cases). The dural defect was closed using vascularized pericranium and fibrin glue. Closure of the basal bone defect was necessary in very large fractures or in special localization of the fistula, such as near the optic nerve. Mean clinical follow-up was 5.7 years. Results: Two patients presented meningitis without sequelae, and 12 with hyposmia. One patient died of the severity of the primary brain injury and associated extracranial lesions. None of the patients had recurrence. Conclusions: Our results indicate that surgical dural repair in selected cases is related to low morbidity and mortality preserving from delayed risks such as recurrence and infections. (c) 2005 Elsevier Inc. All rights reserved.	Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Neurosurg, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Maxillofacial Surg, I-00185 Rome, Italy; IRCCS, Dept Neurosurg, INM Neuromed, Pozzilli, Italy		Caroli, E (corresponding author), Via Meropia 85, I-00147 Rome, Italy.	manucarol2000@yahoo.it	Salvati, Maurizio/AAC-5215-2022				AARABI B, 1992, Ear Nose and Throat Journal, V71, P300; AHMADI J, 1985, NEUROSURGERY, V16, P54, DOI 10.1227/00006123-198501000-00011; ALLEN MB, 1972, J NEUROL NEUROSUR PS, V35, P664, DOI 10.1136/jnnp.35.5.664; ALMEFTY O, 1993, SURG CRANIAL BASE TU; BRUTON E, 1990, AM J NEURORADIOL, V11, P205; Cairns H., 1937, J LARYNG, V52, P589, DOI 10.1017/S0022215100043991; CHRISTIE M, 1987, NEUROSURGERY, V20, P31, DOI 10.1227/00006123-198701000-00008; COMOY J, 1986, J NEURORADIOLOGY, V13, P248; Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001; DRAYER BP, 1978, J NEUROSURG, V48, P946, DOI 10.3171/jns.1978.48.6.0946; DUCKERT LG, 1977, LARYNGOSCOPE, V87, P18; El Gammal T, 1998, AM J NEURORADIOL, V19, P627; ELJAMEL M S M, 1990, British Journal of Neurosurgery, V4, P479, DOI 10.3109/02688699008993796; ELJAMEL MS, 1995, J NEUROSURG, V83, P795, DOI 10.3171/jns.1995.83.5.0795; ELJAMEL MS, 1993, THESIS U LIVERPOOL L, P207; GHOSHHAJRA K, 1980, J COMPUT ASSIST TOMO, V4, P306, DOI 10.1097/00004728-198006000-00003; GRAF CJ, 1981, J NEUROSURG, V54, P392, DOI 10.3171/jns.1981.54.3.0392; Griffith H B, 1990, Br J Neurosurg, V4, P369, DOI 10.3109/02688699008992757; JEFFERSON A, 1972, BRIT J SURG, V59, P585, DOI 10.1002/bjs.1800590802; JENNETT B, 1981, MANAGEMENT HEAD INJU, P193; LANTZ EJ, 1980, AM J NEURORADIOL, V1, P391; LEECH PJ, 1973, LANCET, V1, P1013; LEVIN S, 1972, AM J MED SCI, V264, P319, DOI 10.1097/00000441-197210000-00010; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; Loew F, 1984, Adv Tech Stand Neurosurg, V11, P169; MANELFE C, 1982, AM J ROENTGENOL, V138, P471, DOI 10.2214/ajr.138.3.471; Minutoli F, 1999, EUR RADIOL, V9, P571; NAIDICH TP, 1980, J NEUROSURG, V53, P222, DOI 10.3171/jns.1980.53.2.0222; OKADA J, 1991, SURG NEUROL, V35, P213, DOI 10.1016/0090-3019(91)90073-I; OMMAYA AK, 1985, NEUROSURGERY, P1637; PARK JI, 1983, LARYNGOSCOPE, V93, P1294; Passagia JG, 1999, ADV TECH STAND NEUR, V25, P195; RAY BS, 1968, J NEUROSURG, V28, P180, DOI 10.3171/jns.1968.28.2.0180; Sakas DE, 1998, J NEUROSURG, V88, P471, DOI 10.3171/jns.1998.88.3.0471; SALAR G, 1978, NEURORADIOLOGY, V15, P185, DOI 10.1007/BF00329067; SAMII J, 1989, SURG SKULL BASE INTE, P12; Servadei F, 1998, ACTA NEUROCHIR, V140, P1183, DOI 10.1007/s007010050235; Shetty PG, 1998, AM J NEURORADIOL, V19, P633; TAKAHASHI T, 1988, J NEUROSURG, V68, P721, DOI 10.3171/jns.1988.68.5.0721; Talamonti G, 1995, ACTA NEUROCHIR, V137, P164, DOI 10.1007/BF02187189; Talamonti G, 1995, J Neurosurg Sci, V39, P191; WAKHLOO AK, 1991, ACTA NEUROCHIR, V111, P119, DOI 10.1007/BF01400499; YEATES AE, 1994, AM J NEURORADIOL, V5, P820	43	35	40	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2005	63	6					559	564		10.1016/j.surneu.2004.07.047			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	938JU	WOS:000229996700013	15936387				2022-02-06	
J	Ufberg, JW; Bushra, JS; Karras, DJ; Satz, WA; Kueppers, F				Ufberg, JW; Bushra, JS; Karras, DJ; Satz, WA; Kueppers, F			Aspiration of gastric contents: association with prehospital intubation	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; ENDOTRACHEAL INTUBATION; PULMONARY ASPIRATION; HEAD-INJURY; COMPLICATIONS; FIELD; EMERGENCY; SURVIVAL	We prospectively compared the incidence of pulmonary aspiration of gastric contents between patients endotracheally intubated in the prehospital (PH) setting and those intubated in the emergency department (ED). Tracheal aspirates were collected using a standard Leukens trap from all patients as soon as possible after endotracheal intubation. Tracheal aspirates were then tested for the presence of pepsin, a sensitive and specific marker of gastric contents, using a fibrinogen digestion technique. Over 8 months, 168 patients were enrolled. The pepsin assay was positive in 10 of 20 (50%) patients intubated in the PH group, as opposed to 33 of 148 (22%) of those intubated in the ED (chi(2) p =.008; odds ratio, 3.5; 95% CI, 1.34-9.08). Patients endotracheally intubated in the PH setting are more likely to have aspirated gastric contents than those intubated in the ED. (c) 2005 Elsevier Inc. All rights reserved.	Temple Univ, Sch Med, Dept Emergency Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Internal Med, Sect Pulm & Crit Care Med, Philadelphia, PA 19140 USA		Ufberg, JW (corresponding author), Temple Univ, Sch Med, Dept Emergency Med, Philadelphia, PA 19140 USA.	jacob.ufberg@verizon.net					ALDRICH T, 1980, SOUTHERN MED J, V73, P456, DOI 10.1097/00007611-198004000-00017; Badellino MM, 1996, CRIT CARE MED, V24, P1881, DOI 10.1097/00003246-199611000-00019; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BUSHRA JA, 2002, ACAD EMERG MED, V9, P405; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Krishnan U, 2002, J PEDIATR GASTR NUTR, V35, P303, DOI 10.1097/00005176-200209000-00012; KUEPPERS F, 2002, RESP CRIT CARE MDD, V165, pA828; LANDAY MJ, 1978, AM J ROENTGENOL, V131, P587, DOI 10.2214/ajr.131.4.587; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; Metheny NA, 2002, AM J CRIT CARE, V11, P150, DOI 10.4037/ajcc2002.11.2.150; MOINE P, 1994, CHEST, V105, P1487, DOI 10.1378/chest.105.5.1487; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; OLSSON GL, 1986, ACTA ANAESTH SCAND, V30, P84, DOI 10.1111/j.1399-6576.1986.tb02373.x; OSWALT JL, 1992, AM J EMERG MED, V10, P511, DOI 10.1016/0735-6757(92)90173-U; RASHKIN MC, 1986, CHEST, V89, P165, DOI 10.1378/chest.89.2.165; REDAN JA, 1991, J TRAUMA, V31, P371, DOI 10.1097/00005373-199103000-00010; ROY TM, 1989, CHEST, V96, P852, DOI 10.1378/chest.96.4.852; Sayre MR, 1998, ANN EMERG MED, V31, P228, DOI 10.1016/S0196-0644(98)70312-9; SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; TARYLE DA, 1979, CHEST, V75, P541, DOI 10.1378/chest.75.5.541; Thibodeau LG, 1997, AM J EMERG MED, V15, P562, DOI 10.1016/S0735-6757(97)90157-1; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; UFBERG JW, 2004, IN PRESS AM J EMERG; WARNER MA, 1993, ANESTHESIOLOGY, V78, P56, DOI 10.1097/00000542-199301000-00010; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	30	35	35	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAY	2005	23	3					379	382		10.1016/j.ajem.2005.02.005			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	936YH	WOS:000229891000027	15915418				2022-02-06	
J	Ji, YC; Kim, YB; Park, SW; Hwang, SN; Min, BK; Hong, HJ; Kwon, JT; Suk, JS				Ji, YC; Kim, YB; Park, SW; Hwang, SN; Min, BK; Hong, HJ; Kwon, JT; Suk, JS			Neuroprotective effect of ginseng total saponins in experimental traumatic brain injury	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						brain injuries; panax; saponins; neuroprotective agents; hippocampus	CONTROLLED CORTICAL IMPACT; INDUCED APOPTOSIS; PANAX-GINSENG; RG1; GINSENOSIDES; NEURONS	In the present study, we investigated whether ginseng total saponins (GTSs) protect hippocampal neurons after experimental traumatic brain injury (TBI) in rats. A moderate-grade TBI was made with the aid of a controlled cortical impact (CCI) device set at a velocity of 3.0 m/sec, a deformation of 3.0 mm, and a compression time of 0.2 sec at the right parietal area for adult male Sprague-Dawley rats. Shamoperated rats that underwent craniectomy without impact served as controls. GTSs (100 and 200 mg/kg) or saline was injected intraperitoneally into the rats immediately post-injury. Twenty-four hours after the injury, the rats underwent neurological evaluation. Contusion volume and the number of hippocampal neurons were calculated with apoptosis evaluated by TUNEL staining. 24 hr post-injury, saline-injected rats showed a significant loss of neuronal cells in the CA2 region of the right hippocampus (53.4%, p < 0.05) and CA3 (34.6%, p < 0.05) compared with contralateral hippocampal region, a significant increase in contusion volume (34 +/- 8 mu L), and significant increase in neurologic deficits compared with the GTSs groups. Treating rats with GTSs seemed to protect the CCI-induced neuronal loss in the hippocampus, decrease cortical contusion volume, and improve neurological deficits.	Chung Ang Univ Hosp, Coll Med, Dept Neurosurg, Seoul 156755, South Korea		Kim, YB (corresponding author), Chung Ang Univ Hosp, Coll Med, Dept Neurosurg, 224-4 Heukseok Dong, Seoul 156755, South Korea.	ybkim1218@cau.ac.kr					Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Chen XC, 2003, EUR J PHARMACOL, V473, P1, DOI 10.1016/S0014-2999(03)01945-9; Chen XC, 2002, ACTA PHARMACOL SIN, V23, P829; CHOI SM, 2002, J KOREAN NEUROSURG S, V32, P29; CHOI SM, 2002, J KOREAN NEUROSURG S, V32, P458; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Kim HE, 1999, LIFE SCI, V65, pPL33, DOI 10.1016/S0024-3205(99)00252-0; Kim S, 2002, BIOCHEM BIOPH RES CO, V296, P247, DOI 10.1016/S0006-291X(02)00870-7; Lee JH, 2002, NEUROSCI LETT, V325, P129, DOI 10.1016/S0304-3940(02)00256-2; Lee YJ, 1997, MOL CELL ENDOCRINOL, V133, P135, DOI 10.1016/S0303-7207(97)00160-3; Liao BS, 2002, EXP NEUROL, V173, P224, DOI 10.1006/exnr.2001.7841; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lim JH, 1997, NEUROSCI RES, V28, P191, DOI 10.1016/S0168-0102(97)00041-2; Shen LH, 2003, NEUROSCI LETT, V344, P1, DOI 10.1016/S0304-3940(03)00318-5; Shibata S, 2001, J KOREAN MED SCI, V16, pS28, DOI 10.3346/jkms.2001.16.S.S28; Stelmasiak Z, 2000, Med Sci Monit, V6, P426; Wang LJ, 2002, J NEUROSCI, V22, P6920; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y	23	35	38	0	2	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	APR	2005	20	2					291	296		10.3346/jkms.2005.20.2.291			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	920QE	WOS:000228704400022	15832003	Green Published, Green Submitted			2022-02-06	
J	Lozada, A; Maegele, M; Stark, H; Neugebauer, EMA; Panula, P				Lozada, A; Maegele, M; Stark, H; Neugebauer, EMA; Panula, P			Traumatic brain injury results in mast cell increase and changes in regulation of central histamine receptors	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article; Proceedings Paper	32nd Meeting of the European-Histamine-Research-Society	MAY 07-11, 2003	Univ Amsterdam, Amsterdam, NETHERLANDS	European Histamine Res Soc	Univ Amsterdam	binding densities; degranulation; gene expression; mast cell tryptase; neuronal cell death; oxidative stress	MANGANESE-SUPEROXIDE-DISMUTASE; RAT-BRAIN; MESSENGER-RNA; HISTIDINE-DECARBOXYLASE; NEURON SYSTEM; TUBEROMAMMILLARY NUCLEUS; INFERIOR COLLICULUS; DOWN-REGULATION; NERVOUS-SYSTEM; H-3 RECEPTORS	Experimental fluid-percussion models produce brain injury by rapidly injecting saline into the closed cranium of rats. In this study our purpose was to determine how the central histaminergic system, which controls excitability and neurotransmitter release through G-protein coupled receptors, is affected by the pathophysiology of traumatic brain injury. We found that mast cell infiltration, as a result of the trauma, occurred primarily in the injured cortex and did not proceed beyond the fimbria of the hippocampus. In comparing injured animals with controls we found that H-3 receptor binding densities are significantly decreased bilaterally in the cortex but are significantly increased bilaterally in the thalamus. H-3 receptor binding densities may well be affected by mast cell secretion of mediators (i.e. histamine, heparin, leukotrienes), evidenced by detection of a cosecreted enzyme (mast cell tryptase) in the extracellular region. Moreover, we detected significant decreases in H-1 and H-3 receptor mRNA as well as Cu/Zn-dependent superoxide dismutase (SOD) mRNA in the thalamic region closest to the trauma. These significant decreases delineate the extent of cellular damage because of trauma and may underlie sustained cognitive and motor deficits displayed by these animals.	Abo Akad Univ, Dept Biol, FIN-20520 Turku, Finland; Univ Cologne, Biochem & Expt Div, Cologne, Germany; Univ Cologne, Surg Clin, Dept Surg 2, Cologne, Germany; Goethe Univ Frankfurt, Inst Pharmazeut Chem, Biozentrum, D-6000 Frankfurt, Germany; Univ Helsinki, Ctr Neurosci, Helsinki, Finland; Univ Helsinki, Inst Biomed Anat, Helsinki, Finland		Panula, P (corresponding author), Abo Akad Univ, Dept Biol, Biocity 2nd Floor,Artillerigatan 6A, FIN-20520 Turku, Finland.	pertti.panula@abo.fi	Stark, Holger/A-4235-2009	Stark, Holger/0000-0003-3336-1710; Panula, Pertti/0000-0002-1189-5132			Abraham WM, 2002, AM J PHYSIOL-LUNG C, V282, pL193, DOI 10.1152/ajplung.00429.2001; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; BARRETT KE, 1991, HDB EXP PHARM, V97, P93; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beil WJ, 2002, PATHOBIOLOGY, V70, P303, DOI 10.1159/000071270; Brown RE, 2001, PROG NEUROBIOL, V63, P637, DOI 10.1016/S0301-0082(00)00039-3; Brown RE, 1999, J PHYSIOL-LONDON, V515, P777, DOI 10.1111/j.1469-7793.1999.777ab.x; CALINGASAN NY, 1995, EXP NEUROL, V134, P64, DOI 10.1006/exnr.1995.1037; CASTREN E, 1990, NEUROSCI LETT, V120, P113, DOI 10.1016/0304-3940(90)90181-8; CHEN Z, 1993, J HISTOCHEM CYTOCHEM, V41, P961, DOI 10.1177/41.7.7685789; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Drutel G, 2001, MOL PHARMACOL, V59, P1; DUX E, 1982, EXP BRAIN RES, V47, P252; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; GALLI SJ, 1993, MAST CELL HLTH DIS, P109; Ghadge GD, 1997, J NEUROSCI, V17, P8756; GOLDSCHMIDT RC, 1984, BRAIN RES, V323, P209, DOI 10.1016/0006-8993(84)90291-9; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Hill SJ, 1997, PHARMACOL REV, V49, P253; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Igaz P, 2001, INFLAMM RES, V50, P123, DOI 10.1007/s000110050735; INAGAKI N, 1990, EXP BRAIN RES, V80, P374; INAGAKI N, 1988, J COMP NEUROL, V273, P283, DOI 10.1002/cne.902730302; Karlstedt K, 1999, J CEREBR BLOOD F MET, V19, P321, DOI 10.1097/00004647-199903000-00010; KITAMURA Y, 1993, AM J MED SCI, V306, P185, DOI 10.1097/00000441-199309000-00011; Kunikowska G, 2001, BRAIN RES, V922, P51, DOI 10.1016/S0006-8993(01)03149-3; LAGUNOFF D, 1991, ARCH BIOCHEM BIOPHYS, V291, P52, DOI 10.1016/0003-9861(91)90104-Q; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; LIGNEAU X, 1994, J PHARMACOL EXP THER, V271, P452; Lintunen M, 1998, EUR J NEUROSCI, V10, P2287, DOI 10.1046/j.1460-9568.1998.00240.x; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; MACKAY GA, 1982, AGENTS ACTIONS, V24, pC315; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McRee RC, 2000, BRAIN RES, V858, P227, DOI 10.1016/S0006-8993(99)02309-4; Meng JS, 2003, NEUROPATHOLOGY, V23, P25, DOI 10.1046/j.1440-1789.2003.00481.x; Michaloudi H, 2003, DEV BRAIN RES, V140, P269, DOI 10.1016/S0165-3806(02)00613-2; MOHANTY S, 1989, J NEUROL SCI, V90, P87, DOI 10.1016/0022-510X(89)90048-8; ONODERA K, 1994, PROG NEUROBIOL, V42, P685, DOI 10.1016/0301-0082(94)90017-5; PALACIOS JM, 1981, NEUROSCIENCE, V6, P15, DOI 10.1016/0306-4522(81)90240-2; PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572; PANULA P, 1989, NEUROSCIENCE, V28, P585, DOI 10.1016/0306-4522(89)90007-9; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pillot C, 2002, NEUROSCIENCE, V114, P173, DOI 10.1016/S0306-4522(02)00135-5; POLLARD H, 1993, NEUROSCIENCE, V52, P169, DOI 10.1016/0306-4522(93)90191-H; RUAT M, 1990, P NATL ACAD SCI USA, V87, P1658, DOI 10.1073/pnas.87.5.1658; SCHLICKER E, 1994, FUND CLIN PHARMACOL, V8, P128, DOI 10.1111/j.1472-8206.1994.tb00789.x; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHWARTZ JC, 2002, NEUROPSYCHOPHARMACOL, P179; Shelton MK, 2000, J NEUROCHEM, V74, P555, DOI 10.1046/j.1471-4159.2000.740555.x; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Takeshita Y, 1998, NEUROSCIENCE, V87, P797, DOI 10.1016/S0306-4522(98)00152-3; Takeuchi A, 2000, J NEUROBIOL, V45, P39, DOI 10.1002/1097-4695(200010)45:1<39::AID-NEU4>3.0.CO;2-A; Tashiro M, 2002, LIFE SCI, V72, P409, DOI 10.1016/S0024-3205(02)02276-2; Toyota H, 2002, MOL PHARMACOL, V62, P389, DOI 10.1124/mol.62.2.389; Troy CM, 1996, J NEUROSCI, V16, P253; Trudgett A, 2003, INT IMMUNOPHARMACOL, V3, P775, DOI 10.1016/S1567-5769(03)00079-1; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; WADA H, 1991, TRENDS NEUROSCI, V14, P415, DOI 10.1016/0166-2236(91)90034-R; WATANABE T, 1984, BRAIN RES, V295, P13, DOI 10.1016/0006-8993(84)90811-4	63	35	35	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	APR	2005	31	2					150	162		10.1111/j.1365-2990.2004.00622.x			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pathology	905VA	WOS:000227597500005	15771708				2022-02-06	
J	Ozsuer, H; Gorgulu, A; Kiris, T; Cobanoglu, S				Ozsuer, H; Gorgulu, A; Kiris, T; Cobanoglu, S			The effects of memantine on lipid peroxidation following closed-head trauma in rats	NEUROSURGICAL REVIEW			English	Article						closed head trauma; excitatory aminoacid; lipid peroxidation; memantine	RECEPTOR-MEDIATED NEUROTOXICITY; CONCUSSIVE BRAIN-INJURY; AMINO-ACID RELEASE; NMDA RECEPTOR; NONCOMPETITIVE ANTAGONIST; NERVOUS-SYSTEM; FREE-RADICALS; GLUTAMATE; DAMAGE; EDEMA	Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Unlike other NMDA antagonists, it has been used clinically for years for the treatment of Parkinson's disease, spasticity, and dementia without serious side effects. We aimed to investigate the therapeutic efficacy of memantine on a closed head trauma model. A total of 132 adult male Sprague-Dawley rats were randomly divided into four groups: sham-operated, control (closed head trauma), sham-vehicle (closed head trauma + saline), treatment (closed head trauma + memantine, 10 mg/kg, i.p.). A cranial impact was delivered to the skull, just in front of the coronal suture, over the left hemisphere, from the height of 7 cm. Saline or memantine were applied 15 min after trauma. Rats were euthanased 0.5, 1, 2, 6, 24, 48 h after trauma. Brain tissue samples were taken 5 mm away from the left frontal pole and also from the corresponding point of the contralateral hemispheres. Malondialdehyde activity (MDA) was considered to reflect the degree of lipid peroxidation. The MDA levels continued to increase for the first 2 h after the injury, then started to decrease gradually. Memantine treatment significantly reduced lipid peroxidation levels in the treatment group compared with other groups (P < 0.01). The findings of the present study indicate that memantine provides beneficial effects after closed head trauma in rats.	Ataturk State Hosp, Dept Neurosurg, TR-35360 Izmir, Turkey; Univ Suleyman Demirel, Sch Med, Dept Neurosurg, TR-32260 Isparta, Turkey; Istanbul Univ, Sch Med, Dept Neurosurg, TR-34390 Istanbul, Turkey; Trakya Univ, Sch Med, Dept Neurosurg, TR-22030 Edirne, Turkey		Gorgulu, A (corresponding author), Suleyman Demirel Bulvari 101 Cadde 73,Sener Apt A, TR-32100 Isparta, Turkey.	askingorgulu@hotmail.com	Kiris, Talat/AAP-4665-2020	Kiris, Talat/0000-0002-2985-3758			BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BLANDPIED TA, 1992, J NEUROPHYSIOL, V77, P309; Block F, 1996, NEUROSCI LETT, V208, P41, DOI 10.1016/0304-3940(96)12545-3; BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gorgulu A, 1999, ACTA NEUROCHIR, V141, P93, DOI 10.1007/s007010050271; Gorgulu A, 2000, ACTA NEUROCHIR, V142, P1287, DOI 10.1007/s007010070027; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; Kaplanski J, 2003, RESUSCITATION, V56, P207, DOI 10.1016/S0300-9572(02)00371-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KOEK W, 1988, J PHARMACOL EXP THER, V245, P969; Koura SS, 1998, ACT NEUR S, V71, P244; KUCHIWAKI H, 1994, ACTA NEUROCHIR, P62; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; NASR MS, 1990, EUR J PHARMACOL, V185, P19; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; PELLEGRINI JW, 1993, ANN NEUROL, V33, P403, DOI 10.1002/ana.410330414; Rao VLR, 2001, BRAIN RES, V911, P96; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Sang CN, 2002, ANESTHESIOLOGY, V96, P1053, DOI 10.1097/00000542-200205000-00005; SCATTON B, 1991, CEREBROVASC DIS, V1, P121, DOI 10.1159/000108829; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SOFFEL M, 1997, ACTA NEUROCHIR WIEN, V70, P91; TANAKA H, 1994, ACTA NEUROCHIR, P524; Uchida K, 2001, EUR J ANAESTH, V18, P295, DOI 10.1046/j.0265-0215.2000.00825.x; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WELLER M, 1993, BRAIN RES, V613, P143, DOI 10.1016/0006-8993(93)90464-X	45	35	37	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	APR	2005	28	2					143	147		10.1007/s10143-004-0374-1			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	910NZ	WOS:000227939900012	15789251				2022-02-06	
J	Scheibel, M; Martinek, V; Imhoff, AB				Scheibel, M; Martinek, V; Imhoff, AB			Arthroscopic reconstruction of an isolated avulsion fracture of the lesser tuberosity	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article						lesser tuberosity fracture; subscapularis avulsion lesion; arthroscopic reconstruction; suture anchor repair	ISOLATED RUPTURE; HUMERUS; TENDON	Isolated avulsion fracture of the lesser tuberosity represents an extremely rare injury that occurs mainly in younger patients. This report outlines the case of a 35-year-old healthy man who sustained a bony avulsion of the subscapularis tendon during an abduction external rotation trauma to his left shoulder. The injury was diagnosed by physical examination, standard radiographs, and magnetic resonance imaging. An arthroscopic reconstruction including closed reduction and internal fixation using suture anchors was performed. After a follow-up of 6 months, the patient's Constant Score increased from 62.4 points preoperatively to 91.3 points. At the latest follow-up, the patient was completely pain free, had regained a full work activity level, and returned to overhead sports. On postoperative standard radiographs and magnetic resonance images, the bony fragment was shown to be consolidated in an anatomic position. In cases of displaced isolated fractures of the lesser tuberosity without significant subluxation or dislocation of the long head of the biceps arthroscopic reconstruction using suture anchors can lead to a good clinical and radiological result.	Tech Univ, Dept Orthopaed & Sports Med, D-80809 Munich, Germany		Scheibel, M (corresponding author), Tech Univ, Dept Orthopaed & Sports Med, Connollystr 32, D-80809 Munich, Germany.	scheibel91@hotmail.com	Imhoff, Andreas B./E-8829-2013	Imhoff, Andreas B./0000-0001-5085-6446			Caniggia M, 1996, PANMINERVA MED, V38, P56; EARWAKER J, 1990, SKELETAL RADIOL, V19, P121; Gerber C, 1996, J BONE JOINT SURG AM, V78A, P1015, DOI 10.2106/00004623-199607000-00005; GERBER C, 1991, J BONE JOINT SURG BR, V73, P389, DOI 10.1302/0301-620X.73B3.1670434; HAAS SL, 1944, AM J SURG, V63, P253; Kuroda T, 1993, J Shoulder Elbow Surg, V2, P221, DOI 10.1016/1058-2746(93)90066-P; LABRIOLA JH, 1975, J BONE JOINT SURG AM, V57, P1011, DOI 10.2106/00004623-197557070-00032; Le Huec J C, 1994, Acta Orthop Belg, V60, P427; Ogawa K, 1997, J TRAUMA, V42, P955, DOI 10.1097/00005373-199705000-00029; PASCHAL SO, 1995, J BONE JOINT SURG AM, V77, P1427, DOI 10.2106/00004623-199509000-00020; ROSS GJ, 1989, RADIOLOGY, V172, P833, DOI 10.1148/radiology.172.3.2772197; Schwamborn T, 1999, SCHULTERINSTABILITAT, P193; SHIBUYA S, 1986, CLIN ORTHOP RELAT R, P215; VANLAARHOVEN HAJ, 1995, J TRAUMA, V39, P997, DOI 10.1097/00005373-199511000-00031; WHITE GM, 1987, J BONE JOINTJ SURG A, V69, P1454	15	35	36	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063			ARTHROSCOPY	Arthroscopy	APR	2005	21	4					487	494		10.1016/j.arthro.2004.11.012			8	Orthopedics; Sport Sciences; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences; Surgery	917RT	WOS:000228487600015	15800530				2022-02-06	
J	Sinnakaruppan, I; Downey, B; Morrison, S				Sinnakaruppan, I; Downey, B; Morrison, S			Head injury and family carers: A pilot study to investigate an innovative community-based educational programme for family carers and patients	BRAIN INJURY			English	Article						head-injury; needs; carers; community; family	TRAUMATIC BRAIN-INJURY; BEHAVIOR MANAGEMENT; CAREGIVER BURDEN; DISTRESS; INDIVIDUALS; RELATIVES; SURVIVORS	Primary objective: The incidence of head injury is increasing among younger people with more family members undertaking their life-long care. Many research studies have highlighted the emotional well-being of such family carers and their unmet needs, however only a few consider the formal help provided for carers. Using a longitudinal, mixed variable, within and between-subject design, this pilot study evaluated the impact of an educational programme for family carers and their head-injured relatives in reducing carer and patient psychological distress and improving their coping ability. Main outcomes and results: The study comprised experimental and control samples each with carer and patient groups. The experimental sample had eight sessions of educational input. All groups were assessed pre- and post-intervention and at 3 months follow-up. The patient sample was further assessed using cognitive measures. There was evidence of reduction in psychological distress in the experimental carer group following the educational input, but these results were not statistically significant. However, the experimental patient population at follow-up assessment showed statistically significant improvements. Conclusions: A larger scale multi-centre study with a longer follow-up period of assessment is required for the generalization of findings. The pilot study identifies points for consideration in a potential main study.	Ayrshire Cent Hosp, Douglas Grant Rehabil Ctr, Dept Psychol, Irvine KA12 8SS, Ayr, Scotland		Sinnakaruppan, I (corresponding author), Ayrshire Cent Hosp, Douglas Grant Rehabil Ctr, Dept Psychol, Irvine KA12 8SS, Ayr, Scotland.	lesley.mcdermott@aaaht.scot.nhs.uk					ACORN S, 1993, J ADV NURS, V18, P39, DOI 10.1046/j.1365-2648.1993.18010039.x; ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; BROOKS WP, 1986, LETT APPL MICROBIOL, V2, P1, DOI 10.1111/j.1472-765X.1986.tb01502.x; Burgess P, 1996, BEHAV ASSESSMENT DYS; Campbell C H, 1988, Rehabil Nurs, V13, P320; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Flanagan DAJ, 1998, BRIT J CLIN PSYCHOL, V37, P431, DOI 10.1111/j.2044-8260.1998.tb01400.x; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Goldberg D., 1978, MANUAL GEN HLTH QUES; Granger CV, 1984, FUNCTIONAL ASSESSMEN; HICKEY AM, 1992, IRISH MED J, V4, P109; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kbler-Ross E., 1969, DEATH DYING; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; KREUTZER JS, 1994, BRAIN INJURY, V8, P222; Liamaki G, 2003, CLIN PSYCHOL, V26, P28; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Pace GM, 1999, BRAIN INJURY, V13, P535; ROSE FD, 1996, BRAIN INJURY IMPROVE; Rosenberg M, 1989, SOC ADOLESCENT SELF; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; WECSHLER D, 1997, ADULT INTELLIGENCE S; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; Williams J., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	35	35	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					283	308		10.1080/02699050400003924			26	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400006	15832874				2022-02-06	
J	Solaroglu, I; Okutan, O; Kaptanoglu, E; Beskonakli, E; Kilinc, K				Solaroglu, I; Okutan, O; Kaptanoglu, E; Beskonakli, E; Kilinc, K			Increased xanthine oxidase activity after traumatic brain injury in rats	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						brain injury; oxygen free radical; lipid peroxidation; xanthine oxidase	CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; RADICAL PRODUCTION; OXYGEN RADICALS; NITRIC-OXIDE; SUPEROXIDE; ISCHEMIA; PEROXYNITRITE; ALLOPURINOL; REPERFUSION	Oxidative stress may contribute to many of the pathophysiologic changes that occur after traumatic brain injury (TBI). There are a number of potential sources and mechanisms for oxygen free radical (OFR) production and lipid peroxiclation after TBI. In this study, we investigate the time-dependent changes in xanthine oxidase (XO) activity and lipid peroxiclation using a focal TBI animal model. We demonstrate that there is an immediate increase in lipid peroxiclation by-products and in XO enzyme activity after TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Hacettepe Univ, Sch Med, Ankara Numune Res & Educ Hosp, Dept Neurol Surg, Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, Ankara, Turkey		Solaroglu, I (corresponding author), Yeni Ziraat Mehallesi,13 Sokak Fulya Apt 8-15, TR-06550 Ankara, Turkey.	isolaroglu@hotmail.com	Solaroglu, Ihsan/ABE-8816-2020; Solaroglu, Ihsan/ABF-7606-2020	Solaroglu, Ihsan/0000-0002-9472-1735; 			Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HILLERED L, 1991, RES EXP MED, V191, P219, DOI 10.1007/BF02576677; ITOH T, 1986, STROKE, V17, P1284, DOI 10.1161/01.STR.17.6.1284; KANEMITSU H, 1989, BRAIN RES, V499, P367, DOI 10.1016/0006-8993(89)90786-5; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Nishio S, 1997, ACT NEUR S, V70, P84; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEI EP, 1986, AM J PHYSIOL, V251, P693	27	35	42	0	11	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2005	12	3					273	275		10.1016/j.jocn.2004.12.002			3	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	929YU	WOS:000229383400014	15851081				2022-02-06	
J	Chan, RCK				Chan, RCK			Sustained attention in patients with mild traumatic brain injury	CLINICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; EVERYDAY ATTENTION; FRONTAL LESIONS; SCHIZOPHRENIA; PERFORMANCE; DEFICITS; TASK; VALIDITY	Objective: To demonstrate that two tests of sustained attention were sensitive to attention deficits in patients with mild traumatic brain injury (TBI). Design: A cross-sectional study recruiting 51 patients with TBI and 51 matched controls. Outcome measures: The Sustained Attention to Response Task (SART) and Monotone Counting Test. Results: The patient groups performed significantly worse than the normal controls in both sustained attention tests. The SART performance was also correlated with pathology severity in the patient group in terms of loss of consciousness (r = 0.247, p = 0.05). A cut-off of less than 1 standard deviation (SD) gives optimal diagnostic information in terms of sensitivity in the present sample (0.61 for Monotone Counting Test; 0.75 for SART). Conclusion: These findings suggest that the SART and Monotone Counting Test are sensitive to patients with mild TBI. The SART-assessed sustained attention is also sensitive enough to detect attention impairment in this clinical group regardless of diagnosis and may provide clinicians with an alternative method of assessing sustained attention in these clinical groups.	Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Peoples R China; Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China		Chan, RCK (corresponding author), Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Peoples R China.	rckchan2003@yahoo.com.hk	Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Chan RCK, 2004, CLIN NEUROPSYCHOL, V18, P114, DOI 10.1080/13854040490507208; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, CLIN REHABIL, V16, P900, DOI 10.1191/0269215502cr574oa; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P695, DOI 10.1076/jcen.24.5.695.1003; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Chen EYH, 2001, EUR ARCH PSY CLIN N, V251, P1, DOI 10.1007/s004060170059; Chen EYH, 1997, SCHIZOPHR RES, V24, P299, DOI 10.1016/S0920-9964(96)00120-X; Cohen J., 2013, STAT POWER ANAL BEHA; HOLDNACK JA, 1995, NEUROPSY NEUROPSY BE, V8, P282; Kurtz MM, 2001, SCHIZOPHR RES, V48, P307, DOI 10.1016/S0920-9964(00)00060-8; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; Robertson I., 1994, TEST EVERYDAY ATTENT; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; Snedecor G.W., 1980, STAT METHODS, V7th; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8	22	35	36	0	3	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	MAR	2005	19	2					188	193		10.1191/0269215505cr838oa			6	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	901TY	WOS:000227306000009	15759534				2022-02-06	
J	David, AS; Prince, M				David, AS; Prince, M			Psychosis following head injury: A critical review	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; RISK-FACTORS; SCHIZOPHRENIA; BIRTH	Schizophrenia is the most common form of psychotic mental disorder, with a point prevalence generally estimated to lie between 0.6-1.0%. Genetically informative studies have indicated a multifactorial aetiology, with an important heritable (genetic) component, but with environmental exposures also undoubtedly relevant. The "neurodevelopmental hypothesis" has informed a body of research that fairly consistently identifies birth complications as a risk factor for the later onset of schizophrenia.(1 2) Injury to the head or brain after birth and beyond has been posited as a risk factor for psychosis for many decades but has enjoyed little systematic research (see Lishman,(3) van Reckurn et al,(4) and Fujii and Ahmed(5) for reviews). The purpose of this article is to review this information systematically. Computerised databases including Medline and Psychinfo were searched using head/brain injury and psychosis or schizophrenia as search terms, covering the period from 1966 to end 2003. Citations from published reviews were also retrieved and yielded important articles and monographs, sonic published more than two decades ago, not included in these databases. Four types of study design have been used to assess the relation between head injury and schizophrenia: the case report; the long term follow up of series of head injured persons; the cross sectional survey; and the case-control study.	Inst Psychiat, Sect Cognit Neuropsychiat, London SE5 8AF, England; Inst Psychiat, Epidemiol Sect, London, England		David, AS (corresponding author), Inst Psychiat, Sect Cognit Neuropsychiat, POB 68,De Crespigny Pk, London SE5 8AF, England.	a.david@iop.kcl.ac.uk	Prince, Martin J/A-9170-2010; David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	Prince, Martin J/0000-0003-1379-7146; David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X			AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; ANTHONY JC, 1985, ARCH GEN PSYCHIAT, V42, P667; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Corcoran C, 2001, INT J MENT HLTH, V30, P17; Dalman C, 2001, BRIT J PSYCHIAT, V179, P403, DOI 10.1192/bjp.179.5.403; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; De Mol J, 1987, J ARCH PSYCHOL NEURO, V48, P336; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii Daryl, 2002, Cogn Neuropsychiatry, V7, P41, DOI 10.1080/135468000143000131; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; LIBERMAN JJ, 1964, ZH NEVROPATOL PSIKH, V64, P1369; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; [No title captured]	24	35	36	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2005	76			1			I53	I60		10.1136/jnnp.2004.060475			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	902CV	WOS:000227329900009	15718223	Green Published, Bronze			2022-02-06	
J	Hunter, JV; Thornton, RJ; Wang, ZJ; Levin, HS; Roberson, G; Brooks, WM; Swank, PR				Hunter, JV; Thornton, RJ; Wang, ZJ; Levin, HS; Roberson, G; Brooks, WM; Swank, PR			Late proton MR spectroscopy in children after traumatic brain injury: Correlation with cognitive outcomes	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; METABOLITE CONCENTRATIONS; IN-VIVO; N-ACETYLASPARTATE; AXONAL INJURY; HEAD-INJURY; QUANTITATION; ASYMMETRY	BACKGROUND AND PURPOSE: Proton MR spectroscopy has demonstrated reduced levels of N-acetylaspartate (NAA) in normal-appearing occipital and frontal regions of patients with acute nonpenetrating traumatic brain injury (TBI). We studied the relationship of frontoparietal NAA, choline (Cho), and creatine (Cr) to test the hypothesis that reduction in NAA is predictive of cognitive outcome. METHODS: Proton spectra were collected by using conventional 2D chemical shift imaging in five healthy children and seven children (6 weeks to 3 years) with severe (n = 4), moderate (n = 2), or mild (n = 1) TBI. Spectra in the anterior and posterior regions of the left and right frontoparietal areas were averaged for analysis by using LCModel, with a phantom-established basis function, for quantification of NAA, Cho, and Cr concentrations. Intellectual function, expressive language, and arithmetic capability were measured within 4 months of imaging. RESULTS: NAA/Cho concentration was lower in TBI patients than in control subjects, but no group differences were present for Cho or Cr. Hemispheric levels for NAA, Cho, and Cr were higher on the left than on the right, but we found no effect of region and no interactions. Cognition was lower in the TBI group than the control group and correlated with NAA levels. Left frontal Cho was also correlated with arithmetic scores, whereas Cr was not significantly correlated. CONCLUSION. NAA levels remain low after TBI and are related to cognitive function. Neurometabolite values are greater in the left frontoparietal region than in the right, and the left frontal Cho level is related to arithmetic ability.	Texas Childrens Hosp, Baylor Coll Med, Dept OI, Houston, TX 77030 USA; Texas Childrens Hosp, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Kansas, Med Ctr, Hoglund Imaging Ctr, Kansas City, KS 66103 USA		Hunter, JV (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept OI, 6621 Fannin St, Houston, TX 77030 USA.		Wang, Zhiyue J/L-3851-2014	Wang, Zhiyue J/0000-0002-5649-2900; brooks, william/0000-0001-6227-7636	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R21NS045573] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889, R21 NS-45573, R21 NS045573, R01 NS-21889] Funding Source: Medline		Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cady EB, 1996, MAGN RESON MED, V36, P878, DOI 10.1002/mrm.1910360610; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Gonen O, 1998, MAGNET RESON MED, V40, P684, DOI 10.1002/mrm.1910400506; HUPPI PS, 1991, PEDIATR RES, V30, P574; HUPPI PS, 1995, PEDIATR RES, V37, P145; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; Maton B, 2001, J NEUROIMAGING, V11, P194, DOI 10.1111/j.1552-6569.2001.tb00033.x; Moore CM, 2002, SCHIZOPHR RES, V57, P35, DOI 10.1016/S0920-9964(01)00302-4; Pouwels PJW, 1998, MAGN RESON MED, V39, P53, DOI 10.1002/mrm.1910390110; PROVENCHER S, 2003, LCMODEL 1 LCMGUI 2 U; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Semel E., 1995, CLIN EVALUATION LANG, VThird; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Sowell ER, 2002, CEREB CORTEX, V12, P17, DOI 10.1093/cercor/12.1.17; TEASDALE G, 1974, LANCET, V2, P81; TONG KA, 2002, P 10 ANN M ISMRM HON, P46; Wechsler D., 2011, WECHSLER ABBREVIATED; WOODCOCK RW, 1990, WOODCOCKJOHNSON TEST	29	35	36	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2005	26	3					482	488					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	906GK	WOS:000227628500008	15760852				2022-02-06	
J	Hang, CH; Shi, JX; Li, JS; Li, WQ; Yin, HX				Hang, Chun-Hua; Shi, Ji-Xin; Li, Jie-Shou; Li, Wei-Qin; Yin, Hong-Xia			Up-regulation of intestinal nuclear factor kappa B and intercellular adhesion molecule-1 following traumatic brain injury in rats	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Traumatic brain injury; Intestine; Nuclear factor kappa B; Intercellular adhesion molecule-1; Inflammatory response	PLATELET-ACTIVATING-FACTOR; IN-VIVO; TRANSCRIPTIONAL REGULATION; HEMORRHAGIC-SHOCK; LUNG INJURY; TNF-ALPHA; PERMEABILITY; EXPRESSION; GUT; CELLS	AIM: Nuclear factor kappa B (NF-kappa B) regulates a large number of genes involved in the inflammatory response to critical illnesses, but it is not known if and how NF-kappa B is activated and intercellular adhesion molecule-1 (ICAM-1) expressed in the gut following traumatic brain injury (TBI). The aim of current study was to investigate the temporal pattern of intestinal NF-kappa B activation and ICAM-1 expression following TBI. METHODS: Male Wistar rats were randomly divided into six groups (6 rats in each group) including controls with sham operation and TBI groups at hours 3, 12, 24, and 72, and on d 7. Parietal brain contusion was adopted using weight-dropping method. All rats were decapitated at corresponding time point and mid-jejunum samples were taken. NF-kappa B binding activity in jejunal tissue was measured using EMSA. Immunohistochemistry was used for detection of ICAM-1 expression in jejunal samples. RESULTS: There was a very low NF-kappa B binding activity and little ICAM-1 expression in the gut of control rats after sham surgery. NF-kappa B binding activity in jejunum significantly increased by 160% at 3 h following TBI (P<0.05 vs control), peaked at 72 h (500% increase) and remained elevated on d 7 post-injury by 390% increase. Compared to controls, ICAM-1 was significantly up-regulated on the endothelia of microvessels in villous interstitium and lamina propria by 24 h following TBI and maximally expressed at 72 h post-injury (P<0.001). The endothelial ICAM-1 immunoreactivity in jejunal mucosa still remained strong on d 7 post-injury. The peak of NF-kappa B activation and endothelial ICAM-1 expression coincided in time with the period during which secondary mucosal injury of the gut was also at their culmination following TBI. CONCLUSION: TBI could induce an immediate and persistent up-regulation of NF-kappa B activity and subsequent up-regulation of ICAM-1 expression in the intestine. Inflammatory response mediated by increased NF-kappa B activation and ICAM-1 expression may play an important role in the pathogenesis of acute gut mucosal injury following TBI. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.	[Hang, Chun-Hua; Shi, Ji-Xin; Yin, Hong-Xia] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Clin Med, Nanjing 210002, Jiangsu Provinc, Peoples R China; [Li, Jie-Shou; Li, Wei-Qin] Nanjing Univ, Res Inst Gen Surg, Jinling Hosp, Sch Clin Med, Nanjing 210002, Jiangsu Provinc, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Clin Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Provinc, Peoples R China.	hang1965@public1.ptt.js.cn	Yin, Hong/AAC-5784-2020		Scientific Research Foundation of the Chinese PLA [01Z011]	Supported by Scientific Research Foundation of the Chinese PLA Key Medical Programs During the 10th Five-Year Plan Period, No. 01Z011	Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BLACKWELL TS, 1994, AM J RESP CELL MOL, V11, P464, DOI 10.1165/ajrcmb.11.4.7917314; CHEN CC, 1995, AGENT ACTION SUPPL, V47, P135; De Plaen IG, 1998, BBA-LIPID LIPID MET, V1392, P185, DOI 10.1016/S0005-2760(98)00024-1; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769, DOI 10.1152/ajpgi.1997.273.4.G769; Frossard JL, 1999, GASTROENTEROLOGY, V116, P694, DOI 10.1016/S0016-5085(99)70192-7; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; HUANG L, 1994, IMMUNOLOGY, V83, P65; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liu SF, 1997, J IMMUNOL, V159, P3976; Lush CW, 2003, GASTROENTEROLOGY, V124, P118, DOI 10.1053/gast.2003.50001; Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008; MEYER TA, 1995, SURGERY, V118, P336, DOI 10.1016/S0039-6060(05)80342-3; Molla M, 2003, INT J RADIAT ONCOL, V57, P264, DOI 10.1016/S0360-3016(03)00523-6; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Neurath MF, 1997, IMMUNOBIOLOGY, V198, P91, DOI 10.1016/S0171-2985(97)80030-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015; Pritts TA, 2000, ARCH SURG-CHICAGO, V135, P860, DOI 10.1001/archsurg.135.7.860; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Shenkar R, 1996, AM J PHYSIOL-LUNG C, V270, pL729, DOI 10.1152/ajplung.1996.270.5.L729; Shimada T, 1999, J PHARMACOL EXP THER, V291, P345; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; Spies M, 2002, AM J PHYSIOL-GASTR L, V283, pG703, DOI 10.1152/ajpgi.00149.2001; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Wang P, 1998, J SURG RES, V74, P141, DOI 10.1006/jsre.1997.5246; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	36	35	39	0	1	BAISHIDENG PUBL GRP CO LTD	BEIJING	RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU, BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA	1007-9327			WORLD J GASTROENTERO	World J. Gastroenterol.	FEB 28	2005	11	8					1149	1154		10.3748/wjg.v11.i8.1149			6	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	V19VX	WOS:000208101000009	15754395	Green Published, hybrid			2022-02-06	
J	Dash, PK; Moore, AN; Moody, MR; Treadwell, R; Felix, JL; Clifton, GL				Dash, PK; Moore, AN; Moody, MR; Treadwell, R; Felix, JL; Clifton, GL			Post-trauma administration of caffeine plus ethanol reduces contusion volume and improves working memory in rats	JOURNAL OF NEUROTRAUMA			English	Article						caffeinol; combination therapy; hippocampus; prefrontal cortex; trace fear conditioning; working memory	TRAUMATIC BRAIN-INJURY; OUTCOME FOLLOWING MODERATE; CORTICAL IMPACT INJURY; PREFRONTAL CORTEX; HEAD TRAUMA; DEFICITS; DAMAGE; TRACE; MODEL; INTOXICATION	It has been demonstrated that ethanol exerts dose-dependent effects, both beneficial and detrimental, on the outcome of traumatic brain injury (TBI). Recently, it has been reported that co-administration of caffeine (10 mg/kg) and a low amount of alcohol (0.65 g/kg; caffeinol) reduces cortical infarct volume up to 80%, and improves motor coordination, following a rodent model of reversible common carotid/middle cerebral artery occlusion. However, the protective effects of caffeinol following other CNS insults, nor its influence on cognitive function, have been examined. Using a controlled cortical impact model of brain injury, the effect of caffeinol administration on TBI-associated motor and cognitive deficits was assessed. When given 15 min following injury, caffeinol reduced cortical tissue loss and improved working memory. However, no influence on motor skills, Morris water maze performance or associative learning and memory was observed. Delayed administration (6 h post-injury) of caffeinol containing a dose of ethanol (I g/kg) previously demonstrated to improve motor performance eliminated the working memory benefit and cortical protection. These results indicate that early administration of caffeinol may be beneficial in lessening some of the deficits and cortical tissue loss associated with brain trauma.	Univ Texas, Sch Med, Smith Ctr Neurol Res, Dept Neurobiol, Houston, TX 77225 USA; Univ Texas, Sch Med, Smith Ctr Neurol Res, Dept Anat, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Smith Ctr Neurol Res, Dept Neurobiol, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; DeWitt D S, 1995, New Horiz, V3, P376; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Katoh H, 1998, ACT NEUR S, V71, P247; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Lesort M, 1997, NEUROSCI LETT, V221, P213, DOI 10.1016/S0304-3940(96)13310-3; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MARTINEZSERRANO A, 1989, BIOCHEM BIOPH RES CO, V161, P965, DOI 10.1016/0006-291X(89)91337-5; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McEchron MD, 1998, HIPPOCAMPUS, V8, P638, DOI 10.1002/(SICI)1098-1063(1998)8:6<638::AID-HIPO6>3.0.CO;2-Q; McLaughlin J, 2002, BEHAV NEUROSCI, V116, P37, DOI 10.1037//0735-7044.116.1.37; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Murphy BL, 1996, J NEUROSCI, V16, P7768; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; Quinn JJ, 2002, HIPPOCAMPUS, V12, P495, DOI 10.1002/hipo.10029; Ragozzino ME, 2002, LEARN MEMORY, V9, P18, DOI 10.1101/lm.45802; Rao VLR, 2001, BRAIN RES, V911, P96; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Runyan JD, 2004, J NEUROSCI, V24, P1288, DOI 10.1523/JNEUROSCI.4880-03.2004; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; Sebastiao AM, 2000, TRENDS PHARMACOL SCI, V21, P341, DOI 10.1016/S0165-6147(00)01517-0; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Whitten RJ, 1996, ALCOHOL CLIN EXP RES, V20, P1313, DOI 10.1111/j.1530-0277.1996.tb01128.x; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WORLEY PF, 1993, J NEUROSCI, V13, P4776; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	53	35	37	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1573	1583		10.1089/0897715042441828			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800005	15684650				2022-02-06	
J	Guskiewicz, KM; Bruce, SL; Cantu, RC; Ferrara, MS; Kelly, JP; McCrea, M; Putukian, M; Valovich, TC				Guskiewicz, KM; Bruce, SL; Cantu, RC; Ferrara, MS; Kelly, JP; McCrea, M; Putukian, M; Valovich, TC			Recommendations on management of sport-related concussion: Summary of the National Athletic Trainers' Association position statement	NEUROSURGERY			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COMPUTERIZED COGNITIVE ASSESSMENT; COLLEGIATE FOOTBALL PLAYERS; POSTURAL STABILITY; SAFE RETURN; HEAD-INJURY; MILD; RECOVERY; PATHOPHYSIOLOGY; CONSCIOUSNESS		Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; Calif State Univ Penn, California, PA USA; Emerson Hosp, Neurosurg Serv, Concord, MA USA; Brigham & Womens Hosp, Neurol Sports Injury Ctr, Boston, MA 02115 USA; Univ Georgia, Athens, GA 30602 USA; Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; Waukesha Mem Hosp, Program Neurosci, Neuropsychol Serv, Waukesha, WI USA; Princeton Univ, Princeton, NJ 08544 USA; Arizona Sch Hlth Sci, Dept Sport Hlth Care, Mesa, AZ USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, 211 Fetzer Gym CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Valovich McLeod, Tamara/AAU-9435-2020; Bruce, Scott L./AAQ-1907-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Bruce, Scott L./0000-0002-3251-073X; Guskiewicz, Kevin/0000-0002-8682-2130			Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guskiewicz KM, 2004, AM J MED SPORTS, V6, P13; Halstead PD, 2001, J ATHL TRAINING, V36, P322; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MUELLER FO, 2002, 19 NAT CTR CAT SPORT; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pottinger LS, 1999, ARCH CLIN NEUROPSYCH, V14, P39, DOI 10.1093/arclin/14.1.39a; Riemann BL, 2000, J ATHL TRAINING, V35, P19	43	35	37	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2004	55	4					891	895		10.1227/01.NEU.0000143800.49798.19			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100035	15458597				2022-02-06	
J	Stiefel, MF; Heuer, GG; Abrahams, JM; Bloom, S; Smith, MJ; Maloney-Wilensky, E; Grady, MS; LeRoux, PD				Stiefel, MF; Heuer, GG; Abrahams, JM; Bloom, S; Smith, MJ; Maloney-Wilensky, E; Grady, MS; LeRoux, PD			The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; cerebral oxygenation; nimodipine	PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; COOPERATIVE ANEURYSM; CALCIUM-ANTAGONISTS; CHANNEL BLOCKERS; RANDOMIZED TRIAL; ARTERIAL SPASM; TISSUE OXYGEN	Object. Nimodipine has been shown to improve neurological outcome after subarachnoid hemorrhage (SAH); the mechanism of this improvement, however, is uncertain. In addition, adverse systemic effects such as hypotension have been described. The authors investigated the effect of nimodipine on brain tissue PO2. Methods. Patients in whom Hunt and Hess Grade IV or V SAH had occurred who underwent aneurysm occlusion and had stable blood pressure were prospectively evaluated using continuous brain tissue PO, monitoring. Nimodipine (60 mg) was delivered through a nasogastric or Dobhoff tube every 4 hours. Data were obtained from 11 patients and measurements of brain tissue PO2, intracranial pressure (ICP), mean arterial blood pressure (MABP), and cerebral perfusion pressure (CPP) were recorded every 15 minutes. Nimodipine resulted in a significant reduction in brain tissue PO2 in seven (64%) of 11 patients. The baseline PO2 before nimodipine administration was 38.4 +/- 10.9 mm Ha. The baseline MABP and CPP were 90 +/- 20 and 84 +/- 19 mm Hg, respectively. The greatest reduction in brain tissue PO2 occurred 15 minutes after administration, when the mean pressure was 26.9 +/- 7.7 mm Hg (p < 0.05). The PO2 remained suppressed at 30 minutes (27.5 +/- 7.7 min Hg [p < 0.05]) and at 60 minutes (29.7 +/- 11.1 min Hg [p < 0.05]) after nimodipine administration but returned to baseline levels 2 hours later. In the seven patients in whom brain tissue PO2 decreased, other physiological variables such as arterial saturation, end-tidal CO2 heart rate, MABP, ICP, and CPP did not demonstrate any association with the nimodipine-induced reduction in PO2. In four patients PO2 remained stable and none of these patients had a significant increase in brain tissue PO2. Conclusions. Although nimodipine use is associated with improved outcome following SAH, in some patients it can temporarily reduce brain tissue PO2.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19107 USA		LeRoux, PD (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; AUER LM, 1986, ACTA NEUROCHIR, V82, P7, DOI 10.1007/BF01456313; Barker FG, 1996, J NEUROSURG, V84, P405, DOI 10.3171/jns.1996.84.3.0405; Charbel FT, 2000, SURG NEUROL, V54, P432, DOI 10.1016/S0090-3019(00)00340-2; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Devlin JW, 2000, NEUROSURGERY, V47, P1243, DOI 10.1097/00006123-200011000-00048; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dorsch Nicholas W C, 2002, Curr Opin Crit Care, V8, P128; DORSCH NWC, 1995, BRIT J NEUROSURG, V9, P403, DOI 10.1080/02688699550041403; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1097/00006123-200212000-00017; EDVINSSON L, 1979, SURG NEUROL, V11, P327; Feigin VL, 1998, NEUROLOGY, V50, P876, DOI 10.1212/WNL.50.4.876; FORSMAN M, 1989, ANESTH ANALG, V68, P436; GAAB MR, 1985, BRIT J CLIN PHARMACO, V20, pS67, DOI 10.1111/j.1365-2125.1985.tb05145.x; GELMERS HJ, 1985, AM J CARDIOL, V55, pB144, DOI 10.1016/0002-9149(85)90623-X; HALEY EC, 1993, J NEUROSURG, V78, P537, DOI 10.3171/jns.1993.78.4.0537; HALEY EC, 1994, J NEUROSURG, V80, P788, DOI 10.3171/jns.1994.80.5.0788; HALEY EC, 1993, J NEUROSURG, V78, P548, DOI 10.3171/jns.1993.78.4.0548; HANDA J, 1975, SURG NEUROL, V3, P195; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Horn J, 2001, STROKE, V32, P2433, DOI 10.1161/hs1001.096009; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JUVELA S, 1990, STROKE, V21, P1283, DOI 10.1161/01.STR.21.9.1283; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037; KAZDA S, 1982, ACTA NEUROCHIR, V63, P259, DOI 10.1007/BF01728880; Kett-White R, 2002, ACT NEUR S, V81, P363; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; LANGLEY MS, 1989, DRUGS, V37, P669, DOI 10.2165/00003495-198937050-00004; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; McKhann GM, 2004, MANAGEMENT CEREBRAL, P431; MEE E, 1988, NEUROSURGERY, V22, P484, DOI 10.1227/00006123-198803000-00006; MOHAMED AA, 1984, J CEREBR BLOOD F MET, V4, P206, DOI 10.1038/jcbfm.1984.29; MULLERSCHWEINITZER E, 1983, J CEREBR BLOOD F MET, V3, P354; MURPHY JJ, 1990, LANCET, V336, P1205; NOSKO M, 1986, J NEUROSURG, V65, P376, DOI 10.3171/jns.1986.65.3.0376; OHMAN J, 1988, J NEUROSURG, V69, P683, DOI 10.3171/jns.1988.69.5.0683; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; PHILIPPON J, 1986, ACTA NEUROCHIR, V82, P110, DOI 10.1007/BF01456369; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Pisani A, 1998, STROKE, V29, P196, DOI 10.1161/01.STR.29.1.196; PORCHET F, 1995, ACTA NEUROCHIR, V137, P62, DOI 10.1007/BF02188783; Radhakrishnan D, 1997, ANAESTHESIA, V52, P489, DOI 10.1111/j.1365-2044.1997.112-az0105.x; Rasmussen G, 1999, ACTA NEUROL SCAND, V99, P182, DOI 10.1111/j.1600-0404.1999.tb07341.x; Roos Y, 2000, NEUROLOGY, V54, P77, DOI 10.1212/WNL.54.1.77; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vath A, 2001, NEUROL RES, V23, P315, DOI 10.1179/016164101101198677; Weir B, 1993, Clin Neurosurg, V40, P40; Zumkeller M, 1997, NEUROSURG REV, V20, P259, DOI 10.1007/BF01105897; ZYGMUNT SC, 1995, ACTA NEUROCHIR, V135, P179, DOI 10.1007/BF02187765	53	35	40	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2004	101	4					594	599		10.3171/jns.2004.101.4.0594			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	865MP	WOS:000224707500009	15481712				2022-02-06	
J	Palchak, MJ; Holmes, JF; Vance, CW; Gelber, RE; Schauer, BA; Harrison, MJ; Willis-Shore, J; Wootton-Gorges, SL; Derlet, RW; Kuppermann, N				Palchak, MJ; Holmes, JF; Vance, CW; Gelber, RE; Schauer, BA; Harrison, MJ; Willis-Shore, J; Wootton-Gorges, SL; Derlet, RW; Kuppermann, N			Does an isolated history of loss of consciousness or amnesia predict brain injuries in children after blunt head trauma?	PEDIATRICS			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine (SAEM)	MAY 19-23, 2002	ST LOUIS, MO	Soc Acad Emergency Med		traumatic brain injury; loss of consciousness and/or amnesia; CT; cranial tomography; emergency department evaluation; children	COMPUTED-TOMOGRAPHY SCANS; GLASGOW COMA SCALE; INTRACRANIAL INJURY; EMERGENCY PHYSICIANS; CLINICAL PREDICTORS; SKULL FRACTURE; CANCER RISKS; CT; ABNORMALITIES; EVENTS	Background. A history of loss of consciousness (LOC) is frequently used as an indication for cranial computed tomography (CT) in the emergency department (ED) evaluation of children with blunt head trauma. Objective. We sought to determine whether an isolated LOC and/or amnesia is predictive of traumatic brain injury (TBI) in children with blunt head trauma. Methods. We prospectively enrolled children < 18 years old presenting to a level I trauma center ED between July 1998 and September 2001 with blunt head trauma. We evaluated the association of LOC and/or amnesia with 1) TBI identified on CT and 2) TBI requiring acute intervention. We defined the latter by a neurosurgical procedure, antiepileptic medication for > 1 week, persistent neurologic deficits, or hospitalization for > 2 nights. We then investigated the association of LOC and/or amnesia with TBI in those patients without other symptoms or signs of TBI ("isolated" LOC and/or amnesia). Results. Of eligible children, 2043 (77%) were enrolled, 1271 (62%) of whom underwent CT; 1159 (91%) of these 1271 had their LOC and/or amnesia status known. A total of 801 (39%) of the 2043 enrolled children had a documented history of LOC and/or amnesia. Of the 745 with documented LOC and/or amnesia who underwent CT, 70 (9.4%; 95% confidence interval [CI]: 7.4%, 11.7%) had TBI identified on CT versus 11 of 414 (2.7%; 95% CI: 1.3%, 4.7%) without LOC and/or amnesia ( difference: 6.7%; 95% CI: 4.1%, 9.3%). Of the 801 children known to have had LOC and/or amnesia ( regardless of whether they underwent CT), 77 (9.6%; 95% CI: 7.7%, 11.9%) had TBI requiring acute intervention versus 11 of 1115 (1%; 95% CI: 0.5%, 1.8%) of those without LOC and/or amnesia ( difference: 8.6%; 95% CI: 6.5%, 10.7%). For those with an isolated LOC and/or amnesia without other signs or symptoms of TBI, however, 0 of 142 (95% CI: 0%, 2.1%) had TBI identified on CT, and 0 of 164 ( 95% CI: 0%, 1.8%) had TBI requiring acute intervention. Conclusions. Isolated LOC and/or amnesia, defined by the absence of other clinical findings suggestive of TBI, are not predictive of either TBI on CT or TBI requiring acute intervention. Elimination of an isolated LOC and/or amnesia as an indication for CT may decrease unnecessary CT use in those patients without an appreciable risk of TBI.	Univ Calif Davis, Med Ctr, Sch Med, Dept Internal Med,Div Emergency Med, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Radiol, Sacramento, CA 95817 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Emergency Med, Portland, OR 97201 USA		Palchak, MJ (corresponding author), Univ Calif Davis, Med Ctr, Sch Med, Dept Internal Med,Div Emergency Med, 2315 Stockton Blvd,PSSB 2100, Sacramento, CA 95817 USA.	mjpalchak@ucdavis.edu; nkuppermann@ucdavis.edu					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Batchelor J, 2002, EMERG MED J, V19, P515, DOI 10.1136/emj.19.6.515; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Durch J, 1993, EMERGENCY MED SERVIC; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Hall EJ, 2002, PEDIATR RADIOL, V32, P700, DOI 10.1007/S00247-002-0774-8; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; HOYERT DL, 2001, NATL VITAL STAT REPO, V49; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois J., 2001, TRAUMATIC BRAIN INJU, P1; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; National Center for Injury Prevention and Control, 2002, TRAUM BRAIN INJ US A; Ng SM, 2002, J PAEDIATR CHILD H, V38, P388, DOI 10.1046/j.1440-1754.2002.00012.x; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; Ratan SK, 2001, CLIN PEDIATR, V40, P375, DOI 10.1177/000992280104000702; RIVARA F, 1987, PEDIATRICS, V80, P579; ROSENBERG NM, 1988, PEDIATR EMERG CARE, V14, P436; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Seidel JS, 1999, ANN EMERG MED, V33, P206, DOI 10.1016/S0196-0644(99)70395-1; Sharma P, 2001, J Indian Med Assoc, V99, P81; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Svensson E, 1996, NEUROL RES, V18, P487; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	55	35	35	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2004	113	6					E507	E513		10.1542/peds.113.6.e507			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pediatrics	825TP	WOS:000221781500062	15173529				2022-02-06	
J	Marciano, PG; Brettschneider, J; Manduchi, E; Davis, JE; Eastman, S; Raghupathi, R; Saatman, KE; Speed, TP; Stoeckert, CJ; Eberwine, JH; McIntosh, TK				Marciano, PG; Brettschneider, J; Manduchi, E; Davis, JE; Eastman, S; Raghupathi, R; Saatman, KE; Speed, TP; Stoeckert, CJ; Eberwine, JH; McIntosh, TK			Neuron-specific mRNA complexity responses during hippocampal apoptosis after traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; traumatic brain injury; hippocampus; CA3; dentate; single-cell amplification; microarray; cell death; differential expression; real-time quantitative PCR	CONTROLLED CORTICAL IMPACT; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; SPATIAL MEMORY; HEAD-INJURY; CELL LOSS; PROTEIN; SINGLE; DEATH; CLEAVAGE	In an effort to understand the complexity of genomic responses within selectively vulnerable regions after experimental brain injury, we examined whether single apoptotic neurons from both the CA3 and dentate differed from those in an uninjured brain. The mRNA from individual active caspase 3(+)/terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling [TUNEL(-)] and active caspase 3(+)/TUNEL(+) pyramidal and granule neurons in brain-injured mice were amplified and compared with those from nonlabeled neurons in uninjured brains. Gene analysis revealed that overall expression of mRNAs increased with activation of caspase 3 and decreased to below uninjured levels with TUNEL reactivity. Cell type specificity of the apoptotic response was observed with both regionally distinct expression of mRNAs and differences in those mRNAs that were maximally regulated. Immunohistochemical analysis for two of the most highly differentially expressed genes (prion and Sos2) demonstrated a correlation between the observed differential gene expression after traumatic brain injury and corresponding protein translation.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioinformat, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; Incyte Genom, Palo Alto, CA 94304 USA		Eberwine, JH (corresponding author), Univ Penn, Dept Pharmacol, 37B John Morgan,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	eberwine@mail.med.upenn.edu	Lazarus, Michael/G-3130-2010; Raghupathi, Ramesh/AAX-5538-2021; Speed, Terence P/B-8085-2009; Eberwine, James/B-2247-2010	Lazarus, Michael/0000-0003-3863-4474; Speed, Terence P/0000-0002-5403-7998; Manduchi, Elisabetta/0000-0002-4110-3714	NHGRI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [K25 HG002296, HG02296] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG009900, AG 9900, R37 AG009900] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34790] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS008803, P50 NS08803, R01-NS40978, R01 NS040978] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-41699] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [K25HG002296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG009900, R37AG009900] Funding Source: NIH RePORTER		ADAMS R, 1994, IEEE T PATTERN ANAL, V16, P641, DOI 10.1109/34.295913; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dudoit S, 2002, STAT SINICA, V12, P111; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; EBERWINE J, 1992, METHOD ENZYMOL, V216, P80; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; JOHNSTON R, 2004, IN PRESS GENOME RES; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; NIMNUAL A, 2002, SCI STKE, V145, pPE36; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith PM, 2002, J SPORT SCI, V20, P27; Soille P., 1999, MORPHOLOGICAL IMAGE; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Walz R, 1999, EPILEPSIA, V40, P1679, DOI 10.1111/j.1528-1157.1999.tb01583.x; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; YANG YH, 2002, J COMPUT GRAPH STAT, V11, P1; YANG YH, 2002, MICROARRAYS OPTICAL, P141; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; [No title captured]	60	35	37	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 24	2004	24	12					2866	2876		10.1523/JNEUROSCI.5051-03.2004			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	807KR	WOS:000220500900002	15044525	Green Published, hybrid			2022-02-06	
J	Bezeau, SC; Bogod, NM; Mateer, CA				Bezeau, SC; Bogod, NM; Mateer, CA			Sexually intrusive behaviour following brain injury: approaches to assessment and rehabilitation	BRAIN INJURY			English	Article							VIEWING TIME; METAANALYSIS; AGGRESSION; THERAPY	Sexually intrusive behaviour, which may range from inappropriate commentary to rape, is often observed following a traumatic brain injury. It may represent novel behaviour patterns or an exacerbation of pre-injury personality traits, attitudes, and tendencies. Sexually intrusive behaviour poses a risk to staff and residents of residential facilities and to the community at large, and the development of a sound assessment and treatment plan for sexually intrusive behaviour is therefore very important. A comprehensive evaluation is best served by drawing on the fields of neuropsychology, forensic psychology, and cognitive rehabilitation. The paper discusses the types of brain damage that commonly lead to sexually intrusive behaviour, provides guidance for its assessment, and presents a three-stage treatment model. The importance of a multidisciplinary approach to both assessment and treatment is emphasized. Finally, a case example is provided to illustrate the problem and the possibilities for successful management.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada		Bezeau, SC (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	scottb_ca@yahoo.com	McCarthy, Jodie/B-5760-2012				BENNETT TL, 1997, NEUROPSYCHOLOGY HDB, V2, P123; Benson D.F., 1986, FRONTAL LOBES; BOLLER F, 1982, SEXUAL DYSFUNCTION N; Bradford JMW, 2001, CAN J PSYCHIAT, V46, P26, DOI 10.1177/070674370104600104; CHAMPAGNE MP, 1982, SEX DISABIL, V5, P172, DOI 10.1007/BF01116416; CHOW TW, 1999, SCI PRACT NEUROPSYCH, P3; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; DEATON A, 1988, REHABIL PSYCHOL, V31, P231; DUCHARME S, 1987, REHABIL PSYCHOL, P419; EMORY LE, 1995, J HEAD TRAUMA REHAB, V10, P47; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fleming JM, 1996, BRAIN INJURY, V10, P1; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; HALL GCN, 1995, J CONSULT CLIN PSYCH, V63, P802, DOI 10.1037/0022-006X.63.5.802; Hanson, 1997, DEV BRIEF ACTUARIAL; Hanson RK, 1998, J CONSULT CLIN PSYCH, V66, P348, DOI 10.1037/0022-006X.66.2.348; Harris GT, 1996, BEHAV RES THER, V34, P389, DOI 10.1016/0005-7967(95)00070-4; Hayman LA, 1998, J NEUROPSYCH CLIN N, V10, P354, DOI 10.1176/jnp.10.3.354; KAUFER DI, 1999, SCI PRACT NEUROPSYCH, P27; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Laws D R, 2001, Sex Abuse, V13, P275, DOI 10.1177/107906320101300405; LAWS DR, 1995, J RES TREATMENT, V7, P155; LILLY R, 1983, NEUROLOGY, V33, P1141, DOI 10.1212/WNL.33.9.1141; Maletzky BM, 2002, BEHAV MODIF, V26, P123, DOI 10.1177/0145445502262001; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; Marlatt GA, 1985, RELAPSE PREVENTION M; MATEER C, 2000, UNPUB PREVALENCE SEX; Mateer C A, 1999, Semin Clin Neuropsychiatry, V4, P50; Mateer C. A., 1997, NEUROPSYCHOL REHABIL, P285; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; OTT BR, 1995, CLIN NEUROPHARMACOL, V18, P443, DOI 10.1097/00002826-199510000-00007; Pithers WD, 1999, J INTERPERS VIOLENCE, V14, P257, DOI 10.1177/088626099014003004; PITHERS WD, 1983, SEXUAL AGGRESSOR CUR, P214; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Quinsey VL, 1996, ETHOL SOCIOBIOL, V17, P341, DOI 10.1016/S0162-3095(96)00060-X; Raymond NC, 1999, AM J PSYCHIAT, V156, P786; Redoute J, 2000, HUM BRAIN MAPP, V11, P162, DOI 10.1002/1097-0193(200011)11:3<162::AID-HBM30>3.0.CO;2-A; Rolls ET, 1999, NEUROCASE, V5, P301, DOI 10.1093/neucas/5.4.301; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; SIMPSON GK, 1999, YOU ME ED PROGRAM SE; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; Starkstein SE, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P163; Wesolowski M. D., 1993, BEHAV RESIDENTIAL TR, V8, P89, DOI DOI 10.1002/BIN; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; WITTIG P, 1999, THESIS ROYAL ROADS U; WONG TM, 1998, AVOIDING ETHICAL MIS, P187	51	35	35	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2004	18	3					299	313		10.1080/02699050310001617398			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900006	14726288				2022-02-06	
J	Scheff, SW; Dhillon, HS				Scheff, SW; Dhillon, HS			Creatine-enhanced diet alters levels of lactate and free fatty acids after experimental brain injury	NEUROCHEMICAL RESEARCH			English	Article						brain damage; excitotoxicity; lactic acid; neuroprotection; trauma	SIGNAL-TRANSDUCTION PATHWAY; EVANS BLUE EXTRAVASATION; PHOSPHATIDYLINOSITOL BISPHOSPHATE; CORTICAL CONTUSION; REGIONAL LEVELS; AMINO-ACIDS; MOUSE MODEL; RAT; ACCUMULATION; SUPPLEMENTATION	Free fatty acids (FFA) and lactic acid are markers of secondary cellular injury following traumatic brain injury (TBI). We previously showed that animals fed a creatine (Cr)-enriched diet are afforded neuroprotection following TBI. To further characterize the neuroprotective Cr diet, we studied neurochemical changes in cortex and hippocampus following a moderate injury. Adult rats were fed either a control or Cr-supplemented diet (0.5%, 1%) for 2 weeks before TBI. At 30 min or 6 h after injury, tissue was processed for quantitative analysis of neurochemical changes. Both lactate and FFA were significantly increased in all tissues ipsilateral to the injury. Cr-fed animals had significantly lower levels, although the levels were elevated compared to sham controls. Animals fed a 1% Cr-diet were afforded greater neuroprotection than animals fed a 0.5% Cr diet. These results support the idea that a Cr-enriched diet can provide substantial neuroprotection in part by suppressing secondary brain injury.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA.	sscheff@email.uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG021981] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Balestrino M, 1999, BRAIN RES, V816, P124, DOI 10.1016/S0006-8993(98)01131-7; BALLY PR, 1960, J BIOL CHEM, V235, P333; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dhillon HS, 1998, BRAIN RES, V804, P231, DOI 10.1016/S0006-8993(98)00639-8; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Dhillon HS, 1995, J NEUROTRAUM, V12, P1035, DOI 10.1089/neu.1995.12.1035; Dhillon HS, 1999, BRAIN RES, V832, P7, DOI 10.1016/S0006-8993(99)01437-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GORMAN LK, 1994, NEUROSCI LETT, V166, P199, DOI 10.1016/0304-3940(94)90485-5; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Holtzman D, 1998, PEDIATR RES, V44, P410, DOI 10.1203/00006450-199809000-00024; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Ipsiroglu OS, 2001, LIFE SCI, V69, P1805, DOI 10.1016/S0024-3205(01)01268-1; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; Matthews RT, 1998, J NEUROSCI, V18, P156; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Prasad RM, 1997, J NEUROTRAUM, V14, P919, DOI 10.1089/neu.1997.14.919; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SHAPIRO B, 1955, BIOCHEM PROBL, P347; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TZIGARET C, 1993, J NEUROCHEM, V60, P827, DOI 10.1111/j.1471-4159.1993.tb03226.x; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wilken B, 1998, PEDIATR RES, V43, P8, DOI 10.1203/00006450-199801000-00002; Zhang WH, 2003, ANN NEUROL, V53, P267, DOI 10.1002/ana.10476	58	35	38	0	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	FEB	2004	29	2					469	479		10.1023/B:NERE.0000013753.22615.59			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	769CZ	WOS:000188610000019	15002746				2022-02-06	
J	Shah, MK; Al-Adawi, S; Dorvlo, ASS; Burke, DT				Shah, MK; Al-Adawi, S; Dorvlo, ASS; Burke, DT			Functional outcomes following anoxic brain injury: a comparison with traumatic brain injury	BRAIN INJURY			English	Article							CARDIAC-ARREST SURVIVORS; NEUROLOGICAL REHABILITATION; ISCHEMIC COMA; PROGNOSIS	Primary objective: To compare the functional outcomes of patients with anoxic brain injury (ABI) and patients with traumatic brain injury (TBI) following inpatient rehabilitation. Research design: Retrospective chart review. Methods and procedures: Data on 68 patients with brain injury ( 34 with ABI and 34 with TBI) were collected. Main outcomes and results: The ABI and TBI groups were demographically similar, except that patients with ABI were more likely to be married. Both groups significantly improved their function and were similar upon discharge. For the ABI group, there were trends toward a shorter length of stay, increased total FIM efficiency and decreased cost of stay when compared with the TBI group. The patients with ABI tended to be discharged to a sub-acute rehabilitation facility more than those in the TBI group. Conclusions: This study is important because it shows that patients with ABI benefit from inpatient rehabilitation and made significant functional gains comparable to the gains of patients with TBI.	Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; Sultan Qaboos Univ, Coll Med, Muscat, Oman; Sultan Qaboos Univ, Coll Sci, Dept Math & Stat, Muscat, Oman		Shah, MK (corresponding author), 9262 Forest Lane,Suite 101, Dallas, TX 75243 USA.		Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86, DOI 10.1017/S1355617700611116; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Fertl E, 2000, RESUSCITATION, V47, P231, DOI 10.1016/S0300-9572(00)00239-2; Graves JR, 1997, RESUSCITATION, V35, P117; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Ornato JP, 2001, RESUSCITATION, V48, P117, DOI 10.1016/S0300-9572(00)00255-0; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; SAZBON L, 1993, J NEUROL NEUROSUR PS, V56, P407, DOI 10.1136/jnnp.56.4.407; Schmidt JG, 1997, J NEUROL REHABIL, V11, P189; SYNDER BD, 1977, NEUROLOGY, V27, P807; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	13	35	35	1	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2004	18	2					111	117		10.1080/0269905031000149551			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000001	14660224				2022-02-06	
J	Hanten, G; Dennis, M; Zhang, LF; Barnes, M; Roberson, G; Archibald, J; Song, J; Levin, HS				Hanten, G; Dennis, M; Zhang, LF; Barnes, M; Roberson, G; Archibald, J; Song, J; Levin, HS			Childhood head injury and metacognitive processes in language and memory	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; VERBAL REHEARSAL; WORKING-MEMORY; CHILDREN; COMPREHENSION; AWARENESS; RECALL	We studied the metacognitive functioning of children with severe and mild traumatic brain injury (TBI) and typically developing children. To test metacognition for memory, children were tested on a modified Judgment of Learning task. We found that children with severe TBI were impaired in their ability to predict recall of specific items prior to study-recall trials, but were unimpaired in predicting recall on a delayed test when the judgment was made after study-recall trials. Metacognitive knowledge impairment for memorial abilities was also demonstrated in children with severe TBI by poor estimation of memory span and exaggerated overconfidence in performance. To test metacognition within the language domain, we gave children a sentence anomaly detection and repair task in which spoken sentences were monitored for semantic anomalies. Children with severe TBI were impaired on the detection of semantic anomalies, especially under conditions of high memory load. However, metalinguistic knowledge in the form of adequate repairs of anomalous sentences, was preserved. Results are discussed in terms of effects of age at test and injury severity.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Bayer Pharmaceut, Dept Biometry, New Haven, CT USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA		Hanten, G (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6550 Fannin St,Ste 1144,Box 67, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; Anderson VA, 2000, BRAIN INJURY, V14, P679; APPEL LF, 1972, CHILD DEV, V43, P1365, DOI 10.2307/1127522; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Brown A. L., 1978, CHILDRENS THINKING W, P3; Brown AL, 1978, ADV INSTRUCTIONAL PS, P367; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DUFRESNE A, 1989, J EXP CHILD PSYCHOL, V47, P274, DOI 10.1016/0022-0965(89)90033-7; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FLAVELL JH, 1970, COGNITIVE PSYCHOL, V1, P324, DOI 10.1016/0010-0285(70)90019-8; FLAVELL JH, 1966, CHILD DEV, V37, P283, DOI 10.2307/1126804; FLAVELL JH, 1985, DEV PSYCHOL, V21, P207, DOI 10.1037/0012-1649.21.2.207; GARRITY LI, 1975, DEV PSYCHOL, V11, P274, DOI 10.1037/h0076563; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; HOLCOMB PJ, 1992, DEV NEUROPSYCHOL, V8, P203, DOI 10.1080/87565649209540525; KEENEY TJ, 1967, CHILD DEV, V38, P953, DOI 10.1111/j.1467-8624.1967.tb04373.x; KENNEDY BA, 1976, CHILD DEV, V47, P566, DOI 10.2307/1128824; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEONESIO RJ, 1990, J EXP PSYCHOL LEARN, V16, P464, DOI 10.1037/0278-7393.16.3.464; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Liu H, 1997, APPL PSYCHOLINGUIST, V18, P157, DOI 10.1017/S0142716400009954; Martin R., 1994, NEUROPSYCHOLOGY, V8, P506, DOI [10.1037/0894-4105.8.4.506, DOI 10.1037/0894-4105.8.4.506]; Mazzoni G, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, pIX; Metcalfe J., 1994, METACOGNITION KNOWIN; MOYNAHAN ED, 1973, CHILD DEV, V44, P238; Nelson T. O., 1992, METACOGNITION CORE R; Rogoff B., 1974, CHILD DEV, V44, P238; Schneider W, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P1; Schneider W, 2000, COGNITIVE DEV, V15, P115, DOI 10.1016/S0885-2014(00)00024-1; Shallice T., 1990, NEUROPSYCHOLOGICAL I, P11, DOI DOI 10.1017/CBO9780511665547.003; SUTTER JC, 1990, J SPEECH HEAR RES, V33, P84, DOI 10.1044/jshr.3301.84; Swanson HL, 1996, BRIT J EDUC PSYCHOL, V66, P333, DOI 10.1111/j.2044-8279.1996.tb01201.x; TEASDALE G, 1974, LANCET, V2, P81; TYLER LK, 1981, J VERB LEARN VERB BE, V20, P400, DOI 10.1016/S0022-5371(81)90524-7; WELLMAN HM, 1981, CHILD DEV, V52, P1313, DOI 10.2307/1129522; WORDEN PE, 1982, J EDUC PSYCHOL, V74, P341, DOI 10.1037/0022-0663.74.3.341; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; [No title captured]	46	35	35	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					85	106		10.1207/s15326942dn2501&2_6			22	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	774CG	WOS:000188961700006	14984330				2022-02-06	
J	Vezzani, A; Moneta, D; Richichi, C; Perego, C; De Simoni, MG				Vezzani, A; Moneta, D; Richichi, C; Perego, C; De Simoni, MG			Functional role of proinflammatory and anti-inflammatory cytokines in seizures	RECENT ADVANCES IN EPILEPSY RESEARCH	ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY		English	Article							CENTRAL-NERVOUS-SYSTEM; LONG-TERM POTENTIATION; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; TEMPORAL-LOBE EPILEPSY; GYRUS IN-VITRO; RAT-BRAIN; KAINIC ACID; CEREBROSPINAL-FLUID; FEBRILE SEIZURES	Recent evidence has shown that proinflammatory and anti-inflammatory molecules are synthesized during epileptic activity in glial cells in CNS regions where seizures initiate and spread. These molecules are released and interact with specific receptors on neurons. Since various cytokines have been shown to affect neuronal excitability, this led to the hypothesis that they may have a role in altering synaptic transmission in epileptic conditions. Indeed, intracerebral application of IL-1beta enhances epileptic activity in experimental models while its naturally occurring receptor antagonist (IL-1Ra) mediates anticonvulsant actions. Transgenic mice overexpressing IL-1Ra in astrocytes are less susceptible to seizures, indicating that endogenous IL-1 has proconvulsant activity. Several studies indicate a central role of IL-1beta for the exacerbation of brain damage after ischemic, traumatic or excitotoxic insults, suggesting that it may also contribute to neuronal cell injury associated with seizures. Finally, a functional polymorphism in the IL-1beta gene promoter, possibly associated with enhanced ability to produce this cytokine, has been specifically found in temporal lobe epilepsy patients with hippocampal sclerosis and in children with febrile seizures. Thus, the IL-1 system may represent a novel target for controlling seizure activity and/or the associated long-term sequelae. Furthermore, these studies suggest that other inflammatory and anti-inflammatory molecules produced in the CNS may have a role in the pathophysiology of seizure disorders.	Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20157 Milan, Italy		Vezzani, A (corresponding author), Mario Negri Inst Pharmacol Res, Dept Neurosci, Via Eritrea 62, I-20157 Milan, Italy.		De Simoni, Maria Grazia/I-6021-2012; Vezzani, Annamaria/AAB-1882-2020	De Simoni, Maria Grazia/0000-0001-6695-5297; Vezzani, Annamaria/0000-0003-0573-6175; Perego, Carlo/0000-0002-0259-0003			Akassoglou K, 1997, J IMMUNOL, V158, P438; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BARRES BA, 1991, J NEUROSCI, V11, P3685; BARTFAI T, 1993, NEUROCHEM INT, V22, P435, DOI 10.1016/0197-0186(93)90038-7; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Coogan A, 1997, NEUROREPORT, V8, P2107, DOI 10.1097/00001756-199707070-00004; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; DArcangelo G, 1997, NEUROREPORT, V8, P2079, DOI 10.1097/00001756-199705260-00053; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; De Simoni MG, 1998, BIOL SIGNAL RECEPT, V7, P33; DEBOCK F, 1996, NEUROREPORT, V7, P1126; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; Gahring LC, 1997, NEUROBIOL DIS, V3, P263, DOI 10.1006/nbdi.1996.0123; Hopkinson M, 2001, PRINT Q, V18, P83; Ichiyama T, 1998, NEUROLOGY, V50, P407, DOI 10.1212/WNL.50.2.407; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; KAMIKAWA H, 1998, AM J PHYSIOL, V274, pR806; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Lahat E, 1997, PEDIATR NEUROL, V17, P34, DOI 10.1016/S0887-8994(97)00034-9; LAPCHAK PA, 1993, NEUROREPORT, V4, P303, DOI 10.1097/00001756-199303000-00019; Luk WP, 1999, J NEUROSCI, V19, P4238; MILLER LG, 1991, MOL PHARMACOL, V39, P105; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; Nishiyori A, 1997, MOL BRAIN RES, V50, P237, DOI 10.1016/S0169-328X(97)00195-2; NITSCH C, 1986, ADV EXPT MED BIOL, P175; Peltola J, 2000, EPILEPSY RES, V41, P205, DOI 10.1016/S0920-1211(00)00140-6; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PLATASALAMAN CR, 1992, BRAIN RES BULL, V29, P221, DOI 10.1016/0361-9230(92)90029-W; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P549, DOI 10.1210/endo-124-1-549; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; SHENG JG, 1994, J NEUROCHEM, V63, P1872; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; Vezzani A, 1999, J NEUROSCI, V19, P5054; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; VEZZANI A, 2001, 31 ANN M SOC NEUR NO, V557, P18; Virta N, 2002, PEDIATR NEUROL, V26, P192, DOI 10.1016/S0887-8994(01)00380-0; Wang S, 2000, J PHARMACOL EXP THER, V292, P497; YABUUCHI K, 1993, MOL BRAIN RES, V20, P153, DOI 10.1016/0169-328X(93)90121-5; YE ZC, 1996, NEUROREPORT, V72, P181; Zeise ML, 1997, BRAIN RES, V768, P341, DOI 10.1016/S0006-8993(97)00787-7; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I	50	35	35	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598			ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2004	548						123	133					11	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	BAV10	WOS:000223703200010	15250591				2022-02-06	
J	Grossman, R; Shohami, E; Alexandrovich, A; Yatsiv, I; Kloog, Y; Biegon, A				Grossman, R; Shohami, E; Alexandrovich, A; Yatsiv, I; Kloog, Y; Biegon, A			Increase in peripheral benzodiazepine receptors and loss of glutamate NMDA receptors in a mouse model of closed head injury: a quantitative autoradiographic study	NEUROIMAGE			English	Article							TRANS-FARNESYLTHIOSALICYLIC ACID; TRAUMATIC BRAIN-INJURY; BINDING-SITES; RAT-BRAIN; NITRIC-OXIDE; IN-VIVO; MICROGLIAL ACTIVATION; CULTURED ASTROCYTES; INCREASED DENSITIES; MULTIPLE-SCLEROSIS	Increases in peripheral type benzodiazepine receptors (PTBR) have been utilized for the detection of neuroinflammation and neurotoxicity in the brain. We have investigated the relationship between PTBR and NMDA receptor binding density in mice with closed head injury (CHI) using quantitative autoradiography. CHI was induced by a weight drop in nine mice, four of which received a single injection of the rat sarcoma (Ras) inhibitor famesyl thiosalicylate (FTS) 1 h after the insult. Sham controls received anesthesia but no contusion. The neurological status of the mice was evaluated at 1 h, and hence up to 7 days using a neurological severity score (NSS). Animals were killed 7 days after CHI and consecutive brain sections were incubated with [H-3]PK11195, a PTBR antagonist, or [H-3]MK801, an n-methyl-d-aspartate receptor (NMDAR) use-dependent antagonist. CHI produced large (two- to threefold), widespread increases in PK11195 binding in the traumatized hemisphere and a significant decrease (20%-40%) in NMDAR binding limited to regions at close proximity to the lesion. Histologically, these regions were characterized by glial proliferation and neuronal loss. Significant increases in PTBR binding, but no concomitant decrease in NMDAR, were identified in several regions remote from the lesion, including the contralateral ventrolateral striatum and the ipsilateral ventral thalamus. Drug treatment significantly improved the neurological deficits but had only a marginal effect on PTBR. These results support a complex role for glial activation and PTBR increases in the context of CHI. (C) 2003 Elsevier Inc. All rights reserved.	Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Funct Imaging, Berkeley, CA 94720 USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel		Biegon, A (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Funct Imaging, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	abiegon@lbl.gov					Bal-Price A, 2001, J NEUROSCI, V21, P6480; Banati RB, 1999, NEUROLOGY, V53, P2199, DOI 10.1212/WNL.53.9.2199; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; BARON JC, 1991, CEREBROVASC DIS, V1, P22, DOI 10.1159/000108877; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bhat NR, 1998, J NEUROSCI, V18, P1633; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BOWERY NG, 1988, BRIT J PHARMACOL, V93, P944, DOI 10.1111/j.1476-5381.1988.tb11484.x; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Castellano C, 2001, CURR DRUG TARGETS, V2, P273, DOI 10.2174/1389450013348515; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DOBKIN JA, 1989, ARCH NEUROL-CHICAGO, V46, P1333, DOI 10.1001/archneur.1989.00520480077023; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; Gagliardi RJ, 2000, ARQ NEURO-PSIQUIAT, V58, P583, DOI 10.1590/S0004-282X2000000300030; Gavish M, 1997, CLIN NEUROPHARMACOL, V20, P473, DOI 10.1097/00002826-199712000-00001; Gibbs AR, 2002, J LABELLED COMPD RAD, V45, P395, DOI 10.1002/jlcr.561; Giraldez L, 1998, NEUROCHEM RES, V23, P1327, DOI 10.1023/A:1020708603495; GIULIAN D, 1993, J NEUROSCI, V13, P29; GUILARTE TR, 1995, NEUROTOXICOLOGY, V16, P441; Hu SX, 1996, CLIN IMMUNOL IMMUNOP, V78, P93, DOI 10.1006/clin.1996.0015; ITZHAK Y, 1993, GLIA, V9, P211, DOI 10.1002/glia.440090306; Karussis D, 2001, J NEUROIMMUNOL, V120, P1; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; LAGREZE HL, 1987, STROKE, V18, P882, DOI 10.1161/01.STR.18.5.882; LAVOIE J, 1990, HEPATOLOGY, V11, P874, DOI 10.1002/hep.1840110524; LEONG DK, 1994, J CEREBR BLOOD F MET, V14, P100, DOI 10.1038/jcbfm.1994.14; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Lipton SA, 1998, PROG BRAIN RES, V118, P73; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Miyazawa N, 1995, ACTA NEUROCHIR, V137, P207, DOI 10.1007/BF02187195; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Papadopoulos V, 1998, P SOC EXP BIOL MED, V217, P130; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; PAXINOS G, MOUSE BRAIN STEROTOX; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; von Monakow C., 1914, DIASCHISIS LOKALISAT, P26; Von Monakow C, 1895, ARCH PSYCHIAT NERVEN, V27, P1; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Willard LB, 2000, EXP BRAIN RES, V134, P58, DOI 10.1007/s002210000446; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	59	35	36	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	DEC	2003	20	4					1971	1981		10.1016/j.neuroimage.2003.06.003			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	756CM	WOS:000187448300008	14683703				2022-02-06	
J	Mather, FJ; Tate, RL; Hannan, TJ				Mather, FJ; Tate, RL; Hannan, TJ			Post-traumatic stress disorder in children following road traffic accidents: a comparison of those with and without mild traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; CONSEQUENCES	Background: It is now recognized that post-traumatic stress disorder ( PTSD) can occur following road traffic accidents, but controversy exists about the possibility of PTSD in people sustaining traumatic brain injury (TBI). The present investigation examined the frequency, course and comorbidity of PTSD in children with and without mild TBI after traffic accidents. Method: Interviews were conducted with 43 children and their parents 6 weeks after a traffic accident, assessing PTSD and associated symptomatology. Fourteen children sustained mild TBI and 29 had no TBI. A sub-set (n = 32) was re-interviewed 7 weeks later. Results: Children both with and without TBI reported PTSD symptomatology, but no significant group differences were found. At initial assessment, 74% of children were classified as having clinically significant PTSD symptomatology (86% and 69% in groups with and without TBI, respectively), which was strongly associated with report of general anxiety. At follow-up, PTSD symptomatology decreased, but 44% remained symptomatic (38% and 46% for those with and without TBI, respectively). Child and parental report of PTSD symptomatology were not significantly correlated. Conclusions: Presence of mild TBI did not influence the likelihood of experiencing PTSD symptomatology following a traffic accident. Given that PTSD symptomatology is a common consequence of traffic accidents in children, there is a clear need for provision of systematic assessment and, where appropriate, the implementation of intervention strategies to treat children.	Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia; New Childrens Hosp, Dept Rehabil, Sydney, NSW, Australia		Tate, RL (corresponding author), Univ Sydney, Royal Rehabil Ctr, Rehabil Studies Unit, Dept Med, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au					Achenbach T., 1991, INTEGRATIVE GUIDE 19; Albano A. M., 1996, ANXIETY DISORDERS IN; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Boake C, 1996, J HEAD TRAUMA REHAB, V11, P98; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Cohen JA, 1998, J AM ACAD CHILD PSY, V37, p4S, DOI 10.1097/00004583-199810001-00002; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; FOA EB, 1995, CURR DIR PSYCHOL SCI, V4, P61, DOI 10.1111/1467-8721.ep10771786; FREDERICK C, 1992, CHILDHOOD PTS REACTI; HANDFORD HA, 1986, J AM ACAD CHILD PSY, V25, P409, DOI 10.1016/S0002-7138(09)60264-8; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Kovacs M., 1977, DEPRESSION CHILDHOOD, P1; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCGRATH B, 1997, THESIS U SYDNEY; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050118030; McNally R. J., 1991, PSYCHOL ASSESSMENT, V3, P531, DOI [DOI 10.1037/1040-3590.3.4.531, 10.1037/1040-3590.3.4.531]; Mirza KAH, 1998, BRIT J PSYCHIAT, V172, P443, DOI 10.1192/bjp.172.5.443; NADER KO, 1996, ASSESSING PSYCHOL TR, P291; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Pfefferbaum B, 1997, J AM ACAD CHILD PSY, V36, P1503, DOI 10.1016/S0890-8567(09)66558-8; Pfefferbaum B, 1998, CHILD ADOL PSYCH CL, V7, P183, DOI 10.1016/S1056-4993(18)30267-0; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; SACK WH, 1986, J AM ACAD CHILD PSY, V25, P377, DOI 10.1016/S0002-7138(09)60260-0; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Stallard P, 1998, BRIT MED J, V317, P1619, DOI 10.1136/bmj.317.7173.1619; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334	32	35	35	2	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2003	17	12					1077	1087		10.1080/0269905031000114045			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731WR	WOS:000185909900006	14555366				2022-02-06	
J	Porter, MD				Porter, MD			A 9-year controlled prospective neuropsychologic assessment of amateur boxing	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						amateur boxing; prospective; neuropsychology; chronic traumatic encephalopathy	SPINAL-CORD INJURIES; CHRONIC BRAIN-DAMAGE; MINOR HEAD-INJURY; PROFESSIONAL BOXERS; FOOTBALLERS	Objective: To test the hypothesis that there is an association between amateur boxing and chronic traumatic encephalopathy using neuropsychologic assessments. Design: A prospective, controlled, blinded, observational, neuropsychologic study. Setting: Amateur boxing clubs in Dublin, Ireland, March 1992 to April 2001. Participants: Twenty randomly selected, actively competing, male amateur boxers and 20 age-matched, socioeconomic controls. Interventions: The boxers participated in amateur competition and sparring. Main Outcome Measures: Raw scores and changes in scores over time were recorded in the following neuropsychologic tests: Trail Making Tests A and B, Digit Symbol, Finger Tapping (dominant and nondominant hands), modified versions of the Finger Tapping Tests, Paired-Associate Learning, Digit Span, Re-Osterrieth Complex Figure Tests A and B, and Serial Addition. Raw scores and changes in scores for the two groups were compared, and a regression analysis was performed to detect any association between these values and exposure to boxing. Results: The boxers showed superior performance in the Trail Making Tests A and B at all time points and an inferior performance in both standard Finger Tapping Tests at all time points except baseline for the dominant hand. This inferior performance was not found in the modified versions of the tests. The controls showed significant deterioration in their performance in the Rey-Osterrieth Complex Figure Tests A and B. Conclusions: In this small controlled, prospective study of competitive amateur boxers, there was no evidence of neuropsychologic deterioration over 9 years. The amateur boxers demonstrated relative preservation and/or improvement of some neuropsychologic skills relative to the socioeconomic controls.	Sports Med Ctr, Oconnor, ACT 2602, Australia		Porter, MD (corresponding author), Sports Med Ctr, 190 Dryandra St, Oconnor, ACT 2602, Australia.						Boden BP, 2001, AM J SPORT MED, V29, P50, DOI 10.1177/03635465010290011301; BRAND D, 1998, AUSTR MED ASS   1008; BRENNAN TNN, 1968, BRIT J IND MED, V25, P326; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUSSE EW, 1952, JAMA-J AM MED ASSOC, V149, P1522, DOI 10.1001/jama.1952.02930340006003; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Caulfield TA, 1999, GENET TEST, V3, P107, DOI 10.1089/gte.1999.3.107; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; *COUNC SCI AFF, 1983, JAMA-J AM MED ASSOC, V249, P254; Cripps R, 1998, AUSTR INJURY PREVENT, V18, P1; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; CRUIKSHANK JK, 1980, LANCET, V1, P626; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; GEFFEN S, 1999, J SCI MED SPORT S, V2, P7; GONZALES TA, 1951, JAMA-J AM MED ASSOC, V46, P1506; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; INGLIS J, 1959, BRAIN, P440; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; KAPLAN HA, 1954, JAMA-J AM MED ASSOC, V156, P1138, DOI 10.1001/jama.1954.02950120012004; KASTE M, 1982, LANCET, V2, P1186; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Lewis R, 1979, MANUAL REPEATABLE CO; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET, V2, P795; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; McCunny RJ, 1984, PHYSICIAN SPORTSMED, V12, P53; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; *NAT SAF COUNC, 1980, SPORTING NEWS   0801, P8; NEUBUERGER KT, 1959, ARCH NEURO PSYCHIATR, V81, P403, DOI 10.1001/archneurpsyc.1959.02340160001001; PARKINSON D, 1987, CLIN NEUROSURG, V20, P131; Porter MD, 1996, CLIN J SPORT MED, V6, P90, DOI 10.1097/00042752-199604000-00005; REFSHAUGE JGH, 1996, MED J AUSTRALIA, V1, P611; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Ross J, 2000, HAEMOPHILIA, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Rotem TR, 1998, MED J AUSTRALIA, V168, P379, DOI 10.5694/j.1326-5377.1998.tb138989.x; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; Ryan AJ, 1998, CLIN SPORT MED, V17, P155, DOI 10.1016/S0278-5919(05)70070-3; SCHIRRING L, 2001, PHYSICIAN SPORTSMED, V29, P11; SERCL M, 1962, WORLD NEUROL, V3, P350; Sironi V A, 1982, J Neurosurg Sci, V26, P165; SPILLANE J D, 1962, Br Med J, V2, P1205; Spreen O, 1991, COMPENDIUM NEUROPSYC; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; TAYLOR TKF, 1987, MED J AUSTRALIA, V147, P112, DOI 10.5694/j.1326-5377.1987.tb133298.x; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Wechsler D., 1971, MANUAL WECHSLER ADUL; 1976, LANCET, V1, P401	58	35	36	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2003	13	6					339	352		10.1097/00042752-200311000-00002			14	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	746JL	WOS:000186743200002	14608222				2022-02-06	
J	Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Montpetite, M				Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Montpetite, M			Long-term educational interventions after traumatic brain injury in children	REHABILITATION PSYCHOLOGY			English	Article							ACADEMIC-PERFORMANCE; SCHOOL REENTRY; HEAD-INJURIES; BIRTH-WEIGHT; ADOLESCENTS; OUTCOMES; RECOVERY; DISABILITIES; ACHIEVEMENT; PLACEMENT	Objectives: To track educational interventions received by children with traumatic brain injury (TBI), examine factors associated with placement in special education, and explore the concordance of placement with children's needs. Methods: Interventions were monitored in 42 children with severe TBI, 42 with moderate TBI, and 50 with orthopedic injuries only (ORTHO group). A baseline assessment was completed soon after injury. Follow-up assessments were conducted 6 and 12 months after the baseline and at an extended follow-up about 4 years postinjury. Results: Rates of special education were higher in the severe TBI group than in the ORTHO. Predictors of special education included TBI severity, socioeconomic status, and measures of pre- and postinjury child status. Several children with TBI with residual deficits who were in regular education prior to injury did not receive special education at the extended follow-up. Conclusion: Although special education is frequently provided for several years after severe TBI, existing programs are of limited scope.	Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Ohio State Univ, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA; Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Cleveland, OH 44109 USA		Taylor, HG (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.		Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			Achenbach, 1991, MANUAL TEACHERS REPO; Achenbach TM, 1991, MANUAL CHILD BEHAV C; Bernstein JH, 1986, DEV SCORING SYSTEM R; Blosser JL, 1991, J HEAD TRAUMA REHAB, V6, P73; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BROWN L, 1990, TEST NONVERBAL INTEL; CARNEY J, 1994, PEDIATR ANN, V23, P47, DOI 10.3928/0090-4481-19940101-10; CARNEY J, 1990, Pediatrician, V17, P222; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DELIS DC, 1986, CALIFORNIA VERBAL LE; DISIMONI F, 1978, TOKEN TEST CHILDREN; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1999, COGNITIVE ASPECTS OF CHRONIC ILLNESS IN CHILDREN, P262; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FARMER JE, 1995, NEUROREHABILITATION, V5, P49, DOI 10.3233/NRE-1995-5105; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; HANSON SL, 1992, PHYSICAL MED REHABIL, V6, P483; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MAYER T, 1980, J PEDIATR SURG, V15, P19; MOOS R, 1988, LIFE STRESSORS SOCIA; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Resnick MB, 1998, PEDIATRICS, V102, P308, DOI 10.1542/peds.102.2.308; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; SEMEL E, 1987, CELF R CLIN EVALUATI; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; Spreen O, 1991, COMPENDIUM NEUROPSYC; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; SZEKERES SF, 1994, TOP LANG DISORD, V15, P21, DOI 10.1097/00011363-199411000-00004; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; TELZROW CF, 1991, J HEAD TRAUMA REHAB, V6, P23; Wechsler D., 1991, WISC 3 WECHSLER INTE; Wiig EH, 1985, TEST LANGUAGE COMPET; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P369; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109; [No title captured]; [No title captured]; [No title captured]	67	35	35	0	10	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2003	48	4					227	236		10.1037/0090-5550.48.4.227			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	741ER	WOS:000186446200001					2022-02-06	
J	Peerdeman, SM; Girbes, ARJ; Polderman, KH; Vandertop, WP				Peerdeman, SM; Girbes, ARJ; Polderman, KH; Vandertop, WP			Changes in cerebral interstitial glycerol concentration in head-injured patients; correlation with secondary events	INTENSIVE CARE MEDICINE			English	Article						head injury; microdialysis; glycerol; outcome	MEMBRANE PHOSPHOLIPID DEGRADATION; SUBARACHNOID HEMORRHAGE; INTRACEREBRAL MICRODIALYSIS; HUMAN BRAIN; MARKER; TOOL	Objective. To investigate the association between the occurrence of secondary events, clinical outcome and the interstitial glycerol levels as measured with cerebral microdialysis. Design. All patients received a ventriculostomy, a Camino pressure sensor and a CMA 70 microdialysis catheter. Intracranial pressure (ICP), cerebral perfusion pressure (CPP), blood pressure and arterial oxygen saturation (SaO(2)) were continuously monitored. Hourly microdialysis samples were collected and glycerol concentrations analyzed on-line. Glasgow Coma Score (GCS) scoring, blood gas and other laboratory analyses or investigations followed the routine of the intensive care unit. The Glasgow Outcome Scale (GOS) was assessed 6 months after injury. Setting. Intensive Care Unit and Department of Neurosurgery, VU University Hospital. Patients. Fifteen consecutive patients with severe traumatic brain injury and a GCS of 8 or less. Results. No association was found between low CPP, high ICP, low PaCO2, low SaO(2) or rise in temperature and the level of interstitial glycerol. In patients with a favorable outcome, the glycerol concentration never reached a level above 150 mumol/l, whereas a peak glycerol level above 150 mumol/l had a positive predictive value of 100% for an unfavorable outcome. The average of the area under the curve during the first 24 h of monitoring was significantly higher in the group with an unfavorable outcome (Kolmogorov-Smirnov test, p=0.044). Conclusion. Measuring interstitial glycerol for early detection of secondary adverse events, which possibly lead to secondary brain damage, does not seem useful. A peak level of interstitial glycerol above 150 mumol/l has a positive predictive value of 100% for an unfavorable outcome and hence indicates the severity of the parenchymal damage.	Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Intens Care, NL-1007 MB Amsterdam, Netherlands		Peerdeman, SM (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, POB 7057, NL-1007 MB Amsterdam, Netherlands.	sm.peerdeman@vumc.nl	Polderman, Kees H/K-3623-2012; Vandertop, William P./K-9288-2018				ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; BAZAN NG, 1970, LIFE SCI, V9, P501, DOI 10.1016/0024-3205(70)90205-5; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; SIESJO BK, 1992, ADV EXP MED BIOL, V318, P41	16	35	35	1	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	OCT	2003	29	10					1825	1828		10.1007/s00134-003-1850-8			4	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732AJ	WOS:000185918400036	12827237				2022-02-06	
J	Wu, KLH; Chan, SHH; Chao, YM; Chan, JYH				Wu, KLH; Chan, SHH; Chao, YM; Chan, JYH			Expression of pro-inflammatory cytokine and caspase genes promotes neuronal apoptosis in pontine reticular formation after spinal cord transection	NEUROBIOLOGY OF DISEASE			English	Article						apoptosis; proinflammatory genes; cytokines; caspases; pontine reticular formation; spinal cord injury	INTERLEUKIN-1-BETA CONVERTING-ENZYME; NUCLEUS-TRACTUS-SOLITARII; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; POLY(ADP-RIBOSE) POLYMERASE; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; TRAUMATIC INJURY; MICE DEFICIENT	We identified apoptotic neurons in pontine reticular formation (PRF), the origin of pontine reticulospinal fibers, in adult Sprague-Dawley rats after complete spinal cord transection (SCT) at T8 level. SCT also increased the expression in PRF of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, caspase-1, or caspase-3 mRNA. This was followed by an augmented expression of activated caspase-3 protein, an increase in caspase-3 activity, and expression of a cleaved fragment of poly(ADP-ribose) polymerase (PARP), a proteolytic substrate of the activated caspase-3. Microinjection bilaterally into the PRF of an antiserum against TNF-a attenuated the expression of IL-6 mRNA and up-regulation of caspase-3 mRNA, and a caspase-3 inhibitor, DEVD-CHO, suppressed the augmentation in activated caspase-3 or cleaved PARP expression after SCT. Both treatments also reduced the number of SCT-induced apoptotic PRF neurons. We conclude that PRF neurons in adult mammalian brain may actively degrade themselves after SCT through apoptosis, via signaling processes that involve activation of proinflammatory cytokine genes and the intracellular caspase-3 pathway. (C) 2003 Elsevier Science (USA). All rights reserved.	Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan; Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 804, Taiwan		Chan, JYH (corresponding author), Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan.		Chan, Julie/X-5253-2019				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Armstrong RC, 1997, J NEUROSCI, V17, P553; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Binder C, 1999, ANTICANCER RES, V19, P1715; Chan JYH, 2000, NEUROSCIENCE, V95, P155; Chen J, 1998, J NEUROSCI, V18, P4914; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friesen VJ, 1996, IEEE NETWORK, V10, P10, DOI 10.1109/65.539856; Geloso MC, 2002, EXP NEUROL, V175, P152, DOI 10.1006/exnr.2002.7866; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juan TSC, 1996, ONCOGENE, V13, P749; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KEANE KM, 1995, CYTOKINE, V7, P105, DOI 10.1006/cyto.1995.1014; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MAJNO G, 1995, AM J PATHOL, V146, P3; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Park IC, 2000, INT J ONCOL, V16, P1243; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Paxinos G, 1997, RAT BRAIN STEREOTAXI; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; ROBBINS A, 1992, EXP BRAIN RES, V92, P46; Ruemmele FM, 1999, BIOCHEM BIOPH RES CO, V260, P159, DOI 10.1006/bbrc.1999.0734; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SAMBROOK J, 1989, MOL CLONING LABORATO, V9, P16; SAWADA M, 1992, BRAIN RES, V583, P296, DOI 10.1016/S0006-8993(10)80037-X; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi K, 1999, J COMP NEUROL, V404, P159, DOI 10.1002/(SICI)1096-9861(19990208)404:2<159::AID-CNE2>3.0.CO;2-E; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TETZLAFF W, 1994, PROG BRAIN RES, V103, P271; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang LL, 2001, NEUROSCIENCE, V103, P143, DOI 10.1016/S0306-4522(00)00543-1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	58	35	40	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	OCT	2003	14	1					19	31		10.1016/S0969-9961(03)00078-0			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	723NP	WOS:000185438700003	13678663				2022-02-06	
J	Blostein, P; Jones, SJ				Blostein, P; Jones, SJ			Identification and evaluation of patients with mild traumatic brain injury: Results of a national survey of level I trauma centers	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild traumatic brain injury; brain injury; cognitive deficits	MINOR HEAD-INJURIES; UNITED-STATES; MANAGEMENT; HOSPITALIZATION; CONCUSSION; GUIDELINES	Background: Mild traumatic brain injury (MTBI), alone or in combination with other injuries, is frequently present in trauma patients requiring hospital admission. A survey was conducted to characterize the current practices of identification and management of patients with MTBI at Level I trauma centers in the United States. Methods. Surveys were mailed to trauma program managers at 68 verified Level I trauma centers. Results: Thirty-five (51.4%) centers responded, representing 24 states. Multiple terms are used synonymously with MTBI, and less than half (45%) of centers formally evaluate all trauma patients with MTBI. Patients identified with MTBI discharged from the emergency department are referred for further evaluation at only 34% of centers. There is no consistent practice for determining which hospitalized patients with MTBI are formally evaluated, who performs the evaluations, or which evaluation tool(s) are used. Patients with MTBI and cognitive deficits are referred to a variety of specialists after discharge. Conclusion: There is currently no standard practice for defining, evaluating, or managing MTBI at Level I trauma centers. A consistent definition of MTBI and its management could promote recognition of MTBI; facilitate data collection, analysis, and comparison; and provide guidelines for activity modification during recovery.	Bronson Methodist Hosp, Trauma Surg Serv, Kalamazoo, MI 49007 USA; Bronson Methodist Hosp, Rehabil Serv, Kalamazoo, MI 49007 USA		Blostein, P (corresponding author), Bronson Methodist Hosp, Trauma Surg Serv, 601 John St, Kalamazoo, MI 49007 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DENTON GL, 1999, BRAINLASH MAXIMIZE Y; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KURTZKE JF, 1993, CLIN NEUROLOGY, P111; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; Levin HS, 1996, NEUROTRAUMA, P749; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; OSBORNE CL, 1998, OVER HEAD DOCTORS OW; Owings JT, 1998, ARCH SURG-CHICAGO, V133, P941, DOI 10.1001/archsurg.133.9.941; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STEIN SC, 1996, NEUROTRAUMA, P755; Swanson Kara L., 1999, ILL CARRY FORK RECOV; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; [No title captured]	32	35	35	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2003	55	3					450	453		10.1097/01.TA.0000038545.24879.4D			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	721DZ	WOS:000185302900012	14501885				2022-02-06	
J	Piper, I; Citerio, G; Chambers, I; Contant, C; Enblad, P; Fiddes, H; Howells, T; Kiening, K; Nilsson, P; Yau, YH				Piper, I; Citerio, G; Chambers, I; Contant, C; Enblad, P; Fiddes, H; Howells, T; Kiening, K; Nilsson, P; Yau, YH		BrainIT Grp	The BrainIT group: concept and core dataset definition	ACTA NEUROCHIRURGICA			English	Article						head injury; multi-centre network; health technology assessment	HEAD-INJURED PATIENTS; INTENSIVE-CARE; SECONDARY INSULTS; UNITED-KINGDOM; MANAGEMENT; CONSORTIUM; ADULTS	Introduction. An open collaborative international network has been established which aims to improve inter-centre standards for collection of high-resolution, neurointensive care data on patients with traumatic brain injury. The group is also working towards the creation of an open access, detailed and validated database that will be useful for post-hoc hypothesis testing. In Part A, the underlying concept, the group coordination structure, membership guidelines and database access and publication criteria are described. Secondly, in part B, we describe a set of meetings funded by the EEC that allowed us to define a "Core Dataset" and we present the results of a feasibility exercise for collection of this core dataset. Methods. Four group meetings funded by the EEC have enabled definition of a "Core Dataset" to be collected from all centres regardless of specific project aim. A paper based pilot collection of data was conducted to determine the feasibility for collection of the core dataset. Specially designed forms to collect the core dataset demographic and clinical information as well as sample the time-series data elements were distributed by both email and standard mail to 22 BrainIT centres. A deadline of two months was set to receive completed forms back from centres. A pilot data collection of minute by minute physiological monitoring data was also performed. Findings. A core-dataset was defined and can be downloaded from the BrainIT web-site (go to "Core dataset" link at: www.brainit.org). Eighteen centres (82%) returned completed forms by the set deadline. Overall the feasibility for collection of the core data elements was high with only 10 of the 64 questions (16%) showing missing data. Of those 10 fields with missing data, the average number of centres not responding was 12% and the median 6%. An SQL database to hold the data has been designed and is being tested. Software tools for collection of the core dataset have been developed. Ethics approval has been granted for collection of multi-centre data as part of a pilot data collection study. Interpretation. The BrainIT network provides a more standardised and higher resolution data collection mechanism for research groups, organisations and the device industry to conduct multi-centre trials of new health care technology in patients with traumatic brain injury.	So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Osped San Gerardo, Monza, Italy; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; Addenbrookes Hosp, Cambridge, England; Univ Rotterdam Hosp, Rotterdam, Netherlands; Cattedra Anestesiol Novara, Novara, Italy; Univ Uppsala Hosp, Uppsala, Sweden; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Univ Hosp Brno, Brno, Czech Republic; Rigshosp, DK-2100 Copenhagen, Denmark; Catholic Univ Louvain, Hosp Gasthuisberg, B-3000 Louvain, Belgium; SF Treime Hosp, Iasi, Romania; Vilnius Univ Hosp, Vilnius, Lithuania; Univ Kliniken Saarlandes, Homburg, Germany; Univ Heidelberg, D-6900 Heidelberg, Germany; Hop Gabriel Montpied, Clermont Ferrand, France; Hosp 12 Octubre, E-28041 Madrid, Spain; Osped Molinette, Turin, Italy; Univ Hosp Leipzig, Leipzig, Germany; Univ Lund Hosp, S-22185 Lund, Sweden; Kaunas Med Univ Hosp, Kaunas, Lithuania; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; Valle Hebron Univ Hosp Barcelona, Barcelona, Spain; Terapia Intens Neurosci, Milan, Italy; Univ Spital Zurich, Zurich, Switzerland; Univ Hosp Mannheim, Mannheim, Germany; Natl Hosp, London WC1N 3BG, England; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Hosp Clin Barcelona, UCI Quirurg, Barcelona, Spain		Piper, I (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.		Citerio, Giuseppe/B-1839-2015	Citerio, Giuseppe/0000-0002-5374-3161			*AM ASS NEUR SURG, 1995, GUID MAN HEAD INJ; Berkowitz Monroe, 1993, Journal of Emergency Medicine, V11, P63; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CORRIE J, 1993, BRIT J INT CARE, V3, P225; *CPP, HYDR FLUID COL; GABE IT, 1972, ACTA PHYSL SCAND, V19, P306; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; McKeating EG, 1998, BRIT J NEUROSURG, V12, P7; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; PIPER IR, 1991, BR J INTENS CARE, V1, P73; ROBERTSON CS, 1997, P 10 INT S INTR PRES, P3; Robertson N, 2002, SIMULAT PRACT THEORY, V9, P349, DOI 10.1016/S0928-4869(01)00055-6; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; *SOC BRIT NEUR SUR, 1998, B J NEUROSURG, V14; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397	24	35	35	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	AUG	2003	145	8					615	629		10.1007/s00701-003-0066-6			15	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	719WL	WOS:000185228000003	14520540				2022-02-06	
J	Boone, KB; Lu, P				Boone, KB; Lu, P			Noncredible cognitive performance in the context of severe brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; MMPI-2; SENSITIVITY	In two litigating patients with histories of severe brain injury (i.e., coma greater than or equal to2 days and residual brain imaging abnormalities), noncredible cognitive symptomatology was demonstrated by: (1) "failed" performance on multiple cognitive "effort" tests, (2) noncredible performance on standard neuropsychological instruments, (3) questionable validity of personality inventory profiles, and (4) marked inconsistency in test performance across testing evaluations or marked inconsistency between test scores and activities of daily living documented through surveillance videotapes. Some patients with severe traumatic brain injury show substantial, if not full recovery, and in a litigating context, may feign cognitive symptoms. These cases indicate that tests to verify cognitive effort should be routinely administered to all patients in litigation or who have other motive to feign symptoms, not just patients with mild or questionable brain injury.	Harbor UCLA Med Ctr, Dept Psychiat, ABPP ABCN, Torrance, CA 90509 USA		Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, ABPP ABCN, Box 495,1000 W Carson St,F-9, Torrance, CA 90509 USA.	kboone@rei.edu					ANDRIKOPOULOS J, 1998, 26 ANN M INT NEUR SO; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Boone K., 2002, B TEST MANUAL; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Hoofien D, 2001, BRAIN INJURY, V15, P189; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LU P, 2003, 31 ANN M INT NEUR SO; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; PALMER BW, 1995, CLIN NEUROPSYCHOL, V9, P68, DOI 10.1080/13854049508402060; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	34	35	35	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2003	17	2					244	254		10.1076/clin.17.2.244.16497			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	734PF	WOS:000186065200014	13680432				2022-02-06	
J	Kushimoto, S; Shibata, Y; Yamamoto, Y				Kushimoto, S; Shibata, Y; Yamamoto, Y			Implications of fibrinogenolysis in patients with closed head injury	JOURNAL OF NEUROTRAUMA			English	Article						alpha(2)-plasmin inhibitor; fibrinogenolysis; fibrinolysis; head injury; intravascular coagulation; plasmin	DISSEMINATED INTRAVASCULAR COAGULATION; ALPHA-2-PLASMIN INHIBITOR DEFICIENCY; FIBRIN DEGRADATION PRODUCTS; ENZYME-IMMUNOASSAY; BRAIN INJURY; SYSTEMIC FIBRINOGENOLYSIS; ALPHA2-PLASMIN INHIBITOR; MONOCLONAL-ANTIBODY; PLASMA; ABNORMALITIES	The objective of this study was to determine the clinical significance of fibrinogenolysis in patients with isolated closed head injury. We correlated indices of fibrinolytic activity, fibrinogen degradation products (FgDP), and fibrin degradation products (FbDP) with outcome in order to accomplish this. This study consisted of 40 patients with isolated closed head trauma in whom blood sampling could be initiated within 3 h after injury. Patients were divided into two groups according to Glasgow Outcome Scale status at 3 months after injury, characterized as good recovery or moderate disability (group 1, n = 21); and severe disability, vegetative, or death (group 2, n = 19). The plasma fibrinogen concentration correlated with the Glasgow Coma Scale score on admission (r(2) = 0.201, p < 0.01), and plasma fibrinogen concentrations in group 2 were lower than in group 1 (p < 0.05). Plasma concentrations of fibrin/fibrinogen degradation products (FDP) and plasmin-alpha(2)-plasmin inhibitor complex (PIC), molecular markers of activation of fibrinolysis, were higher in group 2 than in group 1 (p < 0.001), and both FgDP and FbDP concentrations in group 2 also were higher than in group 1 (p < 0.001). Both the FgDP and FbDP concentrations correlated with the PIC concentration. Moreover, the plasma FgDP concentrations correlated inversely with alpha(2)-plasmin inhibitor activity, a potent inhibitor of the fibrinolytic system, as did the FbDP concentration. This study reveals that both fibrinolysis and fibrinogenolysis are involved in the coagulopathy that develops during the acute phase of head injury and correlate with fibrinolytic activity. Decreased activity of alpha(2)-plasmin inhibitor may contribute to fibrinogenolysis.	Nippon Med Coll, Dept Emergency & Crit Care Med, Bunkyo Ku, Tokyo 1138603, Japan		Kushimoto, S (corresponding author), Nippon Med Coll, Dept Emergency & Crit Care Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.						AOKI N, 1984, SEMIN THROMB HEMOST, V10, P24, DOI 10.1055/s-2007-1004405; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; BLANKENSTEIJN JD, 1992, TRANSPLANT INT, V5, P43, DOI 10.1007/BF00337189; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; FRADE LJG, 1992, ACTA HAEMATOL-BASEL, V88, P7; FRANCIS CW, 1994, HEMOSTASIS THROMBOSI, P1076; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; HANTGAN RR, 1994, HEMOSTASIS THROMBOSI, P277; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; ISOGAI N, 1993, JPN J CLIN PATHOL, V41, P1349; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; KOOPMAN J, 1987, J LAB CLIN MED, V109, P75; KOPPERT PW, 1988, THROMB HAEMOSTASIS, V59, P310; KOPPERT PW, 1987, THROMB HAEMOSTASIS, V57, P25; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; KUSHIMOTO S, 2001, J JPN BIOMED FORUM, V11, P19; MARDER VJ, 1990, HEMATOLOGY, P1522; MAZZI G, 1994, HAEMATOLOGICA, V79, P283; MIMURO J, 1987, BLOOD, V69, P446; MOROI M, 1977, THROMB RES, V10, P851, DOI 10.1016/0049-3848(77)90142-6; OKAJIMA K, 1992, THROMB RES, V66, P717, DOI 10.1016/0049-3848(92)90047-E; OKAJIMA K, 1994, AM J HEMATOL, V45, P16, DOI 10.1002/ajh.2830450104; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SCHWARTZ BS, 1986, ANN INTERN MED, V105, P873, DOI 10.7326/0003-4819-105-6-873; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; TAKAHASHI H, 1990, THROMB HAEMOSTASIS, V63, P340; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; von Sommoggy S, 1991, Eur J Vasc Surg, V5, P247	35	35	38	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					357	363		10.1089/089771503765172318			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900005	12866815				2022-02-06	
J	Kolitz, BP; Vanderploeg, RD; Curtiss, G				Kolitz, BP; Vanderploeg, RD; Curtiss, G			Development of the key behaviors change inventory: A traumatic brain injury behavioral outcome assessment instrument	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the American-Association-of-Spinal-Cord-Injury-Psychologists-and-Social-Workers	SEP, 2001	LAS VEGAS, NEVADA	American Assoc Spinal Cord Injury Psychologists Social Workers		brain injuries; multiple sclerosis; Neurobehavioral manifestations; rehabilitation; treatment outcome	NEUROPSYCHOLOGY BEHAVIOR; AFFECT PROFILE; REHABILITATION; REPLICATION; VALIDITY; SCALES	Objective: To describe the development and initial validation of a neurobehavioral outcome measure, the Key Behaviors Change Inventory (KBCI), for individuals with traumatic brain injury (TBI). Design: Scale construction and development, and validity study. Setting: Large state university and postal survey. Participants: Seventy-five volunteer undergraduate students and 25 volunteer collateral informants of individuals with TBI participated in the item-analysis phase. Thirty members of the Brain Injury Association and 20 members of the National Multiple Sclerosis Society rated both an identified patient and an age- and gender-equated control in the validation phase. Interventions: Not applicable. Main Outcome Measure: Content validity was examined through expert panel item sorts. Scale internal consistencies were examined with the Cronbach a. Construct validity was examined by comparing scale elevations between controls and 2 neurologic groups. Results: Item-analysis procedures resulted in 8 scales of 8 items each: inattention, impulsivity, unawareness of problems, apathy, interpersonal difficulties, communication problems, somatic difficulties, and emotional adjustment. Internal consistency reliability coefficients ranged from .82 to .91. Multivariate analysis of variance revealed significant (P<.001) differences in scale elevations among TBI, multiple sclerosis (MS), and control groups. The TBI and MS groups scored significantly higher than the control group on all scales; a subset of KBCI scales discriminated between the 2 neurologic groups. Conclusions: The KBCI was both sensitive and specific to typical behavioral changes after TBI, thus supporting its usefulness in rehabilitation settings. Cross-validation and development of a normative database are future steps necessary in its development.	Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; James A Haley Vet Affairs Med Ctr, Tampa, FL USA; Def & Vet Head Injury Program, Tampa, FL USA		Kolitz, BP (corresponding author), Off Russell & Kolitz, Financial Ctr 9350, 9350 S Dixie Hwy,Penthouse 3, Miami, FL 33156 USA.		Curtiss, Glenn/ABB-5566-2020				Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Beatty WW, 1996, NEUROPSYCHOLOGY CLIN, P225; BENYISHAY Y, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P194; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; BURISCH M, 1984, AM PSYCHOL, V39, P214, DOI 10.1037/0003-066X.39.3.214; CAMPBELL JJ, 1994, J NEUROPSYCH CLIN N, V6, P411; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; GILES GM, 1994, AM J OCCUP THER, V48, P199, DOI 10.5014/ajot.48.3.199; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Granger, 1987, FUNCTIONAL INDEPENDE; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Holden R.R., 1990, PSYCHOL ASSESSMENT, V2, P35, DOI https://doi.org/10.1037/1040-3590.2.1.35; HOLDEN RR, 1989, J CLIN PSYCHOL, V45, P583, DOI 10.1002/1097-4679(198907)45:4<583::AID-JCLP2270450413>3.0.CO;2-H; JACKSON DN, 1970, CURRENT TOPICS CLIN, V2, P62; JOHNSTON MV, 1995, J HEAD TRAUMA REHAB, V10, pR7, DOI 10.1097/00001199-199502000-00002; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KNIGHT RG, 1992, NEUROPSYCHOLOGY DEGE; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1989, FRONTIERS CLIN NEURO, V7, P113; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; Malloy PF, 1996, ASSESSMENT, V3, P327, DOI DOI 10.1177/1073191196003003012; MARSHALL RC, 1989, FRONTIERS CLIN NEURO, V7, P87; MAYER NH, 1993, J HEAD TRAUMA REHAB, V8, pR5; MENDE JM, 1998, DISS ABSTR INT SCI E, V59, P2476; Morey, 1991, PERSONALITY ASSESSME; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; NELSON LD, 1993, PSYCHOL ASSESSMENT, V5, P374; PAUL RH, 1997, DISS ABSTR INT SCI E, V58, P2173; PETERSON GW, 1989, J CLIN PSYCHOL, V45, P575, DOI 10.1002/1097-4679(198907)45:4<575::AID-JCLP2270450412>3.0.CO;2-F; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; PRIGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; RAO SM, 1990, SUBCORTICAL DEMENTIA, P164; ROSENTHAL M, 1987, J HEAD TRAUMA REHAB, V2, pR7; Satz P, 1996, PSYCHOL ASSESSMENT, V8, P115; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; THOMSEN IV, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P52; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wishart H, 1997, J CLIN EXP NEUROPSYC, V19, P810, DOI 10.1080/01688639708403762; WOOD RLL, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P3; [No title captured]	48	35	35	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					277	284		10.1053/apmr.2003.50100			8	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700019	12601661				2022-02-06	
J	Johnstone, B; Price, T; Bounds, T; Schopp, LH; Schootman, M; Schumate, D				Johnstone, B; Price, T; Bounds, T; Schopp, LH; Schootman, M; Schumate, D			Rural/urban differences in vocational outcomes for state vocational rehabilitation clients with TBI	NEUROREHABILITATION			English	Article						traumatic brain injury; vocational rehabilitation; rural		Objective: To evaluate differences in demographics, injury severity, and vocational outcomes for persons with TBI based on rural vs. urban residency. Participants: 78 individuals with TBI (28 from rural counties, 50 from urban counties) who requested services from the Missouri Division of Vocational Rehabilitation (VR) over a two year period. Measures: Demographics (i.e., age, race, education), injury severity (i.e., loss of consciousness, post traumatic amnesia, length of hospitalization, neuropsychological test scores), VR services provided (e.g., transportation, maintenance, on-the-job training, etc.), and VR outcomes (successfully vs. unsuccessfully employed; cost per case). Procedure: All participants completed a standard neuropsychological evaluation and completed VR services (i.e., were followed from enrollment to case closure). Rural and urban residency was determined using U.S Office of Management and Budget definitions of metropolitan and non-metropolitan areas. Analyses: Chi-squares, Fisher's Exact tests, Wilcoxon Rank Sums test, and MANOVAs. Results: Few if any differences were found between the groups in demographics (i.e., more African Americans in urban areas), injury severity (i.e., more rural residents with multiple TBIs), or neuropsychological test scores. However, individuals from urban areas received significantly more maintenance funds (46% vs. 21 %), transportation services (36% vs. 11%), and on-the-job training (28% vs. 7%), and had more spent on them ($1,816 vs $1,242). Although statistically non-significant (p < 0.15), 24% of individuals from urban areas were successfully employed at VR case closure, compared to only 7% of individuals from rural areas. Conclusions: Individuals with TBI from rural and urban settings have generally similar demographic, injury severity, and neuropsychological abilities, although they appear to differ in terms of vocational outcomes and number of VR services received, possibly related to limited availability of resources in rural areas.	Univ Missouri, Columbia, MO USA; Inst Rehabil, Kansas City, MO USA; Washington Univ, St Louis, MO USA; Div Vocat Rehabil, Columbia, MO USA		Johnstone, B (corresponding author), Dept Hlth Psychol, DC046-46, Columbia, MO 65212 USA.	john-stoneg@health.missouri.edu	Schootman, Mario/AAF-3941-2019	Schootman, Mario/0000-0003-1162-8824; Johnstone, Brick/0000-0001-8845-9649			BOUNDS T, IN PRESS NEUROREHAB; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; DEFILIPPIS NA, 1991, MANUAL BOOKLET CATEG; GOODALL P, 1994, J HEAD TRAUMA REHAB, V9, P61; HURT GD, 2000, NEUROPSYCHOLOGICAL M; Innes B., 2000, J DISABIL POLICY STU, V10, P207, DOI [10.1177/104420730001000205, DOI 10.1177/104420730001000205]; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; *KESSL MED REH RES, 2001, TRAUM BRAIN INJ FACT; KlOve H, 1963, MED CLIN N AM; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; PRICKEL D, 1989, COGNITIVE REHABILITA, V7, P22; Reitan RM, 1992, TRAIL MAKING TEST MA; Reitan RM, 1985, HALSTEADREITAN NEURO; *RUR POL RES I, 1999, METR NONM COUNT DEF; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schneider M J, 1986, Annu Rev Rehabil, V5, P217; Schootman M, 2000, BRAIN INJURY, V14, P373; Schootman M, 1999, BRAIN INJURY, V13, P995; Schootman M, 1998, BIOM HLTH R, V21, P73; SKEEL RL, IN PRESS REHAB PSYCH; *US BUR CENS, 1998, ANN TIM SER; US Census Bureau, 2000, STAT COUNT QUICK FAC; WECHSLER D, 1997, WMS, V3; Wechsler D, 1997, WAIS, VIII; HLTH US 2001 URBAN R; [No title captured]	27	35	35	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2003	18	3					197	203					7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	733ZZ	WOS:000186031900003	14530584				2022-02-06	
J	Hauber, RP; Jones, ML				Hauber, RP; Jones, ML			Telerehabilitation support for families at home caring for individuals in prolonged states of reduced consciousness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						family caregiver; severe brain injury; telerehabilitation	TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; COMA DATA-BANK; VEGETATIVE STATE; NEEDS; IMPACT	Objective: To investigate the use of telerehabilitation to support families caring at home for individuals with prolonged states of reduced consciousness. Design: A comparison group approach. Participants: Participants were recruited from a special program that is part of a Model Systems brain injury program located in the Southeast. Five patients, ranging from Rancho I to Rancho 3 were discharged home with family members as the primary caregivers. Procedures: Participant families were followed for 4 to 8 weeks via videophone. Follow-up telephone surveys were conducted with a family member 6 to 9 months after discharge and compared with a similar group that had not received the videophone follow-up. Main Outcome Measures: Present living status, number of emergency room visits, number of hospitalizations, the caregivers' perceptions of functional status and care needs, readmission for rehabilitation and perceived family needs as measured by the Family Needs Questionnaire (FNQ). Results: More patients in the videoconferencing group were still living at home and had returned for rehabilitation. On the FNQ, families in the videophone group reported more of their needs met than families in the comparison group. Conclusions: The use of videoconferencing to bridge the transition to home for families caring for a family member at the Rancho I to Rancho 3 level may assist families in successfully caring for the individual in the home and reducing the number of perceived family needs.	Univ Tampa, Dept Nursing, Tampa, FL 33606 USA; Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA		Hauber, RP (corresponding author), Shepherd Ctr, TeleRehabil Program, 2020 Peachtree Rd, Atlanta, GA 30309 USA.						ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; CHILDS NL, 1993, NEUROLOGY, V43, P1464; FIELD MJ, 1996, TELEMEDICINE GUIDE A; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; Hauber R P, 2000, J Neurosci Nurs, V32, P22; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; Jones ML, 1998, TOPICS SPINAL CORD I, V3, P61; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Phillips VL, 2001, PUBLIC HEALTH REP, V116, P94, DOI 10.1093/phr/116.S1.94; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Vesmarovich S, 1999, Adv Wound Care, V12, P264; Walker WC, 1996, BRAIN INJURY, V10, P65	22	35	37	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					535	541		10.1097/00001199-200212000-00005			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900005	12802244				2022-02-06	
J	Nassogne, MC; Sharrard, M; Hertz-Pannier, L; Armengaud, D; Touati, G; Delonlay-Debeney, P; Zerah, M; Brunelle, F; Saudubray, JM				Nassogne, MC; Sharrard, M; Hertz-Pannier, L; Armengaud, D; Touati, G; Delonlay-Debeney, P; Zerah, M; Brunelle, F; Saudubray, JM			Massive subdural haematomas in Menkes disease mimicking shaken baby syndrome	CHILDS NERVOUS SYSTEM			English	Article						brain diseases; inborn; metabolic; intracranial haemorrhage; traumatic		Introduction: Menkes disease is an X-linked inherited disorder of intestinal copper absorption resulting in copper deficiency. Cardinal features include hair abnormalities, facial dysmorphism, severe neurological impairment, hypothermia, arterial anomalies, bone abnormalities and a fatal outcome. Case report: We present a case of Menkes disease complicated by progressive macrocephaly following the development of massive subdural haematomas. These lesions associated with femoral metaphyseal spurs could be confused with nonaccidental injury such as that seen in the shaken baby syndrome. Discussion: This case emphasises that Menkes disease, like glutaric aciduria type 1, should be included in the differential diagnosis of unexplained subdural haematomas and neurological deficits in infants.	Hop Necker Enfants Malad, Serv Malad Metab Neurol & Genet, Paris, France; Clin Univ St Luc, Serv Neurol Pediat, B-1200 Brussels, Belgium		Nassogne, MC (corresponding author), Hop Necker Enfants Malad, Serv Malad Metab Neurol & Genet, Paris, France.		ZERAH, Michel/E-6473-2012	Nassogne, Marie-Cecile/0000-0001-6936-1611; Hertz-Pannier, Lucie/0000-0003-4952-7009			ADAMS PC, 1974, RADIOLOGY, V112, P401, DOI 10.1148/112.2.401; Baric I, 1998, J INHERIT METAB DIS, V21, P326, DOI 10.1023/A:1005390105171; DANKS DM, 1995, METABOLIC MOL BASES, V2, P2211; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Kodama K, 1999, PEDIATR INT, V41, P430, DOI 10.1046/j.1442-200x.1999.01091.x; MENKES JH, 1962, PEDIATRICS, V29, P764	6	35	37	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	DEC	2002	18	12					729	731		10.1007/s00381-002-0630-z			3	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	629HR	WOS:000180044700016	12483361				2022-02-06	
J	Yun, SJ; Kim, MO; Kim, SO; Park, J; Kwon, YK; Kim, IS; Lee, EH				Yun, SJ; Kim, MO; Kim, SO; Park, J; Kwon, YK; Kim, IS; Lee, EH			Induction of TGF-beta-inducible gene-h3 (beta ig-h3) by TGF-beta 1 in astrocytes: implications for astrocyte response to brain injury	MOLECULAR BRAIN RESEARCH			English	Article						astrocyte; beta ig-h3; brain injury; gliosis; TGF-beta 1; wound healing	GROWTH-FACTOR-BETA; CENTRAL-NERVOUS-SYSTEM; 5Q31-LINKED CORNEAL DYSTROPHIES; TRANSFORMING GROWTH-FACTOR-BETA-1; REACTIVE ASTROCYTES; MESSENGER-RNA; RAT-BRAIN; EXTRACELLULAR-MATRIX; SEQUENCE-ANALYSIS; CELL-ADHESION	Transforming growth factor (TGF)-beta-inducible gene-h3 (betaig-h3) product is a secreted protein that is induced by TGF-beta in several cell types and implicated in various tissue pathologies. The aims of this study were to determine the effect of TGF-beta1 on betaig-h3 expression in cultured astrocytes and to examine whether betaig-h3 is expressed in the brain after traumatic injury. The results showed that betaig-h3 mRNA and protein increased in response to TGF-beta1 in U87 human astrocytoma cells and mouse cortical astrocytes. Treatment with other cytokines, including tumor necrosis factor-alpha and fibroblast growth factor-2, did not enhance the expression of betaig-h3 in astrocytes. betaig-h3 was significantly expressed in reactive astrocytes at the site of a stab wound in the cerebral cortex of adult rats. These results provide an insight into understanding a novel role for betaig-h3 protein in the response of astrocytes to brain injury. (C) 2002 Elsevier Science B.V. All rights reserved.	Kyung Hee Univ, Grad Sch EW Med Sci, Yongin 449701, South Korea; Kyung Hee Univ, Dept Biol, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 702701, South Korea; Kyungpook Natl Univ, Cell & Matrix Natl Res Lab, Taegu 702701, South Korea		Lee, EH (corresponding author), Kyung Hee Univ, Grad Sch EW Med Sci, Yongin 449701, South Korea.	ehwang@khu.ac.kr	김, 인산/I-8988-2014; Kwon, Yunhee Kim/AAV-8420-2021; Park, Ji-Ho/AAI-8644-2020	Park, Ji-Ho/0000-0001-9722-8463; Lee, Eunjoo H./0000-0002-5569-0067			Asher RA, 2000, J NEUROSCI, V20, P2427; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Billings PC, 2000, AM J RESP CELL MOL, V22, P352, DOI 10.1165/ajrcmb.22.3.3732; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Gilbert RE, 1998, KIDNEY INT, V54, P1052, DOI 10.1046/j.1523-1755.1998.00081.x; Hashimoto K, 1997, BBA-MOL CELL RES, V1355, P303, DOI 10.1016/S0167-4889(96)00147-4; Kawasaki S, 1999, AM J OPHTHALMOL, V127, P456, DOI 10.1016/S0002-9394(98)00360-2; KIEFER R, 1995, INT J DEV NEUROSCI, V13, P331; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Lee EH, 2000, INVEST OPHTH VIS SCI, V41, P1840; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; MORGAN TE, 1993, EXP NEUROL, V120, P291, DOI 10.1006/exnr.1993.1063; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Pratt Bruce M., 1997, Cytokine and Growth Factor Reviews, V8, P267, DOI 10.1016/S1359-6101(97)00018-X; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; Schorderet DF, 2000, BIOCHEM BIOPH RES CO, V274, P267, DOI 10.1006/bbrc.2000.3116; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Smith GM, 1997, J NEUROSCI, V17, P9624; Srivastava OP, 1999, CURR EYE RES, V19, P348, DOI 10.1076/ceyr.19.4.348.5303; Streeten BW, 1999, ARCH OPHTHALMOL-CHIC, V117, P67; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; Vawter MP, 1996, EXP NEUROL, V142, P313, DOI 10.1006/exnr.1996.0200; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	50	35	38	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	OCT 30	2002	107	1					57	64	PII S0169-328X(02)00447-3	10.1016/S0169-328X(02)00447-3			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	619AH	WOS:000179450500008	12414124				2022-02-06	
J	Koh, JO; Watkinson, EJ				Koh, JO; Watkinson, EJ			Video analysis of blows to the head and face at the 1999 World Taekwondo Championships	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						video analysis; brain injuries, diagnosis; brain injiuries, prevention and control; exercise	INJURIES; CONCUSSION	Background. Limited research has been done on head blows that may result in mild traumatic brain injury in Taekwondo. The purpose of this study was to investigate the fighting conditions under which blows to the head commonly take place, with a view to determining the typical conditions under which injury may occur. Methods. Experimental design: videotape analysis (retrospective). Setting: the semi-final and final matches (a total of 48 matches) at the 14(th) World Taekwondo Championships in 1999. Participants: 64 athletes (32 females and 32 males) who won elimination-round matches (out of 563 competitors), aged 15 to 38 years. Measures: frequency, mechanism of head blows, characteristics of situations leading up to and following head blows, frequency of multiple impacts. Results. A total of 35 incidents of head blow occurred (365 blows per 1,000 athlete exposures). All of these head blows were associated with a direct head or face contact and frequently involved: a closed sparring stance, shorter athletes, axe or roundhouse type kicks, attacker's offensive kick, and head-blow-receiver's offensive action with absence of a blocking skill. Conclusions. To prevent possible brain injury resulting from direct head blows, updated safety education, a complete understanding of concussion for athletes, coaches, and referees, and a rule change in competition Taekwondo are recommended.	Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB T6G 2H9, Canada		Koh, JO (corresponding author), Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB T6G 2H9, Canada.			Koh, Jae Ok/0000-0002-3639-0739			Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT, 1989, MILD HEAD INJURY, P257; CHUANG TY, 1992, J BIOMECH ENG-T ASME, V114, P346, DOI 10.1115/1.2891394; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; LLOYD LE, 1987, TEX MED, V83, P30; MASTER EJT, 2000, PHYSICIAN SPORTSMED, V28, P87; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; SERINA ER, 1991, J BIOMECH, V24, P951, DOI 10.1016/0021-9290(91)90173-K; Siana J E, 1986, Br J Sports Med, V20, P165; Sung N.J., 1987, US TAEKWONDO J, V6, P10	14	35	35	0	3	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707			J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	SEP	2002	42	3					348	353					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	602TD	WOS:000178519800014	12094126				2022-02-06	
J	Potter, DD; Jory, SH; Bassett, MRA; Barrett, K; Mychalkiw, W				Potter, DD; Jory, SH; Bassett, MRA; Barrett, K; Mychalkiw, W			Effect of mild head injury on event-related potential correlates of Stroop task performance	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						ERP; traumatic brain injury; memory; P3; CHI; closed head injury	AUDITORY ODDBALL TASK; BRAIN POTENTIALS; INTERFERENCE; ATTENTION; SYMPTOMS; SEQUELAE; DISTRACTIBILITY; PERSISTENCE; ANATOMY; P300	The effect of mild head injury on event-related potential (ERP) correlates of Stroop task performance was explored with the aim of further elucidating the basis of processing impairments after mild head injury. Computer- and card-bused Stroop tasks were employed to assess attention function. A sequence of incongruent color words were presented followed by a sequence of congruent color words (printed in congruent colors). Control performance was equivalent on computer- and card-based versions of the incongruent task and faster on the congruent card task than the preceding congruent computer task. The mild head injury group were as fast as controls on the computer-based task but made more errors. However, they were relatively slower on both the congruent and incongruent parts of the card-based task and made more errors in the incongruent task. ERP correlates of computer-based Stroop task performance suggested a greater allocation of attention resources in the incongruent condition in both groups in the form of relatively greater negativity in the latency range 350 to 450 ins with a distribution consistent with the activation of the anterior cingulate gyrus. In addition the mild head injured group showed relatively greater enhancement than the control group in this latency range in both congruent and incongruent conditions. There was, however no evidence of reduced amplitude P1, N1, N2, or P3b deflections. Trails, digit symbol, digit span and auditory verbal learning tests (AVLT) were also administered. Mild head injured participants were impaired only on the AVLT. The finding of greater ERP negativity in the mild head injured group is consistent with greater allocation of attention resources to achieve equivalent performance in the computer-based Stroop task.	Keele Univ, Dept Psychol, Keele, Staffs, England; Haywood Hosp, Neurobehav Unit, Stoke On Trent ST6 7AG, Staffs, England; City Gen Hosp, Dept Psychol, Stoke On Trent, Staffs, England		Potter, DD (corresponding author), Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland.	d.d.potter@dundee.ac.uk					Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; COHEN JD, 1990, PSYCHOL REV, V97, P332, DOI 10.1037/0033-295X.97.3.332; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; CZIGLER I, 1991, INT J PSYCHOPHYSIOL, V11, P281, DOI 10.1016/0167-8760(91)90023-Q; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; DUNCANJOHNSON CC, 1981, SCIENCE, V214, P938, DOI 10.1126/science.7302571; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; George M S, 1994, Hum Brain Mapp, V1, P194, DOI 10.1002/hbm.460010305; Grapperon J, 1998, NEUROPHYSIOL CLIN, V28, P207, DOI 10.1016/S0987-7053(98)80112-3; Jory SH, 2000, J PSYCHOPHYSIOL, V14, P187; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kaiser J, 1997, INT J PSYCHOPHYSIOL, V27, P215, DOI 10.1016/S0167-8760(97)00055-X; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; LARRUE V, 1994, J CEREBR BLOOD F MET, V14, P958, DOI 10.1038/jcbfm.1994.128; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MACLEOD CM, 1988, J EXP PSYCHOL LEARN, V14, P126, DOI 10.1037/0278-7393.14.1.126; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; McKeown MJ, 1998, P NATL ACAD SCI USA, V95, P803, DOI 10.1073/pnas.95.3.803; Nelson H.E., 1982, NATL ADULT READING T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nobre AC, 2000, NEUROIMAGE, V11, P210, DOI 10.1006/nimg.2000.0539; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; Petrides M., 1998, PREFRONTAL CORTEX EX, P103; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Posner MI, 1975, INFORM PROCESSING CO, P55; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 1999, J PSYCHOPHYSIOL, V13, P173, DOI 10.1027//0269-8803.13.3.173; POTTER DD, 2001, BRIT PSYCH SOC ANN C; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Rey A., 1964, EXAMEN CLIN PSYCHOL; Robbins T. W., 1998, PREFRONTAL CORTEX EX, P117; ROLLS ET, 1998, PREFRONTAL CORTEX EX, P67; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spreen O, 1991, COMPENDIUM NEUROPSYC; Taylor SF, 1997, NEUROIMAGE, V6, P81, DOI 10.1006/nimg.1997.0285; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Wechsler, 1997, WECHSLER ADULT INTEL; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; Wylie G, 2000, PSYCHOL RES-PSYCH FO, V63, P212, DOI 10.1007/s004269900003; Zhang HZ, 1998, J EXP PSYCHOL HUMAN, V24, P3, DOI 10.1037/0096-1523.24.1.3	57	35	38	1	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2002	8	6					828	837		10.1017/S1355617702860118			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	592CZ	WOS:000177920300011	12240747				2022-02-06	
J	Williams, WH; Evans, JJ; Wilson, BA; Needham, P				Williams, WH; Evans, JJ; Wilson, BA; Needham, P			Prevalence of post-traumatic stress disorder symptoms after severe traumatic brain injury in a representative community sample	BRAIN INJURY			English	Article							EVENT SCALE; HEAD-INJURY; DEPRESSION; IMPACT	Primary objective: In this study, the authors investigated the prevalence of symptoms of post-traumatic stress disorder (PTSD) in a community sample of 66 survivors of severe traumatic brain injury (TBI). Research design, method and procedures: A representative sample of survivors of TBI were selected on the basis of having suffered significant disturbance in consciousness following their trauma event in the form of coma and/or post-traumatic amnesia. Neuropsychological testing confirmed that participants had suffered cognitive deficits consistent with severe brain injury. Participants were administered the Impact of Events inventory for symptoms of PTSD. Main outcomes and results: The authors found a prevalence rate of 18% for moderate-to-severe PTSD symptoms. Conclusions: PTSD symptoms are common following severe TBI. Further research is needed to establish protective and predictive factors for PTSD in TBI groups.	Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter, Devon, England; Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, England; Cognit & Brain Sci Unit, Cambridge, England		Williams, WH (corresponding author), Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter, Devon, England.	w.h.williams@exeter.ac.uk		williams, huw/0000-0003-0670-2620			Baddeley A., 1992, SPEED CAPACITY LANGU; Bond M. R., 1990, REHABILITATION ADULT, P179; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Briere J, 1998, ASSESSMENT, V5, P171, DOI 10.1177/107319119800500207; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; CORNEIL W, 1999, J OCCUP HEALTH, V4, P1; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Markowitsch HJ, 1998, NEUROCASE, V4, P429, DOI 10.1080/13554799808410636; McKenna P., 1983, GRADED NAMING TEST; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050118030; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Raven J.C., 1947, RAVENS PROGR MATRICE; Robertson I., 1994, TEST EVERYDAY ATTENT; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; TURNER S, 1998, MEASURES POST TRAUMA; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; [No title captured]	29	35	35	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2002	16	8					673	679		10.1080/02699050210128861			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	583GP	WOS:000177399100003	12167192				2022-02-06	
J	Hofman, PAM; Verhey, FRJ; Wilmink, JT; Rozendaal, N; Jolles, J				Hofman, PAM; Verhey, FRJ; Wilmink, JT; Rozendaal, N; Jolles, J			Brain lesions in patients visiting a memory clinic with postconcussional sequelae after mild to moderate brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED-HEAD-INJURY; MAGNETIZATION-TRANSFER; MULTIPLE-SCLEROSIS; HISTOPATHOLOGIC CORRELATION; CEREBRAL CONCUSSION; MICROSCOPIC DISEASE; WHITE-MATTER; MR; DEGENERATION; PERFORMANCE	Postconcussional disorder after a relatively mild head injury is common. Although a partial organic etiology is presumed, little imaging evidence exists for this assumption, In this study, patients with mild to moderate brain injury (median Glasgow Coma Scale score of 14) had more parenchymal brain lesions than control subjects (P = 0.02). Additionally, the authors investigated the potential of quantifying brain injury by the magnetization transfer ratio (MTR). The curve amplitude of the MTR histogram was used as a measure of normal white matter. Patients had a lower curve amplitude than control subjects (P = 0.008). This study provides evidence of persistent traumatic brain alterations in patients who sustained a relatively mild traumatic brain injury.	Univ Hosp Maastricht, Dept Radiol, NL-6200 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Psychiat & Neuropsychol, NL-6200 AZ Maastricht, Netherlands		Hofman, PAM (corresponding author), Univ Hosp Maastricht, Dept Radiol, POB 5800, NL-6200 AZ Maastricht, Netherlands.	pho@rdia.azm.nl					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOORSTEIN JM, 1994, RADIOLOGY, V191, P799, DOI 10.1148/radiology.191.3.8184068; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BRAND N, 1987, PSYCHOL MED, V17, P145, DOI 10.1017/S0033291700013040; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; Gean AD, 1994, IMAGING HEAD TRAUMA; HAJNAL JV, 1992, J COMPUT ASSIST TOMO, V16, P7, DOI 10.1097/00004728-199201000-00003; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hofman PAM, 1999, MAGN RESON MED, V42, P803, DOI 10.1002/(SICI)1522-2594(199910)42:4<803::AID-MRM24>3.3.CO;2-6; HOUX P, 1991, COGNITIVE AGING HLTH; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jacobs A, 1996, J NUCL MED, V37, P1605; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLEIN M, 1997, THESIS MAASTRICHT U; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRUGER J, 1991, NERVENARZT, V62, P226; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; TEASDALE G, 1974, LANCET, V2, P81; vanBoxtel MPJ, 1996, EXP AGING RES, V22, P363, DOI 10.1080/03610739608254017; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; Verhage F, 1964, INTELLIGENTIE LEEFTI; VERHEY FRJ, 1993, J NEUROPSYCH CLIN N, V5, P78; Wilmink JT, 1997, NEURORADIOLOGY, V39, P589, DOI 10.1007/s002340050473; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	54	35	35	0	2	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2002	14	2					176	184		10.1176/appi.neuropsych.14.2.176			9	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	555JB	WOS:000175790000007	11983792				2022-02-06	
J	Hutchison, JS; Derrane, RE; Johnston, DL; Gendron, N; Barnes, D; Fliss, H; King, WJ; Rasquinha, I; MacManus, J; Robertson, GS; MacKenzie, AE				Hutchison, JS; Derrane, RE; Johnston, DL; Gendron, N; Barnes, D; Fliss, H; King, WJ; Rasquinha, I; MacManus, J; Robertson, GS; MacKenzie, AE			Neuronal apoptosis inhibitory protein expression after traumatic brain injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; caspase; microglia; neuronal apoptosis inhibitor protein (NAIP); tumor necrosis factor-alpha (TNF alpha); immunofluorescence; Western blot	NECROSIS-FACTOR-ALPHA; PROGRAMMED CELL-DEATH; SPINAL-CORD INJURY; CLOSED-HEAD INJURY; DNA FRAGMENTATION; POLY(ADP-RIBOSE) POLYMERASE; COGNITIVE DEFICITS; RAT-BRAIN; TNF-ALPHA; IN-VIVO	Apoptosis of brain cells is triggered by traumatic brain injury (TBI) and is blocked by caspase inhibitors. The neuronal apoptosis inhibitor protein (NAIP), which has been shown to inhibit apoptosis by both caspase-dependant and caspase-independent mechanisms, is neuroprotective in rat models of cerebral ischemia and axotomy. In order to gain a better appreciation of CNS apoptosis following head injury in general and the possible involvement of NAIP specifically, we have configured a mouse model of TBI. In addition to demonstrating apoptosis, the spatiotemporal expression or levels of a number of proteins with apoptosis modulating effects have been determined. Apoptosis of neurons and oligodendrocytes following TBI was observed in brain sections which were triple-stained with in situ end labeling, bisbenzimide and immunofluorescent stain for neuron specific nuclear protein and myelin-associated glycoprotein, respectively. Further evidence for apoptosis following TBI in this model was obtained in brain samples using ligation-mediated PCR amplification of DNA fragments and gel electrophoresis. The temporal profile of apoptosis was similar to the temporal profile of microglial activation determined by CD11b staining and TNF alpha expression induced by TBI. NAIP staining in sections of cerebral cortex and subcortical white matter increased at 6 h and decreased towards control levels at 24 h post-TBI. Temporal changes in the expression of NAIP were also observed using Western blot analysis of brain samples removed from injured cortex and sub-cortical white matter. At the time that NAIP expression decreased markedly (24 h post-TBI), procaspase-3 levels also decreased, PARP cleavage increased, and the highest levels of apoptosis were observed. These findings have implications in our understanding of traumatically induced programmed cell death and may be useful in the configuration of therapies for this common injury state.	Univ Ottawa, Fac Med, Dept Pediat, Div Pediat Intens Care, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Inst Res, Genet Mol Lab, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Fac Med, Dept Pediat, Ottawa, ON, Canada; Natl Res Council Canada, Inst Biol Sci, Apoptosis Res Grp, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Biochem, Ottawa, ON, Canada		Hutchison, JS (corresponding author), Univ Ottawa, Fac Med, Dept Pediat, Div Pediat Intens Care, Ottawa, ON, Canada.		Fliss, Henry/ABG-2561-2020	Gendron, Nathalie/0000-0001-5636-7408; Robertson, George/0000-0001-8411-7721			ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Diez E, 2000, J IMMUNOL, V164, P1470, DOI 10.4049/jimmunol.164.3.1470; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HILL IE, 1995, BRAIN RES, V676, P398, DOI 10.1016/0006-8993(95)00145-G; Holcik M, 2000, P NATL ACAD SCI USA, V97, P2286, DOI 10.1073/pnas.040469797; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kreider BQ, 1996, J NEUROSCI RES, V44, P459; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Liu XZ, 1997, J NEUROSCI, V17, P5395; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MACMANUS JP, 1994, NEUROREPORT, V5, P493, DOI 10.1097/00001756-199401120-00031; Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Perrelet D, 2000, EUR J NEUROSCI, V12, P2059, DOI 10.1046/j.1460-9568.2000.00098.x; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shah GM, 1995, ANAL BIOCHEM, V232, P251, DOI 10.1006/abio.1995.0016; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Westmoreland SV, 1996, J NEUROVIROL, V2, P118, DOI 10.3109/13550289609146545; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378; Ye P, 1999, ENDOCRINOLOGY, V140, P3063, DOI 10.1210/en.140.7.3063	50	35	36	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2001	18	12					1333	1347		10.1089/08977150152725632			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	504RE	WOS:000172869000004	11780864				2022-02-06	
J	Matuja, WBP; Kilonzo, G; Mbena, P; Mwango'mbola, RL; Wong, P; Goodfellow, P; Jilek-Aall, L				Matuja, WBP; Kilonzo, G; Mbena, P; Mwango'mbola, RL; Wong, P; Goodfellow, P; Jilek-Aall, L			Risk factors for epilepsy in a rural area in Tanzania - A community-based case-control study	NEUROEPIDEMIOLOGY			English	Article						epilepsy; risk factors; electroencephalography; Tanzania; Africa	FEBRILE CONVULSIONS; UNPROVOKED SEIZURES; CLASSIFICATION; EPIDEMIOLOGY; POPULATION; ROCHESTER; MINNESOTA	Background and Methods: The high prevalence of epilepsy detected in rural Tanzania by Dr. Jilek-Aall since 1960, was verified by the World Health Organization (WHO) survey on neurological and seizure disorders. Neurologists and psychiatrists further interviewed both patients and controls using standard methods. The presence of possible risk factors was complemented by corroborative evidence through interviewing close relatives and scrutinizing medical records. Seizures were classified based on clinical symptoms and the use of EEG. Results: A family history of epilepsy in first-degree relatives was found in 46.6% of patients, but in only 19.6% of controls. The odds ratio for family history with epilepsy was 3.52 (95% confidence interval, CI 2.4-5.74, p < 0.001). A past history of febrile convulsion was found in 44% of patients in comparison to 23% of the control group which was significant (odds ratio 2.4, 95% CI 1.5-3.8; p < 0.001). A history of intrapartum complications was found in 12.1% of patients and 1.8% of controls (odds ratio 7.3, 95% CI 2.5-25.2; p < 0.002). Head injury was not a significant risk factor for epilepsy in this rural community. Conclusion: The results indicated a strongly independent association between four factors and the risk of developing epilepsy. It would seem more likely that previous brain insults/diseases play a significant major role in the cause of epilepsy in the Mahenge area. However, a genetic predisposition to low threshold for convulsions cannot be excluded. Copyright (C) 2001 S. Karger AG, Basel.	Muhimbili Univ, Coll Hlth Sci, Dept Med, Neurol Unit, Dar Es Salaam, Tanzania; Muhimbili Univ, Coll Hlth Sci, Dept Psychiat, Neurol Unit, Dar Es Salaam, Tanzania; Mahenge Dist Hosp, Morogoro, Tanzania; Morogoro Reg Hosp, Morogoro, Tanzania; Univ British Columbia, Neuroelectrophysiol Dept, Vancouver, BC, Canada; Univ British Columbia, Dept Genet, Vancouver, BC, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada		Matuja, WBP (corresponding author), Muhimbili Univ, Coll Hlth Sci, Dept Med, Neurol Unit, POB 65001, Dar Es Salaam, Tanzania.						ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; BANCAUD J, 1981, EPILEPSIA, V22, P489, DOI 10.1111/j.1528-1157.1981.tb06159.x; CAMPBELL CD, 1987, S AFR MED J, V72, P885; DANESI MA, 1985, EPILEPSIA, V26, P131, DOI 10.1111/j.1528-1157.1985.tb05396.x; GERRITS C, 1983, LANCET, V1, P358; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GOODSMIT J, 1983, NEUROEPIDEMIOLOGY, V2, P24; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; JILEK W G, 1970, African Journal of Medical Sciences, V1, P305; JILEKAALL L, 1994, 12 INT C TROP NEUR S; JILEKAALL L, 1979, EPILEPSIA, V20, P612; KIPP W, 1992, LANCET, V340, P789, DOI 10.1016/0140-6736(92)92329-E; KIPP W, 1994, LANCET, V343, P183, DOI 10.1016/S0140-6736(94)90980-6; LEVITON A, 1982, Neuroepidemiology, V1, P40, DOI 10.1159/000110688; LI SC, 1985, EPILEPSIA, V26, P391, DOI 10.1111/j.1528-1157.1985.tb05669.x; MATUJA W B P, 1990, African Journal of Medicine and Medical Sciences, V19, P89; MATUJA WBP, 1994, E AFR MED J, V71, P236; MATUJA WBP, 1989, E AFR MED J, V66, P343; OGUNNIYI A, 1987, EPILEPSIA, V28, P280, DOI 10.1111/j.1528-1157.1987.tb04219.x; OSUNTOKUN BO, 1974, DEV MED CHILD NEUROL, V16, P659; OSUNTONKUN BO, 1982, NEUROEPIDEMIOLOGY, V1, P145; OTTMAN R, 1995, NEUROLOGY, V39, P442; ROCCA WA, 1987, ANN NEUROL, V21, P22, DOI 10.1002/ana.410210106; RWIZA HT, 1992, EPILEPSIA, V33, P1051, DOI 10.1111/j.1528-1157.1992.tb01758.x; SANDER JW, 1990, LANCET, V335, P267; SHORVON SD, 1988, EPILEPSIA, V29, pS36, DOI 10.1111/j.1528-1157.1988.tb05790.x; SRIDHARAN R, 1986, EPILEPSIA, V27, P60, DOI 10.1111/j.1528-1157.1986.tb03502.x; TAYLOR J, 1978, PRELIMINARY REPORT C; TECKLEHAIMANOT R, 1990, EPILEPSY RES, V7, P230; WEGESA P, 1970, TROP GEOGR MED, V22, P345; WHO, 1981, RES PROT MEAS PREV N	34	35	36	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350			NEUROEPIDEMIOLOGY	Neuroepidemiology	OCT	2001	20	4					242	247		10.1159/000054797			6	Public, Environmental & Occupational Health; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Neurosciences & Neurology	491UN	WOS:000172128600005	11684900				2022-02-06	
J	Zec, RF; Zellers, D; Belman, J; Miller, J; Matthews, J; Ferneau-Belman, D; Robbs, R				Zec, RF; Zellers, D; Belman, J; Miller, J; Matthews, J; Ferneau-Belman, D; Robbs, R			Long-term consequences of severe closed head injury on episodic memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DEGENERATIVE CHANGES; MILD HEAD; CHILDREN; DAMAGE; RISK; PREVALENCE; STRATEGIES; MORPHOLOGY	This is the first systematic investigation of the very long-term effects of severe closed head injury (CFH) on objective measures of memory, and the first to employ both a normal control group and an 'other injury' control group consisting of spinal cord injury (SCI) patients. The CM group displayed significantly poorer performance on every memory measure, and the effect sizes were large. This impairment in episodic memory is neither due to pre-injury nor post-injury differences between CHI and normal control subjects because the same differences were found when the CHI group was compared to a group of SCI patients. The findings demonstrate severe impairment in learning and retention many years after sustaining a severe CHI, which is likely in part due to the bilateral hippocampal damage shown in neuropathological studies. This lifelong memory impairment needs to be addressed by community service programs.	So Illinois Univ, Sch Med, Ctr Alzheimer Dis & Related Disorders, Springfield, IL 62794 USA; So Illinois Univ, Sch Med, Dept Neurol, Springfield, IL 62794 USA; So Illinois Univ, Sch Med, Dept Psychiat, Springfield, IL 62794 USA; Univ Illinois, Dept Psychol, Springfield, IL USA; Illinois Sch Profess Psychol, Chicago, IL USA		Zec, RF (corresponding author), So Illinois Univ, Sch Med, Ctr Alzheimer Dis & Related Disorders, Springfield, IL 62794 USA.	rzec@siumed.edu					ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; BIGLER ED, 1987, J LEARN DISABIL, V20, P458, DOI 10.1177/002221948702000804; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BIJUR PE, 1990, PEDIATRICS, V86, P337; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CONKEY RC, 1938, ARCH PSYCHOL, V33, P232; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CULLUM CM, 1985, INT J NEUROSCI, V28, P279, DOI 10.3109/00207458508985395; DENCKER SJ, 1960, ARCH GEN PSYCHIAT, V2, P569; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DUHAIME AC, 1990, BRAIN RES, V512, P169, DOI 10.1016/0006-8993(90)91188-M; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HEATON SR, 1981, HDB CLIN NEUROPSYCHO; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HIRST W, 1988, BRAIN COGNITION, V8, P379, DOI 10.1016/0278-2626(88)90060-7; HYMAN BT, 1993, NEUROPSYCHOLOGY ALZH, P138; JENNETT WB, 1969, SPECIAL PUBLICATION, V4; Kesler SR, 2000, BRAIN INJURY, V14, P851; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1991, INTRACRANIAL PRESSUR, V8; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MARION DW, 1999, TRAUMATIC BRAIN INJU; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rey A., 1964, EXAMEN CLIN PSYCHOL; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SMITH E, 1974, J NEUROL NEUROSUR PS, V37, P719, DOI 10.1136/jnnp.37.6.719; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; WECHSLER D, 1987, MANUAL WECHSLER MEM; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177; Zec RF, 1993, NEUROPSYCHOLOGY ALZH, P3; ZEC RF, 1992, HDB HEAD TRAUMA ACUT, P219; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; [No title captured]	66	35	35	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2001	23	5					671	691		10.1076/jcen.23.5.671.1247			21	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	480RN	WOS:000171476200011	11778644				2022-02-06	
J	Bergemalm, PO; Borg, E				Bergemalm, PO; Borg, E			Long-term objective and subjective audiologic consequences of closed head injury	ACTA OTO-LARYNGOLOGICA			English	Article						closed head injury; hearing loss; progressive hearing loss; quality of life	HEARING-LOSS	During a period of 5 years, a total of 47 patients, 16-60 years of age, with major closed head injury (CHI) were admitted to 2 Swedish medical centres. Seven to 11 years after injury, 25 of them (mean age 40.8 years; range 25 59 years) were evaluated using peripheral and central auditory tests, and most of them also completed 2 questionnaires concerning self-assessed hearing ability and quality of life. Twenty-two patients did not participate in the long-term follow-up tests: 15 were excluded for medical reasons and 4 did not wish to participate; an additional 2 were impossible to trace and I had died. As many as 68% of patients (17/25) demonstrated abnormalities on 1 or more of the audiometric tests, 14 on pure-tone audiometry (p < 0.02) and/or central audiometric tests (3 on central tests only and 2 on pure-tone audiometry only). Four out of six patients with available early post-traumatic audiograms showed a significant progressive deterioration. As a group, their assessments of hearing ability and quality of life were equal to or better than those of the controls. These results may indicate that a higher priority should be given to obtaining an early audiologic evaluation of every CHI patient than is the rule today. The impact of post-traumatic progress and central lesions on social hearing at an advanced age is highlighted.	Orebro Med Ctr Hosp, Ahlsen Res Inst, SE-70185 Orebro, Sweden; Lindesberg Cty Hosp, ENT Dept, Lindesberg, Sweden		Bergemalm, PO (corresponding author), Orebro Med Ctr Hosp, Ahlsen Res Inst, SE-70185 Orebro, Sweden.						Borg E, 2000, ACTA OTO-LARYNGOL, V120, P234, DOI 10.1080/000164800750001008; BROWNING GG, 1982, ARCH OTOLARYNGOL, V108, P474; Chiappa KH, 1989, EVOKED POTENTIALS CL, P173; COCKRELL J L, 1992, Brain Injury, V6, P261, DOI 10.3109/02699059209029667; DAVIES A, 1995, HEARING ADULTS; ELWANY S, 1988, J LARYNGOL OTOL, V102, P755, DOI 10.1017/S0022215100106383; FELDMANN H, 1987, ACTA OTO-LARYNGOL, V103, P379; GRIFFITH MV, 1979, J LARYNGOL OTOL, V93, P252; GROVE WE, 1947, ANN OTO RHINOL LARYN, V56, P264; Hugosson S, 1997, INT J PEDIATR OTORHI, V42, P149, DOI 10.1016/S0165-5876(97)00129-8; KAJANDI M, 1992, SOCIALMEDICINSK TIDS, V1, P21; Korsan-Bengtsen M, 1973, Acta Otolaryngol Suppl, V310, P1; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P176; MAKISHIMA K, 1976, LARYNGOSCOPE, V86, P1303, DOI 10.1288/00005537-197609000-00002; MAKISHIMA K, 1975, LARYNGOSCOPE, V85, P1947, DOI 10.1288/00005537-197512000-00001; Mellergard P, 1998, BASIC NEUROSURGERY, P189; Musiek FE, 1995, EAR HEARING, V16, P631, DOI 10.1097/00003446-199512000-00009; PAULSEN K, 1971, Z LARYNGOL RHINO, V5, P297; Ringdahl A, 1998, BRIT J AUDIOL, V32, P375, DOI 10.3109/03005364000000089; RONNBERG J, 1989, J SPEECH HEAR RES, V32, P725, DOI 10.1044/jshr.3204.725; ROSENHALL U, 1985, SCAND AUDIOL, V14, P187, DOI 10.3109/01050398509045940; SCHWETZ F, 1987, HNO, V35, P416; Tos M., 1971, J LARYNGOL OTOL, V85, P147; Wennmo C, 1989, Acta Otolaryngol Suppl, V468, P379	25	35	37	0	1	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0001-6489			ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	SEP	2001	121	6					724	734		10.1080/00016480152583674			11	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	481ZG	WOS:000171549900010	11678172				2022-02-06	
J	Peek-Asa, C; McArthur, D; Hovda, D; Kraus, J				Peek-Asa, C; McArthur, D; Hovda, D; Kraus, J			Early predictors of mortality in penetrating compared with closed brain injury	BRAIN INJURY			English	Article							GLASGOW-COMA-SCALE; GUNSHOT WOUNDS; HEAD-INJURY; CRANIOCEREBRAL INJURY; EMERGENCY; PROGNOSIS; CIVILIANS; SEVERITY; SCORE-3; DEATH	Introduction: Although brain injury incidence rates have been decreasing, the proportion of these injuries which are penetrating has been increasing. This study compares mortality amongst persons with penetrating and closed brain injuries and explores the relationship of early predictors of mortality. Methods: The study included 795 moderately or severely brain injured individuals identified through the UCLA Brain Injury Research Centre. Logistic regression was used to predict mortality by GCS level and brain injury type, controlling for age, gender, and presence of multiple trauma. Results: Of the 795 individuals, 110 had penetrating and 685 had closed brain injury. Case fatality rates were higher for penetrating than closed injuries for all GCS, gender, age, and cause of injury categories. When controlling for GCS level at admission, age, gender, and multiple trauma, those with penetrating injuries were 6.6 (95% CI = 3.9-11.1) times more likely to die. Conclusions: As the pool of information about survival and recovery from penetrating injuries grows, decisions regarding clinical care and prevention activities can be more appropriately focused.	Univ Calif Los Angeles, Sch Publ Hlth, SCIPR, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90024 USA		Peek-Asa, C (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, SCIPR, Dept Epidemiol, 10911 Weybum Ave,Suite 200, Los Angeles, CA 90024 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; BANDAK FA, 1995, J NEUROTRAUM, V12, P645; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Fingerhut LA., 1997, INJURY CHARTBOOK HLT; Gennarelli T.A., 1996, NEUROSURGERY, P2611; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1985, NEUROSURGERY, V16, P754, DOI 10.1227/00006123-198506000-00002; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; KORDESTANI RK, 1995, NEUROSURG CLIN N AM, V6, P657; Kraus J, 2000, HEAD INJURY, P1; Kraus JF, 1993, HEAD INJURY, P1; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Marion D W, 1999, Clin Neurosurg, V45, P184; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; REYES D, 1999, MISSILE WOUNDS HEAD, V2, P257; *SAS I INC, 1997, SAS VERS 6 12; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; SNYDER HN, 1999, JUVENILE OFFENDERS V; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Winston, 1998, CHILD MALTREATMENT, V3, P116, DOI [DOI 10.1177/1077559598003002006, 10.1177/1077559598003002006]; Zafonte RD, 1997, BRAIN INJURY, V11, P403	32	35	36	0	0	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					801	810		10.1080/02699050010025768			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400005	11516348				2022-02-06	
J	Borgens, RB				Borgens, RB			Cellular engineering: Molecular repair of membranes to rescue cells of the damaged nervous system	NEUROSURGERY			English	Article						neurotrauma; poloxamers; polyethylene glycol; spinal cord injury	SPINAL-CORD-INJURY; APPLIED ELECTRIC-FIELDS; CONTROLLED-TRIAL; GUINEA-PIGS; RECOVERY; FUSION; HYBRIDIZATION; HEMISECTION; CONDUCTION; MODEL	PURPOSE: The acute administration of hydrophilic polymers (polyethylene glycol) can immediately seal nerve membranes, preventing their continuing dissolution and secondary axotomy. Polymer application can even be used to reconnect, or fuse, the proximal and distal segments of severed axons in completely transected adult mammalian spinal cord. CONCEPT: The sealing or fusion of damaged nerve membranes leads to a very rapid (minutes or hours) recovery of excitability in severely damaged nerve fibers, observed as a rapid return of nerve impulse conduction in vitro, as well as an in vivo recovery of spinal cord conduction and behavioral loss in spinal cord-injured adult guinea pigs. RATIONALE: Surfactant application produces a rapid repair of membrane breaches through mechanisms of interaction between the polymers and the aqueous phase of damaged membranes, and their ability to insert into, or seal, the hydrophobic core of the axolemma exposed by mechanical damage. DISCUSSION: This new technology applied to severe neurotrauma offers a clinically safe and practical means to rescue significant populations of spinal cord nerve fibers within 8 hours after damage-preventing their continued dissolution and secondary axotomy by secondary injury mechanisms. Application of this novel technology to other injuries to the peripheral and central nervous system is discussed, as well as a general application to soft tissue trauma.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci,Inst Appl Neurol, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci,Inst Appl Neurol, 1244 VCPR, W Lafayette, IN 47907 USA.	CPR@vet.purdue.edu					Bisby Mark A., 1995, P553; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; BLIGHT AR, 1993, ADV NEUROL, V59, P91; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1980, P NATL ACAD SCI-BIOL, V77, P1209, DOI 10.1073/pnas.77.2.1209; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1989, ELECT FIELDS VERTEBR, P71; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Carafoli E., 1976, S SOC EXP BIOL, V30, P89; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; JOHNSON AJ, 1971, BRIT J HAEMATOL, V21, P21, DOI 10.1111/j.1365-2141.1971.tb03414.x; KRAUSE TL, 1990, P NATL ACAD SCI USA, V87, P1471, DOI 10.1073/pnas.87.4.1471; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MALMGREN L, 1977, J HISTOCHEM CYTOCHEM, V25, P1280, DOI 10.1177/25.11.915248; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; PALMER JS, 1988, J UROLOGY, V159, P2136; SCHMOLKA IR, 1994, ANN NY ACAD SCI, V720, P92, DOI 10.1111/j.1749-6632.1994.tb30437.x; Sharma V, 1996, BIOPHYS J, V71, P3229, DOI 10.1016/S0006-3495(96)79516-4; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572, DOI 10.1152/jn.1996.76.3.1572; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; STYS PK, 1990, P NATL ACAD SCI USA, V87, P4212, DOI 10.1073/pnas.87.11.4212; THERIAULT E, 1988, J NEUROPHYSIOL, V60, P446, DOI 10.1152/jn.1988.60.2.446; Working PK, 1997, ACS SYM SER, V680, P45; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	48	35	37	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2001	49	2					370	378		10.1097/00006123-200108000-00021			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	457MQ	WOS:000170141700065	11504113				2022-02-06	
J	Powell, JW				Powell, JW			Cerebral concussion: Causes, effects, and risks in sports	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; head injury; injury prevention	TRAUMATIC BRAIN INJURY; HEAD-INJURY; GUIDELINES	Objective: To characterize the causes, effects, and risks associated with concussion in sports. Background. Concussion is an injury associated with sports and is most often identified with boxing, football, ice hockey, and the martial arts. In addition, recent research has shown that concussion occurs in many different sports. In the decade of the 1990s, concussion became a primary issue for discussion among the media, sports sponsors, sports medicine professionals, and athletes. Description: Concussion is an injury that results from a wide variety of mechanisms and has numerous signs and symptoms that are common to different types of injury. Continued improvement in prevention and management strategies for concussion requires a strong body of research from a variety of different disciplines. It is essential that research efforts focus on both prevention and management and that researchers and clinicians work closely toward their common goals. Conclusions/Recommendations: Until the research community is able to provide sound recommendations for the prevention and management of the concussion, the care of the injured player falls squarely on the clinician. It is important for sports medicine professionals to continue to stay up to date on the advances in understanding concussions and how to care individually for each player who sustains a concussion.	Michigan State Univ, E Lansing, MI 48824 USA		Powell, JW (corresponding author), Michigan State Univ, 40 IM Sports Circle, E Lansing, MI 48824 USA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Cantu, 1991, Adolesc Med, V2, P141; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; *COL MED SOC, 1991, GUID MAN CONC SPORTS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; HADDON W, 1972, J TRAUM, V12, P193, DOI 10.1097/00005373-197203000-00002; Jordan B. D., 1991, P MILD BRAIN INJ SPO, P43; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lowrance W., 1976, ACCEPTABLE RISK; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SPO, P2; *NAT FED STAT HIGH, 1996, 1996 HIGH SCH ATHL P, P97; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001	21	35	38	0	15	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					307	311					5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	557NC	WOS:000175913800015	12937501				2022-02-06	
J	Richards, HK; Simac, S; Piechnik, S; Pickard, JD				Richards, HK; Simac, S; Piechnik, S; Pickard, JD			Uncoupling of cerebral blood flow and metabolism after cerebral contusion in the rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						head injury; LCBF; LCGU	TRAUMATIC BRAIN INJURY; AUTORADIOGRAPHIC DETERMINATION; GLUCOSE-UTILIZATION	Positron emission tomography scans of patients with head injuries often show discrete areas of increased F-18- fluorodeoxyglucose uptake ("hot spots") when performed hours to days after the initial ictus. Using quantitative autoradiographic methods, the authors have investigated whether cerebral blood flow and glucose metabolism are uncoupled 2 hours after controlled head injury in an animal model, and whether any "hot spots" are accompanied by changes in cerebral glucose concentration. Experiments were performed on 18 anesthetized, ventilated (1.5% halothane in 2:1 nitrous oxide:oxygen) Sprague-Dawley rats weighing 300 to 330 g. A burr hole was made over the left parietal cortex, and all animals received a piston impact on the intact dura (2 mm in diameter, 2.0 m/sec, 2 mm in depth). All animals remained anesthetized and ventilated for a further 2 hours, after which quantitative autoradiography was used to determine either (1) local cerebral blood flow (LCBF) using C-14-iodoantipyrine, (2) local cerebral glucose utilization (LCGU) using C-14-deoxyglucose, or (3) local cerebral glucose content (LCGC) using C-14-methylglucose. Local CBF, LCGU, and LCGC were measured in five regions adjacent to the contusion, and values then were normalized on the contralateral cortex. Normalized LCBF, LCGU, or LCGC varied in parallel in ipsilateral cortex (no change) and in the ischemic core of the contusion (reduced). However, there were marked changes in the patterns observed in the boundary zone (within 1 mm of the contusion). In all six rats used for LCGU measurement, there were discrete areas of high metabolism, whereas in all six rats used for LCBF measurement, flow was universally depressed in the boundary zone. Of the six rats used for LCGC determination, there was a discrete area of high signal in only one. The authors conclude that there are discrete areas of uncoupling of cerebral blood flow and metabolism after head injury within 2 hours of cerebral contusion in the rat that cannot be explained by changes in cerebral glucose content in the majority of animals.	Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Cambridge Ctr Brain Repair, Cambridge CB2 2QQ, England		Richards, HK (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, Box 167, Cambridge CB2 2QQ, England.			Piechnik, Stefan K./0000-0002-0268-5221			Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERGSNEIDER M, 1999, J CEREB BLOOD FLO S1, V19, pS360; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GJEDDE A, 1983, J CEREBR BLOOD F MET, V3, P303, DOI 10.1038/jcbfm.1983.45; KELLY PAT, 1992, NEUROSCIENCE, V48, P417, DOI 10.1016/0306-4522(92)90501-R; MENON DK, 1999, J CEREB BLOOD FLO S1, V19, pS372; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; [No title captured]	10	35	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2001	21	7					779	781		10.1097/00004647-200107000-00002			3	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	448WV	WOS:000169653700002	11435789	Bronze			2022-02-06	
J	Armstead, WM				Armstead, WM			Vasopressin-induced protein kinase C-dependent superoxide generation contributes to ATP-sensitive potassium channel but not calcium-sensitive potassium channel function impairment after brain injury	STROKE			English	Article						brain injuries; cerebral circulation; free radicals; newborn; potassium channels; vasopressin	CEREBRAL BLOOD-FLOW; GENE-RELATED PEPTIDE; MISSILE HEAD-INJURY; BASILAR ARTERY; SMOOTH-MUSCLE; NEWBORN PIGS; NITRIC-OXIDE; K+ CHANNELS; RESPONSES; ACTIVATION	Background and Purpose-Pial artery dilation in response to activators of the ATP-sensitive Kt (KATP) and calcium-sensitive K+ (K-Ca) channels is impaired after fluid percussion brain injury (FPI). Vasopressin, when coadministered with the K-ATP and K-Ca channel agonists cromakalim and NS1619 in a concentration approximating that observed in cerebrospinal fluid (CSF) after FPI, blunted K-ATP and K-Ca channel-mediated vasodilation. Vasopressin also contributes to impaired K-ATP and Kc, channel vasodilation after FPI. In addition, protein kinase C (PKC) activation generates superoxide anion (O-2(-)), which in turn contributes to K-ATP channel impairment after FPI. We tested whether vasopressin generates O-2(-) in a protein kinase C (PKC)-dependent manner, which could link vasopressin release to impaired KATP and K-Ca channel-induced pial artery dilation after FPI. Methods-injury of moderate severity (1.9 to 2.1 atm) was produced with the lateral FPI technique in anesthetized newborn pigs equipped with a closed cranial window. Superoxide dismutase-inhibitable nitroblue tetrazolium (NBT) reduction was determined as an index of O-2(-) generation. Results-Under sham injury conditions, topical vasopressin (40 pg/mL, the concentration present in CSF after FPI) increased superoxide dismutase-inhibitable NET reduction from 1 +/-1 to 23 +/-4 pmol/mm(2). Chelerythrine (10(-7) mol/L, a PKC inhibitor) blunted such NET reduction (1 +/-1 to 9 +/-2 pmol/mm(2)), whereas the vasopressin antagonist 1-(beta -mercapto-beta,beta -cyclopentamethylene propionic acid)2-(o-methyl) -Tyr-arginine vasopressin (MEAVP) blocked NET reduction. Chelerythrine and MEAVP also blunted the NET reduction observed after FPI (1 +/-1 to 15 +/-1, 1 +/-1 to 4 +/-1, and 1 +/-1 to 5 +/-1 pmol/mm(2) for sham-, chelerythrine-, and MEAVP-treated animals, respectively). Under sham injury conditions, vasopressin (40 pg/mL) coadministered with cromakalim or NS1619 blunted dilation in response to these K+ channel agonists, whereas chelerythrine partially restored such impaired vasodilation for cromakalim but not NS1619. Cromakalim- and NS1619-induced pial artery dilation also was blunted after FPI. MEAVP partially protected dilation to both Kt channel agonists after FPI, whereas chelerythrine did so for only cromakalim responses (for cromakalim at 10(-8) and 10(-6) mol/L, 13 +/-1% and 23 +/-1%, 2 +/-1% and 5 +/-1%, 9 +/-1% and 15 +/-2%, and 9 +/-1% and 16 +/-2% for sham-, FPI-, FPI-MEAVP-, and FPI-chelerythrine-pretreated animals, respectively). Conclusions-These data show that vasopressin, in concentrations present in CSF after FPI, increased O-2(-) production in a PKC-dependent manner and contributes to such production after FPI. These data show that vasopressin contributes to K-ATP but not K-Ca channel function impairment in a PKC-dependent manner after FPI and suggest that vasopressin contributes to K-Ca, channel function impairment after FPI via a mechanism independent of PKC activation.	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA		Armstead, WM (corresponding author), Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.	armsteaw@mail.med.upenn.edu					ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; Armstead WM, 1996, J NEUROTRAUM, V13, P115, DOI 10.1089/neu.1996.13.115; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, STROKE, V30, P153, DOI 10.1161/01.STR.30.1.153; Armstead WM, 1997, BRAIN RES, V747, P252, DOI 10.1016/S0006-8993(96)01284-X; ARMSTEAD WM, 1990, AM J PHYSIOL, V258, pH408, DOI 10.1152/ajpheart.1990.258.2.H408; ARMSTEAD WM, 1989, CIRC RES, V64, P136, DOI 10.1161/01.RES.64.1.136; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423, DOI 10.1152/ajpheart.1996.270.2.H423; ARMSTEAD WM, 1992, J PHARMACOL EXP THER, V260, P1107; Armstead WM, 2000, AM J PHYSIOL-HEART C, V279, pH2678, DOI 10.1152/ajpheart.2000.279.6.H2678; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faraci FM, 1998, PHYSIOL REV, V78, P53, DOI 10.1152/physrev.1998.78.1.53; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Holland M, 1996, BRIT J PHARMACOL, V117, P119, DOI 10.1111/j.1476-5381.1996.tb15163.x; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KITAZONO T, 1993, HYPERTENSION, V22, P677, DOI 10.1161/01.HYP.22.5.677; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581, DOI 10.1152/ajpheart.1993.265.2.H581; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAYHAN WG, 1993, AM J PHYSIOL, V265, pH152, DOI 10.1152/ajpheart.1993.265.1.H152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; SAITO A, 1989, J PHARMACOL EXP THER, V248, P455; Salvucci A, 2000, BRAIN RES, V887, P406, DOI 10.1016/S0006-8993(00)03079-1; SHANKAR V, 1995, AM J PHYSIOL-HEART C, V269, pH997, DOI 10.1152/ajpheart.1995.269.3.H997; Tepas J J 3rd, 1995, Semin Pediatr Surg, V4, P120; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; WAKATSUKI T, 1992, AM J PHYSIOL, V263, pH491, DOI 10.1152/ajpheart.1992.263.2.H491; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; WEI EP, 1985, AM J PHYSIOL, V248, pH157, DOI 10.1152/ajpheart.1985.248.2.H157; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	45	35	38	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUN	2001	32	6					1408	1414		10.1161/01.STR.32.6.1408			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	440PZ	WOS:000169184600034	11387506	Bronze, Green Submitted			2022-02-06	
J	Pineda, JA; Aono, M; Sheng, HX; Lynch, J; Wellons, JC; Laskowitz, DT; Pearlstein, RD; Bowler, R; Crapo, J; Warner, DS				Pineda, JA; Aono, M; Sheng, HX; Lynch, J; Wellons, JC; Laskowitz, DT; Pearlstein, RD; Bowler, R; Crapo, J; Warner, DS			Extracellular superoxide dismutase overexpression improves behavioral outcome from closed head injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						behavior; brain; extracellular superoxide dismutase; histology; mouse; trauma	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; HEPARIN-BINDING DOMAIN; HUMAN CELL-LINES; OXIDATIVE STRESS; TRANSGENIC MICE; NITRIC-OXIDE; INCREASED RESISTANCE; GENERATION; RAT	Oxidative stress is known to play an important role in the response of brain to traumatic insults. We tested the hypothesis that increased extracellular superoxide dismutase (EC-SOD) expression can reduce injury in a mouse model of closed head injury. Neurologic, cognitive, and histologic outcomes were compared between transgenic mice exhibiting a fivefold increase in EC-SOD activity and wild-type littermate controls. Severe or moderate transcranial impact was induced in anesthetized and physiologically controlled animals. After severe impact, transgenic mice had better neurological outcome at 24 hr postinjury (p = 0.038), Brain water content was increased, but there was no difference between groups. Moderate impact resulted in predominantly mild neurologic deficits in both groups at both 24 hr and 14 days postinjury, Morris water maze performance, testing cognitive function at 14-17 days after trauma, was better in EC-SOD overexpressors (p = 0.018), No differences were observed between groups for histologic damage in hippocampal CA1 and CA3, We conclude that EC-SOD has a beneficial effect on behavioral outcome after both severe and moderate closed head injury in mice. Because EC-SOD is believed to be predominantly located in the extracellular space, these data implicate an adverse effect of extracellular superoxide anion on outcome from closed head injury.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Pediat Crit Care, Durham, NC 27710 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA		Warner, DS (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	warne002@mc.duke.edu	Pineda, Jose/W-2806-2019; Bowler, Russell P/J-8283-2015	Bowler, Russell P/0000-0003-4651-363X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL031992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038944] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01 HL 31992] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38944] Funding Source: Medline		BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Crow JP, 1996, ADV EXP MED BIOL, V387, P147; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1999, ANN NY ACAD SCI, V860, P462; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; HOFFSTEIN ST, 1985, INFLAMMATION, V9, P425, DOI 10.1007/BF00916342; KINNULA VL, 1995, LAB INVEST, V73, P3; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Levin ED, 1998, BEHAV GENET, V28, P381, DOI 10.1023/A:1021673703129; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; MARKLUND S, 1980, ACTA PHYSIOL SCAND, P19; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; McIntosh TK, 1996, LAB INVEST, V74, P315; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murakami K, 1998, J NEUROSCI, V18, P205; Murakami K, 1997, STROKE, V28, P1797, DOI 10.1161/01.STR.28.9.1797; OURY TD, 1993, J BIOL CHEM, V268, P15394; Oury TD, 1999, BRAIN RES, V850, P96, DOI 10.1016/S0006-8993(99)02103-4; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; Sankarapandi S, 1998, ARCH BIOCHEM BIOPHYS, V353, P312, DOI 10.1006/abbi.1998.0658; Sheng H, 1999, NEUROSCIENCE, V88, P185, DOI 10.1016/S0306-4522(98)00208-5; Sheng H, 2000, EXP NEUROL, V163, P392, DOI 10.1006/exnr.2000.7363; Sheng HX, 1999, NEUROSCI LETT, V267, P13, DOI 10.1016/S0304-3940(99)00316-X; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SINSON G, 1995, J NEUROCHEM, V65, P2209; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thiels E, 2000, J NEUROSCI, V20, P7631; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	39	35	36	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2001	18	6					625	634		10.1089/089771501750291864			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	445ZQ	WOS:000169488800006	11437085				2022-02-06	
J	Zwienenberg, M; Gong, QZ; Berman, RF; Muizelaar, JP; Lyeth, BG				Zwienenberg, M; Gong, QZ; Berman, RF; Muizelaar, JP; Lyeth, BG			The effect of groups II and III metabotropic glutamate receptor activation on neuronal injury in a rodent model of traumatic brain injury	NEUROSURGERY			English	Article						fluoro-jade; metabotropic glutamate receptor; rat; traumatic brain injury	AGONIST DCG-IV; FLUORO-JADE; CORTICAL-NEURONS; AMINO-ACIDS; RAT-BRAIN; DEGENERATION; HIPPOCAMPUS; SUBTYPES; POTENT; DEATH	OBJECTIVE: The role of metabotropic glutamate receptor activation after traumatic brain injury (TBI) is not well understood. In vitro studies suggest that activation of Groups II and III metabotropic glutamate receptors may provide some degree of neuroprotection and may be potential targets for the development of therapeutic strategies. Thus, we examined the effects of Group II and Group III selective agonists on neuronal degeneration after in vivo TBI. METHODS: fifty male Sprague-Dawley rats were subjected to lateral fluid percussion brain injury immediately followed by an intracranial injection of 2-(2',3')-dicarboxycyclopropylglycine (DCG-IV) (Group II) or (R,S)-4-phosphonophenylglycine (Group III) in the CA2 and CA3 areas of the hippocampus. DCG-IV was injected at doses of 20 fmol, 100 fmol, and 500 fmol, and (R,S)-4-phosphonophenylglycine was injected at 8 nmol, 40 nmol, and 200 nmol. Vehicle injection control groups were used for comparison with each drug group. All animals were killed 24 hours after TBI was induced. Four 50-mum brain sections were obtained from each animal and stained for degenerating neurons with the fluorochrome Fluoro-Jade. Two independent, blinded investigators counted the number of degenerating (Fluoro-Jade-positive) neurons in the CA2 and CA3 areas of the hippocampus of each brain section. RESULTS: Compared with vehicle, the 500-fmol dose of DCG-IV significantly reduced the number of Fluoro-Jade-positive degenerating neurons (P < 0.001). Lower doses of DCG-IV were associated with a decreased but not statistically significant number of Fluoro-Jade-positive neurons. In contrast, (R,S)-4-phosphonophenylglycine had no significant effect on the number of degenerating neurons. CONCLUSION: Administration of selective Group II metabotropic glutamate receptor agonists protects neurons against in vive TBI. These receptors may thus be a promising target for future neuroprotective drugs.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995] Funding Source: Medline		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Blumcke I, 1996, BRAIN RES, V736, P217; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Bradley SR, 1996, J NEUROSCI, V16, P2044; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Cartmell J, 1998, BRIT J PHARMACOL, V123, P497, DOI 10.1038/sj.bjp.0701647; Collins J G, 1990, Vital Health Stat 10, P1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Gasparini F, 1999, J PHARMACOL EXP THER, V289, P1678; GLAUM SR, 1994, METABOTROPIC GLUTAMA, P147; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALLAM TM, 1999, J NEUROTRAUM, V16, P1000; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Johnson BG, 1999, NEUROPHARMACOLOGY, V38, P1519, DOI 10.1016/S0028-3908(99)00053-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kokaia Z, 1998, EXP NEUROL, V154, P289, DOI 10.1006/exnr.1998.6888; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Miyamoto M, 1997, NEUROSCIENCE, V77, P131, DOI 10.1016/S0306-4522(96)00442-3; Monn JA, 1997, J MED CHEM, V40, P528, DOI 10.1021/jm9606756; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; WILSCH VW, 1994, EUR J PHARMACOL, V262, P287, DOI 10.1016/0014-2999(94)90743-9	46	35	36	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2001	48	5					1119	1126		10.1097/00006123-200105000-00031			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	424GB	WOS:000168223000078	11334279				2022-02-06	
J	Zafonte, RD; Lexell, J; Cullen, N				Zafonte, RD; Lexell, J; Cullen, N			Possible applications for dopaminergic agents following traumatic brain injury: Part 2	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							EARLY PARKINSONS-DISEASE; DOUBLE-BLIND; PRAMIPEXOLE; AGONIST; AMANTADINE; PLACEBO; ROPINIROLE; TOLCAPONE; THERAPY; STATE		Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; UPMC Hlth Syst, Pittsburgh, PA USA; Lund Univ, Brain Injury Unit, Lund, Sweden; Univ Toronto, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada		Zafonte, RD (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Lillian Kaufmann Bldg,3471 5th Ave,Suite 901, Pittsburgh, PA 15213 USA.			Lexell, Jan/0000-0001-5294-3332; Cullen, Nora/0000-0001-6359-9418			ACTON G, 1989, BRIT J CLIN PHARMACO, V28, P435, DOI 10.1111/j.1365-2125.1989.tb03524.x; Adler CH, 1997, NEUROLOGY, V49, P393, DOI 10.1212/WNL.49.2.393; ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; Becker PM, 1998, NEUROLOGY, V51, P1221, DOI 10.1212/WNL.51.4.1221; CHANDLER M, 1988, BRAIN INJURY, V4, P309; Corrigan MH, 2000, DEPRESS ANXIETY, V11, P58, DOI 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Jungerman T, 1999, J CLIN PSYCHOPHARM, V19, P522, DOI 10.1097/00004714-199912000-00006; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kunig G, 1999, CLIN NEUROPHARMACOL, V22, P301; Kuzel MD, 1999, AM J HEALTH-SYST PH, V56, P217, DOI 10.1093/ajhp/56.3.217; Larsen JP, 1999, EUR J NEUROL, V6, P539, DOI 10.1046/j.1468-1331.1999.650539.x; Ling ZD, 1999, J PHARMACOL EXP THER, V289, P202; Maj J, 1997, J NEURAL TRANSM, V104, P525, DOI 10.1007/BF01277669; Olanow CW, 2000, ARCH NEUROL-CHICAGO, V57, P263, DOI 10.1001/archneur.57.2.263; Rajput AH, 1997, NEUROLOGY, V49, P1066, DOI 10.1212/WNL.49.4.1066; Rinne UK, 1998, NEUROLOGY, V51, P1309, DOI 10.1212/WNL.51.5.1309; Schneider WN, 1999, BRAIN INJURY, V13, P863; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Sporn J, 2000, Ann Clin Psychiatry, V12, P137; WELLER M, 1992, MED HYPOTHESES, V38, P329, DOI 10.1016/0306-9877(92)90027-A; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zou LL, 2000, NEUROSCI LETT, V281, P167, DOI 10.1016/S0304-3940(00)00853-3	23	35	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					112	116		10.1097/00001199-200102000-00014			5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100016	11277855				2022-02-06	
J	Mancini, J; Lethel, V; Hugonenq, C; Chabrol, B				Mancini, J; Lethel, V; Hugonenq, C; Chabrol, B			Brain injuries in early foetal life: consequences for brain development	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							NEURONAL MIGRATION; MATERNAL TRAUMA; EXPOSURE; LESIONS; INFANTS; DAMAGE	Learning disability and cerebral palsy are often related to factors present before birth. We report three patients (two with schizencephaly, one with unilateral cerebellar agenesis) in whom the timing of an insult to the foetus was known. In the first case, the mother had a trauma at 16 weeks of pregnancy and schizencephaly was discovered in the male infant associated with a left hemiplegia. In the second child, amniocentesis performed at 16 weeks into pregnancy may have been responsible for the same cortical anomaly. In the third case, sequential foetal echographies clearly demonstrated that an apparent unilateral cerebellar agenesis was related to an haemorrhagic event secondary to cerebellar trauma that occurred at 19 weeks of pregnancy, It is suggested that these brain malformations are related to an ischemic mechanism or a traumatic event in foetal life.	Paediat Univ Hosp, Dept Paediat Neurol, Marseille, France		Mancini, J (corresponding author), Paediat Univ Hosp, Dept Paediat Neurol, Marseille, France.						Baethmann M, 1996, ACTA PAEDIATR, V85, P1331, DOI 10.1111/j.1651-2227.1996.tb13920.x; BURNELLI S, 1996, NAT GENET, V12, P94; COHEN M, 1994, DEV MED CHILD NEUROL, V36, P263; des Portes V, 1998, CELL, V92, P51; EATON DGM, 1991, BRIT J OBSTET GYNAEC, V98, P1292, DOI 10.1111/j.1471-0528.1991.tb15406.x; ELLER KM, 1995, OBSTET GYNECOL, V85, P865, DOI 10.1016/0029-7844(94)00315-5; FERRIE CD, 1995, NEUROLOGY, V45, P150, DOI 10.1212/WNL.45.1.150; KOMARNISKI CA, 1990, J ULTRAS MED, V9, P305; LANDRIEU P, 1994, CLIN NEUROPATHOL, V13, P192; MARRET S, 1995, J NEUROPATH EXP NEUR, V54, P358, DOI 10.1097/00005072-199505000-00009; Mercuri E, 1997, PEDIATR RADIOL, V27, P139, DOI 10.1007/s002470050085; PATI S, 1994, REPROD TOXICOL, V8, P115, DOI 10.1016/0890-6238(94)90018-3; YAKOVLEV PI, 1946, J NEUROPATH EXP NEUR, V5, P169, DOI 10.1097/00005072-194607000-00001; YAKOVLEV PI, 1946, J NEUROPATH EXP NEUR, V5, P116, DOI 10.1097/00005072-194604000-00003	14	35	35	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JAN	2001	43	1					52	55		10.1017/S0012162201000081			4	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	394EA	WOS:000166510100008	11201424				2022-02-06	
J	Kaipio, ML; Cheour, M; Ceponiene, R; Ohman, J; Alku, P; Naatanen, R				Kaipio, ML; Cheour, M; Ceponiene, R; Ohman, J; Alku, P; Naatanen, R			Increased distractibility in closed head injury as revealed by event-related potentials	NEUROREPORT			English	Article						attention; audition; closed head injury; distractibility; event-related brain potential (ERP); mismatch negativity (MMN); P3a	PHONEME REPRESENTATIONS; AUDITORY-CORTEX; FRONTAL-CORTEX; BRAIN; STIMULI; LESIONS	The present study demonstrates that event-related potentials (ERPs) may be used to reveal increased distractibility as a physiologically measurable condition after chronic closed head injury (CHI). ERPs were recorded from 17 chronic CHI subjects and from 17 healthy age-matched controls. Auditory stimuli consisted of variants of vowel /(o) over bar/ (standards) occasionally replaced by an /(e) over bar/ vowel (deviant). Subjects were instructed to ignore auditory stimuli while watching a silent movie. In the constant-standard condition, the vowel /(o) over bar/ served as the standard and vowel /(e) over bar/ as the deviant. In the roving-standard condition, four variants of the vowel /(o) over bar/ were randomly used as standards in the same stimulus block. None of the stimuli were prototypes in the subjects' mother tongues. Deviant stimuli elicited significant MMNs in both groups in both conditions, which were significantly smaller in the roving-standard than in the constant-standard condition. CHI victims showed significantly larger P3a amplitudes than controls in both conditions, apparently reflecting their enhanced involuntary sifting of attention and thus their increased distractibility. NeuroReport 11:1463-1468 (C) 2000 Lippincott Williams & Wilkins.	Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Neurosurg, SF-00260 Helsinki, Finland; Aalto Univ, Acoust Lab, FIN-02015 Helsinki, Finland		Kaipio, ML (corresponding author), Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, POB 13, FIN-00014 Helsinki, Finland.		Hari, Riitta K/J-1880-2012; Alku, Paavo/E-2400-2012	Hari, Riitta K/0000-0002-3142-2703; Ohman, Juha/0000-0002-6592-1367; Alku, Paavo/0000-0002-8173-9418			Alain C, 1998, BRAIN RES, V812, P23, DOI 10.1016/S0006-8993(98)00851-8; Alho K, 1998, PSYCHOPHYSIOLOGY, V35, P211, DOI 10.1111/1469-8986.3520211; ALHO K, 1994, ELECTROEN CLIN NEURO, V91, P353, DOI 10.1016/0013-4694(94)00173-1; Alku P, 1999, CLIN NEUROPHYSIOL, V110, P1329, DOI 10.1016/S1388-2457(99)00088-7; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; Cheour M, 1998, NAT NEUROSCI, V1, P351, DOI 10.1038/1561; Damasio A., 1994, DESCARTES ERROR EMOT; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; Naatanen R, 1997, NATURE, V385, P432, DOI 10.1038/385432a0; NAATANEN R, 1995, HDB NEUROPSYCHOLOGY, V10, P75; Naatanen R, 1992, ATTENTION BRAIN FUNC; NELSON C, 1993, J EXP NEUROPSYCHOLOG, V19, P909; PAAVILAINEN P, 1991, ELECTROEN CLIN NEURO, V78, P466, DOI 10.1016/0013-4694(91)90064-B; Pearl GS, 1998, CLIN LAB MED, V18, P39; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; Scherg M, 1989, J Cogn Neurosci, V1, P336, DOI 10.1162/jocn.1989.1.4.336; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY, P63; Zampolini M, 1997, EUR J NEUROL, V4, P246, DOI 10.1111/j.1468-1331.1997.tb00343.x	25	35	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	MAY 15	2000	11	7					1463	1468					6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	316WN	WOS:000087191200022	10841358				2022-02-06	
J	Wang, MY; Griffith, P; Sterling, J; McComb, JG; Levy, ML				Wang, MY; Griffith, P; Sterling, J; McComb, JG; Levy, ML			A prospective population-based study of pediatric trauma patients with mild alterations in consciousness (Glasgow Coma Scale Score of 13-14)	NEUROSURGERY			English	Article						closed head trauma; Glasgow Coma Scale; pediatric head trauma	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; TRIAGE CRITERIA; CT SCANS; EMERGENCY; CHILDREN; RISK	OBJECTIVE: Considerable controversy surrounds the appropriate evaluation of children with mild alterations in consciousness after closed head trauma (Glasgow Coma Scale [GCS] score of 13-14). The objective of the current study was to determine the incidence of intracranial lesions in pediatric patients with a field CCS score of 13 or 14 after closed head injuries. METHODS: The current study is a population-based, multicenter prospective study of all patients to whom emergency medical services responded during a 12-month period. The setting was urban Los Angeles County, encompassing a patient population of 2.3 million children, 13 designated trauma centers, and 94 receiving hospitals. RESULTS: In the pediatric age group (<15 yr old), 8488 patients were transported by emergency medical services for injuries. Of these, 209 had a documented field CCS score of 13 or 14. One hundred fifty-seven patients were taken to trauma centers, and 135 (86%) underwent computed tomography. Forty-three patients (27.4%) had abnormal results on computed tomographic scans, 30 (19.1%) had an intracranial hemorrhage, and 5 required an operative neurosurgical procedure for hematoma evacuation. Positive and negative predictive values of deteriorating mental status (0.500 and 0.844, respectively), loss of consciousness (0.173 and 0.809), cranial fracture (0.483 and 0.875, and extracranial injuries (0.205 and 0.814) were poor predictors of intracranial hemorrhage. CONCLUSION: Pediatric patients who have mild alterations in consciousness in the field have a significant incidence of intracranial injury. The great majority of these patients will not require operative intervention, but the implications of missing these hemorrhages can be severe for this subgroup of head-injured patients. Because clinical criteria and cranial x-rays are poor predictors of intracranial hemorrhage, it is recommended that all children with a GCS score of 13 or 14 routinely undergo screening via non-contrast-enhanced computed tomography.	Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Pediat Neurosurg, Los Angeles, CA 90027 USA; Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Trauma Program, Los Angeles, CA 90027 USA		Levy, ML (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Pediat Neurosurg, Suite 906,1300 N Vermont Ave, Los Angeles, CA 90027 USA.						Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; BUNTAIN WL, 1987, ADV TRAUMA, V2, P43; COOPER PR, 1983, NEUROSURGERY, V13, P136, DOI 10.1227/00006123-198308000-00005; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HECKMAN JD, 1992, EMERGENCY CARE TRANS, P322; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Johnson DL, 1996, PEDIATR NEUROSURG, V25, P309, DOI 10.1159/000121145; Kissoon N, 1996, PEDIATR EMERG CARE, V12, P272, DOI 10.1097/00006565-199608000-00009; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Moront ML, 1996, J PEDIATR SURG, V31, P1183, DOI 10.1016/S0022-3468(96)90114-1; Phillips S, 1996, PEDIATR EMERG CARE, V12, P394, DOI 10.1097/00006565-199612000-00002; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RIVARA F, 1987, PEDIATRICS, V80, P579; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SIMMONS E, 1995, ANN EMERG MED, V26, P461, DOI 10.1016/S0196-0644(95)70115-X; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE G, 1974, LANCET, V2, P81	28	35	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2000	46	5					1093	1099		10.1097/00006123-200005000-00014			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	310JK	WOS:000086822600029	10807241				2022-02-06	
J	Mattiasson, GJ; Philips, MF; Tomasevic, G; Johansson, BB; Wieloch, T; McIntosh, TK				Mattiasson, GJ; Philips, MF; Tomasevic, G; Johansson, BB; Wieloch, T; McIntosh, TK			The rotating pole test: evaluation of its effectiveness in assessing functional motor deficits following experimental head injury in the rat	JOURNAL OF NEUROSCIENCE METHODS			English	Article						traumatic brain injury; lateral fluid percussion; neurological motor deficit; outcome measure; behavior; rat	EXPERIMENTAL BRAIN INJURY; FLUID-PERCUSSION MODEL; GLASGOW OUTCOME SCALE; ENRICHED ENVIRONMENT; CEREBRAL INFARCTION; DAMAGE; GROWTH; DYSFUNCTION; ANTAGONIST; APOPTOSIS	Neurological motor dysfunction is often an integral component of the neurological sequelae of traumatic brain injury (TBI). In experimental TBI, neurological motor testing is an outcome measure used to monitor severity of injury, and the response to treatment. This study evaluates the effectiveness and sensitivity of the rotating pole test (RP) to characterize and evaluate the temporal course of motor deficits after lateral fluid percussion (FP) injury to the rat brain. The results are compared with the previously characterized and widely used composite neuroscore of motor function (NS). The animals were required to walk across an elevated wooden pole that was either stationary or rotating to left or right directions at different speeds. Male Wistar rats underwent lateral FP injury of moderate severity (mean 2.4 atm, n = 9) or sham surgery (n = 9), and were tested at 48 h and 7 days post-injury using the NS and RP. The results of the NS directly correlated to the results of the RP, showing a significant injury effect at both 48 h and 7 days. This is the first study to show that the RP-test detects neurological motor deficits after lateral FP injury, and suggests that this technique is a reliable behavioral tool for evaluating neurological motor function in the acute period after experimental TBI. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Brain Res, S-22185 Lund, Sweden; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Neurol, S-22185 Lund, Sweden		Mattiasson, GJ (corresponding author), Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Brain Res, S-22185 Lund, Sweden.			Wieloch, Tadeusz/0000-0002-7669-2520			ALTMAN DG, 1993, PRACTICAL STAT MED R, P210; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Conti AC, 1998, J NEUROSCI, V18, P5663; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRABOWSKI M, 1995, EXP NEUROL, V133, P96, DOI 10.1006/exnr.1995.1011; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS SP, 1975, AM J ANAT, V143, P1, DOI 10.1002/aja.1001430102; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; JONES TA, 1994, J NEUROSCI, V14, P2140; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KOLB B, 1983, CAN J PSYCHOL, V37, P211, DOI 10.1037/h0080724; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PAXINOS G, 1995, RAT NERVOUS SYSTEM, P632; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; RINK A, 1995, AM J PATHOL, V147, P1575; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SULLIVAN SJ, 1994, BRAIN INJURY, V8, P613, DOI 10.3109/02699059409151014; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	41	35	36	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	JAN 31	2000	95	1					75	82		10.1016/S0165-0270(99)00162-4			8	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	284NN	WOS:000085338600008	10776817				2022-02-06	
J	Reinvang, I; Nordby, H; Nielsen, CS				Reinvang, I; Nordby, H; Nielsen, CS			Information processing deficits in head injury assessed with ERPs reflecting early and late processing stages	NEUROPSYCHOLOGIA			English	Article						P3; Nl; attention; oddball paradigm	EVOKED-POTENTIAL FINDINGS; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN INJURY; AUDITORY ODDBALL TASK; ATTENTION; ATTENUATION; WAVE; EEG	ERPs provide informative measures of slowed information processing in head injury. While several studies have reported changes in long latency ERPs (N2, P3) in head injury, the data on early ERP components related to attention selection are inconclusive. The problem may be partly methodological because the standard oddball paradigm does not give an adequate basis for discriminating components contributing to the N1 and P2 waveforms. Following a suggestion by Garcia-Larrea et al. [10: Garcia-Larrea L, Lukasziewicz A-C, Maugiere F. Revisiting the oddball paradigm. Non-target vs neutral stimuli and the evaluation of ERP attention effects. Neuropsychologia 1992;30:723-741] we used an extended oddball paradigm to study measures of early processing (N1-average, P250) as well as conventional cognitive ERPs (N1, P2, N2, P3) in a group of head injured patients and controls. We found evidence of deficits in early processing of neutral and non-target stimuli in the patient group, and interpret the findings as an indication that the patients are less efficient in terminating processing of irrelevant stimuli. The results further indicate that processing deviations affect both target and non-target stimuli in the oddball paradigm and thus the allocation of attention in the task as a whole. (C) 2000 Elsevier Science Ltd. All rights reserved.	Univ Oslo, Dept Psychol, N-0317 Oslo, Norway; Univ Bergen, Dept Med & Biol Psychol, Bergen, Norway		Reinvang, I (corresponding author), Univ Oslo, Dept Psychol, Box 1094 Blindern, N-0317 Oslo, Norway.						ALHO K, 1992, PSYCHOPHYSIOLOGY, V29, P247, DOI 10.1111/j.1469-8986.1992.tb01695.x; BARIBEAU J, 1990, PSYCHOPHYSIOLOGICAL, P161; CAMPBELL KB, 1995, EVENT RELATED POTENT, V10, P269; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P16, DOI 10.1097/00001199-199606000-00005; GARCIALARREA L, 1992, NEUROPSYCHOLOGIA, V30, P723, DOI 10.1016/0028-3932(92)90042-K; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; KNIGHT RT, 1984, ELECTROENCEPHALOGRAP, V50, P112; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; NIELSEN CS, 1997, READPEAK DATA PROGRA; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Reinvang I, 1998, J CLIN EXP NEUROPSYC, V20, P885, DOI 10.1076/jcen.20.6.885.1106; REINVANG I, 1995, J INT NEUROPSYCH SOC, V1, P357; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1992, HDB NEUROPSYCHOLOGIC, P393; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6; [No title captured]	30	35	38	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2000	38	7					995	1005		10.1016/S0028-3932(99)00153-0			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	316HC	WOS:000087160700010	10775710				2022-02-06	
J	Schmidt, RH; Scholten, KJ; Maughan, PH				Schmidt, RH; Scholten, KJ; Maughan, PH			Time course for recovery of water maze performance and central cholinergic innervation after fluid percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic; fluid percussion injury; neural plasticity; traumatic brain injury; water maze	TRAUMATIC BRAIN INJURY; CONTROLLED CORTICAL IMPACT; REDUCED EVOKED RELEASE; CLOSED-HEAD INJURY; COGNITIVE IMPAIRMENT; ACETYLCHOLINE; HIPPOCAMPAL; RATS; DEFICITS; MEMORY	This study further investigates the possible connection between postconcussive cognitive impairment and damage to forebrain cholinergic innervation. Moderate parasagittal fluid percussion injury was delivered to adult male rats. Water maze performance and synaptosomal choline uptake was measured at various times following injury. Water maze learning was severely impaired between 1 and 5 weeks, but recovered to normal by 10 weeks. Synaptosomal choline uptake was significantly decreased by 15-27% in the ipsilateral hippocampus and parietal cortex 3 and 7 days following injury, but not by 3 weeks or thereafter. Choline acetyltransferase was also significantly decreased in the ipsilateral cortex at 3 and 7 days with subsequent recovery. This study shoes that parasagittal fluid percussion injury causes significant impairment in water maze learning and ipsilateral forebrain cholinergic innervation. Both of these parameters recover spontaneously, but with different time courses.	Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA		Schmidt, RH (corresponding author), Univ Utah, Dept Neurosurg, 50 N Med Dr, Salt Lake City, UT 84132 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001866] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01866] Funding Source: Medline		BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; DACY RG, 1993, HEAD INJURY, P159; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DESNER RP, 1988, NEUROBIOL AGING, V9, P609; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; GAGE FH, 1986, J NEUROSCI, V6, P2837; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GRAFDY MS, 1999, J NEUROTRAUM, V16, P13; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; JOPE RS, 1979, BRAIN RES REV, V1, P313, DOI 10.1016/0165-0173(79)90009-2; LAPCHAK PA, 1988, J NEUROCHEM, V50, P68; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin HS., 1982, NEUROBEHAVIORAL CONS; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; Muir JL, 1997, PHARMACOL BIOCHEM BE, V56, P687, DOI 10.1016/S0091-3057(96)00431-5; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Pike BR, 1997, J NEUROTRAUM, V14, P897, DOI 10.1089/neu.1997.14.897; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SHAPIRO SM, 1993, MINOR HEAD TRAUMA, P1; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259	41	35	41	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1139	1147		10.1089/neu.1999.16.1139			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400002	10619193				2022-02-06	
J	Leder, SB				Leder, SB			Fiberoptic endoscopic evaluation of swallowing in patients with acute traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aspiration; deglutition; deglutition disorders; dysphagia; fiberoptic endoscopic evaluation of swallowing; silent aspiration; traumatic brain injury	ASPIRATION; DYSPHAGIA	Dysphagia and aspiration in intensive care unit patients with acute traumatic brain injury (TBI) is a frequent and potentially life-threatening problem. Any diagnostic technique used with this population, therefore, must be able to be performed in a timely and efficient manner while providing objective information on the nature of the swallowing problem. The purpose of the present study was to investigate the utility of using the fiberoptic endoscopic evaluation of swallowing (FEES) technique to diagnosis pharyngeal stage dysphagia and determine aspiration status in patients who presented with acute TBI. A total of 47 subjects were assessed with FEES. Thirty of 47 (64%) subjects swallowed successfully and were able to take an oral diet: 2 of 30 (7%) thickened liquids and puree consistencies, 8 of 30 (27%) a soft diet, and 20 of 30 (67%) a regular diet. Seventeen of 47 (36%) subjects exhibited pharyngeal stage dysphagia with aspiration and were not permitted an oral diet based on objective results provided by FEES. Of the 17 subjects who aspirated, 9 of 17 (53%) exhibited silent aspiration. Younger subjects (mean age 34 years, 3 months) aspirated significantly less often than older subjects (mean age 51 years, 8 months). No significant age difference was observed for gender or between overt and silent aspirators. It was concluded that FEES is an objective and sensitive tool that can be used successfully to diagnose pharyngeal stage dysphagia, determine aspiration status. and make recommendations for oral or nonoral feeding in patients with acute TBI.	Yale Univ, Sch Med, Dept Surg, Otolaryngol Sect, New Haven, CT 06510 USA		Leder, SB (corresponding author), Yale New Haven Hosp, Otolaryngol Sect, Commun Disorders Ctr, 20 York St,YPB-468, New Haven, CT 06514 USA.						Bastian Robert W., 1993, Dysphagia, V8, P359, DOI 10.1007/BF01321780; BASTIAN RW, 1991, OTOLARYNG HEAD NECK, V104, P339, DOI 10.1177/019459989110400309; ELPERN EH, 1994, CHEST, V105, P563, DOI 10.1378/chest.105.2.563; Kidder Thomas M., 1994, Dysphagia, V9, P256, DOI 10.1007/BF00301919; Langmore S E, 1988, Dysphagia, V2, P216, DOI 10.1007/BF02414429; LANGMORE SE, 1991, ANN OTO RHINOL LARYN, V100, P678; LANGMORE SE, 1996, DEGLUTITION ITS DISO; Leder SB, 1998, DYSPHAGIA, V13, P19, DOI 10.1007/PL00009544; Leder SB, 1998, DYSPHAGIA, V13, P208, DOI 10.1007/PL00009573; Leder SB, 1997, J SPEECH LANG HEAR R, V40, P1352, DOI 10.1044/jslhr.4006.1352; Leder SB, 1998, ARCH PHYS MED REHAB, V79, P1264, DOI 10.1016/S0003-9993(98)90273-8; LINDEN P, 1983, ARCH PHYS MED REHAB, V64, P281; Logemann JA, 1983, EVALUATION TREATMENT; Murray J, 1996, DYSPHAGIA, V11, P99, DOI 10.1007/BF00417898; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; TEASDALE G, 1974, LANCET, V2, P81; YLVISAKER M, 1986, MANAGEMENT HEAD INJU	17	35	37	0	8	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					448	453		10.1097/00001199-199910000-00005			6	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600005	10653940				2022-02-06	
J	Sleigh, JW; Havill, JH; Frith, R; Kersel, D; Marsh, NV; Ulyatt, D				Sleigh, JW; Havill, JH; Frith, R; Kersel, D; Marsh, NV; Ulyatt, D			Somatosensory evoked potentials in severe traumatic brain injury: a blinded study	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; evoked potential; coma; outcome prediction	HEAD-INJURY; PREDICTION; CHILDREN	Object. Beginning in 1979, the results of somatosensory evoked potential (SSEP) monitoring have been used to predict outcome in patients who have suffered severe brain trauma. The data indicate that if the cortical components of the SSEPs were bilaterally absent, the outcome was always death or a vegetative state, but previous studies have not been blinded. The aims of this study were to correlate the results of SSEP recordings with the outcome in a prospectively blinded manner and to assess whether monitoring of SSEPs was a useful adjunct to clinical judgment in the prediction of outcome. Methods. The authors studied 105 severely head injured patients (median Glasgow Coma Scale score of 6) who were admitted to the Waikato Intensive Care Unit. The upper limb SSEPs were classified according to the central conduction time (CCT) as normal, of increased latency, or absent. The outcome as assessed using the Glasgow Outcome Scale (GOS) score was evaluated 12 months after the injury. Conclusions. Of 51 patients with a bilaterally normal CCT, 29 (57%) had a good outcome (GOS Score 5). Any delay in CCT was associated with a decreased incidence of good outcome (30%). Unilateral absence of the cortical component of the SSEP was usually associated with a poor outcome (death or severe disability), and bilateral absence was always associated with a poor outcome. The authors conclude that SSEPs correlate well with outcome and that this is not the result of investigator bias.	Waikato Hosp, Intens Care Unit, Dept Intens Care, Hamilton, New Zealand; Waikato Hosp, Dept Crit Care, Hamilton, New Zealand; Waikato Hosp, Dept Neuropsychol, Hamilton, New Zealand; Auckland Hosp, Dept Neurol, Auckland, New Zealand; Mercy Hosp, Intens Care Unit, Brisbane, Qld, Australia		Sleigh, JW (corresponding author), Waikato Hosp, Intens Care Unit, Dept Intens Care, Hamilton, New Zealand.	sleighj@hwl.co.nz	Marsh, Nigel V./F-5433-2019; Marsh, Nigel/ABA-3609-2021	Marsh, Nigel V./0000-0002-4060-6432; Marsh, Nigel/0000-0002-4060-6432			Adams E, 1996, J PEDIATR-US, V128, P438, DOI 10.1016/S0022-3476(96)70305-0; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; CHIAPPA KH, 1997, EVOKED POTENTIALS CL, P389; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; Havill JH, 1998, ANAESTH INTENS CARE, V26, P642, DOI 10.1177/0310057X9802600605; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KEREN O, 1994, BRAIN INJURY, V8, P239, DOI 10.3109/02699059409150976; MARKAND ON, 1990, ELECTROEN CLIN NEURO, V77, P416, DOI 10.1016/0168-5597(90)90002-U; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; PETERSON PL, 1995, CURR OPIN CRIT CARE, V1, P98; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; 1996, J NEUROTRAUMA, V13, P643	13	35	38	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	1999	91	4					577	580		10.3171/jns.1999.91.4.0577			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	239HV	WOS:000082763400007	10507377				2022-02-06	
J	Cooper, JB; Jane, JA; Alves, WM; Cooper, EB				Cooper, JB; Jane, JA; Alves, WM; Cooper, EB			Right median nerve electrical stimulation to hasten awakening from coma	BRAIN INJURY			English	Article								Electrical stimulation of the right median nerve may hasten the awakening of closed head injured, comatose patients. A series of 25 comatose patients have been treated. These patients made better recoveries than similar individuals reported in the literature. In a double-blind pilot project patients in the treated group scored better on interval Glasgow Coma Scale scores, spent fewer days in the intensive care unit, and showed better Glasgow Outcome Scores at 1 month post-injury. Peripheral electrical stimulation of the right median nerve, through activation of the ascending reticular activating system, may be sufficient to arouse the moderate to severely comatose patient.	E Carolina Univ, Sch Med, Greenville, NC USA; Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA; Neuroclin Trials Ctr Inc, Charlottesville, VA USA; E Carolina Univ, Dept Phys Med & Rehabil, Greenville, NC USA		Cooper, JB (corresponding author), 1902 Stanton Rd, Kinston, NC 28504 USA.						CARMICK J, 1993, PHYS THER, V73, P21; COOPER E, 1988, P AM IMP OUTP SYST A; Cooper E B Jr, 1973, Surg Forum, V24, P477; Glanz M, 1996, ARCH PHYS MED REHAB, V77, P549, DOI 10.1016/S0003-9993(96)90293-2; GRADY MS, 1989, J NEUROSURG, V71, P534, DOI 10.3171/jns.1989.71.4.0534; HAMILTON G, 1987, P 10 INT WORLD CONF; KANNO T, 1989, PACE, V12, P733, DOI 10.1111/j.1540-8159.1989.tb02724.x; KANNO T, 1992, SOC TREATMENT COMA, V1, P67; LAWRENCE F, 1991, J NEUROSURG, V75, pS28; MONTGOMERY G, 1989, DISCOVER, V10, P58; SCHERDER EJA, 1992, J CLIN EXP NEUROPSYC, V14, P951, DOI 10.1080/01688639208402546; SNYDERMACKLER L, 1995, J BONE JOINT SURG AM, V77A, P1166, DOI 10.2106/00004623-199508000-00004; Suzuki A, 1994, SOC TREATMENT COMA, V3, P75; Yokoyama T, 1996, SOC TREAT COMA, V5, P117	14	35	41	1	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1999	13	4					261	267		10.1080/026990599121638			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	186RH	WOS:000079742400005	10230527				2022-02-06	
J	Stancin, T; Taylor, HG; Thompson, GH; Wade, S; Drotar, D; Yeates, KO				Stancin, T; Taylor, HG; Thompson, GH; Wade, S; Drotar, D; Yeates, KO			Acute psychosocial impact of pediatric orthopedic trauma with and without accompanying brain injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Behavioral-Pediatrics	SEP   18, 1995	PHILADELPHIA, PENNSYLVANIA	Soc Behavioral Pediat		psychosocial; injuries; fractures; family	ACQUIRED LIMB DEFICIENCIES; FAMILY ASSESSMENT DEVICE; HEAD-INJURY; SEVERITY SCALE; CHILDREN; RELIABILITY; MORBIDITY; VALIDITY	Background: The acute psychosocial effects of orthopedic injuries on children and their families are poorly understood. Previous studies have relied on retrospective reports or failed to take into account accompanying brain injuries. The purpose of the present study was to examine prospectively the psychosocial impact of pediatric orthopedic traumatic fractures with and without accompanying brain injuries. Methods: Participants were 108 children 6 to 12 years old with orthopedic injuries requiring hospitalization: group 1 (n = 80) had fractures only, group 2 (n = 28) also had moderate or severe brain injuries. Using standardized measures and parent interviews, we obtained preinjury estimates of family functioning and child behavior problems and postinjury measures of parental distress, family stresses, and child behavior. Results: Parents reported significant clinical distress (35% in group 1, 57% in group 2), family burdens (group 2 > group 1), and child behavioral changes (41% in group 1, 89% in group 2), Multiple regression analyses indicated that preinjury family status and brain injuries predicted postinjury parental and family distress. Conclusion: Pediatric orthopedic injuries have greater social effects on children with accompanying brain injuries and poorer preinjury family functioning.	Case Western Reserve Univ, Sch Med, Cleveland, OH USA; Ohio State Univ, Sch Med, Columbus, OH 43210 USA		Stancin, T (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Dept Pediat, 2500 MetroHealth Dr, Cleveland, OH 44109 USA.		Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892			Achenbach TM, 1991, MANUAL CHILD BEHAV C; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Christoffel KK, 1996, PEDIATRICS, V97, P33; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EISEN M, 1980, RAND CORP PUBL; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FREEMAN HE, 1986, HLTH AFFAIRS     SPR, P6; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; HENKER FO, 1979, PSYCHOSOMATICS, V20, P812; KASHANI JH, 1981, BRIT J PSYCHIAT, V138, P21, DOI 10.1192/bjp.138.1.21; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LANGLEY J, 1983, Journal of Pediatric Psychology, V8, P181, DOI 10.1093/jpepsy/8.2.181; LODER RT, 1995, J PEDIATR ORTHOPED, V15, P41, DOI 10.1097/01241398-199501000-00010; MARCUS IM, 1986, TRAUMA CHILDREN, P245; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MAYER T, 1984, J TRAUMA, V24, P31, DOI 10.1097/00005373-198401000-00004; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS R, 1988, LIFE STRESSORS SOCIA; *NAT CTR HLTH STAT, 1980, NAT HLTH SURV SER, V10, P139; PRUGH DG, 1980, ADV BEHAV PEDIAT, V1, P181; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; Shindi J, 1983, Int J Soc Psychiatry, V29, P292, DOI 10.1177/002076408302900409; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Suhr M A, 1986, Adv Psychosom Med, V16, P31; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; THOMPSON GH, 1983, J PEDIATR ORTHOPED, V3, P443, DOI 10.1097/01241398-198309000-00005; VARNI JW, 1989, J DEV BEHAV PEDIATR, V10, P13; VARNI JW, 1989, J PEDIATR PSYCHOL, V14, P515, DOI 10.1093/jpepsy/14.4.515; VARNI JW, 1989, PEDIATRICS, V84, P320; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609	41	35	35	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1998	45	6					1031	1038		10.1097/00005373-199812000-00010			8	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	151DF	WOS:000077704900009	9867044				2022-02-06	
J	Kane, NM; Moss, TH; Curry, SH; Butler, SR				Kane, NM; Moss, TH; Curry, SH; Butler, SR			Quantitative electroencephalographic evaluation of non-fatal and fatal traumatic coma	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						quantitative electroencephalogram (EEG); brain-stem auditory evoked potentials (BAEPs); head injury; coma	DIFFUSE AXONAL INJURY; COMPRESSED SPECTRAL ARRAY; NONMISSILE HEAD-INJURY; EEG; PREDICTION; MANAGEMENT; COHERENCE; MILD	Diffuse axonal injury (DAI) is an important cause of morbidity and mortality after traumatic brain injury (TBI), and its severity is therefore a major determinant of outcome. There have been suggestions that the extent of DAI may be reflected in quantitative measures of cerebral function, including the electroencephalogram (EEG) and brain-stem auditory evoked potentials (BAEPs). It has therefore been proposed that these quantitative methods of analysis may provide objective predictors of outcome following TBI. We prospectively investigated the relationship between quantitative EEG and BAEP measures and outcome, in 60 comatose patients (47 male and 13 female; age range 1-80 years, mean 36.4) after severe, closed head injury (post-resuscitation Glasgow Coma Scale (GCS) of 8): The Spearman correlation coefficients (r(s)) have been calculated for quantitative EEG measures (mean regional power and interhemispheric coherence) and BAEPs with patient outcome on the Glasgow Outcome and Disability Rating Scales at 6 months and 1 year. The measures most significantly correlated with outcome (P < 0.001) are over the left hemisphere, beta activity power (amplitude squared) in the fronto-central and centro-temporal regions, and alpha activity power in the centro-temporal region. We found no correlation between interhemispheric coherence (a statistical measure of cross-correlation in the frequency domain) and outcome at either 6 months or 1 year post-injury. In 10 fatalities, we examined the relationship between interhemispheric EEG coherence prior to deaths and the histopathological severity of DAI, in concordant regions. The only significant correlation between DAI and interhemispheric coherence is seen in the alpha band at the temporo-occipital site (r(s) = -0.79, P = 0.007). Our data indicate that there is regional information in EEG power spectra over the left hemisphere, which could be used in prognostic predictions for patients in coma after severe TBI. We were unable to demonstrate a correlation between interhemispheric coherence and outcome, or any clear and consistent evidence of a relationship between interhemispheric coherence and the severity of DAI. (C) 1998 Elsevier Science Ireland Ltd.	Burden Neurol Inst, Bristol BS16 1QT, Avon, England; Frenchay Hosp, Dept Neuropathol, Bristol BS16 1LE, Avon, England		Butler, SR (corresponding author), Burden Neurol Inst, Stoke Lane, Bristol BS16 1QT, Avon, England.						ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBERT ML, 1976, ARCH NEUROL-CHICAGO, V33, P453, DOI 10.1001/archneur.1976.00500060059013; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARNES MP, 1991, CURR OPIN NEUROL NEU, V4, P12; BEAUMONT JG, 1978, ELECTROEN CLIN NEURO, V45, P393, DOI 10.1016/0013-4694(78)90190-6; Bricolo A, 1979, Acta Neurochir Suppl (Wien), V28, P35; BRICOLO A, 1976, CLIN ELECTROENCEPHAL, V7, P184, DOI 10.1177/155005947600700402; BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; BUSK J, 1975, ELECTROEN CLIN NEURO, V38, P415, DOI 10.1016/0013-4694(75)90265-5; CANT BR, 1984, NEUROLOGY, V34, P35, DOI 10.1212/WNL.34.1.35; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; DASILVA FL, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI 10.1016/0013-4694(91)90044-5; DAWSON RE, 1951, J NEUROSURG, V8, P613, DOI 10.3171/jns.1951.8.6.0613; DEATON A, 1993, BRAIN INJURY, V2, P99; DENNYBROWN D, 1941, BRAIN, V64, P94; DIMITRIJEVIC M R, 1989, Journal of Neurotrauma, V6, P25, DOI 10.1089/neu.1989.6.25; DIRINGER MN, 1992, CURR OPIN NEUROL NEU, V5, P826; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; FRANCZEK S, 1995, J CLIN NEUROPHYSIOL, V12, P521; GARCIALARREA L, 1992, J NEUROL NEUROSUR PS, V55, P792, DOI 10.1136/jnnp.55.9.792; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GESCHWIND N, 1985, ANN NY ACAD SCI, V386, P683; GEVINS A, 1992, J HEAD TRAUMA REHAB, V7, P78; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; KARNAZE DS, 1982, NEUROLOGY, V32, P289, DOI 10.1212/WNL.32.3.289; LEVIN HS, 1989, NEUROTRAUMA TREATMEN, P89; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUMPL E, 1993, ELECTROENCEPHALOGRAP, P383; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SERAFETINIDES EA, 1965, BRAIN, V88, P102; SHAW JC, 1981, J MED ENG TECHNOL, V5, P279, DOI 10.3109/03091908109009362; *SOC CRIT CAR MED, 1988, CRIT CARE MED, V16, P807; Steudel W I, 1979, Acta Neurochir Suppl (Wien), V28, P40; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYMONDS C, 1962, LANCET, V1, P1; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; VESELIS RA, 1992, BRIT J ANAESTH, V69, P246, DOI 10.1093/bja/69.3.246	46	35	41	1	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	MAR	1998	106	3					244	250		10.1016/S0013-4694(97)00141-7			7	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	ZF715	WOS:000072924800010	9743283				2022-02-06	
J	McGuire, LM; Burright, RG; Williams, R; Donovick, PJ				McGuire, LM; Burright, RG; Williams, R; Donovick, PJ			Prevalence of traumatic brain injury in psychiatric and non-psychiatric subjects	BRAIN INJURY			English	Article							HEAD-INJURY	Traumatic brain injury (TBI) and its sequelae may impact the expression and treatment of psychiatric disorders. The prevalence of TBI in psychiatric patients is unknown and investigations in the general population are limited. This study examined the prevalence of TBI with loss of consciousness in mental health setting patients (n = 231), general hospital and university staff and students (n = 534) and non-psychiatric medical clinical patients (n = 59). The Traumatic Brain Injury Questionnaire was used to assess TBI. A greater percentage of psychiatric patients reported TBI than medical patients or staff and students. Traumatic brain injuries were typically mild-moderate, medical assistance was frequently sought and use of alcohol and drugs was reported in a minority of TBI incidents. Multiple injuries were most common in psychiatric patients. The percentage of medical patients and staff and students reporting TBI was similar to previous research. The greater percentage of psychiatric patients reporting TBI indicates the need to assess TBI in this population. The role of TBI in the emergence, expression and treatment outcome of psychiatric disorders and the risk factors that leave psychiatric patients vulnerable to TBI should be further examined.	SUNY Binghamton, Dept Psychol, Environm Neuropsychol Lab, Binghamton, NY 13902 USA; SUNY Coll Potsdam, Dept Psychol, Potsdam, Germany; United Hlth Serv Hosp, Div Behav Hlth, Neuropsychol Unit, Johnson City, NY USA		McGuire, LM (corresponding author), SUNY Binghamton, Dept Psychol, Environm Neuropsychol Lab, Binghamton, NY 13902 USA.						Burg JS, 1996, J CLIN PSYCHOL MED S, V3, P243, DOI 10.1007/BF01993910; CROVITZ HF, 1992, CORTEX, V28, P509, DOI 10.1016/S0010-9452(13)80160-8; HOLMES CB, 1991, PERCEPT MOTOR SKILL, V73, P497, DOI 10.2466/PMS.73.5.497-498; Kraus Jess F., 1994, P3; Levin HS., 1982, NEUROBEHAVIORAL CONS; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Silver JM., 1994, NEUROPSYCHIATRY TRAU; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004	9	35	36	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	1998	12	3					207	214		10.1080/026990598122683			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZA456	WOS:000072365100004	9547951				2022-02-06	
J	Hoane, MR; Irish, SL; Marks, BB; Barth, TM				Hoane, MR; Irish, SL; Marks, BB; Barth, TM			Preoperative regimens of magnesium facilitate recovery of function and prevent subcortical atrophy following lesions of the rat sensorimotor cortex	BRAIN RESEARCH BULLETIN			English	Article						sensorimotor function; secondary brain injury; glutamate neurotoxicity; striatum; magnesium chloride; behavior	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; MOUSE CENTRAL NEURONS; GLUTAMATE NEUROTOXICITY; CORTICAL DAMAGE; RESPONSES; ISCHEMIA; CULTURE; DISEASE; MOTOR	Following brain injury, there is a reduction of intra- and extracellular levels of magnesium (Mg++), which may contribute to the severity of the lesion-induced behavioral impairments. Injections of magnesium prior to or after brain injury attenuate these behavioral impairments. The present study extends these findings by manipulating the number of injections and the time period between the injections and the time of injury, Rats were given either two or five daily preoperative injections of MgCl2 (1 mmol/kg, ip), or saline (1 ml/kg, ip) with the final injection given 24 h prior to electrolytic lesions of the somatic sensorimotor cortex (SMC). Following SMC lesions the rats exhibited contralateral deficits in forelimb placing and locomotor placing. Rats treated with either two or five preoperative injections of MgCl2 showed a reduction in the initial magnitude of the contralateral deficits and an accelerated rate of recovery compared to saline-treated rats. In addition, analysis of striatal atrophy revealed that MgCl2 treatment prevented atrophy in the ipsilateral posterior striatum compared to rats treated with saline. These data suggest that preoperative injections of MgCl2 produce facilitation of sensorimotor recovery and reduce subcortical atrophy. Moreover, to observe the beneficial effects of MgCl2, the timing of injections need not be tied to the period immediately around the brain injury. The present data may indicate that daily supplements of magnesium may partially protect against some of the deleterious effects of brain injury. (C) 1998 Elsevier Science Inc.	Texas Christian Univ, Dept Psychol, Ft Worth, TX 76129 USA; Texas Christian Univ, Program Neurosci, Ft Worth, TX 76129 USA		Hoane, MR (corresponding author), Cytotherapeutics, 701 George Washington Highway, Lincoln, RI 02865 USA.			Hoane, Michael/0000-0001-7779-2657			Aikawa J.W., 1981, MAGNESIUM ITS BIOL S, P21; ALTURA B M, 1985, Magnesium, V4, P245; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Bara M., 1984, MAGNESIUM, V3, P212; BARKER ES, 1959, J CLIN INVEST, V38, P1733, DOI 10.1172/JCI103952; BARTH TM, 1990, STROKE, V21, P153; BARTH TM, 1990, J NEUROSCI, V10, P3449; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BASHIR Y, 1993, AM J CARDIOL, V72, P1156, DOI 10.1016/0002-9149(93)90986-M; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; GARFINKEL L, 1985, Magnesium, V4, P60; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GUNTHER T, 1986, MAGNESIUM, V5, P53; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HARA H, 1993, BRAIN RES, V618, P251, DOI 10.1016/0006-8993(93)91273-U; Hoane M. R., 1995, Society for Neuroscience Abstracts, V21, P172; Hoane M. R., 1994, Society for Neuroscience Abstracts, V20, P1430; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; HOANE MR, 1996, J NEUROTRAUM, V13, P610; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Lasserre Bertrand, 1994, Magnesium Research, V7, P145; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; SAPONJIC RM, 1995, RESTOR NEUROL NEUROS, V8, P205, DOI 10.3233/RNN-1995-8406; SCHALLERT T, 1990, STROKE, V21, P143; Sjostrom I, 1994, SOC NEUR ABST, V20, P181; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	43	35	35	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.		1998	45	1					45	51		10.1016/S0361-9230(97)00288-8			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YM060	WOS:000071023900008	9434201				2022-02-06	
J	Wicky, S; Capasso, P; Meuli, R; Fischer, A; von Segesser, L; Schnyder, P				Wicky, S; Capasso, P; Meuli, R; Fischer, A; von Segesser, L; Schnyder, P			Spiral CT aortography: an efficient technique for the diagnosis of traumatic aortic injury	EUROPEAN RADIOLOGY			English	Article						thoracic aorta; trauma; aorta rupture; spiral CT; angiography	OSSEOUS PINCH; HELICAL CT; RUPTURE; CHEST; MECHANISM	The objective of this study was to assess the efficiency of spiral CT (SCT) aortography for diagnosing acute aortic lesions in blunt thoracic trauma patients. Between October 1992 and June 1997, 487 SCT scans of the chest were performed on blunt thoracic trauma patients. To assess aortic injury, the following SCT criteria were considered: hemomediastinum, peri-aortic hematoma, irregular aspect of the aortic wall, aortic pseudodiverticulum, intimal flap and traumatic dissection. Aortic injury was diagnosed on 14 SCT examinations (2.9 %), five of the patients having had an additional digital aortography that confirmed the aortic trauma. Twelve subjects underwent surgical repair of the thoracic aorta, which in all but one case confirmed the aortic injury. Two patients died before surgery from severe brain lesions. The aortic blunt lesions were confirmed at autopsy. According to the follow-up of the other 473 patients, we are aware of no false-negative SCT examination. Our Limited series shows a sensitivity of 100% and specificity of 99.8 % of SCT aortography in the diagnosis of aortic injury. It is concluded that SCT aortagraphy is an accurate diagnostic method for the assessment of aortic injury in blunt thoracic trauma patients.	CHU Vaudois, Dept Radiol & Intervent Radiol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Dept Cardiovasc Surg, CH-1011 Lausanne, Switzerland		Schnyder, P (corresponding author), CHU Vaudois, Dept Radiol & Intervent Radiol, CH-1011 Lausanne, Switzerland.						BESSON A, 1983, COLOR ATLAS CHEST TR, V2, P127; COHEN AM, 1992, AM J ROENTGENOL, V159, P271, DOI 10.2214/ajr.159.2.1632338; CRASS JR, 1990, RADIOLOGY, V176, P645, DOI 10.1148/radiology.176.3.2389022; ECKERT WG, 1977, FORENSIC MED STUDY T, V2, P853; FISHER RG, 1994, AM J ROENTGENOL, V162, P1047, DOI 10.2214/ajr.162.5.8165979; Gavant ML, 1996, AM J ROENTGENOL, V166, P955, DOI 10.2214/ajr.166.4.8610581; GAVANT ML, 1995, RADIOLOGY, V197, P125, DOI 10.1148/radiology.197.1.7568809; MILLER FB, 1989, SURGERY, V106, P596; MIRVIS SE, 1987, RADIOLOGY, V163, P487, DOI 10.1148/radiology.163.2.3562831; Mirvis SE, 1994, EMERG RADIOL, V1, P24; MIRVIS SE, 1997, EUR RADIOL S, V7, pS278; MORGAN PW, 1992, RADIOLOGY, V182, P661, DOI 10.1148/radiology.182.3.1535878; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; RAPTOPOULOS V, 1992, RADIOLOGY, V182, P667, DOI 10.1148/radiology.182.3.1535879; SANDOR F, 1967, THORAX, V22, P43, DOI 10.1136/thx.22.1.43; Schnyder P, 1996, J THORAC IMAG, V11, P39, DOI 10.1097/00005382-199601110-00003; ZEHNDER MAX A., 1956, ANGIOLOGY, V7, P252, DOI 10.1177/000331975600700306	17	35	35	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0938-7994			EUR RADIOL	Eur. Radiol.		1998	8	5					828	833		10.1007/s003300050480			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	ZT363	WOS:000074077600022	9601973				2022-02-06	
J	Viano, D; vonHolst, H; Gordon, E				Viano, D; vonHolst, H; Gordon, E			Serious brain injury from traffic-related causes: Priorities for primary prevention	ACCIDENT ANALYSIS AND PREVENTION			English	Article						disability; epidemiology; head injury; traffic crashes; traumatic brain injury	HEAD-INJURY	This study evaluated the incidence and outcome of serious brain injury from traffic-related causes in 695 patients admitted to the Department of Neurosurgery at Karolinska Hospital during 1981-1992. A total of 37.3% of patients were car occupants, 28.1% pedestrians, 12.9% bicyclists, 12.2% car-bicycle/car-moped and 9.5% motorcycle riders. The dominating injury was brain contusion (61.6%) verified with computerized tomography. The level of consciousness was evaluated by the Glasgow Coma Scale (GCS) and outcome by the Glasgow Outcome Scale (GOS) at discharge and 6-36 months thereafter. The final outcome was 67.5% good recovery (GOS 4-5), 11.5% severely disabled (GOS 2-3) and 21.0% GOS 1 or brain dead. Patients with GOS <4 (32.5%) were severely disabled and motivate priorities for injury prevention. Car occupants represent 40.7% of the total, followed by pedestrians at 33.6% and bicyclists at 18.2%. Much remains to be done in the primary prevention of disabling brain injury to car occupants and pedestrians. In order to achieve a more-effective primary prevention, future research should be directed toward biomechanical aspects of brain contusion as a dominating brain injury. (C) 1997 Elsevier Science Ltd.	KAROLINSKA HOSP,DEPT NEUROSURG,S-10401 STOCKHOLM,SWEDEN; ROYAL INST TECHNOL,DEPT LIGHTWEIGHT STRUCT,S-10044 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT ANESTHESIOL,S-10401 STOCKHOLM,SWEDEN								GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; GRAHAM J, 1992, 3 NAT INJ CONTR C US; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1991, NEUROEPIDEMIOLOGY TR, P333; Kraus JF, 1993, HEAD INJURY, P1; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	9	35	41	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	NOV	1997	29	6					811	816		10.1016/S0001-4575(97)00050-X			6	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	YD872	WOS:A1997YD87200012	9370017				2022-02-06	
J	Duke, BJ; Ryu, RK; Brega, KE; Coldwell, DM				Duke, BJ; Ryu, RK; Brega, KE; Coldwell, DM			Traumatic bilateral jugular vein thrombosis: Case report and review of the literature	NEUROSURGERY			English	Article						injury; jugular vein; stent; thrombosis	PSEUDOTUMOR CEREBRI; SINUS THROMBOSIS	OBJECTIVE AND IMPORTANCE: Thrombosis of the internal jugular vein (IJV) with associated elevated intracranial pressure (ICP) is a rare complication of central venous catheterization but has not been reported as a result of blunt trauma. CLINICAL PRESENTATION: An 18-year-old male patient was observed to be obtunded after an assault, The initial examination was remarkable for somnolence, bruising of the anterior neck, and diffuse, edematous swelling of the face and scalp, The results of computed tomography of the brain were normal. An angiogram obtained on the 2nd hospital day to rule out carotid injury revealed bilateral IJV thromboses to the cranial base. An ICP monitor was placed with an opening pressure of 33 mm Hg. The central venous pressure was measured to be 9 mm Hg. A catheter was passed through the left IJV thrombus and into the sigmoid sinus, where the pressure was 17 mm Hg, INTERVENTION: An intravascular stent was deployed in the left IJV. ICP rapidly normalized. A regimen of coumadin was administered to the patient for 6 weeks, at which time the stent remained patent. CONCLUSION: We conclude that traumatic jugular vein thrombosis can be associated with significant elevation in ICP and that treatment with an endovascular stent can affect the rapid correction of intracranial hypertension in patients who are candidates for anticoagulation.	UNIV COLORADO,HLTH SCI CTR,DIV NEUROSURG,DENVER,CO; UNIV COLORADO,HLTH SCI CTR,DEPT RADIOL,DENVER,CO 80262; DENVER HLTH MED CTR,DENVER,CO								AGMED N, 1976, MED J AUSTRALIA, V1, P217; CHOWDHURY K, 1990, HEAD NECK-J SCI SPEC, V12, P168, DOI 10.1002/hed.2880120214; COHEN JP, 1985, LARYNGOSCOPE, V95, P1478; DEBRUIJN NP, 1981, ANESTH ANALG, V60, P448; DUNSKER SB, 1970, ARCH NEUROL-CHICAGO, V23, P120, DOI 10.1001/archneur.1970.00480260026004; EMERSON TE, 1975, CEREBRAL CIRCULATION, P10; FITZHUGH GS, 1966, LARYNGOSCOPE, V76, P893; GOODMAN C, 1917, ANN OTO RHINOL LARYN, V26, P527; GUTTERIDGE IF, 1987, STROKE, V18, P808, DOI 10.1161/01.STR.18.4.808; KAPLAN RE, 1985, J PEDIATR-US, V107, P266; KOTANI J, 1992, BRIT J ORAL MAX SURG, V30, P171, DOI 10.1016/0266-4356(92)90151-8; LAM BL, 1992, OPHTHALMOLOGY, V99, P706; Long JW, 1912, SURG GYNECOL OBSTET, V14, P86; MARKS MP, 1994, RADIOLOGY, V191, P441, DOI 10.1148/radiology.191.2.8153318; MARR WG, 1965, AM J OPHTHALMOL, V51, P605; MOFIT HM, 1958, ARCH SURG-CHICAGO, V76, P713; MULLER KM, 1976, DEUT MED WOCHENSCHR, V101, P411; OTUAMA LA, 1973, LANCET, V2, P1101; RAISANEN H, 1979, NEW TESTAMENT STUD, V26, P101, DOI 10.1017/S0028688500008699; SAXENA VK, 1976, JAMA-J AM MED ASSOC, V235, P2124, DOI 10.1001/jama.235.19.2124; SEGAL J, 1993, NEUROSURGERY, V32, P468, DOI 10.1227/00006123-199303000-00023; STEPHENS PH, 1991, BRIT J ANAESTH, V67, P476, DOI 10.1093/bja/67.4.476; TOBIN HA, 1972, LARYNGOSCOPE, V82, P817, DOI 10.1288/00005537-197205000-00007; TOUNG TJK, 1988, ANESTHESIOLOGY, V68, P53, DOI 10.1097/00000542-198801000-00009	24	35	37	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1997	41	3					680	683		10.1097/00006123-199709000-00036			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XU972	WOS:A1997XU97200101	9310989				2022-02-06	
J	McGregor, K; Pentland, B				McGregor, K; Pentland, B			Head injury rehabilitation in the UK: An economic perspective	SOCIAL SCIENCE & MEDICINE			English	Article						brain injury; rehabilitation; economic evaluation; review; UK	TRAUMATIC BRAIN INJURY; COST-EFFECTIVENESS; HEALTH-STATUS; PROGRAM; DISABILITY; COMMUNITY; BENEFIT; IMPACT; SCALE; COMA	The human and societal costs as a result of traumatic brain injury (TBI) are extensive with approximately 200-300/100000 of the population requiring hospitalisation each year in the U.K. Advances in neurosurgical management have meant that more people sustaining head injuries are surviving. The need for rehabilitation programmes for these individuals is therefore ever increasing. While in the U.S.A. rehabilitation programmes for TBI patients are well established, in the U.K. the provision of such services is patchy and varies widely in different localities. The belated response to the rehabilitation needs of this group of individuals in the U.K., has coincided with an increased awareness of the economic efficiency of health care provision. This paper critically reviews published studies looking at the economics of rehabilitation services for brain injured patients. No studies in the U.K. were identified and all the sources discussed are from the U.S.A. The methodological guidelines underlying economic appraisal of health care are summarised and the studies assessed to determine the extent to which they fulfil these guidelines. The paper concludes that most studies purporting to provide evidence of cost-effectiveness did not include appropriate data, nor followed the methodological guidelines allowing such claims to be made. Some recommendations for future research are presented. (C) 1997 Elsevier Science Ltd.	UNIV EDINBURGH, REHABIL STUDIES UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND		McGregor, K (corresponding author), LOTHIAN CLIN AUDIT, 158-162 CAUSEWAYSIDE, 3RD FLOOR, EDINBURGH EH9 1PZ, MIDLOTHIAN, SCOTLAND.						Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Andrews K., 1991, CLIN REHABIL, V5, P5, DOI DOI 10.1177/026921559100500102; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BARRY P, 1993, J HEAD TRAUMA REHAB, V8, P48; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; Drummond M., 1987, METHODS EC EVALUATIO, V4th; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GILES GM, 1994, AM J OCCUP THER, V48, P199, DOI 10.5014/ajot.48.3.199; GLADMAN JRF, 1991, CLIN REHABIL, V5, P9; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HARLAN LC, 1990, AM J PUBLIC HEALTH, V80, P453, DOI 10.2105/AJPH.80.4.453; HENDERSON EJ, 1990, CLIN REHABIL, V41, P167; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MAHONEY F I, 1965, Md State Med J, V14, P61; MAIR A, 1972, MED REHABILITATION P; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALKAMUS D, 1979, REHABILITATION HEAD; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McKinlay W W, 1987, Brain Inj, V1, P3, DOI 10.3109/02699058709034438; McLaughlin Ann Marie, 1993, Brain Injury, V7, P71, DOI 10.3109/02699059309008158; MCMILLAN T, 1993, NEUROLOGICAL REHABIL, P437; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MILLIMAN JF, 1990, RES PERS H, V2, P21; Pentland B, 1990, Int Disabil Stud, V12, P86; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sakata R, 1991, Brain Inj, V5, P411, DOI 10.3109/02699059109008114; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; TEASDALE G, 1974, LANCET, V2, P81; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WEST M, 1991, ARCH PHYSICAL REHABI, V72, P1127; 1990, LANCET, V335, P886	50	35	35	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	JUL	1997	45	2					295	303		10.1016/S0277-9536(96)00345-0			9	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Biomedical Social Sciences	XE610	WOS:A1997XE61000011	9225416				2022-02-06	
J	Cobbs, CS; Fenoy, A; Bredt, DS; Noble, LJ				Cobbs, CS; Fenoy, A; Bredt, DS; Noble, LJ			Expression of nitric oxide synthase in the cerebral microvasculature after traumatic brain injury in the rat	BRAIN RESEARCH			English	Article						traumatic brain injury; endothelial nitric oxide synthase; NADPHd	BLOOD-FLOW; BARRIER; AUTOREGULATION; INHIBITION; MECHANISMS; BREAKDOWN; PROTEIN	Reduced nicotinamide adenine dinucleotide phosphate-diaphorase (NADPHd) histochemistry and nitric oxide synthase (NOS) immunocytochemistry were performed on sections of brain after moderate traumatic brain injury. There was a pronounced increase in NADPHd reactivity and an induction of the endothelial NOS (eNOS) isoform in microvessels surrounding the cortical contusion by 24 h post-injury. This altered microvascular state may contribute to barrier breakdown and hyperemia which characterize traumatic brain injury.	SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; KOBARI M, 1994, BRAIN RES, V667, P255, DOI 10.1016/0006-8993(94)91503-2; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; TALMAN WT, 1995, BRAIN RES, V672, P48, DOI 10.1016/0006-8993(94)01381-Q; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; WEIMER G, 1994, BRAIN RES, V638, P261	11	35	35	1	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 21	1997	751	2					336	338		10.1016/S0006-8993(96)01429-1			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WQ807	WOS:A1997WQ80700021	9099824				2022-02-06	
J	Thatcher, RW; Camacho, M; Salazar, A; Linden, C; Biver, C; Clarke, L				Thatcher, RW; Camacho, M; Salazar, A; Linden, C; Biver, C; Clarke, L			Quantitative MRI of the gray-white matter distribution in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						quantitative MRI; pixel intensity change; traumatic brain injury	MAGNETIC-RESONANCE IMAGES; DIFFUSE AXONAL INJURY; HEAD-INJURY	Quantitative analyses were performed on magnetic resonance images (MRIs) obtained from the brains of 31 traumatic brain-injured (TBI) patients and 25 normal control subjects. The quantitative analyses involved comparisons of the shapes of proton density gray scale pixel histograms obtained from both 3-mm and 5-mm slice thickness. Image segmentation was accomplished by a multispectral fuzzy C-means and/or k-nearest-neighbor (kNN) algorithms and manual classification was used to label segmented classes into CSF, white matter, gray matter, and other. Shape descriptors were derived from the pixel intensity histograms of the combined gray matter and white matter classes for each MRI slice. Statistical analyses revealed significant differences in pixel intensity distributions between TBI and control subjects. Normal control subjects tended to exhibit bimodal gray matter-white matter histograms, whereas, TBI patients tended to exhibit unimodal gray matter-white matter histograms. In the control subjects the pixels intermediate in intensity between gray and white matter were located primarily at the border between the gray and white matter, whereas TBI patients exhibited a thickening of the number of intermediate pixels at the border as well as an increase in intermediate pixels in the middle of the gray and white matter. The greater the severity of TBI, then the larger the number of intermediate intensity pixels within and between gray and white matter. Further analyses demonstrated shifts in magnetic resonance relaxation times in gray and white matter in TBI patients, which suggested that the tendency toward unimodality in TBI patients represents a pathological reduction in brain differentiation due to measurable biophysical change.	UNIV S FLORIDA,COLL MED,DEPT NEUROL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT RADIOL,TAMPA,FL 33612; DEF & VET HEAD INJURY PROGRAM,WASHINGTON,DC		Thatcher, RW (corresponding author), VET ADM MED CTR,RES & DEV SERV 151,BAY PINES,FL 33744, USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P257; BENES FM, 1977, BRAIN RES, V122, P1, DOI 10.1016/0006-8993(77)90658-8; BENSAID AM, 1994, P SOC PHOTO-OPT INS, V2167, P454, DOI 10.1117/12.175079; BEZDEK JC, 1993, MED PHYS, V20, P100; BIGLER ED, 1996, NEUROPSYCHOLOGY, V10, P33; BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535; BRANDT ME, 1994, COMPUT MED IMAG GRAP, V18, P25, DOI 10.1016/0895-6111(94)90058-2; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; ELSTER AD, 1988, J COMPUT ASSIST TOMO, V12, P130, DOI 10.1097/00004728-198801000-00025; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HALL LO, 1992, IEEE T NEURAL NETWOR, V3, P672, DOI 10.1109/72.159057; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; PRAYER LM, 1994, MAGNETIC RESONANCE N, P441; PRIGATANO GP, 1987, BARROW NEUROL I Q, V3, P18; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; STREIT WJ, 1995, SCI AM, V273, P54, DOI 10.1038/scientificamerican1195-54; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; THOMAS LB, 1995, NEUROSCIENTIST, V1, P142; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; [No title captured]	36	35	36	2	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					1	14		10.1089/neu.1997.14.1			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200001	9048306				2022-02-06	
J	McKinley, BA; Morris, WP; Parmley, CL; Butler, BD				McKinley, BA; Morris, WP; Parmley, CL; Butler, BD			Brain parenchyma PO2, PCO2, and pH during and after hypoxic, ischemic brain insult in dogs	CRITICAL CARE MEDICINE			English	Article						fiberoptic sensors; tissue Po-2, Pco(2), pH; brain parenchyma; interstitial fluid; intracranial pressure; head injury; oxygenation; tissue perfusion; blood gas analysis; neurologic emergencies; brain; traumatic brain injury; stroke	INTRAARTERIAL BLOOD-GAS; INTRACELLULAR PH; EXTRACELLULAR PH; GLOBAL-ISCHEMIA; RAT-BRAIN; MONITORING-SYSTEM; CEREBRAL-ISCHEMIA; FLUORESCENCE; HYPERCAPNIA; SENSORS	Objectives: 1) The investigation of fiberoptic Po-2, Pco(2), and pH sensor technology as a monitor of brain parenchyma during and after brain injury, and 2) the comparison of brain parenchyma Po-2, Pco(2), acid pH with intracranial pressure during and after hypoxic, ischemic brain insult. Design: Prospective, controlled, animal study in an acute experimental preparation. Setting: Physiology laboratory in a university medical school. Subjects: Fourteen mongrel dogs (20 to 35 kg), anesthetized, room air ventilated, Interventions: Anesthesia was induced with thiopental and maintained after intubation using 1% to 1.5% halothane in room air (Re, 0.21). Mechanical ventilation was established to maintain end-tidal Pco(2) similar to 35 torr (similar to 4.7 kPa). Intravenous, femoral artery, and pulmonary artery catheters were placed. The common carotid arteries were surgically exposed, and ultrasonic blood flow probes were applied. A calibrated intracranial pressure probe was placed through a right side transcranial bolt, and a calibrated intracranial chemistry probe with optical sensors for Po-2, Pco(2), and pH was placed through a left-side bolt into brain parenchyma. Brain insult was induced in the experimental group (n = 6) by hypoxia (Flo(2) 0.1), ischemia (bilateral carotid artery occlusion), and hypotension (mean arterial pressure [MAP] similar to 40 mm Hg produced with isoflurane similar to 4%). After 45 mins, carotid artery occlusion was released, Flo(2) was reset to 0.21, and anesthetic was returned to halothane (similar to 1.25%). The control group (n = 5) had the same surgical preparation and sequence of anesthetic agent exposure but no brain insult. Measurements and Main Results: Monitored variables included brain parenchyma Po-2, Pco(2), and pH, which were monitored at 1-min intervals, and intracranial pressure, MAP, arterial hemoglobin oxygen saturation (by pulse oximetry), end-tidal Pco(2), and carotid artery blood flow rate, for which data were collected at 15-min intervals for 7 hrs. Arterial and mixed venous blood gas analyses were done at similar to 1-hr intervals. Baseline data agreed closely with other published results: brain parenchyma PO2 of 27 +/- 7 (SD) torr (3.6 +/- 0.9 kPa); brain parenchyma PCO2 of 69 +/- 12 torr (9.2 +/- 1.6 kPa); and brain parenchyma pH of 7.13 +/- 0.09. Postcalibration data were accurate, indicating stability and durability over several hours. In six experiments, during the brain insult, brain parenchyma PO2 decreased to 16 +/- 2 torr (2.1 +/- 0.3 kPa), brain parenchyma Pco(2) increased to 105 +/- 44 torr (14 +/- 5.9 kPa) (p <.05), and brain parenchyma pH decreased to 6.75 +/- 0.08 (p <.05). Intracranial pressure (ICP) remained nearly constant (baseline 16 +/- 6 to 14 +/- 5 mm Hg at the end of the brain insult). Cerebral perfusion pressure (CPP = MAP - ICP) decreased (baseline 95 +/- 15 to 28 +/- 8 mm Hg; p <.05). On release of brain insult stresses, ICP increased to 30 +/- 9 mm Hg and CPP increased to 71 +/- 19 mm Hg (p<.05). A biphasic recovery was observed for brain parenchyma pH, which had the slowest recovery of the monitored variables. On average, brain parenchyma pH gradually returned toward baseline, and was no longer significantly different from baseline 3 hrs after release of insult stresses. Brain parenchyma Pco(2) continued to decrease rapidly after brain insult and then remained -52 +/- 10 torr (-6.9 +/- 1.3 kPa) (p <.05). Brain parenchyma Po-2 increased from a minimum at the end of brain insult to a maximum of 43 +/- 17 torr (5.7 +/- 2.3 kPa) within 1.25 hrs (p <.05), and then gradually decreased to -35 +/-10 torr (similar to 4.7 +/- 1.3 kPa). Cerebral perfusion pressure gradually decreased as ICP increased 3 to 5 hrs after insult. Conclusions: Intracranial chemistry probes with optical sensors demonstrated stable, reproducible monitoring of brain parenchyma Po-2, Pco(2), and pH in dogs for periods lasting 28 hrs. Significant changes in brain parenchyma Po-2, Pco(2), and pH occurred without corresponding changes in intracranial pressure. Placement of intracranial chemistry probes can be accomplished with techniques similar to those used for standard intracranial pressure probes.			McKinley, BA (corresponding author), UNIV TEXAS, SCH MED, DEPT ANESTHESIOL, HOUSTON, TX 77030 USA.						ADAMS JE, 1962, J NEUROSURG, V19, P959, DOI 10.3171/jns.1962.19.11.0959; ANDERSON RE, 1983, J CEREBR BLOOD F MET, V3, P493, DOI 10.1038/jcbfm.1983.76; Behar K L, 1993, Acta Neurochir Suppl (Wien), V57, P9; BICKLER PE, 1988, J APPL PHYSIOL, V65, P422, DOI 10.1152/jappl.1988.65.1.422; CLARK LC, 1958, J APPL PHYSIOL, V13, P85, DOI 10.1152/jappl.1958.13.1.85; CROCKARD HA, 1976, J NEUROL SCI, V27, P17, DOI 10.1016/0022-510X(76)90231-8; CROWELL JW, 1961, AM J PHYSIOL, V200, P743, DOI 10.1152/ajplegacy.1961.200.4.743; Gadian D G, 1993, Acta Neurochir Suppl (Wien), V57, P1; GAHAR J, 1995, CRIT CARE MED, V23, P560; GEHRICH JL, 1986, IEEE T BIO-MED ENG, V33, P117, DOI 10.1109/TBME.1986.325886; GLEICHMANN U, 1962, ACTA PHYSIOL SCAND, V55, P127, DOI 10.1111/j.1748-1716.1962.tb02425.x; GRABER ML, 1986, ANAL BIOCHEM, V156, P202, DOI 10.1016/0003-2697(86)90174-0; GRIFFITH JK, 1992, BRAIN RES, V573, P1, DOI 10.1016/0006-8993(92)90108-L; GUYTON AC, 1976, TXB MED PHYSL, P485; HALLER M, 1994, CRIT CARE MED, V22, P580, DOI 10.1097/00003246-199404000-00012; HARRIS RJ, 1987, J CEREBR BLOOD F MET, V7, P599, DOI 10.1038/jcbfm.1987.111; Hossmann K A, 1993, Acta Neurochir Suppl (Wien), V57, P21; INGVAR DH, 1960, ACTA PHYSIOL SCAND, V48, P373, DOI 10.1111/j.1748-1716.1960.tb01870.x; JAVAHERI S, 1982, B EUR PHYSIOPATH RES, V18, P775; KATSURA K, 1993, J CEREBR BLOOD F MET, V13, P820, DOI 10.1038/jcbfm.1993.104; KATSURA K, 1994, BRAIN RES, V651, P47, DOI 10.1016/0006-8993(94)90679-3; KENNEALY JA, 1980, AM REV RESPIR DIS, V122, P407; LARSON CP, 1994, ANESTHESIOLOGY, V81, P543, DOI 10.1097/00000542-199409000-00005; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; LUBBERS DW, 1995, ACTA ANAESTH SCAND, V39, P37; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MAHUTTE CK, 1990, J CLIN MONITOR, V6, P147, DOI 10.1007/BF02828293; MCKINLEY BA, 1995, CRIT CARE MED S, V23, pA247; Middleman S., 1972, TRANSPORT PHENOMENA, P116; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; OPITZ N, 1987, INT ANESTHESIOL CLIN, V25, P177; PONTEN U, 1966, ACTA PHYSIOL SCAND, V67, P129, DOI 10.1111/j.1748-1716.1966.tb03294.x; PORTMAN MA, 1991, J APPL PHYSIOL, V71, P2168, DOI 10.1152/jappl.1991.71.6.2168; SCHLAIN L, 1994, P SOC PHOTO-OPT INS, V2131, P452, DOI 10.1117/12.180742; SEITZ WR, 1988, CRC CR REV ANAL CHEM, V19, P135, DOI 10.1080/10408348808542810; SEYLAZ J, 1978, J APPL PHYSIOL, V44, P528, DOI 10.1152/jappl.1978.44.4.528; SHAPIRO BA, 1989, CRIT CARE MED, V17, P455, DOI 10.1097/00003246-198905000-00016; SHAPIRO HM, 1986, ANESTHESIA, V2, P1266; SIESJO BK, 1972, J NEUROCHEM, V19, P2483, DOI 10.1111/j.1471-4159.1972.tb01308.x; SNYDER JV, 1975, STROKE, V6, P21, DOI 10.1161/01.STR.6.1.21; SONNENSCHEIN RR, 1953, REV SCI INSTRUM, V24, P702, DOI 10.1063/1.1770819; SUNDT TM, 1980, J NEUROPHYSIOL, V44, P60, DOI 10.1152/jn.1980.44.1.60; SYMON L, 1993, ACTA NEUROCHIR S, V59, P102; TOMLINSON FH, 1993, STROKE, V24, P435, DOI 10.1161/01.STR.24.3.435; VENKATESH B, 1994, CRIT CARE MED, V22, P588, DOI 10.1097/00003246-199404000-00013; ZIMMERMAN J, 1994, CRIT CARE MED, V22, P588	47	35	37	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	1996	24	11					1858	1868		10.1097/00003246-199611000-00016			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT116	WOS:A1996VT11600016	8917037				2022-02-06	
J	Uchikawa, O; Fukatsu, K; Suno, M; Aono, T; Doi, T				Uchikawa, O; Fukatsu, K; Suno, M; Aono, T; Doi, T			In vivo biological activity of antioxidative aminothiazole derivatives	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						thiazoloazepine; thiazolopyridine; iron(II) chloride intrathecal injection; antioxidant; central nervous system	CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; RAT-BRAIN; IRON; INHIBITOR; INJECTION; ISCHEMIA; TRAUMA; CORTEX; ASSAY	For the development of novel antioxidants having therapeutic utility, a new series of condensed 4- and 5-aminothiazole derivatives has been synthesized using simple methods. Condensed 4-aminothiazoles were prepared by the reaction of alpha-bromolactans a;with thioamides in ethanol and 5-aminothiazole derivatives were obtained by the treatment of 3-(acylamino)lactams with a thiating agent such as phosphorus pentasulfide and Lawesson's reagent in pyridine. In vitro assay of the condensed 5-aminothiazole derivatives showed them to be potent inhibitors of lipid peroxidation. In order to evaluate these compounds in an in vivo system, we devised a simple and reproducible method in which the inhibition of characteristic behaviors induced by spinal injection of FeCl2 was expressed numerically. Compounds having strong in vitro activity protected the central nervous system from injury caused by iron-dependent lipid peroxidation. The results suggest that the in vivo assay developed in this study should be useful as a screening method for antioxidants and also that condensed 5-aminothiazole derivatives are promising candidates for the treatment of traumatic and ischemic injury of the central nervous system.	TAKEDA CHEM IND LTD, DIV PHARMACEUT RES, PHARMACEUT RES LABS 3, YODOGAWA KU, OSAKA 532, JAPAN; TAKEDA CHEM IND LTD, DIV DISCOVERY RES, RES RES, TSUKUBA, IBARAKI 30042, JAPAN		Uchikawa, O (corresponding author), TAKEDA CHEM IND LTD, DIV PHARMACEUT RES, PHARMACEUT RES LABS 1, YODOGAWA KU, OSAKA 532, JAPAN.						BLADEFONT A, 1980, TETRAHEDRON LETT, P2443; BOYER SK, 1988, HELV CHIM ACTA, V71, P337, DOI 10.1002/hlca.19880710205; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; COLOMBO JA, 1975, BRAIN RES, V96, P88; DOI T, 1987, EUR J PHARMACOL, V137, P227, DOI 10.1016/0014-2999(87)90226-3; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARRISON SC, 1994, BRAIN RES, V639, P102; JACOBSEN EJ, 1992, J MED CHEM, V35, P4464, DOI 10.1021/jm00101a025; NAGASAWA HT, 1971, J MED CHEM, V14, P501, DOI 10.1021/jm00288a010; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PAPPALARDO G, 1966, FARMACO-ED SCI, V21, P740; PELLEGATA R, 1978, SYNTHESIS-STUTTGART, P614; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; STOCKS J, 1974, CLIN SCI MOL MED, V47, P215, DOI 10.1042/cs0470215; SUBBARAO KV, 1990, J NEUROSCI RES, V26, P224, DOI 10.1002/jnr.490260212; THORSETT ED, 1986, J MED CHEM, V29, P251, DOI 10.1021/jm00152a014; UCHIKAWA O, 1994, J HETEROCYCLIC CHEM, V31, P1545, DOI 10.1002/jhet.5570310645; UCHIKAWA O, 1994, J HETEROCYCLIC CHEM, V31, P877, DOI 10.1002/jhet.5570310432; WILLMORE LJ, 1983, BRAIN RES, V277, P393, DOI 10.1016/0006-8993(83)90954-X; WILLMORE LJ, 1978, BRAIN RES, V152, P406, DOI 10.1016/0006-8993(78)90273-1; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; WINEMAN RJ, 1958, J AM CHEM SOC, V80, P6233, DOI 10.1021/ja01556a019; WINTER W, 1983, LIEBIGS ANN CHEM, P2021	25	35	37	0	5	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	1996	44	11					2070	2077					8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy; Chemistry	VV313	WOS:A1996VV31300013	8945772				2022-02-06	
J	Gates, MA; Laywell, ED; Fillmore, H; Steindler, DA				Gates, MA; Laywell, ED; Fillmore, H; Steindler, DA			Astrocytes and extracellular matrix following intracerebral transplantation of embryonic ventral mesencephalon or lateral ganglionic eminence	NEUROSCIENCE			English	Article						brain grafts; glia; tenascin; chondroitin sulfate proteoglycans; dopaminergic neurons	CHONDROITIN SULFATE PROTEOGLYCAN; FETAL STRIATAL PRIMORDIA; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT-BRAIN; NEURITE OUTGROWTH; SPINAL-CORD; RADIAL GLIA; INHIBITORY MOLECULES; CNS INJURY; MONOCLONAL-ANTIBODY	Transplantation of embryonic neurons to the adult mammalian central nervous system (CNS) offers the possibility of re-establishing neural functions lost after traumatic injuries or neurodegenerative disease. In the adult CNS, however, transplanted neurons and their growing neurites can become confined to the graft region, and there may also be a relative paucity of afferents innervating grafted neurons. Because glia may influence the development and regeneration of CNS neurons, the present study has characterized the distribution of astrocytes and developmentally regulated glycoconjugates (chondroitin-6-sulfate proteoglycan and tenascin) within regions of the embryonic mouse CNS used as donor tissues, and in and around these grafts to the adult striatum and substantia nigra. Both chondroitin-6-sulfate proteoglycan and tenascin are present in the embryonic ventral mesencephalon (in association with radial glia and their endfeet, and glial boundaries that cordon off the ventral mesencephalon dopamine neuron migratory zone) and lateral ganglionic eminence before transplantation, and they are conserved within grafts of these tissues to the adult mouse. Neostriatal grafts exhibit a heterogeneous pattern of astrocyte and extracellular matrix molecule distribution, unlike ventral mesencephalon grafts, which are rather homogeneous. There is evidence to suggest that, in addition to variation in astroglial/extracellular matrix immunostaining within different compartments in striatal grafts to either adult striatum or substantia nigra, there are also boundaries between these compartments that are rich in glial fibrillary acidic protein/extracellular matrix components. Substantia nigra grafts, with cells immunoreactive for tyrosine hydroxylase, are also rich in immature astroglia (RC-2-immunopositive), and as the astroglia mature (to glial fibrillary acidic protein-positive) over time the expression of chondroitin-6-sulfate proteoglycan and tenascin is also reduced. These same extracellular matrix constituents, however, are only slightly up-regulated in an area of the adult host which surrounds the grafted tissue. Glial scar components exhibit no obvious differences between grafts from different sources to homotopic (e.g., striatum to striatum) or heterotopic (e.g., substantia nigra to striatum) sites, and likewise grafts of non-synaptically associated structures (e.g., cerebellum to striatum), needle lesions or vehicle injections all yield astroglial/extracellular matrix scars in the host that are indistinguishable. Studies utilizing the ROSA-26 transgenic (beta-galactosidase-positive) mouse as a host for non-5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside-labeled grafts indicate that the early astroglial/extracellular matrix response to the graft is derived from the surrounding host structures. Furthermore, biochemical analysis of one of the ''boundary molecules'', tenascin, from the developing ventral mesencephalon versus adult striatal lesions, suggests that different forms of the molecule predominate in the embryonic versus lesioned adult brain. Such differences in the nature and distribution of astroglia and developmentally regulated extracellular matrix molecules between donor and host regions may affect the growth and differentiation of transplanted neurons. The present study suggests that transplanted neurons and their processes may flourish within graft versus host regions, in part due to a confining glial scar, but also because the extracellular milieu within the graft site remains more representative of the developmental environment from which the donor neurons were obtained [Gates M. A., et at. (1994) Sec. Neurosci Abstr. 20, 471]. Copyright (C) 1996 IBRO. Published by Elsevier Science Ltd.	UNIV TENNESSEE, COLL MED, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA				Steindler, Dennis/AAJ-5811-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29225] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029225] Funding Source: NIH RePORTER		ARD MD, 1991, ANN NY ACAD SCI, V633, P566; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; AZMITIA EC, 1983, NEUROSCI LETT, V38, P145, DOI 10.1016/0304-3940(83)90031-9; BAKAY RAE, 1993, ACTA NEUROCHIR, P8; BARTSCH S, 1992, J NEUROSCI, V12, P736; BICKNESE AR, 1994, J NEUROSCI, V14, P3500; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P1; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BREEZE RE, 1995, NEUROSURGERY, V36, P1044, DOI 10.1227/00006123-199505000-00027; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; BRODKEY JA, 1993, EXP NEUROL, V123, P251, DOI 10.1006/exnr.1993.1158; CRANDALL JE, 1990, DEV BRAIN RES, V55, P87, DOI 10.1016/0165-3806(90)90108-B; CULICAN SM, 1990, J NEUROSCI, V10, P684; DAVIES SJA, 1994, J NEUROSCI, V14, P1596, DOI 10.1523/JNEUROSCI.14-03-01596.1994; DOUCET G, 1990, EUR J NEUROSCI, V2, P279, DOI 10.1111/j.1460-9568.1990.tb00419.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EDWARDS MA, 1990, NEUROSCIENCE, V36, P121, DOI 10.1016/0306-4522(90)90356-9; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1988, DIFFERENTIATION, V37, P104, DOI 10.1111/j.1432-0436.1988.tb00802.x; Faissner A, 1993, Perspect Dev Neurobiol, V1, P155; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; FISHER LJ, 1994, FASEB J, V8, P489, DOI 10.1096/fasebj.8.8.8181667; FISHER LJ, 1993, PHYSIOL REV, V73, P583, DOI 10.1152/physrev.1993.73.3.583; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gates M. A., 1994, Society for Neuroscience Abstracts, V20, P471; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; GATES MA, 1993, J CHEM NEUROANAT, V6, P179, DOI 10.1016/0891-0618(93)90040-B; GRAYBIEL AM, 1990, PROG BRAIN RES, V82, P401; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; GROVES AK, 1993, DEV BIOL, V159, P87, DOI 10.1006/dbio.1993.1223; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HALLAS BH, 1980, AM J ANAT, V158, P147, DOI 10.1002/aja.1001580205; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LAYWELL ED, 1991, ANN NY ACAD SCI, V633, P122; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; LUND RD, 1976, SCIENCE, V193, P582, DOI 10.1126/science.959815; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; NAGAO M, 1993, NEUROSCI LETT, V156, P47, DOI 10.1016/0304-3940(93)90436-O; Nieto-Sampedro M, 1988, PHARM APPROACHES TRE, P301; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; NIKKAH G, 1994, THESIS LUND SWEDEN; NIKKHAH G, 1994, BRAIN RES, V633, P133, DOI 10.1016/0006-8993(94)91532-6; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OBRIEN TF, 1992, DEV BRAIN RES, V65, P259, DOI 10.1016/0165-3806(92)90187-2; OBRIEN TF, 1995, CELLULAR MOL MECH ST, P21; PAINO CL, 1994, J NEUROCYTOL, V23, P433, DOI 10.1007/BF01207115; Reier P J, 1988, Adv Neurol, V47, P87; ROBSON JA, 1994, J COMP NEUROL, V340, P349, DOI 10.1002/cne.903400306; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SAJIN B, 1994, PERSPECT DEV NEUROBI, V2, P275; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SHULTS CW, 1990, NEUROSCIENCE, V38, P427, DOI 10.1016/0306-4522(90)90039-7; SMITH GM, 1986, J COMP NEUROL, V251, P23, DOI 10.1002/cne.902510103; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STEINDLER DA, 1989, DEV BIOL, V131, P243, DOI 10.1016/S0012-1606(89)80056-9; STEINDLER DA, 1993, ANNU REV NEUROSCI, V16, P445, DOI 10.1146/annurev.ne.16.030193.002305; STEINDLER DA, 1988, J COMP NEUROL, V267, P357, DOI 10.1002/cne.902670306; STEINDLER DA, 1995, J NEUROSCI, V15, P1971, DOI 10.1523/JNEUROSCI.15-03-01971.1995; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; STEINDLER DA, 1989, COMMENTS DEV NEUROBI, V1, P29; STENEVI U, 1976, BRAIN RES, V114, P1, DOI 10.1016/0006-8993(76)91003-9; THOMAS LB, 1995, NEUROSCIENTIST, V1, P142; TRIMMER PA, 1990, J COMP NEUROL, V296, P359, DOI 10.1002/cne.902960303; WALKER PD, 1987, BRAIN RES, V425, P34, DOI 10.1016/0006-8993(87)90480-X; XU ZC, 1992, NEUROSCIENCE, V48, P95, DOI 10.1016/0306-4522(92)90341-X; ZHOU FC, 1989, NEUROSCIENCE, V30, P19, DOI 10.1016/0306-4522(89)90350-3; ZHOU FC, 1987, J NEUROSCI RES, V17, P235, DOI 10.1002/jnr.490170306; ZHOU HF, 1990, J COMP NEUROL, V292, P320, DOI 10.1002/cne.902920213	82	35	37	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	SEP	1996	74	2					579	597		10.1016/0306-4522(96)00146-7			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VC755	WOS:A1996VC75500026	8865207				2022-02-06	
J	Hux, K; Walker, M; Sanger, DD				Hux, K; Walker, M; Sanger, DD			Traumatic brain injury: Knowledge and self-perceptions of school speech-language pathologists	LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS			English	Article						traumatic brain injury; service delivery; cognitive-communication deficits	CLOSED HEAD-INJURY; VERBAL IMPAIRMENT	School-based speech-language pathologists from 10 states, responded to a survey concerning their readiness to provide services to students with traumatic brain injuries (TBIs). Survey responses provided a means of exploring speech-language pathologists' knowledge of TBI and facilitated recognition of accurate and inaccurate conceptions held by school-based speech-language pathologists concerning the characteristics and behaviors, criteria for identification and verification, and procedures for the assessment, treatment, and reintegration of students with TBI. Findings indicated that training had a positive effect on speech-language pathologists' knowledge of assessment, treatment, and overall management of students with TBI; however, a large percentage of school-based speech-language pathologists remain uncertain about providing services to students with TBI even after receiving specific TBI training. Furthermore, school-based speech-language pathologists continue to hold many misconceptions concerning TBI and its consequences.			Hux, K (corresponding author), UNIV NEBRASKA, 318 BARKLEY MEM CTR, LINCOLN, NE 68583 USA.		Hux, Karen/AAQ-2078-2020				ADAMOVICH BB, 1990, REHABILITATION ADULT, P374; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BLOSSER JL, 1989, TOP LANG DISORD, V9, P67, DOI 10.1097/00011363-198903000-00007; Blosser JL, 1991, J HEAD TRAUMA REHAB, V6, P73; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CARTER S, 1993, OFF SPECIAL ED REHAB; Caveness W F, 1979, Adv Neurol, V22, P1; Cohen SB, 1985, HEAD INJURY REHABILI, P383; Colson S. E, 1992, INTERV SCH CLIN, V27, P198; DePompei R, 1987, LANG SPEECH HEAR SER, V18, P292, DOI 10.1044/0161-1461.1804.292; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; GROHER ME, 1990, REHABILITATION ADULT, P148; Hagen C, 1981, TOP LANG DIS, V1, P73; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS., 1982, NEUROBEHAVIORAL CONS; MILLER JD, 1990, REHABILITATION ADULT, P236; Mira M. P., 1992, TRAUMATIC BRAIN INJU; Russell N, 1993, LANG SPEECH HEAR SER, V24, P67; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; TELZROW CF, 1990, TRAUMATIC BRAIN INJU, P251; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P35; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48; YLVISAKER MA, 1991, CLIN CONNECTION, V5, P1; 1992, FED REGISTER, V57, P44794; 1990, AM J DISEASE CONTROL, V144, P627	30	35	35	0	6	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	0161-1461	1558-9129		LANG SPEECH HEAR SER	Lang. Speech Hear. Serv. Sch.	APR	1996	27	2					171	184		10.1044/0161-1461.2702.171			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	UE675	WOS:A1996UE67500008					2022-02-06	
J	Boake, C; High, WM				Boake, C; High, WM			Functional outcome from traumatic brain injury - Unidimensional or multidimensional?	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						brain injury; head injury; functional assessment outcome assessment; quality of life; rehabilitation	HEAD-INJURY; DISABILITY; SCALE	This study compared multidimensional and unidimensional measures of functional outcome from traumatic brain injury in a referred sample of 67 persons with moderate to severe traumatic brain injury who resided in the community or in a nonhospital facility. Four outcome indicators (independence in self-care, independence in travel, paid employment, and friendship) were correlated with the patients' ratings on two unidimensional outcome measures, the Disability Rating Scale (DRS) and Glasgow Outcome Scale (COS), and on a multidimensional outcome measure, the Craig Handicap Assessment and Reporting Technique (CHART). The results showed that the CHART Occupation and Social Integration scales were associated with different outcome indicators, controlling for overall outcome as measured by the DRS and COS. DRS and GOS ratings were associated more strongly with the self-care and travel indicators than with the employment or friendship indicators. The results support a multidimensional model of functional outcome from brain injury, suggest that the CHART may measure some outcome dimensions more specifically than do the DRS and COS, and point to limitations of unidimensional outcome scales.	UNIV TEXAS,SCH MED,DEPT PHYS MED & REHABIL,HOUSTON,TX; INST REHABIL & RES,HOUSTON,TX; BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030								[Anonymous], 1980, INT CLASSIFICATION I; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Condeluci A., 1992, J HEAD TRAUMA REHAB, V7, P37; DILLER L, 1987, REHABILITATION OUTCO, P209; DODDARD D, 1988, J NEUROL NEUROSUR PS, V51, P833; Hamilton BB, 1987, REHABILITATION OUTCO, P137; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JONES ML, 1991, CASE MANAGER     JAN, P44; Kraus JF, 1993, HEAD INJURY, P1; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; WADE DT, 1993, MEASUREMENT NEUROLOG; WHITENECK G, 1988, GUIDE USE CHART CRAI; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	17	35	35	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR-APR	1996	75	2					105	113		10.1097/00002060-199603000-00005			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	UF391	WOS:A1996UF39100005	8630190				2022-02-06	
J	Rimaniol, AC; Lekieffre, D; Serrano, A; Masson, A; Benavides, J; Zavala, F				Rimaniol, AC; Lekieffre, D; Serrano, A; Masson, A; Benavides, J; Zavala, F			Biphasic transforming growth factor-beta production flanking the pro-inflammatory cytokine response in cerebral trauma	NEUROREPORT			English	Article						transforming growth factor-beta; cytokines; brain; trauma	RAT-BRAIN; INJURY; PROLIFERATION; CHEMOTAXIS; INCREASE	WE determined the time-course of the production of transforming growth factor-beta (TGF-beta) after fluid-percussion injury using a bioassay. Biophasic production of TGF-beta composed mainly of TGF-beta(2) was detected in the ipsilateral cortex, with a first peak 30 min and a second peak 48 h after the lesion, flanking the transient production of tumor necrosis factor-alpha and interleukin-6 occurring between 5 and 18 h after trauma. This temporal pattern suggested that TGF-beta plays alternatively a pro- and anti-inflammatory role in the regulation of the brain cytokine network in response to injury, providing an endogenous mechanism for the control of the inflammatory reaction in traumatic brain injury.	HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE; SYNTHELABO RECH, F-92225 BAGNEUX, FRANCE				ZAvALA, Flora/E-7973-2017	ZAvALA, Flora/0000-0002-2338-6802			Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; CHANTRY D, 1989, J IMMUNOL, V142, P4295; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; CHAO CC, 1992, J CLIN INVEST, V90, P1786, DOI 10.1172/JCI116053; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; HENRICHNOACK P, 1995, J CEREBR BLOOD FLOW, V15, pS403; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MCNEILL H, 1994, NEUROREPORT, V5, P901, DOI 10.1097/00001756-199404000-00012; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NICHOLS NR, 1991, J NEUROSCI RES, V28, P134, DOI 10.1002/jnr.490280114; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; PREHN JHM, 1994, PHARM CEREBRAL ISCHE, P404; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1988, J IMMUNOL, V140, P3026; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	25	35	37	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	DEC 29	1995	7	1					133	136		10.1097/00001756-199512290-00032			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TX369	WOS:A1995TX36900032	8742435				2022-02-06	
J	KOSCIULEK, JF				KOSCIULEK, JF			RELATIONSHIP OF FAMILY COPING WITH HEAD-INJURY TO FAMILY ADAPTATION	REHABILITATION PSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; ASSESSMENT DEVICE; VALIDITY; RELIABILITY; CHILDREN; STRESS	Strategies families use to cope with a member's head injury and their relation to family adaptation were investigated. Participants were primary caregivers of persons with head injuries recruited through the Wisconsin Brain Trauma Association. Using cluster analysis, the following family coping variables were identified: (a) positive appraisal, (b) resource acquisition, (c) family tension management, (d) head injury demand reduction, and (e) acquiring social support. Stepwise multiple regression of these variables on family adaptation indicated that positive appraisal and family tension management were predictive of family adaptation. Thus the hypothesis that family adaptation can be predicted from variables measuring family coping with head injury was supported. Clinical, theoretical, and head injury family research implications are discussed.			KOSCIULEK, JF (corresponding author), UNIV MISSOURI,DEPT EDUC & COUNSELING PSYCHOL,16 HILL HALL,COLUMBIA,MO 65211, USA.						Antonovsky A., 1993, COGNITIVE COPING FAM, P111; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Blashfield R.K., 1984, CLUSTER ANAL; Bond M. R., 1990, REHABILITATION ADULT, P179; BORENSTEIN M, 1988, STATISTICAL POWER AN; Boss P., 1987, HDB MARRIAGE FAMILY, P695; BOX GEP, 1976, J AM STAT ASSOC, V71, P791, DOI 10.2307/2286841; Brooks D. N, 1990, REHABILITATION ADULT, P163; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN BW, 1988, FAM RELAT, V37, P300; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; COHEN J, 1988, STATISTICAL POWER AN; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Filsinger E. E., 1990, FAMILY VARIABLES CON, P90; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; HAIR JF, 1987, MULTIVARIATE DATA AN; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1990, REHABILITATION ADULT, P3; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kay, 1991, HEAD INJURY FAMILY M, P81; KAY T, 1990, TRAUMATIC BRAIN INJU, P21; KOSCIULEK JF, 1993, J REHABIL, V59, P40; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Lipsey M., 1990, DESIGN SENSITIVITY S; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; Livingston MG., 1990, REHABILITATION ADULT, P225; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MCCUBBIN HI, 1980, J MARRIAGE FAM, V42, P855, DOI 10.2307/351829; McCubbin HI., 1993, COGNITIVE COPING FAM, P239; MCCUBBIN HI, 1983, SOCIAL STRESS FAMILY, P00007, DOI DOI 10.1300/J002V06N01_02; MCCUBBIN HI, 1981, FCOPES FAMILY CRISIS; MCCUBBIN MA, 1988, FAM RELAT, V37, P203, DOI 10.2307/584321; McCubin M. A., 1991, FAMILY ASSESSMENT IN, P3; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLSON DH, 1982, FACES II FAMILY ADAP; PARKER RM, 1993, REHABIL COUNS BULL, V36, P130; Patterson JM, 1988, FAMILY SYSTEMS MED, V6, P202, DOI [10.1037/h0089739, DOI 10.1037/H0089739]; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; SHUTTY M, 1993, REHABIL PSYCHOL, V38, P145; SZYMANSKI EM, 1993, REHABIL COUNS BULL, V36, P178; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANDERVEEN F, 1981, UNPUB MANUAL HDB FAM; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Williams J., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; 1992, SPSS WINDOWS BASE SY; [No title captured]; [No title captured]	59	35	35	0	2	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	WIN	1994	39	4					215	230		10.1037/h0080325			16	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	QM828	WOS:A1994QM82800001					2022-02-06	
J	PERSINGER, MA				PERSINGER, MA			SENSE OF A PRESENCE AND SUICIDAL IDEATION FOLLOWING TRAUMATIC BRAIN INJURY - INDICATIONS OF RIGHT-HEMISPHERIC INTRUSIONS FROM NEUROPSYCHOLOGICAL PROFILES	PSYCHOLOGICAL REPORTS			English	Article							TEMPORAL-LOBE EPILEPSY; MYSTICAL EXPERIENCES; SELF	50 patients who had sustained a traumatic brain injury were given complete neuropsychological assessments between 0.5 and 4.0 years after the incident; 62% of these patients reported that episodes of a ''sensed presence'' (left side: 71%; right side: 19%; both: 10%) had occurred. Sensed presences along the left side were primarily (82%) associated with anxiety or fear while those which occurred along the right side were more pleasant (83%). The neuropsychological profiles of patients who reported these experiences suggested elevated complex partial epileptic-like signs and a pattern of mild dysfunction within the right prefrontal and temporoparietal lobes which would promote brief hypermetabolic periods within the latter region. Patients who displayed this profile in conjunction with fragmentation of the self-concept and concomitantly lowered left-hemispheric linguistic functions reported more frequent suicidal impulses. The results are compatible with the hypothesis that the ''sense of a presence'' is an intrusion of the right-hemispheric homologue of the sense of self into left-hemispheric awareness.			PERSINGER, MA (corresponding author), LAURENTIAN UNIV,DEPT PSYCHOL,CLIN NEUROPSYCHOL LAB,RAMSEY LAKE RD,SUDBURY,ON P3E 2C6,CANADA.						ARDILA A, 1988, EPILEPSIA, V29, P188, DOI 10.1111/j.1528-1157.1988.tb04417.x; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; Critchley M., 1953, PARIETAL LOBES; Edelman GM, 1989, REMEMBERED PRESENT B; GLOOR P, 1982, ANN NEUROL, V12, P129, DOI 10.1002/ana.410120203; HULL CL, 1952, BEHAVIOR SYSTEM; JIBIKI I, 1994, NEUROSCI BIOBEHAV R, V18, P281, DOI 10.1016/0149-7634(94)90030-2; Kolb B., 1990, FUNDAMENTALS HUMAN N; MacLean P.D., 1990, TRIUNE BRAIN EVOLUTI; MILLER L, 1993, PSYCHOTHERAPY BRAIN; PERSINGER MA, 1993, PERCEPT MOTOR SKILL, V76, P915, DOI 10.2466/pms.1993.76.3.915; PERSINGER MA, 1983, PERCEPT MOTOR SKILL, V57, P1255, DOI 10.2466/pms.1983.57.3f.1255; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; Persinger MA, 1987, NEUROPSYCHOLOGICAL B; PERSINGER MA, UNPUB HYPERPERFUSION; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; Prigatano GP., 1988, J HEAD TRAUMA REHAB, V3, P45; Reitan R, 1985, HALSTEAD REITAN NEUR; RICHARDS P, 1992, PERCEPT MOTOR SKILL, V74, P1027, DOI 10.2466/PMS.74.4.1027-1030; Roberts RJ, 1990, NEUROPSYCHOLOGY, V4, P65; ROBERTS RJ, 1990, J CLIN EXP NEUROPSYC, V12, P448, DOI 10.1080/01688639008400992; SABOURIN L, 1987, PERCEPT MOTOR SKILL, V64, P309, DOI 10.2466/pms.1987.64.1.309; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	23	35	37	0	3	PSYCHOLOGICAL REPORTS	MISSOULA	P O BOX 9229, MISSOULA, MT 59807	0033-2941			PSYCHOL REP	Psychol. Rep.	DEC	1994	75	3	1				1059	1070		10.2466/pr0.1994.75.3.1059			12	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	PX548	WOS:A1994PX54800001	7892368				2022-02-06	
J	PIERCE, JES; SMITH, DH; EISON, MS; MCINTOSH, TK				PIERCE, JES; SMITH, DH; EISON, MS; MCINTOSH, TK			THE NOOTROPIC COMPOUND BMY-21502 IMPROVES SPATIAL-LEARNING ABILITY IN BRAIN-INJURED RATS	BRAIN RESEARCH			English	Article						FLUID-PERCUSSION BRAIN INJURY; COGNITIVE ENHANCER; NOOTROPIC DRUG; MORRIS WATER MAZE (MWM)	LONG-TERM POTENTIATION; FLUID-PERCUSSION MODEL; ASPARTATE RECEPTOR ANTAGONIST; RABBIT FOLLOWING STIMULATION; HEAD-INJURY; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; SELECTIVE IMPAIRMENT; GLUCOSE-UTILIZATION; MEMORY IMPAIRMENT	Although long-lasting cognitive dysfunction often follows clinical traumatic brain injury (TBI), few pharmacologic regimens have been developed to treat post-traumatic cognitive deficits. We have previously shown that, in the rat, experimental lateral fluid-percussion (FP) brain injury induces a profound impairment in retrograde memory. In the present study, we characterized alterations in the ability of rats to learn a novel task following lateral FP brain injury and examined the potential modulatory effects of the nootropic cognitive enhancer BMY-21502 on post-injury learning. Male Sprague-Dawley rats were subjected to lateral (parasagittal) FP brain injury of moderate severity (2.4 atm) or sham surgery (no injury). On days 7 and 8 post-injury, animals were tested in a Morris water maze for their ability to learn to navigate to a submerged, invisible platform using external visual cues. BMY-21502 (10 mg/kg) or vehicle was administered 30 min prior to the first trial on both days. A highly significant (P < 0.001) impairment in post-injury learning was observed in vehicle-treated brain-injured animals compared with vehicle-treated sham animals. Injured animals treated with BMY-21502 at one week post-injury showed significant (P < 0.05) improvement in post-injury learning ability compared to injured animals treated with vehicle. Paradoxically, in uninjured control animals BMY-21502 treatment appeared to worsen learning scores. The results of this study indicate that BMY-21502 may be useful for attenuating the dysfunction in learning ability that occurs following TBI.	UNIV CONNECTICUT, CTR HLTH, CTR NEUROL SCI, FARMINGTON, CT 06030 USA; BRISTOL MYERS SQUIBB CO, CNS DRUG DISCOVERY, PHARMACEUT RES INST, WALLINGFORD, CT 06492 USA		PIERCE, JES (corresponding author), UNIV PENN, DIV NEUROSURG, 105 HAYDEN HALL, 240 S 33RD ST, PHILADELPHIA, PA 19104 USA.		smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, R01NS026818] Funding Source: NIH RePORTER		BARTUS RT, 1981, AGING-US, V17, P209; BERARDI A, 1991, Society for Neuroscience Abstracts, V17, P698; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; BUCZEK M, 1991, J CEREBR BLOOD F MET, V11, P845, DOI 10.1038/jcbfm.1991.144; CHOI DW, 1987, J NEUROSCI, V7, P357; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COPANI A, 1992, J NEUROCHEM, V58, P1199, DOI 10.1111/j.1471-4159.1992.tb11329.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DAVIS S, 1992, J NEUROSCI, V12, P21; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; Dworetzky S. I., 1992, Society for Neuroscience Abstracts, V18, P1154; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRIS SH, 1982, ALZHEIMERS DISEASE R, P475; FITTEN LJ, 1990, PHARMACOL BIOCHEM BE, V35, P553; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GRIBKOFF VK, 1990, NEUROPHARMACOLOGY, V29, P1001, DOI 10.1016/0028-3908(90)90105-Z; GRIBKOFF VK, 1989, ALZHEIMERS DISEASE A, P709; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, IN PRESS J NEUROTRAU; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KREPS M H, 1991, Society for Neuroscience Abstracts, V17, P874; LAL H, 1991, Society for Neuroscience Abstracts, V17, P1235; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LINDNER MD, 1992, PSYCHOPHARMACOLOGY, V107, P485, DOI 10.1007/BF02245260; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH T, 1989, Society for Neuroscience Abstracts, V15, P132; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, FIDIA RES F S SERIES, V9, P247; MCLEAN A JR, 1991, Brain Injury, V5, P375, DOI 10.3109/02699059109008110; MEANS L W, 1990, Society for Neuroscience Abstracts, V16, P1331; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Miyazaki S, 1989, INTRACRANIAL PRESSUR, P651; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAGHAN DT, 1983, NATURE, V306, P176, DOI 10.1038/306176a0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLPE HR, 1982, EUR J PHARMACOL, V80, P415, DOI 10.1016/0014-2999(82)90088-7; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RUTHERFORD WH, 1977, LANCET, V1, P1; SATOH M, 1986, NEUROSCI LETT, V68, P216, DOI 10.1016/0304-3940(86)90145-X; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Smith D. H., 1992, Society for Neuroscience Abstracts, V18, P170; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; STAUBLI U, 1992, HIPPOCAMPUS, V2, P49, DOI 10.1002/hipo.450020107; STEGINK AJ, 1972, ARZNEI-FORSCHUNG, V22, P975; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEYLER TJ, 1984, BRAIN RES REV, V7, P15, DOI 10.1016/0165-0173(84)90027-4; TOCCO G, 1992, BRAIN RES, V573, P228, DOI 10.1016/0006-8993(92)90767-4; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	72	35	35	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 8	1993	624	1-2					199	208		10.1016/0006-8993(93)90078-2			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MA059	WOS:A1993MA05900026	8252392				2022-02-06	
J	KRIEL, RL; KRACH, LE; JONESSAETE, C				KRIEL, RL; KRACH, LE; JONESSAETE, C			OUTCOME OF CHILDREN WITH PROLONGED UNCONSCIOUSNESS AND VEGETATIVE STATES	PEDIATRIC NEUROLOGY			English	Article							CLOSED-HEAD-INJURY; COMA	The outcomes of 60 children unconscious for 90 days or longer following acquired brain injury are reported. Eight children who died had remained in persistent vegetative states. As expected, most neurologic improvement occurred within the first year after injury, although some delayed improvements were observed. Outcomes were strongly correlated with causes of brain injury. Better cognitive and motor function was observed with nonanoxic injuries. No child in this report with anoxic brain injury regained functional cognitive or motor skills, although 3 became socially responsive. The remarkable contrast with adults following acquired brain injury is the significantly longer survival of children. The only children who died had remained in persistent vegetative states.	HENNEPIN CTY MED CTR,DEPT PEDIAT,MINNEAPOLIS,MN 55415; GILLETTE CHILDRENS HOSP,DEPT PEDIAT NEUROL,ST PAUL,MN 55101; GILLETTE CHILDRENS HOSP,DEPT REHABIL,ST PAUL,MN 55101		KRIEL, RL (corresponding author), HENNEPIN CTY MED CTR,DEPT NEUROL,867-B,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.						[Anonymous], 1989, NEUROLOGY, V39, P125; ASHWAL S, 1992, ANN NEUROL, V32, P454; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; COLE G, 1984, BRIT MED J, V289, P1620, DOI 10.1136/bmj.289.6458.1620-c; EYMAN RK, 1990, NEW ENGL J MED, V323, P584, DOI 10.1056/NEJM199008303230906; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; JOHNSTON RB, 1980, DEV MED CHILD NEUROL, V22, P3; JORDAN F M, 1990, Brain Injury, V4, P101, DOI 10.3109/02699059009026154; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LUYENDIJK W, 1992, CLIN NEUROL NEUROSUR, V94, pS113; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARGOLIS LH, 1980, PEDIATRICS, V665, P477; 1990, JAMA-J AM MED ASSOC, V263, P426	16	35	35	0	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	SEP-OCT	1993	9	5					362	368		10.1016/0887-8994(93)90104-K			7	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	MC808	WOS:A1993MC80800004	8292210				2022-02-06	
J	MICHAUD, LJ; RIVARA, FP; JAFFE, KM; FAY, G; DAILEY, JL				MICHAUD, LJ; RIVARA, FP; JAFFE, KM; FAY, G; DAILEY, JL			TRAUMATIC BRAIN INJURY AS A RISK FACTOR FOR BEHAVIORAL-DISORDER IN CHILDREN	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; CHILD BEHAVIOR DISORDERS; CHILDREN; HEAD INJURIES; TRAUMA	CLOSED HEAD-INJURY; PSYCHOLOGICAL SEQUELAE; FOLLOW-UP; CHILDHOOD; ADOLESCENTS; DAMAGE; MOTOR		CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT REHABIL MED,SEATTLE,WA; OFF SUPERINTENDENT PUBL INSTRUCT,OLYMPIA,WA; CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT PEDIAT,SEATTLE,WA; CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT EPIDEMIOL,SEATTLE,WA; CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT NEURODIAGNOST,SEATTLE,WA; UNIV WASHINGTON,SEATTLE,WA 98195						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002570-04] Funding Source: Medline		Austin H., 1982, EPIDEMIOLOGIC ANAL P; BAKER SP, 1984, INJURY FACT BOOK, P24; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROUILLET FB, 1988, STATE WASHINGTON RUL, V1, pC392; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P72; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Cohen S. B., 1986, J HEAD TRAUMA REHAB, V1, P22; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; DAVIDSON LL, 1988, PEDIATRICS, V82, P644; DERSHEWITZ RA, 1983, PEDIATRICS, V72, P602; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P86, DOI 10.1001/jama.1961.03040020012003; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JACOBSON MS, 1986, PEDIATRICS, V77, P236; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jennett B, 1978, Practitioner, V221, P77; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LANGLEY J, 1983, Journal of Pediatric Psychology, V8, P181, DOI 10.1093/jpepsy/8.2.181; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MATHENY AP, 1971, J PEDIATR-US, V79, P122, DOI 10.1016/S0022-3476(71)80071-9; MCGUIRE TL, 1986, J HEAD TRAUMA REHAB, V1, P1; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; NORUSIS MJ, 1986, SPSS PC PLUS IBM PC; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; REEVE R, 1978, BEHAVIOR EXCEPTIONAL, P123; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SINGER HS, 1978, PEDIATRICS, V62, P819; SPIVACK MP, 1986, J HEAD TRQAUMA REHAB, V1, P41	47	35	35	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1993	74	4					368	375					8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	KX398	WOS:A1993KX39800005	8466417				2022-02-06	
J	HASHIMOTO, T; NAKAMURA, N; RICHARD, KE; FROWEIN, RA				HASHIMOTO, T; NAKAMURA, N; RICHARD, KE; FROWEIN, RA			PRIMARY BRAIN-STEM LESIONS CAUSED BY CLOSED-HEAD INJURIES	NEUROSURGICAL REVIEW			English	Article						DIFFUSE AXONAL INJURY; HEAD INJURY; PRIMARY BRAIN STEM INJURY; SHEARING INJURY		Traumatic lesions of the brain stem are of two types: primary, which are considered to be caused at the moment of impact, and secondary, associated with supratentorial mass lesion. Of the 239 patients with a serious head injury who showed a severe disturbance of consciousness upon admisision and who had CT scan carried out immediately, 21 cases were considered to have a primary brain stem lesion with initial CT scan. A primary brain stem lesion was found in 21 of 239 (8.8%) of patients with serious head injury. Their injuries were caused primarily by traffic accidents. Sixteen of the 21 cases showed not only brain stem lesions but also other brain injuries such as cerebral contusion of the white and gray matter, callosal injury, intraventricular hemorrhage, and subarachnoid hemorrhage, which are considered to be caused by a diffuse shearing injury. Five cases who showed a single injury to the brain stem with no other brain lesions were considered to have a pure brain stem lesion. Primary brain stem lesions were observed on the dorsal side of the midbrain, where they can be differentiated from secondary brain stem lesions. These lesions are considered to result from the shearing mechanism in and around the brain stem very close to the tentorial edge, or to an injury of the lower brain stem by hyperextension of the cervical vertebrae. The prognosis of patients with a primary brain stem lesion was usually unfavorable, except in those with a single brain stem lesion.	UNIV COLOGNE, FAC MED, DEPT NEUROSURG, W-5000 COLOGNE 41, GERMANY		HASHIMOTO, T (corresponding author), JIKEI UNIV SCH MED, DEPT NEUROSURG, 3-25-8 NISHI SHINBASHI, MINATO KU, TOKYO 105, JAPAN.						Abe T, 1979, No Shinkei Geka, V7, P345; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ADV NEUROPATHOLOGY, V2; BRITT RH, 1980, NEUROSURGERY, V6, P623, DOI 10.1227/00006123-198006000-00002; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; CROMPTON MR, 1971, LANCET, V1, P669; DIRNHOFER R, 1977, RECHTSMEDIZIN, V79, P25; FRENCH BN, 1977, SURG NEUROL, V7, P171; FROWEIN RA, 1976, ACTA NEUROCHIR, V34, P5, DOI 10.1007/BF01405858; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Huhn B, 1970, Nervenarzt, V41, P326; KOBAYASHI S, 1980, Neurological Surgery, V8, P1165; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Mayer E T, 1969, Radiologe, V9, P16; MITCHELL DE, 1973, LANCET, V2, P215; NAKAJIMA S, 1980, JIKEIKAI MED J, V95, P529; NAKAMURA N, 1985, HEAD INJURY; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PILZ P, 1982, J NEUROL NEUROSUR PS, V45, P422, DOI 10.1136/jnnp.45.5.422; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SAEKI N, 1985, Neurologia Medico-Chirurgica, V25, P939, DOI 10.2176/nmc.25.939; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1969, LATE EFFECT HEAD INJ; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; TSAI FY, 1980, AM J NEURORADIOL, V1, P23; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27; ZUCCARELLO M, 1983, ACTA NEUROCHIR, V67, P103, DOI 10.1007/BF01401670	29	35	35	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.		1993	16	4					291	298		10.1007/BF00383839			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MR330	WOS:A1993MR33000006	8127442				2022-02-06	
J	SCHMITTEREDGECOMBE, ME; MARKS, W; FAHY, JF; LONG, CJ				SCHMITTEREDGECOMBE, ME; MARKS, W; FAHY, JF; LONG, CJ			EFFECTS OF SEVERE CLOSED-HEAD INJURY ON 3 STAGES OF INFORMATION-PROCESSING	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							REACTION-TIME; MEMORY; TASK; PERFORMANCE; SPEED; P300	The present study investigated the loci of the information-processing delay that characteristically follows severe closed-head injury (CHI). Sternberg's additive-factors logic was used to determine the effects of severe CHI on the central information-processing stages of stimulus encoding, memory comparison, and decision-making/response-selection. The task variables used to define the stages operationally were stimulus quality, memory set size, and stimulus-response compatibility. Twenty subjects who had sustained a severe CHI more than 18 months earlier and 20 matched control subjects completed a stimulus encoding by response selection task in Experiment 1, and a Sternberg high-speed memory scanning task in Experiment 2. The CHI group performed the stimulus encoding and decision-making/response-selection stages of processing significantly slower than did the control group. However, no significant group differences were found on the memory comparison stage, suggesting that memory comparison processes may be relatively intact in long-term patients with severe head trauma. The results are discussed in relation to a global and a late-specificity hypothesis of central processing deficits following severe CHI. The possibility that cognitive processes demanding less attention may be more resilient to injury is also considered.			SCHMITTEREDGECOMBE, ME (corresponding author), MEMPHIS STATE UNIV, DEPT PSYCHOL, MEMPHIS, TN 38152 USA.						ANDERS TR, 1973, DEV PSYCHOL, V9, P411, DOI 10.1037/h0034930; Baddeley A. D., 1976, PSYCHOL MEMORY; Bashore T.R., 1990, EVENT RELATED BRAIN, P242; BOND MR, 1983, REHABILITATION HEAD, P185; CALLAWAY E, 1983, PSYCHOPHYSIOLOGY, V20, P359, DOI 10.1111/j.1469-8986.1983.tb00915.x; CURRY SH, 1984, ANN NY ACAD SCI, V425, P171, DOI 10.1111/j.1749-6632.1984.tb23529.x; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; Gronwall D, 1974, PSYCHOL EFFECTS CONC; HANNAY H J, 1982, Journal of Clinical Neuropsychology, V4, P117; HARRIS GJ, 1974, J EXP CHILD PSYCHOL, V17, P452, DOI 10.1016/0022-0965(74)90055-1; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; Jennett B, 1981, MANAGEMENT HEAD INJU; LOFTUS GR, 1978, MEM COGNITION, V6, P312, DOI 10.3758/BF03197461; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MARKS W, 1989, BEHAV RES METH INSTR, V21, P574, DOI 10.3758/BF03210579; MARSH G R, 1975, Experimental Aging Research, V1, P3, DOI 10.1080/03610737508257942; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; Miller E, 1970, Cortex, V6, P121; NAVON D, 1979, PSYCHOL REV, V86, P214, DOI 10.1037/0033-295X.86.3.214; PIETERS JPM, 1983, PSYCHOL BULL, V93, P411, DOI 10.1037/0033-2909.93.3.411; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Ruesch J, 1944, J NEUROSURG, V1, P243, DOI 10.3171/jns.1944.1.4.0243; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Sanders A. F., 1980, TUTORIALS MOTOR BEHA, P331, DOI DOI 10.1016/S0166-4115(08)61955-X; SATTLER JM, 1988, ASSESSMENT CHILDRENS; SCHMITT JC, 1977, AM J PSYCHOL, V90, P565, DOI 10.2307/1421730; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SININGER YS, 1989, J SPEECH HEAR RES, V32, P289, DOI 10.1044/jshr.3202.289; STERNBERG S, 1969, AM SCI, V57, P421; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Van Zomeren A. H., 1981, REACTION TIME ATTENT; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Wechsler, 1997, WECHSLER ADULT INTEL; WILSON RS, 1980, CORTEX, V16, P67, DOI 10.1016/S0010-9452(80)80022-0; [No title captured]	42	35	35	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	SEP	1992	14	5					717	737		10.1080/01688639208402858			21	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	JY191	WOS:A1992JY19100006	1474141				2022-02-06	
J	JINKINS, JR; DADSETAN, MR; SENER, RN; DESAI, S; WILLIAMS, RG				JINKINS, JR; DADSETAN, MR; SENER, RN; DESAI, S; WILLIAMS, RG			VALUE OF ACUTE-PHASE ANGIOGRAPHY IN THE DETECTION OF VASCULAR INJURIES CAUSED BY GUNSHOT WOUNDS TO THE HEAD - ANALYSIS OF 12 CASES	AMERICAN JOURNAL OF ROENTGENOLOGY			English	Article							TRAUMATIC INTRACRANIAL ANEURYSMS; CEREBRAL ANEURYSMS; ORBITOFACIAL WOUNDS; BRAIN	A study of the angiographic findings in consecutive civilian patients with cranial gunshot wounds examined in the acute stage has not been done. Most prior clinical studies have evaluated the findings in survivors in the subacute or chronic stages and have often been of war-time casualties, We determined the clinicoradiologic features of six cases of posttraumatic intracranial aneurysm, vascular occlusion, or arteriovenous fistula caused by penetrating missiles among 12 civilian patients who were examined in the acute posttraumatic stage (within 48 hr of injury) during a 1-year period. Three internal carotid/vertebral artery aneurysms, one external carotid artery aneurysm, one combined aneurysm/arteriovenous fistula of the vertebrobasilar circulation, and one cerebral venous occlusion were identified. The 50% overall prevalence ot major vascular lesions in this series of civilian patients with penetrating missile injuries examined in the acute stage suggests these injuries are more common than previously suspected. It may indicate that selective cerebral angiography should be considered in the evaluation of the cranial vascular system of such persons.	METHODIST HOSP SAN ANTONIO,DEPT RADIOL,SAN ANTONIO,TX 78229		JINKINS, JR (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT RADIOL,NEURORADIOL SECT,SAN ANTONIO,TX 78284, USA.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACHRAM M, 1980, BRIT J RADIOL, V53, P1144, DOI 10.1259/0007-1285-53-636-1144; BANK WO, 1972, AJR, V130, P957; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CAROTHERS A, 1978, JAMA-J AM MED ASSOC, V239, P1151, DOI 10.1001/jama.239.12.1151; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HANDEL SF, 1978, AM J ROENTGENOL, V130, P507, DOI 10.2214/ajr.130.3.507; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; JACKSON F, 1976, HDB CLIN NEUROLOGY, P381; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; KUHN RA, 1964, J NEUROSURG, V21, P92, DOI 10.3171/jns.1964.21.2.0092; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; RAIMONDI AJ, 1968, NEUROCHIRURGIA, V11, P219; STEHBENS WE, 1972, PATHOLOGY CEREBRAL B, P452; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163	26	35	35	0	1	AMER ROENTGEN RAY SOC	RESTON	1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091	0361-803X			AM J ROENTGENOL	Am. J. Roentgenol.	AUG	1992	159	2					365	368		10.2214/ajr.159.2.1632358			4	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	JE567	WOS:A1992JE56700028	1632358				2022-02-06	
J	YING, Z; SCHMID, UD; SCHMID, J; HESS, CW				YING, Z; SCHMID, UD; SCHMID, J; HESS, CW			MOTOR AND SOMATOSENSORY EVOKED-POTENTIALS IN COMA - ANALYSIS AND RELATION TO CLINICAL STATUS AND OUTCOME	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; NITROUS-OXIDE; ELECTRICAL-STIMULATION; MAGNETIC STIMULATION; CEREBRAL-CORTEX; BRAIN; PREDICTION; TRAUMA; SCALE	Central sensory and motor conduction were studied in 23 comatose and three brain-dead patients. Motor evoked potentials (MEPs) to transcranial magnetic (magMEP) and electrical (elMEP) stimulation were recorded from the hypothenar muscle, and somatosensory evoked potentials (SEPs) were recorded after median nerve stimulation. Comparison of clinical with evoked potential (EP) findings revealed: 1) a painful stimulus applied to the skin of the arm lowered excitation threshold to cortical stimulation and was a prerequisite to obtain MEPs in 14 instances; 2) only in brain-dead patients were all EPs abolished simultaneously and bilaterally; 3) MEPS (p less-than-or-equal-to 0-05, chi-2-Test), but not necessarily SEPs (p > 0.1) were preserved in the arms that showed normal motor reaction during clinical examination; 4) no correlation was found between EP findings and the Glasgow Coma Scale (GCS). The results of clinical and EP testing were examined in. the light of the patient's outcome 10 months later: 1) fatal outcome was predicted by a GCS of three (38% of cases, p less-than-or-equal-to 0.05, Fisher's exact test), abolished brainstem- or pupillary reflexes (38%, p less-than-or-equal-to 0.05), the combination of these clinical signs (54%, p less-than-or-equal-to 0.01), bilateral abolition of elMEPs (38%, p less-than-or-equal-to 0.05), magMEPs (38%, p less-than-or-equal-to 0.05), or SEPs (23%, p > 0.1), or a combination of clinical and EP data (85%, p less-than-or-equal-to 0.0005); 2) good outcome was predicted by a GCS of greater-than-or-equal-to 8 only in post-traumatic coma, and EPs did not help to predict quality of survival. It is concluded that EPs may be studied to predict fatal outcome of coma; 1) if this appears impossible on the basis of clinical data alone; 2) if a second indicator is needed to confirm a clinical impression; 3) SEPs may be first evaluated during the acute stage of coma treatment, because they can be recorded in the presence of anaesthetic or relaxant agents; 4) MEP may be studied if outcome prediction remains ambiguous, and if the clinical situation allows for discontinuation of these agents.	BERNE UNIV HOSP,DEPT NEUROL,BERN,SWITZERLAND; BERNE UNIV HOSP,DEPT NEUROSURG,BERN,SWITZERLAND								AMASSIAN VE, 1987, NEUROSURGERY, V20, P74; BARKER AT, 1985, LANCET, V1, P1106; BESSER R, 1988, NEUROSURG REV, V11, P171, DOI 10.1007/BF01794684; BORN J, 1989, ACTA NEUROCHIR WIEN, V91, P1; Braakman R, 1986, Acta Neurochir Suppl (Wien), V36, P112; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; DATE M, 1991, ELECTROENCEPHALOGR S, V43, P209; DAY BL, 1988, J PHYSL LOND P, V68, P399; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HACKE W, 1987, EEG-EMG-Z ELEK ELEKT, V18, P173; HESS CW, 1987, J PHYSIOL-LONDON, V388, P397, DOI 10.1113/jphysiol.1987.sp016621; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KOHT A, 1988, ANESTH ANALG, V67, P435; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MACDONELL RAL, 1989, ANN NEUROL, V25, P68, DOI 10.1002/ana.410250111; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; MULLERJENSEN A, 1987, J NEUROL NEUROSUR PS, V50, P389; PATHAK KS, 1989, ANESTHESIOLOGY, V70, P207, DOI 10.1097/00000542-198902000-00005; PLUM F, 1980, DIAGNOSIS STUPOR COM, P313; RIFFEL B, 1989, ANAESTHESIST, V38, P51; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; SCHMID U, 1991, NEUROSURGERY, V30, P85; SCHMID UD, 1988, J NEUROL NEUROSUR PS, V51, P182, DOI 10.1136/jnnp.51.2.182; SCHMID UD, 1990, J NEUROL NEUROSUR PS, V53, P770, DOI 10.1136/jnnp.53.9.770; TEASDALE G, 1974, LANCET, V2, P81; TUNG H C, 1988, Anesthesiology (Hagerstown), V69, pA313, DOI 10.1097/00000542-198809010-00312; TURNER F, 1988, SPINAL CORD MONITORI, P82; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989; ZENTNER J, 1989, NEUROSURGERY, V24, P60, DOI 10.1227/00006123-198901000-00009; ZENTNER J, 1988, EUR ARCH PSY CLIN N, V237, P184, DOI 10.1007/BF00451288; ZENTNER J, 1989, NEUROSURGERY, V24, P253, DOI 10.1227/00006123-198902000-00016	34	35	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1992	55	6					470	474		10.1136/jnnp.55.6.470			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	HZ150	WOS:A1992HZ15000011	1619414	Green Published, Bronze			2022-02-06	
J	HURVITZ, EA; MANDAC, BR; DAVIDOFF, G; JOHNSON, JH; NELSON, VS				HURVITZ, EA; MANDAC, BR; DAVIDOFF, G; JOHNSON, JH; NELSON, VS			RISK-FACTORS FOR HETEROTOPIC OSSIFICATION IN CHILDREN AND ADOLESCENTS WITH SEVERE TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; HETEROTOPIC; OSSIFICATION	BONE-FORMATION; HEAD-INJURY; PATIENT	Previous reports on the incidence of heterotopic ossification (HO) in children and adolescents with traumatic brain injury (TBI) have ranged from 3% to 20%. These studies mention HO briefly or address patient cohorts with coma more than three months. We reviewed the medical records of 90 children younger than 19 years old, who were comatose more than 24 hours after TBI. Mean followup was 33.1 months (range = 2 to 128 months). Incidence of HO was 14.4% (n = 13). One to five sites were involved, with hip and knee most frequent, followed by shoulder, elbow, and nonjoint sites. Children with HO were older than 11 years (relative risk [RR] = 18.85, confidence interval [CI] = 3.7, 95.7), had a greater length of coma (RR = 7.22, CI = 1.4, 37.1), and had a greater associated risk for poor functional outcome (RR = 2.89, CI = 1.02, 7.9) compared to those without RO. Multiple limb fractures showed a trend toward association with increased incidence of HO. Other factors, including gender, history of skull fracture, brain CAT scan findings, and presence of spasticity, were not predictive of HO. Eleven children were treated with etidronate, four with nonsteroidal antiinflammatory drugs, and one with surgery. Only three children had residual functional impairments attributed to the presence of HO.	UNIV MICHIGAN,MED CTR,DEPT PHYS MED & REHABIL,ANN ARBOR,MI 48109		HURVITZ, EA (corresponding author), VET AFFAIRS MED CTR,REHABIL MED SERV,2215 FULLER RD,ANN ARBOR,MI 48105, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001120] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-01120-03] Funding Source: Medline		ALEXANDER MA, 1990, ARCH PHYS MED REHAB, V71, P769; BRINK JD, 1978, ORTHOP CLIN N AM, V9, P451; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BURING K, 1975, CLIN ORTHOP RELAT R, V110, P293; CHIODO AE, 1987, ARCH PHYS MED REHAB, V68, P645; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EVANS EB, 1968, J AMER MED ASSOC, V204, P843, DOI 10.1001/jama.204.10.843; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARCIAMORTEO O, 1983, J BONE JOINT SURG AM, V65, P812, DOI 10.2106/00004623-198365060-00013; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P531; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; HOFFER MM, 1975, CLIN ORTHOPAEDICS, V110, P244; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; MINAIRE P, 1980, ARCH PHYS MED REHAB, V61, P214; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; Ommaya A K, 1966, Ann R Coll Surg Engl, V39, P317; RITTER MA, 1987, ORTHOPEDICS, V10, P1379; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120, DOI 10.1302/0301-620X.63B1.7204466; SAZBON L, 1982, SCAND J REHABIL MED, V15, P43; SHAPIRO K, 1983, PEDIATRIC HEAD TRAUM; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; 1985, SAS USERS GUIDE STAT, P403	24	35	38	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1992	73	5					459	462					4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	HU709	WOS:A1992HU70900011	1580774				2022-02-06	
J	GALLYAS, F; ZOLTAY, G; BALAS, I				GALLYAS, F; ZOLTAY, G; BALAS, I			AN IMMEDIATE LIGHT MICROSCOPIC RESPONSE OF NEURONAL SOMATA, DENDRITES AND AXONS TO CONTUSING CONCUSSIVE HEAD-INJURY IN THE RAT	ACTA NEUROPATHOLOGICA			English	Article						CONTUSING CONCUSSIVE HEAD INJURY; INDUCED ARGYROPHILIA; NEURONS; DENDRITES; AXONS	BRAIN; DAMAGE; TRAUMA	Thirty-four rats were killed by transcardial perfusion fixation 1 min after a contusing concussive head injury, and 17 rats 1 day later. From the results obtained with a new silver method demonstrating traumatically damaged neuronal somata, dendrites and axons the following conclusions were drawn: (1) outside the contused territories all features of traumatically induced neuronal argyrophilia are similar to those found in non-contusing concussive head injury, as reported in an accompanying paper; (2) within contused territories the neuronal argyrophilia is abolished by some substance released either from damaged blood vessels or from damaged parenchymal cells, while the neuronal damage otherwise underlying the induction of argyrophilia is present; (3) different phenotypes of neurons are vulnerable to different values of the parameters of the intracranial pressure wave generated by the trauma; (4) some of the neurons may recover from the traumatically induced argyrophilic damage; (5) traumatically induced inundation of neurons with extracellular tracers, as reported by other authors, and somato-dendritic argyrophilia may be different manifestations of one and the same phenomenon; and (6) diffuse primary traumatic axonal injury in human neuropathology may be closely correlated to axonal argyrophilia.			GALLYAS, F (corresponding author), UNIV PECS,DEPT NEUROSURG,RET UTCA 2,H-7623 PECS,HUNGARY.		Gallyas, Ferenc/C-5450-2009				ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; GALLYAS F, 1992, IN PRESS ACTA NEUROP, V83; GRIFFITHS IR, 1974, J NEUROL SCI, V22, P291, DOI 10.1016/0022-510X(74)90002-1; KLATZO IGOR, 1962, ACTA NEUROPATHOLOGICA, V2, P144; MAXWELL WL, 1990, J NEUROCYTOL, V19, P235, DOI 10.1007/BF01217301; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410; VANEGAS H, 1978, J COMP NEUROL, V177, P193, DOI 10.1002/cne.901770203	18	35	35	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAR	1992	83	4					394	401		10.1007/BF00713531			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	HK264	WOS:A1992HK26400010	1374205				2022-02-06	
J	MCKENNAN, KX; CHOLE, RA				MCKENNAN, KX; CHOLE, RA			FACIAL PARALYSIS IN TEMPORAL BONE TRAUMA	AMERICAN JOURNAL OF OTOLOGY			English	Article							NERVE; PALSY	A retrospective review of 36 patients with delayed-onset (19 patients) and immediate-onset (17 patients) traumatic facial paralysis was performed. We hypothesized that traumatic delayed-onset facial paralysis does not necessitate surgical decompression under any routine circumstances. Of 19 patients in this group, normal recovery (House grade 1) occurred in 94 percent of the patients without surgical intervention. The small percentage (6%) of these patients who failed to recover completely demonstrated mild degrees of weakness and synkinesis (House grade 2). Immediate-onset paralysis occurred in 1 7 patients. It has a much poorer prognosis. Seven patients with penetrating wounds had facial nerve transections, usually of the vertical portion of the facial nerve. Closed head injured patients with immediate-onset facial paralysis sustained injuries usually to the horizontal and perigeniculate portion of the facial nerve. For those cases in which surgical exploration of the traumatized facial nerve is indicated, the operating surgeon should have the capacity to enlarge the exposure with a translabyrinthine or middle-fossa dissection.	UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,SACRAMENTO,CA 95817		MCKENNAN, KX (corresponding author), SACRAMENTO EAR NOSE & THROAT SURG & MED GRP,3810 J ST,SACRAMENTO,CA 95816, USA.						ADOUR KK, 1977, LARYNGOSCOPE, V87, P389; BOYLE WF, 1967, LARYNGOSCOPE, V77, P1168, DOI 10.1288/00005537-196707000-00009; FISCH U, 1979, CLIN PLAST SURG, V6, P377; GREER JA, 1974, ANN OTO RHINOL LARYN, V83, P582, DOI 10.1177/000348947408300503; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; MAIMAN DJ, 1985, J TRAUMA, V25, P644, DOI 10.1097/00005373-198507000-00012; MAY M, 1979, LARYNGOSCOPE, V89, P906; MCCABE BF, 1972, LARYNGOSCOPE, V82, P1891, DOI 10.1288/00005537-197210000-00011; TURNER JW, 1944, LANCET          0610, P756; YANAGIHARA N, 1982, OTOLARYNG HEAD NECK, V90, P616, DOI 10.1177/019459988209000521	10	35	38	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0192-9763			AM J OTOL	Am. J. Otol.	MAR	1992	13	2					167	172					6	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	HJ274	WOS:A1992HJ27400014	1599010				2022-02-06	
J	LINDSAY, RM; ALDERSON, RF; FRIEDMAN, B; HYMAN, C; FURTH, ME; MAISONPIERRE, PC; SQUINTO, SP; YANCOPOULOS, GD				LINDSAY, RM; ALDERSON, RF; FRIEDMAN, B; HYMAN, C; FURTH, ME; MAISONPIERRE, PC; SQUINTO, SP; YANCOPOULOS, GD			THE NEUROTROPHIN FAMILY OF NGF-RELATED NEUROTROPHIC FACTORS	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article								The recent molecular cloning of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) has established the existence of an NGF-related family of neurotrophic factors - the neurotrophins. Purification and recombinant production of BDNF and NT-3 has allowed the initiation or extension of in vitro studies of the neuronal specificity of each of these factors. We have found that NT-3, like NGF and BDNF, promotes survival and neurite outgrowth from certain populations of sensory neurons. There appear to be both distinct and overlapping specificities of the 3 neurotrophins towards peripheral neurons - sympathetic neurons and subpopulations of neural crest and neural placode-derived sensory neurons. Using cultures of central nervous system neurons, we have recently established that BDNF: (i) promotes the survival and phenotypic differentiation of rat septal cholinergic neurons, a property consistent with the discovery of high levels of BDNF mRNA expression within the hippocampus; (ii) promotes the survival of rat nigral dopaminergic neurons and furthermore protects these neurons from two dopaminergic neurotoxins, 6-hydroxydopamine (6-OHDA) and MPTP. Thus the neurotrophic effects of these factors towards peripheral neurons and neuronal populations known to degenerate in two of the major human neurodegenerative diseases - Alzheimer's and Parkinson's disease - provokes the question of whether neurotrophic factors may have therapeutic potential in halting the progression and ameliorating the symptoms of devastating neurological disorders of the CNS or PNS, or improving regeneration of neurons of CNS or PNS after traumatic injury.			LINDSAY, RM (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.			Ip, Nancy Yuk-Yu/0000-0002-2763-8907			ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; AUBURGER G, 1987, DEV BIOL, V120, P322, DOI 10.1016/0012-1606(87)90235-1; Barde YA, 1987, PROG BRAIN RES <D>, V71, P185; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; DAVIES AM, 1986, J NEUROSCI, V6, P1897; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HEFTI F, 1986, J NEUROSCI, V6, P2155; HEFTI F, 1989, NEUROBIOL AGING, V10, P515, DOI 10.1016/0197-4580(89)90118-8; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, IN PRESS NATURE; KNUSEL B, 1990, J NEUROSCI, V10, P558; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801, DOI 10.1523/JNEUROSCI.10-12-03801.1990; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1985, DEV BIOL, V112, P30, DOI 10.1016/0012-1606(85)90116-2; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; LINDSAY RM, 1985, J CELL SCI, P115; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; LINDSAY RM, 1988, MAKING NERVOUS SYSTE, P148; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; OTTO D, 1990, J NEUROSCI, V10, P1912; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WHITTEMORE SR, 1986, P NATL ACAD SCI USA, V83, P817, DOI 10.1073/pnas.83.3.817; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YANCOPOULOS GD, IN PRESS SPR COLD HA; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	41	35	35	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	JUL	1991	2	4-6					211	220					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ024	WOS:A1991FZ02400008	21551605				2022-02-06	
J	VOLPE, BT; MCDOWELL, FH				VOLPE, BT; MCDOWELL, FH			THE EFFICACY OF COGNITIVE REHABILITATION IN PATIENTS WITH TRAUMATIC BRAIN INJURY	ARCHIVES OF NEUROLOGY			English	Article											VOLPE, BT (corresponding author), CORNELL UNIV,SCH MED,BURKE REHABIL CTR,DEPT NEUROL,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.		volpe, b/U-8409-2019	Volpe, Bruce/0000-0002-1098-1848			ABREU BC, 1987, AM J OCCUP THER, V41, P439, DOI 10.5014/ajot.41.7.439; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANDERSON DW, 1980, NATIONAL HEAD SPINAL; ASHENASY JJM, 1987, AM J PHYS MED, V66, P315; BACHYRITA P, 1988, PRINCIPLES PRACTICE, pCH10; Balliet R, 1987, Int Rehabil Med, V8, P148; BECKER DP, 1985, CENTRAL NERVOUS SYST; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; CARAMAZZA A, 1984, BRAIN LANG, V21, P9, DOI 10.1016/0093-934X(84)90032-4; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Cotman C W, 1988, Adv Neurol, V47, P313; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DILLER L, 1981, J CONSULT CLIN PSYCH, V49, P822, DOI 10.1037/0022-006X.49.6.822; EKBERG K, 1984, SCAND J WORK ENV HEA, V10, P36; Fodor J.A., 1983, MODULARITY MIND; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P282; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hayden M E, 1986, Adv Psychosom Med, V16, P194; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20, P77; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P2400; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P3187; KOTSORIS HO, 1987, J NEURO REHAB, V2, P73; LANDAU WM, 1988, ARCH NEUROL-CHICAGO, V45, P371; LEVIN HS, 1987, J NEUROSURG, V66, P716; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P436; MARLER JR, 1989, PRINCETON C CEREBRAL, P17; MULLER R, 1956, ARCH NEURO PSYCHIATR, V76, P597; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RYAN EB, 1986, J LEARN DISABIL, V19, P521, DOI 10.1177/002221948601900902; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; WEINBERG J, 1979, ARCH PHYS MED REHAB, V60, P491; Willis S L, 1987, Annu Rev Gerontol Geriatr, V7, P159; 1982, LANCET, V2, P1034	39	35	35	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	FEB	1990	47	2					220	222		10.1001/archneur.1990.00530020128026			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CM306	WOS:A1990CM30600024	2405821				2022-02-06	
J	LAWSON, MJ; RICE, DN				LAWSON, MJ; RICE, DN			EFFECTS OF TRAINING IN USE OF EXECUTIVE STRATEGIES ON A VERBAL MEMORY PROBLEM RESULTING FROM CLOSED HEAD-INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									S AUSTRALIAN COLL ADV EDUC,INST STUDY LEARNING DIFFICULTIES,STURT,SA,AUSTRALIA		LAWSON, MJ (corresponding author), FLINDERS UNIV,SCH EDUC,BEDFORD PK,SA 5042,AUSTRALIA.			Lawson, Michael/0000-0002-0175-3683			*AUSTR COUN ED RES, 1972, PROGR ACH TEST READ; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; BINDER L M, 1980, Journal of Clinical Neuropsychology, V2, P71, DOI 10.1080/01688638008403782; BROOKS LR, 1968, CAN J PSYCHOLOGY, V22, P349, DOI 10.1037/h0082775; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CERMAK L S, 1975, Cortex, V11, P163; Cermak L. S., 1982, HUMAN MEMORY AMNESIA; CORVITZ H, 1979, CORTEX, V15, P131; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; DESROSIERS G, 1986, J CLIN EXP NEUROPSYC, V8, P637, DOI 10.1080/01688638608405184; Flavell J H, 1970, Adv Child Dev Behav, V5, P181, DOI 10.1016/S0065-2407(08)60467-X; GASPARRINI B, 1979, Journal of Clinical Neuropsychology, V1, P137, DOI 10.1080/01688637908414447; GIANUTSOS R, 1981, Journal of Clinical Neuropsychology, V3, P143, DOI 10.1080/01688638108403119; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; Glaser, 1978, ADV INSTRUCTIONAL PS, V1, P77; GODFREY HPD, 1987, BRIT J CLIN PSYCHOL, V26, P83, DOI 10.1111/j.2044-8260.1987.tb00735.x; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; KEARCOLWELL JJ, 1980, J CLIN PSYCHOL, V36, P782, DOI 10.1002/1097-4679(198007)36:3<782::AID-JCLP2270360334>3.0.CO;2-K; KOVNER R, 1985, J CLIN EXP NEUROPSYC, V7, P395, DOI 10.1080/01688638508401272; Lawson M., 1984, COGNITIVE STRATEGIES, P89; Lawson M. J., 1980, COGNITION DEV INSTRU, P145; LAWSON MJ, 1986, MENTAL RETARDATION L, V14, P2; LAWSON MJ, 1987, COGNITIVE STRATEGY T; PAIVIO A, 1968, J EXPT PSYCHOL MON 2, V76; PARIS SG, 1984, J EDUC PSYCHOL, V76, P1239, DOI 10.1037/0022-0663.76.6.1239; REY A, 1959, EDIITIONS CTR PSYCHO; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; WABER DP, 1985, J CLIN EXP NEUROPSYC, V7, P264, DOI 10.1080/01688638508401259; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILSON B, 1982, CORTEX, V18, P581, DOI 10.1016/S0010-9452(82)80055-5; [No title captured]; [No title captured]	34	35	35	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1989	11	6					842	854		10.1080/01688638908400939			13	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	CC215	WOS:A1989CC21500005	2592526				2022-02-06	
J	RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN				RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN			CNV ABNORMALITIES FOLLOWING CLOSED HEAD-INJURY	BRAIN			English	Article									DUNDEE ROYAL INFIRM,DEPT SURG NEUROL,DUNDEE,SCOTLAND; UNIV GLASGOW,DEPT PSYCHOL MED,GLASGOW G12 8QQ,SCOTLAND		RUGG, MD (corresponding author), UNIV ST ANDREWS,DEPT PSYCHOL,MRC,COGNIT NEUROSCI RES GRP,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.						Benson D.F., 1986, FRONTAL LOBES; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS N, 1984, CLOSED HEAD INJURY P; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; CURRY SH, 1984, ANN NY ACAD SCI, V425, P171, DOI 10.1111/j.1749-6632.1984.tb23529.x; CURRY SH, 1983, THESIS U BRISTOL; DREWE E A, 1975, Cortex, V11, P8; JENKINS A, 1986, LANCET, V2, P445; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levin HS., 1982, NEUROBEHAVIORAL CONS; Loveless NE, 1979, ORIENTING REFLEX HUM, P77; MCCALLUM WC, 1973, ELECTROEN CLIN NEURO, V35, P449, DOI 10.1016/0013-4694(73)90020-5; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; Rohrbaugh J W, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P189; Rohrbaugh JW, 1983, ADV PSYCHOL, V10, P269; ROHRBAUGH JW, 1984, VARIETIES ATTENTION, P323; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; STEPHENSON WA, 1951, ELECTROEN CLIN NEURO, V3, P237, DOI 10.1016/0013-4694(51)90017-X; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VERFAELLIE M, 1987, ARCH NEUROL-CHICAGO, V44, P1265, DOI 10.1001/archneur.1987.00520240045010; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	27	35	35	0	0	OXFORD UNIV PRESS UNITED KINGDOM	OXFORD	WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP	0006-8950			BRAIN	Brain	APR	1989	112		2				489	506		10.1093/brain/112.2.489			18	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	U5295	WOS:A1989U529500011	2706441				2022-02-06	
J	KRIEL, RL; KRACH, LE; SHEEHAN, M				KRIEL, RL; KRACH, LE; SHEEHAN, M			PEDIATRIC CLOSED HEAD-INJURY - OUTCOME FOLLOWING PROLONGED UNCONSCIOUSNESS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									GILLETTE CHILDRENS HOSP,DEPT REHABIL,ST PAUL,MN 55101		KRACH, LE (corresponding author), GILLETTE CHILDRENS HOSP,DEPT PEDIAT NEUROL,200 E UNIV AVE,ST PAUL,MN 55101, USA.			Krach, Linda/0000-0002-0993-8199			ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; BARTKOWSKI HM, 1986, HEAD TRAUMA REHABIL, V1, P1; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1983, PEDIATRIC HEAD TRAUM, P213; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON RB, 1980, DEV MED CHILD NEUROL, V22, P3; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MAY PG, 1968, DIS NERV SYST, V29, P837; MAYER T, 1981, JAMA-J AM MED ASSOC, V245, P719; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; OVERGAARD J, 1973, LANCET, V2, P631; Pagni C A, 1975, J Neurosurg Sci, V19, P120; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SHUTTLEWORTH E, 1983, NEUROLOGY, V33, P372, DOI 10.1212/WNL.33.3.372; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; TEASDALE G, 1974, LANCET, V2, P81; THIENPRASIT P, 1985, MINN MED, V68, P559	27	35	36	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1988	69	9					678	681					4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	Q3078	WOS:A1988Q307800005	3421822				2022-02-06	
J	LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; WILLIAMS, D				LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; WILLIAMS, D			AUTOMATIC AND EFFORTFUL PROCESSING AFTER SEVERE CLOSED HEAD-INJURY	BRAIN AND COGNITION			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		ALBA JW, 1980, J EXP PSYCHOL-HUM L, V6, P370, DOI 10.1037/0278-7393.6.4.370; ATTIG M, 1980, J GERONTOL, V35, P66, DOI 10.1093/geronj/35.1.66; BROOKS JE, 1985, AM J PSYCHOL, V98, P363, DOI 10.2307/1422622; FLEXSER AJ, 1975, B PSYCHONOMIC SOC, V6, P321, DOI 10.3758/BF03336675; GOLDSTEIN D, 1983, AM J PSYCHOL, V96, P229, DOI 10.2307/1422814; GRONWALL D, 1974, LANCET, V2, P605; HASHER L, 1984, AM PSYCHOL, V39, P1372, DOI 10.1037/0003-066X.39.12.1372; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; HUPPERT FA, 1978, Q J EXP PSYCHOL, V30, P347, DOI 10.1080/14640747808400681; NEWMAN RP, 1984, NEUROLOGY, V34, P805, DOI 10.1212/WNL.34.6.805; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAIVIO A, 1968, J EXPT PSYCHOL M 2 S, V76; ROYBYRNE PP, 1986, ARCH GEN PSYCHIAT, V43, P265; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SMITH ML, 1983, SOC NEUR ABSTR, V9, P30; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thorndike E. L., 1944, TEACHERS WORD BOOK 3; VAKIL E, 1985, 13TH ANN CONV INT NE; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; WEINGARTNER H, 1983, SCIENCE, V221, P380, DOI 10.1126/science.6867715; WEINGARTNER H, 1984, PSYCHIAT RES, V11, P223, DOI 10.1016/0165-1781(84)90071-4; WEINGARTNER H, 1982, ALZHEIMERS DISEASE R; ZACKS RT, 1982, J EXP PSYCHOL-HUM L, V8, P106, DOI 10.1037/0278-7393.8.2.106	24	35	35	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	JUN	1988	7	3					283	297		10.1016/0278-2626(88)90003-6			15	Neurosciences; Psychology, Experimental	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	N7297	WOS:A1988N729700003	3401383				2022-02-06	
J	GURDJIAN, ES; LISSNER, HR				GURDJIAN, ES; LISSNER, HR			PHOTOELASTIC CONFIRMATION OF PRESENCE OF SHEARSTRAINS AT CRANIOSPINAL JUNCTION IN CLOSED HEAD INJURY	JOURNAL OF NEUROSURGERY			English	Article																	CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; Gurdjian ES, 1944, J NEUROSURG, V1, P393, DOI 10.3171/jns.1944.1.6.0393; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GURDJIAN ES, 1958, HEAD INJURIES MECHAN, P1; HADDAD B. F., 1955, NEUROLOGY, V5, P798; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; WALKER EA, 1944, J NEUROSURG, V1, P103	7	35	36	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1961	18	1					58	&		10.3171/jns.1961.18.1.0058			0	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	6057B	WOS:A19616057B00004	13709838				2022-02-06	
J	Wang, JL; Chu, RL; Ni, N; Nan, GX				Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin			The effect of Matrigel as scaffold material for neural stem cell transplantation for treating spinal cord injury	SCIENTIFIC REPORTS			English	Article							BASEMENT-MEMBRANE MATRIX; FUNCTIONAL RECOVERY; AXONAL REGENERATION; GROWTH-FACTOR; SURVIVAL; THERAPY	Traumatic injury to the spinal cord causes permanent loss of function and major personal, social, and economic problems. Cell-based delivery strategies is a promising approach for treating spinal cord injury (SCI). However, the inhospitable microenvironment in the injured spinal cord results in poor cell survival and uncontrolled differentiation of the transplanted stem cells. The combination of a scaffold with cells has been developed with a tendency for achieving greater survival and integration with the host tissue. We investigated the effect of Matrigel combined with neural stem cells (NSCs) in vitro and in vivo. We compared the effect of different types of scaffold on the survival and differentiation of brain-derived NSCs in an in vitro culture. Subsequently, NSCs were transplanted subcutaneously into nude mice to detect graft survival and differentiation in vivo. Finally, phosphate-buffered saline (PBS), Matrigel alone, or Matrigel seeded with NSCs was injected into 48 subacute, clinically relevant rat models of SCI (16 rats per group). Matrigel supported cell survival and differentiation efficiently in vitro and in vivo. SCI rats transplanted with NSCs in Matrigel showed improved behavioral recovery and neuronal and reactive astrocyte marker expression levels compared to PBS- or Matrigel-transplanted rats. Functional repair and neuronal and reactive astrocyte marker expression was slightly improved in the Matrigel-alone group relative to the PBS group, but not statistically significantly. These data suggest that Matrigel is a promising scaffold material for cell transplantation to the injured spinal cord.	[Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] Chongqing Med Univ, Childrens Hosp, Dept Pediat Res Inst, Minist Educ,Key Lab Child Dev & Disorders, Chongqing 400014, Peoples R China; [Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China; [Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] Chongqing Engn Res Ctr Stem Cell Therapy, Chongqing, Peoples R China; [Wang, Jiuling; Chu, Ruiliang; Ni, Na; Nan, Guoxin] ChongqingMed Univ, Childrens Hosp, Dept Orthopaed, Chongqing, Peoples R China		Nan, GX (corresponding author), Chongqing Med Univ, Childrens Hosp, Dept Pediat Res Inst, Minist Educ,Key Lab Child Dev & Disorders, Chongqing 400014, Peoples R China.; Nan, GX (corresponding author), China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China.; Nan, GX (corresponding author), Chongqing Engn Res Ctr Stem Cell Therapy, Chongqing, Peoples R China.; Nan, GX (corresponding author), ChongqingMed Univ, Childrens Hosp, Dept Orthopaed, Chongqing, Peoples R China.	ngx1215@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81272172]; National Key Specialty Construction of Clinical Project [2013-544]	This work was supported in part by research grants from the National Natural Science Foundation of China (#81272172 to NAN) and National Key Specialty Construction of Clinical Project (#2013-544).	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Bliss TM, 2010, NEUROBIOL DIS, V37, P275, DOI 10.1016/j.nbd.2009.10.003; Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083; Engbring JA, 2003, J PATHOL, V200, P465, DOI 10.1002/path.1396; English D, 2013, J CELL BIOCHEM, V114, P764, DOI 10.1002/jcb.24436; Fujimoto Y, 2012, STEM CELLS, V30, P1163, DOI 10.1002/stem.1083; Garcia-Altes A, 2012, NEUROEPIDEMIOLOGY, V39, P103, DOI 10.1159/000338297; Guo XD, 2012, CELL TRANSPLANT, V21, P1177, DOI 10.3727/096368911X612503; Hall PE, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-71; He B, 2016, SPINE J, V16, P1459, DOI 10.1016/j.spinee.2016.06.020; Iwai H, 2014, CELL TRANSPLANT, V23, P1451, DOI 10.3727/096368913X670967; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Jones LL, 2001, MICROSC RES TECHNIQ, V54, P317, DOI 10.1002/jemt.1144; Jurga M, 2011, BIOMATERIALS, V32, P3423, DOI 10.1016/j.biomaterials.2011.01.049; Kaneko A, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/1/015008; Kim HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016694; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Meijs MFL, 2004, J NEUROTRAUM, V21, P1415, DOI 10.1089/neu.2004.21.1415; Miller FD, 2009, CELL STEM CELL, V4, P507, DOI 10.1016/j.stem.2009.05.008; Mothe AJ, 2013, BIOMATERIALS, V34, P3775, DOI 10.1016/j.biomaterials.2013.02.002; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Nomura H, 2006, J NEUROTRAUM, V23, P496, DOI 10.1089/neu.2006.23.496; Novikova LN, 2008, BIOMATERIALS, V29, P1198, DOI 10.1016/j.biomaterials.2007.11.033; Novikova LN, 2003, CURR OPIN NEUROL, V16, P711, DOI 10.1097/00019052-200312000-00011; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Okano H, 2003, SEMIN CELL DEV BIOL, V14, P191, DOI 10.1016/S1084-9521(03)00011-9; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Park SS, 2012, CYTOTHERAPY, V14, P584, DOI 10.3109/14653249.2012.658913; Parr AM, 2008, NEUROSCIENCE, V155, P760, DOI 10.1016/j.neuroscience.2008.05.042; Parr AM, 2007, NEUROSURGERY, V60, P926, DOI 10.1227/01.NEU.0000255441.59612.98; Raspa A, 2016, NANOSCALE, V8, P253, DOI 10.1039/c5nr03698d; Sypecka J, 2009, ACTA NEUROBIOL EXP, V69, P37; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tsintou M, 2015, NEURAL REGEN RES, V10, P726, DOI 10.4103/1673-5374.156966; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; Uemura M, 2010, J NEUROSCI RES, V88, P542, DOI 10.1002/jnr.22223; Wang D, 2013, NEURAL REGEN RES, V8, P677, DOI 10.3969/j.issn.1673-5374.2013.08.001; Willerth SM, 2007, ADV DRUG DELIVER REV, V59, P325, DOI 10.1016/j.addr.2007.03.014; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113	40	34	34	12	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 13	2020	10	1							2576	10.1038/s41598-020-59148-3			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE8XO	WOS:000562888700010	32054865	gold, Green Published			2022-02-06	
J	McCrea, M; Broglio, SP; McAllister, TW; Gill, J; Giza, CC; Huber, DL; Harezlak, J; Cameron, KL; Houston, MN; McGinty, G; Jackson, JC; Guskiewicz, K; Mihalik, J; Brooks, MA; Duma, S; Rowson, S; Nelson, LD; Pasquina, P; Meier, TB; Foroud, T; Katz, BP; Saykin, AJ; Campbell, DE; Svoboda, SJ; Goldman, J; DiFiori, J				McCrea, Michael; Broglio, Steven P.; McAllister, Thomas W.; Gill, Jessica; Giza, Christopher C.; Huber, Daniel L.; Harezlak, Jaroslaw; Cameron, Kenneth L.; Houston, Megan N.; McGinty, Gerald; Jackson, Jonathan C.; Guskiewicz, Kevin; Mihalik, Jason; Brooks, M. Alison; Duma, Stephan; Rowson, Steven; Nelson, Lindsay D.; Pasquina, Paul; Meier, Timothy B.; Foroud, Tatiana; Katz, Barry P.; Saykin, Andrew J.; Campbell, Darren E.; Svoboda, Steven J.; Goldman, Joshua; DiFiori, Jon		CARE Consortium Investigators	Association of Blood Biomarkers With Acute Sport-Related Concussion in Collegiate Athletes Findings From the NCAA and Department of Defense CARE Consortium	JAMA NETWORK OPEN			English	Article							TRAUMATIC BRAIN-INJURY	Question Is sport-related concussion associated with levels of traumatic brain injury biomarkers in collegiate athletes? Findings In this case-control study of 504 collegiate athletes with concussion, contact sport control athletes, and non-contact sport athletes, the athletes with concussion had significant elevations in multiple traumatic brain injury biomarkers compared with preseason baseline and with 2 groups of control athletes without concussion during the acute postinjury period. Meaning These results suggest that blood biomarkers can be used as research tools to inform the underlying pathophysiological mechanism of concussion and provide additional support for future studies to optimize and validate biomarkers for potential clinical use in sport-related concussion. This case-control study examines the association between sport-related concussion and levels of traumatic brain injury biomarkers in collegiate athletes. Importance There is potential scientific and clinical value in validation of objective biomarkers for sport-related concussion (SRC). Objective To investigate the association of acute-phase blood biomarker levels with SRC in collegiate athletes. Design, Setting, and Participants This multicenter, prospective, case-control study was conducted by the National Collegiate Athletic Association (NCAA) and the US Department of Defense Concussion Assessment, Research, and Education (CARE) Consortium from February 20, 2015, to May 31, 2018, at 6 CARE Advanced Research Core sites. A total of 504 collegiate athletes with concussion, contact sport control athletes, and non-contact sport control athletes completed clinical testing and blood collection at preseason baseline, the acute postinjury period, 24 to 48 hours after injury, the point of reporting being asymptomatic, and 7 days after return to play. Data analysis was conducted from March 1 to November 30, 2019. Main Outcomes and Measures Glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCH-L1), neurofilament light chain, and tau were quantified using the Quanterix Simoa multiplex assay. Clinical outcome measures included the Sport Concussion Assessment Tool-Third Edition (SCAT-3) symptom evaluation, Standardized Assessment of Concussion, Balance Error Scoring System, and Brief Symptom Inventory 18. Results A total of 264 athletes with concussion (mean [SD] age, 19.08 [1.24] years; 211 [79.9%] male), 138 contact sport controls (mean [SD] age, 19.03 [1.27] years; 107 [77.5%] male), and 102 non-contact sport controls (mean [SD] age, 19.39 [1.25] years; 82 [80.4%] male) were included in the study. Athletes with concussion had significant elevation in GFAP (mean difference, 0.430 pg/mL; 95% CI, 0.339-0.521 pg/mL; P < .001), UCH-L1 (mean difference, 0.449 pg/mL; 95% CI, 0.167-0.732 pg/mL; P < .001), and tau levels (mean difference, 0.221 pg/mL; 95% CI, 0.046-0.396 pg/mL; P = .004) at the acute postinjury time point compared with preseason baseline. Longitudinally, a significant interaction (group x visit) was found for GFAP (F-7,F-1507.36 = 16.18, P < .001), UCH-L1 (F-7,F-1153.09 = 5.71, P < .001), and tau (F-7,F-1480.55 = 6.81, P < .001); the interaction for neurofilament light chain was not significant (F-7,F-1506.90 = 1.33, P = .23). The area under the curve for the combination of GFAP and UCH-L1 in differentiating athletes with concussion from contact sport controls at the acute postinjury period was 0.71 (95% CI, 0.64-0.78; P < .001); the acute postinjury area under the curve for all 4 biomarkers combined was 0.72 (95% CI, 0.65-0.79; P < .001). Beyond SCAT-3 symptom score, GFAP at the acute postinjury time point was associated with the classification of athletes with concussion from contact controls (beta = 12.298; 95% CI, 2.776-54.481; P = .001) and non-contact sport controls (beta = 5.438; 95% CI, 1.676-17.645; P = .005). Athletes with concussion with loss of consciousness or posttraumatic amnesia had significantly higher levels of GFAP than athletes with concussion with neither loss of consciousness nor posttraumatic amnesia at the acute postinjury time point (mean difference, 0.583 pg/mL; 95% CI, 0.369-0.797 pg/mL; P < .001). Conclusions and Relevance The results suggest that blood biomarkers can be used as research tools to inform the underlying pathophysiological mechanism of concussion and provide additional support for future studies to optimize and validate biomarkers for potential clinical use in SRC.	[McCrea, Michael; Huber, Daniel L.; Nelson, Lindsay D.; Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Broglio, Steven P.] Univ Michigan, Michigan Concuss Ctr, Ann Arbor, MI 48109 USA; [McAllister, Thomas W.; Foroud, Tatiana; Katz, Barry P.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Gill, Jessica] NINR, NIH, Bethesda, MD 20892 USA; [Giza, Christopher C.; Goldman, Joshua; DiFiori, Jon] Univ Calif Los Angeles, UCLA Steve Tisch BrainSPORT Program, Dept Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.; Goldman, Joshua; DiFiori, Jon] Univ Calif Los Angeles, Dept Pediat, UCLA Steve Tisch BrainSPORT Program, Los Angeles, CA 90024 USA; [Harezlak, Jaroslaw] Indiana Univ, Sch Publ Hlth Bloomington, Dept Epidemiol & Biostat, Bloomington, IN USA; [Cameron, Kenneth L.; Houston, Megan N.; Svoboda, Steven J.] Keller Army Community Hosp, West Point, NY USA; [McGinty, Gerald; Jackson, Jonathan C.; Campbell, Darren E.] US Air Force Acad, Colorado Springs, CO 80840 USA; [Guskiewicz, Kevin; Mihalik, Jason] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA; [Brooks, M. Alison] Univ Wisconsin, Sch Med & Publ Hlth, Dept Orthoped & Rehabil, Madison, WI USA; [Duma, Stephan; Rowson, Steven] Virginia Polytech Inst & State Univ, Dept Biomed Engn, Blacksburg, VA 24061 USA; [Pasquina, Paul] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD USA		McCrea, M (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mmccrea@mcw.edu	Rowson, Steven/B-1270-2012; Harezlak, Jaroslaw/P-8557-2014	Rowson, Steven/0000-0002-3227-0596; Harezlak, Jaroslaw/0000-0002-3070-7686	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - NCAA; DODUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This work received support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium funded in part by the NCAA and the DOD andwas supported by award W81XWH-14-2-0151 from the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program.	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Dadas A, 2018, NEUROPSYCH DIS TREAT, V14, P2989, DOI 10.2147/NDT.S125620; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Klein AP, 2019, J NEUROTRAUM, V36, P1776, DOI 10.1089/neu.2018.6055; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Lewis LM, 2017, ACAD EMERG MED, V24, P710, DOI 10.1111/acem.13174; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; Meier TB, 2017, J NEUROTRAUM, V34, P3134, DOI 10.1089/neu.2017.5046; Papa L, 2015, BRAIN NEUROTRAUMA MO, DOI [DOI 10.1201/B18126-27, 10.1201/b18126-27]; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Vandenbroucke JP, 2014, INT J SURG, V12, P1500, DOI 10.1016/j.ijsu.2014.07.014; WechslerD, 2001, WECHSLER TEST ADULT; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	17	34	34	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	JAN 24	2020	3	1							e1919771	10.1001/jamanetworkopen.2019.19771			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF5YS	WOS:000509318000006	31977061	Green Published, gold			2022-02-06	
J	Alosco, ML; Stein, TD; Tripodis, Y; Chua, AS; Kowall, NW; Huber, BR; Goldstein, LE; Cantu, RC; Katz, DI; Palmisano, JN; Martin, B; Cherry, JD; Mahar, I; Killiany, RJ; McClean, MD; Au, R; Alvarez, V; Stern, RA; Mez, J; McKee, AC				Alosco, Michael L.; Stein, Thor D.; Tripodis, Yorghos; Chua, Alicia S.; Kowall, Neil W.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Palmisano, Joseph N.; Martin, Brett; Cherry, Jonathan D.; Mahar, Ian; Killiany, Ronald J.; McClean, Michael D.; Au, Rhoda; Alvarez, Victor; Stern, Robert A.; Mez, Jesse; McKee, Ann C.			Association of White Matter Rarefaction, Arteriolosclerosis, and Tau With Dementia in Chronic Traumatic Encephalopathy	JAMA NEUROLOGY			English	Article							21ST-CENTURY BRAIN BANKING; FOOTBALL LEAGUE PLAYERS; BODY-MASS INDEX; ALZHEIMERS-DISEASE; CEREBROVASCULAR-DISEASE; MIXED NEUROPATHOLOGIES; COGNITIVE DYSFUNCTION; CLINICAL EXPRESSION; BARRIER DYSFUNCTION; SINGLE SEASON	IMPORTANCE Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive head impacts, including those from US football, that presents with cognitive and neuropsychiatric disturbances that can progress to dementia. Pathways to dementia in CTE are unclear and likely involve tau and nontau pathologic conditions. OBJECTIVE To investigate the association of white matter rarefaction and cerebrovascular disease with dementia in deceased men older than 40 years who played football and had CTE. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study involves analyses of data from the ongoing Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) Study, which is conducted via and included brain donors from the Veterans Affairs-Boston University-Concussion Legacy Foundation brain bank between 2008 and 2017. An original sample of 224 men who had played football and were neuropathologically diagnosed with CTE was reduced after exclusion of those younger than 40 years and those missing data. EXPOSURES The number of years of football play as a proxy for repetitive head impacts. MAIN OUTCOMES AND MEASURES Neuropathological assessment of white matter rarefaction and arteriolosclerosis severity (on a scale of 0-3, where 3 is severe); number of infarcts, microinfarcts, and microbleeds; and phosphorylated tau accumulation determined by CTE stage and semiquantitative rating of dorsolateral frontal cortex (DLFC) neurofibrillary tangles (NFTs) (none or mild vs moderate or severe). Informant-based retrospective clinical interviews determined dementia diagnoses via diagnostic consensus conferences. RESULTS A total of 180 men were included. The mean (SD) age of the sample at death was 67.9 (12.7) years. Of 180, 120 [66.7%]) were found to have had dementia prior to death. Moderate to severe white matter rarefaction (84 of 180 [46.6%]) and arteriolosclerosis (85 of 180 [47.2%]) were common; infarcts, microinfarcts, and microbleeds were not. A simultaneous equations regression model controlling for age and race showed that more years of play was associated with more severe white matter rarefaction (beta, 0.16 [95% CI, 0.02-0.29]; P=.03) and greater phosphorylated tau accumulation (DLFC NFTs: beta, 0.15 [95% CI, 0.004-0.30]; P=.04; CTE stage: beta, 0.27 [95% CI, 0.14-0.41]; P<.001). White matter rarefaction (beta, 0.16 [95% CI, 0.02-0.29]; P=.03) and DLFC NFTs (beta, 0.16 [95% CI, 0.03-0.28]; P=.01) were associated with dementia. Arteriolosclerosis and years of play were not associated, but arteriolosclerosis was independently associated with dementia (beta, 0.21 [95% CI, 0.07-0.35]; P=.003). CONCLUSIONS AND RELEVANCE Among older men who had played football and had CTE, more years of football play were associated with more severe white matter rarefaction and greater DLFC NFT burden. White matter rarefaction, arteriolosclerosis, and DLFC NFTs were independently associated with dementia. Dementia in CTE is likely a result of neuropathologic changes, including white matter rarefaction and phosphorylated tau, associated with repetitive head impact and pathologic changes not associated with head trauma, such as arteriolosclerosis.	[Alosco, Michael L.; Stein, Thor D.; Tripodis, Yorghos; Kowall, Neil W.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Palmisano, Joseph N.; Martin, Brett; Cherry, Jonathan D.; Mahar, Ian; Killiany, Ronald J.; Au, Rhoda; Alvarez, Victor; Stern, Robert A.; Mez, Jesse; McKee, Ann C.] Boston Univ, Alzheimers Dis Ctr, 72 E Concord St,B7800, Boston, MA 02118 USA; [Alosco, Michael L.; Stein, Thor D.; Tripodis, Yorghos; Kowall, Neil W.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Palmisano, Joseph N.; Martin, Brett; Cherry, Jonathan D.; Mahar, Ian; Killiany, Ronald J.; Au, Rhoda; Alvarez, Victor; Stern, Robert A.; Mez, Jesse; McKee, Ann C.] Boston Univ, CTE Ctr, Dept Neurol, Sch Med, 72 E Concord St,B7800, Boston, MA 02118 USA; [Stein, Thor D.; Kowall, Neil W.; Goldstein, Lee E.; Cherry, Jonathan D.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Stein, Thor D.; Kowall, Neil W.; Huber, Bertrand Russell; Cherry, Jonathan D.; Alvarez, Victor; McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [Stein, Thor D.; McKee, Ann C.] Bedford Vet Affairs Med Ctr, Bedford, MA USA; [Tripodis, Yorghos; Chua, Alicia S.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Huber, Bertrand Russell] VA Boston Healthcare, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Elect & Comp Engn, Coll Engn, Boston, MA 02215 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Biomed Engn, Coll Engn, Boston, MA 02215 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Concuss Legacy Fdn, Boston, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Palmisano, Joseph N.; Martin, Brett] Boston Univ, Sch Publ Hlth, Biostat & Epidemiol Data Analyt Ctr, Boston, MA USA; [Killiany, Ronald J.; Au, Rhoda; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Killiany, Ronald J.] Boston Univ, Sch Med, Ctr Biomed Imaging, Boston, MA 02118 USA; [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Au, Rhoda] NHLBI, Framingham Heart Study, Boston, MA USA; [Au, Rhoda] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA		McKee, AC (corresponding author), Boston Univ, Alzheimers Dis Ctr, 72 E Concord St,B7800, Boston, MA 02118 USA.; McKee, AC (corresponding author), Boston Univ, CTE Ctr, Dept Neurol, Sch Med, 72 E Concord St,B7800, Boston, MA 02118 USA.	amckee@bu.edu	, Bob/ABA-8507-2020		National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG057902, RF1AG054156, R56AG057768, K23AG046377]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS102399]; Department of Veterans Affairs Merit AwardUS Department of Veterans Affairs [I01-CX001038]; Nick and Lynn Buoniconti Foundation; National Center for Advancing Translational Sciences (BU-CTSI) [1UL1TR001430]; Fonds de Recherche du Quebec-SanteFonds de la Recherche en Sante du Quebec; Alzheimer's AssociationAlzheimer's Association [AARF-17-529888]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS102399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RF1AG054156, RF1AG057902, R01AG062348] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by grant funding from the National Institute on Aging (grants AG057902, RF1AG054156, R56AG057768, K23AG046377), National Institute of Neurological Disorders and Stroke (grant K23NS102399), a Department of Veterans Affairs Merit Award (grant I01-CX001038), the Nick and Lynn Buoniconti Foundation, and the National Center for Advancing Translational Sciences (BU-CTSI grant 1UL1TR001430). Dr Mahar is funded by the Fonds de Recherche du Quebec-Sante. Dr Cherry is funded by the Alzheimer's Association (grant AARF-17-529888).	ALOSCO M, 2017, ALZHEIMERS DEMENT, V10, P56, DOI DOI 10.1016/J.DADM.2017.10.003; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Alosco ML, 2017, J ALZHEIMERS DIS, V57, P953, DOI 10.3233/JAD-161205; Alosco ML, 2017, J NEUROPSYCH CLIN N, V29, P6, DOI 10.1176/appi.neuropsych.16030043; Amen DG, 2016, J ALZHEIMERS DIS, V53, P237, DOI 10.3233/JAD-160207; Arvanitakis Z, 2016, LANCET NEUROL, V15, P934, DOI 10.1016/S1474-4422(16)30029-1; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Beekly DL, 2004, ALZ DIS ASSOC DIS, V18, P270; Bennett DA, 2013, J ALZHEIMERS DIS, V33, pS397, DOI 10.3233/JAD-2012-129007; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bos D, 2018, ALZHEIMERS DEMENT, V14, P1482, DOI 10.1016/j.jalz.2018.04.007; Bouhrara M, 2018, ALZHEIMERS DEMENT, V14, P998, DOI 10.1016/j.jalz.2018.03.007; Boyle PA, 2018, ANN NEUROL, V83, P74, DOI 10.1002/ana.25123; Brenowitz WD, 2017, NEUROLOGY, V89, P1773, DOI 10.1212/WNL.0000000000004567; Brenowitz WD, 2017, ALZHEIMERS DEMENT, V13, P654, DOI 10.1016/j.jalz.2016.09.015; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Cherry JD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185541; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Chui HC, 2006, ANN NEUROL, V60, P677, DOI 10.1002/ana.21009; Clark MD, 2018, RADIOLOGY, V286, P975, DOI 10.1148/radiol.2017170539; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Deramecourt V, 2012, NEUROLOGY, V78, P1043, DOI 10.1212/WNL.0b013e31824e8e7f; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Filley CM, 2018, J ALZHEIMERS DIS, V65, P345, DOI 10.3233/JAD-180287; Gangolli M, 2019, J NEUROTRAUM, V36, P735, DOI 10.1089/neu.2018.5700; Gardner Raquel C, 2015, Neurol Clin Pract, V5, P285; Haneuse S, 2009, NEUROEPIDEMIOLOGY, V32, P229, DOI 10.1159/000197389; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Holleran L, 2017, ACTA NEUROPATHOL, V133, P367, DOI 10.1007/s00401-017-1686-x; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; James BD, 2016, BRAIN, V139, P2983, DOI 10.1093/brain/aww224; Kalaria RN, 1999, ALZ DIS ASSOC DIS, V13, pS115, DOI 10.1097/00002093-199912003-00017; Kapasi A, 2017, ACTA NEUROPATHOL, V134, P171, DOI 10.1007/s00401-017-1717-7; Kim Julia, 2017, J Alzheimers Dis, V55, P381; Kuzminski SJ, 2018, AM J NEURORADIOL, V39, P245, DOI 10.3174/ajnr.A5489; Lee S, 2016, ANN NEUROL, V79, P929, DOI 10.1002/ana.24647; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Mahar I, 2017, NEUROSCI BIOBEHAV R, V83, P622, DOI 10.1016/j.neubiorev.2017.08.023; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mayinger MC, 2018, BRAIN IMAGING BEHAV, V12, P44, DOI 10.1007/s11682-017-9672-4; McAleese KE, 2017, ACTA NEUROPATHOL, V134, P459, DOI 10.1007/s00401-017-1738-2; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Nelson AR, 2016, BBA-MOL BASIS DIS, V1862, P887, DOI 10.1016/j.bbadis.2015.12.016; Nelson PT, 2007, J NEUROPATH EXP NEUR, V66, P1136, DOI 10.1097/nen.0b013e31815c5efb; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Toledo JB, 2013, BRAIN, V136, P2697, DOI 10.1093/brain/awt188; Tucker AM, 2009, JAMA-J AM MED ASSOC, V301, P2111, DOI 10.1001/jama.2009.716; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	63	34	34	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	NOV	2019	76	11					1298	1308		10.1001/jamaneurol.2019.2244			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JW7ER	WOS:000503211500006	31380975	Green Published, Bronze			2022-02-06	
J	Lindberg, DM; Stence, NV; Grubenhoff, JA; Lewis, T; Mirsky, DM; Miller, AL; O'Neill, BR; Grice, K; Mourani, PM; Runyan, DK				Lindberg, Daniel M.; Stence, Nicholas, V; Grubenhoff, Joseph A.; Lewis, Terri; Mirsky, David M.; Miller, Angie L.; O'Neill, Brent R.; Grice, Kathleen; Mourani, Peter M.; Runyan, Desmond K.			Feasibility and Accuracy of Fast MRI Versus CT for Traumatic Brain Injury in Young Children	PEDIATRICS			English	Article							COMPUTED-TOMOGRAPHY; INFANTS; AGE	This study measured fast MRI completion rate, duration, and accuracy in 225 children who underwent head CT and received care at a pediatric ED. BACKGROUND: Computed tomography (CT) is commonly used for children when there is concern for traumatic brain injury (TBI) and is a significant source of ionizing radiation. Our objective was to determine the feasibility and accuracy of fast MRI (motion-tolerant MRI sequences performed without sedation) in young children. METHODS: In this prospective cohort study, we attempted fast MRI in children <6 years old who had head CT performed and were seen in the emergency department of a single, level 1 pediatric trauma center. Fast MRI sequences included 3T axial and sagittal T2 single-shot turbo spin echo, axial T1 turbo field echo, axial fluid-attenuated inversion recovery, axial gradient echo, and axial diffusion-weighted single-shot turbo spin echo planar imaging. Feasibility was assessed by completion rate and imaging time. Fast MRI accuracy was measured against CT findings of TBI, including skull fracture, intracranial hemorrhage, or parenchymal injury. RESULTS: Among 299 participants, fast MRI was available and attempted in 225 (75%) and completed in 223 (99%). Median imaging time was 59 seconds (interquartile range 52-78) for CT and 365 seconds (interquartile range 340-392) for fast MRI. TBI was identified by CT in 111 (50%) participants, including 81 skull fractures, 27 subdural hematomas, 24 subarachnoid hemorrhages, and 35 other injuries. Fast MRI identified TBI in 103 of these (sensitivity 92.8%; 95% confidence interval 86.3-96.8), missing 6 participants with isolated skull fractures and 2 with subarachnoid hemorrhage. CONCLUSIONS: Fast MRI is feasible and accurate relative to CT in clinically stable children with concern for TBI.	[Lindberg, Daniel M.; Grubenhoff, Joseph A.; Lewis, Terri; Grice, Kathleen; Mourani, Peter M.; Runyan, Desmond K.] Univ Colorado, Dept Pediat, Denver, CO 80045 USA; [Lindberg, Daniel M.] Univ Colorado, Dept Emergency Med, Denver, CO 80045 USA; [Stence, Nicholas, V; Mirsky, David M.; Miller, Angie L.] Univ Colorado, Dept Radiol, Denver, CO 80045 USA; [O'Neill, Brent R.] Univ Colorado, Dept Neurosurg, Denver, CO 80045 USA; [Mourani, Peter M.] Univ Colorado, Sect Crit Care, Denver, CO 80045 USA; [Lindberg, Daniel M.; Lewis, Terri; Runyan, Desmond K.] Univ Colorado, Kempe Ctr Prevent & Treatment Child Abuse & Negle, Denver, CO 80045 USA; [Lindberg, Daniel M.; Stence, Nicholas, V; Grubenhoff, Joseph A.; Lewis, Terri; Mirsky, David M.; Miller, Angie L.; O'Neill, Brent R.; Grice, Kathleen; Mourani, Peter M.; Runyan, Desmond K.] Univ Colorado, Sch Med, Denver, CO 80045 USA		Lindberg, DM (corresponding author), Univ Colorado, Sch Med, Dept Emergency Med, 12401 E 17th Ave,Mailstop B215, Denver, CO 80045 USA.	daniel.lindberg@cuanschutz.edu	Grubenhoff, Joseph A/H-9994-2019; Lewis, Terri/ABC-3668-2020	Grubenhoff, Joseph A/0000-0001-5072-4064; 	Colorado Traumatic Brain Injury Trust Fund; Colorado Clinical and Translational Sciences Institute	Funded by the Colorado Traumatic Brain Injury Trust Fund (MindSource) and the Colorado Clinical and Translational Sciences Institute. The funders had no role in the design; collection, analysis, or interpretation of data; writing of the article; or decision to submit results for publication.	Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1373/clinchem.2015.246280, 10.1136/bmj.h5527, 10.1148/radiol.2015151516]; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bressan S, 2018, ANN EMERG MED, V71, P714, DOI 10.1016/j.annemergmed.2017.10.014; Burstein B, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0814; Christian CW, 2015, PEDIATRICS, V135, pE1337, DOI 10.1542/peds.2015-0356; Cohen AR, 2015, AM J EMERG MED, V33, P887, DOI 10.1016/j.ajem.2015.03.052; Deye KP, 2013, J TRAUMA ACUTE CARE, V74, P1553, DOI 10.1097/TA.0b013e31828b7fc4; Dingman AL, 2018, PEDIATR NEUROL, V82, P29, DOI 10.1016/j.pediatrneurol.2017.12.003; Dremmen MHG, 2017, AM J NEURORADIOL, V38, P2187, DOI 10.3174/ajnr.A5405; Faul M, 2010, TRAUMATIC BRAIN INJU; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Flom L, 2016, PEDIATR RADIOL, V46, P519, DOI 10.1007/s00247-015-3500-z; Iskandar BJ, 2004, J NEUROSURG, V101, P147, DOI 10.3171/ped.2004.101.2.0147; Kralik SF, 2017, AM J NEURORADIOL, V38, P807, DOI 10.3174/ajnr.A5093; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Laskey AL, 2013, J PEDIATR-US, V162, P86, DOI 10.1016/j.jpeds.2012.06.038; Lustig M, 2007, MAGN RESON MED, V58, P1182, DOI 10.1002/mrm.21391; Magana JN, 2017, ACAD EMERG MED, V24, P382, DOI 10.1111/acem.13155; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Mehta H, 2016, AM J NEURORADIOL, V37, P11, DOI 10.3174/ajnr.A4464; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; O'Leary JD, 2019, JAMA PEDIATR, V173, P29, DOI 10.1001/jamapediatrics.2018.3662; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; Ryan ME, 2016, NEURORADIOLOGY, V58, P793, DOI 10.1007/s00234-016-1686-x; Section on Radiology, 2009, PEDIATRICS, V123, P1430, DOI DOI 10.1542/PEDS.2009-0558; Stanley RM, 2014, J PEDIATR-US, V165, P1201, DOI 10.1016/j.jpeds.2014.08.008; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467; Young JY, 2016, EMERG RADIOL, V23, P325, DOI 10.1007/s10140-016-1392-3	30	34	34	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2019	144	4							e20190419	10.1542/peds.2019-0419			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	JA2LW	WOS:000487649200005	31533974	Bronze			2022-02-06	
J	Cross, MJ; Tucker, R; Raftery, M; Hester, B; Williams, S; Stokes, KA; Ranson, C; Mathema, P; Kemp, S				Cross, Matthew J.; Tucker, Ross; Raftery, Martin; Hester, Ben; Williams, Sean; Stokes, Keith A.; Ranson, Craig; Mathema, Pray; Kemp, Simon			Tackling concussion in professional rugby union: a case-control study of tackle-based risk factors and recommendations for primary prevention	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INJURY; EVENTS	Background/aim Concussion, the most common injury in professional rugby union, occurs most commonly during the tackle. Thus, we investigated the association between tackle characteristics and concussion. Methods 182 video clips of tackles leading to clinically diagnosed concussion and 4619 tackles that did not were coded across three professional rugby union competitions. A variable selection process was undertaken to identify the most important variables for interpretation. A multivariate generalised linear model was used to model the association between retained variables and concussion risk. Magnitude-based inferences provided an interpretation of the real-world relevance of the outcomes. Results The four retained variables were: accelerating player, tackler speed, head contact type and tackle type. Overall, 70% of concussions occurred to the tackler and 30% to the ball carrier. There was a higher risk of concussion if the tackler accelerated into the tackle (OR: 2.49, 95% CI 1.70 to 3.64) or the tackler was moving at high speed (OR: 2.64, 95% CI 1.92 to 3.63). Head contact with the opposing player's head (OR: 39.9, 95% CI 22.2 to 71.1) resulted in a substantially greater risk of concussion compared with all other head contact locations. Conclusions Interventions that reduce the speed and acceleration of the tackler and reduce exposure to headto- head contact would likely reduce concussion risk in professional rugby union.	[Cross, Matthew J.; Kemp, Simon] Rugby Football Union, Prof Rugby Dept, London, England; [Cross, Matthew J.; Williams, Sean; Stokes, Keith A.] Univ Bath, Dept Hlth, Bath, Avon, England; [Tucker, Ross; Raftery, Martin; Hester, Ben] World Rugby, Dublin, Ireland; [Ranson, Craig] Cardiff Metropolitan Univ, Sports Injury Res Grp, Cardiff, S Glam, Wales; [Ranson, Craig; Mathema, Pray] Welsh Rugby Union, Cardiff, S Glam, Wales		Cross, MJ (corresponding author), Rugby Football Union, Prof Rugby Dept, Twickenham TW2 7BA, England.	m.cross@bath.ac.uk	Williams, Sean/AAB-2790-2022; Ranson, Craig/AAQ-5452-2020; Williams, Sean/AAA-9361-2022; Stokes, Keith/C-2605-2009	Williams, Sean/0000-0003-1460-0085; Williams, Sean/0000-0003-1460-0085; Kemp, Simon/0000-0002-3250-2713; Ranson, Craig/0000-0002-3783-0505; Stokes, Keith/0000-0002-5049-2838			Batten J, 2016, BRIT J SPORT MED, V50, P1293, DOI 10.1136/bjsports-2015-095949; Batterham AM, 2006, INTJ SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, CLIN J SPORT MED, V17, P182, DOI 10.1097/JSM.0b013e31805930b0; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Genuer R, 2010, PATTERN RECOGN LETT, V31, P2225, DOI 10.1016/j.patrec.2010.03.014; Greenland S, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1981; Hagel B, 2004, RISK COMPENSATION SI; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hopkins W.G., 2010, SPORTSCIENCE, V14, P49; Hopkins WG., 2007, SPORTSCIENCE, V11, P16; Kemp S, 2016, BR J SPORTS MED, V50; Kutner M.H., 2004, APPL LINEAR REGRESSI, V4th; Lachance J, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-57; Li HJ, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-291; Liaw A., 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; Preatoni E, 2016, SCAND J MED SCI SPOR, V26, P1398, DOI 10.1111/sms.12592; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Raftery M, 2016, BRIT J SPORT MED, V50, P642, DOI 10.1136/bjsports-2016-095959; Rugby Football Union, 2017, PROF RUGB INJ SURV P; Seminati E, 2017, BRIT J SPORT MED, V51; Tierney GJ, 2016, BRAIN INJURY, V30, P1350, DOI 10.1080/02699052.2016.1193630; Tucker R, 2016, BRIT J SPORT MED, V50, P921, DOI 10.1136/bjsports-2016-096322; World Rugby, 2017, NEW TACKL LAWS LIM C	28	34	34	1	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2019	53	16					1021	+		10.1136/bjsports-2017-097912			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	IT0BD	WOS:000482510800010	29021244	Bronze			2022-02-06	
J	Denning, JH; Shura, RD				Denning, John H.; Shura, Robert D.			Cost of malingering mild traumatic brain injury-related cognitive deficits during compensation and pension evaluations in the veterans benefits administration	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Malingering; medical symptom validity test; neuropsychology; test of memory malingering; traumatic brain injury; veterans	POSTTRAUMATIC-STRESS-DISORDER; PERFORMANCE VALIDITY TESTS; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; WORD MEMORY TEST; PERSISTENT POSTCONCUSSIVE SYMPTOMS; IRAQI FREEDOM VETERANS; TRIAL 1; OEF/OIF VETERANS; SERVICE MEMBERS; TEST FAILURE	Given the high rates of exaggeration in those claiming long-term cognitive deficits as a result of mild traumatic brain injury (mTBI), the aim of this study was to evaluate the rates of malingering in those seeking disability through the Veterans Benefits Administration and estimate the financial burden of disability payments for those receiving compensation despite exaggerated mTBI-related cognitive deficits. Retrospective review included 74 veterans seen for Compensation and Pension evaluations for mTBI. Rates of malingering were based on failure of the Medical Symptom Validity Test (MSVT) and/or the Test of Memory Malingering (TOMM) trial 1 <= 40. Total estimated compensation was based on the level of disability awarded and the number of individuals found to be malingering cognitive deficits. Overall, 33-52% of the sample was found to be malingering mTBI-related cognitive deficits. The malingering groups were receiving approximately $71,000-$121,000/year ($6,390-$7,063 per year, per veteran on average). Estimated nationwide disability payments for those possibly malingering mTBI-related cognitive deficits would be $136-$235 million/year (projected costs from 2015-2020 = $700 million-$1.2 billion). It is critical that providers and administrative officials identify those exaggerating disability claims attributed to mTBI. The cost of malingering impacts society in general as well as veterans themselves, as it diverts needed funds/resources away from those legitimately impaired by their military service.	[Denning, John H.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Dept Vet Affairs, Charleston, SC USA; [Denning, John H.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA; [Shura, Robert D.] Midatlantic Mental Illness Res Educ & Clin Ctr, Salisbury, NC USA; [Shura, Robert D.] WG Bill Hefner Vet Affairs Med Ctr VAMC, Mental Hlth & Behav Sci Serv Line, Salisbury, NC USA; [Shura, Robert D.] Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC USA		Denning, JH (corresponding author), Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv Line, 109 Bee St, Charleston, SC 29401 USA.	john.denning@va.gov	Shura, Robert D/J-6749-2019	Shura, Robert/0000-0002-9505-0080	Office of Research and Development, Medical Research Service, Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, and the Mid-Atlantic MIRECC.	Adams C., 2013, MCCLATCHY NEWSPAPERS; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Armistead-Jehle P, 2018, ARCH CLIN NEUROPSYCH, V33, P120, DOI 10.1093/arclin/acx031; Armistead-Jehle P, 2016, APPL NEUROPSYCH-ADUL, V23, P264, DOI 10.1080/23279095.2015.1055564; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Ashendorf L, 2016, CLIN NEUROPSYCHOL, V30, P599, DOI 10.1080/13854046.2016.1172668; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benitez A, 2011, ARCH CLIN NEUROPSYCH, V26, P184, DOI 10.1093/arclin/acr001; Bolzenius JD, 2015, APPL NEUROPSYCH-ADUL, V22, P79, DOI 10.1080/23279095.2013.845823; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carone D.A., 2013, MILD TRAUMATIC BRAIN; Carone DA, 2014, CLIN NEUROPSYCHOL, V28, P146, DOI 10.1080/13854046.2013.861019; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chafetz M, 2013, ARCH CLIN NEUROPSYCH, V28, P633, DOI 10.1093/arclin/act038; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Clark AL, 2016, J HEAD TRAUMA REHAB, V31, P346, DOI 10.1097/HTR.0000000000000183; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Combs HL, 2015, J NEUROTRAUM, V32, P956, DOI 10.1089/neu.2014.3585; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Cook CM, 2016, CLIN NEUROPSYCHOL, V30, P284, DOI 10.1080/13854046.2016.1139186; Cooper DB, 2014, J REHABIL RES DEV, V51, P1023, DOI [10.1682/JRRD.2013.05.0104, 10.1682/JRRD.2013.05.0140]; Defense and Veterans Brain Injury Center, 2016, DOD NUMB TRAUM BRAIN; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Denning JH, 2014, APPL NEUROPSYCH-ADUL, V21, P269, DOI 10.1080/23279095.2013.811076; Department of Veterans Affairs/Department of Defense, 2009, VA DOD CLIN PRACT GU; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dretsch MN, 2015, J NEUROTRAUM, V32, P1217, DOI 10.1089/neu.2014.3637; Fazio RL, 2017, CLIN NEUROPSYCHOL, V31, P251, DOI 10.1080/13854046.2016.1213316; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Franke LM, 2015, J HEAD TRAUMA REHAB, V30, pE34, DOI 10.1097/HTR.0000000000000042; Gfeller JD, 2013, BEHAV SCI LAW, V31, P833, DOI 10.1002/bsl.2084; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GREEN P, 2006, INT J FORENSIC PSYCH, V1, P1; Green P, 2004, GREENS MED SYMPTOM V; Green P, 2016, APPL NEUROPSYCH-CHIL, V5, P25, DOI 10.1080/21622965.2014.935378; Grills CE, 2016, APPL NEUROPSYCH-ADUL, V23, P295, DOI 10.1080/23279095.2015.1079713; Guilmette T.J., 2013, MILD TRAUMATIC BRAIN, P31; Hanson KL, 2016, J CLIN EXP NEUROPSYC, V38, P1115, DOI 10.1080/13803395.2016.1198468; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Heltemes KJ, 2011, MIL MED, V176, P132, DOI 10.7205/MILMED-D-09-00238; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Heyanka DJ, 2015, ARCH CLIN NEUROPSYCH, V30, P369, DOI 10.1093/arclin/acv025; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2017, ARCH CLIN NEUROPSYCH, V32, P228, DOI 10.1093/arclin/acw094; Horner MD, 2014, CLIN NEUROPSYCHOL, V28, P703, DOI 10.1080/13854046.2014.925143; Ioachimescu AG, 2015, PITUITARY, V18, P535, DOI 10.1007/s11102-014-0606-5; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; Jak AJ, 2015, J CLIN EXP NEUROPSYC, V37, P379, DOI 10.1080/13803395.2015.1020769; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1373, DOI 10.1080/13854046.2013.851740; Jones A, 2012, CLIN NEUROPSYCHOL, V26, P790, DOI 10.1080/13854046.2012.693202; Kehle-Forbes SM, 2017, J HEAD TRAUMA REHAB, V32, pE16, DOI 10.1097/HTR.0000000000000227; King PR, 2014, J NERV MENT DIS, V202, P231, DOI 10.1097/NMD.0000000000000103; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2012, FORENSIC NEUROPSYCHO, P2; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Larson EB, 2013, J INT NEUROPSYCH SOC, V19, P88, DOI 10.1017/S1355617712000999; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2017, APPL NEUROPSYCH-ADUL, V24, P73, DOI 10.1080/23279095.2015.1100617; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Macciocchi SN, 2017, ARCH CLIN NEUROPSYCH, V32, P339, DOI 10.1093/arclin/acw112; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; McNally RJ, 2013, J ANXIETY DISORD, V27, P520, DOI 10.1016/j.janxdis.2013.07.002; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mendez MF, 2013, BRAIN INJURY, V27, P10, DOI 10.3109/02699052.2012.722252; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morel KR, 2008, CLIN NEUROPSYCHOL, V22, P350, DOI 10.1080/13854040701300531; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Office of Inspector General, 2014, SEM REP C, P72; Office of the Inspector General, 2013, SEM REP C; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Reslan S, 2017, APPL NEUROPSYCH-ADUL, V24, P132, DOI 10.1080/23279095.2015.1107565; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roth RS, 2013, J PALLIAT CARE MED, V1, P105, DOI DOI 10.4172/2329-9096.1000105; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Salmi L Rachid, 2014, Arch Phys Med Rehabil, V95, pS95, DOI 10.1016/j.apmr.2013.10.026; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2017, BRAIN INJURY, V31, P32, DOI 10.1080/02699052.2016.1218546; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Storzbach D, 2015, J INT NEUROPSYCH SOC, V21, P353, DOI 10.1017/S1355617715000326; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Troyanskaya M, 2015, MIL MED, V180, P285, DOI 10.7205/MILMED-D-14-00256; US Department of Veterans Affairs, COMPENSATION; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Veterans Benefits Administration, 2014, REG 3 310 1 DIS AR P; Veterans Benefits Administration, 2016, VBA ANN BEN REP FISC; Whitney KA, 2013, ARCH CLIN NEUROPSYCH, V28, P222, DOI 10.1093/arclin/act012; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P263, DOI 10.1093/arclin/acp034; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P208, DOI 10.1093/arclin/acr107; Worthen MD, 2011, PSYCHOL INJ LAW, V4, P187, DOI 10.1007/s12207-011-9115-2; Wrocklage KM, 2016, J INT NEUROPSYCH SOC, V22, P399, DOI 10.1017/S1355617716000059; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	133	34	34	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	JAN 2	2019	26	1					1	16		10.1080/23279095.2017.1350684			16	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	HR3RQ	WOS:000463057500001	28816502				2022-02-06	
J	Henry, RJ; Doran, SJ; Barrett, JP; Meadows, VE; Sabirzhanov, B; Stoica, BA; Loane, DJ; Faden, AI				Henry, Rebecca J.; Doran, Sarah J.; Barrett, James P.; Meadows, Victoria E.; Sabirzhanov, Boris; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.			Inhibition of miR-155 Limits Neuroinflammation and Improves Functional Recovery After Experimental Traumatic Brain Injury in Mice	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; miR-155; microglial activation; neuroinflammation; neuroprotection	PROGRESSIVE NEURODEGENERATION; MICRORNA-155; ACTIVATION; EXPRESSION; MICROGLIA; POLARIZATION; HIPPOCAMPUS; CYTOKINE; IMMUNITY; MODELS	Micro-RNAs (miRs) are short, noncoding RNAs that negatively regulate gene expression at the post-transcriptional level and have been implicated in the pathophysiology of secondary damage after traumatic brain injury (TBI). Among miRs linked to inflammation, miR-155 has been implicated as a pro-inflammatory factor in a variety of organ systems. We examined the expression profile of miR-155, following experimental TBI (controlled cortical impact) in adult male C57Bl/6 mice, as well as the effects of acute or delayed administration of a miR-155 antagomir on post-traumatic neuroinflammatory responses and neurological recovery. Trauma robustly increased miR-155 expression in the injured cortex over 7days. Similar TBI-induced miR-155 expression changes were also found in microglia/macrophages isolated from the injured cortex at 7days post-injury. A miR-155 hairpin inhibitor (antagomir; 0.5nmol), administered intracerebroventricularly (ICV) immediately after injury, attenuated neuroinflammatory markers at both 1day and 7days post-injury and reduced impairments in spatial working memory. Delayed ICV infusion of the miR-155 antagomir (0.5nmol/day), beginning 24h post-injury and continuing for 6days, attenuated neuroinflammatory markers at 7days post-injury and improved motor, but not cognitive, function through 28days. The latter treatment limited NADPH oxidase 2 expression changes in microglia/macrophages in the injured cortex and reduced cortical lesion volume. In summary, TBI causes a robust and persistent neuroinflammatory response that is associated with increased miR-155 expression in microglia/macrophages, and miR-155 inhibition reduces post-traumatic neuroinflammatory responses and improves neurological recovery. Thus, miR-155 may be a therapeutic target for TBI-related neuroinflammation.	[Henry, Rebecca J.; Doran, Sarah J.; Barrett, James P.; Meadows, Victoria E.; Sabirzhanov, Boris; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Henry, Rebecca J.; Doran, Sarah J.; Barrett, James P.; Meadows, Victoria E.; Sabirzhanov, Boris; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, 685 West Baltimore St,MSTF 6-02, Baltimore, MD 21201 USA		Loane, DJ; Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.; Loane, DJ; Faden, AI (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA.; Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.; Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 West Baltimore St,MSTF 6-02, Baltimore, MD 21201 USA.	rhenry@som.umaryland.edu; sarah.doran@som.umaryland.edu; jbarrett@som.umaryland.edu; vmeadows@som.umaryland.edu; bsabirzhanov@som.umaryland.edu; bstoica@som.umaryland.edu; dloane@som.umaryland.edu; afaden@som.umaryland.edu	Loane, David/ABD-5177-2021	Loane, David/0000-0003-0393-3503; Henry, Rebecca/0000-0001-8548-1170; Barrett, James/0000-0002-0924-9449; Faden, Alan I./0000-0003-0128-2348	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS037313, R01 NS082308, T32 AI095190]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI095190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082308, R01NS037313] Funding Source: NIH RePORTER	This work was supported by NIH R01 NS037313 (AIF), R01 NS082308 (DJL), and T32 AI095190 (SJD).	Al-Haidari AA, 2017, ONCOTARGET, V8, P14887, DOI 10.18632/oncotarget.14841; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Pena-Philippides JC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0753-x; Dickey LL, 2017, J NEUROIMMUNOL, V308, P17, DOI 10.1016/j.jneuroim.2017.01.016; Elmesmari A, 2016, RHEUMATOLOGY, V55, P2056, DOI 10.1093/rheumatology/kew272; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Freilich RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079416; Gaudet AD, 2018, NEUROSCIENTIST, V24, P221, DOI 10.1177/1073858417721150; Gaudet AD, 2016, J NEUROSCI, V36, P8516, DOI 10.1523/JNEUROSCI.0735-16.2016; Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129; Harmon JL, 2017, J NEUROTRAUM, V34, P487, DOI 10.1089/neu.2015.4395; Harrison EB, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00228; Hu RZ, 2014, IMMUNITY, V41, P605, DOI 10.1016/j.immuni.2014.09.015; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Jablonski KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159724; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Keck-Wherley J, 2011, DEV NEUROSCI-BASEL, V33, P451, DOI 10.1159/000330884; Kerr WG, 2011, ANN NY ACAD SCI, V1217, P1, DOI 10.1111/j.1749-6632.2010.05869.x; Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; LaPlaca M. C, 2018, CLIN BIOMECH BRISTOL; Levine J, 2016, GLIA, V64, P668, DOI 10.1002/glia.22953; Lippai D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070945; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; Matsukura S, 2016, ALLERGOL INT, V65, pS17, DOI 10.1016/j.alit.2016.04.018; McCoy CE, 2010, J BIOL CHEM, V285, P20492, DOI 10.1074/jbc.M110.102111; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morris G, 2018, EPILEPSIA, V59, P1518, DOI 10.1111/epi.14475; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Quinn SR, 2011, INT IMMUNOL, V23, P421, DOI 10.1093/intimm/dxr034; Rajasekhar M, 2017, J AUTOIMMUN, V79, P53, DOI 10.1016/j.jaut.2017.01.002; Reschke CR, 2017, MOL THER-NUCL ACIDS, V6, P45, DOI 10.1016/j.omtn.2016.11.002; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841; Stenvang Jan, 2012, Silence, V3, P1, DOI 10.1186/1758-907X-3-1; Sun YX, 2012, IMMUNOL LETT, V146, P25, DOI 10.1016/j.imlet.2012.04.007; Tan Y, 2015, NEUROCHEM RES, V40, P550, DOI 10.1007/s11064-014-1500-2; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Torres Adrian G, 1800, Artif DNA PNA XNA, V2, P71; Vermeulen A, 2007, RNA, V13, P723, DOI 10.1261/rna.448107; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Wang WX, 2015, EXP NEUROL, V265, P84, DOI 10.1016/j.expneurol.2014.12.018; Woodbury ME, 2015, J NEUROSCI, V35, P9764, DOI 10.1523/JNEUROSCI.4790-14.2015; Yuan ZH, 2016, AM J PHYSIOL-LUNG C, V310, pL426, DOI 10.1152/ajplung.00195.2015	62	34	37	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2019	16	1					216	230		10.1007/s13311-018-0665-9			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	HJ8PD	WOS:000457460900022	30225790	Green Published, Bronze			2022-02-06	
J	Rao, F; Zhang, DY; Fang, TJZ; Lu, CF; Wang, B; Ding, X; Wei, S; Zhang, YR; Pi, W; Xu, HL; Wang, YH; Jiang, BG; Zhang, PX				Rao, Feng; Zhang, Dianying; Fang, Tengjiaozi; Lu, Changfeng; Wang, Bo; Ding, Xiao; Wei, Shuai; Zhang, Yiran; Pi, Wei; Xu, Hailin; Wang, Yanhua; Jiang, Baoguo; Zhang, Peixun			Exosomes from Human Gingiva-Derived Mesenchymal Stem Cells Combined with Biodegradable Chitin Conduits Promote Rat Sciatic Nerve Regeneration	STEM CELLS INTERNATIONAL			English	Article							TRAUMATIC BRAIN-INJURY; EXTRACELLULAR VESICLES; AXONAL REGENERATION; NEURITE OUTGROWTH; SCHWANN-CELLS; GAP; DEGENERATION; RECOVERY; SCAFFOLD	At present, repair methods for peripheral nerve injury often fail to get satisfactory result. Although various strategies have been adopted to investigate the microenvironment after peripheral nerve injury, the underlying molecular mechanisms of neurite outgrowth remain unclear. In this study, we evaluate the effects of exosomes from gingival mesenchymal stem cells (GMSCs) combined with biodegradable chitin conduits on peripheral nerve regeneration. GMSCs were isolated from human gingival tissue and characterized by surface antigen analysis and in vitro multipotent differentiation. The cell supernatant was collected to isolate the exosomes. The exosomes were characterized by transmission electron microscopy, Western blot, and size distribution analysis. The effects of exosomes on peripheral nerve regeneration in vitro were evaluated by coculture with Schwann cells and DRGs. The chitin conduit was prepared and combined with the exosomes to repair rat sciatic nerve defect. Histology, electrophysiology, and gait analysis were used to test the effects of exosomes on sciatic nerve function recovery in vivo. We have successfully cultured GMSCs and isolated exosomes. The exosomes from GMSCs could significantly promote Schwann cell proliferation and DRG axon growth. The in vivo studies showed that chitin conduit combined with exosomes from GMSCs could significantly increase the number and diameter of nerve fibers and promote myelin formation. In addition, muscle function, nerve conduction function, and motor function were also obviously recovered. In summary, this study suggests that GMSC-derived exosomes combined with biodegradable chitin conduits are a useful and novel therapeutic intervention in peripheral nerve repair.	[Rao, Feng; Zhang, Dianying; Lu, Changfeng; Wang, Bo; Zhang, Yiran; Pi, Wei; Xu, Hailin; Wang, Yanhua; Jiang, Baoguo; Zhang, Peixun] Peking Univ, Dept Orthoped & Trauma, Peoples Hosp, Beijing, Peoples R China; [Fang, Tengjiaozi] Peking Univ, Sch & Hosp Stomatol, Dept Pediat Dent, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China; [Fang, Tengjiaozi] Beijing Key Lab Digital Stomatol, Beijing 100081, Peoples R China; [Lu, Changfeng; Ding, Xiao; Wei, Shuai] Chinese Peoples Liberat Army Gen Hosp, Beijing Key Lab Regenerat Med Orthoped, Inst Orthoped, Beijing, Peoples R China		Jiang, BG; Zhang, PX (corresponding author), Peking Univ, Dept Orthoped & Trauma, Peoples Hosp, Beijing, Peoples R China.	jiangbaoguo@vip.sina.com; zhangpeixun@bjmu.edu.cn	wei, shuai/AAN-7430-2021	wei, shuai/0000-0002-2435-815X; Rao, Feng/0000-0001-8638-409X	Major R&D Program of National Ministry of Science and Technology [2018YFB1105504]; National Key R&D Program of China [2016YFC1101604]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [31771322, 31571235, 81671215]; Beijing Municipal Science and Technology Commission Science and Technology Nova Cross Project [2018019]; R&D Foundation of PKUPH [2018-01, 2017-01]; Ministry of Education Innovation Program of China [IRT_16R01]; National S&T Major Project of China [SQ2018ZX100301]	The authors would like to thank Kuan Chen from Beijing Hui Fukang Medical Device Co. Ltd. for his technical help about the preparation of chitin conduits and Xin Chang from School of Basic Medical Sciences, Peking University, for the help with transmission electron microscopy. This work was supported by the Major R&D Program of National Ministry of Science and Technology (2018YFB1105504), National Key R&D Program of China (2016YFC1101604), National Natural Science Foundation (31771322, 31571235, and 81671215), Beijing Municipal Science and Technology Commission Science and Technology Nova Cross Project (2018019), R&D Foundation of PKUPH (2018-01, 2017-01), Ministry of Education Innovation Program of China (IRT_16R01), and National S&T Major Project of China (SQ2018ZX100301).	Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Lopez-Verrilli MA, 2013, GLIA, V61, P1795, DOI 10.1002/glia.22558; Ansari S, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700670; Asplund M, 2009, NEUROEPIDEMIOLOGY, V32, P217, DOI 10.1159/000197900; Beigi MH, 2014, J BIOMED MATER RES A, V102, P4554, DOI 10.1002/jbm.a.35119; Bell JHA, 2012, TISSUE ENG PART B-RE, V18, P116, DOI [10.1089/ten.teb.2011.0498, 10.1089/ten.TEB.2011.0498]; Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006; Bucan V, 2019, MOL NEUROBIOL, V56, P1812, DOI 10.1007/s12035-018-1172-z; Burrello J, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00083; Cao Y, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/9328347; Chen PW, 2015, ACTA NEUROPATHOL, V130, P605, DOI 10.1007/s00401-015-1482-4; Ching RC, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1017-8; Court FA, 2011, GLIA, V59, P1529, DOI 10.1002/glia.21196; Daly W, 2012, J R SOC INTERFACE, V9, P202, DOI 10.1098/rsif.2011.0438; Defrancesco-Lisowitz A, 2015, NEUROSCIENCE, V302, P174, DOI 10.1016/j.neuroscience.2014.09.027; Del Fattore A, 2015, CELL TRANSPLANT, V24, P2615, DOI 10.3727/096368915X687543; Diomede F, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00419; Diomede F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020329; Du J, 2018, BIOMATERIALS, V181, P347, DOI 10.1016/j.biomaterials.2018.07.015; Gu XS, 2014, BIOMATERIALS, V35, P6143, DOI 10.1016/j.biomaterials.2014.04.064; Gu Y, 2014, BIOMATERIALS, V35, P2253, DOI 10.1016/j.biomaterials.2013.11.087; Hao ZC, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12359; Hu XY, 2009, TISSUE ENG PT A, V15, P3297, DOI [10.1089/ten.tea.2009.0017, 10.1089/ten.TEA.2009.0017]; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Jiang BG, 2010, ARTIF CELL BLOOD SUB, V38, P1, DOI 10.3109/10731190903495652; Jiang BG, 2006, ARTIF CELL BLOOD SUB, V34, P55, DOI 10.1080/10731190500430149; Kou XX, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aai8524; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Li R, 2018, BIOMATERIALS, V168, P24, DOI 10.1016/j.biomaterials.2018.03.044; Li Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0648-5; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Marquardt LM, 2013, CURR OPIN BIOTECH, V24, P887, DOI 10.1016/j.copbio.2013.05.006; Noble J, 1998, J TRAUMA, V45, P116, DOI 10.1097/00005373-199807000-00025; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472; Rani S, 2016, ADV MATER, V28, P5542, DOI 10.1002/adma.201504009; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Sanen K, 2017, J TISSUE ENG REGEN M, V11, P3362, DOI 10.1002/term.2249; Shi Q, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00904; Taylor CA, 2008, AM J PHYS MED REHAB, V87, P381, DOI 10.1097/PHM.0b013e31815e6370; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Todorova D, 2017, CIRC RES, V120, P1658, DOI 10.1161/CIRCRESAHA.117.309681; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Wang YF, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0632-0; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zhang B, 2015, STEM CELL TRANSL MED, V4, P513, DOI 10.5966/sctm.2014-0267; Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479; Zhang PX, 2015, LANCET, V386, P40; Zhang QZ, 2018, MOL NEUROBIOL, V55, P6965, DOI 10.1007/s12035-018-0913-3; Zhang QZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24888-w; Zhang QZ, 2017, STEM CELL TRANSL MED, V6, P458, DOI 10.5966/sctm.2016-0177; Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318	54	34	35	7	14	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-966X	1687-9678		STEM CELLS INT	Stem Cells Int.		2019	2019								2546367	10.1155/2019/2546367			12	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	IG0IS	WOS:000473475000001	31191669	gold, Green Submitted, Green Published			2022-02-06	
J	Abdullah, A; Zhang, M; Frugier, T; Bedoui, S; Taylor, JM; Crack, PJ				Abdullah, Amar; Zhang, Moses; Frugier, Tony; Bedoui, Sammy; Taylor, Juliet M.; Crack, Peter J.			STING-mediated type-I interferons contribute to the neuroinflammatory process and detrimental effects following traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						STING; Type-I interferon; Traumatic brain injury; Neuroinflammation; Autophagy	TUMOR-NECROSIS-FACTOR; TUBERCULOSIS DNA; FACTOR-ALPHA; CELL-DEATH; AUTOPHAGY; ACTIVATION; EXPRESSION; RECEPTORS; PATHWAY; IFN	Background: Traumatic brain injury (TBI) represents a major cause of disability and death worldwide with sustained neuroinflammation and autophagy dysfunction contributing to the cellular damage. Stimulator of interferon genes (STING)-induced type-I interferon (IFN) signalling is known to be essential in mounting the innate immune response against infections and cell injury in the periphery, but its role in the CNS remains unclear. We previously identified the type-I IFN pathway as a key mediator of neuroinflammation and neuronal cell death in TBI. However, the modulation of the type-I IFN and neuroinflammatory responses by STING and its contribution to autophagy and neuronal cell death after TBI has not been explored. Methods: C57BL/6J wild-type (WT) and STING(-/-) mice (8-10-week-old males) were subjected to controlled cortical impact (CCI) surgery and brains analysed by QPCR, Western blot and immunohistochemical analyses at 2 h or 24 h. STING expression was also analysed by QPCR in post-mortem human brain samples. Results: A significant upregulation in STING expression was identified in late trauma human brain samples that was confirmed in wild-type mice at 2 h and 24 h after CCI. This correlated with an elevated pro-inflammatory cytokine profile with increased TNF-alpha, IL-6, IL-1 beta and type-I IFN (IFN-alpha and IFN-beta) levels. This expression was suppressed in the STING(-/-) mice with a smaller lesion volume in the knockout animals at 24 h post CCI. Wild-type mice also displayed increased levels of autophagy markers, LC3-II, p62 and LAMP2 after TBI; however, STING(-/-) mice showed reduced LAMP2 expression suggesting a role for STING in driving dysfunctional autophagy after TBI. Conclusion: Our data implicates a detrimental role for STING in mediating the TBI-induced neuroinflammatory response and autophagy dysfunction, potentially identifying a new therapeutic target for reducing cellular damage in TBI.	[Abdullah, Amar; Zhang, Moses; Frugier, Tony; Taylor, Juliet M.; Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Neuropharmacol Lab, Melbourne, Vic 3010, Australia; [Bedoui, Sammy] Peter Doherty Inst, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia		Taylor, JM; Crack, PJ (corresponding author), Univ Melbourne, Dept Pharmacol & Therapeut, Neuropharmacol Lab, Melbourne, Vic 3010, Australia.	aabdullah@student.unimelb.edu.au; juliett@unimelb.edu.au; pcrack@unimelb.edu.au	Crack, Peter/ABE-2065-2020	Crack, Peter/0000-0002-5030-0330; Taylor, Juliet/0000-0002-4596-6760; BEDOUI, SAMMY/0000-0002-7443-0543	National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council of Australia	This study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia to PJC and JMT.	Blaauboer SM, 2014, J IMMUNOL, V192, P492, DOI 10.4049/jimmunol.1301812; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Burdette DL, 2013, NAT IMMUNOL, V14, P19, DOI 10.1038/ni.2491; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025; Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; de Weerd NA, 2007, J BIOL CHEM, V282, P20053, DOI 10.1074/jbc.R700006200; de Weerd NA, 2012, IMMUNOL CELL BIOL, V90, P483, DOI 10.1038/icb.2012.9; Field R, 2010, BRAIN BEHAV IMMUN, V24, P996, DOI 10.1016/j.bbi.2010.04.004; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Gehrke N, 2015, CELL DEATH DIFFER, V22, P826, DOI 10.1038/cdd.2014.178; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gough DJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000361; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim DY, 2015, J NEUROTRAUM, V32, P1815, DOI 10.1089/neu.2014.3728; Klarquist J, 2014, J IMMUNOL, V193, P6124, DOI 10.4049/jimmunol.1401869; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu CF, 2016, ONCOTARGET, V7, P46972, DOI 10.18632/oncotarget.10503; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Main BS, 2016, GLIA, V64, P1590, DOI 10.1002/glia.23028; Mathur V, 2017, NEURON, V96, P1290, DOI 10.1016/j.neuron.2017.11.032; Minter MR, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0341-4; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nazmi A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00347; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Paludan SR, 2013, IMMUNITY, V38, P870, DOI 10.1016/j.immuni.2013.05.004; Petrasek J, 2013, P NATL ACAD SCI USA, V110, P16544, DOI 10.1073/pnas.1308331110; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Qiao JT, 2018, METABOLISM, V81, P13, DOI 10.1016/j.metabol.2017.09.010; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Schmeisser H, 2014, J INTERF CYTOK RES, V34, P71, DOI 10.1089/jir.2013.0128; Schmeisser H, 2013, AUTOPHAGY, V9, P683, DOI 10.4161/auto.23921; Seki E, 2008, HEPATOLOGY, V48, P322, DOI 10.1002/hep.22306; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Vitner EB, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0570-2; Vogan K, 2014, NAT GENET, V46, P933, DOI [10.1038/ng.3082, DOI 10.1038/NG.3082]; Watson RO, 2015, CELL HOST MICROBE, V17, P811, DOI 10.1016/j.chom.2015.05.004; Watson RO, 2012, CELL, V150, P803, DOI 10.1016/j.cell.2012.06.040; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Woo SR, 2013, J IMMUNOL, V190; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Zhang JY, 2018, J NEUROTRAUM, V35, P802, DOI 10.1089/neu.2016.4871; Zhang MY, 2017, CELL MOL NEUROBIOL, V37, P291, DOI 10.1007/s10571-016-0369-9; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	75	34	35	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	NOV 21	2018	15								323	10.1186/s12974-018-1354-7			17	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	HB3HQ	WOS:000450942200002	30463579	Green Published, gold			2022-02-06	
J	Burstein, B; Upton, JE; Terra, HF; Neuman, MI				Burstein, Brett; Upton, Julia E. M.; Terra, Heloisa Fuzaro; Neuman, Mark I.			Use of CT for Head Trauma: 2007-2015	PEDIATRICS			English	Article							COMPUTED-TOMOGRAPHY USE; EMERGENCY-DEPARTMENT; UNITED-STATES; RADIATION-EXPOSURE; PREDICTION RULES; DECISION RULE; CHILDREN; INJURY; PECARN; VALIDATION	In this study, we used a nationwide US sample to evaluate the trend in CT neuroimaging for children with head injuries presenting to EDs. BACKGROUND AND OBJECTIVES:International efforts have been focused on identifying children at low risk of clinically important traumatic brain injury in whom computed tomography (CT) neuroimaging can be avoided. We sought to determine if CT use for pediatric head trauma has decreased among US emergency departments (EDs).METHODS:This was a cross-sectional analysis of the National Hospital Ambulatory Care Medical Survey database of nationally representative ED visits from 2007 to 2015. We included children <18 years of age evaluated in the ED for head injury. Survey weighting procedures were used to estimate the annual proportion of children who underwent CT neuroimaging and to perform multivariable logistic regression.RESULTS:There were an estimated 14.3 million pediatric head trauma visits during the 9-year study period. Overall, 32% (95% confidence interval [CI]: 29%-35%) of children underwent CT neuroimaging with no significant annual linear trend (P trend = .50). Multivariate analysis similarly revealed no difference by year (adjusted odds ratio [aOR]: 1.02; 95% CI: 0.97-1.07) after adjustment for patient- and ED-level covariates. CT use was associated with age 2 years (aOR: 1.51; 95% CI: 1.13-2.01), white race (aOR: 1.43; 95% CI: 1.10-1.86), highest triage acuity (aOR: 8.24 [95% CI: 4.00-16.95]; P < .001), and presentation to a nonteaching (aOR: 1.47; 95% CI: 1.05-2.06) or nonpediatric (aOR: 1.53; 95% CI: 1.05-2.23) hospital.CONCLUSIONS:CT neuroimaging did not decrease from 2007 to 2015. Findings suggest an important need for quality improvement initiatives to decrease CT use among children with head injuries.	[Burstein, Brett] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Pediat Emergency Med,Dept Pediat, 1001 Decarie Blvd, Montreal, PQ H4C 3J1, Canada; [Burstein, Brett; Upton, Julia E. M.; Terra, Heloisa Fuzaro] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA; [Upton, Julia E. M.] Univ Toronto, Dept Pediat, Div Immunol & Allergy, Toronto, ON, Canada; [Upton, Julia E. M.] Hosp Sick Children, Toronto, ON, Canada; [Terra, Heloisa Fuzaro] Virginia Commonwealth Univ, Sch Dent, Richmond, VA USA; [Neuman, Mark I.] Harvard Univ, Harvard Med Sch, Dept Pediat, Div Emergency Med, Boston, MA 02115 USA; [Neuman, Mark I.] Boston Childrens Hosp, Boston, MA USA		Burstein, B (corresponding author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Pediat Emergency Med,Dept Pediat, 1001 Decarie Blvd, Montreal, PQ H4C 3J1, Canada.	brett.burstein@mail.mcgill.ca	Upton, Julia/T-7425-2019				Babl FE, 2017, LANCET, V389, P2393, DOI 10.1016/S0140-6736(17)30555-X; Bender JM, 2014, J CLIN LAB ANAL, V28, P349, DOI 10.1002/jcla.21692; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bulas D, 2009, PEDIATR RADIOL, V39, P112, DOI [10.1007/s00247-009-1178-9, 10.1007/s00247-008-1101-9]; Dayan PS, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2709; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Fortin EM, 2016, EMERG RADIOL, V23, P597, DOI 10.1007/s10140-016-1424-z; Goldwasser T, 2015, EUR J EMERG MED, V22, P413, DOI 10.1097/MEJ.0000000000000201; Goske MJ, 2008, AM J ROENTGENOL, V190, P273, DOI 10.2214/AJR.07.3526; Goske Marilyn J, 2008, J Am Coll Radiol, V5, P1200, DOI 10.1016/j.jacr.2008.06.007; Green Lawrence W, 2014, Front Public Health Serv Syst Res, V3, P3; Hoyle JD, 2014, PEDIATR EMERG CARE, V30, P1, DOI 10.1097/PEC.0000000000000059; Ide K, 2017, ACAD EMERG MED, V24, P308, DOI 10.1111/acem.13129; Image Gently Alliance, CAMP OV; Jennings RM, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1349; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Larson DB, 2011, RADIOLOGY, V259, P793, DOI 10.1148/radiol.11101939; Lin MP, 2017, ACAD EMERG MED, V24, P668, DOI 10.1111/acem.13167; Lodwick DL, 2015, PEDIATRICS, V136, pE1212, DOI 10.1542/peds.2015-1671; Lorton F, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0287-3; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Marin JR, 2014, ACAD EMERG MED, V21, P987, DOI 10.1111/acem.12458; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marr A., 2004, CENTRAL NERVOUS SYST; Melnick ER, 2015, ACAD EMERG MED, V22, P1474, DOI 10.1111/acem.12824; Miescier MJ, 2017, PEDIATR EMERG CARE, V33, P156, DOI 10.1097/PEC.0000000000000500; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; Natale JE, 2012, ARCH PEDIAT ADOL MED, V166, P732, DOI 10.1001/archpediatrics.2012.307; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Slovis TL, 2002, PEDIATR RADIOL, V32, P217, DOI 10.1007/s00247-002-0669-8; Stanley RM, 2014, J PEDIATR-US, V165, P1201, DOI 10.1016/j.jpeds.2014.08.008; Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403	38	34	34	2	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2018	142	4							e20180814	10.1542/peds.2018-0814			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	GZ0EU	WOS:000449034300025	30181120	Bronze			2022-02-06	
J	Vay, SU; Flitsch, LJ; Rabenstein, M; Rogall, R; Blaschke, S; Kleinhaus, J; Reinert, N; Bach, A; Fink, GR; Schroeter, M; Rueger, MA				Vay, Sabine Ulrike; Flitsch, Lea Jessica; Rabenstein, Monika; Rogall, Rebecca; Blaschke, Stefan; Kleinhaus, Judith; Reinert, Noemie; Bach, Annika; Fink, Gereon Rudolf; Schroeter, Michael; Rueger, Maria Adele			The plasticity of primary microglia and their multifaceted effects on endogenous neural stem cells in vitro and in vivo	JOURNAL OF NEUROINFLAMMATION			English	Article						Neuroinflammation; Neuroprotection; Stem cell-mediated regeneration; M1 microglia; M2 microglia; Hybrid microglia; Cerebral ischemia	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; M2 MICROGLIA; NEURODEGENERATIVE DISEASES; MACROPHAGE ACTIVATION; STEM/PROGENITOR CELLS; REACTIVE ASTROCYTES; CHRONIC PHASE; WHITE-MATTER	Background: Microglia-the resident immune cells of the brain-are activated after brain lesions, e.g., cerebral ischemia, and polarize towards a classic "M1" pro-inflammatory or an alternative "M2" anti-inflammatory phenotype following characteristic temporo-spatial patterns, contributing either to secondary tissue damage or to regenerative responses. They closely interact with endogenous neural stem cells (NSCs) residing in distinct niches of the adult brain. The current study aimed at elucidating the dynamics of microglia polarization and their differential effects on NSC function. Results: Primary rat microglia in vitro were polarized towards a M1 phenotype by LPS, or to a M2 phenotype by IL4, while simultaneous exposure to LPS plus IL4 resulted in a hybrid phenotype expressing both M1- and M2-characteristic markers. M2 microglia migrated less but exhibit higher phagocytic activity than M1 microglia. Defined mediators switched microglia from one polarization state to the other, a process more effective when transforming M2 microglia towards M1 than vice versa. Polarized microglia had differential effects on the differentiation potential of NSCs in vitro and in vivo, with M1 microglia promoting astrocytogenesis, while M2 microglia supported neurogenesis. Regardless of their polarization, microglia inhibited NSC proliferation, increased NSC migration, and accelerated NSC differentiation. Conclusion: Overall, this study shed light on the complex conditions governing microglia polarization and the effects of differentially polarized microglia on critical functions of NSCs in vitro and in vivo. Refining the understanding of microglia activation and their modulatory effects on NSCs is likely to facilitate the development of innovative therapeutic concepts supporting the innate regenerative capacity of the brain.	[Vay, Sabine Ulrike; Flitsch, Lea Jessica; Rabenstein, Monika; Rogall, Rebecca; Blaschke, Stefan; Kleinhaus, Judith; Reinert, Noemie; Bach, Annika; Fink, Gereon Rudolf; Schroeter, Michael; Rueger, Maria Adele] Univ Hosp Cologne, Dept Neurol, Kerpener Str 62, D-50924 Cologne, Germany; [Blaschke, Stefan; Fink, Gereon Rudolf; Schroeter, Michael; Rueger, Maria Adele] Res Ctr Juelich, Inst Neurosci & Med INM 3, Cognit Neurosci, Julich, Germany		Vay, SU (corresponding author), Univ Hosp Cologne, Dept Neurol, Kerpener Str 62, D-50924 Cologne, Germany.	sabine.vay@uk-koeln.de	Fink, Gereon R./E-1616-2012; Vay, Sabine Ulrike/AAP-3842-2020; Blaschke, Stefan/AAM-9468-2021	Fink, Gereon R./0000-0002-8230-1856; Vay, Sabine Ulrike/0000-0002-3289-7807; 	Marga-und-Walter-Boll-Foundation [210-10-15]; "Koeln Fortune Program"/Faculty of Medicine, University of Cologne, Germany [339/2015]	This research work was supported by the "Marga-und-Walter-Boll-Foundation" (#210-10-15) and by the "Koeln Fortune Program"/Faculty of Medicine, University of Cologne, Germany (339/2015).	Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Dooley D, 2014, PHARMACOL THERAPEUT, V141, P21, DOI 10.1016/j.pharmthera.2013.08.001; Ekdahl CT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00041; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Ghisletti S, 2010, IMMUNITY, V32, P317, DOI 10.1016/j.immuni.2010.02.008; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; L'Episcopo F, 2018, STEM CELLS, V36, P1179, DOI 10.1002/stem.2827; L'Episcopo F, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00012; L'Episcopo F, 2013, J NEUROSCI, V33, P1462, DOI 10.1523/JNEUROSCI.3206-12.2013; L'Episcopo F, 2012, J NEUROSCI, V32, P2062, DOI 10.1523/JNEUROSCI.5259-11.2012; Lam D, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0941-3; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Martino G, 2011, PHYSIOL REV, V91, P1281, DOI 10.1152/physrev.00032.2010; MATTHEWS MA, 1974, CELL TISSUE RES, V148, P477; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mosher KI, 2012, NAT NEUROSCI, V15, P1485, DOI 10.1038/nn.3233; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Osman AM, 2019, NEUROSCIENCE, V405, P92, DOI 10.1016/j.neuroscience.2017.10.034; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Rabenstein M, 2016, J NEUROIMMUNOL, V299, P130, DOI 10.1016/j.jneuroim.2016.09.009; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Rivest Serge, 2011, Expert Rev Neurother, V11, P783, DOI 10.1586/ern.11.64; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rueger MA, 2010, J NEUROSCI, V30, P6454, DOI 10.1523/JNEUROSCI.6092-09.2010; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Shechter R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027969; Sierra A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00240; Sierra A, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/610343; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Vay SU, 2016, J NEUROSCI RES, V94, P149, DOI 10.1002/jnr.23686; Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35; Walberer M, 2014, BRAIN RES, V1581, P80, DOI 10.1016/j.brainres.2014.05.030; Walberer Maureen, 2010, Exp Transl Stroke Med, V2, P22, DOI 10.1186/2040-7378-2-22; Walter HL, 2015, NEUROSCIENCE, V292, P71, DOI 10.1016/j.neuroscience.2015.02.024; Xu HZ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/5405104; Yuan JC, 2017, ONCOTARGET, V8, P19855, DOI 10.18632/oncotarget.15774	70	34	36	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 13	2018	15								226	10.1186/s12974-018-1261-y			21	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	GQ2QW	WOS:000441501400001	30103769	gold, Green Published			2022-02-06	
J	Schafer, MKE; Tegeder, I				Schaefer, Michael K. E.; Tegeder, Irmgard			NG2/CSPG4 and progranulin in the posttraumatic glial scar	MATRIX BIOLOGY			English	Article							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; CHONDROITIN-SULFATE PROTEOGLYCAN; PROTEIN-TYROSINE-PHOSPHATASE; CENTRAL-NERVOUS-SYSTEM; LONG-TERM POTENTIATION; MEMBRANE-SPANNING PROTEOGLYCAN; PROMOTES FUNCTIONAL RECOVERY; ANTIGEN-RELATED PHOSPHATASE; GROWTH-FACTOR PROGRANULIN	Traumatic injury of the central nervous system is one of the leading causes of death and disability in young adults. Failure of regeneration is caused by autonomous neuronal obstacles and by formation of the glial scar, which is essential to seal the injury but also constitutes a barrier for regrowing axons. The scar center is highly inflammatory and populated by NG2+ glia, whereas astrocytes form the sealing border and trap regrowing axons, suggesting that the non-permissive environment of activated astrocytes and extracellular matrix components is one of the reasons for the regenerative failure. Particularly, secreted chondroitin-sulfate proteoglycans, CSPGs, of the lectican family hinder axonal regrowth. In contrast, the transmembrane CSPG, NG2/CSPG4, appears to be functionally closer related to axon growth permissive heparan sulfate proteoglycans, HSPGs, and synaptic adhesion molecules, which all regulate synaptic signaling and plasticity upon alpha-secretase mediated shedding. Consequently, knockout of NG2/CSPG4 aggravates tissue loss, inflammation and neurologic deficits after brain injury, a phenotype partly mimicked by deletion of HSPG-binding proteins such as the HSPG2/perlecan-interacting protein, progranulin that is also a functional ligand of Notch and Eph2a. Indeed, structural features or progranulin's targets and NG2 may point to direct reciprocal regulations that may act in concert to overcome injury -evoked inflammation and neuronal dystrophy. This review provides an overview of the pathophysiology of the glial scar after brain injury, with a specific focus on NG2/CSPG4, its functions before and after shedding and putative reciprocal influences with the glycoprotein progranulin. (C) 2017 Elsevier B.V. All rights reserved.	[Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Mainz, Germany; [Tegeder, Irmgard] Goethe Univ Hosp, Inst Clin Pharmacol, Frankfurt, Germany		Tegeder, I (corresponding author), Goethe Univ Hosp, Inst Clin Pharmacol ZAFES, Frankfurt, Germany.	tegeder@em.uni-frankfurt.de	Tegeder, Irmgard/AAM-2246-2020; Schaefer, Michael K.E./S-1715-2019	Tegeder, Irmgard/0000-0001-7524-8025; Schaefer, Michael K.E./0000-0001-6055-6244; Schaefer, Michael/0000-0002-1581-706X	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [CRC1080]	We acknowledge the financial support of the Deutsche Forschungsgemeinschaft (CRC1080, A03 to IT).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Altmann C, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0132-1; Altmann C, 2016, NEUROBIOL DIS, V96, P294, DOI 10.1016/j.nbd.2016.09.010; Anderegg U, 2009, J INVEST DERMATOL, V129, P1471, DOI 10.1038/jid.2008.323; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Asher RA, 2005, MOL CELL NEUROSCI, V29, P82, DOI 10.1016/j.mcn.2005.02.001; Assinck P., 2017, J NEUROSCI; Babayan AH, 2012, J NEUROSCI, V32, P12854, DOI 10.1523/JNEUROSCI.2024-12.2012; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Beller JA, 2014, NEURAL REGEN RES, V9, P343, DOI 10.4103/1673-5374.128235; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Birbrair A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt512; Bonfanti E, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.256; Bozkulak EC, 2009, MOL CELL BIOL, V29, P5679, DOI 10.1128/MCB.00406-09; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brakebusch C, 2002, MOL CELL BIOL, V22, P7417, DOI 10.1128/MCB.22.21.7417-7427.2002; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Chan CS, 2007, LEARN MEMORY, V14, P606, DOI 10.1101/lm.648607; Chan CS, 2006, J NEUROSCI, V26, P223, DOI 10.1523/JNEUROSCI.4110-05.2006; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen ZY, 2005, J NEUROSCI, V25, P6156, DOI 10.1523/JNEUROSCI.1017-05.2005; Coles CH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6209; Coles CH, 2011, SCIENCE, V332, P484, DOI 10.1126/science.1200840; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; De Biase LM, 2010, J NEUROSCI, V30, P3600, DOI 10.1523/JNEUROSCI.6000-09.2010; Deguchi Y, 2002, J NEUROCHEM, V83, P381, DOI 10.1046/j.1471-4159.2002.01129.x; DOU CL, 1994, J NEUROSCI, V14, P7616; Dyck SM, 2015, STEM CELLS, V33, P2550, DOI 10.1002/stem.1979; Egashira Y, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-105; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Faux C, 2007, BBA-MOL CELL RES, V1773, P1689, DOI 10.1016/j.bbamcr.2007.06.008; Fawcett JW, 2015, PROG BRAIN RES, V218, P213, DOI 10.1016/bs.pbr.2015.02.001; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Filous AR, 2014, J NEUROSCI, V34, P16369, DOI 10.1523/JNEUROSCI.1309-14.2014; Fisher D, 2011, J NEUROSCI, V31, P14051, DOI 10.1523/JNEUROSCI.1737-11.2011; Fox AN, 2005, CURR BIOL, V15, P1701, DOI 10.1016/j.cub.2005.08.035; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Gao K, 2013, GLIA, V61, P2063, DOI 10.1002/glia.22577; Gaudet AD, 2014, EXP NEUROL, V258, P24, DOI 10.1016/j.expneurol.2013.11.020; Gherardini L, 2015, CEREB CORTEX, V25, P202, DOI 10.1093/cercor/bht217; Gokce O, 2013, J NEUROSCI, V33, P14617, DOI 10.1523/JNEUROSCI.1232-13.2013; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; Grako KA, 1999, J CELL SCI, V112, P905; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Grimpe B, 2004, J NEUROSCI, V24, P1393, DOI 10.1523/JNEUROSCI.4986-03.2004; Gubbiotti MA, 2017, MATRIX BIOL, V57-58, P285, DOI 10.1016/j.matbio.2016.09.003; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Hackett AR, 2016, NEUROBIOL DIS, V89, P10, DOI 10.1016/j.nbd.2016.01.017; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; He ZH, 2002, CANCER RES, V62, P5590; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Heinrich C, 2014, STEM CELL REP, V3, P1000, DOI 10.1016/j.stemcr.2014.10.007; Hering TM, 2015, MATRIX BIOL, V41, P8, DOI 10.1016/j.matbio.2014.11.006; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Honsa P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036816; Hossain-Ibrahim MK, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-80; Hsieh T. H., 2016, CEREB CORTEX; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Huang CS, 2016, GLIA, V64, P507, DOI 10.1002/glia.22944; Huang WH, 2014, GLIA, V62, P896, DOI 10.1002/glia.22648; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Johnson KG, 2006, NEURON, V49, P517, DOI 10.1016/j.neuron.2006.01.026; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Joo NE, 2014, DNA CELL BIOL, V33, P854, DOI 10.1089/dna.2014.2399; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Juttner R, 2005, NEURON, V46, P233, DOI 10.1016/j.neuron.2005.02.027; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Karus M, 2016, GLIA, V64, P270, DOI 10.1002/glia.22928; Kattenstroth G, 2004, P NATL ACAD SCI USA, V101, P2607, DOI 10.1073/pnas.0308626100; Kerever A, 2014, STEM CELL RES, V12, P492, DOI 10.1016/j.scr.2013.12.009; Kim SY, 2016, J NEUROSCI RES, V94, P794, DOI 10.1002/jnr.23758; Komitova M, 2011, GLIA, V59, P800, DOI 10.1002/glia.21152; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kramar EA, 2006, P NATL ACAD SCI USA, V103, P5579, DOI 10.1073/pnas.0601354103; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Kucharova K, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-158; Kuhn PH, 2016, ELIFE, V5, DOI 10.7554/eLife.12748; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kurihara D, 2012, J BIOL CHEM, V287, P13822, DOI 10.1074/jbc.M111.314070; Kwon SK, 2010, J BIOL CHEM, V285, P13966, DOI 10.1074/jbc.M109.061127; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lang BT, 2015, NATURE, V518, P404, DOI 10.1038/nature13974; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Leadbeater WE, 2006, J NEUROCHEM, V96, P1189, DOI 10.1111/j.1471-4159.2005.03632.x; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lin B, 2003, J NEUROPHYSIOL, V89, P2874, DOI 10.1152/jn.00783.2002; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Lin RY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014557; Liu HQ, 2011, EXP NEUROL, V231, P236, DOI 10.1016/j.expneurol.2011.06.015; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Losada-Perez M, 2017, NEURAL REGEN RES, V12, P31, DOI 10.4103/1673-5374.198969; Losada-Perez M, 2016, J CELL BIOL, V214, P587, DOI 10.1083/jcb.201603054; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lukovic D, 2014, STEM CELLS, V32, P594, DOI 10.1002/stem.1562; Mangin JM, 2012, NAT NEUROSCI, V15, P1192, DOI 10.1038/nn.3190; Matusica D, 2008, J NEUROSCI RES, V86, P553, DOI 10.1002/jnr.21507; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; McRae PA, 2007, J NEUROSCI, V27, P5405, DOI 10.1523/JNEUROSCI.5425-06.2007; Menzel L., 2016, GLIA; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Neill T, 2016, J CELL BIOL, V215, P687, DOI 10.1083/jcb.201603079; Nishihara T, 2015, J BIOL CHEM, V290, P3693, DOI 10.1074/jbc.M114.603431; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nowicka D, 2009, EUR J NEUROSCI, V30, P2053, DOI 10.1111/j.1460-9568.2009.06996.x; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Orduz D, 2015, ELIFE, V4, DOI 10.7554/eLife.06953; Orlando C, 2015, BRAIN STRUCT FUNCT, V220, P1077, DOI 10.1007/s00429-013-0701-9; Passlick S, 2013, J NEUROSCI, V33, P12030, DOI 10.1523/JNEUROSCI.5562-12.2013; Perez-Moreno JJ, 2017, J CELL SCI, V130, P950, DOI 10.1242/jcs.197459; Pickford F, 2011, AM J PATHOL, V178, P284, DOI 10.1016/j.ajpath.2010.11.002; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Poluzzi C, 2014, J BIOL CHEM, V289, P16114, DOI 10.1074/jbc.M114.556530; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Pottker B., 2017, BRAIN STRUCT FUNCT; Rademakers R, 2012, NAT REV NEUROL, V8, P423, DOI 10.1038/nrneurol.2012.117; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Raposo C, 2014, GLIA, V62, P1895, DOI 10.1002/glia.22676; Rauch U, 2005, BIOCHEM BIOPH RES CO, V328, P608, DOI 10.1016/j.bbrc.2005.01.026; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Robins SC, 2013, GLIA, V61, P1735, DOI 10.1002/glia.22554; Rogers CJ, 2011, P NATL ACAD SCI USA, V108, P9747, DOI 10.1073/pnas.1102962108; Rolls A, 2008, PLOS MED, V5, P1262, DOI 10.1371/journal.pmed.0050171; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Saftig P, 2015, PROG NEUROBIOL, V135, P1, DOI 10.1016/j.pneurobio.2015.10.003; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Sakry D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001993; Sarhan AR, 2016, J CELL SCI, V129, P2962, DOI 10.1242/jcs.191379; Sarrazin S, 2011, COLD SPRING HARB PER, V3; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Schultz N, 2014, J NEUROPATH EXP NEUR, V73, P684, DOI 10.1097/NEN.0000000000000084; Shen YJ, 2009, SCIENCE, V326, P592, DOI 10.1126/science.1178310; Shinozaki Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep04329; Shuo T, 2007, J NEUROCHEM, V102, P1561, DOI 10.1111/j.1471-4159.2007.04658.x; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sirko S, 2007, DEVELOPMENT, V134, P2727, DOI 10.1242/dev.02871; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309; Smith PD, 2015, EXP NEUROL, V274, P100, DOI 10.1016/j.expneurol.2015.08.004; SMITHTHOMAS LC, 1995, J CELL SCI, V108, P1307; Soderblom C, 2013, J NEUROSCI, V33, P13882, DOI 10.1523/JNEUROSCI.2524-13.2013; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Soleman S, 2013, NEUROSCIENCE, V253, P194, DOI 10.1016/j.neuroscience.2013.08.050; Sprinzak D, 2010, NATURE, V465, P86, DOI 10.1038/nature08959; Stegmuller J, 2003, J BIOL CHEM, V278, P3590, DOI 10.1074/jbc.M210010200; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Takahashi H, 2013, TRENDS NEUROSCI, V36, P522, DOI 10.1016/j.tins.2013.06.002; Takahashi H, 2011, NEURON, V69, P287, DOI 10.1016/j.neuron.2010.12.024; Tan AM, 2006, J NEUROSCI, V26, P4729, DOI 10.1523/JNEUROSCI.3900-05.2006; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Tangkeangsirisin W, 2004, CARCINOGENESIS, V25, P1587, DOI 10.1093/carcin/bgh171; Tanimoto R., 2017, MATRIX BIOL; Thallmair M, 2006, EXP NEUROL, V202, P167, DOI 10.1016/j.expneurol.2006.05.025; Tillet E, 1997, J BIOL CHEM, V272, P10769; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Troeberg L, 2014, CHEM BIOL, V21, P1300, DOI 10.1016/j.chembiol.2014.07.014; Uetani N, 2000, EMBO J, V19, P2775, DOI 10.1093/emboj/19.12.2775; Ughrin YM, 2003, J NEUROSCI, V23, P175; Um JW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6423; Um JW, 2013, TRENDS CELL BIOL, V23, P465, DOI 10.1016/j.tcb.2013.07.004; Vadivelu S, 2015, STEM CELL TRANSL MED, V4, P401, DOI 10.5966/sctm.2014-0107; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Velez-Fort M, 2010, J NEUROSCI, V30, P6921, DOI 10.1523/JNEUROSCI.0238-10.2010; Vigano F, 2016, GLIA, V64, P287, DOI 10.1002/glia.22929; Vischer P, 1997, EUR J CELL BIOL, V73, P332; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson MT, 2000, J COMP NEUROL, V424, P532, DOI 10.1002/1096-9861(20000828)424:3<532::AID-CNE10>3.0.CO;2-Z; Woo J, 2009, NAT NEUROSCI, V12, P428, DOI 10.1038/nn.2279; Xie YM, 2001, J NEUROSCI, V21, P5130, DOI 10.1523/JNEUROSCI.21-14-05130.2001; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yaron A, 2012, TRENDS NEUROSCI, V35, P230, DOI 10.1016/j.tins.2011.12.003; Ye Q, 2013, MATRIX BIOL, V32, P352, DOI 10.1016/j.matbio.2013.04.001; Yim YS, 2013, P NATL ACAD SCI USA, V110, P4057, DOI 10.1073/pnas.1209881110; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; You WK, 2014, ANGIOGENESIS, V17, P61, DOI 10.1007/s10456-013-9378-1; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Zhou XH, 2001, MOL CELL BIOL, V21, P5970, DOI 10.1128/MCB.21.17.5970-5978.2001; Zhu Y, 2015, NEUROBIOL DIS, V74, P114, DOI 10.1016/j.nbd.2014.10.024; Zimmer G, 2010, CEREB CORTEX, V20, P2411, DOI 10.1093/cercor/bhp309; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	216	34	38	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0945-053X	1569-1802		MATRIX BIOL	Matrix Biol.	AUG	2018	68-69				SI		571	588		10.1016/j.matbio.2017.10.002			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GM8LO	WOS:000438480300036	29054751				2022-02-06	
J	Silverberg, ND; Panenka, WJ; Iverson, GL				Silverberg, Noah D.; Panenka, William J.; Iverson, Grant L.			Fear Avoidance and Clinical Outcomes from Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adaptation; psychological; brain concussion; cohort studies; fear; post-concussion symptoms	COMMON DATA ELEMENTS; INTERNATIONAL CLASSIFICATION; CORE SETS; HEALTH; DISABILITY; RECOMMENDATIONS; FRAMEWORK; ICF	Characterizing psychological factors that contribute to persistent symptoms after mild traumatic brain injury (MTBI) can inform early intervention. To determine whether fear avoidance, a known risk factor for chronic disability after musculoskeletal injury, is associated with worse clinical outcomes from MTBI, adults were recruited from four outpatient MTBI clinics and assessed at their first clinic visit (mean= 2.7, standard deviation= 1.5 weeks post -injury) and again four to five months later. Of 273 patients screened, 102 completed the initial assessment, and 87 returned for the outcome assessment. The initial assessment included a battery of questionnaires that measure activity avoidance and associated fears. Endurance, an opposite behavior pattern, was measured with the Behavioral Response to Illness Questionnaire The multi -dimensional outcome assessment included measures of post -concussion symptoms (British Columbia Postconcussion Symptom Inventory), functional disability (World Health Organization Disability Assessment Schedule -12 2.0), return to work status, and psychiatric complications (MINI Neuropsychiatric Interview). A single component was retained from principal components analysis of the six avoidance subscales. In generalized linear modeling, the avoidance composite score predicted symptom severity (95% confidence interval [CI] for B =1.22-6.33) and disability (95% CI for B = 2.16-5.48), but not return to work (95% CI for B = -0.68-0.24). The avoidance composite was also associated with an increased risk for depression (odds ratio [OR] =1.76, 95% CI= 1.02-3.02) and anxiety disorders (OR= 1.89, 95% CI= 1.16-3.19). Endurance behavior predicted the same outcomes, except for depression. In summary, avoidance and endurance behavior were associated with a range of adverse clinical outcomes from MTBI. These may represent early intervention targets.	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Rehabil Res Program, GF Strong Rehab Ctr, Vancouver, BC, Canada; [Panenka, William J.] Univ British Columbia, British Columbia Neuropsychiat Program, Dept Psychiat, Vancouver, BC, Canada; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] A Red Sox Fdn, Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA		Silverberg, ND (corresponding author), Univ British Columbia, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570; Panenka, William/0000-0001-7143-6512			Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Donovan J, 2014, CHIROPR MAN THER, V22, DOI 10.1186/s12998-014-0038-3; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Ellis MJ, 2017, CLIN J SPORT MED, V27, P179, DOI 10.1097/JSM.0000000000000305; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Laxe S, 2013, BRAIN INJURY, V27, P379, DOI 10.3109/02699052.2012.750757; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; Stucki G, 2005, AM J PHYS MED REHAB, V84, P733, DOI 10.1097/01.phm.0000179521.70639.83; Sveen U, 2013, DISABIL REHABIL, V35, P749, DOI 10.3109/09638288.2012.707741; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	23	34	34	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2018	35	16					1864	1873		10.1089/neu.2018.5662			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GQ2YY	WOS:000441527400004	29665736				2022-02-06	
J	Elbin, RJ; Sufrinko, A; Anderson, MN; Mohler, S; Schatz, P; Covassin, T; Mucha, A; Collins, MW; Kontos, AP				Elbin, R. J.; Sufrinko, Alicia; Anderson, Morgan N.; Mohler, Samantha; Schatz, Philip; Covassin, Tracey; Mucha, Anne; Collins, Michael W.; Kontos, Anthony P.			Prospective Changes in Vestibular and Ocular Motor Impairment After Concussion	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						brain; human movement system; sport; VOMS; youth	SPORT-RELATED CONCUSSION; SCREENING VOMS; BASE-LINE; RECOVERY-TIME; HIGH-SCHOOL; RELIABILITY; CHILDREN; STATEMENT; OUTCOMES; PERFORMANCE	Background and Purpose: The utility of prospective changes on the Vestibular/Ocular Motor Screening (VOMS) assessment are unknown, and 2 methods of scoring are published in the literature. Total scores are the total symptom scores for each VOMS component, and change scores are the difference between the pretest total symptom score and component total symptom scores. This study documented prospective changes in vestibular and ocular motor impairments and symptoms in high school athletes with concussion using the total and change scoring methods and compared the percentage of scores over clinical cutoffs using the total and change scoring methods for the VOMS. Methods: Sixty-three athletes (15.53 1.06 years) completed the VOMS at baseline (ie, preinjury), 1 to 7 days, and 8 to 14 days after concussion. A series of repeated-measures multivariate analyses of variance were conducted on total and change scores. A 2-way repeated-measures analysis of variance was performed on the near-point convergence distance. A series of (2) analyses compared scores exceeding clinical cutoffs between the total and change scoring methods. Results: Total scoring revealed impairments (Wilks = 0.39, F-16,F-47 = 4.54, P < 0.001, (2) = 0.61) on all VOMS components at 1 to 7 and 8 to 14 days compared to baseline. Change scoring revealed postinjury impairments compared with baseline (Wilks = 0.58, F-14,F-49 = 2.52, P = 0.009, (2) = 0.42) on all components at 1 to 7 days; however, impairments at 8 to 14 days were revealed only for the vertical vestibular oculomotor reflex and vestibular motor sensitivity components. Total scoring identified significantly more scores over cutoffs at 1 to 7 days ((2)(1,63) = 5.97, P = 0.02) compared with change scores. Discussion and Conclusions: Both total and change scoring methods on the VOMS are useful for identifying impairments following concussion. Video Abstract available for more insights from the authors (see Supplemental Digital Content 1, http://links.lww.com/JNPT/A230)	[Elbin, R. J.; Mohler, Samantha] Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA; [Sufrinko, Alicia; Mucha, Anne; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Dept Orthoped Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Anderson, Morgan N.; Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Mucha, Anne] UPMC Ctr Rehabil Serv, Pittsburgh, PA USA		Elbin, RJ (corresponding author), Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA.	rjelbin@uark.edu		Anderson, Morgan/0000-0001-9170-6663	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01 DC012332] Funding Source: Medline		Akin FW, 2003, J REHABIL RES DEV, V40, P415, DOI 10.1682/JRRD.2003.09.0415; Anzalone AJ, 2017, AM J SPORT MED, V45, P474, DOI 10.1177/0363546516668624; Asken BM, 2017, CLIN NEUROPSYCHOL, V31, P138, DOI 10.1080/13854046.2016.1246672; Barth JT, 1989, MILD HEAD INJURY SPO; BOWER CM, 1995, ARCH OTOLARYNGOL, V121, P911; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T, 2010, OPEN ACCESS J SPORTS, V1, P55; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; Elbin RJ, 2016, MED SCI SPORT EXER, V48, P525, DOI 10.1249/01.mss.0000486580.32473.21; Eviatar L, 1986, Pediatr Neurol, V2, P61, DOI 10.1016/0887-8994(86)90058-5; Gaikwad SB, 2018, J NEUROL PHYS THER, V42, P72, DOI 10.1097/NPT.0000000000000216; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Herdman SJ, 1998, AM J OTOL, V19, P790; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kemper AR, 2004, OPTOMETRY VISION SCI, V81, P7, DOI 10.1097/00006324-200401000-00003; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murray DA, 2017, BRIT J SPORT MED, V51, P442, DOI 10.1136/bjsports-2016-096081; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Riina N, 2005, ARCH OTOLARYNGOL, V131, P996, DOI 10.1001/archotol.131.11.996; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Schatz P, 2014, ARCH CLIN NEUROPSYCH, V29, P625, DOI 10.1093/arclin/acu041; Sufrinko AM, 2017, CLIN J SPORT MED, V27, P133, DOI 10.1097/JSM.0000000000000324; Yorke AM, 2017, SPORTS HEALTH, V9, P174, DOI 10.1177/1941738116678411; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	37	34	34	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUL	2018	42	3			SI		142	148		10.1097/NPT.0000000000000230			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	GL1OM	WOS:000436873100005	29864101	Green Accepted, Bronze			2022-02-06	
J	Liu, ZM; Chen, QX; Chen, ZB; Tian, DF; Li, MC; Wang, JM; Wang, L; Liu, BH; Zhang, SQ; Li, F; Ye, H; Zhou, L				Liu, Zai-Ming; Chen, Qian-Xue; Chen, Zhi-Biao; Tian, Dao-Feng; Li, Ming-Chang; Wang, Jun-Min; Wang, Long; Liu, Bao-Hui; Zhang, Shen-Qi; Li, Fei; Ye, Hui; Zhou, Long			RIP3 deficiency protects against traumatic brain injury (TBI) through suppressing oxidative stress, inflammation and apoptosis: Dependent on AMPK pathway	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Traumatic brain injury; RIP3; Inflammation; Oxidative stress; Apoptosis	CELL-DEATH; TNF-ALPHA; NECROPTOSIS; INHIBITOR; CANCER; AUTOPHAGY; ISCHEMIA; KINASE	Traumatic brain injury (TBI) is a leading cause of disability and mortality in young adults worldwide. The pathophysiology is not fully understood. Programmed necrosis (necroptosis) is a newly identified mechanism of cell death combining features of both apoptosis and necrosis. Receptor-interacting protein 3 (RIP3) plays an important role in programmed necrosis. However, the effect of RIP3-related pathway in TBI is little to be known. We attempted to explore the significance of RIP3 in regulating TBI in vivo. Significantly, TBI induced over-expression of RIP3 in the hippocampus of mice, as well as RIP1 and phosphorylated mixed lineage kinase domain-like protein (MLKL). Mice after TBI exhibited cognitive dysfunction and activation of glia cells, which were significantly attenuated by RIP3-knockout (KO). Moreover, inflammation and oxidative stress in hippocampus were markedly induced by TBI in wild type (WT) mice. Of note, the reduction of pro-inflammatory cytokines and oxidants was observed in RIP3-deficient mice, which was linked to the blockage of NLR pyrin domain containing 3 (NLRP3)/apoptosis-associated speck-like protein containing a CARD (ASC)/Caspase-1 and kelch-like ECH-associated protein 1 (Keap 1) pathways. Further, TBI induced hippocampus apoptosis, evidenced by the increase of cleaved Caspase-8/-3 and poly (ADP)-ribose polymerase (PARP) in WT mice, whereas being decreased by RIP3-knockout. In addition, RIP3 knockout led to phosphorylation of AMP-activated protein kinase a (AMPK alpha) in hippocampus of mice after TBI. And of note, the in vitro findings indicated that RIP3-ablation attenuated oxidative stress, inflammation and apoptosis in astrocytes, which was dependent on AMPK alpha activation. Together, suppressing RIP3 might be served as a therapeutic target against brain injury through inhibiting inflammation, oxidative stress and apoptosis. (C) 2018 Published by Elsevier Inc.	[Liu, Zai-Ming; Chen, Qian-Xue; Chen, Zhi-Biao; Tian, Dao-Feng; Li, Ming-Chang; Wang, Jun-Min; Wang, Long; Liu, Bao-Hui; Zhang, Shen-Qi; Li, Fei; Ye, Hui; Zhou, Long] Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan 430060, Hubei, Peoples R China		Chen, QX (corresponding author), Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan 430060, Hubei, Peoples R China.	chenqx666@sohu.com		Chen, Qianxue/0000-0002-9413-1030; tian, daofeng/0000-0002-2023-0060			Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Hardie DG, 2014, PHYSIOLOGY, V29, P99, DOI 10.1152/physiol.00050.2013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Ibrahim AS, 2010, MOL VIS, V16, P2033; Jin CC, 2010, J CLIN IMMUNOL, V30, P628, DOI 10.1007/s10875-010-9440-3; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Li JX, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.241; Linkermann A, 2013, AM J TRANSPLANT, V13, P2797, DOI 10.1111/ajt.12448; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu HC, 2012, BRAIN RES, V1474, P73, DOI 10.1016/j.brainres.2012.07.028; Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579; Meng LJ, 2015, P NATL ACAD SCI USA, V112, P11007, DOI 10.1073/pnas.1514730112; Metzig MO, 2016, ONCOGENE, V35, P3399, DOI 10.1038/onc.2015.398; Murphy JM, 2014, EMBO REP, V15, P155, DOI 10.1002/embr.201337970; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x; Philipp S, 2016, CELL MOL LIFE SCI, V73, P2183, DOI 10.1007/s00018-016-2193-2; Ren JM, 2017, CELL MOL IMMUNOL, V14, P639, DOI 10.1038/cmi.2017.31; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Su ZY, 2015, ONCOTARGET, V6, P8474, DOI 10.18632/oncotarget.3523; Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012; Vincent EE, 2015, ONCOGENE, V34, P3627, DOI 10.1038/onc.2014.301; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Yabal M, 2014, CELL REP, V7, P1796, DOI 10.1016/j.celrep.2014.05.008; Yu XF, 2015, ONCOTARGET, V6, P1995, DOI 10.18632/oncotarget.3038; Zhang HS, 2012, LIFE SCI, V90, P747, DOI 10.1016/j.lfs.2012.03.013; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	31	34	38	2	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	MAY 5	2018	499	2					112	119		10.1016/j.bbrc.2018.02.150			8	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	GD0AF	WOS:000430159400003	29470982				2022-02-06	
J	Zhao, W; Choate, B; Ji, SB				Zhao, Wei; Choate, Bryan; Ji, Songbai			Material properties of the brain in injury-relevant conditions - Experiments and computational modeling	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Traumatic brain injury; Concussion; Material properties; Head injury model; Hyperelasticity; Viscoelasticity	MECHANICAL CHARACTERIZATION; IN-VIVO; HEAD; TISSUE; STRAIN; DEFORMATION; BEHAVIOR; CONCUSSIONS; VALIDATION; IMPACT	Material properties of the brain have been extensively studied but remain poorly characterized. The vast variations in constitutive models and material constants are well documented. However, no study exists to translate the variations into disparities in impact-induced brain strains most relevant to brain injury. Here, we reviewed a subset of injury-relevant brain material properties either characterized in experiments or adopted in recent head injury models. To highlight how variations in measured brain material properties manifested in simulated brain strains, we selected six experiments that have provided a complete set of brain material model and constants to implement a common head injury model. Responses resulting from two extreme events representing a high-rate cadaveric head impact and a low-rate in vivo head rotation, respectively, varied substantially. We hypothesized, and further confirmed, that the time-varying shear moduli at the appropriate time scales (e.g., similar to 5 ms and similar to 40 ms corresponding to the impulse durations of the major acceleration peaks for the two impacts, respectively), rather than the initial or long-term shear moduli, were the most indicative of impact-induced brain strains. These results underscored the need to implement measured brain material properties into an actual head injury model for evaluation. They may also provide guidelines to better characterize brain material properties in future experiments and head injury models. Finally, our finding provided a practical solution to satisfy head injury model validation requirements at both ends of the impact severity spectrum. This would improve the confidence in model simulation performance across a range of time scales relevant to concussion and sub concussion in the real-world.	[Zhao, Wei; Choate, Bryan; Ji, Songbai] Worcester Polytech Inst, Dept Biomed Engn, 60 Prescott St, Worcester, MA 01605 USA; [Ji, Songbai] Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA		Ji, SB (corresponding author), Worcester Polytech Inst, Dept Biomed Engn, 60 Prescott St, Worcester, MA 01605 USA.	sji@wpi.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS092853, R21 NS088781]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092853, R21NS088781] Funding Source: NIH RePORTER	Funding is provided by the NIH Grants R01 NS092853 and R21 NS088781.	Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Bigler ED, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00055; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Budday S, 2017, J MECH BEHAV BIOMED, V74, P463, DOI 10.1016/j.jmbbm.2017.07.014; Budday S, 2017, ACTA BIOMATER, V60, P315, DOI 10.1016/j.actbio.2017.06.024; Budday S, 2017, ACTA BIOMATER, V48, P319, DOI 10.1016/j.actbio.2016.10.036; Chatelin Simon, 2013, Journal of Biorheology, V27, P26, DOI 10.1007/s12573-012-0055-6; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Daneshvar D.H., 2011, CLIN SPORTS MED; de Rooij R, 2016, APPL MECH REV, V68, DOI 10.1115/1.4032436; Di Ieva A, 2010, NEUROSURG REV, V33, P137, DOI 10.1007/s10143-010-0249-6; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Feng Y, 2017, J MECH BEHAV BIOMED, V65, P490, DOI 10.1016/j.jmbbm.2016.09.020; Finan JD, 2017, ACTA BIOMATER, V55, P333, DOI 10.1016/j.actbio.2017.03.037; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Ganpule S, 2017, J NEUROTRAUM, V34, P2154, DOI 10.1089/neu.2016.4744; Garimella HT, 2017, INT J NUMER METH BIO, V33, DOI 10.1002/cnm.2823; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Giordano Chiara, 2016, Stapp Car Crash J, V60, P363; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Goriely A, 2015, ADV APPL MECH, V48, P79, DOI 10.1016/bs.aams.2015.10.002; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hrapko M., 2008, OURNAL BIOMECH ENG, V130; Ji S., 2015, ANN BIOMED ENG, V43; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; King A. I., 2003, IRCOBI C LISB PORT; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lytton W.W., 2017, BRAIN INFORM; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Mihalik JP, 2017, MED SCI SPORT EXER, V49, P247, DOI 10.1249/MSS.0000000000001089; Miller LE, 2017, COMPUT METHOD BIOMEC, V20, P1273, DOI 10.1080/10255842.2017.1340462; Miller LE, 2016, BIOMECH MODEL MECHAN, V15, P1201, DOI 10.1007/s10237-015-0754-1; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Peden M., 2004, WORLD REPORT ROAD TR; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shigeta K., 2009, P 21 INT TECHN C ENH, P1; Shuck L.Z., 1972, J BASIC ENG; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tamura A., 2008, J BIOMECH SCI ENG, V3; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; van Dommelen J. A. W., 2009, V2, P249; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang King H, 2006, Stapp Car Crash J, V50, P429; Zhao W, 2017, ANN BIOMED ENG, V45, P2437, DOI 10.1007/s10439-017-1888-3; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P1709, DOI 10.1007/s10237-017-0915-5; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P449, DOI 10.1007/s10237-016-0829-7; Zhao W, 2016, J NEUROTRAUM, V33, P1834, DOI 10.1089/neu.2015.4239; Zhao W, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0091	75	34	34	4	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	APR	2018	80						222	234		10.1016/j.jmbbm.2018.02.005			13	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	GA7AK	WOS:000428486800028	29453025	Green Accepted			2022-02-06	
J	Glushakova, OY; Glushakov, AO; Borlongan, CV; Valadka, AB; Hayes, RL; Glushakov, AV				Glushakova, Olena Y.; Glushakov, Andriy O.; Borlongan, Cesar V.; Valadka, Alex B.; Hayes, Ronald L.; Glushakov, Alexander V.			Role of Caspase-3-Mediated Apoptosis in Chronic Caspase-3-Cleaved Tau Accumulation and Blood-Brain Barrier Damage in the Corpus Callosum after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						BBB; caspase-3-cleaved tau; chronic TBI; cleaved-caspase-3; GFAP	CORTICAL IMPACT INJURY; WHITE-MATTER; CEREBROSPINAL-FLUID; ALZHEIMER-DISEASE; CASPASE-CLEAVAGE; AMYLOID-BETA; NEURODEGENERATIVE DISEASE; NEURONAL APOPTOSIS; TEMPORAL PROFILE; PATHOLOGICAL TAU	Traumatic brain injury (TBI) may be a significant risk factor for development of neurodegenerative disorders such as chronic traumatic encephalopathy (CTE), post-traumatic epilepsy (PTE), and Alzheimer's (AD) and Parkinson's (PD) diseases. Chronic TBI is associated with several pathological features that are also characteristic of neurodegenerative diseases, including tau pathologies, caspase-3-mediated apoptosis, neuroinflammation, and microvascular alterations. The goal of this study was to evaluate changes following TBI in cleaved-caspase-3 and caspase-3-cleaved tau truncated at Asp421, and their relationships to cellular markers potentially associated with inflammation and blood-brain (BBB) barrier damage. We studied astrocytes (glial fibrillary acidic protein [GFAP]), microglia (ionized calcium-binding adapter molecule 1 [Iba1]), BBB (endothelial barrier antigen [EBA]), and activated microglia/macrophages (cluster of differentiation 68 [CD68]). We employed immunohistochemistry at different time points from 24h to 3 months after controlled cortical impact (CCI) injury in rats, with particular interest in white matter. The study demonstrated that CCI caused chronic upregulation of cleaved-caspase-3 in the white matter of the corpus callosum. Increases in cleaved-caspase-3 in the corpus callosum were accompanied by accumulation of caspase-3-cleaved tau, with increasing perivascular aggregation 3 months after CCI. Immunofluorescence experiments further showed cellular co-localization of cleaved-caspase-3 with GFAP and CD68 and its adjacent localization with EBA, suggesting involvement of apoptosis and neuroinflammation in mechanisms of delayed BBB and microvascular damage that could contribute to white matter changes. This study also provides the first evidence that evolving upregulation of cleaved-caspase-3 is associated with accumulation of caspase-3-cleaved tau following experimental TBI, thus providing new insights into potential common mechanisms mediated by caspase-3 and underlying chronic TBI pathologies and neurodegenerative diseases.	[Glushakova, Olena Y.; Valadka, Alex B.; Hayes, Ronald L.] Virginia Commonwealth Univ, Dept Neurosurg, POB 980631, Richmond, VA 23298 USA; [Glushakov, Andriy O.; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg, Tampa, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Glushakov, Alexander V.] Single Breath Inc, Gainesville, FL USA		Glushakova, OY (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980631, Richmond, VA 23298 USA.; Glushakov, AV (corresponding author), Single Breath Inc, POB 1074, Midlothian, VA 23113 USA.	olenaglushakova@gmail.com; glushakov@single-breath.com	Glushakova, Olena/AAY-1130-2021; Glushakov, Alexander V/B-5452-2008	Glushakova, Olena/0000-0002-2109-3651; Glushakov, Alexander V/0000-0003-2872-8960			Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Albayram O, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0124-4; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Bolos M, 2016, J ALZHEIMERS DIS, V50, P77, DOI 10.3233/JAD-150704; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Cai Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037599; Cartagena CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158576; Carvey PM, 2009, J NEUROCHEM, V111, P291, DOI 10.1111/j.1471-4159.2009.06319.x; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Cotman CW, 2005, J NEUROPATH EXP NEUR, V64, P104, DOI 10.1093/jnen/64.2.104; Dams-O'Connor K, 2016, NEURODEGENER DIS MAN, V6, P417, DOI 10.2217/nmt-2016-0017; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Day RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132637; Edwards G, 2017, BIOCHEM BIOPH RES CO, V483, P1137, DOI 10.1016/j.bbrc.2016.07.123; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gendron TF, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-13; Glushakov AV, 2016, METHODS MOL BIOL, V1462, P481, DOI 10.1007/978-1-4939-3816-2_27; Glushakov AV, 2016, FRONT MOL BIOSCI, V3, DOI 10.3389/fmolb.2016.00034; Glushakov AV, 2015, J NEUROTRAUM, V32, pA47; Glushakov AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113689; Glushakov AV, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-132; Glushakova O.Y., 2017, BRAIN CIRC IN PRESS; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Henriksen K, 2015, J ALZHEIMERS DIS, V43, P1331, DOI 10.3233/JAD-140984; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLNESS CL, 1993, BLOOD, V81, P1607; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Huh JW, 2011, J NEUROTRAUM, V28, P245, DOI 10.1089/neu.2010.1639; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Ji W, 2017, CELL MOL NEUROBIOL, V37, P683, DOI 10.1007/s10571-016-0404-x; Johnson EA, 2005, EXP BRAIN RES, V167, P17, DOI 10.1007/s00221-005-2362-2; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kaneko Y, 2012, CELL MED, V4, P55, DOI 10.3727/215517912X639306; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Laskowitz D., 2016, TRANSLATIONAL RES TR; Lingor P, 2012, CELL TISSUE RES, V349, P289, DOI 10.1007/s00441-012-1362-3; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Lorente L, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0485-z; Lorente L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121739; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Love S, 2000, NEUROREPORT, V11, P2495, DOI 10.1097/00001756-200008030-00030; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002; Luo WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11161; Lyck L, 2008, J HISTOCHEM CYTOCHEM, V56, P201, DOI 10.1369/jhc.7A7187.2007; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; Majerova P, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0161-z; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mendez MF, 2015, J ALZHEIMERS DIS, V47, P985, DOI 10.3233/JAD-143207; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Pozueta J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2927; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Reyes-Haro D, 2013, BIOL RES, V46, P27, DOI 10.4067/S0716-97602013000100004; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Rodhe J, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0365-9; Rohn Troy T, 2015, Int J Neurol Neurother, V2, P014; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Taylor KM, 2016, PARKINSONISM RELAT D, V23, P57, DOI 10.1016/j.parkreldis.2015.12.005; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Woertgen C, 2002, ACT NEUR S, V81, P205; Yang Xinyu, 2002, Chin J Traumatol, V5, P250; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhao XH, 2016, NAT MED, V22, P1268, DOI 10.1038/nm.4199; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	103	34	38	4	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					157	173		10.1089/neu.2017.4999			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000419569700018	28637381				2022-02-06	
J	Singh, R; Mason, S; Lecky, F; Dawson, J				Singh, Rajiv; Mason, Suzanne; Lecky, Fiona; Dawson, Jeremy			Prevalence of depression after TBI in a prospective cohort: The SHEFBIT study	BRAIN INJURY			English	Article						traumatic brain injury; depression; outcome; follow-up; cohort; rehabilitation	TRAUMATIC BRAIN-INJURY; HOSPITAL ANXIETY; HEAD-INJURY; PSYCHIATRIC-DISORDERS; RATING-SCALE; DSM-IV; SYMPTOMS; VALIDITY; COMORBIDITY; MODERATE	Objective: The objective is to measure the prevalence of depression after traumatic brain injury (TBI) and the features associated with increased risk in a cohort that reflects clinical practice. Methods: Prospective TBI admissions to a large Teaching Hospital Emergency Department were recruited over a 2-year period. Assessments for depression and other psychosocial and global outcomes were completed at 3 months post-injury. Comparisons were made with demographic and injury features of interest to establish any associations of depression risk. Results: Out of 827 individuals, 774 (94%) successfully attended follow-up. A percentage of 56.3 had depression using a HADS-D > 8. Depressed individuals had higher levels of post-concussion symptoms and worse psychosocial and global outcome ratings. In multivariable analysis, features associated with depression were TBI severity, previous psychiatric history, alcohol intoxication at time of injury, female gender and nonwhite ethnicity. Those with a normal CT scan showed higher risk than those with only mild abnormality and were comparable to those with much more marked CT changes. Conclusion: The 3-month prevalence of depression after TBI is very high and associated with several injury and demographic features. Future long-term follow-up of this cohort aims to confirm the features that increase risk; this may allow the earlier targeting of susceptible individuals for depression interventions.	[Singh, Rajiv] Sheffield Teaching Hosp, Dept Rehabil Med, Osborn Neurorehabilitat Unit, Sheffield S5 7AU, S Yorkshire, England; [Singh, Rajiv; Mason, Suzanne; Lecky, Fiona] Univ Sheffield, Sch Hlth & Related Res ScHARR, Hlth Serv Res, Emergency Med Res Sheffield EMRiS, Sheffield, S Yorkshire, England; [Dawson, Jeremy] Univ Sheffield, Management Sch, Inst Work Psychol, Sheffield, S Yorkshire, England		Singh, R (corresponding author), Sheffield Teaching Hosp, Dept Rehabil Med, Osborn Neurorehabilitat Unit, Sheffield S5 7AU, S Yorkshire, England.	rajiv.singh@sth.nhs.uk		singh, rajiv/0000-0002-3173-9591; Mason, Suzanne/0000-0002-1701-0577			[Anonymous], 2014, HEAD INJ TRIAG ASS I; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chandola T, 2000, J PUBLIC HEALTH MED, V22, P182, DOI 10.1093/pubmed/22.2.182; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Gertler P, 2015, COCHRANE DATABASE SY, V12; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Guillamondegui OD, 2011, AHRQ PUBLICATION; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hinds, 1995, PREVALENCE PSYCHIAT; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Huang DB, 2005, BRAIN INJURY, V19, P903, DOI 10.1080/02699050400004773; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Sigurdardottir S, 2013, J REHABIL MED, V45, P808, DOI 10.2340/16501977-1156; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; Ulfarsson T, 2014, BRAIN INJURY, V28, P1675, DOI 10.3109/02699052.2014.947625; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	48	34	34	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	1					84	90		10.1080/02699052.2017.1376756			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FY7VS	WOS:000427072300009	29190146				2022-02-06	
J	Rivera-Lara, L; Geocadin, R; Zorrilla-Vaca, A; Healy, R; Radzik, BR; Palmisano, C; Mirski, M; Ziai, WC; Hogue, C				Rivera-Lara, Lucia; Geocadin, Romergryko; Zorrilla-Vaca, Andres; Healy, Ryan; Radzik, Batya R.; Palmisano, Caitlin; Mirski, Marek; Ziai, Wendy C.; Hogue, Charles			Validation of Near-Infrared Spectroscopy for Monitoring Cerebral Autoregulation in Comatose Patients	NEUROCRITICAL CARE			English	Article						Cerebral oximetry; Transcranial Doppler; Blood flow velocity; Cerebral perfusion; Near-infrared spectroscopy; Cerebral autoregulation	BLOOD-FLOW AUTOREGULATION; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL DOPPLER; CEREBROVASCULAR AUTOREGULATION; SUBARACHNOID HEMORRHAGE; CARDIAC-SURGERY; PRESSURE; HYPOTENSION; ULTRASOUND; REACTIVITY	Transcranial Doppler (TCD) noninvasively measures cerebral blood flow (CBF) velocity and is a well-studied method to monitor cerebral autoregulation (CA). Near-infrared spectroscopy (NIRS) has emerged as a promising noninvasive method to determine CA continuously by using regional cerebral oxygen saturation (rSO(2)) as a surrogate for CBF. Little is known about its accuracy to determine CA in patients with intracranial lesions. The purpose of this study was to assess the accuracy of rSO(2)-based CA monitoring with TCD methods in comatose patients with acute neurological injury. Thirty-three comatose patients were monitored at the bedside to measure CA using both TCD and NIRS. Patients were monitored daily for up to three days from coma onset. The cerebral oximetry index (COx) was calculated as the moving correlation between the slow waves of rSO(2) and mean arterial pressure (MAP). The mean velocity index (Mx) was calculated as a similar coefficient between slow waves of TCD-measured CBF velocity and MAP. Optimal blood pressure was defined as the MAP with the lowest Mx and COx. Averaged Mx and COx as well as optimal MAP, based on both Mx and COx, were compared using Pearson's correlation. Bias analysis was performed between these same CA metrics. The median duration of monitoring was 60 min (interquartile range [IQR] 48-78). There was a moderate correlation between the averaged values of COx and Mx (R = 0.40, p = 0.005). Similarly, there was a strong correlation between optimal MAP calculated for COx and Mx (R = 0.87, p < 0.001). Bland-Altman analysis showed moderate agreement with bias (+/- standard deviation) of -0.107 (+/- 0.191) for COx versus Mx and good agreement with bias of 1.90 (+/- 7.94) for optimal MAP determined by COx versus Mx. Monitoring CA with NIRS-derived COx is correlated and had good agreement with previously validated TCD-based method. These results suggest that COx may be an acceptable substitute for Mx monitoring in patients with acute intracranial injury.	[Rivera-Lara, Lucia; Geocadin, Romergryko; Ziai, Wendy C.] Johns Hopkins Univ, Sch Med, Dept Neurol Anesthesiol & Crit Care Med, 600 N Wolfe St,Phipps 455, Baltimore, MD 21287 USA; [Rivera-Lara, Lucia; Geocadin, Romergryko; Zorrilla-Vaca, Andres; Healy, Ryan; Radzik, Batya R.; Palmisano, Caitlin; Mirski, Marek; Ziai, Wendy C.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Zorrilla-Vaca, Andres] Univ Valle, Sch Med, Fac Hlth, Cali, Colombia; [Hogue, Charles] Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, Chicago, IL 60611 USA		Rivera-Lara, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol Anesthesiol & Crit Care Med, 600 N Wolfe St,Phipps 455, Baltimore, MD 21287 USA.; Rivera-Lara, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA.	lriver14@jhmi.edu	Vaca, Andres Zorrilla/I-9274-2014; Rivera-Lara, Lucia/AAX-8233-2020	Vaca, Andres Zorrilla/0000-0001-8140-8486; Rivera-Lara, Lucia/0000-0002-9053-2283	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL 92259]; Medtronic/Covidien, Dublin, IR; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL092259] Funding Source: NIH RePORTER	Dr. Hogue is the PI on an NIH-sponsored clinical study (R01 HL 92259). Dr. Rivera Lara is the PI on an American Academy of Neurology/American Brain Foundation and grant from Medtronic/Covidien, Dublin, IR.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Bazan R, 2015, ULTRASOUND MED BIOL, V41, P2131, DOI 10.1016/j.ultrasmedbio.2015.04.008; Berg RMG, 2016, SCAND J CLIN LAB INV, V76, P88, DOI 10.3109/00365513.2015.1091495; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Budohoski KP, 2013, J CEREBR BLOOD F MET, V33, P449, DOI 10.1038/jcbfm.2012.189; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Hori D, 2016, INTERACT CARDIOV TH, V22, P445, DOI 10.1093/icvts/ivv371; Hori D, 2015, ANN THORAC SURG, V100, P487, DOI 10.1016/j.athoracsur.2015.03.036; Howlett JA, 2013, PEDIATR RES, V74, P525, DOI 10.1038/pr.2013.132; Hughes CG, 2012, CURR OPIN CRIT CARE, V18, P518, DOI 10.1097/MCC.0b013e328357effa; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; NEWELL DW, 1992, CEREBROVAS BRAIN MET, V4, P122; Olsen KS, 1996, J NEUROSURG ANESTH, V8, P280, DOI 10.1097/00008506-199610000-00004; Ono M, 2013, ANESTH ANALG, V116, P198, DOI 10.1213/ANE.0b013e318271fb10; Reinhard M, 2006, J NEUROL SCI, V250, P103, DOI 10.1016/j.jns.2006.07.011; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stevens RD, 2006, CRIT CARE MED, V34, P31, DOI 10.1097/01.CCM.0000194534.42661.9F; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; Tsuji M, 1998, PEDIATR RES, V44, P591, DOI 10.1203/00006450-199810000-00020; Vernieri F, 2008, CEPHALALGIA, V28, P689, DOI 10.1111/j.1468-2982.2008.01579.x; Vretzakis G, 2014, J THORAC DIS, V6, pS60, DOI 10.3978/j.issn.2072-1439.2013.10.22; Wang XH, 2012, ASAIO J, V58, P122, DOI 10.1097/MAT.0b013e318241abd3; Weerakkody RA, 2010, ACTA NEUROCHIR, V152, P1763, DOI 10.1007/s00701-010-0748-9; Yoshitani K, 2002, ANESTH ANALG, V94, P586, DOI 10.1097/00000539-200203000-00020; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320	29	34	35	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2017	27	3					362	369		10.1007/s12028-017-0421-8			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	FN7DT	WOS:000416179300009	28664392	Green Accepted			2022-02-06	
J	Schreiber, JE; Palmer, SL; Conklin, HM; Mabbott, DJ; Swain, MA; Bonner, MJ; Chapieski, ML; Huang, L; Zhang, H; Gajjar, A				Schreiber, Jane E.; Palmer, Shawna L.; Conklin, Heather M.; Mabbott, Donald J.; Swain, Michelle A.; Bonner, Melanie J.; Chapieski, Mary L.; Huang, Lu; Zhang, Hui; Gajjar, Amar			Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study	NEURO-ONCOLOGY			English	Article						brain tumor; medulloblastoma; neuropsychological outcomes; posterior fossa syndrome	CEREBELLAR MUTISM SYNDROME; TRAUMATIC BRAIN-INJURY; COGNITIVE-AFFECTIVE SYNDROME; TUMOR RESECTION; EXECUTIVE FUNCTION; WORKING-MEMORY; NEUROCOGNITIVE CONSEQUENCES; PEDIATRIC MEDULLOBLASTOMA; RHESUS-MONKEY; FOLLOW-UP	Background. Patients treated for medulloblastoma who experience posterior fossa syndrome (PFS) demonstrate increased risk for neurocognitive impairment at one year post diagnosis. The aim of the study was to examine longitudinal trajectories of neuropsychological outcomes in patients who experienced PFS compared with patients who did not. Methods. Participants were 36 patients (22 males) who experienced PFS and 36 comparison patients (21 males) who were matched on age at diagnosis and treatment exposure but did not experience PFS. All patients underwent serial evaluation of neurocognitive functioning spanning 1 to 5 years post diagnosis. Results. The PFS group demonstrated lower estimated mean scores at 1, 3, and 5 years post diagnosis on measures of general intellectual ability, processing speed, broad attention, working memory, and spatial relations compared with the non-PFS group. The PFS group exhibited estimated mean scores that were at least one standard deviation below the mean for intellectual ability, processing speed, and broad attention across all time points and for working memory by 5 years post diagnosis. Processing speed was stable over time. Attention and working memory declined over time. Despite some change over time, caregiver ratings of executive function and behavior problem symptoms remained within the average range. Conclusion. Compared with patients who do not experience PFS, patients who experience PFS exhibit greater neurocognitive impairment, show little recovery over time, and decline further in some domains. Findings highlight the particularly high risk for long-term neurocognitive problems in patients who experience PFS and the need for close follow-up and intervention.	[Schreiber, Jane E.; Palmer, Shawna L.; Conklin, Heather M.] St Jude Childrens Res Hosp, Dept Psychol, 262 Danny Thomas Pl,MS 740, Memphis, TN 38105 USA; [Huang, Lu; Zhang, Hui] St Jude Childrens Res Hosp, Dept Biostat, 332 N Lauderdale St, Memphis, TN 38105 USA; [Gajjar, Amar] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Mabbott, Donald J.] Hosp Sick Children, Dept Psychol, Toronto, ON, Canada; [Swain, Michelle A.] Lady Cilento Childrens Hosp, South Brisbane, Qld, Australia; [Bonner, Melanie J.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; [Chapieski, Mary L.] Texas Childrens Hosp, Dept Pediat Med, Houston, TX 77030 USA		Schreiber, JE (corresponding author), St Jude Childrens Res Hosp, Dept Psychol, 262 Danny Thomas Pl,MS 740, Memphis, TN 38105 USA.	Jane.schreiber@stjude.org	Gajjar, Amar/N-8059-2018; Conklin, Heather M/N-2696-2018	Zhang, Hui/0000-0001-6825-5649	National Cancer Institute through a Cancer Center Support (CORE) grant [P30-CA21765]; Noyes Brain Tumor Foundation; Musicians Against Childhood Cancer (MACC); American Lebanese Syrian Associated Charities (ALSAC)American Lebanese Syrian Associated Charities (ALSAC)	This work was supported in part by the National Cancer Institute through a Cancer Center Support (CORE) grant (P30-CA21765), the Noyes Brain Tumor Foundation, Musicians Against Childhood Cancer (MACC), and the American Lebanese Syrian Associated Charities (ALSAC).	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Catsman-Berrevoets CE, 2010, CORTEX, V46, P933, DOI 10.1016/j.cortex.2009.10.007; CHANG CH, 1969, RADIOLOGY, V93, P1351, DOI 10.1148/93.6.1351; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Conklin HM, 2010, J CLIN ONCOL, V28, P4465, DOI 10.1200/JCO.2010.28.4026; De Ruiter MA, 2013, DEV MED CHILD NEUROL, V55, P408, DOI 10.1111/dmcn.12020; De Smet HJ, 2007, EUR J PAEDIATR NEURO, V11, P193, DOI 10.1016/j.ejpn.2007.01.007; De Smet HJ, 2009, NEUROPSYCHOLOGY, V23, P694, DOI 10.1037/a0016106; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA IP, 2000, BEHAV RATING INVENTO; Gudrunardottir T, 2016, CHILD NERV SYST, V32, P1195, DOI 10.1007/s00381-016-3093-3; Gudrunardottir T, 2011, CHILD NERV SYST, V27, P355, DOI 10.1007/s00381-010-1328-2; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; Huber JF, 2006, CHILD NERV SYST, V22, P132, DOI 10.1007/s00381-005-1223-4; Huber JF, 2007, J CHILD NEUROL, V22, P848, DOI 10.1177/0883073807303995; Knight SJ, 2014, J PEDIATR PSYCHOL, V39, P501, DOI 10.1093/jpepsy/jsu009; Korah MP, 2010, INT J RADIAT ONCOL, V77, P106, DOI 10.1016/j.ijrobp.2009.04.058; Law N, 2017, J NEUROPSYCHOL, V11, P174, DOI 10.1111/jnp.12082; Law N, 2015, HUM BRAIN MAPP, V36, P2615, DOI 10.1002/hbm.22795; Law N, 2012, NEURO-ONCOLOGY, V14, P1294, DOI 10.1093/neuonc/nos160; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; Miller NG, 2010, AM J NEURORADIOL, V31, P288, DOI 10.3174/ajnr.A1821; Moxon-Emre I, 2014, J CLIN ONCOL, V32, P1760, DOI 10.1200/JCO.2013.52.3290; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Mulhern RK, 2001, J CLIN ONCOL, V19, P472, DOI 10.1200/JCO.2001.19.2.472; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Palmer SL, 2013, J CLIN ONCOL, V31, P3494, DOI 10.1200/JCO.2012.47.4775; Palmer SL, 2010, NEURO-ONCOLOGY, V12, P1311, DOI 10.1093/neuonc/noq094; Patay Z, 2014, AM J NEURORADIOL, V35, P797, DOI 10.3174/ajnr.A3762; Robertson PL, 2006, J NEUROSURG, V105, P444, DOI 10.3171/ped.2006.105.6.444; Robinson KE, 2013, J INT NEUROPSYCH SOC, V19, P44, DOI 10.1017/S1355617712000987; SCHMAHMANN JD, 1995, NEUROSCI LETT, V199, P175, DOI 10.1016/0304-3940(95)12056-A; Schmahmann JD, 1997, INT REV NEUROBIOL, V41, P31, DOI 10.1016/S0074-7742(08)60346-3; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Schmahmann JD, 1997, J NEUROSCI, V17, P438, DOI 10.1523/JNEUROSCI.17-01-00438.1997; Schreiber JE, 2014, NEURO-ONCOLOGY, V16, P1129, DOI 10.1093/neuonc/nou006; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Steinbok P, 2003, PEDIATR NEUROSURG, V39, P179, DOI 10.1159/000072468; Steinlin M, 2003, BRAIN, V126, P1998, DOI 10.1093/brain/awg195; Steinlin M, 2008, CEREBELLUM, V7, P607, DOI 10.1007/s12311-008-0083-3; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wolfe-Christensen C, 2007, PEDIATR BLOOD CANCER, V49, P723, DOI 10.1002/pbc.21084; Woodcock R, 2001, WOODCOCK JOHNSON 3 E; Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832	46	34	35	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1522-8517	1523-5866		NEURO-ONCOLOGY	Neuro-Oncology	DEC	2017	19	12					1673	1682		10.1093/neuonc/nox135			10	Oncology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Neurosciences & Neurology	FO9JQ	WOS:000417204200019	29016818	Green Published			2022-02-06	
J	Zhu, XY; Frechou, M; Liere, P; Zhang, SD; Pianos, A; Fernandez, N; Denier, C; Mattern, C; Schumacher, M; Guennoun, R				Zhu, Xiaoyan; Frechou, Magalie; Liere, Philippe; Zhang, Shaodong; Pianos, Antoine; Fernandez, Neike; Denier, Christian; Mattern, Claudia; Schumacher, Michael; Guennoun, Rachida			A Role of Endogenous Progesterone in Stroke Cerebroprotection Revealed by the Neural-Specific Deletion of Its Intracellular Receptors	JOURNAL OF NEUROSCIENCE			English	Article						aging; endogenous; neuroprotection; progesterone receptors; sex differences; steroids	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; NERVOUS-SYSTEM; GABA(A) RECEPTORS; PERMANENT STROKE; ISCHEMIC-STROKE; INFARCT VOLUME; STEROID-LEVELS; TIME; NEUROSTEROIDS	Treatment with progesterone protects the male and female brain against damage after middle cerebral artery occlusion (MCAO). However, in both sexes, the brain contains significant amounts of endogenous progesterone. It is not known whether endogenously produced progesterone enhances the resistance of the brain to ischemic insult. Here, we used steroid profiling by gas chromatography-tandem mass spectrometry (GC-MS/ MS) for exploring adaptive and sex-specific changes in brain levels of progesterone and its metabolites after MCAO. Weshow that, in the male mouse brain, progesterone is mainly metabolized via 5 alpha-reduction leading to 5 alpha-dihydroprogesterone (5 alpha-DHP), also a progesterone receptor (PR) agonist ligand in neural cells, then to 3 alpha,5 alpha-tetrahydroprogesterone (3 alpha,5 alpha-THP). In the female mouse brain, levels of 5 alpha-DHP and 3 alpha,5 alpha-THP are lower and levels of 20 alpha-DHP are higher than in males. After MCAO, levels of progesterone and 5 alpha-DHP are upregulated rapidly to pregnancy-like levels in the male but not in the female brain. To assess whether endogenous progesterone and 5 alpha-DHPcontribute to the resistance of neural cells to ischemic damage, weinactivatedPRselectively in the CNS. Deletion of PR in the brain reduced its resistance to MCAO, resulting in increased infarct volumes and neurological deficits in both sexes. Importantly, endogenous PR ligands continue to protect the brain of aging mice. These results uncover the unexpected importance of endogenous progesterone and its metabolites in cerebroprotection. They also reveal that the female reproductive hormone progesterone is an endogenous cerebroprotective neurosteroid in both sexes.	[Zhu, Xiaoyan; Frechou, Magalie; Liere, Philippe; Zhang, Shaodong; Pianos, Antoine; Fernandez, Neike; Denier, Christian; Schumacher, Michael; Guennoun, Rachida] U1195 Inserm, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France; [Zhu, Xiaoyan; Frechou, Magalie; Liere, Philippe; Zhang, Shaodong; Pianos, Antoine; Fernandez, Neike; Denier, Christian; Schumacher, Michael; Guennoun, Rachida] Univ Paris Sud, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France; [Zhu, Xiaoyan; Frechou, Magalie; Liere, Philippe; Zhang, Shaodong; Pianos, Antoine; Fernandez, Neike; Denier, Christian; Schumacher, Michael; Guennoun, Rachida] Univ Paris Saclay, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France; [Zhang, Shaodong] Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [Denier, Christian] Bicetre Hosp, Dept Neurol, F-94276 Le Kremlin Bicetre, France; [Denier, Christian] Bicetre Hosp, Stroke Ctr, F-94276 Le Kremlin Bicetre, France; [Mattern, Claudia] MetP Pharma AG, CH-6376 Emmetten, Switzerland; [Zhu, Xiaoyan] Northwest A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China		Schumacher, M; Guennoun, R (corresponding author), U1195 Inserm, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.; Schumacher, M; Guennoun, R (corresponding author), Univ Paris Sud, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.; Schumacher, M; Guennoun, R (corresponding author), Univ Paris Saclay, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	michael.schumacher@inserm.fr; rachida.guennoun@inserm.fr	Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013; Frechou, Magalie/I-6598-2015	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371; Fernandez, Neike/0000-0001-9127-248X; Frechou, Magalie/0000-0001-8676-1000	China Scholarship CouncilChina Scholarship Council	X.Z. was funded by a Scholarship from the China Scholarship Council. We thank Pr. Pierre Chambon and the Mouse Clinical Institute (MCI, Illkirch, France) for the generous gift of the PR <SUP>+/loxP</SUP> mice and Brigitte Delespierre, Fanny Aprahamian, and Annie Cambourg for excellent technical assistance.	Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Belelli D, 1996, NEUROPHARMACOLOGY, V35, P1223, DOI 10.1016/S0028-3908(96)00066-4; Lopez-Rodriguez AB, 2016, ENDOCRINOLOGY, V157, P3983, DOI 10.1210/en.2016-1316; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Brinton RD, 2013, NAT REV ENDOCRINOL, V9, P241, DOI 10.1038/nrendo.2013.31; BROWN TJ, 1987, J NEUROSCI, V7, P2529; Byers SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035538; Campbell BCV, 2015, LANCET NEUROL, V14, P846, DOI 10.1016/S1474-4422(15)00140-4; Carmichael ST, 2010, STROKE, V41, pS124, DOI 10.1161/STROKEAHA.110.597146; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290, DOI 10.1152/ajpheart.2000.278.1.H290; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; Chen M, 2014, STEROIDS, V83, P17, DOI 10.1016/j.steroids.2014.01.013; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Donnan GA, 2011, NAT REV NEUROL, V7, P400, DOI 10.1038/nrneurol.2011.89; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Espinosa-Garcia C, 2017, BRAIN BEHAV IMMUN; Fisher M, 2011, STROKE, V42, pS24, DOI 10.1161/STROKEAHA.110.592394; Frechou M, 2015, NEUROPHARMACOLOGY, V97, P394, DOI 10.1016/j.neuropharm.2015.06.002; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Grimm SL, 2016, J MOL BIOL, V428, P3831, DOI 10.1016/j.jmb.2016.06.020; Gunn BG, 2015, FRONT NEUROENDOCRIN, V36, P28, DOI 10.1016/j.yfrne.2014.06.001; Hill KK, 2012, MOL CELL ENDOCRINOL, V348, P418, DOI 10.1016/j.mce.2011.07.017; Hillisch A, 2003, STEROIDS, V68, P869, DOI 10.1016/j.steroids.2003.08.009; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Kumar N, 2017, ENDOCRINOLOGY, V158, P170, DOI 10.1210/en.2016-1426; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lambert J.J., 2009, PSYCHONEUROENDOCRINO, V34, P48; Lange CA, 2007, ANNU REV PHYSIOL, V69, P171, DOI 10.1146/annurev.physiol.69.031905.160319; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu FD, 2009, J CEREBR BLOOD F MET, V29, P792, DOI 10.1038/jcbfm.2009.5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Melcangi RC, 2014, PROG NEUROBIOL, V113, P1, DOI 10.1016/j.pneurobio.2013.09.005; Mergenthaler P, 2011, J PHYSIOL-LONDON, V589, P4147, DOI 10.1113/jphysiol.2011.209718; MURR SM, 1974, ENDOCRINOLOGY, V94, P1209, DOI 10.1210/endo-94-4-1209; Nadeem L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11565; Nilsson ME, 2015, ENDOCRINOLOGY, V156, P2492, DOI 10.1210/en.2014-1890; Paxinos G., 2008, MOUSE BRAIN STEREOTA; Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-3; Pelletier G, 2010, STEROIDOGENIC ENZYME; Poletti A, 1998, STEROIDS, V63, P246, DOI 10.1016/S0039-128X(98)00018-X; Raskin K, 2009, J NEUROSCI, V29, P4461, DOI 10.1523/JNEUROSCI.0296-09.2009; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Sarkar J, 2011, J NEUROSCI, V31, P18198, DOI 10.1523/JNEUROSCI.2560-11.2011; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROGESTERONE NEUROPR; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sitruk-Ware R, 2013, CLIMACTERIC, V16, P69, DOI 10.3109/13697137.2013.802556; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; TRAISH AM, 1990, ENDOCRINOLOGY, V127, P1167, DOI 10.1210/endo-127-3-1167; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; Vivien D, 2011, J CEREBR BLOOD F MET, V31, P2119, DOI 10.1038/jcbfm.2011.127; Wali B, 2016, BEHAV BRAIN RES, V305, P46, DOI 10.1016/j.bbr.2016.02.024; Wali B, 2014, BRAIN, V137, P486, DOI 10.1093/brain/awt319; Wang JP, 2010, BEHAV BRAIN RES, V209, P119, DOI 10.1016/j.bbr.2010.01.026; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; Westberry JM, 2008, NEUROSCIENCE, V152, P982, DOI 10.1016/j.neuroscience.2008.01.048; Williams KC, 2012, P NATL ACAD SCI USA, V109, P7529, DOI 10.1073/pnas.1200650109; Wong R, 2013, J NEUROENDOCRINOL, V25, P1088, DOI 10.1111/jne.12042; Yousuf S, 2014, J CEREBR BLOOD F MET, V34, P297, DOI 10.1038/jcbfm.2013.198	69	34	35	1	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 8	2017	37	45					10998	11020		10.1523/JNEUROSCI.3874-16.2017			23	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FM0MX	WOS:000414662100023	28986464	Green Published, Bronze			2022-02-06	
J	Davies, MAM; Judge, AD; Delmestri, A; Kemp, SPT; Stokes, KA; Arden, NK; Newton, JL				Davies, Madeleine A. M.; Judge, Andrew D.; Delmestri, Antonella; Kemp, Simon P. T.; Stokes, Keith A.; Arden, Nigel K.; Newton, Julia L.			Health amongst former rugby union players: A cross-sectional study of morbidity and health-related quality of life	SCIENTIFIC REPORTS			English	Article							BONE-MINERAL DENSITY; PHYSICAL-ACTIVITY; GENERAL-POPULATION; OSTEOARTHRITIS; INJURIES; EQ-5D; RISK; RELIABILITY; CONCUSSION; BENEFITS	In the general population, physical activity is associated with improved health outcomes. However, long-term sports participation may be associated with adverse outcomes, particularly at the elite level. The aims of this study were to assess morbidity and health-related quality of life (HrQoL) amongst former rugby players, compared to an age-standardised general population sample. A cross-sectional study of former elite, male, rugby players (n = 259) was undertaken, and standardised morbidity ratios (SMR) calculated, assessing morbidity prevalence relative to English Longitudinal Study of Aging participants (ELSA, n = 5186). HrQoL, measured using the EQ-5D, was compared to a Health Survey for England (HSE, n = 2981) sample. In SMR analyses of participants aged 50+, diabetes was significantly lower amongst former players, (0.28, 95% CI 0.11-0.66), whereas osteoarthritis (4.00, 95% CI 3.32-4.81), joint replacement (6.02, 95% CI 4.66-7.77), osteoporosis (2.69, 95% CI 1.35-5.38), and anxiety (2.00, 95% CI 1.11-3.61) were significantly higher. More problems in HrQoL were reported amongst former players within the domains of mobility (p < 0.001), self-care (p = 0.041), usual activities (p < 0.001) and pain/discomfort (p < 0.001). Morbidity and HrQoL differ between players and the general population, with higher musculoskeletal morbidity and lower diabetes amongst former players. The magnitude of musculoskeletal morbidity may warrant proactive osteoarthritis management within this population.	[Davies, Madeleine A. M.; Judge, Andrew D.; Delmestri, Antonella; Arden, Nigel K.; Newton, Julia L.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Oxford, England; [Kemp, Simon P. T.] Rugby Football Union, Twickenham, England; [Stokes, Keith A.] Univ Bath, Dept Hlth, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Bath, Avon, England		Arden, NK (corresponding author), Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Oxford, England.	nigel.arden@ndorms.ox.ac.uk	Stokes, Keith/C-2605-2009	Stokes, Keith/0000-0002-5049-2838; Delmestri, Antonella/0000-0003-0388-3403; Kemp, Simon/0000-0002-3250-2713; Arden, Nigel/0000-0002-3452-3382; Davies, Madeleine/0000-0002-6047-7340	National Institute of Aging in the United StatesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Office for National Statistics; Arthritis Research UK Centre for Sport, Exercise and OsteoarthritisVersus Arthritis; Rugby Football Union	The authors gratefully acknowledge Tim Stevens and Sally Wright at Oxford University Rugby Football Club, Ian Minto and Nykki Webber at Cambridge University Rugby Football Club, and Philip Lay for all their guidance and assistance during Oxbridge recruitment. We also gratefully acknowledge Bill Treadwell and the England Rugby Internationals Club Committee for their guidance and assistance with English International player recruitment and Richard Bryan at the Rugby Players Association for his continued support. We would like to thank our Project Steering Group for their insight and contributions throughout the duration of the project, particularly our lay representatives. We would also like to thank the players who have contributed to player involvement in the study, and are indebted to the participants who have given their time and continued to inspire this player health study. ELSA data were made available through the UK Data Archive. ELSA was developed by a team of researchers based at the NatCen Social Research, University College London and the Institute for Fiscal Studies. The data were collected by NatCen Social Research. The funding is provided by the National Institute of Aging in the United States, and a consortium of UK government departments coordinated by the Office for National Statistics. The developers and funders of ELSA and the Archive do not bear any responsibility for the analyses or interpretations presented here. The study was supported financially by the Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis (Grant reference 20194) and also received funding from the Rugby Football Union.	Bayram N, 2008, SOC PSYCH PSYCH EPID, V43, P667, DOI 10.1007/s00127-008-0345-x; Bennell K, 2012, NAT REV RHEUMATOL, V8, P747, DOI 10.1038/nrrheum.2012.119; Blair SN, 2009, BRIT J SPORT MED, V43, P1; Brilleman S. L., 2013, BR J GEN PRACT, V63; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Caine DJ, 2011, BRIT J SPORT MED, V45, P298, DOI 10.1136/bjsm.2010.081984; Carter M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h26; Conaghan PG, 2002, BRIT J SPORT MED, V36, P330, DOI 10.1136/bjsm.36.5.330; Conner-Spady BL, 2015, QUAL LIFE RES, V24, P1775, DOI 10.1007/s11136-014-0910-6; Cosh S., 2012, QUAL RES SPORT EXERC, V5, P1; Curtis Gannon L, 2017, J Clin Med Res, V9, P375, DOI 10.14740/jocmr3001w; Daghestani HN, 2015, OSTEOARTHR CARTILAGE, V23, P1890, DOI 10.1016/j.joca.2015.02.009; Davies Madeleine A M, 2017, Res Involv Engagem, V3, P8, DOI 10.1186/s40900-017-0055-1; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; Deshpande AD, 2008, PHYS THER, V88, P1254, DOI 10.2522/ptj.20080020; Egan E, 2006, BONE, V38, P227, DOI 10.1016/j.bone.2005.08.024; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Elloumi M, 2006, INT J SPORTS MED, V27, P351, DOI 10.1055/s-2005-865742; Fagard RH, 1999, MED SCI SPORT EXER, V31, pS624, DOI 10.1097/00005768-199911001-00022; Fransen M, 1999, RHEUMATOLOGY, V38, P807, DOI 10.1093/rheumatology/38.9.807; Godlee F., 2015, BMJ-BRIT MED J, V350; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HART DJ, 1994, ANN RHEUM DIS, V53, P158, DOI 10.1136/ard.53.3.158; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Hume PA, 2017, SPORTS MED, V47, P1209, DOI 10.1007/s40279-016-0608-8; Janssen B., 2015, EQ 5D 5L USER GUIDE; Janssen MF, 2011, DIABETIC MED, V28, P395, DOI 10.1111/j.1464-5491.2010.03136.x; Jeon CY, 2007, DIABETES CARE, V30, P744, DOI 10.2337/dc06-1842; Johnson JA, 1998, QUAL LIFE RES, V7, P155, DOI 10.1023/A:1008809610703; Johnson JA, 2000, MED CARE, V38, P115, DOI 10.1097/00005650-200001000-00013; King NA, 2005, EUROPEAN J SPORTS SC, V5, P73, DOI DOI 10.1080/17461390500148466; Kohl HW, 2001, MED SCI SPORT EXER, V33, pS472, DOI 10.1097/00005768-200106001-00017; Lee AJ, 2001, BRIT J SPORT MED, V35, P38, DOI 10.1136/bjsm.35.1.38; Lohmander LS, 2007, AM J SPORT MED, V35, P1756, DOI 10.1177/0363546507307396; Marmot M, 2016, ENGLISH LONGITUDINAL, P5050; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McKenna J, 2007, SPORT EDUC SOC, V12, P19, DOI 10.1080/13573320601081500; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Melzer K, 2004, CURR OPIN CLIN NUTR, V7, P641, DOI 10.1097/00075197-200411000-00009; Morel J, 2001, OSTEOPOROSIS INT, V12, P152, DOI 10.1007/s001980170148; Multiple sclerosis in adults: management, 2014, CLIN GUIDELINE; Musumeci G, 2015, INT J MOL SCI, V16, P6093, DOI 10.3390/ijms16036093; NatCen Social Research, 2016, HLTH SURV ENGL; Orchard JW, 2006, J SCI MED SPORT, V9, P459, DOI 10.1016/j.jsams.2006.05.001; Patricios JS, 2014, BRIT J SPORT MED, V48, P76, DOI 10.1136/bjsports-2013-093031; Pickard AS, 2008, RESP MED, V102, P519, DOI 10.1016/j.rmed.2007.11.016; Public Health England, 2014, AUTH, P1; Roberts SP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003998; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Vogl T., 2012, OXFORD HDB HLTH EC; Wang YF, 2005, AM J CLIN NUTR, V81, P555; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1	54	34	34	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 28	2017	7								11786	10.1038/s41598-017-12130-y			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI5CI	WOS:000411998400001	28959048	Green Published, Green Accepted, gold			2022-02-06	
J	Cooper, DB; Bowles, AO; Kennedy, JE; Curtiss, G; French, LM; Tate, DF; Vanderploeg, RD				Cooper, Douglas B.; Bowles, Amy O.; Kennedy, Jan E.; Curtiss, Glenn; French, Louis M.; Tate, David F.; Vanderploeg, Rodney D.			Cognitive Rehabilitation for Military Service Members With Mild Traumatic Brain Injury: A Randomized Clinical Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast injuries; clinical trial; cognitive rehabilitation; concussion; mild TBI; postconcussive syndrome; posttraumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; ROUTINE FOLLOW-UP; HEAD-INJURY; SYMPTOMS; PILOT; VETERANS; INTERVENTION; PREVALENCE; PERSONNEL; MODERATE	Objective: To compare cognitive rehabilitation (CR) interventions for mild traumatic brain injury (mTBI) with standard of care management, including psychoeducation and medical care for noncognitive symptoms. Setting: Military medical center. Participants: A total of 126 service members who received mTBI from 3 to 24 months before baseline evaluation and reported ongoing cognitive difficulties. Interventions: Randomized clinical trial with treatment outcomes assessed at baseline, 3-week, 6-week, 12-week, and 18-week follow-ups. Participants were randomly assigned to one of four 6-week treatment arms: (1) psychoeducation, (2) computer-based CR, (3) therapist-directed manualized CR, and (4) integrated therapist-directed CR combined with cognitive-behavioral psychotherapy (CBT). Treatment dosage was constant (10 h/wk) for intervention arms 2 to 4. Measures: Paced Auditory Serial Addition Test (PASAT); Symptom Checklist-90 Revised (SCL-90-R); Key Behaviors Change Inventory (KBCI). Results: No differences were noted between treatment arms on demographics, injury-related characteristics, or psychiatric comorbidity apart from education, with participants assigned to the computer arm having less education. Using mixed-model analysis of variance, all 4 treatment groups showed a significant improvement over time on the 3 primary outcome measures. Treatment groups showed equivalent improvement on the PASAT. The therapist-directed CR and integrated CR treatment groups had better KBCI outcomes compared with the psychoeducation group. Improvements on primary outcome measures during treatment were maintained at follow-up with no differences among arms. Conclusions: Both therapist-directed CR and integrated CR with CBT reduced functional cognitive symptoms in service members after mTBI beyond psychoeducation and medical management alone.	[Cooper, Douglas B.; Kennedy, Jan E.; Curtiss, Glenn; French, Louis M.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Cooper, Douglas B.; Kennedy, Jan E.] Brooke Army Med Ctr, Dept Neurol, San Antonio, TX USA; [Bowles, Amy O.] Brooke Army Med Ctr, Dept Rehabil Med, San Antonio, TX USA; [Cooper, Douglas B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Bowles, Amy O.] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD 20814 USA; [Curtiss, Glenn; Vanderploeg, Rodney D.] James A Haley VA Med Ctr, Tampa, FL USA; [Curtiss, Glenn; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA; [French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Tate, David F.] Univ Missouri St Louis, Missouri Inst Mental Hlth, Berkeley, CA USA		Cooper, DB (corresponding author), Brooke Army Med Ctr, Def & Vet Brain Injury Ctr, MCHE MDU DVBIC, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	douglas.b.cooper.ctr@mail.mil	Curtiss, Glenn/ABB-5566-2020; french, louis/AAB-2083-2020; Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; french, louis/0000-0002-9451-0604	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development ServiceUS Department of Veterans Affairs [VA HSRD IIR 13-196-1]; Clinical Sciences Research and Development [VA CSRDW81XWH-13-2-0095]; TATRC research grant (ERMS) [12286030]	This work is the result of work supported with resources and the use of the facilities at Brooke Army Medical Center (BAMC), Joint Base San Antonio. Research staff and resources were provided in part by the Defense and Veterans Brain Injury Centers (DVBIC) and the Telemedicine and Advanced Technology Research Center. Individuals providing the interventions were Department of the Army civilian employees. Psychoeducational materials were based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (VA HSR&D IIR 13-196-1), and Clinical Sciences Research and Development (VA CSRDW81XWH-13-2-0095). Data management was supported by TATRC research grant (ERMS#12286030) to David Tate, PhD.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Belanger HG, 2015, MIL MED, V180, P192, DOI 10.7205/MILMED-D-14-00388; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carroll LJ, 2004, J REHABIL MED S, P106; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Citrome L, 2016, J AFFECT DISORDERS, V196, P225, DOI 10.1016/j.jad.2016.02.042; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Cuijpers P, 2014, PSYCHOL MED, V44, P685, DOI 10.1017/S0033291713000457; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; Department of Veterans Affairs & Department of Defense, 2009, J REHABIL RES DEV, V46; Derogatis LR, 1994, SYMPTOM CHECKLIST 90; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HEITJAN DF, 1991, J R STAT SOC C-APPL, V40, P13; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Institute of Medicine (IOM), 2011, COGN REH THER TRAUM; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Janak JC, 2017, J HEAD TRAUMA REHAB, V32, P1, DOI 10.1097/HTR.0000000000000202; King EG, 2013, REHABIL PSYCHOL, V58, P272, DOI 10.1037/a0033116; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MCCAFFREY RJ, 1995, ARCH CLIN NEUROPSYCH, V10, P241, DOI 10.1016/0887-6177(94)00048-U; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Nelson LA, 2013, NEUROPSYCHOLOGY, V27, P666, DOI 10.1037/a0034117; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schenker N, 1996, COMPUT STAT DATA AN, V22, P425, DOI 10.1016/0167-9473(95)00057-7; Schmitt JS, 2004, J CLIN EPIDEMIOL, V57, P1008, DOI 10.1016/j.jclinepi.2004.02.007; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sullivan KW, 2012, STUD HEALTH TECHNOL, V181, P71, DOI 10.3233/978-1-61499-121-2-71; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Weathers F. W, 1993, PCL M FOR DSM IV; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME; Zickefoose S, 2013, BRAIN INJURY, V27, P707, DOI 10.3109/02699052.2013.775484	64	34	34	2	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E1	E15		10.1097/HTR.0000000000000254			15	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900008	27603763				2022-02-06	
J	Howell, DR; Stracciolini, A; Geminiani, E; Meehan, WP				Howell, David R.; Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III			Dual-task gait differences in female and male adolescents following sport-related concussion	GAIT & POSTURE			English	Article						Brain concussion; Mild traumatic brain injury; Postural balance; Divided attention; Sex difference	BALANCE CONTROL; YOUNG-ADULTS; RECOVERY TRAJECTORIES; GENDER-DIFFERENCES; BASE-LINE; POSTCONCUSSION; MANAGEMENT; STABILITY; WALKING; SINGLE	Concussion may affect females and males differentially. Identification of gender-related differences after concussion, therefore, may help clinicians with individualized evaluations. We examined potential differences in dual-task gait between females and males after concussion. Thirty-five participants diagnosed with a concussion (49% female, mean age = 15.0 +/- 2.1 years, 7.5 +/- 3.0 days post-injury) and 51 controls (51% female, mean age = 14.4 +/- 2.1 years) completed a symptom inventory and single/dual-task gait assessment. The primary outcome variable, the dual-task cost, was calculated as the percent change between single-task and dual-task conditions to account for individual differences in spatio-temporal gait variables. No significant differences in symptom severity measured by the post-concussion symptom scale were observed between females (32.0 +/- 18.0) and males (27.8 +/- 18.2). Compared with males, adolescent females walked with significantly decreased cadence dual-task costs after concussion (-19.7% +/- 10.0% vs. -11.3% +/- 9.2%, p = 0.007) when adjusted for age, height, and prior concussion history. No significant differences were found between female and male control groups on other dual-task cost gait measures. Females and males with concussion also walked with significantly shorter stride lengths than controls during single-task (females: 1.13 +/- 0.11 m vs. 1.26 +/- 0.11 m, p = 0.001; males: 1.14 +/- 0.14 m vs. 1.22 +/- 0.15 m, p = 0.04) and dual-task gait (females: 0.99 +/- 0.10 m vs. 1.10 +/- 0.11 m, p = 0.001; males: 1.00 +/- 0.13 m vs. 1.08 +/- 0.14 m, p = 0.04). Females demonstrated a significantly greater amount of cadence change between single-task and dual-task gait than males after a sport related concussion. Thus, differential alterations may exist during gait among those with a concussion; gender may be one prominent factor affecting dual-task gait.	[Howell, David R.; Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.; Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Stracciolini, Andrea; Geminiani, Ellen; Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA		Howell, DR (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu			National Hockey League Alumni Association through the Corey C. Griffin Pro Am Tournament	This study was funded by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro Am Tournament.	Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P417, DOI 10.1016/j.jshs.2015.03.010; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Cossette I., 2016, BRAIN INJURY, P1; Coulthard JT, 2015, GAIT POSTURE, V41, P882, DOI 10.1016/j.gaitpost.2015.03.009; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dewey DC, 2014, J NEUROL SCI, V345, P131, DOI 10.1016/j.jns.2014.07.026; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fino PC, 2016, J BIOMECH, V49, P1983, DOI 10.1016/j.jbiomech.2016.05.004; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Horak F, 2015, PHYS THER, V95, P461, DOI 10.2522/ptj.20140253; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D. R, 2016, CLIN J SPORT MED; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kerrigan DC, 1998, AM J PHYS MED REHAB, V77, P2, DOI 10.1097/00002060-199801000-00002; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lax ID, 2015, BRAIN INJURY, V29, P1409, DOI 10.3109/02699052.2015.1043344; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Ponta ML, 2014, OBES SURG, V24, P1915, DOI 10.1007/s11695-014-1254-6; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004	30	34	34	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	MAY	2017	54						284	289		10.1016/j.gaitpost.2017.03.034			6	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics; Sport Sciences	EZ9IT	WOS:000405044400045	28384609				2022-02-06	
J	Jagielska, A; Lowe, AL; Makhija, E; Wroblewska, L; Guck, J; Franklin, RJM; Shivashankar, GV; Van Vliet, KJ				Jagielska, Anna; Lowe, Alexis L.; Makhija, Ekta; Wroblewska, Liliana; Guck, Jochen; Franklin, Robin J. M.; Shivashankar, G. V.; Van Vliet, Krystyn J.			Mechanical Strain Promotes Oligodendrocyte Differentiation by Global Changes of Gene Expression	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						oligodendrocytes; oligodendrocyte precursor cell (OPC); oligodendrocyte differentiation; mechanical strain; multiple sclerosis (MS); mechanotransduction; chromatin remodeling; cell nucleus shape	CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS LESIONS; TRAUMATIC BRAIN-INJURY; EXTRACELLULAR-MATRIX; MORPHOLOGICAL-DIFFERENTIATION; PRECURSOR DIFFERENTIATION; PROGENITOR CELLS; AXONAL INJURY; GROWTH CONES; STEM-CELLS	Differentiation of oligodendrocyte progenitor cells (OPC) to oligodendrocytes and subsequent axon myelination are critical steps in vertebrate central nervous system (CNS) development and regeneration. Growing evidence supports the significance of mechanical factors in oligodendrocyte biology. Here, we explore the effect of mechanical strains within physiological range on OPC proliferation and differentiation, and strain-associated changes in chromatin structure, epigenetics, and gene expression. Sustained tensile strain of 10-15% inhibited OPC proliferation and promoted differentiation into oligodendrocytes. This response to strain required specific interactions of OPCs with extracellular matrix ligands. Applied strain induced changes in nuclear shape, chromatin organization, and resulted in enhanced histone deacetylation, consistent with increased oligodendrocyte differentiation. This response was concurrent with increased mRNA levels of the epigenetic modifier histone deacetylase Hdac11. Inhibition of HDAC proteins eliminated the strain-mediated increase of OPC differentiation, demonstrating a role of HDACs in mechanotransduction of strain to chromatin. RNA sequencing revealed global changes in gene expression associated with strain. Specifically, expression of multiple genes associated with oligodendrocyte differentiation and axon-oligodendrocyte interactions was increased, including cell surface ligands (Ncam, ephrins), cyto-and nucleo-skeleton genes (Fyn, actinins, myosin, nesprin, Sun1), transcription factors (Sox10, Zfp191, Nkx2.2), and myelin genes (Cnp, Plp, Mag). These findings show how mechanical strain can be transmitted to the nucleus to promote oligodendrocyte differentiation, and identify the global landscape of signaling pathways involved in mechanotransduction. These data provide a source of potential new therapeutic avenues to enhance OPC differentiation in vivo.	[Jagielska, Anna; Van Vliet, Krystyn J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Lowe, Alexis L.] Wellesley Coll, Dept Neurosci, Wellesley, MA 02181 USA; [Makhija, Ekta; Shivashankar, G. V.] Natl Univ Singapore, Mechanobiol Inst, Singapore, Singapore; [Wroblewska, Liliana; Van Vliet, Krystyn J.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Guck, Jochen] Tech Univ Dresden, Biotechnol Ctr, Dresden, Germany; [Franklin, Robin J. M.] Univ Cambridge, Wellcome Trust Med Res Council, Cambridge Stem Cell Inst, Cambridge, England; [Franklin, Robin J. M.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Makhija, Ekta; Van Vliet, Krystyn J.] Singapore MIT Alliance Res & Technol, BioSyst & Micromech Interdisciplinary Res Grp, Singapore, Singapore; [Wroblewska, Liliana] Pfizer, Cambridge, MA USA		Van Vliet, KJ (corresponding author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.; Van Vliet, KJ (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Van Vliet, KJ (corresponding author), Singapore MIT Alliance Res & Technol, BioSyst & Micromech Interdisciplinary Res Grp, Singapore, Singapore.	krystyn@mit.edu	Guck, Jochen/B-4412-2014	Guck, Jochen/0000-0002-1453-6119; Franklin, Robin/0000-0001-6522-2104	National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4855A1/1]; Human Frontiers Science ProgramHuman Frontier Science Program [RGP0015/2009-C]; National Research Foundation of Singapore through Singapore-MIT Alliance for Research and Technology (SMART), BioSystems and Micromechanics (BioSyM) interdisciplinary research group; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_12009] Funding Source: researchfish	We gratefully acknowledge funding from the National Multiple Sclerosis Society (RG4855A1/1), the Human Frontiers Science Program (RGP0015/2009-C), and the National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology (SMART), BioSystems and Micromechanics (BioSyM) interdisciplinary research group.	Ahmed WW, 2013, LAB CHIP, V13, P570, DOI 10.1039/c2lc41109a; Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Arulmoli J, 2015, SCI REP-UK, V5, DOI 10.1038/srep08499; Baer AS, 2009, BRAIN, V132, P465, DOI 10.1093/brain/awn334; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Bauer NG, 2009, GLIA, V57, P1691, DOI 10.1002/glia.20885; Betz T, 2011, P NATL ACAD SCI USA, V108, P13420, DOI 10.1073/pnas.1106145108; BLAKEMORE WF, 1974, NATURE, V249, P577, DOI 10.1038/249577a0; BRAY D, 1979, J CELL SCI, V37, P391; Bray D, 1984, BIOPHYS J, V102, P379; Buttery PC, 1999, MOL CELL NEUROSCI, V14, P199, DOI 10.1006/mcne.1999.0781; Camara J, 2009, J CELL BIOL, V185, P699, DOI 10.1083/jcb.200807010; Chalut KJ, 2012, BIOPHYS J, V103, P2060, DOI 10.1016/j.bpj.2012.10.015; Chambliss AB, 2013, SCI REP-UK, V3, DOI 10.1038/srep01087; Chew LJ, 2009, J NEUROSCI RES, V87, P3277, DOI 10.1002/jnr.22128; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Colognato H, 2004, J CELL BIOL, V167, P365, DOI 10.1083/jcb.200404076; Colognato H, 2007, DEVELOPMENT, V134, P1723, DOI 10.1242/dev.02819; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Dahl KN, 2008, CIRC RES, V102, P1307, DOI 10.1161/CIRCRESAHA.108.173989; Driscoll TP, 2015, BIOPHYS J, V108, P2783, DOI 10.1016/j.bpj.2015.05.010; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Fisher E, 2007, ANN NEUROL, V62, P219, DOI 10.1002/ana.21113; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Franklin RJM, 1999, J NEUROSCI RES, V58, P207, DOI 10.1002/(SICI)1097-4547(19991015)58:2<207::AID-JNR1>3.0.CO;2-1; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Franze K, 2013, ANNU REV BIOMED ENG, V15, P227, DOI 10.1146/annurev-bioeng-071811-150045; Franze K, 2013, DEVELOPMENT, V140, P3069, DOI 10.1242/dev.079145; Franze K, 2011, SOFT MATTER, V7, P3147, DOI 10.1039/c0sm01017k; Franze K, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/9/094601; Franze K, 2009, BIOPHYS J, V97, P1883, DOI 10.1016/j.bpj.2009.07.033; Fuhs T, 2013, CYTOSKELETON, V70, P44, DOI 10.1002/cm.21080; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Graham DM, 2016, CURR OPIN CELL BIOL, V40, P98, DOI 10.1016/j.ceb.2016.03.006; Harlow DE, 2014, EXP NEUROL, V251, P39, DOI 10.1016/j.expneurol.2013.10.017; Hernandez M, 2016, J NEUROSCI, V36, P806, DOI 10.1523/JNEUROSCI.2873-15.2016; Hubner MR, 2010, ANNU REV BIOPHYS, V39, P471, DOI 10.1146/annurev.biophys.093008.131348; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jagielska A, 2012, STEM CELLS DEV, V21, P2905, DOI 10.1089/scd.2012.0189; Kippert A, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-71; Kuhlmann T, 2008, BRAIN, V131, P1749, DOI 10.1093/brain/awn096; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Laursen LS, 2009, J NEUROSCI, V29, P9174, DOI 10.1523/JNEUROSCI.5942-08.2009; Lindqvist N, 2010, INVEST OPHTH VIS SCI, V51, P1683, DOI 10.1167/iovs.09-4159; Linneberg C, 2015, ASN NEURO, V7, DOI 10.1177/1759091415602859; Liu H, 2009, GLIA, V57, P1, DOI 10.1002/glia.20729; Liu J, 2010, TRENDS NEUROSCI, V33, P193, DOI 10.1016/j.tins.2010.01.007; Lourenco T, 2016, SCI REP-UK, V6, DOI 10.1038/srep21563; Lu Y, 2010, FASEB J, V24; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Makhija E, 2016, P NATL ACAD SCI USA, V113, pE32, DOI 10.1073/pnas.1513189113; Mammoto A, 2012, J CELL SCI, V125, P3061, DOI 10.1242/jcs.093005; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mendez MG, 2012, INT J BIOCHEM CELL B, V44, P728, DOI 10.1016/j.biocel.2012.02.003; Milner R, 1997, GLIA, V21, P350; Milstein JN, 2011, J R SOC INTERFACE, V8, P1673, DOI 10.1098/rsif.2011.0371; Moshayedi P, 2014, BIOMATERIALS, V35, P3919, DOI 10.1016/j.biomaterials.2014.01.038; Moshayedi P, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/19/194114; Nave KA, 2014, ANNU REV CELL DEV BI, V30, P503, DOI 10.1146/annurev-cellbio-100913-013101; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Palser AL, 2009, J NEUROSCI RES, V87, P3356, DOI 10.1002/jnr.22248; Payne SC, 2012, INVEST OPHTH VIS SCI, V53, P6093, DOI 10.1167/iovs.12-10080; Poitelon Y, 2016, NAT NEUROSCI, V19, P879, DOI 10.1038/nn.4316; Relvas JB, 2001, CURR BIOL, V11, P1039, DOI 10.1016/S0960-9822(01)00292-5; Rosenberg SS, 2008, P NATL ACAD SCI USA, V105, P14662, DOI 10.1073/pnas.0805640105; Roux KJ, 2009, P NATL ACAD SCI USA, V106, P2194, DOI 10.1073/pnas.0808602106; Rusielewicz T, 2014, GLIA, V62, P580, DOI 10.1002/glia.22627; Saha K, 2008, BIOPHYS J, V95, P4426, DOI 10.1529/biophysj.108.132217; Schregel K, 2012, P NATL ACAD SCI USA, V109, P6650, DOI 10.1073/pnas.1200151109; Schwartz MA, 2008, CURR OPIN CELL BIOL, V20, P551, DOI 10.1016/j.ceb.2008.05.005; Sherman DL, 2005, NAT REV NEUROSCI, V6, P683, DOI 10.1038/nrn1743; Shimizu T, 2017, GLIA, V65, P360, DOI 10.1002/glia.23096; Shivashankar GV, 2011, ANNU REV BIOPHYS, V40, P361, DOI 10.1146/annurev-biophys-042910-155319; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2009, PROG NEUROBIOL, V89, P231, DOI 10.1016/j.pneurobio.2009.07.006; SOBEL RA, 1989, AM J PATHOL, V135, P161; Song J, 2001, MOL CELL NEUROSCI, V17, P624, DOI 10.1006/mcne.2001.0974; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Urbanski MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep33751; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Wang HB, 2008, J CELL BIOL, V182, P1171, DOI 10.1083/jcb.200802091; Wang HB, 2012, J NEUROSCI RES, V90, P1547, DOI 10.1002/jnr.23036; Wang N, 2009, NAT REV MOL CELL BIO, V10, P75, DOI 10.1038/nrm2594; Wu J, 2013, NUCLEIC ACIDS RES, V41, P5149, DOI 10.1093/nar/gkt216; Zeiger A., 2013, THESIS; Zeiger AS, 2016, PHYS BIOL, V13, DOI 10.1088/1478-3975/13/4/046006; Zuchero JB, 2015, DEV CELL, V34, P152, DOI 10.1016/j.devcel.2015.06.011	94	34	34	0	10	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	APR 20	2017	11								93	10.3389/fncel.2017.00093			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4DS	WOS:000403184200001	28473753	Green Published, gold			2022-02-06	
J	Roy, A; Bernier, RA; Wang, JL; Benson, M; French, JJ; Good, DC; Hillary, FG				Roy, Arnab; Bernier, Rachel A.; Wang, Jianli; Benson, Monica; French, Jerry J., Jr.; Good, David C.; Hillary, Frank G.			The evolution of cost-efficiency in neural networks during recovery from traumatic brain injury	PLOS ONE			English	Article							DEFAULT MODE NETWORK; AMYLOID-BETA; FUNCTIONAL CONNECTIVITY; COMPONENT ANALYSIS; HIPPOCAMPAL; MEMORY; FMRI; SIGNAL; AXONS; ACCUMULATION	A somewhat perplexing finding in the systems neuroscience has been the observation that physical injury to neural systems may result in enhanced functional connectivity (i.e., hyperconnectivity) relative to the typical network response. The consequences of local or global enhancement of functional connectivity remain uncertain and this is particularly true for the overall metabolic cost of the network. We examine the hyperconnectivity hypothesis in a sample of 14 individuals with TBI with data collected at approximately 3, 6, and 12 months following moderate and severe TBI. As anticipated, individuals with TBI showed increased network strength and cost early after injury, but by one-year post injury hyperconnectivity was more circumscribed to frontal DMN and temporal-parietal attentional control regions. Cost in these subregions was a significant predictor of cognitive performance. Cost-efficiency analysis in the Power 264 data parcellation suggested that at 6 months post injury the network requires higher cost connections to achieve high efficiency as compared to the network 12 months post injury. These results demonstrate that networks self-organize to re-establish connectivity while balancing cost-efficiency trade-offs.	[Roy, Arnab; Bernier, Rachel A.; Benson, Monica; French, Jerry J., Jr.; Hillary, Frank G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Wang, Jianli] Hershey Med Ctr, Dept Radiol, Hershey, PA USA; [Good, David C.; Hillary, Frank G.] Hershey Med Ctr, Dept Neurol, Hershey, PA 17033 USA; [Hillary, Frank G.] Social Life & Engn Sci Imaging Ctr, University Pk, PA 16802 USA		Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.; Hillary, FG (corresponding author), Hershey Med Ctr, Dept Neurol, Hershey, PA 17033 USA.; Hillary, FG (corresponding author), Social Life & Engn Sci Imaging Ctr, University Pk, PA 16802 USA.	fhillary@psu.edu	Hillary, Frank/AAN-8622-2021	Bernier, Rachel/0000-0002-2759-9186	New Jersey Commission for Brain Injury Research [09.001.BIR1]; Social Sciences Research Institute at Pennsylvania State University in University Park, Pennsylvania; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); NIHUL through Penn State University's Clinical Translational Science Institute [Tr000127]; Social Life and Engineering Sciences Imaging Center; Hershey Medical Center and the Social Sciences Research Institute at the Pennsylvania State University, University Park [PA -16801]; NIHUL through the Clinical Translational Science Institute [Tr000127]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000127, UL1TR002014] Funding Source: NIH RePORTER	This work was funded in part by the New Jersey Commission for Brain Injury Research (09.001.BIR1) and the Social Sciences Research Institute at Pennsylvania State University in University Park, Pennsylvania. The research was also supported by the National Center for Advancing Translational Sciences, NIHUL Tr000127, through Penn State University's Clinical Translational Science Institute. Work was supported by the Social Life and Engineering Sciences Imaging Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported by the National Center for Advancing Translational Sciences, NIHUL Tr000127 through the Clinical Translational Science Institute, Hershey Medical Center and the Social Sciences Research Institute at the Pennsylvania State University, University Park, PA -16801.	Abou-Elseoud A, 2010, HUM BRAIN MAPP, V31, P1207, DOI 10.1002/hbm.20929; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Aerts H, 2016, BRAIN; Aerts H, 2016, BRAIN, V139, P3063, DOI 10.1093/brain/aww194; Aiello GL, 2000, J NEUROSCI METH, V103, P145, DOI 10.1016/S0165-0270(00)00308-3; Albert R, 2000, PHYS REV LETT, V85, P5234, DOI 10.1103/PhysRevLett.85.5234; Alexander-Bloch A.F., 2012, CEREB CORTEX; Allen EA, 2012, NEUROIMAGE, V59, P4141, DOI 10.1016/j.neuroimage.2011.10.010; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bassett DS, 2009, P NATL ACAD SCI USA, V106, P11747, DOI 10.1073/pnas.0903641106; Bernal-Casas D, 2013, NEUROIMAGE, V82, P555, DOI 10.1016/j.neuroimage.2013.05.120; Bero AW, 2012, J NEUROSCI, V32, P4334, DOI 10.1523/JNEUROSCI.5845-11.2012; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bullmore ET, 2012, NAT REV NEUROSCI, V13, P336, DOI 10.1038/nrn3214; Busche MA, 2012, P NATL ACAD SCI USA, V109, P8740, DOI 10.1073/pnas.1206171109; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 1800, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Carrera E, 2014, BRAIN, V137, P2408, DOI 10.1093/brain/awu101; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Catani M, 2005, BRAIN, V128, P2224, DOI 10.1093/brain/awh622; Chen BL, 2006, P NATL ACAD SCI USA, V103, P4723, DOI 10.1073/pnas.0506806103; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; de Haan W, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002582; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Giessing C, 2013, J NEUROSCI, V33, P5903, DOI 10.1523/JNEUROSCI.4854-12.2013; Hahn A, 2014, BRAIN CONNECT, V20, P1; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Horvat S, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002512; Irimia A, 2014, J NEUROSURG SCI, V58, P129; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; Lindquist MA, 2008, HUM BRAIN MAPP, V29, P1276, DOI 10.1002/hbm.20475; Marchitelli R, 2016, HUM BRAIN MAPP, V37, P2114, DOI 10.1002/hbm.23157; Mazaika PK, 2009, HUM BRAIN MAPP; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Myers N, 2014, BRAIN, V137, P2052, DOI 10.1093/brain/awu103; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nugent AC, 2015, J CEREBR BLOOD F MET, V35, P583, DOI 10.1038/jcbfm.2014.228; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Schroeter MS, 2015, J NEUROSCI, V35, P5459, DOI 10.1523/JNEUROSCI.4259-14.2015; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Skudlarski P, 2010, BIOL PSYCHIAT, V68, P61, DOI 10.1016/j.biopsych.2010.03.035; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tomasi D, 2013, P NATL ACAD SCI USA, V110, P13642, DOI 10.1073/pnas.1303346110; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; van Wijk BCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013701; Venkatesan UM, 2014, J NEUROTRAUM, V13, P1; Vlassenko AG, 2010, P NATL ACAD SCI USA, V107, P17763, DOI 10.1073/pnas.1010461107; Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zalesky A, 2012, HUM BRAIN MAPP, V33, P2535, DOI 10.1002/hbm.21379	71	34	34	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2017	12	4							e0170541	10.1371/journal.pone.0170541			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ES9KK	WOS:000399875600003	28422992	gold, Green Submitted, Green Published			2022-02-06	
J	Jha, RM; Puccio, AM; Okonkwo, DO; Zusman, BE; Park, SY; Wallisch, J; Empey, PE; Shutter, LA; Clark, RSB; Kochanek, PM; Conley, YP				Jha, Ruchira M.; Puccio, Ava M.; Okonkwo, David O.; Zusman, Benjamin E.; Park, Seo-Young; Wallisch, Jessica; Empey, Philip E.; Shutter, Lori A.; Clark, Robert S. B.; Kochanek, Patrick M.; Conley, Yvette P.			ABCC8 Single Nucleotide Polymorphisms are Associated with Cerebral Edema in Severe TBI	NEUROCRITICAL CARE			English	Article						ABCC8; Cerebral edema; Traumatic brain injury; Single nucleotide polymorphism (SNP); Sulfonylurea receptor-1 (Sur1)	SULFONYLUREA RECEPTOR 1; TRAUMATIC BRAIN-INJURY; CONGENITAL HYPERINSULINISM; GENETIC-VARIATION; AQUAPORIN-4; GLYBURIDE; PRESSURE; DNA	Cerebral edema (CE) in traumatic brain injury (TBI) is the consequence of multiple underlying mechanisms and is associated with unfavorable outcomes. Genetic variability in these pathways likely explains some of the clinical heterogeneity observed in edema development. A role for sulfonylurea receptor-1 (Sur1) in CE is supported. However, there are no prior studies examining the effect of genetic variability in the Sur1 gene (ABCC8) on the development of CE. We hypothesize that ABCC8 single nucleotide polymorphisms (SNPs) are predictive of CE. DNA was extracted from 385 patients. SNPs in ABCC8 were genotyped using the Human Core Exome v1.2 (Illumina). CE measurements included acute CT edema, mean and peak intracranial pressure (ICP), and need for decompressive craniotomy. Fourteen SNPs with minor allele frequency > 0.2 were identified. Four SNPS rs2283261, rs3819521, rs2283258, and rs1799857 were associated with CE measures. In multiple regression models, homozygote-variant genotypes in rs2283261, rs3819521, and rs2283258 had increased odds of CT edema (OR 2.45, p = 0.007; OR 2.95, p = 0.025; OR 3.00, p = 0.013), had higher mean (beta = 3.13, p = 0.000; beta = 2.95, p = 0.005; beta = 3.20, p = 0.008), and peak ICP (beta = 8.00, p = 0.001; beta = 7.64, p = 0.007; beta = 6.89, p = 0.034). The homozygote wild-type genotype of rs1799857 had decreased odds of decompressive craniotomy (OR 0.47, p = 0.004). This is the first report assessing the impact of ABCC8 genetic variability on CE development in TBI. Minor allele ABCC8 SNP genotypes had increased risk of CE, while major SNP alleles were protective-potentially suggesting an evolutionary advantage. These findings could guide risk stratification, treatment responders, and the development of novel targeted or gene-based therapies against CE in TBI and other neurological disorders.	[Jha, Ruchira M.; Wallisch, Jessica; Shutter, Lori A.; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Puccio, Ava M.; Okonkwo, David O.; Zusman, Benjamin E.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Wallisch, Jessica; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA; [Park, Seo-Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA; [Park, Seo-Young] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA; [Jha, Ruchira M.; Empey, Philip E.; Kochanek, Patrick M.; Conley, Yvette P.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA		Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA.	ruchirajha@gmail.com	Empey, Philip/L-9604-2019; Shutter, Lori A/G-2957-2013	Empey, Philip/0000-0001-7474-2339; Shutter, Lori/0000-0002-1390-0628; Conley, Yvette/0000-0002-1784-6067; Wallisch, Jessica/0000-0002-7908-9479; Jha, Ruchira/0000-0002-3047-7649	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [KL2 TR000146, R00 NR013176, R01 NR013342, T32 HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R00NR013176, R01NR013342] Funding Source: NIH RePORTER	We are grateful to NIH Grant Nos. KL2 TR000146 (RMJ), R00 NR013176 (YPC), R01 NR013342 (YPC) and T32 HD040686 (JW) for their generous support.	Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60; Chen JH, 2016, INT J MOL MED, V37, P1059, DOI 10.3892/ijmm.2016.2506; Conley YP, 2014, J NEUROTRAUM, V31, P34, DOI 10.1089/neu.2013.2855; Cousar JL, 2013, NEUROCRIT CARE, V19, P192, DOI 10.1007/s12028-013-9881-7; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Dardiotis E, 2011, PHARMACOGENET GENOM, V21, P136, DOI 10.1097/FPC.0b013e328343ab15; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Denton JS, 2012, TRENDS ENDOCRIN MET, V23, P41, DOI 10.1016/j.tem.2011.09.004; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Flanagan SE, 2009, HUM MUTAT, V30, P170, DOI 10.1002/humu.20838; Glaser B, 1999, DIABETES, V48, P1652, DOI 10.2337/diabetes.48.8.1652; Hardy OT, 2007, J PEDIATR-US, V150, P140, DOI 10.1016/j.jpeds.2006.08.028; Huang LQ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-102; Jha R, 2016, NEUROLOGY, V86; Kimberly WT, 2014, NEUROCRIT CARE, V20, P193, DOI 10.1007/s12028-013-9917-z; Knight JC, 2003, CLIN SCI, V104, P493, DOI 10.1042/CS20020304; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Liang FY, 2015, NEUROSCI LETT, V598, P29, DOI 10.1016/j.neulet.2015.05.006; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Martinez-Valverde T, 2015, J NEUROTRAUM, V32, P1478, DOI 10.1089/neu.2014.3706; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narum SR, 2006, CONSERV GENET, V7, P783, DOI 10.1007/s10592-005-9056-y; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Proverbio MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068740; Remedy Pharmaceuticals Inc., 2016, PHAS 1 RAND DOUBL BL, P1; Ritter AC, 2016, EPILEPSIA, V57, P984, DOI 10.1111/epi.13397; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sheth KN, 2016, NEUROCRIT CARE, V24, P132, DOI 10.1007/s12028-015-0189-7; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Stanley CA, 2004, J CLIN ENDOCR METAB, V89, P288, DOI 10.1210/jc.2003-030965; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675	40	34	34	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2017	26	2					213	224		10.1007/s12028-016-0309-z			12	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EN5EV	WOS:000396029300009	27677908	Green Accepted			2022-02-06	
J	Kulbe, JR; Hill, RL; Singh, IN; Wang, JA; Hall, ED				Kulbe, Jacqueline R.; Hill, Rachel L.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Synaptic Mitochondria Sustain More Damage than Non-Synaptic Mitochondria after Traumatic Brain Injury and Are Protected by Cyclosporine A	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporine A; mitochondria; neuroprotection; synaptic and non-synaptic; traumatic brain injury	NERVOUS-SYSTEM TOXICITY; MEDIATED CYTOSKELETAL DEGRADATION; SKELETAL-MUSCLE MITOCHONDRIA; PERMEABILITY TRANSITION PORE; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; CORTICAL CONTUSION; CYCLOPHILIN-D; SPINAL-CORD; NEUROLOGIC COMPLICATIONS	Currently, there are no Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of those with traumatic brain injury (TBI). As central mediators of the secondary injury cascade, mitochondria are promising therapeutic targets for prevention of cellular death and dysfunction after TBI. One of the most promising and extensively studied mitochondrial targeted TBI therapies is inhibition of the mitochondrial permeability transition pore (mPTP) by the FDA-approved drug, cyclosporine A (CsA). A number of studies have evaluated the effects of CsA on total brain mitochondria after TBI; however, no study has investigated the effects of CsA on isolated synaptic and non-synaptic mitochondria. Synaptic mitochondria are considered essential for proper neurotransmission and synaptic plasticity, and their dysfunction has been implicated in neurodegeneration. Synaptic and non-synaptic mitochondria have heterogeneous characteristics, but their heterogeneity can be masked in total mitochondrial (synaptic and non-synaptic) preparations. Therefore, it is essential that mitochondria targeted pharmacotherapies, such as CsA, be evaluated in both populations. This is the first study to examine the effects of CsA on isolated synaptic and non-synaptic mitochondria after experimental TBI. We conclude that synaptic mitochondria sustain more damage than non-synaptic mitochondria 24 h after severe controlled cortical impact injury (CCI), and that intraperitoneal administration of CsA (20 mg/kg) 15 min after injury improves synaptic and non-synaptic respiration, with a significant improvement being seen in the more severely impaired synaptic population. As such, CsA remains a promising neuroprotective candidate for the treatment of those with TBI.	[Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013	Kulbe, Jacqueline/0000-0002-7070-9264	Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT) [5R01 NS083405, 5R01 NS084857, 5P30 NS051220, 1F30 NS096876]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS096876, R01NS083405, T32NS077889] Funding Source: NIH RePORTER	This work was supported by 5R01 NS083405, 5R01 NS084857, 5P30 NS051220, 1F30 NS096876, and funding from the Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BERDEN JHM, 1985, LANCET, V1, P219; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cheng AW, 2010, ASN NEURO, V2, P243, DOI 10.1042/AN20100019; Colley BS, 2010, EXP NEUROL, V224, P241, DOI 10.1016/j.expneurol.2010.03.026; Coronado VG, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P84; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Finkelstein E., 2006, INCIDENCE EC BURDEN; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gilmer LK, 2010, MECH AGEING DEV, V131, P133, DOI 10.1016/j.mad.2009.12.011; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Greco T, 2016, J CEREBR BLOOD F MET, V36, P1603, DOI 10.1177/0271678X15610584; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2016, J BIOENERG BIOMEMBR, V48, P169, DOI 10.1007/s10863-015-9600-5; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Hazelton JL, 2009, J NEUROSCI RES, V87, P1250, DOI 10.1002/jnr.21921; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kristian T, 2006, J NEUROSCI METH, V152, P136, DOI 10.1016/j.jneumeth.2005.08.018; LAI JCK, 1976, BIOCHEM J, V154, P423, DOI 10.1042/bj1540423; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MacAskill AF, 2010, EUR J NEUROSCI, V32, P231, DOI 10.1111/j.1460-9568.2010.07345.x; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; NASSBERGER L, 1990, PHARMACOL TOXICOL, V67, P147; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; Picklo MJ, 1999, J NEUROCHEM, V72, P1617, DOI 10.1046/j.1471-4159.1999.721617.x; Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sanchez H, 2001, BRIT J PHARMACOL, V133, P781, DOI 10.1038/sj.bjp.0704129; Sanchez H, 2000, J MOL CELL CARDIOL, V32, P323, DOI 10.1006/jmcc.1999.1078; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sheng ZH, 2012, NAT REV NEUROSCI, V13, P77, DOI 10.1038/nrn3156; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang ZQ, 2013, OXID MED CELL LONGEV, V2013, DOI [10.1155/2013/329183, 10.1155/2013/146860]	106	34	34	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1291	1301		10.1089/neu.2016.4628			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600001	27596283	Green Published			2022-02-06	
J	Lim, SW; Shiue, YL; Liao, JC; Wee, HY; Wang, CC; Chio, CC; Chang, CH; Hu, CY; Kuo, JR				Lim, Sher-Wei; Shiue, Yow-Ling; Liao, Jen-Chieh; Wee, Hsiao-Yue; Wang, Che-Chuan; Chio, Chung-Ching; Chang, Chin-Hung; Hu, Chiao-Ya; Kuo, Jinn-Rung			Simvastatin Therapy in the Acute Stage of Traumatic Brain Injury Attenuates Brain Trauma-Induced Depression-Like Behavior in Rats by Reducing Neuroinflammation in the Hippocampus	NEUROCRITICAL CARE			English	Article						Fluid percussion injury; Depression-Like behavior; Forced swim; Hippocampus; Maximal angle; Microglia; Tumor necrosis factor-alpha; Simvastatin	LATERAL FLUID-PERCUSSION; NECROSIS-FACTOR-ALPHA; MICROGLIAL ACTIVATION; NEURONAL INJURY; NITRIC-OXIDE; LIPID-LEVELS; STATINS; MODEL; INCREASE; DEGENERATION	The antidepressant-like effects of simvastatin on traumatic brain injury (TBI) remain unclear. The present study aimed to investigate the neuroprotective effects of simvastatin and determine whether simvastatin attenuates TBI-induced depression-like behavior and, more specifically, acts as an antineuroinflammatory. Anesthetized male Sprague-Dawley rats were divided into five groups: sham-operated controls, TBI controls, and TBI treatment with simvastatin 4, 10, or 20 mg/kg. Simvastatin was intraperitoneally injected 0, 24, and 48 h after TBI. The motor function was measured using an inclined plane, and depression-like behavior was evaluated using forced swimming tests. Neuronal apoptosis (markers: NeuN, TUNEL, caspase-3), microglia (marker: OX42) and astrocyte (marker: GFAP) activation, and TNF-alpha expression in the microglia and astrocytes of the hippocampal CA3 area were investigated using immunofluorescence assay. All parameters were measured on the 4th, 8th, and 15th day, or only on the 15th day after TBI. TBI-induced depression-like behavior, which increased duration of immobility, was significantly attenuated by 20 mg simvastatin therapy on day 15 after TBI. TBI-induced neuronal apoptosis, microglia and astrocyte activation, and TNF-alpha expression in the microglia and astrocytes of the CA3 area of the hippocampus were significantly reduced by simvastatin treatment, particularly when 20 mg/kg was administered for 3 days. Intraperitoneal injection of simvastatin attenuated TBI in rats during the acute stage by reducing neuronal apoptosis, microglia, and TNF-alpha expression, thereby resulting in a reduction of depressive-like behavior. Our results suggest that simvastatin may be a promising treatment for TBI-induced depression-like behavior.	[Lim, Sher-Wei; Shiue, Yow-Ling] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan; [Lim, Sher-Wei; Liao, Jen-Chieh; Wee, Hsiao-Yue; Wang, Che-Chuan; Chio, Chung-Ching; Chang, Chin-Hung; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan; [Wang, Che-Chuan] Southern Taiwan Univ Sci & Technol, Dept Child Care, Tainan, Taiwan; [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Hu, Chiao-Ya; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Lim, Sher-Wei] Min Hwei Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan; [Kuo, Jinn-Rung] Chi Mei Med Ctr, 901 Chung Hwa Rd, Tainan, Taiwan		Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.; Kuo, JR (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.; Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.; Kuo, JR (corresponding author), Chi Mei Med Ctr, 901 Chung Hwa Rd, Tainan, Taiwan.	kuojinnrung@gmail.com			 [CHMFHR10357]	The authors thank all of the researchers, especially Chio-Ya Hu, who participated in this study. Research has been funded by CHMFHR10357 grants.	Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Ancelin ML, 2010, BIOL PSYCHIAT, V68, P125, DOI 10.1016/j.biopsych.2010.04.011; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Basso AM, 2005, NEUROPSYCHOPHARMACOL, V30, P1257, DOI 10.1038/sj.npp.1300677; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chuang CS, 2014, GEN HOSP PSYCHIAT, V36, P497, DOI 10.1016/j.genhosppsych.2014.05.008; Chuang TJ, 2012, J TRAUMA ACUTE CARE, V73, P1161, DOI 10.1097/TA.0b013e318265d128; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Fang CY, 2013, J BEHAV MED, V36, P143, DOI 10.1007/s10865-012-9409-1; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Kaster MP, 2012, NEUROPHARMACOLOGY, V62, P419, DOI 10.1016/j.neuropharm.2011.08.018; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Laskowitz DT, 2008, NEUROCRIT CARE, V8, P3, DOI 10.1007/s12028-007-9040-0; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lindberg C, 2005, J NEUROSCI RES, V82, P10, DOI 10.1002/jnr.20615; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; MAURO VF, 1993, CLIN PHARMACOKINET, V24, P195, DOI 10.2165/00003088-199324030-00002; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Morales K, 2006, J AM GERIATR SOC, V54, P70, DOI 10.1111/j.1532-5415.2005.00542.x; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; Tsai YT, 2014, J SURG RES, V189, P106, DOI 10.1016/j.jss.2014.02.009; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CC, 2013, J SURG RES, V184, P1045, DOI 10.1016/j.jss.2013.04.059; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang KW, 2014, ANN CLIN LAB SCI, V44, P145; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	45	34	35	0	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2017	26	1					122	132		10.1007/s12028-016-0290-6			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EI2AI	WOS:000392287900019	27406816				2022-02-06	
J	Black, AM; Sergio, LE; Macpherson, AK				Black, Amanda M.; Sergio, Lauren E.; Macpherson, Alison K.			The Epidemiology of Concussions: Number and Nature of Concussions and Time to Recovery Among Female and Male Canadian Varsity Athletes 2008 to 2011	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						incidence; athletic injuries; concussion; female; male; recovery of function; neuropsychological tests; students; universities	HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; SPORT; INJURIES; PREVENTION; STATEMENT; FOOTBALL; IMPACT; RATES	Objective: To provide incidence rates and days to symptom resolution and cognitive recovery stratified by sex and sport at a Canadian institution. Study Design: A retrospective chart analysis. Subjects: Seven hundred fifty-nine varsity level athletes competing in men's football, men's and women's soccer, men's and women's volleyball, men's and women's basketball, men's and women's ice hockey, women's field hockey, women's rugby, men's and women's tennis, men's and women's water polo, men's and women's swimming, badminton, cross-country, and track and field in the 2008 to 2009 season through the 2010 to 2011 season. Main Outcome Measures: Incidence of concussion, days to symptom recovery, and days to cognitive recovery as measured by clinical interpretation using the sports concussion assessment tool (SCAT)/SCAT2 and Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) with baseline and follow-up data. Results: A total of 81 concussions were reported and diagnosed among 759 athletes. Significantly, more female athletes were concussed than male athletes (13.08%-7.53%, respectively; P = 0.014) with the highest rates in women's rugby [incidence density (ID) = 20.00 concussions per athlete-season], women's ice hockey (ID = 18.67 per athlete-season), and men's basketball (ID = 20.00 per athlete-season). Sex differences in symptom recovery and cognitive recovery were not significant. Conclusions: The incidence of concussion across multiple sports in a Canadian varsity athlete population is of concern. There are inconsistencies found between the time an athlete claims to have no symptoms and the time of neurocognitive recovery as measured by computerized neurocognitive testing. Therefore, objective computerized testing is recommended to ensure that athletes are functionally recovered before return to play.	[Black, Amanda M.; Sergio, Lauren E.; Macpherson, Alison K.] York Univ, Sch Kinesiol & Hlth Sci, Fac Hlth, Toronto, ON, Canada; [Black, Amanda M.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada		Black, AM (corresponding author), Sport Injury Res Prevent Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	ablack@ucalgary.ca	Black, Amanda/O-7675-2017; Sergio, Lauren/AAK-3274-2020	Black, Amanda/0000-0001-5668-9706; 			Bloom GA, 2008, EUR J SPORT SCI, V8, P295, DOI 10.1080/17461390802251836; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meeuwisse WH, 2000, AM J SPORT MED, V28, P516, DOI 10.1177/03635465000280041201; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Underhill J, 2006, CHRONIC DIS CAN, V27, P163	21	34	34	0	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2017	27	1					52	56		10.1097/JSM.0000000000000308			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	EH9OP	WOS:000392101000010	26862834				2022-02-06	
J	Rodriguez Cruz, Y; Strehaiano, M; Obaya, TR; Rodriguez, JCG; Maurice, T				Rodriguez Cruz, Yamila; Strehaiano, Manon; Rodriguez Obaya, Teresita; Garcia Rodriguez, Julio Cesar; Maurice, Tangui			An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APP(Swe) Transgenic Mouse Model of Alzheimer's Disease	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; erythropoietin; intranasal formulation; learning and memory; Neuro-EPO; neuroprotection	COGNITIVE IMPAIRMENT; SYNAPTIC PLASTICITY; BRAIN; MICE; RECEPTOR; IMPROVES; HIPPOCAMPAL; MODULATION; EXPRESSION; INJURY	Erythropoietin (EPO) is a cytokine known to have effective cytoprotective action in the brain, particularly in ischemic, traumatic, inflammatory, and neurodegenerative conditions. We previously reported the neuroprotective effect of a low sialic form of EPO, Neuro-EPO, applied intranasally in rodent models of stroke or cerebellar ataxia and in a non-transgenic mouse model of Alzheimer's disease (AD). Here we analyzed the protective effect of Neuro-EPO in APP(Swe) mice, a reference transgenic mouse model of AD. Mice were administered 3 times a day, 3 days in the week with Neuro-EPO (125, 250 mu g/kg) intranasally, between 12 and 14 months of age. Motor responses, general activity, and memory responses were analyzed during and after treatment. The deficits in spontaneous alternation, place learning in the water-maze, and novel object recognition observed in APP(Swe) mice were alleviated by the low dose of Neuro-EPO. Oxidative stress, neuroinflammation, trophic factor levels, and a synaptic marker were analyzed in the hippocampus or cortex of the animals. The increases in lipid peroxidation or in GFAP and Iba-1 contents in APP(Swe) mice were significantly reduced after Neuro-EPO. Activation of intrinsic and extrinsic apoptotic pathways was analyzed. The increases in Bax/Bcl-2 ratio, TNF alpha, or Fas ligand levels observed in APP(Swe) mice were reduced by Neuro-EPO. Finally, immunohistochemical and ELISA analyses of A beta(1-42) levels in the APP(Swe) mouse cortex and hippocampus showed a marked reduction in A beta deposits and in soluble and insoluble A beta(1-42) forms. This study therefore confirmed the neuroprotective activity of EPO, particularly for an intranasally deliverable formulation, devoid of erythropoietic side effects, in a transgenic mouse model of AD. Neuro-EPO alleviated memory alterations, oxidative stress, neuroinflammation, apoptosis induction, and amyloid load in 14-month-old APP(Swe) mice.	[Rodriguez Cruz, Yamila; Garcia Rodriguez, Julio Cesar] Univ Med Sci, Inst Preclin & Basic Sci, Dept Histol, Havana, Cuba; [Rodriguez Cruz, Yamila; Rodriguez Obaya, Teresita] Ctr Mol Immunol CIM, Havana, Cuba; [Strehaiano, Manon; Maurice, Tangui] INSERM, U1198, Montpellier, France; [Strehaiano, Manon; Maurice, Tangui] Univ Montpellier, Montpellier, France; [Strehaiano, Manon; Maurice, Tangui] EPHE, Paris, France		Maurice, T (corresponding author), Univ Montpellier, INSERM, U1198, CC105, Pl Eugene Bataillon, F-34095 Montpellier 5, France.	tangui.maurice@umontpellier.fr	Maurice, Tangui/AAP-2499-2020; Rodriguez, Julio Cesar Garcia/V-7643-2019	Maurice, Tangui/0000-0002-4074-6793; 	program FSP Cuba (Havana, Cuba) [2011-16, 29967RG]; University of Montpellier; Franco-Cuban scientific	We thank Drs. Gaelle Naert and Catherine Desrumaux (INSERM U1198, Montpellier, France) for helpful advices and CIMAB (Habana, Cuba) for providing Neuro-EPO. This work is a scientific collaboration between the University of Montpellier and the University of Medical Sciences of Havana, Institute of Basic and Preclinical Sciences "Victoria de Giron". It was funded by a Franco-Cuban scientific cooperation between the French Embassy in Cuba and the Cuban Ministry of Foreign Trade and Foreign Investment (MINCEX), program FSP Cuba 2011-16, 29967RG (Havana, Cuba) and external resources from Inserm (Paris, France) and the University of Montpellier (Montpellier, France). JCGR acknowledges a visiting professor fellowship from the University of Montpellier.	Adamcio B, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-37; Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134; Almaguer-Melian W, 2016, SYNAPSE, V70, P240, DOI 10.1002/syn.21895; Arabpoor Zohreh, 2012, Adv Biomed Res, V1, P50, DOI 10.4103/2277-9175.100157; Armand-Ugon M, 2015, J ALZHEIMERS DIS, V45, P407, DOI [10.3233/JAD-141389, 10.3233/JAD-150002]; Assaraf MI, 2007, J NEUROPATH EXP NEUR, V66, P389, DOI 10.1097/nen.0b013e3180517b28; Bailey DM, 2014, ACTA PHYSIOL, V212, P175, DOI 10.1111/apha.12313; Barichello T, 2014, TRANSL RES, V163, P503, DOI 10.1016/j.trsl.2013.12.008; Bartesaghi S, 2005, NEUROTOXICOLOGY, V26, P923, DOI 10.1016/j.neuro.2005.01.016; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bond WS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00523; Brettschneider J, 2006, NEUROSCI LETT, V404, P347, DOI 10.1016/j.neulet.2006.06.011; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brureau A, 2013, NEUROBIOL AGING, V34, P1426, DOI 10.1016/j.neurobiolaging.2012.11.015; Castatneda-Arellano R, 2014, NEUROSCI LETT, V583, P16, DOI 10.1016/j.neulet.2014.09.013; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chateauvieux S, 2011, BIOCHEM PHARMACOL, V82, P1291, DOI 10.1016/j.bcp.2011.06.045; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P387, DOI 10.2174/156720205774962683; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; Cruz Rodr?guez J., 2006, PHARM ONLINE, V1, P100; Dey S, 2015, BRAIN RES, V1608, P14, DOI 10.1016/j.brainres.2015.02.052; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; El-Kordi A, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-37; Frautschy SA, 1998, AM J PATHOL, V152, P307; Rodriguez JCG, 2009, THESCIENTIFICWORLDJO, V9, P970, DOI 10.1100/tsw.2009.103; Garcia-Rodriguez JC, 2012, CURR PSYCHOPHARMACOL, V1, P228, DOI DOI 10.2174/2211556011201030228]; Genc S, 2011, EXPERT OPIN DRUG DEL, V8, P19, DOI 10.1517/17425247.2011.540236; Goodnough LT, 2007, EXP HEMATOL, V35, P167, DOI 10.1016/j.exphem.2007.01.026; Hassouna I, 2016, MOL PSYCHIATR, V21, P1752, DOI 10.1038/mp.2015.212; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Jubinsky PT, 1997, BLOOD, V90, P1867, DOI 10.1182/blood.V90.5.1867; Jung JH, 2011, MOL CELLS, V32, P197, DOI 10.1007/s10059-011-0077-8; Kumral A, 2005, BIOL NEONATE, V87, P15, DOI 10.1159/000080490; Kumral A, 2004, BIOL NEONATE, V85, P51, DOI 10.1159/000074958; Lahmy V, 2013, NEUROPSYCHOPHARMACOL, V38, P1706, DOI 10.1038/npp.2013.70; Lanz TA, 2003, NEUROBIOL DIS, V13, P246, DOI 10.1016/S0969-9961(03)00079-2; Lee ST, 2012, J NEUROCHEM, V120, P115, DOI 10.1111/j.1471-4159.2011.07534.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758; Li G, 2008, NEUROSCI LETT, V442, P143, DOI 10.1016/j.neulet.2008.07.007; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; Ma R, 2009, NEUROPHARMACOLOGY, V56, P1027, DOI 10.1016/j.neuropharm.2009.02.006; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Maiese K, 2009, THESCIENTIFICWORLDJO, V9, P1072, DOI 10.1100/tsw.2009.121; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; Maurice T, 2013, J PSYCHOPHARMACOL, V27, P1044, DOI 10.1177/0269881113494939; McGeer Edith G., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P569, DOI 10.2174/156800705774322067; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Nadam J, 2007, NEUROBIOL DIS, V25, P412, DOI 10.1016/j.nbd.2006.10.009; Naert G, 2011, MOL CELL NEUROSCI, V46, P55, DOI 10.1016/j.mcn.2010.08.006; Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386, DOI 10.1093/jnen/60.4.386; Ott C, 2015, MOL MED, V21, P803, DOI 10.2119/molmed.2015.00192; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Cruz YR, 2010, THESCIENTIFICWORLDJO, V10, P2288, DOI 10.1100/tsw.2010.215; Rothman SM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.005; Sanchez PE, 2009, P NATL ACAD SCI USA, V106, P9848, DOI 10.1073/pnas.0901840106; Shang YC, 2012, AGING-US, V4, P187, DOI 10.18632/aging.100440; Stewart S, 2011, J ALZHEIMERS DIS, V26, P105, DOI 10.3233/JAD-2011-101827; Sun ZK, 2008, J NEUROSCI RES, V86, P3018, DOI 10.1002/jnr.21745; Tringali G, 2007, ENDOCRINOLOGY, V148, P4711, DOI 10.1210/en.2007-0431; van Woensel Matthias, 2013, Cancers (Basel), V5, P1020, DOI 10.3390/cancers5031020; VANPAPENDRECHT MAH, 1992, EUR J SURG, V158, P83; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Webster SJ, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00088; Yazihan N, 2008, INJURY, V39, P1408, DOI 10.1016/j.injury.2008.03.010; Zussy C, 2011, AM J PATHOL, V179, P315, DOI 10.1016/j.ajpath.2011.03.021	74	34	34	0	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2017	55	1					231	248		10.3233/JAD-160500			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EB8WI	WOS:000387671600019	27662300				2022-02-06	
J	Shen, WB; Anastasiadis, P; Nguyen, B; Yarnell, D; Yarowsky, PJ; Frenkel, V; Fishman, PS				Shen, Wei-Bin; Anastasiadis, Pavlos; Nguyen, Ben; Yarnell, Deborah; Yarowsky, Paul J.; Frenkel, Victor; Fishman, Paul S.			Magnetic Enhancement of Stem Cell-Targeted Delivery into the Brain Following MR-Guided Focused Ultrasound for Opening the Blood-Brain Barrier	CELL TRANSPLANTATION			English	Article						blood-brain barrier; magnetic resonance imaging; focused ultrasound; human neural progenitor cells; magnetic attraction	IN-VIVO; DRUG-DELIVERY; FUNCTIONAL BENEFIT; CONTRAST AGENT; TUMOR-MODEL; RHODAMINE-B; DISRUPTION; RETENTION; THERAPY; MICROBUBBLES	Focused ultrasound (FUS)-mediated blood-brain barrier disruption (BBBD) can enable even large therapeutics such as stem cells to enter the brain from the bloodstream. However, the efficiency is relatively low. Our previous study showed that human neural progenitor cells (hNPCs) loaded with superparamagnetic iron oxide nanoparticles (SPIONs) in culture were attracted by an external magnetic field. In vivo, enhanced brain retention was observed near a magnet mounted on the skull in a rat model of traumatic brain injury, where BBBD also occurs. The goal of the current study was to determine whether magnetic attraction of SPION-loaded hNPCs would also enhance their retention in the brain after FUS-mediated BBBD. A small animal magnetic resonance imaging (MRI)-guided FUS system operating at 1.5 MHz was used to treat rats (similar to 120 g) without tissue damage or hemorrhage. Evidence of successful BBBD was validated with both radiologic enhancement of gadolinium on postsonication TI MRI and whole brain section visualization of Evans blue dye. The procedure was then combined with the application of a powerful magnet to the head directly after intravenous injection of the hNPCs. Validation of cells within the brain was performed by staining with Perls' Prussian blue for iron and by immunohistochemistry with a human-specific antigen. By injecting equal numbers of iron oxide (SPIONs) and noniron oxide nanoparticles-loaded hNPCs, each labeled with a different fluorophore, we found significantly greater numbers of SPIONs-loaded cells retained in the brain at the site of BBBD as compared to noniron loaded cells. This result was most pronounced in regions of the brain closest to the skull (dorsal cortex) in proximity to the magnet surface. A more powerful magnet and a Halbach magnetic array resulted in more effective retention of SPION-labeled cells in even deeper brain regions such as the striatum and ventral cortex. There, up to 90% of hNPCs observed contained SPIONs compared to 60% to 70% with the less powerful magnet. Fewer cells were observed at 24 h posttreatment compared to 2 h (primarily in the dorsal cortex). These results demonstrate that magnetic attraction can substantially enhance the retention of stem cells after FUS-mediated BBBD. This procedure could provide a safer and less invasive approach for delivering stem cells to the brain, compared to direct intracranial injections, substantially reducing the risk of bleeding and infection.	[Shen, Wei-Bin; Yarowsky, Paul J.] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA; [Anastasiadis, Pavlos; Nguyen, Ben; Frenkel, Victor] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Yarnell, Deborah; Fishman, Paul S.] VA Maryland Healthcare Syst, Neurol Serv, 10 North Greene St, Baltimore, MD 21201 USA; [Yarowsky, Paul J.] VA Maryland Healthcare Syst, Res Serv, Baltimore, MD USA; [Frenkel, Victor] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Fishman, Paul S.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA		Fishman, PS (corresponding author), VA Maryland Healthcare Syst, Neurol Serv, 10 North Greene St, Baltimore, MD 21201 USA.	paul.fishman@va.gov	Anastasiadis, Pavlos/B-3685-2011	Anastasiadis, Pavlos/0000-0002-0230-7925	Focused Ultrasound Surgery Foundation; US Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA154274] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This study was supported by a research grant from the Focused Ultrasound Surgery Foundation (P.S.F.) and to the US Department of Veterans Affairs (P.S.F.).	Alkins R, 2013, CANCER RES, V73, P1892, DOI 10.1158/0008-5472.CAN-12-2609; Arbab AS, 2006, STEM CELLS, V24, P671, DOI 10.1634/stemcells.2005-0017; Arbab AS, 2004, HUM GENE THER, V15, P351, DOI 10.1089/104303404322959506; Barnsley LC, 2015, PHYS MED BIOL, V60, P8303, DOI 10.1088/0031-9155/60/21/8303; Berman SMC, 2011, METHODS MOL BIOL, V711, P435, DOI 10.1007/978-1-61737-992-5_22; Burgess A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027877; Chatterjee S, 2015, AM J PHYSIOL-HEART C, V308, pH1451, DOI 10.1152/ajpheart.00105.2015; Chaudeurge A, 2012, CELL TRANSPLANT, V21, P679, DOI 10.3727/096368911X612440; Cheng K, 2012, CELL TRANSPLANT, V21, P1121, DOI 10.3727/096368911X627381; Cheng K, 2010, CIRC RES, V106, P1570, DOI 10.1161/CIRCRESAHA.109.212589; Chopra R, 2010, ACS CHEM NEUROSCI, V1, P391, DOI 10.1021/cn9000445; Connell JJ, 2015, REGEN MED, V10, P757, DOI 10.2217/rme.15.36; Crake C, 2016, ULTRASOUND MED BIOL, V42, P3022, DOI 10.1016/j.ultrasmedbio.2016.08.002; Deng JM, 2012, J MOL NEUROSCI, V46, P677, DOI 10.1007/s12031-011-9629-9; Dervishi E, 2013, INT J HYPERTHER, V29, P598, DOI 10.3109/02656736.2013.820357; Etame AB, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.10.FOCUS11252; Fan CH, 2016, THERANOSTICS, V6, P1542, DOI 10.7150/thno.15297; Gonzalez-Molina J, 2012, J R SOC INTERFACE, V9, P3008, DOI 10.1098/rsif.2012.0316; HALBACH K, 1980, NUCL INSTRUM METHODS, V169, P1, DOI 10.1016/0029-554X(80)90094-4; Hersh DS, 2016, CURR PHARM DESIGN, V22, P1177, DOI 10.2174/1381612822666151221150733; Kinoshita M, 2006, P NATL ACAD SCI USA, V103, P11719, DOI 10.1073/pnas.0604318103; Kyrtatos PG, 2009, JACC-CARDIOVASC INTE, V2, P794, DOI 10.1016/j.jcin.2009.05.014; Li QY, 2013, BIOMATERIALS, V34, P4982, DOI 10.1016/j.biomaterials.2013.03.030; Luciani A, 2009, EUR RADIOL, V19, P1087, DOI 10.1007/s00330-008-1262-9; Magnin R, 2015, J THER ULTRASOUND, V3, DOI 10.1186/s40349-015-0044-5; Marty B, 2012, J CEREBR BLOOD F MET, V32, P1948, DOI 10.1038/jcbfm.2012.100; McDannold N, 2006, PHYS MED BIOL, V51, P793, DOI 10.1088/0031-9155/51/4/003; Mcdannold N, 2008, ULTRASOUND MED BIOL, V34, P930, DOI 10.1016/j.ultrasmedbio.2007.11.009; McDannold N, 2008, ULTRASOUND MED BIOL, V34, P834, DOI 10.1016/j.ultrasmedbio.2007.10.016; Muthana M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9009; Nance E, 2014, J CONTROL RELEASE, V189, P123, DOI 10.1016/j.jconrel.2014.06.031; Oshima S, 2014, J ORTHOP SCI, V19, P478, DOI 10.1007/s00776-014-0548-9; Pardridge WM, 2012, METHOD ENZYMOL, V503, P269, DOI 10.1016/B978-0-12-396962-0.00011-2; Ranjan A, 2012, J CONTROL RELEASE, V158, P487, DOI 10.1016/j.jconrel.2011.12.011; Riegler J, 2011, MED PHYS, V38, P3932, DOI 10.1118/1.3593363; Riegler J, 2010, BIOMATERIALS, V31, P5366, DOI 10.1016/j.biomaterials.2010.03.032; Samiotaki G, 2013, IEEE T ULTRASON FERR, V60, P2257, DOI 10.1109/TUFFC.2013.6644731; She WH, 2016, HONG KONG MED J, V22, P382, DOI 10.12809/hkmj154755; Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010; Sheikov N, 2008, ULTRASOUND MED BIOL, V34, P1093, DOI 10.1016/j.ultrasmedbio.2007.12.015; Shen WB, 2016, CONTRAST MEDIA MOL I, V11, P222, DOI 10.1002/cmmi.1684; Shen WB, 2016, CELL TRANSPLANT, V25, P1085, DOI 10.3727/096368915X689550; Shen WB, 2013, INT J NANOMED, V8, P4593, DOI 10.2147/IJN.S53012; Shen YL, 2015, CELL TRANSPLANT, V24, P1981, DOI 10.3727/096368914X685302; Silvestrini MT, 2013, STEREOT FUNCT NEUROS, V91, P92, DOI 10.1159/000343213; Song M, 2010, HUM GENE THER, V21, P603, DOI 10.1089/hum.2009.144; Tebebi PA, 2015, STEM CELLS, V33, P1173, DOI 10.1002/stem.1927; Vanecek V, 2012, INT J NANOMED, V7, P3719, DOI 10.2147/IJN.S32824; Wang F, 2012, ADV MATER RES-SWITZ, V411, P7, DOI 10.4028/www.scientific.net/AMR.411.7; Wei KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058995; Wintermark M, 2014, AM J NEURORADIOL, V35, P891, DOI 10.3174/ajnr.A3808; Ziadloo A, 2012, STEM CELLS, V30, P1216, DOI 10.1002/stem.1099	52	34	37	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	7					1235	1246		10.1177/0963689717715824			12	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	EZ4GO	WOS:000404671800011	28933214	Green Published, gold			2022-02-06	
J	Ewing-Cobbs, L; Johnson, CP; Juranek, J; DeMaster, D; Prasad, M; Duque, G; Kramer, L; Cox, CS; Swank, PR				Ewing-Cobbs, Linda; Johnson, Chad Parker; Juranek, Jenifer; DeMaster, Dana; Prasad, Mary; Duque, Gerardo; Kramer, Larry; Cox, Charles S.; Swank, Paul R.			Longitudinal diffusion tensor imaging after pediatric traumatic brain injury: Impact of age at injury and time since injury on pathway integrity	HUMAN BRAIN MAPPING			English	Article						tract-based spatial statistics; fractional anisotropy; radial diffusivity; axial diffusivity; children; microstructure; neurodegeneration; dysmyelination; chronic	WHITE-MATTER; CORPUS-CALLOSUM; FRACTIONAL ANISOTROPY; UNCINATE FASCICULUS; CHILDREN; ADOLESCENTS; CHILDHOOD; RECOVERY; MODERATE; MICROSTRUCTURE	Following pediatric traumatic brain injury (TBI), longitudinal diffusion tensor imaging may characterize alterations in initial recovery and subsequent trajectory of white matter development. Our primary aim examined effects of age at injury and time since injury on pathway microstructure in children ages 6-15 scanned 3 and 24 months after TBI. Microstructural values generated using tract-based spatial statistics extracted from core association, limbic, and projection pathways were analyzed using general linear mixed models. Relative to children with orthopedic injury, the TBI group had lower fractional anisotropy (FA) bilaterally in all seven pathways. In left-hemisphere association pathways, school-aged children with TBI had the lowest initial pathway integrity and showed the greatest increase in FA over time suggesting continued development despite incomplete recovery. Adolescents showed limited change in FA and radial diffusivity and had the greatest residual deficit suggesting relatively arrested development. Radial diffusivity was persistently elevated in the TBI group, implicating dysmyelination as a core contributor to chronic post-traumatic neurodegenerative changes. The secondary aim compared FA values over time in the total sample, including participants contributing either one or two scans to the analysis, to the longitudinal cases contributing two scans. For each pathway, FA values and effect sizes were very similar and indicated extremely small differences in measurement of change over time in the total and longitudinal samples. Statistical approaches incorporating missing data may reliably estimate the effects of TBI and provide increased power to identify whether pathways show neurodegeneration, arrested development, or continued growth following pediatric TBI. Hum Brain Mapp 37:3929-3945, 2016. (c) 2016 Wiley Periodicals, Inc.	[Ewing-Cobbs, Linda; Johnson, Chad Parker; Juranek, Jenifer; DeMaster, Dana; Prasad, Mary; Duque, Gerardo] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda; Johnson, Chad Parker; Juranek, Jenifer; DeMaster, Dana; Prasad, Mary; Duque, Gerardo] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA; [Kramer, Larry] Univ Texas Hlth Sci Ctr Houston, Diagnost & Intervent Radiol, Houston, TX 77030 USA; [Cox, Charles S.] Univ Texas Hlth Sci Ctr Houston, Pediat Surg, Houston, TX 77030 USA; [Swank, Paul R.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA		Ewing-Cobbs, L (corresponding author), Dept Pediat, 7000 Fannin St,Suite 2401, Houston, TX 77030 USA.	Linda.ewing-cobbs@uth.tmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS046308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant number: R01 NS046308.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Andersson J., 2007, TR07JA2 FMRIB CTR; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Catani M., 2012, ATLAS HUMAN BRAIN CO; Cohen J., 1998, STAT POWER ANAL BEHA, V2nd; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Dennis EL, 2013, INT J DEV NEUROSCI, V31, P525, DOI 10.1016/j.ijdevneu.2013.05.007; Dennis EL, 2013, NEUROIMAGE, V64, P671, DOI 10.1016/j.neuroimage.2012.09.004; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Durlak JA, 2009, J PEDIATR PSYCHOL, V34, P917, DOI 10.1093/jpepsy/jsp004; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Faul M, 2010, TRAUMATIC BRAIN INJU; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Johnson CP, 2015, NEUROIMAGE-CLIN, V9, P668, DOI 10.1016/j.nicl.2015.10.009; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Krogsrud SK, 2016, NEUROIMAGE, V124, P473, DOI 10.1016/j.neuroimage.2015.09.017; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Lipsey M., 1990, DESIGN SENSITIVITY S; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Mori S, 2005, MRI ATLAS HUMAN WHIT; Park HJ, 2013, SCIENCE, V342, P579, DOI 10.1126/science.1238411; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Rosema S, 2015, J NEUROTRAUM, V32, P976, DOI 10.1089/neu.2014.3567; Scheibel RS, 2011, SOC NEUROSCI-UK, V6, P582, DOI 10.1080/17470919.2011.588844; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Simmonds DJ, 2014, NEUROIMAGE, V92, P356, DOI 10.1016/j.neuroimage.2013.12.044; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; TEASDALE G, 1974, LANCET, V2, P81; Urger SE, 2015, J CHILD NEUROL, V30, P9, DOI 10.1177/0883073813520503; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yu QW, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00228	62	34	35	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	NOV	2016	37	11					3929	3945		10.1002/hbm.23286			17	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DZ7VM	WOS:000386075900018	27329317	Green Accepted, Green Published			2022-02-06	
J	Lu, KP; Kondo, A; Albayram, O; Herbert, MK; Liu, HK; Zhou, XZ				Lu, Kun Ping; Kondo, Asami; Albayram, Onder; Herbert, Megan K.; Liu, Hekun; Zhou, Xiao Zhen			Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury	JAMA NEUROLOGY			English	Article							PROLYL ISOMERASE PIN1; PROTEIN PHOSPHATASE 2A; AMYLOID-BETA; A-BETA; MOUSE MODEL; NEURODEGENERATIVE DISORDERS; MEDIATED NEURODEGENERATION; NEUROFIBRILLARY TANGLES; UNITED-STATES; HEAD TRAUMA	Alzheimer disease (AD) and chronic traumatic encephalopathy (CTE) share a common neuropathologic signature-neurofibrillary tangles made of phosphorylated tau-but do not have the same pathogenesis or symptoms. Although whether traumatic brain injury (TBI) could cause AD has not been established, CTE is shown to be associated with TBI. Until recently, whether and how TBI leads to tau-mediated neurodegeneration was unknown. The unique prolyl isomerase Pin1 protects against the development of tau-mediated neurodegeneration in AD by converting the phosphorylated Thr231-Pro motif in tau (ptau) from the pathogenic cis conformation to the physiologic trans conformation, thereby restoring ptau function. The recent development of antibodies able to distinguish and eliminate both conformations specifically has led to the discovery of cis-ptau as a precursor of tau-induced pathologic change and an early driver of neurodegeneration that directly links TBI to CTE and possibly to AD. Within hours of TBI in mice or neuronal stress in vitro, neurons prominently produce cis-ptau, which causes and spreads cis-ptau pathologic changes, termed cistauosis. Cistauosis eventually leads to widespread tau-mediated neurodegeneration and brain atrophy. Cistauosis is effectively blocked by the cis-ptau antibody, which targets intracellular cis-ptau for proteasome-mediated degradation and prevents extracellular cis-ptau from spreading to other neurons. Treating TBI mice with cis-ptau antibody not only blocks early cistauosis but also prevents development and spreading of tau-mediated neurodegeneration and brain atrophy and restores brain histopathologic features and functional outcomes. Thus, cistauosis is a common early disease mechanism for AD, TBI, and CTE, and cis-ptau and its antibody may be useful for early diagnosis, treatment, and prevention of these devastating diseases.	[Lu, Kun Ping; Kondo, Asami; Albayram, Onder; Herbert, Megan K.; Liu, Hekun; Zhou, Xiao Zhen] Harvard Med Sch, Div Translat Therapeut, Dept Med, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA; [Lu, Kun Ping; Kondo, Asami; Albayram, Onder; Herbert, Megan K.; Liu, Hekun; Zhou, Xiao Zhen] Harvard Med Sch, Ctr Canc, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA; [Lu, Kun Ping; Liu, Hekun] Fujian Med Univ, Inst Translat Med, Fuzhou, Peoples R China		Lu, KP (corresponding author), Harvard Med Sch, Div Translat Therapeut, Dept Med, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA.; Lu, KP (corresponding author), Harvard Med Sch, Ctr Canc, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Ctr Life Sci Room 0408, Boston, MA 02215 USA.	klu@bidmc.harvard.edu	Herbert, Megan/AAN-8333-2021; LIU, Hekun/AAI-6583-2020; Herbert, Megan/E-6348-2015	Herbert, Megan/0000-0003-1599-4362; Albayram, Onder/0000-0002-2028-1458	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AG029385, R01AG046319, R01CA167677, R01HL111430]; Alzheimer's AssociationAlzheimer's Association [DVT-14-322623]	This work was supported by grants R01AG029385, R01AG046319, R01CA167677, and R01HL111430 from the National Institutes of Health; grant DVT-14-322623 from the Alzheimer's Association (Dr Lu); and gift donations from the Owens Family Foundation (Drs Lu and Zhou).	Alzheimer's Association, 2016, ALZH DIS FACTS FIG; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Brody DL, 2008, ANNU REV NEUROSCI, V31, P175, DOI 10.1146/annurev.neuro.31.060407.125529; Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837; Castillo-Carranza DL, 2014, J NEUROSCI, V34, P4260, DOI 10.1523/JNEUROSCI.3192-13.2014; Chen CH, 2015, NEUROBIOL DIS, V76, P13, DOI 10.1016/j.nbd.2014.12.027; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Clavaguera F, 2015, NEUROPATH APPL NEURO, V41, P47, DOI 10.1111/nan.12197; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dolan PJ, 2010, CURR OPIN DRUG DISC, V13, P595; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Eichner T, 2016, J MOL BIOL, V428, P1760, DOI 10.1016/j.jmb.2016.03.009; Faul M, 2010, TRAUMATIC BRAIN INJU; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goedert M, 2000, J NEUROCHEM, V75, P2155, DOI 10.1046/j.1471-4159.2000.0752155.x; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Gotz J, 2007, BRAIN PATHOL, V17, P91, DOI 10.1111/j.1750-3639.2007.00051.x; Golde TE, 2011, NEURON, V69, P203, DOI 10.1016/j.neuron.2011.01.002; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hamdane M, 2006, MOL CELL NEUROSCI, V32, P155, DOI 10.1016/j.mcn.2006.03.006; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kimura T, 2013, J BIOL CHEM, V288, P7968, DOI 10.1074/jbc.M112.433326; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Krishnamurthy Pavan K, 2011, Front Psychiatry, V2, P59, DOI 10.3389/fpsyt.2011.00059; Kutter S, 2016, J MOL BIOL, V428, P1742, DOI 10.1016/j.jmb.2016.03.010; Lee TH, 2011, MOL CELL, V42, P147, DOI 10.1016/j.molcel.2011.03.005; Lee TH, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001906; Lim J, 2008, J CLIN INVEST, V118, P1877, DOI 10.1172/JCI34308; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Lu JC, 2009, CARCINOGENESIS, V30, P1717, DOI 10.1093/carcin/bgp171; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2003, BIOESSAYS, V25, P174, DOI 10.1002/bies.10223; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 1999, NATURE, V399, P784; Luna-Munoz J, 2007, J ALZHEIMERS DIS, V12, P365; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Ma SL, 2012, NEUROBIOL AGING, V33, P804, DOI 10.1016/j.neurobiolaging.2010.05.018; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Min SW, 2015, NAT MED, V21, P1154, DOI 10.1038/nm.3951; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nowotny P, 2007, NEUROSCI LETT, V419, P15, DOI 10.1016/j.neulet.2007.03.071; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Roberson ED, 2006, SCIENCE, V314, P781, DOI 10.1126/science.1132813; Rosenmann H, 2013, CURR ALZHEIMER RES, V10, P217, DOI 10.2174/1567205011310030001; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Segat L, 2007, NEUROBIOL AGING, V28, P69, DOI 10.1016/j.neurobiolaging.2005.11.009; Sigurdsson EM, 2014, NEURODEGENER DIS, V13, P103, DOI 10.1159/000354491; Smet C, 2004, BIOCHEMISTRY-US, V43, P2032, DOI 10.1021/bi035479x; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Sultana R, 2006, NEUROBIOL AGING, V27, P918, DOI 10.1016/j.neurobiolaging.2005.05.005; Tampellini D, 2007, J BIOL CHEM, V282, P18895, DOI 10.1074/jbc.M700373200; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Troquier L, 2012, CURR ALZHEIMER RES, V9, P397, DOI 10.2174/156720512800492503; Wang YP, 2016, NAT REV NEUROSCI, V17, P5, DOI 10.1038/nrn.2015.1; Wijsman EM, 2004, AM J HUM GENET, V75, P398, DOI 10.1086/423393; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(05)00083-3; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	92	34	34	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	NOV 1	2016	73	11					1356	1362		10.1001/jamaneurol.2016.2027			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ED1BL	WOS:000388578600017	27654282	Bronze			2022-02-06	
J	Crair, MC; Mason, CA				Crair, Michael C.; Mason, Carol A.			Reconnecting Eye to Brain	JOURNAL OF NEUROSCIENCE			English	Article						axon; axon guidance; axon regeneration; eye; lateral geniculate nucleus; optic nerve; regeneration; retina; retinal ganglion cells; superior colliculus; traumatic brain injury; vision; visual cortex	OPTIC-NERVE REGENERATION; RETINAL GANGLION-CELLS; SPINAL-CORD-INJURY; LATERAL GENICULATE-NUCLEUS; INHIBITORY NEURON TRANSPLANTATION; PROMOTES AXON REGENERATION; PRIMARY VISUAL-CORTEX; IN-VIVO; GROWTH-CONE; RETINOGENICULATE SYNAPSE	Although much is known about the regenerative capacity of retinal ganglion cells, very significant barriers remain in our ability to restore visual function following traumatic injury or disease-induced degeneration. Here we summarize our current understanding of the factors regulating axon guidance and target engagement in regenerating axons, and review the state of the field of neural regeneration, focusing on the visual system and highlighting studies using other model systems that can inform analysis of visual system regeneration. This overview is motivated by a Society for Neuroscience Satellite meeting, "Reconnecting Neurons in the Visual System," held in October 2015 sponsored by the National Eye Institute as part of their " Audacious Goals Initiative" and co-organized by Carol Mason (Columbia University) and Michael Crair (Yale University). The collective wisdom of the conference participants pointed to important gaps in our knowledge and barriers to progress in promoting the restoration of visual system function. This article is thus a summary of our existing understanding of visual system regeneration and provides a blueprint for future progress in the field.	[Crair, Michael C.] Yale Univ, Dept Neurosci, New Haven, CT 06520 USA; [Crair, Michael C.] Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA; [Mason, Carol A.] Columbia Univ, Mortimer B Zuckerman Mind Brain Behav Inst, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Mason, Carol A.] Columbia Univ, Mortimer B Zuckerman Mind Brain Behav Inst, Dept Neurosci, New York, NY 10032 USA; [Mason, Carol A.] Columbia Univ, Mortimer B Zuckerman Mind Brain Behav Inst, Dept Ophthalmol, New York, NY 10032 USA		Crair, MC (corresponding author), Yale Univ, Sch Med, Dept Neurosci, 333 Cedar St,SHM B301, New Haven, CT 06520 USA.; Mason, CA (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, 630 W 168th St,14-509 P&S Bldg, New York, NY 10032 USA.	michael.crair@yale.edu; cam4@columbia.edu		Mason, Carol/0000-0001-6253-505X	Family of William Ziegler, III; National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY015788, EY023105, EY012736, EY015290]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY023105, R01EY015290, P30EY026878, R01EY012736, R01EY015788] Funding Source: NIH RePORTER	This work was supported by the Family of William Ziegler, III and the National Eye Institute Grants EY015788 and EY023105 to M.C.C. and EY012736 and EY015290 to C.A.M. We thank Paul Sieving, Tom Greenwell, and Steve Becker of the National Eye Institute for convening the Satellite meeting from which this article emanated and the conference panelists and participants for their enthusiastic participation.	Aktas O, 2016, CURR OPIN NEUROL, V29, P199, DOI 10.1097/WCO.0000000000000327; Amamoto R, 2016, ELIFE, V5, DOI 10.7554/eLife.13998; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Aralci M, 2014, NEURAL REGEN RES, V9, P2125, DOI 10.4103/1673-5374.147942; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; Baden T, 2016, NATURE, V529, P345, DOI 10.1038/nature16468; Baier H, 2013, ANNU REV CELL DEV BI, V29, P385, DOI 10.1146/annurev-cellbio-101011-155748; Balasubramanian R, 2014, GENE EXPR PATTERNS, V14, P1, DOI 10.1016/j.gep.2013.12.001; Baldwin KT, 2015, P NATL ACAD SCI USA, V112, P2581, DOI 10.1073/pnas.1423221112; Balmer TS, 2015, CEREB CORTEX, V25, P904, DOI 10.1093/cercor/bht281; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beazley LD, 2003, J NEUROTRAUM, V20, P1263, DOI 10.1089/089771503770802925; Becker CG, 2015, DEV CELL, V32, P516, DOI 10.1016/j.devcel.2015.01.001; Bei FF, 2016, CELL, V164, P219, DOI 10.1016/j.cell.2015.11.036; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Benowitz LI, 2017, EXP NEUROL, V287, P365, DOI 10.1016/j.expneurol.2015.12.015; Berardi N, 1999, J NEUROBIOL, V41, P119, DOI 10.1002/(SICI)1097-4695(199910)41:1<119::AID-NEU15>3.3.CO;2-E; Blackmore MG, 2012, P NATL ACAD SCI USA, V109, P7517, DOI 10.1073/pnas.1120684109; Bochner DN, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010157; Brace EJ, 2014, J NEUROSCI, V34, P8398, DOI 10.1523/JNEUROSCI.4715-13.2014; Bradke F, 2012, NAT REV NEUROSCI, V13, P183, DOI 10.1038/nrn3176; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; BRITTIS PA, 1995, MOL CELL NEUROSCI, V6, P413, DOI 10.1006/mcne.1995.1031; Bryson JB, 2014, SCIENCE, V344, P94, DOI 10.1126/science.1248523; Byrne AB, 2011, JOVE-J VIS EXP, DOI 10.3791/2707; Callahan A, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw040; Cattin AL, 2015, CELL, V162, P1127, DOI 10.1016/j.cell.2015.07.021; CHAN SO, 1994, J COMP NEUROL, V344, P20, DOI 10.1002/cne.903440103; Chandran V, 2016, NEURON, V89, P956, DOI 10.1016/j.neuron.2016.01.034; Chang WC, 2010, WIRES NANOMED NANOBI, V2, P151, DOI 10.1002/wnan.76; Chen LZ, 2016, ELIFE, V5, DOI 10.7554/eLife.16072; Chen SK, 2011, NATURE, V476, P92, DOI 10.1038/nature10206; Davis MF, 2015, NEURON, V86, P1055, DOI 10.1016/j.neuron.2015.03.062; de Lima S, 2012, P NATL ACAD SCI USA, V109, P9149, DOI 10.1073/pnas.1119449109; Dell AL, 2013, J NEUROSCI, V33, P11076, DOI 10.1523/JNEUROSCI.0197-13.2013; Delloye-Bourgeois C, 2014, JOVE-J VIS EXP, DOI 10.3791/50883; Dhande OS, 2014, CURR BIOL, V24, pR155, DOI 10.1016/j.cub.2013.12.045; Diekmann H, 2013, EXP NEUROL, V248, P254, DOI 10.1016/j.expneurol.2013.06.021; Dilger EK, 2015, J NEUROSCI, V35, P3652, DOI 10.1523/JNEUROSCI.2343-14.2015; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Duan X, 2015, NEURON, V85, P1244, DOI 10.1016/j.neuron.2015.02.017; El-Danaf RN, 2015, NEURAL DEV, V10, DOI 10.1186/s13064-015-0046-6; Elsaeidi F, 2014, J NEUROSCI, V34, P2632, DOI 10.1523/JNEUROSCI.3898-13.2014; Endo M, 2016, SCI REP-UK, V6, DOI 10.1038/srep23976; Enes J, 2010, CURR BIOL, V20, P1154, DOI 10.1016/j.cub.2010.05.055; Erskine L, 2011, NEURON, V70, P951, DOI 10.1016/j.neuron.2011.02.052; Espinosa JS, 2012, NEURON, V75, P230, DOI 10.1016/j.neuron.2012.06.009; Fabre PJ, 2010, J NEUROSCI, V30, P266, DOI 10.1523/JNEUROSCI.3778-09.2010; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; FRASER SE, 1990, J EXP BIOL, V153, P61; Fu QL, 2011, INVEST OPHTH VIS SCI, V52, P8374, DOI 10.1167/iovs.11-7667; Furman M, 2013, J NEUROPHYSIOL, V110, P1441, DOI 10.1152/jn.01066.2012; Gallo V, 2014, NEURON, V83, P283, DOI 10.1016/j.neuron.2014.06.010; Garcia-Frigola C, 2010, EMBO J, V29, P3170, DOI 10.1038/emboj.2010.172; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; GODEMENT P, 1984, J COMP NEUROL, V230, P552, DOI 10.1002/cne.902300406; GODEMENT P, 1994, J NEUROSCI, V14, P7024; Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; GUILLERY RW, 1987, J COMP NEUROL, V265, P203, DOI 10.1002/cne.902650205; Guy AT, 2015, SCIENCE, V349, P974, DOI 10.1126/science.aab3516; Hamid S, 2008, EUR SPINE J, V17, P1256, DOI 10.1007/s00586-008-0729-3; Hammarlund M, 2014, CURR OPIN NEUROBIOL, V27, P199, DOI 10.1016/j.conb.2014.04.001; HARRIS WA, 1987, DEVELOPMENT, V101, P123; He HY, 2007, NAT NEUROSCI, V10, P1134, DOI 10.1038/nn1965; He ZG, 2016, NEURON, V90, P437, DOI 10.1016/j.neuron.2016.04.022; Herrera E, 2003, CELL, V114, P545, DOI 10.1016/S0092-8674(03)00684-6; Hong S, 2016, CURR OPIN NEUROBIOL, V36, P128, DOI 10.1016/j.conb.2015.12.004; Hong YK, 2014, NEURON, V84, P332, DOI 10.1016/j.neuron.2014.08.059; Hong YK, 2011, CURR OPIN NEUROBIOL, V21, P228, DOI 10.1016/j.conb.2011.02.007; Hooks BM, 2008, J NEUROSCI, V28, P4807, DOI 10.1523/JNEUROSCI.4667-07.2008; Hooks BM, 2007, NEURON, V56, P312, DOI 10.1016/j.neuron.2007.10.003; Hooks BM, 2006, NEURON, V52, P281, DOI 10.1016/j.neuron.2006.07.007; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Imai T, 2009, SCIENCE, V325, P585, DOI 10.1126/science.1173596; Isaacman-Beck J, 2015, NEURON, V88, P691, DOI 10.1016/j.neuron.2015.10.004; Jaubert-Miazza L, 2005, VISUAL NEUROSCI, V22, P661, DOI 10.1017/S0952523805225154; Jaworski A, 2015, SCIENCE, V350, P961, DOI 10.1126/science.aad2615; Jia ZQ, 2016, NEURAL REGEN RES, V11, P137, DOI 10.4103/1673-5374.175061; Jin KX, 2016, DEV NEUROBIOL, V76, P900, DOI 10.1002/dneu.22365; Jin XM, 2016, J BIOCHEM, V159, P491, DOI 10.1093/jb/mvw009; Kalia A, 2014, P NATL ACAD SCI USA, V111, P2035, DOI 10.1073/pnas.1311041111; KALIL K, 1986, J NEUROSCI, V6, P2563; Kaneko M, 2014, ELIFE, V3, DOI 10.7554/eLife.02798; Kay JN, 2011, J NEUROSCI, V31, P7753, DOI 10.1523/JNEUROSCI.0907-11.2011; Kim IJ, 2008, NATURE, V452, P478, DOI 10.1038/nature06739; King C, 2004, EXP NEUROL, V187, P380, DOI 10.1016/j.expneurol.2004.02.006; Kobayashi Y, 2015, NEURON, V86, P264, DOI 10.1016/j.neuron.2015.02.036; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Kurup N, 2015, CURR BIOL, V25, P1594, DOI 10.1016/j.cub.2015.04.061; Kuwajima T, 2012, NEURON, V74, P676, DOI 10.1016/j.neuron.2012.03.025; Lee HM, 2014, NATURE, V509, P195, DOI 10.1038/nature13154; LeGates TA, 2014, NAT REV NEUROSCI, V15, P443, DOI 10.1038/nrn3743; LeGates TA, 2012, NATURE, V491, P594, DOI 10.1038/nature11673; Li H, 2016, CELL REP, V16, P545, DOI 10.1016/j.celrep.2016.06.013; Li RW, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001135; Li S, 2015, NAT NEUROSCI, V18, P1737, DOI 10.1038/nn.4146; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Lim JHA, 2016, NAT NEUROSCI, V19, P1073, DOI 10.1038/nn.4340; Lindwall C, 2007, CURR OPIN NEUROBIOL, V17, P3, DOI 10.1016/j.conb.2007.01.008; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Lodato S, 2015, ANNU REV CELL DEV BI, V31, P699, DOI 10.1146/annurev-cellbio-100814-125353; Lom B, 1999, J NEUROSCI, V19, P9928; Lorenzana AO, 2015, NEURON, V86, P947, DOI 10.1016/j.neuron.2015.03.061; Lu DC, 2016, NEUROREHAB NEURAL RE, V30, P951, DOI 10.1177/1545968316644344; Luo LQ, 2007, NEURON, V56, P284, DOI 10.1016/j.neuron.2007.10.014; Luo XT, 2016, CELL REP, V15, P398, DOI 10.1016/j.celrep.2016.03.029; Luo XT, 2013, EXP NEUROL, V247, P653, DOI 10.1016/j.expneurol.2013.03.001; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; MASON C, 2014, VISUAL NEUROSCIENCES, P1317; Mason CA, 1997, CURR OPIN NEUROBIOL, V7, P647, DOI 10.1016/S0959-4388(97)80084-0; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Moore DL, 2009, SCIENCE, V326, P298, DOI 10.1126/science.1175737; Nahmani M, 2014, NEUROSCIENCE, V283, P4, DOI 10.1016/j.neuroscience.2014.04.029; Nakagawa S, 2000, NEURON, V25, P599, DOI 10.1016/S0896-6273(00)81063-6; Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009; Nawabi H, 2015, NEURON, V88, P704, DOI 10.1016/j.neuron.2015.10.005; Neves J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf3646; Niemi JP, 2016, EXP NEUROL, V275, P25, DOI 10.1016/j.expneurol.2015.09.018; Nikolaou N, 2015, NEURON, V88, P999, DOI 10.1016/j.neuron.2015.10.020; Nishiyama A, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00133; Nix P, 2014, J NEUROSCI, V34, P629, DOI 10.1523/JNEUROSCI.3859-13.2014; Ozel MN, 2015, ELIFE, V4, DOI 10.7554/eLife.10721; Omura T, 2015, NEURON, V86, P1215, DOI 10.1016/j.neuron.2015.05.005; Osterhout JA, 2015, NEURON, V86, P985, DOI 10.1016/j.neuron.2015.04.005; Osterhout JA, 2014, CELL REP, V8, P1006, DOI 10.1016/j.celrep.2014.06.063; Osterhout JA, 2011, NEURON, V71, P632, DOI 10.1016/j.neuron.2011.07.006; Pak W, 2004, CELL, V119, P567, DOI 10.1016/j.cell.2004.10.026; Parrinello S, 2010, CELL, V143, P145, DOI 10.1016/j.cell.2010.08.039; Peng SS, 2016, EXP EYE RES, V148, P90, DOI 10.1016/j.exer.2016.06.001; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Plas DT, 2005, J COMP NEUROL, V491, P305, DOI 10.1002/cne.20694; Poliak S, 2016, CELL, V164, P512, DOI 10.1016/j.cell.2015.12.049; Prins D, 2016, ACTA OPHTHALMOL, V94, P113, DOI 10.1111/aos.12825; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111; Richardson DS, 2015, CELL, V162, P246, DOI 10.1016/j.cell.2015.06.067; Rishal I, 2014, NAT REV NEUROSCI, V15, P32, DOI 10.1038/nrn3609; Robles E, 2014, CURR BIOL, V24, P2085, DOI 10.1016/j.cub.2014.07.080; Rodger J, 2004, MOL CELL NEUROSCI, V25, P56, DOI 10.1016/j.mcn.2003.09.010; Rodger J, 2001, EUR J NEUROSCI, V14, P1929, DOI 10.1046/j.0953-816x.2001.01822.x; Rousso DL, 2016, CELL REP, V15, P1930, DOI 10.1016/j.celrep.2016.04.069; Ruschel J, 2015, SCIENCE, V348, P347, DOI 10.1126/science.aaa2958; Ruthazer ES, 2010, TRENDS NEUROSCI, V33, P183, DOI 10.1016/j.tins.2010.01.003; Ruthazer ES, 2004, J NEUROBIOL, V59, P134, DOI 10.1002/neu.10344; Sakai JA, 2006, DEVELOPMENT, V133, P1035, DOI 10.1242/dev.02272; Sanchez-Arrones L, 2013, J NEUROSCI, V33, P8596, DOI 10.1523/JNEUROSCI.2083-12.2013; Sanchez-Camacho C, 2008, DEVELOPMENT, V135, P3531, DOI 10.1242/dev.023663; Sanes JR, 2015, ANNU REV NEUROSCI, V38, P221, DOI 10.1146/annurev-neuro-071714-034120; Schmidt TM, 2014, NEURON, V82, P781, DOI 10.1016/j.neuron.2014.03.022; Schwab ME, 2014, CURR OPIN NEUROBIOL, V27, P53, DOI 10.1016/j.conb.2014.02.011; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Shah RD, 2008, J NEUROSCI, V28, P292, DOI 10.1523/JNEUROSCI.4276-07.2008; Shanks JA, 2016, J NEUROSCI, V36, P5252, DOI 10.1523/JNEUROSCI.4599-15.2016; Shi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076347; Shigeoka T, 2016, CELL, V166, P181, DOI 10.1016/j.cell.2016.05.029; Shirkey NJ, 2012, DEV NEUROBIOL, V72, P628, DOI 10.1002/dneu.20967; Silver J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020602; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Sofroniew MV, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020420; Song YQ, 2015, NAT NEUROSCI, V18, P817, DOI 10.1038/nn.4019; Southwell DG, 2010, SCIENCE, V327, P1145, DOI 10.1126/science.1183962; Sridhar A, 2016, STEM CELL TRANSL MED, V5, P417, DOI 10.5966/sctm.2015-0093; Steward O, 2003, J COMP NEUROL, V459, P1, DOI 10.1002/cne.10593; Suetterlin P, 2014, NEURON, V84, P740, DOI 10.1016/j.neuron.2014.09.023; Sugitani K, 2016, ADV EXP MED BIOL, V854, P671, DOI 10.1007/978-3-319-17121-0_89; Sun LO, 2015, NEURON, V86, P971, DOI 10.1016/j.neuron.2015.03.064; Symonds ACE, 2007, EUR J NEUROSCI, V25, P744, DOI 10.1111/j.1460-9568.2007.05321.x; Takesian AE, 2013, PROG BRAIN RES, V207, P3, DOI 10.1016/B978-0-444-63327-9.00001-1; Tan LM, 2015, CELL, V163, P1756, DOI 10.1016/j.cell.2015.11.021; Tang YS, 2014, P NATL ACAD SCI USA, V111, P18339, DOI 10.1073/pnas.1421844112; Tedeschi A, 2016, NEURON IN PRESS; Thompson H, 2006, J NEUROSCI, V26, P8082, DOI 10.1523/JNEUROSCI.1342-06.2006; TORREALBA F, 1982, J COMP NEUROL, V211, P377, DOI 10.1002/cne.902110405; Tuszynski MH, 2012, NEURON, V74, P777, DOI 10.1016/j.neuron.2012.05.006; Ueki Y, 2015, P NATL ACAD SCI USA, V112, P13717, DOI 10.1073/pnas.1510595112; Vagge A, 2016, CURR OPIN OPHTHALMOL, V27, P380, DOI 10.1097/ICU.0000000000000293; Valakh V, 2015, NEUROBIOL DIS, V77, P13, DOI 10.1016/j.nbd.2015.02.014; Veldman MB, 2007, DEV BIOL, V312, P596, DOI 10.1016/j.ydbio.2007.09.019; Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472; Vigneswara V, 2015, MOL CELL NEUROSCI, V68, P212, DOI 10.1016/j.mcn.2015.08.001; Wada F, 2016, CELL REP, V15, P1329, DOI 10.1016/j.celrep.2016.04.021; Wang JC, 2016, INT WORKS DISCRETE, P291, DOI 10.1109/WODES.2016.7497862; Wang XX, 2015, INVEST OPHTH VIS SCI, V56, P1357, DOI 10.1167/iovs.14-15472; Watkins TA, 2013, P NATL ACAD SCI USA, V110, P4039, DOI 10.1073/pnas.1211074110; Weth F, 2014, SEMIN CELL DEV BIOL, V35, P126, DOI 10.1016/j.semcdb.2014.07.010; Williams RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118918; Williams SE, 2006, NEURON, V50, P535, DOI 10.1016/j.neuron.2006.03.037; Williams SE, 2003, NEURON, V39, P919, DOI 10.1016/j.neuron.2003.08.017; WILSON JR, 1984, PROC R SOC SER B-BIO, V221, P411, DOI 10.1098/rspb.1984.0042; Yan B, 2016, VISION RES, V121, P57, DOI 10.1016/j.visres.2016.01.006; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yoshimatsu T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10590; Yucel YH, 2003, PROG RETIN EYE RES, V22, P465, DOI 10.1016/S1350-9462(03)00026-0; Zhou J, 2013, P NATL ACAD SCI USA, V110, pE2714, DOI 10.1073/pnas.1310233110; Zivraj KH, 2010, J NEUROSCI, V30, P15464, DOI 10.1523/JNEUROSCI.1800-10.2010; Zou YX, 2015, J NEUROSCI, V35, P10429, DOI 10.1523/JNEUROSCI.1718-15.2015	199	34	35	0	24	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 19	2016	36	42					10707	10722		10.1523/JNEUROSCI.1711-16.2016			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE1BK	WOS:000389315300001	27798125	Bronze, Green Published			2022-02-06	
J	Caccese, JB; Lamond, LC; Buckley, TA; Kaminski, TW				Caccese, Jaclyn B.; Lamond, Lindsey C.; Buckley, Thomas A.; Kaminski, Thomas W.			Reducing purposeful headers from goal kicks and punts may reduce cumulative exposure to head acceleration	RESEARCH IN SPORTS MEDICINE			English	Article						Soccer; concussion; subconcussion; repetitive head impacts	FEMALE SOCCER PLAYERS; POSTURAL CONTROL; YOUTH SOCCER; CONCUSSION; INJURY; GENDER	The purpose of this study was to measure peak linear and rotational head acceleration in women's collegiate soccer and explore the variations in acceleration across different strategic scenarios. Game videos from 14 games were used to identify the strategic scenario in which the athlete headed the ball. Strategic scenarios included: bounce, secondary header, punt, throw-in, goal kick, corner kick, and kick. Peak linear and rotational accelerations were measured using the Smart Impact Monitor (Triax Technologies Inc., Norwalk, CT). Goal kick (38.8 +/- 19.4g, p=0.001, ss=8.9; 9.3 +/- 3.9krad/s(2), p=0.004, ss=1.9) and punt (36.0 +/- 15.1g, p=0.055, ss=6.3; 10.1 +/- 4.8krad/s(2), p=0.002, ss=2.5) impacts resulted in higher linear and rotational head accelerations than the base variable, kick (30.0 +/- 19.5g; 7.5 +/- 4.1krad/s(2)). This suggests that limiting headers from goal kicks and punts in younger athletes who are still learning proper heading technique may limit cumulative linear and rotational accelerations.	[Caccese, Jaclyn B.; Buckley, Thomas A.; Kaminski, Thomas W.] Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, 541 S Coll Ave, Newark, DE 19716 USA; [Caccese, Jaclyn B.; Lamond, Lindsey C.; Buckley, Thomas A.; Kaminski, Thomas W.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA		Caccese, JB (corresponding author), Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, 541 S Coll Ave, Newark, DE 19716 USA.	jcaccese@udel.edu	Buckley, Thomas A/B-7525-2016; Caccese, Jaclyn B./AAH-4571-2020	Buckley, Thomas A/0000-0002-0515-0150; Caccese, Jaclyn B./0000-0003-2329-3603			Babwah T, 2014, RES SPORTS MED, V22, P334, DOI 10.1080/15438627.2014.945644; Babwah TJ, 2014, RES SPORTS MED, V22, P327, DOI 10.1080/15438627.2014.944304; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2016, J ATHL TRAINING, V51, P511, DOI 10.4085/1062-6050-51.7.04; Caccese J. B., 2016, INT RES SCI SOCCER; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dorminy M, 2015, BRAIN INJURY, V29, P1158, DOI 10.3109/02699052.2015.1035324; Federation Internationale de Football Association, 2007, FIFA BIG COUNT 2006; Greig M, 2014, RES SPORTS MED, V22, P368, DOI 10.1080/15438627.2014.944300; Hammes D, 2015, RES SPORTS MED, V23, P215, DOI 10.1080/15438627.2015.1005295; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Irick E., 2015, SPORTS SPONSORSHIP P; Karton C, 2016, MEASUREMENT ACCURACY; King D, 2016, SPORTS MED, V46, P151, DOI 10.1007/s40279-015-0423-7; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Oeur R. A., 2016, IMPACT FREQUENCY VAL; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Ruestow PS, 2015, J OCCUP ENVIRON HYG, V12, P875, DOI 10.1080/15459624.2015.1072632; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Self BP, 2006, ENG SPORT 6, V6, P81; US Youth Soccer Association, 2014, KEY STAT MEMB STAT; Yang YT, 2016, JAMA PEDIATR, V170, P413, DOI 10.1001/jamapediatrics.2016.0338; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	36	34	34	2	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1543-8627	1543-8635		RES SPORTS MED	Res. Sports Med.	OCT-DEC	2016	24	4			SI		407	415		10.1080/15438627.2016.1230549			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EB8NX	WOS:000387648900011	27598519				2022-02-06	
J	Keller, U; van Hedel, HJA; Klamroth-Marganska, V; Riener, R				Keller, Urs; van Hedel, Hubertus J. A.; Klamroth-Marganska, Verena; Riener, Robert			ChARMin: The First Actuated Exoskeleton Robot for Pediatric Arm Rehabilitation	IEEE-ASME TRANSACTIONS ON MECHATRONICS			English	Article						Control engineering; medical robotics; pediatrics; robot kinematics; virtual reality	CEREBRAL-PALSY; MOTOR FUNCTION; CHILDREN; THERAPY; STABILITY	ChARMin is the first actuated exoskeleton robot for pediatric arm rehabilitation. The device was specifically designed to provide intensive rehabilitative training for children with affected arm motor function, e.g., due to cerebral palsy; therewith complementing conventional therapies. This paper gives a comprehensive overview of the ChARMin robot, which provides six actuated degrees of freedom, and is designed to cover the complete target group of children and adolescents aged 5-18 years. Moreover, the new audiovisual game-like interface is presented, which motivates active participation of the child. To support the child's arm movements with the exoskeleton, a patient-cooperative control strategy was implemented. The controller enables free arm movements, assistance-asneeded, and complete guidance of the arm. Five children aged 5-17 years with impaired arm motor function due to cerebral palsy, stroke, and traumatic brain injury tested the various training scenarios with different amounts of support, and robot settings depending on the therapeutic goals and the children's movement capabilities and preferences. These preliminary tests suggest that the ChARMin setup can be used as an advanced exercise tool for arm neurorehabilitation that optimally challenges children and adolescents with severely tomoderately affected armmotor functions.	[Keller, Urs; Klamroth-Marganska, Verena; Riener, Robert] Swiss Fed Inst Technol, Sensory Motor Syst Lab, CH-8092 Zurich, Switzerland; [Keller, Urs; Klamroth-Marganska, Verena; Riener, Robert] Univ Zurich, Univ Hosp Balgrist, CH-8008 Zurich, Switzerland; [Keller, Urs; van Hedel, Hubertus J. A.] Univ Childrens Hosp Zurich, Rehabil Ctr, CH-8910 Affoltern Am Albis, Switzerland		Keller, U (corresponding author), Swiss Fed Inst Technol, Sensory Motor Syst Lab, CH-8092 Zurich, Switzerland.; Keller, U (corresponding author), Univ Zurich, Univ Hosp Balgrist, CH-8008 Zurich, Switzerland.; Keller, U (corresponding author), Univ Childrens Hosp Zurich, Rehabil Ctr, CH-8910 Affoltern Am Albis, Switzerland.	urs.keller@kispi.uzh.ch; hubertus.vanhedel@kispi.uzh.ch; verena.klamroth@hest.ethz.ch; robert.riener@hest.ethz.ch	van Hedel, Hubertus/AAL-3818-2021; LUO, JINGJING/AAZ-6697-2021	LUO, JINGJING/0000-0002-3222-1276; van Hedel, Hubertus/0000-0002-9577-5049; Keller, Urs/0000-0001-6615-6452	Highly-Specialized Medicine Project of the Canton of Zurich; Gottfried und Julia Bangerter-Rhyner Foundation; Maxi Foundation; Gaydoul Foundation; National Centre of Competence in Research (NCCR) Neural Plasticity and RepairSwiss National Science Foundation (SNSF); Clinical Research Priority Program Neuro-Rehabilitation of the Medical Faculty of the University of Zurich; NCCR Robotics, Switzerland	This work was supported by the Highly-Specialized Medicine Project of the Canton of Zurich, by the Gottfried und Julia Bangerter-Rhyner Foundation, by the Maxi Foundation, by the Gaydoul Foundation, by the National Centre of Competence in Research (NCCR) Neural Plasticity and Repair, by the Clinical Research Priority Program Neuro-Rehabilitation of the Medical Faculty of the University of Zurich, and by NCCR Robotics, Switzerland.	Aisen ML, 2011, LANCET NEUROL, V10, P844, DOI 10.1016/S1474-4422(11)70176-4; ARMSTRONGHELOUVRY B, 1994, AUTOMATICA, V30, P1083, DOI 10.1016/0005-1098(94)90209-7; Boyd RN, 2001, EUR J NEUROL, V8, P150, DOI 10.1046/j.1468-1331.2001.00048.x; COLGATE JE, 1988, THESIS; Damiano DL, 2006, PHYS THER, V86, P1534, DOI 10.2522/ptj.20050397; Diolaiti N, 2006, IEEE T ROBOT, V22, P256, DOI 10.1109/TRO.2005.862487; Dominici N, 2012, NAT MED, V18, P1142, DOI 10.1038/nm.2845; Fasoli SE, 2008, AM J PHYS MED REHAB, V87, P929, DOI 10.1097/PHM.0b013e31818a6aa4; Fluet GG, 2010, DEV NEUROREHABIL, V13, P335, DOI 10.3109/17518423.2010.501362; Gilliaux M, 2015, NEUROREHAB NEURAL RE, V29, P183, DOI 10.1177/1545968314541172; GUIDALI M, 2011, P 2011 IEEE INT C RE, P00001, DOI DOI 10.1109/ICORR.2011.5975434; Guidali M, 2011, MED BIOL ENG COMPUT, V49, P1213, DOI 10.1007/s11517-011-0809-0; Hanna SE, 2009, DEV MED CHILD NEUROL, V51, P295, DOI 10.1111/j.1469-8749.2008.03196.x; Hogan N, 2006, J REHABIL RES DEV, V43, P605, DOI 10.1682/JRRD.2005.06.0103; Jarrasse N, 2012, IEEE T ROBOT, V28, P697, DOI 10.1109/TRO.2011.2178151; Keller U., 2012, AUT C, V286, P55; KELLER U, 2013, P IEEE 13 INT C REH, P1; Keller U, 2014, P IEEE RAS-EMBS INT, P530, DOI 10.1109/BIOROB.2014.6913832; Keller U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126948; Keller U, 2013, IEEE INT CONF ROBOT, P3908, DOI 10.1109/ICRA.2013.6631127; Kim H, 2012, IEEE T BIO-MED ENG, V59, P1770, DOI 10.1109/TBME.2012.2194489; Lo Albert C, 2012, Am J Phys Med Rehabil, V91, pS204, DOI 10.1097/PHM.0b013e31826bcfa3; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Martin AL, 2014, NEUROL REHABIL, V20, P215; Nef Tobias, 2009, Applied Bionics and Biomechanics, V6, P127, DOI 10.1080/11762320902840179; Nef T, 2007, MED BIOL ENG COMPUT, V45, P887, DOI 10.1007/s11517-007-0226-6; Negrello F, 2015, IEEE-RAS INT C HUMAN, P414, DOI 10.1109/HUMANOIDS.2015.7363567; Olson H. F., 1967, MUSIC PHYS ENG, P249; Oskoui M, 2013, DEV MED CHILD NEUROL, V55, P509, DOI 10.1111/dmcn.12080; Patton JL, 2006, EXP BRAIN RES, V168, P368, DOI 10.1007/s00221-005-0097-8; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Ryu JH, 2005, IEEE T CONTR SYST T, V13, P737, DOI 10.1109/TCST.2005.847336; Sakzewski L, 2014, J CHILD NEUROL, V29, P1077, DOI 10.1177/0883073814533150; Shikako-Thomas Keiko, 2008, Phys Occup Ther Pediatr, V28, P155, DOI 10.1080/01942630802031834; Siciliano B., 2008, SPRINGER HDB ROBOTIC; Stienen AHA, 2010, IEEE T BIO-MED ENG, V57, P728, DOI 10.1109/TBME.2009.2018628; Stienen AHA, 2009, IEEE T ROBOT, V25, P628, DOI 10.1109/TRO.2009.2019147; Ugurlu B, 2015, IEEE T HUM-MACH SYST, V45, P110, DOI 10.1109/THMS.2014.2362816; Vallery H, 2009, INT C REHAB ROBOT, P623, DOI 10.1109/ICORR.2009.5209595; VANDERSCHAFT A, 1999, L2 GAIN PASSIVITY NO	41	34	37	3	89	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1083-4435	1941-014X		IEEE-ASME T MECH	IEEE-ASME Trans. Mechatron.	OCT	2016	21	5					2201	2213		10.1109/TMECH.2016.2559799			13	Automation & Control Systems; Engineering, Manufacturing; Engineering, Electrical & Electronic; Engineering, Mechanical	Science Citation Index Expanded (SCI-EXPANDED)	Automation & Control Systems; Engineering	DU8OH	WOS:000382472600001					2022-02-06	
J	Makdissi, M; Davis, G				Makdissi, Michael; Davis, Gavin			The reliability and validity of video analysis for the assessment of the clinical signs of concussion in Australian football	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Football; Diagnosis; Sensitivity and specificity; Video analysis	HOCKEY LEAGUE NHL	Objectives: The objective of this study was to determine the reliability and validity of identifying clinical signs of concussion using video analysis in Australian football. Design: Prospective cohort study. Methods: All impacts and collisions potentially resulting in a concussion were identified during 2012 and 2013 Australian Football League seasons. Consensus definitions were developed for clinical signs associated with concussion. For intra- and inter-rater reliability analysis, two experienced clinicians independently assessed 102 randomly selected videos on two occasions. Sensitivity, specificity, positive and negative predictive values were calculated based on the diagnosis provided by team medical staff. Results: 212 incidents resulting in possible concussion were identified in 414 Australian Football League games. The intra-rater reliability of the video-based identification of signs associated with concussion was good to excellent. Inter-rater reliability was good to excellent for impact seizure, slow to get up, motor incoordination, ragdoll appearance (2 of 4 analyses), clutching at head and facial injury. Inter-rater reliability for loss of responsiveness and blank and vacant look was only fair and did not reach statistical significance. The feature with the highest sensitivity was slow to get up (87%), but this sign had a low specificity (19%). Other video signs had a high specificity but low sensitivity. Blank and vacant look (100%) and motor incoordination (81%) had the highest positive predictive value. Conclusions: Video analysis may be a useful adjunct to the side-line assessment of a possible concussion. Video analysis however should not replace the need for a thorough multimodal clinical assessment. (C) 2016 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Makdissi, Michael; Davis, Gavin] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Melbourne, Vic, Australia; [Makdissi, Michael] Federat Univ, ACRISP, Mt Helen, Australia; [Makdissi, Michael] La Trobe Univ, Sch Allied Hlth, Bundoora, Vic 3086, Australia; [Davis, Gavin] Austin Hosp, Dept Neurosurg, Heidelberg, Vic, Australia; [Davis, Gavin] Cabrini Hlth, Dept Neurosurg, Malvern, Australia		Makdissi, M (corresponding author), Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Melbourne, Vic, Australia.; Makdissi, M (corresponding author), Federat Univ, ACRISP, Mt Helen, Australia.; Makdissi, M (corresponding author), La Trobe Univ, Sch Allied Hlth, Bundoora, Vic 3086, Australia.	makdissi@unimelb.edu.au		makdissi, michael/0000-0003-0334-7133			Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; Gardner AJ, 2015, BRAIN INJURY, V17, P1; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158	14	34	34	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	OCT	2016	19	10					859	863		10.1016/j.jsams.2016.02.015			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DY2SZ	WOS:000384943600017	27009774				2022-02-06	
J	Phang, I; Zoumprouli, A; Papadopoulos, MC; Saadoun, S				Phang, Isaac; Zoumprouli, Argyro; Papadopoulos, Marios C.; Saadoun, Samira			Microdialysis to Optimize Cord Perfusion and Drug Delivery in Spinal Cord Injury	ANNALS OF NEUROLOGY			English	Article							ACUTE BRAIN-INJURY; CEREBRAL MICRODIALYSIS; INTRASPINAL PRESSURE; METHYLPREDNISOLONE; MANAGEMENT; SYSTEM; TRIAL; MATER; DURA	Objective: There is lack of monitoring from the injury site to guide management of patients with acute traumatic spinal cord injury. Here, we describe a bedside microdialysis monitoring technique for optimizing spinal cord perfusion and drug delivery at the injury site. Methods: Fourteen patients were recruited within 72 hours of severe spinal cord injury. We inserted intradurally at the injury site a pressure probe, to monitor continuously spinal cord perfusion pressure, and a microdialysis catheter, to monitor hourly glycerol, glutamate, glucose, lactate, and pyruvate. The pressure probe and microdialysis catheter were placed on the surface of the injured cord. Results: Microdialysis monitoring did not cause serious complications. Spinal cord perfusion pressure 90 to 100mm Hg and tissue glucose > 4.5mM minimized metabolic derangement at the injury site. Increasing spinal cord perfusion pressure by similar to 10mm Hg increased the entry of intravenously administered dexamethasone at the injury site 3-fold. Interpretation: This study determined the optimum spinal cord perfusion pressure and optimum tissue glucose concentration at the injury site. We also identified spinal cord perfusion pressure as a key determinant of drug entry into the injured spinal cord. Our findings challenge current guidelines, which recommend maintaining mean arterial pressure at 85 to 90mm Hg for a week after spinal cord injury. We propose that future drug trials for spinal cord injury include pressure and microdialysis monitoring to optimize spinal cord perfusion and maximize drug delivery at the injury site.	[Phang, Isaac; Papadopoulos, Marios C.; Saadoun, Samira] St Georges Univ London, Acad Neurosurg Unit, London, England; [Zoumprouli, Argyro] St George Hosp, Neurointens Care Unit, London, England		Saadoun, S (corresponding author), St Georges Univ London, Room 0-136,Jenner Wing, London SW17 0RE, England.	ssaadoun@sgul.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176; Saadoun, Samira/0000-0002-5480-5678; Zoumprouli, Argyro/0000-0003-0890-690X	Wings for Life Spinal Cord Research Foundation; Fletcher Fund; Neurosciences Research Foundation; London Deanery	Supported by research funds from Wings for Life Spinal Cord Research Foundation (S.S., M.C.P.), Fletcher Fund (M.C.P.), Neurosciences Research Foundation (M.C.P., I.P.), and London Deanery (I.P.).	Abrahamsson P, 2016, J SURG RES, V200, P480, DOI 10.1016/j.jss.2015.09.009; Abrahamsson P, 2011, CLIN PHYSIOL FUNCT I, V31, P175, DOI 10.1111/j.1475-097X.2010.00995.x; BALIS FM, 1987, J CLIN ONCOL, V5, P202, DOI 10.1200/JCO.1987.5.2.202; BERNARDS CM, 1990, ANESTHESIOLOGY, V73, P1214, DOI 10.1097/00000542-199012000-00020; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Dahyot-Fizelier C, 2013, ANTIMICROB AGENTS CH, V57, P2738, DOI 10.1128/AAC.02570-12; Fehlings MG, 2016, SPINAL CORD, V54, P8, DOI 10.1038/sc.2015.95; Fehlings MG, 2010, SPINE, V35, pS166, DOI 10.1097/BRS.0b013e3181f386f6; Frasca D, 2014, ANTIMICROB AGENTS CH, V58, P1019, DOI 10.1128/AAC.01760-13; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Kitagawa R, 2013, NEUROSURG CLIN N AM, V24, P417, DOI 10.1016/j.nec.2013.02.002; Kobayakawa K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009430; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Okon EB, 2013, J NEUROTRAUM, V30, P1564, DOI 10.1089/neu.2013.2956; Papadopoulos MC, 2015, NEUROSURGERY, V77, pE500, DOI 10.1227/NEU.0000000000000862; Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317; Phang I, 2016, SPINE, V41, pE605, DOI 10.1097/BRS.0000000000001334; Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6; Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668; Plock N, 2005, EUR J PHARM SCI, V25, P1, DOI 10.1016/j.ejps.2005.01.017; QUAN N, 1989, BRAIN RES BULL, V22, P621, DOI 10.1016/0361-9230(89)90080-4; Saadoun S, 2016, BRIT J NEUROSURG, V30, P1; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Shannon RJ, 2014, BRIT J CLIN PHARMACO, V78, P981, DOI 10.1111/bcp.12414; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Vandenabeele F, 1996, J ANAT, V189, P417; Varsos GV, 2015, J NEUROSURG-SPINE, V23, P763, DOI 10.3171/2015.3.SPINE14870; Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f; Werndle MC, 2016, ACTA NEUROCHIR SUPPL, V122, P323, DOI 10.1007/978-3-319-22533-3_64; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	36	34	34	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2016	80	4					522	531		10.1002/ana.24750			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ED0XZ	WOS:000388568700005	27463064	Green Accepted			2022-02-06	
J	Guo, L; Zhang, HY; Hou, YL; Wei, TS; Liu, J				Guo, Ling; Zhang, Hongyan; Hou, Yinglong; Wei, Tianshu; Liu, Ju			Plasmalemma vesicle-associated protein: A crucial component of vascular homeostasis	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						plasmalemma vesicle-associated protein-1; endothelial cell; diaphragms; permeability; homeostasis	FAMILIAL EXUDATIVE VITREORETINOPATHY; SPINAL-CORD-INJURY; FENESTRAL DIAPHRAGMS; GENE-EXPRESSION; PHENOTYPIC HETEROGENEITY; DIABETIC-RETINOPATHY; ENDOTHELIAL-CELLS; LYMPH-NODES; VEGF-A; PAL-E	Endothelial subcellular structures, including caveolae, fenestrae and transendothelial channels, are crucial for regulating microvascular function. Plasmalemma vesicle-associated protein (PLVAP) is an endothelial cell-specific protein that forms the stomatal and fenestral diaphragms of blood vessels and regulates basal permeability, leukocyte migration and angiogenesis. Loss of PLVAP in mice leads to premature mortality due to disrupted homeostasis. Evidence from previous studies suggested that PLVAP is involved in cancer, traumatic spinal cord injury, acute ischemic brain disease, transplant glomerulopathy, Norrie disease and diabetic retinopathy. Specifically, PLVAP expression has been demonstrated to be upregulated in these diseases, accompanied by pro-angiogenic or pro-inflammatory responses. Therefore, PLVAP is considered a novel therapeutic target, in addition to an endothelial cell marker. The present review summarizes the structure and functions of PLVAP, and its roles in pathophysiological processes.	[Guo, Ling; Liu, Ju] Shandong Univ, Shandong Prov Qianfoshan Hosp, Med Res Ctr, Lab Microvasc Med, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China; [Zhang, Hongyan] Taishan Med Univ, Dept Cardiovasc Med, Xintai City Peoples Hosp, Xintai 271200, Shandong, Peoples R China; [Hou, Yinglong] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Cardiol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China; [Wei, Tianshu] Univ Melbourne, Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic 3010, Australia		Liu, J (corresponding author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Med Res Ctr, Lab Microvasc Med, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.; Hou, YL (corresponding author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Cardiol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.	houyinglong2013@hotmail.com; ju.liu@sdu.edu.cn	Liu, Ju/Q-6319-2016	Liu, Ju/0000-0001-9932-2613	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81370269]; Shandong Taishan Scholarship	The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81370269). We are grateful for the support from the Shandong Taishan Scholarship, which was awarded to Dr Ju Liu.	Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; BEARER EL, 1985, J CELL BIOL, V100, P418, DOI 10.1083/jcb.100.2.418; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; Black GCM, 1999, HUM MOL GENET, V8, P2031, DOI 10.1093/hmg/8.11.2031; Carson-Walter EB, 2005, CLIN CANCER RES, V11, P7643, DOI 10.1158/1078-0432.CCR-05-1099; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; CHEN ZY, 1993, NAT GENET, V5, P180, DOI 10.1038/ng1093-180; Deharvengt SJ, 2012, J CELL MOL MED, V16, P2690, DOI 10.1111/j.1582-4934.2012.01587.x; Germain RN, 2012, SCIENCE, V336, P1676, DOI 10.1126/science.1221063; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; HALLMANN R, 1995, DEV DYNAM, V202, P325, DOI 10.1002/aja.1002020402; Herrnberger L, 2012, HISTOCHEM CELL BIOL, V138, P709, DOI 10.1007/s00418-012-0987-3; Hisatsune H, 2005, BLOOD, V105, P4657, DOI 10.1182/blood-2004-09-3554; Hnasko R, 2002, J ENDOCRINOL, V175, P649, DOI 10.1677/joe.0.1750649; Hnasko R, 2006, CELL CYCLE, V5, P2012, DOI 10.4161/cc.5.17.3216; Hofman P, 2001, OPHTHALMIC RES, V33, P156, DOI 10.1159/000055663; Hofman P, 2000, CURR EYE RES, V21, P637, DOI 10.1076/0271-3683(200008)21:2;1-V;FT637; Ichimura K, 2008, J AM SOC NEPHROL, V19, P1463, DOI 10.1681/ASN.2007101138; Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103; Joosten SA, 2005, KIDNEY INT, V68, P1, DOI 10.1111/j.1523-1755.2005.00376.x; Keuschnigg J, 2009, BLOOD, V114, P478, DOI 10.1182/blood-2008-11-188763; Klaassen I, 2009, EXP EYE RES, V89, P4, DOI 10.1016/j.exer.2009.01.006; Liu Y, 2010, J NEURO-ONCOL, V99, P13, DOI 10.1007/s11060-009-0105-0; Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05-0174; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; MILICI AJ, 1985, CIRC RES, V56, P709, DOI 10.1161/01.RES.56.5.709; Minshall R. D., 2006, V176, P107; Mozer AB, 2010, CURR NEUROVASC RES, V7, P238; Niemela H, 2005, BLOOD, V106, P3405, DOI 10.1182/blood-2005-01-0254; Rantakari P, 2015, NAT IMMUNOL, V16, P386, DOI 10.1038/ni.3101; Rostgaard J, 1997, MICROVASC RES, V53, P1, DOI 10.1006/mvre.1996.1987; Schafer NF, 2009, INVEST OPHTH VIS SCI, V50, P906, DOI 10.1167/iovs.08-1731; Shastry BS, 1997, HUM MUTAT, V9, P396, DOI 10.1002/(SICI)1098-1004(1997)9:5<396::AID-HUMU3>3.0.CO;2-2; Shue EH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-29; SIMIONESCU M, 1981, J CELL BIOL, V90, P614, DOI 10.1083/jcb.90.3.614; Stan RV, 2007, J CELL MOL MED, V11, P621, DOI 10.1111/j.1582-4934.2007.00075.x; Stan RV, 2012, DEV CELL, V23, P1203, DOI 10.1016/j.devcel.2012.11.003; Stan RV, 1999, J CELL BIOL, V145, P1189, DOI 10.1083/jcb.145.6.1189; Stan RV, 2004, MOL BIOL CELL, V15, P3615, DOI 10.1091/mbc.E03-08-0593; Stan RV, 2004, AM J PHYSIOL-HEART C, V286, pH1347, DOI 10.1152/ajpheart.00909.2003; Stan RV, 2001, GENOMICS, V72, P304, DOI 10.1006/geno.2000.6489; Stan RV, 1999, P NATL ACAD SCI USA, V96, P13203, DOI 10.1073/pnas.96.23.13203; Stan RV, 2005, BBA-MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008; Strickland LA, 2005, J PATHOL, V206, P466, DOI 10.1002/path.1805; Tichauer KM, 2014, MOL IMAGING BIOL, V16, P372, DOI 10.1007/s11307-013-0692-1; Tse D, 2010, SEMIN THROMB HEMOST, V36, P236, DOI 10.1055/s-0030-1253447; Wang YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-815; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; WILLIAMSON J, 1961, AM J PATHOL, V39, P239; Wisniewska-Kruk J, 2014, EXP EYE RES, V122, P123, DOI 10.1016/j.exer.2014.03.005; Wisniewska-Kruk J, 2012, EXP EYE RES, V96, P181, DOI 10.1016/j.exer.2011.12.003; Yamamoto I, 2007, AM J TRANSPLANT, V7, P1954, DOI 10.1111/j.1600-6143.2007.01876.x	53	34	34	5	14	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	SEP	2016	12	3					1639	1644		10.3892/etm.2016.3557			6	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	DU8EL	WOS:000382446000062	27602081	gold, Green Published, Green Submitted			2022-02-06	
J	Hanninen, T; Tuominen, M; Parkkari, J; Vartiainen, M; Ohman, J; Iverson, GL; Luoto, TM				Hanninen, Timo; Tuominen, Markku; Parkkari, Jari; Vartiainen, Matti; Ohman, Juha; Iverson, Grant L.; Luoto, Teemu M.			Sport concussion assessment tool-3rd edition - normative reference values for professional ice hockey players	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Head injuries; Baseline survey; Clinical assessment	BASE-LINE VALUES; HIGH-SCHOOL; SCAT2; STATEMENT; SIDELINE; HISTORY; MENS	Objectives: To determine normative reference values for the Sport Concussion Assessment Tool-3rd Edition (SCAT3) using a large sample of professional male ice hockey players. Design: A descriptive cross-sectional study. Methods: Preseason baseline testing was administered individually to 304 professional male ice hockey players. Results: The participants were aged between 16 and 40 with a mean (M) age of 25.3 years. Over 60% of the athletes reported previous concussion, almost 20% had been hospitalized or medically imaged following a head trauma. Of the players, 48% reported no symptoms. The symptom score median (Md) was 1.0 (M=1.5) and severity median was 1.0 (M=2.3). The median of the SAC score was 27.0 (M= 27.0). The median of the M-BESS was 1.0 (M=2.0). The Tandem gait median was 10.9 s (M=10.8 s). The most common baseline symptom was neck pain (24%). Delayed recall was the most difficult component of the SAC (Md=4); only 24% performed it flawlessly. All athletes completed the double-leg stance of the M-BESS without errors, but there was performance variability in the tandem stance (Md=0, M=0.6, range = 0-10) and single-leg stance (Md=1.0, M = 1.4, range = 0-10). Conclusions: Representative normative reference values for the SCAT3 among professional male ice hockey players are provided. (C) 2015 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Hanninen, Timo; Parkkari, Jari] UKK Inst Hlth Promot Res, Tampere Res Ctr Sports Med, Tampere, Finland; [Tuominen, Markku] Int Ice Hockey Federat IIHF, Med Comm, Zurich, Switzerland; [Tuominen, Markku] Liiga Finnish Ice Hockey Assoc, Liiga, Finland; [Tuominen, Markku] Medisport Ltd, Tampere, Finland; [Vartiainen, Matti] Univ Helsinki, Div Cognit Psychol & Neuropsychol, Inst Behav Sci, Helsinki, Finland; [Ohman, Juha; Luoto, Teemu M.] Tampere Univ Hosp, Dept Neurosurg, Tampere, Finland; [Iverson, Grant L.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Children Sport Concuss Program, Boston, MA 02114 USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Hanninen, T (corresponding author), UKK Inst Hlth Promot Res, Tampere Res Ctr Sports Med, Tampere, Finland.	timo.hanninen@fimnet.fi	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Ohman, Juha/0000-0002-6592-1367; Iverson, Grant/0000-0001-7348-9570	Finnish Ministry of Education and Culture and Finnish Hockey League; Finnish Hockey League; Finnish Ice Hockey Association (FIHA); Finnish Hockey Player Association (FHPA)	This study was financially supported by the Finnish Ministry of Education and Culture and Finnish Hockey League. We greatly appreciate the cooperation of all the team physicians and physiotherapists (Davies Paul, Huttunen Jussi, Hyde Jacob, Hamalainen Jari, Ikonen Juhani, Isotupa Juha, Kuosmanen Mika, Kuutamoinen Ville, Lahtinen Teppo, Mali Hero, Piekkola Ville, Pihkoluoma Tomi, Pohjonen Veli-Matti, Puustinen Vesa, Tikanto Jukka, Toivanen Tero, Tahkapaa Mikko, Uotila Toni, Vahtera Ville, Virtala Mika, Vaisanen Jonne) who volunteered their time to collect the data for this project. We sincerely thank Mr. Kari Tokola, M.Sc., for the statistical advice, Ms. Birgitta Jarvinen, M.Sc. for help in conducting literature searches and research assistant Anne Simi for her contribution in data collection. We would like to thank the Finnish Hockey League, Finnish Ice Hockey Association (FIHA) and Finnish Hockey Player Association (FHPA) for all their support. This study was partly presented at the Ice Hockey Summit II-Action on Concussion in Rochester, MN, USA, in October 2013.	Agel J, 2010, CAN J SURG, V53, P319; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruhe A, 2014, BRIT J SPORT MED, V48, P102, DOI 10.1136/bjsports-2012-091609; SCAT3, 2013, BRIT J SPORT MED, V47, P259; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; Swaine BR, 2005, ARCH PHYS MED REHAB, V86, P1665, DOI 10.1016/j.apmr.2004.11.021; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	29	34	34	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	AUG	2016	19	8					636	641		10.1016/j.jsams.2015.08.005			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DQ7FI	WOS:000379371900007	26383876				2022-02-06	
J	Mohr, NM; Harland, KK; Shane, DM; Miller, SL; Torner, JC				Mohr, Nicholas M.; Harland, Karisa K.; Shane, Dan M.; Miller, Sarah L.; Torner, James C.			Potentially Avoidable Pediatric Interfacility Transfer Is a Costly Burden for Rural Families: A Cohort Study	ACADEMIC EMERGENCY MEDICINE			English	Article							CARE; TELEMEDICINE; CHILDREN	Objectives: Interhospital transfer is a common strategy to provide high-quality regionalized care in rural emergency departments (EDs), but several reports have highlighted problems with selection of children for transfer. The purpose of this study is to characterize the burden of potentially avoidable transfer (PAT) and to estimate the medical and family-oriented costs associated with PAT. Methods: This study was a cohort study of all children treated in Iowa EDs between 2004 and 2013. PAT was defined as a child who was transferred and then either discharged from the receiving ED or admitted for <= 1 day, without having any separately billed procedures performed. Costs of care were estimated from 1) medical costs, 2) ambulance transfer, and 3) family costs (travel and lodging). Results: Over 10 years, 2,117,317 children were included (1% transferred to another hospital). Only 63% were transferred to a designated children's hospital, and PATs were identified in 39% of all transfers. PAT was associated with $909 in additional cost. The conditions most strongly associated with PAT were seizure (additional cost $1,138), fracture ($814), isolated traumatic brain injury without extra-axial bleeding ($1,455), respiratory infection ($556), and wheezing ($804). Few of these charges are attributable to nonmedical family costs ($21). Conclusions: Potentially avoidable pediatric interhospital transfer is common and is responsible for significant healthcare-related costs. Future work should focus on improving selection of children who benefit from interhospital transfer for high-yield conditions, to reduce the costly and distressing burden that PAT places on rural patients and their families. (C) 2016 by the Society for Academic Emergency Medicine	[Mohr, Nicholas M.; Harland, Karisa K.; Miller, Sarah L.] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA; [Shane, Dan M.; Torner, James C.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA		Mohr, NM (corresponding author), Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA.	nicholas-mohr@uiowa.edu	Mohr, Nicholas/N-1112-2017	Mohr, Nicholas/0000-0003-0497-5828; Harland, Karisa/0000-0001-9482-8447; Miller, Sarah/0000-0002-2726-962X	Children's Miracle Network; University of Iowa Carver College of Medicine; University of Iowa Stead Family Department of Pediatrics; University of Iowa Department of Emergency Medicine; Emergency Medicine Foundation; Federal Office of Rural Health Policy	This project was supported by a grant from the Children's Miracle Network, the University of Iowa Carver College of Medicine, the University of Iowa Stead Family Department of Pediatrics, and the University of Iowa Department of Emergency Medicine. Dr. Mohr is additionally supported by a grant from the Emergency Medicine Foundation and a grant from the Federal Office of Rural Health Policy.	[Anonymous], 2010, PED CAR RUR HOSP EM; Basco WT, 2013, PEDIATRICS, V132, P390, DOI 10.1542/peds.2013-1517; DeLia D, 2016, J PUBLIC HEALTH DENT, V76, P1, DOI 10.1111/jphd.12103; Feudtner C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e99; Gattu RK, 2014, PEDIATR EMERG CARE, V30, P26, DOI 10.1097/PEC.0000000000000061; Goudie A, 2014, PEDIATRICS, V133, pE1525, DOI 10.1542/peds.2013-3795; Groth H, 2013, WEST J EMERG MED, V14, P186, DOI 10.5811/westjem.2012.8.12783; Hernandez M, 2016, TELEMED E-HEALTH, V22, P51, DOI 10.1089/tmj.2015.0043; Krug SE, 2007, PEDIATRICS, V119, P161, DOI 10.1542/peds.2006-2900; Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65; Li J, 2012, PEDIATRICS, V130, P83, DOI 10.1542/peds.2011-1819; Miyamoto S, 2014, CHILD ABUSE NEGLECT, V38, P1533, DOI 10.1016/j.chiabu.2014.04.015; Ogola GO, 2016, J TRAUMA ACUTE CARE, V80, P265, DOI 10.1097/TA.0000000000000911; Sullivan AF, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-13; Wiebe RA, 2000, PEDIATRICS, V105, P647; Yang NH, 2015, MED DECIS MAKING; Yang Nikki H, 2015, Pediatr Crit Care Med, V16, pe59, DOI 10.1097/PCC.0000000000000337	17	34	34	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2016	23	8					885	894		10.1111/acem.12972			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DW1BQ	WOS:000383378200006	27018337				2022-02-06	
J	Parola, A; Gabbatore, I; Bosco, FM; Bara, BG; Cossa, FM; Gindri, P; Sacco, K				Parola, Alberto; Gabbatore, Ilaria; Bosco, Francesca M.; Bara, Bruno G.; Cossa, Federico M.; Gindri, Patrizia; Sacco, Katiuscia			Assessment of pragmatic impairment in right hemisphere damage	JOURNAL OF NEUROLINGUISTICS			English	Article						Communication; Assessment; Right hemisphere damage; Non-verbal; ABaCo; Pragmatic	TRAUMATIC BRAIN-INJURY; RIGHT CEREBRAL HEMISPHERE; EXECUTIVE FUNCTIONS; EMOTIONAL PROSODY; COMMUNICATION; DISCOURSE; MIND; LANGUAGE; NEUROPRAGMATICS; COMPREHENSION	Aim of the present study is to provide a multifocal assessment of pragmatic abilities in patients with right hemisphere damage (RHD). Pragmatics refers to the ability to use language and non-verbal expressive means (e.g., gestures) to convey meaning in a given context, and it also involves the appropriate use of connotative elements such as rhythm and prosody. Patients with RHD frequently report a wide range of pragmatic disorders: despite the heterogeneity of their clinical profiles, these difficulties can seriously undermine their ability to effectively communicate in everyday situations. We analysed the performance of 17 patients with RHD and 17 healthy controls using the Assessment Battery for Communication, a clinical tool for assessing a wide range of pragmatic phenomena both in comprehension and production- and considering different expressive means. The results suggest patients have difficulties both in comprehending and producing pragmatic phenomena of differing complexity; in particular, patients seem to be significantly impaired when dealing with non-verbal modality, i.e., gestures and facial expressions. Moreover a hierarchical cluster analysis revealed the presence of a number of clusters corresponding to different outcomes of pragmatic performance, in line with the heterogeneity of communicative profiles following RHD frequently reported in the literature. (C) 2015 Elsevier Ltd. All rights reserved.	[Parola, Alberto; Gabbatore, Ilaria; Bosco, Francesca M.; Bara, Bruno G.; Sacco, Katiuscia] Univ Turin, Dept Psychol, Ctr Cognit Sci, I-10124 Turin, Italy; [Bosco, Francesca M.; Bara, Bruno G.; Sacco, Katiuscia] Neurosci Inst Turin, Turin, Italy; [Cossa, Federico M.] Fdn Salvatore Maugeri, Dipartimento Riabilitaz Neurol, Turin, Italy; [Gindri, Patrizia] Presidio Sanit San Camillo, Turin, Italy; [Sacco, Katiuscia] Brain Imaging Grp, Turin, Italy; [Gabbatore, Ilaria] Univ Oulu, Fac Humanities, Child Language Res Ctr, POB 1000, Oulu 90014, Finland		Gabbatore, I (corresponding author), Univ Oulu, Fac Humanities, Child Language Res Ctr, POB 1000, Oulu 90014, Finland.	ilaria.gabbatore@oulu.fi	Parola, alberto/AAK-3748-2020; bosco, francesca marina/B-6746-2013; Gabbatore, Ilaria/AAC-1925-2019	bosco, francesca marina/0000-0001-6101-8587; Gabbatore, Ilaria/0000-0002-9724-8066; PAROLA, ALBERTO/0000-0002-6039-0907			AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1207/s15516709cog1702_2; ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R., 2015, BATTERIA ASSESSMENT; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; [Anonymous], 2014, MINERVA PSICHIATRICA; Bambini V, 2011, BRAIN RES BULL, V86, P203, DOI 10.1016/j.brainresbull.2011.07.015; Bara B. G., 2011, EUROPEAN PERSPECTIVE, P1; Bara BG, 2000, BRAIN LANG, V71, P10, DOI 10.1006/brln.1999.2198; Bara Bruno, 2010, COGNITIVE PRAGMATICS; Bartels-Tobin LR, 2005, J NEUROLINGUIST, V18, P461, DOI 10.1016/j.jneuroling.2005.04.001; Beeman MJ, 2000, BRAIN LANG, V71, P310, DOI 10.1006/brln.1999.2268; Blake ML, 2007, AM J SPEECH-LANG PAT, V16, P331, DOI 10.1044/1058-0360(2007/037); Blake ML, 2006, AM J SPEECH-LANG PAT, V15, P255, DOI 10.1044/1058-0360(2006/024); Blake ML, 2009, J SPEECH LANG HEAR R, V52, P359, DOI 10.1044/1092-4388(2009/07-0012); BOSCO FM, 2006, ENCY LANGUAGE LINGUI, P546; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COGN PSYCHOL, V24, P525, DOI 10.1080/20445911.2012.658156; Bosco FM, 2009, J COGN SCI, V10, P245; Bosco FM, 2012, J COMMUN DISORD, V45, P290, DOI 10.1016/j.jcomdis.2012.03.002; BROWNELL HH, 1992, BRAIN LANG, V43, P121, DOI 10.1016/0093-934X(92)90025-A; BRUNDAGE S, 1996, CLIN APHASIOLOGY, V24, P215; Bryan K., 1995, RIGHT HEMISPHERE LAN, V2nd ed.; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Champagne-Lavau M, 2009, J NEUROLINGUIST, V22, P413, DOI 10.1016/j.jneuroling.2009.02.002; Chantraine Y, 1998, J NEUROLINGUIST, V11, P21, DOI 10.1016/S0911-6044(98)00003-7; Cheang HS, 2006, CLIN LINGUIST PHONET, V20, P447, DOI 10.1080/02699200500135684; Cocks N, 2007, APHASIOLOGY, V21, P299, DOI 10.1080/02687030600911393; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Cote H, 2007, APHASIOLOGY, V21, P739, DOI 10.1080/02687030701192331; Cummings L., 2014, PRAGMATIC DISORDERS; Cutica I, 2006, BRAIN LANG, V98, P12, DOI 10.1016/j.bandl.2006.01.001; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Gardner H, 1986, RIGHT HEMISPHERE COM; GARDNER H, 1983, COGNITIVE PROCESSING, P37; Goodglass H, 1983, ASSESSMENT APHASIA R; Griffin R, 2006, LATERALITY, V11, P195, DOI 10.1080/13576500500450552; Hird K, 2003, CLIN LINGUIST PHONET, V17, P309, DOI 10.1080/0269920031000080037; Joanette Y., 1990, RIGHT HEMISPHERE VER; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; Kasher Asa, 1991, CHOMSKYAN TURN, P122; KRAUSS RM, 1991, J PERS SOC PSYCHOL, V61, P743, DOI 10.1037/0022-3514.61.5.743; Krauss RM, 1998, CURR DIR PSYCHOL SCI, V7, P54, DOI 10.1111/1467-8721.ep13175642; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Levinson SC, 1983, PRAGMATICS CAMBRIDGE; MACKENZIE C, 2001, ADV SPEECH LANGUAGE, V3, P81, DOI DOI 10.3109/14417040109003716; MacSweeney M, 2008, TRENDS COGN SCI, V12, P432, DOI 10.1016/j.tics.2008.07.010; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2012, SEMIN SPEECH LANG, V33, P68, DOI 10.1055/s-0031-1301164; Mason R.A., 2006, HDB PSYCHOLINGUISTIC, P765, DOI DOI 10.1016/B978-012369374-7/50020-1; McDonald S, 2000, BRAIN LANG, V75, P82, DOI 10.1006/brln.2000.2342; Myers PS, 2001, APHASIOLOGY, V15, P913, DOI 10.1080/02687040143000285; MYERS PS, 1999, RIGHT HEMISPHERE DIS; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Papagno C, 2006, NEUROPSYCHOLOGY, V20, P598, DOI 10.1037/0894-4105.20.5.598; Pell MD, 1998, NEUROPSYCHOLOGIA, V36, P701, DOI 10.1016/S0028-3932(98)00008-6; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; Pell MD, 1999, BRAIN LANG, V69, P161, DOI 10.1006/brln.1999.2065; Rainville C, 2003, NEUROCASE, V9, P356, DOI 10.1076/neur.9.4.356.15548; Rinaldi M. C., 2004, BLED SANTALUCIA BATT; Sabbagh MA, 1999, BRAIN LANG, V70, P29, DOI 10.1006/brln.1999.2139; Sacco K, 2008, J COGN SCI, V9, P111; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Sherratt S, 2012, J NEUROLINGUIST, V25, P213, DOI 10.1016/j.jneuroling.2012.01.001; Spinnler H., 1987, ITALIAN J NEUROLOGIC, V6, P20; Tompkins C.A., 1995, RIGHT HEMISPHERE COM; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; Tompkins CA, 1999, APHASIOLOGY, V13, P725, DOI 10.1080/026870399401830; TOMPKINS CA, 2002, HDB ADULT LANGUAGE D, P429; Tompkins CA, 2012, ARCH PHYS MED REHAB, V93, pS61, DOI 10.1016/j.apmr.2011.10.015; Vaissiere J, 2005, BLACKW HBK LINGUIST, P236, DOI 10.1002/9780470757024.ch10; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Xu J, 2009, P NATL ACAD SCI USA, V106, P20664, DOI 10.1073/pnas.0909197106; Zaidel E, 2002, BRAIN LANG, V80, P510, DOI 10.1006/brln.2001.2612	79	34	34	0	27	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0911-6044			J NEUROLINGUIST	J. Neurolinguist.	AUG	2016	39						10	25		10.1016/j.jneuroling.2015.12.003			16	Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Linguistics; Neurosciences & Neurology; Psychology	DO5NL	WOS:000377829700002					2022-02-06	
J	Cariou, A; Deye, N; Vivien, B; Richard, O; Pichon, N; Bourg, A; Huet, L; Buleon, C; Frey, J; Asfar, P; Legriel, S; Narcisse, S; Mathonnet, A; Cravoisy, A; Dequin, PF; Wiel, E; Razazi, K; Daubin, C; Kimmoun, A; Lamhaut, L; Marx, JS; de la Garanderie, DP; Ecollan, P; Combes, A; Spaulding, C; Barat, F; Ben Boutieb, M; Coste, J; Chiche, JD; Pene, F; Mira, JP; Treluyer, JM; Hermine, O; Carli, P				Cariou, Alain; Deye, Nicolas; Vivien, Benoit; Richard, Olivier; Pichon, Nicolas; Bourg, Angele; Huet, Loic; Buleon, Clement; Frey, Jerome; Asfar, Pierre; Legriel, Stephane; Narcisse, Sophie; Mathonnet, Armelle; Cravoisy, Aurelie; Dequin, Pierre-Francois; Wiel, Eric; Razazi, Keyvan; Daubin, Cedric; Kimmoun, Antoine; Lamhaut, Lionel; Marx, Jean-Sebastien; de la Garanderie, Didier Payen; Ecollan, Patrick; Combes, Alain; Spaulding, Christian; Barat, Florence; Ben Boutieb, Myriam; Coste, Joel; Chiche, Jean-Daniel; Pene, Frederic; Mira, Jean-Paul; Treluyer, Jean-Marc; Hermine, Olivier; Carli, Pierre		Epo-ACR-02 Study Grp	Early High-Dose Erythropoietin Therapy After Out-of-Hospital Cardiac Arrest A Multicenter, Randomized Controlled Trial	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY			English	Article						For a supplemental figure; please see the online version of this article	PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION; TRAUMATIC BRAIN-INJURY; COMATOSE SURVIVORS; RESUSCITATION; ISCHEMIA; RATS; CARE; CARDIOPULMONARY; NEUROPROTECTION	BACKGROUND Preliminary data suggested a clinical benefit in treating out-of-hospital cardiac arrest (OHCA) patients with a high dose of erythropoietin (Epo) analogs. OBJECTIVES The authors aimed to evaluate the efficacy of epoetin alfa treatment on the outcome of OHCA patients in a phase 3 trial. METHODS The authors performed a multicenter, single-blind, randomized controlled trial. Patients still comatose after a witnessed OHCA of presumed cardiac origin were eligible. In the intervention group, patients received 5 intravenous injections spaced 12 h apart during the first 48 h (40,000 units each, resulting in a maximal dose of 200,000 total units), started as soon as possible after resuscitation. In the control group, patients received standard care without Epo. The main endpoint was the proportion of patients in each group reaching level 1 on the Cerebral Performance Category (CPC) scale (survival with no or minor neurological sequelae) at day 60. Secondary endpoints included all-cause mortality rate, distribution of patients in CPC levels at different time points, and side effects. RESULTS In total, 476 patients were included in the primary analysis. Baseline characteristics were similar in the 2 groups. At day 60, 32.4% of patients (76 of 234) in the intervention group reached a CPC 1 level, as compared with 32.1% of patients (78 of 242) in the control group (odds ratio: 1.01; 95% confidence interval: 0.68 to 1.48). The mortality rate and proportion of patients in each CPC level did not differ at any time points. Serious adverse events were more frequent in Epo-treated patients as compared with controls (22.6% vs. 14.9%; p = 0.03), particularly thrombotic complications (12.4% vs. 5.8%; p = 0.01). CONCLUSIONS In patients resuscitated from an OHCA of presumed cardiac cause, early administration of erythropoietin plus standard therapy did not confer a benefit, and was associated with a higher complication rate. (High Dose of Erythropoietin Analogue After Cardiac Arrest [Epo-ACR-02]; NCT00999583) (C) 2016 by the American College of Cardiology Foundation.	[Cariou, Alain; Chiche, Jean-Daniel; Pene, Frederic; Mira, Jean-Paul] Cochin Hosp, AP HP, Med Intens Care Unit, 27 Rue Faubourg St Jacques, F-75679 Paris 1, France; [Cariou, Alain; Vivien, Benoit; Spaulding, Christian; Coste, Joel; Chiche, Jean-Daniel; Pene, Frederic; Mira, Jean-Paul; Treluyer, Jean-Marc; Hermine, Olivier; Carli, Pierre] Paris Descartes Univ, Paris, France; [Cariou, Alain; Lamhaut, Lionel; Spaulding, Christian] Paris Descartes Univ, Parisian Cardiovasc Res Ctr, INSERM, U970,Team 4, Paris, France; [Deye, Nicolas] Lariboisiere Hosp, AP HP, Med Intens Care Unit, Paris, France; [Deye, Nicolas] INSERM, U942, Paris, France; [Vivien, Benoit; Lamhaut, Lionel; Marx, Jean-Sebastien; Carli, Pierre] Hop Necker Enfants Malad, AP HP, SAMU 75, Paris, France; [Richard, Olivier] Ctr Hosp Versailles, SAMU 78, Versailles, France; [Pichon, Nicolas] CHU Dupuytren, Med ICU, Limoges, France; [Bourg, Angele] SAMU 87, Limoges, France; [Bourg, Angele] CHU Dupuytren, Limoges, France; [Huet, Loic] Henri Mondor Hosp, AP HP, SAMU 94, Creteil, France; [Buleon, Clement] CHU Caen, SAMU, Pole Reanimat, Anesthesie, F-14000 Caen, France; [Frey, Jerome] CHU Nancy, SAMU 54, Nancy, France; [Asfar, Pierre] CHU Angers, Reanimat Med & Med Hyperbare, Angers, France; [Legriel, Stephane] Ctr Hosp Versailles, Med ICU, Versailles, France; [Narcisse, Sophie] Hop La Source, SAMU 45, Orleans, France; [Mathonnet, Armelle] Ctr Hosp Reg Orleans, Hop La Source, Med Surg Intens Care Unit, Orleans, France; [Cravoisy, Aurelie] CHU Nancy, Med ICU, Nancy, France; [Dequin, Pierre-Francois] Univ Tours, INSERM, Med ICU, U1100, Tours, France; [Dequin, Pierre-Francois] CRICS Grp, Tours, France; [Wiel, Eric] Lille Univ Hosp, Emergency Dept, Lille, France; [Wiel, Eric] Lille Univ Hosp, SAMU 59, Lille, France; [Razazi, Keyvan] Hop Henri Mondor, AP HP, Med ICU, F-94010 Creteil, France; [Daubin, Cedric] CHU Caen, Dept Med Intens Care, F-14000 Caen, France; [Kimmoun, Antoine] CHU Nancy, Serv Reanimat Med Brabois, Vandoeuvre Les Nancy, France; [Lamhaut, Lionel] Necker Univ Hosp, AP HP, Intens Care Unit, Paris, France; [de la Garanderie, Didier Payen] Lariboisiere Univ Hosp, AP HP, SMUR Surg Intens Care, Paris, France; [de la Garanderie, Didier Payen] Univ Paris 07, Univ Denis Diderot, Paris, France; [Ecollan, Patrick] AP HP, SMUR Pitie Salpetriere, Paris, France; [Combes, Alain] Univ Paris 06, Hop La Pitie Salpetriere, AP HP, Inst Cardiometab & Nutr,INSERM,iCAN,UMRS 1166,Med, Paris, France; [Spaulding, Christian] Cochin Univ Hosp, AP HP, Dept Cardiol, Paris, France; [Barat, Florence] AP HP, Cent Pharm, Clin Trial Unit, Paris, France; [Ben Boutieb, Myriam; Coste, Joel] Hop Hotel Dieu, AP HP, Biostat & Epidemiol Unit, Paris, France; [Treluyer, Jean-Marc] Paris Ctr, Clin Res Unit, Paris, France; [Treluyer, Jean-Marc] Paris Descartes Univ, Paris, France; [Hermine, Olivier] Hop Necker Enfants Malad, AP HP, INSERM, CNRS,Imagine Inst,U1123,Erl 8654,Dept Hematol, Paris, France		Cariou, A (corresponding author), Cochin Hosp, AP HP, Med Intens Care Unit, 27 Rue Faubourg St Jacques, F-75679 Paris 1, France.	alain.cariou@aphp.fr	Hermine, Olivier/Q-7072-2018; Chiche, Jean-Daniel/P-5220-2017; Lamhaut, Lionel/AAM-8449-2021; Legriel, Stephane/J-1307-2017	Chiche, Jean-Daniel/0000-0002-6433-6254; Lamhaut, Lionel/0000-0003-4160-9456; Legriel, Stephane/0000-0003-4782-6734; Pene, Frederic/0000-0003-3639-3849; Hermine, Olivier/0000-0003-2574-3874	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [PHRC-AOM P 071217]; Baxter [NCT02068287]	This work was funded by a research grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC-AOM P 071217). Dr. Kimmoun has received a grant from Baxter for the Esmosepsis clinical trial (NCT02068287) and fees for a consultancy activity. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Carli and Hermine contributed equally to this work. Previous presentations: Annual Meeting of the European Society of Intensive Care Medicine, Barcelona, Spain, October 2014.	ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; Bennett CL, 2008, JAMA-J AM MED ASSOC, V299, P914, DOI 10.1001/jama.299.8.914; Bottiger BW, 2008, NEW ENGL J MED, V359, P2651, DOI 10.1056/NEJMoa070570; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cariou A, 2008, RESUSCITATION, V76, P397, DOI 10.1016/j.resuscitation.2007.10.003; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Dumas F, 2010, CIRC-CARDIOVASC INTE, V3, P200, DOI 10.1161/CIRCINTERVENTIONS.109.913665; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Genc S, 2004, RESTOR NEUROL NEUROS, V22, P105; Grmec S, 2009, RESUSCITATION, V80, P631, DOI 10.1016/j.resuscitation.2009.03.010; Joffre J, 2014, RESUSCITATION, V85, P769, DOI 10.1016/j.resuscitation.2014.02.013; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Leuchter RHV, 2014, JAMA-J AM MED ASSOC, V312, P817, DOI 10.1001/jama.2014.9645; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; Morrison LJ, 2010, CIRCULATION, V122, P8345, DOI 10.1161/CIRCULATIONAHA.110.971051; Najjar SS, 2011, JAMA-J AM MED ASSOC, V305, P1863, DOI 10.1001/jama.2011.592; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Olsen NV, 2003, CLIN INFECT DIS, V37, pS323, DOI 10.1086/376912; Ott I, 2010, CIRC-CARDIOVASC INTE, V3, P408, DOI 10.1161/CIRCINTERVENTIONS.109.904425; Popp E, 2007, RESUSCITATION, V74, P344, DOI 10.1016/j.resuscitation.2007.01.019; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Suh JW, 2011, INT J CARDIOL, V149, P216, DOI 10.1016/j.ijcard.2010.02.002	32	34	34	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0735-1097	1558-3597		J AM COLL CARDIOL	J. Am. Coll. Cardiol.	JUL 5	2016	68	1					40	49		10.1016/j.jacc.2016.04.040			10	Cardiac & Cardiovascular Systems	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	DP5IB	WOS:000378528400007	27364049	Bronze			2022-02-06	
J	Shahan, CP; Magnotti, LJ; McBeth, PB; Weinberg, JA; Croce, MA; Fabian, TC				Shahan, Charles P.; Magnotti, Louis J.; McBeth, Paul B.; Weinberg, Jordan A.; Croce, Martin A.; Fabian, Timothy C.			Early antithrombotic therapy is safe and effective in patients with blunt cerebrovascular injury and solid organ injury or traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	29th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		Blunt cerebrovascular injury; antithrombotic therapy; traumatic brain injury; solid organ injury; bleeding complications	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CAROTID INJURIES; FOLLOW-UP; OUTCOMES; ANTICOAGULATION; ACCURACY; DIAGNOSIS	BACKGROUND: Early antithrombotic therapy (AT) is the mainstay of treatment in the management of blunt cerebrovascular injury (BCVI). Despite this, optimal timing of initiation of AT in patients with BCVI in the presence of concomitant traumatic brain injury (TBI) or solid organ injury (SOI) remains controversial. The purpose of this study was to evaluate the impact of early initiation of AT on outcomes in patients with BCVI and TBI and/or SOI. METHODS: Patients with BCVI and concomitant TBI and/or SOI over 6 years were identified. Aspirin and/or clopidogrel or low-intensity heparin infusion (AT) was instituted in all patients immediately upon diagnosis of BCVI. Cessation of AT, worsening TBI, the need for delayed operative intervention, ischemic stroke, and mortality were reviewed and compared. Worsening of TBI or delayed operative intervention for SOI were compared with those of patients without BCVI treated at the same institution during the study period. RESULTS: A total of 119 patients (74 with TBI, 26 with SOI, and 19 with both) were identified. Seventy-one percent were treated with heparin infusion (goal activated partial thromboplastin time, 45-60 seconds), and 29% received antiplatelet therapy alone. When compared with patients without BCVI, there was no difference in worsening of TBI (9% vs. 10% with no BCVI, p = 0.75) or need for delayed operative intervention for SOI (7% vs. 5% with no BCVI, p = 0.61). No patients required cessation of AT. A total of 11 patients (9%) experienced a BCVI-related stroke. CONCLUSION: Initiation of early AT for patients with BCVI and concomitant TBI or SOI does not increase risk of worsening TBI or SOI above baseline. Close monitoring is required, but our results suggest that appropriate antiplatelet or heparin therapy should not be withheld in patients with BCVI and concomitant TBI or SOI. In fact, prompt treatment with either antiplatelet or heparin therapy remains the mainstay for prevention of stroke-related morbidity and mortality in these patients. (J Trauma Acute Care Surg. 2016; 81: 173-177. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.)	[Shahan, Charles P.; Magnotti, Louis J.; McBeth, Paul B.; Weinberg, Jordan A.; Croce, Martin A.; Fabian, Timothy C.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA		Magnotti, LJ (corresponding author), Dept Surg, 910 Madison Ave,Suite 220, Memphis, TN 38163 USA.	lmagnotti@uthsc.edu					Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Byrnes MC, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-25; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; DiCocco JM, 2013, J TRAUMA ACUTE CARE, V74, P955, DOI 10.1097/TA.0b013e318287800f; DiCocco JM, 2011, J AM COLL SURGEONS, V212, P549, DOI 10.1016/j.jamcollsurg.2010.12.035; Edwards NM, 2007, J AM COLL SURGEONS, V204, P1007, DOI 10.1016/j.jamcollsurg.2006.12.041; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Kitagawa RS, 2013, J NEUROSURG, V119, P324, DOI 10.3171/2013.5.JNS1397; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; Mutze S, 2005, RADIOLOGY, V237, P884, DOI 10.1148/radiol.2373042189; Paulus EM, 2014, J TRAUMA ACUTE CARE, V76, P279, DOI 10.1097/TA.0000000000000101; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146	17	34	34	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2016	81	1					173	177		10.1097/TA.0000000000001058			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	DS5BV	WOS:000380796400027	27027559				2022-02-06	
J	Failla, MD; Juengst, SB; Arenth, PM; Wagner, AK				Failla, Michelle D.; Juengst, Shannon B.; Arenth, Patricia M.; Wagner, Amy K.			Preliminary Associations Between Brain-Derived Neurotrophic Factor, Memory Impairment, Functional Cognition, and Depressive Symptoms Following Severe TBI	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; depression; cognitive impairment; BDNF; biomarker; rehabilomics	FACTOR BDNF; BLOOD-BRAIN; INDEPENDENCE MEASURE; EXECUTIVE FUNCTION; FUTURE-DIRECTIONS; SELF-AWARENESS; OLDER-ADULTS; SHORT-TERM; INJURY; SERUM	Background. Traumatic brain injury (TBI) often leads to mood and cognitive complications, affecting functional recovery. Understanding neurobiological alterations common in post-TBI depression (PTD) and cognition may identify novel biomarkers for TBI complications. Brain-derived neurotrophic factor (BDNF) is a likely target based on evidence of reduced BDNF signaling in experimental TBI and depression models and its role in learning and memory. Objective. To evaluate BDNF as a biomarker for PTD, cognitive impairment, and functional cognition in a prospective cohort with severe TBI. Methods. Participants with TBI (n = 113) were evaluated for PTD (Patient Health Questionnaire-9 [PHQ-9]), cognitive impairment (cognitive composite score), and functional cognition (Functional Independence Measure-Cognition, FIM-Cog). BDNF levels were measured in cerebrospinal fluid and serum at 0 to 6 days postinjury and in serum at 6 and 12 months postinjury. Results. Serum BDNF was reduced after TBI versus controls at all time points. Acute serum BDNF positively correlated with memory composites (6 months: r = 0.43, P = .019, n = 30; 12 months: r = 0.53, P = .005, n = 26) and FIM-Memory scores (6 months: r = 0.35, P = .019, n = 45; 12 months: r = 0.38, P = .018, n = 38). Acute serum BDNF negatively correlated with 12-month PHQ-9 scores (r = -0.38; P = .044; n = 29). At 12 months, chronic serum BDNF tended to be lower in participants with PTD (P = .07) and correlated with PHQ-9 scores (r = -0.41; P = .019; n = 32). Conclusions. Acute BDNF associations with memory recovery may implicate hippocampal damage/degeneration. Comparatively, BDNF associations with PTD status were not as strong as associations with PTD severity. Further investigation may delineate longitudinal BDNF patterns, and BDNF responsive treatments, reflecting mood and cognitive recovery following TBI.	[Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Juengst, Shannon B.; Arenth, Patricia M.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Neurosci, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Juengst, Shannon B/AAC-5891-2019; Failla, Michelle/AAI-3788-2021	Juengst, Shannon B/0000-0003-4709-545X; Failla, Michelle/0000-0001-9734-3373	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162]; NIDRR [H133A120087]; University of Pittsburgh Women's Studies Faculty Research Fund [CDC R49 CCR 323155];  [DODW81XWH-071-0701]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by NIH R01 HD048162; NIDRR H133A120087; DODW81XWH-071-0701; CDC R49 CCR 323155, University of Pittsburgh Women's Studies Faculty Research Fund.	Alonso M, 2002, HIPPOCAMPUS, V12, P551, DOI 10.1002/hipo.10035; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Bekinschtein P, 2008, P NATL ACAD SCI USA, V105, P2711, DOI 10.1073/pnas.0711863105; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x; Dawood T, 2007, MOL PSYCHIATR, V12, P981, DOI 10.1038/sj.mp.4002059; Dawson JD, 2010, J AM GERIATR SOC, V58, P1090, DOI 10.1111/j.1532-5415.2010.02872.x; Delis D.C., 2000, CALIFORNIA VERBAL LE; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Failla MD, 2015, J HEAD TRAUMA REHAB, V30, pE54, DOI 10.1097/HTR.0000000000000118; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fleming J, 1999, BRAIN INJURY, V13, P417; Gass P, 2010, INT J NEUROPSYCHOPH, V13, P1, DOI 10.1017/S1461145709991039; Gotlib IH, 2010, ANNU REV CLIN PSYCHO, V6, P285, DOI 10.1146/annurev.clinpsy.121208.131305; Goverover Y, 2014, BRAIN INJURY, V28, P174, DOI 10.3109/02699052.2013.860474; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griffin EW, 2011, PHYSIOL BEHAV, V104, P934, DOI 10.1016/j.physbeh.2011.06.005; Gunstad J, 2008, J GERIATR PSYCH NEUR, V21, P166, DOI 10.1177/0891988708316860; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hashimoto K, 2010, PSYCHIAT CLIN NEUROS, V64, P341, DOI 10.1111/j.1440-1819.2010.02113.x; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Juengst S, 2013, ARCH PHYS MED REHAB, V94, P74, DOI 10.1016/j.apmr.2012.07.025; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Karege F, 2005, BIOL PSYCHIAT, V57, P1068, DOI 10.1016/j.biopsych.2005.01.008; Karege F, 2002, PSYCHIAT RES, V109, P143, DOI 10.1016/S0165-1781(02)00005-7; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; Larsson J, 2013, J REHABIL MED, V45, P765, DOI 10.2340/16501977-1184; Levin RL, 2007, COGNITIVE THER RES, V31, P211, DOI 10.1007/s10608-007-9128-z; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nettiksimmons J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091339; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Osterrieth P, 1944, ARCH PSYCHOL, V20, P206; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Petzold A, 2015, NEUROBIOL LEARN MEM, V120, P52, DOI 10.1016/j.nlm.2015.02.009; Piccinni A, 2008, J AFFECT DISORDERS, V105, P279, DOI 10.1016/j.jad.2007.05.005; Pittenger C, 2008, NEUROPSYCHOPHARMACOL, V33, P88, DOI 10.1038/sj.npp.1301574; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Reitan R, 1985, HALSTEAD REITAN NEUR; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Siuciak JA, 1997, PHARMACOL BIOCHEM BE, V56, P131, DOI 10.1016/S0091-3057(96)00169-4; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Terracciano A, 2013, WORLD J BIOL PSYCHIA, V14, P583, DOI 10.3109/15622975.2011.616533; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; van Veelen NMJ, 2010, SCHIZOPHR RES, V120, P191, DOI 10.1016/j.schres.2010.04.011; Dias VV, 2009, BIPOLAR DISORD, V11, P663, DOI 10.1111/j.1399-5618.2009.00733.x; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wise EK, 2012, ARCH PHYS MED REHAB, V93, P1319, DOI 10.1016/j.apmr.2012.05.009; Yang LL, 2011, INT J GERIATR PSYCH, V26, P495, DOI 10.1002/gps.2552; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	77	34	35	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUN	2016	30	5					419	430		10.1177/1545968315600525			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DL6BR	WOS:000375723200004	26276123	Green Accepted			2022-02-06	
J	Hendrickson, CM; Howard, BM; Kornblith, LZ; Conroy, AS; Nelson, MF; Zhuo, HJ; Liu, KD; Manley, GT; Matthay, MA; Calfee, CS; Cohen, MJ				Hendrickson, Carolyn M.; Howard, Benjamin M.; Kornblith, Lucy Z.; Conroy, Amanda S.; Nelson, Mary F.; Zhuo, Hanjing; Liu, Kathleen D.; Manley, Geoffrey T.; Matthay, Michael A.; Calfee, Carolyn S.; Cohen, Mitchell J.			The acute respiratory distress syndrome following isolated severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury (TBI); acute respiratory distress syndrome (ARDS); platelet transfusion; crystalloid	ACUTE LUNG INJURY; MULTIPLE ORGAN FAILURE; PLATELET TRANSFUSION; BLOOD-TRANSFUSION; BLUNT TRAUMA; COAGULOPATHY; PLASMA; RISK; DYSFUNCTION; MORTALITY	BACKGROUND Acute respiratory distress syndrome (ARDS) is common after traumatic brain injury (TBI) and is associated with worse neurologic outcomes and longer hospitalization. However, the incidence and associated causes of ARDS in isolated TBI have not been well studied. METHODS We performed a subgroup analysis of 210 consecutive patients with isolated severe TBI enrolled in a prospective observational cohort at a Level 1 trauma center between 2005 and 2014. Subjects required endotracheal intubation and had isolated severe TBI defined by a head Abbreviated Injury Scale (AIS) score of 3 or greater and AIS score lower than 3 in all other categories. ARDS within the first 8 days of admission was rigorously adjudicated using Berlin criteria. Regression analyses were used to test the association between predictors of interest and ARDS. RESULTS The incidence of ARDS in the first 8 days after severe isolated TBI was 30%. Patients who developed ARDS were administered more crystalloids (4.3 L vs. 3.5 L, p = 0.005) and blood products in the first 12 hours of admission. Patients with ARDS had significantly worse clinical outcomes measured at 28 days, including longer median intensive care unit and hospital stays (4 days vs. 13 days, p < 0.001, and 7.5 days vs. 14.5 days, p < 0.001, respectively). In unadjusted logistic regression analyses, the odds of developing ARDS were significantly associated with head AIS score (odds ratio [OR], 1.8; p = 0.018), male sex (OR, 2.9; p = 0.012), and early transfusion of platelets (OR, 2.8; p = 0.003). These associations were similar in a multivariate logistic regression model. CONCLUSION In the era of balanced hemostatic resuscitation practices, severity of head injury, male sex, early crystalloids, and early transfusion of platelets are associated with a higher risk of ARDS after severe isolated TBI. Early transfusion of platelets after severe TBI may be a modifiable risk factor for ARDS, and these findings invite further investigation into causal mechanisms driving this observed association. LEVEL OF EVIDENCE Prognostic/epidemiologic study, level III.	[Hendrickson, Carolyn M.; Zhuo, Hanjing; Matthay, Michael A.; Calfee, Carolyn S.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit CareMedicine, San Francisco, CA USA; [Hendrickson, Carolyn M.; Zhuo, Hanjing; Matthay, Michael A.; Calfee, Carolyn S.] Univ Calif San Francisco, Dept Anesthesia, Div Pulm & Crit CareMedicine, San Francisco, CA USA; [Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, Div Nephrol & Crit Care Med, San Francisco, CA USA; [Liu, Kathleen D.] Univ Calif San Francisco, Dept Anesthesia, Div Nephrol & Crit Care Med, San Francisco, CA USA; [Howard, Benjamin M.; Kornblith, Lucy Z.; Conroy, Amanda S.; Nelson, Mary F.; Cohen, Mitchell J.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA		Cohen, MJ (corresponding author), San Francisco Gen Hosp, Dept Surg, Ward 3A,1001 Potrero Ave, San Francisco, CA 94110 USA.	mcohen@sfghsurg.ucsf.edu		Liu, Kathleen/0000-0003-4891-8649	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM-085689, HL090833, HL110969, 5T32HL007185-37, 1F32HL124911-01]; DoDUnited States Department of Defense [W911NF-10-1-0384]; PICORI [ME-1306-02735, R37 HL51856]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL090833, F32HL124911, R37HL051856, R01HL110969, T32HL007185, K23HL133495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM085689] Funding Source: NIH RePORTER	This study was supported by NIH GM-085689 and DoD W911NF-10-1-0384 (to M.J.C.), NIH HL090833 and HL110969 (to C.S.C.), PICORI ME-1306-02735 (to G.M.), R37 HL51856 (M.A.M. and K.D.L.), as well as NIH 5T32HL007185-37 and 1F32HL124911-01 (to C.M.H.)	Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Calfee CS, 2011, AM J RESP CRIT CARE, V183, P1660, DOI 10.1164/rccm.201011-1802OC; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Centers for Disease Control and Prevention, 2017, INJ PREV CONTR TRAUM; Chaiwat O, 2009, ANESTHESIOLOGY, V110, P351, DOI 10.1097/ALN.0b013e3181948a97; Chi X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044829; Christie JD, 2003, CHEST, V124, P1232, DOI 10.1378/chest.124.4.1232; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Croce MA, 2005, J TRAUMA, V59, P19, DOI 10.1097/01.TA.0000171459.21450.DC; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; Faul M, 2010, TRAUMATIC BRAIN INJU; Hendrickson CM, 2015, J TRAUMA ACUTE CARE, V79, P417, DOI 10.1097/TA.0000000000000760; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holena DN, 2012, J TRAUMA ACUTE CARE, V73, P825, DOI 10.1097/TA.0b013e318256de38; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Howard BM, 2015, J TRAUMA ACUTE CARE, V78, P735, DOI 10.1097/TA.0000000000000583; Kemp CD, 2008, AM SURGEON, V74, P866; Kim DY, 2015, J NEUROTRAUM, V32, P1815, DOI 10.1089/neu.2014.3728; Larsen AM, 2015, TRANSFUSION MED, V25, P174, DOI 10.1111/tme.12209; Lingappan K, 2013, TOXICOL APPL PHARM, V272, P281, DOI 10.1016/j.taap.2013.06.007; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Marik PE, 2008, CRIT CARE MED, V36, P3080, DOI 10.1097/CCM.0b013e31818c3801; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; Miller PR, 2002, AM SURGEON, V68, P845; Miller PR, 2002, AM SURGEON, V68, P50; Ortiz-Munoz G, 2014, BLOOD, V124, P2625, DOI 10.1182/blood-2014-03-562876; Plurad D, 2007, J TRAUMA, V63, P1, DOI 10.1097/TA.0b013e318068b1ed; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Salim A, 2008, INJURY, V39, P30, DOI 10.1016/j.injury.2007.06.015; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; Schmidt ME, 1997, NEUROPSYCHOPHARMACOL, V16, P298, DOI 10.1016/S0893-133X(96)00264-3; Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135; Silverboard H, 2005, J TRAUMA, V59, P717, DOI 10.1097/01.ta.0000174919.35240.21; Spiess BD, 2004, TRANSFUSION, V44, P1143, DOI 10.1111/j.1537-2995.2004.03322.x; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932; Vlaar APJ, 2010, BLOOD, V116, P1360, DOI 10.1182/blood-2009-10-248732; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Wu B, 2014, TRANSFUSION MED, V24, P400, DOI 10.1111/tme.12162; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	51	34	35	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2016	80	6					989	997		10.1097/TA.0000000000000982			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	DO5MX	WOS:000377828300028	26881489	Green Accepted			2022-02-06	
J	Oliver, JM; Jones, MT; Kirk, KM; Gable, DA; Repshas, JT; Johnson, TA; Andreasson, U; Norgren, N; Blennow, K; Zetterberg, H				Oliver, Jonathan M.; Jones, Margaret T.; Kirk, K. Michele; Gable, David A.; Repshas, Justin T.; Johnson, Torie A.; Andreasson, Ulf; Norgren, Niklas; Blennow, Kaj; Zetterberg, Henrik			Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; HEAD TRAUMA; NEUROFILAMENT LIGHT; DHA	DIFFUSE AXONAL INJURY; IMPACT EXPOSURE; BRAIN-INJURY; BODY-COMPOSITION; SPORTS-MEDICINE; DIVISION-I; EXERCISE; BLOOD; SIZE	Purpose American football athletes are exposed to subconcussive impacts over the course of the season resulting in elevations in serum neurofilament light (NFL), a biomarker of axonal injury. Docosahexaenoic acid (DHA) has been reported to reduce axonal trauma associated with traumatic brain injury in rodent models. However, the optimal dose in American football athletes is unknown. This study examined the effect of differing doses of DHA on serum NFL over the course of a season of American football. Methods In a randomized, double-blind, placebo-controlled, parallel design, 81 National Collegiate Athletic Association Division I American football athletes were assigned to ingest either 2, 4, 6 gd(-1) of DHA or placebo. Blood was sampled at specific times over the course of 189 d, coincident with changes in intensity, hours of contact, and likely changes in head impacts. Standardized magnitude-based inference was used to define outcomes. Results DHA supplementation increased plasma DHA in a dose-dependent manner (2 gd(-1): mean difference from baseline; 90% CL; 2 gd(-1): 1.3; +/- 0.6; 4 gd(-1): 1.6; +/- 0.7%; 6 gd(-1): 2.8; +/- 1.2%). Serum NFL increased to a greater extent in starters (area under the curve, 1995 +/- 1383 pgmL(-1)) versus nonstarters (1398 +/- 581 pgmL(-1); P = 0.024). Irrespective of dose, supplemental DHA likely attenuated serum NFL coincident with increases in serum NFL by likely small and moderate magnitude (effect size = 0.4-0.7). Conclusions Findings from this study, the first large-scale study examining potential prophylactic use of DHA in American football athletes, include identification of optimal dose of DHA, suggesting a neuroprotective effect of DHA supplementation.	[Oliver, Jonathan M.; Kirk, K. Michele; Gable, David A.; Repshas, Justin T.; Johnson, Torie A.] Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, TCU Box 297730, Ft Worth, TX 76129 USA; [Jones, Margaret T.] George Mason Univ, Div Hlth & Human Performance, Manassas, VA USA; [Kirk, K. Michele; Gable, David A.] Texas Christian Univ, Dept Sport Med, Ft Worth, TX 76129 USA; [Kirk, K. Michele] John Peter Smith Hosp, Dept Sport Med, Ft Worth, TX 76104 USA; [Norgren, Niklas] UmanDiagnostics, Umea, Sweden; [Andreasson, Ulf; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England		Oliver, JM (corresponding author), Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, TCU Box 297730, Ft Worth, TX 76129 USA.	jonathan.oliver@tcu.edu			DSM Nutritional Products; Office of the Provost for Texas Christian University; College of Education and Human Development at George Mason University; Swedish Research CouncilSwedish Research CouncilEuropean Commission; VINNOVAVinnova; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Frimurarestiftelsen	Supplements were provided by DSM Nutritional Products. Support for this study was received from the following: DSM Nutritional Products, Office of the Provost for Texas Christian University, the College of Education and Human Development at George Mason University, Swedish Research Council, VINNOVA, the Knut and Alice Wallenberg Foundation, Frimurarestiftelsen.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams TH, 2010, BRIT J NUTR, V103, P91, DOI 10.1017/S0007114509991516; Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Ervin R Bethene, 2004, Adv Data, P1; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Melvin MN, 2014, J STRENGTH COND RES, V28, P3320, DOI 10.1519/JSC.0000000000000651; Mori TA, 1999, HYPERTENSION, V34, P253, DOI 10.1161/01.HYP.34.2.253; Mori TA, 2000, AM J CLIN NUTR, V71, P1085; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Nikolaidis MG, 2004, SPORTS MED, V34, P1051, DOI 10.2165/00007256-200434150-00004; Oliver JM, 2012, J ATHL TRAINING, V47, P257, DOI 10.4085/1062-6050-47.3.12; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schober ME, 2015, J NEUROTRAUM, V32, P1; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tuor UI, 2014, NEUROIMAGE-CLIN, V6, P32, DOI 10.1016/j.nicl.2014.08.003; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Yamamoto Joelle B, 2008, Res Sports Med, V16, P111, DOI 10.1080/15438620802103320; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	40	34	34	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2016	48	6					974	982		10.1249/MSS.0000000000000875			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DM8MO	WOS:000376617900002	26765633	Green Submitted			2022-02-06	
J	Imbach, LL; Buchele, F; Valko, PO; Li, TZ; Maric, A; Stover, JF; Bassetti, CL; Mica, L; Werth, E; Baumann, CR				Imbach, Lukas L.; Buchele, Fabian; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Stover, John F.; Bassetti, Claudio L.; Mica, Ladislav; Werth, Esther; Baumann, Christian R.			Sleep-wake disorders persist 18 months after traumatic brain injury but remain underrecognized	NEUROLOGY			English	Article							DISTURBANCES; INSOMNIA; NEED	Objective:This study is a prospective, controlled clinical and electrophysiologic trial examining the chronic course of posttraumatic sleep-wake disturbances (SWD).Methods:We screened 140 patients with acute, first-ever traumatic brain injury of any severity and included 60 patients for prospective follow-up examinations. Patients with prior brain trauma, other neurologic or systemic disease, drug abuse, or psychiatric comorbidities were excluded. Eighteen months after trauma, we performed detailed sleep assessment in 31 participants. As a control group, we enrolled healthy individuals without prior brain trauma matched for age, sex, and sleep satiation.Results:In the chronic state after traumatic brain injury, sleep need per 24 hours was persistently increased in trauma patients (8.1 0.5 hours) as compared to healthy controls (7.1 +/- 0.7 hours). The prevalence of chronic objective excessive daytime sleepiness was 67% in patients with brain trauma compared to 19% in controls. Patients significantly underestimated excessive daytime sleepiness and sleep need, emphasizing the unreliability of self-assessments on SWD in trauma patients.Conclusions:This study provides prospective, controlled, and objective evidence for chronic persistence of posttraumatic SWD, which remain underestimated by patients. These results have clinical and medicolegal implications given that SWD can exacerbate other outcomes of traumatic brain injury, impair quality of life, and are associated with public safety hazards.	[Imbach, Lukas L.; Buchele, Fabian; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Werth, Esther; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland; [Stover, John F.; Mica, Ladislav] Univ Zurich Hosp, Dept Traumatol, Zurich, Switzerland; [Bassetti, Claudio L.] Inselspital Bern, Dept Neurol, Bern, Switzerland		Imbach, LL (corresponding author), Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland.	lukas.imbach@usz.ch	Werth, E/AAN-7955-2021	Maric, Angelina/0000-0002-1416-6728; Baumann, Christian/0000-0003-3417-1978; Buechele, Fabian/0000-0001-7091-1676; Werth, Esther/0000-0002-5099-3122; Bassetti, Claudio/0000-0002-4535-0245; Imbach, Lukas/0000-0002-6135-8642	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [SNF 125504]; Clinical Research Priority Program Sleep and Health of the University of Zurich	This study was supported by the Swiss National Science Foundation (SNF 125504) and the Clinical Research Priority Program Sleep and Health of the University of Zurich.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Cippa MAT, 2013, J SLEEP RES, V22, P589, DOI 10.1111/jsr.12053; Drake C, 2010, SLEEP, V33, P745, DOI 10.1093/sleep/33.6.745; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298	17	34	35	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 24	2016	86	21					1945	1949		10.1212/WNL.0000000000002697			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DN3KD	WOS:000376959900008	27164676	Green Accepted, Green Published			2022-02-06	
J	Tian, RF; Hou, ZG; Hao, SY; Wu, WC; Mao, X; Tao, XG; Lu, T; Liu, BY				Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Wu, Weichuan; Mao, Xiang; Tao, Xiaogang; Lu, Te; Liu, Baiyun			Hydrogen-rich water attenuates brain damage and inflammation after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Anti-inflammatory; Controlled cortical impact; Hydrogen-rich water; Neuroprotective effect; Traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; REDUCING OXIDATIVE STRESS; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; PROINFLAMMATORY CYTOKINE; MICROGLIAL ACTIVATION; SEPTIC ENCEPHALOPATHY; PARKINSONS-DISEASE; REPERFUSION INJURY; MODEL	Inflammation and oxidative stress are the two major causes of apoptosis after traumatic brain injury (TBI). Most previous studies of the neuroprotective effects of hydrogen-rich water on TBI primarily focused on antioxidant effects. The present study investigated whether hydrogen-rich water (HRW) could attenuate brain damage and inflammation after traumatic brain injury in rats. A TBI model was induced using a controlled cortical impact injury. HRW or distilled water was injected intraperitoneally daily following surgery. We measured survival rate, brain edema, blood-brain barrier (BBB) breakdown and neurological dysfunction in all animals. Changes in inflammatory cytokines, inflammatory cells and Cho/Cr metabolites in brain tissues were also detected. Our results demonstrated that TBI-challenged rats exhibited significant brain injuries that were characterized by decreased survival rate and increased BBB permeability, brain edema, and neurological dysfunction, while HRW treatment ameliorated the consequences of TBI. HRW treatment also decreased the levels of pro-inflammatory cytokines (TNF-alpha, IL-1 beta and HMGB1), inflammatory cell number (Iba1) and inflammatory metabolites (Cho) and increased the levels of an anti-inflammatory cytokine (IL-10) in the brain tissues of TBI-challenged rats. In conclusion, HRW could exert a neuroprotective effect against TBI and attenuate inflammation, which suggests HRW as an effective therapeutic strategy for TBI patients. (C) 2016 Published by Elsevier B.V.	[Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Tao, Xiaogang; Lu, Te; Liu, Baiyun] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Tao, Xiaogang; Lu, Te; Liu, Baiyun] China Natl Clin Res Ctr Neurol Dis, Beijing 100050, Peoples R China; [Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Tao, Xiaogang; Lu, Te; Liu, Baiyun] Beijing Key Lab Cent Nervous Syst Injury, Beijing 100050, Peoples R China; [Wu, Weichuan] Baoan Cent Hosp, Dept Neurosurg, Shenzhen 518102, Peoples R China; [Mao, Xiang] Anhui Med Univ, Dept Neurosurg, Affiliated Hosp 1, Hefei 230000, Peoples R China; [Liu, Baiyun] Capital Med Univ, Beijing Neurosurg Inst, Neurotrauma Lab, Beijing 100050, Peoples R China; [Liu, Baiyun] Beijing Inst Brain Disorders, Nerve Injury & Repair Ctr, Beijing 100050, Peoples R China; [Liu, Baiyun] Gen Hosp Armed Police Forces, Dept Neurotrauma, Beijing 100039, Peoples R China		Liu, BY (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Tiantan Xili 6, Beijing 100050, Peoples R China.	liubaiyun1212@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171144, 81471238]; Beijing Nova programBeijing Municipal Science & Technology Commission [XX2012033]; National Key Technology Research and Development Program of the Ministry of Science and Technology of ChinaNational Key Technology R&D Program [2013BAI09B03]; Beijing Institute for Brain Disorders [BIBD-PXM2013_014226_07_000084]	We would like to acknowledge the assistance of Feifan Xu and Xuetao Chen for their support of this study. This study was supported by National Natural Science Foundation of China (No. 81171144 and No. 81471238), Beijing Nova program (No. XX2012033), National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2013BAI09B03) and Beijing Institute for Brain Disorders (BIBD-PXM2013_014226_07_000084). We also thank Beijing Huoli Qingyuan Co, Ltd. (China) for their assistance in providing the hydrogen-rich water.	Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048; Calabresi P, 2013, LANCET NEUROL, V12, P811, DOI 10.1016/S1474-4422(13)70118-2; Chavan SS, 2012, MOL MED, V18, P930, DOI 10.2119/molmed.2012.00195; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Elkind MSV, 2010, STROKE, V41, pS3, DOI 10.1161/STROKEAHA.110.594945; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fu Y, 2009, NEUROSCI LETT, V453, P81, DOI 10.1016/j.neulet.2009.02.016; Fukuda KI, 2007, BIOCHEM BIOPH RES CO, V361, P670, DOI 10.1016/j.bbrc.2007.07.088; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; George JF, 2010, KIDNEY INT, V77, P85, DOI 10.1038/ki.2009.432; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Han L, 2015, BRAIN RES, V1615, P129, DOI 10.1016/j.brainres.2015.04.038; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hayashida K, 2014, CIRCULATION, V130, P2173, DOI 10.1161/CIRCULATIONAHA.114.011848; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Hu N, 2014, BRAIN RES, V1551, P13, DOI 10.1016/j.brainres.2014.01.015; Huang WC, 2010, CYTOKINE, V51, P119, DOI 10.1016/j.cyto.2010.02.021; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; Kadowaki T, 2007, NEUROSCI LETT, V411, P26, DOI 10.1016/j.neulet.2006.07.079; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kumar A., 2015, J NEUROTRAUMA; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee HF, 2012, RESP PHYSIOL NEUROBI, V182, P1, DOI 10.1016/j.resp.2012.01.016; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishioku T, 2009, CELL MOL NEUROBIOL, V29, P309, DOI 10.1007/s10571-008-9322-x; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Price WS, 1996, J MAGN RESON SER B, V112, P190, DOI 10.1006/jmrb.1996.0129; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Pytel P, 2009, CURR OPIN NEUROL, V22, P283, DOI 10.1097/WCO.0b013e32832b3101; Saghaei E, 2013, NEUROSCI RES, V75, P316, DOI 10.1016/j.neures.2013.01.010; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Sha YG, 2008, J IMMUNOL, V180, P2531, DOI 10.4049/jimmunol.180.4.2531; SHARIEF MK, 1992, J NEUROIMMUNOL, V38, P27, DOI 10.1016/0165-5728(92)90087-2; Sheu JN, 2013, COMP IMMUNOL MICROB, V36, P137, DOI 10.1016/j.cimid.2012.11.002; Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Suda S, 2013, EUR J PHARMACOL, V707, P26, DOI 10.1016/j.ejphar.2013.03.020; Sun QA, 2011, CRIT CARE MED, V39, P765, DOI 10.1097/CCM.0b013e318206bf44; Tian RF, 2015, BRAIN RES, V1622, P339, DOI 10.1016/j.brainres.2015.06.039; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zweckberger K, 2011, NEUROL RES, V33, P875, DOI 10.1179/1743132811Y.0000000017	55	34	41	3	35	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2016	1637						1	13		10.1016/j.brainres.2016.01.029			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DK0NY	WOS:000374610700001	26826009				2022-02-06	
J	Dams-O'Connor, K; Gibbons, LE; Landau, A; Larson, EB; Crane, PK				Dams-O'Connor, Kristen; Gibbons, Laura E.; Landau, Alexandra; Larson, Eric B.; Crane, Paul K.			Health Problems Precede Traumatic Brain Injury in Older Adults	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY			English	Article						traumatic brain injury; health; older adults	RISK; AGE; DISEASE; EPIDEMIOLOGY; MORTALITY; DEMENTIA; FALLS	ObjectivesTo evaluate whether indices of preinjury health and functioning are associated with risk of incident traumatic brain injury (TBI) with loss of consciousness (LOC) and to evaluate health-related factors associated with mortality in individuals with incident TBI. DesignProspective community cohort study. SettingGroup Health, Seattle, Washington. ParticipantsIndividuals aged 65 and older with no self-reported prior TBI with LOC (N = 3,363) were enrolled and followed every 2 years for an average of 7.5 years (range 0-18 years). MeasurementsWeibull survival models were used to evaluate baseline and time-varying predictors of incident TBI with LOC, including measures of depression, activities of daily living (ADLs), cerebrovascular disease, and disease comorbidity. ResultsIn an adjusted multivariate model, baseline depression symptoms as measured according to Center for Epidemiologic Studies Depression Scale (CES-D) score (hazard ratio (HR) for 4 points = 1.23, 95% confidence interval (CI) = 1.02-1.49, P = .03) and baseline activity of daily living (ADL) impairment (HR = 2.37, 95% CI = 1.24-4.53, P = .009) were associated with incident TBI. In a model that included time-dependent covariates, cerebrovascular disease at the previous visit (HR = 2.28, 95% CI = 1.37-3.78, P < .001), CES-D score the previous visit (HR for 4 points = 1.23, 95% CI = 1.02-1.49, P < .04) and baseline ADL impairment (HR 2.14, 95% CI = 1.11-4.13, P = .02) predicted incident TBI. Of factors considered, cerebrovascular disease and ADL impairment were associated with earlier mortality in participants with incident TBI with LOC. ConclusionIndices of health, mood, and functional status predict incident TBI with LOC in older adults. These findings may have implications for injury prevention and postinjury clinical management.	[Dams-O'Connor, Kristen; Landau, Alexandra] Icahn Sch Med Mt Sinai, Dept Rehabil Med, One Gustave L Levy Pl,Box 1240, New York, NY 10029 USA; [Gibbons, Laura E.; Crane, Paul K.] Univ Washington, Sch Med, Div Gen Internal Med, Seattle, WA 98195 USA; [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA		Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, One Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org			National Institutes of Health (NIH), National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG006781]; NIH, National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651-01A1]; NIH, NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05136]; NIH, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086625]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136, U01AG006781] Funding Source: NIH RePORTER	This project was supported by Grants U01 AG006781 (Larson, National Institutes of Health (NIH), National Institute on Aging (NIA)), K01HD074651-01A1 (DamsO'Connor, NIH, National Institute of Child Health and Human Development), P50 AG05136 (Montine, NIH, NIA), and U01 NS086625 (PI Wayne Gordon, NIH, National Institute of Neurological Disorders and Stroke).	Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Faul M, 2010, TRAUMATIC BRAIN INJU; Fishman PA, 2003, MED CARE, V41, P84, DOI 10.1097/00005650-200301000-00011; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Gray SL, 2013, J GERONTOL A-BIOL, V68, P1083, DOI 10.1093/gerona/glt013; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Koepsell TD, 2004, J AM GERIATR SOC, V52, P1495, DOI 10.1111/j.1532-5415.2004.52412.x; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Lindsey JC, 1998, STAT MED, V17, P219, DOI 10.1002/(SICI)1097-0258(19980130)17:2<219::AID-SIM735>3.0.CO;2-O; Maruish M., 2004, USE PSYCHOL TESTING, P363, DOI DOI 10.1111/J.1083-6101.2007.00367.X; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2014, J NEUROL NEUROSUR PS, V85, P1214, DOI 10.1136/jnnp-2013-307279; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shumway-Cook A, 2009, PHYS THER, V89, P324, DOI 10.2522/ptj.20070107; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Wang L, 2002, J AM GERIATR SOC, V50, P1525, DOI 10.1046/j.1532-5415.2002.50408.x	29	34	35	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-8614	1532-5415		J AM GERIATR SOC	J. Am. Geriatr. Soc.	APR	2016	64	4					844	848		10.1111/jgs.14014			5	Geriatrics & Gerontology; Gerontology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology	DK1WO	WOS:000374705900016	26925541	Green Accepted, Bronze			2022-02-06	
J	Mitra, J; Shen, KK; Ghose, S; Bourgeat, P; Fripp, J; Salvado, O; Pannek, K; Taylor, DJ; Mathias, JL; Rose, S				Mitra, Jhimli; Shen, Kai-kai; Ghose, Soumya; Bourgeat, Pierrick; Fripp, Jurgen; Salvado, Olivier; Pannek, Kerstin; Taylor, D. Jamie; Mathias, Jane L.; Rose, Stephen			Statistical machine learning to identify traumatic brain injury (TBI) from structural disconnections of white matter networks	NEUROIMAGE			English	Article						Diffusion tractography; Structural network connections; Traumatic brain injury; Network-based statistics; Machine learning	DIFFUSE AXONAL INJURY; NONMISSILE HEAD-INJURY; COGNITIVE DYSFUNCTION; EXECUTIVE FUNCTION; CORPUS-CALLOSUM; MILD; MRI; CLASSIFICATION; MODERATE; MOTION	Identifying diffuse axonal injury (DAI) in patients with traumatic brain injury (TBI) presenting with normal appearing radiological MRI presents a significant challenge. Neuroimaging methods such as diffusion MRI and probabilistic tractography, which probe the connectivity of neural networks, show significant promise. We present a machine learning approach to classify TBI participants primarily with mild traumatic brain injury (mTBI) based on altered structural connectivity patterns derived through the network based statistical analysis of structural connectomes generated from TBI and age-matched control groups. In this approach, higher order diffusion models were used to map white matter connections between 116 cortical and subcortical regions. Tracts between these regions were generated using probabilistic tracking and mean fractional anisotropy (FA) measures along these connections were encoded in the connectivity matrices. Network-based statistical analysis of the connectivity matrices was performed to identify the network differences between a representative subset of the two groups. The affected network connections provided the feature vectors for principal component analysis and subsequent classification by random forest. The validity of the approach was tested using data acquired from a total of 179 TBI patients and 146 controls participants. The analysis revealed altered connectivity within a number of intra-and inter-hemispheric white matter pathways associated with DAI, in consensus with existing literature. A mean classification accuracy of 68.16% +/- 1.81% and mean sensitivity of 80.0% +/- 2.36% were achieved in correctly classifying the TBI patients evaluated on the subset of the participants that was not used for the statistical analysis, in a 10-fold cross-validation framework. These results highlight the potential for statistical machine learning approaches applied to structural connectomes to identify patients with diffusive axonal injury. (C) 2016 Elsevier Inc. All rights reserved.	[Mitra, Jhimli; Shen, Kai-kai; Ghose, Soumya; Bourgeat, Pierrick; Fripp, Jurgen; Salvado, Olivier; Rose, Stephen] CSIRO Hlth & Biosecur, Australian E Hlth & Res Ctr, Herston, Qld, Australia; [Mathias, Jane L.] Univ Adelaide, Sch Psychol, Adelaide, SA, Australia; [Taylor, D. Jamie] Royal Adelaide Hosp, Dept Radiol, Adelaide, SA 5000, Australia; [Pannek, Kerstin] Univ London Imperial Coll Sci Technol & Med, Dept Comp, London, England; [Mitra, Jhimli; Ghose, Soumya] Case Western Reserve Univ, Ctr Computat Imaging & Personalized Diagnost, Cleveland, OH 44106 USA; [Mitra, Jhimli] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA		Mitra, J (corresponding author), CSIRO Hlth & Biosecur, Australian E Hlth & Res Ctr, Herston, Qld, Australia.	jhimli.mitra@case.edu; kaikai.shen@csiro.au; soumya.ghose@case.edu; pierrick.bourgeat@csiro.au; jurgen.fripp@csiro.au; olivier.salvado@csiro.au; kerstin.pannek@gmail.com; jamie.taylor@health.sa.gov.au; jane.mathias@adelaide.edu.au; stephen.rose@csiro.au	Fripp, Jurgen/A-8763-2011; Salvado, Olivier/C-8910-2009; Shen, Kai-kai/B-8724-2011; Ghose, Soumya/C-8767-2014; Bourgeat, Pierrick T/A-1419-2010; Pannek, Kerstin/C-8059-2011; Rose, Stephen/C-8044-2009; Shen, Kaikai/AAD-9970-2019	Fripp, Jurgen/0000-0001-9705-0079; Salvado, Olivier/0000-0002-2720-8739; Shen, Kai-kai/0000-0002-5956-501X; Bourgeat, Pierrick T/0000-0002-2605-4766; Pannek, Kerstin/0000-0002-6512-7630; Shen, Kaikai/0000-0002-5956-501X; Rose, Stephen/0000-0003-1558-6297; Mathias, Jane/0000-0001-8957-8594	National Health and Medical Research Project [519220]	This research was funded by a National Health and Medical Research Project Grant (ID 519220). The authors wish to thank Ms. V. Dennington and Dr. Y. Harman-Smith for their efforts in subject recruitment.	Acosta O, 2009, MED IMAGE ANAL, V13, P730, DOI 10.1016/j.media.2009.07.003; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; Aljabar P, 2009, NEUROIMAGE, V46, P726, DOI 10.1016/j.neuroimage.2009.02.018; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Archer KJ, 2008, COMPUT STAT DATA AN, V52, P2249, DOI 10.1016/j.csda.2007.08.015; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aribisala BS, 2010, LECT NOTES COMPUT SC, V6326, P51; Bai Y, 2008, I S BIOMED IMAGING, P947, DOI 10.1109/ISBI.2008.4541154; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Breiman L, 2001, STAT SCI, V16, P199, DOI 10.1214/ss/1009213726; Breiman L., 1984, CLASSIFICATION REGRE; BREIMAN L, 2001, MACH LEARN, V45; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Costafreda SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006353; Dosenbach NUF, 2010, SCIENCE, V329, P1358, DOI 10.1126/science.1194144; Fang P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045972; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Goh SYM, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00019; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; Guyon I., 2003, J MACH LEARN RES, V3, P1157, DOI DOI 10.1162/153244303322753616; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hastie T., 2008, RANDOM FORESTS, DOI DOI 10.1007/978-0-387-84858-7_15; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jenkinson M, 2003, MAGNET RESON MED, V49, P193, DOI 10.1002/mrm.10354; Jenkinson M., 2004, 10 ANN M ORG HUM BRA, P1; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jolliffe I.T., 2002, PRINCIPAL COMPONENT; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Langs G, 2011, NEUROIMAGE, V56, P497, DOI 10.1016/j.neuroimage.2010.07.074; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu H, 2008, CH CRC DATA MIN KNOW, P3; Liu MJ, 2012, NEUROREPORT, V23, P265, DOI 10.1097/WNR.0b013e32834f60a5; Love RJ, 1992, NEUROLOGY SPEECH LAN; Lui YW, 2014, NEUROLOGY, V83, P1235, DOI 10.1212/WNL.0000000000000834; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Morris D, 2011, MAGN RESON MED, V66, P92, DOI 10.1002/mrm.22786; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ourselin S., 2002, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2002. 5th International Conference. Proceedings, Part II (Lecture Notes in Computer Science Vol.2489), P140; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Pannek K, 2012, PEDIATR RADIOL, V42, P1169, DOI 10.1007/s00247-012-2427-x; Pannek K, 2012, NEUROIMAGE, V63, P835, DOI 10.1016/j.neuroimage.2012.07.022; Pannek K, 2010, NEUROIMAGE, V50, P1044, DOI 10.1016/j.neuroimage.2010.01.020; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Robinson EC, 2010, NEUROIMAGE, V50, P910, DOI 10.1016/j.neuroimage.2010.01.019; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Rose S, 2012, NEUROIMAGE, V59, P2661, DOI 10.1016/j.neuroimage.2011.08.054; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Sanchez CE, 2012, DEV NEUROPSYCHOL, V37, P379, DOI 10.1080/87565641.2012.688900; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith RE, 2015, NEUROIMAGE, V104, P253, DOI 10.1016/j.neuroimage.2014.10.004; Smith RE, 2013, NEUROIMAGE, V67, P298, DOI 10.1016/j.neuroimage.2012.11.049; Smith RE, 2012, NEUROIMAGE, V62, P1924, DOI 10.1016/j.neuroimage.2012.06.005; Sugiyama K., 2013, CASE REPORTS MED, P1; Taber Katherine H, 2013, J Neuropsychiatry Clin Neurosci, V25, P1, DOI 10.1176/appi.neuropsych.12120401; Tang J, 2014, DATA CLASSIFICATION, P37, DOI 10.1201/b17320; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; van Horn JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037454; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P897, DOI 10.1109/42.811270; Vapnik V., 1963, AUTOM REMOTE CONTROL, V24; Vapnik V.N., 1964, AUTOM REMOTE CONTROL, V25; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang LB, 2012, NEUROIMAGE, V61, P931, DOI 10.1016/j.neuroimage.2012.03.080; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeh P.-H., 2012, OPEN J MED IMAGING, V2, P137, DOI [10.4236/ojmi.2012.24025, DOI 10.4236/OJMI.2012.24025]; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Ziv E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078824	95	34	35	2	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 1	2016	129						247	259		10.1016/j.neuroimage.2016.01.056			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DH4HD	WOS:000372745300021	26827816				2022-02-06	
J	Sukumari-Ramesh, S; Alleyne, CH; Dhandapani, KM				Sukumari-Ramesh, Sangeetha; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.			The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice	TRANSLATIONAL STROKE RESEARCH			English	Article						Microglial activation; Stroke; Gliosis	TRAUMATIC BRAIN-INJURY; T-CELL LYMPHOMA; NF-KAPPA-B; HEME OXYGENASE; GENE-EXPRESSION; TIME-COURSE; VORINOSTAT; EDEMA; TRANSCRIPTION; INFLAMMATION	Spontaneous intracerebral hemorrhage (ICH) is a stroke subtype with no effective treatment. Though ICH is known to induce severe neurological damage, the molecular mechanisms of neurological injury after ICH remain largely unclear. Given the emerging role of epigenetic mechanisms in neurodegeneration, the present study evaluated whether suberoylanilide hydroxamic acid (SAHA: vorinostat), a clinically well-tolerated pan-histone deacetylase inhibitor (HDACi), would attenuate neurological injury and improve functional outcomes in a preclinical model of ICH. Mice were administered with SAHA or vehicle after an induction of ICH and acute neuronal death, glial activation, and neurological outcomes were assessed. SAHA-treated mice exhibited less neurodegeneration with concomitant improvement in neurological outcomes than vehicle-treated mice. Furthermore, SAHA downregulated glial activation and the expression of heme oxygenase-1, a stress-inducible enzyme that plays critical roles in neurological damage after ICH. Altogether, the data strongly suggest the role of epigenetic mechanisms in inducing neurological injury after ICH and raise the possible clinical utility of SAHA for therapeutic intervention after ICH.	[Sukumari-Ramesh, Sangeetha; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.] Georgia Regents Univ, Dept Neurosurg, 1120 15th St CA1010, Augusta, GA 30912 USA		Sukumari-Ramesh, S (corresponding author), Georgia Regents Univ, Dept Neurosurg, 1120 15th St CA1010, Augusta, GA 30912 USA.	sramesh@gru.edu		Dhandapani, Krishnan/0000-0001-7044-1117	American Heart AssociationAmerican Heart Association [14SDG18730034]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS065172, R21NS075774]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075774, R01NS065172] Funding Source: NIH RePORTER	This work was supported by grants from the American Heart Association (14SDG18730034 to SSR) and National Institute of Health (R01NS065172, R21NS075774 to KMD).	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Babu R, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11366; Baltan S, 2011, TRANSL STROKE RES, V2, P411, DOI 10.1007/s12975-011-0087-z; Bode KA, 2007, IMMUNOLOGY, V122, P596, DOI 10.1111/j.1365-2567.2007.02678.x; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Chen M, 2007, J NEUROCHEM, V103, P2015, DOI 10.1111/j.1471-4159.2007.04885.x; Choo QY, 2010, RHEUMATOLOGY, V49, P1447, DOI 10.1093/rheumatology/keq108; Ciccone A, 2008, NEUROL SCI, V29, pS256, DOI 10.1007/s10072-008-0955-9; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Faraco G, 2009, NEUROBIOL DIS, V36, P269, DOI 10.1016/j.nbd.2009.07.019; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Kirschbaum M, 2011, J CLIN ONCOL, V29, P1198, DOI 10.1200/JCO.2010.32.1398; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Liu DZ, 2012, SCI WORLD J, DOI 10.1100/2012/491737; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Manno Edward M, 2012, Continuum (Minneap Minn), V18, P598, DOI 10.1212/01.CON.0000415430.99394.3e; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ramalingam SS, 2010, J CLIN ONCOL, V28, P56, DOI 10.1200/JCO.2009.24.9094; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sansing LH, 2011, ANN NEUROL, V70, P646, DOI 10.1002/ana.22528; Sukumari-Ramesh S, 2012, J NEUROTRAUM, V29, P2798, DOI 10.1089/neu.2011.2243; Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05-041; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Ziesche E, 2013, NUCLEIC ACIDS RES, V41, P90, DOI 10.1093/nar/gks916	44	34	34	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	APR	2016	7	2					141	148		10.1007/s12975-015-0421-y			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DF5XJ	WOS:000371425900008	26338677				2022-02-06	
J	Astrand, R; Rosenlund, C; Unden, J				Astrand, Ramona; Rosenlund, Christina; Unden, Johan		SNC	Scandinavian guidelines for initial management of minor and moderate head trauma in children	BMC MEDICINE			English	Article						Guidelines; Prediction rule; Children; Mild; moderate; head trauma; Brain injury; Computed tomography; Evidence-based; GRADE	CRANIAL COMPUTED-TOMOGRAPHY; GLASGOW COMA SCALE; NOMINAL GROUP TECHNIQUE; BRAIN-INJURY; INTRACRANIAL INJURY; PEDIATRIC-PATIENTS; SKULL FRACTURE; DECISION RULE; REQUIRE HOSPITALIZATION; ROUTINE HOSPITALIZATION	Background: The management of minor and moderate head trauma in children differs widely between countries. Presently, there are no existing guidelines for management of these children in Scandinavia. The purpose of this study was to produce new evidence-based guidelines for the initial management of head trauma in the paediatric population in Scandinavia. The primary aim was to detect all children in need of neurosurgical intervention. Detection of any traumatic intracranial injury on CT scan was an important secondary aim. Methods: General methodology according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used. Systematic evidence-based review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology and based upon relevant clinical questions with respect to patient-important outcomes. Quality ratings of the included studies were performed using Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 and Centre of Evidence Based Medicine (CEBM)-2 tools. Based upon the results, GRADE recommendations, a guideline, discharge instructions and in-hospital observation instructions were drafted. For elements with low evidence, a modified Delphi process was used for consensus, which included relevant clinical stakeholders. Results: The guidelines include criteria for selecting children for CT scans, in-hospital observation or early discharge, and suggestions for monitoring routines and discharge advice for children and guardians. The guidelines separate mild head trauma patients into high-, medium-and low-risk categories, favouring observation for mild, low-risk patients as an attempt to reduce CT scans in children. Conclusions: We present new evidence and consensus based Scandinavian Neurotrauma Committee guidelines for initial management of minor and moderate head trauma in children. These guidelines should be validated before extensive clinical use and updated within four years due to rapid development of new diagnostic tools within paediatric neurotrauma.	[Astrand, Ramona] Rigshosp, Dept Neurosurg, Neuroctr 2091, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Rosenlund, Christina] Odense Univ Hosp, Dept Neurosurg, Sdr Blvd 29, DK-5000 Odense C, Denmark; [Unden, Johan] Skane Univ Hosp, Inst Clin Sci, Dept Intens Care & Perioperat Med, Sodra Forstadsgatan 101, S-20502 Malmo, Sweden		Unden, J (corresponding author), Skane Univ Hosp, Inst Clin Sci, Dept Intens Care & Perioperat Med, Sodra Forstadsgatan 101, S-20502 Malmo, Sweden.	dr.johan.unden@gmail.com		Sundstrom, Terje/0000-0002-6503-7141; Marklund, Niklas/0000-0002-9797-5626			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; AGREE Next Steps Consortium, 2009, AGREE 2 INSTR; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Astrand R, 2006, ACTA NEUROL SCAND, V113, P262, DOI 10.1111/j.1600-0404.2005.00573.x; Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Aziz H, 2013, J TRAUMA ACUTE CARE, V75, P550, DOI 10.1097/TA.0b013e3182a53a77; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Bergman DA, 1999, PEDIATRICS, V104, P1407; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Bouvier D, 2012, CLIN CHEM, V58, P1116, DOI 10.1373/clinchem.2011.180828; Bouvier D, 2011, CLIN BIOCHEM, V44, P927, DOI 10.1016/j.clinbiochem.2011.05.004; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brooks JC, 2015, ARCH PHYS MED REHAB, V96, P1000, DOI 10.1016/j.apmr.2015.02.002; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Center for Disease Control and Prevention and American College of Emergency Physicians, 2008, HEADS SER WHAT EXP C; CHAN KH, 1990, J NEUROSURG, V72, P189, DOI 10.3171/jns.1990.72.2.0189; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; Chiappelli F, 2010, EVIDENCE BASED PRACT, DOI [10.1007/978-3-642-05025-1_2, DOI 10.1007/978-3-642-05025-1_2]; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; Da Dalt L, 2007, J PEDIATR-US, V150, P274, DOI 10.1016/j.jpeds.2006.11.060; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Dawson EC, 2012, PEDIATR NEUROSURG, V48, P221, DOI 10.1159/000346697; Dayan PS, 2015, PEDIATRICS, V135, P504, DOI 10.1542/peds.2014-2695; Dayan PS, 2014, ANN EMERG MED, V64, P153, DOI 10.1016/j.annemergmed.2014.02.003; Dayan PS, 2014, ANN EMERG MED, V63, P657, DOI 10.1016/j.annemergmed.2014.01.009; Dias MS, 1999, PEDIATR NEUROSURG, V30, P232, DOI 10.1159/000028803; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Durham SR, 2006, J NEUROSURG, V105, P365, DOI 10.3171/ped.2006.105.5.365; Edwards AD, 2011, PEDIATR RADIOL, V41, P1353, DOI 10.1007/s00247-011-2147-7; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Garcia JJG, 2009, AN PEDIATR, V71, P31, DOI 10.1016/j.anpedi.2009.03.009; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Goldet Gabrielle, 2013, J Evid Based Med, V6, P50, DOI 10.1111/jebm.12018; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012; Guzel A, 2009, PEDIATR NEUROSURG, V45, P262, DOI 10.1159/000228984; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Hall P, 2005, LAKARTIDNINGEN, V102, P220; Hall P, 2005, LAKARTIDNINGEN, V102, P217; Hall Per, 2005, Lakartidningen, V102, P214; Hallen M, 2010, J TRAUMA, V69, P284, DOI 10.1097/TA.0b013e3181ca060b; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Heskestad B, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-6; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Holsti M, 2005, PEDIATR EMERG CARE, V21, P639, DOI 10.1097/01.pec.0000181426.25342.a9; Howick J., OXFORD 2011 LEVELS E; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hutchings Andrew, 2006, J Health Serv Res Policy, V11, P218, DOI 10.1258/135581906778476553; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ismail R, 2016, J GLAUCOMA, V25, P539, DOI 10.1097/IJG.0000000000000301; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Klemetti S, 2009, PEDIATR EMERG CARE, V25, P811, DOI 10.1097/PEC.0b013e3181c32e74; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee LK, 2014, JAMA PEDIATR, V168, P837, DOI 10.1001/jamapediatrics.2014.361; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Lossius HM, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-80; da Silva PSL, 2008, J TRAUMA, V65, P1293, DOI 10.1097/TA.0b013e318156866c; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Makdissi M, 2014, AUST FAM PHYSICIAN, V43, P94; Mandera M, 2000, CHILD NERV SYST, V16, P156, DOI 10.1007/s003810050484; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Munivenkatappa A, 2013, J PEDIATR NEUROSCI, V8, P183, DOI 10.4103/1817-1745.123659; Munoz-Sanchez M, 2005, CHILD NERV SYST, V21, P128, DOI 10.1007/s00381-004-1036-x; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Ng SM, 2002, J PAEDIATR CHILD H, V38, P388, DOI 10.1046/j.1440-1754.2002.00012.x; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Nigrovic LE, 2013, ANN EMERG MED, V61, P389, DOI 10.1016/j.annemergmed.2012.08.030; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Odgaard L, 2015, CLIN EPIDEMIOL, V7, P225, DOI 10.2147/CLEP.S78141; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Perheentupa U, 2010, INT J PEDIATR OTORHI, V74, P1245, DOI 10.1016/j.ijporl.2010.07.023; Powell EC, 2015, PEDIATRICS, V135, pE851, DOI 10.1542/peds.2014-2858; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; Ratan SK, 2001, CLIN PEDIATR, V40, P375, DOI 10.1177/000992280104000702; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Roguski M, 2015, J NEUROSURG-PEDIATR, V15, P529, DOI 10.3171/2014.10.PEDS14128; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; *ROYAL COLL RAD, 2008, STAND RAD INV SUSP N; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schnellinger MG, 2010, CLIN PEDIATR, V49, P569, DOI 10.1177/0009922809352375; Schonfeld D, 2013, ANN EMERG MED, V62, P597, DOI 10.1016/j.annemergmed.2013.06.020; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Shane SA, 1997, PEDIATR EMERG CARE, V13, P198, DOI 10.1097/00006565-199706000-00006; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Spencer MT, 2003, AM J EMERG MED, V21, P111, DOI 10.1053/ajem.2003.50031; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; TEASDALE G, 1974, LANCET, V2, P81; Melo JRT, 2008, ARQ NEURO-PSIQUIAT, V66, P708, DOI 10.1590/S0004-282X2008000500019; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; van Teijlingen E, 2006, J FAM PLAN REPROD H, V32, P249, DOI 10.1783/147118906778586598; Vestergaard V, 2014, ACTA NEUROL SCAND, V129, P168, DOI 10.1111/ane.12158; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550	126	34	34	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	FEB 18	2016	14								33	10.1186/s12916-016-0574-x			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE1QO	WOS:000370401700001	26888597	Green Published, gold			2022-02-06	
J	Bajwa, NM; Halavi, S; Hamer, M; Semple, BD; Noble-Haeusslein, LJ; Baghchechi, M; Hiroto, A; Hartman, RE; Obenaus, A				Bajwa, Nikita M.; Halavi, Shina; Hamer, Mary; Semple, Bridgette D.; Noble-Haeusslein, Linda J.; Baghchechi, Mohsen; Hiroto, Alex; Hartman, Richard E.; Obenaus, Andre			Mild Concussion, but Not Moderate Traumatic Brain Injury, Is Associated with Long-Term Depression-Like Phenotype in Mice	PLOS ONE			English	Article							MOUSE MODEL; BEHAVIORAL DEFICITS; MOOD DISORDERS; ANIMAL-MODEL; IMPACT; IMPAIRMENTS; BLAST; MOTOR; MAZE; RATS	Mild traumatic brain injuries can lead to long-lasting cognitive and motor deficits, increasing the risk of future behavioral, neurological, and affective disorders. Our study focused on long-term behavioral deficits after repeated injury in which mice received either a single mild CHI (mCHI), a repeated mild CHI (rmCHI) consisting of one impact to each hemisphere separated by 3 days, or a moderate controlled cortical impact injury (CCI). Shams received only anesthesia. Behavioral tests were administered at 1, 3, 5, 7, and 90 days post-injury (dpi). CCI animals showed significant motor and sensory deficits in the early (1-7 dpi) and long-term (90 dpi) stages of testing. Interestingly, sensory and subtle motor deficits in rmCHI animals were found at 90 dpi. Most importantly, depression-like behaviors and social passiveness were observed in rmCHI animals at 90 dpi. These data suggest that mild concussive injuries lead to motor and sensory deficits and affective disorders that are not observed after moderate TBI.	[Bajwa, Nikita M.; Halavi, Shina; Hartman, Richard E.] Loma Linda Univ, Sch Behav Hlth, Dept Psychol, Loma Linda, CA 92350 USA; [Hamer, Mary; Baghchechi, Mohsen; Hiroto, Alex; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; [Semple, Bridgette D.] Univ Melbourne, Melbourne Brain Ctr, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Sch Med, Dept Neurol Surg, San Francisco, CA USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Sch Med, Dept Phys Therapy & Rehabil Sci, San Francisco, CA USA; [Obenaus, Andre] Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA; [Obenaus, Andre] Loma Linda Univ, Sch Behav Hlth, Div Interdisciplinary Studies, Loma Linda, CA 92350 USA		Hartman, RE (corresponding author), Loma Linda Univ, Sch Behav Hlth, Dept Psychol, Loma Linda, CA 92350 USA.; Obenaus, A (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA.; Obenaus, A (corresponding author), Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA.; Obenaus, A (corresponding author), Loma Linda Univ, Sch Behav Hlth, Div Interdisciplinary Studies, Loma Linda, CA 92350 USA.	behavioralneuroscience@gmail.com; aobenaus@llu.edu			School of Behavioral Health seed grant at Loma Linda University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077767] Funding Source: NIH RePORTER	Funding for this study was provided by the School of Behavioral Health seed grant at Loma Linda University.; This work was supported by School of Behavioral Health seed grant at Loma Linda University. We are thankful to Chris Nishioka for his assistance in behavioral testing and CHI surgeries. Lastly, we would like to thank the Biomedical Undergraduate Research Program at University of California, Riverside for providing research students to assist in MRI analysis.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Arakawa H, 2008, NEUROSCI BIOBEHAV R, V32, P1236, DOI 10.1016/j.neubiorev.2008.05.012; Arakawa H, 2009, BEHAV BRAIN RES, V205, P138, DOI 10.1016/j.bbr.2009.07.007; Awwad HO, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00132; Ballachey EL, 1932, U CALIFORNIA PUBLICA, V6, P1; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Costa TL, 2015, NEUROPSYCHOLOGIA, V78, P142, DOI 10.1016/j.neuropsychologia.2015.10.008; Craft TKS, 2006, BIOL PSYCHIAT, V60, P812, DOI 10.1016/j.biopsych.2006.03.011; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Dantzer R, 2006, NEUROL CLIN, V24, P441, DOI 10.1016/j.ncl.2006.03.003; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Di Battista A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101842; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dulcich MS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/940830; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M, 2010, TRAUMATIC BRAIN INJU; Fenn AM, 2013, BIOL PSYCHIAT, P1; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gerberding JL, 2003, REPORT TO CONGRESS O; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Guley NH, 2015, J NEUROTRAUM, P1; Hartman RE, 2006, NEUROBIOL DIS, V24, P506, DOI 10.1016/j.nbd.2006.08.006; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Hua Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/272976; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; JONES BJ, 1968, N-S ARCH PHARMAKOL, V259, P211, DOI 10.1007/BF00537801; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laskowski R.A., 2015, BRAIN NEUROTRAUMA MO, DOI [10.1201/b18126-6, DOI 10.1201/B18126-6]; Lekic T, 2011, EXP NEUROL, V227, P96, DOI 10.1016/j.expneurol.2010.09.017; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Obenaus A., 2012, MILD TRAUMATIC BRAIN, P53; Obenaus A, 2015, ENCYCLOPEDIA OF MENT; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Semple BD, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00069; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yu HR, 2014, BRAIN INJURY, V28, P244, DOI 10.3109/02699052.2013.859735; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	76	34	34	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2016	11	1							e0146886	10.1371/journal.pone.0146886			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5CE	WOS:000368530300014	26796696	Green Published, gold			2022-02-06	
J	Amen, DG; Willeumier, K; Omalu, B; Newberg, A; Raghavendra, C; Raji, CA				Amen, Daniel G.; Willeumier, Kristen; Omalu, Bennet; Newberg, Andrew; Raghavendra, Cauligi; Raji, Cyrus A.			Perfusion Neuroimaging Abnormalities Alone Distinguish National Football League Players from a Healthy Population	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Brain imaging; cognition; concussion; football; NFL; SPECT; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; RETIRED NFL PLAYERS; PROFESSIONAL FOOTBALL; DEPRESSIVE SYMPTOMS; CONCUSSION HISTORY; BRAIN; PATTERNS; ATROPHY	Background: National Football League (NFL) players are exposed to multiple head collisions during their careers. Increasing awareness of the adverse long-term effects of repetitive head trauma has raised substantial concern among players, medical professionals, and the general public. Objective: To determine whether low perfusion in specific brain regions on neuroimaging can accurately separate professional football players from healthy controls. Method: A cohort of retired and current NFL players (n = 161) were recruited in a longitudinal study starting in 2009 with ongoing interval follow up. A healthy control group (n = 124) was separately recruited for comparison. Assessments included medical examinations, neuropsychological tests, and perfusion neuroimaging with single photon emission computed tomography (SPECT). Perfusion estimates of each scan were quantified using a standard atlas. We hypothesized that hypoperfusion particularly in the orbital frontal, anterior cingulate, anterior temporal, hippocampal, amygdala, insular, caudate, superior/mid occipital, and cerebellar sub-regions alone would reliably separate controls from NFL players. Cerebral perfusion differences were calculated using a one-way ANOVA and diagnostic separation was determined with discriminant and automatic linear regression predictive models. Results: NFL players showed lower cerebral perfusion on average (p < 0.01) in 36 brain regions. The discriminant analysis subsequently distinguished NFL players from controls with 90% sensitivity, 86% specificity, and 94% accuracy (95% CI 95-99). Automatic linear modeling achieved similar results. Inclusion of age and clinical co-morbidities did not improve diagnostic classification. Conclusion: Specific brain regions commonly damaged in traumatic brain injury show abnormally low perfusion on SPECT in professional NFL players. These same regions alone can distinguish this group from healthy subjects with high diagnostic accuracy. This study carries implications for the neurological safety of NFL players.	[Amen, Daniel G.; Willeumier, Kristen] Amen Clin Inc, Costa Mesa, CA USA; [Omalu, Bennet] Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA; [Newberg, Andrew] Thomas Jefferson Univ, Myrna Brind Ctr Integrat Med, Philadelphia, PA 19107 USA; [Raghavendra, Cauligi] Univ Southern Calif, Dept Comp Sci, Los Angeles, CA USA; [Raji, Cyrus A.] Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA USA		Raji, CA (corresponding author), Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA.	cyrusraji@gmail.com		Willeumier, Kristen/0000-0002-1229-8516			Alhilali LM, 2015, RADIOLOGY, V277, P793, DOI 10.1148/radiol.2015142974; Amen DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129659; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Centers for Disease Control and Prevention, SPORTS REL REC BRAIN; Conners K, CONNERS CPT 2 V 5; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Grothe MJ, 2016, HUM BRAIN MAPP, V37, P35, DOI 10.1002/hbm.23018; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Moller C, 2016, RADIOLOGY, V279, P838, DOI 10.1148/radiol.2015150220; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Raji CA, 2015, BRAIN IMAGING BEHAV, V9, P527, DOI 10.1007/s11682-015-9385-5; Raji CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091088; Raymond PD, 2006, CLIN NEUROPSYCHOL, V20, P261, DOI 10.1080/13854040590947416; Richieri R, 2015, PSYCHIAT RES-NEUROIM, V231, P134, DOI 10.1016/j.pscychresns.2014.11.013; Robbins L, 2013, HEADACHE, V53, P817, DOI 10.1111/head.12104; Selverstein SM, 2007, BEHAV RES METHODS, V39, P940, DOI 10.3758/BF03192989; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Yang H, 2013, MULT LINEAR REGRESSI, V92, P27	27	34	34	0	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	53	1					237	241		10.3233/JAD-160207			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DR2NW	WOS:000379742200021	27128374	Green Published, Green Submitted			2022-02-06	
J	Brickler, T; Gresham, K; Meza, A; Coutermarsh-Ott, S; Williams, TM; Rothschild, DE; Allen, IC; Theus, MH				Brickler, Thomas; Gresham, Kisha; Meza, Armand; Coutermarsh-Ott, Sheryl; Williams, Tere M.; Rothschild, Daniel E.; Allen, Irving C.; Theus, Michelle H.			Nonessential Role for the NLRP1 Inflammasome Complex in a Murine Model of Traumatic Brain Injury	MEDIATORS OF INFLAMMATION			English	Article							NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CONTROLLED CORTICAL IMPACT; NEURAL PROGENITOR CELLS; NF-KAPPA-B; SUBVENTRICULAR ZONE; NEGATIVE REGULATION; RAT-BRAIN; EXPRESSION; DEATH	Traumatic brain injury (TBI) elicits the immediate production of proinflammatory cytokines which participate in regulating the immune response. While the mechanisms of adaptive immunity in secondary injury are well characterized, the role of the innate response is unclear. Recently, the NLR inflammasome has been shown to become activated following TBI, causing processing and release of interleukin-1 beta (IL-1 beta). The inflammasome is a multiprotein complex consisting of nucleotide-binding domain and leucine-rich repeat containing proteins (NLR), caspase-1, and apoptosis-associated speck-like protein (ASC). ASC is upregulated after TBI and is critical in coupling the proteins during complex formation resulting in IL-1 beta. cleavage. To directly test whether inflammasome activation contributes to acute TBI-induced damage, we assessed IL-1 beta, IL-18, and IL-6 expression, contusion volume, hippocampal cell death, and motor behavior recovery in Nlrp1(-/-), Asc(-/-), and wild type mice after moderate controlled cortical impact (CCI) injury. Although IL-1 beta expression is significantly attenuated in the cortex of Nlrp1(-/-) and Asc(-/-) mice following CCI injury, no difference in motor recovery, cell death, or contusion volume is observed compared to wild type. These findings indicate that inflammasome activation does not significantly contribute to acute neural injury in the murine model of moderate CCI injury.	[Brickler, Thomas; Gresham, Kisha; Meza, Armand; Coutermarsh-Ott, Sheryl; Williams, Tere M.; Rothschild, Daniel E.; Allen, Irving C.; Theus, Michelle H.] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Duck Pond Dr, Blacksburg, VA 24061 USA		Theus, MH (corresponding author), Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Duck Pond Dr, Blacksburg, VA 24061 USA.	mtheus@vt.edu		Coutermarsh-Ott, Sheryl/0000-0001-7385-3969	VT's OASF; National Institute of Allergy and Infectious Diseases Animal Model Research for Veterinarians (AMRV) [T32-OD010430];  [R01 NS096281];  [R15 NS081623]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS096281, R15NS081623] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32OD010430] Funding Source: NIH RePORTER	The authors would like to thank Dr. Beverly H. Koller (UNC Chapel Hill) for kindly providing the Nlrp1<SUP>-/-</SUP> mice used in this study. The authors would also like to recognize Genetech for providing the Asc<SUP>-/-</SUP> (Pycard<SUP>-/-</SUP>) mice. This work was supported by R01 NS096281, R15 NS081623, and VT's OASF. The authors recognize the VT-PREP and VT-IMSD Programs for student support (Tere M. Williams; Armand Meza) and the Virginia-Maryland College of Veterinary Medicine (Irving C. Allen; Daniel E. Rothschild). Student work (Sheryl Coutermarsh-Ott) on this paper was supported by the National Institute of Allergy and Infectious Diseases Animal Model Research for Veterinarians (AMRV) training grant (T32-OD010430).	Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alboni S, 2014, BRAIN BEHAV IMMUN, V40, P85, DOI 10.1016/j.bbi.2014.02.015; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012; Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Baumann G, 2013, EXP BIOL MED, V238, P830, DOI 10.1177/1535370213494558; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Boutin H, 2003, MOL NEUROBIOL, V27, P239, DOI 10.1385/MN:27:3:239; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; Brough D, 2011, TRENDS PHARMACOL SCI, V32, P617, DOI 10.1016/j.tips.2011.06.002; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SZ, 2013, PROTEIN CELL, V4, P251, DOI 10.1007/s13238-013-2128-8; CINAT ME, 1994, J AM COLL SURGEONS, V179, P529; Crampton SJ, 2012, J NEUROCHEM, V120, P964, DOI 10.1111/j.1471-4159.2011.07634.x; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kovarova M, 2012, J IMMUNOL, V189, P2006, DOI 10.4049/jimmunol.1201065; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mills CD, 2001, J NEUROTRAUM, V18, P743, DOI 10.1089/089771501316919111; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Miyoshi K, 2008, J NEUROSCI, V28, P12775, DOI 10.1523/JNEUROSCI.3512-08.2008; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Pedra JHF, 2009, CURR OPIN IMMUNOL, V21, P10, DOI 10.1016/j.coi.2009.01.006; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Theus MH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.165; Theus MH, 2010, STEM CELLS, V28, P1231, DOI 10.1002/stem.449; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Williams TM, 2015, J IMMUNOL, V194, P3369, DOI 10.4049/jimmunol.1402098; Williams TM, 2015, AM J PHYSIOL-GASTR L, V308, pG139, DOI 10.1152/ajpgi.00234.2014; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100	58	34	35	1	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2016	2016								6373506	10.1155/2016/6373506			11	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	DL0GP	WOS:000375310700001	27199506	Green Submitted, Green Published, gold			2022-02-06	
J	Carlozzi, NE; Brickell, TA; French, LM; Sander, A; Kratz, AL; Tulsky, DS; Chiaravalloti, ND; Hahn, EA; Kallen, M; Austin, AM; Miner, JA; Lange, RT				Carlozzi, Noelle E.; Brickell, Tracey A.; French, Louis M.; Sander, Angelle; Kratz, Anna L.; Tulsky, David S.; Chiaravalloti, Nancy D.; Hahn, Elizabeth A.; Kallen, Michael; Austin, Amy M.; Miner, Jennifer A.; Lange, Rael T.			Caring for our wounded warriors: A qualitative examination of health-related quality of life in caregivers of individuals with military-related traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						caregiver; health-related quality of life; outcome assessment (health care); quality of life; rehabilitation; service-members; traumatic brain injury; underserved populations; Veterans; wounded warriors	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; FAMILY ADJUSTMENT; ISSUES RELEVANT; DEPLOYMENT; VETERANS; SYMPTOMS; IRAQ; IDENTIFICATION; AFGHANISTAN	The purpose of this study was to develop a conceptual framework that captures aspects of health-related quality of life (HRQOL) for caregivers of individuals with military-related traumatic brain injury (TBI). We analyzed qualitative data from nine focus groups composed of caregivers of wounded warriors with a medically documented TBI. Focus group participants were recruited through hospital-based and/or community outreach efforts at the Walter Reed National Military Medical Center, the University of Michigan, and Hearts of Valor support groups (Tennessee and Washington). Participants were the caregivers (n = 45) of wounded warriors who had sustained a mild, moderate, severe, or penetrating TBI. Qualitative frequency analysis indicated that caregivers most frequently discussed social health (44% of comments), followed by emotional (40%) and physical health (12%). Areas of discussion that were specific to this population included anger regarding barriers to health services (for caregivers and servicemembers), emotional suppression (putting on a brave face for others even when things are not going well), and hypervigilance (controlling one's behavior/environment to prevent upsetting the servicemember). Caring for wounded warriors with TBI is a complex experience that positively and negatively affects HRQOL. While some aspects of HRQOL can be evaluated with existing measures, evaluation tools for other important components do not exist. The development of military-specific measures would help facilitate better care for these individuals.	[Carlozzi, Noelle E.; Kratz, Anna L.; Austin, Amy M.; Miner, Jennifer A.] Univ Michigan, Sch Med, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,G216, Ann Arbor, MI 48109 USA; [Brickell, Tracey A.; French, Louis M.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Sander, Angelle] Baylor Coll Med, TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77030 USA; [Sander, Angelle] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle] Harris Hlth Syst, Houston, TX USA; [Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE USA; [Chiaravalloti, Nancy D.] Kessler Fdn Res Ctr, Traumatic Brain Injury Lab, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [Hahn, Elizabeth A.; Kallen, Michael] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada		Carlozzi, NE (corresponding author), Univ Michigan, Sch Med, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,G216, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Chiaravalloti, Nancy/0000-0003-2943-7567; Tulsky, David/0000-0002-4335-4509	National Institutes of Health, National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01-NR013658]; Defense and Veterans Brain Injury Center, U.S. Army Medical Research and Materiel Command; National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K01AR064275]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K01AR064275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	This material was based on work supported by the National Institutes of Health, National Institute of Nursing Research (grant R01-NR013658). This material is also based upon work supported in part by the Defense and Veterans Brain Injury Center, U.S. Army Medical Research and Materiel Command. Dr. Kratz's contribution to this manuscript was supported, in part, by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K01AR064275).	[Anonymous], DOD WORLDW NUMB TBI; Bagalman E, 2013, R40941 C RES SERV US; BASCH CE, 1987, HEALTH EDUC QUART, V14, P411, DOI 10.1177/109019818701400404; BASCH CE, 1989, HEALTH EDUC QUART, V16, P389, DOI 10.1177/109019818901600307; Campbell A.-Ph. E. Converse-W. L., 1976, QUALITY AM LIFE PERC; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Carlozzi NE, 2013, ARCH PHYS MED REHAB, V94, P1721, DOI 10.1016/j.apmr.2013.02.024; Carlozzi NE, 2013, J HEALTH PSYCHOL, V18, P212, DOI 10.1177/1359105312438109; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; CELLA DF, 1995, SEMIN ONCOL, V22, P73; Coll JE, 2011, SOC WORK HEALTH CARE, V50, P487, DOI 10.1080/00981389.2010.528727; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Fischer H, 2015, RS22452 C RES SERV U; Frappell-Cooke W, 2010, OCCUP MED-OXFORD, V60, P645, DOI 10.1093/occmed/kqq149; Griffin JM, 2012, J HEAD TRAUMA REHAB, V27, P3, DOI 10.1097/HTR.0b013e3182274260; Hall LK, 2011, SOC WORK HEALTH CARE, V50, P4, DOI 10.1080/00981389.2010.513914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Kisala Pamela A, 2010, J Appl Meas, V11, P315; Kratz AL, 2015, NEUROPSYCHOL REHABIL, P1; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; McFarlane AC, 2009, CURR OPIN PSYCHIATR, V22, P369, DOI 10.1097/YCO.0b013e32832c9064; Melcer T, 2013, J TRAUMA ACUTE CARE, V75, pS247, DOI 10.1097/TA.0b013e318299d95e; Meyer EG, 2015, ACAD PSYCHIATR, V39, P416, DOI 10.1007/s40596-015-0285-1; National Alliance for Caregiving & United Health Foundation, 2010, CAR VET SERV HOM; Patrick D. L., 1988, CLIN NUTR, V7, P53; Phelan SM, 2011, DISABIL HEALTH J, V4, P177, DOI 10.1016/j.dhjo.2011.03.003; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Riviere LA, 2012, MIL MED, V177, P1169, DOI 10.7205/MILMED-D-12-00164; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taft CT, 2008, J CONSULT CLIN PSYCH, V76, P648, DOI 10.1037/a0012576; Traumatic Brain Injury Model Systems National Data Center, 2006, TRAUM BRAIN INJ MOD; Wilkinson C. W., 2012, FRONT NEUROL, V3, P11, DOI DOI 10.3389/FNEUR.2012.00011; Zemke R., 1985, FIGURING THINGS OUT	40	34	34	0	1	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2016	53	6					669	679		10.1682/JRRD.2015.07.0136			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	EK5SC	WOS:000393985100003	27997672	Green Accepted, gold			2022-02-06	
J	Gao, JL; Grill, RJ; Dunn, TJ; Bedi, S; Labastida, JA; Hetz, RA; Xue, HS; Thonhoff, JR; DeWitt, DS; Prough, DS; Cox, CS; Wu, P				Gao, Junling; Grill, Raymond J.; Dunn, Tiffany J.; Bedi, Supinder; Labastida, Javier Allende; Hetz, Robert A.; Xue, Hasen; Thonhoff, Jason R.; DeWitt, Douglas S.; Prough, Donald S.; Cox, Charles S., Jr.; Wu, Ping			Human Neural Stem Cell Transplantation-Mediated Alteration of Microglial/Macrophage Phenotypes After Traumatic Brain Injury	CELL TRANSPLANTATION			English	Article						Neural stem cells (NSCs); Microglia; Traumatic brain injury (TBI); Transplantation; Immunomodulation	SPINAL-CORD-INJURY; MACROPHAGE ACTIVATION; INFLAMMATORY RESPONSE; STEM/PROGENITOR CELLS; M2 MICROGLIA; THERAPY; POLARIZATION; SYSTEM; NEUROINFLAMMATION; IMMUNOGENICITY	Neural stem cells (NSCs) promote recovery from brain trauma, but neuronal replacement is unlikely the sole underlying mechanism. We hypothesize that grafted NSCs enhance neural repair at least partially through modulating the host immune response after traumatic brain injury (TBI). C57BL/6 mice were intracerebrally injected with primed human NSCs (hNSCs) or vehicle 24 h after a severe controlled cortical impact injury. Six days after transplantation, brain tissues were collected for Western blot and immunohistochemical analyses. Observations included indicators of microglia/macrophage activation, M1 and M2 phenotypes, axonal injury detected by amyloid precursor protein (APP), lesion size, and the fate of grafted hNSCs. Animals receiving hNSC transplantation did not show significant decreases of brain lesion volumes compared to transplantation procedures with vehicle alone, but did show significantly reduced injury-dependent accumulation of APP. Furthermore, intracerebral transplantation of hNSCs reduced microglial activation as shown by a diminished intensity of Ibal immunostaining and a transition of microglia/macrophages toward the M2 anti-inflammatory phenotype. The latter was represented by an increase in the brain M2/M1 ratio and increases of M2 microglial proteins. These phenotypic switches were accompanied by the increased expression of anti-inflammatory interleukin-4 receptor alpha and decreased proinflammatory interferon-gamma receptor beta. Finally, grafted hNSCs mainly differentiated into neurons and were phagocytized by either M1 or M2 microglia/macrophages. Thus, intracerebral transplantation of primed hNSCs efficiently leads host microglia/macrophages toward an anti-inflammatory phenotype that presumably contributes to stem cell-mediated neuroprotective effects after severe TBI in mice.	[Gao, Junling; Dunn, Tiffany J.; Labastida, Javier Allende; Thonhoff, Jason R.; Wu, Ping] Univ Texas Med Branch Galveston, Dept Neurosci & Cell Biol, 301 Univ Blvd,Res Bldg 17, Galveston, TX 77555 USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Bedi, Supinder; Hetz, Robert A.; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [DeWitt, Douglas S.; Prough, Donald S.] Univ Texas Med Branch Galveston, Dept Anesthesiol, Galveston, TX USA; [Wu, Ping] Beijing Inst Brain Disorders, Beijing, Peoples R China		Wu, P (corresponding author), Univ Texas Med Branch Galveston, Dept Neurosci & Cell Biol, 301 Univ Blvd,Res Bldg 17, Galveston, TX 77555 USA.; Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu; piwu@utmb.edu	Allende Labastida, Javier/AAA-4500-2021; Prough, Donald S/G-5793-2013	Allende Labastida, Javier/0000-0001-6372-3300; Prough, Donald S/0000-0001-7994-532X	TIRR Foundation Mission Connect; Coalition for Brain Injury Research; Gilson Longenbaugh Foundation; Moody Project; J. S. Dunn Foundation	The work was supported by grants from the TIRR Foundation Mission Connect to P.W., C.S.C., and R.J.G.; the Coalition for Brain Injury Research to P.W.; the Gilson Longenbaugh Foundation to P.W; the Moody Project to P.W, D.S.D., and D.S.P.; and the J. S. Dunn Foundation to P.W. The authors thank Dr. Yongjia Yu and Dr. Richard Coggeshall for the critical reading of the manuscript. The authors declare no conflicts of interest.	Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Canton J, 2014, J LEUKOCYTE BIOL, V96, P729, DOI 10.1189/jlb.1MR0114-021R; Capetian P, 2011, SEMIN IMMUNOPATHOL, V33, P619, DOI 10.1007/s00281-011-0272-x; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu J, 2013, STEM CELL RES, V10, P325, DOI 10.1016/j.scr.2013.01.001; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martino G, 2011, PHYSIOL REV, V91, P1281, DOI 10.1152/physrev.00032.2010; McManus MM, 2011, JOVE-J VIS EXP, V58, P3246; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mosher KI, 2012, NAT NEUROSCI, V15, P1485, DOI 10.1038/nn.3233; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Payne Natalie, 2011, Curr Stem Cell Res Ther, V6, P50, DOI 10.2174/157488811794480735; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2013, GLIA, V61, P1379, DOI 10.1002/glia.22500; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Snyder EY, 2012, NEW ENGL J MED, V366, P1940, DOI 10.1056/NEJMcibr1200138; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	51	34	35	0	9	COGNIZANT COMMUNICATION CORP	PUTNAM VALLEY	18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2016	25	10					1863	1877		10.3727/096368916X691150			15	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	DY4FV	WOS:000385055300010	26980267	Bronze			2022-02-06	
J	Harvey, L; Mitchell, R; Brodaty, H; Draper, B; Close, J				Harvey, Lara; Mitchell, Rebecca; Brodaty, Henry; Draper, Brian; Close, Jacqueline			The influence of dementia on injury-related hospitalisations and outcomes in older adults	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Injury; Hospitalisations; Dementia; Prevalence; Mortality; Probabilistic data linkage	TRAUMATIC BRAIN-INJURY; HIP FRACTURE; PEOPLE; POPULATION; MORTALITY; COMMUNITY; SURVIVAL; DISEASE	Introduction: Injury is the most common reason for admission to hospital in people with dementia in Australia. However relatively little is known about the temporal trends and the hospital experience of people with dementia hospitalised for an injury. This population-based data linkage study compared the causes, temporal trends and health outcomes for injury-related hospitalisations in people with and without dementia. Methods: Hospitalisation and death data for 235,612 individuals aged 65 years and over admitted to hospital for an injury over the ten year period (2003-2012) in New South Wales, Australia were probabilistically linked. Descriptive statistics including chi square tests, observed and age-standardised admission rates and rate ratios (RRs) were calculated. Trends over time were analysed using negative binomial regression. Results: There were 331,432 injury-related hospitalisations over the study period. Both the observed (RR 3.16; 95% CI 3.13-3.19) and age-standardised admission rate ratios (RR 1.78; 95% CI 1.77-1.79) were higher for people with dementia. Age-standardised rates increased by 3.5% (95% CI 3.1-3.9) per annum over the study period for people without dementia. In contrast, for people with dementia, rates increased by 2.4% (95% CI 1.8-3.1) per annum until 2007 and then decreased by 3.1% (95% CI -4.4 to -1.7) per annum from 2007 onwards. Compared to people without dementia, a higher proportion of people with dementia were hospitalised as a result of a fall (90.9% vs 75.2%, p < 0.0001), sustained a fracture (57.2% vs 52.1%, p < 0.0001), notably hip fracture (30.7% vs 14.7%, p < 0.0001), had longer mean hospital lengths of stay (LOS) (16.5 vs 13.6 days), and higher 30-day mortality (8.7% vs 3.6% p < 0.0001), although this pattern was not consistent across all injury types. Conclusions: People with dementia are disproportionately represented in injury-related hospitalisations, experience longer hospital LOS and have poorer outcomes. Ninety percent of hospitalisations for people with dementia were as a result of a fall, highlighting the importance of developing and implementing effective fall-related preventive strategies in this high risk population. (C) 2015 Elsevier Ltd. All rights reserved.	[Harvey, Lara; Mitchell, Rebecca; Close, Jacqueline] UNSW, Neurosci Res Australia, Falls & Injury Prevent Grp, Sydney, NSW, Australia; [Mitchell, Rebecca] Macquarie Univ, Australian Inst Hlth Innovat, N Ryde, NSW 2109, Australia; [Brodaty, Henry; Draper, Brian] UNSW, Dementia Collaborat Res Ctr Assessment & Better C, Sydney, NSW, Australia; [Brodaty, Henry; Draper, Brian] UNSW, Sch Psychiat, Ctr Hlth Brain Ageing, Sydney, NSW, Australia; [Close, Jacqueline] UNSW, Prince Wales Clin Sch, Sydney, NSW, Australia		Harvey, L (corresponding author), Neurosci Res Australia, Barker St, Sydney, NSW 2031, Australia.	l.harvey@neura.edu.au	Mitchell, Rebecca/Z-5476-2019	Mitchell, Rebecca/0000-0003-1939-1761	Dementia Collaborative Research Centres-Assessment and Better Care, University of New South Wales	This study was funded by the Dementia Collaborative Research Centres-Assessment and Better Care, University of New South Wales. The authors would like to thank the NSW Ministry of Health and the NSW Registry of Birth Deaths and Marriages for the provision of the hospitalisation and death data extracts, and the Centre for Health Record Linkage (CHeReL) for the provision of the unique patient identifiers used to link the datasets.	Abrahamsen B, 2010, OSTEOPOROSIS INT, V21, P373, DOI 10.1007/s00198-009-0957-3; *ACC EC, 2005, DEM EST PROJ AUSTR S; Allan LM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005521; Australian Bureau of Statistics, 2013, 3101 0 AUSTR DEM STA; Australian Health Performance Authority, 2013, HOSP PERF LENGTH S S; Australian Institute of Health and Welfare, 2009, NAT HLTH PERF FRAM; Berry J., 2006, GUIDE STAT METHODS I; Centre for Health Record Linkage, 2012, MAST LINK KEY QUAL A; Cummings E, 2011, HEALTH INF MANAG J, V40, P5, DOI 10.1177/183335831104000301; Deloitte Access Economics, 2011, DEM AUSTR 2011 2050; Dewey ME, 2001, INT J GERIATR PSYCH, V16, P751, DOI 10.1002/gps.397.abs; Draper B, 2011, INT PSYCHOGERIATR, V23, P1649, DOI 10.1017/S1041610211001694; Fong TG, 2012, ANN INTERN MED, V156, P848, DOI 10.7326/0003-4819-156-12-201206190-00005; Hartholt KA, 2011, J NEUROTRAUM, V28, P739, DOI 10.1089/neu.2010.1488; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Kannus P, 2006, J BONE MINER RES, V21, P1836, DOI 10.1359/JBMR.060815; Knopp-Sihota JA, 2014, GERIATR GERONTOL INT, V14, P121, DOI 10.1111/ggi.12069; National Centre for Classification in Health, 2010, INT STAT CLASS DIS R; National Centre for Classification in Health N, 2010, AUSTR COD STAND ICD; Preen DB, 2006, J CLIN EPIDEMIOL, V59, P940, DOI 10.1016/j.jclinepi.2005.12.013; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rudolph JL, 2010, J AM GERIATR SOC, V58, P1542, DOI 10.1111/j.1532-5415.2010.02924.x; SAS Institute, 2013, SAS ENT GUID 6 1 64; Scandol JP, 2013, INJURY, V44, P776, DOI 10.1016/j.injury.2012.11.023; Stevens JA, 2013, OSTEOPOROSIS INT, V24, P2725, DOI 10.1007/s00198-013-2375-9; Toson B, 2015, J CLIN EPIDEMIOL, V68, P44, DOI 10.1016/j.jclinepi.2014.09.017; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Waring SC, 2005, ALZ DIS ASSOC DIS, V19, P178, DOI 10.1097/01.wad.0000189033.35579.2d; Xie J, 2008, BMJ-BRIT MED J, V336, P258, DOI 10.1136/bmj.39433.616678.25	30	34	34	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2016	47	1					226	234		10.1016/j.injury.2015.09.021			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CZ8HD	WOS:000367339900040	26534784				2022-02-06	
J	Merritt, VC; Arnett, PA				Merritt, Victoria C.; Arnett, Peter A.			Apolipoprotein E (APOE) epsilon 4 Allele Is Associated with Increased Symptom Reporting Following Sports Concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						APOE gene; Genetics; Mild traumatic brain injury; Post-concussion symptoms; Sports injuries; Collegiate athletes	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; E GENOTYPE; PREDICTORS; MODERATE	Exploring the relationship between genetic factors and outcome following brain injury has received increased attention in recent years. However, few studies have evaluated the influence of genes on specific sequelae of concussion. The purpose of this study was to determine how the E4 allele of the apolipoprotein E (APOE) gene influences symptom expression following sports-related concussion. Participants included 42 collegiate athletes who underwent neuropsychological testing, including completion of the Post-Concussion Symptom Scale (PCSS), within 3 months after sustaining a concussion (73.8% were evaluated within 1 week). Athletes provided buccal samples that were analyzed to determine the make-up of their APOE genotype. Dependent variables included a total symptom score and four symptom clusters derived from the PCSS. Mann-Whitney U tests showed higher scores reported by athletes with the E4 allele compared to those without it on the total symptom score and the physical and cognitive symptom clusters. Furthermore, logistic regression showed that the E4 allele independently predicted those athletes who reported physical and cognitive symptoms following concussion. These findings illustrate that E4+ athletes report greater symptomatology post-concussion than E4- athletes, suggesting that the E4 genotype may confer risk for poorer post-concussion outcome. (JINS, 2016, 22, 89-94)	[Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, University Pk, PA 16802 USA		Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu		Merritt, Victoria/0000-0001-5683-4168	American Psychological Foundation	We thank Dr. Deborah Grove, PhD, Director of the Genomics Core Facility at Penn State, who was instrumental in processing the genetic data for this study. She also was involved in writing the description of the laboratory procedures (under the Method section). We also thank Dr. Wayne Sebastianelli, MD, Director of Athletic Medicine at Penn State, and Penn State Sports Medicine, for their ongoing support of our research. Ms. Merritt has no conflicts of interest to report. Dr. Arnett has served as part of a paid speaker series sponsored by EMD Serono. He has also served as a consultant for Biogen IDEC. Finally, the research described in this manuscript was supported by a grant to the first author from the American Psychological Foundation.	Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen Helen, 2008, BMC Geriatr, V8, P14, DOI 10.1186/1471-2318-8-14; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Eisenberg DTA, 2010, AM J PHYS ANTHROPOL, V143, P100, DOI 10.1002/ajpa.21298; Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738; Ingelsson M, 2003, CURRENT PROTOCOLS HU, DOI DOI 10.1002/0471142905.HG0914S38.; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595	20	34	34	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2016	22	1					89	94		10.1017/S1355617715001022			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	DA1XW	WOS:000367590300010	26483005				2022-02-06	
J	Turner-Stokes, L; Williams, H; Bill, A; Bassett, P; Sephton, K				Turner-Stokes, Lynne; Williams, Heather; Bill, Alan; Bassett, Paul; Sephton, Keith			Cost-efficiency of specialist inpatient rehabilitation for working-aged adults with complex neurological disabilities: a multicentre cohort analysis of a national clinical data set	BMJ OPEN			English	Article							UNIFORM DATA SYSTEM; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; PROGRAMS; CARE; DEPENDENCY; OUTCOMES; CASEMIX; SCORE; STAY	Objectives: To evaluate functional outcomes, care needs and cost-efficiency of specialist rehabilitation for a multicentre cohort of inpatients with complex neurological disability, comparing different diagnostic groups across 3 levels of dependency. Design: A multicentre cohort analysis of prospectively collected clinical data from the UK Rehabilitation Outcomes Collaborative (UKROC) national clinical database, 2010-2015. Setting: All 62 specialist (levels 1 and 2) rehabilitation services in England. Participants: Working-aged adults (16-65 years) with complex neurological disability. Inclusion criteria: all episodes with length of stay (LOS) 8-400 days and complete outcome measures recorded on admission and discharge. Total N= 5739: acquired brain injury n= 4182 (73%); spinal cord injury n= 506 (9%); peripheral neurological conditions n= 282 (5%); progressive conditions n= 769 (13%). Intervention: Specialist inpatient multidisciplinary rehabilitation. Outcome measures: Dependency and care costs: Northwick Park Dependency Scale/ Care Needs Assessment (NPDS/ NPCNA). Functional independence: UK Functional Assessment Measure (UK Functional Independence Measure (FIM)+ FAM). Cost-efficiency: (1) time taken to offset rehabilitation costs by savings in NPCNA-estimated costs of ongoing care, (2) FIM efficiency (FIM gain/ LOS days), (3) FIM+ FAM efficiency (FIM+ FAM gain/ LOS days). Patients were analysed in 3 groups of dependency. Results: Mean LOS 90.1 (SD 66) days. All groups showed significant reduction in dependency between admission and discharge on all measures (paired t tests: p< 0.001). Mean reduction in `weekly care costs' was greatest in the high-dependency group at xi 760/ week (95% CI 726 to 794)), compared with the medium-dependency (xi 408/ week (95% CI 370 to 445)), and low-dependency ( 130/ week (95% CI 82 to 178)), groups. Despite longer LOS, time taken to offset the cost of rehabilitation was 14.2 (95% CI 9.9 to 18.8) months in the high-dependency group, compared with 22.3 (95% CI 16.9 to 29.2) months (medium dependency), and 27.7 (95% CI 15.9 to 39.7) months (low dependency). FIM efficiency appeared greatest in medium-dependency patients (0.54), compared with the low-dependency (0.37) and high-dependency (0.38) groups. Broadly similar patterns were seen across all 4 diagnostic groups. Conclusions: Specialist rehabilitation can be highly cost-efficient for all neurological conditions, producing substantial savings in ongoing care costs, especially in high-dependency patients.	[Turner-Stokes, Lynne] Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, London, England; [Turner-Stokes, Lynne; Williams, Heather; Bill, Alan; Sephton, Keith] Northwick Pk Hosp & Clin Res Ctr, Reg Hyper Acute Rehabil Unit, Harrow, Middx, England; [Bassett, Paul] Statsconsultancy Ltd, London, England		Turner-Stokes, L (corresponding author), Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, London, England.; Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Reg Hyper Acute Rehabil Unit, Harrow, Middx, England.	lynne.turner-stokes@dial.pipex.com	Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462; Bassett, Paul/0000-0001-7830-4563	National Institute for Health Research (NIHR) under Programme Grants for Applied Research programme [RP-PG-0407-10 185]; Dunhill Medical TrustDunhill Medical Trust; National Institute for Health ResearchNational Institute for Health Research (NIHR) [RP-PG-0407-10185] Funding Source: researchfish	This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research programme (RP-PG-0407-10 185). Financial support for the preparation of this manuscript was also provided by the Dunhill Medical Trust.	[Anonymous], 2015, SPEC NEUR SERV PROV; [Anonymous], 2003, NEUR A BRIEF REV NUM; [Anonymous], 2013, GUID HEALTHC SYST EN; [Anonymous], 2005, NATL SERV FRAM LONG; Bottemiller KL, 2006, REHABIL NURS, V31, P22, DOI 10.1002/j.2048-7940.2006.tb00006.x; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Granger CV, 2012, AM J PHYS MED REHAB, V91, P289, DOI 10.1097/PHM.0b013e31824ad2fd; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Khan F, 2009, MULT SCLER J, V15, P869, DOI 10.1177/1352458509105230; Khan F., 2010, J CLIN MED RES, V2, P91; Khan F, 2007, COCHRANE DB SYST REV, V8; Oddy M, 2013, BRAIN INJURY, V27, P1500, DOI 10.3109/02699052.2013.830332; Office for National Statistics, 2014, 2012 BAS PER COH LIF; Siegert RJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004231; Siegert RJ, 2010, J REHABIL MED, V42, P936, DOI 10.2340/16501977-0602; Stineman MG, 2001, MED CARE, V39, P123, DOI 10.1097/00005650-200102000-00003; Tesiberg E., 2006, REDEFINING HLTH CARE; Turner-Stokes L, 2006, J NEUROL NEUROSUR PS, V77, P634, DOI 10.1136/jnnp.2005.073411; Turner-Stokes L, 2004, CLIN MED, V4, P10, DOI 10.7861/clinmedicine.4-1-10; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 1999, CLIN REHABIL, V13, P253, DOI 10.1191/026921599677787870; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Turner-Stokes L, 1998, CLIN REHABIL, V12, P304, DOI 10.1191/026921598669173600; Turner-Stokes L, 2015, RPPG040710185 NIH RE; Turner-Stokes L, 2007, BRAIN INJURY, V21, P1015, DOI 10.1080/02699050701591445; Turner-Stokes L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132275; Turner-Stokes L, 2013, DISABIL REHABIL, V35, P1885, DOI 10.3109/09638288.2013.766271; Turner-Stokes L, 2012, CLIN REHABIL, V26, P264, DOI 10.1177/0269215511417467	31	34	35	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2016	6	2								10.1136/bmjopen-2015-010238			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT5HX	WOS:000381514500105	26911586	Green Published, Green Submitted, gold			2022-02-06	
J	von Steinbuechel, N; Covic, A; Polinder, S; Kohlmann, T; Cepulyte, U; Poinstingl, H; Backhaus, J; Bakx, W; Bullinger, M; Christensen, AL; Formisano, R; Gibbons, H; Hofer, S; Koskinen, S; Maas, A; Neugebauer, E; Powell, J; Sarajuuri, J; Sasse, N; Schmidt, S; Muhlan, H; von Wild, K; Zitnay, G; Truelle, JL				von Steinbuechel, Nicole; Covic, Amra; Polinder, Suzanne; Kohlmann, Thomas; Cepulyte, Ugne; Poinstingl, Herbert; Backhaus, Joy; Bakx, Wilbert; Bullinger, Monika; Christensen, Anne-Lise; Formisano, Rita; Gibbons, Henning; Hoefer, Stefan; Koskinen, Sanna; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; Sarajuuri, Jaana; Sasse, Nadine; Schmidt, Silke; Muehlan, Holger; von Wild, Klaus; Zitnay, George; Truelle, Jean-Luc			Assessment of Health-Related Quality of Life after TBI: Comparison of a Disease-Specific (QOLIBRI) with a Generic (SF-36) Instrument	BEHAVIOURAL NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HOSPITAL ANXIETY; ITEM BANKS; 1ST YEAR; DEPRESSION; MODERATE; MILD; SCALE; INDIVIDUALS; EQ-5D	Psychosocial, emotional, and physical problems can emerge after traumatic brain injury (TBI), potentially impacting health-related quality of life (HRQoL). Until now, however, neither the discriminatory power of disease-specific (QOLIBRI) and generic (SF-36) HRQoL nor their correlates have been compared in detail. These aspects as well as some psychometric item characteristics were studied in a sample of 795 TBI survivors. The Shannon H' index absolute informativity, as an indicator of an instrument's power to differentiate between individuals within a specific group or health state, was investigated. Psychometric performance of the two instruments was predominantly good, generally higher, and more homogenous for the QOLIBRI than for the SF-36 subscales. Notably, the SF-36 "Role Physical," " Role Emotional," and "Social Functioning" subscales showed less satisfactory discriminatory power than all other dimensions or the sum scores of both instruments. The absolute informativity of disease-specific as well as generic HRQoL instruments concerning the different groups defined by different correlates differed significantly. When the focus is on how a certain subscale or sum score differentiates between individuals in one specific dimension/health state, the QOLIBRI can be recommended as the preferable instrument.	[von Steinbuechel, Nicole; Covic, Amra; Cepulyte, Ugne; Poinstingl, Herbert; Backhaus, Joy; Gibbons, Henning; Hoefer, Stefan; Sasse, Nadine] Univ Med Gottingen, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany; [Polinder, Suzanne] Erasmus Med Coll, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Kohlmann, Thomas] Ernst Moritz Arndt Univ Greifswald, Sect Methods Community Med, Inst Community Med, Walther Rathenau Str 48, D-17475 Greifswald, Germany; [Bakx, Wilbert] Hoensbroeck Rehabil Ctr, Postbus 88, NL-6430 AB Hoensbroek, Netherlands; [Bakx, Wilbert] Maastricht Univ, POB 616, NL-6200 MD Maastricht, Netherlands; [Bullinger, Monika] Univ Hosp Eppendorf, Dept Med Psychol, Martinistr 52, D-20251 Hamburg, Germany; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen, Denmark; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Cognit & Memory, Njalsgade 88, DK-2300 Copenhagen, Denmark; [Formisano, Rita] Santa Lucia Fdn, Rehabil Hosp, IRCCS, Via Ardeatina 306-354, I-00179 Rome, Italy; [Gibbons, Henning] Univ Bonn, Dept Psychol, Kaiser Karl Ring 9, D-53111 Bonn, Germany; [Hoefer, Stefan] Med Univ Innsbruck, Dept Med Psychol, Schopfstr 23a, A-6020 Innsbruck, Austria; [Koskinen, Sanna] Univ Helsinki, Inst Behav Sci, Siltavuorenpenger 5 A,POB 9, FIN-00014 Helsinki, Finland; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstraat 10, B-2650 Antwerp, Belgium; [Maas, Andrew] Univ Antwerp, Wilrijkstraat 10, B-2650 Antwerp, Belgium; [Neugebauer, Edmund] Private Univ ofWitten Herdecke, IFOM, Ostmerheimer Str 200, D-51109 Cologne, Germany; [Powell, Jane] Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; [Sarajuuri, Jaana] Validia Rehabil, Dept Clin Neuropsychol & Psychol, Mannerheimintie 107, Helsinki 00280, Finland; [Schmidt, Silke; Muehlan, Holger] Ernst Moritz Arndt Univ Greifswald, Dept Hlth & Prevent, Inst Psychol, D-17475 Greifswald, Germany; [von Wild, Klaus] Univ Munster, Fac Med, Domagkstr 3, D-48149 Munster, Germany; [Zitnay, George] Martha Jefferson Assoc Hosp, 459 Locust Ave, Charlottesville, VA 22902 USA; [Truelle, Jean-Luc] Hop Raymond Poincare, Serv Phys Med & Rehabil MPR, 104 Blvd Raymond Poincare, F-92380 Garches, France		von Steinbuechel, N (corresponding author), Univ Med Gottingen, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany.	nvsteinbuechel@med.uni-goettingen.de	Sarajuuri, Jaana/AAD-8665-2019; Hofer, Stefan/B-8393-2008; Hofer, Stefan/N-8253-2019	Sarajuuri, Jaana/0000-0002-6432-0295; Hofer, Stefan/0000-0002-6128-3687; Hofer, Stefan/0000-0002-6128-3687; Koskinen, Sanna/0000-0002-3453-5084; Bullinger, Monika/0000-0001-8876-0159	ZNS-Hannelore Kohl Stiftung [2008014/2008019]	The authors are grateful to all researchers who helped in collecting data in each country and to the patients who provided them. They wish to cordially thank Dr. Ralph Telgmann for revision of the paper and technical assistance in the preparation. This work was generously founded by the ZNS-Hannelore Kohl Stiftung, Grants 2008014/2008019.	Almeida OP, 2015, INT J GERIATR PSYCH, V30, P1215, DOI 10.1002/gps.4276; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Bullinger M, 2001, CURR PROB E, V16, P277; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cella D., 2007, MED CARE S1, V45, p3S3; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; George D., 2010, SPSS WINDOWS STEP ST, V10th; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Giustini M, 2014, FUNCT NEUROL, V29, P167, DOI 10.11138/FNeur/2014.29.3.167; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Janssen MF, 2008, VALUE HEALTH, V11, P275, DOI 10.1111/j.1524-4733.2007.00230.x; Janssen MFB, 2007, QUAL LIFE RES, V16, P895, DOI 10.1007/s11136-006-9160-6; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Lin YN, 2014, J HEAD TRAUMA REHAB, V29, pE37, DOI 10.1097/HTR.0b013e3182816363; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; Nutt DJ, 2004, J CLIN PSYCHIAT, V65, P11; Olsson I, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-46; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Perez Lori, 2007, J Neurosci Nurs, V39, P342; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Polinder S, 2010, INJURY PREV, V16, P147, DOI 10.1136/ip.2009.022418; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Power M, 2005, QUAL LIFE RES, V14, P2197, DOI 10.1007/s11136-005-7380-9; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Royston P., 1992, STAT COMPUT, V2, P117, DOI [10.1007/BF01891203, DOI 10.1007/BF01891203, 10.1007/bf01891203]; Sasse N, 2013, J HEAD TRAUMA REHAB, V28, P464, DOI 10.1097/HTR.0b013e318263977d; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; SCHRIESHEIM CA, 1981, EDUC PSYCHOL MEAS, V41, P1101, DOI 10.1177/001316448104100420; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Sukraeny N., 2014, SONGKLANAGARIND NU S, V34, P119; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; TEASDALE G, 1974, LANCET, V2, P81; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Ware JE, 1993, MANUAL INTERPRETATIO; Ware Jr JE, 2008, SF 36V2 HLTH SURVEY; Williamson M. L., 2015, J HEAD TRAUMA REHABI; Williamson MLC, 2013, BRAIN INJURY, V27, P992, DOI 10.3109/02699052.2013.801512; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	65	34	34	1	24	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0953-4180	1875-8584		BEHAV NEUROL	Behav. Neurol.		2016	2016								7928014	10.1155/2016/7928014			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DD9TR	WOS:000370269100001	27022207	Green Published, Green Submitted, gold			2022-02-06	
J	Ghasemzadeh, A; Mundinger, GS; Swanson, EW; Utria, AF; Dorafshar, AH				Ghasemzadeh, Ali; Mundinger, Gerhard S.; Swanson, Edward W.; Utria, Alan F.; Dorafshar, Amir H.			Treatment of Pediatric Condylar Fractures: A 20-Year Experience	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							MANDIBLE FRACTURES; OPEN REDUCTION; FOLLOW-UP; CHILDREN; CLASSIFICATION; DEMOGRAPHICS; MANAGEMENT; INJURIES; FIXATION; PATTERNS	Background: The purpose of this study was to define patterns of injury and treatment for condylar and subcondylar fractures and evaluate short-term outcomes in the pediatric population. Methods: A retrospective chart review was performed on pediatric patients with mandibular condylar fractures who presented between 1990 and 2010. Computed tomographic imaging was reviewed for all patients to assess fracture characteristics. Mandibular fractures were codified using the Strasbourg Osteosynthesis Research Group and Lindahl classification methods. Results: Sixty-four patients with 92 condylar fractures were identified. Of these patients, 29 had isolated condylar fracture and 35 had a condylar fracture associated with an additional mandibular arch fracture. The most common fracture patterns were diacapitular fracture in the Strasbourg Osteosynthesis Research Group system (n = 46) and vertical condylar head fracture in the Lindahl system (n = 14). Condylar fracture with additional mandibular arch fractures were treated with maxillomandibular fixation more often than patients with condylar fracture [n = 40 (74.1 percent) versus n = 14 (25.9 percent); p = 0.004]. No condylar fracture was treated in an open fashion. Forty-three patients returned for follow-up. The median follow-up period was 81 days (interquartile range, 35 to 294 days). Ten patients had complications (23.3 percent). The most common complication was malocclusion (n = 5). Nine of 10 patients with complications had condylar fracture with an additional mandibular arch fracture. Conclusions: Closed treatment of condylar fractures yields satisfactory results in pediatric patients. Pediatric patients with condylar fractures combined with additional arch fractures experience a higher rate of unfavorable outcomes.	[Ghasemzadeh, Ali; Mundinger, Gerhard S.; Swanson, Edward W.; Utria, Alan F.; Dorafshar, Amir H.] Johns Hopkins Univ Hosp, Dept Plast & Reconstruct Surg, Baltimore, MD 21287 USA		Dorafshar, AH (corresponding author), Johns Hopkins Univ Hosp, Dept Plast & Reconstruct Surg, JHOC 8150,600 North Wolfe St, Baltimore, MD 21287 USA.	adorafs1@jhmi.edu	Dorafshar, Amir/AAP-2657-2021	Utria, Alan/0000-0003-2431-7611; Ghasemzadeh, Ali/0000-0001-6605-4835; Swanson, Edward/0000-0001-5689-4419; Dorafshar, Amir/0000-0001-7045-3601	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM007309] Funding Source: Medline		Bos RRM, 1999, BRIT J ORAL MAX SURG, V37, P87; Cenzi R, 2009, J CRANIOFAC SURG, V20, P24, DOI [10.1097/SCS.0b013e31819032a3, 10.1097/scs.0b013e31819032a3]; Deleyiannis FWB, 2006, ANN PLAS SURG, V57, P495, DOI 10.1097/01.sap.0000226943.79337.bf; Dodson Thomas B, 2005, Oral Maxillofac Surg Clin North Am, V17, P447, DOI 10.1016/j.coms.2005.06.001; Ellis E, 2005, J ORAL MAXIL SURG, V63, P115, DOI 10.1016/j.joms.2004.02.019; Goth S, 2012, J CRANIOFAC SURG, V23, P47, DOI 10.1097/SCS.0b013e318240c8ab; Grunwaldt L, 2011, PLAST RECONSTR SURG, V128, P1263, DOI 10.1097/PRS.0b013e318230c8cf; Lekven N, 2011, J ORAL MAXIL SURG, V69, P2853, DOI 10.1016/j.joms.2011.03.019; LINDAHL L, 1977, INT J ORAL MAXILLOF, V6, P12, DOI 10.1016/S0300-9785(77)80067-7; Loukota RA, 2005, BRIT J ORAL MAX SURG, V43, P72, DOI 10.1016/j.bjoms.2004.08.018; Pereira MD, 1995, J CRANIO MAXILL SURG, V23, P369, DOI 10.1016/S1010-5182(05)80132-5; Schiel S, 2013, J ORAL MAXIL SURG, V71, P1220, DOI 10.1016/j.joms.2013.03.023; Smartt JM, 2005, PLAST RECONSTR SURG, V116, p28E, DOI 10.1097/01.prs.0000173445.10908.f8; Smith DM, 2013, PLAST RECONSTR SURG, V131, P1348, DOI 10.1097/PRS.0b013e31828bd503; Thoren H, 1997, BRIT J ORAL MAX SURG, V35, P306, DOI 10.1016/S0266-4356(97)90401-0; Thoren H, 2001, J ORAL MAXIL SURG, V59, P768, DOI 10.1053/joms.2001.23369; Wheeler J, 2011, CRANIOMAX TRAUM REC, V4, P43, DOI 10.1055/s-0031-1272901	17	34	35	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	DEC	2015	136	6					1279	1288		10.1097/PRS.0000000000001811			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CW6LJ	WOS:000365108700002	26595021	Green Accepted			2022-02-06	
J	Bohrer, C; Pfurr, S; Mammadzada, K; Schildge, S; Plappert, L; Hils, M; Pous, L; Rauch, KS; Dumit, VI; Pfeifer, D; Dengjel, J; Kirsch, M; Schachtrup, K; Schachtrup, C				Bohrer, Christian; Pfurr, Sabrina; Mammadzada, Koenuel; Schildge, Sebastian; Plappert, Leandra; Hils, Miriam; Pous, Lauriane; Rauch, Katharina S.; Dumit, Veronica I.; Pfeifer, Dietmar; Dengjel, Joern; Kirsch, Matthias; Schachtrup, Kristina; Schachtrup, Christian			The balance of Id3 and E47 determines neural stem/precursor cell differentiation into astrocytes	EMBO JOURNAL			English	Article						astrocyte-specific genes; basic helix-loop-helix transcription factor; bone morphogenetic protein; traumatic brain injury; vascular damage	TRANSCRIPTION FACTOR OLIG2; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; SUBVENTRICULAR ZONE; TGF-BETA; POSTNATAL NEUROGENESIS; ADULT NEUROGENESIS; BRAIN; PROTEINS; NICHE	Adult neural stem/precursor cells (NSPCs) of the subventricular zone (SVZ) are an endogenous source for neuronal replacement in CNS disease. However, adult neurogenesis is compromised after brain injury in favor of a glial cell fate, which is mainly attributed to changes in the NSPC environment. Yet, it is unknown how this unfavorable extracellular environment translates into a transcriptional program altering NSPC differentiation. Here, we show that genetic depletion of the transcriptional regulator Id3 decreased the number of astrocytes generated from SVZ-derived adult NSPCs in the cortical lesion area after traumatic brain injury. Cortical brain injury resulted in rapid BMP-2 and Id3 up-regulation in the SVZ stem cell niche. Id3(-/-) adult NSPCs failed to differentiate into BMP-2-induced astrocytes, while NSPCs deficient for the Id3-controlled transcription factor E47 readily differentiated into astrocytes in the absence of BMP-2. Mechanistically, E47 repressed the expression of several astrocyte-specific genes in adult NSPCs. These results identify Id3 as the BMP-2-induced transcriptional regulator, promoting adult NSPC differentiation into astrocytes upon CNS injury and reveal a molecular link between environmental changes and NSPC differentiation in the CNS after injury.	[Bohrer, Christian; Pfurr, Sabrina; Mammadzada, Koenuel; Schildge, Sebastian; Plappert, Leandra; Pous, Lauriane; Kirsch, Matthias; Schachtrup, Christian] Univ Freiburg, Inst Anat & Cell Biol, D-79106 Freiburg, Germany; [Bohrer, Christian; Pfurr, Sabrina; Mammadzada, Koenuel; Schildge, Sebastian; Plappert, Leandra; Hils, Miriam; Pous, Lauriane; Rauch, Katharina S.] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany; [Hils, Miriam; Rauch, Katharina S.; Schachtrup, Kristina] Univ Freiburg, Univ Med Ctr Freiburg, CCI, D-79106 Freiburg, Germany; [Dumit, Veronica I.; Dengjel, Joern] Univ Freiburg, Dept Dermatol, Med Ctr,BIOSS Ctr Biol Signalling Studies, Freiburg Inst Adv Studies FRIAS,ZBSA Ctr Biol Sys, D-79106 Freiburg, Germany; [Pfeifer, Dietmar] Univ Freiburg, Univ Med Ctr Freiburg, Dept Hematol Oncol & Stem Cell Transplantat, D-79106 Freiburg, Germany		Schachtrup, C (corresponding author), Univ Freiburg, Inst Anat & Cell Biol, Hugstetter Str 55, D-79106 Freiburg, Germany.	christian.schachtrup@anat.uni-freiburg.de	Dengjel, Joern/AAI-3682-2020; Kirsch, Matthias/G-7227-2015	Kirsch, Matthias/0000-0002-2090-8556; Dengjel, Joern/0000-0002-9453-4614; Schachtrup, Kristina/0000-0002-9385-8254	International Graduate Academy Fellowship; German Academic Exchange Service Fellowship; Fazit Foundation Graduate Fellowship; European Commission FP7 Grant [PIRG08-GA-2010-276989, PIRG08-GA-2010-276906]; NEUREX; German Research FoundationGerman Research Foundation (DFG) [SCHA 1442/3-2]; German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF 01EO1303]	We are grateful to Cornelis Murre for the Id3<SUP>-/-</SUP> mice. We thank Meike Ast-Dumbach for outstanding technical assistance and Gary Howard for editorial assistance. This work was supported by the International Graduate Academy Fellowship to C.B. and K.S.R., a German Academic Exchange Service Fellowship to K.M., the Fazit Foundation Graduate Fellowship to S.S., the European Commission FP7 Grant PIRG08-GA-2010-276989, NEUREX, and the German Research Foundation Grant SCHA 1442/3-2 to C.S., the European Commission FP7 Grant PIRG08-GA-2010-276906 and the German Federal Ministry of Education and Research (BMBF 01EO1303) to K.S.	ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Beck K, 2009, J EXP MED, V206, P2271, DOI 10.1084/jem.20090756; Belvindrah R, 2009, REV NEUROSCIENCE, V20, P331, DOI 10.1515/REVNEURO.2009.20.5-6.331; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bonaguidi MA, 2005, DEVELOPMENT, V132, P5503, DOI 10.1242/dev.02166; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chen Y, 2008, J NEUROSCI, V28, P10983, DOI 10.1523/JNEUROSCI.3545-08.2008; Codega P, 2014, NEURON, V82, P545, DOI 10.1016/j.neuron.2014.02.039; Colak D, 2008, J NEUROSCI, V28, P434, DOI 10.1523/JNEUROSCI.4374-07.2008; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Emsley JG, 2003, EXP NEUROL, V183, P298, DOI 10.1016/S0014-4886(03)00129-8; Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928; Fuentealba LC, 2012, CELL STEM CELL, V10, P698, DOI 10.1016/j.stem.2012.05.012; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gajera CR, 2010, J CELL SCI, V123, P1922, DOI 10.1242/jcs.065912; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hampton DW, 2007, EUR J NEUROSCI, V26, P3024, DOI 10.1111/j.1460-9568.2007.05940.x; Havrda MC, 2008, J NEUROSCI, V28, P14074, DOI 10.1523/JNEUROSCI.3188-08.2008; He YB, 2014, NAT NEUROSCI, V17, P943, DOI 10.1038/nn.3732; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; Jung S, 2010, STEM CELLS DEV, V19, P831, DOI 10.1089/scd.2009.0093; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kessaris N, 2008, PHILOS T R SOC B, V363, P71, DOI 10.1098/rstb.2006.2013; Kitajima K, 2006, BRAIN RES, V1073, P93, DOI 10.1016/j.brainres.2005.12.048; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Li L, 2010, GLIA, V58, P1610, DOI 10.1002/glia.21033; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Liu F, 2009, J NEUROSCI, V29, P5075, DOI 10.1523/JNEUROSCI.0201-09.2009; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mira H, 2010, CELL STEM CELL, V7, P78, DOI 10.1016/j.stem.2010.04.016; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Morales-Garcia JA, 2011, GLIA, V59, P293, DOI 10.1002/glia.21101; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Nam HS, 2009, CELL STEM CELL, V5, P515, DOI 10.1016/j.stem.2009.08.017; Niola F, 2012, NAT CELL BIOL, V14, P477, DOI 10.1038/ncb2490; Obernier K, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00162; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; Porlan E, 2013, NAT NEUROSCI, V16, P1567, DOI 10.1038/nn.3545; Qi XA, 2010, EXP NEUROL, V221, P353, DOI 10.1016/j.expneurol.2009.12.003; Raponi E, 2007, GLIA, V55, P165, DOI 10.1002/glia.20445; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schildge S, 2014, CURR MED CHEM, V21, P2190, DOI 10.2174/0929867321666131227162215; Stipursky J, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00393; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tzeng SF, 1999, GLIA, V26, P139, DOI 10.1002/(SICI)1098-1136(199904)26:2<139::AID-GLIA5>3.0.CO;2-1; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013	70	34	34	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0261-4189	1460-2075		EMBO J	Embo J.	NOV 12	2015	34	22					2804	2819		10.15252/embj.201591118			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CY7QR	WOS:000366604300010	26438726	Green Published			2022-02-06	
J	Bajsarowicz, P; Prakash, I; Lamoureux, J; Saluja, RS; Feyz, M; Maleki, M; Marcoux, J				Bajsarowicz, Paul; Prakash, Ipshita; Lamoureux, Julie; Saluja, Rajeet Singh; Feyz, Mitra; Maleki, Mohammad; Marcoux, Judith			Nonsurgical acute traumatic subdural hematoma: what is the risk?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; subdural hematoma; acute subdural hematoma; nonsurgical subdural hematoma; trauma	CEREBRAL ATROPHY; PRACTICAL SCALE; INJURY; BICAUDATE; SCORE; COMA	OBJECT The Brain Trauma Foundation has published guidelines on the surgical management of traumatic subdural hematoma (SDH). However, no data exist on the proportion of patients with SDH that can be selected for conservative management and what is the outcome of these patients. The goals of this study were as follows: 1) to establish what proportion of patients are initially treated conservatively; 2) to determine what proportion of patients will deteriorate and require surgical evacuation; and 3) to identify risk factors associated with deterioration and delayed surgery. METHODS All cases of acute traumatic SDH (869 when inclusion criteria were met) presenting over a 4-year period were reviewed. For all conservatively treated SDH, the proportion of delayed surgical intervention and the Glasgow Outcome Scale score were taken as outcome measures. Multiple factors were compared between patients who required delayed surgery and patients without surgery. RESULTS Of the 869 patients with acute traumatic SDH, 646 (74.3%) were initially treated conservatively. A good outcome was achieved in 76.7% of the patients. Only 6.5% eventually required delayed surgery, and the median delay for surgery was 9.5 days. Factors associated with deterioration were as follows: 1) thicker SDH (p < 0.001); 2) greater midline shift (p < 0.001); 3) location at the convexity (p = 0.001); 4) alcohol abuse (p = 0.0260); and 5) history of falls (p = 0.018). There was no significant difference in regard to age, sex, Glasgow Coma Scale score, Injury Severity Score, abnormal coagulation, use of blood thinners, and presence of cerebral atrophy or white matter disease. CONCLUSIONS The majority of patients with SDH are treated conservatively. Of those, only 6.5% later required surgery, for raised intracranial pressure or SDH progression. Patients at risk can be identified and followed more carefully.	[Bajsarowicz, Paul] McGill Univ, Dept Radiol, Montreal, PQ H3A 2T5, Canada; [Prakash, Ipshita] McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; [Saluja, Rajeet Singh; Maleki, Mohammad; Marcoux, Judith] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2T5, Canada; [Feyz, Mitra] McGill Univ, Dept Surg, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Maleki, Mohammad; Marcoux, Judith] McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada; [Lamoureux, Julie] Baptist Hlth South Florida, Miami, FL USA		Marcoux, J (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Dept Neurosurg, 1650 Cedar Ave,Rm L7-516, Montreal, PQ H3G 1A4, Canada.	judith.marcoux@mcgill.ca					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; Doraiswamy P M, 1994, J Geriatr Psychiatry Neurol, V7, P13; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; Institut de la Statistique du Quebec, 2006, PROJ POP QUEB SEL TE; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lee KS, 1998, BRAIN INJURY, V12, P901; Marion DW, 2006, NEUROSURGERY, V58, P655; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; TEASDALE G, 1974, LANCET, V2, P81; Tokmak M, 2007, J NEUROSURG, V107, P290, DOI 10.3171/JNS-07/08/0290; van Zagten M, 1999, NEURORADIOLOGY, V41, P261, DOI 10.1007/s002340050743; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Yang AIL, 2012, BRAIN INJURY, V26, P1731, DOI 10.3109/02699052.2012.698364	18	34	35	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1176	1183		10.3171/2014.10.JNS141728			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800010	25955872	Bronze			2022-02-06	
J	Garner, AA; Mann, KP; Fearnside, M; Poynter, E; Gebski, V				Garner, Alan A.; Mann, Kristy P.; Fearnside, Michael; Poynter, Elwyn; Gebski, Val			The Head Injury Retrieval Trial (HIRT): a single-centre randomised controlled trial of physician prehospital management of severe blunt head injury compared with management by paramedics only	EMERGENCY MEDICINE JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; MORTALITY; CARE	Background Advanced prehospital interventions for severe brain injury remains controversial. No previous randomised trial has been conducted to evaluate additional physician intervention compared with paramedic only care. Methods Participants in this prospective, randomised controlled trial were adult patients with blunt trauma with either a scene GCS score <9 (original definition), or GCS<13 and an Abbreviated Injury Scale score for the head region >= 3 (modified definition). Patients were randomised to either standard ground paramedic treatment or standard treatment plus a physician arriving by helicopter. Patients were evaluated by 30-day mortality and 6-month Glasgow Outcome Scale (GOS) scores. Due to high non-compliance rates, both intention-to-treat and as-treated analyses were preplanned. Results 375 patients met the original definition, of which 197 was allocated to physician care. Differences in the 6-month GOS scores were not significant on intention-to-treat analysis (OR 1.11, 95% CI 0.74 to 1.66, p=0.62) nor was the 30-day mortality (OR 0.91, 95% CI 0.60 to 1.38, p=0.66). As-treated analysis showed a 16% reduction in 30-day mortality in those receiving additional physician care; 60/195 (29%) versus 81/180 (45%), p<0.01, Number needed to treat =6. 338 patients met the modified definition, of which 182 were allocated to physician care. The 6-month GOS scores were not significantly different on intention-to-treat analysis (OR 1.14, 95% CI 0.73 to 1.75, p=0.56) nor was the 30-day mortality (OR 1.05, 95% CI 0.66 to 1.66, p=0.84). As-treated analyses were also not significantly different. Conclusions This trial suggests a potential mortality reduction in patients with blunt trauma with GCS<9 receiving additional physician care (original definition only). Confirmatory studies which also address noncompliance issues are needed.	[Garner, Alan A.; Poynter, Elwyn] CareFlight, Wentworthville, NSW 2145, Australia; [Mann, Kristy P.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia; [Fearnside, Michael] Westmead Hosp, Dept Surg, Sydney, NSW, Australia; [Gebski, Val] Univ Sydney, NHMRC Clin Trials Ctr, Biostat & Res Methodol, Sydney, NSW 2006, Australia		Garner, AA (corresponding author), CareFlight, Locked Bag 2002, Wentworthville, NSW 2145, Australia.	alang@careflight.org	Garner, Alan/AAN-1513-2020	Garner, Alan/0000-0002-4010-9137; Robledo, Kristy/0000-0003-0213-7652; Gebski, Val/0000-0001-8748-1844	Insurance Australia Group, NSW Motor Accident Authority	Insurance Australia Group, NSW Motor Accident Authority.	BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Early Management of Severe Trauma course content, 2013, EARL MAN SEV TRAUM C; Franschman G, 2012, INJURY, V43, P1838, DOI 10.1016/j.injury.2012.05.020; Garner A, 2001, INJURY, V32, P455, DOI 10.1016/S0020-1383(01)00013-4; Garner AA, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-69; JENNETT B, 1975, LANCET, V1, P480; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 1987, NEUROBEHAVIORAL RECO, P206; RICE WR, 1988, BIOMETRICS, V44, P1, DOI 10.2307/2531892; Stewart KE, 2011, ACAD EMERG MED, V18, P1208, DOI 10.1111/j.1553-2712.2011.01207.x; WHITEHEAD J, 1993, STAT MED, V12, P2257, DOI 10.1002/sim.4780122404; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	15	34	34	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	NOV	2015	32	11					869	875		10.1136/emermed-2014-204390			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CU4CK	WOS:000363473600010	25795741	Green Published, hybrid			2022-02-06	
J	Reeser, JC; Gregory, A; Berg, RL; Comstock, RD				Reeser, Jonathan C.; Gregory, Andrew; Berg, Richard L.; Comstock, R. Dawn			A Comparison of Women's Collegiate and Girls' High School Volleyball Injury Data Collected Prospectively Over a 4-Year Period	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						volleyball; injury surveillance; injury patterns; high school athletes; collegiate athletes	STATES HIGH-SCHOOL; SPORTS INJURIES; PROSPECTIVE COHORT; KNEE INJURIES; RISK-FACTORS; EPIDEMIOLOGY; CONCUSSIONS; MECHANISMS; PREVENTION	Background: There is a relative paucity of research examining the sport-specific injury epidemiology of high school and collegiate volleyball athletes. Moreover, differences in study methodology frequently limit our ability to compare and contrast injury data collected from selected populations. Hypothesis: There are differences between the injury patterns characteristic of high school and collegiate female volleyball athletes. Study Design: Retrospective clinical review. Level of Evidence: Level 3. Methods: We statistically analyzed injury incidence and outcome data collected over a 4-year interval (2005-2006 to 2008-2009) by 2 similar injury surveillance systems, the National Collegiate Athletic Association's Injury Surveillance System (NCAA ISS) and the High School Reporting Injuries Online (HS RIO). We compared diagnoses, anatomic distribution of injuries, mechanisms of injury, and time lost from training or competition between high school and collegiate volleyball athletes. Results: The overall volleyball-related injury rate was significantly greater among collegiate athletes than among high school athletes during both competition (injury rate ratio, 2.9; 95% CI, 2.5-3.4) and practice (injury rate ratio, 3.5; 95% CI, 3.1-3.9). Collegiate athletes had a higher rate of ankle sprain, knee injury, and shoulder injury. Concussions represented a relatively high percentage of injuries in both populations (5.0% of total NCAA ISS injuries vs 4.8% of total HS RIO injuries, respectively). Conclusion: The data suggest that although similar, there were distinct differences between the injury patterns of the 2 populations. Compared with high school volleyball players, collegiate athletes have a higher rate of acute time loss injury as well as overuse time loss injury (particularly patellar tendinosis). Concussions represented a significant and worrisome component of the injury pattern for both study populations.	[Reeser, Jonathan C.; Berg, Richard L.] Marshfield Clin Res Fdn, Marshfield, WI USA; [Gregory, Andrew] Vanderbilt Sports Med Med Ctr East, Nashville, TN USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Colorado Sch Publ Hlth Epidemiol, Pediat Pediat Injury Prevent Educ & Res PIPER Pro, Aurora, CO 80309 USA		Reeser, JC (corresponding author), Marshfield Res Fdn, 1000 North Oak Ave, Marshfield, WI 54449 USA.	jreeser@charter.net			Marshfield Clinic Research Foundation	This study was funded by personal research funds provided to JCR from the Marshfield Clinic Research Foundation.	Aagaard H, 1997, INT J SPORTS MED, V18, P217, DOI 10.1055/s-2007-972623; Agel J, 2004, J ATHL TRAINING, V42, P295; Bahr R, 1997, SCAND J MED SCI SPOR, V7, P166, DOI 10.1111/j.1600-0838.1997.tb00134.x; BAHR R, 1994, AM J SPORT MED, V22, P595, DOI 10.1177/036354659402200505; Belechri M, 2001, EUR J EPIDEMIOL, V17, P1005, DOI 10.1023/A:1020078522493; Bonza JE, 2013, J ATHL TRAINING, V44, P76; Clarsen B, 2013, BRIT J SPORT MED, V47, P495, DOI 10.1136/bjsports-2012-091524; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; FERRETTI A, 1986, SPORTS MED, V3, P289, DOI 10.2165/00007256-198603040-00005; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Lian OB, 2005, AM J SPORT MED, V33, P561, DOI 10.1177/0363546504270454; Maffulli N, 1996, BRIT J SPORT MED, V30, P218, DOI 10.1136/bjsm.30.3.218; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Pollard KA, 2011, CLIN PEDIATR, V50, P844, DOI 10.1177/0009922811406262; Rauh MJ, 2007, J ATHL TRAINING, V42, P486; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Reeser JC, 2006, BRIT J SPORT MED, V40, P594, DOI 10.1136/bjsm.2005.018234; Reeser JC, 2010, PM&R, V2, P27, DOI 10.1016/j.pmrj.2009.11.010; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; SOLGARD L, 1995, BRIT J SPORT MED, V29, P200, DOI 10.1136/bjsm.29.3.200; Swenson DM, 2013, CLIN J SPORT MED, V23, P190, DOI 10.1097/JSM.0b013e31827d21fe; Swenson DM, 2013, MED SCI SPORT EXER, V45, P462, DOI 10.1249/MSS.0b013e318277acca; Verhagen EALM, 2004, BRIT J SPORT MED, V38, P477, DOI 10.1136/bjsm.2003.005785; Vetter RE, 2010, J STRENGTH COND RES, V24, P587, DOI 10.1519/JSC.0b013e3181c7c2eb; Vrbanic TSL, 2007, COLLEGIUM ANTROPOL, V31, P253; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	28	34	34	1	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	NOV-DEC	2015	7	6					504	510		10.1177/1941738115600143			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	V20OH	WOS:000214895400005	26502443	Green Published			2022-02-06	
J	Pitman, I; Haddlesey, C; Ramos, SDS; Oddy, M; Fortescue, D				Pitman, Ivan; Haddlesey, Claire; Ramos, Sara D. S.; Oddy, Michael; Fortescue, Deborah			The association between neuropsychological performance and self-reported traumatic brain injury in a sample of adult male prisoners in the UK	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Rehabilitation; Index; Offenders; Questionnaire; Screening	MINOR HEAD-INJURY; CRIMINAL BEHAVIOR; REPEATABLE BATTERY; POPULATION; PREVALENCE; PERSONALITY; DISORDERS; SEQUELAE; HOMELESS; VIOLENT	This study employed a correlational and group comparison design to investigate whether self-report of traumatic brain injury (TBI) in a sample of male prisoners screened using the Brain Injury Screening Index (BISI) was associated with impaired cognitive performance on standardised questionnaires and neuropsychological tests. A total of 139 male prisoners who reported having suffered a TBI in the BISI were interviewed, and completed further questionnaires and neuropsychological assessments. Their results were compared to 50 prisoners who had no reported history of TBI. The results of the screening questionnaire correlated with responses in a follow-up interview, with self-report questionnaires of neurobehavioural disorder (.31 to .50) and neuropsychological measures (-.24 to -.45). The "TBI Index", an indicator summarising the number and severity of self-reported injuries in a single score, also correlated well with scores on formal neuropsychological tests (-.20 to -.42). Self-report of traumatic brain injury among prisoners is consistently associated with measurable neuropsychological and neurobehavioural disability. The implications of these findings for current practice in identifying and referring individuals to specialist services are considered.	[Pitman, Ivan; Haddlesey, Claire; Ramos, Sara D. S.; Oddy, Michael; Fortescue, Deborah] Disabil Trust Fdn, Burgess Hill, W Sussex, England; [Pitman, Ivan; Ramos, Sara D. S.; Oddy, Michael] Brain Injury Rehabil Trust, Slinfold RH13 0TP, W Sussex, England		Ramos, SDS (corresponding author), Brain Injury Rehabil Trust, Kerwin Court, 5 Oaks Rd, Slinfold RH13 0TP, W Sussex, England.	sara.dasilvaramos@thedtgroup.org			Disabilities Trust Foundation, Disabilities Trust	The study was carried out and funded by The Disabilities Trust Foundation, a constituent of The Disabilities Trust.	Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beck AT, 1993, BECK ANXIETY INVENTO; Bradley Lord, 2009, REV PEOPLE MENTAL HL; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burgess P, 1996, BEHAV ASSESSMENT DYS; Coid J. W., 2005, TXB PERSONALITY DISO, P579; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; FOWLES GP, 1988, PSYCHIAT ANN, V18, P692; Goldberg D., 1992, GEN HLTH QUESTIONNAI; Hansard H. C., 2010, PRISON REFORM TRUST; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Kraus J, 2006, NEUROLOGY AND TRAUMA, P3; Kushel MB, 2005, AM J PUBLIC HEALTH, V95, P1747, DOI 10.2105/AJPH.2005.065094; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Macleod MR, 2002, INTENS CARE MED, V28, P1729, DOI 10.1007/s00134-002-1519-8; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Marwitz J. H., 2000, NEUROBEHAVIOURAL FUN; Merbitz C., 1995, J OFFENDER REHABILIT, V22, P11, DOI DOI 10.1300/J076V22N03_02; Ministry of Justice, 2012, ACC HOM REOFF PRIS; Ministry of Justice, 2012, MIN JUST Q B; Morrell R.F., 1998, J OFFENDER REHABIL, V27, P1, DOI [DOI 10.1300/J076V27N03_01, https://doi.org/10.1300/J076v27n03_01]; Mount Sinai Injury Control Research Centre, 1998, BRAIN INJ SCREEN QUE; Novitski J, 2012, ARCH CLIN NEUROPSYCH, V27, P190, DOI 10.1093/arclin/acr119; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Picard M., 1991, HELPS; Randolph C., 1998, REPEATABLE BATTERY A; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; *US DEP HHS, HEADS FACTS PHYS MIL; Wechsler D., 2011, TEST PREMORBID FUNCT; Wechsler D, 2011, WASI 2 WECHSLER ABBR; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	49	34	34	0	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	SEP 3	2015	25	5					763	779		10.1080/09602011.2014.973887			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	CP0ZW	WOS:000359606600006	25351687				2022-02-06	
J	Flynn, LMC; Rhodes, J; Andrews, PJD				Flynn, Liam M. C.; Rhodes, Jonathan; Andrews, Peter J. D.			Therapeutic Hypothermia Reduces Intracranial Pressure and Partial Brain Oxygen Tension in Patients with Severe Traumatic Brain Injury: Preliminary Data from the Eurotherm3235 Trial	THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT			English	Article							TISSUE OXYGEN; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBROVASCULAR AUTOREGULATION; CEREBRAL EDEMA; EPIDEMIOLOGY; HYPERTENSION; MANNITOL; TEMPERATURE; HEMORRHAGE	Traumatic brain injury (TBI) is a significant cause of disability and death and a huge economic burden throughout the world. Much of the morbidity associated with TBI is attributed to secondary brain injuries resulting in hypoxia and ischemia after the initial trauma. Intracranial hypertension and decreased partial brain oxygen tension (PbtO2) are targeted as potentially avoidable causes of morbidity. Therapeutic hypothermia (TH) may be an effective intervention to reduce intracranial pressure (ICP), but could also affect cerebral blood flow (CBF). This is a retrospective analysis of prospectively collected data from 17 patients admitted to the Western General Hospital, Edinburgh. Patients with an ICP >20mmHg refractory to initial therapy were randomized to standard care or standard care and TH (intervention group) titrated between 32 degrees C and 35 degrees C to reduce ICP. ICP and PbtO2 were measured using the Licox system and core temperature was recorded through rectal thermometer. Data were analyzed at the hour before cooling, the first hour at target temperature, 2 consecutive hours at target temperature, and after 6 hours of hypothermia. There was a mean decrease in ICP of 4.3 +/- 1.6mmHg (p<0.04) from 15.7 to 11.4mmHg, from precooling to the first epoch of hypothermia in the intervention group (n=9) that was not seen in the control group (n=8). A decrease in ICP was maintained throughout all time periods. There was a mean decrease in PbtO2 of 7.8 +/- 3.1mmHg (p<0.05) from 30.2 to 22.4mmHg, from precooling to stable hypothermia, which was not seen in the control group. This research supports others in demonstrating a decrease in ICP with temperature, which could facilitate a reduction in the use of hyperosmolar agents or other stage II interventions. The decrease in PbtO2 is not below the suggested treatment threshold of 20mmHg, but might indicate a decrease in CBF.	[Flynn, Liam M. C.; Andrews, Peter J. D.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland; [Rhodes, Jonathan] Univ Edinburgh, Dept Anesthesia & Crit Care, Edinburgh EH16 4SB, Midlothian, Scotland; [Rhodes, Jonathan] Western Gen Hosp, NHS Lothian, Edinburgh EH4 2XU, Midlothian, Scotland		Flynn, LMC (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.	liam.flynn@nhs.net			NIHRH's Technology Assessment Program; National Institute for Health ResearchNational Institute for Health Research (NIHR) [11/01/30] Funding Source: researchfish	The authors would like to thank Cat Graham for her help with designing the methods of statistical analysis. The Eurotherm3235 trial is funded by the NIHRH's Technology Assessment Program and J.R. has a Chief Scientists Office NHS research fellowship. Informed written consent was received from participants/their representatives to take part in the Eurotherm3235 trial and subsequent publication of information thereafter. Copies of the consent form are held in the patients' clinical records and in the Welcome Trust Clinical Research Facility, Edinburgh, and are available for review by the Editor-in-Chief upon request.	Andrews P, 2003, BRIT J ANAESTH, V90, P251, DOI 10.1093/bja/aeg517; Andrews P, 2014, EUROTHERM3235 TRIAL; Andrews PJD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-8; Arrich J, 2009, COCHRANE DB SYST REV, V4; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; De Georgia MA, 2015, J INTENSIVE CARE MED, V30, P473, DOI 10.1177/0885066614529254; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Geukens P, 2012, ANN UPDATE INTENSIVE, V2012, P735; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Keller E, 2000, Neurosurg Focus, V8, pe4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCGRAW CP, 1978, SURG NEUROL, V10, P127; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; National Institute for Clinical Excellence, THER HYP INTR TEMP M; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Oddo M, 2014, NEUROCRIT CARE, V21, P103, DOI 10.1007/s12028-014-0024-6; Oddo M, 2012, INTENS CARE MED, V38, P1497, DOI 10.1007/s00134-012-2593-1; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Romner B, 2013, NAT REV NEUROL, V9, P185, DOI 10.1038/nrneurol.2013.37; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sahuquillo J, 2009, INTENS CARE MED, V35, P890, DOI 10.1007/s00134-008-1357-4; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smrcka M, 2005, ACT NEUR S, V95, P273; Sorani MD, 2008, J NEUROTRAUM, V25, P291, DOI 10.1089/neu.2007.0411; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub3; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Torre-Healy A, 2012, NEUROCRIT CARE, V17, P117, DOI 10.1007/s12028-011-9649-x; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Zeng JS, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-19; Zhang Sai, 2002, Chin J Traumatol, V5, P43; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	64	34	38	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2153-7658	2153-7933		THER HYPOTHERMIA TEM	Ther. Hypothermia Temp. Manag.	SEP 1	2015	5	3					143	151		10.1089/ther.2015.0002			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR1UC	WOS:000361109600007	25989236	Green Submitted, Green Published			2022-02-06	
J	Kurowski, BG; Pomerantz, WJ; Schaiper, C; Ho, MN; Gittelman, MA				Kurowski, Brad G.; Pomerantz, Wendy J.; Schaiper, Courtney; Ho, Mona; Gittelman, Michael A.			Impact of preseason concussion education on knowledge, attitudes, and behaviors of high school athletes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	19th Annual Meeting of the Injury Free Coalition for Kids	DEC 05-07, 2014	Fort Lauderdale, FL			Concussion; education; athlete; adolescent; brain injury	4TH INTERNATIONAL-CONFERENCE; SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURIES; CONSENSUS STATEMENT; FOOTBALL PLAYERS; NOVEMBER 2012; HEAD-INJURY; CDC HEADS; COLLEGIATE; ZURICH	BACKGROUND: The benefit of preseason concussion education on athletes' knowledge, attitudes, and behaviors is unclear. The purpose of the study was to determine the influence of preseason concussion education on knowledge and self-reported attitudes and reporting behaviors. We hypothesized that preseason education would lead to better knowledge and self-reported attitudes and better reporting of concussion symptoms during the season. METHODS: This study involved a prospective cohort comparing the benefits of a preseason lectured-based concussion education session at one high school with a control school. Participants included males and females age 13 years to 18 years from two community high schools who were participating in higher concussion risk, fall or winter sports (football, soccer, wrestling, and basketball). The education school and control school included 234 and 262 participants, respectively. Outcomes were a preseason and postseason survey assessing knowledge and self-reported attitudes about concussions and an end-of-season questionnaire assessing concussion reporting behaviors during the season. RESULTS: Total scores on the combined (p < 0.0001), knowledge-based (p = 0.016), and behavioral-based (p < 0.0001) questions demonstrated statistically significant improvement in the education group. Scores peaked immediately after education but dissipated at the end of the season. There was a lower proportion in the education school (72%) compared with the control school (88%) that reported continued play despite having concussion symptoms during the season (p = 0.025). A similar proportion of athletes diagnosed with concussion during the season in the education (27%) and control schools (23%) reported returning to play before symptoms resolved (p = 0.81). CONCLUSION: These findings suggest that a didactic-based preseason concussion education likely has minimal benefits. Other factors besides knowledge are likely influencing student-athlete concussion reporting behavior. Future research focused on changing the culture of concussion reporting is needed. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Kurowski, Brad G.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Phys Med & Rehabil, Cincinnati, OH USA; [Pomerantz, Wendy J.; Ho, Mona; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Emergency Med, Cincinnati, OH USA; [Kurowski, Brad G.; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA; [Kurowski, Brad G.; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Comprehens Childrens Injury Ctr, Cincinnati, OH USA		Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org			Ohio Department of Public Safety; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2K12 HD001097-16]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD074683-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683, K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER	This work was supported in part by (1) Ohio Department of Public Safety, (2) National Institutes of Health grant 2K12 HD001097-16, and (3) National Institute of Child Health and Human Development grant 1K23HD074683-01A1. Funding from these organizations supported the institutions/investigators in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript for publication.	[Anonymous], 2013, HEADS 10 YEARS ANN V; Bramley HP, 2011, CLIN PEDIAT PHILA, V51, P332; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Delaney JS, 2015, CLIN J SPORT MED, V25, P113, DOI 10.1097/JSM.0000000000000112; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kay MC, 2014, J SPORT REHABIL; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kinzie MB, 2005, PATIENT EDUC COUNS, V56, P3, DOI 10.1016/j.pec.2004.02.005; Kroshus E, 2014, CLIN J SPORT MED; Kroshus E, 2014, HEALTH EDUC BEHAV, V42, P153; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Mannings C, 2014, J TRAUMA ACUTE CARE, V77, pS18, DOI 10.1097/TA.0000000000000371; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Meier TB, 2014, J SCI MED SPORT; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Onate JA., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Robert G, 2014, SPORTS RELATED CONCU; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Silverberg ND, 2013, J NEUROTRAUM, V30, P1398, DOI 10.1089/neu.2012.2827; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Theye Fred, 2004, Clin Med Res, V2, P165; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	51	34	34	1	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2015	79	3		1			S21	S28		10.1097/TA.0000000000000675			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	DJ7FH	WOS:000374376800005	26308118	Green Accepted			2022-02-06	
J	Datto, JP; Bastidas, JC; Miller, NL; Shah, AK; Arheart, KL; Marcillo, AE; Dietrich, WD; Pearse, DD				Datto, Jeffrey P.; Bastidas, Johana C.; Miller, Nicole L.; Shah, Anna K.; Arheart, Kristopher L.; Marcillo, Alexander E.; Dietrich, W. Dalton; Pearse, Damien D.			Female Rats Demonstrate Improved Locomotor Recovery and Greater Preservation of White and Gray Matter after Traumatic Spinal Cord Injury Compared to Males	JOURNAL OF NEUROTRAUMA			English	Article						BBB; CatWalk; gender; GridWalk; spinal cord injury	OLFACTORY ENSHEATHING GLIA; GENDER-RELATED DIFFERENCES; FUNCTIONAL RECOVERY; SCHWANN-CELLS; BRAIN-INJURY; PROGESTERONE NEUROPROTECTION; MEDIATED NEUROPROTECTION; NERVOUS-SYSTEM; ESTROGEN; TESTOSTERONE	The possibility of a gender-related difference in recovery after spinal cord injury (SCI) remains a controversial subject. Current empirical animal research lacks sizable test groups to definitively determine whether significant differences exist. Evaluating locomotor recovery variances between sexes following a precise, clinically relevant spinal cord contusion model can provide valuable insight into a possible gender-related advantage in outcome post-SCI. In the current study, we hypothesized that by employing larger sample sizes in a reproducible contusive SCI paradigm, subtle distinctions in locomotor recovery between sexes, if they exist, would be elucidated through a broad range of behavioral tests. During 13 weeks of functional assessment after a thoracic (T8) contusive SCI in rat, significant differences owing to gender existed for the Basso, Beattie, and Bresnahan score and CatWalk hindlimb swing, support four, and single stance analyses. Significant differences in locomotor performance were noticeable as early as 4 weeks post-SCI. Stereological tissue-volume analysis determined that females, more so than males, also exhibited greater volumes of preserved gray and white matter within the injured cord segment as well as more spared ventral white matter area at the center of the lesion. The stereological tissue analysis differences favoring females directly correlated with the female rats' greater functional improvement observed at endpoint.	[Datto, Jeffrey P.; Bastidas, Johana C.; Miller, Nicole L.; Shah, Anna K.; Marcillo, Alexander E.; Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA; [Arheart, Kristopher L.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Neurosci Program, Miami, FL 33101 USA; [Pearse, Damien D.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33101 USA		Pearse, DD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Lois Pope Life Ctr, Locator Code R-48,POB 016960, Miami, FL 33101 USA.	DPearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X	Department of Defense Congressionally Directed Medical Research Programs SCIRP [W81XWH-10-1-0793]; Miami Project to Cure Paralysis; Buoniconti Fund	The authors thank Denise Koivisto, Eva Juarez, Alex Basagoitia, Ronald Zambrano, Miguel Martinez, and Ramon German for help with animal care; Paulo Diaz for surgical assistance; Carlos Concepcion, Layne Keathly, Isabel Lee, Jingwen Yang, and Vivien Chen for critical review and proofreading of the manuscript; Dr. Richard Morris for guidance and help with statistical analysis; Lindsay Connor for data analysis; and Leah Colucci and Hanna Mathers for data organization, quality assurance review of the CatWalk data, and proofreading of the manuscript. This research was supported by The Department of Defense Congressionally Directed Medical Research Programs SCIRP (Award No. W81XWH-10-1-0793), The Miami Project to Cure Paralysis, and The Buoniconti Fund.	Al-Habib AF, 2011, J NEUROTRAUM, V28, P1431, DOI 10.1089/neu.2009.1157; Antunes F, 2001, FREE RADICAL BIO MED, V30, P1008, DOI 10.1016/S0891-5849(01)00493-2; Bagetta G, 2004, NEUROSCI LETT, V368, P87, DOI 10.1016/j.neulet.2004.06.062; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Battistuzzo CR, 2012, J NEUROTRAUM, V29, P1600, DOI 10.1089/neu.2011.2199; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Belviranli M, 2012, NEUROSCIENCE, V227, P1, DOI 10.1016/j.neuroscience.2012.09.036; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; Bialek M, 2004, POL J PHARMACOL, V56, P509; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Byers JS, 2012, J COMP NEUROL, V520, P2683, DOI 10.1002/cne.23066; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Everitt B, 2002, CAMBRIDGE DICT STAT; Fargo KN, 2009, DEV NEUROBIOL, V69, P825, DOI 10.1002/dneu.20743; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Fee DB, 2007, BRAIN RES, V1137, P146, DOI 10.1016/j.brainres.2006.12.024; Furlan JC, 2005, J NEUROTRAUM, V22, P368, DOI 10.1089/neu.2005.22.368; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Greenwald BD, 2001, ARCH PHYS MED REHAB, V82, P1181, DOI 10.1053/apmr.2001.24891; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Jung SY, 2014, EXP THER MED, V7, P587, DOI 10.3892/etm.2013.1451; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kay E, 2010, PM&R, V2, P504, DOI 10.1016/j.pmrj.2010.03.010; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Little CM, 2009, J COMP NEUROL, V512, P359, DOI 10.1002/cne.21885; McAllister C, 2010, J NEUROSCI, V30, P7326, DOI 10.1523/JNEUROSCI.1180-10.2010; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Morinaga A, 2011, EXP NEUROL, V228, P298, DOI 10.1016/j.expneurol.2011.01.011; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Perreau VM, 2004, GENE EXPRESSION, V12, P107, DOI 10.3727/000000005783992115; Petrovska S, 2012, J PHYSIOL BIOCHEM, V68, P455, DOI 10.1007/s13105-012-0159-x; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; Andrade MSR, 2010, BRAIN RES, V1346, P266, DOI 10.1016/j.brainres.2010.05.070; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P86, DOI 10.1111/j.1749-6632.2009.05360.x; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Schaal SM, 2007, CELL TRANSPLANT, V16, P207, DOI 10.3727/000000007783464768; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Singh A, 2011, NEUROREHAB NEURAL RE, V25, P24, DOI 10.1177/1545968310378510; Singh M, 2006, EXP BIOL MED, V231, P514; Sipski ML, 2004, ARCH PHYS MED REHAB, V85, P1826, DOI 10.1016/j.apmr.2004.04.031; Siriphorn A, 2010, J NEUROCHEM, V115, P864, DOI 10.1111/j.1471-4159.2010.06770.x; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Supriti S, 2010, OPEN DRUG DISCOV J, V2, P174; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Tajiri N, 2010, BRAIN RES, V1310, P200, DOI 10.1016/j.brainres.2009.10.075; Takami T, 2002, J NEUROSCI, V22, P6670; Tehranipour M, 2010, J MOTOR BEHAV, V42, P151, DOI 10.1080/00222891003697921; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Ung RV, 2007, SPINAL CORD, V45, P367, DOI 10.1038/sj.sc.3101970; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Vickers A J, 2001, BMC Med Res Methodol, V1, P6, DOI 10.1186/1471-2288-1-6; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057	76	34	34	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 1	2015	32	15					1146	1157		10.1089/neu.2014.3702			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0JK	WOS:000363936800002	25715192	Green Published			2022-02-06	
J	Oeur, RA; Karton, C; Post, A; Rousseau, P; Hoshizaki, TB; Marshall, S; Brien, SE; Smith, A; Cusimano, MD; Gilchrist, MD				Oeur, R. Anna; Karton, Clara; Post, Andrew; Rousseau, Philippe; Hoshizaki, T. Blaine; Marshall, Shawn; Brien, Susan E.; Smith, Aynsley; Cusimano, Michael D.; Gilchrist, Michael D.			A comparison of head dynamic response and brain tissue stress and strain using accident reconstructions for concussion, concussion with persistent postconcussive symptoms, and subdural hematoma	JOURNAL OF NEUROSURGERY			English	Article						accident reconstruction; traumatic brain injury; concussion; finite element modeling; Hybrid III headform; subdural hematoma; persistent postconcussive symptoms	CHRONIC TRAUMATIC ENCEPHALOPATHY; FINITE-ELEMENT-ANALYSIS; MULTIBODY DYNAMICS; INJURY CRITERIA; FE MODEL; IMPACT; FALLS; BIOMECHANICS; PREDICTORS	OBJECT Concussions typically resolve within several days, but in a few cases the symptoms last for a month or longer and are termed persistent postconcussive symptoms (PPCS). These persisting symptoms may also be associated with more serious brain trauma similar to subdural hematoma (SDH). The objective of this study was to investigate the head dynamic and brain tissue responses of injury reconstructions resulting in concussion, PPCS, and SDH. METHODS Reconstruction cases were obtained from sports medicine clinics and hospitals. All subjects received a direct blow to the head resulting in symptoms. Those symptoms that resolved in 9 days or fewer were defined as concussions (n = 3). Those with symptoms lasting longer than 18 months were defined as PPCS (n = 3), and 3 patients presented with SDHs (n = 3). A Hybrid III headform was used in reconstruction to obtain linear and rotational accelerations of the head. These dynamic response data were then input into the University College Dublin Brain Trauma Model to calculate maximum principal strain and von Mises stress. A Kruskal-Wallis test followed by Tukey post hoc tests were used to compare head dynamic and brain tissue responses between injury groups. Statistical significance was set at p < 0.05. RESULTS A significant difference was identified for peak resultant linear and rotational acceleration between injury groups. Post hoc analyses revealed the SDH group had higher linear and rotational acceleration responses (316 g and 23,181 rad/sec(2), respectively) than the concussion group (149 g and 8111 rad/sec(2), respectively; p < 0.05). No significant differences were found between groups for either brain tissue measures of maximum principal strain or von Mises stress. CONCLUSIONS The reconstruction of accidents resulting in a concussion with transient symptoms (low severity) and SDHs revealed a positive relationship between an increase in head dynamic response and the risk for more serious brain injury. This type of relationship was not found for brain tissue stress and strain results derived by finite element analysis. Future research should be undertaken using a larger sample size to confirm these initial findings. Understanding the relationship between the head dynamic and brain tissue response and the nature of the injury provides important information for developing strategies for injury prevention.	[Oeur, R. Anna; Karton, Clara; Post, Andrew; Rousseau, Philippe; Hoshizaki, T. Blaine] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1S 5S9, Canada; [Marshall, Shawn] Ottawa Hosp, Res Inst, Clin Epidemiol, Ottawa, ON, Canada; [Brien, Susan E.] Ctr Sante & Serv Sociaux CSSS Gatineau Hull Site, Dept Neurosurg, Quebec City, PQ, Canada; [Smith, Aynsley] Mayo Clin, Dept Orthoped & Phys Med & Rehabil, Rochester, MN USA; [Cusimano, Michael D.] St Michaels Hosp, Injury Prevent Res Off, Toronto, ON, Canada; [Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland		Oeur, RA (corresponding author), Univ Ottawa, Neurotrauma Impact Sci Lab, 200 Lees Ave,A-106, Ottawa, ON K1S 5S9, Canada.	anna.oeur@uottawa.ca	Lang, Steven/AAE-8102-2021; Cusimano, Michael/X-4059-2019	Lang, Steven/0000-0003-1669-9146; Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946] Funding Source: Medline		Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Finkelstein E., 2006, INCIDENCE EC BURDEN; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist MD, 2008, FORENSIC SCI INT, V177, P52, DOI 10.1016/j.forsciint.2007.10.010; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Karton C, 2013, 1 INT C HELM PERF DE, pA3; Kendall M, 2012, 2012 INT RES COUNC B; King AI, IS HEAD INJURY CAUSE; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lamy Michael, 2011, Ann Adv Automot Med, V55, P125; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Nahum AM, 1977, 21ST P STAPP CAR CRA, P303; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2013, THESIS U OTTAWA CANA; Post A, 2013, COMPUT METHOD BIOMEC, V16, P511, DOI 10.1080/10255842.2011.627559; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Tator CH, 2012, J CLIN SPORT PSYCHOL, V6, P293, DOI 10.1123/jcsp.6.3.293; Thibault L., 1971, P 15 STAPP CAR CRASH; Trosseille X, DEV FEM HUMAN HEAD A; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Ward C, FINITE ELEMENT MODEL; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/ijcr.2003.0264; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	34	34	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2015	123	2					415	422		10.3171/2014.10.JNS14440			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CS6OV	WOS:000362200800019	25909574	Bronze, Green Submitted			2022-02-06	
J	Sarkaki, A; Farbood, Y; Gharib-Naseri, MK; Badavi, M; Mansouri, MT; Haghparast, A; Mirshekar, MA				Sarkaki, Alireza; Farbood, Yaghoub; Gharib-Naseri, Mohammad Kazem; Badavi, Mohammad; Mansouri, Mohammad Taghi; Haghparast, Abbas; Mirshekar, Mohammad Ali			Gallic acid improved behavior, brain electrophysiology, and inflammation in a rat model of traumatic brain injury	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article						traumatic brain injury; gallic acid; memory; long-term potentiation; cerebral cytokines; rat	LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; PROGESTERONE; EXPRESSION; APOPTOSIS; CYTOKINES; CELLS; CALCIUM; DAMAGE	Traumatic brain injury (TBI) is one of the main causes of intellectual and cognitive disabilities. In the clinic it is essential to limit the development of cognitive impairment after TBI. In this study, the effects of gallic acid (GA; 100 mg/kg, per oral, from 7 days before to 2 days after TBI induction) on neurological score, passive avoidance memory, long-term potentiation (LTP) deficits, and levels of proinflammatory cytokines including interleukin-1 beta (IL-1 beta), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in the brain have been evaluated. Brain injury was induced following Marmarou's method. Data were analyzed by one-way and repeated measures ANOVA followed by Tukey's post-hoc test. The results indicated that memory was significantly impaired (p < 0.001) in the group treated with TBI + vehicle, together with deterioration of the hippocampal LTP and increased brain tissue levels of IL-1 beta, IL-6, and TNF-alpha. GA treatment significantly improved memory and LTP in the TBI rats. The brain tissue levels of IL-1 beta, IL-6, and TNF-alpha were significantly reduced (p < 0.001) in the group treated with GA. The results suggest that GA has neuroprotective properties against TBI-induced behavioral, electrophysiological, and inflammatory disorders, probably via the decrease of cerebral proinflammatory cytokines.	[Sarkaki, Alireza; Farbood, Yaghoub; Gharib-Naseri, Mohammad Kazem; Badavi, Mohammad; Mansouri, Mohammad Taghi; Mirshekar, Mohammad Ali] Ahvaz Jundishapur Univ Med Sci, Ahvaz Physiol Res Ctr, Ahvaz 6135715794, Iran; [Sarkaki, Alireza; Farbood, Yaghoub; Badavi, Mohammad; Mirshekar, Mohammad Ali] Ahvaz Jundishapur Univ Med Sci, Dept Physiol, Sch Med, Ahvaz 6135715794, Iran; [Mansouri, Mohammad Taghi] Ahvaz Jundishapur Univ Med Sci, Dept Pharmacol, Sch Med, Ahvaz 6135715794, Iran; [Haghparast, Abbas] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran		Mirshekar, MA (corresponding author), Ahvaz Jundishapur Univ Med Sci, Dept Physiol, Golestan Blvd,POB 45, Ahvaz 6135715794, Iran.	ma_mib78@yahoo.com	Haghparast, Abbas/B-3023-2009; Farbood, Yaghoob/M-3076-2017; Badavi, Mohammad/C-1452-2013; Mansouri, Seyed Mohammad Taghi/F-3847-2014; Sarkaki, Alireza/Q-8363-2017; Mirshekar, Mohammad Ali/S-4167-2017; Haghparast, Abbas/AAW-3722-2021	Haghparast, Abbas/0000-0003-1084-180X; Farbood, Yaghoob/0000-0002-6390-0079; Badavi, Mohammad/0000-0003-2290-8565; Mansouri, Seyed Mohammad Taghi/0000-0002-7549-0708; Sarkaki, Alireza/0000-0001-9272-6228; Mirshekar, Mohammad Ali/0000-0002-0449-6440; 	Ahvaz Jundishapur University of Medical Sciences, Physiology Research Center [APRC-146]	This article is part of Mohammad Ali Mirshekar's Ph.D. thesis. This project was supported financially by the Ahvaz Jundishapur University of Medical Sciences, Physiology Research Center (grant No. APRC-146). Conflict of interest: the authors declare that there is no conflict of interest associated with this study.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Butler MP, 2004, NEUROSCIENCE, V124, P319, DOI 10.1016/j.neuroscience.2003.11.040; Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Deadwyler SA, 1996, J NEUROSCI, V16, P354; del Zoppo G J, 2000, Thromb Res, V98, P73, DOI 10.1016/S0049-3848(00)00218-8; DeVries HE, 1997, PHARMACOL REV, V49, P143; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Golan H, 2004, CEREB CORTEX, V14, P97, DOI 10.1093/cercor/bhg108; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; INOUE M, 1995, BIOL PHARM BULL, V18, P1526; Isuzugawa K, 2001, BIOL PHARM BULL, V24, P1022, DOI 10.1248/bpb.24.1022; Jadon A, 2007, J ETHNOPHARMACOL, V109, P214, DOI 10.1016/j.jep.2006.07.033; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kim YJ, 2007, BIOL PHARM BULL, V30, P1052, DOI 10.1248/bpb.30.1052; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Korani MS, 2014, EUR J PHARMACOL, V733, P62, DOI 10.1016/j.ejphar.2014.03.044; Kratz JM, 2008, MEM I OSWALDO CRUZ, V103, P437, DOI 10.1590/S0074-02762008000500005; Lashgari R, 2006, BEHAV BRAIN RES, V171, P324, DOI 10.1016/j.bbr.2006.04.013; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Mansouri MT, 2013, FOOD CHEM, V138, P1028, DOI 10.1016/j.foodchem.2012.11.022; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Paxinos G., 2006, RAT BRAIN STEREOTAXI, P25; Qi FH, 2009, LETT APPL MICROBIOL, V49, P98, DOI 10.1111/j.1472-765X.2009.02626.x; Roohbakhsh A, 2007, CLIN EXP PHARMACOL P, V34, P223, DOI 10.1111/j.1440-1681.2007.04576.x; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Sakaguchi N, 1998, BIOCHEM PHARMACOL, V55, P1973, DOI 10.1016/S0006-2952(98)00041-0; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Shahrzad S, 2001, J NUTR, V131, P1207, DOI 10.1093/jn/131.4.1207; Sirota L, 2001, BIOL NEONATE, V79, P103, DOI 10.1159/000047075; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Valizadeh Z, 2012, HEALTHMED, V6, P3648; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.243S, 10.1093/ajcn/81.1.230S]; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yang HL, 2006, FOOD CHEM TOXICOL, V44, P1978, DOI 10.1016/j.fct.2006.06.027	58	34	35	1	14	CANADIAN SCIENCE PUBLISHING	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4212	1205-7541		CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	AUG	2015	93	8					687	694		10.1139/cjpp-2014-0546			8	Pharmacology & Pharmacy; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Physiology	CO4XI	WOS:000359163800011	26222320				2022-02-06	
J	Adam, O; Mac Donald, CL; Rivet, D; Ritter, J; May, T; Barefield, M; Duckworth, J; LaBarge, D; Asher, D; Drinkwine, B; Woods, Y; Connor, M; Brody, DL				Adam, Octavian; Mac Donald, Christine L.; Rivet, Dennis; Ritter, John; May, Todd; Barefield, Maria; Duckworth, Josh; LaBarge, Donald; Asher, Dean; Drinkwine, Benjamin; Woods, Yvette; Connor, Michael; Brody, David L.			Clinical and imaging assessment of acute combat mild traumatic brain injury in Afghanistan	NEUROLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; AXONAL INJURY; MILITARY PERSONNEL; CONCUSSION; BLAST; DEPRESSION; SPORTS; PERFORMANCE; MANAGEMENT	Objective: To evaluate whether diffusion tensor imaging (DTI) will noninvasively reveal white matter changes not present on conventional MRI in acute blast-related mild traumatic brain injury (mTBI) and to determine correlations with clinical measures and recovery. Methods: Prospective observational study of 95 US military service members with mTBI enrolled within 7 days from injury in Afghanistan and 101 healthy controls. Assessments included Rivermead Post-Concussion Symptoms Questionnaire (RPCSQ), Post-Traumatic Stress Disorder Checklist Military (PCLM), Beck Depression Inventory (BDI), Balance Error Scoring System (BESS), Automated Neuropsychological Assessment Metrics (ANAM), conventional MRI, and DTI. Results: Significantly greater impairment was observed in participants with mTBI vs controls: RPCSQ (19.7 +/- 12.9 vs 3.6 +/- 7.1, p < 0.001), PCLM (32 +/- 13.2 vs 20.9 +/- 7.1, p < 0.001), BDI (7.4 +/- 6.8 vs 2.5 +/- 4.9, p < 0.001), and BESS (18.2 +/- 8.4 vs 15.1 +/- 8.3, p = 0.01). The largest effect size in ANAM performance decline was in simple reaction time (mTBI 74.5 +/- 148.4 vs control -11 +/- 46.6 milliseconds, p < 0.001). Fractional anisotropy was significantly reduced in mTBI compared with controls in the right superior longitudinal fasciculus (0.393 +/- 0.022 vs 0.405 +/- 0.023, p < 0.001). No abnormalities were detected with conventional MRI. Time to return to duty correlated with RPCSQ (r = 0.53, p < 0.001), ANAM simple reaction time decline (r = 0.49, p < 0.0001), PCLM (r = 0.47, p < 0.0001), and BDI (r = 0.36 p = 0.0005). Conclusions: Somatic, behavioral, and cognitive symptoms and performance deficits are substantially elevated in acute blast-related mTBI. Postconcussive symptoms and performance on measures of posttraumatic stress disorder, depression, and neurocognitive performance at initial presentation correlate with return-to-duty time. Although changes in fractional anisotropy are uncommon and subtle, DTI is more sensitive than conventional MRI in imaging white matter integrity in blast-related mTBI acutely.	[Adam, Octavian] Naval Med Ctr Portsmouth, Div Neurol, Portsmouth, VA USA; [Rivet, Dennis] Naval Med Ctr Portsmouth, Dept Neurol Surg, Portsmouth, VA USA; [LaBarge, Donald] Naval Med Ctr Portsmouth, Dept Radiol, Portsmouth, VA USA; [Mac Donald, Christine L.; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO USA; [Rivet, Dennis] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Ritter, John] San Antonio Mil Med Ctr, Dept Radiol, San Antonio, TX USA; [Woods, Yvette] San Antonio Mil Med Ctr, Dept Orthoped & Rehabil, Occupat Therapy Serv, San Antonio, TX USA; [May, Todd] Naval Hosp, Dept Sports Med, Camp Pendleton, CA USA; [Barefield, Maria] Naval Hosp Jacksonville, Dept Occupat Therapy, Jacksonville, FL USA; [Duckworth, Josh] San Diego Naval Med Ctr, Dept Neurol, San Diego, CA USA; [Asher, Dean; Drinkwine, Benjamin] San Diego Naval Med Ctr, Dept Radiol, San Diego, CA USA; [Connor, Michael] Naval Air Stn Jacksonville, Branch Hlth Clin, Jacksonville, FL USA		Adam, O (corresponding author), Berkshire Med Ctr, Dept Neurol, Pittsfield, MA 01201 USA.	oadam@bhs1.org	Ritter, John/AAG-8899-2020		Congressionally Directed Medical Research ProgramUnited States Department of Defense	Grant funding was provided by the Congressionally Directed Medical Research Program (D. Brody). The funding agency did not take part in and in no way influenced the research design, data collection, data analysis, interpretation of data, or preparation of the manuscript.	BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Mori S, 2009, CURR OPIN NEUROL, V22, P362, DOI 10.1097/WCO.0b013e32832d954b; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sotiropoulos SN, 2013, NEUROIMAGE, V80, P125, DOI 10.1016/j.neuroimage.2013.05.057; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Tombough T., 1996, TEST MEMORY MALINGER; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	38	34	36	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 21	2015	85	3					219	227		10.1212/WNL.0000000000001758			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN1GR	WOS:000358167100004	26109715	Green Published			2022-02-06	
J	Mayer, AR; Ling, JM; Allen, EA; Klimaj, SD; Yeo, RA; Hanlon, FM				Mayer, Andrew R.; Ling, Josef M.; Allen, Elena A.; Klimaj, Stefan D.; Yeo, Ronald A.; Hanlon, Faith M.			Static and Dynamic Intrinsic Connectivity following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional; ICA; mild TBI; resting state networks; RSFC	DEFAULT-MODE NETWORK; FUNCTIONAL CONNECTIVITY; CONCUSSED INDIVIDUALS; HEAD MOTION; TIME; MRI; DISRUPTION; RELEVANCE; ATTENTION; VETERANS	Mild traumatic brain injury (mTBI) is the most common neurological disorder and is typically characterized by temporally limited cognitive impairment and emotional symptoms. Previous examinations of intrinsic resting state networks in mTBI have primarily focused on abnormalities in static functional connectivity, and deficits in dynamic functional connectivity have yet to be explored in this population. Resting-state data was collected on 48 semi-acute (mean=14 days post-injury) mTBI patients and 48 matched healthy controls. A high-dimensional independent component analysis (N=100) was utilized to parcellate intrinsic connectivity networks (ICN), with a priori hypotheses focusing on the default-mode network (DMN) and sub-cortical structures. Dynamic connectivity was characterized using a sliding window approach over 126 temporal epochs, with standard deviation serving as the primary outcome measure. Finally, distribution-corrected z-scores (DisCo-Z) were calculated to investigate changes in connectivity in a spatially invariant manner on a per-subject basis. Following appropriate correction for multiple comparisons, no significant group differences were evident on measures of static or dynamic connectivity within a priori ICN. Reduced (HC>mTBI patients) static connectivity was observed in the DMN at uncorrected (p<0.005) thresholds. Finally, a trend (p=0.07) for decreased dynamic connectivity in patients across all ICN was observed during spatially invariant analyses (DisCo-Z). In the semi-acute phase of recovery, mTBI was not reliably associated with abnormalities in static or dynamic functional connectivity within the DMN or sub-cortical structures.	[Mayer, Andrew R.; Ling, Josef M.; Allen, Elena A.; Klimaj, Stefan D.; Hanlon, Faith M.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21-NS064464-01A1, 3R21NS064464-01A1S1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grant numbers R21-NS064464-01A1, 3R21NS064464-01A1S1 to A.M). Special thanks to Diana South and Cathy Smith for assistance with data collection.	Allen EA, 2014, CEREB CORTEX, V24, P663, DOI 10.1093/cercor/bhs352; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chang C, 2010, NEUROIMAGE, V50, P81, DOI 10.1016/j.neuroimage.2009.12.011; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Franco AR, 2013, BRAIN CONNECT, V3, P363, DOI 10.1089/brain.2012.0134; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Heffernan ME, 2013, J NEUROTRAUM, V30, P1007, DOI 10.1089/neu.2012.2366; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Hutchison RM, 2013, HUM BRAIN MAPP, V34, P2154, DOI 10.1002/hbm.22058; Hutchison RM, 2012, FRONT NEUROANAT, V6, P1, DOI 10.3389/fnana.2012.00029; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Mangia S, 2009, J CEREBR BLOOD F MET, V29, P441, DOI 10.1038/jcbfm.2008.134; Margulies DS, 2010, MAGN RESON MATER PHY, V23, P289, DOI 10.1007/s10334-010-0228-5; Mayer A. R., 2014, HUM BRAIN MAPP; Mayer AR, 2007, J INT NEUROPSYCH SOC, V13, P839, DOI 10.1017/S1355617707071081; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Pawela CP, 2010, NEUROIMAGE, V49, P2467, DOI 10.1016/j.neuroimage.2009.09.054; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Sarno S, 2003, BRAIN INJURY, V17, P413, DOI 10.1080/0269905031000070161; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stamatakis EA, 2002, J NUCL MED, V43, P476; Starck T, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00802; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	58	34	36	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1046	1055		10.1089/neu.2014.3542			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000002	25318005	Green Published			2022-02-06	
J	Frank, BS; Register-Mihalik, J; Padua, DA				Frank, Barnett S.; Register-Mihalik, Johna; Padua, Darin A.			High levels of coach intent to integrate a ACL injury prevention program into training does not translate to effective implementation	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Athletic injuries; Anterior cruciate ligament; Primary prevention; Physical education and training; Compliance	FOOTBALL PLAYERS; KNEE INJURIES; WARM-UP; FEMALE; SPORTS; SOCCER; RISK; RECOMMENDATIONS; EPIDEMIOLOGY; CONCUSSION	Objectives: Evaluate the effect of a anterior cruciate ligament injury prevention program coaching workshop on elite-level youth soccer coaches' behavioral determinants to implement a injury prevention program and describe coaches' subsequent injury prevention program implementation compliance. Design: Descriptive study. Methods: We evaluated a soccer club's coaches' behavioral determinants regarding injury prevention programming implementation before and after a coaching workshop using pre- and post-workshop surveys. We then described the club's coaches' subsequent adoption of and implementation compliance with the injury prevention programming during the following season. Results: The injury prevention workshop increased coaches' attitudes toward conducting a program at the beginning of practice (p < 0.05), substituting the program for a warm-up prior to practice (p < 0.05), and improving player cutting and landing technique by implementing the program (p < 0.05). The injury prevention program workshop increased coaches' perceived behavioral control; feeling more comfortable in their ability to teach their team a program (p < 0.05), and more confident leading a program if given instructions (p < 0.05). The injury prevention program workshop increased coaches' intent to implement a program the next season (p < 0.05), to implement a program for 15 min (p < 0.05), and 20 min (p < 0.05) prior to the start of a training session. Only 53% of the club's teams implemented the injury prevention program, with implementers demonstrating high variability in program fidelity. Conclusions: Coaching workshops can effectively increase coach attitudes, perceived behavioral control, and intent to implement a injury prevention program. However, high levels of behavioral determinants do not appear to translate to high levels of implementation compliance. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Frank, Barnett S.; Register-Mihalik, Johna; Padua, Darin A.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA		Frank, BS (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA.	bsfrank@unc.edu	Mista, Wlodzimierz/K-3369-2017	Mista, Wlodzimierz/0000-0003-1298-2198; Register-Mihalik, Johna/0000-0002-4229-4743; Padua, Darin/0000-0002-9383-4236	North Carolina Injury Prevention Research Center	The researchers would like to thank the research assistants who contributed to the data collection and implementation facilitation during the study. This study was financially supported by The North Carolina Injury Prevention Research Center.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; DiStefano LJ, 2010, J STRENGTH COND RES, V24, P332, DOI 10.1519/JSC.0b013e3181cc2225; Donaldson A, 2012, BRIT J SPORT MED, V46, P306, DOI 10.1136/bjsports-2011-090461; Donaldson A, 2013, BRIT J SPORT MED, V47, P473, DOI 10.1136/bjsports-2013-092323; Ferguson R, 2013, GAME CHANGERS STATS; Finch CF, 2010, BRIT J SPORT MED, V44, P973, DOI 10.1136/bjsm.2008.056069; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Fixsen D, 2005, IMPLEMENTATION RES S, P1; Gianotti S, 2010, J SCI MED SPORT, V13, P32, DOI 10.1016/j.jsams.2008.07.010; Hagglund M, 2013, BRIT J SPORT MED, V47, P974, DOI 10.1136/bjsports-2013-092644; Hagglund M, 2013, BRIT J SPORT MED, V47, P738, DOI 10.1136/bjsports-2013-092215; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Joy EA, 2013, J STRENGTH COND RES, V27, P2263, DOI 10.1519/JSC.0b013e31827ef12e; Junge A, 2011, AM J SPORT MED, V39, P57, DOI 10.1177/0363546510377424; Keats MR, 2012, SPORTS MED, V42, P175, DOI 10.2165/11597050-000000000-00000; LaBella CR, 2011, ARCH PEDIAT ADOL MED, V165, P1033, DOI 10.1001/archpediatrics.2011.168; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; Myklebust G, 2013, BRIT J SPORT MED, V47, P476, DOI 10.1136/bjsports-2012-091862; Renstrom PA, 2013, BRIT J SPORT MED, V47, P367, DOI 10.1136/bjsports-2012-091623; Sadoghi P, 2012, J BONE JOINT SURG AM, V94A, P769, DOI 10.2106/JBJS.K.00467; Saunders N, 2010, BRIT J SPORT MED, V44, P1128, DOI 10.1136/bjsm.2009.069039; Shultz SJ, 2012, J ATHL TRAINING, V47, P591, DOI 10.4085/1062-6050-47.5.13; Soligard T, 2010, BRIT J SPORT MED, V44, P787, DOI 10.1136/bjsm.2009.070672; Steffen K, 2013, BRIT J SPORT MED, V47, P794, DOI 10.1136/bjsports-2012-091886; Sugimoto D, 2012, J ATHL TRAINING, V47, P714, DOI 10.4085/1062-6050-47.6.10; Swenson DM, 2013, MED SCI SPORT EXER, V45, P462, DOI 10.1249/MSS.0b013e318277acca; Viljoen W, 2012, BRIT J SPORT MED, V46, P692, DOI 10.1136/bjsports-2012-091278; White PE, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2012-091987; White PE, 2014, BRIT J SPORT MED, V48, P119, DOI 10.1136/bjsports-2013-092785	30	34	34	0	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUL	2015	18	4					400	406		10.1016/j.jsams.2014.06.008			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CL3HL	WOS:000356840900008	25086795				2022-02-06	
J	Stemper, BD; Shah, AS; Pintar, FA; McCrea, M; Kurpad, SN; Glavaski-Joksimovic, A; Olsen, C; Budde, MD				Stemper, Brian D.; Shah, Alok S.; Pintar, Frank A.; McCrea, Michael; Kurpad, Shekar N.; Glavaski-Joksimovic, Aleksandra; Olsen, Christopher; Budde, Matthew D.			Head Rotational Acceleration Characteristics Influence Behavioral and Diffusion Tensor Imaging Outcomes Following Concussion	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury (mTBI); Diffusion tensor imaging (DTI); Behavioral assessments; Biomechanics	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; WHITE-MATTER INTEGRITY; FINITE-ELEMENT MODEL; HIGH-SCHOOL FOOTBALL; ELEVATED PLUS-MAZE; PROFESSIONAL FOOTBALL; ANIMAL-MODEL; RECURRENT CONCUSSION	A majority of traumatic brain injuries (TBI) in motor vehicle crashes and sporting environments are mild and caused by high-rate acceleration of the head. For injuries caused by rotational acceleration, both magnitude and duration of the acceleration pulse were shown to influence injury outcomes. This study incorporated a unique rodent model of rotational acceleration-induced mild TBI (mTBI) to quantify independent effects of magnitude and duration on behavioral and neuroimaging outcomes. Ninety-two Sprague-Dawley rats were exposed to head rotational acceleration at peak magnitudes of 214 or 350 krad/s(2) and acceleration pulse durations of 1.6 or 3.4 ms in a full factorial design. Rats underwent a series of behavioral tests including the Composite Neuroscore (CN), Elevated Plus Maze (EPM), and Morris Water Maze (MWM). Ex vivo diffusion tensor imaging (DTI) of the fixed brains was conducted to assess the effects of rotational injury on brain microstructure as revealed by the parameter fractional anisotropy (FA). While the injury did not cause significant locomotor or cognitive deficits measured with the CN and MWM, respectively, a main effect of duration was consistently observed for the EPM. Increased duration caused significantly greater activity and exploratory behaviors measured as open arm time and number of arm changes. DTI demonstrated significant effects of both magnitude and duration, with the FA of the amygdala related to both the magnitude and duration. Increased duration also caused FA changes at the interface of gray and white matter. Collectively, the findings demonstrate that the consequences of rotational acceleration mTBI were more closely associated with duration of the rotational acceleration impulse, which is often neglected as an independent factor, and highlight the need for animal models of TBI with strong biomechanical foundations to associate behavioral outcomes with brain microstructure.	[Stemper, Brian D.; Shah, Alok S.; Pintar, Frank A.; McCrea, Michael; Kurpad, Shekar N.; Glavaski-Joksimovic, Aleksandra; Olsen, Christopher; Budde, Matthew D.] Med Coll Wisconsin, Dept Neurosurg, Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA		Stemper, BD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA.	bstemper@mcw.edu	Stemper, Brian/AAX-7611-2020; Olsen, Christopher/G-9595-2013; Kurpad, Shekar/V-2188-2019	Olsen, Christopher/0000-0003-2700-0310; 	Merit Review Award from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service Program [I01 RX000380]; Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin [5520207]; Department of Neurosurgery, Medical College of Wisconsin; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R21DA039276] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000380] Funding Source: NIH RePORTER	This work was supported in part by Merit Review Award number I01 RX000380 from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service Program (PI: FAP), the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin (5520207 to MDB), and the Department of Neurosurgery, Medical College of Wisconsin. The authors acknowledge the considerable contributions of Rachel Chiariello, Natasha Wilkins, and Andrea Winegar.	ABEL JM, 1978, 22 STAPP CAR CRASH C, P35; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Baykara B, 2012, TURK NEUROSURG, V22, P604, DOI 10.5137/1019-5149.JTN.5633-11.1; Bolouri H, 2012, ACTA NEUROL SCAND, V125, P241, DOI 10.1111/j.1600-0404.2011.01614.x; Bortolato M, 2009, NEUROPSYCHOPHARMACOL, V34, P2746, DOI 10.1038/npp.2009.118; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Budde MD, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00003; Budde MD, 2012, NEUROIMAGE, V63, P1, DOI 10.1016/j.neuroimage.2012.06.042; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; DECKER MW, 1995, NEUROBIOL LEARN MEM, V64, P156, DOI 10.1006/nlme.1995.1055; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Fan LW, 2008, EUR J NEUROSCI, V27, P1475, DOI 10.1111/j.1460-9568.2008.06121.x; Fijalkowski RJ, 2007, P INT IRCOBI C BIOM, P161; Fijalkowski RJ, 2007, BIOMED SCI INSTRUM, V43, P18; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; Fijalkowski RJ, 2009, STAPP CAR CRASH JO, V53, P193; Fijalkowski RJ, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3078182; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gao W, 2013, NEUROSCI LETT, V533, P50, DOI 10.1016/j.neulet.2012.11.020; Gennarelli T., 2003, ANN P ASS ADV AUTOMO, V47, P624; Gennarelli T. A., 1972, 16 STAPP CAR CRASH C, P296; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Higgins L. S., 1967, 11 STAPP CAR CRASH C, P57; Hirsch Arthur E., 1970, STAPP CAR CRASH J, P144; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jespersen SN, 2013, NMR BIOMED, V26, P1647, DOI 10.1002/nbm.2999; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; King PR, 2012, J CLIN PSYCHOL MED S, V19, P376, DOI 10.1007/s10880-012-9345-9; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lamy M, 2013, MED BIOL ENG COMPUT, V51, P353, DOI 10.1007/s11517-012-1004-7; Lindemann Sven, 2007, Physiol Behav, V91, P551, DOI 10.1016/j.physbeh.2007.04.008; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; Meyer JS, 2008, ANN NY ACAD SCI, V1139, P151, DOI 10.1196/annals.1432.029; Moller C, 1997, BRAIN RES, V760, P94, DOI 10.1016/S0006-8993(97)00308-9; MOSER E, 1993, J NEUROSCI, V13, P3916; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; Napieralski JA, 1998, EXP NEUROL, V154, P80, DOI 10.1006/exnr.1998.6893; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Ommaya AK, 1967, 11 STAPP CAR CRASH C, P73; Ono K., 1980, 24 STAPP CAR CRASH C, P103; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Primeaux SD, 1999, PHYSIOL BEHAV, V67, P41, DOI 10.1016/S0031-9384(99)00027-X; Ramamoorthy R, 2008, BEHAV PHARMACOL, V19, P29, DOI 10.1097/FBP.0b013e3282f3cfd4; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Simpson D. A., 2005, HEAD INJURY, P143; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; Thiabault LE, 1990, 34 ANN P ASS ADV AUT, V34, P337; UNTERHARNSCHEIDT F, 1969, ACTA NEUROPATHOL, V12, P200, DOI 10.1007/BF00692508; Ventura-Silva AP, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00032; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Wiest-Daessle N, 2007, LECT NOTES COMPUT SC, V4792, P344; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhang H, 2007, LECT NOTES COMPUT SC, V4792, P211; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501	102	34	36	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2015	43	5					1071	1088		10.1007/s10439-014-1171-9			18	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	CH1KM	WOS:000353780300002	25344352	Green Accepted			2022-02-06	
J	Sullivan, KA; Edmed, SL; Allan, AC; Karlsson, LJE; Smith, SS				Sullivan, Karen A.; Edmed, Shannon L.; Allan, Alicia C.; Karlsson, Lina J. E.; Smith, Simon S.			Characterizing Self-Reported Sleep Disturbance after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						insomnia; concussion; post-concussion syndrome; excessive daytime sleepiness	INSOMNIA SEVERITY INDEX; OUTCOME MEASURES; DISORDERS; RECOMMENDATIONS; PREVALENCE; ADULTS; VALIDATION; COMPLAINTS; LATENCY; SCALE	Sleep disturbance after mild traumatic brain injury (mTBI) is commonly reported as debilitating and persistent. However, the nature of this disturbance is poorly understood. This study sought to characterize sleep after mTBI compared with a control group. A cross-sectional matched case control design was used. Thirty-three persons with recent mTBI (1-6 months ago) and 33 age, sex, and ethnicity matched controls completed established questionnaires of sleep quality, quantity, timing, and sleep-related daytime impairment. The mTBI participants were compared with an independent sample of close-matched controls (CMCs; n=33) to allow partial internal replication. Compared with controls, persons with mTBI reported significantly greater sleep disturbance, more severe insomnia symptoms, a longer duration of wake after sleep onset, and greater sleep-related impairment (all medium to large effects, Cohen's d>0.5). No differences were found in sleep quantity, timing, sleep onset latency, sleep efficiency, or daytime sleepiness. All findings except a measure of sleep timing (i.e., sleep midpoint) were replicated for CMCs. These results indicate a difference in the magnitude and nature of perceived sleep disturbance after mTBI compared with controls, where persons with mTBI report poorer sleep quality and greater sleep-related impairment. Sleep quantity and timing did not differ between the groups. These preliminary findings should guide the provision of clearer advice to patients about the aspects of their sleep that may change after mTBI and could inform treatment selection.	[Sullivan, Karen A.; Edmed, Shannon L.; Allan, Alicia C.; Karlsson, Lina J. E.; Smith, Simon S.] Queensland Univ Technol, Sch Psychol & Counselling, Clin Neuropsychol Res Grp, Brisbane, Qld 4059, Australia; [Sullivan, Karen A.; Edmed, Shannon L.; Allan, Alicia C.; Karlsson, Lina J. E.; Smith, Simon S.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia; [Allan, Alicia C.; Smith, Simon S.] Queensland Univ Technol, Ctr Accid Res & Rd Safety, Brisbane, Qld 4059, Australia		Sullivan, KA (corresponding author), Queensland Univ Technol, O Block B Wing Room B523, Kelvin Grove Campus, Brisbane, Qld 4059, Australia.	karen.sullivan@qut.edu.au	Smith, Simon/P-1859-2017	Smith, Simon/0000-0002-0362-9045	School of Psychology and Counselling, Queensland University of Technology	The Human Research Ethics Committee of Queensland University of Technology (QUT-HREC #1300000224) approved this research. This project was granted an occupational workplace health and safety clearance. Funding was contributed by the School of Psychology and Counselling, Queensland University of Technology.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Arnedt JT, 2012, BEHAV SLEEP MED, V10, P25, DOI 10.1080/15402002.2012.636267; Augner C, 2011, CENT EUR J PUBL HEAL, V19, P115, DOI 10.21101/cejph.a3647; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Barclay NL, 2013, SLEEP MED REV, V17, P29, DOI 10.1016/j.smrv.2012.01.008; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Burgess Helen J, 2003, Behav Sleep Med, V1, P102, DOI 10.1207/S15402010BSM0102_3; Buysse DJ, 2010, SLEEP, V33, P781, DOI 10.1093/sleep/33.6.781; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chandra P. S., 2007, SLEEP MED, V8, pS92; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Cohen J., 2013, STAT POWER ANAL BEHA; Conway A, 2013, RES NURS HEALTH, V36, P320, DOI 10.1002/nur.21536; Drotar D, 2010, J PEDIATR PSYCHOL, V35, P801, DOI 10.1093/jpepsy/jsq049; Farrell-Carnahan L, 2013, MIL MED, V178, P951, DOI 10.7205/MILMED-D-13-00037; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Field A., 2018, DISCOVERING STAT USI, V5th ed.; Gander PH, 2005, SLEEP, V28, P249, DOI 10.1093/sleep/28.2.249; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Hedman E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061713; Ho DE, 2011, J STAT SOFTW, V42, p[8, 1], DOI DOI 10.18637/JSS.V042.I08; Hou LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076087; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/415740; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Lagos L., 2012, BIOFEEDBACK, V40, P150, DOI [10.5298/1081-5937-40.4.05, DOI 10.5298/1081-5937-40.4.05]; Levin Kate Ann, 2006, Evid Based Dent, V7, P83, DOI 10.1038/sj.ebd.6400436; LINDSAY RM, 1993, AM STAT, V47, P217, DOI 10.2307/2684982; Lund HG, 2010, J ADOLESCENT HEALTH, V46, P124, DOI 10.1016/j.jadohealth.2009.06.016; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Malec JF, 2013, J HEAD TRAUMA REHAB, V28, P476, DOI 10.1097/HTR.0000000000000003; Manber R, 2008, SLEEP, V31, P489, DOI 10.1093/sleep/31.4.489; Martin SK, 2002, CHRONOBIOL INT, V19, P695, DOI 10.1081/CBI-120006080; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McAllister TW, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1034; Monk TH, 2003, SLEEP, V26, P208, DOI 10.1093/sleep/26.2.208; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008; Niven D. J., 2013, CLIN EPIDEMIOL, V4, P99; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Oppenheimer DM, 2009, J EXP SOC PSYCHOL, V45, P867, DOI 10.1016/j.jesp.2009.03.009; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P707; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Patient-Reported Outcomes Information System, 2011, PROMIS SCORING GUIDE; Ponsford J., 2012, 9 WORLD C INT BRAIN; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Weber M, 2013, J SLEEP DISORDERS TH, V2, P2; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; World Health Organization, 2004, ICD 10 INT STAT CLAS; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Yu L, 2012, BEHAV SLEEP MED, V10, P6, DOI 10.1080/15402002.2012.636266; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	68	34	34	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					474	486		10.1089/neu.2013.3284			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400007	25275933	Green Published			2022-02-06	
J	Tsitsilonis, S; Seemann, R; Misch, M; Wichlas, F; Haas, NP; Schmidt-Bleek, K; Kleber, C; Schaser, KD				Tsitsilonis, Serafeim; Seemann, Ricarda; Misch, Martin; Wichlas, Florian; Haas, Norbert P.; Schmidt-Bleek, Katharina; Kleber, Christian; Schaser, Klaus-Dieter			The effect of traumatic brain injury on bone healing: an experimental study in a novel in vivo animal model	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Fracture healing; Animal model; Heterotopic ossification; Callus formation	CORTICAL IMPACT INJURY; RAT MODEL; FRACTURE; MICROCIRCULATION; EXPRESSION	Introduction: Among many factors determining the outcome of complex fractures in polytrauma patients, the role of traumatic brain injury (TBI) remains only partly understood. The aim of the present study was to examine the effect of traumatic brain injury on bone healing through the establishment of a novel standardised animal model that sequentially combines traumatic brain injury (TBI) with a long bone injury. Materials and methods: Thirty-six female twelve-week old C57/BL6 mice were randomised in two groups (fracture (Fx)-group and combined-trauma (Fx/TBI) group). The methods of the Control Cortical Impact Injury for induction of TBI and of the femoral osteotomy, fixed with an external fixator for the simulation of the long bone fracture, were combined. No TBI was induced in the Fx-group. Bone healing was examined using in vivo micro-CT measurements over a period of three weeks. Results: The severity of the TBI was sufficient to stimulate a significantly increased callus formation in the Fx/TBI-group with an acceptable mortality rate. The micro-CT analysis of fracture healing displayed a significantly increased callus volume in the Fx/TBI-group already from the second postoperative week. This difference remained significant throughout the entire study period. Discussion: The successful and standardised combination of TBI and fracture in a mouse model allows systematic and quantitative in vivo analysis of underlying pathways that trigger the mutual interaction between musculoskeletal trauma and brain injury, as well as, corresponding differences in fracture healing using micro-CT methods. Conclusion: The present study offers three new aspects: a standardised model for combined injury of TBI and femoral osteotomy; direct and serial in vivo imaging and quantification of fracture healing response using micro-CT; testing of potentially beneficial therapeutic regimens for fracture treatment in presence of TBI. Thus this model provides a valuable basic approach for the study of the amplifying effect of TBI on callus formation seen in patients with craniocerebral injury and concomitant skeletal trauma. (C) 2015 Elsevier Ltd. All rights reserved.	[Tsitsilonis, Serafeim; Seemann, Ricarda; Wichlas, Florian; Haas, Norbert P.; Kleber, Christian; Schaser, Klaus-Dieter] Charite, Ctr Musculoskeletal Surg, D-13353 Berlin, Germany; [Tsitsilonis, Serafeim; Kleber, Christian] Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany; [Misch, Martin] Charite, Dept Neurosurg, D-13353 Berlin, Germany; [Schmidt-Bleek, Katharina] Charite, Julius Wolff Inst, D-13353 Berlin, Germany		Tsitsilonis, S (corresponding author), Charite, Ctr Musculoskeletal Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.	serafeim.tsitsilonis@charite.de	Schmidt-Bleek, Katharina/O-9816-2015	Seemann, Ricarda/0000-0001-5752-070X; Misch, Martin/0000-0001-5283-5753			Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Hannouche D, 2001, J BONE JOINT SURG BR, V83B, P157, DOI 10.1302/0301-620X.83B2.12106; Kushwaha V P, 1998, J Am Acad Orthop Surg, V6, P298; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Mirzayan MJ, 2012, EXP TOXICOL PATHOL, V64, P133, DOI 10.1016/j.etp.2010.07.007; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; Schaser KD, 2005, J ORTHOP RES, V23, P231, DOI 10.1016/j.orthres.2004.05.009; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319	20	34	37	1	23	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	APR	2015	46	4					661	665		10.1016/j.injury.2015.01.044			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CD7MZ	WOS:000351275900025	25682315				2022-02-06	
J	Wang, X; Xie, H; Cotton, AS; Tamburrino, MB; Brickman, KR; Lewis, TJ; McLean, SA; Liberzon, I				Wang, Xin; Xie, Hong; Cotton, Andrew S.; Tamburrino, Marijo B.; Brickman, Kristopher R.; Lewis, Terrence J.; McLean, Samuel A.; Liberzon, Israel			Early Cortical Thickness Change after Mild Traumatic Brain Injury following Motor Vehicle Collision	JOURNAL OF NEUROTRAUMA			English	Article						motor vehicle collision; cortical thickness; mild TBI; progression; subacute	TENSOR IMAGING FINDINGS; HUMAN CEREBRAL-CORTEX; WORKING-MEMORY; ANATOMY; ABNORMALITIES; CONCUSSION; ACTIVATION; CHILDREN; OUTCOMES; IMPACT	In a motor vehicle collision (MVC), survivors often receive mild traumatic brain injuries (mTBI). Although there have been some reports of early white matter changes after an mTBI, much less is known about early cortical structural changes. To investigate early cortical changes within a few days after an MVC, we compared cortical thickness of mTBI survivors with non-mTBI survivors, then reexamined cortical thickness in the same survivors 3 months later. MVC survivors were categorized as mTBI or non-mTBI based on concussive symptoms documented in emergency departments (EDs). Cortical thickness was measured from MRI images using FreeSurfer within a few days and again at 3 months after MVC. Post-traumatic stress symptoms and physical conditions were also assessed. Compared with the non-mTBI group (n=23), the mTBI group (n=21) had thicker cortex in the left rostral middle frontal (rMFG) and right precuneus gyri, but thinner cortex in the left posterior middle temporal gyrus at 7.2 +/- 3.1 days after MVC. After 3 months, cortical thickness had decreased in left rMFG in the mTBI group but not in the non-mTBI group. The cortical thickness of the right precuneus region in the initial scans was positively correlated with acute traumatic stress symptoms for all survivors and with the number of reduced activity days for mTBI survivors who completed the follow-up. The preliminary results suggest that alterations in cortical thickness may occur at an early stage of mTBI and that frontal cortex structure may change dynamically over the initial 3 months after mTBI.	[Wang, Xin; Cotton, Andrew S.; Tamburrino, Marijo B.] Univ Toledo, Dept Psychiat, Toledo, OH 43614 USA; [Wang, Xin; Xie, Hong] Univ Toledo, Dept Neurosci, Toledo, OH 43614 USA; [Wang, Xin; Lewis, Terrence J.] Univ Toledo, Dept Radiol, Toledo, OH 43614 USA; [Brickman, Kristopher R.] Univ Toledo, Dept Emergency Med, Toledo, OH 43614 USA; [Wang, Xin; Liberzon, Israel] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA		Wang, X (corresponding author), Univ Toledo, Dept Psychiat, 3120 Glendale Ave, Toledo, OH 43614 USA.	Xin.Wang2@utoledo.edu		Liberzon, Israel/0000-0002-4990-556X; McLean, Samuel/0000-0001-9482-3582	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21MH098198-01]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH098198] Funding Source: NIH RePORTER	The work is funded by NIH R21MH098198-01. We thank Dr. Michael M. Dennis, Cindy Grey, Susan Yeager, Lindsey Katschke, Michelle Haunus, and the Department of Radiology at the University of Toledo for technical support, Drs. Joe Migliori, Jr., and Eric Ferguson for clinical support, Dr. John Wall and Ms. Carol Brikmanis, MA, for editing the manuscript, and Karen Brenner, RN, and Rochelle Armola, RN, of ProMedica Health System for survivor recruitment.	Abu-Judeh H H, 2000, Nucl Med Rev Cent East Eur, V3, P5; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Caner B, 2012, J NEUROCHEM, V123, P12, DOI 10.1111/j.1471-4159.2012.07939.x; Carlo CN, 2013, P NATL ACAD SCI USA, V110, P1488, DOI 10.1073/pnas.1221398110; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cruz-Orive LM, 2014, J MICROSC-OXFORD, V253, P119, DOI 10.1111/jmi.12103; Dale WE, 1999, CAN J PHYSIOL PHARM, V77, P763, DOI 10.1139/cjpp-77-10-763; DaSilva AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Fox WC, 2013, NEUROL RES, V35, P223, DOI 10.1179/1743132813Y.0000000162; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Friedman L, 1998, BRAIN LANG, V64, P231, DOI 10.1006/brln.1998.1953; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Goel V, 2007, TRENDS COGN SCI, V11, P435, DOI 10.1016/j.tics.2007.09.003; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hayasaka S, 2004, NEUROIMAGE, V22, P676, DOI 10.1016/j.neuroimage.2004.01.041; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; IADECOLA C, 1989, BRAIN RES, V501, P188, DOI 10.1016/0006-8993(89)91042-1; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Liberzon I, 2006, ANN NY ACAD SCI, V1071, P87, DOI 10.1196/annals.1364.009; Lillie Elizabeth M, 2013, Biomed Sci Instrum, V49, P297; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Makris N, 2006, NEUROIMAGE, V33, P139, DOI 10.1016/j.neuroimage.2006.04.220; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sekiguchi A, 2013, MOL PSYCHIATR, V18, P618, DOI 10.1038/mp.2012.51; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tate DF, 2012, BRAIN IMAGING BEHAV, V6, P103, DOI 10.1007/s11682-012-9185-0; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Tuor UI, 2001, EXP NEUROL, V167, P272, DOI 10.1006/exnr.2000.7565; Urban JE, 2012, J NEUROTRAUM, V29, P2774, DOI 10.1089/neu.2012.2373; Vorobyev VA, 2004, COGNITIVE BRAIN RES, V20, P309, DOI 10.1016/j.cogbrainres.2004.03.011; Wang X, 2008, NEUROSCI LETT, V441, P145, DOI 10.1016/j.neulet.2008.06.013; Wang X, 2010, CEREB CORTEX, V20, P1513, DOI 10.1093/cercor/bhp226; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zhang SR, 2009, J REHABIL MED, V41, P1062, DOI 10.2340/16501977-0462; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	72	34	36	4	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					455	463		10.1089/neu.2014.3492			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400005	25118568	Green Submitted, Green Published			2022-02-06	
J	Zhang, YL; Chopp, M; Meng, YL; Zhang, ZG; Doppler, E; Winter, S; Schallert, T; Mahmood, A; Xiong, Y				Zhang, Yanlu; Chopp, Michael; Meng, Yuling; Zhang, Zheng Gang; Doppler, Edith; Winter, Stefan; Schallert, Timothy; Mahmood, Asim; Xiong, Ye			Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						amyloid precursor protein; Cerebrolysin; cognitive function; mild closed head injury; neuroblast; neurogenesis; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; GENERATED GRANULE CELLS; ODOR RECOGNITION MEMORY; ACUTE ISCHEMIC-STROKE; DOUBLE-BLIND; DENTATE GYRUS; REACTIVE ASTROCYTES; HEAD-INJURY; NEUROTROPHIC TREATMENT; FUNCTIONAL RECOVERY	OBJECT Long-term memory deficits occur after mild traumatic brain injuries (mTBIs), and effective treatment modalities are currently unavailable. Cerebrolysin, a peptide preparation mimicking the action of neurotrophic factors, has beneficial effects on neurodegenerative diseasds and brain injuries. The present study investigated the long-term effects of Cerebrolysin treatment on cognitive function in rats after mTBI. METHODS Rats subjected to closed-head mTBI were treated with saline (n = 11) or Cerebrolysin (2.5 ml/kg, n = 11) starting 24 hours after injury and then daily for 28 days. Sham animals underwent surgery without injury (n = 8). To evaluate cognitive function, the modified Morris water maze (MWM) test and a social odor based novelty recognition task were performed after mTBI. All rats were killed on Day 90 after mTBI, and brain sections were immunostained for histological analyses of amyloid precursor protein (APP), astrogliosis, neuroblasts, and neurogenesis. RESULTS Mild TBI caused long-lasting cognitive memory deficits in the MWM and social odor recognition tests up to 90 days after injury. Compared with saline treatment, Cerebrolysin treatment significantly improved both long-term spatial learning and memory in the MWM test and nonspatial recognition memory in the social odor recognition task up to 90 days after mTBI (p < 0.05). Cerebrolysin significantly increased the number of neuroblasts and promoted neurogenesi in the dentate gyrus, and it reduced APP levels and astrogliosis in the corpus callosum, cortex, dentate gyrus, CA1, and CA3 regions (p < 0.05). CONCLUSIONS These results indicate that Cerebrolysin treatment of mTBI improves long-term cognitive function, and this improvement may be partially related to decreased brain APP accumulation and astrogliosis as well as increased neuroblasts and neurogenesis.	[Zhang, Yanlu; Meng, Yuling; Mahmood, Asim; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael; Zhang, Zheng Gang] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MN USA; [Doppler, Edith; Winter, Stefan] EVER Neuro Pharma GmbH, Clin Res & Pharmacol, Unterach, Austria; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Rm 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	EVER Neuro Pharma GmbH	This work was funded by EVER Neuro Pharma GmbH, the manufacturer of Cerebrolysin. Edith Doppler and Stefan Winter are employees of EVER Neuro Pharma GmbH in the Clinical Research and Pharmacology department.	Allegri RF, 2012, DRUG TODAY, V48, P25, DOI 10.1358/dot.2012.48(Suppl.A).1739721; Alvarez XA, 2011, EUR J NEUROL, V18, P59, DOI 10.1111/j.1468-1331.2010.03092.x; Alvarez XA, 2006, EUR J NEUROL, V13, P43, DOI 10.1111/j.1468-1331.2006.01222.x; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bernal-Mondragon C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-104; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Chen CC, 2013, BRIT J NEUROSURG, V27, P803, DOI 10.3109/02688697.2013.793287; Chen N., 2013, COCHRANE DB SYST REV, V1, P1; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dancause N, 2011, PROG BRAIN RES, V192, P273, DOI 10.1016/B978-0-444-53355-5.00015-4; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hampson RE, 1999, NATURE, V402, P610, DOI 10.1038/45154; Heiss WD, 2012, STROKE, V43, P630, DOI 10.1161/STROKEAHA.111.628537; Hong Z, 2009, INT J STROKE, V4, P406, DOI 10.1111/j.1747-4949.2009.00340.x; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kee N, 2007, NAT PROTOC, V2, P3033, DOI 10.1038/nprot.2007.415; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kerr AL, 2011, J COMMUN DISORD, V44, P538, DOI 10.1016/j.jcomdis.2011.04.011; Kesner RP, 2010, NEUROBIOL LEARN MEM, V93, P111, DOI 10.1016/j.nlm.2009.08.010; Kitabatake Y, 2007, NEUROSURG CLIN N AM, V18, P105, DOI 10.1016/j.nec.2006.10.008; Kleim JA, 2011, J COMMUN DISORD, V44, P521, DOI 10.1016/j.jcomdis.2011.04.006; Kogel D, 2012, EXP BRAIN RES, V217, P471, DOI 10.1007/s00221-011-2932-4; Koehl M, 2011, EUR J NEUROSCI, V33, P1101, DOI 10.1111/j.1460-9568.2011.07609.x; Kohler SJ, 2011, P NATL ACAD SCI USA, V108, P10326, DOI 10.1073/pnas.1017099108; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kumaran D, 2007, NEUROPSYCHOLOGIA, V45, P2699, DOI 10.1016/j.neuropsychologia.2007.04.007; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lang W, 2013, INT J STROKE, V8, P95, DOI 10.1111/j.1747-4949.2012.00901.x; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Levy DA, 2004, LEARN MEMORY, V11, P794, DOI 10.1101/lm.82504; Levy DA, 2003, LEARN MEMORY, V10, P531, DOI 10.1101/lm.66703; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Liu P, 2013, BRAIN RES, V1522, P67, DOI 10.1016/j.brainres.2013.05.032; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marin-Burgin A, 2012, BEHAV BRAIN RES, V227, P391, DOI 10.1016/j.bbr.2011.07.001; Markakis EA, 1999, J COMP NEUROL, V406, P449; Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Masliah E, 2012, DRUG TODAY, V48, P3, DOI 10.1358/dot.2012.48(Suppl.A).1739716; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Menon PK, 2012, CNS NEUROL DISORD-DR, V11, P40; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Newcombe VFJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1522; Ngwenya LB, 2006, J COMP NEUROL, V498, P204, DOI 10.1002/cne.21045; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; O'Dell SJ, 2011, BEHAV BRAIN RES, V216, P396, DOI 10.1016/j.bbr.2010.08.022; Plosker GL, 2009, DRUG AGING, V26, P893, DOI 10.2165/11203320-000000000-00000; Rockenstein E, 2007, ACTA NEUROPATHOL, V113, P265, DOI 10.1007/s00401-006-0166-5; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; Ruether E, 2001, INT CLIN PSYCHOPHARM, V16, P253, DOI 10.1097/00004850-200109000-00002; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Sharma A, 2012, CNS NEUROL DISORD-DR, V11, P7, DOI 10.2174/187152712799960790; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Spinetta MJ, 2008, PSYCHOPHARMACOLOGY, V201, P361, DOI 10.1007/s00213-008-1294-5; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Terry AV, 2009, METHODS BEHAV ANAL N, P153; Thome J, 2012, DRUG TODAY, V48, P63, DOI 10.1358/dot.2012.48(Suppl.A).1739724; Ubhi K, 2009, ACTA NEUROPATHOL, V117, P699, DOI 10.1007/s00401-009-0505-4; Vukovic J, 2013, J NEUROSCI, V33, P6603, DOI 10.1523/JNEUROSCI.3064-12.2013; Xiao SF, 2012, AUST NZ J PSYCHIAT, V46, P153, DOI 10.1177/0004867411433213; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495; Zhang L, 2013, STROKE, V44, P1965, DOI 10.1161/STROKEAHA.111.000831; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang YL, 2013, J NEUROSURG, V118, P1343, DOI 10.3171/2013.3.JNS122061; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Ziganshina LE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007026.pub2; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	110	34	34	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2015	122	4					843	855		10.3171/2014.11.JNS14271			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CE2PW	WOS:000351658500016	25614944	Bronze			2022-02-06	
J	Moenninghoff, C; Kraff, O; Maderwald, S; Umutlu, L; Theysohn, JM; Ringelstein, A; Wrede, KH; Deuschl, C; Altmeppen, J; Ladd, ME; Forsting, M; Quick, HH; Schlamann, M				Moenninghoff, Christoph; Kraff, Oliver; Maderwald, Stefan; Umutlu, Lale; Theysohn, Jens M.; Ringelstein, Adrian; Wrede, Karsten H.; Deuschl, Cornelius; Altmeppen, Jan; Ladd, Mark E.; Forsting, Michael; Quick, Harald H.; Schlamann, Marc			Diffuse Axonal Injury at Ultra-High Field MRI	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; CEREBRAL MICROBLEEDS; INTRACEREBRAL HEMORRHAGE; WHITE-MATTER; PROGNOSTIC VALUE; 1.5 TESLA; 7 T; LESIONS; DEMENTIA	Objective Diffuse axonal injury (DAI) is a specific type of traumatic brain injury caused by shearing forces leading to widespread tearing of axons and small vessels. Traumatic microbleeds (TMBs) are regarded as a radiological marker for DAI. This study aims to compare DAIassociated TMBs at 3 Tesla (T) and 7 T susceptibility weighted imaging (SWI) to evaluate possible diagnostic benefits of ultra-high field (UHF) MRI. Material and Methods 10 study participants (4 male, 6 female, age range 20-74 years) with known DAI were included. All MR exams were performed with a 3 T MR system (Magnetom Skyra) and a 7 T MR research system (Magnetom 7 T, Siemens AG, Healthcare Sector, Erlangen, Germany) each in combination with a 32-channel-receive coil. The average time interval between trauma and imaging was 22 months. Location and count of TMBs were independently evaluated by two neuroradiologists on 3 T and 7 T SWI images with similar and additionally increased spatial resolution at 7 T. Inter-and intraobserver reliability was assessed using the interclass correlation coefficient (ICC). Count and diameter of TMB were evaluated with Wilcoxon signed rank test. Results Susceptibility weighted imaging revealed a total of 485 TMBs (range 1-190, median 25) at 3 T, 584 TMBs (plus 20%, range 1-262, median 30.5) at 7 T with similar spatial resolution, and 684 TMBs (plus 41%, range 1-288, median 39.5) at 7 T with 10-times higher spatial resolution. Hemorrhagic DAI appeared significantly larger at 7 T compared to 3 T (p = 0.005). Inter-and intraobserver correlation regarding the counted TMB was high and almost equal 3 T and 7 T. Conclusion 7 T SWI improves the depiction of small hemorrhagic DAI compared to 3 T and may be supplementary to lower field strengths for diagnostic in inconclusive or medicolegal cases.	[Moenninghoff, Christoph; Kraff, Oliver; Maderwald, Stefan; Umutlu, Lale; Theysohn, Jens M.; Ringelstein, Adrian; Deuschl, Cornelius; Altmeppen, Jan; Forsting, Michael; Schlamann, Marc] Univ Hosp Essen, Inst Diagnost & Intervent Radiol & Neuroradiol, Essen, Germany; [Moenninghoff, Christoph; Kraff, Oliver; Maderwald, Stefan; Umutlu, Lale; Theysohn, Jens M.; Wrede, Karsten H.; Deuschl, Cornelius; Ladd, Mark E.; Forsting, Michael; Quick, Harald H.; Schlamann, Marc] Univ Duisburg Essen, Erwin L Hahn Inst Magnet Resonance Imaging, Essen, Germany; [Wrede, Karsten H.] Univ Hosp Essen, Dept Neurosurg, Essen, Germany; [Ladd, Mark E.] German Canc Res Ctr, Div Med Phys Radiol, Heidelberg, Germany; [Quick, Harald H.] Univ Hosp Essen, High Field & Hybrid MR Imaging, Essen, Germany; [Schlamann, Marc] Univ Hosp Giessen, Inst Neuroradiol, Giessen, Germany		Moenninghoff, C (corresponding author), Univ Hosp Essen, Inst Diagnost & Intervent Radiol & Neuroradiol, Essen, Germany.	christoph.moenninghoff@uk-essen.de	Maderwald, Stefan/B-4241-2011; Wrede, Karsten/AAZ-2154-2020; Kraff, Oliver/AAE-2238-2020	Wrede, Karsten/0000-0001-7076-3503; Kraff, Oliver/0000-0002-6006-8934			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Akter M, 2007, ACAD RADIOL, V14, P1011, DOI 10.1016/j.acra.2007.05.013; Allkemper T, 2004, EUR RADIOL, V14, P1000, DOI 10.1007/s00330-004-2241-4; Chang MC, 2010, NEUROREHABILITATION, V26, P339, DOI 10.3233/NRE-2010-0571; Conijn MMA, 2011, AM J NEURORADIOL, V32, P1043, DOI 10.3174/ajnr.A2450; Deistung A, 2006, Z MED PHYS, V16, P261, DOI 10.1078/0939-3889-00324; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Hilal S, 2014, ALZ DIS ASSOC DIS, V28, P106, DOI 10.1097/WAD.0000000000000015; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Luccichenti G, 2010, FUNCT NEUROL, V25, P109; Lupo JM, 2012, INT J RADIAT ONCOL, V82, pE493, DOI 10.1016/j.ijrobp.2011.05.046; Lupo Janine M, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P747; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MONACO EA, 2013, NEUROSURGERY, V72, DOI DOI 10.1227/01.NEU; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Polders DL, 2011, J MAGN RESON IMAGING, V33, P1456, DOI 10.1002/jmri.22554; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Scheid R, 2010, DTSCH ARZTEBL INT, V107, P199, DOI 10.3238/arztebl.2010.0199; Schilling S, 2013, NEUROLOGY, V81, P292, DOI 10.1212/WNL.0b013e31829bfda4; Schlamann M, 2010, ACAD RADIOL, V17, P3, DOI 10.1016/j.acra.2009.10.001; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Soria G, 2011, ANAT REC, V294, P1035, DOI 10.1002/ar.21383; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Tatsumi S, 2008, AJNR Am J Neuroradiol, V29, pe13, DOI 10.3174/ajnr.A0908; Theysohn JM, 2011, J MAGN RESON IMAGING, V33, P782, DOI 10.1002/jmri.22513; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Vernooij MW, 2009, ARCH NEUROL-CHICAGO, V66, P714, DOI 10.1001/archneurol.2009.42; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Wargo CJ, 2013, MAGN RESON IMAGING, V31, P810, DOI 10.1016/j.mri.2013.01.013; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107	47	34	36	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0122329	10.1371/journal.pone.0122329			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	WOS:000352083900177	25793614	Green Submitted, Green Published, gold			2022-02-06	
J	Bekelis, K; Missios, S; Mackenzie, TA				Bekelis, Kimon; Missios, Symeon; Mackenzie, Todd A.			Prehospital Helicopter Transport and Survival of Patients With Traumatic Brain Injury	ANNALS OF SURGERY			English	Article						ground emergency medical services; helicopter; traumatic brain injury; mortality; NTDB	EMERGENCY MEDICAL-SERVICES; IN-HOSPITAL MORTALITY; GROUND TRANSPORT; SCENE TRANSPORT; DATA-BANK; ASSOCIATION; PATTERNS; OUTCOMES; ADULTS; IMPACT	Objective: To investigate the association of helicopter transport with survival of patients with traumatic brain injury (TBI), in comparison with ground emergency medical services (EMS). Background: Helicopter utilization and its effect on the outcomes of TBI remain controversial. Methods: We performed a retrospective cohort study involving patients with TBI who were registered in the National Trauma Data Bank between 2009 and 2011. Regression techniques with propensity score matching were used to investigate the association of helicopter transport with survival of patients with TBI, in comparison with ground EMS. Results: During the study period, there were 209,529 patients with TBI who were registered in the National Trauma Data Bank and met the inclusion criteria. Of these patients, 35,334 were transported via helicopters and 174,195 via ground EMS. For patients transported to level I trauma centers, 2797 deaths (12%) were recorded after helicopter transport and 8161 (7.8%) after ground EMS. Multivariable logistic regression analysis demonstrated an association of helicopter transport with increased survival [OR (odds ratio), 1.95; 95% confidence interval (CI), 1.81-2.10; absolute risk reduction (ARR), 6.37%]. This persisted after propensity score matching (OR, 1.88; 95% CI, 1.74-2.03; ARR, 5.93%). For patients transported to level II trauma centers, 1282 deaths (10.6%) were recorded after helicopter transport and 5097 (7.3%) after ground EMS. Multivariable logistic regression analysis demonstrated an association of helicopter transport with increased survival (OR, 1.81; 95% CI, 1.64-2.00; ARR 5.17%). This again persisted after propensity score matching (OR, 1.73; 95% CI, 1.55-1.94; ARR, 4.69). Conclusions: Helicopter transport of patients with TBI to level I and II trauma centers was associated with improved survival, in comparison with ground EMS.	[Bekelis, Kimon] Dartmouth Hitchcock Med Ctr, Neurosurg Sect, Lebanon, NH 03756 USA; [Missios, Symeon] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA; [Mackenzie, Todd A.] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; [Mackenzie, Todd A.] Dartmouth Hitchcock Med Ctr, Dept Community & Family Med, Lebanon, NH 03756 USA; [Mackenzie, Todd A.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA		Bekelis, K (corresponding author), Dartmouth Hitchcock Med Ctr, Neurosurg Sect, One Med Ctr Dr, Lebanon, NH 03756 USA.	kbekelis@gmail.com	Bekelis, Kimon/Y-3402-2019		National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [PO1-AG19783]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG019783] Funding Source: NIH RePORTER	Supported by grant from the National Institute on Aging (PO1-AG19783). The authors declare no conflicts of interest.	American College of Surgeons, 2011, ANN REPORT; [Anonymous], 2010, TRAUMATIC BRAIN INJU; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; Bledsoe BE, 2006, J TRAUMA, V60, P1257, DOI 10.1097/01.ta.0000196489.19928.c0; Bledsoe Bryan E, 2003, Emerg Med Serv, V32, P88; Brown JB, 2010, J TRAUMA, V69, P1030, DOI 10.1097/TA.0b013e3181f6f450; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Delgado MK, 2014, ANN EMERG MED, V63, P411; Delgado MK, 2013, ANN EMERG MED, V62, P351, DOI 10.1016/j.annemergmed.2013.02.025; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Galvagno SM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009228.pub2; Galvagno SM, 2012, JAMA-J AM MED ASSOC, V307, P1602, DOI 10.1001/jama.2012.467; Haider AH, 2012, J AM COLL SURGEONS, V214, P756, DOI 10.1016/j.jamcollsurg.2011.12.013; Hirano K., 2001, HEALTH SERV OUTCOME, V2, P259, DOI DOI 10.1023/A:1020371312283; Ho D, 2007, MATCHIT NONPARAMETRI; Imai K, 2009, ZELIG EVERYONES STAT; Imai K, 2008, J COMPUT GRAPH STAT, V17, P892, DOI 10.1198/106186008X384898; Lindenauer PK, 2004, JAMA-J AM MED ASSOC, V291, P2092, DOI 10.1001/jama.291.17.2092; Mitchell AD, 2007, CAN J SURG, V50, P129; Oyetunji TA, 2011, J SURG RES, V165, pE37, DOI 10.1016/j.jss.2010.09.025; Ringburg Akkie N, 2009, Air Med J, V28, P298, DOI 10.1016/j.amj.2009.03.007; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739; SCHILLER WR, 1988, J TRAUMA, V28, P1127, DOI 10.1097/00005373-198808000-00004; Stewart KE, 2011, ACAD EMERG MED, V18, P1208, DOI 10.1111/j.1553-2712.2011.01207.x; Sullivent EE, 2011, PREHOSP EMERG CARE, V15, P295, DOI 10.3109/10903127.2011.569849; Taylor CB, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2009.09.030; Thomas SH, 2002, J TRAUMA, V52, P136, DOI 10.1097/00005373-200201000-00023; Thomas Stephen H, 2003, Curr Opin Anaesthesiol, V16, P153, DOI 10.1097/00001503-200304000-00008; Thomas Stephen H, 2002, Prehosp Emerg Care, V6, P359, DOI 10.1080/10903120290938508; [No title captured]	34	34	35	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAR	2015	261	3					579	585		10.1097/SLA.0000000000000672			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CB3WK	WOS:000349559900057	24743624	Green Accepted			2022-02-06	
J	Sessoms, PH; Gottshall, KR; Collins, JD; Markham, AE; Service, KA; Reini, SA				Sessoms, Pinata H.; Gottshall, Kim R.; Collins, John-David; Markham, Amanda E.; Service, Kathrine A.; Reini, Seth A.			Improvements in Gait Speed and Weight Shift of Persons With Traumatic Brain Injury and Vestibular Dysfunction Using a Virtual Reality Computer-Assisted Rehabilitation Environment	MILITARY MEDICINE			English	Article; Proceedings Paper	Military Health Systems Research Symposium (MHSRS)	AUG 13-16, 2012	Fort Lauderdale, FL				DISORDERS; BALANCE; HEAD	Many people sustaining a traumatic brain injury experience vestibular pathology requiring physical therapy for treatment. This study measured improvements in gait speed and weight shift for subjects receiving vestibular physical therapy using a Computer-Assisted Rehabilitation Environment (CAREN). A 6-session CAREN, 6-session traditional vestibular therapy group was compared with a 12-session CAREN only (0 traditional sessions) therapy group. These two groups were compared to each other and with data from healthy controls performing similar tasks on the CAREN. Those participating in 12 CAREN sessions had greater improvements in gait speed (p = 0.014) and weight shift scores (p < 0.001) and demonstrated similar values achieved by a healthy control population.	[Sessoms, Pinata H.; Collins, John-David; Markham, Amanda E.; Service, Kathrine A.; Reini, Seth A.] Naval Hlth Res Ctr, Warfighter Performance Dept, San Diego, CA 92106 USA; [Gottshall, Kim R.] Naval Med Ctr San Diego, Phys Therapy Dept, San Diego, CA 92134 USA		Sessoms, PH (corresponding author), Naval Hlth Res Ctr, Warfighter Performance Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.			Sessoms, Pinata/0000-0002-6960-0659; Collins, John-David/0000-0002-9867-5465	Bureau of Medicine and Surgery Wounded, Ill, and Injured grant R116 [60818]	We thank Sarah E. Kruger from Walter Reed National Military Medical Center National Intrepid Center of Excellence for her initial work on establishing a scoring system for the boat-steering application, from which our scoring system is based. This work was supported by the Bureau of Medicine and Surgery Wounded, Ill, and Injured grant R116 under work unit no. 60818.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Collins JD, 2015, WORK, V50, P121, DOI 10.3233/WOR-141927; Gottshall Kim, 2005, Work, V24, P381; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2012, IEEE ENG MED BIO, P6141, DOI 10.1109/EMBC.2012.6347395; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Johnson CM, 2014, OTOLARYNG HEAD NECK, V150, P437, DOI 10.1177/0194599813515184; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85	12	34	37	1	17	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR	2015	180	3		S			143	149		10.7205/MILMED-D-14-00385			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	CD3OQ	WOS:000350988500026	25747645	Bronze			2022-02-06	
J	Catroppa, C; Crossley, L; Hearps, SJC; Yeates, KO; Beauchamp, M; Rogers, K; Anderson, V				Catroppa, Cathy; Crossley, Louise; Hearps, Stephen J. C.; Yeates, Keith Owen; Beauchamp, Miriam; Rogers, Kirrily; Anderson, Vicki			Social and Behavioral Outcomes: Pre-Injury to Six Months following Childhood Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral; social; children; traumatic brain injury	FUNCTIONAL RECOVERY; CHILDREN; ADOLESCENTS; PARTICIPATION; LIFE; PREDICTORS; DISORDERS; MEDIATOR; HEALTH; SKILLS	This study aimed to extend the limited research investigating social and behavioral outcomes following childhood traumatic brain injury (TBI). The study compared pre-and post-injury measures of these skills and investigated the role of pre-injury child status and pre-injury family functioning in the prediction of outcome at six months post-injury. A secondary aim was to compare rates of impairment at six months post-injury between children post-TBI and a typically developing (TD) control group. This study comprised 140 children, 97 survivors of TBI (67 males) and 43 TD children (24 males), matched for age, sex, and socio-economic status. All participants were ascertained between 2007 and 2010, and were between ages 5.5 and 15.0 years. Children with TBI represented consecutive hospital admissions and were recruited at time of injury into a longitudinal study. TD children were recruited from the community, through local schools chosen to provide a range of socio-economic backgrounds. Findings indicated a deterioration of social participation skills post-injury, particularly for those sustaining a more severe injury, and a consistently higher rate of impairment in social and behavioral outcomes in the TBI group. Pre-injury function, injury severity and restrictions to social participation (e.g., reduced sport activities) as recommended by clinicians contributed significantly to outcome. Difficulties are evident in the short-term post-childhood TBI in social and behavioral domains. It is essential to monitor children long-term, particularly as societal expectations and demands increase.	[Catroppa, Cathy; Crossley, Louise; Hearps, Stephen J. C.; Rogers, Kirrily; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia; [Catroppa, Cathy; Rogers, Kirrily; Anderson, Vicki] Univ Melbourne, Melbourne, Vic, Australia; [Beauchamp, Miriam] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam] St Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwides Childrens Hosp, Res Inst, Columbus, OH USA		Catroppa, C (corresponding author), Murdoch Childrens Res Inst, 4 West,Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021; Yeates, Keith/AAJ-4223-2020; Hearps, Stephen/L-6853-2016	Catroppa, Cathy/0000-0002-9750-0436; Rogers, Kirrily/0000-0001-8282-537X; Yeates, Keith/0000-0001-7680-2892; Hearps, Stephen/0000-0003-2984-1172	Victorian Neurotrauma Initiative; Victorian Government Operational Infrastructure Scheme	The Victorian Neurotrauma Initiative funded this research, and it was also supported by the Victorian Government Operational Infrastructure Scheme.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Anaby D, 2012, DEV MED CHILD NEUROL, V54, P339, DOI 10.1111/j.1469-8749.2011.04204.x; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell G, 2008, J HEAD TRAUMA REHAB, V23, P341, DOI 10.1097/01.HTR.0000336850.29574.7a; Bedell Gary M, 2002, Pediatr Rehabil, V5, P107, DOI 10.1080/1363849021000013540; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Crowe LM, 2011, CLIN PSYCHOL REV, V31, P767, DOI 10.1016/j.cpr.2011.03.008; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Fidell L.S., 2000, USING MULTIVARIATE S; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Galvin J, 2010, AUST OCCUP THER J, V57, P118, DOI 10.1111/j.1440-1630.2009.00822.x; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gauvin-Lepage J, 2010, BRAIN INJURY, V24, P1087, DOI 10.3109/02699052.2010.494593; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Kaldoja ML, 2012, BRAIN INJURY, V26, P1005, DOI 10.3109/02699052.2012.660516; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Prigatano G.P., 2010, PED HLTH, V4, P447; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Renstrom B, 2012, BRAIN INJURY, V26, P1405, DOI 10.3109/02699052.2012.694559; Roscigno CI, 2011, BRAIN INJURY, V25, P882, DOI 10.3109/02699052.2011.581638; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Sonnenberg LK, 2010, BRAIN INJURY, V24, P1003, DOI 10.3109/02699052.2010.489033; TEASDALE G, 1974, LANCET, V2, P81; Thompson H, 2012, J NEUROTRAUM, V29, pA189; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; UCLA: Academic Technology Services, 2012, STAT DAT AN EX TOB A; Van Tol E., BRAIN INJ, V25, P1279; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Warschausky S, 1997, Pediatr Rehabil, V1, P77; WECHSLER D, 1990, WECHSLER ABBREVIATED; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	54	34	34	1	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					109	115		10.1089/neu.2013.3276			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700005	24773028				2022-02-06	
J	Majdan, M; Steyerberg, EW; Nieboer, D; Mauritz, W; Rusnak, M; Lingsma, HF				Majdan, Marek; Steyerberg, Ewout W.; Nieboer, Daan; Mauritz, Walter; Rusnak, Martin; Lingsma, Hester F.			Glasgow Coma Scale Motor Score and Pupillary Reaction To Predict Six-Month Mortality in Patients with Traumatic Brain Injury: Comparison of Field and Admission Assessment	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Coma Scale; prehospital assessment; pupillary reactivity; assessment at admission; traumatic brain injuries	HEAD-INJURY	The Glasgow Coma Scale (GCS) and pupillary reactivity are well-known prognostic factors in traumatic brain injury (TBI). The aim of this study was to compare the GCS motor score and pupillary reactivity assessed in the field and at hospital admission and assess their prognostic value for 6-month mortality in patients with moderate or severe TBI. We studied 445 patients with moderate or severe TBI from Austria enrolled to hospital in 2009-2012. The area under the curve (AUC) and Nagelkerke's R-2 were used to evaluate the predictive ability of GCS motor score and pupillary reactivity assessed in the field and at admission. Uni- and multi-variable analyses-adjusting for age, other clinical, and computed tomography findings-were performed using combinations of field and admission GCS motor score and pupillary reactivity. Motor scores generally deteriorated from the field to admission, whereas pupillary reactivity was similar. GCS motor score assessed in field (AUC=0.754; R-2=0.273) and pupillary assessment at admission (AUC=0.662; R-2=0.214) performed best as predictors of 6-month mortality in the univariate analysis. This combination also showed best performance in the adjusted analyses (AUC=0.876; R-2=0.508), but the performance of both predictors assessed at admission was not much worse (AUC=0.857; R-2=0.460). Field GCS motor score and pupillary reactivity at hospital admission, compared to other combinations of these parameters, possess the best prognostic value to predict 6-month mortality in patients with moderate-to-severe TBI. Given that differences in prognostic performance are only small, both the field and admission values of GCS motor score and pupillary reaction may be reasonable to use in multi-variable prediction models to predict 6-month outcome.	[Majdan, Marek; Rusnak, Martin] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava 91701, Slovakia; [Majdan, Marek; Mauritz, Walter; Rusnak, Martin] INRO, Vienna, Austria; [Steyerberg, Ewout W.; Nieboer, Daan; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands		Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia.	mmajdan@igeh.org	Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016	Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042	Austrian Ministry of Health; Austrian Worker's Compensation Board (AUVA) [FK 11/2008, FK 11/2010]; AUVA [FK 09/13]; European UnionEuropean Commission [602150]	The project was funded jointly by the Austrian Ministry of Health (Contract: October 15, 2008) and by the Austrian Worker's Compensation Board (AUVA; FK 11/2008 and FK 11/2010). Data analysis was supported by a grant from AUVA (FK 09/13). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham and by small donations from various sources. The preparation of this article was partly done within the CENTER-TBI project that has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 602150.	Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; Kung WM, 2011, INJURY, V42, P940, DOI 10.1016/j.injury.2010.09.019; Majidi S, 2013, AM J EMERG MED, V31, P1215, DOI 10.1016/j.ajem.2013.05.026; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Mauritz W, 2009, EUR J EMERG MED, V16, P153, DOI 10.1097/MEJ.0b013e32832a0864; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81	20	34	35	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					101	108		10.1089/neu.2014.3438			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700004	25227136	Green Published			2022-02-06	
J	Xu, DY; Huang, P; Yte, ZS; Xing, DH; Ouyang, S; Xing, GQ				Xu, Dongying; Huang, Ping; Yte, Zhaosheng; Xing, Daniel H.; Ouyang, Shuai; Xing, Guoqiang			Efficacy and safety of Panax notoginseng saponin therapy for acute intracerebral hemorrhage, meta-analysis, and mini review of potential mechanisms of action	FRONTIERS IN NEUROLOGY			English	Article						notoginsenosides; botanical medicine; nutraceutica Is; TBI and stroke recovery; randomized controlled clinical trials; hemostasis; anti-coagulation; pharmacological mechanisms	ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; GINSENOSIDE RG1; STEM-CELLS; RAT MODEL; GLUCOCORTICOID-RECEPTOR; PERIHEMATOMAL EDEMA; INDUCED APOPTOSIS	Intracranial/intracerebral hemorrhage (ICH) is a leading cause of death and disability in people with traumatic brain injury (TBI) and stroke. No proven drug is available for ICH. Panax notoginseng (total saponin extraction, PNS) is one of the most valuable herb medicines for stroke and cerebralvascular disorders in China. We searched for randomized controlled clinical trials (RCTs) involving PNS injection to treat cerebral hemorrhage for meta-analysis from various databases including the Chinese Stroke Trials Register, the trials register of the Cochrane Complementary Medicine Field, the Cochrane Central Register of Controlled Trials, MEDLINE, Chinese BioMedical disk, and China Doctorate/Master Dissertations Databases. The quality of the eligible trials was assessed by Jadad's scale. Twenty (20) of the 24 identified randomized controlled trials matched the inclusive criteria including 984 ICH patients with PNS injection and 907 ICH patients with current treatment (CT). Compared to the CT groups, PNS-treated patients showed better outcomes in the effectiveness rate (ER), neurological deficit score, intracranial hematoma volume, intracerebral edema volume, Barthel index, the number of patients died, and incidence of adverse events. Conclusion: PNS injection is superior to CT for acute ICH. A review of the literature shows that PNS may exert multiple protective mechanisms against ICH-induced brain damage including hemostasis, anti-coagulation, anti-thromboembolism, cerebral vasodilation, invigorated blood dynamics, anti-inflammation, antioxidation, and anti-hyperglycemic effects. Since vitamin C and other brain cell activators (BCA) that are not considered common practice were also used as parts of the CT in several trials, potential PNS and BCA interactions could exist that may have made the effect of PNS therapy less or more impressive than by PNS therapy alone. Future PNS trials with and without the inclusion of such controversial BCAs as part of the CT could clarify the situation. As PNS has a long clinical track record in Asia, it could potentially become a therapy option to treat ICH in the US and Europe. Further clinical trials with better experimental design could determine the long-term effects of PNS treatment for TB I and stroke.	[Xu, Dongying; Huang, Ping] Guangxi Univ Chinese Med, Fac Nursing, Nanning 530022, Guangxi, Peoples R China; [Yte, Zhaosheng] Huanggang Hosp Tradit Chinese Med, Dept Oncol, Huanggang, Peoples R China; [Xing, Daniel H.] Thomas Wootton High Sch, Rockville, MD USA; [Ouyang, Shuai] Univ Alberta, Sch Business, Edmonton, AB, Canada; [Xing, Guoqiang] Lotus Biotech Com LLC, Rockville, MD USA		Xu, DY (corresponding author), Guangxi Univ Chinese Med, Fac Nursing, 61 Dongge Rd, Nanning 530022, Guangxi, Peoples R China.	donnaxu_cn@hotmail.com; gxing99@yahoo.com	Xing, Guoqiang/ABA-8450-2020		Department of Education, Guangxi Zhuang Autonomous Region, P.R. China (New Century Higher Education Reform program in Guangxi: Research and Practice of English Curriculum System in Nursing at Guangxi Traditional Chinese Medicine College) [2011JGZD. 014]	Ms. Jillian W. Wen edited the manuscript. Mr. Zhongjian Chen of Panax Notoginseng Research Institute of Wenshan State/Region, Yunnan Province, China provided the artistic drawing of noto-ginseng. This study is supported, in part, by a grant from the Department of Education, Guangxi Zhuang Autonomous Region, P.R. China (New Century Higher Education Reform program in Guangxi: Research and Practice of English Curriculum System in Nursing at Guangxi Traditional Chinese Medicine College) (2011JGZD. 014) (to Dongying Xu).	Abou-Chebl A, 2007, CATHETER CARDIO INTE, V69, P690, DOI 10.1002/ccd.20693; Abou-Chebl A, 2010, STROKE, V41, P1996, DOI 10.1161/STROKEAHA.110.578997; Adu-Bonsaffoh K, 2013, INT J GYNECOL OBSTET, V123, P110, DOI 10.1016/j.ijgo.2013.05.017; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; An DS, 2011, INT J SYST EVOL MICR, V61, P2606, DOI 10.1099/ijs.0.028431-0; Anderson CS, 2010, STROKE, V41, P307, DOI 10.1161/STROKEAHA.109.561795; [Anonymous], 2013, J Mol Med (Berl), V91, P645, DOI 10.1007/s00109-013-1018-0; Arauz A, 2014, CURR OPIN NEUROL, V27, P8, DOI 10.1097/WCO.0000000000000045; Aung HH, 2007, CANCER CHEMOTH PHARM, V59, P369, DOI 10.1007/s00280-006-0278-6; Auriat A, 2005, J CEREBR BLOOD F MET, V25, P247, DOI 10.1038/sj.jcbfm.9600026; Bai YL, 2012, J CLIN NEUROSCI, V19, P1376, DOI 10.1016/j.jocn.2011.10.021; Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2; Balsevich JJ, 2009, PHYTOCHEM ANALYSIS, V20, P38, DOI 10.1002/pca.1095; Berek L, 2001, IN VIVO, V15, P151; Cadilhac DA, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-49; Chai H, 2009, J SURG RES, V157, P193, DOI 10.1016/j.jss.2008.07.005; Chan CM, 2010, CRIT CARE, V14, DOI 10.1186/cc8996; Chan ECY, 2007, RAPID COMMUN MASS SP, V21, P519, DOI 10.1002/rcm.2864; Chang SH, 2007, CLIN NUTR, V26, P785, DOI 10.1016/j.clnu.2007.07.008; Chang Y, 2006, J THORAC CARDIOV SUR, V132, P867, DOI 10.1016/j.jtcvs.2006.06.029; Chen C, 2014, ACTA PHARMACOL SIN, V35, P143, DOI 10.1038/aps.2013.136; Chen Gang, 2011, Zhongguo Zhong Yao Za Zhi, V36, P1815; Chen GT, 2007, J NAT PROD, V70, P1203, DOI 10.1021/np070053v; Chen Hui-zhen, 2012, Zhejiang Da Xue Xue Bao Yi Xue Ban, V41, P32; Chen J, 2011, TRADIT CHIN EMERG ME, V20, P1273; Chen KZ, 2013, HUNAN J TRADIT CHIN, V29, P41; Chen SX, 2011, J ETHNOPHARMACOL, V137, P263, DOI 10.1016/j.jep.2011.05.011; Chen SL, 2006, CHIN J INTEGR MED CA, V4, P80; Chen W, 2000, Se Pu, V18, P439; Chen XF, 2011, J CLIN NEURO, V24, P191; Cheng WD, 2013, INT ORTHOP, V37, P2065, DOI 10.1007/s00264-013-1990-6; Cheng Y, 2005, ACTA PHARMACOL SIN, V26, P143, DOI 10.1111/j.1745-7254.2005.00034.x; Cheung LWT, 2011, CARDIOVASC RES, V89, P419, DOI 10.1093/cvr/cvq300; Chiu CD, 2013, STROKE, V44, P1682, DOI 10.1161/STROKEAHA.113.675983; CNS TtCNCoN, 1996, CHIN J NEUROL SCI, V29, P379; Cui Han-ming, 2009, Zhong Yao Cai, V32, P1810; Cui X, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006556.pub2; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Ding HY, 2008, NEURAL INJ FUNCT REC, V3, P386; Ding HY, 2010, CHINA MOD MED, V17, P56; Dong YH, 2006, J MED THEORY PRACT, V19, P253; Edwards P, 2005, LANCET, V365, P1957; Emiru T, 2013, CLIN APPL THROMB-HEM, V19, P652, DOI 10.1177/1076029612454938; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Bernal EF, 2013, MED INTENSIVA, V37, P327, DOI 10.1016/j.medin.2012.05.015; FUJII Y, 1994, NEUROSURGERY, V35, P592, DOI 10.1227/00006123-199410000-00003; Gao B, 2014, BRIT J PHARMACOL, V171, P214, DOI 10.1111/bph.12435; Gao B, 2014, LIFE SCI, V108, P63, DOI 10.1016/j.lfs.2014.05.010; Gao L, 2012, J NEUROL SCI, V323, P236, DOI 10.1016/j.jns.2012.09.028; [高颖 Gao Ying], 2011, [中成药, Chinese Traditional Patent Medicine], V33, P1851; Garrett MC, 2009, BRAIN RES, V1298, P171, DOI 10.1016/j.brainres.2009.04.047; Gebel JM, 2000, STROKE, V31, P596, DOI 10.1161/01.STR.31.3.596; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gong Wan, 2013, Zhongguo Zhong Yao Za Zhi, V38, P1046; Gong Y, 2008, ACTA NEUROCHIR SUPPL, V105, P67; Gu P, 2006, J CHIN CLIN MED, V13, P527; Guo XF, 2002, CHIN J MISDIAGN, V2, P1355; Han DH, 2012, METABOLISM, V61, P1615, DOI 10.1016/j.metabol.2012.04.008; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hashimoto R, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/693717; He D, 2002, CHIN J INTEGR TRADIT, V9, P27; He W, 2011, J ASIAN NAT PROD RES, V13, P1, DOI 10.1080/10286020.2010.535519; Huang LF, 2014, THROMB RES, V133, P848, DOI 10.1016/j.thromres.2014.02.009; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jia D, 2014, INT J BIOL MACROMOL, V63, P177, DOI 10.1016/j.ijbiomac.2013.10.034; Kim DH, 2013, J GINSENG RES, V37, P54, DOI 10.5142/jgr.2013.37.54; Kim EJ, 2009, BMB REP, V42, P194, DOI 10.5483/BMBRep.2009.42.4.194; Korivi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/932165; Lan TH, 2011, BIOCHEM PHARMACOL, V82, P148, DOI 10.1016/j.bcp.2011.04.001; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597; Lauer A, 2011, J CEREBR BLOOD F MET, V31, P1736, DOI 10.1038/jcbfm.2011.22; Lee HM, 2012, PHYTOTHER RES, V26, P1017, DOI 10.1002/ptr.3686; Lee IA, 2012, J AGR FOOD CHEM, V60, P9595, DOI 10.1021/jf301372g; Lee KT, 2011, ARCH PHARM RES, V34, P1201, DOI 10.1007/s12272-011-0719-6; Leung KW, 2011, ANGIOGENESIS, V14, P515, DOI 10.1007/s10456-011-9235-z; Leys Didier, 2012, Rev Prat, V62, P1239; Li C, 2014, AM J PHYSIOL-GASTR L, V306, pG111, DOI 10.1152/ajpgi.00123.2013; Li H, 2004, CHIN J INTEGR TRADIT, V11, P50; Li H, 2014, UROL INT, V93, P92, DOI 10.1159/000354878; Li L, 2004, BIOMED CHROMATOGR, V18, P849, DOI 10.1002/bmc.400; Li Q, 2004, CHIN J MISDIAGN, V4, P262; Li WH, 2014, J ETHNOPHARMACOL, V151, P686, DOI 10.1016/j.jep.2013.11.035; Li XY, 2010, CLIN EXP PHARMACOL P, V37, P199, DOI 10.1111/j.1440-1681.2009.05286.x; Li XY, 2007, BIOMED CHROMATOGR, V21, P735, DOI 10.1002/bmc.813; Li XY, 2007, BIOL PHARM BULL, V30, P847, DOI 10.1248/bpb.30.847; Liang XH, 1998, CHIN J PHARM TOXICOL, V12, P40; [林力 LIN Li], 2009, [中国药学杂志, Chinese Pharmaceutical Journal], V44, P373; Lin N, 2014, CELL BIOCHEM BIOPHYS, V68, P189, DOI 10.1007/s12013-013-9688-3; Lin T, 2012, J ETHNOPHARMACOL, V142, P754, DOI 10.1016/j.jep.2012.05.057; Lin WM, 2007, J NEURAL TRANSM-SUPP, P105; Liu DH, 2012, J CARDIOVASC PHARM, V59, P222, DOI 10.1097/FJC.0b013e31823c1d34; Liu H Z, 1982, Yao Xue Xue Bao, V17, P801; Liu HF, 2009, DRUG METAB DISPOS, V37, P2290, DOI 10.1124/dmd.109.029819; Liu JF, 2012, NEUROCHEM RES, V37, P2738, DOI 10.1007/s11064-012-0866-2; Liu L, 2011, BRAIN RES, V1382, P147, DOI 10.1016/j.brainres.2011.01.051; Liu QA, 2011, NEUROCHEM INT, V58, P119, DOI 10.1016/j.neuint.2010.11.004; Liu RY, 2014, NEUROSCI BULL, V30, P90, DOI 10.1007/s12264-013-1371-6; Liu YW, 2012, PHARMACOL BIOCHEM BE, V101, P93, DOI 10.1016/j.pbb.2011.12.003; Liu ZC, 2013, MOL MED REP, V8, P1397, DOI 10.3892/mmr.2013.1658; Loftspring MC, 2009, J CEREBR BLOOD F MET, V29, P137, DOI 10.1038/jcbfm.2008.114; Lok J, 2011, ACTA NEUROCHIR SUPPL, V111, P63, DOI 10.1007/978-3-7091-0693-8_11; Lu TT, 2011, BIOL PHARM BULL, V34, P1319, DOI 10.1248/bpb.34.1319; Luo FC, 2010, J ETHNOPHARMACOL, V127, P419, DOI 10.1016/j.jep.2009.10.023; Luo PD, 2008, J PREV MED, V35, P4307; Ma JX, 2010, NEUROSCI LETT, V478, P66, DOI 10.1016/j.neulet.2010.04.064; MA LY, 1998, CHINESE PHARMACOL B, V14, P27; Ma Xiaofen, 2010, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V27, P342; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Meng X, 2014, FREE RADICAL RES, V48, P445, DOI 10.3109/10715762.2014.885117; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Na JY, 2012, J GINSENG RES, V36, P242, DOI 10.5142/jgr.2012.36.3.242; Ning MH, 2004, J TRADIT CHIN MED, V8, P592; Ogata T, 2008, J NEUROL SCI, V272, P83, DOI 10.1016/j.jns.2008.04.032; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Qian YH, 2009, NEUROL RES, V31, P663, DOI 10.1179/174313209X385572; Revel-Vilk S, 2004, J PEDIATR-US, V144, P490, DOI 10.1016/j.jpeds.2003.12.016; Rodriguez-Yanez M, 2013, NEUROLOGIA, V28, P236, DOI 10.1016/j.nrl.2011.03.010; Shen KK, 2014, BIOCHEM PHARMACOL, V88, P66, DOI 10.1016/j.bcp.2014.01.007; Shen KK, 2012, BIOCHEM PHARMACOL, V84, P784, DOI 10.1016/j.bcp.2012.05.024; Shi YH, 2011, PHARM BIOL, V49, P900, DOI 10.3109/13880209.2011.554845; Skolarus LE, 2013, J STROKE CEREBROVASC, V22, P15, DOI 10.1016/j.jstrokecerebrovasdis.2011.05.025; Song Y, 2008, CHIN J MISDIAGN, V8, P8875; Sun Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080859; Tan Zhen-Yuan, 2013, Zhong Yao Cai, V36, P1121; Tang BZ, 2011, CNS NEUROL DISORD-DR, V10, P235, DOI 10.2174/187152711794480456; Tang JL, 2000, J CLIN EPIDEMIOL, V53, P477, DOI 10.1016/S0895-4356(99)00204-8; Tang YH, 2007, MOD J INTEGR TRADIT, V16, P4285; Tian ZX, 2004, J PRACT TRADIT CHIN, V18, P68; Tveiten A, 2014, ACTA NEUROL SCAND, V129, P269, DOI 10.1111/ane.12185; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Vogel T, 2008, UNFALLCHIRURG, V111, P898, DOI 10.1007/s00113-008-1502-0; Wang De-Jian, 2011, Sichuan Da Xue Xue Bao Yi Xue Ban, V42, P503; Wang JH, 2007, SHAANXI TRADIT CHIN, V28, P1314; Wang J, 2009, NEUROCHEM INT, V54, P43, DOI 10.1016/j.neuint.2008.10.003; Wang P, 2014, PHYTOMEDICINE, V21, P177, DOI 10.1016/j.phymed.2013.08.021; Wang YL, 2011, NEUROSCI LETT, V487, P70, DOI 10.1016/j.neulet.2010.09.076; Wu JY, 2013, NEUROCHEM INT, V62, P92, DOI 10.1016/j.neuint.2012.09.016; Wu Wei, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P799; Xia R, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/767930; Xia W, 2011, PHYTOMEDICINE, V18, P516, DOI 10.1016/j.phymed.2010.09.007; Xie GQ, 2005, CHIN J INTEGR MED CA, V3, P496; Xie XS, 2009, CHIN J INTEGR MED, V15, P133, DOI 10.1007/s11655-009-0133-9; Xie X, 2010, MOL MED REP, V3, P635, DOI 10.3892/mmr_00000308; Xiong Y, 2010, DIABETES, V59, P2505, DOI 10.2337/db10-0315; Xu DY, 2005, ZHONGGUO ZHONG YAO Z, V30, P1465; Xu H. L., 1997, Yaoxue Xuebao, V32, P502; Xu QF, 2003, J ETHNOPHARMACOL, V84, P187, DOI 10.1016/S0378-8741(02)00317-3; Xu YQ, 2003, INNER MONGOL J TRADI, V22, P41; Yan JP, 2013, J ETHNOPHARMACOL, V147, P456, DOI 10.1016/j.jep.2013.03.039; Yang NQ, 2012, ACTA BIOCH BIOPH SIN, V44, P999, DOI 10.1093/abbs/gms092; Yao Xiao-hao, 2002, Zhongguo Zhongyao Zazhi, V27, P371; Ye RD, 2011, NEUROTHERAPEUTICS, V8, P515, DOI 10.1007/s13311-011-0051-3; Ye RD, 2011, NEUROPHARMACOLOGY, V61, P815, DOI 10.1016/j.neuropharm.2011.05.029; Ye RD, 2011, NEUROCHEM INT, V58, P391, DOI 10.1016/j.neuint.2010.12.015; Yong-Xin X, 2013, INDIAN J MED RES, V137, P151; Yoshikawa M, 1997, CHEM PHARM BULL, V45, P1039, DOI 10.1248/cpb.45.1039; Yoshikawa M, 2001, CHEM PHARM BULL, V49, P1452, DOI 10.1248/cpb.49.1452; Yu SH, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-23; Yuan KZ, 2010, CHIN COMMUNITY DOCTO, V12, P136; Yuan Y, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005569.pub2; Zhang X, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00152; Zhang Y, 2007, JPMT, V14, P1877; Zhang YX, 2013, INT IMMUNOPHARMACOL, V17, P1094, DOI 10.1016/j.intimp.2013.10.013; Zhang ZG, 2014, MOL MED REP, V9, P989, DOI 10.3892/mmr.2013.1870; ZHAO GQ, 1986, CHINESE TRADITIONAL, V17, P34; Zhao XS, 2013, INT TRADIT CHIN MED, V8, P787; Zheng HZ, 2013, J ETHNOPHARMACOL, V147, P595, DOI 10.1016/j.jep.2013.03.043; Zheng XD, 2007, J MOD CLIN MED, V33, P112; Zhou Q, 2014, THROMB RES, V133, P57, DOI 10.1016/j.thromres.2013.10.032; Zhou YH, 2007, CHIN J INTEGR MED CA, V5, P69; Zhou YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/374963; Zou Y, 2013, J SURG RES, V183, P760, DOI 10.1016/j.jss.2013.01.068; 李俊明, 2003, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V23, P546	177	34	38	0	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 7	2015	5								274	10.3389/fneur.2014.00274			19	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU7VB	WOS:000363748800001	25620952	Green Published, gold			2022-02-06	
J	Lucas, K; Morris, G; Anderson, G; Maes, M				Lucas, Kurt; Morris, Gerwyn; Anderson, George; Maes, Michael			The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Antioxidants; chronic fatigue syndrome; depression; inflammation; myalgic encephalomyelitis; oxidative and nitrosative stress; lipopolysaccharides; toll-like receptor	INFLAMMATORY-BOWEL-DISEASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TRAUMATIC BRAIN-INJURY; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; FACTOR-KAPPA-B; INCREASED INTESTINAL PERMEABILITY; STRESS-INDUCED NEUROINFLAMMATION; COGNITIVE-BEHAVIORAL THERAPY; POLYUNSATURATED FATTY-ACIDS	In this review we discuss that peripheral and central activation of the Toll-like receptor 2/4 (TLR2/4) Radical Cycle may underpin the pathophysiology of immune-related chronic fatigue secondary to other medical diseases and conditions. The TLR Radical Cycle plays a role in illnesses and conditions that are disproportionately commonly comorbid with secondary chronic fatigue, including a) neuroinflammatory disorders, e.g. Parkinson's disease, stroke, depression, psychological stressors, and b) systemic disorders, e.g. (auto) immune disorders, chronic obstructive pulmonary disease, ankylosing spondylitis, chronic kidney disease, inflammatory bowel disease, cardiovascular disease, incl. myocardial infarction, cancer and its treatments. Increased TLR signaling is driven by activated immune-inflammatory and oxidative and nitrosative stress pathways, pathogen derived molecular patterns, including lipopolysaccharides, and damage associated molecular patterns (DAMPs). Newly formed redox-derived DAMPs, secondary to oxidative processes, may further activate the TLR complex leading to an auto-amplifying TLR Radical feedback loop. Increased gut permeability with translocation of gram negative bacteria and LPS, which activates the TLR Radical Cycle, is another pathway that may play a role in most of the abovementioned diseases and the secondary fatigue accompanying them. It is concluded that secondary fatigue may be associated with activation of the TLR Radical Cycle pathway due to activated immune-inflammatory pathways, classical and redox-derived DAMPs and PAMPs plays a role in its pathophysiology. Such an activation of the TLR Radical Cycle pathway may also explain why the abovementioned conditions are primed for an increased expression of secondary chronic fatigue. Targeting the TLR Radical Cycle pathway may be an effective method to treat TLR-Radical Cycle-related diseases such as secondary chronic fatigue.	[Lucas, Kurt] Max Planck Inst Chem, Multiphase Chem Dept, D-55128 Mainz, Germany; [Morris, Gerwyn] Tir Na Nog, Pembrey, Llanelli, Wales; [Anderson, George] CRC, Glasgow G11, Lanark, Scotland; [Maes, Michael] Deakin Univ, Dept Psychiat, Geelong, Vic 3217, Australia; [Maes, Michael] Chulalongkorn Univ, Dept Psychiat, Bangkok, Thailand; [Maes, Michael] Univ Estadual Londrina, Dept Psychiat, Londrina, Brazil		Maes, M (corresponding author), Deakin Univ, Dept Psychiat, Geelong, Vic 3217, Australia.	dr.michaelmaes@hotmail.com	Maes, Michael/B-8546-2011	Maes, Michael/0000-0002-2012-871X; Anderson, George/0000-0001-7243-0817			Abreu MT, 2010, GASTROENTEROLOGY, V138, P39, DOI 10.1053/j.gastro.2009.11.031; Achitei D, 2013, DIGEST DIS SCI, V58, P1244, DOI 10.1007/s10620-012-2510-z; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; ALEXANDROVSKY YA, 1988, ZH NEVROPATOL PSIKH, V88, P95; Alkan BM, 2013, MOD RHEUMATOL, V23, P1101, DOI [10.1007/s10165-012-0800-0, 10.3109/s10165-012-0800-0]; Alkhawajah MM, 2013, MULT SCLER J, V19, P259, DOI 10.1177/1352458512461393; Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Almenier Hazem A, 2012, Front Biosci (Elite Ed), V4, P1335; Alsen P, 2013, J CLIN NURS, V22, P1647, DOI 10.1111/jocn.12114; Anders HJ, 2013, KIDNEY INT, V83, P1010, DOI 10.1038/ki.2012.440; Anderson G, 2014, CURR PHARM DESIGN, V20, P3812, DOI 10.2174/13816128113196660738; Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; [Anonymous], 2013, OXIDATIVE NITRATIVE; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arrieta MC, 2006, GUT, V55, DOI 10.1136/gut.2005.085373; Aryan Z, 2014, INT ARCH ALLERGY IMM, V164, P46, DOI 10.1159/000362553; Assassi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026061; Assassi S, 2011, J RHEUMATOL, V38, P87, DOI 10.3899/jrheum.100469; Bailey MT, 2007, AM J PHYSIOL-REG I, V293, pR1180, DOI 10.1152/ajpregu.00307.2007; Baltzan MA, 2011, CHRON RESP DIS, V8, P119, DOI 10.1177/1479972310396737; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Barton SH, 2008, GASTROENTEROL CLIN N, V37, P411, DOI 10.1016/j.gtc.2008.02.001; Belforte FS, 2013, MOL BIOL REP, V40, P3015, DOI 10.1007/s11033-012-2374-5; Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33; Bezemer GFG, 2012, PHARMACOL REV, V64, P337, DOI 10.1124/pr.111.004622; Bhattacharyya S, 2007, BLOOD, V109, P4313, DOI 10.1182/blood-2006-10-048215; Blair IA, 2001, EXP GERONTOL, V36, P1473, DOI 10.1016/S0531-5565(01)00133-4; Bombardieri M, 2012, CURR PHARM BIOTECHNO, V13, P1989, DOI 10.2174/138920112802273209; Bonner A, 2013, NURS HEALTH SCI, V15, P360, DOI 10.1111/nhs.12038; Bonomini F, 2008, HISTOL HISTOPATHOL, V23, P381, DOI 10.14670/HH-23.381; Bossola M, 2011, SEMIN DIALYSIS, V24, P550, DOI 10.1111/j.1525-139X.2011.00956.x; Brentano Fabia, 2009, V517, P329, DOI 10.1007/978-1-59745-541-1_20; Brophy S, 2013, SEMIN ARTHRITIS RHEU, V42, P361, DOI 10.1016/j.semarthrit.2012.06.002; BRUENNER BA, 1995, CHEM RES TOXICOL, V8, P552, DOI 10.1021/tx00046a009; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Budulac SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043124; Cario E, 2010, INFLAMM BOWEL DIS, V16, P1583, DOI 10.1002/ibd.21282; Carta S, 2009, J LEUKOCYTE BIOL, V86, P549, DOI 10.1189/jlb.1008598; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; Caso JR, 2009, AM J PHYSIOL-REG I, V296, pR979, DOI 10.1152/ajpregu.90825.2008; Cervantes JL, 2011, P NATL ACAD SCI USA, V108, P3683, DOI 10.1073/pnas.1013776108; Chandankhede M, 2013, INT J BIOL MED RES, V4, P3088; Chang YL, 2014, J CELL MOL MED, V18, P1344, DOI 10.1111/jcmm.12294; Charalambous BM, 2007, SHOCK, V28, P15, DOI 10.1097/shk.0b013e318033ebc5; Chen YY, 2013, LIFE SCI, V92, P582, DOI 10.1016/j.lfs.2013.01.021; Chen Y, 2007, MOL INTERV, V7, P147, DOI 10.1124/mi.7.3.6; Choi AJS, 2014, MOL CELLS, V37, P441, DOI 10.14348/molcells.2014.0104; Chong ZZ, 2004, ANTIOXID REDOX SIGN, V6, P277, DOI 10.1089/152308604322899341; Christia P, 2013, EUR J CLIN INVEST, V43, P986, DOI 10.1111/eci.12118; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Crane PB, 2005, HEART LUNG, V34, P30, DOI 10.1016/j.hrtlng.2004.08.007; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Davies H, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-163; de Zoete MR, 2010, INFECT IMMUN, V78, P1229, DOI 10.1128/IAI.00897-09; Dhaouadi T, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-20; di Penta A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054722; Dianzani MU, 1999, ACTA BIOCHIM POL, V46, P61, DOI 10.18388/abp.1999_4184; Ding HS, 2013, GENE, V527, P389, DOI 10.1016/j.gene.2013.05.041; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Drexler SK, 2010, INT J BIOCHEM CELL B, V42, P506, DOI 10.1016/j.biocel.2009.10.009; Drouin-Ouellet J, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu103; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; Elsenberg EHAM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060467; Emin O, 2014, ALLERGOL IMMUNOPATHO; Fagundes-Netto FS, 2013, INT IMMUNOPHARMACOL, V17, P924, DOI 10.1016/j.intimp.2013.09.018; Fairweather D, 2003, J IMMUNOL, V170, P4731, DOI 10.4049/jimmunol.170.9.4731; Famakin BM, 2014, J CEREBR BLOOD F MET, V34, P258, DOI 10.1038/jcbfm.2013.182; Farooqui T, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/247467; FAZIO VM, 1993, MOL ASPECTS MED, V14, P217, DOI 10.1016/0098-2997(93)90008-2; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Fellner L, 2013, GLIA, V61, P349, DOI 10.1002/glia.22437; Ferrari CC, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/436813; Ferrari R, 2005, ANN RHEUM DIS, V64, P1337, DOI 10.1136/ard.2004.034447; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Forsyth CB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028032; Fortin JD, 2002, WHIPLASH, P249, DOI 10.1016/B978-1-56053-438-9.50020-5; Francescato MP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099062; Francois A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/123241; Frangogiannis NG, 2014, J CARDIOVASC PHARM, V63, P185, DOI 10.1097/FJC.0000000000000003; Frantz S, 2001, J BIOL CHEM, V276, P5197, DOI 10.1074/jbc.M009160200; Frazer LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030747; Freitas F, 2014, INT J ENV RES PUB HE, V11, P9024, DOI 10.3390/ijerph110909024; Fresko I, 2001, ANN RHEUM DIS, V60, P65, DOI 10.1136/ard.60.1.65; Friedman JH, 2011, EXPERT OPIN PHARMACO, V12, P1999, DOI 10.1517/14656566.2011.587120; Friis LM, 2009, INFECT IMMUN, V77, P1553, DOI 10.1128/IAI.00707-08; Frisancho-Kiss S, 2007, J IMMUNOL, V178, P6710, DOI 10.4049/jimmunol.178.11.6710; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gambuzza ME, 2014, CNS NEUROL DISORD-DR, V13, P1542, DOI 10.2174/1871527313666140806124850; Gamondi Claudia, 2013, Swiss Med Wkly, V143, pw13750, DOI 10.4414/smw.2013.13750; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Garate I, 2013, BIOL PSYCHIAT, V73, P32, DOI 10.1016/j.biopsych.2012.07.005; Garcia-Bonilla L, 2012, NAT MED, V18, P858, DOI 10.1038/nm.2797; Garcia-Bueno B, 2008, ENDOCRINOLOGY, V149, P1969, DOI 10.1210/en.2007-0482; Garip Y, 2011, ACTA REUMATOL PORT, V36, P364; Gazewood JD, 2013, AM FAM PHYSICIAN, V87, P267; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; GEFFARD M, 1993, BRAIN RES BULL, V30, P365, DOI 10.1016/0361-9230(93)90266-E; Gerdle B, 2008, EUR J PAIN, V12, P82, DOI 10.1016/j.ejpain.2007.03.009; Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006; Gironi M, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/961863; Goehler LE, 2007, BRAIN BEHAV IMMUN, V21, P721, DOI 10.1016/j.bbi.2007.02.005; Goh FG, 2012, RHEUMATOLOGY, V51, P7, DOI 10.1093/rheumatology/ker257; Golovkin AS, 2014, GENE, V550, P101, DOI 10.1016/j.gene.2014.08.022; Gooshe M, 2014, REV NEUROSCIENCE, V25, P713, DOI 10.1515/revneuro-2014-0026; Graff LA, 2011, INFLAMM BOWEL DIS, V17, P1882, DOI 10.1002/ibd.21580; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Gupta A, 2010, INDIAN J BIOCHEM BIO, V47, P96; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Haldorsen K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3487; Hambali Z, 2011, Indian J Nephrol, V21, P21, DOI 10.4103/0971-4065.75218; Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c; Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916; Hartmann A, 1997, NEUROBIOL AGING, V18, P285, DOI 10.1016/S0197-4580(97)80309-0; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hickie IB, 2000, J CLIN PSYCHIAT, V61, P643, DOI 10.4088/JCP.v61n0909; Hilgart AA, 2008, J NEUROCHEM, V104, P123; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Honstettre A, 2004, J IMMUNOL, V172, P3695, DOI 10.4049/jimmunol.172.6.3695; Horigan Ann, 2012, Medsurg Nurs, V21, P158; Horneber M, 2012, DTSCH ARZTEBL INT, V109, P161, DOI 10.3238/arztebl.2012.0161; Hsu GJ, 2011, CHINESE J PHYSIOL, V54, P367, DOI 10.4077/CJP.2011.AMM060; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Huang Qi-Quan, 2009, Curr Rheumatol Rep, V11, P357; Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; Irie M, 2001, INT ARCH OCC ENV HEA, V74, P153, DOI 10.1007/s004200000209; Ishii T, 2006, CHEM RES TOXICOL, V19, P122, DOI 10.1021/tx050231p; Iwakiri D, 2009, J EXP MED, V206, P2091, DOI 10.1084/jem.20081761; Jelsness-Jorgensen LP, 2011, INFLAMM BOWEL DIS, V17, P1564, DOI 10.1002/ibd.21530; JENKINS RT, 1987, BRIT J RHEUMATOL, V26, P103; Jhamb M, 2011, AM J NEPHROL, V33, P515, DOI 10.1159/000328004; Jimenez-Jimenez FJ, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00369; Jounai N, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2012.00168; Kamat PK, 2014, MOL NEUROBIOL; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Karatas F, 2003, INDIAN J MED RES, V118, P178; Kasapovic J, 2010, CLIN BIOCHEM, V43, P1287, DOI 10.1016/j.clinbiochem.2010.08.009; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; KEELING DM, 1993, BLOOD REV, V7, P199, DOI 10.1016/0268-960X(93)90006-P; Keri S, 2014, BRAIN BEHAV IMMUN, V40, P235, DOI 10.1016/j.bbi.2014.03.020; Kim C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2534; Kim K, 2013, CLIN NUTR, V32, P855, DOI 10.1016/j.clnu.2012.11.026; Kim WU, 2009, AUTOIMMUN REV, V8, P204, DOI 10.1016/j.autrev.2008.07.046; Kishida KT, 2007, ANTIOXID REDOX SIGN, V9, P233, DOI 10.1089/ars.2007.9.233; Kivioja J, 2001, J CLIN IMMUNOL, V21, P272, DOI 10.1023/A:1010931309088; Kivioja J, 2001, CLIN IMMUNOL, V101, P106, DOI 10.1006/clim.2001.5086; Klein GL, 2013, CURR OPIN SUPPORT PA, V7, P361, DOI 10.1097/SPC.0000000000000017; Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune; Ko EA, 2012, J IMMUNOL, V188; Koc M, 2011, NEPHROL DIAL TRANSPL, V26, P955, DOI 10.1093/ndt/gfq500; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Konttinen YT, 2012, J AUTOIMMUN, V39, P49, DOI 10.1016/j.jaut.2012.01.004; Kozaci LD, 2010, MOD RHEUMATOL, V20, P34, DOI 10.1007/s10165-009-0230-9; Kraan TCTMV, 2014, J MOL CELL CARDIOL, V67, P94, DOI 10.1016/j.yjmcc.2013.12.021; Krysko O, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.156; Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967; Kuroki Y, 2007, INT J MOL MED, V19, P783; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Lemire P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113940; Lepenies J, 2011, NEPHRON CLIN PRACT, V119, pC97, DOI 10.1159/000324765; Letchmi S, 2011, NURS HEALTH SCI, V13, P60, DOI 10.1111/j.1442-2018.2011.00579.x; Lewthwaite J, 2002, CIRCULATION, V106, P196, DOI 10.1161/01.CIR.0000021121.26290.2C; Lin JL, 2010, COPD, V7, P291, DOI 10.3109/15412555.2010.496818; Lindersson EK, 2004, NEUROREPORT, V15, P2735; Lindqvist D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047387; Lobo JC, 2013, RENAL FAILURE, V35, P361, DOI 10.3109/0886022X.2013.764274; Lorenzen JM, 2011, NEPHROL DIAL TRANSPL, V26, P1421, DOI 10.1093/ndt/gfq758; Low HZ, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3318; Lu C, 2014, BBA-MOL BASIS DIS, V1842, P22, DOI 10.1016/j.bbadis.2013.10.006; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Lyte M, 2006, PHYSIOL BEHAV, V89, P350, DOI 10.1016/j.physbeh.2006.06.019; Maes M, 2005, NEUROENDOCRINOL LETT, V26, P745; Maes M, 1998, PSYCHIAT RES, V77, P63, DOI 10.1016/S0165-1781(97)00131-5; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P313; Maes M, 2007, NEUROENDOCRINOL LETT, V28, P861; Maes M, 2007, J AFFECT DISORDERS, V99, P237, DOI 10.1016/j.jad.2006.08.021; Maes Michael, 2013, Expert Opin Med Diagn, V7, P221, DOI 10.1517/17530059.2013.776039; Maes M, 2012, PSYCHIAT RES, V200, P754, DOI 10.1016/j.psychres.2012.03.031; Maes M, 2012, J AFFECT DISORDERS, V136, P933, DOI 10.1016/j.jad.2011.09.004; Maes M, 2012, J AFFECT DISORDERS, V136, P909, DOI 10.1016/j.jad.2011.09.010; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P784, DOI 10.1016/j.pnpbp.2010.06.023; Maes M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-35; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004; Maes M, 2009, NEUROENDOCRINOL LETT, V30, P677; Maghraby A, 2012, RADIAT ENVIRON BIOPH, V51, P255, DOI 10.1007/s00411-012-0415-z; Malathi M, 2011, J CLIN DIAGN RES, V5, P249; MANDEL S, 1989, POSTGRAD MED, V85, P213; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; Martin HJ, 2007, J VIROL, V81, P9748, DOI 10.1128/JVI.01122-07; MARTINEZGONZALEZ O, 1994, BRIT J RHEUMATOL, V33, P644; Masi AT, 2011, ARTHRITIS, DOI 10.1155/2011/205904; Mavragani CP, 2010, J AUTOIMMUN, V35, P225, DOI 10.1016/j.jaut.2010.06.012; McInnes IB, 2001, RHEUM DIS CLIN N AM, V27, P373, DOI 10.1016/S0889-857X(05)70207-6; Meena NK, 2013, J CLIN GASTROENTEROL, V47, P773, DOI 10.1097/MCG.0b013e31828a6e93; Mehmetoglu I, 2012, INT J ARTIF ORGANS, V35, P226, DOI 10.5301/ijao.5000078; Melief J, 2013, ACTA NEUROPATHOL, V126, P237, DOI 10.1007/s00401-013-1140-7; Mengshoel AM, 2010, ARTHRIT CARE RES, V62, P1272, DOI 10.1002/acr.20216; Metcalfe HJ, 2014, CLIN EXP IMMUNOL, V176, P461, DOI 10.1111/cei.12289; MICHELSON D, 1994, J CLIN ENDOCR METAB, V79, P848, DOI 10.1210/jc.79.3.848; Minderhoud IM, 2003, AM J GASTROENTEROL, V98, P1088, DOI 10.1016/S0002-9270(03)00132-1; Miura K, 2014, WORLD J GASTROENTERO, V20, P7381, DOI 10.3748/wjg.v20.i23.7381; Miwa H, 2011, INTERNAL MED, V50, P1553, DOI 10.2169/internalmedicine.50.4954; Moghaddam AE, 2011, J IMMUNOL, V187, P1626, DOI 10.4049/jimmunol.1003906; Monea A, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/917631; Morris G, 2014, CURR NEUROPHARMACOL, V12, P168, DOI 10.2174/1570159X11666131120224653; Morris G, 2013, METAB BRAIN DIS, V28, P523, DOI 10.1007/s11011-012-9324-8; Morris G, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-205; Morris G, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-64; Morris G, 2012, MED HYPOTHESES, V79, P607, DOI 10.1016/j.mehy.2012.07.034; Moss SF, 2005, NAT CLIN PRACT ONCOL, V2, P90, DOI 10.1038/ncponc0081; Mueller C, 2012, DIGEST DIS, V30, P40, DOI 10.1159/000342600; Munoz LE, 2010, AUTOIMMUN REV, V10, P38, DOI 10.1016/j.autrev.2010.08.015; Murakami Y, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-91; Murtagh FEM, 2007, ADV CHRONIC KIDNEY D, V14, P82, DOI 10.1053/j.ackd.2006.10.001; Nabavi SF, 2015, CURR MED CHEM, V22, P343; Naess H, 2012, J NEUROL SCI, V312, P138, DOI 10.1016/j.jns.2011.08.002; Nagyoszi P, 2010, NEUROCHEM INT, V57, P556, DOI 10.1016/j.neuint.2010.07.002; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; Nijhof SL, 2014, PSYCHONEUROENDOCRINO, V42, P199, DOI 10.1016/j.psyneuen.2014.01.017; Norris PC, 2012, P NATL ACAD SCI USA, V109, P8517, DOI 10.1073/pnas.1200189109; O'Connell CM, 2011, INFECT IMMUN, V79, P1044, DOI 10.1128/IAI.01118-10; Oliveira SR, 2012, J NEUROL SCI, V321, P49, DOI 10.1016/j.jns.2012.07.045; Ortiz GG, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/708659; Ospelt C, 2010, INT J BIOCHEM CELL B, V42, P495, DOI 10.1016/j.biocel.2009.10.010; Ozgocmen S, 2004, RHEUMATOL INT, V24, P80, DOI 10.1007/s00296-003-0335-y; Paddison JS, 2013, EUR RESPIR J, V41, P565, DOI 10.1183/09031936.00021412; Pagano G, 2013, FREE RADICAL RES, V47, P71, DOI 10.3109/10715762.2012.748904; Pandey R, 2013, J CLIN DIAGN RES, V7, P580, DOI 10.7860/JCDR/2013/4360.2832; Pantcheva P, 2014, NEURAL REGEN RES, V9, P1430, DOI 10.4103/1673-5374.139458; Papadopoulos AS, 2012, NAT REV ENDOCRINOL, V8, P22, DOI 10.1038/nrendo.2011.153; Pardini M, 2014, EUR NEUROPSYCHOPHARM, V24, P939, DOI 10.1016/j.euroneuro.2014.02.010; Pariante CM, 2008, TRENDS NEUROSCI, V31, P464, DOI 10.1016/j.tins.2008.06.006; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Paul S, 2013, INFLAMM RES, V62, P681, DOI 10.1007/s00011-013-0620-5; Pertsov S S, 1995, Biull Eksp Biol Med, V120, P244; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Pouwels SD, 2014, MUCOSAL IMMUNOL, V7, P215, DOI 10.1038/mi.2013.77; Powell DJH, 2013, PSYCHONEUROENDOCRINO, V38, P2405, DOI 10.1016/j.psyneuen.2013.07.004; Prajapati B, 2014, CURR DIABETES REV, V10, P190, DOI 10.2174/1573399810666140515112609; Puri BK, 2004, INT J CLIN PRACT, V58, P297, DOI 10.1111/j.1368-5031.2004.00073.x; Rahman AH, 2006, SPRINGER SEMIN IMMUN, V28, P131, DOI 10.1007/s00281-006-0034-3; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; Reynaud J.M., 2013, ISRN VIROL, V2013, P1, DOI [10.5402/2013/834890, DOI 10.5402/2013/834890]; Richer MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004127; Rieu P, 2003, NEPHROLOGIE, V24, P329; Roberts ADL, 2010, PSYCHOL MED, V40, P515, DOI 10.1017/S0033291709990390; Roberts BJ, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-25; Rodrigo R, 2013, CLIN SCI, V124, P1, DOI 10.1042/CS20110663; Rogler G, 2014, EUR HEART J, V35, P426, DOI 10.1093/eurheartj/eht271; Rovina N, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/413735; Rutten EPA, 2014, CHEST, V145, P245, DOI 10.1378/chest.13-0584; Sabitha KE, 1999, ORAL ONCOL, V35, P273, DOI 10.1016/S1368-8375(98)00115-8; Saez-Francas N, 2013, BEHAV NEUROSCI, V127, P237, DOI 10.1037/a0031531; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Salat-Foix D, 2012, CAN J NEUROL SCI, V39, P185, DOI 10.1017/S0317167100013202; Salazar JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000444; Salman B, 2007, ADV THER, V24, P648, DOI 10.1007/BF02848790; Sandek A, 2008, CURR OPIN CLIN NUTR, V11, P632, DOI 10.1097/MCO.0b013e32830a4c6e; Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x; Sato Y, 2009, CANCER MICROENVIRON, V2, pS205, DOI 10.1007/s12307-009-0022-y; Sattar N, 2003, CIRCULATION, V108, P2957, DOI 10.1161/01.CIR.0000099844.31524.05; Senes M, 2007, ANN CLIN BIOCHEM, V44, P43, DOI 10.1258/000456307779596057; Shen J, 2013, MOL ASPECTS MED, V34, P39, DOI 10.1016/j.mam.2012.11.001; Shen XD, 2005, AM J TRANSPLANT, V5, P1793, DOI 10.1111/j.1600-6143.2005.00932.x; Sies H, 2014, J BIOL CHEM, V289, P8735, DOI 10.1074/jbc.R113.544635; Silverman MN, 2012, ANN NY ACAD SCI, V1261, P55, DOI 10.1111/j.1749-6632.2012.06633.x; Singh Uma, 2006, Pathophysiology, V13, P129, DOI 10.1016/j.pathophys.2006.05.002; Sivonova M, 2004, STRESS, V7, P183, DOI 10.1080/10253890400012685; Sklar AH, 1996, AM J KIDNEY DIS, V28, P732, DOI 10.1016/S0272-6386(96)90256-5; SLAGA TJ, 1978, J NATL CANCER I, V60, P425; Sloane JA, 2010, P NATL ACAD SCI USA, V107, P11555, DOI 10.1073/pnas.1006496107; SMITH MD, 1985, J RHEUMATOL, V12, P299; Sorini C, 2013, AM J CLIN EXP IMMUNO, V2, P156; Sosnovskii A. S., 1992, Byulleten' Eksperimental'noi Biologii i Meditsiny, V113, P486; Spittle MA, 2001, AM J KIDNEY DIS, V38, P1408, DOI 10.1053/ajkd.2001.29280; Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284; Steptoe A, 2001, CLIN SCI, V101, P185, DOI 10.1042/CS20010038; Stockley RA, 2009, CURR MED RES OPIN, V25, P1235, DOI 10.1185/03007990902868971 ; Strayer DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031334; Stridsman C, 2014, SCAND J CARING SCI, V28, P130, DOI 10.1111/scs.12033; Sultan SM, 1999, RHEUMATOLOGY, V38, P917, DOI 10.1093/rheumatology/38.10.917; Sun CJ, 2014, HUM IMMUNOL, V75, P1084, DOI 10.1016/j.humimm.2014.09.008; Suzuki Y, 2005, INT J MOL MED, V15, P871; Svensson MY, 1998, ORTHOPADE, V27, P820; Tascilar N, 2010, BRATISL MED J, V111, P194; Theander K, 2004, J ADV NURS, V45, P172, DOI 10.1046/j.1365-2648.2003.02878.x; Tiffin N, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-2; Trudler D, 2010, MEDIAT INFLAMM, V2010; Tsang AHK, 2009, BBA-MOL BASIS DIS, V1792, P643, DOI 10.1016/j.bbadis.2008.12.006; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Urbanska-Krawiec Dagmara, 2010, Pol Merkur Lekarski, V29, P320; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; van Heukelom RO, 2006, EUR J NEUROL, V13, P55; van Horssen J, 2008, FREE RADICAL BIO MED, V45, P1729, DOI 10.1016/j.freeradbiomed.2008.09.023; van Langenberg DR, 2010, ALIMENT PHARM THER, V32, P131, DOI 10.1111/j.1365-2036.2010.04347.x; van Suijlekom H, 2010, PAIN PRACT, V10, P131, DOI 10.1111/j.1533-2500.2009.00356.x; van Vliet MJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000879; Vivot K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107656; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wakamatsu TH, 2013, INVEST OPHTH VIS SCI, V54, P201, DOI 10.1167/iovs.12-10325; Walsh D, 2013, CYTOKINE GROWTH F R, V24, P91, DOI 10.1016/j.cytogfr.2012.09.003; Wang FQ, 2012, NEPHROLOGY, V17, P733, DOI 10.1111/j.1440-1797.2012.01647.x; Wang GD, 2010, ARTHRITIS RHEUM-US, V62, P2064, DOI 10.1002/art.27442; Wang P, 2014, EUR NEUROL, V72, P249, DOI 10.1159/000363515; Wang Y, 2014, CIRC RES, V114, P421, DOI 10.1161/CIRCRESAHA.114.302153; Wolfe F, 1996, J RHEUMATOL, V23, P1407; Wong SW, 2009, J BIOL CHEM, V284, P27384, DOI 10.1074/jbc.M109.044065; Yacyshyn B, 1996, DIGEST DIS SCI, V41, P2493, DOI 10.1007/BF02100148; Yang ZX, 2007, CLIN EXP IMMUNOL, V149, P48, DOI 10.1111/j.1365-2249.2007.03396.x; Ye DW, 2012, GUT, V61, P1058, DOI 10.1136/gutjnl-2011-300269; Yoon HJ, 2014, WORLD J HEPATOL, V6, P800, DOI 10.4254/wjh.v6.i11.800; Younesi V, 2010, MICROBIOL IMMUNOL, V54, P534, DOI 10.1111/j.1348-0421.2010.00248.x; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zaki MH, 2005, J PHARMACOL SCI, V98, P117, DOI 10.1254/jphs.CRJ05004X; Zamboni DS, 2004, J BIOL CHEM, V279, P54405, DOI 10.1074/jbc.M410340200; Zhang J, 2012, J CANC THER RES, V1, P19, DOI DOI 10.1371/J0URNAL.P0NE.0029902; Zhang X, 2015, JPEN-PARENTER ENTER, V39, P114, DOI 10.1177/0148607113501881; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhou Y, 2009, J NEUROSCI RES, V87, P2916, DOI 10.1002/jnr.22110; Zhu H, 2012, EXP BIOL MED, V237, P474, DOI 10.1258/ebm.2011.011358	331	34	35	0	19	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2015	14	7					838	854		10.2174/1871527314666150317224645			17	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	CO0TW	WOS:000358867200003	25801843				2022-02-06	
J	Mendez, MF; Paholpak, P; Lin, A; Zhang, JY; Teng, E				Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Zhang, Jeannie Y.; Teng, Edmond			Prevalence of Traumatic Brain Injury in Early Versus Late-Onset Alzheimer's Disease	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Aging; Alzheimer's disease; concussion; dementia; epidemiology; head injury; memory loss; neurodegeneration; risk factors; traumatic brain injury	HEAD-INJURY; RISK-FACTOR; DEMENTIA; AGE; ENCEPHALOPATHY; POPULATION; INDIVIDUALS; TAUOPATHY; AD	Background: Traumatic brain injury (TBI) is the most established environmental risk factor for Alzheimer's disease (AD), but it is unclear if TBI is specifically associated with early-onset AD (EOAD). Objective: To evaluate the relationship between TBI and EOAD (<65 years). Methods: We identified 1,449 EOAD, 4,337 late-onset AD (LOAD), and corresponding EOAD-matched and LOAD-matched normal controls (NC) in the National Alzheimer's Coordinating Center Uniform (NACC) database and compared the prevalence of any history of TBI as well as measures of cognition, function, behavior, and neuropathology. For validation, we determined TBI prevalence among 115 well-characterized clinic patients with EOAD. Results: Part A: The prevalence of any TBI in the NACC-database EOAD participants (13.3%) was comparable to that observed in the clinic EOAD patients (13.9%) but significantly higher than in the NACC-database LOAD participants (7.7%; p < 0.0001) and trended to higher compared to EOAD-matched NC (11.1%; logistic regression p = 0.053). Part B: When we compared EOAD patients with documented non-acute and non-residually impairing TBI to EOAD without a documented history of prior TBI, those with TBI had significantly more disinhibition. Part C: Autopsies did not reveal differences in AD neuropathology based on a history of TBI. Conclusions: These findings suggest, but do not establish, that TBI is a specific risk factor for EOAD and may lead to disinhibition, a feature that often results from the frontal effects of head injury. This study recommends further research on the effects of TBI in EOAD in larger numbers of participants.	[Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Teng, Edmond] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Zhang, Jeannie Y.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Dept Neurol, Los Angeles, CA USA		Mendez, MF (corresponding author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	mmendez@UCLA.edu			Medical Student Training in Aging Research Program, the National Institute on Aging [T35AG026736]; John A. Hartford Foundation; Lillian R. Gleitsman Foundation; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976, P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; The NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG010161, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG033514, P50AG016573, P50AG023501, P50AG005133, P30AG008051, P50AG016574, P50AG025688, P50AG005681, P30AG019610, P50AG005136, P50AG016570, P30AG010133, P50AG005131, P50AG008702, P30AG035982, P30AG010129, P50AG005134, P30AG010124, P30AG010161, P30AG013854, P30AG028383, P50AG005146, P50AG005142, P30AG013846, U01AG016976, T35AG026736, P30AG008017, P30AG012300, R01AG034499, P50AG005138] Funding Source: NIH RePORTER	This research was funded by The Medical Student Training in Aging Research Program, the National Institute on Aging (T35AG026736), the John A. Hartford Foundation, the Lillian R. Gleitsman Foundation, and NIA Grant U01 AG016976.; The authors thank Michelle Mather, Kate Heller, and Dr. Stephen Hawes for their contributions. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD).	Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Corrada MM, 2008, NEUROLOGY, V71, P337, DOI 10.1212/01.wnl.0000310773.65918.cd; Dams-O'Connor K, 2013, NEUROREHABILITATION, V32, P199, DOI 10.3233/NRE-130838; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/jnp.12.2.233; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mendez MF, 2012, ARCH MED RES, V43, P677, DOI 10.1016/j.arcmed.2012.11.009; Mendez MF, 2012, AM J ALZHEIMERS DIS, V27, P413, DOI 10.1177/1533317512454711; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P166, DOI 10.1176/appi.neuropsych.22.2.166; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhu XC, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.19; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	51	34	34	0	23	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2015	47	4					985	993		10.3233/JAD-143207			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CQ9JS	WOS:000360931300017	26401777	Green Accepted			2022-02-06	
J	Rusch, HL; Guardado, P; Baxter, T; Mysliwiec, V; Gill, JM				Rusch, Heather L.; Guardado, Pedro; Baxter, Tristin; Mysliwiec, Vincent; Gill, Jessica M.			Improved Sleep Quality is Associated with Reductions in Depression and PTSD Arousal Symptoms and Increases in IGF-1 Concentrations	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						BDNF; depression; IGF-1; insomnia; military; PTSD; sleep quality; mTBI; trauma	GROWTH-FACTOR-I; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; NEUROTROPHIC FACTOR; CLINICIAN; INSOMNIA; HOMEOSTASIS; DISTURBANCE; NIGHTMARES	Study Objectives: One-third of deployed military personnel will be diagnosed with insomnia, placing them at high risk for comorbid depression, posttraumatic stress disorder (PTSD), and medical conditions. The disruption of trophic factors has been implicated in these comorbid conditions, which can impede postdeployment recovery. This study determined if improved sleep quality is associated with (1) reductions in depression and posttraumatic symptoms, as well as enrichments in health-related quality of life (HRQOL), and (2) changes in plasma concentrations of brain derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1). Methods: Forty-four military personnel diagnosed with insomnia underwent clinical evaluations and blood draws at pretreatment and at posttreatment following cognitive behavioral therapy for insomnia and automatic positive airway pressure treatment. Participants were classified as sleep improved (n = 28) or sleep declined (n = 16) based on their change in pretreatment to posttreatment Pittsburgh Sleep Quality Index (PSQI) score. Both groups were compared on outcomes of depression, PTSD, HRQOL, BDNF, and IGF-1. Results: Paired t-tests of the sleep improved group revealed significant declines in depression (p = 0.005) and posttraumatic arousal (p = 0.006) symptoms, and a significant increase in concentrations of IGF-1 (p = 0.009). The sleep declined group had no relevant change in psychiatric symptoms or trophic factors, and had further declines on five of eight dimensions of HRQOL. Between-group change score differences were significant at p < 0.05. Conclusions: These findings suggest that interventions, which successfully improve sleep quality, are an effective means to reduce the depression and posttraumatic arousal symptoms common to military personnel, as well as increase protective trophic factors implicated in these conditions.	[Rusch, Heather L.; Guardado, Pedro; Gill, Jessica M.] NINR, NIH, Bethesda, MD 20892 USA; [Rusch, Heather L.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Baxter, Tristin; Mysliwiec, Vincent] Madigan Army Med Ctr, Tacoma, WA 98431 USA		Rusch, HL (corresponding author), 1 Cloister Court,Bldg 60 259, Bethesda, MD 20892 USA.	heather.rusch@nih.gov	Gill, Gill M/Q-2020-2017	Rusch, Heather/0000-0002-4061-8628	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000027] Funding Source: NIH RePORTER	This was not an industry supported study. The authors have indicated no financial conflicts of interest. The work was performed at the Madigan Army Medical Center, Tacoma, WA. Support for this work included funding from Department of Defense in the Center for Neuroscience and Regenerative Medicine.	American Academy of Sleep Medicine, 2005, INT CLASSLEEP DIS; Andero R, 2014, PROG MOL BIOL TRANSL, V122, P169, DOI 10.1016/B978-0-12-420170-5.00006-4; Angelucci F, 2014, BRAIN COGNITION, V84, P118, DOI 10.1016/j.bandc.2013.11.012; Bachmann V, 2012, SLEEP, V35, P335, DOI 10.5665/sleep.1690; Bonne O, 2011, J CLIN PSYCHIAT, V72, P1124, DOI 10.4088/JCP.09m05106blu; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Britton WB, 2012, PSYCHOTHER PSYCHOSOM, V81, P296, DOI 10.1159/000332755; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cho HJ, 2008, AM J PSYCHIAT, V165, P1543, DOI 10.1176/appi.ajp.2008.07121882; Creyghton Wouter M, 2004, Semin Vasc Med, V4, P167, DOI 10.1055/s-2004-835375; Escamilla M, 2012, CURR PSYCHIAT REP, V14, P529, DOI 10.1007/s11920-012-0306-7; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Giese M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076050; Gomez-Merino D, 2005, NEUROIMMUNOMODULAT, V12, P164, DOI 10.1159/000084849; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoyos CM, 2014, SLEEP, V37, P733, DOI 10.5665/sleep.3580; JARRETT DB, 1990, BIOL PSYCHIAT, V27, P497, DOI 10.1016/0006-3223(90)90441-4; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnson-Farley NN, 2006, J PHARMACOL EXP THER, V316, P1062, DOI 10.1124/jpet.105.094433; Koffel E, 2013, J ANXIETY DISORD, V27, P512, DOI 10.1016/j.janxdis.2013.07.003; Molendijk ML, 2011, MOL PSYCHIATR, V16, P1088, DOI 10.1038/mp.2010.98; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Nakamura Y, 2011, J PSYCHOSOM RES, V70, P335, DOI 10.1016/j.jpsychores.2010.09.007; Paslakis G, 2012, MED HYPOTHESES, V79, P222, DOI 10.1016/j.mehy.2012.04.045; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Pigeon WR, 2013, J PSYCHOSOM RES, V75, P546, DOI 10.1016/j.jpsychores.2013.09.004; Pittenger C, 2008, NEUROPSYCHOPHARMACOL, V33, P88, DOI 10.1038/sj.npp.1301574; Rajpathak SN, 2009, DIABETES-METAB RES, V25, P3, DOI 10.1002/dmrr.919; Rosario ER, 2013, J HEAD TRAUMA REHAB, V28, P390, DOI 10.1097/HTR.0b013e318250eac6; Rush AJ, 1998, BIOL PSYCHIAT, V44, P3, DOI 10.1016/S0006-3223(98)00092-4; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Schilling C, 2011, J CLIN PSYCHOPHARM, V31, P390, DOI 10.1097/JCP.0b013e3182189d86; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Siebern AT, 2011, PSYCHOL RES BEHAV MA, V4, P21, DOI 10.2147/PRBM.S10041; Suzuki G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089455; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Weber-Hamann B, 2009, PHARMACOPSYCHIATRY, V42, P23, DOI 10.1055/s-0028-1085442; Williams J, 2013, CHEST, V143, P554, DOI 10.1378/chest.12-0731	43	34	35	3	17	AMER ACAD SLEEP MEDICINE	WESTCHESTER	ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2015	11	6					615	623	PII jc-00412-14	10.5664/jcsm.4770			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CY3BZ	WOS:000366284500007	25766717	Green Published, Bronze			2022-02-06	
J	Logsdon, AF; Turner, RC; Lucke-Wold, BP; Robson, MJ; Naser, ZJ; Smith, KE; Matsumoto, RR; Huber, JD; Rosen, CL				Logsdon, Aric Flint; Turner, Ryan Coddington; Lucke-Wold, Brandon Peter; Robson, Matthew James; Naser, Zachary James; Smith, Kelly Elizabeth; Matsumoto, Rae Reiko; Huber, Jason Delwyn; Rosen, Charles Lee			Altering endoplasmic reticulum stress in a model of blast-induced traumatic brain injury controls cellular fate and ameliorates neuropsychiatric symptoms	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blast-induced traumatic brain injury; blood-brain barrier; endoplasmic reticulum stress; salubrinal; CHOP; apoptosis; prefrontal cortex	UNFOLDED PROTEIN RESPONSE; ER STRESS; AXONAL INJURY; APOPTOSIS; ACTIVATION; BCL-2; CASPASE-12; EXPRESSION; HEAD; INHIBITION	Neuronal injury following blast-induced traumatic brain injury (bTBI) increases the risk for neuropsychiatric disorders, yet the pathophysiology remains poorly understood. Blood-brain-barrier (BBB) disruption, endoplasmic reticulum (ER) stress, and apoptosis have all been implicated in bTBI. Microvessel compromise is a primary effect of bTBI and is postulated to cause subcellular secondary effects such as ER stress. What remains unclear is how these secondary effects progress to personality disorders in humans exposed to head trauma. To investigate this we exposed male rats to a clinically relevant bTBI model we have recently developed. The study examined initial BBB disruption using Evan's blue (EB), ER stress mechanisms, apoptosis and impulsive-like behavior measured with elevated plus maze (EPM). Large BBB openings were observed immediately following bTBI, and persisted for at least 6 h. Data showed increased mRNA abundance of stress response genes at 3 h, with subsequent increases in the ER stress markers C/EBP homologous protein (CHOP) and growth arrest and DNA damage-inducible protein 34 (GADD34) at 24 h. Caspase-12 and Caspase-3 were both cleaved at 24 h following bTBI. The ER stress inhibitor, salubrinal (SAL), was administered (1 mg/kg i.p.) to investigate its effects on neuronal injury and impulsive-like behavior associated with bTBI. SAL reduced CHOP protein expression, and diminished Caspase-3 cleavage, suggesting apoptosis attenuation. Interestingly, SAL also ameliorated impulsive-like behavior indicative of head trauma. These results suggest SAL plays a role in apoptosis regulation and the pathology of chronic disease. These observations provide evidence that bTBI involves ER stress and that the unfolded protein response (UPR) is a promising molecular target for the attenuation of neuronal injury.	[Logsdon, Aric Flint; Robson, Matthew James; Smith, Kelly Elizabeth; Matsumoto, Rae Reiko; Huber, Jason Delwyn] W Virginia Univ, Sch Pharm, Dept Pharmaceut Sci, Morgantown, WV 26506 USA; [Logsdon, Aric Flint; Turner, Ryan Coddington; Lucke-Wold, Brandon Peter; Huber, Jason Delwyn; Rosen, Charles Lee] W Virginia Univ, Hlth Sci Ctr, Ctr Neurosci, Morgantown, WV 26506 USA; [Logsdon, Aric Flint; Turner, Ryan Coddington; Lucke-Wold, Brandon Peter; Naser, Zachary James; Huber, Jason Delwyn; Rosen, Charles Lee] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Robson, Matthew James] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37235 USA; [Matsumoto, Rae Reiko] Touro Univ Calif, Coll Pharm, Deans Off, Vallejo, CA USA		Rosen, CL (corresponding author), W Virginia Univ, Hlth Sci Ctr, Sch Med, Dept Neurosurg, Med Ctr Dr,Suite 4300,POB 9183, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu	Lucke-Wold, Brandon/AAW-3525-2021; Robson, Matthew/H-3127-2013; Lucke-Wold, Brandon/AAW-1881-2021	Lucke-Wold, Brandon/0000-0001-6577-4080; Robson, Matthew/0000-0002-3277-3062; Turner, Ryan/0000-0001-5523-0645; Fraser, Kelly/0000-0003-1563-050X	Mary Babb Randolph Cancer Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 RR016550, P30 RR032138/GM103488, P20 RR016477]; West Virginia University Health Sciences Center Office of Research and Graduate Education; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM08174]	We thank Dr. James P. O'Callaghan and Dr. Diane B. Miller of the Center for Disease Control (CDC) and the National Institute for Occupational Safety and Health (NIOSH). The authors also acknowledge the work done by Zhenjun Tan, Corey Brown and Diana Richardson. The authors are grateful for the assistance of Dr. Robert T.T. Gettens and Nicholas St. John of Western New England University for the design of the blast model and Mr. Peter Bennett and Mr. James Edward Robson for model construction. Imaging experiments and image analysis were performed in the West Virginia University Microscope Imaging Facility, which has been supported by the Mary Babb Randolph Cancer Center and NIH grants P20 RR016550, P30 RR032138/GM103488 and P20 RR016477. This work was supported by a Research Funding and Development (RFDG) grant from the West Virginia University Health Sciences Center Office of Research and Graduate Education (to Jason Delwyn Huber and Charles Lee Rosen) and a training grant from the National Institutes of Health (to Ryan Coddington Turner) (5T32GM08174).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Badiola N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.31; Beerten J, 2012, CURR TOP MED CHEM, V12, P2470; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Bernales S, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00005; Bidzan L, 2012, MED SCI MONITOR, V18, pCR182, DOI 10.12659/MSM.882523; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chen Y, 2013, J NEUROPSYCH CLIN N, V25, P103, DOI 10.1176/appi.neuropsych.12030058; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00119; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Costa RO, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.04.011; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Farrell-Carnahan L, 2013, MIL MED, V178, P951, DOI 10.7205/MILMED-D-13-00037; Galehdar Z, 2010, J NEUROSCI, V30, P16938, DOI 10.1523/JNEUROSCI.1598-10.2010; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gurkoff G, 2013, PHARMACEUTICALS, V6, P788, DOI 10.3390/ph6070788; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Ho YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036752; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25; Kessel D, 2006, BIOCHEM BIOPH RES CO, V346, P1320, DOI 10.1016/j.bbrc.2006.06.056; Liu CL, 2012, J GERIATR CARDIOL, V9, P258, DOI 10.3724/SP.J.1263.2012.02292; Liu Y, 2014, CAN J CARDIOL, V30, P368, DOI 10.1016/j.cjca.2013.11.001; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Methippara M, 2012, NEUROSCIENCE, V209, P108, DOI 10.1016/j.neuroscience.2012.02.016; Mosienko V, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.44; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Nijholt DAT, 2012, J PATHOL, V226, P693, DOI 10.1002/path.3969; O'Callaghan JP, 2004, J NEUROSCI METH, V135, P159, DOI 10.1016/j.jneumeth.2003.12.006; Osada N, 2009, NEUROCHEM INT, V54, P403, DOI 10.1016/j.neuint.2009.01.010; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Plattner F, 2006, J BIOL CHEM, V281, P25457, DOI 10.1074/jbc.M603469200; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rubovitch V, 2011, NEUROCHEM INT, V58, P443, DOI 10.1016/j.neuint.2011.01.009; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Salminen A, 2010, AGEING RES REV, V9, P211, DOI 10.1016/j.arr.2010.04.003; Scheper W, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007641; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Yang FW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057869; Yen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068595; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang Y, 2014, PHYSIOL BEHAV, V131, P41, DOI 10.1016/j.physbeh.2014.04.014; Zhu F, 2013, INT J NUMER METH BIO, V29, P392, DOI 10.1002/cnm.2518; Zhu Feng, 2010, Stapp Car Crash J, V54, P211	66	34	34	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	DEC 10	2014	8								421	10.3389/fncel.2014.00421			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX9QG	WOS:000347236400002	25540611	gold, Green Published			2022-02-06	
J	Chou, SHY; Robertson, CS				Chou, Sherry H-Y.; Robertson, Claudia S.		Int Multidisciplinary Consensus	Monitoring Biomarkers of Cellular Injury and Death in Acute Brain Injury	NEUROCRITICAL CARE			English	Article						Biomarker; Traumatic brain injury; Subarachnoid hemorrhage; Stroke; Intracerebral hemorrhage; Cardiac arrest; Outcome	ANEURYSMAL SUBARACHNOID HEMORRHAGE; NEURON-SPECIFIC ENOLASE; ACUTE ISCHEMIC-STROKE; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; C-REACTIVE-PROTEIN; BASAL GANGLIA HEMORRHAGE; CEREBRAL-ARTERY OCCLUSION; HOSPITAL CARDIAC-ARREST; SEVERE HEAD-INJURY; EARLY NEUROLOGIC DETERIORATION	Molecular biomarkers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction. Urgent need for high-fidelity biomarkers in neurocritical care has resulted in numerous studies reporting potential candidate biomarkers. We performed an electronic literature search and systematic review of English language articles on cellular/molecular biomarkers associated with outcome and with disease-specific secondary complications in adult patients with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), and post-cardiac arrest hypoxic ischemic encephalopathic injuries (HIE). A total of 135 articles were included. Though a wide variety of potential biomarkers have been identified, only neuron-specific enolase has been validated in large cohorts and shows 100 % specificity for poor outcome prediction in HIE patients not treated with therapeutic hypothermia. There are many promising candidate blood and CSF biomarkers in SAH, AIS, ICH, and TBI, but none yet meets criteria for routine clinical use. Current studies vary significantly in patient selection, biosample collection/processing, and biomarker measurement protocols, thereby limiting the generalizability of overall results. Future large prospective studies with standardized treatment, biosample collection, and biomarker measurement and validation protocols are necessary to identify high-fidelity biomarkers in neurocritical care.	[Chou, Sherry H-Y.] Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, Boston, MA 02115 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Chou, SHY (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	schou1@partners.org; claudiar@bcm.tmc.edu	Diringer, Michael N/C-1165-2008; Oddo, Mauro/R-3370-2016; Chou, Sherry/G-5779-2015	Diringer, Michael N/0000-0003-2337-5537; Oddo, Mauro/0000-0002-6155-2525; Chou, Sherry/0000-0002-5483-2908; Brophy, Gretchen/0000-0002-4749-2693; Provencio, Jose Javier/0000-0003-1298-1806; Hutchinson, Peter/0000-0002-2796-1835; Figaji, Anthony/0000-0002-3357-6490; Citerio, Giuseppe/0000-0002-5374-3161; Schmidt, J. Michael/0000-0001-8141-2944	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23-NS073806, U01-NS062091, R01-DC12584]; American Heart AssociationAmerican Heart Association [10CRP2610341]; NovartisNovartis; Neurocritical Care Society; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986, G1002277] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0600986, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish	Sherry H-Y. Chou is funded by NIH Grant # K23-NS073806 and has received research support from the American Heart Association (Grant # 10CRP2610341). She receives stipend for service as a clinical endpoint committee member for a clinical trial funded by Novartis, as the site principal investigator for ATACH-II study funded by the NIH Grant # U01-NS062091, and as DSMB member for a study funded by NIH Grant # R01-DC12584. She has received speaker honorarium from the American Academy of Neurology and travel scholarship from the Neurocritical Care Society.	Abilleira S, 2003, J NEUROSURG, V99, P65, DOI 10.3171/jns.2003.99.1.0065; Agnihotri S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-160; Alvarez-Sabin J, 2004, STROKE, V35, P1316, DOI 10.1161/01.STR.0000126827.69286.90; Antunes Alessandra Armstrong, 2010, Asian J Neurosurg, V5, P68; Barr TL, 2010, STROKE, V41, pE123, DOI 10.1161/STROKEAHA.109.570515; Beeftink MMA, 2011, NEUROCRIT CARE, V15, P405, DOI 10.1007/s12028-011-9556-1; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bottiger BW, 2001, CIRCULATION, V103, P2694; Brea D, 2009, CLIN CHEM LAB MED, V47, P1513, DOI 10.1515/CCLM.2009.337; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Cai JY, 2013, CLIN CHIM ACTA, V424, P182, DOI 10.1016/j.cca.2013.06.019; Castellanos M, 2004, STROKE, V35, P1671, DOI 10.1161/01.STR.0000131656.47979.39; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Castellanos M, 2007, STROKE, V38, P1855, DOI 10.1161/STROKEAHA.106.481556; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chen YC, 2011, J NEUROSURG, V115, P1184, DOI 10.3171/2011.7.JNS11718; Chiquete E, 2013, CEREBROVASC DIS, V35, P168, DOI 10.1159/000346603; Chiu CC, 2012, J CLIN NEUROSCI, V19, P810, DOI 10.1016/j.jocn.2011.08.032; Chou SHY, 2011, TRANSL STROKE RES, V2, P600, DOI 10.1007/s12975-011-0117-x; Chou SHY, 2012, J INVEST MED, V60, P1054, DOI 10.2310/JIM.0b013e3182686932; Chou SHY, 2011, STROKE, V42, P3624, DOI 10.1161/STROKEAHA.111.631135; Coplin WM, 1999, ARCH NEUROL-CHICAGO, V56, P1348, DOI 10.1001/archneur.56.11.1348; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Cronberg T, 2013, RESUSCITATION, V84, P867, DOI 10.1016/j.resuscitation.2013.01.019; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Daubin C, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471-2261-11-48; Delgado P, 2006, STROKE, V37, P2837, DOI 10.1161/01.STR.0000245085.58807.ad; den Hertog HM, 2009, J NEUROL, V256, P2003, DOI 10.1007/s00415-009-5228-x; Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4; Di Napoli M, 2011, STROKE, V42, P1230, DOI 10.1161/STROKEAHA.110.604983; Diaz-Arrastia R, 2013, J NEUROTRAUM, V7, P1; Diedler J, 2009, CEREBROVASC DIS, V27, P272, DOI 10.1159/000199465; Dietmann A, 2012, CEREBROVASC DIS, V33, P16, DOI 10.1159/000331925; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; Einav S, 2012, J AM COLL CARDIOL, V60, P304, DOI 10.1016/j.jacc.2012.04.020; Elkind MSV, 2006, ARCH INTERN MED, V166, P2073, DOI 10.1001/archinte.166.19.2073; Fang HY, 2005, SURG NEUROL, V64, P511, DOI 10.1016/j.surneu.2005.03.018; Fang HY, 2005, SURG NEUROL, V64, P7; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; Fernandez-Patron C, 1999, CIRC RES, V85, P906; Fernandez-Patron C, 2001, FASEB J, V15, P2230, DOI 10.1096/fj.01-0178com; Foerch C, 2005, ARCH NEUROL-CHICAGO, V62, P1130, DOI 10.1001/archneur.62.7.1130; Foerch C, 2004, STROKE, V35, P2160, DOI 10.1161/01.STR.0000138730.03264.ac; Foerch C, 2003, J NEUROL NEUROSUR PS, V74, P322, DOI 10.1136/jnnp.74.3.322; Frijns CJM, 2006, J NEUROL NEUROSUR PS, V77, P77, DOI 10.1136/jnnp.2005.064956; FUJIMORI A, 1990, LANCET, V336, P633, DOI 10.1016/0140-6736(90)93432-O; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; Gill R, 2004, J CEREBR BLOOD F MET, V24, P1214, DOI 10.1097/01.WCB.0000136517.61642.99; Graetz D, 2010, NEUROL RES, V32, P728, DOI 10.1179/016164109X12464612122650; Graham CA, 2012, CLIN BIOCHEM, V45, P352, DOI 10.1016/j.clinbiochem.2011.12.006; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; Gu SJ, 2013, CLIN CHIM ACTA, V425, P85, DOI 10.1016/j.cca.2013.07.025; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guo ZD, 2011, ACTA NEUROCHIR SUPPL, V110, P63, DOI 10.1007/978-3-7091-0353-1_11; Gurkanlar D, 2009, TURK NEUROSURG, V19, P211; Haapaniemi E, 2000, STROKE, V31, P720, DOI 10.1161/01.STR.31.3.720; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; Hanafy KA, 2010, J NEUROL SCI, V291, P69, DOI 10.1016/j.jns.2009.12.023; Hays A, 2006, NEUROLOGY, V66, P1330, DOI 10.1212/01.wnl.0000210523.22944.9b; Heo JH, 2003, STROKE, V34, pE48, DOI 10.1161/01.STR.0000073788.81170.1C; Hernandez-Guillamon M, 2012, CEREBROVASC DIS, V33, P55, DOI 10.1159/000333370; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu HT, 2012, CLIN BIOCHEM, V45, P1320, DOI 10.1016/j.clinbiochem.2012.06.003; Hu YY, 2010, SHOCK, V33, P134, DOI 10.1097/SHK.0b013e3181ad5c88; Huang M, 2009, SURG NEUROL, V72, P481, DOI 10.1016/j.surneu.2008.12.016; Huang Q, 2013, PEPTIDES, V39, P55, DOI 10.1016/j.peptides.2012.11.006; Huang Y, 2012, CNS NEUROSCI THER, V18, P261, DOI 10.1111/j.1755-5949.2012.00296.x; Idicula TT, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-18; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; James ML, 2009, BIOMARKERS, V14, P388, DOI 10.1080/13547500903015784; Jin Y, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.01.002; Juvela S, 2009, J NEUROSURG, V110, P989, DOI 10.3171/2008.11.JNS081266; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Kasai A, 2012, CIRC J, V76, P891, DOI 10.1253/circj.CJ-11-0449; Kay A, 2003, STROKE, V34, P637, DOI 10.1161/01.STR.0000057579.25430.16; Kazmierski R, 2012, NEUROLOGY, V79, P1677, DOI 10.1212/WNL.0b013e31826e9a83; Kim J, 2012, ATHEROSCLEROSIS, V222, P464, DOI 10.1016/j.atherosclerosis.2012.02.042; KOBAYASHI H, 1991, NEUROSURGERY, V28, P673, DOI 10.1227/00006123-199105000-00006; Kobayashi H, 1991, NEUROSURGERY, V28, P8; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; Lanterna LA, 2007, NEUROLOGY, V69, P766, DOI 10.1212/01.wnl.0000267640.03300.6b; Lanterna LA, 2005, NEUROLOGY, V64, P1238, DOI 10.1212/01.WNL.0000156523.77347.B4; Le Huong T, 2011, Exp Transl Stroke Med, V3, P13, DOI 10.1186/2040-7378-3-13; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Leung CHS, 2002, STROKE, V33, P548, DOI 10.1161/hs0202.102326; Li N, 2013, STROKE, V44, P658, DOI 10.1161/STROKEAHA.112.673590; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Mack WJ, 2002, J NEUROSURG, V96, P71, DOI 10.3171/jns.2002.96.1.0071; Maiuri F, 1987, J Neurosurg Sci, V31, P45; Ramirez-Moreno JM, 2009, STROKE, V40, P1917, DOI 10.1161/STROKEAHA.108.536698; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; MASAOKA H, 1989, LANCET, V2, P1402; Mascia L, 2001, STROKE, V32, P1185, DOI 10.1161/01.STR.32.5.1185; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; Matsumoto M, 2013, CEREBROVASC DIS, V35, P64, DOI 10.1159/000345336; McGirt MJ, 2004, NEUROSURGERY, V55, P473, DOI 10.1227/00006123-200408000-00100; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; McGirt MJ, 2002, NEUROSURGERY, V51, P34; Mees SMD, 2011, NEUROCRIT CARE, V14, P176, DOI 10.1007/s12028-011-9504-0; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mlynash M, 2013, NEUROCRIT CARE, V19, P161, DOI 10.1007/s12028-013-9867-5; Moldes O, 2008, STROKE, V39, P2006, DOI 10.1161/STROKEAHA.107.495044; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Montaner J, 2006, STROKE, V37, P1205, DOI 10.1161/01.STR.0000217744.89208.4e; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Montaner J, 2001, STROKE, V32, P2762, DOI 10.1161/hs1201.99512; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Moussouttas M, 2012, CEREBROVASC DIS, V33, P173, DOI 10.1159/000334660; Nagao K, 2004, CIRC J, V68, P477, DOI 10.1253/circj.68.477; Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620; Nardi K, 2012, J STROKE CEREBROVASC, V21, P819, DOI 10.1016/j.jstrokecerebrovasdis.2011.04.015; Niikawa S, 1997, NEUROL MED CHIR, V37, P4; Niikawa Shuji, 1997, Neurologia Medico-Chirurgica, V37, P881, DOI 10.2176/nmc.37.881; Ning M, 2006, NEUROLOGY, V66, P1550, DOI 10.1212/01.wnl.0000216133.98416.b4; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Oda Y, 2012, RESUSCITATION, V83, P1006, DOI 10.1016/j.resuscitation.2012.01.030; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pan JW, 2013, CRIT CARE, V17, DOI 10.1186/cc12828; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Park SM, 2006, PROTEOMICS, V6, P1192, DOI 10.1002/pmic.200500402; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Provencio JJ, 2005, SEMIN NEUROL, V25, P435, DOI 10.1055/s-2005-923537; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1998, ACTA NEUROCHIR WIEN, V140, P91; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Ramappa P, 2008, NEUROCRIT CARE, V8, P398, DOI 10.1007/s12028-007-9038-7; Rodriguez-Luna D, 2011, STROKE, V42, P2447, DOI 10.1161/STROKEAHA.110.609461; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 2004, J NEUROL SCI, V221, P19, DOI 10.1016/j.jns.2004.03.003; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Sadamasa N, 2011, NEUROL MED-CHIR, V51, P745; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; Serena J, 2005, STROKE, V36, P1921, DOI 10.1161/01.STR.0000177870.14967.94; Shantikumar S, 2009, STROKE, V40, P977, DOI 10.1161/STROKEAHA.108.525105; Sherman AL, 2000, NEUROLOGY, V54, P889, DOI 10.1212/WNL.54.4.889; Shinozaki K, 2011, RESUSCITATION, V82, P404, DOI 10.1016/j.resuscitation.2010.10.026; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; Silva Y, 2005, STROKE, V36, P86, DOI 10.1161/01.STR.0000149615.51204.0b; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sodeck GH, 2007, RESUSCITATION, V74, P439, DOI 10.1016/j.resuscitation.2007.02.001; SPALLONE A, 1987, SURG NEUROL, V27, P253, DOI 10.1016/0090-3019(87)90038-3; Stammet P, 2013, J AM COLL CARDIOL, V62, P851, DOI 10.1016/j.jacc.2013.04.039; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Stranjalis G, 2007, ACTA NEUROCHIR, V149, P231, DOI 10.1007/s00701-006-1106-9; Stranjalis G, 2007, ACTA NEUROCHIR WIEN, V149, P7; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; SUZUKI R, 1992, J NEUROSURG, V77, P96, DOI 10.3171/jns.1992.77.1.0096; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Taub PR, 2011, NEUROCRIT CARE, V15, P13, DOI 10.1007/s12028-011-9535-6; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; THOMAS D G T, 1978, Lancet, V1, P113; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Tirschwell DL, 1997, NEUROLOGY, V48, P352, DOI 10.1212/WNL.48.2.352; Topakian R, 2008, J NEUROL, V255, P1190, DOI 10.1007/s00415-008-0866-y; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Vergouwen MDI, 2009, J CEREBR BLOOD F MET, V29, P1734, DOI 10.1038/jcbfm.2009.88; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang HC, 2012, EUR J NEUROL, V19, P1532, DOI 10.1111/j.1468-1331.2012.03761.x; Wang HC, 2011, CRIT CARE, V15, DOI 10.1186/cc10568; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Wijman CAC, 2012, NEUROCRIT CARE, V16, P42, DOI 10.1007/s12028-011-9609-5; Winbeck K, 2002, STROKE, V33, P2459, DOI 10.1161/01.STR.0000029828.51413.82; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Xu JF, 2012, J TRAUMA ACUTE CARE, V72, P491, DOI 10.1097/TA.0b013e318226ec39; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yarlagadda S, 2006, NEUROCRIT CARE, V5, P102, DOI 10.1385/NCC:5:2:102; Yin CG, 2013, PEPTIDES, V42, P101, DOI 10.1016/j.peptides.2013.01.005; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zhang X, 2013, PEPTIDES, V43, P133, DOI 10.1016/j.peptides.2013.03.010; Zhang X, 2012, PEPTIDES, V33, P336, DOI 10.1016/j.peptides.2012.01.011; Zhao DQ, 2013, CLIN CHIM ACTA, V415, P202, DOI 10.1016/j.cca.2012.10.048; Zheng HW, 2012, CNS NEUROSCI THER, V18, P1003, DOI 10.1111/cns.12019; ZIV I, 1992, STROKE, V23, P1014, DOI 10.1161/01.STR.23.7.1014	208	34	34	1	17	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2014	21			2			187	214		10.1007/s12028-014-0039-z			28	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CD7AM	WOS:000351242600014	25208676	Green Accepted			2022-02-06	
J	Gerrard, P; Zafonte, R; Giacino, JT				Gerrard, Paul; Zafonte, Ross; Giacino, Joseph T.			Coma Recovery Scale-Revised: Evidentiary Support for Hierarchical Grading of Level of Consciousness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Traumatic brain injury; Disorders of consciousness; Psychometrics; Rehabilitation	RECOMMENDATIONS; DISORDERS; ACCURACY	Objective: To investigate the neurobehavioral pattern of recovery of consciousness as reflected by performance on the subscales of the Coma Recovery Scale-Revised (CRS-R). Design: Retrospective item response theory (IRT) and factor analysis. Setting: Inpatient rehabilitation facilities. Participants: Rehabilitation inpatients (N = 180) with posttraumatic disturbance in consciousness who participated in a double-blinded, randomized, controlled drug trial. Interventions: Not applicable. Main Outcome Measures: Scores on CRS-R subscales. Results: The CRS-R was found to fit factor analytic models adhering to the assumptions of unidimensionality and monotonicity. In addition, subscales were mutually independent based on residual correlations. Nonparametric IRT reaffirmed the finding of monotonicity. A highly constrained confirmatory factor analysis model, which imposed equal factor loadings on all items, was found to fit the data well and was used to estimate a 1-parameter IRT model. Conclusions: This study provides evidence of the unidimensionality of the CRS-R and supports the hierarchical structure of the CRS-R subscales, suggesting that it is an effective tool for establishing diagnosis and monitoring recovery of consciousness after severe traumatic brain injury. (C) 2014 by the American Congress of Rehabilitation Medicine	Spaulding Rehabil Hosp, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA		Giacino, JT (corresponding author), Spaulding Rehabil Hosp, 300 First Ave, Charlestown, MA 02129 USA.	jgiacino@partners.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698	National Institute on Disability and Rehabilitation Research (NIDRR), United States Department of Education [H133A031713]; NIDRR [H133A120085]	The data used in this article were extracted from a database developed with grant support from the National Institute on Disability and Rehabilitation Research (NIDRR), United States Department of Education (grant no. H133A031713: JFK-Johnson Rehabilitation Institute TEE Model System). Contributions were partially supported by NIDRR grant no. H133A120085 (Spaulding-Harvard TBI Model System). The contents do not necessarily represent the policy of the Department of Education, and endorsement by the Federal Government should not be assumed.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Chalmers RP, 2012, J STAT SOFTW, V48, P1; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Crick F., 1990, Seminars in the Neurosciences, V2, P263; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 1993, ARCH PHYS MED REHAB, V74, P662; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; Kamata A, 2008, STRUCT EQU MODELING, V15, P136, DOI 10.1080/10705510701758406; La Porta F, 2013, ARCH PHYS MED REHAB, V94, P527, DOI 10.1016/j.apmr.2012.09.035; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; MEIJER RR, 1990, APPL PSYCH MEAS, V14, P283, DOI 10.1177/014662169001400306; MOKKEN RJ, 1982, APPL PSYCH MEAS, V6, P417, DOI 10.1177/014662168200600404; NELKIN N, 1993, PHILOS SCI, V60, P419, DOI 10.1086/289744; Noe E, 2012, ARCH PHYS MED REHAB, V93, P428, DOI 10.1016/j.apmr.2011.08.048; RAMSAY JO, 1991, PSYCHOMETRIKA, V56, P611, DOI 10.1007/BF02294494; Rees G, 2002, NAT REV NEUROSCI, V3, P261, DOI 10.1038/nrn783; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Seth A, 2009, COGN COMPUT, V1, P50, DOI 10.1007/s12559-009-9007-x; Sijtsma K, 1992, APPL MEAN EDUC, V5, P355, DOI DOI 10.1207/S15324818AME0504_; TAKANE Y, 1987, PSYCHOMETRIKA, V52, P393, DOI 10.1007/BF02294363; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Velozo CA, 2012, ARCH PHYS MED REHAB, V93, pS154, DOI 10.1016/j.apmr.2012.06.001; Zumbo BD, 2007, HANDB STAT, V26, P45, DOI 10.1016/S0169-7161(06)26003-6	29	34	37	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2014	95	12					2335	2341		10.1016/j.apmr.2014.06.018			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	AW0AY	WOS:000345954000014	25010536				2022-02-06	
J	Raasakka, A; Kursula, P				Raasakka, Arne; Kursula, Petri			The myelin membrane-associated enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase: on a highway to structure and function	NEUROSCIENCE BULLETIN			English	Article						2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase; calmodulin; central nervous system; cytoskeleton; myelin proteins; RNA	CENTRAL-NERVOUS-SYSTEM; BRAIN 2',3'-CYCLIC-NUCLEOTIDE 3'-PHOSPHODIESTERASE; MULTIPLE-SCLEROSIS PATIENTS; TRANSFER-RNA LIGASE; N-TERMINAL DOMAIN; MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; SUSCEPTIBILITY GENE; CONVERGENT EVIDENCE; BINDING PROTEIN	The membrane-anchored myelin enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) was discovered in the early 1960s and has since then troubled scientists with its peculiar catalytic activity and high expression levels in the central nervous system. Despite decades of research, the actual physiological relevance of CNPase has only recently begun to unravel. In addition to a role in myelination, CNPase is also involved in local adenosine production in traumatic brain injury and possibly has a regulatory function in mitochondrial membrane permeabilization. Although research focusing on the CNPase phosphodiesterase activity has been helpful, several open questions concerning the protein function in vivo remain unanswered. This review is focused on past research on CNPase, especially in the fields of structural biology and enzymology, and outlines the current understanding regarding the biochemical and physiological significance of CNPase, providing ideas and directions for future research.	[Raasakka, Arne; Kursula, Petri] Univ Oulu, Dept Biochem, Oulu, Finland; [Raasakka, Arne; Kursula, Petri] Univ Oulu, Bioctr Oulu, Oulu, Finland; [Kursula, Petri] Univ Hamburg, Dept Chem, Hamburg, Germany		Kursula, P (corresponding author), Univ Oulu, Dept Biochem, Oulu, Finland.	petri.kursula@oulu.fi	Raasakka, Arne/AAA-5251-2020; Kursula, Petri/AAF-4563-2020	Raasakka, Arne/0000-0002-9443-9959; Kursula, Petri/0000-0001-8529-3751	Department of Biochemistry, University of Oulu; Sigrid Juselius Foundation (Finland)Sigrid Juselius Foundation; Academy of FinlandAcademy of FinlandEuropean Commission; Hamburg Research and Science Foundation (Germany)	This review was supported by grants from the Department of Biochemistry, University of Oulu, the Sigrid Juselius Foundation (Finland), the Academy of Finland, and the Hamburg Research and Science Foundation (Germany). We are grateful to Dr. Matti Myllykoski for building up the CNPase project in our laboratory and his deep insight into this enigmatic protein.	Aggarwal S, 2011, TRENDS CELL BIOL, V21, P585, DOI 10.1016/j.tcb.2011.06.004; Aggarwal S, 2011, DEV CELL, V21, P445, DOI 10.1016/j.devcel.2011.08.001; AGRAWAL HC, 1990, J BIOL CHEM, V265, P11849; Azarashvili T, 2009, AM J PHYSIOL-CELL PH, V296, pC1428, DOI 10.1152/ajpcell.00006.2009; Bankston AN, 2013, NEUROSCI BULL, V29, P216, DOI 10.1007/s12264-013-1321-3; Barley K, 2009, SCHIZOPHR RES, V112, P54, DOI 10.1016/j.schres.2009.04.019; Berggard T, 2006, J PROTEOME RES, V5, P669, DOI 10.1021/pr050421l; Bifulco M, 2002, P NATL ACAD SCI USA, V99, P1807, DOI 10.1073/pnas.042678799; BRAUN PE, 1990, ANN NY ACAD SCI, V605, P55, DOI 10.1111/j.1749-6632.1990.tb42380.x; BRAUN PE, 1991, J NEUROSCI RES, V30, P540, DOI 10.1002/jnr.490300311; Carson JH, 2005, BIOL CELL, V97, P51; de Monasterio-Schrader P, 2012, CELL MOL LIFE SCI, V69, P2879, DOI 10.1007/s00018-012-0958-9; DEANGELIS DA, 1994, J NEUROSCI RES, V39, P386, DOI 10.1002/jnr.490390405; DeAngelis DA, 1996, J NEUROCHEM, V67, P943; DeAngelis DA, 1996, J NEUROCHEM, V66, P2523; Donohoe G, 2007, BIOL PSYCHIAT, V61, p189S; DOUGLAS AJ, 1992, ANN HUM GENET, V56, P243, DOI 10.1111/j.1469-1809.1992.tb01149.x; Dracheva S, 2006, NEUROBIOL DIS, V21, P531, DOI 10.1016/j.nbd.2005.08.012; DRUMMOND G, 1961, J BIOL CHEM, V236, P1126; DRUMMOND GI, 1962, J BIOL CHEM, V237, P3535; Esposito C, 2008, BIOCHEMISTRY-US, V47, P308, DOI 10.1021/bi701474t; Georgieva L, 2006, P NATL ACAD SCI USA, V103, P12469, DOI 10.1073/pnas.0603029103; Gravel M, 2000, J NEUROCHEM, V75, P1940, DOI 10.1046/j.1471-4159.2000.0751940.x; GRAVEL M, 1994, J NEUROSCI RES, V38, P243, DOI 10.1002/jnr.490380302; Gravel M, 1996, MOL CELL NEUROSCI, V7, P453, DOI 10.1006/mcne.1996.0033; Gravel M, 2009, J NEUROSCI RES, V87, P1069, DOI 10.1002/jnr.21939; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Hagemeyer N, 2012, EMBO MOL MED, V4, P528, DOI 10.1002/emmm.201200230; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hartline DK, 2008, NEURON GLIA BIOL, V4, P153, DOI 10.1017/S1740925X09990263; Heaton PA, 1996, NUCLEIC ACIDS RES, V24, P850, DOI 10.1093/nar/24.5.850; Hinman JD, 2008, GLIA, V56, P118, DOI 10.1002/glia.20595; Hobson GM, 2012, SEMIN NEUROL, V32, P62, DOI 10.1055/s-0032-1306388; Jackson EK, 2011, AM J PHYSIOL-RENAL, V301, pF1160, DOI 10.1152/ajprenal.00450.2011; KOONIN EV, 1990, FEBS LETT, V268, P231, DOI 10.1016/0014-5793(90)81015-G; Kozlov G, 2003, J BIOL CHEM, V278, P46021, DOI 10.1074/jbc.M305176200; Kozlov G, 2007, FEBS J, V274, P1600, DOI 10.1111/j.1742-4658.2007.05707.x; KURIHARA T, 1992, NEUROSCI LETT, V138, P49, DOI 10.1016/0304-3940(92)90469-N; KURIHARA T, 1990, BIOCHEM BIOPH RES CO, V170, P1074, DOI 10.1016/0006-291X(90)90502-E; Kursula P, 2008, AMINO ACIDS, V34, P175, DOI 10.1007/s00726-006-0479-7; Kursula P, 2001, INT J MOL MED, V8, P475; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Le-Niculescu H, 2007, AM J MED GENET B, V144B, P129, DOI 10.1002/ajmg.b.30481; Lee J, 2006, MOL CELL NEUROSCI, V31, P446, DOI 10.1016/j.mcn.2005.10.017; Lee J, 2005, J CELL BIOL, V170, P661, DOI 10.1083/jcb.200411047; Lee J, 2001, J BIOL CHEM, V276, P14804, DOI 10.1074/jbc.M009434200; Li J, 2013, MOL NEUROBIOL, V47, P673, DOI 10.1007/s12035-012-8370-x; Lovato L, 2008, MOL CELL PROTEOMICS, V7, P2337, DOI 10.1074/mcp.M700277-MCP200; Ma H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080769; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; Mirshafiey A, 2013, IRAN J ALLERGY ASTHM, V12, P292; Mitkus SN, 2008, SCHIZOPHR RES, V98, P129, DOI 10.1016/j.schres.2007.09.032; MONOH K, 1993, GENE, V129, P297, DOI 10.1016/0378-1119(93)90283-9; Muraro PA, 2002, J NEUROIMMUNOL, V130, P233, DOI 10.1016/S0165-5728(02)00229-1; Myllykoski M, 2010, BMC RES NOTES, V3, P1; Myllykoski M, 2013, J MOL BIOL, V425, P4307, DOI 10.1016/j.jmb.2013.06.012; Myllykoski M, 2012, J NEUROCHEM, V123, P515, DOI 10.1111/jnc.12000; Myllykoski M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032336; Myllykoski M, 2012, AMINO ACIDS, V42, P1467, DOI 10.1007/s00726-011-0911-5; Nasr F, 2000, NUCLEIC ACIDS RES, V28, P1676, DOI 10.1093/nar/28.8.1676; OLAFSON RW, 1969, CAN J BIOCHEM CELL B, V47, P961, DOI 10.1139/o69-151; ONeill RC, 1997, J NEUROSCI RES, V50, P248; Peirce TR, 2006, ARCH GEN PSYCHIAT, V63, P18, DOI 10.1001/archpsyc.63.1.18; Peirce TR, 2004, AM J MED GENET B, V130B, P81; Popow J, 2012, CELL MOL LIFE SCI, V69, P2657, DOI 10.1007/s00018-012-0944-2; Quarles RH, 2002, CELL MOL LIFE SCI, V59, P1851, DOI 10.1007/PL00012510; Radtke C, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/608496; Rosener M, 1997, J NEUROIMMUNOL, V75, P28, DOI 10.1016/S0165-5728(96)00230-5; Sakamoto Y, 2005, J MOL BIOL, V346, P789, DOI 10.1016/j.jmb.2004.12.024; Schwer B, 2008, RNA, V14, P204, DOI 10.1261/rna.858108; Stingo S, 2007, CHEM BIOL DRUG DES, V70, P502, DOI 10.1111/j.1747-0285.2007.00592.x; Tang FL, 2007, NEUROSCI LETT, V416, P113, DOI 10.1016/j.neulet.2007.01.054; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; Toyama BH, 2013, CELL, V154, P971, DOI 10.1016/j.cell.2013.07.037; TRAPP BD, 1988, J NEUROCHEM, V51, P859, DOI 10.1111/j.1471-4159.1988.tb01822.x; Usui H, 2006, SCHIZOPHR RES, V88, P245, DOI 10.1016/j.schres.2006.07.019; Verrier J, 2012, J NEUROTRAUM, V29, pA168; Verrier JD, 2013, GLIA, V61, P1595, DOI 10.1002/glia.22523; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Verrier JD, 2011, J NEUROCHEM, V118, P979, DOI 10.1111/j.1471-4159.2011.07392.x; Vlkolinsky R, 2001, NEUROBIOL AGING, V22, P547, DOI 10.1016/S0197-4580(01)00218-4; Voineskos AN, 2008, PSYCHIAT GENET, V18, P143, DOI 10.1097/YPG.0b013e3282fa1874; Voineskos AN, 2007, BIOL PSYCHIAT, V61, p209S; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Walsh MJ, 1998, J CLIN INVEST, V101, P1923, DOI 10.1172/JCI1983; Wilson SJ, 2012, CELL HOST MICROBE, V12, P585, DOI 10.1016/j.chom.2012.08.012; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; Yamamoto T, 2013, CONGENIT ANOM, V53, P3, DOI 10.1111/cga.12005; Yin X, 1997, J NEUROSCI RES, V50, P238, DOI 10.1002/(SICI)1097-4547(19971015)50:2<238::AID-JNR12>3.0.CO;2-4; [No title captured]	90	34	34	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1673-7067	1995-8218		NEUROSCI BULL	Neurosci. Bull.	DEC	2014	30	6					956	966		10.1007/s12264-013-1437-5			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU6ZO	WOS:000345750500007	24807122	Green Published			2022-02-06	
J	Sandhir, R; Gregory, E; Berman, NEJ				Sandhir, Rajat; Gregory, Eugene; Berman, Nancy E. J.			Differential response of miRNA-21 and its targets after traumatic brain injury in aging mice	NEUROCHEMISTRY INTERNATIONAL			English	Article						Aging; miR-21; PDCD4; PTEN; RECK; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; MICRORNA EXPRESSION; HIPPOCAMPUS; BIOMARKERS; REGULATORS; ISCHEMIA; NEURONS; DISEASE; DEATH	The present study investigated the possible role of miR-21, a miRNA that has known prosurvival function, in poor outcomes in the elderly following traumatic brain injury compared to adults. Controlled cortical impact injury was induced in adult (5-6 months) and aged (22-24 months) C57/BL6 mice. miR-21 and four of its targets (PDCD4, TIMP3, RECK, PTEN) were analyzed at 1, 3, 7 days post injury in samples of injured cortex using real-time PCR analysis. Basal miR-21 expression was higher in the aged brain than in the adult brain. In the adult brain, miR-21 expression increased in response to injury, with the maximum increase 24 hours after injury followed by a gradual decrease, returning to baseline 7 days post-injury. In contrast, in aged mice, miR21 showed no injury response, and expression of miR-21 target genes (PTEN, PDCD4, RECK, TIMP3) was up-regulated at all post injury time points, with a maximal increase at 24 hours post injury. Based on these results, we conclude that the diminished miR21 injury response in the aged brain leads to up-regulation of its targets, with the potential to contribute to the poor prognosis following TBI in aging brain. Therefore, strategies aimed at up-regulation of miR-21 and/or down regulation of its targets might be useful in improving outcomes in the elderly following TBI. (C) 2014 Elsevier Ltd. All rights reserved.	[Sandhir, Rajat; Gregory, Eugene; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA		Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Mail Stop 3038,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	nberman@kumc.edu			National Institute of Aging, University of Kansas Alzheimer's Disease Center and Steve Palermo Endowment; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031140, P30AG035982] Funding Source: NIH RePORTER	This work was supported by the National Institute of Aging, University of Kansas Alzheimer's Disease Center and Steve Palermo Endowment.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI 10.1089/neu.2008-0765; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Bi YJ, 2009, J CELL PHYSIOL, V218, P467, DOI 10.1002/jcp.21639; Brase JC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-306; Brattelid T, 2011, PHYSIOL GENOMICS, V43, P604, DOI 10.1152/physiolgenomics.00131.2010; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chen Y, 2008, CANCER LETT, V272, P197, DOI 10.1016/j.canlet.2008.06.034; Delay C, 2012, NEUROBIOL DIS, V46, P285, DOI 10.1016/j.nbd.2012.01.003; Ding J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080429; Filatova EV, 2012, BIOCHEMISTRY-MOSCOW+, V77, P813, DOI 10.1134/S0006297912080020; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Guay C, 2013, NAT REV ENDOCRINOL, V9, P513, DOI 10.1038/nrendo.2013.86; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Im HI, 2012, TRENDS NEUROSCI, V35, P325, DOI 10.1016/j.tins.2012.01.004; Jacobs David G, 2003, Curr Opin Crit Care, V9, P535, DOI 10.1097/00075198-200312000-00012; Lee P, 2012, EXP NEUROL, V234, P50, DOI 10.1016/j.expneurol.2011.12.016; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Tran N, 2013, ESSAYS BIOCHEM, V54, P17, DOI [10.1042/BSE0540017, 10.1042/bse0540017]; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Petri R, 2014, EXP CELL RES, V321, P84, DOI 10.1016/j.yexcr.2013.09.022; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rao P, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00039; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Shi ZD, 2013, CANCER RES, V73, P5519, DOI 10.1158/0008-5472.CAN-13-0280; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Van Wynsberghe PM, 2011, METHOD CELL BIOL, V106, P219, DOI 10.1016/B978-0-12-544172-8.00008-6; Wang HA, 2010, J NEUROCHEM, V115, P385, DOI 10.1111/j.1471-4159.2010.06933.x; Wang T, 2012, AM J PATHOL, V181, P1911, DOI 10.1016/j.ajpath.2012.08.022; Xu Y, 2013, GENE, V530, P278, DOI 10.1016/j.gene.2013.07.055; Yin KJ, 2014, NEUROCHEM INT, V77, P9, DOI 10.1016/j.neuint.2014.03.013; Zhang XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034688; Zhao J, 2013, NEUROSCIENCE, V238, P242, DOI 10.1016/j.neuroscience.2013.02.046	40	34	35	1	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2014	78						117	121		10.1016/j.neuint.2014.09.009			5	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AY3RY	WOS:000347501400014	25277076	Green Accepted			2022-02-06	
J	Villalba, N; Sonkusare, SK; Longden, TA; Tran, TL; Sackheim, AM; Nelson, MT; Wellman, GC; Freeman, K				Villalba, Nuria; Sonkusare, Swapnil K.; Longden, Thomas A.; Tran, Tram L.; Sackheim, Adrian M.; Nelson, Mark T.; Wellman, George C.; Freeman, Kalev			Traumatic Brain Injury Disrupts Cerebrovascular Tone Through Endothelial Inducible Nitric Oxide Synthase Expression and Nitric Oxide Gain of Function	JOURNAL OF THE AMERICAN HEART ASSOCIATION			English	Article						cerebral artery; endothelium-derived factors; myogenic tone; nitric oxide; traumatic brain injury; vascular endothelial function; vascular reactivity		Background-Traumatic brain injury (TBI) has been reported to increase the concentration of nitric oxide (NO) in the brain and can lead to loss of cerebrovascular tone; however, the sources, amounts, and consequences of excess NO on the cerebral vasculature are unknown. Our objective was to elucidate the mechanism of decreased cerebral artery tone after TBI. Methods and Results-Cerebral arteries were isolated from rats 24 hours after moderate fluid-percussion TBI. Pressure-induced increases in vasoconstriction (myogenic tone) and smooth muscle Ca2+ were severely blunted in cerebral arteries after TBI. However, myogenic tone and smooth muscle Ca2+ were restored by inhibition of NO synthesis or endothelium removal, suggesting that TBI increased endothelial NO levels. Live native cell NO, indexed by 4,5-diaminofluorescein (DAF-2 DA) fluorescence, was increased in endothelium and smooth muscle of cerebral arteries after TBI. Clamped concentrations of 20 to 30 nmol/L NO were required to simulate the loss of myogenic tone and increased (DAF-2T) fluorescence observed following TBI. In comparison, basal NO in control arteries was estimated as 0.4 nmol/L. Consistent with TBI causing enhanced NO-mediated vasodilation, inhibitors of guanylyl cyclase, protein kinase G, and large-conductance Ca2+-activated potassium (BK) channel restored function of arteries from animals with TBI. Expression of the inducible isoform of NO synthase was upregulated in cerebral arteries isolated from animals with TBI, and the inducible isoform of NO synthase inhibitor 1400W restored myogenic responses following TBI. Conclusions-The mechanism of profound cerebral artery vasodilation after TBI is a gain of function in vascular NO production by 60-fold over controls, resulting from upregulation of the inducible isoform of NO synthase in the endothelium.	[Villalba, Nuria; Sonkusare, Swapnil K.; Longden, Thomas A.; Nelson, Mark T.; Wellman, George C.; Freeman, Kalev] Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA; [Tran, Tram L.; Sackheim, Adrian M.; Freeman, Kalev] Univ Vermont, Dept Surg, Burlington, VT 05405 USA; [Nelson, Mark T.] Univ Manchester, Inst Cardiovasc Sci, Manchester, Lancs, England		Freeman, K (corresponding author), Univ Vermont, Given E301, Burlington, VT 05405 USA.	Kalev.Freeman@uvm.edu		Nelson, Mark/0000-0002-6608-8784; Longden, Thomas/0000-0002-7950-7677	American Heart Association fellowshipsAmerican Heart Association [13POST14820015, 12POST12090001]; Totman Medical Research Trust; Fondation LeducqLeducq Foundation; Peter A. Martin Brain Aneurysm Research Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20-RR-16435, P01-HL-095488, UM1-HL-120877-01, R01-HL-044455, R01-HL-098243, R37-DK-053832, P30-RR-032135-02, P30-GM-103498-02, K08-GM-098795-01, K99-HL-121484-01, R01-HL-121706-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P30RR032135, P20RR016435] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL095488, UM1HL120877, R01HL121706, K99HL121484, R01HL044455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R37DK053832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103498, K08GM098795] Funding Source: NIH RePORTER	American Heart Association fellowships to Drs Villalba, Longden (13POST14820015, 12POST12090001); and additional funding from the Totman Medical Research Trust, Fondation Leducq, Peter A. Martin Brain Aneurysm Research Fund, and National Institutes of Health (P20-RR-16435, P01-HL-095488, UM1-HL-120877-01, R01-HL-044455, R01-HL-098243, R37-DK-053832, P30-RR-032135-02, P30-GM-103498-02, K08-GM-098795-01, K99-HL-121484-01, R01-HL-121706-01).	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cheng JJ, 1999, CHINESE J PHYSIOL, V42, P103; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; DACEY RG, 1982, AM J PHYSIOL, V243, pH598, DOI 10.1152/ajpheart.1982.243.4.H598; Faraci FM, 1998, PHYSIOL REV, V78, P53, DOI 10.1152/physrev.1998.78.1.53; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Foley LM, 2013, J CEREBR BLOOD F MET, V33, P129, DOI 10.1038/jcbfm.2012.145; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Golding EM, 2001, J NEUROTRAUM, V18, P691, DOI 10.1089/089771501750357636; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Griffiths C, 2003, MOL PHARMACOL, V64, P1349, DOI 10.1124/mol.64.6.1349; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hah JM, 2001, J MED CHEM, V44, P2667, DOI 10.1021/jm0101491; Hall CN, 2009, NITRIC OXIDE-BIOL CH, V21, P92, DOI 10.1016/j.niox.2009.07.002; Hannah RM, 2011, J CEREBR BLOOD F MET, V31, P1175, DOI 10.1038/jcbfm.2010.214; Held KF, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00130; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hishikawa K, 1997, CIRCULATION, V96, P3610; Hofmann F, 2000, J CELL SCI, V113, P1671; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Kojima H, 1998, CHEM PHARM BULL, V46, P373; Larson BE, 2012, J SURG RES, V173, pE73, DOI 10.1016/j.jss.2011.09.056; Ledoux J, 2008, P NATL ACAD SCI USA, V105, P9627, DOI 10.1073/pnas.0801963105; Li Q, 2013, STROKE, V44, P3183, DOI 10.1161/STROKEAHA.113.002073; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longden TA, 2014, P NATL ACAD SCI USA, V111, P7462, DOI 10.1073/pnas.1401811111; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; Nystoriak MA, 2011, AM J PHYSIOL-HEART C, V300, pH803, DOI 10.1152/ajpheart.00760.2010; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Rafols D, 2004, NEUROSCI LETT, V362, P154, DOI 10.1016/j.neulet.2004.03.021; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sonkusare SK, 2012, SCIENCE, V336, P597, DOI 10.1126/science.1216283; Takimoto Y, 2002, CIRCULATION, V105, P490, DOI 10.1161/hc0402.102662; Terpolilli NA, 2013, J CEREBR BLOOD F MET, V33, P311, DOI 10.1038/jcbfm.2012.176; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wei L, 2014, CLIN EXP PHARMACOL P, V41, P134, DOI 10.1111/1440-1681.12186; Wellman GC, 2003, CELL CALCIUM, V34, P211, DOI 10.1016/S0143-4160(03)00124-6; Wellman GC, 1996, CIRC RES, V79, P1024, DOI 10.1161/01.RES.79.5.1024; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yi FX, 2002, AM J PHYSIOL-HEART C, V283, pH2725, DOI 10.1152/ajpheart.00428.2002; Yu GX, 2014, J NEUROTRAUM, V31, P739, DOI 10.1089/neu.2013.3187; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141; Zhang P, 2007, CIRC RES, V100, P1089, DOI 10.1161/01.RES.0000264081.78659.45	69	34	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2047-9980			J AM HEART ASSOC	J. Am. Heart Assoc.	DEC	2014	3	6							e001474	10.1161/JAHA.114.001474			17	Cardiac & Cardiovascular Systems	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	V61EX	WOS:000210882600036	25527626	Green Published, gold, Green Submitted			2022-02-06	
J	Virji-Babul, N; Hilderman, CGE; Makan, N; Liu, AP; Smith-Forrester, J; Franks, C; Wang, ZJ				Virji-Babul, Naznin; Hilderman, Courtney G. E.; Makan, Nadia; Liu, Aiping; Smith-Forrester, Jenna; Franks, Chris; Wang, Z. J.			Changes in Functional Brain Networks following Sports-Related Concussion in Adolescents	JOURNAL OF NEUROTRAUMA			English	Article						graph theory; mild traumatic brain injury; concussion; adolescents; resting-state EEG	GRAPH-THEORETICAL ANALYSIS; WHITE-MATTER; HEAD-INJURY; CONNECTIVITY; ATTENTION; DEFICITS; FMRI; AGE	Sports-related concussion is a major public health issue; however, little is known about the underlying changes in functional brain networks in adolescents following injury. Our aim was to use the tools from graph theory to evaluate the changes in brain network properties following concussion in adolescent athletes. We recorded resting state electroencephalography (EEG) in 33 healthy adolescent athletes and 9 adolescent athletes with a clinical diagnosis of subacute concussion. Graph theory analysis was applied to these data to evaluate changes in brain networks. Global and local metrics of the structural properties of the graph were calculated for each group and correlated with Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) scores. Brain networks of both groups showed small-world topology with no statistically significant differences in the global metrics; however, significant differences were found in the local metrics. Specifically, in the concussed group, we noted: 1) increased values of betweenness and degree in frontal electrode sites corresponding to the (R) dorsolateral prefrontal cortex and the (R) inferior frontal gyrus and 2) decreased values of degree in the region corresponding to the (R) frontopolar prefrontal cortex. In addition, there was significant negative correlation between degree and hub value, with total symptom score at the electrode site corresponding to the (R) prefrontal cortex. This preliminary report in adolescent athletes shows for the first time that resting-state EEG combined with graph theoretical analysis may provide an objective method of evaluating changes in brain networks following concussion. This approach may be useful in identifying individuals at risk for future injury.	[Virji-Babul, Naznin; Hilderman, Courtney G. E.; Makan, Nadia] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V6T 1Z3, Canada; [Liu, Aiping; Wang, Z. J.] Univ British Columbia, Vancouver, BC V6T 1Z3, Canada; [Smith-Forrester, Jenna] Univ British Columbia, Neurosci Program, Vancouver, BC V6T 1Z3, Canada; [Virji-Babul, Naznin] Child & Family Res Inst, Vancouver, BC, Canada		Virji-Babul, N (corresponding author), Univ British Columbia, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	naznin.virji-babul@ubc.ca	Meijer, Anna/K-5118-2016	Virji-Babul, Naznin/0000-0002-8984-5848; Hilderman, Courtney G E/0000-0003-0209-4939	University of British Columbia; Brain Research Center, University of British Columbia; Whitecaps Residency program; Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate ScholarshipCanadian Institutes of Health Research (CIHR)	This research was supported by the University of British Columbia and the Brain Research Center, University of British Columbia. The authors thank the Whitecaps Residency program for their support and all the participants, trainers, and coaches who took part in this study. Jenna Smith-Forrester is supported by a Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarship. Dr. Naznin Virji-Babul had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Burgess PW, 2007, TRENDS COGN SCI, V11, P290, DOI 10.1016/j.tics.2007.05.004; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Keightley M. L., 2013, J NEUROTRAUM, V15, P1; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kleinberg JM, 1999, J ACM, V46, P604, DOI 10.1145/324133.324140; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Koessler L, 2009, NEUROIMAGE, V46, P64, DOI 10.1016/j.neuroimage.2009.02.006; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Li JN, 2009, J MACH LEARN RES, V10, P475; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newman MEJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.066133; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Rotem-Kohavi N, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00209; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; Stam Cornelis J, 2007, Nonlinear Biomed Phys, V1, P3, DOI 10.1186/1753-4631-1-3; Sun JF, 2012, AGING DIS, V3, P181; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	45	34	34	1	38	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1914	1919		10.1089/neu.2014.3450			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500003	24956041				2022-02-06	
J	Feliciano, DP; Sahbaie, P; Shi, XY; Klukinov, M; Clark, JD; Yeomans, DC				Feliciano, David P.; Sahbaie, Peyman; Shi, Xiaoyou; Klukinov, Michael; Clark, J. David; Yeomans, David C.			Nociceptive sensitization and BDNF up-regulation in a rat model of traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Chronic pain; Brain derived neurotrophic factor	NEUROPATHIC PAIN; SPINAL-CORD; NEUROTROPHIC FACTOR; PERSISTENT PAIN; MICROGLIA; VETERANS; STRESS	Chronic pain after traumatic brain injury (TBI) is very common, but the mechanisms linking TBI to pain experienced in the periphery have not been described. In this set of studies we examined nociceptive sensitization and changes in spinal cord gene expression using the rat lateral fluid percussion model of mild TBI. We did not identify changes in thermal nociceptive thresholds in rats with mild TBI. However, mechanical allodynia in hind paws contralateral to TBI was significant and sustained. We also found that spinal cord levels of brain derived neurotrophic factor (BDNF) but not several other pain-related genes were up-regulated one week after injury. Our findings suggest that TBI-induced up-regulation of spinal BDNF levels might contribute to chronic TBI-related pain, and that the lateral fluid percussion model might be useful for exploring this relationship. Published by Elsevier Ireland Ltd.	[Feliciano, David P.; Shi, Xiaoyou; Klukinov, Michael; Clark, J. David; Yeomans, David C.] Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA; [Sahbaie, Peyman; Shi, Xiaoyou; Clark, J. David] VA Palo Alto Healthcare Syst, Anesthesiol Serv, Palo Alto, CA 94304 USA		Clark, JD (corresponding author), VA Palo Alto Healthcare Syst, Anesthesiol Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	djclark@stanford.edu					Beggs S, 2013, NEUROSCI LETT, V557, P37, DOI 10.1016/j.neulet.2013.08.037; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Constandil L, 2011, BRAIN RES BULL, V86, P454, DOI 10.1016/j.brainresbull.2011.08.008; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; DeFelice M, 2013, ANN NEUROL, V74, P257, DOI 10.1002/ana.23922; Golub A, 2013, SUBST USE MISUSE, V48, P811, DOI 10.3109/10826084.2013.796988; Higgins DM, 2014, PAIN MED, V15, P782, DOI 10.1111/pme.12388; Kerr BJ, 1999, J NEUROSCI, V19, P5138; Li CQ, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-27; Lin YT, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-126; Ling G.S.F., 2004, CURR PROTOC NEUROSCI; Macolino CM, 2014, J NEUROSCI METH, V226, P139, DOI 10.1016/j.jneumeth.2014.01.008; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Obata K, 2006, NEUROSCI RES, V55, P1, DOI 10.1016/j.neures.2006.01.005; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Trang T, 2011, NEURON GLIA BIOL, V7, P99, DOI 10.1017/S1740925X12000087; Tzabazis A, 2005, BRAIN RES, V1037, P148, DOI 10.1016/j.brainres.2005.01.019; Wilkinson H A, 1989, Surg Neurol, V31, P412, DOI 10.1016/0090-3019(89)90080-3; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Yang Q, 2014, J NEUROSCI, V34, P10765, DOI 10.1523/JNEUROSCI.5316-13.2014; Zhu XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091303	28	34	34	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 7	2014	583						55	59		10.1016/j.neulet.2014.09.030			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU4TM	WOS:000345604300011	25246352				2022-02-06	
J	Causin, P; Guidoboni, G; Harris, A; Prada, D; Sacco, R; Terragni, S				Causin, Paola; Guidoboni, Giovanna; Harris, Alon; Prada, Daniele; Sacco, Riccardo; Terragni, Samuele			A poroelastic model for the perfusion of the lamina cribrosa in the optic nerve head	MATHEMATICAL BIOSCIENCES			English	Article						Biological tissues; Eye; Optic nerve head; Lamina cribrosa; Poroelastic models; Finite element method	BLOOD-FLOW AUTOREGULATION; INTRAOCULAR-PRESSURE; MATHEMATICAL-MODEL; HUMAN SCLERA; GLAUCOMA; BIOMECHANICS; TOMOGRAPHY; HEMODYNAMICS; MECHANISMS; PARADIGM	In this work we present a mathematical model for the coupling between biomechanics and hemodynamics in the lamina cribrosa, a thin porous tissue at the base of the optic nerve head which is thought to be the site of injury in ocular neurodegenerative diseases such as glaucoma. In this exploratory two-dimensional investigation, the lamina cribrosa is modeled as a poroelastic material where blood vessels are viewed as pores in a solid elastic matrix. The model is used to investigate the influence on the distributions of stress, blood volume fraction (or vascular porosity) and blood velocity within the lamina cribrosa due to the application of different levels of the intraocular pressure (IOP) and the enforcement of different mechanical constraints at the lamina's boundary. The model simulations suggest that the degree of fixity of the boundary constraint strongly influences the lamina's response to IOP elevation. Specifically, when the boundary is mechanically clamped, KW elevation leads to an increase in stress close to the lamina's boundary, making it more susceptible to tissue damage. On the other hand, when rotations are allowed at the boundary, the most vulnerable region appears to be located at the lamina's central axis, in proximity of the eye globe, where increased stress and reduced vascular porosity and blood velocity are predicted for increased levels of IOP. Published by Elsevier Inc.	[Causin, Paola] Univ Milan, Dipartimento Matemat F Enriques, I-20133 Milan, Italy; [Guidoboni, Giovanna; Prada, Daniele] Indiana Univ Purdue Univ, Dept Math Sci, Indianapolis, IN 46202 USA; [Guidoboni, Giovanna] Indiana Univ, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46204 USA; [Guidoboni, Giovanna] Inst Rech Math Interact & Applicat, F-67084 Strasbourg, France; [Sacco, Riccardo] Politecn Milan, Dipartimento Matemat F Brioschi, I-20133 Milan, Italy; [Terragni, Samuele] Politecn Milan, I-20133 Milan, Italy		Guidoboni, G (corresponding author), Indiana Univ Purdue Univ, Dept Math Sci, N Blackford St,LD270, Indianapolis, IN 46202 USA.			Prada, Daniele/0000-0002-8498-0928; GUIDOBONI, Giovanna/0000-0001-7470-0171	NSF/DMSNational Science Foundation (NSF) [1134731, 1224195]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21EY022101-01A1]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R21EY022101] Funding Source: NIH RePORTER; Direct For Mathematical & Physical ScienNational Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS) [1224195] Funding Source: National Science Foundation	This work was partially supported by the NSF/DMS Grants 1134731 and 1224195, the NIH Grant 1R21EY022101-01A1.	Arciero J, 2013, INVEST OPHTH VIS SCI, V54, P5584, DOI 10.1167/iovs.12-11543; Balaratnasingam C, 2014, EXP EYE RES, V121, P11, DOI 10.1016/j.exer.2014.02.008; Bhole AP, 2009, PHILOS T R SOC A, V367, P3339, DOI 10.1098/rsta.2009.0093; Biot MA, 1941, J APPL PHYS, V12, P155, DOI 10.1063/1.1712886; Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001; Burgoyne CF, 2011, EXP EYE RES, V93, P120, DOI 10.1016/j.exer.2010.09.005; Camp RJ, 2011, J AM CHEM SOC, V133, P4073, DOI 10.1021/ja110098b; Campbell IC, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026286; Caprioli J, 2010, AM J OPHTHALMOL, V149, P704, DOI 10.1016/j.ajo.2010.01.018; Chapelle D, 2010, COMPUT MECH, V46, P91, DOI 10.1007/s00466-009-0452-x; Coussy O, 2004, POROMECHANICS; Cowin SC, 1999, J BIOMECH, V32, P217, DOI 10.1016/S0021-9290(98)00161-4; Detournay E, 1993, COMPREHENSIVE ROCK E, P113, DOI DOI 10.1016/B978-0-08-040615-2.50011-3; Flynn BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012337; Girard M.J.A., 2014, CURR EYE RES, P1, DOI http://dx.doi.org/10.3109/02713683.2014.914543; Girard MJA, 2009, INVEST OPHTH VIS SCI, V50, P5226, DOI 10.1167/iovs.08-3363; Grytz R, 2014, J MECH BEHAV BIOMED, V29, P602, DOI 10.1016/j.jmbbm.2013.03.027; Grytz R, 2012, MECH RES COMMUN, V42, P92, DOI 10.1016/j.mechrescom.2012.01.007; Grytz R, 2011, BIOMECH MODEL MECHAN, V10, P371, DOI 10.1007/s10237-010-0240-8; Guidoboni G, 2014, INVEST OPHTH VIS SCI, V55, P4105, DOI 10.1167/iovs.13-13611; Guidoboni G, 2013, J COUPLED SYST MULTI, V1, P1, DOI 10.1166/jcsmd.2013.1004; Guidoboni G, 2014, MATH BIOSCI ENG, V11, P523, DOI 10.3934/mbe.2014.11.523; Harris A, 2013, EUR J OPHTHALMOL, V23, P139, DOI 10.5301/ejo.5000255; Hatch WV, 1997, BRIT J OPHTHALMOL, V81, P871, DOI 10.1136/bjo.81.10.871; He DQ, 1999, J BIOMECH, V32, P579, DOI 10.1016/S0021-9290(99)00025-1; HERRMANN LR, 1965, AIAA J, V3, P1896, DOI 10.2514/3.3277; HUYGHE JM, 1992, AM J PHYSIOL, V262, pH1256, DOI 10.1152/ajpheart.1992.262.4.H1256; Jerome J., 1996, ANAL CHARGE TRANSPOR; Jonas JB, 2014, ACTA OPHTHALMOL, V92, pe273, DOI 10.1111/aos.12324; Krieglstein, 2003, ATLAS OCULAR BLOOD F; Leske MC, 2007, OPHTHAL EPIDEMIOL, V14, P166, DOI 10.1080/09286580701501931; Li XG, 2013, COMPUT METHOD BIOMEC, V16, P1330, DOI 10.1080/10255842.2012.670853; Morris HJ, 2013, INVEST OPHTH VIS SCI, V54, P7215, DOI 10.1167/iovs.13-12441; Newson T, 2006, J BIOMECH ENG-T ASME, V128, P496, DOI 10.1115/1.2205372; Norman RE, 2011, EXP EYE RES, V93, P4, DOI 10.1016/j.exer.2010.09.014; Showalter RE, 2000, J MATH ANAL APPL, V251, P310, DOI 10.1006/jmaa.2000.7048; Sigal IA, 2014, IEEE T MED IMAGING, V33, P1381, DOI 10.1109/TMI.2014.2312133; Sigal IA, 2005, INVEST OPHTH VIS SCI, V46, P4189, DOI 10.1167/iovs.05-0541; Sigal IA, 2011, INVEST OPHTH VIS SCI, V52, P1896, DOI 10.1167/iovs.10-5500; Tully B, 2011, J FLUID MECH, V667, P188, DOI 10.1017/S0022112010004428; Weinreb RN, 2009, OCULAR BLOOD FLOW GL; WOO SLY, 1972, EXP EYE RES, V14, P29, DOI 10.1016/0014-4835(72)90139-X; Yan DB, 1998, CURR EYE RES, V17, P903, DOI 10.1076/ceyr.17.9.903.5143; Yoon YJ, 2012, J BIOMECH, V45, P716, DOI 10.1016/j.jbiomech.2011.12.007	44	34	36	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0025-5564	1879-3134		MATH BIOSCI	Math. Biosci.	NOV	2014	257				SI		33	41		10.1016/j.mbs.2014.08.002			9	Biology; Mathematical & Computational Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology	AU2ZP	WOS:000345483200005	25149561	Green Submitted			2022-02-06	
J	Gershengorn, HB; Wunsch, H; Scales, DC; Zarychanski, R; Rubenfeld, G; Garland, A				Gershengorn, Hayley B.; Wunsch, Hannah; Scales, Damon C.; Zarychanski, Ryan; Rubenfeld, Gordon; Garland, Allan			Association Between Arterial Catheter Use and Hospital Mortality in Intensive Care Units	JAMA INTERNAL MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; CENTRAL VENOUS CATHETER; RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE-MEASUREMENT; DISCOVERED ADRENAL MASSES; TRAUMATIC BRAIN-INJURY; PULMONARY-ARTERY; STREAM INFECTION; SEPTIC SHOCK; HIGH-RISK	IMPORTANCE Arterial catheters are used frequently in intensive care units (ICUs). Clinical effectiveness and adverse events associated with the use of the catheters have not been formally evaluated in clinical studies. OBJECTIVE To determine whether an association exists between arterial catheter use and hospital mortality in ICU patients. DESIGN, SETTING, AND PARTICIPANTS Propensity-matched cohort analysis of data in the Project IMPACT database, from 2001 to 2008. A total of 139 ICUs in the United States were included. Participants were ICU patients 18 years or older. EXPOSURE Arterial catheter use. MAIN OUTCOMES AND MEASURES Our main outcome was hospital mortality. We assessed a primary cohort of medical patients requiring mechanical ventilation and 9 secondary cohorts. We used propensity score-matched pairs as the primary analytic strategy. Sensitivity analyses included 4 alternative methods of comparison in the primary cohort: multivariate modeling without propensity adjustment, mixed-effects multivariate logistic regression without propensity adjustment, multivariate modeling with propensity adjustment, and stratification based on propensity quintiles. RESULTS Our primary cohort consisted of 60 975 patients; 24 126 of these patients (39.6%) had an arterial catheter in place during their ICU stay, and analyses were based on 13 603 propensity score-matched pairs. We found no association between arterial catheter use and hospital mortality in medical patients requiring mechanical ventilation in the primary analysis (odds ratio [OR], 0.98; 95% CI, 0.93-1.03; P = .40) or the 4 sensitivity analyses (P >= .58 for all). In 8 of 9 secondary cohorts we were unable to detect an association between arterial catheter use and hospital mortality. In the cohort of patients receiving vasopressors, arterial catheter use was associated with an increased odds of death (OR, 1.08; 95% CI, 1.02-1.14; P = .008). CONCLUSIONS AND RELEVANCE In this propensity-matched cohort analysis, arterial catheters were not associated with improvements in hospital mortality in medical ICU patients requiring mechanical ventilation. Given the costs and potential harms associated with invasive catheters, randomized clinical trials are needed to further evaluate the usefulness of these frequently used devices.	[Gershengorn, Hayley B.] Montefiore Med Ctr, Div Crit Care Med, Bronx, NY 10467 USA; [Wunsch, Hannah] Columbia Univ, Dept Anesthesiol, New York, NY USA; [Wunsch, Hannah] Columbia Univ, Dept Epidemiol, New York, NY USA; [Scales, Damon C.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Rubenfeld, Gordon] Univ Toronto, Sch Med, Dept Med, Toronto, ON, Canada; [Rubenfeld, Gordon] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; [Garland, Allan] Univ Manitoba, Dept Med & Community Hlth Sci, Winnipeg, MB, Canada		Gershengorn, HB (corresponding author), Montefiore Med Ctr, Div Crit Care Med, 111 E 210th St,Gold Zone,Main Floor, Bronx, NY 10467 USA.	hgershen@montefiore.org	Zarychanski, Ryan/AAB-6369-2022	Garland, Allan/0000-0001-7129-936X; Zarychanski, Ryan/0000-0001-9455-6138	Physicians' Services Incorporated Foundation	Dr Scales is supported by a fellowship in Translational Health Research from the Physicians' Services Incorporated Foundation.	American Society of Anesthesiologists, STAND PRACT PAR STAN; [Anonymous], 1871, BMJ-BRIT MED J, V1, P283, DOI DOI 10.1136/BMJ.1.533.283; [Anonymous], 2003, DAT COLL THER DRUGS, P77; Arpino B, 2011, COMPUT STAT DATA AN, V55, P1770, DOI 10.1016/j.csda.2010.11.008; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Blackstone EH, 2002, J THORAC CARDIOV SUR, V123, P8, DOI 10.1067/mtc.2002.120329; Brady WJ, 2011, RESUSCITATION, V82, P845, DOI 10.1016/j.resuscitation.2011.02.028; Branco BC, 2012, INJURY, V43, P78, DOI 10.1016/j.injury.2010.12.003; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Bur A, 2003, CRIT CARE MED, V31, P793, DOI 10.1097/01.CCM.0000053650.12025.1A; Bur A, 2000, CRIT CARE MED, V28, P371, DOI 10.1097/00003246-200002000-00014; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cleverley K, 2013, RESUSCITATION, V84, P878, DOI 10.1016/j.resuscitation.2013.01.038; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; COCHRAN WG, 1968, BIOMETRICS, V24, P295, DOI 10.2307/2528036; Coldman AJ, 2012, CAN J PUBLIC HEALTH, V103, pE420, DOI 10.1007/BF03405630; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cook SF, 2002, CRIT CARE MED, V30, P2765, DOI 10.1097/00003246-200212000-00024; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Esteve F, 2011, J INFECTION, V63, P139, DOI 10.1016/j.jinf.2011.05.020; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Gaertner WB, 2010, ANN VASC SURG, V24, DOI 10.1016/j.avsg.2009.07.039; Garland A, 2010, AM J RESP CRIT CARE, V182, P133, DOI 10.1164/rccm.201003-0410ED; Gershengorn HB, 2014, ANESTHESIOLOGY, V120, P650, DOI 10.1097/ALN.0000000000000008; Gershengorn HB, 2013, CRIT CARE MED, V41, P2667, DOI 10.1097/CCM.0b013e318298a41e; Gowardman JR, 2010, J HOSP INFECT, V75, P12, DOI 10.1016/j.jhin.2010.01.005; Guo Shenyang, 2010, PROPENSITY SCORE ANA; Harvey S, 2005, LANCET, V366, P472, DOI 10.1016/S0140-6736(05)67061-4; Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F; Hubbard RA, 2011, ANN INTERN MED, V155, P481, DOI 10.7326/0003-4819-155-8-201110180-00004; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koh DBC, 2008, CRIT CARE MED, V36, P397, DOI 10.1097/CCM.0b013e318161f74b; Koo KKY, 2011, CRIT CARE MED, V39, P1613, DOI 10.1097/CCM.0b013e318218a045; Kumar A, 2010, CRIT CARE MED, V38, P1773, DOI 10.1097/CCM.0b013e3181eb3ccd; Lakhal K, 2012, CRIT CARE MED, V40, P1207, DOI 10.1097/CCM.0b013e31823dae42; Lee JE, 1998, SURGERY, V124, P1115, DOI 10.1067/msy.1998.92009; Leuven E, PSMATCH2 STATA MODUL; LOW LL, 1995, CHEST, V108, P216, DOI 10.1378/chest.108.1.216; Lucet JC, 2010, CRIT CARE MED, V38, P1030, DOI 10.1097/CCM.0b013e3181d4502e; Lumachi F, 2007, TUMORI, V93, P269; Lunt M, PBALCHK STATA MODULE; Maki DG, 2006, MAYO CLIN PROC, V81, P1159, DOI 10.4065/81.9.1159; Manios E, 2007, BLOOD PRESS MONIT, V12, P149, DOI 10.1097/MBP.0b013e3280b083e2; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marrie RA, 2009, J CLIN EPIDEMIOL, V62, P511, DOI 10.1016/j.jclinepi.2008.05.015; Mettes TG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003879.pub3; MUAKKASSA FF, 1990, J TRAUMA, V30, P1087, DOI 10.1097/00005373-199009000-00004; Nazeri A, 2011, ACTA CLIN BELG, V66, P223, DOI 10.2143/ACB.66.3.2062552; O'Horo JC, 2014, CRIT CARE MED, V42, P1334, DOI 10.1097/CCM.0000000000000166; Pedersen T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002013.pub2; Prasad V, 2013, JAMA-J AM MED ASSOC, V309, P241, DOI 10.1001/jama.2012.96867; Quayle FJ, 2007, SURGERY, V142, P497, DOI 10.1016/j.surg.2007.07.013; Richard C, 2003, JAMA-J AM MED ASSOC, V290, P2713, DOI 10.1001/jama.290.20.2713; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Schull MJ, 2000, ACAD EMERG MED, V7, P647, DOI 10.1111/j.1553-2712.2000.tb02038.x; SHINOZAKI T, 1983, JAMA-J AM MED ASSOC, V249, P223, DOI 10.1001/jama.249.2.223; Smith JA, 2005, J ECONOMETRICS, V125, P305, DOI 10.1016/j.jeconom.2004.04.011; Suissa S, 2007, PHARMACOEPIDEM DR S, V16, P241, DOI 10.1002/pds.1357; Sweet BV, 2011, J MANAGE CARE PHARM, V17, P40, DOI 10.18553/jmcp.2011.17.1.40; Thoemmes FJ, 2011, MULTIVAR BEHAV RES, V46, P514, DOI 10.1080/00273171.2011.569395; Traore O, 2005, CRIT CARE MED, V33, P1276, DOI 10.1097/01.CCM.0000166350.90812.D4; Valentine RJ, 2005, J AM COLL SURGEONS, V201, P18, DOI 10.1016/j.jamcollsurg.2005.01.011; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; Wiener RS, 2007, JAMA-J AM MED ASSOC, V298, P423, DOI 10.1001/jama.298.4.423; Zarychanski R, 2008, CRIT CARE MED, V36, P2973, DOI 10.1097/CCM.0b013e31818b8c6b; Zhou Z, 2005, AM J EPIDEMIOL, V162, P1016, DOI 10.1093/aje/kwi307; Zimmerman JE, 1997, CRIT CARE MED, V25, P737, DOI 10.1097/00003246-199705000-00006; Zuur A, 2003, ZERO TRUNCATED ZERO, P261	69	34	34	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	NOV	2014	174	11					1746	1754		10.1001/jamainternmed.2014.3297			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AU9KA	WOS:000345909900011	25201069	Bronze			2022-02-06	
J	Wu, LC; Zarnescu, L; Nangia, V; Cam, B; Camarillo, DB				Wu, Lyndia C.; Zarnescu, Livia; Nangia, Vaibhav; Cam, Bruce; Camarillo, David B.			A Head Impact Detection System Using SVM Classification and Proximity Sensing in an Instrumented Mouthguard	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						Impact detection; infrared proximity sensing; support vector machines (SVMs); traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; BRAIN-INJURY; CONCUSSION; EXPOSURE; VALIDATION; KINEMATICS	Injury from blunt head impacts causes acute neurological deficits and may lead to chronic neurodegeneration. A head impact detection device can serve both as a research tool for studying head injury mechanisms and a clinical tool for real-time trauma screening. The simplest approach is an acceleration thresholding algorithm, which may falsely detect high-acceleration spurious events such as manual manipulation of the device. We designed a head impact detection system that distinguishes head impacts from nonimpacts through two subsystems. First, we use infrared proximity sensing to determine if the mouthguard is worn on the teeth to filter out all off-teeth events. Second, on-teeth, non-impact events are rejected using a support vector machine classifier trained on frequency domain features of linear acceleration and rotational velocity. The remaining events are classified as head impacts. In a controlled laboratory evaluation, the present system performed substantially better than a 10-g acceleration threshold in head impact detection (98% sensitivity, 99.99% specificity, 99% accuracy, and 99.98% precision, compared to 92% sensitivity, 58% specificity, 65% accuracy, and 37% precision). Once adapted for field deployment by training and validation with field data, this system has the potential to effectively detect head trauma in sports, military service, and other high-risk activities.	[Wu, Lyndia C.; Zarnescu, Livia; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Nangia, Vaibhav; Cam, Bruce] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA		Camarillo, DB (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	lyndiacw@stanford.edu; liviaz@stanford.edu; vnangia@stanford.edu; bcam@stanford.edu; dcamarillo@stanford.edu	Wu, Lyndia/AAQ-1106-2020	Wu, Lyndia/0000-0002-8236-032X	Stanford Department of Athletics	The authors would like to thank the Stanford Department of Athletics for their support in this research. A patent application has been filed for the technology described in this paper and will be assigned to Stanford University [49]. Royalties gained from any intellectual property granted for this work will be shared among the inventors, the department, and the school, according to Stanford's technology licensing policies.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Asada G., 1998, ESSCIRC '98. Proceedings of the 24th European Solid-State Circuits Conference, P9; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Benet G, 2002, ROBOT AUTON SYST, V40, P255, DOI 10.1016/S0921-8890(02)00271-3; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cam B., 2014, U.S. Patent, Patent No. [14/199 716, 14199716]; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fawcett T., 2004, MACH LEARN, V31, P1, DOI DOI 10.1016/J.PATREC.2005.10.010; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; FRIED D, 1995, APPL OPTICS, V34, P1278, DOI 10.1364/AO.34.001278; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; GEISSER S, 1975, J AM STAT ASSOC, V70, P320, DOI 10.2307/2285815; Greenwald R. M., 2005, U.S. Patent, Patent No. [11/031 970, 11031970]; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guyon I., 2003, Journal of Machine Learning Research, V3, P1157, DOI 10.1162/153244303322753616; Gwin J. T., 2009, J ASTM INT, V6, P1; Hinckley K., 2000, UIST. Proceedings of the 13th Annual ACM Symposium on User Interface Software and Technology, P91; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hummel JB, 2005, MED PHYS, V32, P2371, DOI 10.1118/1.1944327; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Joiner A, 2004, J DENT, V32, P3, DOI 10.1016/j.jdent.2003.10.013; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kim Y, 2009, IEEE T GEOSCI REMOTE, V47, P1328, DOI 10.1109/TGRS.2009.2012849; LANGER R, 1981, J BIOMED MATER RES, V15, P267, DOI 10.1002/jbm.820150212; Magne P, 2003, J PROSTHET DENT, V89, P453, DOI 10.1016/S0022-3913(03)00125-2; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Ravi N., 2005, P 17 C INN APPL ART, V3, P1541, DOI DOI 10.1007/978-3-642-02481-8_120; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schuldt C, 2004, INT C PATT RECOG, P32, DOI 10.1109/ICPR.2004.1334462; Wang SQ, 2005, PROCEEDINGS OF THE 2005 INTERNATIONAL CONFERENCE ON NEURAL NETWORKS AND BRAIN, VOLS 1-3, P1212; Westerman B, 2002, DENT TRAUMATOL, V18, P24, DOI 10.1034/j.1600-9657.2002.180103.x; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Xu QS, 2001, CHEMOMETR INTELL LAB, V56, P1, DOI 10.1016/S0169-7439(00)00122-2	47	34	34	0	25	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	NOV	2014	61	11					2659	2668		10.1109/TBME.2014.2320153			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	AS2AS	WOS:000344082000001	24800918				2022-02-06	
J	Brooks, BL; Khan, S; Daya, H; Mikrogianakis, A; Barlow, KM				Brooks, Brian L.; Khan, Samna; Daya, Hussain; Mikrogianakis, Angelo; Barlow, Karen M.			Neurocognition in the Emergency Department after a Mild Traumatic Brain Injury in Youth	JOURNAL OF NEUROTRAUMA			English	Article						acute; adolescents; children; concussion; neuropsychology	SPORT-RELATED CONCUSSION; STANDARDIZED ASSESSMENT; CHILDREN; ADOLESCENTS; RECOVERY	The early cognitive effects from a mild traumatic brain injury (mTBI) are poorly understood in youth. The aim of this study was to examine acute neurocognitive functioning in children and adolescents who presented to the emergency department (ED) after an mTBI. Youth 8-17 years of age with an mTBI (n = 77; mean age, 13.6 years; 95% confidence interval [CI], 13.0-14.2) and an orthopedic injury control (OIC) group (n = 28; mean age, 13.9 years; 95% CI, 13.1-14.7) underwent a very brief computerized neurocognitive assessment (four subtests from CNS Vital Signs) in a pediatric trauma hospital ED. The mTBI and OIC groups were not significantly different on age, gender, handedness, computer familiarity, race, median family income, pain rating scales, or time from injury to assessment. There were no significant differences between the mTBI and OIC groups for accuracy on immediate memory, delayed memory, and measures of attention and executive functioning. However, the mTBI group performed significantly worse than the OIC on nearly all measures of psychomotor speed and reaction time. Further, cognitive functioning appears to worsen as more time passes since the mTBI. Neurocognitive deficits are detectable in youth with an mTBI who present to the ED, despite having a Glasgow Coma Scale score of 15/15 and normal neuroimaging (or their presentation does not warrant neuroimaging). Their profile appears to include preserved accuracy on cognitive measures, but at the expense of slower psychomotor speed and longer reaction time.	[Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.; Mikrogianakis, Angelo] Univ Calgary, Dept Pediat, Fac Med, Calgary, AB T2N 1N4, Canada; [Brooks, Brian L.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Res Inst Child & Maternal Hlth, Calgary, AB T3B 6A8, Canada; [Khan, Samna] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Daya, Hussain] Univ Lethbridge, Dept Psychol, Lethbridge, AB T1K 3M4, Canada; [Mikrogianakis, Angelo] Alberta Childrens Prov Gen Hosp, Sect Emergency Med, Calgary, AB T3B 6A8, Canada; [Barlow, Karen M.] Univ Calgary, Fac Med, Calgary, AB, Canada		Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail Northwest, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Mikrogianakis, Angelo/AAW-5929-2021; Barlow, Karen/I-6492-2019; Meijer, Anna/K-5118-2016; Barlow, Karen/C-1323-2014	Mikrogianakis, Angelo/0000-0002-8854-0620; Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507	Pediatric Brain Injury Research Program; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); McCarthy Tetrault Award	Funding for this study was provided by the Pediatric Brain Injury Research Program (administered by the Alberta Children's Hospital Research Institute) awarded to Drs. Barlow and Brooks, a summer studentship from the Canadian Institutes of Health Research training program (administered by the Alberta Children's Hospital Research Institute) to Ms. Khan, and the McCarthy Tetrault Award (administered by the Alberta Children's Hospital Research Institute) awarded to Dr. Brooks. None of the funding sources were involved in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, and the preparation, review, or approval of the manuscript.	*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Andersson EE, 2012, DEV NEUROREHABIL, V15, P26, DOI 10.3109/17518423.2011.633570; [Anonymous], 2010, IBM SPSS STAT WIND V; Brooks BL, 2012, J CHILD NEUROL, V27, P982, DOI 10.1177/0883073811430863; Brooks BL, 2011, J CHILD NEUROL, V26, P786, DOI 10.1177/0883073810391532; Brooks BL, 2010, APPL NEUROPSYCHOL, V17, P37, DOI 10.1080/09084280903526083; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2011, NONF TRAUM BRAIN INJ; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Levine Z, 2010, CAN FAM PHYSICIAN, V56, P658; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Rieger BP, 2013, BRAIN INJURY, V27, P169, DOI 10.3109/02699052.2012.729290; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364	25	34	34	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2014	31	20					1744	1749		10.1089/neu.2014.3356			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	AP8BF	WOS:000342302200008	24849864				2022-02-06	
J	Kobelt, LJ; Wilkinson, AE; McCormick, AM; Willits, RK; Leipzig, ND				Kobelt, Liza J.; Wilkinson, Ashley E.; McCormick, Aleesha M.; Willits, Rebecca Kuntz; Leipzig, Nic D.			Short Duration Electrical Stimulation to Enhance Neurite Outgrowth and Maturation of Adult Neural Stem Progenitor Cells	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Neural stem progenitor cells; Electrical stimulation; Direct current; Neural differentiation; Neurons; Axons; Neurites; Calcium	GROWTH CONE; NERVOUS-SYSTEM; CALCIUM; FIELDS; GRADIENTS; NEURONS; VOLTAGE; DIFFERENTIATION; GALVANOTAXIS; MECHANISMS	New therapies are desperately needed for human central nervous system (CNS) regeneration to circumvent the lack of innate regenerative ability following traumatic injuries. Previously attempted therapies have been stymied by barriers to CNS regeneration largely because of protective mechanisms such as the blood brain barrier, inhibitory molecules, and glial scar formation. The application of electric stimulation (ES) has shown promise for enhancing peripheral nervous system regeneration, but is in its infancy in CNS regeneration. The objective of this study is to better understand how short duration ES can be harnessed to direct adult neural stem progenitor cell (NSPC) neurogenesis, neurite extension, and maturation. Herein, NSPCs were exposed to physiological levels of electrical stimulation of 0.53 or 1.83 V/m (applied power supply setting of 1.2 and 2.5 V) of direct current (DC) for 10 min/days for 2 days with a total differentiation time of 3 days. Culturing conditions consisted of either mitogenic growth factors or the neuronal differentiation factor interferon-gamma (IFN-gamma). Stimulated NSPCs showed lengths that were over five times longer than unstimulated controls (112.0 +/- A 88.8 mu m at 0.53 V/m vs. 21.3 +/- A 8.5 mu m for 0 V/m with IFN-gamma) with the longest neurites reaching up to 600 A mu m. Additionally, ES resulted in mature neuronal morphologies and signs of differentiation through positive beta III tubulin, neuronal nuclei (NeuN), and better organized filamentous-actin (f-actin) staining with growth cone formation. Additionally, the neurites and soma of stimulated NSPCs showed increases in intracellular Ca2+ during stimulation, signifying the presence of functional neurons capable of electrical conductance and communication with other cells. Our study demonstrates that short stimulation times (10 min/ day) result in significant neurite extension of stem cells in a quick time frame (3 days). This ES modality is potentially advantageous for promoting axon re-growth at an injury site using delivered adult stem cells; however, significant work still remains to understand both the delivery approach of cells as well as ES application in vivo.	[Kobelt, Liza J.; Wilkinson, Ashley E.; McCormick, Aleesha M.; Leipzig, Nic D.] Univ Akron, Dept Chem & Biomol Engn, Akron, OH 44325 USA; [Willits, Rebecca Kuntz; Leipzig, Nic D.] Univ Akron, Dept Biomed Engn, Akron, OH 44325 USA		Leipzig, ND (corresponding author), Univ Akron, Dept Chem & Biomol Engn, 200 East Buchtel Common,Whitby Hall 211, Akron, OH 44325 USA.	nl21@uakron.edu	Leipzig, Nic D/AAM-6654-2021; Willits, Rebecca/B-5017-2010	Leipzig, Nic D/0000-0002-6356-7691; Willits, Rebecca/0000-0002-1866-6789; Severs, Liza/0000-0002-9470-8186	University of Akron	We would like to thank The University of Akron for the funding that supported this work.	ANGLISTER L, 1982, DEV BIOL, V94, P351, DOI 10.1016/0012-1606(82)90353-0; Ariza CA, 2010, STEM CELL REV REP, V6, P585, DOI 10.1007/s12015-010-9171-0; Babona-Pilipos R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023808; BOLSOVER SR, 1986, J NEUROSCI, V6, P1934; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; Chang KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018738; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CORK RJ, 1994, J NEUROBIOL, V25, P1509, DOI 10.1002/neu.480251204; Craig CG, 1996, J NEUROSCI, V16, P2649; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Felaco M, 1999, MOL CELL BIOCHEM, V201, P49, DOI 10.1023/A:1007004316433; Feng JF, 2012, STEM CELLS, V30, P349, DOI 10.1002/stem.779; Fitch M., 1999, J NEUROSCI, V19; FREEMAN JA, 1985, J NEUROSCI RES, V13, P257, DOI 10.1002/jnr.490130118; Frohlich F, 2010, NEURON, V67, P129, DOI 10.1016/j.neuron.2010.06.005; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Haugland R. P., HDB GUIDE FLUORESCEN, P1126; HOTARY KB, 1990, DEV BIOL, V140, P149, DOI 10.1016/0012-1606(90)90062-N; JIMBO Y, 1993, IEEE T BIO-MED ENG, V40, P804, DOI 10.1109/10.238465; KATER SB, 1991, J NEUROSCI, V11, P891; Koppes AN, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046023; Kuhn HG, 1997, J NEUROSCI, V17, P5820; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; Leipzig ND, 2011, BIOMATERIALS, V32, P57, DOI 10.1016/j.biomaterials.2010.09.031; Leipzig ND, 2010, J BIOMED MATER RES A, V93A, P625, DOI 10.1002/jbm.a.32573; Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048824; Li Li, 2011, Front Med, V5, P40, DOI 10.1007/s11684-011-0108-z; Li XF, 2002, J VASC RES, V39, P391, DOI 10.1159/000064517; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Matos MA, 2010, BIOTECHNOL PROGR, V26, P664, DOI 10.1002/btpr.389; MCCAIG CD, 1991, EXP PHYSIOL, V76, P473, DOI 10.1113/expphysiol.1991.sp003514; McCaig CD, 2009, J CELL SCI, V122, P4267, DOI 10.1242/jcs.023564; Mycielska ME, 2004, J CELL SCI, V117, P1631, DOI 10.1242/jcs.01125; National Spinal Cord Injury Statistical Center, 2013, FACTS FIG GLANC; PATEL N, 1982, J NEUROSCI, V2, P483; Pullar CE, 2011, BIOL EFF ELECTROMAGN, P1; RAPP B, 1988, EUR BIOPHYS J BIOPHY, V16, P313, DOI 10.1007/BF00254068; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; Rollwitz J, 2004, BBA-GEN SUBJECTS, V1674, P231, DOI 10.1016/j.bbagen.2004.06.024; Schmidt CE, 1997, P NATL ACAD SCI USA, V94, P8948, DOI 10.1073/pnas.94.17.8948; Sheridan DM, 1996, J INVEST DERMATOL, V106, P642, DOI 10.1111/1523-1747.ep12345456; SHI RY, 1995, DEV DYNAM, V202, P101, DOI 10.1002/aja.1002020202; SISKEN BF, 1989, BRAIN RES, V485, P309, DOI 10.1016/0006-8993(89)90575-1; Wan LD, 2010, NEURAL REGEN RES, V5, P1256, DOI 10.3969/j.issn.1673-5374.2010.16.010; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621; Wilkinson A. E., 2011, SYNTH LECT TISSUE EN, V8, P1; Wood M, 2006, BIOELECTROMAGNETICS, V27, P328, DOI 10.1002/bem.20214; Yang G, 2008, INT CONF BIOMED, P548, DOI 10.1109/BMEI.2008.130; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zahir T, 2008, CELL TRANSPLANT, V17, P245, DOI 10.3727/096368908784153887; Zhao M, 2004, J CELL SCI, V117, P397, DOI 10.1242/jcs.00868	52	34	35	0	36	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2014	42	10					2164	2176		10.1007/s10439-014-1058-9			13	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	AP2NF	WOS:000341908500015	24957636				2022-02-06	
J	Stocker, RPJ; Cieply, MA; Paul, B; Khan, H; Henry, L; Kontos, AP; Germain, A				Stocker, Ryan P. J.; Cieply, Marissa A.; Paul, Benjamin; Khan, Hassen; Henry, Luke; Kontos, Anthony P.; Germain, Anne			Combat-related blast exposure and traumatic brain injury influence brain glucose metabolism during REM sleep in military veterans	NEUROIMAGE			English	Article						Blast exposure; mTBI; Military veterans; Cerebral glucose metabolism; Rapid eye movement sleep	POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; WHITE-MATTER INTEGRITY; EYE-MOVEMENT SLEEP; FDG-PET; ANXIETY DISORDERS; SPORTS CONCUSSION; FEAR EXTINCTION; AXONAL INJURY; LIVING BRAIN	Traumatic brain injury (TBI), a signature wound of Operations Enduring and Iraqi Freedom, can result from blunt head trauma or exposure to a blast/explosion. While TBI affects sleep, the neurobiological underpinnings between TBI and sleep are largely unknown. To examine the neurobiological underpinnings of this relationship in military veterans, 118 H-fluorodeoxyglucose positron emission tomography (FDG PET) was used to compare mTBI-related changes in relative cerebral metabolic rate of glucose (rCMRglc) during wakefulness, Rapid Eye Movement (REM) sleep, and non-REM (NREM) sleep, after adjusting for the effects of posttraumatic stress (PTS). Fourteen veterans with a history of blast exposure and/or mTBI (B/mTBI) (age 27.5 +/- 3.9) and eleven veterans with no history (No B/mTBI) (age 28.1 +/- 4.3) completed FDG PET studies during wakefulness, REM sleep, and NREM sleep. Whole-brain analyses were conducted using Statistical Parametric Mapping (SPM8). Between group comparisons revealed that B/mTBI was associated with significantly lower rCMRglc during wakefulness and REM sleep in the amygdala, hippocampus, parahippocampal gyrus, thalamus, insula, uncus, culmen, visual association cortices, and midline medial frontal cortices. These results suggest that alterations in neurobiological networks during wakefulness and REM sleep subsequent to B/mTBI exposure may contribute to chronic sleep disturbances and differ in individuals with acute symptoms. (C) 2014 Elsevier Inc. All rights reserved.	[Stocker, Ryan P. J.; Cieply, Marissa A.; Khan, Hassen] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Stocker, Ryan P. J.] Chatham Univ, Dept Counseling Psychol, Pittsburgh, PA 15213 USA; [Paul, Benjamin] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15213 USA; [Henry, Luke; Kontos, Anthony P.] Dept Orthopaed Surg, Pittsburgh, PA USA; [Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA		Germain, A (corresponding author), Univ Pittsburgh, Sch Med, Mil Sleep Tact & Resilience Res Team, Sterling Plaza 240, Pittsburgh, PA 15213 USA.	germax@upmc.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH083035]; Department of DefenseUnited States Department of Defense; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH083035] Funding Source: NIH RePORTER	Participants data were collected from grants funded by the National Institute of Mental Health (MH083035) and the Department of Defense that were reviewed and approved by the Institutional Review Board at the University of Pittsburgh and Human Research Protection Office of the Department of Defense (ClinicalTrials.gov # NCT01637584 and # NCT00871650).	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bishop SJ, 2007, TRENDS COGN SCI, V11, P307, DOI 10.1016/j.tics.2007.05.008; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Davis M, 2010, NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Drzezga A, 2003, EUR J NUCL MED MOL I, V30, P1104, DOI 10.1007/s00259-003-1194-1; Edison P, 2013, NEUROPSYCHOPHARMACOL, V38, P938, DOI 10.1038/npp.2012.255; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; First M.B., 1996, STRUCTURED CLIN INTE; French L., 2008, J SPECIAL OPERATIONS, V8, P68; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Friston KJ, 1999, NEUROIMAGE, V10, P385, DOI 10.1006/nimg.1999.0484; Germain A, 2004, PSYCHIAT RES-NEUROIM, V130, P259, DOI 10.1016/j.pscychresns.2003.12.003; Germain A, 2004, AM J PSYCHIAT, V161, P1856, DOI 10.1176/appi.ajp.161.10.1856; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Germain A, 2013, PSYCHIAT RES-NEUROIM, V211, P176, DOI 10.1016/j.pscychresns.2012.05.007; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; MESULAM MM, 1992, J COMP NEUROL, V318, P316, DOI 10.1002/cne.903180308; Milad MR, 2006, BIOL PSYCHOL, V73, P61, DOI 10.1016/j.biopsycho.2006.01.008; Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mosconi L, 2004, NEUROLOGY, V63, P2332, DOI 10.1212/01.WNL.0000147469.18313.3B; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Nofzinger EA, 1997, BRAIN RES, V770, P192, DOI 10.1016/S0006-8993(97)00807-X; Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126; Nofzinger EA, 2002, BRAIN, V125, P1105, DOI 10.1093/brain/awf103; Nofzinger EA, 1998, BRAIN RES PROTOC, V2, P191, DOI 10.1016/S1385-299X(97)00042-1; Nofzinger EA, 2006, J CLIN SLEEP MED, V2, P316; O'Donovan A, 2013, NEUROSCI BIOBEHAV R, V37, P96, DOI 10.1016/j.neubiorev.2012.10.013; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rauch SL, 2003, ANN NY ACAD SCI, V985, P389; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Stein DJ, 2011, NEUROSCI BIOBEHAV R, V35, P1075, DOI 10.1016/j.neubiorev.2010.11.012; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T. L., 2008, INVISIBLE WOUNDS WAR, V720; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tsukada H, 2001, SYNAPSE, V42, P242, DOI 10.1002/syn.10011; Viola-Saltzman M, 2012, NEUROL CLIN, V30, P1299, DOI 10.1016/j.ncl.2012.08.008; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	78	34	34	1	43	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 1	2014	99						207	214		10.1016/j.neuroimage.2014.05.067			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AM4XR	WOS:000339860000022	24893322	Green Accepted			2022-02-06	
J	Viscomi, MT; Molinari, M				Viscomi, Maria Teresa; Molinari, Marco			Remote Neurodegeneration: Multiple Actors for One Play	MOLECULAR NEUROBIOLOGY			English	Article						Remote damage; Inflammation; Apoptosis; Nitrergic system; Endocannabinoid system	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; AXOTOMIZED RUBROSPINAL NEURONS; LATERAL GENICULATE-NUCLEUS; CENTRAL-NERVOUS-SYSTEM; INFERIOR OLIVARY NEURONS; MESSENGER-RNA EXPRESSION; RETROGRADE TRANSSYNAPTIC DEGENERATION; CELL-DEATH; NITRIC-OXIDE	Remote neurodegeneration significantly influences the clinical outcome in many central nervous system (CNS) pathologies, such as stroke, multiple sclerosis, and traumatic brain and spinal cord injuries. Because these processes develop days or months after injury, they are accompanied by a therapeutic window of opportunity. The complexity and clinical significance of remote damage is prompting many groups to examine the factors of remote degeneration. This research is providing insights into key unanswered questions, opening new avenues for innovative neuroprotective therapies. In this review, we evaluate data from various remote degeneration models to describe the complexity of the systems that are involved and the importance of their interactions in reducing damage and promoting recovery after brain lesions. Specifically, we recapitulate the current data on remote neuronal degeneration, focusing on molecular and cellular events, as studied in stroke and brain and spinal cord injury models. Remote damage is a multifactorial phenomenon in which many components become active in specific time frames. Days, weeks, or months after injury onset, the interplay between key effectors differentially affects neuronal survival and functional outcomes. In particular, we discuss apoptosis, inflammation, oxidative damage, and autophagy-all of which mediate remote degeneration at specific times. We also review current findings on the pharmacological manipulation of remote degeneration mechanisms in reducing damage and sustaining outcomes. These novel treatments differ from those that have been proposed to limit primary lesion site damage, representing new perspectives on neuroprotection.	[Viscomi, Maria Teresa; Molinari, Marco] Santa Lucia Fdn IRCCS, Expt Neurorehabil Lab, I-00143 Rome, Italy		Viscomi, MT (corresponding author), Santa Lucia Fdn IRCCS, Expt Neurorehabil Lab, Via Fosso di Fiorano 65, I-00143 Rome, Italy.	mt.viscomi@hsantalucia.it; m.molinari@hsantalucia.it	Molinari, Marco/A-9624-2010; Viscomi, Maria Teresa/AAL-6625-2021; Viscomi, Maria Teresa/AAB-9412-2022; Viscomi, Maria Teresa/G-4173-2011	Molinari, Marco/0000-0001-9808-9688; Viscomi, Maria Teresa/0000-0002-9096-4967; Viscomi, Maria Teresa/0000-0002-9096-4967	Italian Ministry of Health (Ricerca Corrente)Ministry of Health, Italy; Wings for Life Spinal Cord Research Foundation; International Foundation for Research in Paraplegia (IFP); Italian Ministry of HealthMinistry of Health, Italy [GR10.184]	This work was supported by the Italian Ministry of Health (Ricerca Corrente - MM), by the Wings for Life Spinal Cord Research Foundation (M. T. V.), by the International Foundation for Research in Paraplegia (IFP) (M. T. V.), and by the program Young Researchers of Italian Ministry of Health (GR10.184; M. T. V.). We thank Prof. G. Bernardi for his continuous support and encouragement. The professional editorial work of Blue Pencil Science is also acknowledged.	Abe N, 2008, CURR OPIN NEUROBIOL, V18, P276, DOI 10.1016/j.conb.2008.06.005; Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 1998, AM J PATHOL, V153, P447, DOI 10.1016/S0002-9440(10)65588-5; Al-Abdulla NA, 2002, NEUROSCIENCE, V115, P7, DOI 10.1016/S0306-4522(02)00363-9; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Arevalo-Martin A, 2010, NEUROBIOL DIS, V38, P304, DOI 10.1016/j.nbd.2010.02.002; Bahr BA, 2006, EXPERT OPIN INV DRUG, V15, P351, DOI 10.1517/13543784.15.4.351; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bari M, 2006, MINI-REV MED CHEM, V6, P257, DOI 10.2174/138955706776073466; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; BARRIONUEVO G, 1978, ELECTROEN CLIN NEURO, V44, P232, DOI 10.1016/0013-4694(78)90269-9; Barron KD, 2004, J NEUROL SCI, V220, P119, DOI 10.1016/j.jns.2004.03.009; BARRON KD, 1967, J NEUROPATH EXP NEUR, V26, P300, DOI 10.1097/00005072-196704000-00007; Bartolomeo P, 2011, CORTEX, V47, P1010, DOI 10.1016/j.cortex.2010.11.007; Ben Taib Nordeyn Oulad, 2009, J Neurosurg, V111, P796, DOI 10.3171/2008.2.17679; Bermudez-Silva FJ, 2010, PHARMACOL BIOCHEM BE, V95, P375, DOI 10.1016/j.pbb.2010.03.012; Bezprozvanny I, 2009, TRENDS MOL MED, V15, P89, DOI 10.1016/j.molmed.2009.01.001; BIALOWAS J, 1984, J HIRNFORSCH, V25, P417; BIRBAMER G, 1992, AM J NEURORADIOL, V13, P1501; Bisicchia E, 2013, CELL MOL LIFE SCI, V70, P2191, DOI 10.1007/s00018-012-1253-5; Block F, 2005, PROG NEUROBIOL, V75, P342, DOI 10.1016/j.pneurobio.2005.03.004; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068; Braeuninger Stefan, 2009, Exp Transl Stroke Med, V1, P8, DOI 10.1186/2040-7378-1-8; Bregman BS, 1998, EXP NEUROL, V149, P13, DOI 10.1006/exnr.1997.6669; Briggs F, 2008, CURR OPIN NEUROBIOL, V18, P403, DOI 10.1016/j.conb.2008.09.002; BROWN LT, 1974, J COMP NEUROL, V154, P169, DOI 10.1002/cne.901540205; Buffo A, 2003, EUR J NEUROSCI, V18, P2146, DOI 10.1046/j.1460-9568.2003.02940.x; Buffo A, 1998, NEUROSCIENCE, V85, P587, DOI 10.1016/S0306-4522(98)00049-9; Buffon F, 2005, J CEREBR BLOOD F MET, V25, P641, DOI 10.1038/sj.jcbfm.9600054; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Burnstock G, 2013, ADV EXP MED BIOL, V986, P1, DOI 10.1007/978-94-007-4719-7_1; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Calabrese V, 2009, ANTIOXID REDOX SIGN, V11, P2717, DOI [10.1089/ars.2009.2721, 10.1089/ARS.2009.2721]; Carter AR, 2012, NEUROREHAB NEURAL RE, V26, P7, DOI 10.1177/1545968311411054; CASTRO AJ, 1978, J COMP NEUROL, V178, P611, DOI 10.1002/cne.901780402; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Chen HJ, 2012, REV NEUROSCIENCE, V23, P279, DOI 10.1515/revneuro-2012-0001; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; CHEN S, 1994, EXP NEUROL, V126, P270, DOI 10.1006/exnr.1994.1064; Chen XH, 2011, J NEUROIMMUNOL, V235, P1, DOI 10.1016/j.jneuroim.2011.04.006; Chen X, 2011, BRAIN RES, V1382, P298, DOI 10.1016/j.brainres.2011.01.045; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Cho DC, 2011, J KOREAN NEUROSURG S, V49, P83, DOI 10.3340/jkns.2011.49.2.83; Cho Y, 2013, CELL, V155, P894, DOI 10.1016/j.cell.2013.10.004; Chrousos George P, 2005, Sci STKE, V2005, ppe48, DOI 10.1126/stke.3042005pe48; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Di Marzo V, 2008, REV PHYSIOL BIOCH P, V160, P1, DOI 10.1007/112_0505; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Dihne M, 2002, STROKE, V33, P3006, DOI 10.1161/01.STR.0000039406.64644.CB; Dihne M, 2001, BRAIN RES, V889, P165, DOI 10.1016/S0006-8993(00)03129-2; El Manira A, 2010, PHYSIOLOGY, V25, P230, DOI 10.1152/physiol.00007.2010; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Esiri MM, 2007, J NEUROIMMUNOL, V184, P4, DOI 10.1016/j.jneuroim.2006.11.013; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; FERINGA ER, 1988, EXP NEUROL, V100, P112, DOI 10.1016/0014-4886(88)90205-1; Fernandez-Ruiz J, 2008, MOL CELL ENDOCRINOL, V286, pS91, DOI 10.1016/j.mce.2008.01.001; Fernandez-Ruiz J, 2010, EXPERT OPIN THER TAR, V14, P387, DOI 10.1517/14728221003709792; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z; Fitzek C, 2004, EUR J RADIOL, V49, P198, DOI 10.1016/S0720-048X(03)00132-3; Florenzano F, 2008, PROG NEUROBIOL, V84, P40, DOI 10.1016/j.pneurobio.2007.10.004; Florenzano F, 2002, NEUROSCIENCE, V115, P425, DOI 10.1016/S0306-4522(02)00397-4; FRY FJ, 1972, J COMP NEUROL, V144, P1, DOI 10.1002/cne.901440102; Fukuoka T, 1997, BRAIN RES, V767, P250, DOI 10.1016/S0006-8993(97)00715-4; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Galve-Roperh I, 2008, CURR PHARM DESIGN, V14, P2279, DOI 10.2174/138161208785740117; Garcia-Ovejero D, 2009, NEUROBIOL DIS, V33, P57, DOI 10.1016/j.nbd.2008.09.015; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gomes JA, 2005, CRIT CARE MED, V33, P1214, DOI 10.1097/01.CCM.0000166389.85273.38; Gonzalez C, 2011, DIABETES-METAB RES, V27, P331, DOI 10.1002/dmrr.1176; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; GOTO N, 1981, ACTA NEUROPATHOL, V54, P275, DOI 10.1007/BF00697000; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Han S, 2013, J MED CHEM, V56, P8224, DOI 10.1021/jm4005626; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hendrickson ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046918; Herve D, 2005, J NEUROL NEUROSUR PS, V76, P200, DOI 10.1136/jnnp.2004.041012; Hohlfeld R, 2007, NEUROLOGY, V68, pS58, DOI 10.1212/01.wnl.0000275234.43506.9b; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Ibanez CF, 2007, TRENDS CELL BIOL, V17, P519, DOI 10.1016/j.tcb.2007.09.003; Inoue Y, 2010, SEMIN CELL DEV BIOL, V21, P664, DOI 10.1016/j.semcdb.2010.03.009; Jindahra P, 2012, BRAIN, V135, P534, DOI 10.1093/brain/awr324; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kanno H, 2009, AUTOPHAGY, V5, P390, DOI 10.4161/auto.5.3.7724; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Khaing ZZ, 2012, J NEUROTRAUM, V29, P488, DOI 10.1089/neu.2011.2106; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kino T, 2009, CELL MOL LIFE SCI, V66, P3435, DOI 10.1007/s00018-009-0098-z; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Kojika S, 1996, LEUKEMIA, V10, P994; Kolodziejak A, 2000, J PHYSIOL PHARMACOL, V51, P41; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kwon BK, 2004, EXP NEUROL, V189, P45, DOI 10.1016/j.expneurol.2004.05.034; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Lam TI, 2013, NEUROREHAB NEURAL RE, V27, P889, DOI 10.1177/1545968313491003; Lee HC, 2007, SURG NEUROL, V68, pS37, DOI 10.1016/j.surneu.2007.06.085; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; LIEBERMAN AR, 1974, J ANAT, V118, P384; Lingor P, 2012, CELL TISSUE RES, V349, P289, DOI 10.1007/s00441-012-1362-3; LIPTON SA, 1994, PROG BRAIN RES, V103, P359; LITTLE JW, 1985, PARAPLEGIA, V23, P39, DOI 10.1038/sc.1985.7; Liu PH, 2003, EXP NEUROL, V179, P111, DOI 10.1006/exnr.2002.8057; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Maccarrone M, 2006, THROMB HAEMOSTASIS, V95, P117, DOI 10.1160/TH05-06-0413; Mandolesi G, 2005, CURR BIOL, V15, P2119, DOI 10.1016/j.cub.2005.10.045; Martin LJ, 2011, J NEUROSCI, V31, P359, DOI 10.1523/JNEUROSCI.2225-10.2011; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; MATTHEWS MA, 1973, J NEUROCYTOL, V2, P265, DOI 10.1007/BF01104030; Matysiak M, 2008, MULT SCLER J, V14, P919, DOI 10.1177/1352458508090666; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002; Missitzi J, 2011, J PHYSIOL-LONDON, V589, P297, DOI 10.1113/jphysiol.2010.200600; Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004; Molina-Holgado F, 2005, MOL CELL NEUROSCI, V28, P189, DOI 10.1016/j.mcn.2004.09.004; Molinari M, 2013, HDB CEREBELLUM CEREB, P1579; Mori F, 1997, EXP NEUROL, V143, P45, DOI 10.1006/exnr.1996.6318; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; Nakamura T, 2012, EXP NEUROL, V238, P12, DOI 10.1016/j.expneurol.2012.06.032; Nielson JL, 2011, J COMP NEUROL, V519, P2852, DOI 10.1002/cne.22661; Nielson JL, 2010, J NEUROSCI, V30, P11516, DOI 10.1523/JNEUROSCI.1433-10.2010; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Nordeyn OBT, 2005, J PHYSIOL-LONDON, V567, P293, DOI 10.1113/jphysiol.2005.088229; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Novikova LN, 2002, J COMP NEUROL, V452, P255, DOI 10.1002/cne.10381; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Oulad Ben Taib N, 2006, BRAIN RES, V1090, P110; Pacher P, 2005, NEUROPHARMACOLOGY, V48, P1130, DOI 10.1016/j.neuropharm.2004.12.005; Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pacher P, 2009, SEMIN IMMUNOPATHOL, V31, P63, DOI 10.1007/s00281-009-0145-8; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pearson-Fuhrhop KM, 2012, CURR OPIN NEUROL, V25, P682, DOI 10.1097/WCO.0b013e32835a360a; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Perry RB, 2012, NEURON, V75, P294, DOI 10.1016/j.neuron.2012.05.033; Perry RBT, 2009, SEMIN CELL DEV BIOL, V20, P600, DOI 10.1016/j.semcdb.2009.04.014; Pertwee RG, 2005, AAPS J, V7, pE625, DOI 10.1208/aapsj070364; Pertwee RG, 2005, HANDB EXP PHARMACOL, V168, P1; PINCHING AJ, 1971, J CELL SCI, V8, P253; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Puyal J, 2012, NEUROSCIENTIST, V18, P224, DOI 10.1177/1073858411404948; Raisman Geoffrey, 2012, Handb Clin Neurol, V109, P541, DOI 10.1016/B978-0-444-52137-8.00033-4; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rigaud M, 2009, ANESTHESIOLOGY, V111, P381, DOI 10.1097/ALN.0b013e3181ae6212; Rishal I, 2014, NAT REV NEUROSCI, V15, P32, DOI 10.1038/nrn3609; Rishal I, 2010, EXP NEUROL, V223, P5, DOI 10.1016/j.expneurol.2009.08.010; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; ROTH EJ, 1991, PARAPLEGIA, V29, P582, DOI 10.1038/sc.1991.86; Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865; RUIGROK TJH, 1990, EUR J MORPHOL, V28, P224; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Sagredo Onintza, 2012, Recent Pat CNS Drug Discov, V7, P41; SAKAI T, 1994, BRAIN DEV-JPN, V16, P229, DOI 10.1016/0387-7604(94)90075-2; Sanchez AJ, 2012, CLIN IMMUNOL, V142, P57, DOI 10.1016/j.clim.2011.02.010; Saxon DW, 1996, J COMP NEUROL, V371, P41; SAXON DW, 1994, NEUROREPORT, V5, P809, DOI 10.1097/00001756-199403000-00018; Sayer Faisal T, 2006, Spine J, V6, P335, DOI 10.1016/j.spinee.2005.11.001; Scotter EL, 2010, BRIT J PHARMACOL, V160, P480, DOI 10.1111/j.1476-5381.2010.00735.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Sharma Alok, 2012, J Assoc Physicians India, V60 Suppl, P13; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Soblosky JS, 2001, BEHAV BRAIN RES, V119, P1, DOI 10.1016/S0166-4328(00)00328-4; Sofroniew M V, 1988, J Chem Neuroanat, V1, P327; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Souza JM, 2008, FREE RADICAL BIO MED, V45, P357, DOI 10.1016/j.freeradbiomed.2008.04.010; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sung YJ, 2001, J NEUROBIOL, V47, P67, DOI 10.1002/neu.1016; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; Thippeswamy T, 2006, HISTOL HISTOPATHOL, V21, P445, DOI 10.14670/HH-21.445; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tohda C, 2011, PHARMACOL THERAPEUT, V132, P57, DOI 10.1016/j.pharmthera.2011.05.006; Tseng GF, 1996, BRAIN RES, V715, P32, DOI 10.1016/0006-8993(95)01418-7; Uchino A, 2006, EUR RADIOL, V16, P592, DOI 10.1007/s00330-005-0014-3; van der Stelt M, 2005, NEUROMOL MED, V7, P37, DOI 10.1385/NMM:7:1-2:037; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Velayudhan L, 2013, CURR PHARM DESIGN, V33, P755; Viscomi MT, 2008, CEREBELLUM, V7, P401, DOI 10.1007/s12311-008-0042-z; Viscomi MT, 2008, NEUROSCIENCE, V154, P1267, DOI 10.1016/j.neuroscience.2008.04.024; Viscomi MT, 2010, EXP NEUROL, V224, P56, DOI 10.1016/j.expneurol.2010.03.023; Viscomi MT, 2009, CEREBELLUM, V8, P184, DOI 10.1007/s12311-009-0107-7; Viscomi MT, 2012, MOL NEUROBIOL, V46, P513, DOI 10.1007/s12035-012-8296-3; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Viscomi MT, 2004, NEUROSCIENCE, V123, P393, DOI 10.1016/j.neuroscience.2003.09.030; Volonte C, 2003, CNS NEUROL DISORD-DR, V2, P403, DOI 10.2174/1568007033482643; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Wang MD, 2011, TISSUE ENG PART B-RE, V17, P177, DOI 10.1089/ten.teb.2010.0648; Wang YJ, 2002, J NEUROTRAUM, V19, P1487, DOI 10.1089/089771502320914714; Wannier-Morino P, 2008, BRAIN RES, V1217, P96, DOI 10.1016/j.brainres.2007.11.019; Weaver LC, 2005, J NEUROTRAUM, V22, P1375, DOI 10.1089/neu.2005.22.1375; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Xiao M, 2007, NEUROBIOL DIS, V26, P363, DOI 10.1016/j.nbd.2007.01.012; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Xing SH, 2012, AUTOPHAGY, V8, P63, DOI 10.4161/auto.8.1.18217; Xu M, 2005, BRAIN RES, V1055, P137, DOI 10.1016/j.brainres.2005.07.003; Xu M, 2000, EXP NEUROL, V161, P472, DOI 10.1006/exnr.1999.7278; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; Yamada K, 1998, AM J ROENTGENOL, V171, P813, DOI 10.2214/ajr.171.3.9725322; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhou LQ, 1999, NEUROREPORT, V10, P3417, DOI 10.1097/00001756-199911080-00029	241	34	37	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	OCT	2014	50	2					368	389		10.1007/s12035-013-8629-x			22	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AQ9GV	WOS:000343157900010	24442481				2022-02-06	
J	Sweeney, ZK; Fu, JP; Wiedmann, B				Sweeney, Zachary K.; Fu, Jiping; Wiedmann, Brigitte			From Chemical Tools to Clinical Medicines: Nonimmunosuppressive Cyclophilin Inhibitors Derived from the Cyclosporin and Sanglifehrin Scaffolds	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; HEPATITIS-C-VIRUS; MYOCARDIAL REPERFUSION INJURY; IMPROVED BINDING-AFFINITY; TRAUMATIC BRAIN-INJURY; REPLICATION IN-VITRO; X-RAY-STRUCTURE; IMMUNOSUPPRESSIVE ACTIVITY; CRYSTAL COMPLEX; N-METHYL-4-ISOLEUCINE CYCLOSPORINE	The cyclophilins are widely expressed enzymes that catalyze the interconversion of the cis and trans peptide bonds of prolines. The immunosuppressive natural products cyclosporine A and sanglifehrin A inhibit the enzymatic activity of the cyclophilins. Chemical modification of both the cyclosporine and sanglifehrin scaffolds has produced many analogues that inhibit cyclophilins in vitro but have reduced immunosuppressive properties. Three nonimmunosuppressive cyclophilin inhibitors (alisporivir, SCY-635, and NIM811) have demonstrated clinical efficacy for the treatment of hepatitis C infection. Additional candidates are in various stages of preclinical development for the treatment of hepatitis C or myocardial reperfusion injury. Recent publications suggest that cyclophilin inhibitors may have utility for the treatment of diverse viral infections, inflammatory indications, and cancer. In this review, we document the structureactivity relationships of the nonimmunosuppressive cyclosporins and sanglifehrins in clinical and preclinical development. Aspects of the pharmacokinetic behavior and chemical biology of these drug candidates are also described.	[Sweeney, Zachary K.; Fu, Jiping; Wiedmann, Brigitte] Novartis Inst BioMed Res, Emeryville, CA 94608 USA		Sweeney, ZK (corresponding author), Novartis Inst BioMed Res, 4560 Horton St, Emeryville, CA 94608 USA.	zachary.sweeney@novartis.com			NovartisNovartis	This work was funded by Novartis. We thank Heinz Moser, Javier De Vicente, James Sutton, and the reviewers for critical evaluations of the manuscript.	Aciro C., 2013, International Patent, Patent No. [WO 2013185090 A1 20131212, 2013185090]; Aciro C., 2013, [No title captured], Patent No. [WO2013185103A1, 2013185103]; Akhlaghi F, 2002, CLIN PHARMACOKINET, V41, P615, DOI 10.2165/00003088-200241090-00001; Alex A, 2011, MEDCHEMCOMM, V2, P669, DOI 10.1039/c1md00093d; Amundsen R, 2010, DRUG METAB DISPOS, V38, P1499, DOI 10.1124/dmd.110.032268; Appleby T., 2012, International Patent, Patent No. [WO 2012078915 A1 20120614, 2012078915]; AWNI WM, 1985, DRUG METAB DISPOS, V13, P127; Baugh J, 2012, BIOL CHEM, V393, P579, DOI 10.1515/hsz-2012-0151; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Bobardt M, 2013, J HEPATOL, V58, P16, DOI 10.1016/j.jhep.2012.08.007; Bockus AT, 2013, CURR TOP MED CHEM, V13, P821, DOI 10.2174/1568026611313070005; BOREL JF, 1989, PHARMACOL REV, V41, P239; Bua J, 2004, BIOORG MED CHEM LETT, V14, P4633, DOI 10.1016/j.bmcl.2004.07.003; Carling W. R., 2012, Patent No. [WO 2012/051193, 2012051193]; Chatterji U, 2005, J BIOL CHEM, V280, P40293, DOI 10.1074/jbc.M506314200; Choi JW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000750; Coelmont L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013687; COLOMBANI PM, 1985, SCIENCE, V228, P337, DOI 10.1126/science.3885394; Davis TL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000439; EBERLE MK, 1995, J MED CHEM, V38, P1853, DOI 10.1021/jm00011a004; El-Sheikh AAK, 2013, TRANSL RES, V162, P398, DOI 10.1016/j.trsl.2013.08.003; Elrod JW, 2013, CIRC J, V77, P1111, DOI 10.1253/circj.CJ-13-0321; Evers M, 2003, BIOORG MED CHEM LETT, V13, P4415, DOI 10.1016/j.bmcl.2003.09.042; Fang F, 2010, J MOL ENDOCRINOL, V44, P319, DOI 10.1677/JME-09-0140; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Flisiak R, 2012, EXPERT OPIN INV DRUG, V21, P375, DOI 10.1517/13543784.2012.658641; Frausto SD, 2013, VIRUSES-BASEL, V5, P1684, DOI 10.3390/v5071684; Friedenberg WR, 2006, CANCER-AM CANCER SOC, V106, P830, DOI 10.1002/cncr.21666; Gaither LA, 2010, VIROLOGY, V397, P43, DOI 10.1016/j.virol.2009.10.043; Galat A, 2004, PROTEINS, V56, P808, DOI 10.1002/prot.20156; Galat A, 2010, CELL MOL LIFE SCI, V67, P3467, DOI 10.1007/s00018-010-0437-0; Gallay PA, 2013, DRUG DES DEV THER, V7, P105, DOI 10.2147/DDDT.S30946; Garcia-Rivera JA, 2012, ANTIMICROB AGENTS CH, V56, P5113, DOI 10.1128/AAC.00919-12; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Gill RS, 2012, SHOCK, V37, P341, DOI 10.1097/SHK.0b013e31824bc9ab; Goto K, 2006, BIOCHEM BIOPH RES CO, V343, P879, DOI 10.1016/j.bbrc.2006.03.059; Gregory MA, 2011, ANTIMICROB AGENTS CH, V55, P1975, DOI 10.1128/AAC.01627-10; Guichou J.-F., 2011, Patent, Patent No. [WO2011076784, 2011076784]; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; Hartel C, 2006, SCAND J IMMUNOL, V63, P26, DOI 10.1111/j.1365-3083.2006.01702.x; Hegmans A., 2012, Patent No. [WO2012-079172 A1, 2012079172, WO 2012079172A1]; Heine SJ, 2011, J INFLAMM RES, V4, P93, DOI 10.2147/JIR.S20733; Heusler K, 2001, SWISS MED WKLY, V131, P299; Hokari M, 2010, J PHARM PHARMACOL, V62, P485, DOI 10.1211/jpp.62.04.0011; Hopkins S, 2012, VIRUSES-BASEL, V4, P2558, DOI 10.3390/v4112558; Hopkins S, 2012, J HEPATOL, V57, P47, DOI 10.1016/j.jhep.2012.02.024; Hopkins S, 2010, ANTIMICROB AGENTS CH, V54, P660, DOI 10.1128/AAC.00660-09; Hubler F, 2000, TETRAHEDRON LETT, V41, P7193, DOI 10.1016/S0040-4039(00)01267-3; Immecke SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018406; Ito K, 2013, MOLECULES, V18, P3502, DOI 10.3390/molecules18033502; Jiang L., 2012, ANN M AM ASS STUD LI; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; Kallen J, 2005, J BIOL CHEM, V280, P21965, DOI 10.1074/jbc.M501623200; Karlgren M, 2012, PHARM RES-DORDR, V29, P411, DOI 10.1007/s11095-011-0564-9; Ko SY, 1997, HELV CHIM ACTA, V80, P695, DOI 10.1002/hlca.19970800307; Kobayashi M., 2006, [No title captured], Patent No. [2006/054801, 2006054801]; Kolitz JE, 2010, BLOOD, V116, P1413, DOI 10.1182/blood-2009-07-229492; Korde AS, 2007, J NEUROTRAUM, V24, P895, DOI 10.1089/neu.2006.0122; Kovacs S. J., 2012, DIG DIS WEEK; LAWEN A, 1991, J BIOL CHEM, V266, P15567; Lawitz E, 2011, ANTIVIR RES, V89, P238, DOI 10.1016/j.antiviral.2011.01.003; Lee J, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-97; Li K., 2011, [No title captured], Patent No. [WO2011-070364 A1, 2011070364]; Lin K, 2011, ANTIVIRAL DRUGS: FROM BASIC DISCOVERY THROUGH CLINICAL TRIALS, P317; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loor F, 2002, J MED CHEM, V45, P4598, DOI 10.1021/jm0109863; Malesevic M, 2013, J MED CHEM, V56, P7302, DOI 10.1021/jm4007577; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mikol V, 1998, J MOL BIOL, V283, P451, DOI 10.1006/jmbi.1998.2109; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; Moss S., 2012, Patent, Patent No. [WO2012/131371 (Al), 2012131371, 2012/131371]; Moss S.J., 2012, Int. Patent Appl., Patent No. [WO 2012/131377 A1, 2012131377]; Moss SJ, 2012, MEDCHEMCOMM, V3, P938, DOI 10.1039/c1md00227a; Neya M., 2007, New Cyclic Peptide Compounds, Patent No. [WO 2007/049803, 2007049803]; Nicolas V, 2010, PKUK 2010 BRIST UK; ODONOHUE MF, 1995, PROTEIN SCI, V4, P2191, DOI 10.1002/pro.5560041025; Ogimura E, 2011, BIOCHEM BIOPH RES CO, V416, P313, DOI 10.1016/j.bbrc.2011.11.032; Owens C. M., 2013, ANN M EUR ASS STUD L; Owens C. M., 2011, ANN M AASLD SAN FRAN; Paeshuyse J, 2006, HEPATOLOGY, V43, P761, DOI 10.1002/hep.21102; PAPAGEORGIOU C, 1994, J MED CHEM, V37, P3674, DOI 10.1021/jm00048a002; PAPAGEORGIOU C, 1994, BIOORG MED CHEM LETT, V4, P267, DOI 10.1016/S0960-894X(01)80127-X; Papageorgiou C, 1997, BIOORGAN MED CHEM, V5, P187, DOI 10.1016/S0968-0896(96)00204-0; Papageorgiou C, 1996, BIOORG MED CHEM LETT, V6, P23, DOI 10.1016/0960-894X(95)00553-6; Peel M, 2013, RSC DRUG DISCOV, V32, P384, DOI 10.1039/9781849737814-00384; Peel M, 2013, BIOORG MED CHEM LETT, V23, P4485, DOI 10.1016/j.bmcl.2013.05.101; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; Pushkarsky T, 2005, J BIOL CHEM, V280, P27866, DOI 10.1074/jbc.M503770200; Puyang XL, 2010, ANTIMICROB AGENTS CH, V54, P1981, DOI 10.1128/AAC.01236-09; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; RADEKE HH, 1992, INT J IMMUNOPHARMACO, V14, P595, DOI 10.1016/0192-0561(92)90120-A; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Rehman H, 2008, J PHARMACOL EXP THER, V327, P699, DOI 10.1124/jpet.108.143578; Rehman H, 2011, TRANSPLANTATION, V91, P406, DOI 10.1097/TP.0b013e318204bdb2; ROSEN MK, 1992, BIOORG MED CHEM LETT, V2, P747, DOI 10.1016/S0960-894X(00)80405-9; SAKAMOTO K, 1993, J ANTIBIOT, V46, P1788, DOI 10.7164/antibiotics.46.1788; Sanglier JJ, 1999, J ANTIBIOT, V52, P466, DOI 10.7164/antibiotics.52.466; Sawada M., 2012, ANN M AM ASS STUD LI; Schaerfer C, 2013, J MED CHEM, V56, P2016, DOI 10.1021/jm3016816; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Scribner A, 2010, BIOORG MED CHEM LETT, V20, P6542, DOI 10.1016/j.bmcl.2010.09.036; Sedrani R, 2003, J AM CHEM SOC, V125, P3849, DOI 10.1021/ja021327y; SEEBACH D, 1993, HELV CHIM ACTA, V76, P1564, DOI 10.1002/hlca.19930760415; SEEBACH D, 1991, HELV CHIM ACTA, V74, P197, DOI 10.1002/hlca.19910740121; Shitara Y, 2009, DRUG METAB DISPOS, V37, P1172, DOI 10.1124/dmd.108.025544; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Steadman V. A., 2013, International Patent, Patent No. [WO 2013185093 A1 20131212, 2013185093]; Stemmy EJ, 2011, AM J RESP CELL MOL, V45, P991, DOI 10.1165/rcmb.2011-0007OC; Su Z., 2012, [No title captured], Patent No. [WO2012-075494 A1, 2012075494]; Su Z., 2012, Patent No. [WO 2012/009715, 2012009715]; Su Z., 2013, Patent No. [WO 2013/028615, 2013028615]; Su Z., 2012, [No title captured], Patent No. [WO 2012021796 A2, 2012021796]; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Taylor P, 1997, PROG BIOPHYS MOL BIO, V67, P155, DOI 10.1016/S0079-6107(97)00014-X; TERAOKA S, 1988, TRANSPLANT P, V20, P868; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; TRABER R, 1987, HELV CHIM ACTA, V70, P13, DOI 10.1002/hlca.19870700103; Vuagniaux G., 2011, Use of Cyclo-undecadepsipeptide Compounds, Patent No. [WO 2011/141891, 2011141891]; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Wang H, 2011, J GASTROEN HEPATOL, V26, P558, DOI 10.1111/j.1440-1746.2010.06406.x; Wang WL, 2011, MED HYPOTHESES, V77, P734, DOI 10.1016/j.mehy.2011.07.026; Wenger R. M., 2000, Novel Cyclosporin with Improved Activity Profile, Patent No. [WO 00/01715, 0001715]; Wenger R.M., 2011, Cydoundecadepsipeptide Compounds and Use of Said Compounds as a Medicament, Patent No. [US 2011/212057, 2011212057]; WENGER RM, 1994, FEBS LETT, V340, P255, DOI 10.1016/0014-5793(94)80149-5; WENGER RM, 1984, HELV CHIM ACTA, V67, P502, DOI 10.1002/hlca.19840670220; WENGER RM, 1985, ANGEW CHEM INT EDIT, V24, P77, DOI 10.1002/anie.198500773; Wenger RM., 1986, PROGR CLIN BIOCH MED, V3, P157; Wissing ER, 2010, NEUROMUSCULAR DISORD, V20, P753, DOI 10.1016/j.nmd.2010.06.016; Wring S., 2010, EUR ASS STUD LIV M; Yamanaka T., 2008, New Cyclic Peptide Compounds, Patent No. [WO 2008/139986, 2008139986]; Yurchenko V, 2006, IMMUNOLOGY, V117, P301, DOI 10.1111/j.1365-2567.2005.02316.x; Yurchenko V, 2010, CLIN EXP IMMUNOL, V160, P305, DOI 10.1111/j.1365-2249.2010.04115.x; ZEDERLUTZ G, 1994, J CHROMATOGR B, V662, P301, DOI 10.1016/0378-4347(94)00211-8; Zeisel MB, 2013, J HEPATOL, V58, P375, DOI 10.1016/j.jhep.2012.09.022; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200; Zhong Z, 2007, AM J TRANSPLANT, V7, P1103, DOI 10.1111/j.1600-6143.2007.01770.x	141	34	35	0	23	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	SEP 11	2014	57	17					7145	7159		10.1021/jm500223x			15	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	AO8QN	WOS:000341619400001	24831536				2022-02-06	
J	Christen, T; Bouzat, P; Pannetier, N; Coquery, N; Moisan, A; Lemasson, B; Thomas, S; Grillon, E; Detante, O; Remy, C; Payen, JF; Barbier, EL				Christen, Thomas; Bouzat, Pierre; Pannetier, Nicolas; Coquery, Nicolas; Moisan, Anaick; Lemasson, Benjamin; Thomas, Sebastien; Grillon, Emmanuelle; Detante, Olivier; Remy, Chantal; Payen, Jean-Francois; Barbier, Emmanuel Luc			Tissue oxygen saturation mapping with magnetic resonance imaging	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain; MRI; oxygenation; stroke; trauma; tumor	CEREBRAL BLOOD-VOLUME; TRAUMATIC BRAIN-INJURY; EXTRACTION FRACTION; VESSEL SIZE; SUSCEPTIBILITY; HYPOXIA; MODEL; MRI; FERUMOXYTOL; PARAMETERS	A quantitative estimate of cerebral blood oxygen saturation is of critical importance in the investigation of cerebrovascular disease. While positron emission tomography can Map in viva the oxygen level in blood, it has limited availability and requires ionizing radiation. Magnetic resonance imaging (MRI) offers an alternative through the blood oxygen level-dependent contrast. Here, we describe an in vivo and non-invasive approach to map brain tissue oxygen saturation (StO(2)) with high spatial resolution. StO(2) obtained with MRI correlated well with results from blood gas analyses for various oxygen and hematocrit challenges. In a stroke model, the hypoxic areas delineated in vivo by MRI spatially matched those observed ex vivo by pimonidazole staining. In a model of diffuse traumatic brain injury, MRI was able to-detect even a reduction in StO(2) that was too small to be detected by histology. In a F98 glioma model, MRI was able to map oxygenation heterogeneity. Thus, the MRI technique may improve our understanding of the pathophysiology of several brain diseases involving impaired oxygenation.	[Christen, Thomas; Bouzat, Pierre; Pannetier, Nicolas; Coquery, Nicolas; Moisan, Anaick; Lemasson, Benjamin; Thomas, Sebastien; Detante, Olivier; Remy, Chantal; Payen, Jean-Francois; Barbier, Emmanuel Luc] INSERM, U836, Grenoble, France; [Christen, Thomas; Bouzat, Pierre; Pannetier, Nicolas; Coquery, Nicolas; Moisan, Anaick; Lemasson, Benjamin; Thomas, Sebastien; Detante, Olivier; Remy, Chantal; Payen, Jean-Francois; Barbier, Emmanuel Luc] Univ Grenoble Alpes, Grenoble Inst Neurosci, Grenoble, France; [Bouzat, Pierre; Thomas, Sebastien; Payen, Jean-Francois] CHU Grenoble, Pole Anesthesie Reanimat, F-38043 Grenoble, France; [Grillon, Emmanuelle] INSERM, US 017, Grenoble, France; [Grillon, Emmanuelle] Univ Grenoble Alpes, IRMaGe, Grenoble, France; [Grillon, Emmanuelle] CHU Grenoble, IRMaGe, F-38043 Grenoble, France; [Grillon, Emmanuelle] CNRS, UMS 3552, Grenoble, France; [Detante, Olivier] CHU Grenoble, Serv Neurol, F-38043 Grenoble, France		Barbier, EL (corresponding author), Grenoble Inst Neurosci, U836, Team 5, UJF Site Sante,BP 170, F-38042 Grenoble 9, France.	emmanuel.barbier@ujf-grenoble.fr	coquery, nicolas/N-9206-2019; christen, thomas/O-4482-2018; Bouzat, Pierre/L-6881-2014; Lemasson, Benjamin/AAC-4092-2019; Payen, Jean-Francois/L-6667-2014; Remy, Chantal/L-9459-2014; Moisan, Anaick/P-4838-2014; Detante, Olivier/M-1737-2014; Bouzat, Pierre/AAC-4105-2019; Lemasson, Benjamin/L-1608-2014; Barbier, Emmanuel/E-6302-2011	christen, thomas/0000-0002-8791-9145; Lemasson, Benjamin/0000-0003-0446-3531; Moisan, Anaick/0000-0002-6680-8593; Bouzat, Pierre/0000-0003-4667-6738; Lemasson, Benjamin/0000-0003-0446-3531; Barbier, Emmanuel/0000-0002-4952-1240; Pannetier, Nicolas/0000-0002-0744-5155	ANR Imoxy programFrench National Research Agency (ANR) [2011-BSV5-004]; Lyon Biopole; 'Fondation Gueules Cassees'; 'fondation ARC pour la recherche sur le cancer'	Financial support for this project was provided by ANR Imoxy program 2011-BSV5-004, Lyon Biopole, 'Fondation Gueules Cassees', and 'fondation ARC pour la recherche sur le cancer'.	An HY, 2009, STROKE, V40, P2165, DOI 10.1161/STROKEAHA.108.540864; An HY, 2002, MAGNET RESON MED, V47, P958, DOI 10.1002/mrm.10148; An HY, 2000, J CEREBR BLOOD F MET, V20, P1225, DOI 10.1097/00004647-200008000-00008; BANDETTINI PA, 1995, INT J IMAG SYST TECH, V6, P133, DOI 10.1002/ima.1850060203; Barcroft J, 1910, J PHYSIOL-LONDON, V39, P411; BENDA P, 1971, J NEUROSURG, V34, P310, DOI 10.3171/jns.1971.34.3.0310; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Bouzat P, 2013, CRIT CARE MED, V41, P1316, DOI 10.1097/CCM.0b013e31827ca64e; Brauer-Krisch E, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3170035; Christen T, 2013, MAGN RESON MED, V70, P705, DOI 10.1002/mrm.24500; Christen T, 2012, MAGN RESON MED, V67, P1458, DOI 10.1002/mrm.23094; Christen T, 2011, NMR BIOMED, V24, P393, DOI 10.1002/nbm.1603; Emblem KE, 2013, NAT MED, V19, P1178, DOI 10.1038/nm.3289; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; GROSS MW, 1995, INT J CANCER, V61, P567, DOI 10.1002/ijc.2910610422; GRUBB RL, 1973, ARCH NEUROL-CHICAGO, V28, P38, DOI 10.1001/archneur.1973.00490190056006; HALL FG, 1966, J APPL PHYSIOL, V21, P375, DOI 10.1152/jappl.1966.21.2.375; He X, 2008, MAGN RESON MED, V60, P882, DOI 10.1002/mrm.21719; He X, 2007, MAGN RESON MED, V57, P115, DOI 10.1002/mrm.21108; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heiss WD, 2010, INT J STROKE, V5, P290, DOI 10.1111/j.1747-4949.2010.00444.x; Jensen-Kondering U, 2012, STROKE, V43, P2264, DOI 10.1161/STROKEAHA.111.632455; Joyeux-Faure M, 2005, J APPL PHYSIOL, V98, P1691, DOI 10.1152/japplphysiol.01146.2004; Klassen LM, 2007, BIOPHYS J, V92, P1014, DOI 10.1529/biophysj.106.087965; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; Lee J, 2012, NEUROIMAGE, V59, P3967, DOI 10.1016/j.neuroimage.2011.10.076; Lemasson B, 2011, NMR BIOMED, V24, P473, DOI 10.1002/nbm.1611; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marques JP, 2005, CONCEPT MAGN RESON B, V25B, P65, DOI 10.1002/cmr.b.20034; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Pittman R. N, 2011, REGULATION TISSUE OX; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; Tropres I, 2001, MAGN RESON MED, V45, P397, DOI 10.1002/1522-2594(200103)45:3<397::AID-MRM1052>3.3.CO;2-V; Valable S, 2008, NMR BIOMED, V21, P1043, DOI 10.1002/nbm.1278; Varallyay CG, 2013, J CEREBR BLOOD F MET, V33, P780, DOI 10.1038/jcbfm.2013.36; Watzman HM, 2000, ANESTHESIOLOGY, V93, P947, DOI 10.1097/00000542-200010000-00012; Wintermark M, 2005, STROKE, V36, pE83, DOI 10.1161/01.STR.0000177884.72657.8b; Yablonskiy DA, 2013, NMR BIOMED, V26, P963, DOI 10.1002/nbm.2839	39	34	34	0	25	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2014	34	9					1550	1557		10.1038/jcbfm.2014.116			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AO4WT	WOS:000341342800016	25005878	Bronze, Green Published			2022-02-06	
J	Gullotti, DM; Beamer, M; Panzer, MB; Chen, YC; Patel, TP; Yu, A; Jaumard, N; Winkelstein, B; Bass, CR; Morrison, B; Meaney, DF				Gullotti, David M.; Beamer, Matthew; Panzer, Matthew B.; Chen, Yung Chia; Patel, Tapan P.; Yu, Allen; Jaumard, Nicolas; Winkelstein, Beth; Bass, Cameron R.; Morrison, Barclay; Meaney, David F.			Significant Head Accelerations Can Influence Immediate Neurological Impairments in a Murine Model of Blast-Induced Traumatic Brain Injury	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						blast; traumatic brain injury; biomechanics; acceleration; overpressure	INTRACRANIAL-PRESSURE RESPONSE; BEHAVIORAL DEFICITS; MOUSE MODEL; RAT; WAVE; OVERPRESSURE; RANGE	Although blast-induced traumatic brain injury (bTBI) is well recognized for its significance in the military population, the unique mechanisms of primary bTBI remain undefined. Animate models of primary bTBI are critical for determining these potentially unique mechanisms, but the biomechanical characteristics of many bTBI models are poorly understood. In this study, we examine some common shock tube configurations used to study blast-induced brain injury in the laboratory and define the optimal configuration to minimize the effect of torso overpressure and blast-induced head accelerations. Pressure transducers indicated that a customized animal holder successfully reduced peak torso overpressures to safe levels across all tested configurations. However, high speed video imaging acquired during the blast showed significant head accelerations occurred when animals were oriented perpendicular to the shock tube axis. These findings of complex head motions during blast are similar to previous reports [Goldstein et al., 2012, "Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model," Sci. Transl. Med., 4(134), 134ra160; Sundaramurthy et al., 2012, " Blast-Induced Biomechanical Loading of the Rat: An Experimental and Anatomically Accurate Computational Blast Injury Model," J. Neurotrauma, 29(13), pp. 2352-2364; Svetlov et al., 2010, "Morphologic and Biochemical Characterization of Brain Injury in a Model of Controlled Blast Overpressure Exposure," J. Trauma, 69(4), pp. 795-804]. Under the same blast input conditions, minimizing head acceleration led to a corresponding elimination of righting time deficits. However, we could still achieve righting time deficits under minimal acceleration conditions by significantly increasing the peak blast overpressure. Together, these data show the importance of characterizing the effect of blast overpressure on head kinematics, with the goal of producing models focused on understanding the effects of blast overpressure on the brain without the complicating factor of superimposed head accelerations.	[Gullotti, David M.; Beamer, Matthew; Chen, Yung Chia; Patel, Tapan P.; Jaumard, Nicolas; Winkelstein, Beth; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Panzer, Matthew B.; Yu, Allen; Bass, Cameron R.] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Winkelstein, Beth; Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Morrison, Barclay] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.		Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Patel, Tapan/0000-0001-8959-6645; Meaney, David/0000-0002-0954-4122	Department of the Army [W911F-10-1-0526]	Funding for this project was provided by the Department of the Army Grant No. W911F-10-1-0526. We would also like to thank Edward W. Vogel III, Christopher D. Hue, and Gwen B. Effgen from Columbia University for their input and help with high speed video acquisition. Finally, we would like to thank Anthony Choo, Rosalind Mott, and Tanya Merdiushev for their input to the project.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Arun P, 2012, NEUROREPORT, V23, P342, DOI 10.1097/WNR.0b013e328351b58d; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; FRIEDLANDER FG, 1946, PROC R SOC LON SER-A, V186, P322, DOI 10.1098/rspa.1946.0046; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Leonardi AD, 2013, ANN BIOMED ENG, V41, P2488, DOI 10.1007/s10439-013-0850-2; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Liu H, 2012, INT J MED SCI, V9, P655, DOI 10.7150/ijms.5004; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Orman JA, 2012, J TRAUMA ACUTE CARE, V73, pS496, DOI 10.1097/TA.0b013e318275473c; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Shah Ms Alok S, 2012, Biomed Sci Instrum, V48, P393; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taniellan T., 2008, MG720CCF; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Yu A. W., 2012, BIOM ENG SOC ANN M B; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	34	34	0	12	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	SEP	2014	136	9							091004	10.1115/1.4027873			11	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	AN5GC	WOS:000340617700004	24950710				2022-02-06	
J	Shein, SL; Shellington, DK; Exo, JL; Jackson, TC; Wisniewski, SR; Jackson, EK; Vagni, VA; Bayir, H; Clark, RSB; Dixon, CE; Janesko-Feldman, KL; Kochanek, PM				Shein, Steven L.; Shellington, David K.; Exo, Jennifer L.; Jackson, Travis C.; Wisniewski, Stephen R.; Jackson, Edwin K.; Vagni, Vincent A.; Bayir, Huelya; Clark, Robert S. B.; Dixon, C. Edward; Janesko-Feldman, Keri L.; Kochanek, Patrick M.			Hemorrhagic Shock Shifts the Serum Cytokine Profile from Pro- to Anti-Inflammatory after Experimental Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; chemokine; head injury; hypotension; interleukin; polytrauma; resuscitation	CLOSED-HEAD INJURY; MONOCYTE CHEMOATTRACTANT PROTEIN-1; GROWTH-FACTOR PRODUCTION; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; IN-SITU DETECTION; CEREBROSPINAL-FLUID; MODERATE HYPOTHERMIA; NEUROLOGICAL DEFICIT; MULTIPLEX ASSESSMENT	Secondary insults, such as hemorrhagic shock (HS), worsen outcome from traumatic brain injury (TBI). Both TBI and HS modulate levels of inflammatory mediators. We evaluated the addition of HS on the inflammatory response to TBI. Adult male C57BL6J mice were randomized into five groups (n = 4 [naive] or 8/group): naive; sham; TBI (through mild-to-moderate controlled cortical impact [CCI] at 5 m/sec, 1-mm depth), HS; and CCI + HS. All non-naive mice underwent identical monitoring and anesthesia. HS and CCI + HS underwent a 35-min period of pressure-controlled hemorrhage (target mean arterial pressure, 25-27 mm Hg) and a 90-min resuscitation with lactated Ringer's injection and autologous blood transfusion. Mice were sacrificed at 2 or 24 h after injury. Levels of 13 cytokines, six chemokines, and three growth factors were measured in serum and in five brain tissue regions. Serum levels of several proinflammatory mediators (eotaxin, interferon-inducible protein 10 [IP-10], keratinocyte chemoattractant [KC], monocyte chemoattractant protein 1 [MCP-1], macrophage inflammatory protein 1alpha [MIP-1 alpha], interleukin [IL]-5, IL-6, tumor necrosis factor alpha, and granulocyte colony-stimulating factor [G-CSF]) were increased after CCI alone. Serum levels of fewer proinflammatory mediators (IL-5, IL-6, regulated upon activation, normal T-cell expressed, and secreted, and G-CSF) were increased after CCI + HS. Serum level of anti-inflammatory IL-10 was significantly increased after CCI + HS versus CCI alone. Brain tissue levels of eotaxin, IP-10, KC, MCP-1, MIP-1a, IL-6, and G-CSF were increased after both CCI and CCI + HS. There were no significant differences between levels after CCI alone and CCI + HS in any mediator. Addition of HS to experimental TBI led to a shift toward an anti-inflammatory serum profile-specifically, a marked increase in IL-10 levels. The brain cytokine and chemokine profile after TBI was minimally affected by the addition of HS.	[Shein, Steven L.; Shellington, David K.; Exo, Jennifer L.; Jackson, Travis C.; Vagni, Vincent A.; Bayir, Huelya; Clark, Robert S. B.; Dixon, C. Edward; Janesko-Feldman, Keri L.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Shein, Steven L.; Shellington, David K.; Exo, Jennifer L.; Jackson, Travis C.; Bayir, Huelya; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Shellington, David K.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Exo, Jennifer L.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Shein, Steven/I-7763-2019; Kochanek, Patrick M/D-2371-2015	Shein, Steven/0000-0003-3382-5159; Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Wisniewski, Stephen/0000-0002-3877-9860	DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-10-C2124]; United States ArmyUnited States Department of Defense [W81XWH-09-2-0187]; U.S. ArmyUnited States Department of Defense [W81XWH-09-2-0187]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686];  [T32HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	Support: DARPA N66001-10-C2124 (PMK), the United States Army W81XWH-09-2-0187 (PMK), and T32HD040686 (SLS, JLE).; The authors thank DARPA (N66001-10-C2124; to P. M. K.) and the U.S. Army (W81XWH-09-2-0187; to P. M. K.), and the NICHD (T32 HD040686; to S. L. S.) for support. The views, opinions, and/or findings contained in this article/presentation are those of the authors/presenters and should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency or the Department of Defense. This article has been approved for public release (distribution unlimited).	Akkose S, 2007, ADV THER, V24, P955, DOI 10.1007/BF02877699; Alam HB, 2004, RESUSCITATION, V60, P91, DOI 10.1016/j.resuscitation.2003.08.006; Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Black KL, 2002, J HEAD TRAUMA REHAB, V17, P489, DOI 10.1097/00001199-200212000-00001; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clendenen Tess V, 2010, BMC Res Notes, V3, P302, DOI 10.1186/1756-0500-3-302; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Denker SP, 2007, J NEUROCHEM, V100, P893, DOI 10.1111/j.1471-4159.2006.04162.x; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hensler T, 2003, SHOCK, V20, P497, DOI 10.1097/01.shk.0000095058.62263.1f; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Park KW, 2007, EXP MOL MED, V39, P812, DOI 10.1038/emm.2007.88; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Watters JM, 2004, SHOCK, V22, P283, DOI 10.1097/01.shk.0000135288.54535.8a; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Widera D, 2004, EUR J CELL BIOL, V83, P381, DOI 10.1078/0171-9335-00403; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yokoyama Y, 2004, AM J PHYSIOL-GASTR L, V286, pG942, DOI 10.1152/ajpgi.00502.2003; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056	74	34	35	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2014	31	16					1386	1395		10.1089/neu.2013.2985			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AN4DB	WOS:000340536700002	24773520	Green Published			2022-02-06	
J	Zhang, Q; Zhou, C; Hamblin, MR; Wu, MX				Zhang, Qi; Zhou, Chang; Hamblin, Michael R.; Wu, Mei X.			Low-level laser therapy effectively prevents secondary brain injury induced by immediate early responsive gene X-1 deficiency	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						IEX-1; inadequate mitochondrial function; LLLT; mTBI	NECROSIS-FACTOR-ALPHA; F1FO-ATPASE INHIBITOR; IEX-1; NEUROINFLAMMATION; LIGHT; MICE; NEUROTOXICITY; EXPRESSION; PROTEIN; MUSCLE	A mild insult to the brain can sometimes trigger secondary brain injury, causing severe postconcussion syndrome, but the underlying mechanism is ill understood. We show here that secondary brain injury occurs consistently in mice lacking immediate early responsive gene X-1 (IEX-1), after a gentle impact to the head, which closely simulates mild traumatic brain injury in humans. The pathologic lesion was characterized by extensive cell death, widespread leukocyte infiltrates, and severe tissue loss. On the contrary, a similar insult did not induce any secondary injury in wild-type mice. Strikingly, noninvasive exposure of the injured head to a low-level laser at 4 hours after injury almost completely prevented the secondary brain injury in IEX-1 knockout mice. The low-level laser therapy (LLLT) suppressed proinflammatory cytokine expression like interleukin (IL)-1 beta and IL-6 but upregulated TNF-alpha. Moreover, although lack of IEX-1 compromised ATP synthesis, LLLT elevated its production in injured brain. The protective effect of LLLT may be ascribed to enhanced ATP production and selective modulation of proinflammatory mediators. This new closed head injury model provides an excellent tool to investigate the pathogenesis of secondary brain injury as well as the mechanism underlying the beneficial effect of LLLT.	[Zhang, Qi; Zhou, Chang; Hamblin, Michael R.; Wu, Mei X.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Zhang, Qi; Zhou, Chang; Hamblin, Michael R.; Wu, Mei X.] Harvard Med Sch, Dept Dermatol, Boston, MA 02114 USA; [Hamblin, Michael R.; Wu, Mei X.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Wu, MX (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	mwu2@partners.org	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605	Air Force Office of Scientific Research Militory Phtomedicine Program [FA9550-11-1-0331]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA158756, R01AI050875]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA158756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work is supported by Air Force Office of Scientific Research Militory Phtomedicine Program (FA9550-11-1-0331) and the National Institutes of Health Grants CA158756 to MW and National Institutes of Health Grants R01AI050875 to MR.	Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Arlt A, 2011, EUR J CELL BIOL, V90, P545, DOI 10.1016/j.ejcb.2010.10.002; Assis L, 2012, LASER SURG MED, V44, P726, DOI 10.1002/lsm.22077; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Campanella M, 2008, CELL METAB, V8, P13, DOI 10.1016/j.cmet.2008.06.001; Carvey PM, 2003, FRONT BIOSCI-LANDMRK, V8, pS826, DOI 10.2741/1158; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; FAN L, 1995, MOL BRAIN RES, V30, P125; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011-1344(89)80088-0; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lehoux S, 2003, CIRC RES, V93, P1139, DOI 10.1161/01.RES.0000108693.79326.A8; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shahid M, 2010, HYPERTENSION, V56, P705, DOI 10.1161/HYPERTENSIONAHA.110.154880; Shen L, 2009, CELL DEATH DIFFER, V16, P603, DOI 10.1038/cdd.2008.184; Shen L, 2006, J BIOL CHEM, V281, P15304, DOI 10.1074/jbc.M600054200; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sutherland JC, 2002, PHOTOCHEM PHOTOBIOL, V76, P164, DOI 10.1562/0031-8655(2002)076<0164:BEOPL>2.0.CO;2; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147	37	34	34	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2014	34	8					1391	1401		10.1038/jcbfm.2014.95			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AM4ZG	WOS:000339864100016	24849666	Green Published, Bronze			2022-02-06	
J	Chan, K; MacDermid, JC; Faber, KJ; King, GJW; Athwal, GS				Chan, Kevin; MacDermid, Joy C.; Faber, Kenneth J.; King, Graham J. W.; Athwal, George S.			Can We Treat Select Terrible Triad Injuries Nonoperatively?	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							CORONOID PROCESS; RADIAL HEAD; ELBOW; FRACTURES; DISLOCATIONS; INSTABILITY; RELIABILITY	While the majority of terrible triad elbow injuries (ulnohumeral dislocation with radial head and coronoid fractures) are managed surgically, nonoperative treatment may be appropriate in selected patients, but results with this approach have been limited by very small studies. We assessed (1) functional outcomes using two validated questionnaires, (2) elbow ROM, strength, and stability, (3) the presence of union and arthritis on radiographs, and (4) complications among a group of patients managed nonoperatively for terrible triad injuries. Between 2006 and 2012, we retrospectively identified 12 patients with terrible triad elbow injuries who were treated nonoperatively and met the following criteria: (1) a concentric joint reduction, (2) a radial head fracture that did not cause a mechanical block to rotation, (3) a smaller coronoid fracture (Regan-Morrey Type 1 or 2), and (4) a stable arc of motion to a minimum of 30A degrees of extension to allow active motion within the first 10 days. Eleven patients were available for followup of at least 12 months after the injury (mean, 36 months; range, 12-90 months). Outcome measures included two patient-reported functional outcome measures (DASH, Mayo Elbow Performance Index [MEPI]), a standardized physical examination to record elbow ROM and stability, isometric strength measurements, and radiographic evidence of bony union and elbow arthrosis. Complications were also recorded. At latest followup, mean +/- A SD DASH score was 8.0 +/- A 11.0 and mean MEPI score was 94 +/- A 9. Mean ROM of the affected elbow was 134A degrees A A +/- A 5A degrees flexion, 6A degrees A A +/- A 8A degrees extension, 87A degrees A A +/- A 4A degrees pronation, and 82A degrees A A +/- A 10A degrees supination. No instability was detected. Strength assessments demonstrated the following mean percentages of the contralateral, unaffected elbow: flexion 100%, extension 89%, pronation 79%, and supination 89%. Four patients had arthritic changes on radiographs that did not call for treatment as of latest followup. Complications included one patient who underwent surgical stabilization for early recurrent instability and another who underwent arthroscopic d,bridement for heterotopic bone. In selected patients, nonoperative treatment of terrible triad injuries is an option that can provide good function and restore stable elbow ROM. However, nonoperative management requires close clinical and radiographic followup to monitor for any delayed elbow subluxation or fracture displacement. Level IV, therapeutic study. See Instructions for Authors for a complete description of levels of evidence.	[Chan, Kevin] McMaster Univ, Div Orthopaed Surg, Hamilton, ON, Canada; [MacDermid, Joy C.] McMaster Univ, Fac Hlth Sci, Inst Appl Hlth Sci, Hamilton, ON, Canada; [MacDermid, Joy C.; Faber, Kenneth J.; King, Graham J. W.; Athwal, George S.] Univ Western Ontario, Hand & Upper Limb Ctr, London, ON N6A 4L6, Canada		Athwal, GS (corresponding author), Univ Western Ontario, Hand & Upper Limb Ctr, 268 Grosvenor St, London, ON N6A 4L6, Canada.	gathwal@uwo.ca	King, Graham JW/B-6177-2015; Athwal, George S/H-1762-2015; Faber, Kenneth J./H-9137-2017; MacDermid, Joy C/H-7837-2013	Faber, Kenneth J./0000-0003-1025-6600; MacDermid, Joy C/0000-0001-9311-7379			Armstrong AD, 1998, J SHOULDER ELB SURG, V7, P573, DOI 10.1016/S1058-2746(98)90003-9; BROBERG MA, 1987, CLIN ORTHOP RELAT R, P109; Chemama B, 2010, ORTHOP TRAUMATOL-SUR, V96, P147, DOI [10.1016/j.rcot.2010.02.008, 10.1016/j.otsr.2009.11.009]; Closkey RF, 2000, J BONE JOINT SURG AM, V82A, P1749, DOI 10.2106/00004623-200012000-00009; Doornberg JN, 2006, J HAND SURG-AM, V31A, P794, DOI 10.1016/j.jhsa.2006.01.004; Guitton TG, 2010, J HAND SURG-AM, V35A, P464, DOI 10.1016/j.jhsa.2009.12.015; Lindenhovius A, 2012, J HAND SURG-AM, V37A, P755, DOI 10.1016/j.jhsa.2011.12.043; Longo UG, 2008, BRIT MED BULL, V87, P131, DOI 10.1093/bmb/ldn023; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; Mathew PK, 2009, J AM ACAD ORTHOP SUR, V17, P137, DOI 10.5435/00124635-200903000-00003; ODRISCOLL SW, 1991, J BONE JOINT SURG AM, V73A, P440, DOI 10.2106/00004623-199173030-00015; Pipicelli Joey G, 2011, Tech Hand Up Extrem Surg, V15, P198, DOI 10.1097/BTH.0b013e31822911fd; Pugh DMW, 2004, J BONE JOINT SURG AM, V86A, P1122, DOI 10.2106/00004623-200406000-00002; Regan W, 2006, J SHOULDER ELB SURG, V15, P344, DOI 10.1016/j.jse.2005.03.009; REGAN W, 1989, J BONE JOINT SURG AM, V71A, P1348, DOI 10.2106/00004623-198971090-00011; Ring D, 2002, J BONE JOINT SURG AM, V84A, P547, DOI 10.2106/00004623-200204000-00006; Rodriguez-Martin J, 2011, INT ORTHOP, V35, P851, DOI 10.1007/s00264-010-1024-6; Schneeberger AG, 2004, J BONE JOINT SURG AM, V86A, P975, DOI 10.2106/00004623-200405000-00013	18	34	39	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	JUL	2014	472	7					2092	2099		10.1007/s11999-014-3518-9			8	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	AI6XP	WOS:000337021300016	24549776	Green Published			2022-02-06	
J	Manevich, Y; Hutchens, S; Halushka, PV; Tew, KD; Townsend, DM; Jauch, EC; Borg, K				Manevich, Y.; Hutchens, S.; Halushka, P. V.; Tew, K. D.; Townsend, D. M.; Jauch, E. C.; Borg, K.			Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Peroxiredoxin VI; Traumatic brain injury; CSF; Oxidant stress; Protein thiol; GSH; Lipid peroxidation; Choroid plexus; Epithelial cells; Ependymal cells; Antioxidant protection; Free radicals	1-CYS PEROXIREDOXIN; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; STRESS; PROTEINS; AQUAPORINS; ENZYME; CELLS	Traumatic brain injury (TBI) patients would benefit from the identification of reliable biomarkers to predict outcomes and treatment strategies. In our study, cerebrospinal fluid (CSF) from patients with severe TBI was evaluated for oxidant stress-mediated damage progression after hospital admission and subsequent ventriculostomy placement. Interestingly, substantial levels of peroxiredoxin VI (Prdx6), a major antioxidant enzyme normally found in astrocytes, were detected in CSF from control and TBI patients and were not associated with blood contamination. Functionally, Prdx6 and its associated binding partner glutathione S-transferase Pi (GSTP1-1, also detected in CSF) act in tandem to detoxify lipid peroxidation damage to membranes. We found Prdx6 was fully active in CSF of control patients but becomes significantly inactivated (oxidized) in TBI. Furthermore, significant and progressive oxidation of "buried" protein thiols in CSF of TBI patients (compared to those of nontrauma controls) was detected over a 24-h period after hospital admission, with increased oxidation correlating with severity of trauma. Conversely, recovery of Prdx6 activity after 24 h indicated more favorable patient outcome. Not only is this the first report of an extracellutar form of Prdx6 but also the first report of its detection at a substantial level in CSF. Taken together, our data suggest a meaningful correlation between TBI-initiated oxidation of Prdx6, its specific phospholipid hydroperoxide peroxidase activity, and severity of trauma outcome. Consequently, we propose that Prdx6 redox status detection has the potential to be a biomarker for TBI outcome and a future indicator of therapeutic efficacy. (C) 2014 Elsevier Inc. All rights reserved.	[Manevich, Y.; Hutchens, S.; Halushka, P. V.; Tew, K. D.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Townsend, D. M.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Jauch, E. C.] Med Univ S Carolina, Dept Med, Div Emergency Med, Charleston, SC 29425 USA; [Borg, K.] Med Univ S Carolina, Dept Pediat, Div Pediat Emergency Med, Charleston, SC 29425 USA		Manevich, Y (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.	manevich@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA08660, CA117259, NCRR P20RR024485, UL1 TR000062, KL2 RR029880, KL2 TRO]; South Carolina Centers of Excellence Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Extramural Research Facilities Program of the National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [COG RR015455]; South Carolina Clinical & Translational Research InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); Medical University of South Carolina; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R41CA117259] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000060, UL1TR000062] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR029880, P20RR024485, C06RR015455, UL1RR029882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103542] Funding Source: NIH RePORTER	The authors thank P. Darwin Bell, Ph.D., and Ms. S. Steele (Department of Nephrology of the Medical University of South Carolina) for their help with collective duct epithelial cell culture; Ms. R.J. Navarro, MSN/MHA (Division of Emergency Medicine of the Medical University of South Carolina) for CSF and plasma sample collection; and Elizabeth Yeh, Ph.D. (Department of Cell and Molecular Pharmacology and Experimental Therapeutics of the Medical University of South Carolina), for helpful discussions and suggestions before submission of our manuscript. This publication was supported by grants from the NIH (CA08660, CA117259, NCRR P20RR024485-COBRE in Oxidants, Redox Balance and Stress Signaling) and support from the South Carolina Centers of Excellence Program and was conducted in a facility constructed with support from the NIH, Grant COG RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. This publication was also supported by the South Carolina Clinical & Translational Research Institute, with an academic home at the Medical University of South Carolina, through NIH Grant UL1 TR000062, and Dr. K. Borg was supported through NIH Grants KL2 RR029880 and KL2 TRO.	Basuroy S, 2009, AM J PHYSIOL-CELL PH, V296, pC422, DOI 10.1152/ajpcell.00381.2008; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bienert GP, 2007, J BIOL CHEM, V282, P1183, DOI 10.1074/jbc.M603761200; Chen AS, 2010, J NEUROTRAUM, V27, P263, DOI 10.1089/neu.2009.1051; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; CSERR HF, 1971, PHYSIOL REV, V51, P273, DOI 10.1152/physrev.1971.51.2.273; Esposito A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003780; Goetzl L, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.034; Greenberg ME, 2008, J BIOL CHEM, V283, P2385, DOI 10.1074/jbc.M707348200; Hansen RE, 2009, P NATL ACAD SCI USA, V106, P422, DOI 10.1073/pnas.0812149106; Hirst RA, 2009, CHILD NERV SYST, V25, P559, DOI 10.1007/s00381-008-0768-4; HUNTER MIS, 1985, NEUROCHEM RES, V10, P1645, DOI 10.1007/BF00988606; Irani D.N, 2009, CEREBROSPINAL FLUID; Jeong JH, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.000513; Laterra J. K., 1999, BASIC NEURO CHEM MOL; Leichert LI, 2006, ANTIOXID REDOX SIGN, V8, P763, DOI 10.1089/ars.2006.8.763; Manevich Y, 2005, FREE RADICAL BIO MED, V38, P1422, DOI 10.1016/j.freeradbiomed.2005.02.011; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; Manevich Y, 2013, FREE RADICAL BIO MED, V54, P62, DOI 10.1016/j.freeradbiomed.2012.10.556; Manevich Y, 2002, P NATL ACAD SCI USA, V99, P11599, DOI 10.1073/pnas.182384499; Manevich Y, 2007, J LIPID RES, V48, P2306, DOI 10.1194/jlr.M700299-JLR200; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3; Reed TT, 2011, FREE RADICAL BIO MED, V51, P1302, DOI 10.1016/j.freeradbiomed.2011.06.027; Resnick A, 2007, BIOPHYS J, V93, P1380, DOI 10.1529/biophysj.107.105007; Saigusa T, 2012, AM J PHYSIOL-RENAL, V302, pF801, DOI 10.1152/ajprenal.00253.2011; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schulte J, 2011, SHOCK, V35, P460, DOI 10.1097/SHK.0b013e3182115f40; Stuhlmeier KM, 2003, EUR J BIOCHEM, V270, P334, DOI 10.1046/j.1432-1033.2003.03393.x; SUBCZYNSKI WK, 1983, BIOPHYS J, V41, P283, DOI 10.1016/S0006-3495(83)84439-7; Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Uys JD, 2011, NEUROPSYCHOPHARMACOL, V36, P2551, DOI 10.1038/npp.2011.143; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Winterbourn CC, 2008, FREE RADICAL BIO MED, V45, P549, DOI 10.1016/j.freeradbiomed.2008.05.004; Wood KC, 2005, FASEB J, V19, P989, DOI 10.1096/fj.04-3218fje; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wu Y, 2009, BIOCHEM J, V419, P669, DOI 10.1042/BJ20082061	41	34	34	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUL	2014	72						210	221		10.1016/j.freeradbiomed.2014.04.002			12	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AJ4OS	WOS:000337656300019	24726861	Green Accepted			2022-02-06	
J	Luedtke, K; Bouchard, SM; Woller, SA; Funk, MK; Aceves, M; Hook, MA				Luedtke, Kelsey; Bouchard, Sioui Maldonado; Woller, Sarah A.; Funk, Mary Katherine; Aceves, Miriam; Hook, Michelle A.			Assessment of Depression in a Rodent Model of Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						contusion; depression; fluoxetine; quality of life; spinal cord injury	PRO-INFLAMMATORY CYTOKINES; TRAUMATIC BRAIN-INJURY; FORCED SWIMMING TEST; MAJOR DEPRESSION; RAT MODEL; FUNCTIONAL RECOVERY; INTERFERON-ALPHA; ANIMAL-MODEL; FLUOXETINE; ACTIVATION	Despite an increased incidence of depression in patients after spinal cord injury (SCI), there is no animal model of depression after SCI. To address this, we used a battery of established tests to assess depression after a rodent contusion injury. Subjects were acclimated to the tasks, and baseline scores were collected before SCI. Testing was conducted on days 9-10 (acute) and 19-20 (chronic) postinjury. To categorize depression, subjects' scores on each behavioral measure were averaged across the acute and chronic stages of injury and subjected to a principal component analysis. This analysis revealed a two-component structure, which explained 72.2% of between-subjects variance. The data were then analyzed with a hierarchical cluster analysis, identifying two clusters that differed significantly on the sucrose preference, open field, social exploration, and burrowing tasks. One cluster (9 of 26 subjects) displayed characteristics of depression. Using these data, a discriminant function analysis was conducted to derive an equation that could classify subjects as "depressed'' on days 9-10. The discriminant function was used in a second experiment examining whether the depression-like symptoms could be reversed with the antidepressant, fluoxetine. Fluoxetine significantly decreased immobility in the forced swim test (FST) in depressed subjects identified with the equation. Subjects that were depressed and treated with saline displayed significantly increased immobility on the FST, relative to not depressed, saline-treated controls. These initial experiments validate our tests of depression, generating a powerful model system for further understanding the relationships between molecular changes induced by SCI and the development of depression.	[Luedtke, Kelsey; Bouchard, Sioui Maldonado; Woller, Sarah A.; Funk, Mary Katherine; Aceves, Miriam; Hook, Michelle A.] Texas A&M Hlth Sci Ctr, Dept Neurosci & Expt Therapeut, Bryan, TX USA		Hook, MA (corresponding author), Texas A&M Univ Hlth Sci Ctr, Dept Neurosci & Expt Therapeut, 8447 State Highway 47, Bryan, TX 77807 USA.	hook@medicine.tamhsc.edu	Hook, Michelle/M-3140-2019	Aceves Rodriguez, Miriam/0000-0002-1778-0213; Woller, Sarah/0000-0001-7767-4845; Hook, Michelle/0000-0002-8709-936X	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 031197] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA031197] Funding Source: NIH RePORTER		ABEL EL, 1990, PHYSIOL BEHAV, V48, P233, DOI 10.1016/0031-9384(90)90306-O; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Angst J, 1997, J AFFECT DISORDERS, V45, P31, DOI 10.1016/S0165-0327(97)00057-8; Anisman H, 1996, BRAIN RES, V731, P1; Anisman H, 2005, NEUROSCI BIOBEHAV R, V29, P525, DOI 10.1016/j.neubiorev.2005.03.007; Anisman H, 2005, CURR PHARM DESIGN, V11, P963, DOI 10.2174/1381612053381701; Anisman H, 1999, ADV EXP MED BIOL, V461, P199; Anisman H, 2009, J PSYCHIATR NEUROSCI, V34, P4; BARBEAU H, 1991, BRAIN RES, V546, P250, DOI 10.1016/0006-8993(91)91489-N; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BEATTIE MS, 1992, J NEUROTRAUM, V9, P157, DOI 10.1089/neu.1992.9.157; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Berry A, 2012, PSYCHONEUROENDOCRINO, V37, P762, DOI 10.1016/j.psyneuen.2011.09.007; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Bombardier CH, 2012, ARCH PHYS MED REHAB, V93, P775, DOI 10.1016/j.apmr.2011.12.020; Brenes JC, 2009, BEHAV BRAIN RES, V198, P199, DOI 10.1016/j.bbr.2008.10.036; Capuron L, 2002, MOL PSYCHIATR, V7, P468, DOI 10.1038/sj.mp.4000995; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Cristante AF, 2013, SPINAL CORD, V51, P501, DOI 10.1038/sc.2013.18; Cryan JF, 2005, PSYCHOPHARMACOLOGY, V182, P335, DOI 10.1007/s00213-005-0093-5; Cryan JF, 2004, MOL PSYCHIATR, V9, P326, DOI 10.1038/sj.mp.4001457; Davies AL, 2007, ARCH PHYS MED REHAB, V88, P1384, DOI 10.1016/j.apmr.2007.08.004; de Carvalho SAD, 1998, GEN HOSP PSYCHIAT, V20, P353, DOI 10.1016/S0163-8343(98)00047-4; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Elliott TR, 2004, REHABIL PSYCHOL, V49, P134, DOI 10.1037/0090-5550.49.2.134; Engesser-Cesar C, 2007, NEUROSCIENCE, V144, P1033, DOI 10.1016/j.neuroscience.2006.10.016; Fong AJ, 2005, J NEUROSCI, V25, P11738, DOI 10.1523/JNEUROSCI.1523-05.2005; FRANK RG, 1985, AM J PSYCHIAT, V142, P252; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; Fumagalli F, 2009, NEUROSCIENCE, V159, P936, DOI 10.1016/j.neuroscience.2009.01.030; Garraway SM, 2011, NEUROSCIENCE, V199, P86, DOI 10.1016/j.neuroscience.2011.10.007; Grau JW, 2004, J NEUROTRAUM, V21, P1795, DOI 10.1089/0897715042664948; Hajebrahimi Z, 2008, NEUROSCI LETT, V441, P261, DOI 10.1016/j.neulet.2008.06.046; Hartkopp A, 1998, ARCH PHYS MED REHAB, V79, P1356, DOI 10.1016/S0003-9993(98)90227-1; Hayes KC, 2002, J NEUROTRAUM, V19, P753, DOI 10.1089/08977150260139129; HILAKIVICLARKE LA, 1990, PHYSIOL BEHAV, V48, P429, DOI 10.1016/0031-9384(90)90339-6; Hollis F, 2011, HORM BEHAV, V59, P331, DOI 10.1016/j.yhbeh.2010.09.005; Hook MA, 2009, J NEUROTRAUM, V26, P741, DOI 10.1089/neu.2008.0710; Huang TL, 2008, J PSYCHIATR RES, V42, P521, DOI 10.1016/j.jpsychires.2007.05.007; Hyun JK, 2009, J NEUROTRAUM, V26, P1773, DOI [10.1089/neu.2007.0485, 10.1089/neu.2007-0485]; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Juruena MF, 2006, PSYCHOPHARMACOLOGY, V189, P225, DOI 10.1007/s00213-006-0555-4; Kalpakjian CZ, 2006, WOMEN HEALTH ISS, V16, P380, DOI 10.1016/j.whi.2006.08.005; Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359; King VR, 2000, EXP NEUROL, V165, P327, DOI 10.1006/exnr.2000.7480; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; Krueger H, 2013, SPINAL CORD, V51, P260, DOI 10.1038/sc.2013.3; Lamkin DM, 2011, BRAIN BEHAV IMMUN, V25, P555, DOI 10.1016/j.bbi.2010.12.010; Lee JY, 2012, BRAIN, V135, P2375, DOI 10.1093/brain/aws171; Li N, 2012, BEHAV BRAIN RES, V233, P428, DOI 10.1016/j.bbr.2012.05.035; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Maes M, 1999, ADV EXP MED BIOL, V461, P25; Makino M, 2000, PSYCHOPHARMACOLOGY, V148, P106, DOI 10.1007/s002130050031; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; MCKINNEY WT, 1969, ARCH GEN PSYCHIAT, V21, P240; Menkes DB, 2000, PSYCHOL MED, V30, P259, DOI 10.1017/S0033291799001774; Migliorini CE, 2009, SPINAL CORD, V47, P783, DOI 10.1038/sc.2009.43; MINKOFF K, 1973, AM J PSYCHIAT, V130, P455; Morikawa O, 1998, EUR J PHARMACOL, V349, P317, DOI 10.1016/S0014-2999(98)00187-3; Pace TWW, 2009, ANN NY ACAD SCI, V1179, P86, DOI 10.1111/j.1749-6632.2009.04984.x; Perona MTG, 2008, BEHAV PHARMACOL, V19, P566, DOI 10.1097/FBP.0b013e32830cd80f; Petit-Demouliere B, 2005, PSYCHOPHARMACOLOGY, V177, P245, DOI 10.1007/s00213-004-2048-7; Popovich PG, 2001, J NEUROTRAUM, V18, P957, DOI 10.1089/089771501750451866; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Pyter LM, 2009, P NATL ACAD SCI USA, V106, P9069, DOI 10.1073/pnas.0811949106; Raison CL, 2011, CURR PSYCHIAT REP, V13, P467, DOI 10.1007/s11920-011-0232-0; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; Scali M, 2013, SCI REP-UK, V3, DOI 10.1038/srep02217; Smith RR, 2006, J NEUROTRAUM, V23, P1654, DOI 10.1089/neu.2006.23.1654; SMITH RS, 1991, MED HYPOTHESES, V35, P298, DOI 10.1016/0306-9877(91)90272-Z; Song C, 1999, NEUROSCIENCE, V88, P823, DOI 10.1016/S0306-4522(98)00271-1; Spradley JM, 2012, PAIN, V153, P1890, DOI 10.1016/j.pain.2012.05.032; Swain MG, 1998, HEPATOLOGY, V28, P6, DOI 10.1002/hep.510280102; Tabachnick BG, 2007, PRINCIPAL COMPONENTS; Vazquez-Palacios G, 2005, PROG NEURO-PSYCHOPH, V29, P39, DOI 10.1016/j.pnpbp.2004.08.008; Wang SH, 2009, J PSYCHOPHARMACOL, V23, P295, DOI 10.1177/0269881108089814; Yang LQ, 2005, J CLIN NEUROSCI, V12, P276, DOI 10.1016/j.jocn.2004.06.011	81	34	37	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 15	2014	31	12					1107	1121		10.1089/neu.2013.3204			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	AK5DC	WOS:000338443600348	24564232	Green Published			2022-02-06	
J	Sibener, L; Zaganjor, I; Snyder, HM; Bain, LJ; Egge, R; Carrillo, MC				Sibener, Leslie; Zaganjor, Ibrahim; Snyder, Heather M.; Bain, Lisa J.; Egge, Robert; Carrillo, Maria C.			Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Military medicine; Traumatic brain injury; Posttraumatic stress disorder; Healthcare costs	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE FUNCTION; UNITED-STATES; OLDER-ADULTS; DEMENTIA; RISK; ATHEROSCLEROSIS; ENCEPHALOPATHY; EPIDEMIOLOGY	By 2050, more than 13 million Americans of all ages are estimated to be living with Alzheimer's disease (AD), and the aggregate costs of care will swell to approximately $1.2 trillion. The rapidly climbing number of those affected with AD includes a growing population of aging military veterans affected who may have an added risk for the disease as a consequence of traumatic brain injury, posttraumatic stress disorder, and/or service-related injuries. The increasing number of individuals, the long duration of disability, and the rising cost of care for AD and other dementia to our society are important public health challenges facing many older adults. These challenges are further compounded by a burgeoning military veteran population that is much younger, with an increased risk of AD and other dementia, and who may experience decades-long periods of disability and care. This outlook underscores the critical need for investments in research at the federal and international levels to accelerate the pace of progress in developing breakthrough discoveries that will change the trajectory of AD and related dementia. (C) 2014 The Alzheimer's Association. All rights reserved.	[Sibener, Leslie; Zaganjor, Ibrahim; Snyder, Heather M.; Carrillo, Maria C.] Alzheimers Assoc, Med & Sci Relat Div, Chicago, IL 60631 USA; [Egge, Robert] Alzheimers Assoc, Publ Policy & Advocacy Div, Washington, DC USA		Carrillo, MC (corresponding author), Alzheimers Assoc, Med & Sci Relat Div, Chicago, IL 60631 USA.	mcarrillo@alz.org	MUNOZ, ROSA ANA/H-3964-2018	MUNOZ, ROSA ANA/0000-0002-7504-2163	United States Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Publication of this article was supported by the United States Army Medical Research and Materiel Command.	Ahmadi N, 2011, AM J CARDIOL, V108, P29, DOI 10.1016/j.amjcard.2011.02.340; Alzheimer's Association, 2010, ALZHEIMERS DEMENT, V6, DOI [DOI 10.1016/J.JALZ.2014.02.001, 10.1016/j.jalz.2010.01.009]; Barnes DE, 2009, NEUROLOGY, V73, P173, DOI 10.1212/WNL.0b013e3181a81636; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Byers AL, 2012, AM J GERIAT PSYCHIAT, V20, P664, DOI 10.1097/JGP.0b013e31822001c1; Bynum J, 2011, UNPUBLISHED TABULATI; Carrillo MC, 2013, ALZHEIMERS DEMENT, V9, P123, DOI 10.1016/j.jalz.2012.12.004; Cohen BE, 2013, J CLIN PSYCHIAT, V74, P1063, DOI 10.4088/JCP.12m08291; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Department of Defense, 2011, CONT TRACK SYST NUMB; Department of Veterans Affairs, 2003, VHA VIS 2020; Eichler HG, 2013, NEW ENGL J MED, V369, P1577, DOI 10.1056/NEJMp1310771; Fischer H., 2010, US MILITARY CASUALTY, P1; Gao Y, 2013, INT J GERIATR PSYCH, V28, P441, DOI 10.1002/gps.3845; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Higgins GA, 1997, PHARMACOL BIOCHEM BE, V56, P675, DOI 10.1016/S0091-3057(96)00420-0; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Loef M, 2013, OBESITY, V21, pE51, DOI 10.1002/oby.20037; Lukaschek K, 2013, J PSYCHOSOM RES, V74, P340, DOI 10.1016/j.jpsychores.2012.12.011; MacKnight C, 2002, DEMENT GERIATR COGN, V14, P77, DOI 10.1159/000064928; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Martland H., 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; MAYEUX R, 1991, ARCH NEUROL-CHICAGO, V48, P269, DOI 10.1001/archneur.1991.00530150037014; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Metropolitan Life Insurance Company, 2012, 2012 METLIFE MARK SU; Moore MJ, 2001, J GERONTOL B-PSYCHOL, V56, pS219, DOI 10.1093/geronb/56.4.S219; National Council on Disability, 2009, INV WOUNDS SERV SERV; Nowinski C, 2006, HEAD GAMES FOOTBALLS; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; Reiman EM, 2011, J ALZHEIMERS DIS, V26, P321, DOI 10.3233/JAD-2011-0059; Roses AD, 2012, ALZHEIMERS DEMENT S4, V8, pS753; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; U. S. Census Bureau, 2012, US CENS BUR 2008 201; van Oijen M, 2007, ANN NEUROL, V61, P403, DOI 10.1002/ana.21073; Weiner MW, 2013, ALZHEIMERS DEMENT, V9, P445, DOI 10.1016/j.jalz.2013.03.005; Yaffe K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7051; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Ziegler-Graham K, 2008, ALZHEIMERS DEMENT, V4, P316, DOI 10.1016/j.jalz.2008.05.2479	52	34	34	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S105	S110		10.1016/j.jalz.2014.04.011			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CP8GM	WOS:000360130700006	24924663	hybrid			2022-02-06	
J	Zhang, YM; Yang, YY; Tang, H; Sun, WJ; Xiong, XX; Smerin, D; Liu, JC				Zhang, Yongming; Yang, Yanyan; Tang, Hong; Sun, Wenjiang; Xiong, Xiaoxing; Smerin, Daniel; Liu, Jiachuan			Hyperbaric Oxygen Therapy Ameliorates Local Brain Metabolism, Brain Edema and Inflammatory Response in a Blast-Induced Traumatic Brain Injury Model in Rabbits	NEUROCHEMICAL RESEARCH			English	Article						Brain injury; Explosive injury; Rabbit Magnetic resonance spectrum; Hyperbaric oxygen	MAGNETIC-RESONANCE-SPECTROSCOPY; FOCAL CEREBRAL-ISCHEMIA; RAT MODEL; TISSUE; INHIBITION; EXPRESSION; PRINCIPLES; DISEASE; BARRIER	Many studies suggest that hyperbaric oxygen therapy (HBOT) can provide some clinically curative effects on blast-induced traumatic brain injury (bTBI). The specific mechanism by which this occurs still remains unknown, and no standardized time or course of hyperbaric oxygen treatment is currently used. In this study, bTBI was produced by paper detonators equivalent to 600 mg of TNT exploding at 6.5 cm vertical to the rabbit's head. HBO (100 % O-2 at 2.0 absolute atmospheres) was used once, 12 h after injury. Magnetic resonance spectroscopy was performed to investigate the impact of HBOT on the metabolism of local injured nerves in brain tissue. We also examined blood-brain barrier (BBB) integrity, brain water content, apoptotic factors, and some inflammatory mediators. Our results demonstrate that hyperbaric oxygen could confer neuroprotection and improve prognosis after explosive injury by promoting the metabolism of local neurons, inhibiting brain edema, protecting BBB integrity, decreasing cell apoptosis, and inhibiting the inflammatory response. Furthermore, timely intervention within 1 week after injury might be more conducive to improving the prognosis of patients with bTBI.	[Zhang, Yongming; Yang, Yanyan; Tang, Hong; Sun, Wenjiang; Liu, Jiachuan] Anhui Med Univ, Dept Neurosurg, Hosp PLA 105, Hefei 230031, Peoples R China; [Zhang, Yongming; Xiong, Xiaoxing] Stanford Univ, Dept Neurosurg, Stanford, CA 94306 USA; [Smerin, Daniel] Stanford Univ, Sch Med, Stanford, CA 94306 USA		Liu, JC (corresponding author), Anhui Med Univ, Dept Neurosurg, Hosp PLA 105, Hefei 230031, Peoples R China.	zymhf2966@163.com; zym_105sjw@163.com		Xiong, Xiaoxing/0000-0001-6983-8547	Nature Science Youth Funding of Anhui Province [1208085QH171]; Nanjing Military Region Fund Project [10MB009]	This study was supported by research Grants from the Nature Science Youth Funding of Anhui Province (1208085QH171) and Nanjing Military Region Fund Project (10MB009). We also thank Professor Bingchang Li (Institute of Battle Surgical Research, Third Military Medicine University) for his support while creating our animal model and Daniel Smerin for his manuscript editing.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Brugger S, 2011, BIOL PSYCHIAT, V69, P495, DOI 10.1016/j.biopsych.2010.10.004; Chamorro A, 2006, STROKE, V37, P291, DOI 10.1161/01.STR.0000200561.69611.f8; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Edwards ML, 2010, J VET EMERG CRIT CAR, V20, P289, DOI 10.1111/j.1476-4431.2010.00535_1.x; Edwards ML, 2010, J VET EMERG CRIT CAR, V20, P284, DOI 10.1111/j.1476-4431.2010.00535.x; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Hedges JC, 2000, AM J RESP CELL MOL, V23, P86, DOI 10.1165/ajrcmb.23.1.4014; Hollin S A, 1968, Prog Brain Res, V30, P479; Huang E, 2013, BRAIN RES, V1529, P125, DOI 10.1016/j.brainres.2013.06.042; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kang GH, 2012, J NEUROL SCI, V318, P25, DOI 10.1016/j.jns.2012.04.013; Lee JH, 2013, NEUROCHEM RES, V38, P2276, DOI 10.1007/s11064-013-1136-7; Li CX, 2008, NEUROCHEM RES, V33, P2342, DOI 10.1007/s11064-008-9739-0; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Liu Zhan, 2006, Chin J Traumatol, V9, P168; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; McLean MA, 2009, BRIT J NEUROSURG, V23, P5, DOI 10.1080/02688690802491673; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Qian JC, 2013, NEUROCHEM RES, V38, P208, DOI 10.1007/s11064-012-0910-2; Ren CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003851; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Samson Y, 2005, REV NEUROL-FRANCE, V161, P1177; Sidaros Annette, 2007, Ugeskr Laeger, V169, P214; Soares DP, 2009, CLIN RADIOL, V64, P12, DOI 10.1016/j.crad.2008.07.002; Tang XQ, 2010, BRAIN RES, V1348, P174, DOI 10.1016/j.brainres.2010.05.082; Voigt C, 2008, ACTA NEUROCHIR SUPPL, V102, P441, DOI 10.1007/978-3-211-85578-2_86; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391; Yang DY, 2007, NEUROL RES, V29, P274, DOI 10.1179/016164107X159171; Yong-Ming Z, 2012, AFR HEALTH SCI, V12, P552, DOI 10.4314/ahs.v12i4.24	44	34	38	1	7	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2014	39	5					950	960		10.1007/s11064-014-1292-4			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AG1HF	WOS:000335165200017	24682753				2022-02-06	
J	Mannelli, LD; Pacini, A; Matera, C; Zanardelli, M; Mello, T; De Amici, M; Dallanoce, C; Ghelardini, C				Mannelli, Lorenzo Di Cesare; Pacini, Alessandra; Matera, Carlo; Zanardelli, Matteo; Mello, Tommaso; De Amici, Marco; Dallanoce, Clelia; Ghelardini, Carla			Involvement of alpha 7 nAChR subtype in rat oxaliplatin-induced neuropathy: Effects of selective activation	NEUROPHARMACOLOGY			English	Article						Neuropathic pain; Microglia; Astrocyte; alpha 7 nAChR; alpha 4 nAChR; Receptor down-regulation; Receptor up-regulation; Neuroprotection	NICOTINIC ACETYLCHOLINE-RECEPTOR; POSITIVE ALLOSTERIC MODULATORS; INDUCED PERIPHERAL NEUROPATHY; TRAUMATIC BRAIN-INJURY; UP-REGULATION; CHRONIC PAIN; DIFFERENT SCHEDULES; CHOLINERGIC SYSTEM; 1ST-LINE TREATMENT; ADJUVANT TREATMENT	Oxaliplatin, unlike other platinum anticancer agents, has only mild toxic effects on the hematopoietic, urinary and gastrointestinal systems. Its dose-limiting side effect is neurotoxicity that may evolve to a neuropathic syndrome which is difficult to treat. In this study we treated rats with oxaliplatin (2.4 mg/kg/day intraperitoneally, for 3 weeks), and observed that expression levels of the alpha 7 nicotinic acetylcholine receptor (nAChR) subunit were dramatically decreased both in the peripheral and central nervous system. The repeated administration (30 mg/kg/day per os, for 3 weeks) of (R)-ICH3, the most active enantiomer of a novel alpha 7 nAChR agonist, and of PNU-282987 prevented the receptor down-regulation. On the other hand, both agonists per se up-regulated the alpha 7 nAChR subunit compared to control. (R)-ICH3 and PNU-282987 significantly reduced oxaliplatin-dependent alterations of the pain threshold when noxious or non-noxious stimuli were used. Further ex vivo analysis highlighted their neuroprotective effects in dorsal root ganglia and peripheral nerves. The two agonists did not prevent the increase in microglia cell number induced by oxaliplatin in the central nervous system. Astrocyte density was enhanced by the agonist treatment in the spinal cord, thalamus and somatosensory area 1 as opposed to the effects of oxaliplatin treatment. (R)-ICH3 and PNU-282987 per se increased glial cell number in a region-specific manner. In summary, alpha 7 nAChR is involved in oxaliplatin-dependent neuropathology and the agonists (R)-ICH3 and PNU-282987 reduce pain and protect nervous tissue with concomitant glial activation. Since glial cells play a role both in pain and in neuroprotection, an alpha 7 AChR-dependent modulation of glial functions is suggested to distinguish rescue signals from the pathological pain-mediating pathway. (C) 2013 Elsevier Ltd. All rights reserved.	[Mannelli, Lorenzo Di Cesare; Zanardelli, Matteo; Ghelardini, Carla] Univ Florence, Dipartimento Neurosci, Area Farmaco & Salute Bambino, Neurofarba,Sez Farmacol & Tossicol, I-50139 Florence, Italy; [Pacini, Alessandra] Univ Florence, DMSC, Sez Anat & Istol, I-50134 Florence, Italy; [Mello, Tommaso] Univ Florence, Dipartimento Sci Biomed Sperimentali & Clin SBSC, I-50134 Florence, Italy; [Matera, Carlo; De Amici, Marco; Dallanoce, Clelia] Univ Milan, Dipartimento Sci Farmaceut, Sez Chim Farmaceut Pietro Pratesi, I-20133 Milan, Italy		Mannelli, LD (corresponding author), Univ Florence, Dipartimento Neurosci, Area Farmaco & Salute Bambino, Neurofarba,Sez Farmacol & Tossicol, Viale Pieraccini 6, I-50139 Florence, Italy.	lorenzo.mannelli@unifi.it	Mello, Tommaso/AAO-7831-2021; Mello, Tommaso/I-4715-2012; Matera, Carlo/G-3808-2015; De Amici, Marco/F-9684-2015; Di Cesare Mannelli, Lorenzo/A-1641-2015	Mello, Tommaso/0000-0002-6192-6902; Mello, Tommaso/0000-0002-6192-6902; Matera, Carlo/0000-0001-6939-3859; GHELARDINI, CARLA/0000-0001-9856-8144; De Amici, Marco/0000-0002-0236-0662; Di Cesare Mannelli, Lorenzo/0000-0001-8374-4432; Dallanoce, Clelia/0000-0002-7383-1484	Italian Ministry of Instruction, University and Research (MIUR)Ministry of Education, Universities and Research (MIUR); University of Florence; Italian MIURMinistry of Education, Universities and Research (MIUR) [PRIN 2009RTWCZS]; "Dote ricerca": FSE, Regione LombardiaRegione Lombardia	This research was funded by the Italian Ministry of Instruction, University and Research (MIUR) and by the University of Florence. In particular, MDA wishes to thank the Italian MIUR, contract grant number: PRIN 2009RTWCZS. Carlo Matera wishes to thank "Dote ricerca": FSE, Regione Lombardia for co-financing his postdoctoral position. The authors have no conflicts of interest to declare.	Albers J.W., 2011, COCHRANE DB SYST REV, V2; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012; Banerjee C, 2000, NEUROBIOL DIS, V7, P666, DOI 10.1006/nbdi.2000.0317; Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Bartolini Alessandro, 2011, Recent Pat CNS Drug Discov, V6, P119; Benfante R, 2011, J NEUROIMMUNOL, V230, P74, DOI 10.1016/j.jneuroim.2010.09.008; Bodnar AL, 2005, J MED CHEM, V48, P905, DOI 10.1021/jm049363q; Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Burghaus L, 2003, PARKINSONISM RELAT D, V9, P243, DOI 10.1016/S1353-8020(03)00028-2; Carnevale D., 2007, CNS & Neurological Disorders-Drug Targets, V6, P388; Cavaletti G, 2001, EUR J CANCER, V37, P2457, DOI 10.1016/S0959-8049(01)00300-8; Chernyavsky AI, 2010, AM J PHYSIOL-CELL PH, V299, pC903, DOI 10.1152/ajpcell.00216.2010; Christensen DZ, 2010, J NEUROCHEM, V114, P1205, DOI 10.1111/j.1471-4159.2010.06845.x; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; COGGESHALL RE, 1990, J NEUROSCI METH, V35, P187, DOI 10.1016/0165-0270(90)90123-W; Czura CJ, 2005, J INTERN MED, V257, P156, DOI 10.1111/j.1365-2796.2004.01442.x; Dallanoce C, 2011, CHEMMEDCHEM, V6, P889, DOI 10.1002/cmdc.201000514; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Di Cesare Mannelli L, 2013, J PAIN, DOI DOI 10.1016/JJPAIN.2013.08.002; Ferchmin PA, 2003, J PHARMACOL EXP THER, V305, P1071, DOI 10.1124/jpet.102.048173; Floto RA, 2003, LANCET, V361, P1069, DOI 10.1016/S0140-6736(03)12902-9; Galitovskiy V, 2011, J IMMUNOL, V187, P2677, DOI 10.4049/jimmunol.1002711; Ghelardini C, 2000, BRIT J PHARMACOL, V129, P1633, DOI 10.1038/sj.bjp.0703268; Govind AP, 2009, BIOCHEM PHARMACOL, V78, P756, DOI 10.1016/j.bcp.2009.06.011; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Guo LH, 2007, CELL MOL LIFE SCI, V64, P1128, DOI 10.1007/s00018-007-6494-3; Hajos M, 2005, J PHARMACOL EXP THER, V312, P1213, DOI 10.1124/jpet.104.076968; Hellstrom-Lindahl E, 1999, MOL BRAIN RES, V66, P94, DOI 10.1016/S0169-328X(99)00030-3; Holmes J, 1998, TOXICOL SCI, V46, P342, DOI 10.1006/toxs.1998.2558; Iwamoto K, 2013, NEUROSCIENCE, V237, P184, DOI 10.1016/j.neuroscience.2013.02.003; Jones PG, 2007, NEUROPHARMACOLOGY, V53, P197, DOI 10.1016/j.neuropharm.2007.04.002; Jonnala RR, 2001, J NEUROSCI RES, V66, P565, DOI 10.1002/jnr.10022; Kaley TJ, 2009, BRIT J HAEMATOL, V145, P3, DOI 10.1111/j.1365-2141.2008.07558.x; Kannarkat G, 2007, CURR OPIN NEUROL, V20, P719; Kawashima K, 2003, LIFE SCI, V74, P675, DOI 10.1016/j.lfs.2003.09.037; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Kim SJ, 2004, MOL CELLS, V17, P242; Laudenbach V, 2002, FASEB J, V16, P423, DOI 10.1096/fj.01-0532fje; LEIGHTON GE, 1988, BRIT J PHARMACOL, V93, P553, DOI 10.1111/j.1476-5381.1988.tb10310.x; Lester HA, 2009, AAPS J, V11, P167, DOI 10.1208/s12248-009-9090-7; Libert C, 2003, NATURE, V421, P328, DOI 10.1038/421328a; Loram LC, 2012, J PAIN, V13, P1162, DOI 10.1016/j.jpain.2012.08.009; Malaspina A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-500; Malysz J, 2009, ASSAY DRUG DEV TECHN, V7, DOI 10.1089/adt.2009.0194; Mannelli LD, 2013, FREE RADICAL BIO MED, V61, P143, DOI 10.1016/j.freeradbiomed.2013.03.019; Mannelli LDC, 2007, EUR J NEUROSCI, V26, P820, DOI 10.1111/j.1460-9568.2007.05722.x; Mannelli LD, 2012, J PAIN, V13, P276, DOI 10.1016/j.jpain.2011.11.009; Mannelli LDC, 2009, J NEUROSCI RES, V87, P200, DOI 10.1002/jnr.21815; Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700; Martin SE, 2004, BRAIN RES, V1022, P254, DOI 10.1016/j.brainres.2004.07.016; Melzack R, 1999, PAIN, pS121, DOI 10.1016/S0304-3959(99)00145-1; Millar NS, 2008, MOL MEMBR BIOL, V25, P279, DOI 10.1080/09687680802035675; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Mudo G, 2007, J NEURAL TRANSM, V114, P135, DOI 10.1007/s00702-006-0561-z; MULLER LJ, 1990, CANCER RES, V50, P2437; Obata K, 2003, PAIN, V101, P65, DOI 10.1016/S0304-3959(02)00296-8; Ono K, 2008, NEUROSCIENCE, V154, P994, DOI 10.1016/j.neuroscience.2008.04.028; Pacini A, 2010, PAIN, V150, P542, DOI 10.1016/j.pain.2010.06.014; Parada E, 2013, ANTIOXID REDOX SIGN, V19, P1135, DOI 10.1089/ars.2012.4671; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Petrioli R, 2008, CANCER CHEMOTH PHARM, V61, P105, DOI 10.1007/s00280-007-0454-3; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Rowbotham MC, 2009, PAIN, V146, P245, DOI 10.1016/j.pain.2009.06.013; Sakurai M, 2009, PAIN, V147, P165, DOI 10.1016/j.pain.2009.09.003; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Seifert F, 2011, CURR OPIN ANESTHESIO, V24, P515, DOI 10.1097/ACO.0b013e32834a1079; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shen H, 2010, BRIT J PHARMACOL, V161, P127, DOI 10.1111/j.1476-5381.2010.00894.x; Souglakos J, 2002, J CLIN ONCOL, V20, P2651, DOI 10.1200/JCO.2002.08.015; Sung CS, 2012, GLIA, V60, P2004, DOI 10.1002/glia.22415; Suzuki T, 2006, J NEUROSCI RES, V83, P1461, DOI 10.1002/jnr.20850; Thomsen MS, 2012, J NEUROCHEM, V123, P73, DOI 10.1111/j.1471-4159.2012.07876.x; Thomsen MS, 2012, J NEUROIMMUNOL, V251, P65, DOI 10.1016/j.jneuroim.2012.07.006; Thomsen MS, 2012, CURR DRUG TARGETS, V13, P707, DOI 10.2174/138945012800399035; TOMIWA K, 1986, ACTA NEUROPATHOL, V69, P295, DOI 10.1007/BF00688308; Tracey KJ, 2001, FASEB J, V15, P1575, DOI 10.1096/fj.01-0148hyp; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Vincler M, 2007, EXPERT OPIN THER TAR, V11, P891, DOI 10.1517/14728222.11.7.891; Wala EP, 2012, ANESTH ANALG, V115, P713, DOI 10.1213/ANE.0b013e31825a3c72; Walker DP, 2006, BIOORGAN MED CHEM, V14, P8219, DOI 10.1016/j.bmc.2006.09.019; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wilson RH, 2002, J CLIN ONCOL, V20, P1767, DOI 10.1200/JCO.2002.07.056; Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z	88	34	34	1	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2014	79						37	48		10.1016/j.neuropharm.2013.10.034			12	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AE1ZX	WOS:000333774200005	24225197				2022-02-06	
J	Mao, WF; Yi, X; Qin, JB; Tian, ML; Jin, GH				Mao, Weifeng; Yi, Xin; Qin, Jianbing; Tian, Meiling; Jin, Guohua			CXCL12 inhibits cortical neuron apoptosis by increasing the ratio of Bcl-2/Bax after traumatic brain injury	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						CXCL12; apoptosis; traumatic brain injury; caspase-3; Bcl-2: Bax ratio	CHEMOKINE RECEPTOR; CELL-SURVIVAL; STEM-CELLS; MIGRATION; CXCR4; EXPRESSION; PATHWAY; ANGIOGENESIS; SDF-1-ALPHA; CASPASE-3	CXCL12 and its physiologic receptor CXCR4 are involved in controlling cell survival, proliferation and migration in adult tissues. This study aimed to investigate the effects of CXCL12 on cortical neuron apoptosis in rats after traumatic brain injury (TBI) and the potential mechanisms involved. At 3 days after TBI, in situ terminal transferase d-UTP nick-end labeling assay (TUNEL) showed that the apoptotic index (AI) deceased significantly in the CXCL12 treatment group compared with the control group (p < 0.05). Immunofluorescence double-labeled staining revealed that most of the TUNEL positive cells were NeuN positive neurons. The change trends of active caspase-3 expression were similar as those of the AI. The Bcl-2: Bax ratio was upregulated in the CXCL12 group compared with the control group. However, the effect of CXCL12 could be partially reverted by the additional use of AMD3100 (a kind of antagonist of CXCR4) (p < 0.05). Our results indicated that after TBI in rats CXCL12 combing CXCR4 receptors could inhibit the caspase-3 pathway by upregulating Bcl-2: Bax ratio, which protect neurons from apoptosis.	[Mao, Weifeng] Soochow Univ, Coll Med, Dept Anat & Cytoneurobiol, Suzhou, Peoples R China; [Mao, Weifeng; Yi, Xin; Qin, Jianbing; Tian, Meiling; Jin, Guohua] Nantong Univ, Dept Anat & Neurobiol, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China		Jin, GH (corresponding author), Nantong Univ, Dept Anat & Neurobiol, Jiangsu Key Lab Neuroregenerat, 19 Qixiu Rd, Nantong 226001, Jiangsu, Peoples R China.	jguohua@ntu.edu.cn			Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by funding from the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dai SJ, 2010, J MOL CELL CARDIOL, V49, P587, DOI 10.1016/j.yjmcc.2010.07.010; Dziembowska M, 2005, GLIA, V50, P258, DOI 10.1002/glia.20170; Fricker SP, 2006, BIOCHEM PHARMACOL, V72, P588, DOI 10.1016/j.bcp.2006.05.010; Gillard SE, 2002, J NEUROIMMUNOL, V124, P16, DOI 10.1016/S0165-5728(02)00005-X; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Hernandez-Lopez C, 2008, IMMUNOL LETT, V120, P72, DOI 10.1016/j.imlet.2008.07.006; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jia JX, 2010, MOL CELL BIOCHEM, V335, P127, DOI 10.1007/s11010-009-0249-4; Khan MZ, 2008, CELL DEATH DIFFER, V15, P1663, DOI 10.1038/cdd.2008.95; Kryczek I, 2005, AM J REPROD IMMUNOL, V54, P270, DOI 10.1111/j.1600-0897.2005.00307.x; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Li MZ, 2008, PROG NEUROBIOL, V84, P116, DOI 10.1016/j.pneurobio.2007.11.003; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Liu XL, 2011, PROTEIN CELL, V2, P845, DOI 10.1007/s13238-011-1097-z; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nicolai J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.10; Salakou S, 2007, IN VIVO, V21, P123; Shi W, 2011, NEUROCHEM RES, V36, P375, DOI 10.1007/s11064-010-0332-y; Shyu WC, 2008, J PHARMACOL EXP THER, V324, P834, DOI 10.1124/jpet.107.127746; Solaroglu I, 2006, NEUROSCIENCE, V143, P965, DOI 10.1016/j.neuroscience.2006.09.014; Stumm RK, 2003, J NEUROSCI, V23, P5123; Xiao DaLiao, 2008, Int J Med Sci, V5, P295; Zhu B, 2012, STEM CELLS, V30, P2571, DOI 10.1002/stem.1239	28	34	35	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.	APR	2014	124	4					281	290		10.3109/00207454.2013.838236			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC6ZB	WOS:000332674400007	23984821				2022-02-06	
J	Dachir, S; Shabashov, D; Trembovler, V; Alexandrovich, AG; Benowitz, LI; Shohami, E				Dachir, Shlomit; Shabashov, Dalia; Trembovler, Victoria; Alexandrovich, Alexander G.; Benowitz, Larry I.; Shohami, Esther			Inosine improves functional recovery after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						Cortical spinal tract (CST); Novel object recognition test (NORT); Y-maze; Synaptophysin; GAP-43	CLOSED-HEAD-INJURY; SPINAL-CORD; SUBTHALAMIC NUCLEUS; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; AXON REGENERATION; MEMORY DEFICITS; MOTOR FUNCTION; URIC-ACID; STIMULATION	Despite years of research, no effective therapy is yet available for the treatment of traumatic brain injury (TBI). The most prevalent and debilitating features in survivors of TBI are cognitive deficits and motor dysfunction. A potential therapeutic method for improving the function of patients following TBI would be to restore, at least in part, plasticity to the CNS in a controlled way that would allow for the formation of compensatory circuits. Inosine, a naturally occurring purine nucleoside, has been shown to promote axon collateral growth in the corticospinal tract (CST) following stroke and focal TBI. In the present study, we investigated the effects of inosine on motor and cognitive deficits, CST sprouting, and expression of synaptic proteins in an experimental model of closed head injury (CHI). Treatment with inosine (100 mg/kg i.p. at 1, 24 and 48 h following CHI) improved outcome after TBI, significantly decreasing the neurological severity score (NSS, p <0.04 vs. saline), an aggregate measure of performance on several tasks. It improved non-spatial cognitive performance (object recognition, p<0.016 vs. saline) but had little effect on sensorimotor coordination (rotarod) and spatial cognitive functions (Y-maze). Inosine did not affect CST sprouting in the lumbar spinal cord but did restore levels of the growth-associated protein GAP-43 in the hippocampus, though not in the cerebral cortex. Our results suggest that inosine may improve functional outcome after TBI. (C) 2014 Published by Elsevier B.V.	[Dachir, Shlomit; Shabashov, Dalia; Trembovler, Victoria; Alexandrovich, Alexander G.; Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Dachir, Shlomit] Israel Inst Biol Res, Dept Pharmacol, IL-70450 Ness Ziona, Israel; [Benowitz, Larry I.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Benowitz, Larry I.] Harvard Univ, Sch Med, Boston, MA 02115 USA		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty.shohami@mail.huji.ac.il		Benowitz, Larry/0000-0002-0277-7222	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)	This study was supported by grants from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) to ES and LB.	Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bay E, 2012, ARCH PSYCHIAT NURS, V26, P477, DOI 10.1016/j.apnu.2012.06.002; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Beni SM, 2006, J CEREBR BLOOD F MET, V26, P478, DOI 10.1038/sj.jcbfm.9600209; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Benowitz LI, 1999, P NATL ACAD SCI USA, V96, P13486, DOI 10.1073/pnas.96.23.13486; Benowitz LI, 1998, J BIOL CHEM, V273, P29626, DOI 10.1074/jbc.273.45.29626; Burello L, 2012, EXP NEUROL, V233, P273, DOI 10.1016/j.expneurol.2011.10.016; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conta A. C., 2008, SPINAL CORD, V46, P151; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Daniele A, 2003, J NEUROL NEUROSUR PS, V74, P175, DOI 10.1136/jnnp.74.2.175; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dellu F, 2000, NEUROBIOL LEARN MEM, V73, P31, DOI 10.1006/nlme.1999.3919; Denny JB, 2006, CURR NEUROPHARMACOL, V4, P293, DOI 10.2174/157015906778520782; Dobkin BH, 2003, CLIN SCI NEUROLOGIC; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fasano A, 2008, MOVEMENT DISORD, V23, P1289, DOI 10.1002/mds.22116; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Grossman R, 2012, FUTUR NEUROL, V7, P329, DOI 10.2217/FNL.12.25; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hasko G, 2004, TRENDS PHARMACOL SCI, V25, P152, DOI 10.1016/j.tips.2004.01.006; Hiebert GW, 2002, J NEUROSCI RES, V69, P160, DOI 10.1002/jnr.10275; Hirshler Y, 2010, EXP NEUROL, V222, P42, DOI 10.1016/j.expneurol.2009.12.006; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Irwin N, 2006, P NATL ACAD SCI USA, V103, P18320, DOI 10.1073/pnas.0605135103; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Kennedy HS, 2011, LAB ANIMAL, V40, P53, DOI 10.1038/laban0211-53; Ladurelle N, 2000, BRAIN RES, V858, P371, DOI 10.1016/S0006-8993(00)01953-3; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lorber B, 2009, NAT NEUROSCI, V12, P1407, DOI 10.1038/nn.2414; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NAKAGAWA S, 1973, J NEUROCHEM, V20, P1143, DOI 10.1111/j.1471-4159.1973.tb00084.x; Nielsen MS, 2007, EUR J NEUROL, V14, P132, DOI 10.1111/j.1468-1331.2006.01569.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PARDRIDGE WM, 1994, J PHARMACOL EXP THER, V268, P14; Petrausch B, 2000, J NEUROSCI, V20, P8031; Rekart JL, 2007, LEARN MEMORY, V14, P416, DOI 10.1101/lm.516507; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shen H, 2005, STROKE, V36, P654, DOI 10.1161/01.STR.0000155747.15679.04; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Thau-Zuchman O, 2012, NEUROSCIENCE, V202, P334, DOI 10.1016/j.neuroscience.2011.11.071; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Viberg H, 2009, INT J DEV NEUROSCI, V27, P423, DOI 10.1016/j.ijdevneu.2009.05.007; WINN HR, 1980, AM J PHYSIOL, V239, pH212, DOI 10.1152/ajpheart.1980.239.2.H212; Witt K, 2008, LANCET NEUROL, V7, P605, DOI 10.1016/S1474-4422(08)70114-5; Yamada M, 2011, J ETHNOPHARMACOL, V135, P737, DOI 10.1016/j.jep.2011.04.010; York MK, 2008, J NEUROL NEUROSUR PS, V79, P789, DOI 10.1136/jnnp.2007.118786; Zai LL, 2011, J NEUROSCI, V31, P5977, DOI 10.1523/JNEUROSCI.4498-10.2011; Zai LL, 2009, J NEUROSCI, V29, P8187, DOI 10.1523/JNEUROSCI.0414-09.2009; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhou LJ, 2003, J NEUROSCI, V23, P1424, DOI 10.1523/JNEUROSCI.23-04-01424.2003	66	34	37	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 25	2014	1555						78	88		10.1016/j.brainres.2014.01.044			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AF1LS	WOS:000334476000008	24502983				2022-02-06	
J	Irimia, A; Van Horn, JD				Irimia, Andrei; Van Horn, John D.			Systematic network lesioning reveals the core white matter scaffold of the human brain	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						connectomics; traumatic brain injury; brain network; neurotrauma; neuroimaging; MRI; DTI	ORGANIZATION	Brain connectivity loss due to traumatic brain injury, stroke or multiple sclerosis can have serious consequences on life quality and a measurable impact upon neural and cognitive function. Though brain network properties are known to be affected disproportionately by injuries to certain gray matter regions, the manner in which white matter (WM) insults affect such properties remains poorly understood. Here, network-theoretic analysis allows us to identify the existence of a macroscopic neural connectivity core in the adult human brain which is particularly sensitive to network lesioning. The systematic lesion analysis of brain connectivity matrices from diffusion neuroimaging over a large sample (N = 110) reveals that the global vulnerability of brain networks can be predicated upon the extent to which injuries disrupt this connectivity core, which is found to be quite distinct from the set of connections between rich club nodes in the brain. Thus, in addition to connectivity within the rich club, the brain as a network also contains a distinct core scaffold of network edges consisting of WM connections whose damage dramatically lowers the integrative properties of brain networks. This pattern of core WM fasciculi whose injury results in major alterations to overall network integrity presents new avenues for clinical outcome prediction following brain injury by relating lesion locations to connectivity core disruption and implications for recovery. The findings of this study contribute substantially to current understanding of the human WM connectome, its sensitivity to injury, and clarify a long-standing debate regarding the relative prominence of gray vs. WM regions in the context of brain structure and connectomic architecture.	[Irimia, Andrei; Van Horn, John D.] Univ So Calif, Dept Neurol, Keck Sch Med, Inst Neuroimaging & Informat, Los Angeles, CA 90089 USA		Van Horn, JD (corresponding author), Univ So Calif, Dept Neurol, Keck Sch Med, Inst Neuroimaging & Informat, 2001 North Soto St,Room 102,MC 9232, Los Angeles, CA 90089 USA.	jvanhorn@usc.edu	Irimia, Andrei/B-8275-2008	Irimia, Andrei/0000-0002-9254-9388; Van Horn, John/0000-0003-1537-0816	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2U54EB005149-06, 1RC1MH088194, R41N5081792-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER	This work was supported by NIH grants 2U54EB005149-06 "NAMIC: Traumatic Brain Injury Driving Biological Project" to John D. Van Horn, 1RC1MH088194 "Informatics Meta-Spaces for the Exploration of Human Neuroanatomy" to John D. Van Horn and R41N5081792-01 "Multimodality Image Based Assessment System for Traumatic Brain Injury" to Stephen R. Aylward. We wish to thank S.Y. Matthew Goh, Carinna M. Torgerson and the dedicated staff of the Institute for Neuroimaging and Informatics at the University of Southern California. The authors declare no competing financial interests.	Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Crofts JJ, 2011, NEUROIMAGE, V54, P161, DOI 10.1016/j.neuroimage.2010.08.032; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Delac K, 2005, INT J IMAG SYST TECH, V15, P252, DOI 10.1002/ima.20059; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dinov I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013070; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Kaiser M, 2011, NETWORK-COMP NEURAL, V22, P143, DOI 10.3109/0954898X.2011.638968; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lu HP, 2008, IEEE T NEURAL NETWOR, V19, P18, DOI 10.1109/TNN.2007.901277; MacKenzie-Graham AJ, 2008, LECT NOTES COMPUT SC, V5272, P208, DOI 10.1007/978-3-540-89965-5_22; Mueller S, 2013, NEURON, V77, P586, DOI 10.1016/j.neuron.2012.12.028; Newman MEJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.208701; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Rencher AC, 2002, METHODS MULTIVARIATE, P731, DOI [10.1002/0471271357, DOI 10.1002/0471271357]; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Semendeferi K, 2002, NAT NEUROSCI, V5, P272, DOI 10.1038/nn814; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sporns O., 2011, NETWORKS BRAIN; Sporns O, 2012, NEUROIMAGE, V62, P881, DOI 10.1016/j.neuroimage.2011.08.085; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; van Horn JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037454; Vargha-Khadem F, 1994, J Child Neurol, V9 Suppl 2, P67; Zalesky A, 2010, NEUROIMAGE, V50, P970, DOI 10.1016/j.neuroimage.2009.12.027; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075	43	34	36	0	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	FEB 11	2014	8									10.3389/fnhum.2014.00051			14	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	AB7CD	WOS:000331946000001	24574993	Green Published, gold			2022-02-06	
J	Weigl, W; Milej, D; Gerega, A; Toczylowska, B; Kacprzak, M; Sawosz, P; Botvvicz, M; Maniewski, R; Mayzner-Zawadzka, E; Liebert, A				Weigl, W.; Milej, D.; Gerega, A.; Toczylowska, B.; Kacprzak, M.; Sawosz, P.; Botvvicz, M.; Maniewski, R.; Mayzner-Zawadzka, E.; Liebert, A.			Assessment of cerebral perfusion in post-traumatic brain injury patients with the use of ICG-bolus tracking method	NEUROIMAGE			English	Article						Traumatic brain injury; TBI; Brain perfusion; Bolus tracking; Time-resolved near-infrared measurements; Diffuse reflectance; Fluorescence; lndocyanine green; ICG	NEAR-INFRARED SPECTROSCOPY; DIFFUSE OPTICAL TOMOGRAPHY; ARTERIAL INPUT FUNCTION; CLOSED-HEAD INJURY; ADULT HUMAN BRAIN; INDOCYANINE GREEN; BLOOD-FLOW; NONINVASIVE MEASUREMENT; SUBARACHNOID HEMORRHAGE; CARDIOPULMONARY BYPASS	The aim of this study was to verify the usefulness of the time-resolved optical method utilizing diffusely reflected photons and fluorescence signals combined with intravenous injection of indocyanine green (ICG) in the assessment of brain perfusion in post-traumatic brain injury patients. The distributions of times of flight (DTOFs) of diffusely reflected photons were acquired together with the distributions of times of arrival (DTAs) of fluorescence photons. The data analysis methodology was based on the observation of delays between the signals of statistical moments (number of photons, mean time of flight and variance) of DTOFs and DTAs related to the inflow of ICG to the extra- and intracerebral tissue compartments. Eleven patients with brain hematoma, 15 patients with brain edema and a group of 9 healthy subjects were included in this study. Statistically significant differences between parameters obtained in healthy subjects and patients with brain hematoma and brain edema were observed. The best optical parameter to differentiate patients and control group was variance of the DTOFs or DTAs. Results of the study suggest that time-resolved optical monitoring of inflow of the ICG seems to be a promising tool for detecting cerebral perfusion insufficiencies in critically ill patients. (C) 2013 Elsevier Inc. All rights reserved.	[Weigl, W.] Med Univ Warsaw, Dept Anesthesia & Intens Care 1, Warsaw, Poland; [Weigl, W.] Warsaw Praski Hosp, Dept Anaesthesia & Intens Care, Warsaw, Poland; [Milej, D.; Gerega, A.; Toczylowska, B.; Kacprzak, M.; Sawosz, P.; Botvvicz, M.; Maniewski, R.; Liebert, A.] Polish Acad Sci, Nalecz Inst Biocybernet & Biomed Engn, Warsaw, Poland; [Mayzner-Zawadzka, E.] Univ Warmia & Mazury, Dept Anaesthesia & Intens Care, Olsztyn, Poland		Weigl, W (corresponding author), Med Univ Warsaw, Dept Anesthesia & Intens Care 1, Warsaw, Poland.	wojciech.weigl@gmail.com	Liebert, Adam/D-7654-2011; Milej, Daniel/B-6729-2014; Weigl, Wojciech/B-4294-2015; Gerega, Anna/AAR-1496-2021	Milej, Daniel/0000-0003-3173-0834; Weigl, Wojciech/0000-0001-5184-6602; Gerega, Anna/0000-0002-9809-6041; Liebert, Adam/0000-0003-1643-7568; Kacprzak, Michal/0000-0002-3149-837X; Toczylowska, Beata/0000-0002-5031-6228; Sawosz, Piotr/0000-0002-0697-3036	EC Seventh Framework ProgrammeEuropean Commission [201076]; Polish National Centre of Science [2011/03/N/ST7/02598]; European Social Fund, Human Capital Operational Programme [UDA-POKL.08.02.01-14-041/09]	Studies were financed by the EC Seventh Framework Programme under grant agreement no. 201076 project nEUROPt "Non-invasive imaging of brain function and disease by pulsed near infrared light". This work has been also supported by the Polish National Centre of Science under grant agreement 2011/03/N/ST7/02598 and by a scholarship from the European Social Fund, Human Capital Operational Programme for the execution of the project "Support for bio tech med scientists in technology transfer"; (UDA-POKL.08.02.01-14-041/09).	Aletti F, 2012, COMPUT BIOL MED, V42, P282, DOI 10.1016/j.compbiomed.2011.06.001; Becker W., 2010, ADV TIME CORRELATED; Bein B, 2006, CRIT CARE, V10, DOI 10.1186/cc3980; Brawanski A, 2002, J CEREBR BLOOD F MET, V22, P605, DOI 10.1097/00004647-200205000-00012; Brown DW, 2002, PEDIATR RES, V51, P564, DOI 10.1203/00006450-200205000-00004; Budohoski KP, 2012, BRIT J ANAESTH, V108, P89, DOI 10.1093/bja/aer324; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; COPE M, 1988, MED BIOL ENG COMPUT, V26, P289, DOI 10.1007/BF02447083; Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5; Diop M, 2011, BIOMED OPT EXPRESS, V2, P2068, DOI 10.1364/BOE.2.002068; Diop M, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3488626; Diop M, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3123347; Ducros N, 2009, PHYS MED BIOL, V54, P7107, DOI 10.1088/0031-9155/54/23/005; Ducros N, 2009, PHYS MED BIOL, V54, P7089, DOI 10.1088/0031-9155/54/23/004; Dunham CM, 2002, J TRAUMA, V52, P40, DOI 10.1097/00005373-200201000-00009; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Elliott JK, 2010, TLS-TIMES LIT SUPPL, P15; Elliott JT, 2013, BIOMED OPT EXPRESS, V4, P206, DOI 10.1364/BOE.4.000206; Gerega A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.8.087001; Gerega A, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3593386; Gora F, 2002, J NEUROSURG ANESTH, V14, P218, DOI 10.1097/00008506-200207000-00008; Habermehl C, 2011, OPT EXPRESS, V19, P18636, DOI 10.1364/OE.19.018636; Heilmann M, 2007, MAGN RESON MATER PHY, V20, P193, DOI 10.1007/s10334-007-0082-2; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529; Hopton P, 1999, J APPL PHYSIOL, V87, P1981, DOI 10.1152/jappl.1999.87.5.1981; Jelzow A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.5.057003; Kacprzak M, 2010, OPTO-ELECTRON REV, V18, P37, DOI 10.2478/s11772-009-0027-6; Kacprzak M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2743964; Kastrup A, 1999, J NEUROL SCI, V166, P91, DOI 10.1016/S0022-510X(99)00121-5; Keller E, 2003, NEUROIMAGE, V20, P828, DOI 10.1016/S1053-8119(03)00315-X; Keller E, 2002, J NEUROSCI METH, V117, P23, DOI 10.1016/S0165-0270(02)00044-4; Keller E, 2001, J NEUROSURG ANESTH, V13, P43, DOI 10.1097/00008506-200101000-00008; Kim DH, 2006, NEUROCRIT CARE, V4, P83, DOI 10.1385/NCC:4:1:083; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim MN, 2014, NEUROCRIT CARE, V20, P443, DOI 10.1007/s12028-013-9849-7; Kim MN, 2010, NEUROCRIT CARE, V12, P173, DOI 10.1007/s12028-009-9305-x; Kohl-Bareis M, 2002, J BIOMED OPT, V7, P464, DOI 10.1117/1.1482719; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kuebler WM, 1998, J CEREBR BLOOD F MET, V18, P445, DOI 10.1097/00004647-199804000-00013; Kusaka T, 2001, NEUROIMAGE, V13, P944, DOI 10.1006/nimg.2001.0755; LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575, DOI 10.1152/jappl.1976.40.4.575; Leal-Noval SR, 2010, INTENS CARE MED, V36, P1309, DOI 10.1007/s00134-010-1920-7; Leung TS, 2004, PEDIATR RES, V55, P134, DOI 10.1203/01.PDR.0000099775.87684.FB; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; Liebert A, 2006, NEUROIMAGE, V31, P600, DOI 10.1016/j.neuroimage.2005.12.046; Liebert A, 2005, NEUROIMAGE, V24, P426, DOI 10.1016/j.neuroimage.2004.08.046; Liebert A, 2004, APPL OPTICS, V43, P3037, DOI 10.1364/AO.43.003037; Liebert A, 2003, APPL OPTICS, V42, P5785, DOI 10.1364/AO.42.005785; Liebert A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.5.057005; Liebert A, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3574018; Lin PY, 2013, JOVE-J VIS EXP, DOI 10.3791/4379; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mesquita RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037322; Milej D, 2010, OPTO-ELECTRON REV, V18, P208, DOI 10.2478/s11772-010-0013-z; Milej D, 2012, PHYS MED BIOL, V57, P6725, DOI 10.1088/0031-9155/57/20/6725; Milej D, 2010, ADV INTEL SOFT COMPU, V69, P85; Mordon S, 1998, MICROVASC RES, V55, P146, DOI 10.1006/mvre.1998.2068; Mulvey JM, 2004, NEUROCRIT CARE, V1, P391, DOI 10.1385/NCC:1:3:391; Nabavi DG, 2001, STROKE, V32, P175, DOI 10.1161/01.STR.32.1.175; Nabavi DG, 2001, NEURORADIOLOGY, V43, P7, DOI 10.1007/s002340000434; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Ohmae E, 2006, NEUROIMAGE, V29, P697, DOI 10.1016/j.neuroimage.2005.08.008; Patel J, 1998, PEDIATR RES, V43, P34, DOI 10.1203/00006450-199801000-00006; Petrella JR, 2000, AM J ROENTGENOL, V175, P207, DOI 10.2214/ajr.175.1.1750207; Port RE, 2001, MAGNET RESON MED, V45, P1030, DOI 10.1002/mrm.1137; Reekers M, 2009, ANESTH ANALG, V109, P441, DOI 10.1213/ane.0b013e3181a8d81f; Roberts HC, 2002, AM J NEURORADIOL, V23, P828; Roberts IG, 1998, J THORAC CARDIOV SUR, V115, P94, DOI 10.1016/S0022-5223(98)70447-7; Sawosz P, 2012, PHYS MED BIOL, V57, P7973, DOI 10.1088/0031-9155/57/23/7973; Schytz HW, 2009, EUR J NEUROL, V16, P461, DOI 10.1111/j.1468-1331.2008.02398.x; Selb J, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1852553; Selb J, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2337320; Sheikh K, 2009, AM J ROENTGENOL, V192, pW321, DOI 10.2214/AJR.07.3677; Springett R, 2001, PHYS MED BIOL, V46, P2209, DOI 10.1088/0031-9155/46/8/312; St Lawrence K, 2013, PHYS MED BIOL, V58, P1591, DOI 10.1088/0031-9155/58/5/1591; Steinbrink J, 2008, NEURODEGENER DIS, V5, P296, DOI 10.1159/000135614; Steinbrink J, 2001, PHYS MED BIOL, V46, P879, DOI 10.1088/0031-9155/46/3/320; Steinbrink J, 2006, J THORAC CARDIOV SUR, V132, P1172, DOI 10.1016/j.jtcvs.2006.05.065; Steinkellner O., 2010, BIOMEDICAL OPTICS; Steinkellner O, 2012, BIOCYBERN BIOMED ENG, V32, P3, DOI 10.1016/S0208-5216(12)70028-1; Steinkellner O, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3505009; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; Terborg C, 2004, J NEUROL NEUROSUR PS, V75, P38; The Brain Trauma Foundation, 2007, J NEUROTRAUM, V24, P7; van Osch MJP, 2001, MAGN RESON MED, V45, P477, DOI 10.1002/1522-2594(200103)45:3<477::AID-MRM1063>3.0.CO;2-4; Verdecchia K, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.027007; VILLRINGER A, 1993, NEUROSCI LETT, V154, P101, DOI 10.1016/0304-3940(93)90181-J; Wabnitz H, 2010, ADV EXP MED BIOL, V662, P143, DOI 10.1007/978-1-4419-1241-1_20; Wintermark M, 2005, J NEURORADIOLOGY, V32, P294, DOI 10.1016/S0150-9861(05)83159-1; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824	93	34	34	0	31	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 15	2014	85		1		SI		555	565		10.1016/j.neuroimage.2013.06.065			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	278DQ	WOS:000328869700053	23831529				2022-02-06	
J	Jones, SAV; Breakey, RW; Evans, PJ				Jones, Simon Andrew Vann; Breakey, Richard William; Evans, Philip John			Heading in football, long-term cognitive decline and dementia: evidence from screening retired professional footballers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Aging; Concussion; Epidemiology; Neurology; Soccer	TRAUMATIC BRAIN-INJURY; SOCCER PLAYERS; MEMORY TEST; IMPAIRMENT; PREVALENCE; DEFICITS	Background Heading impairs cognition in the short and medium-terms; however, little is known about the long-term consequences. This study aimed to investigate the hypothesis that chronic low-level head trauma is associated with persistent cognitive decline. Methods All members of Former Player Associations (FPAs) from four professional football clubs in the UK were contacted to participate in the study. Participants were required to complete a self-assessed test of cognition, the Test Your Memory questionnaire. Further information was collected from respondents in order to analyse the potential effect of a number of variables on cognition. Results 10 of 92 respondents (10.87%) screened positive for possible mild cognitive impairment (MCI) or dementia. There was no association between low-risk and high-risk playing positions (HR=0.40, p=0.456) or length of playing career (HR=1.051 95% CI 0.879 to 1.257, p=0.586) and a positive screening result. Age was a risk factor (HR=1.137 per additional year, 95% CI 1.030 to 1.255, p<0.05), although this was not significantly different from the population prevalence across age groups. Conclusions These results suggest that once a player ends their playing career, their risk of harm falls in line with the population, suggesting either that changes are reversible or that heading may not be as harmful as commonly thought. Future longitudinal studies of large numbers of professional football players are needed to support the findings from this study.	[Jones, Simon Andrew Vann] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England; [Breakey, Richard William] Newcastle Upon Tyne Hosp, Dept Pathol, Newcastle Upon Tyne, Tyne & Wear, England; [Evans, Philip John] Durham & Darlington NHS Fdn Trust, Dept Gen Med, Durham, England		Jones, SAV (corresponding author), Newcastle Univ, Inst Ageing & Hlth, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.	simonvj@gmail.com			National Institute for Health Research (NIHR) Academic Foundation Programme; Newcastle upon Tyne Hospitals (NUTH) NHS Foundation Trust; Newcastle University; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2013-13-017] Funding Source: researchfish	This research was supported by the National Institute for Health Research (NIHR) Academic Foundation Programme and Newcastle upon Tyne Hospitals (NUTH) NHS Foundation Trust and Newcastle University. The views expressed are those of the authors and not necessarily those of the NHS, NUTH, the NIHR or the Department of Health	Brogger J, 2002, AM J EPIDEMIOL, V155, P572, DOI 10.1093/aje/155.6.572; Brown J, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2030; Crawford FC, 2007, BRAIN RES, V1185, P45, DOI 10.1016/j.brainres.2007.09.042; Fish M, 2008, NEUROEPIDEMIOLOGY, V30, P25, DOI 10.1159/000115439; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koekkoek PS, 2013, J NEUROL SCI, V328, P92, DOI 10.1016/j.jns.2013.02.028; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Punnoose AR, 2012, JAMA-J AM MED ASSOC, V307, P1012, DOI 10.1001/jama.2012.231; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; van Schalkwyk G, 2012, J GERIATR PSYCH NEUR, V25, P85, DOI 10.1177/0891988712447895; Ward A, 2012, ALZHEIMERS DEMENT, V8, P14, DOI 10.1016/j.jalz.2011.01.002; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143	20	34	34	1	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					159	U170		10.1136/bjsports-2013-092758			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	276KK	WOS:000328749000020	24026299				2022-02-06	
J	Raj, R; Skrifvars, MB; Bendel, S; Selander, T; Kivisaari, R; Siironen, J; Reinikainen, M				Raj, Rahul; Skrifvars, Markus Benedikt; Bendel, Stepani; Selander, Tuomas; Kivisaari, Riku; Siironen, Jari; Reinikainen, Matti			Predicting six-month mortality of patients with traumatic brain injury: usefulness of common intensive care severity scores	CRITICAL CARE			English	Article							MULTIPLE ORGAN DYSFUNCTION; FAILURE ASSESSMENT SCORE; GLASGOW COMA SCALE; PROGNOSTIC VALUE; EXTERNAL VALIDATION; HOSPITAL MORTALITY; ACUTE PHYSIOLOGY; ICU PATIENTS; SOFA SCORE; SAPS-II	Introduction: The aim of this study was to evaluate the usefulness of the APACHE II (Acute Physiology and Chronic Health Evaluation II), SAPS II (Simplified Acute Physiology Score II) and SOFA (Sequential Organ Failure Assessment) scores compared to simpler models based on age and Glasgow Coma Scale (GCS) in predicting long-term outcome of patients with moderate-to-severe traumatic brain injury (TBI) treated in the intensive care unit (ICU). Methods: A national ICU database was screened for eligible TBI patients (age over 15 years, GCS 3-13) admitted in 2003-2012. Logistic regression was used for customization of APACHE II, SAPS II and SOFA score-based models for six-month mortality prediction. These models were compared to an adjusted SOFA-based model (including age) and a reference model (age and GCS). Internal validation was performed by a randomized split-sample technique. Prognostic performance was determined by assessing discrimination, calibration and precision. Results: In total, 1,625 patients were included. The overall six-month mortality was 33%. The APACHE II and SAPS II-based models showed good discrimination (area under the curve (AUC) 0.79, 95% confidence interval (CI) 0.75 to 0.82; and 0.80, 95% CI 0.77 to 0.83, respectively), calibration (P > 0.05) and precision (Brier score 0.166 to 0.167). The SOFA-based model showed poor discrimination (AUC 0.68, 95% CI 0.64 to 0.72) and precision (Brier score 0.201) but good calibration (P > 0.05). The AUC of the SOFA-based model was significantly improved after the insertion of age and GCS (Delta AUC + 0.11, P < 0.001). The performance of the reference model was comparable to the APACHE II and SAPS II in terms of discrimination (AUC 0.77; compared to APACHE II, Delta AUC -0.02, P = 0.425; compared to SAPS II, Delta AUC -0.03, P = 0.218), calibration (P > 0.05) and precision (Brier score 0.181). Conclusions: A simple prognostic model, based only on age and GCS, displayed a fairly good prognostic performance in predicting six-month mortality of ICU-treated patients with TBI. The use of the more complex scoring systems APACHE II, SAPS II and SOFA added little to the prognostic performance.	[Raj, Rahul; Kivisaari, Riku; Siironen, Jari] Univ Helsinki, Cent Hosp, Dept Neurosurg, FI-00029 Helsinki, HUS, Finland; [Skrifvars, Markus Benedikt] Univ Helsinki, Cent Hosp, Dept Anesthesiol Intens Care Emergency Care & Pai, FI-00029 Helsinki, HUS, Finland; [Bendel, Stepani] Kuopio Univ Hosp, Dept Intens Care, Kuopio 70211, Finland; [Bendel, Stepani] Univ Kuopio, FIN-70211 Kuopio, Finland; [Selander, Tuomas] Kuopio Univ Hosp, Sci Serv Ctr, Kuopio 70211, Finland; [Reinikainen, Matti] North Karelia Cent Hosp, Dept Intens Care, Joensuu 80210, Finland		Raj, R (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, Topeliuksenkatu 5,PB 266, FI-00029 Helsinki, HUS, Finland.	rahul.br.raj@icloud.com	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591; Reinikainen, Matti/0000-0001-6878-3740	Helsinki University Hospital EVO grant [TYH2012142]; Medicinska Understods foreningen Liv och Halsa; Finska Lakaresallskapet; Maire Taponen Foundation	The authors declare that they have no conflict of interest. The study was funded by a Helsinki University Hospital EVO grant (TYH2012142), Medicinska Understods foreningen Liv och Halsa, Finska Lakaresallskapet and the Maire Taponen Foundation.	Angus DC, 2000, CRIT CARE MED, V28, P2145, DOI 10.1097/00003246-200006000-00088; Bertolini G, 2000, J Epidemiol Biostat, V5, P251; Brinkman S, 2013, INTENS CARE MED, V39, P1925, DOI 10.1007/s00134-013-3042-5; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Finazzi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016110; HILDEN J, 1978, METHOD INFORM MED, V17, P238; Hosmer DW, 1997, STAT MED, V16, P965; Huang SS, 2012, RESUSCITATION, V83, P591, DOI 10.1016/j.resuscitation.2011.12.014; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Kundu S, 2011, EUR J EPIDEMIOL, V26, P261, DOI 10.1007/s10654-011-9567-4; Le Gall JR, 2005, INTENS CARE MED, V31, P1618, DOI 10.1007/s00134-005-2825-8; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1994, JAMA-J AM MED ASSOC, V272, P1049, DOI 10.1001/jama.272.13.1049; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Livingston BM, 2000, CRIT CARE MED, V28, P1820, DOI 10.1097/00003246-200006000-00023; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Minne L, 2008, CRIT CARE, V12, DOI 10.1186/cc7160; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nattino G, 2014, STAT MED, V33, P2390, DOI 10.1002/sim.6100; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pettila V, 2002, CRIT CARE MED, V30, P1705, DOI 10.1097/00003246-200208000-00005; PICARD RR, 1990, AM STAT, V44, P140, DOI 10.2307/2684155; Poole D, 2012, INTENS CARE MED, V38, P1280, DOI 10.1007/s00134-012-2578-0; Pouw ME, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5913; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Reinikainen M, 2012, ACTA ANAESTH SCAND, V56, P1114, DOI 10.1111/j.1399-6576.2012.02669.x; Reiter A, 2004, J TRAUMA, V57, P375, DOI 10.1097/01.TA.0000104016.78539.94; Ridley S, 1998, ANAESTHESIA, V53, P1185, DOI 10.1046/j.1365-2044.1998.00615.x; Roberts BW, 2013, CRIT CARE MED, V41, P1492, DOI 10.1097/CCM.0b013e31828a39e9; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; Rothen HU, 2008, CURR OPIN CRIT CARE, V14, P513, DOI 10.1097/MCC.0b013e32830864e9; Schirmer-Mikalsen K, 2013, ACTA ANAESTH SCAND, V57, P46, DOI 10.1111/j.1399-6576.2012.02785.x; Serrano N, 2012, INTENS CARE MED, V38, P1246, DOI 10.1007/s00134-012-2579-z; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Sturdivant RX, 2013, APPL LOGISTIC REGRES, V3rd; Vassar MJ, 1999, J TRAUMA, V47, P324, DOI 10.1097/00005373-199908000-00017; Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8204; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Woodhouse D, 2009, CURR OPIN CRIT CARE, V15, P450, DOI 10.1097/MCC.0b013e32833079fb	51	34	36	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2014	18	2							R60	10.1186/cc13814			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM1SA	WOS:000339627400078	24708781	Green Published, gold			2022-02-06	
J	Hasebe, N; Fujita, Y; Ueno, M; Yoshimura, K; Fujino, Y; Yamashita, T				Hasebe, Noriko; Fujita, Yuki; Ueno, Masaki; Yoshimura, Kazuhiro; Fujino, Yuji; Yamashita, Toshihide			Soluble beta-amyloid Precursor Protein Alpha Binds to p75 Neurotrophin Receptor to Promote Neurite Outgrowth	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; NERVE GROWTH-FACTOR; ALZHEIMERS-DISEASE; CELL-DEATH; APP BINDS; NEURONS; P75(NTR); MICE; RHO; EXPRESSION	Background: The cleavage of beta-amyloid precursor protein (APP) generates multiple proteins: Soluble beta-amyloid Precursor Protein Alpha (sAPP alpha), sAPP beta, and amyloid beta (A beta). Previous studies have shown that sAPP alpha and sAPP beta possess neurotrophic properties, whereas A beta is neurotoxic. However, the underlying mechanism of the opposing effects of APP fragments remains poorly understood. In this study, we have investigated the mechanism of sAPP alpha-mediated neurotrophic effects. sAPP alpha and sAPP beta interact with p75 neurotrophin receptor (p75(NTR)), and sAPP alpha promotes neurite outgrowth. Methods and Findings: First, we investigated whether APP fragments interact with p75(NTR), because full-length APP and A beta have been shown to interact with p75(NTR) in vitro. Both sAPP alpha and sAPP beta were co-immunoprecipitated with p75(NTR) and co-localized with p75(NTR) on COS-7 cells. The binding affinity of sAPP alpha and sAPP beta for p75(NTR) was confirmed by enzyme-linked immunosorbent assay (ELISA). Next, we investigated the effect of sAPP alpha on neurite outgrowth in mouse cortical neurons. Neurite outgrowth was promoted by sAPP alpha, but sAPP alpha was uneffective in a knockdown of p75(NTR). Conclusion: We conclude that p75(NTR) is the receptor for sAPP alpha to mediate neurotrophic effects.	[Hasebe, Noriko; Fujita, Yuki; Ueno, Masaki; Yoshimura, Kazuhiro; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Osaka, Japan; [Hasebe, Noriko; Fujino, Yuji] Osaka Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Osaka, Japan; [Hasebe, Noriko; Fujita, Yuki; Ueno, Masaki; Yamashita, Toshihide] Japan Sci & Technol Agcy JST, CREST, Tokyo, Japan; [Ueno, Masaki] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Yoshimura, Kazuhiro] Osaka Univ, Grad Sch Med, Dept Neurosurg, Osaka, Japan		Yamashita, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Osaka, Japan.	yamashita@molneu.med.osaka-u.ac.jp	Ueno, Masaki/J-1216-2019	Ueno, Masaki/0000-0003-1484-9921; Yamashita, Toshihide/0000-0003-4559-7018	JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [25221309]	This work was supported by a Grant-in-Aid for Scientific Research (S) from JSPS (25221309) to T.Y. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akar CA, 1998, MOL BRAIN RES, V56, P125, DOI 10.1016/S0169-328X(98)00037-0; Ben-Zvi A, 2007, J NEUROSCI, V27, P13000, DOI 10.1523/JNEUROSCI.3373-07.2007; Chasseigneaux S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016301; Clarris HJ, 1997, J NEUROCHEM, V68, P1164; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Fombonne J, 2009, ANN NEUROL, V65, P294, DOI 10.1002/ana.21578; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Guenette S, 2006, EMBO J, V25, P420, DOI 10.1038/sj.emboj.7600926; Hartmann D, 1999, CURR BIOL, V9, P719, DOI 10.1016/S0960-9822(99)80331-5; Hashimoto Y, 2004, J NEUROSCI RES, V75, P417, DOI 10.1002/jnr.10861; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Higuchi H, 2003, BIOCHEM BIOPH RES CO, V301, P804, DOI 10.1016/S0006-291X(03)00029-9; JIN LW, 1994, J NEUROSCI, V14, P5461; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kim D, 2009, CELL, V137, P997, DOI 10.1016/j.cell.2009.05.042; Knowles JK, 2009, J NEUROSCI, V29, P10627, DOI 10.1523/JNEUROSCI.0620-09.2009; Kobayashi S, 2010, NEUROCHEM INT, V56, P387, DOI 10.1016/j.neuint.2009.11.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; Luo JJ, 2001, J NEUROSCI RES, V63, P410, DOI 10.1002/1097-4547(20010301)63:5<410::AID-JNR1036>3.0.CO;2-B; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Nakazawa H, 2012, J NEUROSCI, V32, P12712, DOI 10.1523/JNEUROSCI.0989-12.2012; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; NINOMIYA H, 1994, J NEUROCHEM, V63, P495; Rossner S, 1998, J NEUROCHEM, V71, P757; SALBAUM JM, 1994, J EXP ZOOL, V269, P116, DOI 10.1002/jez.1402690205; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; SMALL DH, 1994, J NEUROSCI, V14, P2117; Sotthibundhu A, 2008, J NEUROSCI, V28, P3941, DOI 10.1523/JNEUROSCI.0350-08.2008; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Ueno M, 2013, NAT NEUROSCI, V16, P543, DOI 10.1038/nn.3358; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Yaar M, 2007, NEUROPATH APPL NEURO, V33, P533, DOI 10.1111/j.1365-2990.2007.00844.x; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yoshimura K, 2011, NEUROSCI RES, V71, P266, DOI 10.1016/j.neures.2011.07.1830	41	34	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e82321	10.1371/journal.pone.0082321			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276GD	WOS:000328735700057	24358169	Green Submitted, Green Published, gold			2022-02-06	
J	Begum, G; Harvey, L; Dixon, CE; Sun, DD				Begum, Gulnaz; Harvey, Lloyd; Dixon, C. Edward; Sun, Dandan			ER Stress and Effects of DHA as an ER Stress Inhibitor	TRANSLATIONAL STROKE RESEARCH			English	Article						C/EBP homologous protein; ER-associated protein degradation; ER Ca2+ dysregulation; Eukaryotic translation initiation factor 2 alpha subunit; Unfolded protein response	TRAUMATIC BRAIN-INJURY; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; POLYUNSATURATED FATTY-ACIDS; SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; INTRACELLULAR CA2+; ANTI-INFLAMMATION; OXIDATIVE STRESS; GENE-EXPRESSION	The endoplasmic reticulum (ER) functions in the synthesis, folding, modification, and transport of newly synthesized transmembrane and secretory proteins. The ER also has important roles in the storage of intracellular Ca2+ and regulation of Ca2+ homeostasis. The integrity of the Ca2+ homeostasis in the ER lumen is vital for proper folding of proteins. Dysregulation of ER Ca2+ could result in an increase in unfolded or misfolded proteins and ER stress. ER stress triggers activation of the unfolded protein response (UPR), which is a fundamentally adaptive cell response and functions as a cytoprotective mechanism by over-expression of relevant chaperones and the global shutdown of protein synthesis. UPR activation occurs when three key ER membrane-sensor proteins detect an accumulation of aberrant proteins. The UPR acts to alleviate ER stress, but if the stress is too severe or prolonged, apoptosis will be triggered. In this review, we focused on ER stress and the effects of docosahexaenoic acid (DHA) on ER stress. DHA and its bioactive compounds, such as protectins and resolvins, provide neuroprotection against oxidative stress and apoptosis and have the ability to resolve inflammation in neurological diseases. New studies reveal that DHA blocks inositol trisphosphate receptor (IP3R)-mediated ER Ca2+ depletion and ER stress. The administration of DHA post-traumatic brain injury (TBI) reduces ER stress, aberrant protein accumulation, and neurological deficits. Therefore, DHA presents therapeutic potentials for TBI via its pleiotropic effects including inhibition of ER stress.	[Begum, Gulnaz; Harvey, Lloyd; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; [Sun, Dandan] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA		Sun, DD (corresponding author), Univ Pittsburgh, Dept Neurol, Sch Med, S-598 South Biomed Sci Tower BST,500 Terrace St, Pittsburgh, PA 15213 USA.	d.sun64@gmail.com		Harvey, Lloyd/0000-0001-5934-9934	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS048216, R01NS48216]; United States Department of Veterans Affairs VA RRD [B6761R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038118, R01NS048216] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health Research grant R01NS048216 and R01NS48216 (DS) and the United States Department of Veterans Affairs VA RR&D#B6761R grant (CED).	Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Anderson Ethan J, 2012, F1000 Med Rep, V4, P13, DOI 10.3410/M4-13; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Banhegyi G, 2007, ANN NY ACAD SCI, V1113, P58, DOI 10.1196/annals.1391.007; Bazan NG, 2006, CELL MOL NEUROBIOL, V26, P901, DOI 10.1007/s10571-006-9064-6; Bazan NG, 2007, CURR OPIN CLIN NUTR, V10, P136, DOI 10.1097/MCO.0b013e32802b7030; Begum G, 2013, DHA REDUCES ER UNPUB; Begum G, 2012, NEUR M PLANN; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; BOURRE JM, 1989, J NUTR, V119, P1880, DOI 10.1093/jn/119.12.1880; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Buck TM, 2007, SEMIN CELL DEV BIOL, V18, P751, DOI 10.1016/j.semcdb.2007.09.001; Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010; Calder PC, 2010, NUTRIENTS, V2, P355, DOI 10.3390/nu2030355; Catalan J, 2002, BEHAV NEUROSCI, V116, P1022, DOI 10.1037//0735-7044.116.6.1022; Chalon S, 1998, J NUTR, V128, P2512, DOI 10.1093/jn/128.12.2512; Chen XZ, 2008, J NEUROCHEM, V106, P1563, DOI 10.1111/j.1471-4159.2008.05501.x; Chiribau CB, 2010, MOL CELL BIOL, V30, P3722, DOI 10.1128/MCB.01507-09; Deckelbaum RJ, 2006, AM J CLIN NUTR, V83, p1520S, DOI 10.1093/ajcn/83.6.1520S; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Eady Tiffany N, 2012, Exp Transl Stroke Med, V4, P19, DOI 10.1186/2040-7378-4-19; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Fedorova I, 2007, PROSTAG LEUKOTR ESS, V77, P269, DOI 10.1016/j.plefa.2007.10.013; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaur P, 2008, NEUROTOXICOLOGY, V29, P978, DOI 10.1016/j.neuro.2008.06.004; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Mirnikjoo B, 2001, J BIOL CHEM, V276, P10888, DOI 10.1074/jbc.M008150200; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Papp S, 2003, J CELL BIOL, V160, P475, DOI 10.1083/jcb.200207136; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; Paschen W, 2003, CELL CALCIUM, V33, P83, DOI 10.1016/S0143-4160(02)00195-1; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Seebungkert B, 2002, EUR J NEUROSCI, V16, P2085, DOI 10.1046/j.1460-9568.2002.02288.x; Sergeeva M, 2005, REPROD NUTR DEV, V45, P633, DOI 10.1051/rnd:2005050; Serhan CN, 2008, BRIT J PHARMACOL, V153, pS200, DOI 10.1038/sj.bjp.0707489; Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031; Sidhu VK, 2011, J PROTEOME RES, V10, P5472, DOI 10.1021/pr2007285; Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311; Singh Meharban, 2005, Indian Journal of Pediatrics, V72, P239, DOI 10.1007/BF02859265; Solovyova N, 2002, EMBO J, V21, P622, DOI 10.1093/emboj/21.4.622; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Suzuki H, 1998, MECH AGEING DEV, V101, P119, DOI 10.1016/S0047-6374(97)00169-3; Thorell WE, 2002, J NEUROTRAUM, V19, P335, DOI 10.1089/089771502753594909; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Turner N, 2003, NATURWISSENSCHAFTEN, V90, P521, DOI 10.1007/s00114-003-0470-z; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Valenzuela V, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.8; Vreugdenhil M, 1996, P NATL ACAD SCI USA, V93, P12559, DOI 10.1073/pnas.93.22.12559; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Wang ZF, 2013, EXP THER MED, V5, P107, DOI 10.3892/etm.2012.745; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Ying Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052998; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Yoshida S, 1997, J NEUROCHEM, V68, P1261; Zhao GX, 2005, BIOCHEM BIOPH RES CO, V336, P909, DOI 10.1016/j.bbrc.2005.08.204	88	34	37	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2013	4	6					635	642		10.1007/s12975-013-0282-1			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	258NE	WOS:000327465200006	24323417	Green Accepted			2022-02-06	
J	Schatz, P; Maerlender, A				Schatz, Philip; Maerlender, Arthur			A Two-Factor Theory for Concussion Assessment Using ImPACT: Memory and Speed	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						concussion; neurocognitive testing; reliability; validity; ImPACT	TEST-RETEST RELIABILITY; CONSTRUCT-VALIDITY; CLINICAL UTILITY; SPORT; BATTERY	We present the initial validation of a two-factor structure of Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) using ImPACT composite scores and document the reliability and validity of this factor structure. Factor analyses were conducted for baseline (N 21,537) and post-concussion (N 560) data, yielding Memory (Verbal and Visual) and Speed (Visual Motor Speed and Reaction Time) Factors; inclusion of Total Symptom Scores resulted in a third discrete factor. Speed and Memory z-scores were calculated, and testretest reliability (using intra-class correlation coefficients) at 1 month (0.88/0.81), 1 year (0.85/0.75), and 2 years (0.76/0.74) were higher than published data using Composite scores. Speed and Memory scores yielded 89 sensitivity and 70 specificity, which was higher than composites (80/62) and comparable with subscales (91/69). This emergent two-factor structure has improved testretest reliability with no loss of sensitivity/specificity and may improve understanding and interpretability of ImPACT test results.	[Schatz, Philip] St Josephs Univ, Philadelphia, PA 19131 USA; [Maerlender, Arthur] Geisel Sch Med Dartmouth, Hanover, NH USA		Schatz, P (corresponding author), St Josephs Univ, 222 Post Hall,5600 City Ave, Philadelphia, PA 19131 USA.	pschatz@sju.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey	P.S. has received funding to study the effects of concussion in high school and collegiate athletes from the International Brain Research Foundation, the Sports Concussion Center of New Jersey. He has also served as a consultant to ImPACT Applications Inc. A. M. has no conflict to declare.	Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; American Psychological Association (APA), 1986, GUID COMP BAS TESTS; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Chicchetti D. V., 1994, PSYCHOL ASSESSMENT, V6, P294, DOI DOI 10.1037//1040-3590.6.4.284; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lovell M. R, 2004, IMPACT VERSION 2 0 C; Lovell M. R., 2005, IMPACT VERSION 4 0 C; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2007, IMPACT VERSION 6 0 C; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nakayama Y., 2013, THESIS MICHIGAN STAT; Randolph C, 2006, J ATHL TRAINING, V41, P138; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1	31	34	34	2	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2013	28	8					791	797		10.1093/arclin/act077			7	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	262FC	WOS:000327718700006	24123401	Bronze, Green Published			2022-02-06	
J	McGannon, KR; Cunningham, SM; Schinke, RJ				McGannon, Kerry R.; Cunningham, Sarah M.; Schinke, Robert J.			Understanding concussion in socio-cultural context: A media analysis of a National Hockey League star's concussion	PSYCHOLOGY OF SPORT AND EXERCISE			English	Article						Concussion; Media analysis; Cultural sport psychology	HEGEMONIC MASCULINITY; SPORTS CONCUSSION; INJURY; PSYCHOLOGY; RISK; REPRESENTATIONS; PLAYERS; ISSUE; BODY	Objectives: Sport psychology researchers have yet to explore the socio-cultural context of concussion. The aim with this study was to explore the contribution of one socio-cultural context (i.e., sport media) toward understanding the construction of meaning(s) of a sport celebrity's concussion and the implications for sport psychology. Design: A qualitative approach was used to explore concussion as a socio-cultural issue shaped by cultural narratives (i.e., news media). The meanings and implications for how sport concussion is understood and "constructed" through a key media incident were of interest. Method: An ethnographic content analysis (see Altheide, 1996) of the mediation of the National Hockey League's (NHL) star player Sidney Crosby's concussion from January 1, am (when the concussion occurred) to June 30, 2011 (end of the NHL season) was undertaken on North American news data. Results: The ethnographic content analysis of 68 articles revealed that Crosby's concussion and its associated meanings were constructed within a central narrative: a culture of-risk and its impact on athletes. Multiple meanings of concussion within the risk narrative emerged depending on three sub-narratives: (a) Crosby's concussion as a cautionary tale, (b) Crosby's concussion as a political platform, and (c) concussion as ambiguous. Conclusions: The culture of risk narrative raises awareness of the physical risks, physiological effects and the politics of concussion. These cultural meanings do not acknowledge/include the psychological implications/effects of concussion. This study furthers understandings of sport concussion within a sociocultural context. (C) 2013 Elsevier Ltd. All rights reserved.	[McGannon, Kerry R.; Cunningham, Sarah M.; Schinke, Robert J.] Laurentian Univ, Sch Human Kinet, Sudbury, ON P3E 2C6, Canada		McGannon, KR (corresponding author), Laurentian Univ, Sch Human Kinet, Sudbury, ON P3E 2C6, Canada.	kmcgannon@laurentian.ca	Schinke, Robert/AAS-2966-2020; McGannon, Kerry R./M-2213-2016	McGannon, Kerry R./0000-0002-8614-697X; Schinke, Robert J./0000-0002-4432-0730			Allain KA, 2011, INT REV SOCIOL SPORT, V46, P3, DOI 10.1177/1012690210376294; Altheide D., 1996, QUALITATIVE RES METH, V38; Amin K., 2012, MEDUCATOR, V1, P14; Anderson E, 2012, MEN MASC, V15, P152, DOI 10.1177/1097184X11430127; ANDREWS DL, 2001, SPORT STARS CULTURAL, P1; Arthur B., 2011, NATL POST       0314; Barth JT, 2012, J CLIN SPORT PSYCHOL, V6, P409, DOI 10.1123/jcsp.6.4.409; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; BIRRELL S, 2000, READING SPORT CRITIC; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Coakley J.J., 2009, SPORTS SOC ISSUES CO, V10th ed.; Connell RW, 2005, GENDER SOC, V19, P829, DOI 10.1177/0891243205278639; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Donnelly Peter., 2004, SPORTING BODIES DAMA, P29, DOI DOI 10.1016/S1476-2854(04)02001-1; Fallis J, 2012, CAN MED ASSOC J, V184, pE113, DOI 10.1503/cmaj.109-4080; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Gutkin C, 2011, CAN FAM PHYSICIAN, V57, P968; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Mainwaring L, 2012, J CLIN SPORT PSYCHOL, V6, P307, DOI 10.1123/jcsp.6.4.307; Mainwaring L, 2012, J CLIN SPORT PSYCHOL, V6, P203, DOI 10.1123/jcsp.6.3.203; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; McCrory P, 2008, S AFR J SPORTS MED, V21, P36; McGannon KR, 2012, PSYCHOL SPORT EXERC, V13, P820, DOI 10.1016/j.psychsport.2012.06.005; McGannon KR, 2012, PSYCHOL SPORT EXERC, V13, P26, DOI 10.1016/j.psychsport.2011.08.001; Messner M. A., 1990, International Review for the Sociology of Sport, V25, P203, DOI 10.1177/101269029002500303; Messner M. A., 2000, Journal of Sport & Social Issues, V24, P380, DOI 10.1177/0193723500244006; Messner M.A., 2007, OUT PLAY CRITICAL ES; Nixon H. L. II, 1992, Journal of Sport and Social Issues, V16, P127, DOI 10.1177/019372359201600208; NIXON HL, 1993, SOCIOL SPORT J, V10, P183, DOI 10.1123/ssj.10.2.183; Ryba T. V., 2010, CULTURAL TURN SPORT; Safai P, 2003, SOCIOL SPORT J, V20, P127, DOI 10.1123/ssj.20.2.127; Schinke R, 2009, SPORTS ATHL PREP PER, P1; Smith B., 2010, INT REV SPORT EXER P, V3, P87, DOI [10.1080/17509840903390937, DOI 10.1080/17509840903390937]; Smith B, 2013, HEALTH PSYCHOL, V32, P110, DOI 10.1037/a0029187; Smith M. D., 1978, SPORT PSYCHOL ANAL A, P187; Sparkes AC, 2008, DISABIL SOC, V23, P679, DOI 10.1080/09687590802469172; Sparkes AC, 2009, PSYCHOL SPORT EXERC, V10, P491, DOI 10.1016/j.psychsport.2009.02.006; TRUJILLO N, 1991, CRIT STUD MASS COMM, V8, P290, DOI 10.1080/15295039109366799; Visek A, 2005, SPORT PSYCHOL, V19, P178, DOI 10.1123/tsp.19.2.178; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Whannel G., 2002, MEDIA SPORT STARS MA; Wiese-Bjornstal DM, 2010, SCAND J MED SCI SPOR, V20, P103, DOI 10.1111/j.1600-0838.2010.01195.x; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Young, 2004, SPORTING BODIES DAMA, P59; YOUNG K, 1994, SOCIOL SPORT J, V11, P175, DOI 10.1123/ssj.11.2.175; YOUNG K, 1993, SOCIOL SPORT J, V10, P373, DOI 10.1123/ssj.10.4.373; Young K., 2004, SPORTING BODIES DAMA, P1; ZIRIN D, 2005, WHATS MY NAME FOOL S	51	34	34	1	31	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1469-0292	1878-5476		PSYCHOL SPORT EXERC	Psychol. Sport Exerc.	NOV	2013	14	6					891	899		10.1016/j.psychsport.2013.08.003			9	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Psychology; Sport Sciences	251DI	WOS:000326907600015					2022-02-06	
J	Sasse, N; Gibbons, H; Wilson, L; Martinez-Olivera, R; Schmidt, H; Hasselhorn, M; von Wild, K; von Steinbuchel, N				Sasse, Nadine; Gibbons, Henning; Wilson, Lindsay; Martinez-Olivera, Ramon; Schmidt, Holger; Hasselhorn, Marcus; von Wild, Klaus; von Steinbuechel, Nicole			Self-Awareness and Health-Related Quality of Life After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						health-related quality of life; impaired self-awareness; self-awareness	THERAPEUTIC WORKING ALLIANCE; COMPETENCE RATING-SCALE; IMPAIRED AWARENESS; HOSPITAL ANXIETY; REHABILITATION; DEPRESSION; VALIDITY; DEFICITS; MODERATE; QOLIBRI	Objective: To investigate the relations among self-awareness (SA), impaired SA, and health-related quality of life (HRQOL) after traumatic brain injury (TBI). Participants: One hundred forty-one adults hospitalized with TBI and their significant others from a cross-sectional multicenter study. Using Glasgow Coma Scale classification, 32 participants had severe injuries, 29 moderate, 44 mild, and 25 complicated mild TBI. Measures: Patient Competency Rating Scale for Neurorehabilitation; Short Form-36 Health Survey; Cognitive Quality of Life; Quality Of Life after Brain Injury; Hospital Anxiety and Depression Scale; Profile of Mood States; Glasgow Outcome Scale Extended. Method: Patient Competency Rating Scale for Neurorehabilitation ratings made by participants and their significant others were used to assess SA and discrepancies between the 2 ratings were used to define impaired SA. Results: Significant associations were identified between SA and HRQOL, anxiety, depression, and severity of injury. Participants with and without impaired SA differed in cognitive HRQOL and leisure activities. Using multiple regression, no direct predictors of SA were identified, although interaction effects were observed. Conclusion: After TBI, lower SA is associated with higher estimates of HRQOL, particularly in the cognitive domain. Although the associations are modest, the assessment of SA should play a role in the interpretation of reported HRQOL after TBI.	[Sasse, Nadine; Gibbons, Henning; von Steinbuechel, Nicole] Univ Med Ctr, Dept Med Psychol & Med Sociol, Gottingen, Germany; [Martinez-Olivera, Ramon] Univ Med Ctr, Dept Neurosurg, Gottingen, Germany; [Schmidt, Holger] Univ Med Ctr, Dept Neurol, Gottingen, Germany; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [Hasselhorn, Marcus] German Inst Int Educ Res DIPF, Frankfurt, Germany; [von Wild, Klaus] KvW Neurosci Consulting, Munster, Germany		Sasse, N (corresponding author), Univ Med Ctr Gottingen, Dept Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany.	n.sasse@med.uni-goettingen.de	Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328	ZNS-Hannelore Kohl Foundation, Germany [2008014]	This study was funded by the ZNS-Hannelore Kohl Foundation, Germany (project number 2008014). Participant recruitment was assisted by Professor K. M. Sturmer and Dr S. Sehmisch, Trauma Surgery, Plastic and Reconstructive Surgery, University Medical Center Gottingen (UMG); Professor V. Rohde, Neurosurgery, UMG; Professor R. Behr, Neurosurgery, Clinical Center Fulda; Professor W. Deinsberger, Neurosurgery, Clinical Center Kassel and Dr W. Puschendorf, Westend Neurological Clinic, Bad Wildungen. The authors thank all these collaborators and individuals after TBI and their significant others who participated in this study.	Acquadro C, 1996, QUALITY LIFE PHARMAC; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Bullinger M, 1990, Z DIFFER DIAGNOSTISC, V11, P53; Bullinger M., 1995, J PUBLIC HEALTH-UK, V3, P21, DOI [10.1007/BF02959944, DOI 10.1007/BF02959944]; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dirette DK, 2007, BRAIN INJURY, V21, P1131, DOI 10.1080/02699050701687326; Eid M, 2003, ENTWICKLUND VALIDIER; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; FLEMING J, 1997, BRIT J OCCUPATIONAL, V60, P295, DOI DOI 10.1177/030802269706000703; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Garmoe W, 2005, J HEAD TRAUMA REHAB, V20, P348, DOI 10.1097/00001199-200507000-00006; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Herrmann-Lingen Ch, 1995, HOSPITAL ANXIETY DEP; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; JENNETT B, 1975, LANCET, V1, P480; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; McNair DM, 1971, EITS MANUAL PROFILE; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Callaghan C, 2006, NEUROPSYCHOL REHABIL, V16, P579, DOI 10.1080/09602010500368834; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, ACT NEUR S, V93, P39; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P537; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JJE, 1996, QUALITY LIFE PHARMAC; *WHOQOL GROUP, 1993, QUAL LIFE RES, V2, P153, DOI DOI 10.1007/BF00435734; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wustenhagen S., 2009, THESIS U MEDICAL CTR; Yeates G, 2007, NEUROPSYCHOL REHABIL, V17, P151, DOI 10.1080/09602010600696423; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	56	34	35	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2013	28	6					464	472		10.1097/HTR.0b013e318263977d			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	299AA	WOS:000330365200011	22935572				2022-02-06	
J	Shen, XF; Li, AP; Zhang, YL; Dong, XM; Shan, T; Wu, Y; Jia, J; Hu, YS				Shen, Xiafeng; Li, Aiping; Zhang, Yuling; Dong, XiaoMin; Shan, Tian; Wu, Yi; Jia, Jie; Hu, Yongshan			The Effect of Different Intensities of Treadmill Exercise on Cognitive Function Deficit Following a Severe Controlled Cortical Impact in Rats	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						controlled cortical impact; treadmill running; spatial memory; intensity; BDNF	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; VOLUNTARY EXERCISE; NEUROTROPHIC FACTOR; CONTUSION INJURY; UP-REGULATION; IMPAIRMENT; PLASTICITY; MICE; NEUROGENESIS	Exercise has been proposed for the treatment of traumatic brain injury (TBI). However, the proper intensity of exercise in the early phase following a severe TBI is largely unknown. To compare two different treadmill exercise intensities on the cognitive function following a severe TBI in its early phase, rats experienced a controlled cortical impact (CCI) and were forced to treadmill exercise for 14 days. The results revealed that the rats in the low intensity exercise group had a shorter latency to locate a platform and a significantly better improvement in spatial memory in the Morris water maze (MWM) compared to the control group (p < 0.05). The high intensity exercise group showed a longer latency and a mild improvement in spatial memory compared to the control group rats in the MWM; however, this difference was not statistically significant (p > 0.05). The brain-derived neurotrophic factor (BDNF) and p-CREB protein levels in the contralateral hippocampus were increased significantly in the low intensity exercise group. Our results suggest that 2 weeks of low intensity of treadmill exercise is beneficial for improving cognitive function and increasing hippocampal BDNF expression after a severe TBI in its early phase.	[Shen, Xiafeng; Zhang, Yuling; Shan, Tian; Wu, Yi; Jia, Jie; Hu, Yongshan] Fudan Univ, Huashan Hosp, Dept Rehabil, Shanghai 200040, Peoples R China; [Li, Aiping; Dong, XiaoMin] Nanjing Mil Reg Sanat Hangzhou, Rehabil Med Ctr, Hangzhou 310007, Zhejiang, Peoples R China; [Shen, Xiafeng] Shanghai Yangpu Dist Geriatr Hosp, Dept Rehabil, Shanghai 200090, Peoples R China		Li, AP (corresponding author), Nanjing Mil Reg Sanat Hangzhou, Rehabil Med Ctr, Hangzhou 310007, Zhejiang, Peoples R China.	shenxiafeng@aliyun.com; drliap@163.com; zhangyuling1982@hotmail.com; dongxiaomin2013@163.com; shantian2008@hotmail.com; wuyi4000@163.com; shannonjj@126.com; drhuys@sina.com			Nanjing Military Area Command Medical Science Innovation Foundation [09Z037]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81272169]	This study was supported by both the Key Research Project of Nanjing Military Area Command Medical Science Innovation Foundation (No. 09Z037) and the National Natural Science Foundation of China (No. 81272169).	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Blustein JE, 2006, PHYSIOL BEHAV, V89, P582, DOI 10.1016/j.physbeh.2006.07.017; Bruunsgaard H, 1997, MED SCI SPORT EXER, V29, P1176, DOI 10.1097/00005768-199709000-00009; Burnfield JM, 2013, PHYS THER, V93, P1331, DOI 10.2522/ptj.20120500; Carek PJ, 2011, INT J PSYCHIAT MED, V41, P15, DOI 10.2190/PM.41.1.c; Cassilhas RC, 2012, NEUROSCIENCE, V202, P309, DOI 10.1016/j.neuroscience.2011.11.029; Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x; Dik MG, 2003, J CLIN EXP NEUROPSYC, V25, P643, DOI 10.1076/jcen.25.5.643.14583; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Franckeviciute Egle, 2006, Medicina (Kaunas), V42, P732; Gibson AS, 2013, SPORTS MED, V43, P413, DOI 10.1007/s40279-013-0044-y; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Hoffman-Goetz L, 2008, BRAIN BEHAV IMMUN, V22, P195, DOI 10.1016/j.bbi.2007.07.002; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Kurayama T, 2013, GAIT POSTURE, V37, P402, DOI 10.1016/j.gaitpost.2012.08.009; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; Miles SC, 2013, ALTERN THER HEALTH M, V19, P38; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moraska A, 2000, AM J PHYSIOL-REG I, V279, pR1321, DOI 10.1152/ajpregu.2000.279.4.R1321; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Szabo Z, 2010, BRAIN RES, V1341, P25, DOI 10.1016/j.brainres.2009.01.035; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Triolo RJ, 2013, ARCH PHYS MED REHAB, V94, P1997, DOI 10.1016/j.apmr.2013.04.010; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Zhang Pengyue, 2012, Front Biosci (Elite Ed), V4, P2476	56	34	38	0	32	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	NOV	2013	14	11					21598	21612		10.3390/ijms141121598			15	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	274RR	WOS:000328624400025	24185909	Green Published, gold			2022-02-06	
J	Hansen, K; Dau, N; Feist, F; Deck, C; Willinger, R; Madey, SM; Bottlang, M				Hansen, Kirk; Dau, Nathan; Feist, Florian; Deck, Caroline; Willinger, Remy; Madey, Steven M.; Bottlang, Michael			Angular Impact Mitigation system for bicycle helmets to reduce head acceleration and risk of traumatic brain injury	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Helmet; Bicycle; Traumatic brain injury; Impact mitigation; Rotational acceleration; Concussion	BIOMECHANICS; PERFORMANCE; ABSORPTION; RESPONSES; FRICTION; DAMAGE; STATE; SIMON	Angular acceleration of the head is a known cause of traumatic brain injury (TBI), but contemporary bicycle helmets lack dedicated mechanisms to mitigate angular acceleration. A novel Angular Impact Mitigation (AIM) system for bicycle helmets has been developed that employs an elastically suspended aluminum honeycomb liner to absorb linear acceleration in normal impacts as well as angular acceleration in oblique impacts. This study tested bicycle helmets with and without AIM technology to comparatively assess impact mitigation. Normal impact tests were performed to measure linear head acceleration. Oblique impact tests were performed to measure angular head acceleration and neck loading. Furthermore, acceleration histories of oblique impacts were analyzed in a computational head model to predict the resulting risk of TBI in the form of concussion and diffuse axonal injury (DAI). Compared to standard helmets, AIM helmets resulted in a 14% reduction in peak linear acceleration (p < 0.001), a 34% reduction in peak angular acceleration (p < 0.001), and a 22-32% reduction in neck loading (p < 0.001). Computational results predicted that AIM helmets reduced the risk of concussion and DAI by 27% and 44%, respectively. In conclusion, these results demonstrated that AIM technology could effectively improve impact mitigation compared to a contemporary expanded polystyrene-based bicycle helmet, and may enhance prevention of bicycle-related TBI. Further research is required. (C) 2013 Elsevier Ltd. All rights reserved.	[Hansen, Kirk; Dau, Nathan; Madey, Steven M.; Bottlang, Michael] Legacy Res Inst, Biomech Lab, Portland, OR 97232 USA; [Feist, Florian] Graz Univ Technol, Vehicle Safety Inst, A-8010 Graz, Austria; [Deck, Caroline; Willinger, Remy] Univ Strasbourg, Inst Mecan Fluides & Solides, Strasbourg, France		Bottlang, M (corresponding author), Legacy Biomech Lab, 1225 NE 2nd Ave, Portland, OR 97215 USA.	mbottlan@lhs.org	Augat, Peter/A-2051-2011	Augat, Peter/0000-0003-4805-2128; Feist, Florian/0000-0003-4384-226X; DECK, Caroline/0000-0003-2289-1222	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R41NS074734, R41 NS074734] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R41NS074734] Funding Source: NIH RePORTER		Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; Abu-Zidan FM, 2007, EMERG MED AUSTRALAS, V19, P366, DOI 10.1111/j.1742-6723.2007.00967.x; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bottlang M, 2007, J NEUROTRAUM, V24, P1068, DOI 10.1089/neu.2006.3772; British Standards Institute, 1997, HELMETS FOR PEDAL CY; Camacho DLA, 1999, J BIOMECH, V32, P293, DOI 10.1016/S0021-9290(98)00178-X; Caserta G, 2010, MECH ADV MATER STRUC, V17, P366, DOI 10.1080/15376494.2010.488612; Caserta GD, 2011, COMPOS STRUCT, V93, P2748, DOI 10.1016/j.compstruct.2011.05.029; Ching RP, 1997, ACCIDENT ANAL PREV, V29, P555, DOI 10.1016/S0001-4575(97)00008-0; Consumer Product Safety Commission, 2011, NATIONAL ELECTRONIC; Consumer Product Safety Commission, 1998, SAFETY STANDARD FOR; Cook A, 2003, INJURY PREV, V9, P266, DOI 10.1136/ip.9.3.266; Dau N., 2012, NORTH WEST BIOMECHAN; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Deck C., 2012, INTERNATIONAL CRASHW; Deck C., 2007, P IRCOBI C MAASTR NE, P185; Finan JD, 2008, TRAFFIC INJ PREV, V9, P483, DOI 10.1080/15389580802272427; Fredriksson R, 2007, STAPP CAR CRASH JO, V51, P155; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldsmith Werner, 2005, Critical Reviews in Biomedical Engineering, V33, P105, DOI 10.1615/CritRevBiomedEng.v33.i2.20; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ivarsson J, 2003, J BIOMECH ENG-T ASME, V125, P523, DOI 10.1115/1.1590360; Karkhaneh M, 2006, INJURY PREV, V12, P76, DOI 10.1136/ip.2005.010942; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 2012, P I MECH ENG P-J SPO, V226, P274, DOI 10.1177/1754337111435294; Mills NJ, 2008, INT J IMPACT ENG, V35, P1075, DOI 10.1016/j.ijimpeng.2007.05.005; Mills NJ, 2008, INT J IMPACT ENG, V35, P1087, DOI 10.1016/j.ijimpeng.2007.05.006; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Pang TY, 2011, INT J CRASHWORTHINES, V16, P297, DOI 10.1080/13588265.2011.559799; Rousseau Philippe, 2010, Stapp Car Crash J, V54, P37; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sances A, 2002, BIOMED SCI INSTRUM, V38, P459; Schulman J, 2002, INJ PREV, V8, P47, DOI 10.1136/ip.8.1.47; Society of Automotive Engineers, 2007, INSTRUMENTATION FOR; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Zarei H, 2008, MATER DESIGN, V29, P193, DOI 10.1016/j.matdes.2006.10.013; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	48	34	34	1	35	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	OCT	2013	59						109	117		10.1016/j.aap.2013.05.019			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	261SX	WOS:000327686000013	23770518	Green Accepted			2022-02-06	
J	Lyons, MJ; Genderson, M; Grant, MD; Logue, M; Zink, T; McKenzie, R; Franz, CE; Panizzon, M; Lohr, JB; Jerskey, B; Kremen, WS				Lyons, Michael J.; Genderson, Margo; Grant, Michael D.; Logue, Mark; Zink, Tyler; McKenzie, Ruth; Franz, Carol E.; Panizzon, Matthew; Lohr, James B.; Jerskey, Beth; Kremen, William S.			Gene-Environment Interaction of ApoE Genotype and Combat Exposure on PTSD	AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS			English	Article						posttraumatic stress disorder; apoE; genetics; GxE interaction	POSTTRAUMATIC-STRESS-DISORDER; SEROTONIN TRANSPORTER GENOTYPE; APOLIPOPROTEIN-E EPSILON-4; TRAUMATIC BRAIN-INJURY; CHILDHOOD ADVERSITY; 5-HTTLPR GENOTYPE; ENTORHINAL CORTEX; OLDER-ADULTS; ASSOCIATION; RISK	Factors determining who develops PTSD following trauma are not well understood. The Euro4 allele of the apolipoprotein E (apoE) gene is associated with dementia and unfavorable outcome following brain insult. PTSD is also associated with dementia. Given evidence that psychological trauma adversely affects the brain, we hypothesized that the apoE genotype moderates effects of psychological trauma on PTSD pathogenesis. To investigate the moderation of the relationship between PTSD symptoms and combat exposure, we used 172 participants with combat trauma sustained during the Vietnam War. PTSD symptoms were the dependent variable and number of combat experiences, apoE genotype, and the combat experiencesxapoE genotype interaction were predictors. We also examined the outcome of a diagnosis of PTSD (n=39) versus no PTSD diagnosis (n=131). The combatxapoE genotype interaction was significant for both PTSD symptoms (P=.014) and PTSD diagnosis (P=.009). ApoE genotype moderates the relationship between combat exposure and PTSD symptoms. Although the pathophysiology of PTSD is not well understood, the Euro4 allele is related to reduced resilience of the brain to insult. Our results are consistent with the Euro4 allele influencing the effects of psychological trauma on the brain, thereby affecting the risk of PTSD. (c) 2013 Wiley Periodicals, Inc.	[Lyons, Michael J.; Genderson, Margo; Grant, Michael D.; Logue, Mark; Zink, Tyler; McKenzie, Ruth] Boston Univ, Boston, MA 02215 USA; [Franz, Carol E.; Panizzon, Matthew; Lohr, James B.; Kremen, William S.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Lohr, James B.; Kremen, William S.] VA San Diego Healthcare Syst, San Diego, CA USA; [Jerskey, Beth] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA		Lyons, MJ (corresponding author), Boston Univ, Dept Psychol, 64 Cummington Mall, Boston, MA 02215 USA.	mlyons@bu.edu		Lyons, Michael/0000-0001-6516-9219; Franz, Carol/0000-0002-8987-1755; Kremen, William/0000-0002-8629-5609	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AG018386, R01 AG022982, R01 AG018384, R01 AG022381, K01 MH076100]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH076100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG018386, R01AG022381, R01AG018384, R01AG022982] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant numbers: R01 AG018386; R01 AG022982; R01 AG018384; R01 AG022381; K01 MH076100.	Amstadter AB, 2012, TWIN RES HUM GENET, V15, P656, DOI 10.1017/thg.2012.43; Amstadter AB, 2009, PSYCHIATRY, V72, P360, DOI 10.1521/psyc.2009.72.4.360; Binder EB, 2008, JAMA-J AM MED ASSOC, V299, P1291, DOI 10.1001/jama.299.11.1291; Boscarino JA, 2012, NEUROPSYCH DIS TREAT, V8, P131, DOI 10.2147/NDT.S29508; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198, DOI 10.1177/1524838009334448; Carlin JB, 2005, INT J EPIDEMIOL, V34, P1089, DOI 10.1093/ije/dyi153; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Duncan LE, 2011, AM J PSYCHIAT, V168, P1041, DOI 10.1176/appi.ajp.2011.11020191; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; Fennema-Notestine C, 2011, J ALZHEIMERS DIS, V26, P49, DOI 10.3233/JAD-2011-0002; Freeman T, 2005, J NEUROPSYCH CLIN N, V17, P541, DOI 10.1176/appi.neuropsych.17.4.541; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; GOLDBERG J, 1987, ACTA GENET MED GEMEL, V36, P67, DOI 10.1017/S0001566000004608; HIXSON JE, 1990, J LIPID RES, V31, P545; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; JANES GR, 1991, J CLIN PSYCHOL, V47, P80, DOI 10.1002/1097-4679(199101)47:1<80::AID-JCLP2270470112>3.0.CO;2-9; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Juottonen K, 1998, J NEUROL NEUROSUR PS, V65, P322, DOI 10.1136/jnnp.65.3.322; Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007; Koenen KC, 2009, AM J EPIDEMIOL, V169, P704, DOI 10.1093/aje/kwn397; Kolassa IT, 2010, J CLIN PSYCHIAT, V71, P543, DOI 10.4088/JCP.08m04787blu; Kolassa IT, 2010, BIOL PSYCHIAT, V67, P304, DOI 10.1016/j.biopsych.2009.10.009; Kremen WS, 2012, NEUROPHARMACOLOGY, V62, P647, DOI 10.1016/j.neuropharm.2011.03.012; Kremen WS, 2010, NEUROIMAGE, V53, P1093, DOI 10.1016/j.neuroimage.2010.02.026; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lee BK, 2011, ARCH GEN PSYCHIAT, V68, P314, DOI 10.1001/archgenpsychiatry.2011.6; Lupien SJ, 2005, J PSYCHIATR NEUROSCI, V30, P328; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Moffitt TE, 2005, ARCH GEN PSYCHIAT, V62, P473, DOI 10.1001/archpsyc.62.5.473; Nelson EC, 2009, MOL PSYCHIATR, V14, P234, DOI 10.1038/mp.2008.81; Nutt DJ, 2004, J CLIN PSYCHIAT, V65, P11; Petkus AJ, 2012, J GERONTOL B-PSYCHOL, V67, P653, DOI 10.1093/geronb/gbr163; ROBINS LN, 1989, PSYCHOL MED, V19, P57, DOI 10.1017/S0033291700011028; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1222; Sartor CE, 2012, ARCH GEN PSYCHIAT, V69, P293, DOI 10.1001/archgenpsychiatry.2011.1385; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Thambisetty M, 2010, ARCH NEUROL-CHICAGO, V67, P93, DOI 10.1001/archneurol.2009.913; TRUE WR, 1993, ARCH GEN PSYCHIAT, V50, P257, DOI 10.1001/archpsyc.1993.01820160019002; Twisk JWR, 2004, EUR J EPIDEMIOL, V19, P769, DOI 10.1023/B:EJEP.0000036572.00663.f2; Wagle J, 2009, DEMENT GERIATR COGN, V27, P525, DOI 10.1159/000223230; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wishart HA, 2006, NEUROLOGY, V67, P1221, DOI 10.1212/01.wnl.0000238079.00472.3a; Xie PX, 2012, AM J MED GENET B, V159B, P644, DOI 10.1002/ajmg.b.32068; Xie P, 2010, NEUROPSYCHOPHARMACOL, V35, P1684, DOI 10.1038/npp.2010.37; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61	49	34	34	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4841	1552-485X		AM J MED GENET B	Am. J. Med. Genet. B	OCT	2013	162	7			SI		762	769		10.1002/ajmg.b.32154			8	Genetics & Heredity; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity; Psychiatry	238WN	WOS:000325982500020	24132908	Green Accepted, Bronze			2022-02-06	
J	Ozen, LJ; Itier, RJ; Preston, FF; Fernandes, MA				Ozen, Lana J.; Itier, Roxane J.; Preston, Frank F.; Fernandes, Myra A.			Long-term working memory deficits after concussion: Electrophysiological evidence	BRAIN INJURY			English	Article						Attention; event-related potential; mild traumatic brain injury; n-back task; P300	TRAUMATIC BRAIN-INJURY; EVENT-RELATED POTENTIALS; HEAD-INJURY; DUAL-TASK; MILD; P300; PERFORMANCE; ATTENTION; QUESTIONNAIRE; METAANALYSIS	Background: Persistent complaints of lingering memory and concentration difficulties are common following a concussion, although the brain basis of these is unknown. Some suggest abnormalities can be found on the P300 event-related potential component, recorded using electroencephalography (EEG), despite unobservable cognitive impairments. Objective: To examine the P300 and cognitive performance following a remote concussion during an n-back task that varies in working memory load. Research design: Seventeen participants with a remote concussion and 17 controls performed a visual n-back task in which working memory demands were systematically increased by manipulating cognitive load. Participants also completed neuropsychological and self-report measures. Results: The concussion group showed a decrease in P300 amplitude compared to controls that was independent of working memory load on the n-back task. While no performance differences were observed between groups, P300 amplitude was negatively correlated with response times at higher loads in both groups. Conclusion: High functioning young adults with a remote concussion may have inefficient recruitment of processing resources for target identification, evident by the attenuated P300. The negative correlations between response time and P300 amplitude suggest that the time necessary to accurately respond to targets increases as the efficiency of allocating processing resources decreases during highly demanding working memory tasks.	[Ozen, Lana J.; Itier, Roxane J.; Preston, Frank F.; Fernandes, Myra A.] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada		Ozen, LJ (corresponding author), St Josephs Care Grp, Res Dept, 580 Algoma North, Thunder Bay, ON P7B 5G4, Canada.	ozenl@tbh.net	Itier, Roxane/AAE-1340-2019	Itier, Roxane/0000-0001-6460-5218	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); ORF; CFICanada Foundation for Innovation; CRC programCanada Research Chairs	The authors report no conflicts of interest. This work was supported by an NSERC Discovery grant to MAF, an NSERC post-graduate scholarship to LJO and funds from the ORF, CFI and the CRC program to RJI.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Faul M, 2010, TRAUMATIC BRAIN INJU; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gaetz M, 2000, BRAIN INJURY, V14, P1077; ISREAL JB, 1980, PSYCHOPHYSIOLOGY, V17, P259, DOI 10.1111/j.1469-8986.1980.tb00146.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAMER AF, 1985, J EXP PSYCHOL HUMAN, V11, P393, DOI 10.1037/0096-1523.11.4.393; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McEvoy LK, 1998, CEREB CORTEX, V8, P563, DOI 10.1093/cercor/8.7.563; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Reason J., 1982, ABSENT MINDED PSYCHO; Reitan R, 1985, HALSTEAD REITAN NEUR; Repovs G, 2006, NEUROSCIENCE, V139, P5, DOI 10.1016/j.neuroscience.2005.12.061; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Schoenberg MR, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P1, DOI 10.1007/978-0-387-76978-3; Schoning S, 2009, HUM BRAIN MAPP, V30, P2746, DOI 10.1002/hbm.20702; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spielberger CD, 1970, MANUAL STATE TRAIT A; Thurman DJ, 2007, BRAIN INJURY MED; Watter S, 2001, PSYCHOPHYSIOLOGY, V38, P998, DOI 10.1111/1469-8986.3860998; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	45	34	35	2	45	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2013	27	11					1244	1255		10.3109/02699052.2013.804207			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	217YQ	WOS:000324399800003	23875864				2022-02-06	
J	Whyte, J; Nakase-Richardson, R				Whyte, John; Nakase-Richardson, Risa			Disorders of Consciousness: Outcomes, Comorbidities, and Care Needs	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Consciousness disorders; Healthcare delivery; Minimally conscious state; Prognosis; Rehabilitation; Systems of care; Vegetative state	VEGETATIVE STATE; REHABILITATION; AWARENESS; RECOVERY	Over the last decade, research on patients with disorders of consciousness (DOC) has suggested that their prognosis for functional recovery early after injury is surprisingly positive, particularly for those with traumatic etiologies; that meaningful recovery proceeds for longer intervals than previously appreciated; and that such individuals are often medically complex and challenging to manage However, access to intensive specialty rehabilitation is limited for most individuals with DOC in the United States. The evolving understanding of DOC calls for a reconsideration of appropriate models of care. This collection of articles provides insight into the functional recovery of individuals with DOC, new tools for assessing prognosis, and the patterns of comorbidity that complicate the recovery process. In addition, models of care from the United States and Europe that attempt to address the needs of patients as well as their caregivers are presented. (c) 2013 by the American Congress of Rehabilitation Medicine	[Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Nakase-Richardson, Risa] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Nakase-Richardson, Risa] Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research (NIDRR), US Department of EducationUS Department of Education [H133A070040, H133A120037]	Supported in part by grant nos. H133A070040 and H133A120037 from the National Institute on Disability and Rehabilitation Research (NIDRR), US Department of Education (T. Hart, Principal Investigator). However, the contents do not necessarily represent the policy of the Department of Education, and endorsement by the federal government should not be assumed. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs or the US government.No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.This represents work from the American Congress of Rehabilitation Medicine, Brain Injury-Interdisciplinary Special Interest Group, Disorders of Consciousness Task Force, and NIDRR TBI Model System Program Special Interest Group on Disorders of Consciousness.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; BERUBE J, 2006, MOHONK REPORT DISORD; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; ESTRANEO A, 2010, NEUROLOGY, P75; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; *MCKESS INC, 2012, INT LEV CAR CRIT 201; McNamee S, 2012, J HEAD TRAUMA REHAB, V27, P244, DOI 10.1097/HTR.0b013e31825e12c8; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; SCLUIACKERS C, 2009, BMC NEUROL, P9; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; TURGEON AF, 2011, CMAJ, V183, P1563; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0	24	34	35	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1851	1854		10.1016/j.apmr.2013.07.003			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	231TU	WOS:000325442100001	23856152				2022-02-06	
J	Scherer, MR; Weightman, MM; Radomski, MV; Davidson, LF; McCulloch, KL				Scherer, Matthew R.; Weightman, Margaret M.; Radomski, Mary V.; Davidson, Leslie F.; McCulloch, Karen L.			Returning Service Members to Duty Following Mild Traumatic Brain Injury: Exploring the Use of Dual-Task and Multitask Assessment Methods	PHYSICAL THERAPY			English	Article							NATURALISTIC ACTION; POSTURAL STABILITY; ATTENTION DEFICITS; EXECUTIVE FUNCTION; CONCUSSION; BALANCE; GAIT; PERFORMANCE; SLEEP; RECOVERY	Within the last decade, more than 220,000 service members have sustained traumatic brain injury asp in support of military operations in Iraq and Afghanistan. Mild TBI may result in subtle cognitive and sensorimotor deficits that adversely affect warfighter performance, creating significant challenges for service members, commanders, and clinicians. In recent conflicts, physical therapists and occupational therapists have played an important role in evaluating service member readiness to return to duty (RTD), incorporating research and best practices from the sports concussion literature. Because premorbid (baseline) performance metrics are not typically available for deployed service members as for athletes, clinicians commonly determine duty readiness based upon the absence of postconcussive symptoms and return to "normal" performance on clinical assessments not yet validated in the military population. Although practices described in the sports concussion literature guide "return-to-play" determinations, resolution of symptoms or improvement of isolated impairments may be inadequate to predict readiness in a military operational environment. Existing clinical metrics informing RTD decision making are limited because they fail to emphasize functional, warrior task demands and they lack versatility to assess the effects of comorbid deficits. Recently, a number of complex task-oriented RTD approaches have emerged from Department of Defense laboratory and clinical settings to address this gap. Immersive virtual reality environments, field-based scenario-driven assessment programs, and militarized dual-task and multitask-based approaches have all been proposed for the evaluation of sensorimotor and cognitive function following TBI. There remains a need for clinically feasible assessment methods that can be used to verify functional performance and operational competence in a variety of practice settings. Complex and ecologically valid assessment techniques incorporating dual-task and multitask methods may prove useful in validating return-to-activity requirements in civilian and military populations.	[Scherer, Matthew R.] US Army Res Inst Environm Med, Mil Performance Div, Natick, MA 01760 USA; [Weightman, Margaret M.; Radomski, Mary V.] Sister Kenny Res Ctr, Minneapolis, MN USA; [Davidson, Leslie F.] Shenandoah Univ, Dept Occupat Therapy, Winchester, VA USA; [McCulloch, Karen L.] Univ N Carolina, Chapel Hill, NC USA		Scherer, MR (corresponding author), US Army Res Inst Environm Med, Mil Performance Div, 15 Kansas St, Natick, MA 01760 USA.	matthew.scherer@us.army.mil			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-09-2-0149]	The research team's ongoing investigation of dual-task and multitask testing methods in service members with mild traumatic brain injury is funded by the US Army Medical Research and Materiel Command (award number W81XWH-09-2-0149).	ABERNETHY B, 1988, J HUM MOVEMENT STUD, V14, P101; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; [Anonymous], 2009, STP; [Anonymous], 649011 DODI US DEP D; [Anonymous], 2008, SYMPTOM MANAGEMENT M; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fischer SC, 2005, MULTITASKING ASSESSM; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Getchell B, 1979, PHYS FITNESS WAY LIF; Goss DL, 2009, J SPEC OPER MED, V9, P29; Gottshall KR, 2012, IEEE ENG MED BIO, P6141, DOI 10.1109/EMBC.2012.6347395; Guskiewicz KM, 2011, PM&R, V3, pS445, DOI 10.1016/j.pmrj.2011.08.009; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hettich Thomas, 2010, J Spec Oper Med, V10, P48; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hyndman D, 2006, DISABIL REHABIL, V28, P849, DOI 10.1080/09638280500534994; Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mancini M, 2012, J BIOENGINEER BIOMED, VS1, P007; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maylor EA, 2001, BRIT J PSYCHOL, V92, P319, DOI 10.1348/000712601162211; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCulloch Karen, 2007, J Neurol Phys Ther, V31, P104; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; McCulloch KL, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932010-00002; Meher I, 2004, J AM GERIATR SOC, V52, P1255, DOI 10.1111/j.1532-5415.2004.52353.x; Melzer I, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-16; Miller NL, 2011, BEHAV SLEEP MED, V9, P53, DOI 10.1080/15402002.2011.533994; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Radomski MV, 2013, MIL MED, V178, P246, DOI 10.7205/MILMED-D-12-00144; Radomski MV, 2009, AM J OCCUP THER, V63, P646, DOI 10.5014/ajot.63.5.646; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Rhon DI, 2010, MIL MED, V175, P305, DOI 10.7205/MILMED-D-09-00099; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Sen A., 1992, INEQUALITY REEXAMINE; ShumwayCook A, 1997, J GERONTOL A-BIOL, V52, pM232, DOI 10.1093/gerona/52A.4.M232; Siu KC, 2009, BRAIN RES, V1248, P59, DOI 10.1016/j.brainres.2008.10.078; Starr B, CPR FOR YOUR BRAIN; Steiner WA, 2002, PHYS THER, V82, P1098, DOI 10.1093/ptj/82.11.1098; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; US Department of Veterans Affairs, MAN CONC MILD TRAUM; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wolf TJ, 2008, WORK, V31, P221; Wolf TJ, 2010, WORK, V36, P405, DOI 10.3233/WOR-2010-1045	79	34	35	1	24	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	SEP	2013	93	9			SI		1254	1267		10.2522/ptj.20120143			14	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Rehabilitation	212OM	WOS:000323992700014	23766395	Bronze, Green Submitted			2022-02-06	
J	Harhausen, D; Sudmann, V; Khojasteh, U; Muller, J; Zille, M; Graham, K; Thiele, A; Dyrks, T; Dirnagl, U; Wunder, A				Harhausen, Denise; Sudmann, Violetta; Khojasteh, Uldus; Mueller, Jochen; Zille, Marietta; Graham, Keith; Thiele, Andrea; Dyrks, Thomas; Dirnagl, Ulrich; Wunder, Andreas			Specific Imaging of Inflammation with the 18kDa Translocator Protein Ligand DPA-714 in Animal Models of Epilepsy and Stroke	PLOS ONE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PERIPHERAL BENZODIAZEPINE-RECEPTORS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; 18 KDA; MULTIPLE-SCLEROSIS; INITIAL EVALUATION; PET; NEUROINFLAMMATION	Inflammation is a pathophysiological hallmark of many diseases of the brain. Specific imaging of cells and molecules that contribute to cerebral inflammation is therefore highly desirable, both for research and in clinical application. The 18 kDa translocator protein (TSPO) has been established as a suitable target for the detection of activated microglia/macrophages. A number of novel TSPO ligands have been developed recently. Here, we evaluated the high affinity TSPO ligand DPA-714 as a marker of brain inflammation in two independent animal models. For the first time, the specificity of radiolabeled DPA-714 for activated microglia/macrophages was studied in a rat model of epilepsy (induced using Kainic acid) and in a mouse model of stroke (transient middle cerebral artery occlusion, tMCAO) using high-resolution autoradiography and immunohistochemistry. Additionally, cold-compound blocking experiments were performed and changes in blood-brain barrier (BBB) permeability were determined. Target-to-background ratios of 2 and 3 were achieved in lesioned vs. unaffected brain tissue in the epilepsy and tMCAO models, respectively. In both models, ligand uptake into the lesion corresponded well with the extent of Ox42- or Iba1-immunoreactive activated microglia/macrophages. In the epilepsy model, ligand uptake was almost completely blocked by pre-injection of DPA-714 and FEDAA1106, another high-affinity TSPO ligand. Ligand uptake was independent of the degree of BBB opening and lesion size in the stroke model. We provide further strong evidence that DPA-714 is a specific ligand to image activated microglia/macrophages in experimental models of brain inflammation.	[Harhausen, Denise; Khojasteh, Uldus; Mueller, Jochen; Zille, Marietta; Dirnagl, Ulrich; Wunder, Andreas] Charite, Dept Expt Neurol, D-13353 Berlin, Germany; [Harhausen, Denise; Zille, Marietta; Dirnagl, Ulrich; Wunder, Andreas] Ctr Stroke Res Berlin CSB, Berlin, Germany; [Sudmann, Violetta; Graham, Keith; Thiele, Andrea; Dyrks, Thomas] Bayer Healthcare, Global Drug Discovery, Berlin, Germany		Harhausen, D (corresponding author), Charite, Dept Expt Neurol, D-13353 Berlin, Germany.	denise.harhausen@charite.de	Zille, Marietta/P-1700-2018	Zille, Marietta/0000-0002-0609-8956; Dirnagl, Ulrich/0000-0003-0755-6119	European UnionEuropean Commission [201024, 202213]; Deutsche Forschungsgemeinschaft (NeuroCure Cluster of Excellence)German Research Foundation (DFG) [Exc 257]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 08 01]; TSB grant entitled "Development of diagnostic markers for the diagnosis of stroke and establishment of a center for small animal imaging research at the Charite Berlin"; Bayer Pharma AG	This work was supported by the European Union's Seventh Framework Programme (FP7/2008-2013) under Grant Agreements 201024 and 202213 (European Stroke Network); the Deutsche Forschungsgemeinschaft (NeuroCure Cluster of Excellence, Exc 257); and the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 08 01) and the TSB grant entitled "Development of diagnostic markers for the diagnosis of stroke and establishment of a center for small animal imaging research at the Charite Berlin." Furthermore, this study was supported and conducted together with Bayer Pharma AG and relevant parties are co-authors. Thomas Dyrks, Andrea Thiele, Keith Graham, Violetta Sudmann are employees of Bayer Pharma AG, Berlin, Germany and they hereby declare that they participated in the preclinical preparation for this study as well as the manuscript preparation. They have seen and approved the final version. None of the products in the manuscript are under development or seeking patent approval. All the other funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abourbeh G, 2012, J NEUROSCI, V32, P5728, DOI 10.1523/JNEUROSCI.2900-11.2012; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Arlicot N, 2012, NUCL MED BIOL, V39, P570, DOI 10.1016/j.nucmedbio.2011.10.012; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; Beckham JD, 2012, NEUROTHERAPEUTICS, V9, P124, DOI 10.1007/s13311-011-0086-5; Boutin H, 2007, GLIA, V55, P1459, DOI 10.1002/glia.20562; Cagnin A, 2007, NEUROTHERAPEUTICS, V4, P443, DOI 10.1016/j.nurt.2007.04.006; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Cosenza-Nashat M, 2009, NEUROPATH APPL NEURO, V35, P306, DOI 10.1111/j.1365-2990.2008.01006.x; Doorduin J, 2009, MOL IMAGING BIOL, V11, P386, DOI 10.1007/s11307-009-0211-6; DORMAN G, 1995, J ORG CHEM, V60, P2292, DOI 10.1021/jo00112a066; Engel O, 2011, JOVE-J VIS EXP, DOI 10.3791/2423; Gulyas B, 2005, J NEUROL SCI, V229, P219, DOI 10.1016/j.jns.2004.11.032; Hellier Jennifer L, 2005, Curr Protoc Neurosci, VChapter 9, DOI 10.1002/0471142301.ns0919s31; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Jacobs AH, 2012, J CEREBR BLOOD F MET, V32, P1393, DOI 10.1038/jcbfm.2012.53; James ML, 2008, J NUCL MED, V49, P814, DOI 10.2967/jnumed.107.046151; Klohs J, 2009, J CEREBR BLOOD F MET, V29, P1284, DOI 10.1038/jcbfm.2009.51; Lavisse S, 2012, J NEUROSCI, V32, P10809, DOI 10.1523/JNEUROSCI.1487-12.2012; Martin A, J CEREB BLOOD FLOW M, V30, P230; Martin A, 2011, MOL IMAGING BIOL, V13, P10, DOI 10.1007/s11307-010-0324-y; Mattner F, 2005, EUR J NUCL MED MOL I, V32, P557, DOI 10.1007/s00259-004-1690-y; Scarf AM, 2011, J NUCL MED, V52, P667, DOI 10.2967/jnumed.110.086629; Stoll G, 2009, NEUROSCIENCE, V158, P1151, DOI 10.1016/j.neuroscience.2008.06.045; Thiel A, 2011, STROKE, V42, P507, DOI 10.1161/STROKEAHA.110.598821; Venneti S, 2012, GLIA; Vezzani A, 2012, NEUROPHARMACOLOGY; Wilson AA, 2008, NUCL MED BIOL, V35, P305, DOI 10.1016/j.nucmedbio.2007.12.009; Winkeler A, 2012, EUR J NUCL MED MOL I, V39, P811, DOI 10.1007/s00259-011-2041-4; Wunder A, 2009, NEUROSCIENCE, V158, P1161, DOI 10.1016/j.neuroscience.2008.10.005; Yanamoto K, 2009, SYNAPSE, V63, P961, DOI 10.1002/syn.20678; Zhang MR, 2003, BIOORG MED CHEM LETT, V13, P201, DOI 10.1016/S0960-894X(02)00886-7; Zheng XY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/457079	34	34	34	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e69529	10.1371/journal.pone.0069529			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219XU	WOS:000324545800020	23936336	gold, Green Published, Green Submitted			2022-02-06	
J	Jacobs, B; Beems, T; van der Vliet, TM; van Vugt, AB; Hoedemaekers, C; Horn, J; Franschman, G; Haitsma, I; van der Naalt, J; Andriessen, TMJC; Borm, GF; Vos, PE				Jacobs, Bram; Beems, Tjemme; van der Vliet, Ton M.; van Vugt, Arie B.; Hoedemaekers, Cornelia; Horn, Janneke; Franschman, Gaby; Haitsma, Ian; van der Naalt, Joukje; Andriessen, Teuntje M. J. C.; Borm, George F.; Vos, Pieter E.			Outcome Prediction in Moderate and Severe Traumatic Brain Injury: A Focus on Computed Tomography Variables	NEUROCRITICAL CARE			English	Article						Moderate traumatic brain injury; Severe traumatic brain injury; Outcome; Predictionmodel; CT-scan; Head injury	SEVERE HEAD-INJURY; PROGNOSTIC MODELS; CLINICAL-VARIABLES; ADMISSION; VALIDATION; IMPACT; SCAN; CLASSIFICATION; HEMORRHAGE; MORTALITY	With this study we aimed to design validated outcome prediction models in moderate and severe traumatic brain injury (TBI) using demographic, clinical, and radiological parameters. Seven hundred consecutive moderate or severe TBI patients were included in this observational prospective cohort study. After inclusion, clinical data were collected, initial head computed tomography (CT) scans were rated, and at 6 months outcome was determined using the extended Glasgow Outcome Scale. Multivariate binary logistic regression analysis was applied to evaluate the association between potential predictors and three different outcome endpoints. The prognostic models that resulted were externally validated in a national Dutch TBI cohort. In line with previous literature we identified age, pupil responses, Glasgow Coma Scale score and the occurrence of a hypotensive episode post-injury as predictors. Furthermore, several CT characteristics were associated with outcome; the aspect of the ambient cisterns being the most powerful. After external validation using Receiver Operating Characteristic (ROC) analysis our prediction models demonstrated adequate discriminative values, quantified by the area under the ROC curve, of 0.86 for death versus survival and 0.83 for unfavorable versus favorable outcome. Discriminative power was less for unfavorable outcome in survivors: 0.69. Outcome prediction in moderate and severe TBI might be improved using the models that were designed in this study. However, conventional demographic, clinical and CT variables proved insufficient to predict disability in surviving patients. The information that can be derived from our prediction rules is important for the selection and stratification of patients recruited into clinical TBI trials.	[Jacobs, Bram; Andriessen, Teuntje M. J. C.; Vos, Pieter E.] RUNMC, Dept Neurol 935, NL-6500 HB Nijmegen, Netherlands; [Beems, Tjemme] RUNMC, Dept Neurosurg 931, NL-6500 HB Nijmegen, Netherlands; [van der Vliet, Ton M.] RUNMC, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; [van Vugt, Arie B.] RUNMC, Dept Emergency Med, NL-6500 HB Nijmegen, Netherlands; [Hoedemaekers, Cornelia] RUNMC, Dept Intens Care Med 632, NL-6500 HB Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [Franschman, Gaby] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, NL-1081 HV Amsterdam, Netherlands; [Haitsma, Ian] Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands; [van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Borm, George F.] RUNMC, Dept Epidemiol Biostat & HTA 133, NL-6500 HB Nijmegen, Netherlands		Vos, PE (corresponding author), RUNMC, Dept Neurol 935, POB 9101, NL-6500 HB Nijmegen, Netherlands.	B.Jacobs@umcg.nl; R.Bartels@nch.umcn.nl; a.van.der.vliet@umcg.nl; a.vanvugt@mst.nl; C.Hoedemaekers@ic.umcn.nl; J.Horn@amc.uva.nl; G.Franschman@vumc.nl; I.Haitsma@erasmusmc.nl; J.van.der.naalt@umcg.nl; TMJC.Andriessen@neuro.umcn.nl; G.Borm@ebh.umcn.nl; P.Vos@neuro.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015	van der Naalt, Joukje/0000-0001-9873-2418	Dutch Brain Foundation [Hersenstichting - HSN-07-01]	The authors wish to thank Ronald H. M. A. Bartels, MD, PhD of the Department of Neurosurgery, Radboud University Nijmegen Medical Centre, for critically reviewing this manuscript and his suggestions, and Robert Huiskes for the development of the prognostic calculator and the website www.tbi-prognosis.com. The POCON study is funded by the Dutch Brain Foundation (Hersenstichting - HSN-07-01). The authors express their gratitude to Dick Drost, Annemiek Coers, Annelou van der Veen, Joshua Field, Vivian de Ruijter, and Heleen Biersteker for their help with data collection. Amon Heijne is thanked for his help with the development and maintenance of the POCON database.	American College of Surgeons, 1997, ADV TRAUM LIF SUPP D, V6th ed; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Franschman G, 2012, INJURY, V43, P1838, DOI 10.1016/j.injury.2012.05.020; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P597; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539; Young NH, 2008, PLOS MED, V5, P1186, DOI 10.1371/journal.pmed.0050168; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	44	34	35	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2013	19	1					79	89		10.1007/s12028-012-9795-9			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	187SP	WOS:000322140000013	23138545				2022-02-06	
J	Zou, YY; Kan, EM; Lu, J; Ng, KC; Tan, MH; Yao, LL; Ling, EA				Zou, Ying-Ying; Kan, Enci Mary; Lu, Jia; Ng, Kian Chye; Tan, Mui Hong; Yao, Linli; Ling, Eng-Ang			Primary blast injury-induced lesions in the retina of adult rats	JOURNAL OF NEUROINFLAMMATION			English	Article						Blast; Retina; Nitric oxide synthase; Vascular endothelial growth factor; Aquaporin-4; Inflammation; Apoptosis	TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; MULLER GLIAL-CELLS; VASCULAR-PERMEABILITY; AQUAPORIN 4; EXPRESSION; DEGENERATION; INFLAMMATION; OVERPRESSURE	Background: The effect of primary blast exposure on the brain is widely reported but its effects on the eye remains unclear. Here, we aim to examine the effects of primary blast exposure on the retina. Methods: Adult male Sprague-Dawley rats were exposed to primary blast high and low injury and sacrificed at 24 h, 72 h, and 2 weeks post injury. The retina was subjected to western analysis for vascular endothelial growth factor (VEGF), aquaporin-4 (AQP4), glutamine synthethase (GS), inducible nitric oxide synthase (NOS), endothelial NOS, neuronal NOS and nestin expression; ELISA analysis for cytokines and chemokines; and immunofluorescence for glial fibrillary acidic protein (GFAP)/VEGF, GFAP/AQP4, GFAP/nestin, GS/AQP4, lectin/iNOS, and TUNEL. Results: The retina showed a blast severity-dependent increase in VEGF, iNOS, eNOS, nNOS, and nestin expression with corresponding increases in inflammatory cytokines and chemokines. There was also increased AQP4 expression and retinal thickness after primary blast exposure that was severity-dependent. Finally, a significant increase in TUNEL+ and Caspase-3+ cells was observed. These changes were observed at 24 h post-injury and sustained up to 2 weeks post injury. Conclusions: Primary blast resulted in severity-dependent pathological changes in the retina, manifested by the increased expression of a variety of proteins involved in inflammation, edema, and apoptosis. These changes were observed immediately after blast exposure and sustained up to 2 weeks suggesting acute and chronic injury mechanisms. These changes were most obvious in the astrocytes and Muller cells and suggest important roles for these cells in retina pathophysiology after blast.	[Zou, Ying-Ying] Kunming Med Univ, Fac Basic Med Sci, Dept Pathol, Kunming 650500, Peoples R China; [Zou, Ying-Ying; Yao, Linli; Ling, Eng-Ang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Kan, Enci Mary; Lu, Jia; Ng, Kian Chye; Tan, Mui Hong] DSO Natl Labs, Def Med & Environm Res Inst, Singapore 117560, Singapore		Lu, J (corresponding author), DSO Natl Labs, Def Med & Environm Res Inst, 27 Med Dr, Singapore 117560, Singapore.	ljia@dso.org.sg; antlea@nus.edu.sg			National University of SingaporeNational University of Singapore [R-181-000-140-592]; DSO National LaboratoriesDSO National Laboratories [20080102]; Youth Science Foundation of National Natural Science Foundation of China [81200840]	This study was supported by grants number R-181-000-140-592 (EAL), National University of Singapore and 20080102, DSO National Laboratories; and partially supported by Youth Science Foundation of National Natural Science Foundation of China; Grant number 81200840 (YYZ).	Abbotts R, 2007, J R Army Med Corps, V153, P119; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Alam M, 2012, J PAK MED ASSOC, V62, P138; Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; BROWN GC, 1995, NEUROSCI LETT, V193, P201, DOI 10.1016/0304-3940(95)11703-Y; Chalioulias K, 2007, J R Army Med Corps, V153, P124; Chavko M, 2009, SHOCK, V32, P325, DOI 10.1097/SHK.0b013e31819c38f1; Cheung SSF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026184; Delyfer MN, 2005, MOL VIS, V11, P688; Dinet V, 2012, AGING CELL, V11, P683, DOI 10.1111/j.1474-9726.2012.00834.x; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Hartani D, 2006, J FR OPHTALMOL, V29, P32, DOI 10.1016/S0181-5512(06)73744-5; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; Jozkowicz A, 2001, CARDIOVASC RES, V51, P773, DOI 10.1016/S0008-6363(01)00344-3; Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kim JE, 2009, NEUROSCIENCE, V163, P781, DOI 10.1016/j.neuroscience.2009.07.028; Konstantinova T. S., 2012, Biofizika, V57, P325; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lamoke F, 2011, EXP EYE RES, V93, P350, DOI 10.1016/j.exer.2011.02.007; Li CR, 2010, INT J OPHTHALMOL-CHI, V3, P224, DOI 10.3980/j.issn.2222-3959.2010.03.10; Liu XQ, 2007, MOL VIS, V13, P309; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Matsuoka Y, 1997, NEUROCHEM INT, V30, P533, DOI 10.1016/S0197-0186(96)00125-8; Morley MG, 2010, DISASTER MED PUBLIC, V4, P154, DOI 10.1001/dmp.v4n2.hra10003; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sajja Venkata Siva Sai S, 2012, Biomed Sci Instrum, V48, P374; Shen F, 2004, INVEST OPHTH VIS SCI, V45, P3107, DOI 10.1167/iovs.03-0948; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; Wang YQ, 2010, INJURY, V41, P707, DOI 10.1016/j.injury.2009.12.003; Xue LP, 2006, NEUROSCIENCE, V143, P117, DOI 10.1016/j.neuroscience.2006.07.044; Xue LP, 2006, NEUROSCIENCE, V139, P723, DOI 10.1016/j.neuroscience.2005.12.032; Zou YY, 2009, NEUROSCIENCE, V160, P698, DOI 10.1016/j.neuroscience.2009.03.007	39	34	35	1	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUL 2	2013	10								79	10.1186/1742-2094-10-79			20	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	180HD	WOS:000321583700001	23819902	Green Published, gold			2022-02-06	
J	Beauchamp, MH; Dooley, JJ; Anderson, V				Beauchamp, M. H.; Dooley, J. J.; Anderson, V.			A preliminary investigation of moral reasoning and empathy after traumatic brain injury in adolescents	BRAIN INJURY			English	Article						Empathy; moral reasoning; social skills; traumatic brain injury	JUVENILE-DELINQUENTS; EXECUTIVE FUNCTION; CONDUCT DISORDER; CHILDREN; BEHAVIOR; EMOTION; CHILDHOOD; DAMAGE; TERM; JUDGMENT	Primary objective: Traumatic brain injury (TBI) sustained during childhood can affect a number of socio-cognitive skills; however, little attention has focused on the integrity of moral reasoning in the assessment of post-TBI social sequelae and the role of empathy and intelligence on moral maturity. Research design: In a quasi-experimental, cross-sectional research design, moral reasoning maturity and empathy in adolescents with mild-to-severe TBI (n = 25) were compared to typically-developing peers (n = 66). Methods and procedures: Participants were administered the So-Moral and So-Mature, tasks of socio-moral reasoning and maturity, the Index of Empathy for Children and Adolescents, the Wechsler Abbreviated Scale of Intelligence and a demographic questionnaire. Main outcomes and results: Participants with TBI had significantly lower levels of moral reasoning maturity. Further, adolescents with moderate-to-severe TBI had lower levels of empathy. Empathy correlated positively with moral reasoning abilities and, together with intellectual function, predicted a small, but significant proportion of moral reasoning outcome. Conclusions: Youth who sustained TBI during childhood have poorer moral reasoning abilities than their non-injured peers, potentially placing them at risk for poor social decision-making and socially maladaptive behaviour. This can have a significant impact on long-term social functioning.	[Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, M. H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Dooley, J. J.] Edith Cowan Univ, Sch Law & Justice, Sellenger Ctr Res Law Justice & Social Change, Joondalup, WA, Australia; [Anderson, V.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, V.] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Anderson, V.] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia		Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca			Murdoch Childrens Research Institute; Social Sciences and Humanities Research Council of CanadaSocial Sciences and Humanities Research Council of Canada (SSHRC); Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Quebec Health Research Funds (FRSQ)Fonds de la Recherche en Sante du Quebec	This project was funded by the Murdoch Childrens Research Institute, the Social Sciences and Humanities Research Council of Canada and by fellowships to MB from the Canadian Institutes of Health Research and the Quebec Health Research Funds (FRSQ). The funding sources were not involved in the design, collection, data analysis or interpretation of data. The authors report no conflicts of interest.	Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; [Anonymous], 2009, J HEAD TRAUMA REHAB, V24, P303; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; BRYANT BK, 1982, CHILD DEV, V53, P413, DOI 10.2307/1128984; Chudzik L, 2007, PSYCHOL REP, V101, P221, DOI 10.2466/PR0.101.1.221-236; Cohn ES, 2010, LAW HUMAN BEHAV, V34, P295, DOI 10.1007/s10979-009-9185-9; Couper E., 2002, BRAIN IMPAIR, V3, P105, DOI [DOI 10.1375/BRIM.3.2.105, 10.1375/brim.3.2.105]; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; Decety J, 2012, CEREB CORTEX, V22, P209, DOI 10.1093/cercor/bhr111; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; Eisenberg N, 2000, ANNU REV PSYCHOL, V51, P665, DOI 10.1146/annurev.psych.51.1.665; EISENBERG N, 1991, DEV PSYCHOL, V27, P849, DOI 10.1037/0012-1649.27.5.849; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gibbs J.C., 1992, MORAL MATURITY MEASU; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Haidt J, 2001, PSYCHOL REV, V108, P814, DOI 10.1037//0033-295X.108.4.814; Hanten G, 2012, DEV SOCIAL NEUROSCIE; Jolliffe D, 2004, AGGRESS VIOLENT BEH, V9, P441, DOI 10.1016/j.avb.2003.03.001; Kenny DT, 2007, CONT ISSUES CRIME JU, V107, P1; Knobe J, 2005, TRENDS COGN SCI, V9, P357, DOI 10.1016/j.tics.2005.06.011; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Kohlberg, 1984, ESSAYS MORAL DEV, V2; Lane JD, 2010, BRIT J DEV PSYCHOL, V28, P871, DOI 10.1348/026151009X483056; Aristu AL, 2008, SPAN J PSYCHOL, V11, P670, DOI 10.1017/S1138741600004674; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malti T, 2009, CHILD DEV, V80, P442, DOI 10.1111/j.1467-8624.2009.01271.x; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Moll J, 2003, NEUROREPORT, V14, P299, DOI 10.1097/01.wnr.0000057866.05120.28; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; NELSON JR, 1990, J ABNORM CHILD PSYCH, V18, P231, DOI 10.1007/BF00916562; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Pujol J, 2008, HUM BRAIN MAPP, V29, P910, DOI 10.1002/hbm.20436; Raaijmakers QAW, 2005, INT J BEHAV DEV, V29, P247, DOI 10.1080/01650250544000035; Raine A, 2002, J ABNORM CHILD PSYCH, V30, P311, DOI 10.1023/A:1015754122318; Roberts G, 2008, J PAEDIATR CHILD H, V44, P276, DOI 10.1111/j.1440-1754.2007.01251.x; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stadler C, 2007, Z KINDER JUG-PSYCH, V35, P169, DOI 10.1024/1422-4917.35.3.169; Stams GJ, 2006, J ABNORM CHILD PSYCH, V34, P697, DOI 10.1007/s10802-006-9056-5; TEASDALE G, 1974, LANCET, V2, P81; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Van Vugt E, 2011, INT J OFFENDER THER, V55, P1234, DOI 10.1177/0306624X11396441; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Wechsler D., 2011, WECHSLER ABBREVIATED; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Young L, 2010, NEURON, V65, P845, DOI 10.1016/j.neuron.2010.03.003	62	34	34	0	28	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					896	902		10.3109/02699052.2013.775486			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200017	23789866				2022-02-06	
J	Mathias, JL; Dennington, V; Bowden, SC; Bigler, ED				Mathias, J. L.; Dennington, V.; Bowden, S. C.; Bigler, E. D.			Community versus orthopaedic controls in traumatic brain injury research: How comparable are they?	BRAIN INJURY			English	Article						Community controls; control groups; injury controls; orthopedic controls; research design; TBI; traumatic brain injury; trauma controls	MILD HEAD-INJURY; UNIVERSITY-STUDENTS; SOCIAL SUPPORT; CHILDREN; ADOLESCENTS; PERFORMANCE; SENSITIVITY; SEVERITY; SYMPTOMS; SCALE	Background: Community (CC) or orthopaedic/injury (OC) control groups are typically used to evaluate the consequences of traumatic brain injuries (TBIs). Whereas CCs match for demographic variables and are readily available, OCs may additionally control for other pre- and post-injury variables but are more costly to recruit. Together, they enable an evaluation of brain-vs general-injury effects. However, the comparability of these two groups and the increase in control over confounding variables when OCs are used has rarely been examined. Method: The current study compared samples of CCs (n = 71) and OCs (n = 69), aged between 18-80, on a range of demographic (age, gender, education, socio-economic status), background (medical history, handedness), psychosocial (alcohol use, fatigue, pain, depression, social support, community integration, 'post-concussion' symptoms) and cognitive (motor and processing speed, memory, intellectual ability) variables. Results: The two groups were comparable on all variables, except alcohol use, with the OC group having higher levels of alcohol consumption. However, alcohol use did not correlate with any other variable, including commonly used measures of outcome following TBI. Conclusion: The current findings suggest that an orthopaedic injury control group does not have any clear advantages over a carefully recruited community control group.	[Mathias, J. L.; Dennington, V.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; [Bowden, S. C.] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; [Bigler, E. D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Bigler, E. D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA		Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594	National Health and Medical Research Foundation [519220]	This research was funded by Project Grant number 519220 from the National Health and Medical Research Foundation.	Adams C., 2008, ERGONOMICS; Alfano MS, 2000, J CLIN PSYCHOL, V56, P975, DOI 10.1002/1097-4679(200007)56:7<975::AID-JCLP13>3.0.CO;2-Z; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; [Australian Bureau of Statistics Statistics ABo], 1999, NAT SURV US MED; Australian Bureau of Statistics, 1995, NAT HLTH SURV SF 36; Australian Bureau of Statistics, 2008, AUSTR SOC TRENDS; Australian Bureau of Statistics, 2008, CENS POP HOUS SOC IN; [Australian Bureau of Statistics Statistics ABo], 2001, NAT HLTH SURV INJ, V4384.0; Babor T. F., 1989, AUDIT ALCOHOL DISORD; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BIJUR PE, 1990, PEDIATRICS, V86, P337; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cook T.D., 1979, QUASIEXPERIMENTAL DE; CURRY LM, 1991, PHILADELPHIA HEAD IN; Day AL, 2003, CAN J BEHAV SCI, V35, P73, DOI 10.1037/h0087190; De Monte VE, 2010, J CLIN EXP NEUROPSYC, V32, P28, DOI 10.1080/13803390902806519; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Reitan R., 1979, MANUAL ADM NEUROPSYC; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Wechsler D., 2011, WECHSLER ABBREVIATED; WechslerD, 2001, WECHSLER TEST ADULT; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Wilson JP, 1996, ASSESSING PSYCHOL TR, P399; WINEFIELD HR, 1992, J PERS ASSESS, V58, P198, DOI 10.1207/s15327752jpa5801_17	45	34	34	0	14	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					887	895		10.3109/02699052.2013.793398			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200016	23758520				2022-02-06	
J	Olsen, AB; Hetz, RA; Xue, H; Aroom, KR; Bhattarai, D; Johnson, E; Bedi, S; Cox, CS; Uray, K				Olsen, A. B.; Hetz, R. A.; Xue, H.; Aroom, K. R.; Bhattarai, D.; Johnson, E.; Bedi, S.; Cox, C. S., Jr.; Uray, K.			Effects of traumatic brain injury on intestinal contractility	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						brain injury; inflammation; intestinal contractility	CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE; INFLAMMATORY RESPONSE; TNF-ALPHA; CELLS; RATS; INTERLEUKIN-1-BETA; DYSFUNCTION; INTOLERANCE; METABOLISM	Background Patients with traumatic brain injury (TBI) often suffer from gastrointestinal dysfunction including intolerance to enteral feedings. However, it is unclear how TBI affects small intestinal contractile activity. The purpose of this study was to determine if TBI affects intestinal smooth muscle function. Methods Sprague-Dawley rats were subjected to controlled cortical impact injury (TBI). Sham animals underwent a similar surgery but no injury (SHAM). Animals were sacrificed 1, 3, and 7days after TBI and intestinal smooth muscle tissue was collected for measurement of contractile activity and transit, NF-kB activity, and cytokine levels. Brains were collected after sacrifice to determine volume loss due to injury. Key Results Contractile activity decreased significantly in ileum, but not jejunum, in the TBI group 7days after injury compared with SHAM. Brain volume loss increased significantly 7days after injury compared with 3days and correlated significantly with the contractile activity 1day after injury. In the intestinal smooth muscle, NF-kB activity increased significantly in the TBI group 3 and 7days after injury vs SHAM. Wet to dry weight ratio, indicating edema, also increased significantly in the TBI group. Interleukin-1, -1, and -17 increased significantly in the TBI group compared with SHAM. Conclusions & Inferences Traumatic brain injury causes a delayed but significant decrease in intestinal contractile activity in the ileum leading to delayed transit. The decreased intestinal contractile activity is attributed to secondary inflammatory injury as evidenced by increased NF-kB activity, increased edema, and increased inflammatory cytokines in the intestinal smooth muscle.	[Olsen, A. B.; Hetz, R. A.; Xue, H.; Bhattarai, D.; Bedi, S.; Cox, C. S., Jr.; Uray, K.] Univ Texas Houston, Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Hetz, R. A.; Xue, H.; Aroom, K. R.; Cox, C. S., Jr.] Univ Texas Houston, Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Johnson, E.] Univ Texas Houston, Med Sch Houston, Dept Internal Med, Houston, TX 77030 USA; [Uray, K.] Texas A&M Univ, Michael E DeBakey Inst, College Stn, TX USA		Uray, K (corresponding author), Univ Texas Houston, Med Sch Houston, Dept Pediat Surg, MSB 5-230,6431 Fannin St, Houston, TX 77030 USA.	Karen.l.davis@uth.tmc.edu		Aroom, Kevin/0000-0003-1504-0585; Uray, Karen/0000-0001-6997-459X	Brown Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK056338] Funding Source: NIH RePORTER	This study was supported by funding from Brown Foundation.	Akiho H, 2002, AM J PHYSIOL-GASTR L, V282, pG226, DOI 10.1152/ajpgi.2002.282.2.G226; Akiho Hirotada, 2011, World J Gastrointest Pathophysiol, V2, P72; Akiho Hirotada, 2010, World J Gastrointest Pathophysiol, V1, P97, DOI 10.4291/wjgp.v1.i3.97; Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; CHIU CJ, 1970, ARCH SURG-CHICAGO, V101, P478; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Conti AC, 1998, J NEUROSCI, V18, P5663; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Engel DR, 2010, NAT MED, V16, P1407, DOI 10.1038/nm.2255; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hu WH, 2008, BIOCHEM J, V412, P35, DOI 10.1042/BJ20080042; Hu WH, 2007, AM J PHYSIOL-CELL PH, V293, pC1991, DOI 10.1152/ajpcell.00300.2007; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kinoshita K, 2003, AM J PHYSIOL-GASTR L, V285, pG483, DOI 10.1152/ajpgi.00038.2003; Koda M, 2002, J NEUROTRAUM, V19, P777, DOI 10.1089/08977150260139147; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Martinez GJ, 2008, ANN NY ACAD SCI, V1143, P188, DOI 10.1196/annals.1443.021; McConnell EL, 2008, J PHARM PHARMACOL, V60, P63, DOI 10.1211/jpp.60.1.0008; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Ohama T, 2007, AM J PHYSIOL-GASTR L, V292, pG1429, DOI 10.1152/ajpgi.00315.2006; Pavlov VA, 2004, CELL MOL LIFE SCI, V61, P2322, DOI 10.1007/s00018-004-4102-3; Pazdrak K, 2004, GASTROENTEROLOGY, V127, P1096, DOI 10.1053/j.gastro.2004.07.008; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; TEASDALE G, 1974, LANCET, V2, P81; Uray KS, 2006, CRIT CARE MED, V34, P2630, DOI 10.1097/01.CCM.0000239195.06781.8C; Uray KS, 2010, CRIT CARE MED, V38, P861, DOI 10.1097/CCM.0b013e3181ce4aaa; Van Oudenhove L, 2004, BEST PRACT RES CL GA, V18, P663, DOI 10.1016/j.bpg.2004.04.010; Wang YB, 2011, WORLD J GASTROENTERO, V17, P657, DOI 10.3748/wjg.v17.i5.657; Zhao AP, 2008, GASTROENTEROLOGY, V135, P217, DOI 10.1053/j.gastro.2008.03.077	44	34	39	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1350-1925	1365-2982		NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	JUL	2013	25	7								10.1111/nmo.12121			10	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Neurosciences & Neurology	164GL	WOS:000320397100011	23551971	Green Accepted			2022-02-06	
J	Zhou, TF; Yu, JG				Zhou, Ting-Fa; Yu, Jin-Gui			Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia	JOURNAL OF SURGICAL RESEARCH			English	Article						Apoptosis; Sepsis; rhEPO; Learning and memory; JAK2/STAT3; Hippocampus; Neuronal cultures; Cecal ligation and peroration	TRAUMATIC BRAIN-INJURY; MEDIATED NEUROPROTECTION; ENHANCES NEUROGENESIS; SEPSIS; RATS; PROTECTS; DISEASE; ENCEPHALOPATHY; DYSFUNCTION; ACTIVATION	Background: Septic encephalopathy is characterized by changes in mental status and an increase in neuronal apoptosis. Accumulating evidence has shown that recombinant human erythropoietin (rhEPO) protects brain against ischemia and hypoxia injury. However, whether rhEPO exerts neuroprotective effects on septic encephalopathy remains unclear. We designed the current study to evaluate possible neuroprotection of rhEPO in a model of sepsis. Methods: For this in vitro study, we determined hippocampal neuronal apoptosis by lactate dehydrogenase release, cell counting kit-8 assay, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining after treatment with lipopolysaccharide. We transfected the signal transducer and activator of transcription 3 (STAT3) short hairpin RNA at 14 d in vitro for 48 h. For the in vivo study, we performed cecal ligation and peroration surgery. We detected the expression of phospho-Janus-activated kinase 2 (JAK2), total JAK2, phospho-STAT3, total STAT3, Bax and Bcl-XL by Western blot, and examined behavior using the Morris water maze. Results: Treatment with rhEPO reduces apoptosis and increases cell viability in lipopolysaccharide-treated neuronal cultures. In cecal ligation and peroration rats, rhEPO attenuated the inhibition of phospho-JAK2 and phospho-STAT3. In addition, rhEPO enhanced the expression of Bcl-XL, but depressed Bax, which was abolished by additional administration of inhibitor of JAK2/STAT3 signaling 2-cyano-3-(3,4-dihydroxyphenyl)-N-(benzyl)-2-propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide or (E)-3(6-bromopyridin-2-yl)-2-cyano-N-([S0-1-phenylethyl]acrylamide) in vivo, and was ameliorated by STAT3 short hairpin RNA transfection in vitro. Alternatively, we confirmed the neuronal protective effect of rhEPO by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelingstaining. For the Morris water maze study, rhEPO improved learning and memory disorders without an alternation in locomotor activity. Conclusions: These results indicated that rhEPO improves brain dysfunction by reducing neuronal apoptosis, and JAK2/STAT3 signaling is likely to be involved. Application of rhEPO may serve as a potential therapy for the treatment of septic encephalopathy. (C) 2013 Elsevier Inc. All rights reserved.	[Zhou, Ting-Fa; Yu, Jin-Gui] Shandong Univ, Dept Anesthesiol, Qilu Hosp, Jinan 250000, Peoples R China		Yu, JG (corresponding author), Shandong Univ, Dept Anesthesiol, Qilu Hosp, 107 Western Wenhua Rd, Jinan 250000, Peoples R China.	yujingui68@yahoo.com.cn					Aher S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004868.pub2; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Aoshiba K, 2009, CRIT CARE MED, V37, P889, DOI 10.1097/CCM.0b013e31819b8371; Assaraf MI, 2007, J NEUROPATH EXP NEUR, V66, P389, DOI 10.1097/nen.0b013e3180517b28; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Chiba T, 2009, MOL PSYCHIATR, V14, P206, DOI 10.1038/mp.2008.105; Chiba T, 2009, EXPERT OPIN THER TAR, V13, P1155, DOI 10.1517/14728220903213426; Comim CM, 2008, MITOCHONDRION, V8, P313, DOI 10.1016/j.mito.2008.07.002; d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Haiden N, 2006, PEDIATRICS, V118, P180, DOI 10.1542/peds.2005-2475; Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58; Kaech S, 2006, NAT PROTOC, V1, P2406, DOI 10.1038/nprot.2006.356; Kanaan NM, 2006, BRAIN RES, V1068, P221, DOI 10.1016/j.brainres.2005.10.078; Kao R, 2007, CRIT CARE, V11, DOI 10.1186/cc5920; Koroglu TF, 2006, PHYSIOL RES, V55, P309; Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; McPherson RJ, 2008, INT J DEV NEUROSCI, V26, P103, DOI 10.1016/j.ijdevneu.2007.08.012; Mitra A, 2007, NEPHROL DIAL TRANSPL, V22, P2349, DOI 10.1093/ndt/gfm216; Nicolas CS, 2012, NEURON, V73, P374, DOI 10.1016/j.neuron.2011.11.024; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ritter C, 2004, CRIT CARE MED, V32, P342, DOI 10.1097/01.CCM.0000109454.13145.CA; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Siami S, 2008, CRIT CARE CLIN, V24, P67, DOI 10.1016/j.ccc.2007.10.001; Wang GS, 2010, J NEUROCHEM, V114, P1039, DOI [10.1111/j.1471-4159.2010.00817.x, 10.1111/j.1471-4159.2010.06817.x]; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Weberpals M, 2009, J NEUROSCI, V29, P14177, DOI 10.1523/JNEUROSCI.3238-09.2009; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	36	34	38	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2013	183	1					304	312		10.1016/j.jss.2012.11.035			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	166ZK	WOS:000320599600045	23236988				2022-02-06	
J	Muehlschlegel, S; Carandang, R; Ouillette, C; Hall, W; Anderson, F; Goldberg, R				Muehlschlegel, Susanne; Carandang, Raphael; Ouillette, Cynthia; Hall, Wiley; Anderson, Fred; Goldberg, Robert			Frequency and Impact of Intensive Care Unit Complications on Moderate-Severe Traumatic Brain Injury: Early Results of the Outcome Prognostication in Traumatic Brain Injury (OPTIMISM) Study	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Adult brain injury; Functional outcome; Intensive care unit complications; Medical complications	ISCHEMIC-STROKE PATIENTS; HEAD-INJURY; PERSISTENT HYPERGLYCEMIA; VALIDATION; PROGNOSIS; PREDICTORS; CRASH; TRIAL	Known predictors of adverse outcomes in patients with moderate-severe TBI (msTBI) explain only a relatively small proportion of patient-related outcomes. The frequency and impact of intensive care unit complications (ICU-COMPL) on msTBI-associated outcomes are poorly understood. In 213 consecutive msTBI patients admitted to a Level I Trauma Center neuro trauma ICU, twenty-eight ICU-COMPL (21 medical and 7 neurological) were prospectively collected and adjudicated by group consensus, using pre-defined criteria. We determined frequencies, and explored associations of ICU-COMPL and hospital discharge outcomes using multivariable logistic regression. The average age of the study sample was 53 years, and the median presenting Glasgow Coma Scale and Injury Severity Scores were 5 and 27, respectively. Hyperglycemia (79 %), fever (62 %), systemic inflammatory response syndrome (60 %), and hypotension requiring vasopressors (42 %) were the four most common medical ICU-COMPL. Herniation (39 %), intracranial rebleed (39 %), and brain edema requiring osmotherapy (37 %) were the three most common neurological ICU-COMPL. After adjusting for admission variables, duration of ventilation, and ICU length-of-stay, patients with brain edema (OR 5.8; 95 % CI 2, 16.7) had a significantly increased odds for dying during hospitalization whereas patients with hospital-acquired urinary tract infection (UTI) had a decreased odds (OR 0.05; 95 % CI 0.005, 0.6). Sensitivity analysis revealed that UTI occurred later, suggesting a non-causal association with survival. Brain herniation (OR 15.7; 95 % CI 2.6, 95.4) was associated with an unfavorable functional status (GOS 1-3). ICU-COMPL are very common after msTBI, have a considerable impact on short-term outcomes, and should be considered in the prognostication of these high risk patients. Survival associations of time-dependent complications warrant cautious interpretation.	[Muehlschlegel, Susanne; Carandang, Raphael; Ouillette, Cynthia; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Neurol, Div Neurocrit Care, Worcester, MA 01605 USA; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Anesthesia Crit Care, Div Neurocrit Care, Worcester, MA USA; [Muehlschlegel, Susanne; Carandang, Raphael; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Surg, Div Neurocrit Care, Worcester, MA USA; [Anderson, Fred] Univ Massachusetts, Sch Med, Dept Surg, Ctr Outcomes Res, Worcester, MA USA; [Anderson, Fred] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Ctr Outcomes Res, Worcester, MA USA; [Goldberg, Robert] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA		Muehlschlegel, S (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, Div Neurocrit Care, Worcester, MA 01605 USA.	susanne.muehlschlegel@umassmemorial.org	Viani, Rafael/V-1196-2018				Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Edwards P, 2005, LANCET, V365, P1957; Fuentes B, 2010, STROKE, V41, P2362, DOI 10.1161/STROKEAHA.110.591529; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kase CS, 2001, NEUROLOGY, V57, P1603, DOI 10.1212/WNL.57.9.1603; King C, 2012, J HOSP INFECT, V82, P219, DOI 10.1016/j.jhin.2012.05.004; Kourbeti IS, 2011, BRIT J NEUROSURG, V25, P9, DOI 10.3109/02688697.2010.500411; Leigh R, 2004, STROKE, V35, P1903, DOI 10.1161/01.STR.0000132571.77987.4c; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Salim A, 2009, AM SURGEON, V75, P25; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Wartenberg KE, 2006, CRIT CARE MED, V34, pA124, DOI 10.1097/00003246-200612002-00426; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Yuan F, 2012, J TRAUMA ACUTE CARE, V73, P137, DOI 10.1097/TA.0b013e31824b00ac; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	34	34	35	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2013	18	3					318	331		10.1007/s12028-013-9817-2			14	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	147II	WOS:000319159600006	23377884	Green Submitted			2022-02-06	
J	Iverson, GL; Koehle, MS				Iverson, Grant L.; Koehle, Michael S.			Normative data for the modified balance error scoring system in adults	BRAIN INJURY			English	Article						Traumatic brain injury; concussion; balance; postural stability; BESS; military; sports	TRAUMATIC BRAIN-INJURY; POSTURAL STABILITY; MOTOR-PERFORMANCE; HEAD-INJURY; CONCUSSION; DEFICITS; INSTABILITY; SPORT	Primary objective: Head trauma, with or without injury to the brain, can impair balance and postural stability. The Modified Balance Error Scoring System (M-BESS) is a rapid, standardized, objective bedside test that can be helpful for monitoring recovery of balance and postural stability following head trauma. The purpose of this study is to develop preliminary normative data for this test for adults. Methods and procedures: Adults between the ages of 20-69 (n = 1234) were administered the M-BESS as part of a comprehensive preventive health screen. They did not have significant medical, neurological or lower extremity problems that might have an adverse effect on balance. Main outcomes and results: M-BESS performance significantly declined with age. Men and women performed similarly on the M-BESS. There was a small significant difference in M-BESS performance, with obese men performing more poorly than non-obese men and a larger significant difference between obese and non-obese women. Conclusions: The M-BESS normative data are presented for the total sample and by age, sex and age-by-sex. These normative data provide a frame of reference for interpreting M-BESS performance in adults who sustain traumatic brain injuries and adults with diverse neurological problems.	Univ British Columbia, Vancouver, BC V6T 2A1, Canada; Copeman Healthcare Ctr, Vancouver, BC, Canada		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@mail.ubc.ca	Koehle, Michael S/C-7850-2013	Koehle, Michael S/0000-0001-7026-8422; Iverson, Grant/0000-0001-7348-9570			Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Bressel E, 2007, J ATHL TRAINING, V42, P42; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	22	34	34	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2013	27	5					596	599		10.3109/02699052.2013.772237			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	124UK	WOS:000317493000010	23473405				2022-02-06	
J	Leitgeb, J; Mauritz, W; Brazinova, A; Majdan, M; Wilbacher, I				Leitgeb, Johannes; Mauritz, Walter; Brazinova, Alexandra; Majdan, Marek; Wilbacher, Ingrid			Impact of concomitant injuries on outcomes after traumatic brain injury	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Traumatic brain injury; Outcome; Concomitant injuries	HEAD-INJURY; INTRACRANIAL-PRESSURE; EPIDEMIOLOGY; MORTALITY	Patients with traumatic brain injury (TBI) frequently have concomitant injuries; we aimed to investigate their impact on outcomes. Between February 2002 and April 2010, 17 Austrian centers prospectively enrolled 863 patients with moderate and severe TBI into observational studies. Data on accident, treatment, and outcomes were collected. Patients who survived until intensive care unit (ICU) admission and had survivable TBI were selected, and were assigned to "isolated TBI" or "TBI + injury" groups. Six-month outcomes were classified as "favorable" if Glasgow Outcome Scale (GOS) scores were five or four, and were classified as "unfavorable" if GOS scores were three or less. Univariate statistics (Fisher's exact test, t test, chi(2)-test) and logistic regression were used to identify factors associated with hospital mortality and unfavorable outcome. Of the 767 patients, 403 (52.5 %) had isolated TBI, 364 (47.5 %) had concomitant injuries. Patients with isolated TBI had higher mean age (53 vs. 44 years, P = 0.001); hospital mortality (30.0 vs. 27.2 %, P = 0.42) and rate of unfavorable outcome (50.4 vs. 41.8 %, P = 0.02) were higher, too. There were no significant mortality differences for factors like age groups, trauma mechanisms, neurologic status, CT findings, or treatment factors. Concomitant injuries were associated with higher mortality (33.3 vs. 12.5 %, P = 0.05) in patients with moderate TBI, and were significantly associated with more ventilation, ICU, and hospitals days. Logistic regression revealed that age, Glasgow Coma Scale score, pupillary reactivity, severity of TBI and CT score were the main factors that influenced outcomes. Concomitant injuries have a significant effect upon the mortality of patients with moderate TBI. They do not affect the mortality in patients with severe TBI. Evidence level 2; prospective, observational prognostic study.	[Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria; [Mauritz, Walter] Trauma Hosp Lorenz Boehler, Anesthesiol & Intens Care Med, Vienna, Austria; [Mauritz, Walter; Brazinova, Alexandra; Majdan, Marek] Int Neurotrauma Res Org, Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek; Wilbacher, Ingrid] Trnava Univ, Fac Hlth & Social Serv, Dept Publ Hlth, Trnava, Slovakia		Leitgeb, J (corresponding author), Med Univ Vienna, Dept Traumatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	johannes.leitgeb@meduniwien.ac.at; walter.mauritz@auva.at; abrazinova@igeh.org; mmajdan@igeh.org; ingrid.wilbacher@hvb.sozvers.at	Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012	Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712	Austrian Worker's Compensation Board (AUVA) [FK 33/2003]; Austrian National Bank [8987]; Ministry of Health; AUVA [FK 11/2008, FK 11/2010]	The data used for this study were collected for a project funded by the Austrian Worker's Compensation Board (AUVA; FK 33/2003) and by the "Jubilee Fund" of the Austrian National Bank (Project 8987), and for a project funded by the Ministry of Health (Contract Oct. 15, 2008) and the AUVA (FK 11/2008 and FK 11/2010). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources.	Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Kemp CD, 2008, AM SURGEON, V74, P866; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Martin RCG, 2002, AM SURGEON, V68, P477; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	24	34	34	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	MAY	2013	133	5					659	668		10.1007/s00402-013-1710-0			10	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	131DL	WOS:000317972300011	23463257	Green Published, hybrid			2022-02-06	
J	Thal, SC; Schaible, EV; Neuhaus, W; Scheffer, D; Brandstetter, M; Engelhard, K; Wunder, C; Forster, CY				Thal, Serge C.; Schaible, Eva-Verena; Neuhaus, Winfried; Scheffer, David; Brandstetter, Moritz; Engelhard, Kristin; Wunder, Christian; Foerster, Carola Y.			Inhibition of Proteasomal Glucocorticoid Receptor Degradation Restores Dexamethasone-Mediated Stabilization of the Blood-Brain Barrier After Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						blood-brain barrier; bortezomib; dexamethasone; GC receptor; glucocorticoid; nuclear receptor; proteasome; steroids; traumatic brain injury	PLACEBO-CONTROLLED TRIAL; FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; IN-VITRO; TIGHT JUNCTIONS; RAT-BRAIN; MRC CRASH; TNF-ALPHA; EXPRESSION; EDEMA	Objectives: To establish the molecular background for glucocorticoid insensitivity, that is, failure to reduce edema formation and to protect blood-brain barrier integrity after acute traumatic brain injury. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male C57Bl/6N mice. Interventions: Mechanical brain lesion by controlled cortical impact. Measurements and Main Results: Our study demonstrates that 1) proteasomal glucocorticoid receptor degradation is established in brain endothelial cells after traumatic brain injury as a form of posttranslational glucocorticoid receptor modification; 2) inhibition of the proteasomal degradation pathway with bortezomib (0.2 mg/kg) in combination with the glucocorticoid dexamethasone (10 mg/kg) by subcutaneous injection 30 minutes postinjury restores levels of barrier sealing glucocorticoid receptor target occludin in brain endothelial cells, improves blood-brain barrier integrity, reduces edema formation, and limits neuronal damage after brain trauma. Conclusions: The results indicate that the stabilizing effect of glucocorticoids on the blood-brain barrier is hampered after cerebral lesions by proteasomal glucocorticoid receptor degradation in brain endothelial cells and restored by inhibition of proteasomal degradation pathways. The results provide underlying mechanisms for the clinically observed inefficacy of glucocorticoids. The novel combined treatment strategy might help to attenuate trauma-induced brain edema formation and neuronal damage as secondary effects of brain trauma. (Crit Care Med 2013; 41:1305-1315)	[Thal, Serge C.; Schaible, Eva-Verena; Brandstetter, Moritz; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany; [Neuhaus, Winfried; Scheffer, David; Wunder, Christian; Foerster, Carola Y.] Univ Wurzburg, Ctr Operat Med, Dept Anesthesia & Crit Care, Wurzburg, Germany; [Neuhaus, Winfried] Univ Vienna, Dept Med Chem, A-1010 Vienna, Austria		Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany.	thal@uni-mainz.de; Foerster_C@klinik.uni-wuerz-burg.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Neuhaus, Winfried/0000-0002-6552-7183	European UnionEuropean Commission [HEALTH-F2-2009-241778]; Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [BMBF01 EO1004]; Focus Program Translational Neurosciences (FTN) of the Johannes Gutenberg-University	Supported, in part, by grants from the European Union (HEALTH-F2-2009-241778) to C.F., the Bundesministerium fur Bildung und Forschung (BMBF01 EO1004) to C.F., and the Focus Program Translational Neurosciences (FTN) of the Johannes Gutenberg-University to Dr. Thal.	Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Blecharz KG, 2008, J CEREBR BLOOD F MET, V28, P1139, DOI 10.1038/jcbfm.2008.2; Blecharz KG, 2014, BIOL CELL, V106, DOI 10.1111/boc.201300083; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; BURNHAM JA, 1991, NEUROLOGY, V41, P1349, DOI 10.1212/WNL.41.9.1349; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Dou Q Ping, 2002, IDrugs, V5, P828; Edwards P, 2005, LANCET, V365, P1957; Fishman R. A., 1992, CEREBROSPINAL FLUID, V2nd; Forster C, 2008, HISTOCHEM CELL BIOL, V130, P55, DOI 10.1007/s00418-008-0424-9; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Forster C, 2007, J PHYSIOL-LONDON, V580, P937, DOI 10.1113/jphysiol.2007.129007; Forster C, 2006, J PHYSIOL-LONDON, V573, P413, DOI 10.1113/jphysiol.2006.106385; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Harke N, 2008, MOL CELL ENDOCRINOL, V295, P39, DOI 10.1016/j.mce.2008.08.011; Henninger N, 2006, NEUROSCI LETT, V398, P300, DOI 10.1016/j.neulet.2006.01.015; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hwang IK, 2006, NEUROSCI RES, V54, P319, DOI 10.1016/j.neures.2005.12.012; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Lahiri S, 2009, EUR J PHARMACOL, V609, P118, DOI 10.1016/j.ejphar.2009.03.005; Lee BH, 2007, NEONATOLOGY, V91, P12, DOI 10.1159/000096966; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Poungvarin N, 2004, STROKE, V35, P229, DOI 10.1161/01.STR.0000105931.81723.26; Reichardt Holger M, 2006, Expert Rev Neurother, V6, P1657, DOI 10.1586/14737175.6.11.1657; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; SAPOLSKY RM, 1984, ENDOCRINOLOGY, V114, P287, DOI 10.1210/endo-114-1-287; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHMIDTKASTNER R, 1993, J NEUROSCI METH, V46, P121, DOI 10.1016/0165-0270(93)90147-J; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Weiss H, 2010, PEDIATRICS, V126, P1141, DOI 10.1542/peds.2010-0271; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Zeni P, 2007, AM J PHYSIOL-CELL PH, V293, pC855, DOI 10.1152/ajpcell.00470.2006; Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.006	53	34	35	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2013	41	5					1305	1315		10.1097/CCM.0b013e31827ca494			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126ZB	WOS:000317661000034	23474678				2022-02-06	
J	Dai, SS; Wang, H; Yang, N; An, JH; Li, W; Ning, YL; Zhu, PF; Chen, JF; Zhou, YG				Dai, Shuang-Shuang; Wang, Hao; Yang, Nan; An, Jian-Hong; Li, Wei; Ning, Ya-Lei; Zhu, Pei-Fang; Chen, Jiang-Fan; Zhou, Yuan-Guo			Plasma glutamate-modulated interaction of A(2A)R and mGluR5 on BMDCs aggravates traumatic brain injury-induced acute lung injury	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; CORTICAL IMPACT MODEL; COUPLED RECEPTOR DIMERIZATION; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW-CELLS; INFLAMMATORY RESPONSE; PULMONARY-EDEMA; ADENOSINE A2A; AMINO-ACIDS; HEAD-INJURY	The bone marrow-derived cell (BMDC)-associated inflammatory response plays a key role in the development of acute lung injury (ALI). Activation of adenosine A(2A) receptor (A(2A)R) is generally considered to be antiinflammatory, inhibiting BMDC activities to protect against ALI. However, in the present study, we found that in a mouse model of neurogenic ALI induced by severe traumatic brain injury (TBI), BMDC A(2A)R exerted a proinflammatory effect, aggravating lung damage. This is in contrast to the antiinflammatory effect observed in the mouse oleic acid-induced ALI model (a nonneurogenic ALI model.) Moreover, the A(2A)R agonist CGS21680 aggravated, whereas the antagonist ZM241385 attenuated, the severe TBI-induced lung inflammatory damage in mice. Further investigation of white blood cells isolated from patients or mouse TBI models and of cultured human or mouse neutrophils demonstrated that elevated plasma glutamate after severe TBI induced interaction between A(2A)R and the metabotropic glutamate receptor 5 (mGluR5) to increase phospholipase C-protein kinase C signaling, which mediated the proinflammatory effect of A(2A)R. These results are in striking contrast to the well-known antiinflammatory and protective role of A(2A)R in nonneurogenic ALI and indicate different therapeutic strategies should be used for nonneurogenic and neurogenic ALI treatment when targeting A(2A)R.	[Dai, Shuang-Shuang] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400042, Peoples R China; [Dai, Shuang-Shuang; Yang, Nan; An, Jian-Hong; Li, Wei; Ning, Ya-Lei; Zhu, Pei-Fang; Zhou, Yuan-Guo] Third Mil Med Univ, Ctr Mol Biol, State Key Lab Trauma Burn & Combined Injury, Chongqing 400042, Peoples R China; [Wang, Hao] Third Mil Med Univ, Dept Neurosurg, Inst Surg Res, Chongqing 400042, Peoples R China; [Wang, Hao] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Chen, Jiang-Fan] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA		Zhou, YG (corresponding author), Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400042, Peoples R China.	ygzhou@tmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30900587, 81172817, 31171022]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]; Science Foundation of Third Military Medical University	This work was supported by grants from the National Natural Science Foundation of China (nos. 30900587, 81172817, and 31171022), the Natural Science Foundation of Chongqing, China (no. CSTC2009BB5317), and the Science Foundation of Third Military Medical University (to S.-S. Dai).	Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137; Aliprandi A, 2005, J CEREBR BLOOD F MET, V25, P513, DOI 10.1038/sj.jcbfm.9600039; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Azoulay E, 2002, CRIT CARE MED, V30, P781, DOI 10.1097/00003246-200204000-00010; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baughman RP, 1996, AM J RESP CRIT CARE, V154, P76, DOI 10.1164/ajrccm.154.1.8680703; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Brown RM, 2012, INT J NEUROPSYCHOPH, V15, P995, DOI 10.1017/S146114571100126X; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheng ZJ, 2003, J BIOL CHEM, V278, P52972, DOI 10.1074/jbc.M310090200; Chung LP, 2009, J CLIN ENDOCR METAB, V94, P3038, DOI 10.1210/jc.2009-0778; Ciruela F, 2001, DRUG DEVELOP RES, V52, P316, DOI 10.1002/ddr.1129; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; DETTBARN CL, 1989, HEART LUNG, V18, P583; Donadieu E, 2007, ACTA HISTOCHEM, V109, P177, DOI 10.1016/j.acthis.2007.01.004; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; Fredholm BB, 2007, PROG NEUROBIOL, V83, P263, DOI 10.1016/j.pneurobio.2007.07.005; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; Gill SS, 2001, TOXICOL PATHOL, V29, P208, DOI 10.1080/019262301317052486; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Graham DB, 2007, J CLIN INVEST, V117, P3445, DOI 10.1172/JCI32729; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Hasko G, 2006, CRIT CARE MED, V34, P1119, DOI 10.1097/01.CCM.0000206467.19509.C6; Hawkins RA, 2006, J NUTR, V136, p218S, DOI 10.1093/jn/136.1.218S; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HENSON PM, 1975, J CLIN INVEST, V56, P1053, DOI 10.1172/JCI108152; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Jin W, 2009, EXP BIOL MED, V234, P181, DOI 10.3181/0807-RM-232; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Keita M, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-3; Lee WJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1101, DOI 10.1152/ajpcell.1998.274.4.C1101; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Liu Xiang-Cheng, 2010, Zhonghua Wai Ke Za Zhi, V48, P1050; Liu Xue-Yun, 2010, Shengli Xuebao, V62, P219; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; Magalhaes MAO, 2007, J LEUKOCYTE BIOL, V82, P559, DOI 10.1189/jlb.0207126; Mascia L, 2008, MINERVA ANESTESIOL, V74, P325; Nakajima T, 2010, J IMMUNOL, V184, P5835, DOI 10.4049/jimmunol.0903238; Nishi A, 2003, P NATL ACAD SCI USA, V100, P1322, DOI 10.1073/pnas.0237126100; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Pacheco R, 2006, J IMMUNOL, V177, P6695, DOI 10.4049/jimmunol.177.10.6695; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Parekh D, 2011, CLIN MED, V11, P615, DOI 10.7861/clinmedicine.11-6-615; Pinto-Duarte A, 2005, J NEUROCHEM, V93, P595, DOI 10.1111/j.1471-4159.2005.03071.x; Qian F, 2012, AM J PHYSIOL-LUNG C, V302, pL866, DOI 10.1152/ajplung.00277.2011; Reutershan J, 2004, CRIT CARE, V8, P453, DOI 10.1186/cc2881; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; Schepp CP, 2008, CRIT CARE, V12, DOI 10.1186/cc6990; Schroder H, 2009, NEUROPHARMACOLOGY, V56, P768, DOI 10.1016/j.neuropharm.2008.12.010; Sharma AK, 2010, J THORAC CARDIOV SUR, V139, P474, DOI 10.1016/j.jtcvs.2009.08.033; Shen L, 2007, ACTA PHARMACOL SIN, V28, P392, DOI 10.1111/j.1745-7254.2007.00511.x; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7; Xu T, 2006, AM J RESP CRIT CARE, V174, P1011, DOI 10.1164/rccm.200511-1751OC; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103; Zlotnik A, 2010, ANESTH ANALG, V111, P1497, DOI 10.1213/ANE.0b013e3181fc0112	73	34	38	2	34	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0022-1007	1540-9538		J EXP MED	J. Exp. Med.	APR 8	2013	210	4					839	851		10.1084/jem.20122196			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	121ZP	WOS:000317284900016	23478188	Green Published, hybrid, Green Submitted			2022-02-06	
J	Crupi, R; Paterniti, I; Campolo, M; Di Paola, R; Cuzzocrea, S; Esposito, E				Crupi, Rosalia; Paterniti, Irene; Campolo, Michela; Di Paola, Rosanna; Cuzzocrea, Salvatore; Esposito, Emanuela			Exogenous T3 administration provides neuroprotection in a murine model of traumatic brain injury	PHARMACOLOGICAL RESEARCH			English	Article						Traumatic brain injury; Neuroinflammation; T3; Cortical impact	ACTIVATED PROTEIN-KINASE; THYROID-HORMONE; NONGENOMIC ACTIONS; SERINE PHOSPHORYLATION; BEHAVIORAL RECOVERY; CEREBRAL-ISCHEMIA; CELL-DEATH; BLOOD; THYROXINE; HYPOTHYROIDISM	Traumatic brain injury (TBI) induces primary and secondary damage in both the endothelium and the brain parenchyma. While neurons die quickly by necrosis, a vicious cycle of secondary injury in endothelial cells exacerbates the initial injury. Thyroid hormones are reported to be decreased in patients with brain injury. Controlled cortical impact injury (CCI) is a widely used, clinically relevant model of TBI. Here, using CCI in adult male mice, we set to determine whether 3,5,3'-triiodothyronine (T3) attenuates posttraumatic neurodegeneration and neuroinflammation in an experimental model of TBI. Treatment with T3 (1.2 mu g/100 g body weight, i.p.) 1 h after TBI resulted in a significant improvement in motor and cognitive recovery after CCI, as well as in marked reduction of lesion volumes. Mouse model for brain injury showed reactive astrocytes with increased glial fibrillary acidic protein, and formation of inducible nitric oxide synthase (iNOS). Western blot analysis revealed the ability of T3 to reduce brain trauma through modulation of cytoplasmic-nuclear shuttling of nuclear factor-kappa B (NF-kappa B). Twenty-four hours after brain trauma, T3-treated mice also showed significantly lower number of TUNEL(+) apoptotic neurons and curtailed induction of Bax, compared to vehicle control. In addition, T3 significantly enhanced the post-TBI expression of the neuroprotective neurotrophins (BDNF and GDNF) compared to vehicle. Our data provide an additional mechanism for the anti-inflammatory effects of thyroid hormone with critical implications in immunopathology at the cross-roads of the immune-endocrine circuits. (C) 2013 Elsevier Ltd. All rights reserved.	[Crupi, Rosalia; Paterniti, Irene; Campolo, Michela; Di Paola, Rosanna; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy		Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	salvator@unime.it	di paola, rosanna/U-4356-2019; Campolo, Michela/K-6432-2016; Crupi, Rosalia/U-4364-2019	di paola, rosanna/0000-0001-6725-8581; Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690			Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Akhoundi FH, 2011, NEUROLOGY, V77, P349, DOI 10.1212/WNL.0b013e3182267ba0; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Alevizaki M, 2006, CLIN ENDOCRINOL, V65, P369, DOI 10.1111/j.1365-2265.2006.02606.x; Axelband F, 2011, J CELL PHYSIOL, V226, P21, DOI 10.1002/jcp.22325; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barreto-Chaves ML, 2011, CURR OPIN ENDOCRINOL, V18, P300, DOI 10.1097/MED.0b013e32834a785c; Bernal J, 2007, NAT CLIN PRACT ENDOC, V3, P249, DOI 10.1038/ncpendmet0424; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; D'Arezzo S, 2004, ENDOCRINOLOGY, V145, P5694, DOI 10.1210/en.2004-0890; Davis PJ, 2011, CURR OPIN ENDOCRINOL, V18, P293, DOI 10.1097/MED.0b013e32834abeb2; Davis PJ, 1996, THYROID, V6, P497, DOI 10.1089/thy.1996.6.497; Davis PJ, 2000, J BIOL CHEM, V275, P38032, DOI 10.1074/jbc.M002560200; De Vito P, 2011, THYROID, V21, P879, DOI 10.1089/thy.2010.0429; DISTEFANO JJ, 1982, ENDOCRINOLOGY, V110, P198, DOI 10.1210/endo-110-1-198; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66; Farwell AP, 2006, ENDOCRINOLOGY, V147, P2567, DOI 10.1210/en.2005-1272; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Kilburn-Watt E, 2010, J NEUROENDOCRINOL, V22, P960, DOI 10.1111/j.1365-2826.2010.02038.x; KINLAW WB, 1985, J CLIN INVEST, V75, P1238, DOI 10.1172/JCI111821; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014, DOI 10.1152/ajpcell.1999.276.5.C1014; Losi G, 2008, NEUROSCIENCE, V151, P155, DOI 10.1016/j.neuroscience.2007.09.064; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malekpour Babak, 2012, Acta Med Iran, V50, P113; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Mendes-de-Aguiar CBN, 2008, J NEUROSCI RES, V86, P3117, DOI 10.1002/jnr.21755; Okosieme OE, 2011, EXPERT OPIN PHARMACO, V12, P2315, DOI 10.1517/14656566.2011.600307; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PETITO CK, 1993, INT J DEV NEUROSCI, V11, P239, DOI 10.1016/0736-5748(93)90082-O; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; RAMI A, 1992, LIFE SCI, V50, P645, DOI 10.1016/0024-3205(92)90251-J; Rastogi L, 2006, EXP NEUROL, V200, P290, DOI 10.1016/j.expneurol.2006.02.013; Sarkozy G, 2007, EUR J PAEDIATR NEURO, V11, P129, DOI 10.1016/j.ejpn.2006.11.009; Schlenker EH, 2008, AM J PHYSIOL-REG I, V294, pR1504, DOI 10.1152/ajpregu.00027.2008; SCHWARTZ HL, 1971, J CLIN INVEST, V50, P1124, DOI 10.1172/JCI106584; Shih A, 2001, BIOCHEMISTRY-US, V40, P2870, DOI 10.1021/bi001978b; SHUAIB A, 1994, EXP NEUROL, V127, P119, DOI 10.1006/exnr.1994.1085; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; Slepkov E, 2004, VITAM HORM, V69, P249, DOI 10.1016/S0083-6729(04)69009-1; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Takano T, 2009, STROKE, V40, pS8, DOI 10.1161/STROKEAHA.108.533166; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yonkers MA, 2008, J NEUROPHYSIOL, V100, P2719, DOI 10.1152/jn.90801.2008; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	63	34	37	0	9	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	APR	2013	70	1					80	89		10.1016/j.phrs.2012.12.009			10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	117BG	WOS:000316926500011	23313345				2022-02-06	
J	Haas, BM; Price, L; Freeman, JA				Haas, B. M.; Price, L.; Freeman, J. A.			Qualitative evaluation of a Community Peer Support Service for people with spinal cord injury	SPINAL CORD			English	Article						peer support; peer mentoring; qualitative research; self-efficacy	TRAUMATIC BRAIN-INJURY; INDIVIDUALS; EXPERIENCES	Study design: Qualitative study involving individual semistructured in-depth interviews. Objectives: To evaluate peer support provided in general hospitals for people with spinal cord injuries (SCIs). Setting: The South West of the United Kingdom. Methods: Fourteen in-depth qualitative interviews were conducted with people with SCI and their close relatives, and with health-care professionals involved in their care. Transcribed interviews were coded inductively and analysed thematically. Themes were patterned around positive and less positive aspects of the experience of the peer support service. Results: The psychological and emotional support provided by the peer support officer was highly valued by the participants. The peer support officer's direct experience of living with a spinal injury gave credibility to the practical advice, information and signposting provided; as well as to the empathy demonstrated by them during their involvement with people with SCI and their families. Health-care professionals appreciated their unique perspective and considered them as a valuable member of the multidisciplinary team. Conclusion: Peer support is valued by the people affected by SCI. There is a need to further investigate the key aspects of the service, including the optimal timing for introducing this peer support as well as more formal training of mentors. Spinal Cord (2013) 51, 295-299; doi:10.1038/sc.2012.143; published online 27 November 2012	[Haas, B. M.; Freeman, J. A.] Univ Plymouth, Sch Hlth Profess, Plymouth PL6 8BH, Devon, England; [Price, L.] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England		Haas, BM (corresponding author), Univ Plymouth, Peninsula Allied Hlth Ctr, Sch Hlth Profess, Derriford Rd, Plymouth PL6 8BH, Devon, England.	bhaas@plymouth.ac.uk	Freeman, Jennifer/AAN-1217-2021		Plymouth University Vice Chancellors Community Research Award	We would like to thank the Spinal Injuries Association (SIA) United Kingdom for their valuable input and support. In particular, we would like to acknowledge the input of Anne Curran, Peter Hutchings and Debbie Schofield. We would also like to thank all those who gave their time freely and generously during the interviews and chat-room discussions. This study was supported through a Plymouth University Vice Chancellors Community Research Award.	Alvarez K, 2011, EUR J SOC PSYCHOL, V41, P397, DOI 10.1002/ejsp.789; Badger K, 2010, SOC WORK HEALTH CARE, V49, P299, DOI 10.1080/00981380903493095; Boschen KA, 2003, INT J REHABIL RES, V26, P157, DOI 10.1097/00004356-200309000-00001; Colella Tracey J F, 2004, Eur J Cardiovasc Nurs, V3, P211; Consortium for Spinal Cord Medicine, 2008, J SPINAL CORD MED, V31, P408; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; Funck-Brentano I, 2005, AIDS, V19, P1501, DOI 10.1097/01.aids.0000183124.86335.0a; Giesbers J, 2010, PSYCHO-ONCOLOGY, V19, P887, DOI 10.1002/pon.1636; Hanks RA, 2012, ARCH PHYS MED REHAB, V93, P1297, DOI 10.1016/j.apmr.2012.04.027; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hoey LM, 2011, EUR J CANCER CARE, V20, P87, DOI 10.1111/j.1365-2354.2009.01151.x; Hughes J, 2009, HEALTH EXPECT, V12, P396, DOI 10.1111/j.1369-7625.2009.00568.x; Ieropoli SC, 2011, EUR J CANCER CARE, V20, P455, DOI 10.1111/j.1365-2354.2010.01218.x; Jalovcic D, 2009, TOP SPINAL CORD INJ, V15, P59; Ljungberg I, 2011, J CLIN NURS, V20, P351, DOI 10.1111/j.1365-2702.2010.03432.x; MacNeil C, 2005, AM J EVAL, V26, P231, DOI 10.1177/1098214005275633; Magasi S, 2009, ARCH PHYS MED REHAB, V90, pe37; Patterson RW, 2005, TOP SPINAL CORD INJ, V10, P30; Percy CA, 2009, J ADV NURS, V65, P2046, DOI 10.1111/j.1365-2648.2009.05061.x; Shem K, 2011, SPINAL CORD, V49, P544, DOI 10.1038/sc.2010.166; Standal OF, 2008, ADAPT PHYS ACT Q, V25, P208, DOI 10.1123/apaq.25.3.208; Thoits PA, 2000, HEALTH PSYCHOL, V19, P264, DOI 10.1037//0278-6133.19.3.264; Veith EM, 2006, REHABIL PSYCHOL, V51, P289, DOI 10.1037/0090-5550.51.4.289	23	34	34	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	APR	2013	51	4					295	299		10.1038/sc.2012.143			5	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	119OO	WOS:000317107400008	23184023	Bronze			2022-02-06	
J	Levin, HS; Li, XQ; McCauley, SR; Hanten, G; Wilde, EA; Swank, P				Levin, Harvey S.; Li, Xiaoqi; McCauley, Stephen R.; Hanten, Gerri; Wilde, Elisabeth A.; Swank, Paul			Neuropsychological Outcome of mTBI: A Principal Component Analysis Approach	JOURNAL OF NEUROTRAUMA			English	Article						mTBI; data reduction; principal components analysis	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; QUESTIONNAIRE; CONCUSSION	The multitude of variables associated with a battery of outcome measures presents a risk for spurious findings in clinical trials and observational studies of mild traumatic brain injury (mTBI). We have used principal components analysis (PCA) to facilitate data reduction by identifying components which represent subsets of neuropsychological measures that are selectively correlated with each other. By merging data from two concurrent mTBI studies using the same outcome measures, we obtained a cohort of 102 mTBI patients and 85 orthopedic injury (OI) comparison patients whom we recruited from 24 hours to 96 hours post-injury and evaluated at one week, 1 month, and 3 months post-injury. Cognitive domains included episodic memory, evaluated by both verbal and visual memory tasks, cognitive processing speed tests, and executive function. Post-concussion and stress-related symptoms were measured by rating scales. PCA identified four components, including cognitive processing speed, verbal memory, visual memory, and a symptom composite representing post-concussion and stress symptoms. mTBI patients older than the mean age of 18 years had slower cognitive processing than the OI patients, but there was no group difference in cognitive processing speed in younger patients. The symptom component score differed significantly as mTBI patients had more severe symptoms than the OI group at each occasion. Our results encourage replication with other cohorts using either the same outcome measures or at least similar domains. PCA is an approach to data reduction that could mitigate spurious findings and increase efficiency in mTBI research.	[Levin, Harvey S.; Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Dept Vet Affairs, Neurorehabil Neurons Networks Traumat Brain Injur, Houston, TX USA; [Levin, Harvey S.; Li, Xiaoqi; McCauley, Stephen R.; Hanten, Gerri; Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.; McCauley, Stephen R.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Swank, Paul] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX USA		Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	hlevin@bcm.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P01NS056202]; Department of Defense (Post-Traumatic Stress Disorder and Traumatic Brain Injury (PTSD/TBI) Research Program) [W81XWH-08-2-0133 PT074693P2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This research was supported by Grant 5P01NS056202 from the National Institute of Neurological Disorders and Stroke and by award W81XWH-08-2-0133 PT074693P2 from the Department of Defense (Post-Traumatic Stress Disorder and Traumatic Brain Injury (PTSD/TBI) Research Program). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Institutes of Health, the US Army, or the Department of Defense.	Benedict R., 1997, BRIEF VISUOSPATIAL M; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bleiberg, 2002, ANAM 2001 USERS MANU; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hoteling AJ, 2004, J AM SOC MASS SPECTR, V15, P523, DOI 10.1016/j.jasms.2003.12.004; IOM (Institute of Medicine), 2009, LONG TERM CONS TRAUM, V7; Iverson G, 2007, BRAIN INJURY MED PRI; Johnson RA, 2007, APPL MULTIVARIATE ST, Vxviii; JOLLIFFE IT, 1995, J APPL STAT, V22, P29, DOI 10.1080/757584395; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Roebuck-Spencer TM, 2012, CLIN NEUROPSYCHOL, V26, P473, DOI 10.1080/13854046.2011.650214; SAS, 2003, SAS STAT SOFTW US GU; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Smith A., 1982, SYMBOL DIGIT MODALIT; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; TEASDALE G, 1974, LANCET, V2, P81; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	30	34	34	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		625	632		10.1089/neu.2012.2627			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500004	22994927	Green Published			2022-02-06	
J	Baker, JF; Devitt, BM; Green, J; McCarthy, C				Baker, J. F.; Devitt, B. M.; Green, J.; McCarthy, C.			Concussion among under 20 rugby union players in Ireland: incidence, attitudes and knowledge	IRISH JOURNAL OF MEDICAL SCIENCE			English	Article						Rugby union; Brain concussion; Head injury; Sports	HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; PROTECTIVE EQUIPMENT; CONSENSUS STATEMENT; SPORTS CONCUSSION; FOOTBALL PLAYERS; HEADGEAR; RETURN; PREVENTION; GUIDELINES	The aim of this study was to determine the incidence of concussion among a cohort of male under 20 rugby players and assess basic knowledge and attitudes. Under 20 age group, players were recruited from local clubs as well as the national academy system. Players were asked to report on their history of concussion as well as a number of factors regarding their recognition of symptoms and behaviours regarding the diagnosis of concussion. 133 players responded (95 % response rate). Players could list a mean of 2.6 concussion related symptoms. 64 reported sustaining at least one concussion (average 2.25) and 36 sought medical attention following a concussion. 61 said that they would report suffering a concussion to their coach while 32 would report it to a 'team physiotherapist' or doctor. 114 believed that concussion is as serious as other rugby injuries and 100 believe that playing on while concussed could lead to long-term medical problems. Further educational efforts are required in this age group of rugby union players to reduce the risk of unnecessary secondary injury. Coaches, managers and players alike need to be targeted in any educational program.	[Baker, J. F.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland; [Devitt, B. M.; McCarthy, C.] Irish Rugby Football Union, Dept Med, Dublin 4, Ireland; [Green, J.] Univ Otago, Sch Pharm, Dunedin, New Zealand		Baker, JF (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland.	joseph.f.baker@gmail.com; bdevitt@hotmail.com; ajamesgreen@gmail.com; conor.mccarthy@irfu.ie	Baker, Joseph F/H-2868-2019; Green, James A/A-8615-2008	Baker, Joseph F/0000-0002-8518-8780; Green, James A/0000-0002-7309-0751			Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; [Anonymous], 2009, BRIT J SPORT MED, V43, pi85; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; IRFU, 2012, CLUB ENG PROGR MARCH; IRFU, 2007, IR RUGB FOOTB UN ANN; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Miller G, 2009, SCIENCE, V325, P670, DOI 10.1126/science.325_670; Pettersen JA, 2002, BRIT J SPORT MED, V36, P19, DOI 10.1136/bjsm.36.1.19; Quarrie KL, 2007, J SPORT SCI, V25, P895, DOI 10.1080/02640410600944659; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	26	34	35	0	77	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0021-1265			IRISH J MED SCI	Irish J. Med. Sci.	MAR	2013	182	1					121	125		10.1007/s11845-012-0846-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	063YQ	WOS:000313038500019	22898834				2022-02-06	
J	Chibbaro, S; Vallee, F; Beccaria, K; Poczos, P; Makiese, O; Fricia, M; Mateo, J; Gobron, C; Guichard, JP; Romano, A; Levy, B; George, B; Vicaut, E				Chibbaro, S.; Vallee, F.; Beccaria, K.; Poczos, P.; Makiese, O.; Fricia, M.; Mateo, J.; Gobron, C.; Guichard, J-P; Romano, A.; Levy, B.; George, B.; Vicaut, E.			The impact of early cranioplasty on cerebral blood flow and its correlation with neurological and cognitive outcome. Prospective multi-centre study on 24 patients	REVUE NEUROLOGIQUE			French	Article						Brain perfusion; CT perfusion; Severe head injury; Neurology and cognitive outcome; Cranioplasty	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SINKING SKIN-FLAP; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL HYPERTENSION; MANAGEMENT; PRESSURE; EXPERIENCE; PERFUSION	Introduction. - Cranioplasty after decompressive craniectomy in patients suffering from severe head injury often leads to a functional improvement although, to date, the pathophysiology of this phenomenon remains unclear. A few hypotheses have been proposed. The impact of cranioplasty on cerebral perfusion could be one explanation. We have evaluated the impact of cranioplasty on the functional status of patients undergoing decompressive craniectomy for severe head injury with its influence on cerebral perfusion. Materials and methods. - Twenty-four patients undergoing craniectomy for severe head injury were included in this multi-centric and prospective study. All of them had a cranioplasty within 12 weeks following decompressive craniectomy. A clinical and radiological evaluation was performed prior to and after cranioplasty. Neurological and cognitive evaluation was performed with the Glasgow Outcome Score (GOS), the Frontal Assessment Battery (FAB) and the Mini Mental State Examination (MMSE). Radiological evaluation was performed by perfusion CT scan and transcranial Doppler. Results. - A statistically significant neurological and cognitive improvement was observed in 92% of patients at 6 months follow-up (F-U). Brain perfusion was improved at 6 weeks F-U, predominantly in the affected hemisphere. Systolic and diastolic blood velocity flow were improved in both middle cerebral arteries. Conclusion. - Cranioplasty after decompressive craniectomy for patients suffering from severe head injury probably improves the functional outcome of these patients, thanks to a global improvement of cerebral perfusion. (C) 2012 Elsevier Masson SAS. All rights reserved.	[Chibbaro, S.; Beccaria, K.; Poczos, P.; Makiese, O.; George, B.] Hop Univ Lariboisiere, Serv Neurochirurg, F-75010 Paris, France; [Fricia, M.] Hop Univ Cannizzaro, Serv Neurochirurg, I-95126 Catania, Italy; [Vallee, F.; Mateo, J.] Hop Univ Lariboisiere, Serv Anesthesie Reanimat, F-75010 Paris, France; [Romano, A.] Hop Univ Parme, Serv Neurochirurg, I-43100 Parma, Italy; [Guichard, J-P] Hop Univ Lariboisiere, Serv Neuroradiol, F-75010 Paris, France; [Gobron, C.; Levy, B.] Hop Univ Lariboisiere, Serv Neurol, F-75010 Paris, France; [Vicaut, E.] Hop Univ Lariboisiere, Unite Rech Clin, F-75010 Paris, France		Chibbaro, S (corresponding author), Hop Univ Lariboisiere, Serv Neurochirurg, 2 Rue Ambroise Pare, F-75010 Paris, France.	schibbaro@hotmail.com	Chibbaro, Salvatore/AAI-6368-2020; BECCARIA, Kevin/AAL-5122-2021; Poczos, Pavel/E-9906-2017	Poczos, Pavel/0000-0002-1456-3010; chibbaro, salvatore/0000-0003-1318-1245			BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Chibbaro S, 2009, J NEUROSURG, V111, P884; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Cooper DJ, 2011, NEW ENGL J MED, V365, P2040; DeWitt D S, 1995, New Horiz, V3, P376; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, 1990, ACT NEUR S, V51, P326; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hodozuka A, 2000, NEUROL SURG TOKYO, V28, P245; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maekawa M, 1999, NEUROL SURG TOKYO, V27, P717; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Nabavi DG, 1999, RADIOLOGY, V213, P141, DOI 10.1148/radiology.213.1.r99oc03141; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Salvatore C, 2008, J NEUROSURG, V108, P74, DOI 10.3171/JNS/2008/108/01/0074; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; STULA D, 1982, J MAXILLOFAC SURG, V10, P142, DOI 10.1016/S0301-0503(82)80030-1; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43	37	34	37	0	4	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0035-3787	2213-0004		REV NEUROL-FRANCE	Rev. Neurol.	MAR	2013	169	3					240	248		10.1016/j.neurol.2012.06.016			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	127OH	WOS:000317707800008	23084153				2022-02-06	
J	Li, HP; Komuta, Y; Kimura-Kuroda, J; van Kuppevelt, TH; Kawano, H				Li, Hong-Peng; Komuta, Yukari; Kimura-Kuroda, Junko; van Kuppevelt, Toin H.; Kawano, Hitoshi			Roles of Chondroitin Sulfate and Dermatan Sulfate in the Formation of a Lesion Scar and Axonal Regeneration after Traumatic Injury of the Mouse Brain	JOURNAL OF NEUROTRAUMA			English	Article						axonal regeneration; extracellular matrix; glial response to injury; in vitro study; traumatic brain injury	GROWTH-FACTOR-BETA; NIGROSTRIATAL DOPAMINERGIC AXONS; ADULT-RAT BRAIN; EMBRYONIC PIG BRAIN; HYBRID CHAINS; FIBROTIC SCAR; SPINAL-CORD; CNS INJURY; NEURITOGENIC ACTIVITY; BINDING ACTIVITIES	Dermatan sulfate (DS) is synthesized from chondroitin sulfate (CS) by epimerization of glucuronic acid of CS to yield iduronic acid. In the present study, the role of CS and DS was examined in mice that received transection of nigrostriatal dopaminergic pathway followed by injection of glycosaminoglycan degrading enzymes into the lesion site. Two weeks after injury, fibrotic and glial scars were formed around the lesion, and transected axons did not regenerate beyond the fibrotic scar. Injection of chondroitinase ABC (ChABC), which degrades both CS and DS, completely suppressed the fibrotic scar formation, reduced the glial scar, and promoted the regeneration of dopaminergic axons. Injection of the DS-degrading enzyme chondroitinase B (ChB) also yielded similar results. By contrast, injection of chondroitinase AC (ChAC), a CS-degrading enzyme, did not suppress the fibrotic and glial scar formation, but reduced CS immunoreactivity and promoted the axonal regeneration. Addition of transforming growth factor-beta 1 (TGF-beta 1) to a co-culture of meningeal fibroblasts and cerebral astrocytes induces a fibrotic scar-like cell cluster. The effect of TGF-beta 1 on cluster formation was suppressed by treatment with ChABC or ChB, but not by ChAC. TGF-beta 1-induced cell cluster repelled neurites of neonatal cerebellar neurons, but addition of ChABC or ChAC suppressed the inhibitory property of clusters on neurite outgrowth. The present study is the first to demonstrate that DS and CS play different functions after brain injury: DS is involved in the lesion scar formation, and CS inhibits axonal regeneration.	[Li, Hong-Peng; Komuta, Yukari; Kimura-Kuroda, Junko; Kawano, Hitoshi] Tokyo Metropolitan Inst Med Sci, Lab Neural Regenerat, Setagaya City, Tokyo 1568506, Japan; [Li, Hong-Peng] China Med Univ, Coll Basic Med Sci, Dept Human Anat, Shenyang, Peoples R China; [van Kuppevelt, Toin H.] Radboud Univ Nijmegen, Med Ctr, Dept Biochem, NL-6525 ED Nijmegen, Netherlands		Kawano, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Lab Neural Regenerat, 2-1-6 Kamikitazawa, Setagaya City, Tokyo 1568506, Japan.	kawano-ht@igakuken.or.jp	van Kuppevelt, A.H.M.S.M./L-4463-2015		Ministry of Education, Culture, Sports, Science and Technology in Japan Contract (Mext)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [23500422]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [NSFC-81171248]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23500422] Funding Source: KAKEN	We thank Dr. G. Raisman for reviewing the manuscript. This study was supported by grants from Grant-in-Aid for Scientific Research (C) from Ministry of Education, Culture, Sports, Science and Technology in Japan Contract (Mext) (23500422) and from The National Natural Science Foundation of China (NSFC-81171248).	Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; Camand E, 2004, EUR J NEUROSCI, V20, P1161, DOI 10.1111/j.1460-9568.2004.03558.x; Clark RAF, 2004, J INVEST DERMATOL, V122, P266, DOI 10.1046/j.0022-202X.2004.22205.x; Denholm EM, 2000, EUR J PHARMACOL, V400, P145, DOI 10.1016/S0014-2999(00)00381-2; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Hamel MG, 2005, J NEUROCHEM, V93, P1533, DOI 10.1111/j.1471-4159.2005.03144.x; Hashiguchi T, 2010, GLYCOCONJUGATE J, V27, P49, DOI 10.1007/s10719-009-9253-x; HIERCK BP, 1994, J HISTOCHEM CYTOCHEM, V42, P1499, DOI 10.1177/42.11.7930532; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Huebener P, 2008, J IMMUNOL, V180, P2625, DOI 10.4049/jimmunol.180.4.2625; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Jarvelainen H, 2006, WOUND REPAIR REGEN, V14, P443, DOI 10.1111/j.1743-6109.2006.00150.x; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; KAWANO H, 1995, DEV BRAIN RES, V86, P101, DOI 10.1016/0165-3806(95)00018-9; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kimura-Kuroda J, 2010, MOL CELL NEUROSCI, V43, P177, DOI 10.1016/j.mcn.2009.10.008; Komuta Y, 2010, CELL MOL NEUROBIOL, V30, P101, DOI 10.1007/s10571-009-9435-x; Kozma EM, 2011, GLYCOBIOLOGY, V21, P1301, DOI 10.1093/glycob/cwr065; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lensen JFM, 2006, MATRIX BIOL, V25, P457, DOI 10.1016/j.matbio.2006.06.003; Li FC, 2007, J BIOL CHEM, V282, P2956, DOI 10.1074/jbc.M609296200; Li HP, 2007, J NEUROSCI RES, V85, P536, DOI 10.1002/jnr.21141; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Maccarana M, 2009, MOL CELL BIOL, V29, P5517, DOI 10.1128/MCB.00430-09; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; Moon C, 2004, NEUROSCI LETT, V367, P133, DOI 10.1016/j.neulet.2004.05.101; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nagata I, 2006, J COMP NEUROL, V499, P274, DOI 10.1002/cne.21102; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; Shearer MC, 2001, CELL TISSUE RES, V305, P267, DOI 10.1007/s004410100384; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stichel CC, 1995, BRAIN RES, V704, P263, DOI 10.1016/0006-8993(95)01131-5; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Stylli SS, 2000, J CLIN NEUROSCI, V7, P137, DOI 10.1054/jocn.1999.0187; Susarla BTS, 2011, J NEUROCHEM, V119, P868, DOI 10.1111/j.1471-4159.2011.07470.x; Teng X, 2008, J NEUROSCI RES, V86, P3140, DOI 10.1002/jnr.21767; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; VERNA JM, 1989, INT J DEV NEUROSCI, V7, P389, DOI 10.1016/0736-5748(89)90060-9; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; WESTERGRENTHORSSON G, 1992, EUR J BIOCHEM, V205, P277, DOI 10.1111/j.1432-1033.1992.tb16778.x; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yoshioka N, 2011, J NEUROSCI RES, V89, P381, DOI 10.1002/jnr.22552; Yoshioka N, 2010, J COMP NEUROL, V518, P3867, DOI 10.1002/cne.22431; Zuo J, 1998, EXP NEUROL, V154, P654, DOI 10.1006/exnr.1998.6951	56	34	35	0	25	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2013	30	5					413	425		10.1089/neu.2012.2513			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	103CI	WOS:000315891600011	23438307	Green Published			2022-02-06	
J	Bigler, ED; Farrer, TJ; Pertab, JL; James, K; Petrie, JA; Hedges, DW				Bigler, Erin D.; Farrer, Thomas J.; Pertab, Jon L.; James, Kelly; Petrie, Jo Ann; Hedges, Dawson W.			Reaffirmed Limitations of Meta-Analytic Methods in the Study of Mild Traumatic Brain Injury: A Response to Rohling et al.	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Meta-analysis limitations; Neuropsychological outcomes	GLASGOW COMA SCALE; MINOR HEAD-INJURY; CEREBRAL ATROPHY; SUICIDAL-BEHAVIOR; FOOTBALL PLAYERS; CONCUSSION; RECOVERY; ADULTS; LONG; POPULATION	In 2009 Pertab, James, and Bigler published a critique of two prior meta-analyses by Binder, Rohling, and Larrabee (1997) and Frencham, Fox, and Maybery (2005) that showed small effect size difference at least 3 months post-injury in individuals who had sustained a mild traumatic brain injury (mTBI). The Binder etal. and Frencham etal. meta-analyses have been widely cited as showing no lasting effect of mTBI. In their critique Pertab etal. (2009) point out many limitations of these two prior meta-analyses, demonstrating that depending on how inclusion/exclusion criteria were defined different meta-analytic findings occur, some supporting the persistence of neuropsychological impairments beyond 3 months. Rohling etal. (2011) have now critiqued Pertab etal. (2009). Herein we respond to the Rolling etal. (2011) critique reaffirming the original findings of Pertab etal. (2009), providing additional details concerning the flaws in prior meta-analytic mTBI studies and the effects on neuropsychological performance.	[Bigler, Erin D.; Farrer, Thomas J.; Pertab, Jon L.; James, Kelly; Petrie, Jo Ann; Hedges, Dawson W.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.; Hedges, Dawson W.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Brain Inst Utah, Salt Lake City, UT USA; [Pertab, Jon L.] Vet Adm Hosp, Salt Lake City, UT USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu		Farrer, Thomas J./0000-0001-8092-6214			Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; Aretouli E, 2011, J INT NEUROPSYCH SOC, V17, P277, DOI 10.1017/S1355617710001621; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler E.D., 2012, PTSD MILD TRAUMATIC; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borenstein M., 2009, INTRO META ANAL; BORNSTEIN RA, 1993, NEUROPSYCHOLOGY, V7, P228, DOI DOI 10.1037/0894-4105.7.2.228; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cappa KA, 2011, HEALTH PSYCHOL, V30, P542, DOI 10.1037/a0025220; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2010, J NEUROL NEUROSUR PS, V81, pE12, DOI 10.1136/jnnp.2010.217554.28; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Contreras R, 2011, BRAIN RES, V1398, P55, DOI 10.1016/j.brainres.2011.05.004; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Duff K, 2010, ARCH CLIN NEUROPSYCH, V25, P429, DOI 10.1093/arclin/acq045; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Fayol P., 2009, Annals of Physical and Rehabilitation Medicine, V52, P497, DOI 10.1016/j.annrmp.2008.06.003; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Franklin G., 2004, CLIN PRACTICE GUIDEL; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geary EK, 2011, J INT NEUROPSYCH SOC, V17, P709, DOI 10.1017/S1355617711000646; GENTLEMAN D, 1981, BRIT MED J, V283, P408, DOI 10.1136/bmj.283.6288.408; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Glasziou PP, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-23; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1; Green Robin, 2010, Neuropsychol Rehabil, V20, P471, DOI 10.1080/09602011003693298; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jennett B, 1997, Int J Trauma Nurs, V3, P114; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lipsey M.W., 2001, PRACTICAL META ANAL; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Menascu S, 2010, PEDIATR NEUROSURG, V46, P82, DOI 10.1159/000319004; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Noguchi K, 2000, AM J NEURORADIOL, V21, P923; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pengel LHM, 2003, BMJ-BRIT MED J, V327, P323, DOI 10.1136/bmj.327.7410.323; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff R. M., 1989, MILD HEAD INJURY, P176; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Senn SJ, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-10; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Stocchetti N, 2008, INTENS CARE MED, V34, P1774, DOI 10.1007/s00134-008-1168-7; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thomson Reuters, 2012, J CITATION REPORTS; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; [No title captured]	123	34	34	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB 1	2013	27	2					176	214		10.1080/13854046.2012.693950			39	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	146MH	WOS:000319094700002	23356775				2022-02-06	
J	Lv, QS; Fan, XY; Xu, GL; Liu, Q; Tian, LL; Cai, XY; Sun, WS; Wang, XM; Cai, QK; Bao, YF; Zhou, LL; Zhang, Y; Ge, L; Guo, RB; Liu, XF				Lv, Qiushi; Fan, Xinying; Xu, Gelin; Liu, Qian; Tian, Lili; Cai, Xiaoyi; Sun, Wenshan; Wang, Xiaomeng; Cai, Qiankun; Bao, Yuanfei; Zhou, Lulu; Zhang, Yao; Ge, Liang; Guo, Ruibing; Liu, Xinfeng			Intranasal delivery of nerve growth factor attenuates aquaporins-4-induced edema following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						TBI; Cerebral edema; AQP4; NGF; Inflammatory Cytokine; NF-kappa B	NF-KAPPA-B; INTRACRANIAL HYPERTENSION; SODIUM-SALICYLATE; WATER TRANSPORT; CELLULAR EDEMA; PROTEIN-KINASE; GLIAL-CELLS; AQUAPORIN-4; BARRIER; EXPRESSION	Traumatic brain injury (TBI) remains the leading cause of injury-related death and disability. Brain edema, one of the most major complications of TBI, contributes to elevated intracranial pressure, and poor prognosis following TBI. Nerve growth factor (NGF) appears to be a viable strategy to treat brain edema and TBI. Unfortunately, due to its poor blood-brain barrier (BBB) permeability, the clinical application of NGF has been greatly limited. We previously demonstrated that intranasal NGF could bypass the BBB and distribute throughout the brain. Here we further studied whether intranasal NGF could attenuate TBI-induced brain edema and its putative mechanisms. TBI was produced by a modified weight-drop model. We found that intranasal administration of NGF (5 mu g/d) attenuated the brain edema, as assayed by hemisphere water content, at 12 h, 24 h and 72 h after TBI induction. This attenuation was associated with a prominent decrease of the content of aquaporin-4, which plays a pivotal role in the formation of brain edema. By the use of RT-PCR and ELISA, we showed that intranasal NGF markedly inhibited the transcription and expression of pro-inflammatory cytokines including IL-1 beta and TNF-alpha. An electrophoretic mobility shift assay (EMSA) displayed a significant activation of nuclear factor-kappa B following TB!, which was, however, much lowered in the NGF-treated rats. Furthermore, upon intranasal NGF supplementation, mitochondria-mediated apoptosis following TBI was minimized, as indicated by upregulation of Bcl-2 and downregulation of caspase-3. Collectively, our findings suggested that intranasal NGF may be a promising strategy to treat brain edema and TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Lv, Qiushi; Fan, Xinying; Xu, Gelin; Liu, Qian; Sun, Wenshan; Wang, Xiaomeng; Cai, Qiankun; Bao, Yuanfei; Zhou, Lulu; Zhang, Yao; Ge, Liang; Guo, Ruibing; Liu, Xinfeng] Nanjing Univ, Sch Med, Dept Neurol, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China; [Tian, Lili] Peoples Hosp Fuyang, Dept Neurol, Fuyang, Anhui, Peoples R China; [Cai, Xiaoyi] Nanjing Univ, Sch Med, Dept Pediat, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China		Guo, RB (corresponding author), Nanjing Univ, Sch Med, Dept Neurol, Jinling Hosp, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	grb1995@yahoo.com.cn; xfliu2@yahoo.com.cn		Xu, Gelin/0000-0002-6194-0341; Liu, Qian/0000-0002-1937-0568	Nature Science Foundation of China (CNSF)National Natural Science Foundation of China (NSFC) [31171016]; Jinling Hospital Foundation [2012005]	This work was supported by the grant from Nature Science Foundation of China to X.L (CNSF #31171016) and Jinling Hospital Foundation to R.G (#2012005). We are thankful for the excellent technical assistance of Genbao Peng.	AGRE P, 1993, AM J PHYSIOL, V265, pF463; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Collins MA, 2012, NEUROTOX RES, V21, P70, DOI 10.1007/s12640-011-9276-5; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Frey WH, 1997, DRUG DELIV, V4, P87, DOI 10.3109/10717549709051878; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Iacovetta C, 2012, VET CLIN PATH, V41, P32, DOI 10.1111/j.1939-165X.2011.00390.x; Iseri SO, 2008, REGUL PEPTIDES, V146, P73, DOI 10.1016/j.regpep.2007.08.014; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1994, ACTA NEUROCHIR, P3; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kruttgen A, 2006, BRAIN PATHOL, V16, P304, DOI 10.1111/j.1750-3639.2006.00037.x; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Liu XF, 2001, J NEUROL SCI, V187, P91, DOI 10.1016/S0022-510X(01)00532-9; Lopez NE, 2012, J NEUROTRAUM, V29, P385, DOI 10.1089/neu.2011.2053; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Nielsen S, 1997, J NEUROSCI, V17, P171; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Qi X, 2008, J CLIN INVEST, V118, P173, DOI 10.1172/JCI32636; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; Saragovi HU, 2000, TRENDS PHARMACOL SCI, V21, P93, DOI 10.1016/S0165-6147(99)01444-3; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Stover JF, 2004, ACTA NEUROCHIR, V146, P819, DOI 10.1007/s00701-004-0281-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Warth A, 2007, J NEUROSCI RES, V85, P1336, DOI 10.1002/jnr.21224; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Yoshioka K, 1998, J VET MED SCI, V60, P257, DOI 10.1292/jvms.60.257	56	34	35	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 1	2013	1493						80	89		10.1016/j.brainres.2012.11.028			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	082FC	WOS:000314376700008	23183041				2022-02-06	
J	Yokobori, S; Gajavelli, S; Mondello, S; Mo-Seaney, J; Bramlett, HM; Dietrich, WD; Bullock, MR				Yokobori, Shoji; Gajavelli, Shyam; Mondello, Stefania; Mo-Seaney, Jixiang; Bramlett, Helen M.; Dietrich, W. Dalton; Bullock, M. Ross			Neuroprotective effect of preoperatively induced mild hypothermia as determined by biomarkers and histopathological estimation in a rat subdural hematoma decompression model	JOURNAL OF NEUROSURGERY			English	Article						ischemia/reperfusion injury; hypothermia; rat; traumatic brain injury; microdialysis; biomarker; neuronal degeneration	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; CENTRAL-NERVOUS-SYSTEM; THERAPEUTIC HYPOTHERMIA; CARDIAC-ARREST; SERUM-LEVELS; HEAD-INJURY; BARRIER DISRUPTION	Object. In patients who have sustained a traumatic brain injury (TBI), hypothermia therapy has not shown efficacy in multicenter clinical trials. Armed with the post hoc data from the latest clinical trial (National Acute Brain Injury Study: Hypothermia II), the authors hypothesized that hypothermia may be beneficial in an acute subdural hematoma (SDH) rat model by blunting the effects of ischemia/reperfusion injury. The major aim of this study was to test the efficacy of temperature management in reducing brain damage after acute SDH. Methods. The rats were induced with acute SDH and placed into 1 of 4 groups: 1) normothermia group (37 degrees C); 2) early hypothermia group, head and body temperature reduced to 33 degrees C 30 minutes prior to craniotomy; 3) late hypothermia group, temperature lowered to 33 degrees C 30 minutes after decompression; and 4) sham group, no acute SDH (only craniotomy with normothermia). To assess for neuronal and glial cell damage, the authors analyzed microdialysate concentrations of GFAP and ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1) by using a 100-kD probe. Fluoro-Jade B positive neurons and injury volume with 2,3,5-triphenyltetrazolium chloride staining were also measured. Results. In the early phase of reperfusion (30 minutes, 2.5 hours after decompression), extracellular UCH-L1 in the early hypothermia group was significantly lower than in the normothermia group (early, 4.9 +/- 1.0 ng/dl; late, 35.2 +/- 12.1 ng/dl; normothermia, 50.20 +/- 28.3 ng/dl; sham, 3.1 +/- 1.3 ng/dl; early vs normothermia, p < 0.01; sham vs normothermia, p < 0.01, analyzed using ANOVA followed by a post hoc Bonferroni test). In the late phase of reperfusion (>2.5 hours after decompression), extracellular GFAP in the early hypothermia group was also lower than in the normothermia and late hypothermia groups (early, 5.5 +/- 2.9 ng/dl; late, 7.4 +/- 3.4 ng/dl; normothermia, 15.3 8.4 ng/dl; sham, 3.3 +/- 1.0 ng/dl; normothermia vs sham; p < 0.01). The number of Fluoro-Jade B positive cells in the early hypothermia group was significantly smaller than that in the normothermia group (normothermia vs early: 774,588 +/- 162,173 vs 180,903 +/- 42,212, p < 0.05). Also, the injury area and volume were smaller in the early hypothermia group in which hypothermia was induced before craniotomy and cerebral reperfusion (early, 115.2 15.4 mm(3); late, 344.7 +/- 29.1 mm(3); normothermia, 311.2 +/- 79.2 mm(3); p < 0.05). Conclusions. The data suggest that early, preoperatively induced hypothermia could mediate the reduction of neuronal and glial damage in the reperfusion phase of ischemia/reperfusion brain injury. (http://thejns.org/doi/abs/10.3171/2012.10.JNS12725)	[Yokobori, Shoji; Gajavelli, Shyam; Bramlett, Helen M.; Dietrich, W. Dalton; Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Mondello, Stefania; Mo-Seaney, Jixiang] Banyan Biomarkers Inc, Alachua, FL USA; [Mondello, Stefania] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Mondello, Stefania] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; [Yokobori, Shoji] Nippon Med Sch, Dept Emergency & Crit Care Med, Tokyo 113, Japan		Yokobori, S (corresponding author), Univ Miami, Miller Sch Med, Dept Neurosurg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	SYokobori@med.miami.edu	Gajavelli, Shyam/AAI-1374-2019; Mondello, Stefania/A-1813-2012	Gajavelli, Shyam/0000-0002-5947-6973; Mondello, Stefania/0000-0002-8587-3614	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 042133]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133] Funding Source: NIH RePORTER	Dr. Mondello and Jiaxing Mo-Seaney are employees of Banyan Biomarkers, Inc. This work was supported by funds from NINDS R01 NS 042133 and the Miami Project to Cure Paralysis.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arnaoutakis GJ, 2011, J THORAC CARDIOV SUR, V142, P902, DOI 10.1016/j.jtcvs.2011.06.027; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; BOLLI R, 1989, CIRC RES, V65, P607, DOI 10.1161/01.RES.65.3.607; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Burger R, 2004, NEUROSURGERY, V54, P701, DOI 10.1227/01.NEU.0000108784.80585.EE; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Fu ES, 2005, CURR OPIN ANESTHESIO, V18, P181, DOI 10.1097/01.aco.0000162838.56344.88; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Honeybul S, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70086-2; Janata A, 2009, PROG CARDIOVASC DIS, V52, P168, DOI 10.1016/j.pcad.2009.07.001; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Johnsson P, 2003, ANN THORAC SURG, V75, P162, DOI 10.1016/S0003-4975(02)04318-7; Jonsson H, 2003, RESTOR NEUROL NEUROS, V21, P151; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; Kawai N, 2000, ACT NEUR S, V76, P529; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; KHALID MA, 1993, CIRC RES, V72, P725, DOI 10.1161/01.RES.72.4.725; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; KURODA Y, 1992, NEUROSURGERY, V30, P687; Kwon TH, 2005, J NEUROSURG, V103, P724, DOI 10.3171/jns.2005.103.4.0724; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Larach DB, 2011, NEUROCRIT CARE, V15, P609, DOI 10.1007/s12028-011-9517-8; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mar J, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-46; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Neumar RW, 2000, ANN EMERG MED, V36, P483, DOI 10.1067/mem.2000.110995; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Nielsen TH, 2011, NEUROCRIT CARE, V15, P585, DOI 10.1007/s12028-011-9563-2; Okauchi M, 2002, J NEUROTRAUM, V19, P741, DOI 10.1089/08977150260139110; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Polderman KH, 2011, LANCET NEUROL, V10, P404, DOI 10.1016/S1474-4422(11)70084-9; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Shao ZH, 2010, AM J PHYSIOL-HEART C, V298, pH2164, DOI 10.1152/ajpheart.00994.2009; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Takeuchi S, 2011, LANCET NEUROL, V10, P404, DOI 10.1016/S1474-4422(11)70083-7; Timmons SD, 2010, CRIT CARE MED, V38, pS431, DOI 10.1097/CCM.0b013e3181ec57ab; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tuttolomondo A, 2009, CURR TOP MED CHEM, V9, P1317, DOI 10.2174/156802609789869646; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yang D, 2009, FEBS LETT, V583, P2500, DOI 10.1016/j.febslet.2009.07.006; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7	80	34	39	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					370	380		10.3171/2012.10.JNS12725			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900022	23140154	Green Accepted			2022-02-06	
J	Carre, E; Ogier, M; Boret, H; Montcriol, A; Bourdon, L; Risso, JJ				Carre, Emilie; Ogier, Michael; Boret, Henry; Montcriol, Ambroise; Bourdon, Lionel; Risso, Jean-Jacques			Metabolic crisis in severely head-injured patients: is ischemia just the tip of the iceberg?	FRONTIERS IN NEUROLOGY			English	Article						metabolic crisis; ischemia; head injury; multimodal monitoring; intracerebral microdialysis	TRAUMATIC BRAIN-INJURY; PENTOSE-PHOSPHATE PATHWAY; ENERGY-METABOLISM; CEREBRAL METABOLISM; LACTATE/PYRUVATE RATIO; INTRACRANIAL-PRESSURE; OXIDATIVE-METABOLISM; GLUCOSE; LACTATE; MICRODIALYSIS	Ischemia and metabolic crisis are frequent post-traumatic secondary brain insults that negatively influence outcome. Clinicians commonly mix up these two types of insults, mainly because high lactate/pyruvate ratio (LPR) is the common marker for both ischemia and metabolic crisis. However, LPR elevations during ischemia and metabolic crisis reflect two different energetic imbalances: ischemia (Type 1 LPR elevations with low oxygenation) is characterized by a drastic deprivation of energetic substrates, whereas metabolic crisis (Type 2 LPR elevations with normal or high oxygenation) is associated with profound mitochondrial dysfunction but normal supply of energetic substrates. The discrimination between ischemia and metabolic crisis is crucial because conventional recommendations against ischemia may be detrimental for patients with metabolic crisis. Multimodal monitoring, including microdialysis and brain tissue oxygen monitoring, allows such discrimination, but these techniques are not easily accessible to all head-injured patients. Thus, a new "gold standard" and adapted medical education are required to optimize the management of patients with metabolic crisis.	[Carre, Emilie; Ogier, Michael; Bourdon, Lionel; Risso, Jean-Jacques] Inst Rech Biomed Armees, Unit Traumatol, BP 73, F-91223 Bretigny Sur Orge, France; [Boret, Henry; Montcriol, Ambroise] Hop Instruct Armees St Anne, Intens Care Unit, F-83800 Toulon, France		Carre, E (corresponding author), Inst Rech Biomed Armees, Unit Traumatol, BP 73, F-91223 Bretigny Sur Orge, France.	emilie_carre@hotmail.com					Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik-Olson BL, 2010, J NEUROTRAUM, V27, P2191, DOI 10.1089/neu.2010.1508; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bor-Seng-Shu E, 2010, J NEUROSURG, V112, P1351, DOI 10.3171/2009.10.JNS091426; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cerdan S, 2006, NEUROCHEM INT, V48, P523, DOI 10.1016/j.neuint.2005.12.036; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Diedler J, 2010, NEUROCRIT CARE, V12, P313, DOI 10.1007/s12028-010-9350-5; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Grewer C, 2008, IUBMB LIFE, V60, P609, DOI 10.1002/iub.98; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kramer AH, 2011, NEUROCRIT CARE, V14, P329, DOI 10.1007/s12028-011-9530-y; Larach DB, 2011, NEUROCRIT CARE, V15, P609, DOI 10.1007/s12028-011-9517-8; LINDQUIST JL, 1942, SURG GYNECOL OBSTET, V75, P28; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Soustiel JF, 2011, PHARM RES-DORDR, V28, P2945, DOI 10.1007/s11095-011-0463-0; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wang X, 2007, BRAIN RES, V1132, P1, DOI 10.1016/j.brainres.2006.11.032; Ward MJ, 2012, NEUROCRIT CARE, V16, P232, DOI 10.1007/s12028-011-9644-2; Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	47	34	35	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								146	10.3389/fneur.2013.00146			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QT	WOS:000209629000145	24130548	Green Published, gold			2022-02-06	
J	Iverson, GL; Koehle, MS				Iverson, Grant L.; Koehle, Michael S.			Normative Data for the Balance Error Scoring System in Adults	REHABILITATION RESEARCH AND PRACTICE			English	Article							TRAUMATIC BRAIN-INJURY; POSTURAL STABILITY; MOTOR-PERFORMANCE; HEAD-INJURY; CONCUSSION; DEFICITS; PARTICIPANTS; INSTABILITY; SYMPTOMS; EXERTION	Background. The balance error scoring system (BESS) is a brief, easily administered test of static balance. The purpose of this study is to develop normative data for this test. Study Design. Cross-sectional, descriptive, and cohort design. Methods. The sample was drawn from a population of clients taking part in a comprehensive preventive health screen at a multidisciplinary healthcare center. Community-dwelling adults aged 20-69 (N = 1, 236) were administered the BESS within the context of a fitness evaluation. They did not have significant medical, neurological, or lower extremity problems that might have an adverse effect on balance. Results. There was a significant positive correlation between BESS scores and age (r = .34). BESS performance was similar for participants between the ages of 20 and 49 and significantly declined between ages 50 and 69. Men performed slightly better than women on the BESS. Women who were overweight performed significantly more poorly on the test compared to women who were not overweight (P < .0001; Cohen's d = .62). The BESS normative data are stratified by age and sex. Conclusions. These normative data provide a frame of reference for interpreting BESS performance in adults who sustain traumatic brain injuries and adults with diverse neurological or vestibular problems.	[Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Boston, MA USA; [Iverson, Grant L.; Koehle, Michael S.] Copeman Healthcare Ctr, Vancouver, BC V6Z 2L4, Canada; [Koehle, Michael S.] Univ British Columbia, Sch Kinesiol, Vancouver, BC V6T IZ1, Canada; [Koehle, Michael S.] Univ British Columbia, Div Sport Med, Vancouver, BC V6T IZ1, Canada		Koehle, MS (corresponding author), Copeman Healthcare Ctr, Vancouver, BC V6Z 2L4, Canada.	michael.koehle@ubc.ca	Koehle, Michael S/C-7850-2013	Koehle, Michael S/0000-0001-7026-8422			Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Allen NE, 2011, MOVEMENT DISORD, V26, P1605, DOI 10.1002/mds.23790; Beazell JR, 2012, J ORTHOP SPORT PHYS, V42, P125, DOI 10.2519/jospt.2012.3729; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Black FO, 2001, ANN NY ACAD SCI, V942, P446, DOI 10.1111/j.1749-6632.2001.tb03765.x; Bressel E, 2007, J ATHL TRAINING, V42, P42; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cameron MH, 2010, CURR NEUROL NEUROSCI, V10, P407, DOI 10.1007/s11910-010-0128-0; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Carver T, 2011, GAIT POSTURE, V33, P615, DOI 10.1016/j.gaitpost.2011.02.001; Cohen H, 1996, AGE AGEING, V25, P39, DOI 10.1093/ageing/25.1.39; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson G. L., 2011, ARCH PHYS MED REHAB, V92, P1695; Iverson G. L., 2011, P AM C REH MED ATL G; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Liaw Mei-Yun, 2009, Chang Gung Med J, V32, P297; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Patel AV, 2007, J ATHL TRAINING, V42, P66; Pollock CL, 2011, CLIN REHABIL, V25, P693, DOI 10.1177/0269215510397394; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Vikram M, 2012, CLIN TER, V163, P383; Visser JE, 2008, CLIN NEUROPHYSIOL, V119, P2424, DOI 10.1016/j.clinph.2008.07.220; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	36	34	34	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-2867	2090-2875		REHABIL RES PRACT	Rehabil. Res. Pract.		2013	2013								846418	10.1155/2013/846418			5	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V18OK	WOS:000214760500012	23577257	gold, Green Published, Green Submitted			2022-02-06	
J	Scheff, SW; Ansari, MA; Roberts, KN				Scheff, Stephen W.; Ansari, Mubeen A.; Roberts, Kelly N.			Neuroprotective effect of Pycnogenol (R) following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Bioflavonoids; Head injury; Natural compounds; Neuroinflammation; Oxidative stress; Synaptic proteins; TBI; Traumatic brain injury	AMYLOID-BETA-PEPTIDE; OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; SIGNALING PATHWAY; CAFFEIC ACID; INFLAMMATORY RESPONSE; SUPEROXIDE-DISMUTASE; AKT PHOSPHORYLATION; CORTICAL CONTUSION; SYNAPTIC PROTEINS	Traumatic brain injury (TBI) involves primary and secondary injury cascades that underlie delayed neuronal dysfunction and death. Oxidative stress is one of the most celebrated secondary injury mechanisms. A close relationship exists between levels of oxidative stress and the pathogenesis of TBI. However, other cascades, such as an increase in proinflammatoty cytokines, also play important roles in the overall response to the trauma. Pharmacologic intervention, in order to be successful, requires a multifaceted approach. Naturally occurring flavonoids are unique in possessing not only tremendous free radical scavenging properties but also the ability to modulate cellular homeostasis leading to a reduction in inflammation and cell toxicity. This study evaluated the therapeutic role of Pycnogenol (PYC), a patented combinational bioflavonoid. Young adult Sprague-Dawley rats were subjected to a unilateral moderate cortical contusion and treated post injury with PYC or vehicle. At either 48 or 96 h post trauma, the animals were killed and the cortex and hippocampus analyzed for changes in enzymatic and non-enzymatic oxidative stress markers. In addition, possible changes in both pre- and post-synaptic proteins (synapsin-1, PSD-95, drebrin, synapse associated protein-97) were analyzed. Finally, a separate cohort of animals was used to evaluate two proinflammatory cytokines (IL-6, TNF-alpha). Following the trauma there was a significant increase in oxidative stress in both the injured cortex and the ipsilateral hippocampus. Animals treated with PYC significantly ameliorated levels of protein carbonyls, lipid peroxidation, and protein nitration. The PYC treatment also significantly reduced the loss of key pre- and post-synaptic proteins with some levels in the hippocampus of PYC treated animals not significantly different from sham operated controls. Although levels of the proinflammatory cytokines were significantly elevated in both injury groups, the cohort treated with PYC showed a significant reduction compared to vehicle treated controls. These results are the first to show a neuroprotective effect of PYC following TBI. They also suggest that the diverse effects of bioflavonoids may provide a unique avenue for possible therapeutic intervention following head trauma. (c) 2012 Elsevier Inc. All rights reserved.	[Scheff, Stephen W.; Ansari, Mubeen A.; Roberts, Kelly N.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA.	sscheff@email.uky.edu; mansa3@email.uky.edu; 1knrobe2@email.uky.edu		Ansari, Mubeen Ahmad/0000-0002-1132-5965	National Institute of Heath Grant [R21NS66117]; Kentucky Spinal Cord and Head Injury Trust [8-15A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS066117] Funding Source: NIH RePORTER	This work was supported by the National Institute of Heath Grant R21NS66117 and Kentucky Spinal Cord and Head Injury Trust 8-15A. Pycnogenol (R) was a very generous gift from Horphag Research Inc., Hoboken, NJ.	Abd El Mohsen MM, 2002, FREE RADICAL BIO MED, V33, P1693, DOI 10.1016/S0891-5849(02)01137-1; Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P1510, DOI 10.1016/j.freeradbiomed.2008.08.025; Ansari MA, 2006, FREE RADICAL BIO MED, V41, P1694, DOI 10.1016/j.freeradbiomed.2006.09.002; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Azevedo MF, 2010, PHYTOTHER RES, V24, pS220, DOI 10.1002/ptr.3118; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BROWN JP, 1980, MUTAT RES, V75, P243, DOI 10.1016/0165-1110(80)90029-9; Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Cho KJ, 2001, ANN NY ACAD SCI, V928, P141; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; DUARTE J, 1993, GEN PHARMACOL-VASC S, V24, P857, DOI 10.1016/0306-3623(93)90159-U; El Mohsen MA, 2006, BRIT J NUTR, V95, P51, DOI 10.1079/BJN20051596; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; Faul M, 2010, TRAUMATIC BRAIN INJU; Gamet-Payrastre L, 1999, GEN PHARMACOL-VASC S, V32, P279, DOI 10.1016/S0306-3623(98)00220-1; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Islekel S, 1999, RES EXP MED, V199, P167, DOI 10.1007/s004330050121; Itoh T, 2011, NEUROMOL MED, V13, P300, DOI 10.1007/s12017-011-8162-x; Jatana M, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-12; Johnson JL, 2011, J MED FOOD, V14, P325, DOI 10.1089/jmf.2010.0310; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kobayashi MS, 2000, FREE RADICAL RES, V32, P115, DOI 10.1080/10715760000300121; Kobuchi H, 1999, METHOD ENZYMOL, V301, P504; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lee HF, 2012, RESP PHYSIOL NEUROBI, V182, P1, DOI 10.1016/j.resp.2012.01.016; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu YH, 2003, CHEM RES TOXICOL, V16, P1589, DOI 10.1021/tx034160a; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Mandel S, 2006, J NEURAL TRANSM-SUPP, P249; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McIntosh TK, 1996, LAB INVEST, V74, P315; Mercer LD, 2005, BIOCHEM PHARMACOL, V69, P339, DOI 10.1016/j.bcp.2004.09.018; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nardini M, 2000, BBA-GEN SUBJECTS, V1474, P219, DOI 10.1016/S0304-4165(00)00009-X; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ozturk Erdogan, 2005, Prog Neuropsychopharmacol Biol Psychiatry, V29, P922, DOI 10.1016/j.pnpbp.2005.04.028; Packer L, 1999, FREE RADICAL BIO MED, V27, P704, DOI 10.1016/S0891-5849(99)00090-8; Paganga G, 1999, FREE RADICAL RES, V30, P153, DOI 10.1080/10715769900300161; Parajuli P, 2011, J NEURO-ONCOL, V101, P15, DOI 10.1007/s11060-010-0221-x; Peng QL, 2002, MOL BRAIN RES, V104, P55, DOI 10.1016/S0169-328X(02)00263-2; Robert AM, 2001, PATHOL BIOL, V49, P298, DOI 10.1016/S0369-8114(01)00148-1; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schroeter H, 2001, BIOCHEM J, V358, P547, DOI 10.1042/0264-6021:3580547; Schultke E, 2005, J NEUROTRAUM, V22, P1475, DOI 10.1089/neu.2005.22.1475; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Spencer JPE, 2008, BRIT J NUTR, V99, pES60, DOI 10.1017/S0007114508965776; Spencer JPE, 2007, GENES NUTR, V2, P257, DOI 10.1007/s12263-007-0056-z; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Vauzour D, 2007, J NEUROCHEM, V103, P1355, DOI 10.1111/j.1471-4159.2007.04841.x; Vauzour D, 2008, GENES NUTR, V3, P115, DOI 10.1007/s12263-008-0091-4; de la Torre AV, 2012, PHARMACOL RES, V65, P66, DOI 10.1016/j.phrs.2011.08.006; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yan JJ, 2001, BRIT J PHARMACOL, V133, P89, DOI 10.1038/sj.bjp.0704047; Youdim KA, 2001, FREE RADICAL BIO MED, V30, P583, DOI 10.1016/S0891-5849(00)00510-4; Zhang L, 2007, LIFE SCI, V80, P530, DOI 10.1016/j.lfs.2006.09.039; Zhou Y, 2006, ACTA PHARMACOL SIN, V27, P1103, DOI 10.1111/j.1745-7254.2006.00406.x	86	34	35	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2013	239						183	191		10.1016/j.expneurol.2012.09.019			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	073TH	WOS:000313765000022	23059456	Green Accepted			2022-02-06	
J	Koyama, Y; Maebara, Y; Hayashi, M; Nagae, R; Tokuyama, S; Michinaga, S				Koyama, Yutaka; Maebara, Yuko; Hayashi, Mio; Nagae, Ryuji; Tokuyama, Shogo; Michinaga, Shotaro			Endothelins reciprocally regulate VEGF-A and angiopoietin-1 production in cultured rat astrocytes: Implications on astrocytic proliferation	GLIA			English	Article						endothelin-1; brain injury; angiogenic factors; gene expression	BLOOD-BRAIN-BARRIER; FOCAL CEREBRAL-ISCHEMIA; GROWTH-FACTOR; RECEPTOR EXPRESSION; CELL-PROLIFERATION; REACTIVE GLIOSIS; ADHESION KINASE; EDEMA FORMATION; D3 EXPRESSION; ANGIOGENESIS	Vascular endothelial growth factors (VEGFs) and angiopoietins (ANGs) are involved in pathophysiological responses in damaged nerve tissues. Astrocytes produce VEGFs and ANGs upon brain ischemia and traumatic injury. To clarify the extracellular signals regulating VEGF and ANG production, effects of endothelins (ETs), a family of endothelium-derived peptides, were examined in cultured rat astrocytes. ET-1 (100 nM) and Ala1,3,11,15-ET-1 (100 nM), an ETB receptor agonist, increased VEGF-A mRNA levels in cultured astrocytes, while ANG-1 mRNA was decreased by ETs. ET-1 did not affect astrocytic VEGF-B, placental growth factor (PLGF), and ANG-2 mRNA levels. The effects of ET-1 on VEGF-A and ANG-1 mRNAs were inhibited by BQ788, an ETB antagonist. Release of VEGF-A proteins from cultured astrocytes was increased by ET-1. In contrast, ET-1 reduced release of astrocytic ANG-1. Exogenous ET-1 (100 nM) and VEGF165 (100 ng/mL), an isopeptide of VEGF-A, stimulated bromodeoxyuridine (BrdU) incorporation into cultured astrocytes. Treatment with ET-1 and VEGF165 increased the numbers of cyclin D1-positive astrocytes. Exogenous ANG-1 (250 ng/mL) did not stimulate the BrdU incorporation. Increases in BrdU incorporation by ET-1 and VEGF165 were not affected by ANG-1. In 6070% confluent cultures, SU4312 (10 mu M), a VEGF receptor tyrosine kinase inhibitor, partially reduced the effects of ET-1 on BrdU incorporation and cyclin D1 expression. ET-induced BrdU incorporation and cyclin D1 expression were reduced by a neutralizing antibody against VEGF-A. Our findings suggest that ET-1 is a factor regulating astrocytic VEGF-A and ANG-1, and that increased VEGF-A production potentiates ET-induced astrocytic proliferation by an autocrine mechanism. (c) 2012 Wiley Periodicals, Inc.	[Koyama, Yutaka; Maebara, Yuko; Hayashi, Mio; Michinaga, Shotaro] Osaka Ohtani Univ, Fac Pharm, Pharmacol Lab, Tondabayashi, Osaka 5848540, Japan; [Nagae, Ryuji; Tokuyama, Shogo] Kobe Gakuin Univ, Dept Clin Pharm, Sch Pharmaceut Sci, Kobe, Hyogo 65121, Japan		Koyama, Y (corresponding author), Osaka Ohtani Univ, Fac Pharm, Pharmacol Lab, 3-11-1 Nishikiori Kita, Tondabayashi, Osaka 5848540, Japan.	koyamay@osaka-ohtani.ac.jp			JPSP [21590108]	Grant sponsor: Grant-in-Aid for Scientific Research (C), JPSP; Grant number: 21590108.	Abdel-Malak NA, 2008, BLOOD, V111, P4145, DOI 10.1182/blood-2007-08-110338; Argaw AT, 2006, J IMMUNOL, V177, P5574, DOI 10.4049/jimmunol.177.8.5574; Beck H, 2002, J NEUROPATH EXP NEUR, V61, P339, DOI 10.1093/jnen/61.4.339; Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12; Cobbs CS, 1998, NEUROSCI LETT, V249, P79, DOI 10.1016/S0304-3940(98)00377-2; Fischer S, 2000, AM J PHYSIOL-CELL PH, V279, pC935, DOI 10.1152/ajpcell.2000.279.4.C935; Freitas-Andrade M, 2008, J NEUROCHEM, V107, P756, DOI 10.1111/j.1471-4159.2008.05660.x; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Kanda S, 2005, CANCER RES, V65, P6820, DOI 10.1158/0008-5472.CAN-05-0522; Kim H, 2008, BIOCHEM BIOPH RES CO, V372, P243, DOI 10.1016/j.bbrc.2008.05.025; Kimura R, 2005, STROKE, V36, P1259, DOI 10.1161/01.STR.0000165925.20413.14; Koyama Y, 2004, J NEUROCHEM, V90, P904, DOI 10.1111/j.1471-4159.2004.02546.x; Koyama Y, 2011, NEUROSCIENCE, V192, P689, DOI 10.1016/j.neuroscience.2011.05.058; Koyama Y, 2003, GLIA, V43, P185, DOI 10.1002/glia.10240; Koyama Y, 1999, GLIA, V26, P268, DOI 10.1002/(SICI)1098-1136(199905)26:3<268::AID-GLIA8>3.0.CO;2-G; Koyama Y, 2006, BRAIN RES, V1112, P65, DOI 10.1016/j.brainres.2006.07.013; Koyama Y, 2012, J PHARMACOL SCI, V118, P401, DOI 10.1254/jphs.11R13CP; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nie XJ, 1996, REV NEUROSCIENCE, V7, P177; Ostrow LW, 2005, BRAIN RES REV, V48, P488, DOI 10.1016/j.brainresrev.2004.09.005; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Peters CM, 2003, EXP NEUROL, V180, P1, DOI 10.1016/S0014-4886(02)00023-7; Ramsauer M, 2002, FASEB J, V16, P1274, DOI 10.1096/fj.01-0814fje; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121; Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087; Schmid-Brunclik N, 2008, AM J PHYSIOL-REG I, V295, pR864, DOI 10.1152/ajpregu.00536.2007; Shibuya M, 2009, FEBS J, V276, P4636, DOI 10.1111/j.1742-4658.2009.07175.x; Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541-7786.MCR-07-0072; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Teixeira A, 2000, J NEUROCHEM, V74, P1034, DOI 10.1046/j.1471-4159.2000.0741034.x; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Yoshida H, 2002, BRAIN RES, V944, P65, DOI 10.1016/S0006-8993(02)02708-7; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306-4522(02)00175-6	46	34	35	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491			GLIA	Glia	DEC	2012	60	12					1954	1963		10.1002/glia.22411			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	026GM	WOS:000310262600012	22927341				2022-02-06	
J	Plurad, DS; Bricker, S; Neville, A; Bongard, F; Putnam, B				Plurad, David S.; Bricker, Scott; Neville, Angela; Bongard, Frederic; Putnam, Brant			Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors	AMERICAN JOURNAL OF SURGERY			English	Article						Arginine vasopressin; Transplantation; Organ donation; Hormone replacement therapy; Brain death; Organ procurement; Thyroxine; Traumatic brain injury; Trauma	MANAGEMENT; DONATION; IMPACT; DEFICIENCY; CRITERIA	BACKGROUND: Hormone replacement therapy increases the number and quality of grafts recovered from brain-dead organ donors. Arginine vasopressin (AVP) has also been shown to have beneficial effects. The aim of this study was to determine the effect of AVP on recovery rates. METHODS: The Organ Procurement and Transplantation Network database was used. Donors treated with hormone replacement therapy and vasopressor agents who were successfully procured between January 1, 2009, and June 30, 2011, were studied. AVP-positive and AVP-negative donors were compared. The primary study end point was the rate of high-yield procurement (>= 4 organs). RESULTS: A total of 10,431 donors were included. AVP was infused in 7,873 (75.5%) and was associated with an increased rate of high-yield procurement (50.5% vs 35.6%, P < .001). There was less overall graft refusal due to poor function (38.9% vs 45.6%, P < .001). AVP independently predicted high yield procurement. CONCLUSIONS: The use of AVP with hormone replacement therapy is independently associated with an increased rate of organ recovery. This strategy should be universally adopted in the management of donors progressing to neurologic death. (C) 2012 Elsevier Inc. All rights reserved.	[Plurad, David S.; Bricker, Scott; Neville, Angela; Bongard, Frederic; Putnam, Brant] Harbor UCLA Med Ctr, Div Trauma Acute Care Surg & Surg Crit Care, Torrance, CA 90509 USA		Plurad, DS (corresponding author), Harbor UCLA Med Ctr, Div Trauma Acute Care Surg & Surg Crit Care, Torrance, CA 90509 USA.	dplurad@dhs.lacounty.gov			Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [234-2005-370011C]	This study was based on Organ Procurement and Transplantation Network data of June 30, 2011. This work was supported in part by Health Resources and Services Administration contract 234-2005-370011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.	Abdelnour T, 2009, J HEART LUNG TRANSPL, V28, P480, DOI 10.1016/j.healun.2009.01.018; Bernat JL, 2006, AM J TRANSPLANT, V6, P281, DOI 10.1111/j.1600-6143.2005.01194.x; Blasco V, 2008, SHOCK, V29, P667, DOI 10.1097/SHK.0b013e31815d0ae7; Cerutti E, 2006, LIVER TRANSPLANT, V12, P1253, DOI 10.1002/lt.20811; Chen JM, 1999, CIRCULATION, V100, P244; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; DuBose Joseph, 2008, J Intensive Care Med, V23, P367, DOI 10.1177/0885066608324208; Forni A, 2011, TRANSPL P, V43, P953, DOI 10.1016/j.transproceed.2011.01.117; Holmes CL, 2001, CHEST, V120, P989, DOI 10.1378/chest.120.3.989; HOWLETT TA, 1989, TRANSPLANTATION, V47, P828, DOI 10.1097/00007890-198905000-00016; Kutsogiannis DJ, 2006, CAN J ANAESTH, V53, P820, DOI 10.1007/BF03022800; Landry DW, 1997, CIRCULATION, V95, P1122; Mitchell SLM, 2007, BRIT J ANAESTH, V99, P154, DOI 10.1093/bja/aem204; NOVITZKY D, 1987, TRANSPLANTATION, V43, P852, DOI 10.1097/00007890-198743060-00016; Organ Procurement and Transplantation Network, ORG DON UT US 1999 2; PENNEFATHER SH, 1995, TRANSPLANTATION, V59, P58, DOI 10.1097/00007890-199501150-00011; POWNER DJ, 1990, CRIT CARE MED, V18, P702; RANDELL TT, 1993, TRANSPLANT P, V25, P1552; Rosendale JD, 2003, TRANSPLANTATION, V75, P1336, DOI 10.1097/01.TP.0000062839.58826.6D; Rosendale JD, 2003, TRANSPLANTATION, V75, P482, DOI 10.1097/01.TP.0000045683.85282.93; ROSS SE, 1990, J TRAUMA, V30, P820, DOI 10.1097/00005373-199007000-00009; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Saidi RF, 2007, AM J TRANSPLANT, V7, P2769, DOI 10.1111/j.1600-6143.2007.01993.x; Salim A, 2005, J TRAUMA, V58, P991, DOI 10.1097/01.TA.0000168708.78049.32; Salim A, 2007, J TRAUMA, V62, P1411, DOI 10.1097/TA.0b013e3180479876; TANIGUCHI S, 1992, EUR J CARDIO-THORAC, V6, P96, DOI 10.1016/1010-7940(92)90082-9; Van Bakel AB, 2004, TRANSPLANT P, V36, P2573, DOI 10.1016/j.transproceed.2004.10.016; Wood KE, 2004, NEW ENGL J MED, V351, P2730, DOI 10.1056/NEJMra013103	28	34	36	2	8	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2012	204	6					856	860		10.1016/j.amjsurg.2012.05.011			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	060UG	WOS:000312803000008	23116641				2022-02-06	
J	Henkin, RI; Schultz, M; Minnick-Poppe, L				Henkin, Robert I.; Schultz, Michael; Minnick-Poppe, Laura			Intranasal Theophylline Treatment of Hyposmia and Hypogeusia A Pilot Study	ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY			English	Article							NASAL MUCUS; PARKINSONS-DISEASE; PAROTID-SALIVA; ETIOLOGIC RELATIONSHIPS; OLFACTORY DYSFUNCTION; CYCLIC-NUCLEOTIDES; SMELL DYSFUNCTION; TASTE; BLOOD; TRANSPORT	Objective: To determine whether intranasal theophylline methylpropyl paraben can correct hyposmia and hypogeusia. Design: We performed an open-label pilot study in patients with hyposmia and hypogeusia under the following 3 conditions: (1) before treatment, (2) after oral theophylline anhydrous treatment, and (3) after intranasal theophylline treatment. Under each condition, we performed subjective evaluations of taste and smell functions, quantitative measurements of taste (gustometry) and smell (olfactometry), and measurements of serum theophylline level and body weight. Setting: The Taste and Smell Clinic in Washington, DC. Patients: Ten patients with hyposmia and hypogeusia clinically related to the effects of viral illness, allergic rhinitis, traumatic brain injury, congenital hyposmia, and other chronic disease processes were selected. Interventions: Oral theophylline anhydrous, 200 to 800 mg/d for 2 to 12 months, was administered to each patient. This treatment was discontinued for 3 weeks to 4 months when intranasal theophylline methylpropyl paraben, 20 mu g/d in each naris, was administered for 4 weeks. Main Outcome Measures: At termination of each condition, taste and smell function was determined subjectively, by means of gustometry and olfactometry, with measurement of serum theophylline levels and body weight. Results: Oral theophylline treatment improved taste and smell acuity in 6 patients after 2 to 12 months of treatment. Intranasal theophylline treatment improved taste and smell acuity in 8 patients after 4 weeks, with improvement greater than after oral administration. No adverse effects accompanied intranasal drug use. Body weight increased with each treatment but was greater after intranasal than after oral administration. Conclusions: Intranasal theophylline treatment is safer and more effective in improving hyposmia and hypogeusia than oral theophylline anhydrous treatment. Arch Otolaryngol Head Neck Surg. 2012;138(11):1064-1070	[Henkin, Robert I.] Taste & Smell Clin, Ctr Mol Nutr & Sensory Disorders, Washington, DC 20016 USA; [Schultz, Michael] Fdn Care, Earth City, MO USA; [Minnick-Poppe, Laura] St Louis Coll Pharm, St Louis, MO USA		Henkin, RI (corresponding author), Taste & Smell Clin, Ctr Mol Nutr & Sensory Disorders, 5125 MacArthur Blvd NW,Ste 20, Washington, DC 20016 USA.	doc@tasteandsmell.com					Al Suleimani YM, 2007, PHARMACOL THERAPEUT, V114, P233, DOI 10.1016/j.pharmthera.2007.01.012; ANSARI KA, 1976, EUR NEUROL, V14, P138, DOI 10.1159/000114736; Banks WA, 2004, EUR J PHARMACOL, V490, P5, DOI 10.1016/j.ejphar.2004.02.040; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; Briner HR, 2003, CLIN OTOLARYNGOL, V28, P417, DOI 10.1046/j.1365-2273.2003.00735.x; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Chow HHS, 1999, J PHARM SCI, V88, P754; CHURCH JA, 1978, ANN ALLERGY, V40, P105; CONSTANTINESCU CS, 1994, J NEUROL NEUROSUR PS, V57, P1011, DOI 10.1136/jnnp.57.8.1011; Cullen MM, 1999, MED CLIN N AM, V83, P57, DOI 10.1016/S0025-7125(05)70087-0; Dahlin M, 2000, PHARMACEUT RES, V17, P737, DOI 10.1023/A:1007542618378; Dahlin M, 2001, EUR J PHARM SCI, V14, P75, DOI 10.1016/S0928-0987(01)00151-8; Dahlin M, 2000, INT J PHARM, V195, P197, DOI 10.1016/S0378-5173(99)00392-0; DJUKANOVIC R, 1995, EUR RESPIR J, V8, P831; Dorman DC, 2002, J TOXICOL ENV HEAL A, V65, P1493, DOI 10.1080/00984100290071630; Doty RL, 1997, CHEM SENSES, V22, P565, DOI 10.1093/chemse/22.5.565; DOTY RL, 1992, J NEUROL NEUROSUR PS, V55, P138, DOI 10.1136/jnnp.55.2.138; Doty RL, 1997, NEW ENGL J MED, V336, P1918, DOI 10.1056/NEJM199706263362617; EVANS J, 1992, FUND APPL TOXICOL, V19, P275, DOI 10.1016/0272-0590(92)90161-A; FJELLESTADPAULSEN A, 1987, ARCH DIS CHILD, V62, P674, DOI 10.1136/adc.62.7.674; Gudziol V, 2009, ARCH OTOLARYNGOL, V135, P291, DOI 10.1001/archoto.2008.524; Harris R, 2006, AM J RHINOL, V20, P101, DOI 10.1177/194589240602000119; Henkin R, 2004, ENCY NEUROSCIENCE, P2010; Henkin RI, 2008, CLIN INVEST MED, V31, pE78; Henkin RI, 2008, CLIN INVEST MED, V31, pE71; Henkin RI, 2010, NUTRITION, V26, P624, DOI 10.1016/j.nut.2009.08.003; Henkin R. I., 2011, HDB GROWTH GROWTH MO, VII, P1417; Henkin RI, 2006, J INVEST MED, V54, pS378; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; Henkin RI, 2003, NUTRITION, V19, P1013, DOI 10.1016/j.nut.2003.08.006; Henkin RI, 2002, J COMPUT ASSIST TOMO, V26, P39, DOI 10.1097/00004728-200201000-00008; HENKIN RI, 1967, LANCET, V2, P1268; HENKIN RI, 1971, LANCET, V1, P823; HENKIN RI, 1984, BIOL TRACE ELEM RES, V6, P263, DOI 10.1007/BF02917511; HENKIN RI, 1975, ANN OTO RHINOL LARYN, V84, P672, DOI 10.1177/000348947508400519; Henkin RI, 1996, FASEB J, V10, P3900; Henkin RI, 1976, SCI FDN OTOLARYNGOLO, P469; HENKIN RI, 1993, OTOLARYNGOLOGY, V2, P1; Henkin RI, 1981, OLFACTORY REV, V1, P1; Henkin RI, 2000, AM J RHINOL, V14, pA; Henkin RI, 2007, AM J MED SCI, V334, P431, DOI 10.1097/MAJ.0b013e3180de4d97; Henkin RI, 2012, ARCH ORAL BIOL, V57, P670, DOI 10.1016/j.archoralbio.2012.01.004; Henkin RI, 2012, J CLIN PATHOL, V65, P447, DOI 10.1136/jclinpath-2012-200698; Henkin RI, 2012, THER DRUG MONIT, V34, P217, DOI 10.1097/FTD.0b013e3182492a20; Henkin RI, 2011, NAT BIOTECHNOL, V29, P480, DOI 10.1038/nbt.1866; Henkin RI, 2011, AM J MED SCI, V341, P17, DOI 10.1097/MAJ.0b013e3181f1fdc8; Henkin RI, 2009, AM J MED SCI, V337, P396, DOI 10.1097/MAJ.0b013e3181914a97; Henkin RI, 2009, METABOLISM, V58, P1717, DOI 10.1016/j.metabol.2009.05.027; HODGES RE, 1978, AM J CLIN NUTR, V31, P876, DOI 10.1093/ajcn/31.5.876; Hummel T, 2005, J NEURAL TRANSM, V112, P669, DOI 10.1007/s00702-004-0207-y; Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022539; JORGENSEN M B, 1961, Acta Otolaryngol, V53, P539, DOI 10.3109/00016486109126521; Kastin AJ, 2006, ENDOCRINOLOGY, V147, P2086, DOI 10.1210/en.2006-0208; KESSLAK JP, 1988, NEUROBIOL AGING, V9, P399, DOI 10.1016/S0197-4580(88)80087-3; Kubek MJ, 2001, BLOOD BRAIN BARRIER, P331; LAW JS, 1986, BIOCHEM MED METAB B, V36, P118, DOI 10.1016/0885-4505(86)90115-5; Liberini P, 2000, J NEUROL, V247, P88, DOI 10.1007/PL00007803; Mattsson LA, 2000, AM J OBSTET GYNECOL, V182, P545, DOI 10.1067/mob.2000.104843; Moberg PJ, 1997, INT J NEUROSCI, V89, P133, DOI 10.3109/00207459708988468; Moharram R, 2004, FASEB J, V18, pA201; Ozben T, 2004, NATO SCI SERIES 1, V358; PARDRIDGE WM, 1985, J NEUROCHEM, V44, P1771, DOI 10.1111/j.1471-4159.1985.tb07167.x; Putcha L, 1996, J PHARM SCI, V85, P899, DOI 10.1021/js950327b; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; SARKAR MA, 1992, PHARM RES-DORDR, V9, P1, DOI 10.1023/A:1018911206646; SCHECHTER PJ, 1974, J NEUROL NEUROSUR PS, V37, P802, DOI 10.1136/jnnp.37.7.802; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1337; Serby MJ, 2001, AM J PSYCHIAT, V158, P1534, DOI 10.1176/appi.ajp.158.9.1534; Syrett N, 2003, NEUROLOGY, V61, pS27, DOI 10.1212/WNL.61.8_suppl_4.S27; THORNE RG, 1995, BRAIN RES, V692, P278, DOI 10.1016/0006-8993(95)00637-6; Tissingh G, 2001, MOVEMENT DISORD, V16, P41, DOI 10.1002/1531-8257(200101)16:1<41::AID-MDS1017>3.0.CO;2-M; WARNER MD, 1986, BIOL PSYCHIAT, V21, P116, DOI 10.1016/0006-3223(86)90013-2; Watelet JB, 2009, DRUG METAB REV, V41, P301, DOI 10.1080/10837450902891204; WEINBERGER M, 1978, J PEDIATR-US, V92, P1, DOI 10.1016/S0022-3476(78)80058-4; Zheng YQ, 2004, WORLD J GASTROENTERO, V10, P3165; ZIAI F, 1978, ARCH INTERN MED, V138, P1382, DOI 10.1001/archinte.138.9.1382; Zivadinov R, 1999, J NEUROL SCI, V168, P127, DOI 10.1016/S0022-510X(99)00189-6	78	34	35	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0886-4470	1538-361X		ARCH OTOLARYNGOL	Arch. Otolaryngol. Head Neck Surg.	NOV	2012	138	11					1064	1070		10.1001/2013.jamaoto.342			7	Otorhinolaryngology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology; Surgery	055FH	WOS:000312400100010	23165381				2022-02-06	
J	Davis, MT; Loyd, AM; Shen, HYH; Mulroy, MH; Nightingale, RW; Myers, BS; Bass, CD				Davis, Matthew T.; Loyd, Andre M.; Shen, Han-yu Henry; Mulroy, Maura H.; Nightingale, Roger W.; Myers, Barry S.; Bass, Cameron Dale			The mechanical and morphological properties of 6 year-old cranial bone	JOURNAL OF BIOMECHANICS			English	Article						Bone; Cranial bone; Pediatric; Biomechanics; Strength; Skull; Mechanical properties; Injury; Structure	TRAUMATIC BRAIN-INJURY; DYNAMIC RESPONSE; INFANT SKULL; HEAD; SUTURE	Traumatic Brain Injury (TBI) is a leading cause of mortality and morbidity for children in the United States. The unavailability of pediatric cadavers makes it difficult to study and characterize the mechanical behavior of the pediatric skull. Computer based finite element modeling could provide valuable insights, but the utility of these models depends upon the accuracy of cranial material property inputs. In this study, 47 samples from one six year-old human cranium were tested to failure via four point bending to study the effects of strain rate and the structure of skull bone on modulus of elasticity and failure properties for both cranial bone and suture. The results show that strain rate does not have a statistically meaningful effect on the mechanical properties of the six year-old skull over the range of strain rates studied (average low rate of 0.045 s(-1), average medium rate of 0.44 s(-1), and an average high rate of 2.2 s(-1)), but that these properties do depend on the growth patterns and morphology of the skull. The thickness of the bone was found to vary with structure. The bending stiffness (per unit width) for tri-layer bone (12.32 +/- 5.18 Nm(2)/m) was significantly higher than that of cortical bone and sutures (5.58 +/- 1.46 Nm(2)/m and 3.70 +/- 1.88 Nm(2)/m respectively). The modulus of elasticity was 9.87 +/- 1.24 GPa for cranial cortical bone and 1.10 +/- 0.53 GPa for sutures. The effective elastic modulus of tri-layer bone was 3.69 +/- 0.92 GPa. Accurate models of the pediatric skull should account for the differences amongst these three distinct tissues in the six year-old skull. (C) 2012 Elsevier Ltd. All rights reserved.	[Davis, Matthew T.; Loyd, Andre M.; Shen, Han-yu Henry; Mulroy, Maura H.; Nightingale, Roger W.; Myers, Barry S.; Bass, Cameron Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA		Nightingale, RW (corresponding author), Duke Univ, Dept Biomed Engn, Box 90281, Durham, NC 27708 USA.	rwn@duke.edu	Nightingale, Roger W/D-2872-2011				Baumer T.G., 2009, J BIOMECHANICAL ENG, V131; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Camacho DLA, 2001, J BIOMECH ENG-T ASME, V123, P432, DOI 10.1115/1.1389086; CARTER DR, 1976, SCIENCE, V194, P1174, DOI 10.1126/science.996549; Coats B., 2007, THESIS U PENNSYLVANI; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Cohen M.M.J., 2000, EVALUATION MANAGEMEN; Desantis Klinich Kathleen, 2002, Stapp Car Crash J, V46, P165; DUTERLOO HS, 1970, AM J ANAT, V127, P357, DOI 10.1002/aja.1001270403; Evans F.G., 1956, J APPL PHYSIOL, V10, P493; Guan FJ, 2011, ANN BIOMED ENG, V39, P85, DOI 10.1007/s10439-010-0125-0; Hibbeler, 2003, BENDING MECH MAT, P324; James HE, 1999, ACT NEUR S, V73, P85; KRIEWALL TJ, 1981, J BIOMECH, V14, P73, DOI 10.1016/0021-9290(81)90166-4; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCELHANEY JH, 1966, J APPL PHYSIOL, V21, P1231, DOI 10.1152/jappl.1966.21.4.1231; MCPHERSON GK, 1980, J BIOMECH, V13, P17, DOI 10.1016/0021-9290(80)90004-4; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; Mulroy M.H., 2011, EVALUATION PEDIAT SK; Nightingale R.W., 1997, P 41 STAPP CAR CRASH, V41, P451; Prange Michael T, 2004, Stapp Car Crash J, V48, P279; Roberts V.L., 1968, ACCIDENT PATHOLOGY; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8	27	34	39	2	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	OCT 11	2012	45	15					2493	2498		10.1016/j.jbiomech.2012.07.001			6	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	024KE	WOS:000310107300002	22939291				2022-02-06	
J	Clifton, GL; Coffey, CS; Fourwinds, S; Zygun, D; Valadka, A; Smith, KR; Frisby, ML; Bucholz, RD; Wilde, EA; Levin, HS; Okonkwo, DO				Clifton, Guy L.; Coffey, Christopher S.; Fourwinds, Sierra; Zygun, David; Valadka, Alex; Smith, Kenneth R., Jr.; Frisby, Melisa L.; Bucholz, Richard D.; Wilde, Elisabeth A.; Levin, Harvey S.; Okonkwo, David O.			Early induction of hypothermia for evacuated intracranial hematomas: a post hoc analysis of two clinical trials Clinical article	JOURNAL OF NEUROSURGERY			English	Article						severe traumatic brain injury; evacuated hematoma; hypothermia	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW	Object. The authors hypothesized that cooling before evacuation of traumatic intracranial hematomas protects the brain from reperfusion injury and, if so, further hypothesized that hypothermia induction before or soon after craniotomy should be associated with improved outcomes. Methods. The National Acute Brain Injury Study: Hypothermia I (NABIS:H I) was a randomized multicenter clinical trial of 392 patients with severe brain injury treated using normothermia or hypothermia for 48 hours with patients reaching 33 degrees C at 8.4 +/- 3 hours after injury. The National Acute Brain Injury Study: Hypothermia II (NABIS:H II) was a randomized, multicenter clinical trial of 97 patients with severe brain injury treated with normothermia or hypothermia for 48 hours with patients reaching 35 degrees C within 2.6 +/- 1.2 hours and 33 degrees C within 4.4 +/- 1.5 hours of injury. Entry and exclusion criteria, management, and outcome measures in the 2 trials were similar. Results. In NABIS:H II among the patients with evacuated intracranial hematomas, outcome was poor (severe disability, vegetative state, or death) in 5 of 15 patients in the hypothermia group and in 9 of 13 patients in the normothermia group (relative risk 0.4-4, 95% CI 0.22-0.88; p = 0.02). All patients randomized to hypothermia reached 35 degrees C within 1.5 hours after surgery start and 33 degrees C within 5.55 hours. Applying these criteria to NABIS:H 1,31 of 54 hypothermia-treated patients reached a temperature of 35 degrees C or lower within 1.5 hours after surgery start time, and the remaining 23 patients reached 35 degrees C at later time points. Outcome was poor in 14(45%) of 31 patients reaching 35 degrees C within 1.5 hours of surgery, in 14 (61%) of 23 patients reaching 35 degrees C more than 1.5 hours of surgery, and in 35 (60%) of 58 patients in the normothermia group (relative risk 0.74,95%, Cl 0.49-1.13; p = 0.16). A meta-analysis of 46 patients with hematomas in both trials who reached 35 degrees C within 1.5 hours of surgery start showed a significantly reduced rate of poor outcomes (41%) compared with 94 patients treated with hypothermia who did not reach 35 degrees C within that time and patients treated at normothermia (62%, p = 0.009). Conclusions. Induction of hypothermia to 35 degrees C before or soon after craniotomy with maintenance at 33 degrees C for 48 hours thereafter may improve outcome of patients with hematomas and severe traumatic brain injury. Clinical trial registration no.: NCT00178711. (http://thejns.org/doi/abs/10.3171/2012.6.JNS111690)	[Clifton, Guy L.; Valadka, Alex] Univ Texas Med Sch, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA; [Frisby, Melisa L.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Rehabil Med, Houston, TX 77030 USA; [Fourwinds, Sierra] Silverwind Enterprises, La Veta, CO USA; [Coffey, Christopher S.] Univ Iowa, Dept Biostat, Iowa City, IA USA; [Zygun, David] Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada; [Smith, Kenneth R., Jr.; Bucholz, Richard D.] St Louis Univ, Dept Surg, Div Neurosurg, St Louis, MO 63103 USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA		Clifton, GL (corresponding author), Univ Texas Med Sch, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, 6431 Fannin,Suite 7-130, Houston, TX 77030 USA.	guy@guyclifton.com			National Institute of Neurological Disorders and Stroke (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS34786, U01 NS043353]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS043353] Funding Source: NIH RePORTER	The NABIS:H I and NABS:H II trials are supported by grants to Guy L. Clifton, M.D., from the National Institute of Neurological Disorders and Stroke (NIH Grant Nos. R01 NS34786 and U01 NS043353).	[Anonymous], 1971, JAMA-J AM MED ASSOC, V215, P277; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUM, V24, pS7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Burger R, 2004, NEUROSURGERY, V54, P701, DOI 10.1227/01.NEU.0000108784.80585.EE; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Jacobs SE, 2010, J PAEDIATR CHILD H, V46, P568, DOI 10.1111/j.1440-1754.2010.01880.x; Janata A, 2009, PROG CARDIOVASC DIS, V52, P168, DOI 10.1016/j.pcad.2009.07.001; KURODA Y, 1992, NEUROSURGERY, V30, P687; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505	15	34	36	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2012	117	4					714	720		10.3171/2012.6.JNS111690			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	015YZ	WOS:000309485600018	22839656				2022-02-06	
J	Saadeh, Y; Gohil, K; Bill, C; Smith, C; Morrison, C; Mosher, B; Schneider, P; Stevens, P; Kepros, JP				Saadeh, Yamaan; Gohil, Kartik; Bill, Charles; Smith, Curtis; Morrison, Chet; Mosher, Benjamin; Schneider, Paul; Stevens, Penny; Kepros, John P.			Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Thromboembolism prophylaxis; intracranial hemorrhage; traumatic brain injury	DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; VENA-CAVA FILTERS; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; PULMONARY-EMBOLISM; PRACTICE PATTERNS; AAST MULTICENTER; PREVENTION; EPIDEMIOLOGY; POPULATION	BACKGROUND: Venous thromboembolism (VTE) continues to be an important complication for patients with trauma, including patients with intracranial hemorrhage. We implemented a protocol starting chemical prophylaxis 24 hours after the absence of progression of hemorrhage on computed tomography (CT) to increase consistency with the use of chemical venous thromboembolic prophylaxis in this population. The objective of this study was to review the protocol of VTE prophylaxis for patients with traumatic brain injury at our institution to determine whether it has been effective and safe in preventing VTE without increasing intracranial hemorrhage. METHODS: A retrospective case series was conducted to study 205 patients with intracranial hemorrhage admitted to a Level I trauma center during a 24-month period. These patients were reviewed with respect to type of intracranial injury, need for surgery, injury severity, time to initiation of chemical prophylaxis, and progression of injury on brain CT. Patients with a hospital length of stay less than 3 days or nonstable CT were excluded in the analysis of administration of chemical prophylaxis. Time to chemical prophylaxis in relation to absence of progression on brain CT was examined as well as the subsequent risk of progression of hemorrhage and risk of VTE events. The overall rate of venous thromboembolism was compared with that of matched historical controls. RESULTS: All patients received mechanical prophylaxis in the form of sequential compression devices. One hundred sixty-two intracranial hemorrhages were identified in 122 patients who met the study's inclusion criteria. Of this group of patients who did not have progression of hemorrhage on follow-up CT, 76.2% received chemical prophylaxis during their hospitalization. No patients had progression of intracranial hemorrhage after initiation of chemical VTE prophylaxis, and no patients developed VTE. This represents a decrease of VTE from previous years. No other complications related to chemical VTE prophylaxis were identified. CONCLUSION: A protocol based on an early use of chemical venous thromboembolic prophylaxis after the absence of progression of tramatic intracranial hemorrhage does not result in increased progression of intracranial hemorrhage and reduced the rate of venous thromboembolic events at our institution. (J Trauma Acute Care Surg. 2012;73:426-430. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Gohil, Kartik; Morrison, Chet; Mosher, Benjamin; Schneider, Paul; Kepros, John P.] Michigan State Univ, Sparrow Hosp, Dept Surg, Lansing, MI 48912 USA; [Saadeh, Yamaan] Michigan State Univ, Sparrow Hosp, Coll Human Med, Lansing, MI 48912 USA; [Bill, Charles; Smith, Curtis; Morrison, Chet; Mosher, Benjamin; Schneider, Paul; Stevens, Penny; Kepros, John P.] Sparrow Hlth Syst, Lansing, MI USA		Kepros, JP (corresponding author), Michigan State Univ, Dept Surg, 1200 Michigan Ave,Suite 655, Lansing, MI 48912 USA.	John.Kepros@hc.msu.edu		Saadeh, Yamaan/0000-0001-6269-4392			Anderson FA, 2010, AM J MED, V123, P1099, DOI 10.1016/j.amjmed.2010.07.011; [Anonymous], 2005, BLOOD, V106, p5a; [Anonymous], 2008, SURG GEN CALL ACT DE; BOEER A, 1991, J NEUROL NEUROSUR PS, V54, P466, DOI 10.1136/jnnp.54.5.466; Brandt MM, 2007, AM J SURG, V193, P383; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; Heit JA, 2006, J THROMB THROMBOLYS, V21, P23, DOI 10.1007/s11239-006-5572-y; Helling TS, 2009, J TRAUMA, V67, P1293, DOI 10.1097/TA.0b013e3181b0637a; Ho KM, 2011, CHEST, V140, P1436, DOI 10.1378/chest.11-1444; Karmy-Jones R, 2007, J TRAUMA, V62, P17, DOI 10.1097/TA.0b013e31802dd72a; Kiphuth IC, 2009, CEREBROVASC DIS, V27, P146, DOI 10.1159/000177923; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Mahan CE, 2011, THROMB HAEMOSTASIS, V106, P405, DOI 10.1160/TH11-02-0132; Malinoski D, 2011, INJURY          1101; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; O'Carroll CB, 2011, NEUROLOGIST, V17, P232, DOI 10.1097/NRL.0b013e318222d6c0; Orken DN, 2009, NEUROLOGIST, V15, P329, DOI 10.1097/NRL.0b013e3181a93bac; Rogers FB, 1997, J TRAUMA, V5, P142; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Shackford SR, 2007, J TRAUMA, V62, P24; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Spyropoulos AC, 2009, THROMB HAEMOSTASIS, V102, P951, DOI 10.1160/TH09-02-0073; Toker S, 2011, THROMBOSIS, DOI DOI 10.1155/2011/505373; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66	26	34	35	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2012	73	2					426	430		10.1097/TA.0b013e31825a758b			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	992VG	WOS:000307807400032	22846950				2022-02-06	
J	Seel, RT; Steyerberg, EW; Malec, JF; Sherer, M; Macciocchi, SN				Seel, Ronald T.; Steyerberg, Ewout W.; Malec, James F.; Sherer, Mark; Macciocchi, Stephen N.			Developing and Evaluating Prediction Models in Rehabilitation Populations	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Biostatistics; Evidence-based medicine; Evidence-based practice; Models, statistical; Multivariate analysis; Prognosis; Rehabilitation; Review literature as topic; Statistics as topic	TRAUMATIC BRAIN-INJURY; LOGISTIC-REGRESSION ANALYSIS; IMPACT DATABASE; PROGNOSIS; VALIDATION; HEURISTICS; SIMULATION; SELECTION; DESIGN; CARE	This article presents a 3-part framework for developing and evaluating prediction models in rehabilitation populations. First, a process for developing and refining prognostic research questions and the scientific approach to prediction models is presented. Primary components of the scientific approach include the study design and sampling of patients, outcome measurement, selecting predictor variable(s), minimizing methodologic sources of bias, assuring a sufficient sample size for statistical power, and selecting an appropriate statistical model. Examples focus on prediction modeling using samples of rehabilitation patients. Second, a brief overview for statistically building and validating multivariable prediction models is provided, which includes the following 7 steps: data inspection, coding of predictors, model specification, model estimation, model performance, model validation, and model presentation. Third, we propose a set of primary considerations for evaluating prediction model studies using specific quality indicators as criteria to help stakeholders evaluate the quality of a prediction model study. Lastly, we offer perspectives on the future development and use of rehabilitation prediction models.	[Seel, Ronald T.; Macciocchi, Stephen N.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA 30309 USA; [Seel, Ronald T.; Macciocchi, Stephen N.] Shepherd Ctr, Brain Injury Program, Atlanta, GA 30309 USA; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands; [Malec, James F.] Indiana Univ, Sch Med, Dept Phys Med, Indianapolis, IN USA; [Sherer, Mark] Univ Texas Houston, Sch Med, TIRR Mem Hermann, Baylor Coll Med, Houston, TX USA; [Sherer, Mark] Univ Texas Houston, Sch Med, Dept Phys Med, Baylor Coll Med, Houston, TX USA		Seel, RT (corresponding author), Shepherd Ctr, Crawford Res Inst, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	ron_seel@shepherd.org	Steyerberg, Ewout W/C-1509-2018	Steyerberg, Ewout W/0000-0002-7787-0122	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133G070171]	Supported in part by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant no. H133G070171).	Agency for Healthcare Research and Quality, 2011, AG HEALTHC RES QUAL; Aiken L. S., 2013, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441; Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO;2-X; Ambler G, 2002, STAT MED, V21, P3803, DOI 10.1002/sim.1422; American Academy of Neurology, 2011, CLIN PRACT GUID PROC; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Beattie PF, 2007, PHYS THER, V87, P1527, DOI 10.2522/ptj.20060284; Biering-Sorensen F, 2011, SPINAL CORD, V49, P60, DOI 10.1038/sc.2010.90; Bishop MA, 2002, PHILOS SCI, V69, pS197, DOI 10.1086/341846; Bond T. G., 2007, APPL RASCH MODEL FUN, V2; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Crocker L., 1986, INTRO CLASSICAL MODE; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; de Vellis RF, 2003, SCALE DEV THEORY APP, V2nd; EVANS RW, 2000, PROGNOSIS NEUROLOGIC; Fischer JE, 2002, ARCH PEDIAT ADOL MED, V156, P1005, DOI 10.1001/archpedi.156.10.1005; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; Grimby G, 2012, J REHABIL MED, V44, P97, DOI 10.2340/16501977-0938; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Harrell FE Jr, 2017, REGRESSION MODELING; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Hemingway H, 2006, J CLIN EPIDEMIOL, V59, P1229, DOI 10.1016/j.jclinepi.2006.02.005; Hudak PL, 1996, ARCH PHYS MED REHAB, V77, P586, DOI 10.1016/S0003-9993(96)90300-7; Institute of Medicine of National Academies, 2011, CLIN PRACT GUID WE C; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Katsikopoulos KV, 2008, THEOR PSYCHOL, V18, P443, DOI 10.1177/0959354308091824; Kattan MW, 2003, J UROLOGY, V170, P1792, DOI 10.1097/01.ju.0000091806.70171.41; Kothari S., 2007, BRAIN INJURY MED PRI, P169; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; Lee KI, 1997, COMMUN STAT-SIMUL C, V26, P559, DOI 10.1080/03610919708813397; Lemeshow S, 2000, APPL LOGISTIC REGRES; Little R. J., 2019, STAT ANAL MISSING DA, V793; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Meehl P.E., 1954, CLIN VERSUS STAT PRE; Norman, 2003, HLTH MEASUREMENT SCA; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; Portney LG, 2000, FDN CLIN RES APPL PR, P113; Roozenbeek B, 2009, J NEUROTRAUM, V26, P1069, DOI 10.1089/neu.2008.0569; Royston P, 2007, COMPUT STAT DATA AN, V51, P4240, DOI 10.1016/j.csda.2006.05.006; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Shadish WR., 2002, EXPT QUASI EXPT DESI; Sherer M, 2010, J HEAD TRAUMA REHAB, V25, P92, DOI 10.1097/HTR.0b013e3181c9d887; Steyerberg, 2019, CLIN PREDICTION MODE; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Swets J A, 2000, Psychol Sci Public Interest, V1, P1, DOI 10.1111/1529-1006.001; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; Velozo CA, 2012, ARCH PHYS MED REHAB, V93, pS154, DOI 10.1016/j.apmr.2012.06.001; Vergouwe Y, 2010, J CLIN EPIDEMIOL, V63, P205, DOI 10.1016/j.jclinepi.2009.03.017; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilson M., 2005, CONSTRUCTING MEASURE; World Health Organization, 2002, COMM LANG FUNCT DIS	62	34	31	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8		2			S138	S153		10.1016/j.apmr.2012.04.021			16	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	983XL	WOS:000307151900006	22840880				2022-02-06	
J	Williams, G; Willmott, C				Williams, G.; Willmott, C.			Higher levels of mobility are associated with greater societal participation and better quality-of-life	BRAIN INJURY			English	Article						Mobility limitation; activities of daily living; social participation; quality-of-life	TRAUMATIC BRAIN-INJURY; ASSESSMENT-TOOL HIMAT; COMMUNITY INTEGRATION; PHYSICAL-ACTIVITY; AEROBIC CAPACITY; REHABILITATION; RELIABILITY; EXERCISE; CLASSIFICATION; SATISFACTION	Introduction: Participation rates and quality-of-life (QoL) have been a major focus of rehabilitation programmes and outcome studies following traumatic brain injury (TBI). The extent to which mobility limitations impact on participation rates and QoL has not been thoroughly explored. The main aim of this study was to investigate the relationship between mobility limitations, participation rates and QoL following TBI. Methods: Thirty-nine people who had sustained an extremely severe TBI were recruited from a major rehabilitation facility. Mobility was quantified using the high-level mobility assessment tool (HiMAT). The Brain Injury Community Rehabilitation Outcome (BICRO-39) and Community Integration Questionnaire (CIQ) were used to measure participation rates and the shorter version of the World Health Organization Quality of Life (WHOQoL-BREF) and Assessment of Quality-of-Life (AQoL-2) were used to measure QoL. Results: Mobility was most strongly correlated with the total BICRO-39 score (r = -0.60, p<0.001) and the mobility domain (r = -0.59, p<0.001) of the BICRO-39. Although mobility had a significant relationship with health-related QoL, AQoL-2 (r = 0.60, p<0.001), it was most strongly related to the AQoL-2 independent living domain (r = 0.79, p<0.001). Conclusion: Greater capacity to mobilize was associated with higher participation rates and better QoL.	[Williams, G.] Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; [Willmott, C.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia		Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavin.williams@epworth.org.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035; Williams, Gavin/0000-0003-2758-7473			Alzahrani MA, 2009, AUST J PHYSIOTHER, V55, P277, DOI 10.1016/S0004-9514(09)70008-X; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Chiu WT, 2006, J NEUROTRAUM, V23, P1609, DOI 10.1089/neu.2006.23.1609; Cohen J, 1988, STAT POWER ANAL BEHA; Eriksson Gunilla, 2005, Scand J Occup Ther, V12, P40, DOI 10.1080/11038120510027630; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Morris S, 2009, EUR J PHYSIOTHER, V11, P218, DOI 10.3109/14038190902856778; Mossberg KA, 2008, PHYS THER, V88, P77, DOI 10.2522/ptj.20070022; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Reavenall S, 2010, INT J THER REHABIL, V17, P360, DOI 10.12968/ijtr.2010.17.7.48893; Richardson J, 2003, ASSESSMENT QUALITY L, DOI http://www.psychiatry.unimelb.edu.au/centres-units/cpro/aqol/index.html; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whittle MW., 2007, GAIT ANAL INTRO; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams GP, 2009, INT J THER REHABIL, V16, P370, DOI 10.12968/ijtr.2009.16.7.43046; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams GP, 2009, BRAIN INJURY, V23, P307, DOI 10.1080/02699050902774170; Williams GP, 2006, PHYS THER, V86, P395, DOI 10.1093/ptj/86.3.395; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711; Wolman RL, 1994, CLIN REHABIL, V8, P253; World Health Organization, 2001, ICF INT CLASS FUNCT	44	34	34	1	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2012	26	9					1065	1071		10.3109/02699052.2012.667586			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	971GI	WOS:000306191400003	22571773				2022-02-06	
J	Lok, J; Zhao, S; Leung, W; Seo, JH; Navaratna, D; Wang, X; Whalen, MJ; Lo, EH				Lok, Josephine; Zhao, Song; Leung, Wendy; Seo, Ji Hae; Navaratna, Deepti; Wang, Xiaoying; Whalen, Michael J.; Lo, Eng H.			Neuregulin-1 Effects on Endothelial and Blood-Brain Barrier Permeability After Experimental Injury	TRANSLATIONAL STROKE RESEARCH			English	Article						Neuregulin-1; Endothelial; Blood-brain barrier; Brain trauma; IL-1 beta; Permeability	TISSUE-DAMAGE; UNITED-STATES; MICE; DISRUPTION; HEALTH; IMPACT	Blood brain barrier (BBB) disruption occurs with a high incidence after traumatic brain injury, and is an important contributor to many pathological processes, including brain edema, inflammation, and neuronal cell death. Therefore, BBB integrity is an important potential therapeutic target in the treatment of the acute phase of brain trauma. In this short communication, we report our data showing that neuregulin-1 (NRG1), a growth factor with diverse functions in the central nervous system (CNS), ameliorates pathological increases in endothelial permeability and in BBB permeability in experimental models of injury. For in vitro studies, rat brain endothelial cells were incubated with the inflammatory cytokine IL-1 beta, which caused an increase in permeability of the cell layer. Co-incubation with NRG1 ameliorated this permeability increase. For in vivo studies, C57B1/6 mice were subjected to controlled cortical impact (CCI) under anesthesia, and BBB permeability was assessed by measuring the amount of Evans blue dye extravasation at 2 h. NRG1 administered by tail-vein injection 10 min after CCI resulted in a decrease in Evans blue dye extravasation by 35 %. Since Evans blue extravasation may result from an increase in BBB permeability or from bleeding due to trauma, hemoglobin ELISA was also performed at the same time point. There was a trend toward lower levels of hemoglobin extravasation in the NRG1 group, but the results did not reach statistical significance. MMP-9 activity was not different between groups at 2 h. These data suggest that NRG1 has beneficial effects on endothelial permeability and BBB permeability following experimental trauma, and may have neuroprotective potential during CNS injury.	[Lok, Josephine; Leung, Wendy; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02114 USA; [Lok, Josephine; Zhao, Song; Leung, Wendy; Seo, Ji Hae; Navaratna, Deepti; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab, Charlestown, MA USA; [Zhao, Song] Jilin Univ, First Hosp, Dept Orthoped, Spine Div, Changchun 130023, Jilin, Peoples R China; [Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; [Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA; [Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Charlestown, MA USA		Lok, J (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02114 USA.	jlok1@partners.org			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08NS057339, R01NS53560, RO1NSO61255, R01-NS76694]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS057339] Funding Source: NIH RePORTER	This study was supported by National Institute of Health grants (K08NS057339 to JL, R01NS53560, RO1NSO61255 to MW, and R01-NS76694 to EHL). The authors declare no conflicts of interest.	Anton ES, 1997, DEVELOPMENT, V124, P3501; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; Lok J, 2009, J CEREBR BLOOD F MET, V29, P39, DOI 10.1038/jcbfm.2008.94; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Talmage D.A., 2008, NOVART FDN SYMP, V289, P93; Talmage David A, 2008, Novartis Found Symp, V289, P74; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Vezzani Annamaria, 2007, Epilepsy Curr, V7, P45, DOI 10.1111/j.1535-7511.2007.00165.x; Viviani B, 2003, J NEUROSCI, V23, P8692; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	19	34	35	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483			TRANSL STROKE RES	Transl. Stroke Res.	JUL	2012	3			1	SI		S119	S124		10.1007/s12975-012-0157-x			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	961AT	WOS:000305436500015	22773936	Green Accepted			2022-02-06	
J	Cole, JT; Sweatt, AJ; Hutson, SM				Cole, Jeffrey T.; Sweatt, Andrew J.; Hutson, Susan M.			Expression of mitochondrial branched-chain aminotransferase and alpha-keto-acid dehydrogenase in rat brain: implications for neurotransmitter metabolism	FRONTIERS IN NEUROANATOMY			English	Article						glutamate; gamma-amino butyric acid; MSUD; branched chain aminotransferase; traumatic brain injury; branched chain amino acid	SYRUP-URINE-DISEASE; AMINO-ACIDS; GLUTAMATE SYNTHESIS; GLIAL-CELLS; ACUTE STAGE; LEUCINE; ISOENZYMES; ACTIVATION; RECOVERY; PATHWAY	In the brain, metabolism of the essential branched chain amino acids (BCAAs) leucine, isoleucine, and valine, is regulated in part by protein synthesis requirements. Excess BCAAs are catabolized or excreted. The first step in BCAA catabolism is catalyzed by the branched chain aminotransferase (BCAT) isozymes, mitochondrial BCATm and cytosolic BCATc. A product of this reaction, glutamate, is the major excitatory neurotransmitter and precursor of the major inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The BCATs are thought to participate in a alpha-keto-acid nitrogen shuttle that provides nitrogen for synthesis of glutamate from alpha-ketoglutarate. The branched-chain alpha-keto acid dehydrogenase enzyme complex (BCKDC) catalyzes the second, irreversible step in BCAA metabolism, which is oxidative decarboxylation of the branched-chain alpha-keto acid (BCKA) products of the BCAT reaction. Maple Syrup Urine Disease (MSUD) results from genetic defects in BCKDC, which leads to accumulation of toxic levels of BCAAs and BCKAs that result in brain swelling. Immunolocalization of BCATm and BCKDC in rats revealed that BCATm is present in astrocytes in white matter and in neuropil, while BCKDC is expressed only in neurons. BCATm appears uniformly distributed in astrocyte cell bodies throughout the brain. The segregation of BCATm to astrocytes and BCKDC to neurons provides further support for the existence of a BCAA-dependent glial-neuronal nitrogen shuttle since the data show that BCKAs produced by glial BCATm must be exported to neurons. Additionally, the neuronal localization of BCKDC suggests that MSUD is a neuronal defect involving insufficient oxidation of BCKAs, with secondary effects extending beyond the neuron.	[Cole, Jeffrey T.] Uniformed Serv Univ Hlth Sci, USUHS, Dept Neurol, Bethesda, MD 20814 USA; [Sweatt, Andrew J.] Wake Forest Univ Hlth Sci, Dept Physiol & Pharmacol, Winston Salem, NC USA; [Hutson, Susan M.] Virginia Tech, Human Nutr Foods & Exercise, Blacksburg, VA USA		Cole, JT (corresponding author), Uniformed Serv Univ Hlth Sci, USUHS, Dept Neurol, 4301 Jones Bridge Rd,B-3012, Bethesda, MD 20814 USA.	jeffrey.cole@usuhs.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-38641]; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38641]	Jeffrey T. Cole and Andrew J. Sweatt conducted the experiments, collected the data and prepared the images. Jeffrey T. Cole, Andrew J. Sweatt, and Susan M. Hutson designed the experiments, interpreted the results, and prepared the manuscript. This work was supported by NIH NS-38641 (Susan M. Hutson). Grant sponsor: National Institutes of Health/National Institute of Neurological Disorders and Stroke; Grant Number NS 38641 (Susan M. Hutson).	Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; Aquilani R, 2008, ARCH PHYS MED REHAB, V89, P1642, DOI 10.1016/j.apmr.2008.02.023; Berl S, 1983, GLUTAMINE GLUTAMATE, P205; BIXEL MG, 1995, J NEUROCHEM, V65, P2450; Bixel MG, 2001, J HISTOCHEM CYTOCHEM, V49, P407, DOI 10.1177/002215540104900314; Bixel MG, 1997, J HISTOCHEM CYTOCHEM, V45, P685, DOI 10.1177/002215549704500506; Blouet C, 2009, J NEUROSCI, V29, P8302, DOI 10.1523/JNEUROSCI.1668-09.2009; CHUANG DI, 2001, METABOLIC BASIS INHE, P1239; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Gamberino WC, 1997, J NEUROCHEM, V69, P2312; Garcia-Espinosa MA, 2007, J NEUROCHEM, V100, P1458, DOI 10.1111/j.1471-4159.2006.04332.x; Ha JS, 2004, PEDIATR RADIOL, V34, P163, DOI 10.1007/s00247-003-1058-7; HALL TR, 1993, J BIOL CHEM, V268, P3092; HARRIS RA, 1990, ADV ENZYME REGUL, V30, P245; Hutson SM, 2005, J NUTR, V135, p1557S, DOI 10.1093/jn/135.6.1557S; Hutson SM, 2001, J NUTR, V131, p846S, DOI 10.1093/jn/131.3.846S; Hutson SM, 1998, J NEUROCHEM, V71, P863; Ichihara A, 1985, TRANSAMINASES, P430; Jan W, 2003, NEURORADIOLOGY, V45, P393, DOI 10.1007/s00234-003-0955-7; Kanamori K, 1998, J NEUROCHEM, V70, P1304; LaNoue KF, 2001, J NEUROSCI RES, V66, P914, DOI 10.1002/jnr.10064; LANOUE KF, 2007, HDB NEUROCHEMISTRY M, P589; LEWANDOWSKI ED, 1990, AM J PHYSIOL, V258, pH1357, DOI 10.1152/ajpheart.1990.258.5.H1357; Lieth E, 2001, J NEUROCHEM, V76, P1712, DOI 10.1046/j.1471-4159.2001.00156.x; McKenna MC, 1998, DEV NEUROSCI-BASEL, V20, P300, DOI 10.1159/000017325; Parmar H, 2004, J COMPUT ASSIST TOMO, V28, P93, DOI 10.1097/00004728-200401000-00015; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Righini A, 2003, J NEUROIMAGING, V13, P162, DOI 10.1177/1051228403251084; RIVIELLO JJ, 1991, J PEDIATR-US, V119, P42, DOI 10.1016/S0022-3476(05)81036-4; Sakai R, 2004, J NEUROCHEM, V88, P612, DOI 10.1111/j.1471-4159.2004.02179.x; Sener RN, 2002, J NEUROIMAGING, V12, P368, DOI 10.1111/j.1552-6569.2002.tb00146.x; She P, 2007, CELL METAB, V6, P181, DOI 10.1016/j.cmet.2007.08.003; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Sweatt AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE64, DOI 10.1152/ajpendo.00276.2003; Waagepetersen HS, 2001, GLIA, V35, P246, DOI 10.1002/glia.1089; Yudkoff M, 2005, J NUTR, V135, p1531S, DOI 10.1093/jn/135.6.1531S; Yudkoff M, 1996, J NEUROCHEM, V66, P378; YUDKOFF M, 1993, DEV NEUROSCI-BASEL, V15, P343, DOI 10.1159/000111354; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W; Yudkoff M, 1996, J NEUROCHEM, V66, P2136; YUDKOFF M, 1983, BIOCHEM BIOPH RES CO, V115, P174, DOI 10.1016/0006-291X(83)90985-3; YUDKOFF M, 1994, J NEUROCHEM, V62, P1192	45	34	34	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5129			FRONT NEUROANAT	Front. Neuroanat.	MAY 28	2012	6								18	10.3389/fnana.2012.00018			11	Anatomy & Morphology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology; Neurosciences & Neurology	948EO	WOS:000304486600001	22654736	gold, Green Published			2022-02-06	
J	Cimolin, V; Beretta, E; Piccinini, L; Turconi, AC; Locatelli, F; Galli, M; Strazzer, S				Cimolin, Veronica; Beretta, Elena; Piccinini, Luigi; Turconi, Anna Carla; Locatelli, Federica; Galli, Manuela; Strazzer, Sandra			Constraint-Induced Movement Therapy for Children With Hemiplegia After Traumatic Brain Injury: A Quantitative Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; CIMT; kinematics; rehabilitation; traumatic brain injury; upper limbs	UPPER EXTREMITY KINEMATICS; MOTOR FUNCTION MEASURE; CEREBRAL-PALSY; UPPER-LIMB; 3-DIMENSIONAL KINEMATICS; EXCITE TRIAL; STROKE; ADOLESCENTS; RELIABILITY; EVALUATE	Objective: The aims of this study are to quantify the movement limitation of upper limbs in hemiplegic children with traumatic brain injury (TBI) by using a clinical-functional scale and upper limb kinematics and to evaluate the effectiveness of constraint-induced movement therapy (CIMT) on upper limbs. Design: Pre-post study. Setting: Clinical rehabilitation research laboratory. Participants: Ten children with TBI. Main Outcome Measures: The participants were evaluated by clinical examinations (Gross Motor Function Measure, Besta scale, Quality of Upper Extremities Skills Test, and Manual Ability Classification System) and 3D kinematic movement analysis of the upper limb before the CIMT program (pretest: 0.7 years after the injury) and at the end of the program (posttest: 10 weeks later). Results: After the CIMT, most of the clinical measures improved significantly. Some significant improvements were present in terms of kinematics, in particular, in the movement duration and the velocity of movement execution of both tasks; the index of curvature and the average jerk improved, respectively, during reaching and hand-to-mouth task, while the adjusting sway parameter decreased during the 2 movements. Significant improvements were found in upper limb joint excursion after the rehabilitative programme too. Conclusions: Our results suggest that the CIMT program can improve movement efficiency and upper limb function in children after TBI. The integration of the clinical outcomes and upper limb kinematics revealed to be crucial in detecting the effects of the CIMT programme.	[Cimolin, Veronica; Galli, Manuela] Politecn Milan, Dept Bioengn, I-20133 Milan, Italy; [Beretta, Elena; Piccinini, Luigi; Turconi, Anna Carla; Locatelli, Federica; Strazzer, Sandra] IRCCS E Medea La Nostra Famiglia, Bosisio Parini, LC, Italy; [Galli, Manuela] IRCCS San Raffaele Pisana Tosinvest Sanita, Rome, Italy		Cimolin, V (corresponding author), Politecn Milan, Dept Bioengn, Pzza Leonardo da Vinci 32, I-20133 Milan, Italy.	veronica.cimolin@biomed.polimi.it	Galli, Manuela/AAH-8783-2019; Cimolin, Veronica/AAF-6414-2019; Turconi, Anna Carla/AAX-6521-2020; piccinini, luigi/AAH-5470-2019; FEDERICA, LOCATELLI/AAA-5601-2020; Cimolin, Veronica/AAA-3326-2021; Beretta, Elena/AAH-5369-2019; Strazzer, Sandra/AAH-5712-2019; Turconi, Anna Carla/ABE-6747-2020	Cimolin, Veronica/0000-0001-6299-7254; piccinini, luigi/0000-0001-7027-6676; FEDERICA, LOCATELLI/0000-0002-8243-5483; Cimolin, Veronica/0000-0001-6299-7254; Beretta, Elena/0000-0002-8036-7624; Strazzer, Sandra/0000-0001-8414-6565; Turconi, Anna Carla/0000-0002-5482-924X; Galli, Manuela/0000-0003-2772-4837			ACHENBACH TM, 1981, MONOGR SOC RES CHILD, V46, P1, DOI 10.2307/1165983; Boyd R, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-4; Brady K, 2009, DEV DISABIL RES REV, V15, P102, DOI 10.1002/ddrr.59; Caimmi M, 2008, NEUROREHAB NEURAL RE, V22, P31, DOI 10.1177/1545968307302923; Chang JJ, 2005, CLIN BIOMECH, V20, P381, DOI 10.1016/j.clinbiomech.2004.11.015; Chevignard A., 2008, Annales de Readaptation et de Medecine Physique, V51, P238, DOI 10.1016/j.annrmp.2008.01.013; Coker P, 2010, DISABIL REHABIL, V32, P402, DOI 10.3109/09638280903171592; Coluccini M, 2007, GAIT POSTURE, V25, P493, DOI 10.1016/j.gaitpost.2006.12.015; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cope SM, 2008, AM J OCCUP THER, V62, P430, DOI 10.5014/ajot.62.4.430; Cope SM, 2010, DEV NEUROREHABIL, V13, P19, DOI 10.3109/17518420903236247; Deluca SC, 2006, J CHILD NEUROL, V21, P931, DOI 10.1177/08830738060210110401; DeMatteo C, 1993, PHYS OCCUP THER PEDI, V13, P833, DOI DOI 10.1080/J006V13N02_01; Eliasson AC, 2006, DEV MED CHILD NEUROL, V48, P549, DOI 10.1017/S0012162206001162; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; Facchin P, 2009, AM J PHYS MED REHAB, V88, P216, DOI 10.1097/PHM.0b013e3181951382; Fedrizzi E, 1994, MOTOR DEV CHILDHOOD, P51; Feng C J, 1997, IEEE Trans Rehabil Eng, V5, P253, DOI 10.1109/86.623017; Gordon A, 2007, DEV MED CHILD NEUROL, V49, P23, DOI 10.1017/S0012162207000072; Hoare B, 2007, CLIN REHABIL, V21, P675, DOI 10.1177/0269215507080783; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Karman N, 2003, J HEAD TRAUMA REHAB, V18, P259, DOI 10.1097/00001199-200305000-00004; Linder-Lucht M, 2007, PEDIATRICS, V120, P880, DOI 10.1542/peds.2006-2258; Mackey AH, 2006, ARCH PHYS MED REHAB, V87, P207, DOI 10.1016/j.apmr.2005.10.023; Mackey AH, 2005, GAIT POSTURE, V22, P1, DOI 10.1016/j.gaitpost.2004.06.002; Massie C, 2009, ARCH PHYS MED REHAB, V90, P571, DOI 10.1016/j.apmr.2008.09.574; Menegoni F, 2009, EUR J NEUROL, V16, P232, DOI 10.1111/j.1468-1331.2008.02396.x; Park SW, 2008, NEUROREHAB NEURAL RE, V22, P486, DOI 10.1177/1545968308316906; Petuskey K, 2007, GAIT POSTURE, V25, P573, DOI 10.1016/j.gaitpost.2006.06.006; Pidcock FS, 2009, TOP STROKE REHABIL, V16, P339, DOI 10.1310/tsr1605-339; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Rab G, 2002, GAIT POSTURE, V15, P113, DOI 10.1016/S0966-6362(01)00155-2; Ramos E, 1997, ARCH PHYS MED REHAB, V78, P491, DOI 10.1016/S0003-9993(97)90162-3; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Schweighofer N, 2009, PHYS THER, V89, P1327, DOI 10.2522/ptj.20080402; Smania N, 2009, EUR J PHYS REHAB MED, V45, P493; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; Wallen M, 2008, DEV NEUROREHABIL, V11, P124, DOI 10.1080/17518420701640897; Wechsler D., 1974, WECHSLER INTELLIGENC; Wolf SL, 2007, RESTOR NEUROL NEUROS, V25, P549; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wu CY, 2007, ARCH PHYS MED REHAB, V88, P964, DOI 10.1016/j.apmr.2007.05.012	42	34	35	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					177	187		10.1097/HTR.0b013e3182172276			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500006	21522025				2022-02-06	
J	Indraswari, F; Wang, HC; Lei, BL; James, ML; Kernagis, D; Warner, DS; Dawson, HN; Laskowitz, DT				Indraswari, Fransisca; Wang, Haichen; Lei, Beilei; James, Michael L.; Kernagis, Dawn; Warner, David S.; Dawson, Hana N.; Laskowitz, Daniel T.			Statins Improve Outcome in Murine Models of Intracranial Hemorrhage and Traumatic Brain Injury: A Translational Approach	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; HMG-CoA reductase inhibitors; intracerebral hemorrhage; neuroinflammation; traumatic brain injury	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; SIMVASTATIN; ATORVASTATIN; RATS; NEUROGENESIS; INCREASE; MOUSE; SYNAPTOGENESIS; DEGENERATION; INFLAMMATION	Traumatic brain injury (TBI) and intracerebral hemorrhage (ICH) are leading causes of neurological mortality and disability in the U.S.. However, therapeutic options are limited and clinical management remains largely supportive. HMG-CoA reductase inhibitors (statins) have pleiotropic mechanisms of action in the setting of acute brain injury, and have been demonstrated to improve outcomes in preclinical models of ICH and TBI. To facilitate translation to clinical practice, we now characterize the optimal statin and dosing paradigm in murine models of ICH and TBI. In a preclinical model of TBI, mice received vehicle, simvastatin, and rosuvastatin at doses of 1mg/kg and 5mg/kg for 5 days after the impact. Immunohistochemistry, differential gene expression, and functional outcomes (rotarod and Morris water maze testing) were assessed to gauge treatment response. Following TBI, administration of rosuvastatin 1 mg/kg was associated with the greatest improvement in functional outcomes. Rosuvastatin treatment was associated with histological evidence of reduced neuronal degeneration at 24 h post-TBI, reduced microgliosis at day 7 post-TBI, and preserved neuronal density in the CA3 region at 35 days post-injury. Administration of rosuvastatin following TBI was also associated with downregulation of inflammatory gene expression in the brain. Following ICH, treatment with simvastatin 1mg/kg was associated with the greatest improvement in functional outcomes, an effect that was independent of hemorrhage volume. Clinically relevant models of acute brain injury may be used to define variables such as optimal statin and dosing paradigms to facilitate the rational design of pilot clinical trials.	[Indraswari, Fransisca; Wang, Haichen; Lei, Beilei; James, Michael L.; Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; [Indraswari, Fransisca; Wang, Haichen; James, Michael L.; Dawson, Hana N.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Indraswari, Fransisca; Wang, Haichen; James, Michael L.; Dawson, Hana N.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC 27710 USA; [Lei, Beilei; James, Michael L.; Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Warner, David S.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [Kernagis, Dawn] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA		Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210; Indraswari, Fransisca/0000-0002-7308-5768	AstraZenecaAstraZeneca	The authors would like to thank Brenden Dawson for his assistance with some of the histological work. This work was partially supported by an investigator-initiated grant from AstraZeneca, which also supplied rosuvastatin.	Barish GD, 2010, GENE DEV, V24, P2760, DOI 10.1101/gad.1998010; Beray-Berthat V, 2010, J NEUROSCI METH, V191, P180, DOI 10.1016/j.jneumeth.2010.06.025; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Bulsara Ketan R, 2006, Neurosurg Focus, V21, pE11; Chauhan NB, 2011, RESTOR NEUROL NEUROS, V29, P23, DOI 10.3233/RNN-2011-0573; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dawson HN, 2010, NEUROSCIENCE, V169, P516, DOI 10.1016/j.neuroscience.2010.04.037; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; Deng P, 2011, J NEUROTRAUM, V28, P1173, DOI 10.1089/neu.2010.1683; Erdos B, 2006, AM J PHYSIOL-HEART C, V290, pH1264, DOI 10.1152/ajpheart.00804.2005; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85; Karki K, 2009, STROKE, V40, P3384, DOI 10.1161/STROKEAHA.108.544395; Labovitz DL, 2005, NEUROLOGY, V65, P518, DOI 10.1212/01.wnl.0000172915.71933.00; Lema PP, 2004, J VET PHARMACOL THER, V27, P321, DOI 10.1111/j.1365-2885.2004.00597.x; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liao JK, 2005, AM J CARDIOL, V96, p24F, DOI 10.1016/j.amjcard.2005.06.009; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; McKenney JM, 2003, CLIN CARDIOL, V26, P32, DOI 10.1002/clc.4960261507; McMellen ME, 2010, SURGERY, V148, P364, DOI 10.1016/j.surg.2010.03.020; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sugiyama Y, 2011, STROKE, V42, P770, DOI 10.1161/STROKEAHA.110.597799; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takata K, 2009, J NEUROSURG ANESTH, V21, P326, DOI 10.1097/ANA.0b013e3181acfde7; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Williams JK, 1998, J AM COLL CARDIOL, V31, P684, DOI 10.1016/S0735-1097(97)00537-8; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yang DM, 2011, J NEUROSURG, V114, P1135, DOI 10.3171/2010.7.JNS10163; Zacco A, 2003, J NEUROSCI, V23, P11104	49	34	38	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1388	1400		10.1089/neu.2011.2117			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600013	22233347				2022-02-06	
J	Wu, JF; Stoica, BA; Dinizo, M; Pajoohesh-Ganji, A; Piao, CS; Faden, AI				Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Pajoohesh-Ganji, Ahdeah; Piao, Chunshu; Faden, Alan I.			Delayed cell cycle pathway modulation facilitates recovery after spinal cord injury	CELL CYCLE			English	Article						spinal cord injury; cyclin-dependent kinases; cell cycle pathway; flavopiridol; oligodendrocytes; myelination; astrocytes; inflammation; neuron	ADHESION MOLECULE L1; INFLAMMATORY RESPONSE; GLIAL SCAR; AXONAL REGENERATION; NEURONAL DEATH; CLOSE HOMOLOG; BRAIN; RAT; NG2; PROLIFERATION	Traumatic spinal cord injury (SCI) causes tissue loss and associated neurological dysfunction through mechanical damage and secondary biochemical and physiological responses. We have previously described the pathobiological role of cell cycle pathways following rat contusion SCI by examining the effects of early intrathecal cell cycle inhibitor treatment initiation or gene knockout on secondary injury. Here, we delineate changes in cell cycle pathway activation following SCI and examine the effects of delayed (24 h) systemic administration of flavopiridol, an inhibitor of major cyclindependent kinases (CDKs), on functional recovery and histopathology in a rat SCI contusion model. Immunoblot analysis demonstrated a marked upregulation of cell cycle-related proteins, including pRb, cyclin D1, CDK4, E2F1 and PCNA, at various time points following SCI, along with downregulation of the endogenous CDK inhibitor p27. Treatment with flavopiridol reduced induction of cell cycle proteins and increased p27 expression in the injured spinal cord. Functional recovery was significantly improved after SCI from day 7 through day 28. Treatment significantly reduced lesion volume and the number of Iba-1(+) microglia in the preserved tissue and increased the myelinated area of spared white matter as well as the number of CC1(+) oligodendrocytes. Furthermore, flavopiridol attenuated expression of Iba-1 and glactin-3, associated with microglial activation and astrocytic reactivity by reduction of GFAP, NG2 and CHL1 expression. Our current study supports the role of cell cycle activation in the pathophysiology of SCI and, by using a clinically relevant treatment model, provides further support for the therapeutic potential of cell cycle inhibitors in the treatment of human SCI.	[Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Piao, Chunshu; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Piao, Chunshu; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Pajoohesh-Ganji, Ahdeah] George Washington Univ, Sch Med, Dept Anat & Regenerat Biol, Washington, DC USA		Wu, JF (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.	jwu@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIHNINDS-01, NS054221-03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054221] Funding Source: NIH RePORTER	Flavopiridol was provided by the NCI/Aventis. This work was supported by a National Institute of Health contract NIHNINDS-01 (NS054221-03).	Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Capello E, 1997, ANN NEUROL, V41, P797, DOI 10.1002/ana.410410616; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Jones LL, 2003, J NEUROSCI, V23, P9276; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Lytle JM, 2009, GLIA, V57, P270, DOI 10.1002/glia.20755; Lytle JM, 2006, J NEUROTRAUM, V23, P1726, DOI 10.1089/neu.2006.23.1726; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mason KA, 2004, INT J RADIAT ONCOL, V59, P1181, DOI 10.1016/j.ijrobp.2004.03.003; McTigue DM, 2006, J NEUROPATH EXP NEUR, V65, P406, DOI 10.1097/01.jnen.0000218447.32320.52; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Newcomb EW, 2004, CELL CYCLE, V3, P230; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stegmuller J, 2002, J NEUROCYTOL, V31, P497, DOI 10.1023/A:1025743731306; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Tator C H, 1996, J Spinal Cord Med, V19, P206; Tator CH, 2002, INJ PREV S4, V8, P33; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Trotter J, 2010, BRAIN RES REV, V63, P72, DOI 10.1016/j.brainresrev.2009.12.006; Wang W, 2008, J CLIN NEUROSCI, V15, P278, DOI 10.1016/j.jocn.2007.02.004; Wu D, 2005, J NEUROCYTOL, V34, P459, DOI 10.1007/s11068-006-8998-4; Wu JF, 2011, J NEUROSCI RES, V89, P628, DOI 10.1002/jnr.22598; Wu JF, 2011, NEUROTHERAPEUTICS, V8, P221, DOI 10.1007/s13311-011-0028-2; Wu JF, 2010, GLIA, V58, P410, DOI 10.1002/glia.20932; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	59	34	35	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	MAY 1	2012	11	9					1782	1795		10.4161/cc.20153			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	935OL	WOS:000303528500020	22510563	Green Published, Bronze			2022-02-06	
J	Zhang, YL; Chopp, M; Mahmood, A; Meng, YL; Qu, CS; Xiong, Y				Zhang, Yanlu; Chopp, Michael; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Xiong, Ye			Impact of inhibition of erythropoietin treatment-mediated neurogenesis in the dentate gyrus of the hippocampus on restoration of spatial learning after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Astrocytes; Erythropoietin; Microglia; Neurogenesis; Spatial learning; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; MARROW STROMAL CELLS; NEURAL STEM-CELLS; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; CA3 REGION; ADULT-RAT; ENHANCES NEUROGENESIS; STRIATAL NEUROGENESIS; COGNITIVE RECOVERY	Our previous study demonstrates that delayed (initiated 24 h post injury) erythropoietin (EPO) therapy for traumatic brain injury (TBI) significantly improves spatial learning. In this study, we investigated the impact of inhibition of EPO treatment-mediated neurogenesis on spatial learning after experimental TBI. Young male Wistar rats (318 +/- 7 g) were subjected to unilateral controlled cortical impact injury. TBI rats received delayed EPO treatment (5000 U/kg in saline) administered intraperitoneally once daily at 1,2, and 3 days post injury and intracerebroventricular (icy) infusion of either a mitotic inhibitor cytosine-b-D-arabinofuranoside or vehicle (saline) for 14 days. Another 2 groups of TBI rats were treated intraperitoneally with saline and infused icy with either a mitotic inhibitor Ara-C or saline for 14 days. Animals receiving sham operation were infused icy with either Ara-C infusion or saline. Bromodeoxyuridine (BrdU) was administered to label dividing cells. Spatial learning was assessed using a modified Morris water maze test. Animals were sacrificed at 35 days after injury and brain sections stained for immunohistochemical analyses. As compared to the saline treatment, immunohistochemical analysis revealed that delayed EPO treatment significantly increased the number of BrdU-positive cells and new neurons co-stained with BrdU and NeuN (mature neuron marker) in the dentate gyrus in TBI rats. EPO treatment improved spatial learning after TBI. Ara-C infusion significantly abolished neurogenesis and spatial learning recovery after TBI and EPO treatment. Both EPO and Ara-C reduced the number of astrocytes and microglia/macrophages in the dentate gyrus after TBI. Our findings are highly suggestive for an important role of EPO-amplified dentate gyrus neurogenesis as one of the mechanisms underlying EPO therapeutic treatments after TBI, strongly indicating that strategies promoting endogenous neurogenesis may hold an important therapeutic potential for treatment of TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Xiong, Ye] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Xiong, Y (corresponding author), Henry Ford Hosp, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS023393]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS62002, PO1 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, R01NS062002] Funding Source: NIH RePORTER	Sources of financial support: NINDS grants RO1 NS62002 (Ye Xiong) and PO1 NS023393 (Michael Chopp).; The authors would like to thank Susan MacPhee-Gray for editorial assistance. This work was supported by NIH grants RO1 NS62002 (yx) and PO1 NS023393 (mc).	Ambrogini P, 2004, BRAIN RES, V1017, P21, DOI 10.1016/j.brainres.2004.05.039; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Castilla-Ortega E, 2011, REV NEUROSCIENCE, V22, P267, DOI 10.1515/RNS.2011.027; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen H Isaac, 2007, Curr Stem Cell Res Ther, V2, P13; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Cotena S, 2008, PANMINERVA MED, V50, P185; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gage Fred H., 2010, Keio Journal of Medicine, V59, P79; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Im SH, 2010, NEUROSCIENCE, V169, P259, DOI 10.1016/j.neuroscience.2010.04.038; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Sandoval CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017689; Koros C, 2007, NEUROTOXICOLOGY, V28, P83, DOI 10.1016/j.neuro.2006.07.016; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Li B, 2010, BRAIN RES, V1327, P91, DOI 10.1016/j.brainres.2010.02.030; Li CQ, 2008, BRAIN RES BULL, V77, P237, DOI 10.1016/j.brainresbull.2008.07.010; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marin-Burgin A, 2012, BEHAV BRAIN RES, V227, P391, DOI 10.1016/j.bbr.2011.07.001; Marklund N., 2010, BRIT J PHARMACOL, V164, P1207; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Mongiat LA, 2011, EUR J NEUROSCI, V33, P1055, DOI 10.1111/j.1460-9568.2011.07603.x; Mongiat LA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005320; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Spiers HJ, 2007, NEUROSCIENCE, V149, P7, DOI 10.1016/j.neuroscience.2007.06.056; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Velly L, 2010, PHARMACOL THERAPEUT, V128, P445, DOI 10.1016/j.pharmthera.2010.08.002; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yau SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024263; Yoshikawa G, 2010, J NEUROSURG, V113, P835, DOI 10.3171/2010.2.JNS09989; Zhang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011016; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zheng W, 2011, J NEUROTRAUMA	71	34	36	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2012	235	1					336	344		10.1016/j.expneurol.2012.02.015			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	934FZ	WOS:000303430400035	22414310	Green Accepted			2022-02-06	
J	Vaccari, JPD; Minkiewicz, J; Wang, XL; Vaccari, JCD; German, R; Marcillo, AE; Dietrich, WD; Keane, RW				de Rivero Vaccari, Juan Pablo; Minkiewicz, Julia; Wang, Xiaoliang; De Rivero Vaccari, Juan Carlos; German, Ramon; Marcillo, Alex E.; Dietrich, W. Dalton; Keane, Robert W.			Astrogliosis involves activation of retinoic acid-inducible gene-like signaling in the innate immune response after spinal cord injury	GLIA			English	Article						innate immunity; neuroinflammation; spinal cord injury; astrocytes	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; REACTIVE ASTROCYTES; I INTERFERON; INFLAMMATION; CULTURE; ROLES; MICE; REGENERATION; PERSPECTIVE	Spinal cord injury (SCI) induces a glial response in which astrocytes become activated and produce inflammatory mediators. The molecular basis for regulation of glial-innate immune responses remains poorly understood. Here, we examined the activation of retinoic acid-inducible gene (RIG)-like receptors (RLRs) and their involvement in regulating inflammation after SCI. We show that astrocytes express two intracellular RLRs: RIG-I and melanoma differentiation-associated gene 5. SCI and stretch injury of cultured astrocytes stimulated RLR signaling as determined by phosphorylation of interferon regulatory factor 3 (IRF3) leading to production of type I interferons (IFNs). RLR signaling stimulation with synthetic ribonucleic acid resulted in RLR activation, phosphorylation of IRF3, and increased expression of glial fibrillary acidic protein (GFAP) and vimentin, two hallmarks of reactive astrocytes. Moreover, mitochondrial E3 ubiquitin protein ligase 1, an RLR inhibitor, decreased production of GFAP and vimentin after RIG-I signaling stimulation. Our findings identify a role for RLR signaling and type I IFN in regulating astrocyte innate immune responses after SCI. (C) 2011 Wiley Periodicals, Inc.	[de Rivero Vaccari, Juan Pablo; German, Ramon; Marcillo, Alex E.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Minkiewicz, Julia; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Wang, Xiaoliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [De Rivero Vaccari, Juan Carlos] Louisiana State Univ, Sch Med, New Orleans, LA USA		Vaccari, JPD (corresponding author), Lois Pope LIFE Ctr, Dept Neurol Surg, 1095 NW 14th Terrace,3-25JJ, Miami, FL 33136 USA.	JdeRivero@med.miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	Miami Project to Cure Paralysis; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS059836]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059836] Funding Source: NIH RePORTER	Grant sponsor: The Miami Project to Cure Paralysis; Grant sponsor: NIH grant to R. W. K.; Grant number: NS059836.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Auerbuch V, 2004, J EXP MED, V200, P527, DOI 10.1084/jem.20040976; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Delhaye S, 2006, P NATL ACAD SCI USA, V103, P7835, DOI 10.1073/pnas.0602460103; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Hamby ME, 2006, GLIA, V54, P566, DOI 10.1002/glia.20411; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Khorooshi R, 2010, J IMMUNOL, V185, P1258, DOI 10.4049/jimmunol.0901753; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Malathi K, 2007, NATURE, V448, P816, DOI 10.1038/nature06042; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Onoguchi K, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001012; Paul S, 2007, BIOCHIMIE, V89, P770, DOI 10.1016/j.biochi.2007.02.009; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Rainer TH, 2006, ANN NY ACAD SCI, V1075, P271, DOI 10.1196/annals.1368.035; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Seo YJ, 2010, ADV APPL MICROBIOL, V73, P83, DOI 10.1016/S0065-2164(10)73004-5; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x; TEDESCHI B, 1986, J CELL BIOL, V102, P2244, DOI 10.1083/jcb.102.6.2244; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilkins C, 2010, CURR OPIN IMMUNOL, V22, P41, DOI 10.1016/j.coi.2009.12.003; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N; Wu VW, 1998, J NEUROCHEM, V71, P749; Yoneyama M, 2008, IMMUNITY, V29, P178, DOI 10.1016/j.immuni.2008.07.009; Yoneyama M, 2007, NAT IMMUNOL, V8, P907, DOI 10.1038/ni0907-907; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200; Yu N, 2011, EXP DERMATOL, V20, P134, DOI 10.1111/j.1600-0625.2010.01208.x	40	34	34	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	2012	60	3					414	421		10.1002/glia.22275			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	880CE	WOS:000299381200008	22161971	Green Accepted			2022-02-06	
J	Novitski, J; Steele, S; Karantzoulis, S; Randolph, C				Novitski, Julia; Steele, Shelly; Karantzoulis, Stella; Randolph, Christopher			The Repeatable Battery for the Assessment of Neuropsychological Status Effort Scale	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Assessment; Test construction	STATUS EFFORT INDEX; ALZHEIMERS-DISEASE; GERIATRIC SAMPLE; STATUS RBANS; DIGIT SPAN; TESTS	The measurement of effort is now considered to be an important component of neuropsychological assessment. In addition to stand-alone measures, built-in, or embedded measures of effort have been derived for a limited number of standard neurocognitive tests. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a widely used brief battery, employed as a core diagnostic tool in dementia and as a neurocognitive screening battery or tracking/outcome measure in a variety of other disorders. An effort index (EI) for the RBANS has been published previously (Silverberg, N. D., Wertheimer, J. C., Fichtenberg, N. L. 2007. An EI for the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Clinical Neuropsychology, 21 (5), 841854), but it has been reported to result in high false positive rates when applied to patients with true amnesia (e.g., Alzheimers disease). We created a new effort scale (ES) for the RBANS based on the observation of patterns of free recall and recognition performance in amnesia versus inadequate effort. The RBANS ES was validated on a sample of patients with amnestic disorders and a sample of mild traumatic brain injury participants who failed a separate measure of effort. The sensitivity and specificity of the new ES was compared with the previously published EI. Receiver-operating characteristic analyses demonstrated much better sensitivity and specificity of the ES, with a marked reduction in false positive errors. Application and limitations of the RBANS ES, including indications for its use, are discussed.	[Novitski, Julia; Steele, Shelly; Randolph, Christopher] Chicago Neuropsychol Serv, Chicago, IL 60611 USA; [Novitski, Julia] Rosalind Franklin Univ Med & Sci, Dept Psychol, N Chicago, IL USA; [Karantzoulis, Stella] NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA		Randolph, C (corresponding author), Chicago Neuropsychol Serv, 1 E Erie,Suite 353, Chicago, IL 60611 USA.	crandol@lumc.edu					Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Barker MD, 2010, CLIN NEUROPSYCHOL, V24, P1064, DOI 10.1080/13854046.2010.486009; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis DC, 1987, CALIFORNIA VERBAL LE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Green P., 2003, GREENS WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Green P.J.E., 2008, MANUAL NONVERBAL MED; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; HODGES JR, 1993, NEUROPSYCHOLOGIA, V31, P775, DOI 10.1016/0028-3932(93)90128-M; Hook JN, 2009, ARCH CLIN NEUROPSYCH, V24, P231, DOI 10.1093/arclin/acp026; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Randolph C., 1998, REPEATABLE BATTERY A; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WECHSLER MEMORY SCAL; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016; WELSH KA, 1992, ARCH NEUROL-CHICAGO, V49, P448, DOI 10.1001/archneur.1992.00530290030008; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	24	34	34	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2012	27	2					190	195		10.1093/arclin/acr119			6	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	895HL	WOS:000300486900008	22277124	Bronze			2022-02-06	
J	Tang, CY; Eaves, E; Dams-O'Connor, K; Ho, L; Leung, E; Wong, E; Carpenter, D; Ng, J; Gordon, W; Pasinetti, G				Tang, Cheuk Ying; Eaves, Emily; Dams-O'Connor, Kristen; Ho, Lap; Leung, Eric; Wong, Edmund; Carpenter, David; Ng, Johnny; Gordon, Wayne; Pasinetti, Giulio			DIFFUSE DISCONNECTIVITY IN TBI: A RESTING STATE FMRI AND DTI STUDY	TRANSLATIONAL NEUROSCIENCE			English	Article						Traumatic Brain Injury (TBI); Functional magnetic resonance imaging (fMRI); DTI; Cognitive Function	TRAUMATIC BRAIN-INJURY; DEFAULT-MODE NETWORK; LATE-LIFE DEPRESSION; AXONAL INJURY; WORKING-MEMORY; FUNCTIONAL CONNECTIVITY; ALZHEIMERS-DISEASE; MRI; TASK; ABNORMALITIES	Diffuse axonal injury is a common pathological consequence of Traumatic Brain Injury (TBI). Diffusion Tensor Imaging is an ideal technique to study white matter integrity using the Fractional Anisotropy (FA) index which is a measure of axonal integrity and coherence. There have been several reports showing reduced FA in individuals with TBI, which suggest demyelination or reduced fiber density in white matter tracts secondary to injury. Individuals with TBI are usually diagnosed with cognitive deficits such as reduced attention span, memory and executive function. In this study we sought to investigate correlations between brain functional networks, white matter integrity, and TBI severity in individuals with TBI ranging from mild to severe. A resting state functional magnetic resonance imaging protocol was used to study the default mode network in subjects at rest. FA values were decreased throughout all white matter tracts in the mild to severe TBI subjects. FA values were also negatively correlated with TBI injury severity ratings. The default mode network showed several brain regions in which connectivity measures were higher among individuals with TBI relative to control subjects. These findings suggest that, subsequent to TBI, the brain may undergo adaptation responses at the cellular level to compensate for functional impairment due to axonal injury.	[Tang, Cheuk Ying; Eaves, Emily; Leung, Eric; Wong, Edmund; Carpenter, David; Ng, Johnny] Mt Sinai Sch Med, Dept Radiol, New York, NY 10029 USA; [Tang, Cheuk Ying; Pasinetti, Giulio] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Pasinetti, Giulio] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Pasinetti, Giulio] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA		Tang, CY (corresponding author), Mt Sinai Sch Med, Dept Radiol, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Pasinetti, Giulio/0000-0002-1524-5196	National Center for Research Resources (NCRR), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG029310] Funding Source: NIH RePORTER	The study was supported by discretionary funding to GMP and Grant Number #UL1RR029887, National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The authors would also like to thank the Image Analysis Core of the Mount Sinai Translational and Molecular Imaging Institute.	Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Cherkassky VL, 2006, NEUROREPORT, V17, P1687, DOI 10.1097/01.wnr.0000239956.45448.4c; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Damoiseaux JS, 2011, NEUROBIOL AGING; Davis SW, 2008, CEREB CORTEX, V18, P1201, DOI 10.1093/cercor/bhm155; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HAIER RJ, 1992, BRAIN RES, V570, P134, DOI 10.1016/0006-8993(92)90573-R; Haler R. J., 1993, BIOL APPROACHES STUD, P317; Herrmann LL, 2008, J NEUROL NEUROSUR PS, V79, P619, DOI 10.1136/jnnp.2007.124651; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Liang M, 2006, NEUROREPORT, V17, P209, DOI 10.1097/01.wnr.0000198434.06518.b8; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Qi ZG, 2010, NEUROIMAGE, V50, P48, DOI 10.1016/j.neuroimage.2009.12.025; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sorg C, 2007, P NATL ACAD SCI USA, V104, P18760, DOI 10.1073/pnas.0708803104; Tang CY, 2010, INTELLIGENCE, V38, P293, DOI 10.1016/j.intell.2010.03.003; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	38	34	36	1	17	VERSITA	WARSAW	SOLIPSKA 14A-1, 02-482 WARSAW, POLAND	2081-3856			TRANSL NEUROSCI	Transl. Neurosci.	MAR	2012	3	1					9	14		10.2478/s13380-012-0003-3			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951CN	WOS:000304698400002	23459252	Green Accepted			2022-02-06	
J	Timaru-Kast, R; Wyschkon, S; Luh, C; Schaible, EV; Lehmann, F; Merk, P; Werner, C; Engelhard, K; Thal, SC				Timaru-Kast, Ralph; Wyschkon, Sebastian; Luh, Clara; Schaible, Eva-Verena; Lehmann, Florian; Merk, Philipp; Werner, Christian; Engelhard, Kristin; Thal, Serge C.			Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma	CRITICAL CARE MEDICINE			English	Article						angiotensin; angiotensin II receptor type 1; AT1; AT1 inhibition; brain trauma; controlled cortical impact; mice; renin-angiotensin system; traumatic brain injury	POSSIBLE THERAPEUTIC IMPLICATIONS; SPONTANEOUSLY HYPERTENSIVE-RATS; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; AUTOIMMUNE INFLAMMATION; EDEMA FORMATION; AT(1) RECEPTOR; MESSENGER-RNA; CNS INJURY; AT1	Objective: To investigate the regulation of the cerebral renin angiotensin system and the effect of angiotensin II receptor type 1 inhibition on secondary brain damage, cerebral inflammation, and neurologic outcome after head trauma. Design: The expression of renin angiotensin system components was determined at 15 mins, 3 hrs, 6 hrs, 12 hrs, and 24 hrs after controlled cortical impact in mice. Angiotensin II receptor type 1 was inhibited using candesartan (0.1, 0.5, 1 mg/kg) after trauma to determine its effect on secondary brain damage, brain edema formation, and inflammation. The window of opportunity was tested by delaying angiotensin II receptor type 1 inhibition for 30 mins, 1 hr, 2 hrs, and 4 hrs. The long-term effect was tested by single and daily repeated treatment with candesartan for 5 days after controlled cortical impact. Setting: University research laboratory. Subjects: Male C57BI/6N mice. Interventions: Brain trauma by use of a controlled cortical impact device. Measurements and Main Results: Expression of angiotensin II receptor type 1A decreased by 42% within 24 hrs after controlled cortical impact, whereas angiotensin II receptor type 1B expression increased to 220% between 6 and 12 hrs. Blockage of angiotensin II receptor type 1with 0.1 mg/kg candesartan within 4 hrs of injury significantly reduced secondary brain damage (30 mins: 25 mm(3) vs. vehicle: 41 mm(3)) and improved neurologic function after 24 hrs but failed to reduce brain edema formation. Daily treatment with candesartan afforded sustained reduction of brain damage and improved neurologic function 5 days after traumatic brain injury compared with single and vehicle treatment. Inhibition of angiotensin II receptor type 1 significantly attenuated posttraumatic inflammation (interleukin-6: -56%; interleukin-1 beta: -42%; inducible nitric oxide synthase: -36%; tumor necrosis factor-alpha: -35%) and microglia activation (vehicle: 163 +/- 25/mm(2) vs. candesartan: 118 +/- 13/mm(2)). Higher dosages (0.5 and 1 mg/kg) resulted in prolonged reduction in blood pressure and failed to reduce brain lesion. Conclusions: The results indicate that angiotensin II receptor type 1 plays a key role in the development of secondary brain damage after brain trauma. Inhibition of angiotensin II receptor type 1 with a delay of up to 4 hrs after traumatic brain injury effectively reduces lesion volume. This reduction makes angiotensin II receptor type 1 a promising therapeutic target for reducing cerebral inflammation and limiting secondary brain damage. (Crit Care Med 2012; 40:935-944)	[Timaru-Kast, Ralph; Wyschkon, Sebastian; Luh, Clara; Schaible, Eva-Verena; Lehmann, Florian; Merk, Philipp; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany		Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Wyschkon, Sebastian/0000-0001-9434-3343	Johannes Gutenberg-University	This work was financially supported by departmental funding and by the Focus Program Translational Neurosciences (FIN) of the Johannes Gutenberg-University.	AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Baranov D, 2003, ANESTHESIOLOGY, V99, P1118, DOI 10.1097/00000542-200311000-00018; Benicky J, 2009, CELL MOL NEUROBIOL, V29, P781, DOI 10.1007/s10571-009-9368-4; Brdon J, 2007, J HYPERTENS, V25, P187, DOI 10.1097/01.hjh.0000254376.80864.d3; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Crowley SD, 2010, HYPERTENSION, V55, P99, DOI 10.1161/HYPERTENSIONAHA.109.144964; Culman J, 2002, J HUM HYPERTENS, V16, pS64, DOI 10.1038/sj.jhh.1001442; Culman J, 2001, J RENIN-ANGIO-ALDO S, V2, P96, DOI 10.3317/jraas.2001.019; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Groth W, 2003, J HYPERTENS, V21, P2175, DOI 10.1097/00004872-200311000-00028; Inagami T, 1995, Curr Opin Nephrol Hypertens, V4, P47, DOI 10.1097/00041552-199501000-00007; Johren O, 1995, NEUROREPORT, V6, P2549; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104, DOI 10.1152/ajpendo.1996.271.1.E104; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Kagiyama T, 2003, REGUL PEPTIDES, V110, P241, DOI 10.1016/S0167-0115(02)00223-9; Katayama Y, 1998, ACT NEUR S, V71, P289; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenkei Z, 1997, FRONT NEUROENDOCRIN, V18, P383, DOI 10.1006/frne.1997.0155; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li J, 2005, FASEB J, V19, P617, DOI 10.1096/fj.04-2960fje; Li JM, 2008, STROKE, V39, P2029, DOI 10.1161/STROKEAHA.107.503458; Luhder F, 2009, J NEUROIMMUNOL, V217, P1, DOI 10.1016/j.jneuroim.2009.08.008; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Makino I, 1996, NEUROPEPTIDES, V30, P596, DOI 10.1016/S0143-4179(96)90043-8; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; Mogi M, 2006, HYPERTENSION, V48, P141, DOI 10.1161/01.HYP.0000229648.67883.f9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Oparil S, 2000, AM J HYPERTENS, V13, p18S, DOI 10.1016/S0895-7061(99)00250-2; Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005; Pelisch N, 2011, AM J HYPERTENS, V24, P362, DOI 10.1038/ajh.2010.241; Pelisch N, 2010, HYPERTENS RES, V33, P161, DOI 10.1038/hr.2009.200; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Saad MAA, 2010, ACTA PHYSIOL HUNG, V97, P159, DOI 10.1556/APhysiol.97.2010.2.2; Saavedra JM, 2004, ANN NY ACAD SCI, V1018, P76, DOI 10.1196/annals.1296.009; Saavedra JM, 2005, CELL MOL NEUROBIOL, V25, P485, DOI 10.1007/s10571-005-4011-5; Saavedra JM, 2007, STRESS, V10, P185, DOI 10.1080/10253890701350735; Saavedra JM, 2006, J HYPERTENS, V24, pS131, DOI 10.1097/01.hjh.0000220418.09021.ee; Saavedra JM, 2006, CELL MOL NEUROBIOL, V26, P1099, DOI 10.1007/s10571-006-9009-0; Speth RC, 2008, N-S ARCH PHARMACOL, V377, P283, DOI 10.1007/s00210-007-0238-7; Stegbauer J, 2009, P NATL ACAD SCI USA, V106, P14942, DOI 10.1073/pnas.0903602106; Takemori K, 2000, AM J HYPERTENS, V13, P1233, DOI 10.1016/S0895-7061(00)01202-4; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; TIMMERMANS PBMWM, 1993, J HUM HYPERTENS, V7, pS19; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; Unger T, 2003, CURR MED RES OPIN, V19, P449, DOI 10.1185/030079903125001974; Unger T, 1996, J HYPERTENS, V14, pS95; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P320, DOI 10.1007/BF00395288; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	61	34	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2012	40	3					935	944		10.1097/CCM.0b013e31822f08b9			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895YO	WOS:000300532800030	21926585				2022-02-06	
J	Zhu, F; Wagner, C; Leonardi, AD; Jin, X; VandeVord, P; Chou, C; Yang, KH; King, AI				Zhu, Feng; Wagner, Christina; Leonardi, Alessandra Dal Cengio; Jin, Xin; VandeVord, Pamela; Chou, Clifford; Yang, King H.; King, Albert I.			Using a gel/plastic surrogate to study the biomechanical response of the head under air shock loading: a combined experimental and numerical investigation	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Blast loading; Biomechanical response; Shock tube; Fluid/solid coupling; ALE method	TRAUMATIC BRAIN-INJURY; BLAST; PRESSURE; EXPOSURE; MODEL	A combined experimental and numerical study was conducted to determine a method to elucidate the biomechanical response of a head surrogate physical model under air shock loading. In the physical experiments, a gel-filled egg-shaped skull/brain surrogate was exposed to blast overpressure in a shock tube environment, and static pressures within the shock tube and the surrogate were recorded throughout the event. A numerical model of the shock tube was developed using the Eulerian approach and validated against experimental data. An arbitrary Lagrangian-Eulerian (ALE) fluid-structure coupling algorithm was then utilized to simulate the interaction of the shock wave and the head surrogate. After model validation, a comprehensive series of parametric studies was carried out on the egg-shaped surrogate FE model to assess the effect of several key factors, such as the elastic modulus of the shell, bulk modulus of the core, head orientation, and internal sensor location, on pressure and strain responses. Results indicate that increasing the elastic modulus of the shell within the range simulated in this study led to considerable rise of the overpressures. Varying the bulk modulus of the core from 0.5 to 2.0 GPa, the overpressure had an increase of 7.2%. The curvature of the surface facing the shock wave significantly affected both the peak positive and negative pressures. Simulations of the head surrogate with the blunt end facing the advancing shock front had a higher pressure compared to the simulations with the pointed end facing the shock front. The influence of an opening (possibly mimicking anatomical apertures) on the peak pressures was evaluated using a surrogate head with a hole on the shell of the blunt end. It was revealed that the presence of the opening had little influence on the positive pressures but could affect the negative pressure evidently.	[Zhu, Feng; Wagner, Christina; Leonardi, Alessandra Dal Cengio; Jin, Xin; VandeVord, Pamela; Chou, Clifford; Yang, King H.; King, Albert I.] Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA		Zhu, F (corresponding author), Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA.	fengzhume@gmail.com	Jin, Xin/J-6476-2015	Chou, Clifford/0000-0002-9127-1660	Small Business Innovation Research (SBIR)United States Department of Agriculture (USDA) [W81XWH-09-C-0068]; Bioengineering Center, Wayne State University	This research was partially supported through Small Business Innovation Research (SBIR) Contract # W81XWH-09-C-0068, and partially supported by the Bioengineering Center, Wayne State University. The financial supports are gratefully acknowledged.	[Anonymous], 2007, LS DYNA KEYW US MAN; Anzelius A, 1943, ACTA PATH MICROBIO S, V48, P153; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bowen IG, 1968, 2133 LOV FDN DEF AT; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; Brands DWA, 1999, 43 STAPP CAR CRASH C, P350; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chafi MS, 2008, PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION 2007, VOL 2, P211; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CONWEP, 1991, CONV WEAP EFF PROGR; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Cullis I G, 2001, J R Army Med Corps, V147, P16; Dal Cengio Leonardi A, 2009, 2 JOINT S INT NATL N; DePalma RG, 2005, NEW ENGL J MED, V37, P664; Gaetani P, 2008, J FLUID MECH, V602, P267, DOI 10.1017/S0022112008000815; Hallquist JO., 1998, LS DYNA THEORETICAL; Ivarsson J, 2002, J BIOMECH ENG-T ASME, V124, P422, DOI 10.1115/1.1485752; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Long J. B., 2009, J NEUROTRAUM, V26, P1; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Meyers MA., 1994, DYNAMIC BEHAV MAT, V2nd ed.; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss W.C., 2009, J ACOUST SOC AM, V125, P2650; Parnaik Yednesh, 2004, Stapp Car Crash J, V48, P259; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Sotudehchafi M, 2007, PROCEEDING OF THE ASME SUMMER BIOENGINEERING CONFERENCE - 2007, P349; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Teland, 2010, J ACOUST SOC AM, V127, P1790; Teland, 2010, POMA, V9; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Zhang JY, 2007, J BIOMECH, V40, P2341, DOI 10.1016/j.jbiomech.2006.10.021; Zhang Jiangyue, 2009, Biomed Sci Instrum, V45, P119; Zhang Jiangyue, 2008, Biomed Sci Instrum, V44, P129; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu F, 2009, STRUCT ENG MECH, V32, P351, DOI 10.12989/sem.2009.32.2.351	40	34	34	1	16	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	MAR	2012	11	3-4					341	353		10.1007/s10237-011-0314-2			13	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	895SZ	WOS:000300518000005	21590345				2022-02-06	
J	Dawish, H; Mahmood, A; Schallert, T; Chopp, M; Therrien, B				Dawish, Hala; Mahmood, Asim; Schallert, Timothy; Chopp, Michael; Therrien, Barbara			Mild traumatic brain injury (MTBI) leads to spatial learning deficits	BRAIN INJURY			English	Article						Hippocampus; synaptophysin; Morris water maze	CONTROLLED CORTICAL IMPACT; HEAD-INJURY; WORKING-MEMORY; AXONAL INJURY; TERM-MEMORY; RATS; HIPPOCAMPUS; ACQUISITION; CONSEQUENCES; ATORVASTATIN	Primary objective: The aim of this study was to investigate the effect of mild and severe TBI on young male Wistar rats' spatial learning. Research design: Randomized repeated measure experimental design was used to examine spatial learning in three independent animal groups. Methods and procedures: Twenty-four (severe n = 9, mild n = 8, sham n = 7) male rats were included in the study. Animals received controlled mild (1.5 mm), severe (2.5 mm) cortical impact injury or sham surgery. Spatial learning was assessed daily using a modified Morris water maze test, 20 days post-trauma, for 5 consecutive days. Percentage time travelled within each quadrant and escape latency were calculated. All animals' hippocampal brain regions were examined post-injury using neuron (MAP2) and pre-synaptic protein (Synaptophysin) biomarkers. Main outcomes and results: It took the animals with mild injury until day 3 to reach the platform; and animals with mild and severe injury spent significantly less time in the target quadrant than the sham. The hippocampal neuron numbers differed proportionately between animals with severe and mild injury, but the percentage of synaptophysin density was significantly less in the dentate gyrus of both animals with mild and severe injury than sham group. Conclusion: Persistent spatial learning deficits exist after mild TBI; these deficits appear equivalent to deficits exhibited after a more severe injury.	[Dawish, Hala] Amer Univ Beirut, Fac Med, Sch Nursing, New York, NY 10017 USA; [Mahmood, Asim; Chopp, Michael] Henry Ford Hlth Syst, Detroit, MI USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Therrien, Barbara] Univ Michigan, Med Surg Nursing Dept, Ann Arbor, MI 48109 USA		Dawish, H (corresponding author), Amer Univ Beirut, Fac Med, Sch Nursing, 3 Dag Hammerskjold Plaza,8th Floor, New York, NY 10017 USA.	hd30@aub.edu.lb		Darwish, Hala/0000-0001-5744-6466	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 NS042345, RO1 NS04225905, RO1 NS 05228001, T32 NR 007074, F31 NR009741]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS04225905, P01 NS042345, R01 NS 05228001] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32 NR007074, T32 NR 007074, F31 NR009741] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007074, F31NR009741] Funding Source: NIH RePORTER	This work was conducted at Henry Ford Hospital and funded from the National Institutes of Health P01 NS042345, RO1 NS04225905, RO1 NS 05228001, T32 NR 007074 and F31 NR009741. The authors report no conflicts of interest.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aubry M, 2002, BRIT J SPORT MED, V36, P888; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bonanomi D, 2007, BIOCHEM J, V404, P525, DOI 10.1042/BJ20061907; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chin-Cheng Y, 2007, J TRAUMA, V62, P657; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Clark RE, 2005, HIPPOCAMPUS, V15, P260, DOI 10.1002/hipo.20056; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hartley T, 2007, HIPPOCAMPUS, V17, P34, DOI 10.1002/hipo.20240; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lee I, 2003, BEHAV NEUROSCI, V117, P1044, DOI 10.1037/0735-7044.117.5.1044; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Ludin A, 2006, BRAIN INJURY, V20, P799; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Martin SJ, 2007, CELL MOL LIFE SCI, V64, P401, DOI 10.1007/s00018-007-6336-3; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Ramirez-Amaya V, 2001, J NEUROSCI, V21, P7340; Rekart JL, 2007, LEARN MEMORY, V14, P416, DOI 10.1101/lm.516507; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shrager Y, 2007, P NATL ACAD SCI USA, V104, P2961, DOI 10.1073/pnas.0611233104; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Swanson KL, 1999, LITTER LINGERIE ILL, P13; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Umile EM, 1998, BRAIN INJURY, V12, P577; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Whiting MD, 2006, J NEUROTRAUM, V23, P1529, DOI 10.1089/neu.2006.23.1529; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247	48	34	34	1	6	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2012	26	2					151	165		10.3109/02699052.2011.635362			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200004	22360521	Green Accepted			2022-02-06	
J	Torres-Chavez, KE; Sanfins, JM; Clemente-Napimoga, JT; Pelegrini-Da-Silva, A; Parada, CA; Fischer, L; Tambeli, CH				Torres-Chavez, K. E.; Sanfins, J. M.; Clemente-Napimoga, J. T.; Pelegrini-Da-Silva, A.; Parada, C. A.; Fischer, L.; Tambeli, C. H.			Effect of gonadal steroid hormones on formalin-induced temporomandibular joint inflammation	EUROPEAN JOURNAL OF PAIN			English	Article							TRAUMATIC BRAIN-INJURY; ADJUVANT-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; FEMALE RATS; SPINOMEDULLARY JUNCTION; REPLACEMENT THERAPY; TESTOSTERONE REPLACEMENT; OVARIECTOMIZED RATS; OPIOID RECEPTORS; MUSCLE-ACTIVITY	We have recently demonstrated that gonadal steroid hormones decrease formalin-induced temporomandibular joint nociception in rats. Given that the attenuation of inflammation is a potential mechanism underlying this antinociceptive effect, we evaluated the effect of gonadal steroid hormones on formalin-induced temporomandibular joint inflammation. Plasma extravasation, a major sign of acute inflammation, and neutrophil migration, an important event related to tissue injury, were evaluated. Formalin induced significantly lower temporomandibular joint plasma extravasation and neutrophil migration in proestrus females than in males and in diestrus females. Since estradiol serum level is high in proestrus females and low in diestrus females and in males, these findings suggest that the high physiological level of estradiol decreases temporomandibular joint inflammation. Estradiol but not progesterone administration in ovariectomized females significantly decreased formalin-induced plasma extravasation and neutrophil migration, an effect that was blocked by the estrogen receptor antagonist ICI 182780. Plasma extravasation and neutrophil migration were not affected by orchiectomy, but testosterone or estradiol administration in orchidectomized males significantly decreased them. The androgen receptor antagonist flutamide blocked the anti-inflammatory effect of testosterone while ICI 182780 blocked that of estradiol in males. Previous intravenous administration of a nonspecific selectin inhibitor significantly decreased formalin-induced temporomandibular joint nociception and neutrophil migration in males, revealing a potent and positive correlation between temporomandibular joint nociception and inflammation. Taken together, these findings demonstrate a pronounced anti-inflammatory effect of estradiol and testosterone in the temporomandibular joint region and suggest that this effect may mediate, at least in part, the antinociceptive effect of these hormones.	[Torres-Chavez, K. E.; Sanfins, J. M.; Clemente-Napimoga, J. T.; Pelegrini-Da-Silva, A.; Tambeli, C. H.] State Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Physiol, Sao Paulo, Brazil; [Parada, C. A.; Tambeli, C. H.] State Univ Campinas UNICAMP, Inst Biol, Dept Anat Cell Biol & Physiol & Biophys, Sao Paulo, Brazil; [Fischer, L.] Univ Fed Parana, Dept Physiol, Div Biol Sci, BR-80060000 Curitiba, Parana, Brazil		Tambeli, CH (corresponding author), State Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Physiol, Sao Paulo, Brazil.	tambeli@fop.unicamp.br	Clemente-Napimoga, Juliana T/E-5163-2013; Tambeli, Claudia/AAQ-4409-2021; Parada, Carlos Amilcar/C-3974-2012	Clemente-Napimoga, Juliana T/0000-0003-1068-3039; 	CAPES (Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo), BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)	We thank our colleagues, Nadia Cristina Favaro Moreira and Maria Claudia Goncalves de Oliveira for their help with experimental procedures and Carlos Alberto Feliciano for technical assistance. This work was supported by CAPES (Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) and FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo), Brazil.	Arthuri MT, 2005, LIFE SCI, V76, P1177, DOI 10.1016/j.lfs.2004.10.019; Badger AM, 1999, J PHARMACOL EXP THER, V291, P1380; Bereiter DA, 2006, PAIN, V126, P175, DOI 10.1016/j.pain.2006.06.030; Bereiter DA, 2001, CELLS TISSUES ORGANS, V169, P226, DOI 10.1159/000047886; Boers M, 2001, ARTHRITIS RHEUM, V44, P2242, DOI 10.1002/1529-0131(200110)44:10<2242::AID-ART386>3.0.CO;2-F; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Cairns BE, 2002, BRAIN RES, V957, P338, DOI 10.1016/S0006-8993(02)03671-5; Campos M, 2003, EUR J PHARMACOL, V471, P149, DOI 10.1016/S0014-2999(03)01822-3; Carlsson G, 1995, EPIDEMIOLOGY TEMPORO, P211; Chaban VV, 2005, J NEUROSCI RES, V81, P31, DOI 10.1002/jnr.20524; Clemente JT, 2004, NEUROSCI LETT, V372, P250, DOI 10.1016/j.neulet.2004.09.048; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; D'Elia HF, 2003, J RHEUMATOL, V30, P1456; DASILVA JAP, 1993, ANN RHEUM DIS, V52, P285, DOI 10.1136/ard.52.4.285; Dong XD, 2007, NEUROSCIENCE, V146, P822, DOI 10.1016/j.neuroscience.2007.01.051; Favaro-Moreira NC, 2009, NEUROSCIENCE, V164, P724, DOI 10.1016/j.neuroscience.2009.08.012; Fiorentino PM, 1999, ARCH ORAL BIOL, V44, P27, DOI 10.1016/S0003-9969(98)00095-8; Fischer L, 2008, J PAIN, V9, P630, DOI 10.1016/j.jpain.2008.02.006; Fischer L, 2007, J PAIN, V8, P437, DOI 10.1016/j.jpain.2006.12.007; Fischer L, 2009, BEHAV NEUROSCI, V123, P1129, DOI 10.1037/a0017063; Flake NM, 2006, AM J PHYSIOL-REG I, V291, pR343, DOI 10.1152/ajpregu.00835.2005; Flake NM, 2005, J NEUROPHYSIOL, V93, P1585, DOI 10.1152/jn.00269.2004; GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787; Gordon FT, 1996, HORM BEHAV, V30, P244, DOI 10.1006/hbeh.1996.0029; Green PG, 1999, J NEUROSCI, V19, P4082; Guan GQ, 2005, J STEROID BIOCHEM, V97, P241, DOI 10.1016/j.jsbmb.2005.05.013; HAAS DA, 1992, ARCH ORAL BIOL, V37, P417, DOI 10.1016/0003-9969(92)90026-5; HALL GM, 1994, ANN RHEUM DIS, V53, P112, DOI 10.1136/ard.53.2.112; HANDA RJ, 1994, HORM BEHAV, V28, P464, DOI 10.1006/hbeh.1994.1044; Harbuz MS, 1995, BRIT J RHEUMATOL, V34, P1117; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Ishizuka M, 2004, CLIN SCI, V106, P293, DOI 10.1042/CS20030317; Iwata K, 1999, J NEUROPHYSIOL, V82, P1244, DOI 10.1152/jn.1999.82.3.1244; JANSSON L, 1994, J NEUROIMMUNOL, V53, P203, DOI 10.1016/0165-5728(94)90030-2; Jochems C, 2007, ARTHRITIS RHEUM-US, V56, P3261, DOI 10.1002/art.22873; Kang IH, 2004, TOXICOLOGY, V199, P145, DOI 10.1016/j.tox.2004.02.019; Keith JC, 2005, ARTHRITIS RES THER, V7, pR427, DOI 10.1186/ar1692; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLEBANOFF SJ, 1991, PEROXIDASES CHEM BIO, P1; Kramer PR, 2004, ARTHRITIS RHEUM, V50, P1967, DOI 10.1002/art.20309; Lamote I, 2004, J DAIRY SCI, V87, P3340, DOI 10.3168/jds.S0022-0302(04)73470-0; Lee DY, 2002, LIFE SCI, V70, P2047, DOI 10.1016/S0024-3205(01)01534-X; LeResche L, 2005, J OROFAC PAIN, V19, P193; LeResche L, 2003, PAIN, V106, P253, DOI 10.1016/j.pain.2003.06.001; MACDONALD AG, 1994, ANN RHEUM DIS, V53, P54, DOI 10.1136/ard.53.1.54; Malkin CJ, 2004, J CLIN ENDOCR METAB, V89, P3313, DOI 10.1210/jc.2003-031069; Murphy AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005539; Nozawa-Inoue K, 2003, ARCH HISTOL CYTOL, V66, P289, DOI 10.1679/aohc.66.289; Okamoto K, 2003, J NEUROPHYSIOL, V89, P1467, DOI 10.1152/jn.00795.2002; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roveroni RC, 2001, PAIN, V94, P185, DOI 10.1016/S0304-3959(01)00357-8; RYAN GB, 1977, AM J PATHOL, V86, P183; Tashiro A, 2007, J NEUROPHYSIOL, V98, P3242, DOI 10.1152/jn.00677.2007; Tashiro A, 2009, NEUROSCIENCE, V164, P1805, DOI 10.1016/j.neuroscience.2009.09.067; Tashiro A, 2009, NEUROSCIENCE, V164, P1813, DOI 10.1016/j.neuroscience.2009.09.058; Tiidus PM, 2001, CAN J PHYSIOL PHARM, V79, P400, DOI 10.1139/cjpp-79-5-400; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Weinstock M, 1998, INT J DEV NEUROSCI, V16, P289, DOI 10.1016/S0736-5748(98)00021-5; Wu YW, 2010, J NEUROSCI, V30, P8710, DOI 10.1523/JNEUROSCI.6323-09.2010; Xing DQ, 2007, AM J PHYSIOL-HEART C, V292, pH2607, DOI 10.1152/ajpheart.01107.2006; YU XM, 1995, PAIN, V60, P143, DOI 10.1016/0304-3959(94)00104-M; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	64	34	35	0	4	WILEY PERIODICALS, INC	SAN FRANCISCO	ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA	1090-3801			EUR J PAIN	Eur. J. Pain	FEB	2012	16	2					204	216		10.1016/j.ejpain.2011.06.007			13	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	980NU	WOS:000306900900006	22323373	Bronze			2022-02-06	
J	Lei, ZG; Deng, P; Li, JQ; Xu, ZC				Lei, Zhigang; Deng, Ping; Li, Jinqing; Xu, Zao C.			Alterations of A-Type Potassium Channels in Hippocampal Neurons after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; hyperexcitability; I-A; Kv4.2; Kv4.3; post-traumatic epilepsy	TEMPORAL-LOBE EPILEPSY; CA1 PYRAMIDAL NEURONS; KV4.2 KNOCKOUT MICE; CLOSED-HEAD INJURY; K+ CHANNELS; POSTTRAUMATIC EPILEPSY; RAT-BRAIN; DIFFERENTIAL EXPRESSION; SUBTHRESHOLD POTENTIALS; HYPEREXCITABILITY	Traumatic brain injury (TBI) is associated with cognitive deficits, memory impairment, and epilepsy. Previous studies have reported neuronal loss and neuronal hyperexcitability in the post-traumatic hippocampus. A-type K+ currents (I-A) play a critical role in modulating the intrinsic membrane excitability of hippocampal neurons. The disruption of I-A is reportedly linked to hippocampal dysfunction. The present study investigates the changes of I-A in the hippocampus after TBI. TBI in rats was induced by controlled cortical impact. The impact induced a reproducible lesion in the cortex and an obvious neuronal death in the ipsilateral hippocampus CA3 region. At one week after TBI, immunohiistochemical staining and Western blotting showed that the expression of I-A channel subunit Kv4.2 was markedly decreased in the ipsilateral hippocampus, but remained unchanged in the contralateral hippocampus. Meanwhile, electrophysiological recording showed that I-A currents in ipsilateral CA1 pyramidal neurons were significantly reduced, which was associated with an increased neuronal excitability. Furthermore, there was an increased sensitivity to bicuculline-induced seizures in TBI rats. At 8 weeks after TBI, immunohistochemical staining and electrophysiological recording indicated that I-A returned to control levels. These findings suggest that TBI causes a transient downregulation of I-A in hippocampal CA1 neurons, which might be associated with the hyperexcitability in the post-traumatic hippocampus, and in turn leads to seizures and epilepsy.	[Lei, Zhigang; Deng, Ping; Li, Jinqing; Xu, Zao C.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA		Xu, ZC (corresponding author), Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS507, Indianapolis, IN 46202 USA.	zcxu@iupui.edu			National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS071238]; American Heart Association (AHA)American Heart Association [10GRNT4500000]; Indiana Spinal Cord and Brain Injury Research Fund [ISDH/A70-0-079212]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U24NS050606]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U24NS050606, R21NS071238] Funding Source: NIH RePORTER	This work was supported by grants from National Institute of Neurological Disorders and Stroke (NINDS) NS071238, American Heart Association (AHA) 10GRNT4500000, and Indiana Spinal Cord and Brain Injury Research Fund ISDH/A70-0-079212.; The monoclonal antibody Kv4.3 was obtained from the University of California, Davis/National Institutes of Health (NTH) NeuroMab,Facility, supported by NIH grant U24NS050606 and maintained by the Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, CA 95616.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Andrasfalvy BK, 2008, J PHYSIOL-LONDON, V586, P3881, DOI 10.1113/jphysiol.2008.154336; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barnwell LFS, 2009, EPILEPSIA, V50, P1741, DOI 10.1111/j.1528-1167.2009.02086.x; Bernard C, 2004, SCIENCE, V305, P532, DOI 10.1126/science.1097065; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cai X, 2004, NEURON, V44, P351, DOI 10.1016/j.neuron.2004.09.026; Chen XX, 2006, J NEUROSCI, V26, P12143, DOI 10.1523/JNEUROSCI.2667-06.2006; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Deng P, 2004, DEV BRAIN RES, V153, P97, DOI 10.1016/j.devbrainres.2004.08.001; Deng P, 2009, J NEUROPHYSIOL, V102, P2453, DOI 10.1152/jn.00325.2009; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Francis J, 1997, NEUROSCI LETT, V232, P91, DOI 10.1016/S0304-3940(97)00593-4; Frick A, 2004, NAT NEUROSCI, V7, P126, DOI 10.1038/nn1178; GANDOLFO G, 1989, BRAIN RES, V495, P189, DOI 10.1016/0006-8993(89)91236-5; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Guo WN, 2005, CIRC RES, V97, P1342, DOI 10.1161/01.RES.0000196559.63223.aa; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kim J, 2005, J PHYSIOL-LONDON, V569, P41, DOI 10.1113/jphysiol.2005.095042; Lei Z, 2010, NEUROSCIENCE, V165, P350, DOI 10.1016/j.neuroscience.2009.10.041; Lei ZG, 2008, J NEUROCHEM, V106, P182, DOI 10.1111/j.1471-4159.2008.05356.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lugo JN, 2008, J NEUROCHEM, V106, P1929, DOI 10.1111/j.1471-4159.2008.05508.x; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Monaghan MM, 2008, NEUROSCIENCE, V156, P550, DOI 10.1016/j.neuroscience.2008.07.057; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schindler CJ, 2004, PHARMACOL BIOCHEM BE, V77, P509, DOI 10.1016/j.pbb.2003.12.012; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; Singh B, 2006, NEUROBIOL DIS, V24, P245, DOI 10.1016/j.nbd.2006.07.001; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; vandenPol AN, 1996, J NEUROSCI, V16, P4283	51	34	34	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					235	245		10.1089/neu.2010.1537			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300004	21895522	Green Published			2022-02-06	
J	Franschman, G; Boer, C; Andriessen, TMJC; van der Naalt, J; Horn, J; Haitsma, I; Jacobs, B; Vos, PE				Franschman, Gaby; Boer, Christa; Andriessen, Teuntje M. J. C.; van der Naalt, Joukje; Horn, Janneke; Haitsma, Iain; Jacobs, Bram; Vos, Pieter E.			Multicenter Evaluation of the Course of Coagulopathy in Patients with Isolated Traumatic Brain Injury: Relation to CT Characteristics and Outcome	JOURNAL OF NEUROTRAUMA			English	Article						coagulation disorders; CT characteristics; hemostatic monitoring; neurotrauma; patient outcome	SEVERE HEAD-INJURY; ROTATION THROMBELASTOGRAPHY; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; CLASSIFICATION; DIAGNOSIS; MODERATE; HYPERFIBRINOLYSIS; ABNORMALITIES; PREDICTORS	This prospective multicenter study investigated the association of the course of coagulation abnormalities with initial computed tomography (CT) characteristics and outcome in patients with isolated traumatic brain injury (TBI). Patient demographics, coagulation parameters, CT characteristics, and outcome data of moderate and severe TBI patients without major extracranial injuries were prospectively collected. Coagulopathy was defined as absent, early but temporary, delayed, or early and sustained. Delayed/sustained coagulopathy was associated with a higher incidence of disturbed pupillary responses (40% versus 27%; p < 0.001) and higher Traumatic Coma Data Bank (TCDB) CT classification (5 (2-5) versus 2 (1-5); p = 0.003) than in patients without or with early, but short-lasting coagulopathy. The initial CT of patients with delayed/sustained coagulopathy more frequently showed intracranial hemorrhage and signs of raised intracranial pressure (ICP) compared to patients with early coagulopathy only. This was paralleled by higher in-hospital mortality rates (51% versus 33%; p < 0.05), and poorer 6-month functional outcome in patients with delayed/sustained coagulopathy. The relative risk for in-hospital mortality was particularly related to disturbed pupillary responses (OR 8.19; 95% CI 3.15,21.32; p < 0.001), early, short-lasting coagulopathy (OR 6.70; 95% CI 1.74,25.78; p = 0.006), or delayed/sustained coagulopathy (OR 5.25; 95% CI 2.06,13.40; p = 0.001). Delayed/sustained coagulopathy is more frequently associated with CT abnormalities and unfavorable outcome at 6 months after TBI than early, short-lasting coagulopathy. Our finding that not only the mere presence but also the time course of coagulopathy holds predictive value for patient outcome underlines the importance of systematic hemostatic monitoring over time in TBI.	[Franschman, Gaby; Boer, Christa] Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Inst Cardiovasc Res, NL-1081 HV Amsterdam, Netherlands; [Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [van der Naalt, Joukje; Jacobs, Bram] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands; [Haitsma, Iain] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands		Franschman, G (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Inst Cardiovasc Res, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	g.franschman@vumc.nl	Vos, Pieter/A-6043-2012	van der Naalt, Joukje/0000-0001-9873-2418; Boer, Christa/0000-0002-7781-6951	Dutch Brain Foundation [Hersenstichting - HSN-07-01]; Netherlands Brain Foundation [HSN-07-01]	The POCON study is funded by the Dutch Brain Foundation (Hersenstichting - HSN-07-01). The authors express their gratitude to Dick Drost, Annemiek Coers, Annelou van der Veen, Joshua Field, Vivian de Ruijter, and Heleen Biersteker for their help with data collection. We thank Amon Heijne for his help with development and maintenance of the POCON database.; The POCON study has been funded by the Netherlands Brain Foundation (HSN-07-01).	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Barklin A, 2009, ANESTHESIOLOGY, V110, P1287, DOI 10.1097/ALN.0b013e3181a10352; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chesnut R. M., 2000, GUIDELINES MANAGEMEN, P155; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Fenger-Eriksen C, 2009, J THROMB HAEMOST, V7, P1099, DOI 10.1111/j.1538-7836.2009.03460.x; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Levrat A, 2008, BRIT J ANAESTH, V100, P792, DOI 10.1093/bja/aen083; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1990, ACT NEUR S, V51, P300; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Pahatouridis D, 2010, BRAIN INJURY, V24, P1189, DOI 10.3109/02699052.2010.490510; Perel P., 2010, COCHRANE DB SYST REV, V20; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rugeri L, 2007, J THROMB HAEMOST, V5, P289, DOI 10.1111/j.1538-7836.2007.02319.x; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	38	34	38	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					128	136		10.1089/neu.2011.2044			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300015	21939390	Green Submitted			2022-02-06	
J	Loughran, T				Loughran, Tracey			Shell Shock, Trauma, and the First World War: The Making of a Diagnosis and Its Histories	JOURNAL OF THE HISTORY OF MEDICINE AND ALLIED SCIENCES			English	Article						shell shock; trauma; First World War; post-traumatic stress disorder; psychology; psychiatry	BRAIN-INJURY	During the First World War, thousands of soldiers were treated for "shell shock," a condition which encompassed a range of physical and psychological symptoms. Shell shock has most often been located within a "genealogy of trauma," and identified as an important marker in the gradual recognition of the psychological afflictions caused by combat. In recent years, shell shock has increasingly been viewed as a powerful emblem of the suffering of war. This article, which focuses on Britain, extends scholarly analyses which question characterizations of shell shock as an early form of post-traumatic stress disorder. It also considers some of the methodological problems raised by recasting shell shock as a wartime medical construction rather than an essentially timeless manifestation of trauma. It argues that shell shock must be analyzed as a diagnosis shaped by a specific set of contemporary concerns, knowledges, and practices. Such an analysis challenges accepted understandings of what shell shock "meant" in the First World War, and also offers new perspectives on the role of shell shock in shaping the emergence of psychology and psychiatry in the early part of the twentieth century. The article also considers what relation, if any, might exist between intellectual and other histories, literary approaches, and perceptions of trauma as timeless and unchanging.	Cardiff Univ, Cardiff CF10 3EU, S Glam, Wales		Loughran, T (corresponding author), Cardiff Univ, Humanities Bldg,Colum Dr, Cardiff CF10 3EU, S Glam, Wales.	loughrantl@cardiff.ac.uk		Loughran, Tracey/0000-0002-6654-820X	Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [PTA 026-27-1613]; ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/F015003/1] Funding Source: UKRI; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/F015003/1] Funding Source: researchfish	I gratefully acknowledge the support of the Economic and Social Research Council (PTA 026-27-1613).	American Psychological Association, 2000, DIAGN STAT MAN MENT, P463; [Anonymous], 1896, KINGS COLL HOSP MED; [Anonymous], 2009, DAILY TELEGRAPH 1109; [Anonymous], 1922, REPORT WAR OFFICE CO, P119; [Anonymous], 1914, LANCET, V2, P802; [Anonymous], 1917, MED WORLD, V9, P173; Armstrong-Jones Robert, 1917, J STATE MED, V25, P290; Armstrong-Jones Robert, 1917, J STATE MED, V25, P289; Binneveld Hans, 1997, SHELL SHOCK COMBAT S, P106; Bond Brian, 2002, UNQUIET W FRONT BRIT, p[vii, 88]; Bourke Joanna, 1996, DISMEMBERING MALE ME, P108; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bury JS, 1918, LANCET, V2, P97; Bury Judson Sykes, 1918, LANCET, V2, P98; Campbell Harry, 1916, PRACTITIONER, V96, P501; Campbell Harry, 1916, PRACTITIONER, V96, P503; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Das Santanu, 2006, TOUCH INTIMACY 1 WOR; Eager R, 1918, Br Med J, V1, P422; Eager Richard, 1918, BMJ-BRIT MED J, V1, P425; Elliott Thomas, REPORT WAR OFFICE CO, p[29, 71]; Elliott TR, 1914, BRIT MED J, V1914, P1005, DOI 10.1136/bmj.2.2815.1005; Flood Alison, 2009, GUARDIAN        1109; Fussell Paul, 1975, GREAT WAR MODERN MEM, P3; Hacking Ian., 1986, RECONSTRUCTING INDIV, P222; Holmes Richard, 2005, TOMMY BRIT SOLDIER W, P485; Hunter Percy, 1919, PRACTITIONER, V103, P343; Hurst AF, 1917, BRIT MED J, V1917, P409, DOI 10.1136/bmj.2.2961.409; Hurst Arthur, 1917, BMJ-BRIT MED J, V2, P413; Hynes Samuel, 1991, WAR IMAGINED 1 WORLD, P27; Ismail Sharif, 2005, Psychoanal Hist, V7, P171, DOI 10.3366/pah.2005.7.2.171; Ismail Sharif, 2005, PSYCHOANAL HIST, V7, P181; Johnson W, 1919, BMJ-BRIT MED J, V1919, P335, DOI 10.1136/bmj.1.3038.335; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Jones Edgar, 2005, SHELL SHOCK PTSD MIL, P30; Jordanova L, 1995, SOC HIST MED, V8, P361, DOI 10.1093/shm/8.3.361; Leese Peter, 2002, SHELL SHOCK TRAUMATI, P1; Loughran T, 2009, SOC HIST MED, V22, P79, DOI 10.1093/shm/hkn093; Loughran Tracey, 2006, THESIS U LONDON, P141; Loughran Tracey, 2007, MANCHESTER PAPERS EC, V58, P7; Loughran Tracey, 2007, MANCHESTER PAPERS EC, V58, P2; Loughran Tracey, 2007, MANCHESTER PAPERS EC, V58, P1; Merskey Harold, 1991, 150 YEARS BRIT PSYCH, p[245, 250, 258]; Micale Mark, 2001, TRAUMATIC HIST PSYCH; Motion Andrew, 2009, GUARDIAN        1107; Mott FW, 1917, J ROY ARMY MED CORPS, V29, P662; Myers C. S., 1940, SHELL SHOCK FRANCE 1, P11; Myers CS, 1915, LANCET, V1, P316; Pines Malcom, 150 YEARS BRIT PSYCH, p[206, 206, 213]; Roper Michael, 2009, SECRET BATTLE EMOTIO, P54; Rose Nikolas, 1989, GOVERNING SOUL SHAPI, P20; Rose Nikolas, 1985, PSYCHOL COMPLEX PSYC, P182; Rows RG, 1916, BMJ-BRIT MED J, V1916, P441, DOI 10.1136/bmj.1.2882.441; Rylance Rick, 2000, VICTORIAN PSYCHOL BR, V5, P8; Sheffield Gary, 2001, FORGOTTEN VICTORY 1, pxiv; Shephard Ben, 1996, 150 YEARS BRIT PSYCH, V2, P434; Shephard Ben, 2002, WAR NERVES SOLDIERS, pxxiii; Shepherd Michael, 1985, ANATOMY MADNESS ESSA, P242; Showalter Elaine., 1987, FEMALE MALADY WOMEN, P167; Stevenson David, 2004, 1914 1918 HIST 1 WOR, P208; Stewart JP, 1919, ARCH NEURO PSYCHIATR, V1, P14, DOI 10.1001/archneurpsyc.1919.02180010017002; Taylor Matthew, 2007, GUARDIAN        1027; Thomson Mathew, 2006, PSYCHOL SUBJECTS IDE, P182; Thomson Mathew, 1999, RACE SCI MED 1700 19, P235; Todman Dan, 2005, GREAT WAR MYTH MEMOR, P153; Turner William Aldren, 1915, BMJ-BRIT MED J, V1, P833; Turner William Aldren, 1915, BMJ-BRIT MED J, V1, P835; Veale Rawdon, 1917, J ROY ARMY MED CORPS, V29, P608; Veale Rawdon, 1917, J ROY ARMY MED CORPS, V29, P607; Von Wild K, 2001, BRAIN INJURY, V15, P273; Wessely Simon, 2004, WAR SOC, V22, P89, DOI DOI 10.1179/072924704791202130; Wiltshire H, 1916, LANCET, V1, P1207; Young A., 1997, HARMONY ILLUSIONS IN; [No title captured]	74	34	34	0	29	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-5045	1468-4373		J HIST MED ALL SCI	J. Hist. Med. Allied Sci.	JAN	2012	67	1					94	119		10.1093/jhmas/jrq052			26	Health Care Sciences & Services; History & Philosophy Of Science	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Health Care Sciences & Services; History & Philosophy of Science	860TY	WOS:000297971800005	20713494	Bronze			2022-02-06	
J	van de Looij, Y; Mauconduit, F; Beaumont, M; Valable, S; Farion, R; Francony, G; Payen, JF; Lahrech, H				van de Looij, Yohan; Mauconduit, Franck; Beaumont, Marine; Valable, Samuel; Farion, Regine; Francony, Gilles; Payen, Jean-Francois; Lahrech, Hana			Diffusion tensor imaging of diffuse axonal injury in a rat brain trauma model	NMR IN BIOMEDICINE			English	Article						rat brain; traumatic brain injury; diffuse axonal injury; diffusion tensor imaging; fractional anisotropy; fiber tracking; impact-acceleration model	WHITE-MATTER INJURY; FIBER TRACKING; WATER DIFFUSION; SPINAL-CORD; CORPUS-CALLOSUM; SKELETAL-MUSCLE; MOUSE-BRAIN; HEAD-INJURY; MRI; TRACTOGRAPHY	Diffusion tensor imaging (DTI) was used to study traumatic brain injury. The impactacceleration trauma model was used in rats. Here, in addition to diffusivities (mean, axial and radial), fractional anisotropy (FA) was used, in particular, as a parameter to characterize the cerebral tissue early after trauma. DTI was implemented at 7T using fast spiral k-space sampling and the twice-refocused spin echo radiofrequency sequence for eddy current minimization. The method was carefully validated on different phantom measurements. DTI of a trauma group (n=5), as well as a sham group (n=5), was performed at different time points during 6h following traumatic brain injury. Two cerebral regions, the cortex and corpus callosum, were analyzed carefully. A significant decrease in diffusivity in the trauma group versus the sham group was observed, suggesting the predominance of cellular edema in both cerebral regions. No significant FA change was detected in the cortex. In the corpus callosum of the trauma group, the FA indices were significantly lower. A net discontinuity in fiber reconstructions in the corpus callosum was observed by fiber tracking using DTI. Histological analysis using Hoechst, myelin basic protein and Bielschowsky staining showed fiber disorganization in the corpus callosum in the brains of the trauma group. On the basis of our histology results and the characteristics of the impactacceleration model responsible for the presence of diffuse axonal injury, the detection of low FA caused by a drastic reduction in axial diffusivity and the presence of fiber disconnections of the DTI track in the corpus callosum were considered to be related to the presence of diffuse axonal injury. Copyright (c) 2011 John Wiley & Sons, Ltd.	[van de Looij, Yohan; Mauconduit, Franck; Beaumont, Marine; Valable, Samuel; Farion, Regine; Francony, Gilles; Lahrech, Hana] CHU, Inst Neurosci GIN, Res Ctr, INSERM,CEA,UJF,U836, Grenoble, France		Lahrech, H (corresponding author), Univ Grenoble 1, Ctr Rech, INSERM, CHU,CEA,UJF,U836, Chemin Fortune Ferrini,Site Sante Bat Edmond J Sa, F-38706 La Tronche, France.	Hana.Lahrech@ujf-grenoble.fr	Payen, Jean-Francois/L-6667-2014; BEAUMONT, MARINE/ABG-8172-2021; valable, samuel/B-7578-2008; Lahrech, Hana/M-5229-2018	valable, samuel/0000-0003-0355-0270; Lahrech, Hana/0000-0003-3843-3410; Mauconduit, Franck/0000-0002-0128-061X; van de Looij, Yohan/0000-0003-2830-5482			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; BODENHAUSEN G, 1977, J MAGN RESON, V27, P511, DOI 10.1016/0022-2364(77)90016-6; Catani M, 2006, CURR OPIN NEUROL, V19, P599, DOI 10.1097/01.wco.0000247610.44106.3f; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; Copen WA, 2001, RADIOLOGY, V221, P27, DOI 10.1148/radiol.2211001397; Darquie A, 2001, P NATL ACAD SCI USA, V98, P9391, DOI 10.1073/pnas.151125698; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ducreux D, 2007, NEUROIMAG CLIN N AM, V17, P137, DOI 10.1016/j.nic.2006.11.005; FIEREMANS E, 2005, P ISMRM, P1301; Fillard P, 2007, IEEE T MED IMAGING, V26, P1472, DOI 10.1109/TMI.2007.899173; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Heemskerk AM, 2007, RADIOLOGY, V243, P413, DOI 10.1148/radiol.2432060491; Hsu EW, 1998, AM J PHYSIOL-HEART C, V274, pH1627, DOI 10.1152/ajpheart.1998.274.5.H1627; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 2003, MAGN RESON MED, V49, P7, DOI 10.1002/mrm.10331; Kim DH, 2003, MAGNET RESON MED, V50, P214, DOI 10.1002/mrm.10493; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lansdown DA, 2007, J APPL PHYSIOL, V103, P673, DOI 10.1152/japplphysiol.00290.2007; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lee FKH, 2006, J MAGN RESON IMAGING, V23, P747, DOI 10.1002/jmri.20553; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mauconduit F, 2010, P 18 ANN M ISMRM STO, P4030; Mayer D, 2007, NEUROIMAGE, V35, P1077, DOI 10.1016/j.neuroimage.2007.01.006; Mori S, 2001, MAGN RESON MED, V46, P18, DOI 10.1002/mrm.1155; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Norris DG, 2006, J MAGN RESON IMAGING, V23, P794, DOI 10.1002/jmri.20587; Nucifora PGP, 2007, RADIOLOGY, V245, P367, DOI 10.1148/radiol.2452060445; Numano T, 2006, MAGN RESON IMAGING, V24, P287, DOI 10.1016/j.mri.2005.12.011; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Oppenheim C, 2007, J RADIOL, V88, P510, DOI 10.1016/S0221-0363(07)89850-7; Ozanne A, 2007, AM J NEURORADIOL, V28, P1271, DOI 10.3174/ajnr.A0541; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.3.CO;2-A; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Poupon C, 2001, MED IMAGE ANAL, V5, P1, DOI 10.1016/S1361-8415(00)00030-X; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; SPIELMAN DM, 1995, MAGNET RESON MED, V34, P580, DOI 10.1002/mrm.1910340414; STEJSKAL EO, 1965, J CHEM PHYS, V43, P3597, DOI 10.1063/1.1696526; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu EX, 2007, MAGN RESON IMAGING, V25, P1048, DOI 10.1016/j.mri.2006.12.008; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Xue R, 1999, MAGNET RESON MED, V42, P1123, DOI 10.1002/(SICI)1522-2594(199912)42:6<1123::AID-MRM17>3.0.CO;2-H; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	64	34	34	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	JAN	2012	25	1					93	103		10.1002/nbm.1721			11	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	875ZF	WOS:000299074600011	21618304				2022-02-06	
J	Siman, R; Giovannone, N; Toraskar, N; Frangos, S; Stein, SC; Levine, JM; Kumar, MA				Siman, Robert; Giovannone, Nicholas; Toraskar, Nikhil; Frangos, Suzanne; Stein, Sherman C.; Levine, Joshua M.; Kumar, Monisha A.			Evidence that a Panel of Neurodegeneration Biomarkers Predicts Vasospasm, Infarction, and Outcome in Aneurysmal Subarachnoid Hemorrhage	PLOS ONE			English	Article							SPECTRIN BREAKDOWN PRODUCTS; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; CEREBROSPINAL-FLUID; CEREBRAL VASOSPASM; SURROGATE MARKERS; CALPAIN-I; DAMAGE; ISCHEMIA; CASPASE	Biomarkers for neurodegeneration could be early prognostic measures of brain damage and dysfunction in aneurysmal subarachnoid hemorrhage (aSAH) with clinical and medical applications. Recently, we developed a new panel of neurodegeneration biomarkers, and report here on their relationships with pathophysiological complications and outcomes following severe aSAH. Fourteen patients provided serial cerebrospinal fluid samples for up to 10 days and were evaluated by ultrasonography, angiography, magnetic resonance imaging, and clinical examination. Functional outcomes were assessed at hospital discharge and 6-9 months thereafter. Eight biomarkers for acute brain damage were quantified: calpain-derived alpha-spectrin N- and C-terminal fragments (CCSntf and CCSctf), hypophosphorylated neurofilament H, 14-3-3 beta and zeta, ubiquitin C-terminal hydrolase L1, neuron-specific enolase, and S100 beta. All 8 biomarkers rose up to 100-fold in a subset of patients. Better than any single biomarker, a set of 6 correlated significantly with cerebral vasospasm, brain infarction, and poor outcome. Furthermore, CSF levels of 14-3-3 beta, CCSntf, and NSE were early predictors of subsequent moderate-to-severe vasospasm. These data provide evidence that a panel of neurodegeneration biomarkers may predict lasting brain dysfunction and the pathophysiological processes that lead to it following aSAH. The panel may be valuable as surrogate endpoints for controlled clinical evaluation of treatment interventions and for guiding aSAH patient care.	[Siman, Robert; Giovannone, Nicholas; Toraskar, Nikhil; Frangos, Suzanne; Stein, Sherman C.; Levine, Joshua M.; Kumar, Monisha A.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kumar, Monisha A.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA		Siman, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu		Giovannone, Nicholas/0000-0001-5391-8729	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS048234]; Groff Foundation; Sharps Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048234] Funding Source: NIH RePORTER	This work was supported by grants to RS from the National Institute of Health (NS048234) and to JML from the Groff Foundation and Sharps Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B; Hoh BL, 2004, NEUROSURGERY, V55, P779, DOI 10.1227/01.NEU.0000137628.51839.D5; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Kramer A, 2009, STROKE, V40, P3403, DOI 10.1161/STROKEAHA.109.560243; LAD SP, 2011, J STROKE CE IN PRESS; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Lewis SB, 2007, J NEUROSURG, V107, P792, DOI 10.3171/JNS-07/10/0792; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Nylen K, 2007, STROKE, V38, P1489, DOI 10.1161/STROKEAHA.106.478362; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z; Shirao S, 2010, CEREBROVASC DIS, V30, P105, DOI 10.1159/000314713; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith ML, 2005, SURG NEUROL, V63, P229, DOI 10.1016/j.surneu.2004.06.017; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	35	34	37	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2011	6	12							e28938	10.1371/journal.pone.0028938			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866FK	WOS:000298365700084	22174930	Green Submitted, Green Published, gold			2022-02-06	
J	Ho, KM; Honeybul, S; Litton, E				Ho, Kwok M.; Honeybul, Stephen; Litton, Edward			Delayed neurological recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						decompressive craniectomy; outcome; prediction; prognosis; traumatic brain injury	DISABILITY; MORTALITY	Objective: This study aimed to assess the incidence and factors associated with delayed neurologic recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury. Design: Retrospective cohort study. Setting: Two major neurotrauma centers in Western Australia. Patients: One hundred and four adult neurotrauma patients who had had a decompressive craniectomy and remained moderately disabled or worse at 6-month follow-up. Measurements and Main Results: Glasgow Outcome Scale scores at 6, 12, and 18 months were used to assess the neurologic recovery of the patients, and logistic regression was used to identify the factors associated with delayed neurologic recovery between 6 and 18 months after surgery. Among a total of 176 patients who required decompressive craniectomy between 2004 and 2010, 104 (59%) had moderate to severe disability 6 months after surgery. Fifty of these patients (48%, 95% confidence interval: 39-58) had >= 1 grade of improvement in Glasgow Outcome Scale score between 6 and 18 months after surgery. Of the 59 patients who had an unfavorable outcome (severe disability or vegetative state) 6 months after surgery, 15 patients (25%, 95% confidence interval: 16-38) improved and had attained a favorable outcome (moderate disability or near normal neurologic function) by the 18-month follow-up. An absence of nonevacuated intracerebral hematoma (> 1 cm in diameter) (odds ratio 6.67, 95% confidence interval: 1.12-33.3; p = .038) and a higher admission Glasgow Coma Scale (odds ratio per point increment 1.44, 95% confidence interval: 1.07-1.96; p = .018) were the only two factors significantly associated with a higher chance of delayed neurologic improvement from unfavorable to favorable neurologic outcome between 6 and 18 months after surgery. Conclusions: Delayed neurologic recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury was very common; absence of nonevacuated intracerebral hematoma and a high admission Glasgow Coma Scale were associated with a higher chance of delayed neurologic recovery after decompressive craniectomy. (Crit Care Med 2011; 39: 2495-2500)	[Ho, Kwok M.; Litton, Edward] Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia		Ho, KM (corresponding author), Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia.	kwok.ho@health.wa.gov.au	Ho, Kwok M./E-3546-2010; litton, edward/C-5384-2017	Ho, Kwok M./0000-0002-6705-6004; litton, edward/0000-0002-5125-6829	Departments of Intensive Care Medicine and Neurosurgery, Royal Perth Hospital	Supported solely by the Departments of Intensive Care Medicine and Neurosurgery, Royal Perth Hospital.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Fins JJ, 2009, ANN NY ACAD SCI, V1157, P131, DOI 10.1111/j.1749-6632.2009.04473.x; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Ho KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003226; HONEYBUL S, 2010, J NEUROTRAUMA; Honeybul S, 2011, J NEUROTRAUM, V28, P13, DOI 10.1089/neu.2010.1584; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Merino MA, 2010, NEUROCIRUGIA, V21, P289; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021	33	34	37	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2011	39	11					2495	2500		10.1097/CCM.0b013e318225764e			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	841JV	WOS:000296509500016	21705893				2022-02-06	
J	Krivitzky, LS; Roebuck-Spencer, TM; Roth, RM; Blackstone, K; Johnson, CP; Gioia, G				Krivitzky, Lauren S.; Roebuck-Spencer, Tresa M.; Roth, Robert M.; Blackstone, Kaitlin; Johnson, Chad P.; Gioia, Gerard			Functional Magnetic Resonance Imaging of Working Memory and Response Inhibition in Children with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Concussion; Brain; Inhibition; Traumatic brain injury; Cerebellum; Prefrontal cortex; Post concussive symptoms	EVENT-RELATED FMRI; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PREFRONTAL CORTEX; MRI; CONCUSSION; ACTIVATION; TASK; DISORDER; RECOVERY	The current pilot study examined functional magnetic resonance imaging (fMRI) activation in children with mild traumatic brain injury (mTBI) during tasks of working memory and inhibitory control, both of which are vulnerable to impairment following mTBI. Thirteen children with symptomatic mTBI and a group of controls completed a version of the Tasks of Executive Control (TEC) during fMRI scanning. Both groups showed greater prefrontal activation in response to increased working memory load. Activation patterns did not differ between groups on the working memory aspects of the task, but children with mTBI showed greater activation in the posterior cerebellum with the addition of a demand for inhibitory control. Children with mTBI showed greater impairment on symptom report and "real world'' measures of executive functioning, but not on traditional "paper and pencil'' tasks. Likewise, cognitive testing did not correlate significantly with imaging results, whereas increased report of post-concussive symptoms were correlated with increased cerebellar activation. Overall, results provide some evidence for the utility of symptom report as an indicator of recovery and the hypothesis that children with mTBI may experience disrupted neural circuitry during recovery. Limitations of the study included a small sample size, wide age range, and lack of in-scanner accuracy data. (JINS, 2011, 17, 1143-1152)	[Krivitzky, Lauren S.; Blackstone, Kaitlin; Johnson, Chad P.; Gioia, Gerard] George Washington Univ, Sch Med & Hlth Sci, Div Pediat Neuropsychol, Dept Psychiat & Behav Sci,Childrens Natl Med Ctr, Washington, DC 20052 USA; [Roebuck-Spencer, Tresa M.] Univ Oklahoma, Norman, OK 73019 USA; [Roth, Robert M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Brain Imaging Lab,Dept Psychiat, Hanover, NH 03756 USA		Gioia, G (corresponding author), Childrens Natl Med Ctr, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20852 USA.	ggioia@cnmc.org			Children's Research Institute (CRI) at the Children's National Medical Center; National Rehabilitation Hospital/Medstar Research Institute; GCRC/CTSA at Children's National Medical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); IDDRC at Children's National Medical Center	This project was supported by an internal RAC grant from the Children's Research Institute (CRI) at the Children's National Medical Center, an internal grant through the National Rehabilitation Hospital/Medstar Research Institute, and through the GCRC/CTSA and IDDRC grants at Children's National Medical Center. We thank Ben Yerys, PhD and Madison Berl, PhD for their assistance with analysis. There are no conflicts of interest.	Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barkley R.A., 1997, ADHD NATURE SELF CON; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Desmond J.E., 1998, TRENDS COGN SCI, V2, P1364; Evans R.W, 2006, NEUROLOGY TRAUMA, P815; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA IP, 2000, BEHAV RATING INVENTO; Giza CC, 2001, J ATHL TRAINING, V36, P228; Habas C, 2009, J NEUROSCI, V29, P8586, DOI 10.1523/JNEUROSCI.1868-09.2009; Isquith P. K., 2010, TASKS EXECUTIVE CONT; Kelly AMC, 2004, EUR J NEUROSCI, V19, P3105, DOI 10.1111/j.0953-816X.2004.03429.x; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Konishi S, 1999, BRAIN, V122, P981, DOI 10.1093/brain/122.5.981; KORKMAN M, 1997, NEPSY DEV NEUROPSYCH; Kramer ME, 2008, J INT NEUROPSYCH SOC, V14, P424, DOI 10.1017/S1355617708080545; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Matthews CG., 1964, INSTRUCTION MANUAL A; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Miyake A., 1999, MODELS WORKING MEMOR; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; O'Hare ED, 2008, NEUROIMAGE, V42, P1678, DOI 10.1016/j.neuroimage.2008.05.057; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Roth RM, 2007, BIOL PSYCHIAT, V62, P901, DOI 10.1016/j.biopsych.2006.12.007; Roth RM, 2006, FOCUS ON NEUROPSYCHOLOGY RESEARCH, P1; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Smith A., 1982, SYMBOL DIGIT MODALIT; Tamm L, 2004, J AM ACAD CHILD PSY, V43, P1430, DOI 10.1097/01.chi.0000140452.51205.8d; Thomason M.E., 2008, J COGNITIVE NEUROSCI, V21, P1; Tiemeier H, 2010, NEUROIMAGE, V49, P63, DOI 10.1016/j.neuroimage.2009.08.016; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 2004, WECHSLER INTELLIGENC, Vfourth; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Woodcock R. W., 2001, WOODCOCKJOHNSON 3 TE; Yeates K. O., 2010, PEDIAT NEUROPSYCHOLO, P112; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	61	34	34	0	29	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2011	17	6					1143	1152		10.1017/S1355617711001226			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	848DF	WOS:000297028500021	22014100				2022-02-06	
J	Maung, AA; Schuster, KM; Kaplan, LJ; Maerz, LL; Davis, KA				Maung, Adrian A.; Schuster, Kevin M.; Kaplan, Lewis J.; Maerz, Linda L.; Davis, Kimberly A.			Risk of Venous Thromboembolism After Spinal Cord Injury: Not All Levels Are the Same	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Spinal cord injury; Venous thromboembolism; Deep vein thrombosis; Pulmonary embolus	TRAUMA PATIENTS; PULMONARY-EMBOLISM; MAJOR TRAUMA; PREVENTION; COMPLICATIONS; THROMBOSIS; HEPARIN	Background: Venous thromboembolism (VTE), a diagnosis that includes both deep vein thrombosis and pulmonary embolism, is a well-recognized complication following injury. Previous studies have identified multiple risk factors including spinal cord injury (SCI). We hypothesized that the level of SCI also influences the likelihood of VTE. Methods: The National Trauma Data Bank was queried to identify all patients with SCI admitted in 2007 and 2008. Rates of VTE, demographics, admitting comorbidities, in-hospital complications, level of SCI (divided by National Trauma Data Bank into five groups), associated injuries, and outcome variables were abstracted. Multiple regression was used to identify independent risk factors for VTE. Results: During the 2-year period, 18,302 patients were admitted with SCI. The overall rate of VTE was 4.3% but varied significantly depending on the level of SCI injury (chi(2), 44.8; p < 0.05). Patients with high cervical spine (C1-4) injury had a rate VTE of 3.4%, whereas patients with high thoracic spine (T1-6) injury had the highest rate of VTE at 6.3%. The lowest rate of VTE was in patients with lumbar injury (3.2%). There were no significant differences in the preexisting comorbidities or in-hospital complications among the five SCI groups with the exception of pneumonia. In a multiple logistic regression model, the level of SCI was an independent risk factor for VTE as was increasing age, increasing Injury Severity Score, male gender, traumatic brain injury, and chest trauma. Conclusions: The rate of VTE differs with various SCI levels. Patients with high thoracic (T1-6) injury seem to be at the highest risk and patients with high cervical (C1-4) injury at one of the lowest. A higher index of suspicion for VTE should therefore be maintained in patients with a high thoracic SCI. Further studies are required to elucidate the underlying mechanisms.	[Maung, Adrian A.; Schuster, Kevin M.; Kaplan, Lewis J.; Maerz, Linda L.; Davis, Kimberly A.] Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA		Maung, AA (corresponding author), Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, 330 Cedar St,BB-310, New Haven, CT 06520 USA.	adrian.maung@yale.edu					Azu MC, 2007, AM SURGEON, V73, P1228; BRACH BB, 1977, J TRAUMA, V17, P289, DOI 10.1097/00005373-197704000-00005; Chen D, 1999, ARCH PHYS MED REHAB, V80, P1397, DOI 10.1016/S0003-9993(99)90250-2; Falcone RA, 2008, J PEDIATR SURG, V43, P1858, DOI 10.1016/j.jpedsurg.2008.01.058; GREEN D, 1990, ANN INTERN MED, V113, P571, DOI 10.7326/0003-4819-113-8-571; Jones T, 2005, ARCH PHYS MED REHAB, V86, P2240, DOI 10.1016/j.apmr.2005.07.286; Maxwell RA, 2002, J TRAUMA, V52, P902, DOI 10.1097/00005373-200205000-00013; Merli G, 2003, J TRAUMA, V54, P1116, DOI 10.1097/01.TA.0000066385.10596.71; Montgomery KD, 1996, CLIN ORTHOP RELAT R, P68; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Paffrath T, 2010, INJURY, V41, P97, DOI 10.1016/j.injury.2009.06.010; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; Sharma OP, 2007, AM SURGEON, V73, P1173; Spinal Cord Injury Thromboprophylaxis Investigators, 2003, J TRAUMA, V54, P1125; WARING WP, 1991, PARAPLEGIA, V29, P8, DOI 10.1038/sc.1991.2	17	34	34	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1241	1245		10.1097/TA.0b013e318235ded0			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	849IG	WOS:000297118600031	22071925				2022-02-06	
J	Snell, DL; Siegert, RJ; Hay-Smith, EJC; Surgenor, LJ				Snell, Deborah L.; Siegert, Richard J.; Hay-Smith, E. Jean C.; Surgenor, Lois J.			Factor Structure of the Brief COPE in People With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Brief COPE; coping; mild traumatic brain injury; MTBI; psychometrics	COPING STRATEGIES; HEAD-INJURY; STRESS; INVENTORY; APPRAISAL; RECOVERY; EMOTION; HEALTH; CANCER; SCALE	Objective: To investigate the factor structure and internal consistency of the Brief COPE, adapted for use with adults with mild traumatic brain injury (MTBI). Design: Prospective cohort study. Setting: Hospital based emergency department and concussion clinic. Participants: A total of 147 adults meeting diagnostic criteria for MTBI. Main Measure: Brief COPE. Analyses: The previously reported 9-factor structure of the Brief COPE was tested by using confirmatory factor analysis (CFA) and then exploratory factor analysis (EFA). The Cronbach alpha was computed for both the original subscales and those derived from EFA. Results: The CFA provided a less than satisfactory fit for the 9-factor model. While the EFA solution was very similar to that of the original scale, the reliability of some derived subscales was low. Further analyses identified improved internal consistency with a 3-factor model reflecting approach, avoidance, and help-seeking coping styles. Conclusions: The Brief COPE has satisfactory psychometric properties for use in MTBI but may be more reliably and meaningfully interpreted using 3 dimensions/subscales rather than 9.	[Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, London WC2R 2LS, England; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand		Snell, DL (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929			Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Coolidge FL, 2000, J ANXIETY DISORD, V14, P157, DOI 10.1016/S0887-6185(99)00046-8; Cooper C, 2008, J NERV MENT DIS, V196, P838, DOI 10.1097/NMD.0b013e31818b504c; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dias C, 2009, SPAN J PSYCHOL, V12, P338, DOI 10.1017/S1138741600001736; Fidell L.S., 2001, USING MULTIVARIATE S, V4th; Fillion L, 2002, CURR PSYCHOL, V21, P17, DOI 10.1007/BF02903157; FOLKMAN S, 1985, J PERS SOC PSYCHOL, V48, P150, DOI 10.1037/0022-3514.48.1.150; Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1984, STRESS; Franks HM, 2006, PSYCHO-ONCOL, V15, P1027, DOI 10.1002/pon.1043; Frydenberg E., 1996, COPING SCALE ADULTS; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lowe R, 2000, BRIT J HEALTH PSYCH, V5, P337, DOI 10.1348/135910700168964; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; New Zealand Guidelines Group, 2006, TRAUM BRIAN INJ DIAG; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; Pett MA., 2003, MAKING SENSE FACTOR; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ptacek JT, 2008, ANXIETY STRESS COPIN, V21, P155, DOI 10.1080/10615800701466467; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Snell Deborah, 2006, N Z Med J, V119, pU1902; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Streiner DL, 2003, J PERS ASSESS, V80, P217, DOI 10.1207/S15327752JPA8003_01; Strom TQ, 2007, BRAIN INJURY, V21, P1137, DOI 10.1080/02699050701687334; Taylor SE, 2007, ANNU REV CLIN PSYCHO, V3, P377, DOI 10.1146/annurev.clinpsy.3.022806.091520; TEASDALE G, 1974, LANCET, V2, P81; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; Watson R, 2006, J ADV NURS, V55, P330, DOI 10.1111/j.1365-2648.2006.03915.x; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	43	34	34	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2011	26	6					468	477		10.1097/HTR.0b013e3181fc5e1e			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	859AC	WOS:000297845000003	21245767				2022-02-06	
J	Cuevas, J; Rodriguez, A; Behensky, A; Katnik, C				Cuevas, Javier; Rodriguez, Alex; Behensky, Adam; Katnik, Chris			Afobazole Modulates Microglial Function via Activation of Both sigma-1 and sigma-2 Receptors	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; HEAT-ACCLIMATED MICE; IN-VITRO; CORTICAL-NEURONS; CELLS; RATS; ISCHEMIA; LIGANDS; SENSOR	Microglial cells play a critical role in the neuroinflammatory response that accompanies various diseases of the central nervous system, such as ischemic stroke, and ATP is a major signaling molecule regulating the response of these cells to these pathophysiological conditions. Experiments were carried out to determine the effects of afobazole on microglial function and to identify the molecular mechanisms by which afobazole affects microglial cells. Afobazole was found to inhibit migration of microglial cells in response to ATP and UTP chemoattraction in a concentration-dependent manner. Inhibition of either sigma-1 or sigma-2 receptors decreased the effects of afobazole on microglia. In addition to inhibiting microglial cell migration, activation of sigma receptors by afobazole decreased intracellular calcium elevation produced by focal application of ATP and UTP in isolated microglial cells. Furthermore, afobazole blocked membrane currents elicited by rapid application of ATP in microglial cells. Taken together, our data indicate that afobazole inhibits microglial response to P2Y and P2X purinergic receptor activation by functioning as a pan-selective sigma-receptor agonist. In addition to modulating response to purinergic receptor activation, the effects of afobazole on microglial survival during in vitro ischemia were assessed. Application of afobazole during in vitro ischemia decreased microglial cell death during the ischemic episode and after a 24-h recovery period. Moreover, when afobazole was only applied after the ischemic episode, a significant enhancement in cell survival was still observed. Thus, afobazole acts via sigma receptors to decrease microglial response to ATP and provides cytoprotection during and after ischemia.	[Cuevas, Javier; Rodriguez, Alex; Behensky, Adam; Katnik, Chris] Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33612 USA		Cuevas, J (corresponding author), Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, 12901 Bruce B Downs Blvd,MDC-9, Tampa, FL 33612 USA.	jcuevas@health.usf.edu	Cuevas, Javier/I-4941-2012		RF Pharmaceuticals Sarl; MDR Pharmaceutical Limited	This study was supported by grants from RF Pharmaceuticals Sarl and MDR Pharmaceutical Limited (to J.C.).	Ajmo CT, 2006, CURR NEUROVASC RES, V3, P89, DOI 10.2174/156720206776875849; Basso AM, 2009, BEHAV BRAIN RES, V198, P83, DOI 10.1016/j.bbr.2008.10.018; Bucolo C, 2006, NEUROREPORT, V17, P287, DOI 10.1097/01.wnr.0000199469.21734.e1; Connor TJ, 1998, NEUROSCIENCE, V84, P923, DOI 10.1016/S0306-4522(97)00533-2; Cuevas J, 1998, J NEUROSCI, V18, P10335; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Galaeva IP, 2005, B EXP BIOL MED+, V140, P535, DOI 10.1007/s10517-006-0017-3; Ghelardini C, 2000, PHARMACOL BIOCHEM BE, V67, P659, DOI 10.1016/S0091-3057(00)00405-6; Hall AA, 2009, GLIA, V57, P744, DOI 10.1002/glia.20802; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Herrera Y, 2008, J PHARMACOL EXP THER, V327, P491, DOI 10.1124/jpet.108.143974; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Husbands SM, 1999, J MED CHEM, V42, P4446, DOI 10.1021/jm9902943; Katnik C, 2006, J PHARMACOL EXP THER, V319, P1355, DOI 10.1124/jpet.106.107557; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lyons SA, 2000, J CEREBR BLOOD F MET, V20, P1537, DOI 10.1097/00004647-200011000-00003; Lyons SA, 1998, J CEREBR BLOOD F MET, V18, P521, DOI 10.1097/00004647-199805000-00007; MATSUMOTO RR, 1995, EUR J PHARMACOL, V280, P301, DOI 10.1016/0014-2999(95)00208-3; Narantuya D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011746; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Seredenin SB, 2008, B EXP BIOL MED+, V145, P207, DOI 10.1007/s10517-008-0051-4; Seredenin SB, 2009, B EXP BIOL MED+, V148, P42, DOI 10.1007/s10517-009-0624-x; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Tuglu C, 2003, PSYCHOPHARMACOLOGY, V170, P429, DOI 10.1007/s00213-003-1566-z; Uyanaev AA, 2006, B EXP BIOL MED+, V142, P202, DOI 10.1007/s10517-006-0327-5; Weinstein JR, 2010, FUTUR NEUROL, V5, P227, DOI 10.2217/FNL.10.1; WU Z, 2003, SOC NEUROSCIENCE; Zenina TA, 2005, B EXP BIOL MED+, V140, P194, DOI 10.1007/s10517-005-0443-7; Zhang HL, 2002, J NEUROPHYSIOL, V87, P2867, DOI 10.1152/jn.2002.87.6.2867	35	34	39	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	2011	339	1					161	172		10.1124/jpet.111.182816			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	821UC	WOS:000294998900018	21715561				2022-02-06	
J	Koponen, S; Taiminen, T; Hiekkanen, H; Tenovuo, O				Koponen, Salla; Taiminen, Tero; Hiekkanen, Heli; Tenovuo, Olli			Axis I and II psychiatric disorders in patients with traumatic brain injury: A 12-month follow-up study	BRAIN INJURY			English	Article						Brain injuries; mental disorders; personality disorders	POSTTRAUMATIC-STRESS-DISORDER; COMORBIDITY; ALCOHOL; PREVALENCE; MOOD	Objective: To evaluate the occurrence of axis I and II psychiatric disorders among patients with traumatic brain injury (TBI). Design: Prospective observational study. Forty-five adult patients, who had attended an emergency unit because of TBI, were recruited. At 12 months, 38 patients were interviewed. Measures: Psychiatric disorders were evaluated using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) and the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). Results: Before TBI, the 12-month rate of axis I psychiatric disorders was relatively high (39.5%) and the rate of alcohol dependence was especially elevated (18.4%). During the 12 months after TBI, axis I disorders were found in 47.4% of subjects. Six patients (15.8%) were found to have a disorder with an onset after TBI. Of these, five patients had depressive disorders (13.2%). Almost one third of the subjects (29.0%) had personality disorders. Antisocial and obsessive-compulsive personality disorders were the most frequent (10.5%). Conclusions: Both axis I and II psychiatric disorders are common among patients with TBI. Alcohol dependence and personality disorders are prevalent in individuals prone to TBI, whereas depressive disorders typically develop after injury. Psychiatric disorders should be addressed in rehabilitation, as otherwise they will hinder the recovery after TBI.	[Koponen, Salla] Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland; [Taiminen, Tero] Turku Univ Hosp, Dept Psychiat, FIN-20520 Turku, Finland; [Hiekkanen, Heli] Jyvaskyla Cent Hosp, Dept Neurol, Jyvaskyla, Finland; [Tenovuo, Olli] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland		Koponen, S (corresponding author), Univ Helsinki, Dept Psychiat, POB 590, FI-00029 Helsinki, Finland.	salla.koponen@helsinki.fi			Finnish Medical Society Duodecim	This study was supported by the Finnish Medical Society Duodecim. The authors report no conflicts of interest.	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; First M., 1997, STRUCTURED CLIN INTE; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Lenzenweger MF, 2007, BIOL PSYCHIAT, V62, P553, DOI 10.1016/j.biopsych.2006.09.019; Mild Traumatic Brain Injury Committee of the Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHABI, V8, P86; Pirkola SP, 2005, SOC PSYCH PSYCH EPID, V40, P1, DOI 10.1007/s00127-005-0848-7; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; *SAS I INC, 2006, SAS ENT GUID 4 1; Stein SC, 1996, NEUROTRAUMA; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	25	34	34	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2011	25	11					1029	1034		10.3109/02699052.2011.607783			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	829WC	WOS:000295614900001	21870901				2022-02-06	
J	Spencer, DD; Jacobi, J; Juenke, JM; Fleck, JD; Kays, MB				Spencer, Dustin D.; Jacobi, Judith; Juenke, JoEtta M.; Fleck, James D.; Kays, Michael B.			Steady-State Pharmacokinetics of Intravenous Levetiracetam in Neurocritical Care Patients	PHARMACOTHERAPY			English	Article						levetiracetam; pharmacokinetics; seizure prophylaxis; neurocritical care	CRITICALLY-ILL PATIENTS; PHARMACODYNAMIC TARGET ATTAINMENT; INTRACEREBRAL HEMORRHAGE; SEIZURE PROPHYLAXIS; INFUSION; TOLERABILITY; EPILEPSY; SAFETY; PHENYTOIN; CHILDREN	Study Objectives. To characterize the steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients requiring seizure prophylaxis after a neurologic injury and to determine which dosing regimens achieve serum concentrations within the recommended therapeutic range of 6-20 mu g/ml. Design. Prospective, open-label, steady-state pharmacokinetic study. Setting. Neurocritical care unit in a tertiary care medical center. Patients. Twelve adults (five men, seven women) admitted to the neurocritical care unit who required prophylactic anticonvulsant therapy after subarachnoid hemorrhage, subdural hematoma, or traumatic brain injury. Intervention. Patients received an intravenous infusion of levetiracetam 500 mg over 15 minutes every 12 hours. Measurements and Main Results. Serial blood samples were collected from all patients after a minimum of four doses of therapy. Serum levetiracetam concentrations were determined by ultraperformance liquid chromatography with tandem mass spectrometry detection, and pharmacokinetic data were analyzed by compartmental and noncompartmental methods. Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 mu g/ml or greater, 20 mu g/ml or greater, and 6-20 mu g/ml. The mean +/- SD levetiracetam maximum serum concentration was 28.0 +/- 8.0 mu g/ml, minimum serum concentration 3.1 +/- 1.8 mu g/ml, half-life 5.2 +/- 1.2 hours, systemic clearance 5.6 +/- 1.8 L/hour, and volume of distribution at steady state 36.8 +/- 6.3 L. Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 mu g/ml or greater but also increased the probability of achieving trough concentrations greater than 20 mu g/ml. Levetiracetam doses of 1000 mg every 8 hours and 1500-2000 mg every 12 hours provided the highest probability of achieving a target trough concentration between 6 and 20 mu g/ml. Conclusion. Compared with previously published results in healthy volunteers and adults in status epilepticus, levetiracetam systemic clearance was faster and the terminal elimination half-life was shorter in neurocritical care patients. Higher doses or more frequent dosing may be needed to achieve target trough concentrations of 6-20 mu g/ml.	[Spencer, Dustin D.; Jacobi, Judith] Indiana Univ Hlth, Methodist Hosp, Dept Pharm, Indianapolis, IN 46202 USA; [Juenke, JoEtta M.] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA; [Fleck, James D.] Indiana Univ Hlth Phys, Indianapolis, IN USA; [Kays, Michael B.] Purdue Univ, Coll Pharm, Dept Pharm Practice, Indianapolis, IN USA		Spencer, DD (corresponding author), Indiana Univ Hlth, Methodist Hosp, Dept Pharm, 1701 N Senate Blvd,AG401, Indianapolis, IN 46202 USA.	dspence2@iuhealth.org	Spencer, Dustin/AAI-2761-2021; Jacobi, Judith/ABE-2757-2020	Jacobi, Judith/0000-0003-2421-0734			Betts T, 2000, SEIZURE-EUR J EPILEP, V9, P80, DOI 10.1053/seiz.2000.0380; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; DeRyke CA, 2007, PHARMACOTHERAPY, V27, P333, DOI 10.1592/phco.27.3.333; Fountain NB, 2009, EPILEPSY CURR, V9, P71, DOI 10.1111/j.1535-7511.2009.01297.x; Gibaldi M., 1982, PHARMACOKINETICS; Glauser TA, 2007, EPILEPSIA, V48, P1117, DOI 10.1111/j.1528-1167.2007.01090.x; Hirsch LJ, 2007, EPILEPSIA, V48, P1351, DOI 10.1111/j.1528-1167.2007.01043.x; Johannessen SI, 2003, THER DRUG MONIT, V25, P347, DOI 10.1097/00007691-200306000-00016; Kim A, 2009, CLIN THER, V31, P2765, DOI 10.1016/j.clinthera.2009.11.026; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; Nau KM, 2009, NEUROCRIT CARE, V11, P34, DOI 10.1007/s12028-009-9185-0; Patsalos PN, 2004, CLIN PHARMACOKINET, V43, P707, DOI 10.2165/00003088-200443110-00002; Pellock JM, 2001, EPILEPSIA, V42, P1574, DOI 10.1046/j.1528-1157.2001.41300.x; Radtke RA, 2001, EPILEPSIA, V42, P24, DOI 10.1046/j.1528-1157.2001.0420s4024.x; Ramael S, 2006, CLIN THER, V28, P734, DOI 10.1016/j.clinthera.2006.05.004; Ramael S, 2006, EPILEPSIA, V47, P1128, DOI 10.1111/j.1528-1167.2006.00586.x; Ruegg S, 2008, EPILEPSY BEHAV, V12, P477, DOI 10.1016/j.yebeh.2008.01.004; Sahaya K, 2010, EPILEPSIA, V51, P2492, DOI 10.1111/j.1528-1167.2010.02788.x; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; *UCB INC, 2008, KEPPR LEV INJ INTR U; Uges JWF, 2009, EPILEPSIA, V50, P415, DOI 10.1111/j.1528-1167.2008.01889.x; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WEISBERG LA, 1991, NEUROLOGY, V41, P1197, DOI 10.1212/WNL.41.8.1197	27	34	34	0	5	PHARMACOTHERAPY PUBLICATIONS INC	BOSTON	NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA	0277-0008			PHARMACOTHERAPY	Pharmacotherapy	OCT	2011	31	10					934	941		10.1592/phco.31.10.934			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	831WI	WOS:000295761400002	21950640				2022-02-06	
J	Watson, WL; Mitchell, R				Watson, W. L.; Mitchell, R.			Conflicting trends in fall-related injury hospitalisations among older people: variations by injury type	OSTEOPOROSIS INTERNATIONAL			English	Article						Fall injury; Fractures; Injury epidemiology; Non-fracture injury; Older persons	NEW-SOUTH-WALES; TRAUMATIC BRAIN-INJURY; HIP FRACTURE RATES; NURSING-HOME; AUSTRALIA; IMPACT; EPIDEMIOLOGY; ADMISSION; ADULTS; COSTS	Despite advances in prevention, fall-related hospitalisation rates among older people are still increasing. Rates between 1998/1999 and 2008/2009 for non-facture-related injuries increased by 6.1% while fracture injuries declined by -0.4%. Varying trends in rates of different injury types makes it difficult to provide a definitive explanation for these changes. Introduction Despite advances in fall prevention research and practice, the rate of fall-related hospitalisations continues to increase. However, hip fracture rates appear to be declining. An examination of trends in types of injuries that contribute to the overall fall injury rate is required to establish which injuries are driving the falls admission rate. The aim of this paper is to examine trends in fall-related injury hospital admissions by injury type in New South Wales (NSW), Australia. Methods A retrospective review of fall-related injury hospitalisations in NSW among individuals aged 65+ years, by injury type, was conducted from 1 July 1998 to 30 June 2009. Direct age-standardised admission rates were calculated. Negative binomial regression was used to examine the statistical significance of changes in trend over time of different hospitalised fall-related injuries. Results The fall-related hospitalisation rate increased by 1.7% each year (p < 0.0001; 95% confidence interval (CI), 1.3-2.1%). However, the rate of fracture declined by -0.4% (p < 0.03; 95% CI, -0.8-0.0%); whereas, the non-fracture rate increased by 6.1% (p < 0.0001; 95% CI, 5.5-6.7%) annually. Rates for severe head injuries, rib and pelvic fracture increased while those for hip and forearm fracture declined. Conclusions It appears that while fall prevention efforts in NSW are not yet affecting the overall rate of injury hospitalisation, there has been a significant decline in the rates of some fractures. Opposing trends in the rates of other fracture admissions and a significant increase in the rate of non-fracture injuries associated with falls makes a definitive explanation for these changes difficult.	[Watson, W. L.; Mitchell, R.] Univ New S Wales, NSW Injury Risk Management Res Ctr, Kensington, NSW 2052, Australia; [Mitchell, R.] Univ New S Wales, Sch Aviat, Kensington, NSW 2052, Australia		Watson, WL (corresponding author), Univ New S Wales, NSW Injury Risk Management Res Ctr, Kensington, NSW 2052, Australia.	w.watson@unsw.edu.au	Mitchell, Rebecca J/J-6105-2012; Mitchell, Rebecca/Z-5476-2019	Mitchell, Rebecca J/0000-0003-1939-1761; Mitchell, Rebecca/0000-0003-1939-1761	NSW Health Department; ARCAustralian Research Council [LP0990057]	W. Watson was supported by the NSW Health Department. R. Mitchell was partially supported by the NSW Health Department and by an ARC-linkage post-doctoral fellowship (LP0990057).	Abrahamsen B, 2010, OSTEOPOROSIS INT, V21, P373, DOI 10.1007/s00198-009-0957-3; Armitage P, 2002, STAT METHODS MED RES, V4th; Boufous S, 2004, MED J AUSTRALIA, V180, P623, DOI 10.5694/j.1326-5377.2004.tb06124.x; Boufous S, 2005, INJURY, V36, P1323, DOI 10.1016/j.injury.2005.02.008; Boufous S, 2005, INJURY PREV, V11, P334, DOI 10.1136/ip.2005.009837; Boufous S, 2006, BONE, V39, P1144, DOI 10.1016/j.bone.2006.05.011; Bradley C, 2008, HOSPITALISATIONS DUE, P38; Centre for Epidemiology and Research, 2006, HLTH OUTC INF STAT T; Centre for Health Advancement & Centre for Epidemiology and Research, 2010, NEW S WAL FALLS PREV; Chung MC, 2009, INT J GERIATR PSYCH, V24, P955, DOI 10.1002/gps.2201; Cumming RG, 2000, J GERONTOL A-BIOL, V55, pM299, DOI 10.1093/gerona/55.5.M299; Dimai H, 2010, OSTEOPOROSI IN PRESS, P1; DOBSON AJ, 1991, STAT MED, V10, P457, DOI 10.1002/sim.4780100317; DOWNTON JH, 1990, INT J GERIATR PSYCH, V5, P93, DOI 10.1002/gps.930050206; Fisher AA, 2009, BONE, V45, P246, DOI 10.1016/j.bone.2009.04.244; Hartholt KA, 2010, ARCH INTERN MED, V170, P905, DOI 10.1001/archinternmed.2010.106; Hindmarsh DM, 2009, OSTEOPOROSIS INT, V20, P221, DOI 10.1007/s00198-008-0641-z; Jaglal SB, 2005, J BONE MINER RES, V20, P898, DOI 10.1359/JBMR.041231; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; Kannus P, 2002, J BONE MINER RES, V17, P1363, DOI 10.1359/jbmr.2002.17.8.1363; Kannus P, 2008, BONE, V43, P340, DOI 10.1016/j.bone.2008.04.015; Kannus P, 2008, J GERONTOL A-BIOL, V63, P642, DOI 10.1093/gerona/63.6.642; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Kannus P, 2006, J BONE MINER RES, V21, P1836, DOI 10.1359/JBMR.060815; Kannus P, 2009, BONE, V44, P656, DOI 10.1016/j.bone.2008.12.007; Kelsey Jennifer L, 2009, Curr Osteoporos Rep, V7, P127; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Langley J, 2011, OSTEOPOROSIS INT, V22, P105, DOI 10.1007/s00198-010-1205-6; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leslie WD, 2009, JAMA-J AM MED ASSOC, V302, P883, DOI 10.1001/jama.2009.1231; Lord SR, 2007, FALLS IN OLDER PEOPLE: RISK FACTORS AND STRATEGIES FOR PREVENTION, 2ND EDITION, P1, DOI 10.1017/CBO9780511722233; Melton L, 2009, OSTEOPOROSIS INT, V20, P687, DOI 10.1007/s00198-008-0742-8; National Centre for Classification in Health, 2006, INT STAT CLASS DIS R; NSW Department of Health Public Health Division, 2000, NEW S WAL OLD PEOPL; NSW Health Quality and Safety Branch, 2008, POL DIR CLOS HEAD IN; Nymark T, 2006, ACTA ORTHOP, V77, P109, DOI 10.1080/17453670610045777; Orces CH, 2009, AGEING RES, V1, pe1, DOI DOI 10.4081/AR.2010.E1; Population Health Division, 2008, HLTH PEOPL NEW S WAL; Rogmark C, 1999, ACTA ORTHOP SCAND, V70, P19, DOI 10.3109/17453679909000950; SAS Institute, 2003, SAS STAT SOFTW VERS; Scuffham P, 2003, J EPIDEMIOL COMMUN H, V57, P740, DOI 10.1136/jech.57.9.740; Stevens JA, 2006, INJURY PREV, V12, P290, DOI 10.1136/ip.2005.011015; Stevens JA, 2010, AGE AGEING, V39, P500, DOI 10.1093/ageing/afq044; TINETTI ME, 1993, J GERONTOL, V48, P35, DOI 10.1093/geronj/48.Special_Issue.35; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Watson W, 2010, AUSTR NZ J IN PRESS	46	34	35	0	4	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	OCT	2011	22	10					2623	2631		10.1007/s00198-010-1511-z			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Endocrinology & Metabolism	819BT	WOS:000294801100007	21161644				2022-02-06	
J	Baxter, PS; Martel, MA; McMahon, A; Kind, PC; Hardingham, GE				Baxter, Paul S.; Martel, Marc-Andre; McMahon, Aoife; Kind, Peter C.; Hardingham, Giles E.			Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1	JOURNAL OF NEUROCHEMISTRY			English	Article						Ca(2+) signaling; CREB; gene regulation; neuroprotective signalling; neurotoxicity; transcription factors	CAM KINASE-IV; SENSITIVE COINCIDENCE DETECTOR; VASOACTIVE-INTESTINAL-PEPTIDE; MEDIATED GENE-EXPRESSION; RAT CORTICAL-NEURONS; CLOSED-HEAD INJURY; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; SYNAPTIC ACTIVITY; TERM POTENTIATION	Pituitary adenylate cyclase-activating peptide (PACAP) is a neuroprotective peptide which exerts its effects mainly through the cAMP-protein kinase A (PKA) pathway. Here, we show that in cortical neurons, PACAP-induced PKA signaling exerts a major part of its neuroprotective effects indirectly, by triggering action potential (AP) firing. Treatment of cortical neurons with PACAP induces a rapid and sustained PKA-dependent increase in AP firing and associated intracellular Ca(2+) transients, which are essential for the anti-apoptotic actions of PACAP. Transient exposure to PACAP induces long-lasting neuroprotection in the face of apoptotic insults which is reliant on AP firing and the activation of cAMP response element (CRE) binding protein (CREB)-mediated gene expression. Although direct, activity-independent PKA signaling is sufficient to trigger phosphorylation on CREB's activating serine-133 site, this is insufficient for activation of CREB-mediated gene expression. Full activation is dependent on CREB-regulated transcription co-activator 1 (CRTC1), whose PACAP-induced nuclear import is dependent on firing activity-dependent calcineurin signaling. Over-expression of CRTC1 is sufficient to rescue PACAP-induced CRE-mediated gene expression in the face of activity-blockade, while dominant negative CRTC1 interferes with PACAP-induced, CREB-mediated neuroprotection. Thus, the enhancement of AP firing may play a significant role in the neuroprotective actions of PACAP and other adenylate cyclase-coupled ligands.	[Baxter, Paul S.; Martel, Marc-Andre; McMahon, Aoife; Kind, Peter C.; Hardingham, Giles E.] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland		Hardingham, GE (corresponding author), Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland.	giles.hardingham@ed.ac.uk		McMahon, Aoife/0000-0003-0978-0309; Hardingham, Giles/0000-0002-7629-5314; Baxter, Paul/0000-0003-2142-1085; Kind, Peter/0000-0002-4256-9639	Wellcome TrustWellcome TrustEuropean Commission; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601584, G0700967, G0902044] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601584, G0902044, G0700967] Funding Source: UKRI	We thank Paulo Sassone-Corsi, Yang Zhou and Dong-Yan Jin for plasmids. This work is funded by the Wellcome Trust, the MRC and the BBSRC.	Al-Mubarak B, 2009, CHANNELS, V3, P233; Atlasz T, 2010, ANN NY ACAD SCI, V1200, P128, DOI 10.1111/j.1749-6632.2010.05512.x; Aubert N, 2006, J NEUROCHEM, V99, P1237, DOI 10.1111/j.1471-4159.2006.04148.x; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Bell KFS, 2011, CURR OPIN NEUROBIOL, V21, P299, DOI 10.1016/j.conb.2011.01.002; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Botia B, 2007, PEPTIDES, V28, P1746, DOI 10.1016/j.peptides.2007.04.013; Brandon EP, 1998, J NEUROSCI, V18, P3639; Brenneman DE, 2007, PEPTIDES, V28, P1720, DOI 10.1016/j.peptides.2007.04.002; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Chen Y, 2006, REGUL PEPTIDES, V137, P4, DOI 10.1016/j.regpep.2006.06.016; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Costa L, 2009, HIPPOCAMPUS, V19, P99, DOI 10.1002/hipo.20488; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Dejda A, 2008, J MOL NEUROSCI, V36, P26, DOI 10.1007/s12031-008-9087-1; Dickson L, 2009, PHARMACOL THERAPEUT, V121, P294, DOI 10.1016/j.pharmthera.2008.11.006; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Falktoft B, 2009, NEUROPEPTIDES, V43, P387, DOI 10.1016/j.npep.2009.08.002; Falluel-Morel A, 2004, J NEUROCHEM, V91, P1231, DOI 10.1111/j.1471-4159.2004.02810.x; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Ferguson GD, 2004, PHYSIOLOGY, V19, P271, DOI 10.1152/physiol.00010.2004; Frechilla D, 2001, NEUROREPORT, V12, P919, DOI 10.1097/00001756-200104170-00011; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gonzalez-Rey E, 2007, CURR PHARM DESIGN, V13, P1113, DOI 10.2174/138161207780618966; Hardingham GE, 2006, BIOCHEM SOC T, V34, P936, DOI 10.1042/BST0340936; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Hu EL, 2011, CEREB CORTEX, V21, P708, DOI 10.1093/cercor/bhq143; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; Lancaster B, 2006, J PHYSIOL-LONDON, V576, P403, DOI 10.1113/jphysiol.2006.115295; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Leveille F, 2010, J NEUROSCI, V30, P2623, DOI 10.1523/JNEUROSCI.5115-09.2010; Li SA, 2009, J NEUROSCI, V29, P2334, DOI 10.1523/JNEUROSCI.2296-08.2009; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; MacDonald JF, 2007, BBA-BIOMEMBRANES, V1768, P941, DOI 10.1016/j.bbamem.2006.12.006; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Mckenzie G, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-10; Mckenzie GJ, 2005, J NEUROCHEM, V93, P171, DOI 10.1111/j.1471-4159.2005.03010.x; Mennerick S, 2000, MOL NEUROBIOL, V22, P41; MINTA A, 1989, J BIOL CHEM, V264, P8171; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Nguyen PV, 2003, PROG NEUROBIOL, V71, P401, DOI 10.1016/j.pneurobio.2003.12.003; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Pedarzani P, 1995, J NEUROPHYSIOL, V74, P2749, DOI 10.1152/jn.1995.74.6.2749; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pokorska A, 2003, J NEUROCHEM, V84, P447, DOI 10.1046/j.1471-4159.2003.01504.x; Racz B, 2006, ANN NY ACAD SCI, V1070, P507, DOI 10.1196/annals.1317.070; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Reglodi D, 2006, ANN NY ACAD SCI, V1070, P518, DOI 10.1196/annals.1317.072; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, REGUL PEPTIDES, V123, P85, DOI 10.1016/j.regpep.2004.05.016; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shintani N, 2005, REGUL PEPTIDES, V126, P123, DOI 10.1016/j.regpep.2004.08.014; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Soriano FX, 2008, J NEUROSCI, V28, P10696, DOI 10.1523/JNEUROSCI.1207-08.2008; Soriano FX, 2008, J NEUROCHEM, V107, P533, DOI 10.1111/j.1471-4159.2008.05648.x; Soriano FX, 2007, J PHYSIOL-LONDON, V584, P381, DOI 10.1113/jphysiol.2007.138875; Soriano FX, 2011, ANTIOXID REDOX SIGN, V14, P1425, DOI 10.1089/ars.2010.3568; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; Tamas A, 2006, ANN NY ACAD SCI, V1070, P570, DOI 10.1196/annals.1317.083; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; Tauskela JS, 2008, J BIOL CHEM, V283, P34667, DOI 10.1074/jbc.M805624200; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Walton M, 1999, J NEUROCHEM, V73, P1836; Wang G, 2008, NEUROPEPTIDES, V42, P267, DOI 10.1016/j.npep.2008.03.002; Watson RF, 2006, J NEUROSCI, V26, P5393, DOI 10.1523/JNEUROSCI.0750-06.2006; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhang SJ, 2011, J NEUROSCI, V31, P4978, DOI 10.1523/JNEUROSCI.2672-10.2011; Zhang SJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000604; Zhou Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000016	91	34	34	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	AUG	2011	118	3					365	378		10.1111/j.1471-4159.2011.07330.x			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	791GY	WOS:000292654300006	21623792	Green Published, Bronze			2022-02-06	
J	Minshall, CT; Eriksson, EA; Leon, SM; Doben, AR; McKinzie, BP; Fakhry, SM				Minshall, Christian T.; Eriksson, Evert A.; Leon, Stuart M.; Doben, Andrew R.; McKinzie, Brian P.; Fakhry, Samir M.			Safety and Efficacy of Heparin or Enoxaparin Prophylaxis in Blunt Trauma Patients With a Head Abbreviated Injury Severity Score > 2	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Trauma; Chemoprophylaxis; Intracranial hemorrhage	MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; BRAIN-INJURY; 1602 EPISODES; DATA-BANK	Background: Timing and type of chemoprophylaxis (CP) that should be used in patients with traumatic brain injury (TBI) remains unclear. We reviewed our institutions experience with low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in TBI. Methods: The charts of all TBI patients with a head abbreviated injury severity score > 2 (HAIS) and an intensive care unit length of stay > 48 hours admitted during a 42-month period between 2006 and 2009 were reviewed. CP was initiated after intracranial hemorrhage was considered stable. We reviewed all operative notes and radiologic reports in these patients to analyze the rate of significant intracranial hemorrhagic complications, deep venous thrombosis, or pulmonary embolus. Results: A total of 386 patients with TBI were identified; 158 were treated with LMWH and 171 were treated with UFH. HAIS was significantly different between the LMWH (3.8 +/- 0.7) and UFH (4.1 +/- 0.7) groups; the time to initiation of CP was not. The UFH group had a significantly higher rate of deep venous thrombosis and pulmonary embolus. Progression of ICH that occurred after the initiation of CP was significantly higher in the UFH-treated patients (59%) when compared with those treated with LMWH (40%). Two patients in the UFH group required craniotomy after the initiation of CP. Conclusion: LMWH is an effective method of CP in patients with TBI, providing a lower rate of venous thromboembolic and hemorrhagic complications when compared with UFH. A large, prospective, randomized study would better evaluate the safety and efficacy of LMWH in patients suffering blunt traumatic brain injury.	[Minshall, Christian T.] Univ Texas SW, Parkland Mem Hosp, Burn Trauma Crit Care Div, Dept Surg, Dallas, TX 75390 USA; [Eriksson, Evert A.; Leon, Stuart M.; McKinzie, Brian P.; Fakhry, Samir M.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Doben, Andrew R.] Baystate Med Ctr, Dept Surg, Springfield, MA 01107 USA		Minshall, CT (corresponding author), Univ Texas SW, Parkland Mem Hosp, Burn Trauma Crit Care Div, Dept Surg, 5323 Harry Hines Blvd,E5-508, Dallas, TX 75390 USA.	ctminshall@gmail.com		Eriksson, Evert/0000-0002-4099-325X			Arnold JD, 2010, AM SURGEON, V76, P563; Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons, 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2007.9991; Brandt MM, 2007, AM J SURG, V193, P383; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Depew AJ, 2008, AM SURGEON, V74, P906; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; NORWOOD SH, 2002, ARCH SURG-CHICAGO, V137, P702; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Shackford SR, 2004, ANN SURG, V240, P496	18	34	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71	2					396	399		10.1097/TA.0b013e31822734c9			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	806XH	WOS:000293850200039	21825943				2022-02-06	
J	Ecker, RD; Mulligan, LP; Dirks, M; Bell, RS; Severson, MA; Howard, RS; Armonda, RA				Ecker, Robert D.; Mulligan, Lisa P.; Dirks, Michael; Bell, Randy S.; Severson, Meryl A.; Howard, Robin S.; Armonda, Rocco A.			Outcomes of 33 patients from the wars in Iraq and Afghanistan undergoing bilateral or bicompartmental craniectomy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						craniectomy; penetrating head injury; traumatic brain injury	MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE SURGERY; MALIGNANT INFARCTION; HEMICRANIECTOMY; EDEMA	Object. There are no published long-term data for patients with penetrating head injury treated with bilateral supratentorial craniectomy, or supra- and infratentorial craniectomy. The authors report their experience with 33 patients treated with bilateral or bicompartmental craniectomy from the ongoing conflicts in Iraq and Afghanistan. Methods. An exploratory analysis of Glasgow Outcome Scale (GOS) scores at 6 months in 33 patients was performed. Follow-up lasting a median of more than 2 years was performed in 30 (91%) of these patients. The association of GOS score with categorical variables was explored using the Wilcoxon rank-sum test or Kruskal-Wallis analysis of variance. The Spearman correlation coefficient was used for ordinal/continuous data. To provide a clinically meaningful format to present GOS scores with categorical variables, patients with GOS scores of 1-3 were categorized as having a poor outcome and those with scores of 4 and 5 as having a good outcome. This analysis does not include the patients who died in theater or in Germany who underwent bilateral decompressive craniectomy because those figures have not been released due to security concerns. Results. All patients were men with a median age of 24 years (range 19-46 years) and a median initial Glasgow Coma Scale (GCS) score of 5 (range 3-14). At 6 months, 9 characteristics were statistically significant: focus of the initial injury, systemic infection, initial GCS score, initial GCS score excluding patients with a GCS score of 3, GCS score on arrival to the US. GCS score on dismissal from the medical center, Injury Severity Score, and patients with cerebrovascular injury. Six factors were significant at long-term follow-up: focus of initial injury, systemic infection, initial GCS score excluding patients with a GCS score of 3, GCS score on arrival to the US, and GCS score on dismissal from the medical center. At long-term follow-up, 7 (23%) of 30 patients had died, 5 (17%) of 30 had a GOS score of 2 or 3, and 18 (60%) of 30 had a GOS score of 4 or 5. Conclusions. In this selected group of patients who underwent bilateral or bicompartmental craniectomy, 60% are independent at long-term follow-up. Patients with bifrontal injury fared best. Systemic infection and cerebrovascular injury corresponded with a worse outcome. (DOI: 10.3171/2011.2.JNS101490)	[Ecker, Robert D.] Maine Med Partners Neurosurg & Spine, Scarborough, ME 04074 USA; [Mulligan, Lisa P.; Bell, Randy S.; Severson, Meryl A.; Armonda, Rocco A.] Natl Naval Med Ctr, Dept Neurosurg, Bethesda, MD USA; [Dirks, Michael] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA; [Howard, Robin S.] Walter Reed Army Med Ctr, Dept Clin Invest, Washington, DC 20307 USA		Ecker, RD (corresponding author), Maine Med Partners Neurosurg & Spine, 49 Spring St, Scarborough, ME 04074 USA.	robertecker@me.com					Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bell RS, 2010, NEUROSURGERY, V66, P66, DOI 10.1227/01.NEU.0000361285.50218.A8; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Vahedi K, 2009, CURR TREAT OPTION N, V11, P113, DOI 10.1007/s11940-009-0014-8; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429	10	34	36	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2011	115	1					124	129		10.3171/2011.2.JNS101490			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	782JO	WOS:000292004700026	21438659				2022-02-06	
J	Yuan, TF; Arias-Carrion, O				Yuan, Ti-Fei; Arias-Carrion, Oscar			Adult Neurogenesis in the Hypothalamus: Evidence, Functions and Implications	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Neurogenesis; hypothalamus; third ventricle; proliferation; bromodeoxyuridine; proliferating cell nuclear antigen; Ki67; neural stem cell; cell transplantation	CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; OLFACTORY-BULB; HIPPOCAMPAL NEUROGENESIS; POSTNATAL NEUROGENESIS; SUBVENTRICULAR ZONE; NEUROTROPHIC FACTOR; MAMMALIAN BRAIN; SUPRACHIASMATIC NUCLEUS	Neurogenesis occurs in the adult brain in a constitutive manner under physiological circumstances within two regions: the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. In contrast to these two so-called neurogenic areas, other regions of the brain were considered to be primarily non-neurogenic in nature, implying that no new neurons were formed there under normal conditions. Recently, low proliferative activity was reported in the hypothalamus and the cell layers surrounding the third ventricle. This review summarizes recent evidence for adult neurogenesis in the hypothalamus, and points out the potential contributions of these new neurons to neural processing. We also discussed some technical considerations in investigating neurogenesis in the adult hypothalamus. It is believed that the hypothalamus could serve as a new source and target for stem cell transplantation.	[Arias-Carrion, Oscar] Univ Marburg, Dept Neurol, D-35033 Marburg, Germany; [Yuan, Ti-Fei] NCI, Shanghai 200001, Peoples R China		Arias-Carrion, O (corresponding author), Univ Marburg, Dept Neurol, Baldingerstr, D-35033 Marburg, Germany.	arias@exp-neuro.de	Arias-Carrion, Oscar/A-4248-2018	Arias-Carrion, Oscar/0000-0002-9982-7571	Forderverein Neurologie Marburg	The authors would like to thank Melissa Sinding M.Sc., for editing the manuscript. OA-C was supported in part by the Forderverein Neurologie Marburg.	Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arias-Carrion O, 2007, REV NEUROLOGIA, V45, P739, DOI 10.33588/rn.4512.2007245; Arias-Carrion Oscar, 2007, CNS & Neurological Disorders-Drug Targets, V6, P326, DOI 10.2174/187152707783220875; Arias-Carrion O, 2009, J NEURAL TRANSM-SUPP, P279, DOI 10.1007/978-3-211-92660-4_23; Arias-Carrion O, 2009, MED HYPOTHESES, V73, P757, DOI 10.1016/j.mehy.2009.04.029; Bath KG, 2010, DEV NEUROBIOL, V70, P339, DOI 10.1002/dneu.20781; Becker S, 2007, TRENDS COGN SCI, V11, P70, DOI 10.1016/j.tics.2006.10.013; Belsham DD, 2009, FASEB J, V23, P4256, DOI 10.1096/fj.09-133454; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Bhardwaj RD, 2006, P NATL ACAD SCI USA, V103, P12564, DOI 10.1073/pnas.0605177103; Breton-Provencher V, 2009, J NEUROSCI, V29, P15245, DOI 10.1523/JNEUROSCI.3606-09.2009; Breunig JJ, 2007, CELL STEM CELL, V1, P612, DOI 10.1016/j.stem.2007.11.008; Cameron HA, 2008, BIOL PSYCHIAT, V63, P650, DOI 10.1016/j.biopsych.2007.09.023; Chen G, 2006, J NEUROBIOL, V66, P537, DOI 10.1002/neu.20247; Chen K, 2007, MOL CELL NEUROSCI, V36, P108, DOI 10.1016/j.mcn.2007.06.004; Cho KO, 2010, ARCH PHARM RES, V33, P1475, DOI 10.1007/s12272-010-1002-y; Chojnacki AK, 2009, NAT REV NEUROSCI, V10, P153, DOI 10.1038/nrn2571; Chow Tiffany W, 2007, Neuropsychiatr Dis Treat, V3, P627; DAVIS FC, 1990, BRAIN RES, V519, P192, DOI 10.1016/0006-8993(90)90077-O; DEVITRY F, 1980, P NATL ACAD SCI-BIOL, V77, P4165, DOI 10.1073/pnas.77.7.4165; Dhanushkodi A, 2008, NEUROSCI BIOBEHAV R, V32, P657, DOI 10.1016/j.neubiorev.2007.10.004; Doetsch F, 2005, CURR OPIN NEUROBIOL, V15, P121, DOI 10.1016/j.conb.2005.01.018; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eisch AJ, 2007, CURR PHARM BIOTECHNO, V8, P147; Fan Y, 2007, EUR J NEUROSCI, V25, P38, DOI 10.1111/j.1460-9568.2006.05269.x; Fowler CD, 2005, J COMP NEUROL, V489, P166, DOI 10.1002/cne.20638; Fowler CD, 2002, J NEUROBIOL, V51, P115, DOI 10.1002/neu.10042; Fowler CD, 2008, BRAIN RES REV, V57, P342, DOI 10.1016/j.brainresrev.2007.06.011; Geoghegan D, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-2; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hawken PAR, 2009, BIOL REPROD, V80, P1146, DOI 10.1095/biolreprod.108.075341; Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365-2184.2008.00486.x; Huang LY, 1998, J NEUROBIOL, V36, P410, DOI 10.1002/(SICI)1097-4695(19980905)36:3<410::AID-NEU8>3.0.CO;2-Z; Ihrie RA, 2008, CELL TISSUE RES, V331, P179, DOI 10.1007/s00441-007-0461-z; IQBAL J, 1995, DEV BRAIN RES, V85, P151, DOI 10.1016/0165-3806(94)00189-7; Jansen HT, 1998, BRAIN RES BULL, V45, P27, DOI 10.1016/S0361-9230(97)00279-7; Jiao J, 2008, STEM CELLS, V26, P1221, DOI 10.1634/stemcells.2007-0513; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kokoeva MV, 2007, J COMP NEUROL, V505, P209, DOI 10.1002/cne.21492; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Lazarini F, 2011, TRENDS NEUROSCI, V34, P20, DOI 10.1016/j.tins.2010.09.006; Lazarini F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007017; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lledo PM, 2005, TRENDS NEUROSCI, V28, P248, DOI 10.1016/j.tins.2005.03.005; Lopez-Toledano MA, 2010, J ALZHEIMERS DIS, V20, P395, DOI 10.3233/JAD-2010-1388; Loseva E, 2009, BRAIN RES REV, V59, P374, DOI 10.1016/j.brainresrev.2008.10.004; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Moraes JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005045; Mu YL, 2010, CURR OPIN NEUROBIOL, V20, P416, DOI 10.1016/j.conb.2010.04.010; Padilla SL, 2010, NAT MED, V16, P403, DOI 10.1038/nm.2126; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Pierce AA, 2010, J NEUROSCI, V30, P723, DOI 10.1523/JNEUROSCI.2479-09.2010; PRICE JL, 1991, J COMP NEUROL, V306, P447, DOI 10.1002/cne.903060309; Rankin SL, 2003, BRAIN RES, V971, P189, DOI 10.1016/S0006-8993(03)02350-3; Raymond AD, 2006, BRAIN RES, V1102, P44, DOI 10.1016/j.brainres.2006.04.113; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; SERESS L, 1985, DEV BRAIN RES, V22, P156, DOI 10.1016/0165-3806(85)90080-X; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shepherd GM, 2007, BRAIN RES REV, V55, P373, DOI 10.1016/j.brainresrev.2007.03.005; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Taupin P, 2006, CURR OPIN MOL THER, V8, P225; Thompson CK, 2009, J NEUROSCI, V29, P4586, DOI 10.1523/JNEUROSCI.5423-08.2009; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Young KM, 2007, J NEUROSCI, V27, P5146, DOI 10.1523/JNEUROSCI.0654-07.2007; Yuan TF, 2010, CELL TISSUE RES, V340, P211, DOI 10.1007/s00441-010-0964-x; Zhang L, 2011, EUR J NEUROSCI, V33, P1, DOI 10.1111/j.1460-9568.2010.7483.x; Zhang RL, 2005, NEUROSCIENTIST, V11, P408, DOI 10.1177/1073858405278865; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	80	34	34	0	18	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	JUN	2011	10	4					433	439		10.2174/187152711795563985			7	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	777PG	WOS:000291634700004	21495965				2022-02-06	
J	Myburgh, J; Bellomo, R; Cass, A; Finfer, S; French, J; Gattas, D; Glass, P; Lee, J; Lipman, J; Liu, B; McArthur, C; McGuinness, S; Rajbhandari, D; Taylor, C; Webb, S				Myburgh, John; Bellomo, Rinaldo; Cass, Alan; Finfer, Simon; French, Julie; Gattas, David; Glass, Parisa; Lee, Joanne; Lipman, Jeffrey; Liu, Bette; McArthur, Colin; McGuinness, Shay; Rajbhandari, Dorrilyn; Taylor, Colman; Webb, Steve		Crystalloid Versus Hydroxyethyl St	The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality	INTENSIVE CARE MEDICINE			English	Article						Hydroxyethyl starch; Fluid therapy; Resuscitation; Colloids; Randomised controlled trials	CRITICALLY-ILL PATIENTS; CARDIAC-SURGERY PATIENTS; SEVERE HEAD-INJURY; RENAL-FUNCTION; ALBUMIN; GELATIN; THERAPY	The intravenous fluid 6% hydroxyethyl starch (130/0.4) (6% HES 130/0.4) is used widely for resuscitation but there is limited information on its efficacy and safety. A large-scale multi-centre randomised controlled trial (CHEST) in critically ill patients is currently underway comparing fluid resuscitation with 6% HES 130/0.4 to 0.9% sodium chloride on 90-day mortality and other clinically relevant outcomes including renal injury. This report describes the study protocol. CHEST will recruit 7,000 patients to concealed, random, parallel assignment of either 6% HES 130/0.4 or 0.9% sodium chloride for all fluid resuscitation needs whilst in the intensive care unit (ICU). The primary outcome will be all-cause mortality at 90 days post-randomisation. Secondary outcomes will include incident renal injury, other organ failures, ICU and hospital mortality, length of ICU stay, quality of life at 6 months, health economic analyses and in patients with traumatic brain injury, functional outcome. Subgroup analyses will be conducted in four predefined subgroups. All analyses will be conducted on an intention-to-treat basis. The study run-in phase has been completed and the main trial commenced in April 2010. CHEST should generate results that will inform and influence prescribing of this commonly used resuscitation fluid.	[Myburgh, John] Univ New S Wales, St George Hosp, George Inst, Sydney, NSW, Australia; [Bellomo, Rinaldo] Univ Melbourne, George Inst, Austin Hosp, Melbourne, Vic 3010, Australia; [Cass, Alan; Liu, Bette; Taylor, Colman] Univ Sydney, George Inst, Sydney, NSW 2006, Australia; [Finfer, Simon] Univ Sydney, George Inst, Royal N Shore Hosp, Sydney, NSW 2006, Australia; [Gattas, David] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Lipman, Jeffrey] Univ Queensland, Royal Brisbane & Womens Hosp, Brisbane, Qld 4072, Australia; [McArthur, Colin; Webb, Steve] Australian & New Zealand Intens Care Soc Clin Tri, Carlton, Vic, Australia; [McGuinness, Shay] Auckland Cardiovasc Hosp, Auckland, New Zealand		Myburgh, J (corresponding author), George Inst Int Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.	jmyburgh@george.org.au	Liu, Bette C/A-7581-2013; Gattas, David/AAN-9668-2020; Lipman, Jeffrey/G-2211-2010	Liu, Bette C/0000-0002-0787-5825; Gattas, David/0000-0002-9282-7093; Lipman, Jeffrey/0000-0002-5965-9876; Cass, Alan/0000-0002-3923-3173; Glass, Parisa/0000-0002-1334-7156; Finfer, Simon/0000-0002-2785-5864	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; New South Wales Department of Health and Fresenius Kabi	The bodies currently funding this study include the Australian National Health and Medical Research Council, New South Wales Department of Health and Fresenius Kabi. The funders had no input into the design of the trial. Fresenius Kabi has provided the blinded study treatment for the conduct of the trial and will manage the warehousing and temperature-controlled distribution of study treatment from the manufacturing plant in Germany to each of the 33 participating centres that are anticipated to be recruiting throughout Australia and New Zealand. All blinded study treatment has been manufactured according to Good Manufacturing Practice requirements as applied to Investigational Medicinal Products. Fresenius Kabi reviewed the protocol to ensure it meets with their regulatory obligations. The funders do not have access to the trial data and all analyses and reports will be conducted independently of the funders.	Antonelli M, 2010, INTENS CARE MED, V36, P412, DOI 10.1007/s00134-010-1770-3; Boldt J, 2008, BRIT J ANAESTH, V100, P457, DOI 10.1093/bja/aen016; Boldt J, 2003, INTENS CARE MED, V29, P763, DOI 10.1007/s00134-003-1702-6; Boldt J, 2007, CRIT CARE MED, V35, P2740, DOI 10.1097/01.CCM.0000288101.02556.DE; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bunn F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001319.pub2; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Fenger-Eriksen C, 2005, ACTA ANAESTH SCAND, V49, P969, DOI 10.1111/j.1399-6576.2005.00714.x; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Fluids Study Investigators, 2008, ACTA ANAESTH SCAND, V52, P750, DOI 10.1111/j.1399-6576.2008.01690.x; Jones D, 2010, ANAESTH INTENS CARE, V38, P266, DOI 10.1177/0310057X1003800207; Kellum JA, 2007, CONTRIB NEPHROL, V156, P10; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mahmood A, 2007, BRIT J SURG, V94, P427, DOI 10.1002/bjs.5726; Martin GS, 2004, AM J RESP CRIT CARE, V170, P1247, DOI 10.1164/rccm.200208-909ST; Miletin MS, 2002, INTENS CARE MED, V28, P917, DOI 10.1007/s00134-002-1337-z; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Neff TA, 2003, ANESTH ANALG, V96, P1453, DOI 10.1213/01.ANE.0000061582.09963.FD; Perel P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub3; Schortgen F, 2004, INTENS CARE MED, V30, P2222, DOI 10.1007/s00134-004-2415-1; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; US Food and Drug Administration, 2003, GUID IND 11 GUID IND 11; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zarychanski R, 2008, CLIN INVESTIGATIVE S, V31, pS26	27	34	34	1	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2011	37	5					816	823		10.1007/s00134-010-2117-9			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747AG	WOS:000289291900013	21308360				2022-02-06	
J	Robertson, CS; Gopinath, SP; Valadka, AB; Van, M; Swank, PR; Goodman, JC				Robertson, Claudia S.; Gopinath, Shankar P.; Valadka, Alex B.; Van, Mai; Swank, Paul R.; Goodman, J. Clay			Variants of the Endothelial Nitric Oxide Gene and Cerebral Blood Flow after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CBF autoregulation; cerebral vascular disease; head trauma; vascular reactivity; traumatic brain injury	CORTICAL IMPACT INJURY; SYNTHASE GENE; APOLIPOPROTEIN-E; ISCHEMIC-STROKE; HEAD-INJURY; L-ARGININE; POLYMORPHIC VARIANTS; T-786C POLYMORPHISM; CAROTID-ARTERY; AUTOREGULATION	Experimental studies suggest that nitric oxide produced by endothelial nitric oxide synthase (NOS3) plays a role in maintaining cerebral blood flow (CBF) after traumatic brain injury (TBI). The purpose of this study was to determine if common variants of the NOS3 gene contribute to hypoperfusion after severe TBI. Fifty-one patients with severe TBI were studied. Cerebral hemodynamics, including global CBF by the stable xenon computed tomography (CT) technique, internal carotid artery flow volume (ICA-FVol), and flow velocity in intracranial vessels, were measured within 12 h of injury, and at 48 h after injury. A blood sample was collected for DNA analysis, and genotyping of the following variants of the NOS3 gene was performed: -786T > C, 894G > T, and 27bp VNTR. Cerebral hemodynamics were most closely related to the -786T > C genotype. CBF averaged 57.7 +/- 3.0 mL/100g/min with the normal T/T genotype, 47.0 +/- 2.5 mL/100g/min with the T/C, and 37.3 +/- 8.8 mL/100g/min with the C/C genotype (p = 0.0146). Cerebrovascular resistance followed an inverse pattern with the highest values occurring with the C/C genotype (p = 0.0027). The lowest ICA-FVol of 124 +/- 43mL/min was found at 12 h post-injury in the more injured hemisphere of the patients with the C/C genotype (p = 0.0085). The mortality rate was 20% in patients with the T/T genotype and 17% with the T/C genotype. In contrast, both of the patients with the C/C genotype were dead at 6 months post-injury (p = 0.022). The findings in this study support the importance of NO produced by NOS3 activity in maintaining CBF after TBI, since lower CBF values were found in patients having the -786C allele. The study suggests that a patient's individual genetic makeup may contribute to the brain's response to injury and determine the patient's chances of surviving the injury. The results here will need to be studied in a larger number of patients, but could explain some of the variability in outcome that occurs following severe TBI.	[Robertson, Claudia S.; Gopinath, Shankar P.; Van, Mai] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Goodman, J. Clay] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Swank, Paul R.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden,Suite 750,MS BCM650, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS048428]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048428] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health grant no. R01-NS048428.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Asif AR, 2009, J PROTEOME RES, V8, P3161, DOI 10.1021/pr800998k; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BUCHANAN JE, 1993, BRAIN RES, V610, P248, DOI 10.1016/0006-8993(93)91408-K; Casas JP, 2004, CIRCULATION, V109, P1359, DOI 10.1161/01.CIR.0000121357.76910.A3; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Cherian L, 2003, J PHARMACOL EXP THER, V304, P617, DOI 10.1124/JPET.102.043430; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; FIELD M, 2001, AM ASS NEUR SURG ABS; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Hlatky R, 2006, NEUROCRIT CARE, V4, P127, DOI 10.1385/NCC:4:2:127; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Howard TD, 2005, STROKE, V36, P1848, DOI 10.1161/01.STR.0000177978.97428.53; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Khurana VG, 2005, J NEUROSURG, V102, P526, DOI 10.3171/jns.2005.102.3.0526; Kleffner I, 2008, STROKE, V39, P1333, DOI 10.1161/STROKEAHA.107.500785; Ko NU, 2008, STROKE, V39, P1103, DOI 10.1161/STROKEAHA.107.496596; KOBARI M, 1994, BRAIN RES, V667, P255, DOI 10.1016/0006-8993(94)91503-2; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Leeson CPM, 2002, CIRC RES, V90, P1153, DOI 10.1161/01.RES.0000020562.07492.D4; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Majumdar V, 2010, J ATHEROSCLER THROMB, V17, P45, DOI 10.5551/jat.1560; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martinez-Lucas P, 2005, INTENS CARE MED, V31, P1168, DOI 10.1007/s00134-005-2715-0; McDonald DM, 2004, PHARMACOGENETICS, V14, P831, DOI 10.1097/00008571-200412000-00006; Miyamoto Y, 2000, HUM MOL GENET, V9, P2629, DOI 10.1093/hmg/9.18.2629; Nasreen S, 2002, ARTERIOSCL THROM VAS, V22, P605, DOI 10.1161/01.ATV.0000013286.60021.FE; Persu A, 2002, HUM MOL GENET, V11, P229, DOI 10.1093/hmg/11.3.229; Reutens DC, 1997, J CEREBR BLOOD F MET, V17, P309, DOI 10.1097/00004647-199703000-00008; Rossi GP, 2003, J AM COLL CARDIOL, V41, P938, DOI 10.1016/S0735-1097(02)03011-5; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Saidi S, 2010, ACTA NEUROL SCAND, V121, P114, DOI 10.1111/j.1600-0404.2009.01192.x; Savvidou MD, 2001, HYPERTENSION, V38, P1289, DOI 10.1161/hy1201.097305; Smielewski P, 1996, STROKE, V27, P2197, DOI 10.1161/01.STR.27.12.2197; Song J, 2010, INT J MOL MED, V25, P819, DOI 10.3892/ijmm_00000410; Sorani MD, 2008, HUM MUTAT, V29, P1108, DOI 10.1002/humu.20762; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tanus-Santos JE, 2001, PHARMACOGENETICS, V11, P719, DOI 10.1097/00008571-200111000-00011; Tao HM, 2009, NEUROSCI RES, V64, P311, DOI 10.1016/j.neures.2009.04.001; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Tsukada T, 1998, BIOCHEM BIOPH RES CO, V245, P190, DOI 10.1006/bbrc.1998.8267; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; White RP, 2000, CLIN SCI, V99, P555, DOI 10.1042/CS20000064; Yemisci M, 2009, FREE RADICAL RES, V43, P272, DOI 10.1080/10715760802691489	53	34	37	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					727	737		10.1089/neu.2010.1476			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100273	21332418	Green Published			2022-02-06	
J	Tepas, JJ; Pracht, EE; Orban, BL; Flint, LM				Tepas, Joseph J., III; Pracht, Etienne E.; Orban, Barbara L.; Flint, Lewis M.			Insurance Status, Not Race, Is a Determinant of Outcomes from Vehicular Injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	122nd Annual Meeting of the Southern-Surgical-Association	DEC, 2010	Palm Beach, FL	So Surg Assoc			ETHNIC DISPARITIES; RACIAL-DIFFERENCES; TRAUMA CENTERS; MORTALITY; CARE; SURVIVAL; SYSTEM	BACKGROUND: Hypothesizing that outcomes from specific injury mechanisms should not vary by race or socioeconomic status, we analyzed the relationship of race and ethnicity to fatality in motor vehicle crash victims treated during 2008 and 2009. STUDY DESIGN: Logistic regression analysis of pooled administrative data assessed the contribution of patient demographics and injury severity to outcome, defined as mortality during acute hospitalization. Demographic factors included age, sex, race, ethnicity, and insurance. Severe injury was defined using ICD-9 Injury Severity Score (survival probability) p < 0.85, presence of up to 3 comorbidities, and/or diagnosis of spinal cord injury and/or traumatic brain injury. Mortality was stratified by survival time after trauma center arrival to death within 24 hours or thereafter. Factors contributing to outcomes were tested using chi square analysis of the calculated model estimate. RESULTS: For 8,758 motor vehicle crash victims treated in state-designated trauma centers, age, sex, injury severity, and 2 or more comorbidities consistently predicted survival. Neither race nor ethnicity was associated with increased mortality risk. Being uninsured was related to death within 24 hours (p < 0.001). The majority of the uninsured who died within 24 hours had an ICD-9 Injury Severity Score p <= 0.5. Mortality risk after 24 hours was driven by traumatic brain injury and comorbidities. CONCLUSIONS: The results of this study indicated that higher immediate mortality of the uninsured is a behavioral and socioeconomic rather than physiologic marker. This higher mortality is driven by increased injury severity that increases cost of care in uninsured survivors. This disparity suggests that risk-taking behavior, especially relating to safety practices and licensing regulations, is an important etiologic factor. Improved outcomes require better public education and enforcement in conjunction with improvements in processes of care. (J Am Coll Surg 2011; 212:722-729. (C) 2011 by the American College of Surgeons)	[Tepas, Joseph J., III] Univ Florida, Hlth Sci Ctr, Dept Surg, Jacksonville, FL 32209 USA; [Orban, Barbara L.] Univ S Florida, Coll Publ Hlth, Jacksonville, FL USA; [Flint, Lewis M.] Univ S Florida, Dept Hlth Policy & Management, Jacksonville, FL USA; [Pracht, Etienne E.] Amer Coll Surg, Chicago, IL USA		Tepas, JJ (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Surg, 655 W 8th St, Jacksonville, FL 32209 USA.						Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Crompton JG, 2010, AM J SURG, V200, P191, DOI 10.1016/j.amjsurg.2009.07.047; Dillingham TR, 2002, ARCH PHYS MED REHAB, V83, P1252, DOI 10.1053/apmr.2002.34805; Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; Greene WR, 2010, AM J SURG, V199, P554, DOI 10.1016/j.amjsurg.2009.11.005; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 1999, J TRAUMA, V47, pS34, DOI 10.1097/00005373-199909001-00008; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Maybury RS, 2010, SURGERY, V148, P202, DOI 10.1016/j.surg.2010.05.010; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler TM, 1998, J TRAUMA, V45, P234, DOI 10.1097/00005373-199808000-00006; Pracht EE, 2007, MED CARE RES REV, V64, P83, DOI 10.1177/1077558706296241; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; Smith WR, 2007, ANN INTERN MED, V147, P654, DOI 10.7326/0003-4819-147-9-200711060-00010; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Tyburski JG, 1998, J TRAUMA, V45, P237	21	34	34	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	APR	2011	212	4					722	727		10.1016/j.jamcollsurg.2010.12.016			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	748YU	WOS:000289430000058	21463821				2022-02-06	
J	Lu, KT; Sun, CL; Wo, PYY; Yen, HH; Tang, TH; Ng, MC; Huang, ML; Yang, YL				Lu, Kwok-Tung; Sun, Chien-Lun; Wo, Peter Y. Y.; Yen, Hao-Han; Tang, Tsao-Hao; Ng, Ming-Chong; Huang, Min-Lang; Yang, Yi-Ling			Hippocampal Neurogenesis after Traumatic Brain Injury Is Mediated by Vascular Endothelial Growth Factor Receptor-2 and the Raf/MEK/ERK Cascade	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; mitogen-activated protein kinase; neurogenesis; rat; traumatic brain injury; vascular endothelial growth factor	STIMULATES NEUROGENESIS; SIGNAL-TRANSDUCTION; DENTATE GYRUS; IN-VITRO; ADULT; VEGF; EDEMA; EXPRESSION; PATHWAY; CELLS	Adult neurogenesis occurs in the subgranular zone of the hippocampal dentate gyrus, and can be modulated by physiological and pathological events. We examined the effect of vascular endothelial growth factor (VEGF), and the correlation between VEGF and the Raf/MEK/ERK cascade in neurogenesis after traumatic brain injury (TBI). The expression of VEGF and the phosphorylation level of Raf/MEK/ERK were analyzed by Western blot, and TBI-induced neurogenesis was determined by immunofluorescence labeling and confocal microscopic detection. Hippocampal VEGF began to increase after 12 h, and reached a peak at day 7. Along with the upregulation of VEGF, neurogenesis in the hippocampus also increased. Administration of the VEGF antisense oligodeoxynucleotide, or the VEGF receptor-2 antagonist SU1498 (10 mu g, ICV), attenuated the phosphorylation of the MAPK cascade proteins and caused a decrease in neurogenesis in the hippocampus. Similarly, administration of the ERK inhibitor PD98059 (500 ng, ICV) also exhibited a suppressive effect on neurogenesis. Our results indicate that VEGF plays an important role in neurogenesis after TBI, and that the process involves VEGF receptor-2 and the Raf/MEK/ERK cascade.	[Sun, Chien-Lun; Wo, Peter Y. Y.; Yen, Hao-Han; Yang, Yi-Ling] Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi, Taiwan; [Lu, Kwok-Tung; Tang, Tsao-Hao; Ng, Ming-Chong] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; [Huang, Min-Lang] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan		Yang, YL (corresponding author), Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw			National Science CouncilMinistry of Science and Technology, Taiwan [NSC 97-2320-B-415-006-MY3, NSC 97-2320-B-003-001-MY3]	This work was supported by National Science Council grants NSC 97-2320-B-415-006-MY3 and NSC 97-2320-B-003-001-MY3.	Bellon A, 2010, NEURON, V66, P205, DOI 10.1016/j.neuron.2010.04.006; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Galvan V, 2006, MINI-REV MED CHEM, V6, P667, DOI 10.2174/138955706777435742; Galvan V, 2007, CLIN INTERV AGING, V2, P605; Gerstner ER, 2009, NAT REV CLIN ONCOL, V6, P229, DOI 10.1038/nrclinonc.2009.14; Hatakeyama M, 2007, HEART VESSELS, V22, P123, DOI 10.1007/s00380-006-0942-0; Hossain MA, 2004, ANN NEUROL, V55, P660, DOI 10.1002/ana.20065; Huang GJ, 2005, NEUROSCIENCE, V135, P803, DOI 10.1016/j.neuroscience.2005.05.056; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kranich S, 2009, NEUROCHEM INT, V55, P747, DOI 10.1016/j.neuint.2009.07.007; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 2000, J NEUROTRAUM, V17, P143; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; Miljan EA, 2009, CURR OPIN MOL THER, V11, P394; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Rao MS, 2005, EUR J NEUROSCI, V21, P464, DOI 10.1111/j.1460-9568.2005.03853.x; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Sun FY, 2005, J NEUROSCI RES, V79, P180, DOI 10.1002/jnr.20321; Sun YJ, 2006, DEV BIOL, V289, P329, DOI 10.1016/j.ydbio.2005.10.016; Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Watari K, 2008, BIOCHEM BIOPH RES CO, V377, P826, DOI 10.1016/j.bbrc.2008.10.077; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9	47	34	41	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					441	450		10.1089/neu.2010.1473			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600009	21091268				2022-02-06	
J	Wong, AC; Kowalenko, T; Roahen-Harrison, S; Smith, B; Maio, RF; Stanley, RM				Wong, Andrew C.; Kowalenko, Terry; Roahen-Harrison, Stephanie; Smith, Barbara; Maio, Ronald F.; Stanley, Rachel M.			A Survey of Emergency Physicians' Fear of Malpractice and Its Association With the Decision to Order Computed Tomography Scans for Children With Minor Head Trauma	PEDIATRIC EMERGENCY CARE			English	Article						malpractice; computed tomography; mild traumatic brain injury	RISK	Objective: The objective of the study was to determine whether fear of malpractice is associated with emergency physicians' decision to order head computed tomography (CT) in 3 age-specific scenarios of pediatric minor head trauma. We hypothesized that physicians with higher fear of malpractice scores will be more likely to order head CT scans. Methods: Board-eligible/board-certified members of the Michigan College of Emergency Physicians were sent a 2-part survey consisting of case scenarios and demographic questions. Effect of fear of malpractice on the decision to order a CT scan was evaluated using a cumulative logit model. Results: Two hundred forty-six members (36.5%) completed the surveys. In scenario 1 (infant), being a male and working in a university setting were associated with reduced odds of ordering a CT scan (odds ratio [OR], 0.40; 95% confidence interval [CI], 0.18-0.88; and OR, 0.35; 95% CI, 0.13-0.96, respectively). In scenario 2 (toddler), working for 15 years or more, at multiple hospitals, and for a private group were associated with reduced odds of ordering a CT scan (OR, 0.46; 95% CI, 0.26-0.79; OR, 0.36; 95% CI, 0.16-0.80; and OR, 0.51; 95% CI, 0.27-0.94, respectively). No demographic variables were significantly associated with ordering a CT scan in scenario 3 (teen). Overall, the fear of malpractice was not significantly associated with ordering a CT scan (OR, 1.28; 95% CI, 0.73-2.26; and OR, 1.70; 95% CI, 0.97-3.0). Only in scenario 2 was high fear significantly associated with increased odds of ordering a CT scan (OR, 2.09; 95% CI, 1.08-4.05). Conclusions: Members of Michigan College of Emergency Physicians with a higher fear of malpractice score tended to order more head CT scans in pediatric minor head trauma. However, this trend was shown to be statistically significant only in 1 case and not overall.	[Wong, Andrew C.; Kowalenko, Terry; Roahen-Harrison, Stephanie; Smith, Barbara; Maio, Ronald F.; Stanley, Rachel M.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA		Wong, AC (corresponding author), Univ Michigan Hosp, Dept Emergency Med, Taubman Ctr B1 380,1500 E Med Ctr, Ann Arbor, MI 48109 USA.	andrewcw@med.umich.edu		Wong, Andrew/0000-0002-5350-1947			GAMEROFF M, SUGI 30 STAT DATA AN; Katz DA, 2005, ANN EMERG MED, V46, P525, DOI 10.1016/j.annemergmed.2005.04.016; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Schriger DL, 2005, ANN EMERG MED, V46, P534, DOI 10.1016/j.annemergmed.2005.06.445; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609	7	34	34	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	MAR	2011	27	3					182	185		10.1097/PEC.0b013e31820d64f7			4	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	730CD	WOS:000288007000005	21346679				2022-02-06	
J	Filippetti, VA; Allegri, RF				Aran Filippetti, Vanessa; Allegri, Ricardo F.			Verbal Fluency in Spanish-Speaking Children: Analysis Model According to Task Type, Clustering, and Switching Strategies and Performance Over Time	CLINICAL NEUROPSYCHOLOGIST			English	Article						Verbal fluency; Cognitive strategies; Cognitive processing; Executive functions; Child neuropsychology	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; SCHOOL-AGED CHILDREN; WORD FLUENCY; EXECUTIVE FUNCTIONS; CATEGORY FLUENCY; NORMATIVE DATA; FRONTAL-LOBE; DEVELOPMENTAL ASPECTS; 12-YEAR-OLD CHILDREN	Verbal fluency (VF) tasks are extensively used to measure strategic retrieval and executive functioning. Results for total production of words, clustering and switching strategies, and performance over time for Spanish-speaking children are provided. A total of 120 children, ranging in age from 8 to 11, were divided by age into two groups and evaluated. A higher total score for words produced in the semantic compared with the phonological task, a correlation between clustering and switching strategies and total score, and decreased task performance over time were evidenced. These scores were higher in the older group. Moreover, an association was found between verbal fluency tasks, strategies employed, and cognitive executive functions. This indicates that clustering and switching strategies provide indicators of strategic retrieval and executive processes. Together the results suggest that these fluency scores are valuable to measure underlying cognitive processes and retrieval strategies and therefore could be useful to assess executive function deficits in children.	[Aran Filippetti, Vanessa] CIIPME CONICET, Interdisciplinary Ctr Math & Expt Psychol Res, RA-1040 Buenos Aires, DF, Argentina; [Allegri, Ricardo F.] FLENI, Serv Cognit Neurol, Buenos Aires, DF, Argentina		Filippetti, VA (corresponding author), CIIPME CONICET, Interdisciplinary Ctr Math & Expt Psychol Res, Tte Gral Peron 2158, RA-1040 Buenos Aires, DF, Argentina.	vanessaaranf@gmail.com	ALLEGRI, RICARDO/AAY-4898-2021	Allegri, Ricardo Francisco/0000-0001-7166-1234	National Council of Scientific and Technological Research (CONICET), ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	This research was supported by the National Council of Scientific and Technological Research (CONICET), Argentina.	Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; ARAM DM, 1987, BRAIN LANG, V31, P61, DOI 10.1016/0093-934X(87)90061-7; ARDILA A, 1994, DEV NEUROPSYCHOL, V10, P97, DOI 10.1080/87565649409540571; Baldo JV, 2006, J INT NEUROPSYCH SOC, V12, P896, DOI 10.1017/S1355617706061078; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Brickenkamp R., 1962, AUFMERKSAMKEITS BELA; Brucki SMD, 2004, BRAZ J MED BIOL RES, V37, P1771, DOI 10.1590/S0100-879X2004001200002; Chugani HT, 1999, NEUROSCIENTIST, V5, P29, DOI 10.1177/107385849900500105; Cohen MJ, 1999, ARCH CLIN NEUROPSYCH, V14, P433, DOI 10.1016/S0887-6177(98)00038-9; Crowe SF, 1998, J CLIN EXP NEUROPSYC, V20, P391, DOI 10.1076/jcen.20.3.391.810; Fernaeus SE, 1998, J CLIN EXP NEUROPSYC, V20, P137, DOI 10.1076/jcen.20.2.137.1170; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Golden CJ, 1978, STROOP COLOR WORD TE; HALPERIN JM, 1989, J CLIN EXP NEUROPSYC, V11, P518, DOI 10.1080/01688638908400910; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Hernandez MT, 2002, NEUROPSYCHOLOGIA, V40, P384, DOI 10.1016/S0028-3932(01)00130-0; Hurks PPM, 2006, J CLIN EXP NEUROPSYC, V28, P684, DOI 10.1080/13803390590954191; Hurks PPM, 2004, BRAIN COGNITION, V55, P535, DOI 10.1016/j.bandc.2004.03.003; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kaufman AS, 1990, K BIT KAUFMAN BRIEF; Kave G, 2006, DEV NEUROPSYCHOL, V29, P493, DOI 10.1207/s15326942dn2903_7; Kave G, 2008, J CLIN EXP NEUROPSYC, V30, P349, DOI 10.1080/13803390701416197; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kodituwakku PW, 2006, J STUD ALCOHOL, V67, P502, DOI 10.15288/jsa.2006.67.502; Koren R, 2005, ARCH CLIN NEUROPSYCH, V20, P1087, DOI 10.1016/j.acn.2005.06.012; Korkman M, 2001, DEV NEUROPSYCHOL, V20, P325, DOI 10.1207/S15326942DN2001_1; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lindgren A, 2004, EPILEPSY BEHAV, V5, P903, DOI 10.1016/j.yebeh.2004.08.004; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; MARTIN A, 1994, NEUROPSYCHOLOGIA, V32, P1487, DOI 10.1016/0028-3932(94)90120-1; MARTIN RC, 1990, NEUROPSYCHOLOGIA, V28, P823, DOI 10.1016/0028-3932(90)90006-A; Martins IP, 2007, CHILD NEUROPSYCHOL, V13, P319, DOI 10.1080/09297040600837370; Matute E, 2004, DEV NEUROPSYCHOL, V26, P647, DOI 10.1207/s15326942dn2602_7; Milner B., 1964, FRONTAL GRANULAR COR, P313; Mummery CJ, 1996, P ROY SOC B-BIOL SCI, V263, P989, DOI 10.1098/rspb.1996.0146; Nash HM, 2008, COGN NEUROPSYCHOL, V25, P690, DOI 10.1080/02643290802274064; Nieto A, 2008, REV NEUROLOGIA, V46, P2, DOI 10.33588/rn.4601.2007390; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; PENDLETON MG, 1982, J CLIN NEUROPSYCHOL, V4, P307, DOI 10.1080/01688638208401139; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Phillips L. H, 1997, METHODOLOGY FRONTAL, P191; Pineda D, 1998, INT J NEUROSCI, V96, P177, DOI 10.3109/00207459808986466; Pineda D, 1999, J LEARN DISABIL, V32, P159, DOI 10.1177/002221949903200206; Raboutet C, 2010, J CLIN EXP NEUROPSYC, V32, P268, DOI 10.1080/13803390902984464; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Reiter A, 2005, DYSLEXIA, V11, P116, DOI 10.1002/dys.289; Rey A., 1964, EXAMEN CLIN PSYCHOL; Riva D, 2000, BRAIN LANG, V71, P267, DOI 10.1006/brln.1999.2166; Rosselli M, 2009, AGING NEUROPSYCHOL C, V16, P721, DOI 10.1080/13825580902912739; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Sauzeon H, 2004, BRAIN LANG, V89, P192, DOI 10.1016/S0093-934X(03)00367-5; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Schonfeld AM, 2001, J STUD ALCOHOL, V62, P239, DOI 10.15288/jsa.2001.62.239; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Szatkowska I, 2000, ACTA NEUROBIOL EXP, V60, P503; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Villodre R, 2006, NEUROLOGIA, V21, P124; Wechsler D, 2003, WECHSLER INTELLIGENC; Zelazo P. D., 1997, LANGUAGE STRUCTURE D, P113; Zelazo PD, 1998, CURR DIR PSYCHOL SCI, V7, P121, DOI 10.1111/1467-8721.ep10774761	71	34	34	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					413	436	PII 936246304	10.1080/13854046.2011.559481			24	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100006	21491348				2022-02-06	
J	Johnson, EW; Kegel, NE; Collins, MW				Johnson, Eric W.; Kegel, Nathan E.; Collins, Michael W.			Neuropsychological Assessment of Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Neuropsychology; Concussion; mTBI; Sports; Assessment; Management	COMPUTER-BASED ASSESSMENT; TEST-RETEST RELIABILITY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES; RECOVERY; COLLEGIATE; PERFORMANCE; STATEMENT; SENSITIVITY	Assessment of concussion can be challenging for medical practitioners given the different factors associated with each individual injury. The use of neuropsychological testing provides an objective method in the evaluation and management of concussion. Over the last 20 years it has become increasingly useful in the realm of sports concussion and has been deemed a cornerstone of concussion management by the Concussion in Sport group at the International Symposia on Concussion in Sport. Neuropsychological assessment has evolved to using computer-based neurocognitive testing, which has become increasingly common over the last decade, especially in organized sports. Neuropsychological assessment has also proven to be effective in the detection of differences based on several individual factors, including age, gender, and history of prior concussion. Despite its documented value, neuropsychological assessment should be one of several tools used as part of the concussion assessment/management process.	[Johnson, Eric W.; Kegel, Nathan E.] Univ Pittsburgh, Med Ctr, Sports Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg & Neurol Surg, Pittsburgh, PA 15203 USA		Johnson, EW (corresponding author), Univ Pittsburgh, Med Ctr, Sports Concuss Program, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15203 USA.	johnsonew@upmc.edu					Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 1989, MILD HEAD INJURY, P257; BARTH JT, 2006, SPORTS NEUROPSYCHOLO; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; COLLIE A, 2001, BRIT J SPORT MED, V35, P7; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gardner A, 2010, ARCH CLIN NEUROPSYCH, V25, P174, DOI 10.1093/arclin/acq007; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2009, BR J SPORTS MED S1, V43, P100; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2010, 2010 BIG SKY ATHL TR; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Lovell MR, 2000, IMMEDIATE POSTCONCUS; Lovell MR, 2006, SPORTS NEUROPSYCHOLO, P176; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI [10.1001/jama.290.19.2556, DOI 10.1001/JAMA.290.19.2556]; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory Paul, 2005, Clin J Sport Med, V15, P48; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; PARDINI D, 2004, 2 INT S CONC SPORT P; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2006, SPORTS NEUROPSYCHOLO, P160; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Zillmer E.., 2006, SPORTS NEUROPSYCHOLO, P17	62	34	34	2	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					73	+		10.1016/j.csm.2010.08.007			18	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	691XR	WOS:000285114800008	21074083				2022-02-06	
J	Kave, G; Heled, E; Vakil, E; Agranov, E				Kave, Gitit; Heled, Eyal; Vakil, Eli; Agranov, Eugenia			Which verbal fluency measure is most useful in demonstrating executive deficits after traumatic brain injury?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Verbal fluency; Traumatic brain injury; Switching and clustering; Executive functions; Language testing; Hebrew	SEMANTIC FLUENCY; CATEGORY FLUENCY; NORMATIVE DATA; DISPROPORTIONATE IMPAIRMENT; ALZHEIMERS-DISEASE; PHONEMIC FLUENCY; PERFORMANCE; MEMORY; COMPONENTS; DEMENTIA	This paper examines switching and clustering in phonemic and semantic fluency tasks in individuals with traumatic brain injury (TBI). Fluency tasks were administered to 30 Hebrew-speaking patients with TBI and 30 age-matched control participants. Significant group differences were found in total output, number of switches, and number of clusters on both tasks, but not in mean cluster size. Unlike prediction, z scores of the number of semantic switches and clusters were lower than the equivalent z scores on the phonemic test. Results highlight the executive component of semantic fluency and the importance of using this task when assessing cognitive functioning after TBI.	[Kave, Gitit] Open Univ, Dept Educ & Psychol, IL-43107 Raanana, Israel; [Heled, Eyal] Hebrew Univ Jerusalem, Jerusalem, Israel; [Heled, Eyal; Agranov, Eugenia] Sheba Med Ctr, Ramat Gan, Israel; [Vakil, Eli] Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel; [Vakil, Eli] Bar Ilan Univ, Leslie & Susan Gonda Goldschmied Multidisciplinar, Ramat Gan, Israel; [Agranov, Eugenia] Tel Aviv Univ, Fac Med, IL-69978 Tel Aviv, Israel		Kave, G (corresponding author), Open Univ, Dept Educ & Psychol, 1 Univ Rd,POB 808, IL-43107 Raanana, Israel.	gkave@012.net.il		Kave, Gitit/0000-0002-4950-5507	Rehabilitation Center for Veterans after traumatic brain injury (TBI) in Jaffa, Israel	This study was partially supported by a grant from the Rehabilitation Center for Veterans after traumatic brain injury (TBI) in Jaffa, Israel, given to the third author. We wish to thank Ayelet Avraham and Reut Lerer for their help in coding the data. There are no financial or other relationships that could be interpreted as a conflict of interests.	Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Axelrod B N, 2001, Appl Neuropsychol, V8, P248, DOI 10.1207/09084280152829101; Bittner RM, 2007, BRAIN INJURY, V21, P709, DOI 10.1080/02699050701468917; Bittner RM, 2006, BRAIN INJURY, V20, P971, DOI 10.1080/02699050600909763; Bokat CE, 2003, SCHIZOPHR RES, V64, P73, DOI 10.1016/S0920-9964(02)00282-7; Bozikas VP, 2005, SCHIZOPHR RES, V74, P51, DOI 10.1016/j.schres.2004.05.001; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Capitani E, 2009, NEUROPSYCHOLOGIA, V47, P423, DOI 10.1016/j.neuropsychologia.2008.09.016; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Epker MO, 1999, J CLIN EXP NEUROPSYC, V21, P425, DOI 10.1076/jcen.21.4.425.890; Fagundo AB, 2008, INT J GERIATR PSYCH, V23, P1007, DOI 10.1002/gps.2025; Fossati P, 2003, PSYCHIAT RES, V117, P17, DOI 10.1016/S0165-1781(02)00300-1; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kave G, 2005, J CLIN EXP NEUROPSYC, V27, P690, DOI 10.1080/13803390490918499; Kave G, 2008, J CLIN EXP NEUROPSYC, V30, P349, DOI 10.1080/13803390701416197; Kave G, 2007, J INT NEUROPSYCH SOC, V13, P424, DOI 10.1017/S1355617707070622; Koren R, 2005, ARCH CLIN NEUROPSYCH, V20, P1087, DOI 10.1016/j.acn.2005.06.012; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Kremen WS, 2003, J INT NEUROPSYCH SOC, V9, P79, DOI 10.1017/S1355617703910095; Lanting S, 2009, J INT NEUROPSYCH SOC, V15, P196, DOI 10.1017/S1355617709090237; Rogers TT, 2006, NEUROPSYCHOLOGY, V20, P319, DOI 10.1037/0894-4105.20.3.319; Rosselli M, 2009, AGING NEUROPSYCHOL C, V16, P721, DOI 10.1080/13825580902912739; ROSSER A, 1994, J NEUROL NEUROSUR PS, V57, P1389, DOI 10.1136/jnnp.57.11.1389; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Troster AI, 1998, NEUROPSYCHOLOGIA, V36, P295, DOI 10.1016/S0028-3932(97)00153-X; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Tucha Oliver, 2005, Cogn Neuropsychiatry, V10, P231, DOI 10.1080/13546800444000047; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vakil E, 2004, CHILD NEUROPSYCHOL, V10, P57, DOI 10.1080/09297040490911078; Woods SP, 2004, NEUROPSYCHOLOGIA, V42, P801, DOI 10.1016/j.neuropsychologia.2003.11.010	36	34	35	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	3					358	365	PII 929133278	10.1080/13803395.2010.518703			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	733LH	WOS:000288263700009	21058118				2022-02-06	
J	Potvin, MJ; Rouleau, I; Senechal, G; Giguere, JF				Potvin, Marie-Julie; Rouleau, Isabelle; Senechal, Genevieve; Giguere, Jean-Francois			Prospective memory rehabilitation based on visual imagery techniques	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Prospective memory; Cognitive rehabilitation; Prospective remembering; Visual imagery; Mnemonic strategy	TRAUMATIC BRAIN-INJURY; MILD ALZHEIMERS-DISEASE; EVERYDAY MEMORY; ADULTS; QUESTIONNAIRE; INDIVIDUALS; RELIABILITY; PERFORMANCE; INTENTIONS; RETRIEVAL	Despite the frequency of prospective memory (PM) problems in the traumatic brain injury (TBI) population, there are only a few rehabilitation programmes that have been specifically designed to address this issue, other than those using external compensatory strategies. In the present study, a PM rehabilitation programme based on visual imagery techniques expected to strengthen the cue-action association was developed. Ten moderate to severe chronic TBI patients learned to create a mental image representing the association between a prospective cue and an intended action within progressively more complex and naturalistic PM tasks. We hypothesised that compared to TBI patients (n = 20) who received a short session of education (control condition), TBI patients in the rehabilitation group would exhibit a greater improvement on the event-based than on the time-based condition of a PM ecological task. Results revealed however that this programme was similarly beneficial for both conditions. TBI patients in the rehabilitation group and their relatives also reported less everyday PM failures following the programme, which suggests generalisation. The PM improvement appears to be specific since results on cognitive control tasks remained similar. Therefore, visual imagery techniques appear to improve PM functioning by strengthening the memory trace of the intentions and inducing an automatic recall of the intentions.	[Rouleau, Isabelle] Univ Quebec, Dept Psychol, Inst Cognit Sci, Montreal, PQ H3C 3P8, Canada; [Potvin, Marie-Julie; Giguere, Jean-Francois] Hop Sacre Coeur Montreal, Neurotraumatol Program, Montreal, PQ, Canada		Rouleau, I (corresponding author), Univ Quebec, Dept Psychol, Inst Cognit Sci, CP 8888,Succursale Ctr Ville, Montreal, PQ H3C 3P8, Canada.	rouleau.isabelle@uqam.ca		Potvin, Marie-Julie/0000-0001-5503-8063	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); FRSQFonds de la Recherche en Sante du Quebec	This research was supported by NSERC and FRSQ scholarships (M.-J. Potvin), as well as an FRSQ clinical research grant (I. Rouleau). We would like to thank Jean Begin, PhD, for suggestions for the statistical analysis, Daniel Lamoureux, PhD, for help with the recruitment of patients, as well as Simon Charbonneau, PhD, for useful comments.	Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck AT, 1993, BECK ANXIETY INVENTO; Benton AL, 1994, MULTILINGUAL APHASIA; Brandt J., 2001, BRIEF VISUOSPATIAL M; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cavallini E, 2003, ARCH GERONTOL GERIAT, V37, P241, DOI 10.1016/S0167-4943(03)00063-3; Chasteen AL, 2001, PSYCHOL SCI, V12, P457, DOI 10.1111/1467-9280.00385; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Coyette F., 2003, EVALUATION PRISE CHA, P333; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dunn L., 1993, ECHELLE VOCABULAIRE; Einstein, 2007, PROSPECTIVE MEMORY O; Einstein, 2008, PROSPECTIVE MEMORY C, P283; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Hannon R, 1999, ARCH CLIN NEUROPSYCH, V14, P798, DOI 10.1016/S0887-6177(99)80344-8; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella GJ, 2007, NEUROPSYCHOL REHABIL, V17, P688, DOI 10.1080/09602010600892824; Kixmiller JS, 2002, BRAIN COGNITION, V49, P237, DOI 10.1006/brcg.2001.1476; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Levine B, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P80; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mackinnon A., 1999, INT J METHODS PSYCHI, V8, P27, DOI [10.1002/mpr.54, DOI 10.1002/MPR.54]; Madjan A., 1996, J CLIN EXP NEUROPSYC, V18, P416; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McDaniel M. A., 1992, ADV LEARNING BEHAVIO, V7, P87; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; MCKITRICK LA, 1992, J GERONTOL, V47, pP337, DOI 10.1093/geronj/47.5.P337; Mesulam M., 1985, CONT NEUROLOGY SERIE, V26; PAIVIO A, 1983, CAN J PSYCHOL, V37, P461, DOI 10.1037/h0080749; Potvin M.-J., 2002, COMM AFF PRES 25 C A; Potvin M.-J., 2004, J INT NEUROPSYCH SOC, V10, P38; Potvin MJ, 2011, BRAIN INJURY, V25, P192, DOI 10.3109/02699052.2010.541896; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rey A, 1958, LEXAMEN CLINIQUE PSY; Rude SS, 1999, COGNITION EMOTION, V13, P267, DOI 10.1080/026999399379276; Salinsky MC, 2001, J INT NEUROPSYCH SOC, V7, P597, DOI 10.1017/S1355617701755075; Schmidt IW, 2001, EDUC GERONTOL, V27, P455, DOI 10.1080/036012701316894162; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Sohlberg M., 2001, COGNITIVE REHABILITA; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; Sullivan K, 2005, ARCH CLIN NEUROPSYCH, V20, P745, DOI 10.1016/j.acn.2005.04.006; Thone-Otto A. I. T., 2008, PROSPECTIVE MEMORY C, P321; van den Broek MD, 2000, BRAIN INJURY, V14, P455; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Waugh N., 1999, THESIS GRIFFITH U BR; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WESCHLER D, 1991, WECHSLER INTELLIGENC; Wilson B, 2009, MEMORY REHABILITATIO	61	34	34	0	26	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	6					899	924		10.1080/09602011.2011.630882			26	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	885OT	WOS:000299789200008	22150454				2022-02-06	
J	Sinopoli, KJ; Schachar, R; Dennis, M				Sinopoli, Katia J.; Schachar, Russell; Dennis, Maureen			Traumatic brain injury and secondary attention-deficit/hyperactivity disorder in children and adolescents: The effect of reward on inhibitory control	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Attention-deficit/hyperactivity disorder; Inhibitory control; Rewards; Development	DEFICIT-HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; RESPONSE-INHIBITION; SUSTAINED ATTENTION; COGNITIVE CONTROL; ADHD; PERFORMANCE; AD/HD; BEHAVIOR; MEMORY	Poor inhibitory control and abnormalities in responding to rewards are characteristic of the developmental or primary form of attention-deficit/hyperactivity disorder (P-ADHD). A secondary form of ADHD (S-ADHD) may occur as a consequence of childhood traumatic brain injury (TBI), but the similarities and differences between these two forms of ADHD have not been well characterized. To address these issues, we studied two inhibitory control tasks under different reward conditions in four groups of children and adolescents: TBI who did not exhibit S-ADHD, TBI who did exhibit S-ADHD, P-ADHD, and healthy controls. Participants with TBI exhibited poor cancellation inhibition relative to controls. Although reward facilitated both cancellation and restraint inhibition similarly across groups, poor performance persisted in the P-ADHD group, and participants with S-ADHD exhibited a selective deficit in cancellation inhibition.	[Sinopoli, Katia J.] Univ Toronto, Fac Med, BrainFit Lab, Toronto, ON M5G 1V7, Canada; [Schachar, Russell] Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; [Sinopoli, Katia J.] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Psychol, Toronto, ON M5G 1V7, Canada		Sinopoli, KJ (corresponding author), Univ Toronto, Fac Med, BrainFit Lab, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	katia.sinopoli@sickkids.ca	Sinopoli, Katia/AAO-7803-2020	Schachar, Russell/0000-0002-2015-4395	Ontario Neurotrauma Foundation [2007-ABI-PHD-565]; NIH (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD048946-01A2]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Funding was provided by the Ontario Neurotrauma Foundation to Katia J. Sinopoli (2007-ABI-PHD-565, The Regulation of Thoughts and Actions in Children Following Traumatic Brain Injury). This research was also supported by an NIH (National Institutes of Health) 1RO1 grant to Keith O. Yeates and Maureen Dennis (HD048946-01A2, Social Outcomes in Pediatric Traumatic Brain Injury). We thank Shirley Chen for her help with the stop signal task and Renee Farrell and Alexandra Basile for their help with scoring and coding of demographic and questionnaire information.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Band GPH, 2003, ACTA PSYCHOL, V112, P105, DOI 10.1016/S0001-6918(02)00079-3; BAND GPH, 1997, THESIS U AMSTERDAM A; Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x; Berwid OG, 2005, J CHILD PSYCHOL PSYC, V46, P1219, DOI 10.1111/j.1469-7610.2005.00417.x; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Chambers CD, 2007, J NEUROPHYSIOL, V98, P3638, DOI 10.1152/jn.00685.2007; Chevrier AD, 2007, HUM BRAIN MAPP, V28, P1347, DOI 10.1002/hbm.20355; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Conners CK, 2008, CONNERS, V3rd; Crone EA, 2003, J CHILD PSYCHOL PSYC, V44, P214, DOI 10.1111/1469-7610.00115; Crosbie J, 2001, AM J PSYCHIAT, V158, P1884, DOI 10.1176/appi.ajp.158.11.1884; Crosbie J, 2008, NEUROSCI BIOBEHAV R, V32, P40, DOI 10.1016/j.neubiorev.2007.05.002; Dennis M, 2008, J INT NEUROPSYCH SOC, V14, P673, DOI 10.1017/S1355617708080983; Desman C, 2008, CHILD NEUROPSYCHOL, V14, P483, DOI 10.1080/09297040701625831; Douglas V. I., 1999, HDB DISRUPTIVE BEHAV, Vxiii, P105, DOI [10.1007/978-1-4615-4881-2_5, DOI 10.1007/978-1-4615-4881-2_5]; Durston S, 2004, J AM ACAD CHILD PSY, V43, P332, DOI 10.1097/00004583-200403000-00016; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gomez R, 2003, J Atten Disord, V6, P111, DOI 10.1177/108705470300600303; HAENLEIN M, 1987, J AM ACAD CHILD PSY, V26, P356, DOI 10.1097/00004583-198705000-00014; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Huang-Pollock CL, 2007, J CLIN CHILD ADOLESC, V36, P127, DOI 10.1080/15374410701274124; IABONI F, 1995, J ABNORM PSYCHOL, V104, P232, DOI 10.1037/0021-843X.104.1.232; Jin C, 2004, CNS SPECTRUMS, V9, P217, DOI 10.1017/S1092852900009019; Kalff AC, 2005, J INT NEUROPSYCH SOC, V11, P173; Kieling C, 2008, CHILD ADOL PSYCH CL, V17, P285, DOI 10.1016/j.chc.2007.11.012; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levy Y, 2009, J CHILD PSYCHOL PSYC, V50, P657, DOI 10.1111/j.1469-7610.2008.01986.x; Lijffijt M, 2005, J ABNORM PSYCHOL, V114, P216, DOI 10.1037/0021-843X.114.2.216; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan Gordon D., 1994, P189; Luman M, 2005, CLIN PSYCHOL REV, V25, P183, DOI 10.1016/j.cpr.2004.11.001; Luman M, 2008, J CHILD PSYCHOL PSYC, V49, P712, DOI 10.1111/j.1469-7610.2008.01910.x; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, BRAIN INJURY, V12, P41; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; Oosterlaan J, 1998, J ABNORM CHILD PSYCH, V26, P161, DOI 10.1023/A:1022650216978; Padmala S, 2010, NEUROPSYCHOLOGIA, V48, P558, DOI 10.1016/j.neuropsychologia.2009.10.017; Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Quay HC, 1997, J ABNORM CHILD PSYCH, V25, P7, DOI 10.1023/A:1025799122529; Rieger M, 2003, NEUROPSYCHOLOGY, V17, P272, DOI 10.1037/0894-4105.17.2.272; Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Rubia K, 1999, AM J PSYCHIAT, V156, P891, DOI 10.1176/ajp.156.6.891; Rubia K, 2007, CHILD NEUROPSYCHOL, V13, P276, DOI 10.1080/09297040600770761; Rubia K, 2010, HUM BRAIN MAPP, V31, P287, DOI 10.1002/hbm.20864; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SCHACHAR R, 1995, J ABNORM CHILD PSYCH, V23, P411, DOI 10.1007/BF01447206; Schachar RJ, 2004, J ABNORM CHILD PSYCH, V32, P285, DOI 10.1023/B:JACP.0000026142.11217.f2; Schachar R, 2007, J ABNORM CHILD PSYCH, V35, P229, DOI 10.1007/s10802-006-9075-2; Scheres A, 2001, CHILD NEUROPSYCHOL, V7, P172, DOI 10.1076/chin.7.3.172.8746; Seidman LJ, 2006, BIOL PSYCHIAT, V60, P1071, DOI 10.1016/j.biopsych.2006.04.031; Shanahan MA, 2008, DEV NEUROPSYCHOL, V33, P137, DOI 10.1080/87565640701884238; Sinopoli K. J., DEV PSYCHOL IN PRESS; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Slusarek M, 2001, J AM ACAD CHILD PSY, V40, P355, DOI 10.1097/00004583-200103000-00016; Sonuga-Barke EJS, 2002, BEHAV BRAIN RES, V130, P29, DOI 10.1016/S0166-4328(01)00432-6; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; Stevens J, 2002, DEV NEUROPSYCHOL, V21, P117, DOI 10.1207/S15326942DN2102_1; Tamm Leanne, 2007, J Atten Disord, V10, P372, DOI 10.1177/1087054706289946; TEASDALE G, 1974, LANCET, V2, P81; Toplak ME, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-8; Vaidya CJ, 2005, AM J PSYCHIAT, V162, P1605, DOI 10.1176/appi.ajp.162.9.1605; Van Meel CS, 2005, J AM ACAD CHILD PSY, V44, P451, DOI 10.1097/01.chi.0000155326.22394.e6; Verbruggen F, 2008, TRENDS COGN SCI, V12, P418, DOI 10.1016/j.tics.2008.07.005; Verbruggen F, 2009, NEUROSCI BIOBEHAV R, V33, P647, DOI 10.1016/j.neubiorev.2008.08.014; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205; Wodka EL, 2007, J CLIN EXP NEUROPSYC, V29, P345, DOI 10.1080/13803390600678046; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Young SE, 2009, J ABNORM PSYCHOL, V118, P117, DOI 10.1037/a0014657; [No title captured]	87	34	34	1	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	7					805	819		10.1080/13803395.2011.562864			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	882HE	WOS:000299553600008	21598155	Green Accepted			2022-02-06	
J	Thomas, CA; Moffett, BS; Wagner, JL; Mott, AR; Feig, DI				Thomas, Christopher A.; Moffett, Brady S.; Wagner, Jeffrey L.; Mott, Antonio R.; Feig, Daniel I.			Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						malignant hypertension; hypertensive urgency; labetalol; neonate; nicardipine; nitroprusside	SODIUM-NITROPRUSSIDE; NICARDIPINE; MANAGEMENT; DIAGNOSIS; THERAPY; DRUG	Objective: To determine the efficacy and safety of labetalol for hypertensive crisis in children <= 24 months of age. Design: Retrospective chart review. Statistical analysis utilized analysis of variance for continuous data, chi-square tests for nominal data, and linear regression. Setting: A 737-bed pediatric teaching institution. Patients: Twenty-seven patients <= 24 months of age were treated with 37 intravenous infusions of labetalol, nicardipine, or nitroprusside for hypertensive crisis or hypertensive urgency. Interventions: None. Measurements and Main Results: The primary end point consisted of time to 20% reduction in systolic blood pressure. Primary safety end points measured the prevalence of deleterious effects of labetalol. Continuous infusion of labetalol reduced mean systolic blood pressure by at least 20% in <8 hrs. This effect was similar to nicardipine and nitroprusside infusions. The reported side effects were similar in each group. Patients receiving labetalol and presenting with ischemic or traumatic brain injury were likely to develop hypotension requiring infusion discontinuation. Conclusions: Continuous intravenous labetalol infusion is efficacious for treatment of hypertensive crisis in children <= 24 months of age. Aside from patients presenting with ischemic or traumatic brain injury, labetalol was safe to use in this population for hypertensive emergencies and had a satisfactory adverse effect profile. Labetalol may reach dose saturation at a much lower dose in young children in comparison to adults. Clinicians should use caution when initiating labetalol infusions in young patients with brain injury. (Pediatr Crit Care Med 2011; 12:28-32)	[Thomas, Christopher A.; Moffett, Brady S.; Wagner, Jeffrey L.] Texas Childrens Hosp, Dept Pharm, Houston, TX 77030 USA; [Mott, Antonio R.] Texas Childrens Hosp, Dept Pediat Cardiol, Houston, TX 77030 USA; [Feig, Daniel I.] Texas Childrens Hosp, Dept Pediat Nephrol, Houston, TX 77030 USA; [Mott, Antonio R.; Feig, Daniel I.] Baylor Coll Med, Houston, TX 77030 USA		Thomas, CA (corresponding author), Texas Childrens Hosp, Dept Pharm, Houston, TX 77030 USA.	cthoma15@clarian.org		Thomas, Christopher/0000-0002-9630-8506; Feig, Daniel/0000-0002-0017-6335			[Anonymous], 2000, LAB HYDR INJ PACK IN; Benedetti MS, 2003, FUND CLIN PHARMACOL, V17, P281, DOI 10.1046/j.1472-8206.2003.00140.x; BUNCHMAN TE, 1992, J PEDIATR-US, V120, P140, DOI 10.1016/S0022-3476(05)80619-5; DEAL JE, 1992, ARCH DIS CHILD, V67, P1089, DOI 10.1136/adc.67.9.1089; Flynn JT, 2009, PEDIATR NEPHROL, V24, P1101, DOI 10.1007/s00467-008-1000-1; Flynn JT, 2000, PEDIATR NEPHROL, V14, P332, DOI 10.1007/s004670050771; Flynn JT, 2001, J PEDIATR-US, V139, P38, DOI 10.1067/mpd.2001.114030; Immink RV, 2008, HYPERTENSION, V52, P236, DOI 10.1161/HYPERTENSIONAHA.108.110395; Jivraj S, 2006, CAN J ANAESTH, V53, P678, DOI 10.1007/BF03021626; Liu-DeRyke X, 2008, NEUROCRIT CARE, V9, P167, DOI 10.1007/s12028-008-9057-z; Milou C, 2000, INTENS CARE MED, V26, P956, DOI 10.1007/s001340051287; Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555; NEUTEL JM, 1994, AM J HYPERTENS, V7, P623, DOI 10.1093/ajh/7.7.623; Nishina K, 2001, ANESTH ANALG, V93, P641, DOI 10.1097/00000539-200109000-00021; Patel HP, 2005, CURR OPIN PEDIATR, V17, P210, DOI 10.1097/01.mop.0000150769.38484.b3; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571; Temple ME, 2000, PHARMACOTHERAPY, V20, P140, DOI 10.1592/phco.20.3.140.34782; Tenney F, 2000, AM J KIDNEY DIS, V35, part. no., DOI 10.1016/S0272-6386(00)70285-X; Varon J, 2000, CHEST, V118, P214, DOI 10.1378/chest.118.1.214; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Yang HJ, 2004, J INT MED RES, V32, P118, DOI 10.1177/147323000403200203	21	34	35	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2011	12	1					28	32		10.1097/PCC.0b013e3181e328d8			5	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	703FT	WOS:000285964500015	20495503				2022-02-06	
J	Wu, WQ; Sun, JF; Jin, Z; Guo, XL; Qiu, YH; Zhu, YS; Tong, SB				Wu, Wenqing; Sun, Junfeng; Jin, Zheng; Guo, Xiaoli; Qiu, Yihong; Zhu, Yisheng; Tong, Shanbao			Impaired neuronal synchrony after focal ischemic stroke in elderly patients	CLINICAL NEUROPHYSIOLOGY			English	Article						Cortical synchrony; Phase synchronization; Ischemic stroke; Electroencephalography	TRAUMATIC BRAIN-INJURY; FUNCTIONAL CONNECTIVITY; PHASE SYNCHRONIZATION; SURFACE LAPLACIANS; SYMMETRY INDEX; EEG; MAGNETOENCEPHALOGRAPHY; ELECTRODE; NETWORKS; SIGNALS	Objective: This study investigated whether cortical synchrony derived from electroencephalography (EEG) in elderly patients is impaired and if the impairment might reflect long-term functional recovery after stroke. Methods: The scalp EEG signals of stroke patients (N = 42) were collected within seven days after the onset of stroke and analyzed with phase synchronization (PS). Neurodeficit outcome was scored twice according to the National Institute of Health Stroke Scale (NIHSS): (1) at the same day of EEG recording and (2) two months after stroke. The correlation between cortical synchrony and NIHSS was analyzed. Results: The level of synchronization between lesion and intact areas in the ipsilateral hemisphere was reduced significantly after stroke, while the synchronization among intact areas increased to 114% among the control subjects. Furthermore, the patients with lower inter-hemispheric synchrony after stroke were observed to have a higher NIHSS two months after stroke. Conclusions: Results indicated that the infarct broke down the cortical synchrony networks and affected large-scale neural communication. Inter-hemispheric synchrony was relevant to long-term functional recovery after stroke. Significance: The prognostic value of PS for functional recovery after stroke might be helpful in understanding the alteration of cortical networks after ischemic injury. (C) 2010 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Sun, Junfeng; Tong, Shanbao] Shanghai Jiao Tong Univ, Med Res Inst X, Shanghai 200030, Peoples R China; [Wu, Wenqing; Guo, Xiaoli; Qiu, Yihong; Zhu, Yisheng] Shanghai Jiao Tong Univ, Dept Biomed Engn, Shanghai 200030, Peoples R China; [Jin, Zheng] Fifth Peoples Hosp Shanghai, Dept Neurol, Shanghai, PR, Peoples R China		Tong, SB (corresponding author), Shanghai Jiao Tong Univ, Med Res Inst X, 1954 Huashan Rd, Shanghai 200030, Peoples R China.	stong@sjtu.edu.cn	Sun, Junfeng/D-1590-2010	Sun, Junfeng/0000-0002-7614-7127; Jin, Zheng/0000-0002-9499-934X	Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [07ZR14054]; Med-X research fund	This work was supported in part by the Science and Technology Commission of Shanghai Municipality (07ZR14054). S. Tong was also supported by the Med-X research fund. The authors are grateful to Dr. Jimin Zhang for her assistance in recording EEG.	Andrew C, 1996, ELECTROEN CLIN NEURO, V98, P144; Angelini L, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.038103; Assenza G, 2009, NEUROIMAGE, V44, P1267, DOI 10.1016/j.neuroimage.2008.09.049; Babiloni Fabio, 1995, Brain Topography, V8, P35, DOI 10.1007/BF01187668; Barry RJ, 2007, CLIN NEUROPHYSIOL, V118, P2765, DOI 10.1016/j.clinph.2007.07.028; Bob P, 2008, NEUROSCI LETT, V447, P73, DOI 10.1016/j.neulet.2008.09.055; Cuspineda E, 2007, CLIN EEG NEUROSCI, V38, P155, DOI 10.1177/155005940703800312; Cuspineda E, 2003, CLIN ELECTROENCEPHAL, V34, P1; David O, 2004, NEUROIMAGE, V21, P659, DOI 10.1016/j.neuroimage.2003.10.006; Fallani FD, 2009, ANAT REC, V292, P2023, DOI 10.1002/ar.20965; Fingelkurts AA, 2005, NEUROSCI BIOBEHAV R, V28, P827, DOI 10.1016/j.neubiorev.2004.10.009; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Galvan A, 2008, CLIN NEUROPHYSIOL, V119, P1459, DOI 10.1016/j.clinph.2008.03.017; Hammond C, 2007, TRENDS NEUROSCI, V30, P357, DOI 10.1016/j.tins.2007.05.004; He BJ, 2007, NEURON, V53, P905, DOI 10.1016/j.neuron.2007.02.013; Herrmann CS, 2005, CLIN NEUROPHYSIOL, V116, P2719, DOI 10.1016/j.clinph.2005.07.007; Ito J, 2005, BIOL CYBERN, V92, P54, DOI 10.1007/s00422-004-0533-z; KRASKOV A, 2008, NIC SERIES, V24; LAW SK, 1993, IEEE T BIO-MED ENG, V40, P145, DOI 10.1109/10.212068; Lehnertz K, 1998, PHYS REV LETT, V80, P5019, DOI 10.1103/PhysRevLett.80.5019; Lukashevich I P, 1999, Neurosci Behav Physiol, V29, P283, DOI 10.1007/BF02465339; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; NUNEZ PL, 1994, ELECTROEN CLIN NEURO, V90, P40, DOI 10.1016/0013-4694(94)90112-0; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; Pereda E, 2005, PROG NEUROBIOL, V77, P1, DOI 10.1016/j.pneurobio.2005.10.003; Pikovsky A., 2002, AM J PHYS, V70, P655, DOI 10.1119/1.1475332; Quiroga RQ, 2000, PHYS REV E, V61, P5142, DOI 10.1103/PhysRevE.61.5142; Quiroga RQ, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041903; SAUSENG P, 2008, NEUROSCI BIOBEHAV R; Shields DC, 2007, SURG NEUROL, V67, P354, DOI 10.1016/j.surneu.2006.09.036; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Sun JF, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.046219; Tecchio F, 2006, J NEUROSCI RES, V83, P1077, DOI 10.1002/jnr.20796; Tecchio F, 2007, J NEUROL, V254, P296, DOI 10.1007/s00415-006-0355-0; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; Thatcher R.W., 1998, DATABASES NEUROTHER, V2, P8, DOI [10.1300/j184v02n04_02, DOI 10.1300/J184V02N04_02]; van Putten MJAM, 2007, CLIN NEUROPHYSIOL, V118, P2362, DOI 10.1016/j.clinph.2007.07.019; van Putten MJAM, 2004, CLIN NEUROPHYSIOL, V115, P1189, DOI 10.1016/j.clinph.2003.12.002; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550	40	34	35	0	22	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2011	122	1					21	26		10.1016/j.clinph.2010.06.003			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	695XS	WOS:000285406600007	20591730				2022-02-06	
J	Perrin, FE; Boniface, G; Serguera, C; Lonjon, N; Serre, A; Prieto, M; Mallet, J; Privat, A				Perrin, Florence E.; Boniface, Guillaume; Serguera, Che; Lonjon, Nicolas; Serre, Angeline; Prieto, Monica; Mallet, Jacques; Privat, Alain			Grafted Human Embryonic Progenitors Expressing Neurogenin-2 Stimulate Axonal Sprouting and Improve Motor Recovery after Severe Spinal Cord Injury	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; TRAUMATIC INJURY; MOUSE MODEL; AUTOFLUORESCENCE; REPAIR; RATS; PROMOTES; BRAIN; DIFFERENTIATION	Background: Spinal cord injury (SCI) is a widely spread pathology with currently no effective treatment for any symptom. Regenerative medicine through cell transplantation is a very attractive strategy and may be used in different non-exclusive ways to promote functional recovery. We investigated functional and structural outcomes after grafting human embryonic neural progenitors (hENPs) in spinal cord-lesioned rats. Methods and Principal Findings: With the objective of translation to clinics we have chosen a paradigm of delayed grafting, i.e., one week after lesion, in a severe model of spinal cord compression in adult rats. hENPs were either naive or engineered to express Neurogenin 2 (Ngn2). Moreover, we have compared integrating and non-integrating lentiviral vectors, since the latter present reduced risks of insertional mutagenesis. We show that transplantation of hENPs transduced to express Ngn2 fully restore weight support and improve functional motor recovery after severe spinal cord compression at thoracic level. This was correlated with partial restoration of serotonin innervations at lumbar level, and translocation of 5HT1A receptors to the plasma membrane of motoneurons. Since hENPs were not detectable 4 weeks after grafting, transitory expression of Ngn2 appears sufficient to achieve motor recovery and to permit axonal regeneration. Importantly, we also demonstrate that transplantation of naive hENPs is detrimental to functional recovery. Conclusions and Significance: Transplantation and short-term survival of Ngn2-expressing hENPs restore weight support after SCI and partially restore serotonin fibers density and 5HT1A receptor pattern caudal to the lesion. Moreover, grafting of naive-hENPs was found to worsen the outcome versus injured only animals, thus pointing to the possible detrimental effect of stem cell-based therapy per se in SCI. This is of major importance given the increasing number of clinical trials involving cell grafting developed for SCI patients.	[Perrin, Florence E.; Privat, Alain] Univ Basque Country UPV EHU, Dept Neurosci, IKERBASQUE Basque Fdn Sci, Bilbao, Spain; [Perrin, Florence E.; Boniface, Guillaume; Lonjon, Nicolas; Privat, Alain] St Eloi Hosp, INSERM, U583, Inst Neurosci Montpellier Pathophysiol & Therapy, Montpellier, France; [Boniface, Guillaume; Lonjon, Nicolas] Gui de Chauliac Hosp, Dept Neurosurg, Montpellier, France; [Serguera, Che; Serre, Angeline; Mallet, Jacques] Univ Paris 06, INSERM UMRS 975, Inst Cerveau & Moelle Epiniere, Hop La Pitie Salpetriere,Ctr Rech,CNRS UMR 7225, Paris, France; [Serguera, Che] CEA INSERM, MIRCen, Fontenay Aux Roses, France; [Prieto, Monica; Privat, Alain] St Eloi Hosp, Neureva Inc INM, Montpellier, France		Perrin, FE (corresponding author), Univ Basque Country UPV EHU, Dept Neurosci, IKERBASQUE Basque Fdn Sci, Bilbao, Spain.	f.perrin@ikerbasque.org	PERRIN, Florence/AAY-6815-2021; Serguera, Che/J-8918-2012	Serguera, Che/0000-0002-9210-0636; PERRIN, Florence/0000-0002-7630-0515	European UnionEuropean Commission; Institut pour la Recherche sur la Moelle Epiniere; Academie de Medecine; Societe Francaise de Neurochirurgie; Verticale; Association Demain Debout Aquitaine	This study was supported by the European Union FP6 "RESCUE" STREP; the "Institut pour la Recherche sur la Moelle Epiniere"; the "Academie de Medecine"; the "Societe Francaise de Neurochirurgie"; "Verticale" and the "Association Demain Debout Aquitaine". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abematsu M, 2010, J CLIN INVEST, V120, P3255, DOI 10.1172/JCI42957; AUBIN JE, 1979, J HISTOCHEM CYTOCHEM, V27, P36, DOI 10.1177/27.1.220325; Baptiste DC, 2007, PROG BRAIN RES, V161, P217, DOI 10.1016/S0079-6123(06)61015-7; Barnabe-Heider F, 2008, CELL STEM CELL, V3, P16, DOI 10.1016/j.stem.2008.06.011; Bauchet L., 2009, Annals of Physical and Rehabilitation Medicine, V52, P330, DOI 10.1016/j.annrmp.2008.10.004; BENSON RC, 1979, J HISTOCHEM CYTOCHEM, V27, P44, DOI 10.1177/27.1.438504; BUCCARON MH, 1995, NEUROBIOL DIS, V2, P37, DOI 10.1006/nbdi.1995.0004; Buchet D, 2002, MOL CELL NEUROSCI, V19, P389, DOI 10.1006/mcne.2001.1086; CAVALIERI B, 1635, CERTAIN METHOD DEV N, P1; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Gaviria M, 2002, J NEUROTRAUM, V19, P205, DOI 10.1089/08977150252806965; HAVENITH CEG, 1993, J LEUKOCYTE BIOL, V53, P504, DOI 10.1002/jlb.53.5.504; Heinrich C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000373; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; LONJON N, 2010, SPINAL CORD IN PRESS; Lonjon N, 2010, J NEUROSURG-SPINE, V12, P106, DOI 10.3171/2009.7.SPINE0989; Lonjon N, 2009, J NEUROSCI RES, V87, P403, DOI 10.1002/jnr.21871; MALLEY A, 1988, J LEUKOCYTE BIOL, V43, P557, DOI 10.1002/jlb.43.6.557; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; NICOD LP, 1989, J LEUKOCYTE BIOL, V45, P458, DOI 10.1002/jlb.45.5.458; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Ramos-Cabrer P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012779; Ribotta MG, 2002, PROG BRAIN RES, V137, P191; RIBOTTA MGY, 1995, J NEUROSCI RES, V41, P79, DOI 10.1002/jnr.490410110; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; Rossi SL, 2009, CURR OPIN BIOTECH, V20, P552, DOI 10.1016/j.copbio.2009.09.008; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Sarkis C, 2008, CURR GENE THER, V8, P430, DOI 10.2174/156652308786848012; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Sedy J, 2007, J NEUROTRAUM, V24, P1487, DOI 10.1089/neu.2006.0252; SHAPIRO S, 1995, J SURG RES, V59, P393, DOI 10.1006/jsre.1995.1181; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115	37	34	35	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2010	5	12							e15914	10.1371/journal.pone.0015914			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	701DD	WOS:000285793600050	21209909	Green Published, Green Submitted, gold			2022-02-06	
J	Schwetye, KE; Cirrito, JR; Esparza, TJ; Mac Donald, CL; Holtzman, DM; Brody, DL				Schwetye, Katherine E.; Cirrito, John R.; Esparza, Thomas J.; Mac Donald, Christine L.; Holtzman, David M.; Brody, David L.			Traumatic brain injury reduces soluble extracellular amyloid-beta in mice: A methodologically novel combined microdialysis-controlled cortical impact study	NEUROBIOLOGY OF DISEASE			English	Article						Amyloid-beta; Traumatic brain injury; Microdialysis; EEG; Alzheimer's disease; Dementia; Mouse	PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; HEAD-INJURY; IN-VIVO; TRANSGENIC MICE; AXONAL INJURY; INTERSTITIAL FLUID; INTRACEREBRAL MICRODIALYSIS; INDUCED INCREASES; MOUSE MODEL	Acute amyloid-beta; peptide (A beta) deposition has been observed in young traumatic brain injury (TB!) patients, leading to the hypothesis that elevated extracellular A beta levels could underlie the increased risk of dementia following TBI. However, a recent microdialysis-based study in human brain injury patients found that extracellular A beta dynamics correlate with changes in neurological status. Because neurological status is generally diminished following injury, this correlation suggested the alternative hypothesis that soluble extracellular A beta levels may instead be reduced after TBI relative to baseline. We have developed a methodologically novel mouse model that combines experimental controlled cortical impact TBI with intracerebral microdialysis. In this model, we found that A beta levels in microdialysates were immediately decreased by 25-50% in the ipsilateral hippocampus following TBI. This result was found in PDAPP. Tg2576, and Tg2576-ApoE2 transgenic mice producing human A beta plus wild-type animals. Changes were not due to altered probe function, edema, changes in APP levels, or A beta deposition. Similar decreases in A beta were observed in phosphate buffered saline-soluble tissue extracts. Hippocampal electroencephalographic activity was also decreased up to 40% following TBI, and correlated with reduced microdialysate A beta; levels. These results support the alternative hypothesis that post-injury extracellular soluble A beta levels are acutely decreased relative to baseline. Reduced neuronal activity may contribute, though the underlying mechanisms have not been definitively determined. Further work will be needed to assess the dynamics of insoluble and oligomeric A beta after TBI. (C) 2010 Elsevier Inc. All rights reserved.	Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA		Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS049237, AG13956]; Burroughs Wellcome Career Award in the Biomedical SciencesBurroughs Wellcome Fund; Thrasher Research Fund; Cure Alzheimer's Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013956, R37AG013956] Funding Source: NIH RePORTER	This work was supported by grants from the NIH NS049237 (DLB), AG13956 (DMH), a Burroughs Wellcome Career Award in the Biomedical Sciences (DLB), Thrasher Research Fund (DLB), and Cure Alzheimer's Fund (DMH). We are grateful to Eli Lilly and Co. for providing antibodies and the founders of our PDAPP mouse colony. The authors have no conflicts of interest to disclose.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Elvang AB, 2009, J NEUROCHEM, V110, P1377, DOI 10.1111/j.1471-4159.2009.06215.x; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Franklin KBJ, 2001, MOUSE BRAIN STEREOTA; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; JACOBSON I C, 1985, J NEUROSCI METH, V15, P263; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kang JE, 2007, P NATL ACAD SCI USA, V104, P10673, DOI 10.1073/pnas.0700148104; KANG JE, 2009, AMYLOID BETA DYNAMIC; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lazarov O, 2002, J NEUROSCI, V22, P9785; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PALMER AM, 1993, J NEUROCHEM, V61, pS284; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X	60	34	35	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	DEC	2010	40	3					555	564		10.1016/j.nbd.2010.06.018			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	675NH	WOS:000283836900005	20682338	Green Accepted			2022-02-06	
J	Jeong, SL; Cho, SY; Oh, SJ				Jeong, Seong Lin; Cho, Sung Yong; Oh, Seung-June			Spinal Cord/Brain Injury and the Neurogenic Bladder	UROLOGIC CLINICS OF NORTH AMERICA			English	Article						Neurogenic bladder; Spinal cord injury; Cerebrovascular accident; Traumatic brain injury; Urodynamics; Disease management	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; CLEAN INTERMITTENT CATHETERIZATION; POSTSTROKE URINARY-INCONTINENCE; AUTONOMIC REFLEX PATHWAY; CORD-INJURY; FOLLOW-UP; CEREBROVASCULAR ACCIDENT; SPHINCTER DYSSYNERGIA; UROLOGICAL MANAGEMENT	This article reviews neurogenic bladder related to traumatic injury as well as vascular lesion of brain/spinal cord Because urological manifestations of traumatic or vascular brain/spinal cord injury are highly diversified and complex, the approaches to achieve accurate diagnosis and administer proper treatment can be complicated The goal of primary treatment is preservation of renal function and attainment of social continence Maintaining low intravesical pressure and adequate bladder emptying are central to the treatment strategy Diagnosis and appropriate urological management of these disease entities should depend on urodynamic studies because of poor correlation between clinical symptoms or somatic neurologic signs and urodynamic findings	[Cho, Sung Yong; Oh, Seung-June] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Urol, Seoul 110744, South Korea; [Jeong, Seong Lin] Seoul Natl Univ, Bundang Hosp, Dept Urol, Songnam 463707, Seongnam, South Korea; [Jeong, Seong Lin] Seoul Natl Univ, Bundang Hosp, Dept Urol, Gyeonggi Do, South Korea		Oh, SJ (corresponding author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Urol, 28 Yeongeon Dong, Seoul 110744, South Korea.		Oh, Seung-June/D-6015-2012	Oh, Seung-June/0000-0002-0322-3539			A. the National Spinal Cord Injury Statistical Center Birmingham, 2009, FACTS FIG GLANC; Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Abrams P, 2008, BJU INT, V101, P989, DOI 10.1111/j.1464-410X.2008.07457.x; [Anonymous], 2006, J SPINAL CORD MED, V29, P527; BEJANY DE, 1987, J UROLOGY, V138, P1390, DOI 10.1016/S0022-5347(17)43651-2; BENNETT CJ, 1995, J UROLOGY, V153, P1458, DOI 10.1016/S0022-5347(01)67432-9; BRINDLEY GS, 1986, J NEUROL NEUROSUR PS, V49, P1104, DOI 10.1136/jnnp.49.10.1104; Brittain KR, 1998, STROKE, V29, P524, DOI 10.1161/01.STR.29.2.524; Burney TL, 1996, UROL CLIN N AM, V23, P483, DOI 10.1016/S0094-0143(05)70327-X; Burney TL, 1996, J UROLOGY, V156, P1748, DOI 10.1016/S0022-5347(01)65498-3; CARDENAS DD, 1995, PARAPLEGIA, V33, P326, DOI 10.1038/sc.1995.73; CARLSSON CA, 1978, ACTA PHARMACOL TOX, V43, P8; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; de la Barrera SS, 2001, SPINAL CORD, V39, P520, DOI 10.1038/sj.sc.3101201; Ersoz M, 2005, CEREBROVASC DIS, V20, P395, DOI 10.1159/000088670; Feifer A, 2008, NEUROUROL URODYNAM, V27, P475, DOI 10.1002/nau.20569; GELBER DA, 1993, STROKE, V24, P378, DOI 10.1161/01.STR.24.3.378; Giannantoni A, 1998, SPINAL CORD, V36, P29, DOI 10.1038/sj.sc.3100509; Giannantoni A, 2009, EUR UROL, V55, P705, DOI 10.1016/j.eururo.2008.08.048; Gomelsky A, 2003, J UROLOGY, V170, P122, DOI 10.1097/01.ju.0000065245.88262.a9; Groah SL, 2002, ARCH PHYS MED REHAB, V83, P346, DOI 10.1053/apmr.2002.29653; Gupta A, 2009, ANN INDIAN ACAD NEUR, V12, P104, DOI 10.4103/0972-2327.53078; Hamid R, 2003, BJU INT, V91, P51, DOI 10.1046/j.1464-410X.2003.04009.x; Han KS, 2010, NEUROUROL URODYNAM, V29, P387, DOI 10.1002/nau.20708; Hansen RB, 2004, SPINAL CORD, V42, P631, DOI 10.1038/sj.sc.3101637; Heard Laura, 2005, Rehabil Nurs, V30, P44; KAPLAN SA, 1991, J UROLOGY, V146, P113, DOI 10.1016/S0022-5347(17)37727-3; KHAN Z, 1990, UROLOGY, V35, P265, DOI 10.1016/0090-4295(90)80048-R; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; Kutzenberger J, 2005, ARTIF ORGANS, V29, P239, DOI 10.1111/j.1525-1594.2005.29043.x; Larsen LD, 1997, UROLOGY, V50, P418, DOI 10.1016/S0090-4295(97)00224-0; Leary SM, 2006, CLIN REHABIL, V20, P1094, DOI 10.1177/0269215506071258; Lin HD, 2009, J NEUROSURG-SPINE, V10, P452, DOI 10.3171/2009.1.SPINE08540; Lujan MS, 2008, ACTAS UROL ESP, V32, P926, DOI 10.1016/S0210-4806(08)73961-5; MACDIARMID SA, 1995, J UROLOGY, V154, P492, DOI 10.1016/S0022-5347(01)67083-6; Masson C, 2004, J NEUROL NEUROSUR PS, V75, P1431, DOI 10.1136/jnnp.2003.031724; Mayer S. A, 2005, MERRITTS NEUROLOGY, P483; Mehta SS, 2006, SPINAL CORD, V44, P1, DOI 10.1038/sj.sc.3101800; Mitsui T, 2000, EUR UROL, V38, P434, DOI 10.1159/000020320; Moiyadi AV, 2007, NEUROREHABILITATION, V22, P93; Nakayama H, 1997, STROKE, V28, P58, DOI 10.1161/01.STR.28.1.58; Nedeltchev K, 2004, STROKE, V35, P560, DOI 10.1161/01.STR.0000111598.78198.EC; Nitti VW, 1996, J UROLOGY, V155, P263, DOI 10.1016/S0022-5347(01)66614-X; Nosseir M, 2007, NEUROUROL URODYNAM, V26, P228, DOI 10.1002/nau.20319; Nygaard IE, 1996, SPINE, V21, P128, DOI 10.1097/00007632-199601010-00028; Oh SJ, 2005, UROLOGY, V65, P306, DOI 10.1016/j.urology.2004.09.032; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; Pan D, 2009, J UROLOGY, V181, P705, DOI 10.1016/j.juro.2008.10.004; Patel M, 2001, J AM GERIATR SOC, V49, P1229, DOI 10.1046/j.1532-5415.2001.49242.x; Patki P, 2006, J UROLOGY, V175, P1784, DOI 10.1016/S0022-5347(05)00979-1; RABAS PLK, 2003, NEUROUROL URODYNAM, V22, P322; Rapidi CA, 2008, SPINAL CORD, V46, P673, DOI 10.1038/sc.2008.16; Rigby Deborah, 2005, Nurs Stand, V19, P57; ROSSIER AB, 1979, J UROLOGY, V122, P783, DOI 10.1016/S0022-5347(17)56603-3; Sacomani CAR, 2003, SPINAL CORD, V41, P12, DOI 10.1038/sj.sc.3101354; Samson Gregory, 2007, Phys Med Rehabil Clin N Am, V18, P255; Schurch B, 2000, J UROLOGY, V164, P692, DOI 10.1016/S0022-5347(05)67283-7; Shekelle P G, 1999, J Spinal Cord Med, V22, P258; SIROKY MB, 1992, J UROLOGY, V148, P1211, DOI 10.1016/S0022-5347(17)36863-5; Sugimura T, 2008, BJU INT, V101, P1396, DOI 10.1111/j.1464-410X.2007.07404.x; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Turhan N, 2006, J AM GERIATR SOC, V54, P1022, DOI 10.1111/j.1532-5415.2006.00764.x; Vaidyananthan S, 1998, SPINAL CORD, V36, P409, DOI 10.1038/sj.sc.3100573; Vastenholt JM, 2003, SPINAL CORD, V41, P397, DOI 10.1038/sj.sc.3101465; Wein AJ, 2007, CAMPBELL WALSH UROLO, P2011; Weld KJ, 2000, J UROLOGY, V163, P768, DOI 10.1016/S0022-5347(05)67800-7; Weld KJ, 2000, UROLOGY, V55, P490, DOI 10.1016/S0090-4295(99)00553-1; Weld KJ, 2000, J UROLOGY, V163, P1228, DOI 10.1016/S0022-5347(05)67730-0; Wyndaele JJ, 1997, SPINAL CORD, V35, P213, DOI 10.1038/sj.sc.3100391; XIAO C-G, 1990, Journal of Urology, V143, p356A; Xiao CG, 2006, EUR UROL, V49, P22, DOI 10.1016/j.eururo.2005.10.004; Xiao CG, 2003, J UROLOGY, V170, P1237, DOI 10.1097/01.ju.0000080710.32964.d0; Yokoyama O, 1998, J UROLOGY, V159, P577, DOI 10.1016/S0022-5347(01)63987-9	74	34	42	2	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0094-0143	1558-318X		UROL CLIN N AM	Urol. Clin. N. Am.	NOV	2010	37	4					537	+		10.1016/j.ucl.2010.06.005			11	Urology & Nephrology	Science Citation Index Expanded (SCI-EXPANDED)	Urology & Nephrology	687RW	WOS:000284796600007	20955905				2022-02-06	
J	Roberts, DJ; MacCulloch, KAM; Versnick, EJ; Hall, RI				Roberts, Derek J.; MacCulloch, Kate A. M.; Versnick, Eric J.; Hall, Richard I.			Should ancillary brain blood flow analyses play a larger role in the neurological determination of death?	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							TRANSTENTORIAL HERNIATION; INJURY; VARIABILITY; MANAGEMENT; GUIDELINES; DIAGNOSIS; CRITERIA; REVERSAL; ORGANS	Purpose We present two patients who regained spontaneous respiration following clinical neurological determination of death (NDD) while ancillary radiological imaging demonstrated brain blood flow. Clinical features A 26-yr-old male with chronic otitis media presented with a Glasgow Coma Scale (GCS) score of 3 and fixed 7-mm pupils. Computed tomography demonstrated right-sided mastoiditis and a temporal lobe abscess associated with uncal herniation. The patient was diagnosed brain dead seven-hr later when motor responses and brainstem reflexes were absent and his apnea test was positive. Approximately 28-hr after NDD, during post-declaration organ resuscitation, the patient regained spontaneous respiration and magnetic resonance imaging revealed brain blood flow. Spontaneous respirations persisted for five-days before cardiovascular collapse occurred. In the second case, a 50-yr-old female presented with a GCS score of 3 and fixed 6-mm pupils following a traumatic brain injury and a five-minute cardiac arrest. The patient was deemed clinically brain dead six-hr later when physical examination revealed absent motor responses and brainstem reflexes and her apnea test was positive. As confirmation of brain death, a cerebral radionuclide angiogram was performed, which surprisingly revealed intracranial arterial flow. During organ resuscitation, 11-hr after NDD, the patient regained spontaneous respiration. She expired hours after family decision to withdraw treatment. Conclusion For both patients, several unrecognized confounding factors for NDD were present. These cases illustrate the difficulties encountered by experienced clinicians in determining brain death using clinical criteria alone, and they suggest that more routine use of ancillary brain blood flow analyses should be recommended.	[Hall, Richard I.] Dalhousie Univ, Dept Anesthesia, Halifax, NS B3H 3A7, Canada; [Hall, Richard I.] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 3A7, Canada; [Hall, Richard I.] Dalhousie Univ, Dept Surg, Halifax, NS B3H 3A7, Canada; [Roberts, Derek J.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Roberts, Derek J.] Foothills Med Ctr, Calgary, AB, Canada; [Roberts, Derek J.; MacCulloch, Kate A. M.; Hall, Richard I.] Dalhousie Univ, Div Crit Care Med, Dept Med, Halifax, NS B3H 3A7, Canada; [Roberts, Derek J.; MacCulloch, Kate A. M.; Versnick, Eric J.; Hall, Richard I.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; [Versnick, Eric J.] Dalhousie Univ, Div Neuroradiol, Dept Radiol, Halifax, NS B3H 3A7, Canada		Hall, RI (corresponding author), Dalhousie Univ, Dept Anesthesia, Halifax, NS B3H 3A7, Canada.	rihall@dal.ca	Roberts, Derek J./L-6229-2019	Roberts, Derek J./0000-0001-6111-6291			Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Heran MKS, 2008, CAN J NEUROL SCI, V35, P409, DOI 10.1017/S0317167100009069; Hornby K, 2006, CAN J ANAESTH, V53, P613, DOI 10.1007/BF03021854; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; KOHRMAN MH, 1990, PEDIATR NEUROL, V6, P47, DOI 10.1016/0887-8994(90)90078-F; Kutsogiannis DJ, 2006, CAN J ANAESTH, V53, P820, DOI 10.1007/BF03022800; Lang CJG, 2005, ACTA NEUROL SCAND, V112, P358, DOI 10.1111/j.1600-0404.2005.00527.x; Mauritz W, 2009, EUR J EMERG MED, V16, P153, DOI 10.1097/MEJ.0b013e32832a0864; Powner DJ, 2004, CRIT CARE MED, V32, P1284, DOI 10.1097/01.ccm.0000127265.62431.0d; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; Rosendale JD, 2003, TRANSPLANTATION, V75, P482, DOI 10.1097/01.TP.0000045683.85282.93; Salim A, 2005, J TRAUMA, V58, P991, DOI 10.1097/01.TA.0000168708.78049.32; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shemie SD, 2008, CAN J NEUROL SCI, V35, P140, DOI 10.1017/S0317167100008544; Shemie Sam D, 2007, Philos Ethics Humanit Med, V2, P18, DOI 10.1186/1747-5341-2-18; Shemie SD, 2006, CAN MED ASSOC J, V174, pS1, DOI 10.1503/cmaj.045142; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Stiver SI, 2009, J NEUROSURG, V110, P1242, DOI 10.3171/2008.8.JNS08314; Wijdicks EFM, 2008, NEUROLOGY, V71, P1240, DOI 10.1212/01.wnl.0000327612.69106.4c; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20; Xiao FR, 2005, SURG NEUROL, V63, P442, DOI 10.1016/j.surneu.2004.08.093; 2000, J NEUROTRAUMA, V17, P471	25	34	35	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	OCT	2010	57	10					927	935		10.1007/s12630-010-9359-4			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	654RF	WOS:000282185000008	20706879	Bronze			2022-02-06	
J	Yoshioka, N; Hisanaga, SI; Kawano, H				Yoshioka, Nozomu; Hisanaga, Shin-Ichi; Kawano, Hitoshi			Suppression of Fibrotic Scar Formation Promotes Axonal Regeneration Without Disturbing Blood-Brain Barrier Repair and Withdrawal of Leukocytes After Traumatic Brain Injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						reactive astrocyte; meningeal fibroblast; leukocyte infiltration; 2,2 '-dipyridyl; nigrostriatal dopaminergic pathway; immunohistochemistry	SPINAL-CORD-INJURY; NIGROSTRIATAL DOPAMINERGIC AXONS; OLFACTORY ENSHEATHING CELLS; NONNEURAL ENDOTHELIAL-CELLS; REACTIVE ASTROCYTES; FUNCTIONAL RECOVERY; GLIAL SCAR; RAT-BRAIN; NEURONAL DEGENERATION; CEREBRAL HEMISPHERE	The fibrotic scar containing type IV collagen (Col IV) formed in a lesion site is considered as an obstacle to axonal regeneration, because intracerebral injection of 2,2'-dipyridyl (DPY), an inhibitor of Col IV triple-helix formation, suppresses fibrotic scar formation in the lesion site and promotes axonal regeneration. To determine the role of the fibrotic scar on the healing process of injured central nervous system (CNS), the restoration of blood-brain barrier (BBB) and withdrawal of inflammatory leukocytes were examined in mice subjected to unilateral transection of the nigrostriatal dopaminergic pathway and intracerebral DPY injection. At 5 days after injury, destruction of BBB represented by leakage of Evans blue (EB) and widespread infiltration of CD45-immunoreactive leukocytes was observed around the lesion site, whereas reactive astrocytes increased surrounding the BBB-destroyed area. By 2 weeks after injury, the region of EB leakage and the diffusion of leukocytes were restricted to the inside of the fibrotic scar, and reactive astrocytes gathered around the fibrotic scar. In the DPY-treated lesion site, formation of the fibrotic scar was suppressed (84% decrease in Col IV-deposited area), reactive astrocytes occupied the lesion center, and areas of both EB leakage and leukocyte infiltration decreased by 86%. DPY treatment increased the number of regenerated dopaminergic axons by 2.53-fold. These results indicate that suppression of fibrotic scar formation does not disturb the healing process in damaged CNS, and suggest that this strategy is a reliable tool to promote axonal regeneration after traumatic injury in the CNS. J. Comp. Neurol. 518:3867-3881, 2010. (C) 2010 Wiley-Liss, Inc.	[Yoshioka, Nozomu; Kawano, Hitoshi] Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, Tokyo 1838526, Japan; [Yoshioka, Nozomu; Hisanaga, Shin-Ichi] Tokyo Metropolitan Univ, Dept Biol Sci, Tokyo 1920397, Japan		Kawano, H (corresponding author), 2-6 Musashidai, Tokyo 1838526, Japan.	kawano-ht@igakuken.or.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20500318]	Grant sponsor: The Ministry of Education, Science, Sports and Culture of Japan; Grant number: 20500318.	ABNET K, 1991, DEV BRAIN RES, V59, P187, DOI 10.1016/0165-3806(91)90099-5; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brazda N, 2009, PROG BRAIN RES, V175, P269, DOI 10.1016/S0079-6123(09)17518-0; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Camand E, 2004, EUR J NEUROSCI, V20, P1161, DOI 10.1111/j.1460-9568.2004.03558.x; De Winter F, 2002, EXP NEUROL, V175, P61, DOI 10.1006/exnr.2002.7884; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Hayashi Y, 1997, GLIA, V19, P13, DOI 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; IKEDA H, 1992, HEPATOLOGY, V15, P282, DOI 10.1002/hep.1840150218; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; Klapka N, 2005, EUR J NEUROSCI, V22, P3047, DOI 10.1111/j.1460-9568.2005.04495.x; Kuchler-Bopp S, 1999, NEUROREPORT, V10, P1347, DOI 10.1097/00001756-199904260-00035; Li HP, 2007, J NEUROSCI RES, V85, P536, DOI 10.1002/jnr.21141; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; McAuliffe JJ, 2008, BRAIN RES, V1190, P175, DOI 10.1016/j.brainres.2007.11.038; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; MOGI M, 1984, ANAL BIOCHEM, V138, P125, DOI 10.1016/0003-2697(84)90779-6; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; Rakos G, 2007, ACTA NEUROBIOL EXP, V67, P149; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; ROSENSTEIN JM, 1994, J COMP NEUROL, V350, P229, DOI 10.1002/cne.903500207; Shearer MC, 2001, CELL TISSUE RES, V305, P267, DOI 10.1007/s004410100384; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Soares HD, 1995, J NEUROSCI, V15, P8223; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Teng X, 2008, J NEUROSCI RES, V86, P3140, DOI 10.1002/jnr.21767; Uemura K, 1996, J BIOL CHEM, V271, P4581; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	47	34	36	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	SEP 15	2010	518	18					3867	3881		10.1002/cne.22431			15	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	634RD	WOS:000280600400013	20653039				2022-02-06	
J	Brown, T; Williams, B; Boyle, M; Molloy, A; McKenna, L; Molloy, L; Lewis, B				Brown, Ted; Williams, Brett; Boyle, Malcolm; Molloy, Andrew; McKenna, Lisa; Molloy, Liz; Lewis, Belinda			Levels of Empathy in Undergraduate Occupational Therapy Students	OCCUPATIONAL THERAPY INTERNATIONAL			English	Article						empathy; occupational therapy; students; education; Jefferson Scale of Physician Empathy; Medical Condition Regard Scale	PHYSICIAN EMPATHY; MEDICAL-STUDENTS; JEFFERSON SCALE; SPECIALTY; GENDER; DRUG	Empathy is an important attribute for occupational therapists in establishing rapport and in better understanding their clients. However, empathy can be compromised by high workloads, personal stressors and pressures to demonstrate efficacy. Occupational therapists also work with patients from a variety of diagnostic groups. The objective of this study was to determine the extent of empathy and attitudes towards clients amongst undergraduate occupational therapy students at one Australian University. A cross-sectional study was undertaken using a written survey of the Jefferson Scale of Physician Empathy (JSPE) and the Medical Condition Regard Scale. Overall, a strong level of empathy was reported amongst students. Four medical conditions that occupational therapists work with (stroke, cerebral palsy, traumatic brain injury and depression) were held in high regard. Substance abuse, however, was held in comparatively low regard. Overall, the year of study appeared to have no significant impact on the students' empathy. Despite having a lower reported empathy level than found in health professions from other studies using the JSPE, occupational therapy students were found to have a good level of empathy. Of concern, however, was the bias reported against the medical condition of substance abuse, highlighting that the there may be a need to reinforce that patients from this diagnostic group are equally deserving of quality care irrespective of their clinical condition. Recommendations for future research include completing a longitudinal study of occupational therapy students' empathy levels and investigating the empathy levels of occupational therapists working with different client groups. Limitations of the study include the convenience sampling of occupational therapy students enrolled at one university which limits the generalizability of the results to groups of participants with similar characteristics. Copyright (C) 2010 John Wiley & Sons, Ltd.	[Brown, Ted; Molloy, Andrew] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Occupat Therapy, Frankston, Vic 3199, Australia; [Williams, Brett; Boyle, Malcolm] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Community Emergency Hlth & Paramed Practice, Frankston, Vic 3199, Australia; [McKenna, Lisa] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Nursing & Midwifery, Frankston, Vic 3199, Australia; [Molloy, Liz] Monash Univ, Fac Med Nursing & Hlth Sci, Notting Hill, Vic, Australia; [Lewis, Belinda] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Hlth Sci, Frankston, Vic 3199, Australia		Brown, T (corresponding author), Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Dept Occupat Therapy Program, Peninsula Campus,POB 527, Frankston, Vic 3199, Australia.	ted.brown@med.monash.edu.au	Williams, Brett/AAJ-2685-2020; Boyle, Malcolm/A-4301-2008; McKenna, Lisa/K-2603-2013; Williams, Brett/F-6776-2014	Williams, Brett/0000-0001-6307-1779; Boyle, Malcolm/0000-0003-4186-1280; McKenna, Lisa/0000-0002-0437-6449; Williams, Brett/0000-0001-6307-1779; Molloy, Elizabeth/0000-0001-9457-9348; Brown, Ted/0000-0001-9403-5877	Monash University Faculty of Medicine, Nursing and Health Sciences Learning and Teaching PerformanceMonash University	The Monash University Faculty of Medicine, Nursing and Health Sciences Learning and Teaching Performance Fund - Projects Grant Scheme provided the funding for this project to be completed. The Monash University health science students who took the time to complete the questionnaires are thanked for their input and insights.	Chen D, 2007, J GEN INTERN MED, V22, P1434, DOI 10.1007/s11606-007-0298-x; CHRISTIANSEN CH, 1977, AM J OCCUP THER, V31, P19; Christison GW, 2002, ACAD MED, V77, P257, DOI 10.1097/00001888-200203000-00017; Fields SK, 2004, EVAL HEALTH PROF, V27, P80, DOI 10.1177/0163278703261206; Gray JM, 1998, AM J OCCUP THER, V52, P354, DOI 10.5014/ajot.52.5.354; GREENE D, 1998, PHYS OCCUPATIONAL TH, V15, P39; Hemmerdinger Joanne M, 2007, BMC Med Educ, V7, P24, DOI 10.1186/1472-6920-7-24; Henry-Tillman R, 2002, AM J SURG, V183, P659, DOI 10.1016/S0002-9610(02)00867-X; Hojat M, 2002, AM J PSYCHIAT, V159, P1563, DOI 10.1176/appi.ajp.159.9.1563; Hojat M, 2005, J SOC PSYCHOL, V145, P663, DOI 10.3200/SOCP.145.6.663-672; Hojat M, 2005, PERS INDIV DIFFER, V39, P1205, DOI 10.1016/j.paid.2005.04.007; Hojat M, 2002, ACAD MED, V77, pS58, DOI 10.1097/00001888-200210001-00019; Hojat M, 2002, MED EDUC, V36, P522, DOI 10.1046/j.1365-2923.2002.01234.x; Hojat M, 2001, EDUC PSYCHOL MEAS, V61, P349, DOI 10.1177/00131640121971158; Hojat M, 2003, SEMINARS INTEGRATIVE, V1, P25, DOI DOI 10.1016/S1543-1150(03)00002-4; Hojat M., 2007, EMPATHY PATIENT CARE; Hojat Mohammadreza, 2003, Nurse Pract, V28, P45, DOI 10.1097/00006205-200304000-00010; Jamieson Margaret, 2006, Can J Occup Ther, V73, P76; LEVASSEUR J, 1993, EMPATHY PRACTICE MED, P76; Lyons M, 1996, DISABIL REHABIL, V18, P197, DOI 10.3109/09638289609166300; Newton BW, 2008, ACAD MED, V83, P244, DOI 10.1097/ACM.0b013e3181637837; Norman R, 2001, J NURS EDUC, V40, P371; PELOQUIN SM, 1995, AM J OCCUP THER, V49, P24, DOI 10.5014/ajot.49.1.24; Reynolds WJ, 2000, J ADV NURS, V31, P226, DOI 10.1046/j.1365-2648.2000.01242.x; Sherman Jeffrey J, 2005, J Dent Educ, V69, P338; Skinner N, 2007, J APPL SOC PSYCHOL, V37, P163, DOI 10.1111/j.0021-9029.2007.00154.x; Spiro HM., 1993, EMPATHY PRACTICE MED; Wilkes M, 2002, MED EDUC, V36, P528, DOI 10.1046/j.1365-2923.2002.01230.x; Yerxa EJ, 2009, AM J OCCUP THER, V63, P490, DOI 10.5014/ajot.63.4.490	29	34	34	1	19	WILEY-HINDAWI	LONDON	ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND	0966-7903	1557-0703		OCCUP THER INT	Occup. Ther. Int.	SEP	2010	17	3					135	141		10.1002/oti.297			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	748YH	WOS:000289428700004	20623554				2022-02-06	
J	Holli, KK; Waljas, M; Harrison, L; Liimatainen, S; Luukkaala, T; Ryymin, P; Eskola, H; Soimakallio, S; Ohman, J; Dastidar, P				Holli, Kirsi K.; Waljas, Minna; Harrison, Lara; Liimatainen, Suvi; Luukkaala, Tiina; Ryymin, Pertti; Eskola, Hannu; Soimakallio, Seppo; Ohman, Juha; Dastidar, Prasun			Mild Traumatic Brain Injury: Tissue Texture Analysis Correlated to Neuropsychological and DTI Findings	ACADEMIC RADIOLOGY			English	Article						Mild traumatic brain injury; texture analysis; magnetic resonance imaging; diffusion tensor imaging	DIFFUSE AXONAL INJURY; NON-HODGKIN-LYMPHOMA; INTRACRANIAL TUMORS; CORPUS-CALLOSUM; SCLEROSIS; MODERATE; IMAGES	Rationale and Objectives: The aim of this study was to evaluate whether texture analysis (TA) can detect subtle changes in cerebral tissue caused by mild traumatic brain injury (MTBI) and to determine whether these changes correlate with neuropsychological and diffusion tensor imaging (DTI) findings. Materials and Methods: Forty-two patients with MTBIs were imaged using 1.5T magnetic resonance imaging within 3 weeks after head injury. TA was performed for the regions corresponding to the mesencephalon, centrum semiovale, and corpus callosum. Using DTI, the fractional anisotropic and apparent diffusion coefficient values for the same regions were evaluated. The same analyses were performed on a group of 10 healthy volunteers. Patients also underwent a battery of neurocognitive tests within 6 weeks after injury. Results: TA revealed textural differences between the right and left hemispheres in patients with MTBIs, whereas differences were minimal in healthy controls. A significant correlation was found between scores on memory tests and texture parameters (sum of squares, sum entropy, inverse difference moment, and sum average) in patients in the area of the mesencephalon and the genu of the corpus callosum. Significant correlations were also found between texture parameters for the left mesencephalon and both fractional anisotropic and apparent diffusion coefficient values. Conclusions: The data suggest that heterogeneous texture and abnormal DTI patterns in the area of the mesencephalon may be linked with verbal memory deficits among patients with MTBIs. Therefore, TA combined with DTI in patients with MTBIs may increase the ability to detect early and subtle neuropathologic changes.	[Holli, Kirsi K.; Harrison, Lara; Ryymin, Pertti; Eskola, Hannu; Soimakallio, Seppo; Dastidar, Prasun] Tampere Univ Hosp, Med Imaging Ctr, Tampere 33521, Finland; [Liimatainen, Suvi] Tampere Univ Hosp, Dept Neurol & Rehabil, Tampere 33521, Finland; [Waljas, Minna; Ohman, Juha] Tampere Univ Hosp, Dept Neurosurg, Tampere 33521, Finland; [Liimatainen, Suvi] Tampere Univ Hosp, Dept Emergency Med Acuta, Tampere 33521, Finland; [Holli, Kirsi K.; Harrison, Lara; Eskola, Hannu] Tampere Univ Technol, Dept Biomed Engn, FIN-33101 Tampere, Finland; [Harrison, Lara; Soimakallio, Seppo; Dastidar, Prasun] Tampere Med Sch, Tampere, Finland; [Luukkaala, Tiina] Pirkanmaa Hosp Dist, Ctr Sci, Tampere, Finland; [Luukkaala, Tiina] Univ Tampere, Tampere Sch Publ Hlth, FIN-33101 Tampere, Finland		Holli, KK (corresponding author), Tampere Univ Hosp, Med Imaging Ctr, Post Box 2000, Tampere 33521, Finland.	kirsi.holli@tut.fi	Eskola, Hannu/G-4279-2014	Eskola, Hannu/0000-0003-1673-2305; Luukkaala, Tiina/0000-0003-4636-9586; Ohman, Juha/0000-0002-6592-1367	Pirkanmaa Hospital District, Tampere University Hospital (Tampere, Finland); Jenny and Antti Wihuri Foundation (Helsinki, Finland); Instrumentarium Science Foundation (Helsinki, Finland)	This study was supported by grants for research funding from the Pirkanmaa Hospital District, Tampere University Hospital (Tampere, Finland); the Jenny and Antti Wihuri Foundation (Helsinki, Finland); and the Instrumentarium Science Foundation (Helsinki, Finland).	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bonilha L, 2003, EPILEPSIA, V44, P1546, DOI 10.1111/j.0013-9580.2003.27103.x; *CAMBR COGN, 2004, CANTAB CAMBR NEUR AU; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Freeborough PA, 1998, IEEE T MED IMAGING, V17, P475, DOI 10.1109/42.712137; Gibbs P, 2003, MAGN RESON MED, V50, P92, DOI 10.1002/mrm.10496; Hajek M, 2006, TEXTURE ANAL MAGNETI; Harrison L, 2008, COMPUT BIOL MED, V38, P519, DOI 10.1016/j.compbiomed.2008.01.016; Harrison LCV, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-87; Herlidou-Meme S, 2003, MAGN RESON IMAGING, V21, P989, DOI 10.1016/S0730-725X(03)00212-1; Holli K, 2010, ACAD RADIOL, V17, P135, DOI 10.1016/j.acra.2009.08.012; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jirak D, 2002, J MAGN RESON IMAGING, V15, P68, DOI 10.1002/jmri.10042; KJAER L, 1995, ACTA RADIOL, V36, P127; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MAHMOUDGHONEIM D, 2008, BMC MED IMAGING, V23, P8; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mitrushina M., 2005, NORMATIVE DATA NEURO; Morrow LA, 2002, CLIN NEUROPSYCHOL, V16, P373, DOI 10.1076/clin.16.3.373.13850; POSSE S, 1995, MAGN RESON MED, V33, P34, DOI 10.1002/mrm.1910330106; Rauscher A, 2006, Z MED PHYS, V16, P240, DOI 10.1078/0939-3889-00322; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; SCHAD LR, 1993, MAGN RESON IMAGING, V11, P889, DOI 10.1016/0730-725X(93)90206-S; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; TEASDALE G, 1974, LANCET, V2, P81; Tuceryan M., 1998, HDB PATTERN RECOGNIT, V2, P207; Zhang J, 2008, MAGN RESON IMAGING, V26, P1160, DOI 10.1016/j.mri.2008.01.016	33	34	35	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	SEP	2010	17	9					1096	1102		10.1016/j.acra.2010.04.009			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	643PL	WOS:000281310500006	20605490				2022-02-06	
J	Koch, H; Huh, SE; Elsen, FP; Carroll, MS; Hodge, RD; Bedogni, F; Turner, MS; Hevner, RF; Ramirez, JM				Koch, Henner; Huh, Sung-Eun; Elsen, Frank P.; Carroll, Michael S.; Hodge, Rebecca D.; Bedogni, Francesco; Turner, Michael S.; Hevner, Robert F.; Ramirez, Jan-Marino			Prostaglandin E2-Induced Synaptic Plasticity in Neocortical Networks of Organotypic Slice Cultures	JOURNAL OF NEUROSCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; SLEEP-WAKE CYCLE; GLIAL TNF-ALPHA; IN-VIVO; CEREBRAL-CORTEX; HOMEOSTATIC PLASTICITY; NEURONAL APOPTOSIS; PYRAMIDAL NEURONS; CELL-DEATH; SEIZURES	Traumatic brain injury (TBI) is a major cause of epilepsy, yet the mechanisms underlying the progression from TBI to epilepsy are unknown. TBI induces the expression of COX-2 (cyclooxygenase-2) and increases levels of prostaglandin E2 (PGE2). Here, we demonstrate that acutely applied PGE2 (2 mu M) decreases neocortical network activity by postsynaptically reducing excitatory synaptic transmission in acute and organotypic neocortical slices of mice. In contrast, long-term exposure to PGE2 (2 mu M; 48 h) presynaptically increases excitatory synaptic transmission, leading to a hyperexcitable network state that is characterized by the generation of paroxysmal depolarization shifts (PDSs). PDSs were also evoked as a result of depriving organotypic slices of activity by treating them with tetrodotoxin (TTX, 1 mu M; 48 h). This treatment predominantly increased postsynaptically excitatory synaptic transmission. The network and cellular effects of PGE2 and TTX treatments reversed within 1 week. Differences in the underlying mechanisms (presynaptic vs postsynaptic) as well as occlusion experiments in which slices were exposed to TTX plus PGE2 suggest that the two substances evoke distinct forms of homeostatic plasticity, both of which result in a hyperexcitable network state. PGE2 and TTX (alone or together with PGE2) also increased levels of apoptotic cell death in organotypic slices. Thus, we hypothesize that the increase in excitability and apoptosis may constitute the first steps in a cascade of events that eventually lead to epileptogenesis triggered by TBI.	[Koch, Henner; Huh, Sung-Eun; Elsen, Frank P.; Carroll, Michael S.; Hodge, Rebecca D.; Bedogni, Francesco; Hevner, Robert F.; Ramirez, Jan-Marino] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA 98101 USA; [Koch, Henner; Hodge, Rebecca D.; Hevner, Robert F.; Ramirez, Jan-Marino] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [Turner, Michael S.] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA		Koch, H (corresponding author), Seattle Childrens Res Inst, Ctr Integrat Brain Res, 1900 9th Ave, Seattle, WA 98101 USA.	henner.koch@seattlechildrens.org	Bedogni, Francesco/ABE-1509-2020	Bedogni, Francesco/0000-0002-4975-6605; bedogni, francesco/0000-0002-6651-0041; Carroll, Michael/0000-0002-0526-7543; Ramirez, Jan-Marino/0000-0002-5626-3999	Tarrson family; Falk Foundation	This work was supported in part by the Tarrson family and the Falk Foundation.	Ahmadi S, 2002, NAT NEUROSCI, V5, P34, DOI 10.1038/nn778; Aizenman CD, 2003, NEURON, V39, P831, DOI 10.1016/S0896-6273(03)00527-0; Akaneya Y, 2006, J NEUROSCI, V26, P10209, DOI 10.1523/JNEUROSCI.3028-06.2006; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; ARMSTRONG CM, 1992, METHOD ENZYMOL, V207, P100; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Chandrasekaran AR, 2007, J NEUROSCI, V27, P1746, DOI 10.1523/JNEUROSCI.4383-06.2007; Chen C, 2005, J NEUROPHYSIOL, V93, P929, DOI 10.1152/jn.00696.2004; CONTRERAS D, 1995, J NEUROSCI, V15, P604; Davis GW, 2001, ANNU REV PHYSIOL, V63, P847, DOI 10.1146/annurev.physiol.63.1.847; Desai NS, 1999, NAT NEUROSCI, V2, P515, DOI 10.1038/9165; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; Heck N, 2008, CEREB CORTEX, V18, P1335, DOI 10.1093/cercor/bhm165; Hevner RF, 2001, NEURON, V29, P353, DOI 10.1016/S0896-6273(01)00211-2; Hodge RD, 2008, J NEUROSCI, V28, P3707, DOI 10.1523/JNEUROSCI.4280-07.2008; Hodge RD, 2007, INT J DEV NEUROSCI, V25, P233, DOI 10.1016/j.ijdevneu.2007.03.004; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Johnson HA, 2007, J NEUROSCI, V27, P5915, DOI 10.1523/JNEUROSCI.0447-07.2007; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kessels HW, 2009, NEURON, V61, P340, DOI 10.1016/j.neuron.2009.01.015; Liang FY, 1997, J NEUROSCI, V17, P2168; Maffei A, 2008, J NEUROSCI, V28, P4377, DOI 10.1523/JNEUROSCI.5298-07.2008; Maffei A, 2006, NATURE, V443, P81, DOI 10.1038/nature05079; Mahon S, 2006, J NEUROSCI, V26, P12587, DOI 10.1523/JNEUROSCI.3987-06.2006; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; Nelson SB, 2008, NEURON, V60, P477, DOI 10.1016/j.neuron.2008.10.020; Newpher TM, 2008, NEURON, V58, P472, DOI 10.1016/j.neuron.2008.04.030; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Okun M, 2010, J NEUROSCI, V30, P4440, DOI 10.1523/JNEUROSCI.5062-09.2010; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Reig R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000670; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027, DOI 10.1038/79848; Sang N, 2005, J NEUROSCI, V25, P9858, DOI 10.1523/JNEUROSCI.2392-05.2005; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Steriade M, 2001, ARCH ITAL BIOL, V139, P37; Timofeev I, 2001, P NATL ACAD SCI USA, V98, P1924, DOI 10.1073/pnas.041430398; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Trasande CA, 2007, J CLIN NEUROPHYSIOL, V24, P154, DOI 10.1097/WNP.0b013e318033787f; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; van Drongelen W, 2003, J NEUROPHYSIOL, V90, P1571, DOI 10.1152/jn.00392.2003; van Drongelen W, 2006, J NEUROPHYSIOL, V96, P2564, DOI 10.1152/jn.00446.2006; Verney C, 2000, DEV NEUROSCI-BASEL, V22, P125, DOI 10.1159/000017434; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wierenga CJ, 2006, J NEUROPHYSIOL, V96, P2127, DOI 10.1152/jn.00107.2006; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067, DOI 10.1152/jn.2001.85.3.1067; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yang HW, 2008, MOL CELL NEUROSCI, V37, P682, DOI 10.1016/j.mcn.2007.12.019	53	34	35	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	2010	30	35					11678	11687		10.1523/JNEUROSCI.4665-09.2010			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	647GV	WOS:000281607300014	20810888	Bronze, Green Published			2022-02-06	
J	Rahme, R; Weil, AG; Sabbagh, M; Moumdjian, R; Bouthillier, A; Bojanowski, MW				Rahme, Ralph; Weil, Alexander G.; Sabbagh, Mike; Moumdjian, Robert; Bouthillier, Alain; Bojanowski, Michel W.			Decompressive Craniectomy Is Not an Independent Risk Factor for Communicating Hydrocephalus in Patients With Increased Intracranial Pressure	NEUROSURGERY			English	Article						Cerebrovascular accident; Cranioplasty; Decompressive craniectomy; Hemicraniectomy; Hydrocephalus; Intracranial pressure; Malignant middle cerebral artery territory infarction	ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; SINUS THROMBOSIS; HEMICRANIECTOMY; INFARCTION	BACKGROUND: It was recently suggested that communicating hydrocephalus is an almost universal finding after hemicraniectomy and that early cranioplasty may prevent the need for permanent cerebrospinal fluid diversion in these patients. OBJECTIVE: To conduct a study in an attempt to verify these findings. METHODS: The medical records of all patients who underwent decompressive craniectomy for medically refractory elevated intracranial pressure between 2001 and 2009 were retrospectively reviewed. Patients with subarachnoid hemorrhage, intraventricular hemorrhage, or head trauma were excluded. Hydrocephalus was classified as internal or external and as clinically significant or asymptomatic. RESULTS: The patient population consisted of 17 patients, 8 men and 9 women, with a median age of 44 years (range, 27-53 years). Etiologies included malignant middle cerebral artery territory infarction in 12 patients, hemorrhagic transformation of ischemic cerebrovascular accident in 2 patients, dural sinus thrombosis in 2 patients, and hemorrhagic cerebrovascular accident in 1 patient. The extent of craniectomy ranged from a large bone flap in 4 patients to a standard hemicraniectomy in 13 patients. Two patients died and 1 was lost to follow-up during the acute stage. The remaining 14 patients underwent cranioplasty after a median interval of 21 days (range, 3-42 days). In none of these patients did clinically significant hydrocephalus develop requiring cerebrospinal fluid diversion. Asymptomatic extra-axial cerebrospinal fluid collections developed in 2 patients that resolved spontaneously after cranioplasty. CONCLUSION: Our results suggest that, contrary to some beliefs, hydrocephalus does not frequently occur after decompressive craniectomy.	[Rahme, Ralph; Weil, Alexander G.; Sabbagh, Mike; Moumdjian, Robert; Bouthillier, Alain; Bojanowski, Michel W.] Univ Montreal, Div Neurosurg, Hop Notre Dame CHUM, Montreal, PQ H2L 4M1, Canada		Bojanowski, MW (corresponding author), Univ Montreal, Div Neurosurg, Hop Notre Dame CHUM, Montreal, PQ H2L 4M1, Canada.	michel.bojanowski.chum@ssss.gouv.qc.ca	Rahme, Ralph/I-6932-2019	Rahme, Ralph/0000-0003-1796-7296; Weil, Alexander/0000-0003-4162-6096			Coutinho JM, 2009, STROKE, V40, P2233, DOI 10.1161/STROKEAHA.108.543421; D'Ambrosio AL, 2005, NEUROSURGERY, V56, P12, DOI 10.1227/01.NEU.0000144820.38439.63; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; Keller E, 2005, ACTA NEUROCHIR SUPPL, V94, P177; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37	9	34	38	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2010	67	3					675	678		10.1227/01.NEU.0000383142.10103.0B			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641TS	WOS:000281153200016	20651634				2022-02-06	
J	Hoh, NZ; Wagner, AK; Alexander, SA; Clark, RB; Beers, SR; Okonkwo, DO; Ren, DX; Conley, YP				Hoh, Nicole Zangrilli; Wagner, Amy K.; Alexander, Sheila A.; Clark, Robert B.; Beers, Sue R.; Okonkwo, David O.; Ren, Dianxu; Conley, Yvette P.			BCL2 Genotypes: Functional and Neurobehavioral Outcomes after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; BCL2; genotype; outcomes; traumatic brain injury	PROGRAMMED CELL-DEATH; SEVERE HEAD-INJURY; RATING-SCALE; APOPTOSIS; GENE; EXPRESSION; PROTOONCOGENE; INCREASES; PROMOTER; SURVIVAL	Traumatic brain injury (TBI) triggers a cascade of apoptotic-related events that include BCL2 expression, a pro-survival protein in the apoptosis pathway. The purpose of this study was to use tagging single nucleotide polymorphism (tSNP) genotypes to screen the BCL2 gene to determine if genetic variability in the BCL2 gene influences outcomes in 205 patients with severe TBI. Outcomes (Glasgow Outcome Scale [GOS], Disability Rating Scale [DRS], mortality, and Neurobehavioral Rating Scale-Revised [NRS-R]) were analyzed at 3, 6, 12, and 24 months. Multivariate analysis demonstrates that there were four tSNPs of significant interest: rs17759659, rs1801018, rs7236090, and rs949037. Presence of the variant allele for rs17759659 was associated with poorer outcomes (GOS p=0.001; DRS p=0.002), higher mortality (p=0.02; OR=4.23; CI 1.31,13.61), and worse NRS-R scores (p=0.05). Presence of the variant allele for rs1801018 was associated with poorer outcomes (GOS p=0.02; DRS p=0.009), and mortality (p=0.03; OR=3.86; CI 1.18,12.59). Being homozygous for the wild-type allele for rs7236090 was associated with favorable outcomes on the NRS-R (p=0.007), while homozygosity for the variant genotype was associated with favorable outcomes on the GOS (p=0.007) and DRS (p=0.006). The homozygous variant for rs949037 was associated with favorable outcomes (GOS p=0.04; DRS p=0.03), and the homozygous wild-type was associated with increased mortality at 3 months (p=0.005; OR=3.67; CI 1.08,12.49). The only finding that stood up to Bonferroni correction was rs17759659 for GOS. These data support the possibility that genetic variability for pro-survival proteins, particularly genetic variation in the BCL2 gene, impacts outcomes after severe TBI.	[Hoh, Nicole Zangrilli; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA; [Alexander, Sheila A.] Acute & Tertiary Care, Pittsburgh, PA USA; [Ren, Dianxu] Hlth & Community Syst, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15261 USA; [Clark, Robert B.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA; [Beers, Sue R.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA		Hoh, NZ (corresponding author), Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, 440 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.	nmzst1@pitt.edu			University of Pittsburgh School of Nursing [T32 NR009759];  [R01NR04801];  [NR008424];  [5P50NS30318];  [R49/CCR 323155-03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR009759, R01NR004801, R01NR008424] Funding Source: NIH RePORTER	This study utilized biological samples and data collected from federally-funded studies that examined genes and gene products in TBI patients, and how they related to outcomes attained by TBI patients (R01NR04801, NR008424, 5P50NS30318, and R49/CCR 323155-03). We thank the nurses of the neurotrauma intensive care unit for their assistance with sample collection and support of our work. Genotype data collection was supported by the Leslie A. Hoffman Endowed Research Award at the University of Pittsburgh School of Nursing, and the Sigma Theta Tau Eta Chapter at the University of Pittsburgh. Postdoctoral fellowship is funded by the University of Pittsburgh School of Nursing, Targeted Research and Academic Training Program for Nurses in Genomics (T32 NR009759).	Bahr M, 2000, TRENDS NEUROSCI, V23, P483, DOI 10.1016/S0166-2236(00)01637-4; BARRETT JC, 2005, BIOINFORMATICS  0115; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; Bredow S, 2007, GENE, V404, P110, DOI 10.1016/j.gene.2007.09.005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JENNETT B, 1976, MED J AUSTRALIA, V2, P475, DOI 10.5694/j.1326-5377.1976.tb130352.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, P ROY SOC MED, V69, P140, DOI 10.1177/003591577606900229; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kim DH, 2009, BLOOD, V113, P2517, DOI 10.1182/blood-2008-07-169110; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEZEK MD, 2004, NEUROPSYCHOLOGICAL A; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Liu Zhan, 2006, Chin J Traumatol, V9, P168; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; MYERS KM, 1995, J NEUROCHEM, V65, P2432; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; POLVISHOCK JTE, 2004, J NEUROTRAUM, V24, pS1; POVLISHOCK EJT, 2000, J NEUROTRAUM, V17, P451; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang Shu-Yuan, 2004, Chin J Traumatol, V7, P159; Yang Xiao-feng, 2006, Chin J Traumatol, V9, P276; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	40	34	36	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1413	1427		10.1089/neu.2009.1256			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900006	20504155	Green Published			2022-02-06	
J	Carrera, E; Schmidt, JM; Fernandez, L; Kurtz, P; Merkow, M; Stuart, M; Lee, K; Claassen, J; Connolly, ES; Mayer, SA; Badjatia, N				Carrera, Emmanuel; Schmidt, J. Michael; Fernandez, Luis; Kurtz, Pedro; Merkow, Maxwell; Stuart, Morgan; Lee, Kiwon; Claassen, Jan; Connolly, E. Sander; Mayer, Stephan A.; Badjatia, Neeraj			Spontaneous hyperventilation and brain tissue hypoxia in patients with severe brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CEREBRAL-BLOOD-FLOW; CENTRAL NEUROGENIC HYPERVENTILATION; CARBON-DIOXIDE; SUBARACHNOID HEMORRHAGE; VESSEL CALIBER; OXYGEN; PRESSURE; ARTERIAL; HYPERCAPNIA; REACTIVITY	Background Hyperventilation has been shown to be associated with cerebral vasoconstriction and increased risk of infarction. Our aim was to determine whether spontaneous reduction in end-tidal CO2 (EtCO2) was associated with an increased in brain tissue hypoxia (BTH). Method We studied 21 consecutive patients (mean age 50 +/- 16 years; 15 women) undergoing continuous monitoring for brain tissue oxygenation (PbtO(2)), intracranial pressure (ICP), cerebral perfusion pressure (CPP) and EtCO2; mean values were recorded hourly BTH was defined as brain tissue oxygen tension (PbtO(2)) <15 mm Hg. Results Diagnoses included subarachnoid haemorrhage (67%), intracranial haemorrhage (24%) and traumatic brain injury (10%). Overall, BTH occurred during 22.5% of the study period (490/2179 hourly data). The frequency of BTH increased progressively from 15.7% in patients with normal EtCO2 (35-44 mm Hg) to 33.9% in patients with EtCO2<25 mm Hg (p<0.001). The mean tidal volume and minute ventilation were 7 +/- 2 ml/kg and 9 +/- 2 1/min, respectively. Hypocapnia was associated with higher measured-than-set respiratory rates and maximal minute ventilation values, suggestive of spontaneous hyperventilation. Using a generalised estimated equation (GEE) and after adjustment for GCS, ICP and core temperature, the variables independently associated with BTH events were EtCO2 (OR: 0.94; 95% CI 0.90 to 0.97; p<0.001) and CPP (OR: 0.98; 95% CI 0.97 to 0.99; p=0.004). Conclusion The risk of brain tissue hypoxia in critically brain-injured patients increases when EtCO2 values are reduced. Unintentional spontaneous hyperventilation may be a common and under-recognised cause of brain tissue hypoxia after severe brain injury.	[Carrera, Emmanuel; Schmidt, J. Michael; Fernandez, Luis; Kurtz, Pedro; Lee, Kiwon; Claassen, Jan; Mayer, Stephan A.; Badjatia, Neeraj] Columbia Univ, Med Ctr, Dept Neurol, Div Neurocrit Care, New York, NY 10032 USA; [Merkow, Maxwell; Stuart, Morgan; Lee, Kiwon; Claassen, Jan; Connolly, E. Sander; Mayer, Stephan A.; Badjatia, Neeraj] Columbia Univ, Med Ctr, Dept Neurosurg, New York, NY 10032 USA		Badjatia, N (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, Div Neurocrit Care, 177 Ft Washington Ave,MHB 8-300, New York, NY 10032 USA.	nbadjatia@neuro.columbia.edu	Claassen, Jan/AAA-5451-2020; Badjatia, Neeraj/AAS-4855-2021	Schmidt, J. Michael/0000-0001-8141-2944; Carrera, Emmanuel/0000-0003-0045-5382; Badjatia, Neeraj/0000-0003-1509-9034	Swiss National Science Foundation, Bern, SwitzerlandSwiss National Science Foundation (SNSF) [PBLAB-119620]; SICPA Foundation, Lausanne, Switzerland; Charles A. Dana Foundation; National Center for Research Resources (NCRR), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR024157]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024157] Funding Source: NIH RePORTER	This work was supported by research grants from the Swiss National Science Foundation (EC) (PBLAB-119620), Bern, Switzerland, the SICPA Foundation, Lausanne, Switzerland (EC) and the Charles A. Dana Foundation (SAM). NB received funding from a K 12 Career Development Award (RR024157; PI: H Ginsberg) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH).	Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; BRATTON SL, 2007, J NEUROTRAUMA S1, V24, pS87; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Gaviani P, 2005, NEUROLOGY, V64, P166, DOI 10.1212/01.WNL.0000148579.80486.F1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; JAECKLE KA, 1990, NEUROLOGY, V40, P1715, DOI 10.1212/WNL.40.11.1715; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marion DW, 2000, J TRAUMA, V48, P1032; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; PETRUK KC, 1974, STROKE, V5, P230, DOI 10.1161/01.STR.5.2.230; REIVICH M, 1964, AM J PHYSIOL, V206, P25, DOI 10.1152/ajplegacy.1964.206.1.25; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; RUSSELL GB, 1995, ANESTH ANALG, V81, P806, DOI 10.1097/00000539-199510000-00025; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tarulli AW, 2005, ARCH NEUROL-CHICAGO, V62, P1632, DOI 10.1001/archneur.62.10.1632; TUOR UI, 1984, AM J PHYSIOL, V247, pH40, DOI 10.1152/ajpheart.1984.247.1.H40; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; WOLLMAN H, 1968, J APPL PHYSIOL, V24, P60, DOI 10.1152/jappl.1968.24.1.60; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	32	34	36	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2010	81	7					793	797		10.1136/jnnp.2009.174425			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	627LK	WOS:000280040800021	19965840				2022-02-06	
J	Goldshmit, Y; Munro, K; Leong, SY; Pebay, A; Turnley, AM				Goldshmit, Yona; Munro, Kathryn; Leong, Soo Yuen; Pebay, Alice; Turnley, Ann M.			LPA receptor expression in the central nervous system in health and following injury	CELL AND TISSUE RESEARCH			English	Article						Lysophosphatidic acid; LPA receptor; Spinal cord injury; Cortical injury neurotrauma; Mouse (C57BL/6)	LYSOPHOSPHATIDIC ACID RECEPTOR; RAT ASTROCYTES; GLUCOSE-UPTAKE; CELL-LINES; MICE; PROLIFERATION; NEURONS; GENE; RHO; VZG-1/LP(A1)/EDG-2	Lysophosphatidic acid (LPA) is released from platelets following injury and also plays a role in neural development but little is known about its effects in the adult central nervous system (CNS). We have examined the expression of LPA receptors 1-3 (LPA(1-3)) in intact mouse spinal cord and cortical tissues and following injury. In intact and injured tissues, LPA(1) was expressed by ependymal cells in the central canal of the spinal cord and was upregulated in reactive astrocytes following spinal cord injury. LPA(2) showed low expression in intact CNS tissue, on grey matter astrocytes in spinal cord and in ependymal cells lining the lateral ventricle. Following injury, its expression was upregulated on astrocytes in both cortex and spinal cord. LPA(3) showed low expression in intact CNS tissue, viz. on cortical neurons and motor neurons in the spinal cord, and was upregulated on neurons in both regions after injury. Therefore, LPA(1-3) are differentially expressed in the CNS and their expression is upregulated in response to injury. LPA release following CNS injury may have different consequences for each cell type because of this differential expression in the adult nervous system.	[Goldshmit, Yona; Munro, Kathryn; Leong, Soo Yuen; Pebay, Alice; Turnley, Ann M.] Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; [Pebay, Alice] Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; [Goldshmit, Yona] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3800, Australia		Turnley, AM (corresponding author), Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia.	apebay@unimelb.edu.au; turnley@unimelb.edu.au	Turnley, Ann/A-8125-2010	Turnley, Ann/0000-0002-8442-127X; Pebay, Alice/0000-0002-7408-9453	NHMRCNational Health and Medical Research Council of Australia [454723, 454384]; SpinalCure Australia Research Fellowship	This work was supported by NHMRC Project Grants 454723 and 454384, an NHMRC-Senior Research Fellowship (A.M.T.) and a SpinalCure Australia Research Fellowship (Y.G.).	Bouquet C, 2007, MOL CELL NEUROSCI, V36, P235, DOI 10.1016/j.mcn.2007.07.002; Choi JW, 2008, BBA-MOL CELL BIOL L, V1781, P531, DOI 10.1016/j.bbalip.2008.03.004; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Contos JJA, 2001, GENE, V267, P243, DOI 10.1016/S0378-1119(01)00410-3; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Elmes SJR, 2004, BRAIN RES, V1022, P205, DOI 10.1016/j.brainres.2004.07.005; Frohnert PW, 2003, J NEUROPATH EXP NEUR, V62, P520, DOI 10.1093/jnen/62.5.520; Fujita R, 2007, NEUROCHEM INT, V50, P351, DOI 10.1016/j.neuint.2006.09.003; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Fukushima N, 2002, MOL BIOL CELL, V13, P2692, DOI 10.1091/mbc.01-09-0465; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Hama K, 2007, BIOL REPROD, V77, P954, DOI 10.1095/biolreprod.107.060293; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Keller JN, 1997, J NEUROCHEM, V69, P1073; Keller JN, 1996, J NEUROCHEM, V67, P2300; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200; Liszewska E, 2009, ENDOCRINOLOGY, V150, P422, DOI 10.1210/en.2008-0749; Manning TJ, 1997, GLIA, V20, P163, DOI 10.1002/(SICI)1098-1136(199706)20:2<163::AID-GLIA8>3.0.CO;2-A; Moller T, 1999, NEUROREPORT, V10, P2929; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Noguchi K, 2009, CURR OPIN PHARMACOL, V9, P15, DOI 10.1016/j.coph.2008.11.010; Ohuchi H, 2008, DEV DYNAM, V237, P3280, DOI 10.1002/dvdy.21736; Pebay A, 1999, GLIA, V28, P25, DOI 10.1002/(SICI)1098-1136(199910)28:1<25::AID-GLIA3>3.0.CO;2-D; Pebay A, 2007, PROSTAG OTH LIPID M, V84, P83, DOI 10.1016/j.prostaglandins.2007.08.004; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Renback K, 1999, NEUROSCI LETT, V270, P59, DOI 10.1016/S0304-3940(99)00464-4; Renback K, 2000, MOL BRAIN RES, V75, P350, DOI 10.1016/S0169-328X(99)00333-2; Rouach N, 2006, EUR J NEUROSCI, V23, P1453, DOI 10.1111/j.1460-9568.2006.04671.x; Savaskan NE, 2007, CELL MOL LIFE SCI, V64, P230, DOI 10.1007/s00018-006-6412-0; Shano S, 2008, NEUROCHEM INT, V52, P216, DOI 10.1016/j.neuint.2007.07.004; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Spohr TCDSE, 2008, J BIOL CHEM, V283, P7470, DOI 10.1074/jbc.M707758200; Stankoff B, 2002, MOL CELL NEUROSCI, V20, P415, DOI 10.1006/mcne.2002.1129; Steiner MR, 2000, ANN NY ACAD SCI, V905, P132; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; Tomas M, 2003, J NEUROCHEM, V87, P220, DOI 10.1046/j.1471-4159.2003.01993.x; Ueda H, 2006, PHARMACOL THERAPEUT, V109, P57, DOI 10.1016/j.pharmthera.2005.06.003; Weiner JA, 1998, J COMP NEUROL, V398, P587; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zheng Zhao-Qing, 2004, Shengli Xuebao, V56, P163; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	50	34	36	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	JUL	2010	341	1					23	32		10.1007/s00441-010-0977-5			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	620LE	WOS:000279500600003	20495828				2022-02-06	
J	Morad, Y; Wygnansky-Jaffe, T; Levin, AV				Morad, Yair; Wygnansky-Jaffe, Tamara; Levin, Alex V.			Retinal haemorrhage in abusive head trauma	CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						child abuse; head trauma; retinal haemorrhage; shaken baby syndrome	SHAKEN BABY SYNDROME; PERMANENT BRAIN-DAMAGE; GLUTARIC ACIDURIA; SUBDURAL-HEMATOMA; CHILD-ABUSE; INJURY; INFANTS; RETINOPATHY; SHAKING; UPDATE	P>Paediatric abusive head injury may have grave consequences, especially when characterized by repetitive acceleration-deceleration forces (shaken baby syndrome). Death occurs in approximately 30% and permanent neurologic damage in up to 80% of the victims. Retinal haemorrhages are a cardinal sign seen in approximately 85% of cases. In most cases haemorrhages are preretinal, intraretinal and subretinal, too numerous to count, and involving the entire retinal surface extending to the ora serrata. Traumatic macular retinoschisis is a lesion with important diagnostic significance. Vitreoretinal traction appears to be the mechanism of haemorrhage and schisis formation along with a possible role of orbital tissue trauma from repetitive acceleration-deceleration forces. Ophthalmologists must carefully document ocular findings. Appropriate autopsy examination should include ocular and orbital tissue removal. Although there is a wide differential diagnosis for retinal haemorrhages, clinical appearance, when considered in the context of systemic and laboratory findings, usually leads to the correct diagnosis.	[Levin, Alex V.] Wills Eye Inst, Philadelphia, PA 19107 USA; [Morad, Yair] Assaf Harofeh Med Ctr, Pediat Ophthalmol Serv, Zerifin, Israel; [Morad, Yair; Wygnansky-Jaffe, Tamara] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Wygnansky-Jaffe, Tamara] Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel		Levin, AV (corresponding author), Wills Eye Inst, 840 Walnut St, Philadelphia, PA 19107 USA.	alevin@willseye.org					Adams G, 2004, EYE, V18, P795, DOI 10.1038/sj.eye.6701643; Aikman J., 1928, ARCH PEDIAT, V45, P56; Altman RL, 2007, EUR J OPHTHALMOL, V17, P648, DOI 10.1177/112067210701700426; Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Bhola RM, 2005, INVEST OPHTH VIS SCI, V46; Bullock DP, 2009, J PEDIATR ORTHOPED, V29, P231, DOI 10.1097/BPO.0b013e31819aad44; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Case ME, 2008, BRAIN PATHOL, V18, P571, DOI 10.1111/j.1750-3639.2008.00204.x; Chapman-Davies Anthony, 2002, Clin Exp Optom, V85, P42; COATS B, 2009, 2 INT C PED AB HEAD; COPPETO JR, 1985, J CLIN NEURO-OPHTHAL, V5, P45; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Gago LC, 2003, RETINA-J RET VIT DIS, V23, P724, DOI 10.1097/00006982-200310000-00027; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GILKES UJ, 1967, FUNDI BATTERED BABIE, P468; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; GOETTING MG, 1990, PEDIATRICS, V85, P585; Goldenberg-Cohen N, 2004, J AAPOS, V8, P20, DOI 10.1016/j.jaapos.2003.08.009; Goldman M, 2006, J PEDIATR-US, V148, P835, DOI 10.1016/j.jpeds.2005.12.052; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Herr S, 2004, PEDIATRICS, V113, P1658, DOI 10.1542/peds.113.6.1658; Hughes LA, 2006, J AAPOS, V10, P102, DOI 10.1016/j.jaapos.2005.12.005; KAUR B, 1992, SURV OPHTHALMOL, V37, P1, DOI 10.1016/0039-6257(92)90002-B; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2008, ARCH OPHTHALMOL-CHIC, V126, P800, DOI 10.1001/archopht.126.6.800; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; KRISHNAN J, 1990, AUST NZ J SURG, V60, P447, DOI 10.1111/j.1445-2197.1990.tb07400.x; Lancon JA, 1998, ANAT REC, V253, P13, DOI 10.1002/(SICI)1097-0185(199802)253:1<13::AID-AR8>3.0.CO;2-F; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Mungan NK, 2007, CURR OPIN OPHTHALMOL, V18, P392, DOI 10.1097/ICU.0b013e3282a167f0; Newton AW, 2005, CURR OPIN PEDIATR, V17, P246, DOI 10.1097/01.mop.0000158730.56669.b1; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Pierce MC, 2008, ANNU REV BIOMED ENG, V10, P85, DOI 10.1146/annurev.bioeng.9.060906.151907; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; PRANGE M, 2002, BIOMECHANICS TRAUMAT; Rangarajan N, 2009, J AAPOS, V13, P364, DOI 10.1016/j.jaapos.2008.11.006; Reddy SC, 2004, ACTA OPHTHALMOL SCAN, V82, P81, DOI 10.1046/j.1600-0420.2003.00197.x; Saleh M, 2009, BRIT J OPHTHALMOL, V93, P424, DOI 10.1136/bjo.2008.147561; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2; Scott AW, 2009, AM J OPHTHALMOL, V147, P364, DOI 10.1016/j.ajo.2008.08.010; SCOTT AW, 2009, AM J OPHTHALMOL, V147, pE2; Sherwood D, 1930, AM J DIS CHILD, V39, P980; Stoodley N, 2006, BRIT J RADIOL, V79, P550, DOI 10.1259/bjr/23921951; Strauss KA, 2003, AM J MED GENET C, V121C, P38, DOI 10.1002/ajmg.c.20007; Sturm V, 2008, AM J OPHTHALMOL, V146, P363, DOI 10.1016/j.ajo.2008.04.023; TARDIEU A, 1860, ANN HYG PUBLIQUE MED, V13, P361, DOI DOI 10.3917/EP.039.0174; TOMASI LG, 1975, AM J DIS CHILD, V129, P1335, DOI 10.1001/archpedi.1975.02120480051012; Tyagi AK, 1997, LANCET, V349, P1224, DOI 10.1016/S0140-6736(05)62418-X; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Watts P, 2008, EYE, V22, P1514, DOI 10.1038/eye.2008.224; Wolfson DR, 2005, P I MECH ENG H, V219, P63, DOI 10.1243/095441105X9237; Wygnanski-Jaffe T, 2007, EYE, V21, P83, DOI 10.1038/sj.eye.6702163; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	76	34	36	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1442-6404	1442-9071		CLIN EXP OPHTHALMOL	Clin. Exp. Ophthalmol.	JUL	2010	38	5					514	520		10.1111/j.1442-9071.2010.02291.x			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	622HA	WOS:000279650800015	20584025	Bronze			2022-02-06	
J	Mrakovcic-Sutic, I; Tokmadzic, VS; Laskarin, G; Mahmutefendic, H; Lucin, P; Zupan, Z; Sustic, A				Mrakovcic-Sutic, I.; Tokmadzic, V. Sotosek; Laskarin, G.; Mahmutefendic, H.; Lucin, P.; Zupan, Z.; Sustic, A.			Early Changes in Frequency of Peripheral Blood Lymphocyte Subpopulations in Severe Traumatic Brain-Injured Patients	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Article							NERVOUS-SYSTEM; INFECTIONS; IMMUNOSUPPRESSION; IMMUNODEPRESSION	Infections are leading causes of increased morbidity and mortality of severe traumatic brain-injured (STBI) patients. The mechanism underlying the susceptibility to the infections is still unexplained. The purpose of the study was to investigate changes in frequency of leucocytes subpopulations in peripheral blood of patients with STBI during the course of intensive care treatment. Twenty patients with STBI were included in the study. Healthy age- and sex- volunteers served as control. Peripheral blood samples were taken from these patients at day 1, 4 and 7, and peripheral blood mononuclear cells (PBMC) were isolated. The percentage of T, B lymphocyte, NK and NKT cells as well as monocytes was analysed by simultaneous detection of surface antigens using fluorochrome-conjugated monoclonal antibodies. The two major subsets of T lymphocytes (CD3+CD56-CD4+ and CD3+CD56-CD8+) and NK cells (CD3-CD56+dim and CD3-CD56+bright) were also analysed by flow cytometry. Extracranial infections were presented in 55% patients with STBI. At day 4, the percentage of T lymphocytes with cytotoxic phenotype significantly diminished and their numbers restored at day 7. The frequency of NKT cells showed the identical time-dependent pattern, whereas the percentage of NK cells diminished on day 4 but did not restore after 7 days. The frequency of B lymphocytes did not change significantly during the time investigated, whereas the percentage of monocytes increased immediately after the injury and gradually diminished. The decrease in cells with cytotoxic phenotype might explain high incidence of susceptibility to infection of patients with STBI.	[Tokmadzic, V. Sotosek; Zupan, Z.; Sustic, A.] Univ Rijeka, Fac Med, Dept Anaesthesiol Reanimatol & Intens Care, Rijeka 51000, Croatia; [Mrakovcic-Sutic, I.; Laskarin, G.; Mahmutefendic, H.; Lucin, P.] Univ Rijeka, Fac Med, Dept Physiol & Immunol, Rijeka 51000, Croatia		Tokmadzic, VS (corresponding author), Univ Rijeka, Fac Med, Dept Anaesthesiol Reanimatol & Intens Care, B Branchetta 20-1, Rijeka 51000, Croatia.	vsotosek@medri.hr	Sotosek Tokmadzic, Vlatka/O-2359-2018; Laskarin, Gordana/O-6972-2018; Mahmutefendic Lucin, Hana/Q-8500-2018; Lucin, Pero/R-8341-2018; Mrakovcic-Sutic, Ines/S-6688-2018; Zupan, Zeljko/S-2786-2018; Zupan, Zeljko/AAO-1749-2021	Sotosek Tokmadzic, Vlatka/0000-0003-2645-5364; Laskarin, Gordana/0000-0002-6134-155X; Mahmutefendic Lucin, Hana/0000-0001-8462-4686; Lucin, Pero/0000-0001-8776-8634; Mrakovcic-Sutic, Ines/0000-0003-0679-2849; Zupan, Zeljko/0000-0003-4576-7961; Zupan, Zeljko/0000-0003-4576-7961	Croatian Ministry of Science, Education and SportsMinistry of Science, Education and Sports, Republic of Croatia [062-0000000-0220]	This investigation was supported by the grant from the Croatian Ministry of Science, Education and Sports (project no. 062-0000000-0220).	Angele MK, 2005, LANGENBECK ARCH SURG, V390, P333, DOI 10.1007/s00423-005-0557-4; Angele MK, 2002, CRIT CARE, V6, P298, DOI 10.1186/cc1514; Babcock GF, 2003, CYTOM PART B-CLIN CY, V53B, P48, DOI 10.1002/cyto.b.10038; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Klehmet J, 2009, NEUROSCIENCE, V158, P1184, DOI 10.1016/j.neuroscience.2008.07.044; Lunemann A, 2008, J IMMUNOL, V181, P6170, DOI 10.4049/jimmunol.181.9.6170; McMahon CW, 2002, J IMMUNOL, V169, P1444, DOI 10.4049/jimmunol.169.3.1444; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; MILLER C H, 1991, Neurological Research, V13, P117; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; Sanders RD, 2009, CRIT CARE CLIN, V25, P551, DOI 10.1016/j.ccc.2009.05.001; Schwacha MG, 2002, INT J MOL MED, V10, P239; Smrcka M, 2005, Bratisl Lek Listy, V106, P144; Tang ME, 2009, MT SINAI J MED, V76, P119, DOI 10.1002/msj.20106; WOLACH B, 1993, BRAIN INJURY, V7, P401, DOI 10.3109/02699059309029683; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706	22	34	36	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	JUL	2010	72	1					57	65		10.1111/j.1365-3083.2010.02407.x			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	608FT	WOS:000278569300009	20591077	Bronze			2022-02-06	
J	Figaji, AA; Zwane, E; Fieggen, AG; Argent, AC; Le Roux, PD; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Peter, Jonathan C.			The Effect of Increased Inspired Fraction of Oxygen on Brain Tissue Oxygen Tension in Children with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Brain tissue oxygen tension; Arterial oxygen tension; Children; Traumatic brain injury; Outcome	SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; PERFUSION-PRESSURE; LUNG INJURY; HYPEROXIA; METABOLISM; ISCHEMIA; DELIVERY; AUTOREGULATION	This study examines the effect of an increase in the inspired fraction of oxygen (FiO(2)) on brain tissue oxygen (PbO2) in children with severe traumatic brain injury (TBI). A prospective observational study of patients who underwent PbO2 monitoring and an oxygen challenge test (temporary increase of FiO(2) for 15 min) was undertaken. Pre- and post-test values for arterial partial pressure of oxygen (PaO2), PbO2, and arterial oxygen content (CaO2) were examined while controlling for any changes in arterial carbon dioxide tension and cerebral perfusion pressure during the test. Baseline transcranial Doppler studies were done. Outcome was assessed at 6 months. A total of 43 tests were performed in 28 patients. In 35 tests in 24 patients, the PbO2 monitor was in normal-appearing white matter and in eight tests in four patients, the monitor was in a pericontusional location. When catheters were pericontusional or in normal white matter the baseline PbO2/PaO2 ratio was similar. PaO2 (P < 0.0001) and PbO2 (P < 0.0001) significantly increased when FiO(2) was increased. The magnitude of the PbO2 response (a dagger PbO2) was correlated with a dagger PaO2 (P < 0.0001, R (2) = 0.37) and a dagger CaO2 (P = 0.001, R (2) = 0.23). The a dagger PbO2/a dagger PaO2 ratio (oxygen reactivity) varied between patients, was related to the baseline PbO2 (P = 0.001, r = 0.54) and was inversely related to outcome (P = 0.02, confidence interval 0.03-0.78). Normobaric hyperoxia increases PbO2 in children with severe TBI, but the response is variable. The magnitude of this response is related to the change in PaO2 and the baseline PbO2. A greater response appears to be associated with worse outcome.	[Figaji, Anthony A.] Red Cross War Mem Childrens Hosp, Inst Child Hlth 617, ZA-7700 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit Biostat, ZA-7925 Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA; [Figaji, Anthony A.; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa		Figaji, AA (corresponding author), Red Cross War Mem Childrens Hosp, Inst Child Hlth 617, Klipfontein Rd, ZA-7700 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za; gfieggen@gmail.com; Andrew.Argent@uct.ac.za; lerouxp@uphs.upenn.edu; Jonathan.Peter@uct.ac.za	Fieggen, Anthony Graham/AAT-6510-2021; Argent, Andrew/J-1605-2019	Fieggen, Anthony Graham/0000-0001-6541-8377; Argent, Andrew/0000-0001-9333-2036; Figaji, Anthony/0000-0002-3357-6490			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; CLARK JM, 1971, PHARMACOL REV, V23, P37; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Habler OP, 1998, TRANSFUSION, V38, P135, DOI 10.1046/j.1537-2995.1998.38298193095.x; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Liu SM, 2006, J CEREBR BLOOD F MET, V26, P1274, DOI 10.1038/sj.jcbfm.9600277; Longhi L, 2002, ACT NEUR S, V81, P315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; NAKAJIMA S, 1983, ARCH NEUROL-CHICAGO, V40, P271, DOI 10.1001/archneur.1983.04050050039004; Nishimura N, 2007, AVIAT SPACE ENVIR MD, V78, P1121, DOI 10.3357/ASEM.2177.2007; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Pagano A, 2003, ANN NY ACAD SCI, V1010, P405, DOI 10.1196/annals.1299.074; PUCCIO AM, 2009, J NEUROTRAUM, DOI DOI 10.1089/NEU.2008-0624; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Shah CV, 2008, CRIT CARE MED, V36, P2309, DOI 10.1097/CCM.0b013e318180dc74; Shin HK, 2007, BRAIN, V130, P1631, DOI 10.1093/brain/awm071; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Suttner S, 2004, ANESTH ANALG, V99, P2, DOI 10.1213/01.ANE.0000120163.44315.47; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017	50	34	35	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2010	12	3					430	437		10.1007/s12028-010-9344-3			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	590RJ	WOS:000277244700019	20232264				2022-02-06	
J	Gilmer, LK; Ansari, MA; Roberts, KN; Scheff, SW				Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.			Age-Related Mitochondrial Changes after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						aging; cortical contusion injury; oxidative damage; respiration; synaptic and extrasynaptic mitochondria; traumatic brain injury	OXYGEN SPECIES PRODUCTION; INDUCED AXONAL INJURY; OXIDATIVE-STRESS; RAT-BRAIN; SYNAPTIC MITOCHONDRIA; LIPID-PEROXIDATION; SKELETAL-MUSCLE; OLDER-ADULTS; DYSFUNCTION; DAMAGE	Mitochondrial dysfunction is known to occur following traumatic brain injury (TBI) and has been well characterized. This study assessed possible age-related changes in the cortical mitochondrial bioenergetics following TBI. Three hours following a moderate TBI, tissue from the ipsilateral hemisphere (site of impact and penumbra) and the corresponding contralateral region were harvested from young (3- to 5-month-old) and aged (22- to 24-month-old) Fischer 344 rats. Synaptic and extrasynaptic mitochondria were isolated using a Ficoll gradient, and several bioenergetic parameters were examined using a Clark-type electrode. Injury-related respiration deficits were observed in both young and aged rats. Synaptic mitochondria showed an age-related decline in the rate of ATP production, and a decline in respiratory control ratios (RCR), which were not apparent in the extrasynaptic fraction. Following respiration analysis, mitochondrial samples were probed for oxidative damage (3-nitrotyrosine [3-NT], 4-hydroxynonenal [4-HNE], and protein carbonyls [PC]). All markers of oxidative damage were elevated with injury and age in the synaptic fraction, but only with injury in the extrasynaptic fraction. Synaptic mitochondria displayed the highest levels of oxidative damage and may contribute to the synaptic bioenergetic deficits seen following injury. Data indicate that cortical synaptic mitochondria appear to have an increased susceptibility to perturbation with age, suggesting that the increased mitochondrial dysfunction observed following injury may impede recovery in aged animals.	[Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown Bldg, Lexington, KY 40536 USA.	sscheff@email.uky.edu		Ansari, Mubeen Ahmad/0000-0002-1132-5965	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981]; NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1T32 DA 022738-01]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant AG21981 and training grant NIH-NIDA 1T32 DA 022738-01.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Atamna H, 2007, MITOCHONDRION, V7, P297, DOI 10.1016/j.mito.2007.06.001; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Brown MR, 2004, J BIOENERG BIOMEMBR, V36, P401, DOI 10.1023/B:JOBB.0000041775.10388.23; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bustamante J, 2008, NEUROCHEM RES, V33, P1216, DOI 10.1007/s11064-007-9570-z; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CHIU YJD, 1980, EXP GERONTOL, V15, P511, DOI 10.1016/0531-5565(80)90003-0; Cocco T, 2005, FREE RADICAL BIO MED, V38, P796, DOI 10.1016/j.freeradbiomed.2004.11.034; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; COTMAN CW, 1979, MECH AGEING DEV, V9, P103, DOI 10.1016/0047-6374(79)90124-6; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1997, J NEUROCHEM, V69, P2564; Davey GP, 1996, J NEUROCHEM, V66, P1617; Dellinger AM, 2006, J SAFETY RES, V37, P519, DOI 10.1016/j.jsr.2006.10.001; Dencher NA, 2007, ANN NY ACAD SCI, V1100, P291, DOI 10.1196/annals.1395.030; DESHMUKH DR, 1980, J NEUROCHEM, V34, P1219, DOI 10.1111/j.1471-4159.1980.tb09962.x; Driver AS, 2000, NEUROTOXICOL TERATOL, V22, P175, DOI 10.1016/S0892-0362(99)00069-0; Erecinska M, 1996, BBA-BIOENERGETICS, V1277, P13, DOI 10.1016/S0005-2728(96)00103-X; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Feng J, 2008, J GERONTOL A-BIOL, V63, P1137, DOI 10.1093/gerona/63.11.1137; Finsterer J, 2008, J NEUROL SCI, V272, P20, DOI 10.1016/j.jns.2008.05.011; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Fukui H, 2008, TRENDS NEUROSCI, V31, P251, DOI 10.1016/j.tins.2008.02.008; Gilmer LK, 2010, MECH AGEING DEV, V131, P133, DOI 10.1016/j.mad.2009.12.011; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gong Y, 2005, ACT NEUR S, V95, P425; Gouspillou G, 2010, BBA-BIOENERGETICS, V1797, P143, DOI 10.1016/j.bbabio.2009.09.004; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacoby SF, 2006, J NURS SCHOLARSHIP, V38, P133, DOI 10.1111/j.1547-5069.2006.00090.x; Joseph JA, 1996, FREE RADICAL BIO MED, V20, P821, DOI 10.1016/0891-5849(95)02225-2; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; LaFrance R, 2005, AGING CELL, V4, P139, DOI 10.1111/j.1474-9726.2005.00156.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LESLIE SW, 1985, BRAIN RES, V329, P177, DOI 10.1016/0006-8993(85)90523-2; Lesnefsky EJ, 2006, AGEING RES REV, V5, P402, DOI 10.1016/j.arr.2006.04.001; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Long JG, 2006, LIFE SCI, V79, P1466, DOI 10.1016/j.lfs.2006.04.024; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Meng QY, 2007, MECH AGEING DEV, V128, P286, DOI 10.1016/j.mad.2006.12.008; Merry BJ, 2004, AGING CELL, V3, P7, DOI 10.1046/j.1474-9728.2003.00074.x; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Navarro A, 2005, AM J PHYSIOL-REG I, V289, pR1392, DOI 10.1152/ajpregu.00834.2004; Navarro A, 2008, AM J PHYSIOL-REG I, V294, pR501, DOI 10.1152/ajpregu.00492.2007; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nicholls DG, 2004, AGING CELL, V3, P35, DOI 10.1111/j.1474-9728.2003.00079.x; Petrosillo G, 2008, NEUROCHEM INT, V53, P126, DOI 10.1016/j.neuint.2008.07.001; Petrosillo G, 2008, REJUV RES, V11, P935, DOI 10.1089/rej.2008.0772; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 1999, ACT NEUR S, V73, P15; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI 10.1089/ARS.2008.2331; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Swerdlow RH, 2007, ANTIOXID REDOX SIGN, V9, P1591, DOI 10.1089/ars.2007.1676; Thompson Hilaire J, 2006, Crit Care Nurs Clin North Am, V18, P419, DOI 10.1016/j.ccell.2006.05.008; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toescu EC, 2003, CELL CALCIUM, V34, P311, DOI 10.1016/S0143-4160(03)00142-8; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; Trifunovic A, 2008, J INTERN MED, V263, P167, DOI 10.1111/j.1365-2796.2007.01905.x; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Victorino GP, 2003, ARCH SURG-CHICAGO, V138, P1093, DOI 10.1001/archsurg.138.10.1093; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Walker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019; Zhu W, 2003, J GERONTOL A-BIOL, V58, P117	97	34	35	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					939	950		10.1089/neu.2009.1181			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400015	20175672	Green Published			2022-02-06	
J	Zollman, FS; Cyborski, C; Duraski, SA				Zollman, Felise S.; Cyborski, Cherina; Duraski, Sylvia A.			Actigraphy for assessment of sleep in traumatic brain injury: Case series, review of the literature and proposed criteria for use	BRAIN INJURY			English	Article						Actigraphy; insomnia; sleep; traumatic brain injury; TBI	INSOMNIA; DISORDERS	Primary objective: To demonstrate that actigraphy is an appropriate means of measuring sleep in patients with TBI and to define parameters for its use in this population. Research design: Case series and review of the literature. Methods and procedures: Subjects participating in one of two externally funded studies addressing the role of acupuncture in treating insomnia in TBI underwent actigraphy for the purpose of quantifying sleep time. Cases selected for presentation illustrate challenges in use of this modality in this population. Main outcomes and results: Caution should be exercised in interpreting actigraphy data in patients with TBI and (1) motor impairment or (2) cognitive and behavioural impairments which include agitation and impulsivity. Conclusions: Guidelines for use of actigraphy in patients with TBI are proposed: (1) Patients should be at Rancho Los Amigos cognitive level of III or above; (2) Patients with paresis, significant spasticity or contractures of one or more limbs should have the device placed on the least affected limb; and (3) For patients with tetraparesis, the device may not be an appropriate instrument for measurement of sleep; if it is to be used, consideration should be given to placing it on the head, rather than limbs or torso.	[Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Dept Phys Med & Rehabil, Chicago, IL 60611 USA		Zollman, FS (corresponding author), Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Dept Phys Med & Rehabil, 345 E Super St, Chicago, IL 60611 USA.	fzollman@ric.org	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604	NIDRR [H133A080045]; CDMRPUnited States Department of Defense [W81XWH-08-1-0752]	The authors wish to thank Laura Wasek, MPH for her assistance in preparation of this manuscript. Supported by grants from NIDRR (#H133A080045) and CDMRP (US Army Medical Research and Material Command #W81XWH-08-1-0752).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Krahn L E, 1997, Ann Clin Psychiatry, V9, P203; Laakso ML, 2004, SLEEP MED, V5, P541, DOI 10.1016/j.sleep.2004.05.002; Lockley SW, 1999, J SLEEP RES, V8, P175, DOI 10.1046/j.1365-2869.1999.00155.x; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Muller U, 2006, BRAIN INJURY, V20, P157, DOI 10.1080/02699050500443467; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; SADEH A, 1995, SLEEP, V18, P288, DOI 10.1093/sleep/18.4.288; Spivak E, 2007, SPINAL CORD, V45, P765, DOI 10.1038/sj.sc.3102040; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; THAXTON L, 2007, BRAIN INJURY MED PRI, P557	21	34	36	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2010	24	5					748	754		10.3109/02699051003692167			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	592PJ	WOS:000277391300007	20334470				2022-02-06	
J	Goffus, AM; Anderson, GD; Hoane, MR				Goffus, Andrea M.; Anderson, Gail D.; Hoane, Michael R.			Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article						neurorehabilitation; therapy; brain injury; behavior; restorative neurology	FOCAL CEREBRAL-ISCHEMIA; NAD(+); PERFORMANCE; INHIBITOR; NEUROPROTECTION; MITOCHONDRIAL; VITAMIN-B-3; INFARCTION; APOPTOSIS; TRANSPORT	Previously, we have demonstrated that nicotinamide (NAM), a neuroprotective soluble B-group vitamin, improves recovery of function following traumatic brain injury (TBI). However, no prior studies have examined whether NAM is beneficial following continuous infusions over 7 days post-TBI. The purpose of this study was to investigate the preclinical efficacy of NAM treatment as it might be delivered clinically; over several days by slow infusion. Rats were prepared with either unilateral controlled cortical impact (CCI) injuries or sham procedures and divided into three groups: CCI-NAM, CCI-vehicle and sham. Thirty minutes following CCI, Alzet osmotic mini-pumps were implanted subcutaneously. NAM was delivered at a rate of 50 mg/kg/day for 7 days immediately post-CCI. On day 7 following injury, the pumps were removed and blood draws were collected for serum NAM and nicotinamide adenine dinucleotide (NAD(+)) analyses. Starting on day 2 post-CCI, animals were tested on a battery of sensorimotor tests (bilateral tactile adhesive removal, locomotor placing and limb-use asymmetry). Continuous infusion of NAM resulted in a significant serum elevation in NAM, but not NAD+. Statistical analyses of the tactile removal and locomotor placing data revealed that continuous administration of NAM significantly reduced the initial magnitude of the injury deficit and improved overall recovery compared to the vehicle-treated animals. NAM treatment also significantly decreased limb-use asymmetries compared to vehicle-treated animals. The overall extent of the cortical damage was also reduced by NAM treatment. No detrimental effects were seen following continuous infusion. The present results suggest that NAM delivered via a clinically relevant therapeutic regimen may truncate behavioral damage following TBI. Thus our results offer strong support for translation into the clinical population.	[Goffus, Andrea M.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Restorat Neurosci Lab, Carbondale, IL 62901 USA; [Anderson, Gail D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA		Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Restorat Neurosci Lab, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	We would like to thank Nicholas Kaufman for his help on this project. This research was funded by NIH grant NS045647 to M.R.H.	Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; KALHORN TF, 1985, ANAL BIOCHEM, V151, P343, DOI 10.1016/0003-2697(85)90185-X; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; LANGLOIS JA, 2006, J HEAD TRAUMA REHAB, V21, P10; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sauve AA, 2008, J PHARMACOL EXP THER, V324, P883, DOI 10.1124/jpet.107.120758; Schallert T, 2005, BEHAV LAB RAT, P129; SPECTOR R, 1979, J NEUROCHEM, V33, P895, DOI 10.1111/j.1471-4159.1979.tb09919.x; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ungerstedt JS, 2003, CLIN EXP IMMUNOL, V131, P48, DOI 10.1046/j.1365-2249.2003.02031.x; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5	36	34	35	0	6	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.	MAR-APR	2010	3	2					145	152		10.4161/oxim.3.2.11315			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	644OW	WOS:000281389700008	20716938	Green Published, gold			2022-02-06	
J	Aaen, GS; Holshouser, BA; Sheridan, C; Colbert, C; McKenney, M; Kido, D; Ashwal, S				Aaen, Gregory S.; Holshouser, Barbara A.; Sheridan, Clare; Colbert, Cherie; McKenney, Melinda; Kido, Daniel; Ashwal, Stephen			Magnetic Resonance Spectroscopy Predicts Outcomes for Children With Nonaccidental Trauma	PEDIATRICS			English	Article						children; infants; nonaccidental trauma; MRI; magnetic resonance spectroscopy; traumatic brain injury	INFLICTED HEAD-INJURY; PROTON MR SPECTROSCOPY; BRAIN-INJURY; YOUNG-CHILDREN; HYPOXIC ENCEPHALOPATHY; N-ACETYLASPARTATE; PROGNOSTIC VALUE; AXONAL INJURY; NEURONAL LOSS; INFANTS	OBJECTIVE: We evaluated proton magnetic resonance spectroscopic imaging (MRSI) findings for children with traumatic brain injury attributable to nonaccidental trauma (NAT) early after injury, to determine whether brain metabolite changes predicted outcomes. METHODS: Proton MRSI (1.5 T) was performed (mean: 5 days after injury [range: 1-30 days]) through the level of the corpus callosum for 90 children with confirmed NAT. Regional N-acetylaspartate/total creatine, N-acetylaspartate/total choline, and choline/creatine ratios and the presence of lactate were measured. Data on long-term outcomes defined at >= 6 months were collected for 44 of 90 infants. We grouped patients into good (normal, mild disability, or moderate disability; n = 32) and poor (severe disability, vegetative state, or dead; n = 12) outcome groups. RESULTS: We found that N-acetylaspartate/creatine and N-acetylaspartate/choline ratios (mean total, corpus callosum, and frontal white matter) were significantly decreased in patients with poor outcomes (P < .001). A logistic regression model using age, initial Glasgow Coma Scale score, presence of retinal hemorrhage, lactate on MRSI scans, and mean total N-acetylaspartate/creatine ratio predicted outcomes accurately in 100% of cases. CONCLUSIONS: Reduced N-acetylaspartate levels (ie, neuronal loss/dysfunction) and elevated lactate levels (altered energy metabolism) correlated with poor neurologic outcomes for infants with NAT. Elevated lactate levels may reflect primary or secondary hypoxic-ischemic injury, which may occur with NAT. Our data suggest that MRSI performed early after injury can be used for long-term prognosis. Pediatrics 2010; 125: 295-303	[Ashwal, Stephen] Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92354 USA; [Sheridan, Clare] Loma Linda Univ, Sch Med, Dept Pediat, Div Forens Med, Loma Linda, CA 92354 USA; [Holshouser, Barbara A.; Colbert, Cherie; McKenney, Melinda; Kido, Daniel] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92354 USA		Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, 11175 Campus St,Room A1120, Loma Linda, CA 92354 USA.	sashwal@llu.edu					Adelson PD, 1999, TRAUMATIC BRAIN INJU, P283; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Broman S. H., 1995, TRAUMATIC HEAD INJUR; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Dolinak D, 2006, ARCH PATHOL LAB MED, V130, P712; Dubowitz DJ, 1998, AM J NEURORADIOL, V19, P1617; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gill JR, 2009, ARCH PATHOL LAB MED, V133, P619, DOI 10.1043/1543-2165-133.4.619; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; HOLMES G, 1982, ELECTROEN CLIN NEURO, V53, P60, DOI 10.1016/0013-4694(82)90106-7; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Signoretti S, 2002, ACT NEUR S, V81, P373; *US ADM CHILDR YOU, 2008, CHILD MALTR 2006; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427	41	34	35	1	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2010	125	2					295	303		10.1542/peds.2008-3312			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	573VH	WOS:000275942900014	20123781				2022-02-06	
J	Chesik, D; De Keyser, J				Chesik, Daniel; De Keyser, Jacques			Progesterone and dexamethasone differentially regulate the IGF-system in glial cells	NEUROSCIENCE LETTERS			English	Article						Insulin-like growth factor; Progesterone; Dexamethasone; Astrocytes; Oligodendrocytes; Multiple sclerosis	TRAUMATIC BRAIN-INJURY; FACTOR BINDING PROTEIN-2; MULTIPLE-SCLEROSIS; SPINAL-CORD; RAT-BRAIN; ESTROGEN; CULTURES; CNS; NEUROPROTECTION; PROLIFERATION	IGF-1 is an important factor for myelin synthesis and hence possesses therapeutic potential in treating demyelinating disease such as multiple sclerosis. However, IGF-1 poorly crosses the blood-brain barrier. In this study, we investigated the effects of the sex steroid progesterone and the glucocorticoid dexamethasone on regulation of the IGF-system in glial cells. By means of quantitative PCR analysis, we demonstrate that progesterone upregulates IGF-1, the type 1 IGF receptor and IGFBP-2 in primary rat astrocytes and both IGF-1 and IGFBP-6 in OLN-93 oligodendroglial progenitor cells. In contrast, dexamethasone showed a negative effect on expression of IGF-1, the type I IGF receptor and the respective IGF binding proteins in both cell types. In oligodendrocytes, the differentiation marker CNPase was positively regulated by progesterone and negatively regulated by dexamethasone. Further, oligodendroglial cell migration was enhanced approximately 4-fold by progesterone. This study implicates progesterone as a positive regulator of IGF-system in glial cells and demonstrates a further biological function of progesterone in oligodendrocyte biology, namely stimulation of progenitor cell migration. Dexamethasone, on the other hand. is a negative regulator of the IGF-system in glial cells. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Chesik, Daniel; De Keyser, Jacques] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands; [De Keyser, Jacques] Univ Hosp Brussels, Dept Neurol, B-1090 Brussels, Belgium		Chesik, D (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	d.chesik@med.umcg.nl	De Keyser, Jacques/D-3725-2013; De Keyser, Jacques/AAA-8721-2021	De Keyser, Jacques/0000-0002-3394-7757; De Keyser, Jacques/0000-0002-3394-7757	Dutch foundation	Daniel Chesik is a grant recipient from the Dutch foundation "Stichting Multiple Sclerose Anders" to which authors are indebted for financial support of this investigation. Authors would also like to thank Reinier Bron for assistance with the migration assays.	Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Chesik D, 2004, J NEUROSCI RES, V77, P354, DOI 10.1002/jnr.20172; Chesik D, 2008, J MOL NEUROSCI, V35, P81, DOI 10.1007/s12031-008-9041-2; Chesik D, 2007, CYTOKINE GROWTH F R, V18, P267, DOI 10.1016/j.cytogfr.2007.04.001; Chesik D, 2006, EUR J NEUROSCI, V24, P1645, DOI 10.1111/j.1460-9568.2006.05034.x; COMPSTON S, 1997, J ANAT 2, V190, P161; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Liu X, 1995, Mult Scler, V1, P2; Marin-Husstege M, 2004, DEV NEUROSCI-BASEL, V26, P245, DOI 10.1159/000082141; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; Micevych P, 2008, BRAIN RES REV, V57, P470, DOI 10.1016/j.brainresrev.2007.06.009; Miller L, 1998, J IMMUNOL, V160, P5098; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Moorthy K, 2005, EXP GERONTOL, V40, P295, DOI 10.1016/j.exger.2005.01.004; MOZELL RL, 1991, J NEUROSCI RES, V30, P382, DOI 10.1002/jnr.490300214; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Quesada A, 2004, J NEUROSCI RES, V75, P107, DOI 10.1002/jnr.10833; Quesada A, 2008, DEV NEUROBIOL, V68, P632, DOI 10.1002/dneu.20609; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Sinchak K, 2003, DEV NEUROSCI-BASEL, V25, P343, DOI 10.1159/000073511; Wilczak N, 2008, NEUROCHEM INT, V52, P1431, DOI 10.1016/j.neuint.2008.03.004; YAO DL, 1995, P NATL ACAD SCI USA, V92, P6190, DOI 10.1073/pnas.92.13.6190	36	34	34	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JAN 14	2010	468	3					178	182		10.1016/j.neulet.2009.10.051			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	547HZ	WOS:000273879100002	19853640				2022-02-06	
J	Fridman, EA; Krimchansky, BZ; Bonetto, M; Galperin, T; Gamzu, ER; Leiguarda, RC; Zafonte, R				Fridman, Esteban A.; Krimchansky, Ben Zion; Bonetto, Mariana; Galperin, Tatyana; Gamzu, Elkan R.; Leiguarda, Ramon C.; Zafonte, Ross			Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury	BRAIN INJURY			English	Article						Brain injury; vegetative state; minimally conscious state; dopaminergic; apomorphine	PERSISTENT VEGETATIVE STATE; DIFFUSE AXONAL INJURY; PARKINSONS-DISEASE; LEVODOPA; BROMOCRIPTINE; AMANTADINE; COMA	Methods: In a prospective open-labelled clinical study, the feasibility, relative efficacy and safety of continuous subcutaneous (s.c.) administration of apomorphine in Vegetative State (VS) or Minimally Conscious State (MCS) patients due to severe traumatic brain injury (TBI) was tested. Apomorphine was administered to eight patients. Outcome measures were the Coma Near-Coma Scale (CNCS) and Disability Rating Scale (DRS). Results: Drug management was implemented without any problems. There was improvement in the primary outcomes for all patients. Awakening was seen as rapidly as within the first 24 hours of drug administration and as late as 4 weeks. Seven of the patients had completely recovered consciousness. All improvements were sustained for at least 1 year, even after apomorphine was discontinued. Drug-related adverse events were all anticipated and resolved after the dose was reduced. Conclusion: Based on this open-label pilot study, continuous s.c. apomorphine infusion appears to be feasible, safe and potentially effective in improving consciousness in patients in VS and MCS due to severe TBI.	[Fridman, Esteban A.] FLENI, Neurol Res Inst, Neurorehabil Sect, Dept Neurol, RA-2325 Buenos Aires, DF, Argentina; [Fridman, Esteban A.] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; [Fridman, Esteban A.] FLENI, Neurol Res Inst, Dept Neurosci, RA-2325 Buenos Aires, DF, Argentina; [Krimchansky, Ben Zion; Galperin, Tatyana] Loewenstein Hosp & Rehabil Ctr, Intens Care Unit, Raanana, Israel; [Zafonte, Ross] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA		Fridman, EA (corresponding author), FLENI, Neurol Res Inst, Neurorehabil Sect, Dept Neurol, C1428AQK, RA-2325 Buenos Aires, DF, Argentina.	efridman@fleni.org.ar		Fridman, Esteban A./0000-0001-7879-8874			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; BROGDEN RN, 1982, DRUGS, V24, P360, DOI 10.2165/00003495-198224050-00002; Deleu D, 2004, DRUG AGING, V21, P687, DOI 10.2165/00002512-200421110-00001; Deleu D, 2002, CLIN PHARMACOKINET, V41, P261, DOI 10.2165/00003088-200241040-00003; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Hurst RS, 2003, EUR J PHARMACOL, V482, P31, DOI 10.1016/j.ejphar.2003.09.054; Kaplan M, 2003, CLIN NEUROL NEUROSUR, V105, P153, DOI 10.1016/S0303-8467(02)00133-6; Katzenschlager R, 2005, MOVEMENT DISORD, V20, P151, DOI 10.1002/mds.20276; Kolls BJ, 2006, CLIN NEUROPHARMACOL, V29, P292, DOI 10.1097/01.WNF.0000220824.57769.E5; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MAWDSLEY C, 1972, CLIN PHARMACOL THER, V13, P575; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MONTASTRUC JL, 1989, J NEUROL NEUROSUR PS, V52, P773, DOI 10.1136/jnnp.52.6.773; NUTT JG, 1984, NEW ENGL J MED, V310, P483, DOI 10.1056/NEJM198402233100802; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; *THOMS PDR, 2006, AP PACK INS PHYS DES, P2132; Tyne HL, 2004, J NEUROL, V251, P1370, DOI 10.1007/s00415-004-0547-4; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	31	34	34	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	4					636	641		10.3109/02699051003610433			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	570ML	WOS:000275682300008	20235766				2022-02-06	
J	Houlden, DA; Taylor, AB; Feinstein, A; Midha, R; Bethune, AJ; Stewart, CP; Schwartz, ML				Houlden, David A.; Taylor, Amanda B.; Feinstein, Anthony; Midha, Rajiv; Bethune, Allison J.; Stewart, Craig P.; Schwartz, Michael L.			Early somatosensory evoked potential grades in comatose traumatic brain injury patients predict cognitive and functional outcome	CRITICAL CARE MEDICINE			English	Article						somatosensory evoked potentials; traumatic brain injury; coma; grading system; outcome prediction; cognitive function	EVENT-RELATED POTENTIALS; SEVERE HEAD-INJURY; PROGNOSTIC VALUE; SCALE; RESPONSES; QUESTIONNAIRE; RECOVERY	Objectives: To relate early somatosensory evoked potential grades from comatose traumatic brain injury patients to neuropsychological and functional outcome 1 yr later; to determine the day (within the first week after traumatic brain injury) that somatosensory evoked potential grade best correlates with outcome; to determine whether somatosensory evoked potential grade improvement in the first week after traumatic brain injury is associated with improved outcome. Design: Prospective cohort study. Setting: Critical care unit at a university hospital. Patients: Median nerve somatosensory evoked potentials were obtained from 81 comatose patients with traumatic brain injury. Somatosensory evoked potential grades were calculated from results obtained on days 1, 3, and 7 after traumatic brain injury. Glasgow Outcome Scale, Barthel Index, Rivermead Head Injury Follow-up Questionnaire, General Health Questionnaire, Stroop Color-Word Test, Paced Auditory Serial Addition Task, and Symbol-Digit Modalities Test scores were obtained 1 yr after injury. Interventions. None. Measurements and Main Results: Somatosensory evoked potential grade on days 1, 3, and 7 related significantly with Glasgow Outcome Scale and Barthel scores (day 3 better than day 1) but did not relate with Rivermead Head Injury Follow-up Questionnaire or General Health Questionnaire scores. Day 3 and day 7 somatosensory evoked potential grades related significantly with Stroop scores. Day 3 somatosensory evoked potential grades related significantly with Symbol-Digit Modalities Test scores. Patients with bilaterally present but abnormal somatosensory evoked potentials, whose somatosensory evoked potential grade improved between days 1 and 3, had marginally better functional outcome than those without somatosensory evoked potential grade improvement. Conclusions: Day 3 somatosensory evoked potential grade related to information-processing speed, working memory, and the ability to attend to tasks 1 yr after traumatic brain injury. Day 3 somatosensory evoked potential grade had the strongest relationship with functional outcome. Somatosensory evoked potential grades were not related to emotional well-being. (Crit Care Med 2010; 38:167-174)	[Houlden, David A.; Taylor, Amanda B.; Bethune, Allison J.; Stewart, Craig P.] Sunnybrook Hlth Sci Ctr, Dept Surg Neuromonitoring, Toronto, ON M4N 3M5, Canada; [Feinstein, Anthony] Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; [Schwartz, Michael L.] Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON M4N 3M5, Canada; [Midha, Rajiv] Univ Calgary, Div Neurosurg, Calgary, AB, Canada		Houlden, DA (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Surg Neuromonitoring, Toronto, ON M4N 3M5, Canada.	david.houlden@sunnybrook.ca			Ontario Neurotrauma [00173]	This study was supported, in part, by Grant ONAO-#00173 received from the Ontario Neurotrauma Fund (DAH, AF, RM, MLS).	Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; DUNN OJ, 1969, J AM STAT ASSOC, V64, P366, DOI 10.2307/2283746; FACCO E, 1990, ELECTROEN CLIN NEURO, P330; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDIE WD, 1981, NEUROLOGY, V31, P248, DOI 10.1212/WNL.31.3.248; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HOULDEN DA, 1992, J TRAUMA, V33, P244, DOI 10.1097/00005373-199208000-00014; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1975, LANCET, V1, P480; Kotchoubey B, 2007, CLIN NEUROPHYSIOL, V118, P477, DOI 10.1016/j.clinph.2006.11.018; Lew HL, 2006, J HEAD TRAUMA REHAB, V21, P350, DOI 10.1097/00001199-200607000-00006; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; LOEWEN SC, 1988, PHYS THER, V68, P1077, DOI 10.1093/ptj/68.7.1077; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; MAHONEY F I, 1965, Md State Med J, V14, P61; Moulton RJ, 1998, CAN J NEUROL SCI, V25, pS7, DOI 10.1017/S031716710003465X; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Newton PG, 1982, J NEUROSURG, V57, P168; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Smith A., 1968, LEARN DISORD, V3, P83, DOI 10.1080/13803390591004428; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989; Wang JT, 2004, CAN J NEUROL SCI, V31, P438, DOI 10.1017/S0317167100003619	31	34	38	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2010	38	1					167	174		10.1097/CCM.0b013e3181c031b3			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AE	WOS:000273224800025	19829103				2022-02-06	
J	Hutchison, JS; Frndova, H; Lo, TYM; Guerguerian, AM				Hutchison, James S.; Frndova, Helena; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie		Hypothermia Pediat Head Injury Tri; Canadian Critical Care Trials Grp	Impact of Hypotension and Low Cerebral Perfusion Pressure on Outcomes in Children Treated with Hypothermia Therapy following Severe Traumatic Brain Injury: A post hoc Analysis of the Hypothermia Pediatric Head Injury Trial	DEVELOPMENTAL NEUROSCIENCE			English	Article						Cerebral perfusion pressure; Children; Hypotension; Hypothermia therapy; Traumatic brain injury	INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; INTENSIVE-CARE; HYPOXIA; PHASE; RATS	Hypotension and low cerebral perfusion pressure are known to be associated with unfavorable outcome in children and adults with traumatic brain injury. Using the database from a previously published, randomized controlled trial of 24 h of hypothermia therapy in children with severe traumatic brain injury, we compared the number of patients with hypotension or low cerebral perfusion pressure between the hypothermia therapy and normothermia groups. We also determined the association between these physiologic insults and unfavorable outcome using regression analysis. There were more patients with episodes of hypotension or low cerebral perfusion pressure in the hypothermia therapy group than in the normothermia group. These physiologic insults were associated with unfavorable outcome in both intervention groups. Hypotension and low cerebral perfusion pressure should be anticipated and prevented in future trials of hypothermia therapy in patients with traumatic brain injury. Copyright (C) 2011 S. Karger AG, Basel	[Hutchison, James S.; Frndova, Helena; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie] Hosp Sick Children, Dept Crit Care, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Frndova, Helena; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie] Hosp Sick Children, Neurosci & Mental Hlth Res Program, Res Inst, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Guerguerian, Anne-Marie] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada		Hutchison, JS (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jamie.hutchison@sickkids.ca	Kirkham, Fenella/C-2442-2009; kasyan, george/ABB-4616-2021	Kirkham, Fenella/0000-0002-2443-7958; kasyan, george/0000-0001-7919-2217; Meyer, Philippe G/0000-0002-3829-6631	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MCT50398]; Ontario Neurotrauma Foundation [ONBO-00009, ONRO-41]; Rick Hansen Institute; Hospital for Sick Children Foundation [XG 99-057]; Physicians Services Incorporated [98-62]; Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec [004095-104]; Children's Hospital of Eastern Ontario Research Institute [98/16S(E)]; Direction de la Recherche Clinique Assistance Publique - Hopitaux de Paris [P010208]	The Hypothermia Pediatric Head Injury Trial was funded by the Canadian Institutes of Health Research (Canadian Neurotrauma Research Program; MCT50398), the Ontario Neurotrauma Foundation (ONBO-00009 and ONRO-41), the Rick Hansen Institute, the Hospital for Sick Children Foundation (XG 99-057), the Physicians Services Incorporated (98-62), the Fonds de la Recherche en Sante du Quebec (004095-104), the Children's Hospital of Eastern Ontario Research Institute [98/16S(E)] and the Direction de la Recherche Clinique Assistance Publique - Hopitaux de Paris (P010208).	ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; [Anonymous], 2006, PEDIATRICS, V117, pe955; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2009, J NEUROTRAUM, V26, P393, DOI 10.1089/neu.2008.0556; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Haque IU, 2007, PEDIATR CRIT CARE ME, V8, P138, DOI 10.1097/01.PCC.0000257039.32593.DC; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Jones PA, 2005, ACT NEUR S, V95, P29; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8	24	34	35	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					406	412		10.1159/000323260			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900008	21252486	Bronze			2022-02-06	
J	Naim, MY; Friess, S; Smith, C; Ralston, J; Ryall, K; Helfaer, MA; Margulies, SS				Naim, Maryam Y.; Friess, Stuart; Smith, Colin; Ralston, Jill; Ryall, Karen; Helfaer, Mark A.; Margulies, Susan S.			Folic Acid Enhances Early Functional Recovery in a Piglet Model of Pediatric Head Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Neuroprotection; Folic acid; Traumatic brain injury; Neurobehavioral assessment; Pediatric brain injury; Axonal injury; Swine	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; SPATIAL MEMORY; AXONAL INJURY; SWINE MODEL; FOLATE; RESUSCITATION; EXPRESSION; NEWBORN; STRESS	For stroke and spinal cord injury, folic acid supplementation has been shown to enhance neurodevelopment and to provide neuroprotection. We hypothesized that folic acid would reduce brain injury and improve neurological outcome in a neonatal piglet model of traumatic brain injury (TBI), using 4 experimental groups of 3- to 5-day-old female piglets. Two groups were intubated, anesthetized and had moderate brain injury induced by rapid axial head rotation without impact. One group of injured (Inj) animals received folic acid (Fol; 80 mu g/kg) by intraperitoneal (IP) injection 15 min following injury, and then daily for 6 days (Inj + Fol; n = 7). The second group of injured animals received an IP injection of saline (Sal) at the same time points (Inj + Sal; n = 8). Two uninjured (Uninj) control groups (Uninj + Fol, n = 8; Uninj + Sal, n = 7) were intubated, anesthetized and received folic acid (80 mu g/kg) or saline by IP injection at the same time points as the injured animals following a sham procedure. Animals underwent neurobehavioral and cognitive testing on days 1 and 4 following injury to assess behavior, memory, learning and problem solving. Serum folic acid and homocysteine levels were collected prior to injury and again before euthanasia. The piglets were euthanized 6 days following injury, and their brains were perfusion fixed for histological analysis. Folic acid levels were significantly higher in both Fol groups on day 6. Homocysteine levels were not affected by treatment. On day 1 following injury, the Inj + Fol group showed significantly more exploratory interest, and better motor function, learning and problem solving compared to the Inj + Sal group. Inj + Fol animals had a significantly lower cognitive composite dysfunction score compared to all other groups on day 1. These functional improvements were not seen on day 4 following injury. Axonal injury measured by beta-amyloid precursor protein staining 6 days after injury was not affected by treatment. These results suggest that folic acid may enhance early functional recovery in this piglet model of pediatric head injury. This is the first study to describe the application of complex functional testing to assess an intervention outcome in a swine model of TBI. Copyright (C) 2011 S. Karger AG, Basel	[Ralston, Jill; Ryall, Karen; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Naim, Maryam Y.; Friess, Stuart; Helfaer, Mark A.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Smith, Colin] Western Gen Hosp, Dept Neuropathol, Edinburgh EH4 2XU, Midlothian, Scotland		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu		Smith, Colin/0000-0002-4507-5132	Thrasheresearch Foundation; Children's Hospital of Philadelphia; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	We are grateful to Ashley Young for her technical help in behavioral testing. This study was supported by the Thrasheresearch Foundation New Investigator award (M.Y.N.), the Endowed Chair in Critical Care Medicine from the Children's Hospital of Philadelphia (M.A.H.) and National Institutes of Health grant R01 NS39679 (S.S.M.).	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Broom DM, 2009, ANIM BEHAV, V78, P1037, DOI 10.1016/j.anbehav.2009.07.027; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Endres M, 2005, STROKE, V36, P321, DOI 10.1161/01.STR.0000153008.60517.ab; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Ho PI, 2003, NEUROBIOL DIS, V14, P32, DOI 10.1016/S0969-9961(03)00070-6; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Iskandar BJ, 2004, ANN NEUROL, V56, P221, DOI 10.1002/ana.20174; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lin YP, 2004, NEUROREPORT, V15, P2241, DOI 10.1097/00001756-200410050-00020; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Luna SPL, 2007, AM J VET RES, V68, P258, DOI 10.2460/ajvr.68.3.258; Martin H, 2007, PEDIATRICS, V119, P1152, DOI 10.1542/peds.2006-2706; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Povlishock JT, 1996, ACT NEUR S, V66, P81; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reynolds EH, 2002, J NEUROL NEUROSUR PS, V72, P567, DOI 10.1136/jnnp.72.5.567; Reynolds EH, 2002, BMJ-BRIT MED J, V324, P1512, DOI 10.1136/bmj.324.7352.1512; Rochat P, 2002, CHILD DEV, V73, P35, DOI 10.1111/1467-8624.00390; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SMITHELLS RW, 1976, ARCH DIS CHILD, V51, P944, DOI 10.1136/adc.51.12.944; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; TEASDALE G, 1974, LANCET, V2, P81; Van Guelpen B, 2005, STROKE, V36, P1426, DOI 10.1161/01.STR.0000169934.96354.3a; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wu DF, 1999, PHARMACEUT RES, V16, P415, DOI 10.1023/A:1018829920158; YEE WM, 1993, EXP BRAIN RES, V94, P193; Zhang J, 2008, EXP NEUROL, V210, P645, DOI 10.1016/j.expneurol.2007.12.019	40	34	35	0	11	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					466	479		10.1159/000322448			14	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900015	21212637	Green Published, Bronze			2022-02-06	
J	Anderson, GD; Temkin, NR; Dikmen, SS; Diaz-Arrastia, R; Machamer, JE; Farhrenbruch, C; Miller, JW; Sadrzadeh, SMH				Anderson, Gail D.; Temkin, Nancy R.; Dikmen, Sureyya S.; Diaz-Arrastia, Ramon; Machamer, Joan E.; Farhrenbruch, Carol; Miller, John W.; Sadrzadeh, S. M. Hossein			Haptoglobin phenotype and apolipoprotein E polymorphism: Relationship to posttraumatic seizures and neuropsychological functioning after traumatic brain injury	EPILEPSY & BEHAVIOR			English	Article						Traumatic brain injury; Posttraumatic seizures; Haptoglobin; Apolipoprotein E	E GENOTYPE; ASSOCIATION; HYPOHAPTOGLOBINEMIA; PREVENTION; HEMOGLOBIN; VALPROATE; RECOVERY; EPILEPSY; CAT	The relationship of genetic predisposition to reduced iron capacity and apolipoprotein E (APOE) to posttraumatic seizures (PTSs) and neuropsychological outcomes was investigated in patients with traumatic brain injuries from a prior valproate clinical study. Haptoglobin concentration/phenotype and APOE genotype were determined in 25 patients with PTSs and 26 control (no PTSs) Subjects similar to 10 years after traumatic brain injury. Haptoglobin phenotype was also determined in previously collected frozen samples for 25 additional patients with PTSs and 32 no-PTS subjects. There was no relationship between haptoglobin phenotype or APOE genotype and occurrence of PTSs. APOE genotype was not related to neuropsychological outcome; however, when adjustments were made for differences in educational levels, APOE FA subjects did worse, especially on tests of verbal intellectual and verbal memory skills. In contrast to our hypothesis, those with haptoglobin 1-1 (high-affinity binder of hemoglobin) scored somewhat worse on Verbal IQ and Tapping D at I and 12 months after injury. (C) 2009 Elsevier Inc. All rights reserved.	[Anderson, Gail D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.; Farhrenbruch, Carol] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.; Machamer, Joan E.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Miller, John W.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Sadrzadeh, S. M. Hossein] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Sch, Dept Neurol, Dallas, TX USA; [Sadrzadeh, S. M. Hossein] Univ Calgary, Dept Pathol & Lab Med, Calgary Lab Serv, Calgary, AB, Canada		Anderson, GD (corresponding author), Univ Washington, Dept Pharm, Box 357630, Seattle, WA 98195 USA.	gaila@u.washington.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	American Epilepsy Society; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER	Funding supported by a Research Initiative Award from the American Epilepsy Society. The valproate study data were collected under NIH/NINDS Grant R01NS19643.	BLACK JA, 1968, NATURE, V218, P736, DOI 10.1038/218736a0; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chesnut R M, 1995, New Horiz, V3, P366; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HALLIWELL B, 2000, FREE RADICAL BIO MED, P175; Javid J, 1978, Curr Top Hematol, V1, P151; KOEHLER J, 1994, BIOSTATISTICS; Langlois MR, 1996, CLIN CHEM, V42, P1589; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Melamed-Frank M, 2001, BLOOD, V98, P3693, DOI 10.1182/blood.V98.13.3693; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; PANTER SS, 1984, T ASSOC AM PHYSICIAN, V97, P56; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; REID SA, 1979, EXP NEUROL, V66, P205, DOI 10.1016/0014-4886(79)90075-X; REITAN R, 1993, H REITAN NEUROPSYCHO; Saccucci P, 2004, NEUROGENETICS, V5, P245, DOI 10.1007/s10048-004-0192-1; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SMITHIES O, 1955, BIOCHEM J, V61, P629, DOI 10.1042/bj0610629; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; VANLENTE F, 1979, CLIN CHEM, V25, P2007; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wechsler D., 1955, MANUAL WECHSLER ADUL; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527	36	34	34	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	NOV	2009	16	3					501	506		10.1016/j.yebeh.2009.08.025			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	521PY	WOS:000271935800025	19766540	Green Accepted			2022-02-06	
J	Foley, LM; Hitchens, TK; Ho, C; Janesko-Feldman, KL; Melick, JA; Bayir, H; Kochanek, PM				Foley, Lesley M.; Hitchens, T. Kevin; Ho, Chien; Janesko-Feldman, Keri L.; Melick, John A.; Bayir, Hulya; Kochanek, Patrick M.			Magnetic Resonance Imaging Assessment of Macrophage Accumulation in Mouse Brain after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; inflammation; MRI	CONTROLLED CORTICAL IMPACT; IRON-OXIDE; INFLAMMATORY RESPONSE; DEFICIENT MICE; STEM-CELLS; BLOOD-FLOW; MICROGLIA; RATS; PARTICLES; INFILTRATION	Macrophages contribute to secondary damage and repair after central nervous system (CNS) injury. Micronsized paramagnetic iron oxide (MPIO) particles can label macrophages in situ, facilitating three-dimensional (3D) mapping of macrophage accumulation following traumatic brain injury (TBI), via ex vivo magnetic resonance microscopy (MRM) and in vivo monitoring with magnetic resonance imaging (MRI). MPIO particles were injected intravenously (iv; 4.5mg Fe/Kg) in male C57BL/6J mice (n = 21). A controlled cortical impact (CCI) was delivered to the left parietal cortex. Five protocols were used in naive and injured mice to assess feasibility, specificity, and optimal labeling time. In vivo imaging was carried out at 4.7 Tesla (T). Brains were then excised for 3D MRM at 11.7 T. Triple-label immunofluorescence (MPIO via Dragon Green, macrophages via F480, and nuclei via 4,6-diamidino-2-phenylindole [DAPI]) of brain sections confirmed MPIO particles within macrophages. MRM of naives showed an even distribution of a small number of MPIO-labeled macrophages in the brain. MRM at 48-72 h after CCI and MPIO injection revealed MPIO-labeled macrophages accumulated in the trauma region. When MPIO particles were injected 6 days before CCI, MRM 48 h after CCI also revealed labeled cells at the injury site. In vivo studies of macrophage accumulation by MRI suggest that this approach is feasible, but requires additional optimization. We conclude that MPIO labeling and ex vivo MRM mapping of macrophage accumulation for assessment of TBI is readily accomplished. This new technique could serve as an adjunct to conventional MR approaches by defining inflammatory mechanisms and therapeutic efficacy of anti-inflammatory agents in experimental TBI.	[Janesko-Feldman, Keri L.; Melick, John A.; Bayir, Hulya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Foley, Lesley M.; Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; [Bayir, Hulya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bayir, Hulya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 101, Pittsburgh, PA 15260 USA.	Kochanekpm@ccm.upmc.edu	Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS30318, NS38087, P41EB-001977]; Pittsburgh NMR Center for Biomedical Research; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB001977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, R01NS038087, P50NS030318] Funding Source: NIH RePORTER	We thank Marci Provins and Fran Mistrick for editorial assistance. We also thank the National Institutes of Health for support (grants NS30318 to P. M. K.; NS38087 to P. M. K.; and P41EB-001977 to C. H.).; This work was performed at the Pittsburgh NMR Center for Biomedical Research, and NIH/NIBIB National Resource, P41EB-001977.	Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI [DOI 10.1117/1.3589100, DOI 10.1201/9781420005615.AX4]; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Foley LM, 2005, MAGN RESON MED, V54, P798, DOI 10.1002/mrm.20621; FORD AL, 1995, J IMMUNOL, V154, P4309; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; Hinds KA, 2003, BLOOD, V102, P867, DOI 10.1182/blood-2002-12-3669; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; McIntosh TK, 1996, LAB INVEST, V74, P315; Mitrasinovic OM, 2005, J NEUROSCI, V25, P4442, DOI 10.1523/JNEUROSCI.0514-05.2005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Ricci A, 2000, GROWTH FACTORS, V18, P193, DOI 10.3109/08977190009003244; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwartz M, 2006, J NEUROTRAUM, V23, P360, DOI 10.1089/neu.2006.23.360; Shapiro EM, 2006, MAGN RESON MED, V55, P242, DOI 10.1002/mrm.20718; Shapiro EM, 2004, P NATL ACAD SCI USA, V101, P10901, DOI 10.1073/pnas.0403918101; Shapiro EM, 2005, MAGNET RESON MED, V53, P329, DOI 10.1002/mrm.20342; Siglienti I, 2006, J NEUROIMMUNOL, V173, P166, DOI 10.1016/j.jneuroim.2005.11.011; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROSCI, V15, P8223; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu YL, 2006, P NATL ACAD SCI USA, V103, P1852, DOI 10.1073/pnas.0507198103; Ye Q, 2008, CIRCULATION, V118, P149, DOI 10.1161/CIRCULATIONAHA.107.746354; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027	48	34	35	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1509	1519		10.1089/neu.2008.0747			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200008	19663686	Green Published			2022-02-06	
J	Mihalik, JP; Ondrak, KS; Guskiewicz, KA; McMurray, RG				Mihalik, Jason P.; Ondrak, Kristin S.; Guskiewicz, Kevin A.; McMurray, Robert G.			The effects of menstrual cycle phase on clinical measures of concussion in healthy college-aged females	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Athletic injuries; Cerebral concussion; Menstrual cycle; Neuropsychological tests; Postural balance; Traumatic brain injuries	SPORTS-RELATED CONCUSSION; IMPACT; SYMPTOMS; INJURIES; WOMEN	The management of concussion and mild traumatic brain injury is an area of clinical uncertainty for many sports medicine professionals. While recent Studies suggest sex differences in neurocognitive function may exist, our understanding of the effects of menstrual cycle phase and oral contraceptive pill (OCP) use in healthy females is limited. The purpose of this study was to investigate whether there were changes in neurocognitive function, postural stability and self-reported symptoms between the early and late stages of the menstrual cycle, and also to identify whether performance across menstrual cycle would differ between females using OCP and eumenorrheic females not using OCP. Healthy college-aged females completed a standard concussion test battery including computerised assessment of neurocognitive function, Postural stability and symptom status. Participants completed the counterbalanced testing design during the early and late phases of their menstrual cycle. No significant main effects or interactions for any neurocognitive function or postural stability Outcome measure were observed. Eumenorrheic females endorsed a higher number of symptoms and reported an increased symptom severity score compared to females using OCP. Menstrual cycle phase had no effect oil the total severity or the number of symptoms endorsed. These results suggest preseason neurocognitive and postural stability baseline tests are stable across the menstrual cycle, regardless Of OCP use. Therefore, decreased performance on these measures following a Suspected concussion is likely not attributable to menstrual cycle phase or use of OCP. (c) 2008 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[McMurray, Robert G.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA		McMurray, RG (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 209 Fetzer Gymnasium,South Rd, Chapel Hill, NC 27599 USA.	exphys@email.unc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			Abraham S, 2003, J PSYCHOSOM OBST GYN, V24, P185, DOI 10.3109/01674820309039672; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Friden C, 2003, GYNECOL ENDOCRINOL, V17, P433, DOI 10.1080/09513590312331290358; GARRETT K F, 1984, International Journal of Psychophysiology, V1, P209, DOI 10.1016/0167-8760(84)90039-4; GORDON HW, 1993, PSYCHONEUROENDOCRINO, V18, P521, DOI 10.1016/0306-4530(93)90045-M; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HAMPSON E, 1990, PSYCHONEUROENDOCRINO, V15, P97, DOI 10.1016/0306-4530(90)90018-5; HAMPSON E, 1990, BRAIN COGNITION, V14, P26, DOI 10.1016/0278-2626(90)90058-V; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maki PM, 2002, NEUROPSYCHOLOGIA, V40, P518, DOI 10.1016/S0028-3932(01)00126-9; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; MIHALIK JP, 2004, BRIT J SPORT MED, V38, P661; MOLLERNIELSEN J, 1989, MED SCI SPORT EXER, V21, P126; Morgan M, 1996, OBSTET GYNECOL, V88, P961, DOI 10.1016/S0029-7844(96)00362-6; Myklebust G, 1998, SCAND J MED SCI SPOR, V8, P149, DOI 10.1111/j.1600-0838.1998.tb00185.x; Ross C, 2003, J PSYCHOSOM OBST GYN, V24, P15, DOI 10.3109/01674820309042797; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Symonds CS, 2004, PSYCHOL MED, V34, P93, DOI 10.1017/S0033291703008535	22	34	34	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2009	12	3					383	387		10.1016/j.jsams.2008.05.003			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	448IN	WOS:000266256400009	18771954				2022-02-06	
J	Boison, D				Boison, Detlev			Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells	NEUROTHERAPEUTICS			English	Article; Proceedings Paper	4th Workshop on New Horizons in the Development of Antiepileptic Drugs	MAR 05-07, 2008	Dublin, IRELAND			Adenosine; epilepsy; cell therapy; stem cells; RNAi; rodent models	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; NEURAL DIFFERENTIATION; REFRACTORY EPILEPSY; PARKINSONIAN RATS; GENE THERAPIES; DENTATE GYRUS; HIPPOCAMPUS; KINASE; RECEPTORS	Adenosine is a modulator of neuronal activity with anticonvulsant and neuroprotective properties. Conversely, focal deficiency in adenosine contributes to ictogenesis. Thus, focal reconstitution of adenosine within an epileptogenic brain region constitutes a rational therapeutic approach, whereas systemic augmentation of adenosine is precluded by side effects. To meet the therapeutic goal of focal adenosine augmentation, genetic disruption of the adenosine metabolizing enzyme, adenosine kinase (ADK) in rodent cells was used as a molecular strategy to induce adenosine release from cellular brain implants, which demonstrated antiepileptic and neuroprotective properties. Currently, the second generation of adenosine-releasing cells is under development based on the rationale to use human stem cell-derived brain implants to avoid xenotransplantation. To effectively engineer human stem cells to release adenosine, a lentiviral vector was constructed to express inhibitory micro-RNA directed against ADK. Lentiviral knockdown of ADK induced therapeutic adenosine release in human mesenchymal stem cells, which reduced acute injury and seizures, as well as chronic seizures, when grafted into the mouse hippocampus. The therapeutic potential of this approach suggests the feasibility to engineer autologous adenosine-releasing stem cells derived from a patient. Human embryonic stem cells (hESCs) have a high proliferative capacity and can be subjected to specific cellular differentiation pathways. hESCs, differentiated in vitro into neuroepithelial cells and grafted into the mouse brain, displayed intrahippocampal location and neuronal morphology. Using the same lentiviral micro-RNA vector, we demonstrated knockdown of ADK in hESCs. New developments and therapeutic challenges in using human mesenchymal stem cells and hESCs for epilepsy therapy will be critically evaluated.	Robert Stone Dow Neurobiol Labs, Portland, OR 97232 USA		Boison, D (corresponding author), Robert Stone Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	dboison@downeurobiology.org	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058780-01, R21 NS057475, R01 NS058780, R21NS057475-01, R21NS057538-01, R01 NS061844, R21 NS057475-02, R01 NS058780-02, R21 NS057538-02, R21 NS057538] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061844, R21NS057538, R01NS058780, R21NS057475] Funding Source: NIH RePORTER		Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067; Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Ben-Hur T, 2004, STEM CELLS, V22, P1246, DOI 10.1634/stemcells.2004-0094; Benarroch EE, 2008, NEUROLOGY, V70, P231, DOI 10.1212/01.wnl.0000297939.18236.ec; Boison D, 2005, NEUROSCIENTIST, V11, P25, DOI 10.1177/1073858404269112; Boison D, 2002, P NATL ACAD SCI USA, V99, P6985, DOI 10.1073/pnas.092642899; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; Boison D, 2008, CURR OPIN PHARMACOL, V8, P2, DOI 10.1016/j.coph.2007.09.002; Boison D, 2007, DRUG NEWS PERSPECT, V20, P607, DOI 10.1358/dnp.2007.20.10.1181353; Boison D, 2007, NEURODEGENER DIS, V4, P28, DOI 10.1159/000100356; Boison D, 2007, CURR NEUROPHARMACOL, V5, P115, DOI 10.2174/157015907780866938; Boison D, 2006, TRENDS PHARMACOL SCI, V27, P652, DOI 10.1016/j.tips.2006.10.008; CICCARELLI R, 1994, J NEUROSCI RES, V39, P556, DOI 10.1002/jnr.490390507; Cohen MA, 2007, CURR PROTOC CELL BIO, V23; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Cunha RA, 2008, NEUROCHEM INT, V52, P65, DOI 10.1016/j.neuint.2007.06.026; Dottori Mirella, 2008, V438, P19, DOI 10.1007/978-1-59745-133-8_3; DUNWIDDIE TV, 1980, EPILEPSIA, V21, P541, DOI 10.1111/j.1528-1157.1980.tb04305.x; Erion M.D., 2000, DRUG DEVELOP RES, V50, pS14; Fedele DE, 2004, NEUROSCI LETT, V370, P160, DOI 10.1016/j.neulet.2004.08.031; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731; Gerrard L, 2005, STEM CELLS, V23, P1234, DOI 10.1634/stemcells.2005-0110; Gouder N, 2003, EPILEPSIA, V44, P877, DOI 10.1046/j.1528-1157.2003.03603.x; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Li JY, 2008, TRENDS NEUROSCI, V31, P146, DOI 10.1016/j.tins.2007.12.001; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2007, BRAIN, V130, P1276, DOI 10.1093/brain/awm057; Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Masino SA, 2008, TRENDS NEUROSCI, V31, P273, DOI 10.1016/j.tins.2008.02.009; MONOPOLI A, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1305; Nilsen KE, 2004, BRAIN RES REV, V44, P141, DOI 10.1016/j.brainresrev.2003.11.003; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Onda T, 2008, J CEREBR BLOOD F MET, V28, P329, DOI 10.1038/sj.jcbfm.9600527; Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707; Pignataro G, 2007, J CEREBR BLOOD F MET, V27, P919, DOI 10.1038/sj.jcbfm.9600422; Raedt R, 2007, SEIZURE-EUR J EPILEP, V16, P565, DOI 10.1016/j.seizure.2007.05.003; Rao MS, 2006, NEUROBIOL DIS, V21, P276, DOI 10.1016/j.nbd.2005.07.009; Rao MS, 2007, NEUROBIOL DIS, V27, P117, DOI 10.1016/j.nbd.2007.03.016; Ren G, 2007, EXP NEUROL, V208, P26, DOI 10.1016/j.expneurol.2007.07.016; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Ribeiro JA, 2003, DRUG NEWS PERSPECT, V16, P80, DOI 10.1358/dnp.2003.16.2.740246; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Shetty AK, 2005, J NEUROSCI, V25, P8391, DOI 10.1523/JNEUROSCI.1538-05.2005; Shetty AK, 2007, HIPPOCAMPUS, V17, P943, DOI 10.1002/hipo.20311; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Thompson KW, 2005, NEUROSCIENCE, V133, P1029, DOI 10.1016/j.neuroscience.2005.03.003; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vajda FJE, 2007, J CLIN NEUROSCI, V14, P813, DOI 10.1016/j.jocn.2007.02.008; Wilz A, 2008, BIOMATERIALS, V29, P3609, DOI 10.1016/j.biomaterials.2008.05.010; Yang DL, 2008, STEM CELLS, V26, P55, DOI 10.1634/stemcells.2007-0494; Zhang SC, 2008, PHILOS T R SOC B, V363, P87, DOI 10.1098/rstb.2006.2014	58	34	36	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213			NEUROTHERAPEUTICS	Neurotherapeutics	APR	2009	6	2					278	283		10.1016/j.nurt.2008.12.001			6	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pharmacology & Pharmacy	425TL	WOS:000264659900009	19332320	Green Accepted, Green Published, Bronze			2022-02-06	
J	Eken, C; Kartal, M; Bacanli, A; Eray, O				Eken, Cenker; Kartal, Mutlu; Bacanli, Ayse; Eray, Oktay			Comparison of the Full Outline of Unresponsiveness Score Coma Scale and the Glasgow Coma Scale in an emergency setting population	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Article						altered level consciousness; emergency population; Full Outline of Unresponsiveness Score; Glasgow Coma Scale	TRAUMATIC BRAIN-INJURY; APACHE-II; INTERRATER RELIABILITY; PREDICTION; CONSCIOUSNESS; VALIDATION; MORTALITY; SYSTEM	Background The Glasgow Coma Scale (GCS) is the most widely used tool for the evaluation of the level of consciousness. The Full Outline of Unresponsiveness (FOUR) Score is a new coma Scale that was developed considering the limitations of the GCS, and has been found to be useful in an intensive care setting. We aimed to compare FOUR Score and GCS in the emergency setting. Methods All patients older than 17 years who presented with an altered level of consciousness, after any trauma to the head or with neurological complaints were included in this study. Three-month mortality, in-hospital mortality, and poor outcome using a Modified Rankin Scale (MRS) of 3-6 points were used as the primary outcome measures. Results A total of 185 patients were included in the study, Area under the curve (AUC) values in predicting 3-month mortality for GCS was 0.726 [P=0.0001 and 95% confidence interval (Cl): 0.656-0.789] and 0.776 (P=0.0001 and 95% Cl: 0.709-834) for FOUR Score. AUC in predicting hospital mortality for GCS was 0.735 (P=0.0001 and 95% Cl: 0.655-0.797) and 0.788 (P=0.0001 and 95% Cl: 0.722-0.844) for FOUR Score. AUC in predicting poor outcome (Modified Rankin Scale: 3-6) was 0.720 (P = 0.001 and 95% Cl: 0.650-784) for GCS and 0.751 (P = 0.0001 and 95% Cl: 0.682-0.812) for FOUR Score. Conclusion The new coma Scale, FOUR Score, is not superior to the GCS. However, the combination of the eye and motor components of FOUR Score is a valuable tool that can be used instead of either the FOUR Score or GCS. European Journal of Emergency Medicine 16:29-36 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	[Eken, Cenker; Kartal, Mutlu; Bacanli, Ayse; Eray, Oktay] Akdeniz Univ, Fac Med, Dept Emergency Med, TR-07058 Antalya, Turkey		Eken, C (corresponding author), Akdeniz Univ, Akdeniz Univ Hastanesi, Acil Tip Anabilim Dali, TR-07059 Antalya, Turkey.	cenkereken@akdeniz.edu.tr	Eray, Oktay/AAU-2598-2020; Eken, Cenker/C-1821-2016	Eray, Oktay/0000-0002-1643-6007; Eken, Cenker/0000-0002-2743-5608	Akdeniz University FoundationAkdeniz University	This study was supported by Akdeniz University Foundation and great thanks to Dr Feras Khan for his contributions to the syntax of the article.	*AM COLL SURG COMM, 1993, ADV SUPP COURS PHYS; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Cho D Y, 1995, Clin Intensive Care, V6, P9, DOI 10.1080/714028868; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Grmec S, 2001, CRIT CARE, V5, P19; HARTLEY C, 1995, BRIT J NEUROSURG, V9, P179, DOI 10.1080/02688699550041520; Hennes HJ, 1992, NOTFALLMEDIZIN, V18, P130; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LIDDY CM, 1999, CRIT CARE MED, V27, P1999; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	22	34	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0969-9546			EUR J EMERG MED	Eur. J. Emerg. Med.	FEB	2009	16	1					29	36		10.1097/MEJ.0b013e32830346ab			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	400CC	WOS:000262844600006	19106717				2022-02-06	
J	Byeon, HK; Lim, YC; Koo, BS; Choi, EC				Byeon, Hyung Kwon; Lim, Young Chang; Koo, Bon Seok; Choi, Eun Chang			Metastasis to the submandibular gland in oral cavity squamous cell carcinomas: Pathologic analysis	ACTA OTO-LARYNGOLOGICA			English	Article						Submandibular gland; metastasis; oral cavity; squamous cell carcinoma	SUBMAXILLARY-GLAND; NECK-CANCER; RADIATION; XEROSTOMIA; HEAD	Conclusion. This study demonstrates that the incidence of submandibular gland metastasis in oral cavity squamous cell carcinoma (SCC) is extremely rare and its involvement is through direct extension from a primary lesion. Therefore, if the primary lesion of the oral cavity carcinoma is not in close proximity and hence does not provide suspicion of direct extension, it may be safe to preserve the submandibular gland. Objectives. Radiotherapy may lead to injury to the salivary glands resulting in xerostomia. This study aimed to determine whether and how the submandibular gland is involved in metastases of SCC of the oral cavity and to provide an oncological basis for preservation of the submandibular gland. Patients and methods. This study reviewed the records and pathologic specimens of 201 patients who were diagnosed as having oral cavity SCC and underwent surgery at our institution, from 1991 to 2006, and pathologic metastasis to submandibular gland was evaluated. Results. In all, 44 cases (21.9%) were found to show ipsilateral level I metastasis on pathologic examination. Only two cases (1%) had carcinoma involvement in the submandibular gland. Both these two cases had direct extension from a primary lesion (retromolar trigone and floor of mouth) and no submandibular glands showed pathologic evidence of isolated metastasis or local extension of metastatic lymph nodes.	[Byeon, Hyung Kwon; Choi, Eun Chang] Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea; [Lim, Young Chang] Konkuk Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; [Koo, Bon Seok] Chungnam Natl Univ, Dept Otorhinolaryngol Head & Neck Surg, Taejon, South Korea		Choi, EC (corresponding author), Yonsei Univ, Coll Med, Dept Otorhinolaryngol, 134 Shinchon Dong, Seoul 120752, South Korea.	eunchangmd@yumc.yonsei.ac.kr		Koo, Bon Seok/0000-0002-5928-0006			ABRAMSON AL, 1971, LARYNGOSCOPE, V81, P793, DOI 10.1288/00005537-197105000-00021; *AJCC, 2002, CANC STAG MAN; Bourdin S, 1982, Ann Otolaryngol Chir Cervicofac, V99, P265; DiNardo LJ, 1998, LARYNGOSCOPE, V108, P206, DOI 10.1097/00005537-199802000-00009; Eisbruch A, 2003, WORLD J SURG, V27, P832, DOI 10.1007/s00268-003-7105-6; Evans R W, 1970, Major Probl Pathol, V1, P1; GRAGE TB, 1962, SURGERY, V52, P284; Hughes PJ, 2000, HEAD NECK-J SCI SPEC, V22, P393, DOI 10.1002/1097-0347(200007)22:4<393::AID-HED13>3.0.CO;2-2; Jha N, 2000, INT J RADIAT ONCOL, V46, P7, DOI 10.1016/S0360-3016(99)00460-5; Junquera L, 2000, Minerva Stomatol, V49, P521; Kies MS, 2001, J CLIN ONCOL, V19, P1961, DOI 10.1200/JCO.2001.19.7.1961; Moudouni SM, 2006, INT J UROL, V13, P431, DOI 10.1111/j.1442-2042.2006.01318.x; RamirezAmador V, 1997, ORAL SURG ORAL MED O, V84, P149, DOI 10.1016/S1079-2104(97)90061-5; ROSTI G, 1987, TUMORI, V73, P413, DOI 10.1177/030089168707300416; Sanchez AJ Burgos, 2002, ACTA OTORRINOLARINGO, V53, P67; Seikaly H, 2004, ARCH OTOLARYNGOL, V130, P956, DOI 10.1001/archotol.130.8.956; SOLOMON MP, 1975, ORAL SURG ORAL MED O, V39, P469, DOI 10.1016/0030-4220(75)90092-4; Spiegel JH, 2001, ARCH OTOLARYNGOL, V127, P991, DOI 10.1001/archotol.127.8.991; SPIEGEL JH, 2004, HEAD NECK-J SCI SPEC, V12, P1064; VESSECCHIA G, 1995, VIRCHOWS ARCH, V427, P349, DOI 10.1007/BF00203404	20	34	34	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.		2009	129	1					96	100	PII 793945927	10.1080/00016480802032801			5	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	385XU	WOS:000261847700015	18607927				2022-02-06	
J	Hiekkanen, H; Kurki, T; Brandstack, N; Kairisto, V; Tenovuo, O				Hiekkanen, Heli; Kurki, Timo; Brandstack, Nina; Kairisto, Veli; Tenovuo, Olli			Association of injury severity, MRI-results and ApoE genotype with 1-year outcome in mainly mild TBI: A preliminary study	BRAIN INJURY			English	Article						Traumatic brain injury; MRI; ApoE; GCS; PTA; outcome	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E POLYMORPHISM; DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; SCALE; RECOVERY; MODERATE; SEQUELAE; SUSCEPTIBILITY	Primary objective: To study the ability of MRI findings, apolipoprotein E (ApoE) genotype, the Glasgow Coma Score (GCS) and duration of post-traumatic amnesia (PTA) to predict the 1-year outcome in traumatic brain injury (TBI). Research design: A prospective study in unselected emergency room patients with an acute TBI, followed for 1 year. Methods and procedures: Thirty-three consecutive patients were studied. The TBI severity was assessed with GCS and duration of PTA. Brain MRI scans were obtained within 1 week post-injury. The ApoE genotypes were determined by standard methods. The outcome was evaluated with the Head Injury Symptom Checklist and the Glasgow Outcome Scale (extended) 1 year after the injury. The prognostic value of the explanatory variables was evaluated with multiple linear regression analysis. Main outcomes and results: The presence of traumatic axonal injury lesions or contusions in MRI and duration of PTA were independent predictors of poor outcome. The ApoE genotype and GCS were not associated with outcome. Conclusions: In multivariate models, the duration of PTA and acute MRI are the best predictors of 1-year outcome in TBI, whereas the prognostic values of GCS and ApoE are modest. The dominating role of GCS in assessing TBI severity should be questioned.	[Hiekkanen, Heli; Tenovuo, Olli] Turku Univ, Dept Neurol, Cent Hosp, Turku, Finland; [Kurki, Timo; Brandstack, Nina] Turku Univ, Cent Hosp, Dept Radiol, Turku, Finland; [Kairisto, Veli] Turku Univ, Cent Hosp, Dept Clin Chem, Turku, Finland		Tenovuo, O (corresponding author), Univ Turku, Dept Neurol, Kiinanmyllynkatu 4-8, FIN-20520 Turku, Finland.	olli.tenovuo@tyks.fi		Kurki, Timo/0000-0001-5532-3534			Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Donohoe GG, 2000, CLIN CHEM, V46, P1540; Donohoe GG, 1999, CLIN CHEM, V45, P143; EHNHOLM C, 1986, J LIPID RES, V27, P227; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GRONWALL D, 1975, LANCET, V2, P995; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; JENNETT B, 1975, LANCET, V1, P480; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McFarland K, 2001, CLIN NEUROPSYCHOL, V15, P59, DOI 10.1076/clin.15.1.59.1916; McIntosh TK, 1996, LAB INVEST, V74, P315; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; W.H. Organization, 2006, NEUR DIS PUBL HLTH C; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	52	34	35	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					396	402	PII 910860859	10.1080/02699050902926259			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700003	19408164				2022-02-06	
J	Hux, K; Schneider, T; Bennett, K				Hux, Karen; Schneider, Trish; Bennett, Keri			Screening for traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; screening; assessment; prevalence; identification	BATTERED WOMEN; DAMAGE; TBI	Primary objective: The researchers implemented a traumatic brain injury (TBI) screening procedure in settings likely to have relatively frequent contacts with survivors to better document TBI occurrence among populations at high-risk for under-identification. Methods and procedures: Professionals from four service agencies administered a TBI screening protocol to all incoming clients over a 6-month period. Main outcomes and results: Of the 1999 protocols collected, 531 (26.56%) were positive for a possible history of TBI of sufficient severity to impact quality of life. Memory challenges were the most common chronic complaint among individuals with positive screen results, with struggles with headaches, depression, concentration and anxiety also commonly reported. Conclusions: Large numbers of people seeking vocational rehabilitation, domestic abuse, homeless shelter or mental health services may experience persistent challenges stemming from unidentified TBIs. Identifying these individuals and the source of their challenges is important when developing intervention and supportive services. Using a TBI screening tool is one means of facilitating this identification process.	[Hux, Karen; Schneider, Trish] Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, Lincoln, NE 68583 USA; [Bennett, Keri] Dept Vocat Rehabil, Lincoln, NE USA		Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr 318N, Lincoln, NE 68583 USA.	khux1@unl.edu	Hux, Karen/AAQ-2078-2020		US Department of Health and Human Resources, Health Resources and Services Administration (HRSA)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [H21MC06758]	Support for this research came in part from the TBI Partnership Implementation Grant #H21MC06758 from the US Department of Health and Human Resources, Health Resources and Services Administration (HRSA). The opinions expressed in this manuscript are those of the authors and do not necessarily reflect those of the Department of Education.	Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BRICKER DD, 1986, SPECIAL ED RES TREND, P28; Burton TM, 2008, WALL ST J, pA1; Colantonio A, 2007, BRAIN INJURY, V21, P1353, DOI 10.1080/02699050701785054; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Gilchrist G, 2005, EUR J PUBLIC HEALTH, V15, P587, DOI 10.1093/eurpub/cki036; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GUERRERO J, 2000, BRAIN INJURY, V14, P8; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Kaiser AP, 2000, BEHAV DISORDERS, V26, P26; Kauffman J., 2003, EXCEPTIONAL LEARNERS; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; *MICH DEP COMM HLT, ADDR MICH PUBL SERV; Monahan K, 1999, HEALTH SOC WORK, V24, P269, DOI 10.1093/hsw/24.4.269; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Picard M., 1991, HELPS TBI SCREENING; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; *US CENS BUR, 2008, STAT COUNTR QUICK FA; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009	26	34	34	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	1					8	14	PII 906994626	10.1080/02699050802590353			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	399FY	WOS:000262787000004	19096967				2022-02-06	
J	Weiss, PL; Sveistrup, H; Rand, D; Kizony, R				Weiss, Patrice L. (Tamar); Sveistrup, Heidi; Rand, Debbie; Kizony, Rachel			Video capture virtual reality: A decade of rehabilitation assessment and intervention	PHYSICAL THERAPY REVIEWS			English	Article						virtual reality; webcam; IREX; EyeToy; motion capture; PlayStation	UPPER-EXTREMITY; CEREBRAL-PALSY; COGNITIVE REHABILITATION; CORTICAL REORGANIZATION; STROKE REHABILITATION; MOTOR REHABILITATION; YOUNG-ADULTS; OLDER-ADULTS; CHILDREN; TASK	Background: Video capture virtual reality (VR) systems display the users on a TV or projected screen where they see themselves within a virtual environment (VE) and interact with the virtual stimuli by naturalistic movements without any encumbrance. This is one of the greatest assets of video capture VR systems, making it ideally suited as a tool for rehabilitation. Objective: To provide an overview of how single camera-based markerless video-capture technology has developed and been applied to rehabilitation over the past decade. Method: Short summaries are provided of the numerous studies that use video capture VR for motor and cognitive rehabilitation of clinical populations including stroke, spinal cord injury, traumatic brain injury, cerebral palsy and intellectual disabilities. Results and conclusions: VEs running on video capture VR systems have been shown to be feasible for clinical use for a wide variety of patient populations. The summarised papers include reports of case studies, group comparisons and review articles. Most of the studies using videocapture VR systems were aimed at improving motor aspects of individuals with neurologic conditions but some also address cognitive impairment and motivation in populations with developmental disorders. The majority of the VEs are gaming environments (involving competitive games such as virtual soccer) but functional environments (e.g. street crossing, supermarket shopping) have also been developed. The VEs have been found to be sensitive to differences in motor and cognitive ability and appear to provide an enjoyable and motivating setting for implementing a wide variety of therapeutic goals.	[Weiss, Patrice L. (Tamar); Rand, Debbie; Kizony, Rachel] Univ Haifa, Dept Occupat Therapy, IL-31905 Haifa, Israel; [Sveistrup, Heidi] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada; [Rand, Debbie] Univ British Columbia, Dept Phys Therapy, Vancouver, BC, Canada; [Kizony, Rachel] Ono Acad Coll, Dept Occupat Therapy, Kiryat Ono, Israel; [Kizony, Rachel] Sheba Med Ctr, Dept Occupat Therapy, Tel Hashomer, Israel		Weiss, PL (corresponding author), Univ Haifa, Dept Occupat Therapy, IL-31905 Haifa, Israel.	tamar@research.haifa.ac.il					Bisson E, 2007, CYBERPSYCHOL BEHAV, V10, P16, DOI 10.1089/cpb.2006.9997; Brien M, 2006, CYBERTHERAPY ABSTRAC; BROWN H, 2005, ISRAEL J OCCUP THER, V14, pE43; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Butler C, 2001, DEV MED CHILD NEUROL, V43, P778, DOI 10.1017/S0012162201001414; Chen YP, 2007, PHYS THER, V87, P1441, DOI 10.2522/ptj.20060062; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Crosbie JH, 2007, DISABIL REHABIL, V29, P1139, DOI 10.1080/09638280600960909; Cunningham D, 1999, ST HEAL T, V62, P90; Cunningham D, 1999, Cyberpsychol Behav, V2, P19, DOI 10.1089/cpb.1999.2.19; De Jesus C, FEASIBILITY SA UNPUB; Deutsch JE, P 9 VIRT RE IN PRESS; Deutsch JE, 2008, PHYS THER, V88, P1196, DOI 10.2522/ptj.20080062; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Dvorkin AY, 2006, CYBERPSYCHOL BEHAV, V9, P133, DOI 10.1089/cpb.2006.9.133; Feintuch U, 2006, CYBERPSYCHOL BEHAV, V9, P129, DOI 10.1089/cpb.2006.9.129; Flynn Sheryl, 2007, J Neurol Phys Ther, V31, P180, DOI 10.1097/NPT.0b013e31815d00d5; Fulk George D, 2005, J Neurol Phys Ther, V29, P34; Haik J, 2006, J BURN CARE RES, V27, P195, DOI 10.1097/01.BCR.0000200890.34084.76; Harris Kristen, 2005, Can J Occup Ther, V72, P21; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Inman DP, 1997, COMMUN ACM, V40, P53, DOI 10.1145/257874.257886; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P2218, DOI 10.1016/j.apmr.2005.04.015; Kizony R, 2005, J REHABIL RES DEV, V42, P595, DOI 10.1682/JRRD.2005.01.0023; Kizony R, 2003, J VISUAL COMP ANIMAT, V14, P261, DOI 10.1002/vis.323; Kizony R, 2006, 11 ANN CYB C OTT CAN; Kizony R., 2006, INT J DISABIL HUM DE, V5, P265, DOI [10.1515/IJDHD.2006.5.3.265, DOI 10.1515/IJDHD.2006.5.3.265]; Kushner D, 2004, TECHNOL REV, P57; Latash ML, 1998, DISABIL REHABIL, V20, P104, DOI 10.3109/09638289809166065; Lotan M, P 9 VIRT RE IN PRESS; Lotan M, 2009, RES DEV DISABIL, V30, P229, DOI 10.1016/j.ridd.2008.03.005; Lourenco CB, 2008, VIRTUAL REALITY; Martini R, 2006, ANN REV CYBERTHERAPY, V4, P103; Pugnetti L., 1998, CYBERPSYCHOLOGY BEHA, V1, P151, DOI DOI 10.1089/CPB.1998.1.151; Rand D, 2005, ANN REV CYBERTHERAPY, V3, P193; Rand D, 2005, PRESENCE-TELEOP VIRT, V14, P147, DOI 10.1162/1054746053967012; Rand D, 2009, EUR J PHYS REHAB MED, V45, P113; Rand D, 2007, DISABIL REHABIL, V29, P1710, DOI 10.1080/09638280601107450; Rand Debbie, 2008, J Neurol Phys Ther, V32, P155, DOI 10.1097/NPT.0b013e31818ee779; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Rand D, 2009, AM J OCCUP THER, V63, P535, DOI 10.5014/ajot.63.5.535; Reid D, 2002, CYBERPSYCHOL BEHAV, V5, P559, DOI 10.1089/109493102321018204; Reid D, 2006, THER RECREAT J, V40, P255; Reid Denise T, 2002, Pediatr Rehabil, V5, P141, DOI 10.1080/1363849021000039344; Rizzo A, 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI 10.1162/1054746053967094; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Rizzo AS, 2002, DISABIL REHABIL, V24, P567, DOI 10.1080/09638280110111315; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; SCHULTHEIS MT, 2002, 10 ANN MED MEETS VIR; Sheridan, 1992, PRESENCE-TELEOP VIRT, V1, P120, DOI [10.1162/pres.1992.1.1.120, DOI 10.1162/PRES.1992.1.1.120]; Strickland D, 1996, PRESENCE-TELEOP VIRT, V5, P319, DOI 10.1162/pres.1996.5.3.319; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Sveistrup Heidi, 2004, J Neuroeng Rehabil, V1, P10, DOI 10.1186/1743-0003-1-10; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Thornton M, USE COMPUTERIZ UNPUB; Thornton M, VIRTUAL REALIT UNPUB; Warren J, 2004, THESIS; Weiss P L, 1998, Work, V11, P277, DOI 10.3233/WOR-1998-11305; Weiss Patrice L, 2004, J Neuroeng Rehabil, V1, P12, DOI 10.1186/1743-0003-1-12; Weiss PLT, 2007, DISABIL REHABIL, V29, P1147, DOI 10.1080/09638280600965759; Weiss PL, 2003, CYBERPSYCHOL BEHAV, V6, P335, DOI 10.1089/109493103322011650; Wiederhold B.K., 1998, CYBERPSYCHOLOGY BEHA, V1, P45, DOI DOI 10.1089/CPB.1998.1.45; Yalon-Chamovitz S, 2008, RES DEV DISABIL, V29, P273, DOI 10.1016/j.ridd.2007.05.004; Yavuzer G, 2008, EUR J PHYS REHAB MED, V44, P237; You SH, 2005, DEV MED CHILD NEUROL, V47, P628, DOI 10.1017/S0012162205001234; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91; [No title captured]	68	34	34	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1083-3196	1743-288X		PHYS THER REV	Phys. Ther. Rev.		2009	14	5			SI		307	321		10.1179/108331909X12488667117339			15	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V72KR	WOS:000211641200003					2022-02-06	
J	Christian, E; Zada, G; Sung, G; Giannotta, SL				Christian, Eisha; Zada, Gabriel; Sung, Gene; Giannotta, Steven L.			A review of selective hypothermia in the management of traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						hypothermia; intracranial pressure; neuroprotection; selective brain cooling; traumatic brain injury	PROLONGED POSTISCHEMIC HYPOTHERMIA; UPPER RESPIRATORY-TRACT; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBRAL HYPOTHERMIA; MARKED PROTECTION; AIR-FLOW; HEAD; ISCHEMIA	Object. Traumatic brain injury (TBI) remains a significant cause of morbidity and death in the US and worldwide. Resuscitative systemic hypothermia following TBI has been established as an effective neuroprotective treatment in multiple studies in animals and humans, although this intervention carries with it a significant risk profile as well. Selective, or preferential, methods of inducing cerebral hypothermia have taken precedence over the past few years in order to minimize systemic adverse effects. In this report, the authors explore the current methods available for inducing selective cerebral hypothermia following TBI and review the literature regarding the results of animal and human trials in which these methods have been implemented. Methods. A search of the PubMed archive (National Library of Medicine) and the reference lists of all relevant articles was conducted to identify all animal and human studies pertaining to the use of selective brain cooling, selective hypothermia, preferential hypothermia, or regional hypothermia following TBI. Results. Multiple methods of inducing selective cerebral hypothermia are currently in the experimental phases, including surface cooling, intranasal selective hypothermia, transarterial or transvenous endovascular cooling, extraluminal vascular cooling, and epidural cerebral cooling. Conclusions. Several methods of conferring preferential neuroprotection via selective hypothermia currently are being tested. Class I prospective clinical trials are required to assess the safety and efficacy of these methods.	[Christian, Eisha; Zada, Gabriel; Giannotta, Steven L.] Univ So Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90089 USA; [Sung, Gene] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90089 USA		Zada, G (corresponding author), Univ So Calif, Keck Sch Med, Dept Neurosurg, 1200 N State St,Suite 5046, Los Angeles, CA 90089 USA.	gzada@usc.edu					Andrews PJD, 2005, BRIT J ANAESTH, V94, P330, DOI 10.1093/bja/aei025; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; Cheng H, 2006, ACTA NEUROCHIR, V148, P559, DOI 10.1007/s00701-006-0735-3; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Covaciu L, 2008, RESUSCITATION, V76, P83, DOI 10.1016/j.resuscitation.2007.07.002; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Harris BA, 2007, BRIT J ANAESTH, V98, P93, DOI 10.1093/bja/ael308; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Jordan JD, 2007, J NEUROL SCI, V261, P35, DOI 10.1016/j.jns.2007.04.029; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; OHTA T, 1992, NEUROSURGERY, V31, P1049, DOI 10.1227/00006123-199212000-00010; PARKINS WM, 1954, ANN SURG, V140, P284, DOI 10.1097/00000658-195409000-00004; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Phelps C., 1897, TRAUMATIC INJURIES B; Qiu Wu-si, 2006, Chin J Traumatol, V9, P238; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Schmitt FC, 2006, NEUROBIOL DIS, V23, P689, DOI 10.1016/j.nbd.2006.05.008; Schwartz AE, 1996, NEUROSURGERY, V39, P577; Takeda Y, 2003, CRIT CARE MED, V31, P255, DOI 10.1097/00003246-200301000-00040; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsai MS, 2008, J AM COLL CARDIOL, V51, P1988, DOI 10.1016/j.jacc.2007.12.057; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Wei G, 2008, J NEUROTRAUM, V25, P549, DOI 10.1089/neu.2007.0498; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30; Wolfson MR, 2008, NEUROCRIT CARE, V8, P437, DOI 10.1007/s12028-008-9064-0; Zhang LH, 2007, SURG NEUROL, V67, P117, DOI 10.1016/j.surneu.2006.05.064	45	34	35	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E9	10.3171/FOC.2008.25.10.E9			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100009	18828707	Bronze			2022-02-06	
J	Fujiwara, T; Okuyama, M; Miyasaka, M				Fujiwara, Takeo; Okuyama, Makiko; Miyasaka, Mikiko			Characteristics that distinguish abusive from nonabusive head trauma among young children who underwent head computed tomography in Japan	PEDIATRICS			English	Article						child abuse; shaken baby syndrome; craniocerebral trauma; abusive head trauma; traumatic brain injury	SHAKEN-BABY-SYNDROME; AGE-RELATED INCIDENCE; BRAIN-INJURY; SUBDURAL HEMORRHAGES; POPULATION; INFANTS; BED; MECHANISMS; HEMATOMAS; CHILDHOOD	OBJECTIVE. Distinguishing abusive head trauma in young children from other diseases by symptoms is difficult in practice. Comparisons between abusive and nonabusive head trauma in young children in Japan, where computed tomography is widely and easily available, might contribute to identifying markers of abusive head trauma that differ from that in Western countries. The objective of this study was to compare the characteristics of abusive and nonabusive head trauma in young children in Japan. METHODS. A comparative case series study involving a retrospective medical chart and social work record review of children who were aged 0 to 2 years, visited the National Center for Child Health and Development (Tokyo, Japan) from March 1, 2002, to December 31, 2005, and underwent computed tomography scanning because of suspected intracranial injury was performed. Patients (N = 260) were identified and classified as having either abusive or nonabusive head trauma on the basis of the published definition. Demographic and perinatal characteristics, injury history, clinical presentation, and outcomes were compared by using chi(2) and Fisher's exact tests. RESULTS. Patients with abusive head trauma were significantly younger than patients with nonabusive head trauma and had a peak at similar to 2 to 4 and 7 to 9 months. Patients with abusive head trauma more likely presented no injury history by the caregiver, neurologic symptoms (unconsciousness, seizure, paralysis), subdural hemorrhage, and retinal hemorrhages. Although patients with abusive head trauma had severe clinical outcomes, only 32% of them were separated from the caregiver by social welfare services. CONCLUSIONS. This study highlights the several clinical markers to detect abusive head trauma at a medical visit, including an absence of injury history, neurologic symptoms, subdural hemorrhage, and retinal hemorrhage. These markers can be used to detect abusive head trauma cases by physicians and social welfare workers to protect children from additional abuse.	[Fujiwara, Takeo] Natl Inst Publ Hlth, Sect Behav Sci, Dept Hlth Promot & Res, Saitama 3510197, Japan; [Fujiwara, Takeo] Univ British Columbia, Dept Pediat, Ctr Community Child Hlth Res, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada; [Fujiwara, Takeo; Okuyama, Makiko] Natl Ctr Child Hlth & Dev, Dept Psychol Med, Tokyo, Japan; [Miyasaka, Mikiko] Natl Ctr Child Hlth & Dev, Dept Radiol, Tokyo, Japan		Fujiwara, T (corresponding author), Natl Inst Publ Hlth, Sect Behav Sci, Dept Hlth Promot & Res, 2-3-6 Wako Shi, Saitama 3510197, Japan.	tfujiwara@niph.go.jp			Research on Prevention, Intervention, and Care for Maltreated Children; Research on Children and Families; Ministry of Health, Labor, and Welfare and Empirical Research on Diagnosis, Cure, and Prevention of Traumatic Brain Injury in Developmental Period and Establishment of Its Guideline; Ministry of Health, Labor, and WelfareMinistry of Health, Labour and Welfare, Japan	This research is supported by Research on Prevention, Intervention, and Care for Maltreated Children, in Research on Children and Families, Health and Labor Sciences Research grants from Ministry of Health, Labor, and Welfare (principal investigator: Dr Okuyama) and Empirical Research on Diagnosis, Cure, and Prevention of Traumatic Brain Injury in Developmental Period and Establishment of Its Guideline, Commission Grant for Mental and Neurological Diseases from Ministry of Health, Labor, and Welfare (principal investigator: Dr Masanori Tamura).; We thank Dr Ronald G. Barr, who helped with interpretation of results.	Alexander R. C, 2001, CHILD ABUSE MED DIAG, P47; AOKI N, 1986, NEUROSURGERY, V18, P475, DOI 10.1227/00006123-198604000-00017; AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; BARR RG, 2008, RUDOLPHS PE IN PRESS; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; BERGER RP, 2002, PEDIATRICS, V109; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Datta S, 2005, ARCH DIS CHILD, V90, P947, DOI 10.1136/adc.2002.021154; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Fujiwara T, 2007, PUBLIC HEALTH, V121, P485, DOI 10.1016/j.puhe.2006.09.013; Fukumizu M, 2005, PEDIATRICS, V115, P217, DOI 10.1542/peds.2004-0815C; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; HELFER RE, 1977, PEDIATRICS, V60, P533; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Jaspan T, 2003, CLIN RADIOL, V58, P44, DOI 10.1053/crad.2002.1094; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; KIVLIN JD, 2001, SHAKEN BABY SYNDROME, P137; Latz S, 1999, ARCH PEDIAT ADOL MED, V153, P339; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEVENE S, 1991, ARCH DIS CHILD, V66, P1047, DOI 10.1136/adc.66.9.1047; LYONS TJ, 1993, PEDIATRICS, V92, P125; Maehashi N, 2006, RES PREVENTION INTER, P375; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Organization for Economic Cooperation and Development, HLTH GLANC OECD IND; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; ROSE P, 1962, AM J NURS, V62, P94, DOI 10.2307/3452159; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; YANAI Y, 2001, PEDIAT PSYCHIAT NEUR, V41, P373; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	45	34	35	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	OCT	2008	122	4					E841	E847		10.1542/peds.2008-0387			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	356YD	WOS:000259812600050	18762487				2022-02-06	
J	Wong, DY; Krebsbach, PH; Hollister, SJ				Wong, Darice Y.; Krebsbach, Paul H.; Hollister, Scott J.			Brain cortex regeneration affected by scaffold architectures	JOURNAL OF NEUROSURGERY			English	Article						poly-(epsilon-caprolactone); polymer scaffold; regeneration; solid free-form fabrication; traumatic brain injury	INJURED RAT-BRAIN; CO-GLYCOLIC ACID; TRAUMATIC BRAIN; TOPOGRAPHICAL CONTROL; NESTIN EXPRESSION; TITANIUM IMPLANTS; CELL-DEATH; ADULT-RAT; TISSUE; TRANSPLANTATION	Object. The aim of this study was to compare designed scaffolds with a random-pored sponge scaffold to determine what role scaffold architecture plays in a cortical injury model. Methods. Cylindrical scaffolds (3 x 3 mm) were made of a poly-(epsilon-caprolactone) polymer with 2 different molds from a 3D printer and had either: 1) unidirectional channels and microgrooves oriented longitudinally within the cylinder or 2) orthogonally intersecting channels and axial microgrooves within the cylinder. Additional randomized porosity was imparted using a salt-leaching method. A control scaffold without channels or microgrooves but containing random pores was also made. Scaffolds were implanted for 1, 4, and 8 weeks in a cylindrical defect created 3 mm posterior to the bregma in rat cortex. Control animals had tissue removed but received no implant. Brains were coronally cryosectioned and sections were stained. Antibodies for nestin, glial fibrillary acidic protein (GFAP), and TUJ1 were used to identify neural progenitors, activated astrocytes, and neuronal axons. Tissue ingrowth (H & E) astrocytic infiltration (GFAP), parenchymal inflammation (GFAP), and defect width (H & E) were quantified from images. Results. Defect widths grew and parenchymal inflammation decreased over time with no statistical difference between groups. Total tissue ingrowth and astrocytic infiltration increased over time and was greatest in the orthogonal design group. Specific cell ingrowth, which was aligned with microgrooves interiorly in the orthogonal group and exteriorly in the longitudinal channel group, was qualitatively assessed from nestin and TUJ1 labeling. Conclusions. Scaffold architecture can benefit brain tissue regeneration by integrating the following design principles: 1) large ( 100s of micrometers) pores or channels oriented toward the parenchyma for increased astrocytic infiltration; 2) microgrooves oriented in the desired direction of cellular migration and neuronal alignment; and 3) fully interconnecting channels for cellular migration and tissue integration.	[Wong, Darice Y.; Krebsbach, Paul H.; Hollister, Scott J.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; [Hollister, Scott J.] Univ Michigan, Dept Mech Engn, Coll Engn, Ann Arbor, MI 48109 USA; [Krebsbach, Paul H.] Univ Michigan, Dept Biol & Mat Sci, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Sch Med, Ann Arbor, MI 48109 USA; [Hollister, Scott J.] Univ Michigan, Dept Neurosurg, Sch Med, Ann Arbor, MI 48109 USA		Wong, DY (corresponding author), 1011 N Univ Ave,Room 4214 Dent Bldg, Ann Arbor, MI USA.	dywong@umich.edu	Hollister, Scott/ABH-3463-2021; Krebsbach, Paul H./AAC-4765-2021	Hollister, Scott/0000-0001-7625-892X; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DE-007057-31]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007057] Funding Source: NIH RePORTER	Funding was provided by the National Institutes of Health Training Grant No. T32 DE-007057-31 (D.Y.W.).	Bullock MR, 2006, NEUROSURGERY S, V58, pSi; CLARK P, 1990, DEVELOPMENT, V108, P635; Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142-9612(97)00144-0; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Goldner JS, 2006, BIOMATERIALS, V27, P460, DOI 10.1016/j.biomaterials.2005.06.035; Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; KRISTT DA, 1987, J NEUROPATH EXP NEUR, V46, P668, DOI 10.1097/00005072-198711000-00006; Li JP, 2007, BIOMATERIALS, V28, P2810, DOI 10.1016/j.biomaterials.2007.02.020; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Malda J, 2005, BIOMATERIALS, V26, P63, DOI 10.1016/j.biomaterials.2004.02.046; Manwaring ME, 2004, BIOMATERIALS, V25, P3631, DOI 10.1016/j.biomaterials.2003.10.043; Marion DW, 2006, NEUROSURGERY, V58, P655; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; Otsuki B, 2006, BIOMATERIALS, V27, P5892, DOI 10.1016/j.biomaterials.2006.08.013; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Tian WM, 2005, J CONTROL RELEASE, V102, P13, DOI 10.1016/j.jconrel.2004.09.025; Tsuruma A, 2006, COLLOID SURFACE A, V284, P470, DOI 10.1016/j.colsurfa.2005.11.100; Vance RJ, 2004, BIOMATERIALS, V25, P2095, DOI 10.1016/j.biomaterials.2003.08.064; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440	29	34	35	0	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					715	722		10.3171/JNS/2008/109/10/0715			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100018	18826360				2022-02-06	
J	Cao, C; Tutwiler, RL; Slobounov, S				Cao, Cheng; Tutwiler, Richard Laurence; Slobounov, Semyon			Automatic classification of athletes with residual functional deficits following concussion by means of EEG signal using support vector machine	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						electroencephalography (EEG); feature selection; mild traumatic brain injury (MTBI); support vector machine (SVM)	MILD HEAD-INJURY; FEATURE-SELECTION; POSTURAL RESPONSES; MUTUAL INFORMATION; QUANTITATIVE EEG; BRAIN-INJURY; RECOVERY; MOVEMENT; SPECT	There is a growing body of knowledge indicating long-lasting residual electroencephalography (EEG) abnormalities in concussed athletes that may persist up to 10-year postinjury. Most often, these abnormalities are initially overlooked using traditional concussion assessment tools. Accordingly, premature return to sport participation may lead to recurrent episodes of concussion, increasing the risk of recurrent concussions with more severe consequences. Sixty-one athletes at high risk for concussion (i.e., collegiate rugby and football players) were recruited and underwent EEG baseline assessment. Thirty of these athletes suffered from concussion and were retested at day 30 postinjury. A number of task-related EEG recordings were conducted. A novel classification algorithm, the support vector machine (SVM), was applied as a classifier to identify residual functional abnormalities in athletes suffering from concussion using a multichannel EEG data set. The total accuracy of the classifier using the 10 features was 77.1%. The classifier has a high sensitivity of 96.7% (linear SVM), 80.0% (nonlinear SVM), and a relatively lower but acceptable selectivity of 69.1% (linear SVM) and 75.0% (nonlinear SVM). The major findings of this report are as follows: 1) discriminative features were observed at theta, alpha, and beta frequency bands, 2) the minimal redundancy relevance method was identified as being superior to the univariate t-test method in selecting features for the model calculation, 3) the EEG features selected for the classification model are linked to temporal and occipital areas, and 4) postural parameters influence EEG data set and can be used as discriminative features for the classification model. Overall, this report provides sufficient evidence that 10 EEG features selected for final analysis and SVM may be potentially used in clinical practice for automatic classification of athletes with residual brain functional abnormalities following a concussion episode.	[Cao, Cheng; Tutwiler, Richard Laurence; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, State Coll, PA 16802 USA; [Cao, Cheng; Tutwiler, Richard Laurence] Penn State Univ, Dept Elect Engn, State Coll, PA 16802 USA		Cao, C (corresponding author), Penn State Univ, Dept Kinesiol, State Coll, PA 16802 USA.	cxc687@psu.edu; rlt1@psu.edu; sins18@psu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	The work of S. Slobounov was supported by the National Institutes of Health under Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury."	Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Acir N, 2005, IEEE T BIO-MED ENG, V52, P30, DOI 10.1109/TBME.2004.839630; BANKMAN IN, 1992, IEEE T BIO-MED ENG, V39, P1305, DOI 10.1109/10.184707; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Ding C, 2003, PROCEEDINGS OF THE 2003 IEEE BIOINFORMATICS CONFERENCE, P523, DOI 10.1109/CSB.2003.1227396; Dong B, 2005, ENERG BUILDINGS, V37, P545, DOI 10.1016/j.enbuild.2004.09.009; Duda RO, 2002, PATTERN CLASSIFICATI; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; GEETS W, 1985, ELECTROEN CLIN NEURO, V14, P333; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iannarilli FJ, 2003, IEEE T PATTERN ANAL, V25, P779, DOI 10.1109/TPAMI.2003.1201827; Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kohavi R, 1997, ARTIF INTELL, V97, P273, DOI 10.1016/S0004-3702(97)00043-X; Kwak N, 2002, IEEE T PATTERN ANAL, V24, P1667, DOI 10.1109/TPAMI.2002.1114861; Lal TN, 2004, IEEE T BIO-MED ENG, V51, P1003, DOI 10.1109/TBME.2004.827827; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Lotte F, 2007, J NEURAL ENG, V4, pR1, DOI 10.1088/1741-2560/4/2/R01; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MORENO L, 1995, IEEE T BIO-MED ENG, V42, P428, DOI 10.1109/10.376139; Noble W.S., 2004, KERNEL METHODS COMPU, p71?; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OZDAMAR O, 1991, COMPUTER BASED MED S, V12, P272; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shimada T, 2000, IEEE T BIO-MED ENG, V47, P369, DOI 10.1109/10.827301; Slobounov S, 2006, BIOL PSYCHOL, V72, P188, DOI 10.1016/j.biopsycho.2005.10.005; Slobounov S, 2006, MOTOR CONTROL, V10, P69, DOI 10.1123/mcj.10.1.69; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P1125, DOI 10.1016/S1388-2457(02)00123-2; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Vapnik V. N., 1998, STAT LEARNING THEORY; Wang L., 2005, SUPPORT VECTOR MACHI; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; XIAO Y, 2007, EURASIP J BIOINFORMA	54	34	37	0	14	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	AUG	2008	16	4					327	335		10.1109/TNSRE.2008.918422			9	Engineering, Biomedical; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Rehabilitation	339IR	WOS:000258571800002	18701381				2022-02-06	
J	Hansen, TS; Engberg, AW; Larsen, K				Hansen, Trine S.; Engberg, Aase W.; Larsen, Klaus			Functional oral intake and time to reach unrestricted dieting for patients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; deglutition disorders; rehabilitation	FORMAL SWALLOWING EVALUATION; IMPROVES DYSPHAGIA OUTCOMES; HEAD-INJURY; DISORDERS; CONSCIOUSNESS; PREDICTORS; THERAPY; STROKE; ADULTS; SCALE	Objectives: To investigate the status of functional oral intake for patients with severe traumatic brain injury (TBI) and time to return to unrestricted dieting; and to investigate whether severity of brain injury is a predictor for unrestricted dieting. Design: Observational retrospective cohort study. Setting: Subacute rehabilitation department, university hospital. Participants: Patients age 16 to 65 years (N=173) with severe TBI (posttraumatic amnesia from 7d to >6mo) admitted over a 5-year period. Patients are transferred to the brain injury unit as soon as they ventilate spontaneously. Intervention: Facial oral tract therapy. Main Outcome Measure: Unrestricted dieting assessed by the Functional Oral Intake Scale (FOIS). Results: We found that 93% of all patients had problems with functional oral intake at admission. Within 126 days of rehabilitation, 64% recovered to unrestricted dieting before discharge. The chance of returning to total oral diet depends on the severity of the brain injury and can be predicted by Glasgow Coma Scale (GCS; measured the day after cessation of sedation; Wald chi(2)=42.78, P<.01), Rancho Los Amigos Scale (RLAS) level (Wald chi(2)=11.84, P=.01), FIM instrument (Wald chi(2)=44.40, P<.01), and FOIS score at admission (Wald chi(2)=82.93, P<.01). Conclusions: Impairment in functional oral intake was found to be very common for patients with severe TBI admitted to a subacute rehabilitation department. For those who recovered during hospital rehabilitation, return to unrestricted dieting happened within 126 days of rehabilitation. The chance of returning to unrestricted dieting depends on the severity of the brain injury and can be predicted by GCS score, RLAS level, FIM score, and functional oral intake at admission. These results are important when planning rehabilitation, giving information to patients and relatives, and designing efficacy studies of facial oral tract therapy, which are highly recommended.	[Hansen, Trine S.; Engberg, Aase W.] Univ Copenhagen, Dept Neurorehabil, Hvidovre Hosp, Brain Injury Unit, DK-2650 Hvidovre, Denmark; [Hansen, Trine S.] Univ Copenhagen, Dept Occupat Therapy, Hvidovre Hosp, DK-2650 Hvidovre, Denmark; [Larsen, Klaus] Univ Copenhagen, Clin Res Unit, Hvidovre Hosp, DK-2650 Hvidovre, Denmark		Hansen, TS (corresponding author), Univ Copenhagen, Dept Neurorehabil, Hvidovre Hosp, Brain Injury Unit, 354 Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	trine.schow@gmail.com					AFFOLTER F, 1980, PERCEPTUAL PROCESSES; AVERYSMITH W, 1994, AM J OCCUP THER, V48, P235, DOI 10.5014/ajot.48.3.235; Brady SL, 2006, BRAIN INJURY, V20, P1329, DOI 10.1080/02699050601111435; Carnaby G, 2006, LANCET NEUROL, V5, P31, DOI 10.1016/S1474-4422(05)70252-0; Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; Coombes K, 1996, WEGE ANFANG FRUHREHA, P137; COOMBES K, 2001, 1991 2001 JUBILAUMSS; Crary MA, 2005, ARCH PHYS MED REHAB, V86, P1516, DOI 10.1016/j.apmr.2004.11.049; DAVIES PM, 1994, STARTING EARLY REHAB; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; Hind JA, 2001, ARCH PHYS MED REHAB, V82, P1661, DOI 10.1053/apmr.2001.28006; HOLLAND A, 1984, LANGUAGE DISORDERS A; JENNETT B, 1976, LANCET, V1, P1031; Jurkovich GJ, 1999, J TRAUMA, V46, P821; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Morgan A, 2003, J HEAD TRAUMA REHAB, V18, P239, DOI 10.1097/00001199-200305000-00002; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; SECHREST L, 1972, J CROSS CULT PSYCHOL, V3, P41, DOI 10.1177/002202217200300103; Ward EC, 2007, J HEAD TRAUMA REHAB, V22, P184, DOI 10.1097/01.HTR.0000271119.96780.f5; Welter F L, 1998, Rehabilitation (Stuttg), V37, P58; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	27	34	40	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2008	89	8					1556	1562		10.1016/j.apmr.2007.11.063			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	336UP	WOS:000258390400019	18674990				2022-02-06	
J	Li, N; Yang, H; Lu, LL; Duan, CL; Zhao, CL; Zhao, HY				Li, Na; Yang, Hui; Lu, Lingling; Duan, Chunli; Zhao, Chunli; Zhao, Huanying			Comparison of the labeling efficiency of BrdU, DiI and FISH labeling techniques in bone marrow stromal cells	BRAIN RESEARCH			English	Article						BrdU; FISH; DiI; labeling; marrow stromal cell	TRAUMATIC BRAIN INJURY; ACUTE MYOCARDIAL-INFARCTION; STEM-CELLS; TRANSPLANTATION; RATS; MICROSCOPY; NEOVASCULARIZATION; HYBRIDIZATION; PROLIFERATION; MACROPHAGES	Cells are generally labeled during in vivo implantation studies enabling the cells to be traced. The relationship between the labeling efficiency and cellular proliferation after transplantation is critical for the interpretation of data obtained by detection of the signals on tissue sections. Here, we compare cellular labeling methods of rat marrow stromal cells that were labeled with 5-bromo-2-deoxyuridine (BrdU), 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) and fluorescence in situ hybridization (FISH). Our data show that (i) BrdU uniformly labeled the nuclei, (ii) DiI-labeled cells had many dots or stained clear and uniform when a longer exposure time was used during detection and (iii) FISH labeled the cells with dots along the edges of the nuclei. The labeling efficiency was 94.1 +/- 8.6%, 97.6 +/- 3.4% and 90.5 +/- 3.0%, in BrdU, DiI- and FISH-labeled cells, respectively. After sub-culturing of labeled cells, the percentage of BrdU-positive cells was found to be 71.9 +/- 18.0% and 18.4 +/- 6.9%, after the first and second passages, respectively. The percentage of DiI-labeled cells detected depended on the exposure time: a long exposure time (> 10 s) resulted in identification of 95.1 +/- 4.0% and 94.5 +/- 3.9% DiI-positive cells after the first and second sub-cultures, respectively. The percentage of FISH-positive cells was found to be 87.0 +/- 3.0% and 89.1 +/- 9.7%. The BrdU labeling signal quickly decreased over time. Thus, BrdU should only be used to temporarily label dividing cells. In contrast, our data indicate that DiI and FISH labeling maybe used to steadily trace cells during in vivo experiments. To our knowledge, this is the first time that the effects of different labeling methods over time have been examined during a cell transplantation study. (c) 2007 Elsevier B.V. All rights reserved.	[Li, Na; Yang, Hui; Lu, Lingling; Duan, Chunli; Zhao, Chunli; Zhao, Huanying] Capital Med Univ, Minist Educ, Beijing Ctr Neural Regenerat & Repairing, Key Lab Neurodegenerat Dis,Beijing Inst Neurosci, Beijing 100069, Peoples R China		Yang, H (corresponding author), Capital Med Univ, Minist Educ, Beijing Ctr Neural Regenerat & Repairing, Key Lab Neurodegenerat Dis,Beijing Inst Neurosci, 10 YouanMen Wai Xitoutiao, Beijing 100069, Peoples R China.	huiyang@ccmu.edu.cn					An J, 1997, J ANDROL, V18, P289; Andrassy M, 2005, CIRC RES, V96, P476, DOI 10.1161/01.RES.0000156903.37007.d1; ARCHARD LC, 1987, EUR HEART J, V8, P437, DOI 10.1093/eurheartj/8.suppl_J.437; ASIM M, 2001, NEUROSURGERY, V49, P1196; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BERG E, 2005, NEUROREPORT, V16, P1419; Cheng Q.N., 2007, CARDIOVASC PATHOL, V16, P127; Coenen M, 2005, J NEUROPATH EXP NEUR, V64, P681, DOI 10.1097/01.jnen.0000173892.24800.03; Dai WD, 2005, CIRCULATION, V112, P214, DOI 10.1161/CIRCULATIONAHA.104.527937; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; Deng J, 2001, ANAT EMBRYOL, V204, P437, DOI 10.1007/s429-001-8001-3; Ehmcke J, 2005, HUM REPROD, V20, P1185, DOI 10.1093/humrep/deh766; Fang BJ, 2004, TRANSPLANTATION, V78, P83, DOI 10.1097/01.TP.0000128326.95294.14; GOZ B, 1977, PHARMACOL REV, V29, P249; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Higuchi Yutaka, 2005, Eur Arch Otorhinolaryngol, V262, P64, DOI 10.1007/s00405-003-0667-y; Hildebrandt K, 1999, J NEURAL TRANSM, V106, P549, DOI 10.1007/s007020050178; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Kamolz LP, 2006, BURNS, V32, P16, DOI 10.1016/j.burns.2005.08.020; Kellermayer R, 2005, DIAGN MOL PATHOL, V14, P159, DOI 10.1097/01.pas.0000176770.56541.dd; Konnai Y, 2000, SPINE, V25, P776, DOI 10.1097/00007632-200004010-00004; LINDEBERG H, 1990, CLIN OTOLARYNGOL, V15, P367, DOI 10.1111/j.1365-2273.1990.tb00485.x; Liu C, 2005, ANN VASC SURG, V19, P241, DOI 10.1007/s10016-004-0173-8; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; McLennan R, 2007, DEV BIOL, V301, P227, DOI 10.1016/j.ydbio.2006.08.019; Michel K, 2000, PFLUG ARCH EUR J PHY, V440, P393, DOI 10.1007/s004240000299; Pasula R, 2002, J IMMUNOL, V169, P4504, DOI 10.4049/jimmunol.169.8.4504; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Radtke C, 2005, NEUROSCI LETT, V387, P85, DOI 10.1016/j.neulet.2005.06.073; RUTTER WJ, 1973, ANNU REV BIOCHEM, V42, P601, DOI 10.1146/annurev.bi.42.070173.003125; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Van Lommel A, 1998, ANAT EMBRYOL, V197, P325, DOI 10.1007/s004290050142; Vogetseder A, 2005, HISTOCHEM CELL BIOL, V124, P97, DOI 10.1007/s00418-005-0023-y; Yang H, 1999, J HISTOCHEM CYTOCHEM, V47, P431, DOI 10.1177/002215549904700402; Yang ZJ, 2007, CLIN CHIM ACTA, V381, P114, DOI 10.1016/j.cca.2007.02.035; Yoon YS, 2004, CIRCULATION, V109, P3154, DOI 10.1161/01.CIR.0000134696.08436.65; Yoshiba K, 2002, HISTOCHEM CELL BIOL, V118, P205, DOI 10.1007/s00418-002-0442-y; Zhou R, 2006, J AM COLL CARDIOL, V48, P2094, DOI 10.1016/j.jacc.2006.08.026	40	34	42	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 18	2008	1215						11	19		10.1016/j.brainres.2007.09.095			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	323CK	WOS:000257421400002	18468584				2022-02-06	
J	Chen, G; Shi, JX; Qi, M; Wang, HX; Hang, CH				Chen, Gang; Shi, Ji-Xin; Qi, Meng; Wang, Hu-Xu; Hang, Chun-Hua			Effects of progesterone on intestinal inflammatory response, mucosa structure alterations, and apoptosis following traumatic brain injury in male rats	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; intestine; inflammation; apoptosis; progesterone	ENDOTHELIAL-CELLS; EXPRESSION; INTERLEUKIN-6; ALLOPREGNANOLONE; PROLIFERATION; ESTROGEN; FAILURE; CORTEX; ALPHA; GUT	Background. Traumatic brain injury (TBI) can induce a persistent inflammatory response, histopathological changes, and apoptosis in the gut. Progesterone given after TBI has been shown to reduce the cerebral inflammation and neuronal apoptosis in the brain. However, the effects of progesterone on the inflammatory response, structure alterations, and apoptosis in the intestinal mucosa following TBI has not been investigated. Materials and methods. Right parietal cortical contusion in male rats was made by using the weight-dropping method. Rats were given 0 or 16 mg/kg injections of progesterone at postinjury at 1 and 6 hours and on days 1, 2, 3, 4, and 5. Gut samples were extracted at 5 days after trauma. We measured the concentrations of interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha, and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay; intercellular adhesion molecule-1 expression by immunohistochemistry; intestinal mucosal morphological changes by histopathological study and electron microscopy; and apoptosis by terminal deoxynucleotidyl transferase. mediated dUTP nick end-labeling staining. Results. Administration of progesterone following TBI could decrease the intestinal concentrations of IL-1 beta and tumor necrosis factor-alpha, but not IL-6. The level of intercellular adhesion molecule-1 expression in the gut was down-regulated by progesterone. TBI-induced damages of gut structure and apoptosis were attenuated after progesterone injections. Conclusions. The results of the present study suggest that post-TBI progesterone administration could suppress the intestinal inflammation, protect the intestinal mucosal structure, and reduce the mucosa apoptosis. (C) 2008 Elsevier Inc. All rights reserved.	[Chen, Gang; Shi, Ji-Xin; Qi, Meng; Wang, Hu-Xu; Hang, Chun-Hua] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	nju_neurosurgery@163.com	QI, Meng/F-2802-2012	Chen, Gang/0000-0002-0758-1907			Bese T, 2006, INT J GYNECOL CANCER, V16, P809, DOI 10.1111/j.1525-1438.2006.00533.x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Gotkin JL, 2006, AM J OBSTET GYNECOL, V195, P1015, DOI 10.1016/j.ajog.2006.07.002; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Keck C, 1998, EXP CLIN ENDOCR DIAB, V106, P334, DOI 10.1055/s-0029-1211994; Kurachi O, 2001, J CLIN ENDOCR METAB, V86, P2275, DOI 10.1210/jc.86.5.2275; Lan L, 1999, MOL CELL ENDOCRINOL, V155, P123, DOI 10.1016/S0303-7207(99)00066-0; Okuda K, 2004, BIOL REPROD, V71, P2065, DOI 10.1095/biolreprod.104.028076; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Piercy KT, 2002, J SURG RES, V105, P215, DOI 10.1006/jsre.2002.6405; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Shields AD, 2005, AM J OBSTET GYNECOL, V193, P1144, DOI 10.1016/j.ajog.2005.05.046; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Telleria CM, 1998, ENDOCRINOLOGY, V139, P3597, DOI 10.1210/en.139.8.3597; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	26	34	40	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUN 1	2008	147	1					92	98		10.1016/j.jss.2007.05.029			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	298EF	WOS:000255668500014	17868700				2022-02-06	
J	Kaminski, TW; Cousino, ES; Glutting, JJ				Kaminski, Thomas W.; Cousino, Eric S.; Glutting, Joseph J.			Examining the relationship between puposeful heading in soccer and computerized neuropsychological test performance	RESEARCH QUARTERLY FOR EXERCISE AND SPORT			English	Article						concussion; memory; neurocognition; reaction time	SPORT-RELATED CONCUSSION; BRAIN-INJURY; FOOTBALL PLAYERS; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; POSTURAL CONTROL; ALTERNATE FORMS; COLLEGIATE; MANAGEMENT; TRAUMA	The Purpose of this study was to determine if a relationship exists between Purposeful heading in soccer and neuropychological test performance. Automated Neuropsychological Assessment Metrics throughput scores were derived on seven subset variables that measure a variety of neurocognitive abilities. Simple Spearman's rank correlations were calculated between headers per game (HPG) and the criterion variables. Interestingly, math processing speed. (Spearman's rho = .160) and continuous performance test #2 (rho = .124) had small but significant correlations; both showed improvement in Performance Pre- to postseason. There were no significant correlations between HPG and the other five variables. This study found no detrimental relationship between the number of purposeful headers and the neurocognitive measures in this population.	[Kaminski, Thomas W.] Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, Newark, DE 19716 USA; [Glutting, Joseph J.] Univ Delaware, Sch Educ, Newark, DE 19716 USA		Kaminski, TW (corresponding author), Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, 159 Fred Rust Ice Arena,541 S Coll Ave, Newark, DE 19716 USA.	kaminski@udel.edu					Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Babbs CF, 2000, JAMA-J AM MED ASSOC, V283, P882, DOI 10.1001/jama.283.7.882; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2001, ATHLET THER TODAY, V6, P28, DOI 10.1123/att.6.1.28; BROWN CN, 2004, J ATHL TRAINING, V39, pS17; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Cohen J., 2013, STAT POWER ANAL BEHA; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Cousino E, 2006, J ATHL TRAINING, V41, pS; COUSINO ES, 2005, J ATHL TRAINING, V40, pS97; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Faude O, 2005, AM J SPORT MED, V33, P1694, DOI 10.1177/0363546505275011; FELD A, 2005, DISCOVERING STAT USI; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grote C, 2000, JAMA-J AM MED ASSOC, V283, P882; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Holbourn AHS, 1943, LANCET, V2, P438; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski T. W., 2002, Medicine & Science in Sports & Exercise, V34, pS2, DOI 10.1097/00005768-200205001-00009; KAMINSKI TW, 2006, J ATHL TRAINING, V41, pS39; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lynch JM, 1996, US SOCCER SPORTS MED, P81; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Maxwell S., 2004, DESIGNING EXPT ANAL; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Overall JE, 1996, J CLIN PSYCHOL, V52, P243, DOI 10.1002/(SICI)1097-4679(199605)52:3<243::AID-JCLP1>3.3.CO;2-U; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Randolph C, 2005, J ATHL TRAINING, V40, P139; RASMUSSEN AM, 2002, J ATHL TRAINING, V3, pS64; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Salvia J., 2007, ASSESSMENT SPECIAL I; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Stevens J.P., 2002, APPL MULTIVARIATE ST, V4th ed.; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Thorndike RobertM., 1997, MEASUREMENT EVALUATI; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Westerman R., 2001, ADF HLTH, V2, P29; [No title captured]	71	34	34	0	8	AMER ALLIANCE HEALTH PHYS EDUC REC & DANCE	RESTON	1900 ASSOCIATION DRIVE, RESTON, VA 22091 USA	0270-1367			RES Q EXERCISE SPORT	Res. Q. Exerc. Sport	JUN	2008	79	2					235	244					10	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Psychology; Sport Sciences	316EJ	WOS:000256931400012	18664047				2022-02-06	
J	Ripley, DL; Harrison-Felix, C; Sendroy-Terrill, M; Cusick, CP; Dannels-McClure, A; Morey, C				Ripley, David L.; Harrison-Felix, Cindy; Sendroy-Terrill, Melissa; Cusick, Christopher P.; Dannels-McClure, Amy; Morey, Clare			The impact of female reproductive function on outcomes after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	67th Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 09-12, 2006	Honolulu, HI	Amer Acad Phys Med & Rehabil		amenorrhea; brain injuries; outcome assessment (health care); rehabilitation	HEAD-INJURY; NEUROENDOCRINE DYSFUNCTION; STRUCTURED INTERVIEWS; PRACTICAL SCALE; INDIVIDUALS; ABNORMALITIES; HYPOGONADISM; ORIENTATION; RELIABILITY; GENDER	Objectives: To determine the impact of traumatic brain injury (TBI) on female menstrual and reproductive functioning and to examine the relationships between severity of injury, duration of amenorrhea, and TBI outcomes. Design: Retrospective cohort survey. Setting: Telephone interview. Participants: Women (N=30; age range, 18-45y), between 1 and 3 years postinjury, who had completed inpatient rehabilitation for TBI. Interventions: Not applicable. Main Outcome Measures: Data collected included menstrual and reproductive functioning pre- and postinjury, demographic, and injury characteristics. Outcome measures included the Glasgow Outcome Scale-Extended (GOS-E), the Mayo-Portland Adaptability Inventory-4 (MPAI-4), and the Medical Outcome Study 12-Item Short-Form Health Survey, Version 2 (SF-12v2). Results: The median duration of amenorrhea was 61 days (range, 20-344d). Many subjects' menstrual function changed after TBI, reporting a significant increase in skipped menses postinjury (P<.001) and a trend toward more painful menses (P=.061). More severe TBI, as measured by the duration of posttraumatic amnesia, was significantly predictive of a longer duration of amenorrhea (P=.004). Subjects with a shorter duration of amenorrhea scored significantly better on the SF-12 physical component subscale (P=.004), the GOS-E (P=.05), and the MPAI-4 participation subscale (P=.05) after controlling for age, injury severity, and time postinjury. Conclusions: The severity of TBI was predictive of duration of amenorrhea and a shorter duration of amenorrhea was predictive of better ratings of global outcome, community participation, and health-related quality of life postinjury.	[Ripley, David L.] Craig Hosp, CNS Med Grp, Englewood, CO 80113 USA; [Ripley, David L.; Harrison-Felix, Cindy] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Ripley, David L.; Harrison-Felix, Cindy] Univ Colorado, Hlth Sci Ctr, Denver, CO USA		Ripley, DL (corresponding author), Craig Hosp, CNS Med Grp, 3425 S Clarkson, Englewood, CO 80113 USA.	dripley@craighospital.org		Ripley, David/0000-0002-5349-1830			Alaca R, 2002, AM J PHYS MED REHAB, V81, P788, DOI 10.1097/00002060-200210000-00013; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; BINGYOU RG, 1992, J CLIN ENDOCR METAB, V75, P1054, DOI 10.1210/jc.75.4.1054; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Burns A S, 2001, Phys Med Rehabil Clin N Am, V12, P183; Cernak I, 1999, BRAIN INJURY, V13, P1005; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Ferin M, 1999, J CLIN ENDOCR METAB, V84, P1768, DOI 10.1210/jc.84.6.1768; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; GROSSMAN WF, 1994, J REPROD MED, V39, P738; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; LEE SC, 1994, BRAIN INJURY, V8, P571; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MALEC J, 2003, MAYOPORTLAND ADAPTAB; MONGA TN, 1986, ARCH PHYS MED REHAB, V67, P19; Mount DL, 2002, BRAIN INJURY, V16, P1051, DOI 10.1080/02699050210154259; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; *QUALITYMETRIC INC, 2005, SF12V2 QUALITYMETRIC; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; ROLIH CA, 1995, MED CLIN N AM, V79, P211, DOI 10.1016/S0025-7125(16)30093-1; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Sipski M L, 2001, Phys Med Rehabil Clin N Am, V12, P79; *SPSS, 2004, SPSS 13 0 WIND VERS; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Tate D G, 2001, Phys Med Rehabil Clin N Am, V12, P23; TEASDALE G, 1974, LANCET, V2, P81; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zafonte RD, 1997, AM J PHYS MED REHAB, V76, P246, DOI 10.1097/00002060-199705000-00018	41	34	36	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2008	89	6					1090	1096		10.1016/j.apmr.2007.10.038			7	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	310TN	WOS:000256553400012	18503804				2022-02-06	
J	Kobeissy, FH; Warren, MW; Ottens, AK; Sadasivan, S; Zhang, ZQ; Gold, MS; Wang, KKW				Kobeissy, Firas H.; Warren, Matthew W.; Ottens, Andrew K.; Sadasivan, Shankar; Zhang, Zhiqun; Gold, Mark S.; Wang, Kevin K. W.			Psychoproteomic analysis of rat cortex following acute methamphetamine exposure	JOURNAL OF PROTEOME RESEARCH			English	Article						autophagy; neurotoxicity; methamphetamine; proteomics; drug of abuse; proteolysis	TRAUMATIC BRAIN-INJURY; TANDEM MASS-SPECTROMETRY; DOPAMINERGIC NEUROTOXICITY; PRELIMINARY VALIDATION; TERMINAL HYDROLASE-L1; NEURONAL APOPTOSIS; ALPHA-SYNUCLEIN; UP-REGULATION; CELL-DEATH; IDENTIFICATION	Methamphetamine (METH) is recognized as one of the most abused psychostimulants in the United States. METH is an illicit drug that is known to exert neurotoxic effects on both dopaminergic and serotonergic neural systems both in vivo and in vitro. Our laboratory and others have been Studying the biochemical mechanisms underlying METH-induced neurotoxicity. Here, we applied a novel psychoproteomic approach to evaluate METH-induced neurotoxicity following acute METH administration (4 x 10 mg/kg, ip injections every 1 h). Samples of cortical tissue collected 24h post METH treatment were pooled, processed and analyzed via a selective psychoproteomic platform. Protein separation was performed using our previously established offline tandem cation-anion exchange chromatography-SDS-1 D-PAGE platform (CAX-PAGE). Gel bands exhibiting 2 or more fold changes were extracted, trypsinized and subjected to reversed-phase liquid chromatography-tandem mass spectrometry (RPLCMS/MS) analyses for protein identification. Differential changes of the selected proteins were further confirmed by quantitative immunoblotting. We identified 82 differentially expressed proteins, 40 of which were downregulated and 42 of which were upregulated following acute METH treatment. Proteins that decreased in abundance included collapsin response mediator protein-2 (CRMP-2), superoxide dismutase 1 (SOD 1), phosphatidylethanolamine-binding protein-1 (PEBP-1) and mitogen activated kinase kinase-1 (MKK-1). Proteins that increased in abundance included authophagy-linked microtubule-associated protein light chain 3 (LC3), synapsin-1, and Parkinsonism linked ubiquitin carboxy-terminal hydroxylase-L1 (UCH-L1). Lastly, we used these differentially expressed protein subsets to construct a "psychoproteomic" spectrum map in an effort to uncover potential protein interactions relevant to acute METH neurotoxicity.	[Kobeissy, Firas H.; Warren, Matthew W.; Ottens, Andrew K.; Sadasivan, Shankar; Zhang, Zhiqun; Gold, Mark S.; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32610 USA; [Kobeissy, Firas H.; Gold, Mark S.; Wang, Kevin K. W.] Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; [Gold, Mark S.] Univ Florida, Coll Med, Dept Community Hlth & Family Med, McKnight Brain Inst, Gainesville, FL 32610 USA		Kobeissy, FH (corresponding author), Univ Florida, Dept Psychiat, L4-100F,POB 100256, Gainesville, FL 32611 USA.	firasko@ufl.edu; kwang@psychiatry.ufl.edu	Ottens, Andrew/K-3352-2012; Sadasivan, Shankar/C-9620-2009; Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473; Ottens, Andrew/0000-0002-2118-3796			Bae SC, 2006, DRUG ALCOHOL DEPEN, V81, P83, DOI 10.1016/j.drugalcdep.2005.05.016; Bodovitz S, 2004, TRENDS BIOTECHNOL, V22, P4, DOI 10.1016/j.tibtech.2003.10.013; Bowyer JF, 2007, NEUROSCIENCE, V144, P66, DOI 10.1016/j.neuroscience.2006.08.076; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Carolan BJ, 2006, CANCER RES, V66, P10729, DOI 10.1158/0008-5472.CAN-06-2224; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chen Q, 2006, J NEUROCHEM, V99, P1133, DOI 10.1111/j.1471-4159.2006.04160.x; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; Fornai F, 2004, ANN NY ACAD SCI, V1025, P162, DOI 10.1196/annals.1316.021; Fornai F, 2004, J NEUROCHEM, V88, P114, DOI 10.1046/j.1471-4159.2003.02137.x; Fornai F, 2006, ANN NY ACAD SCI, V1074, P84, DOI 10.1196/annals.1369.007; Funada M, 2004, ANN NY ACAD SCI, V1025, P76, DOI 10.1196/annals.1316.010; Harada T, 2004, AM J PATHOL, V164, P59, DOI 10.1016/S0002-9440(10)63096-9; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Iwazaki T, 2006, BRAIN RES, V1097, P19, DOI 10.1016/j.brainres.2006.04.052; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; Jimenez A, 2004, TOXICOL APPL PHARM, V196, P223, DOI 10.1016/j.taap.2003.12.017; Kanthasamy A, 2006, ANN NY ACAD SCI, V1074, P234, DOI 10.1196/annals.1369.022; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Lan KC, 1998, J FORMOS MED ASSOC, V97, P528; Larsen KE, 2002, J NEUROSCI, V22, P8951; Liao PC, 2005, J NEUROCHEM, V95, P160, DOI 10.1111/j.1471-4159.2005.03346.x; Lonart G, 2006, BRAIN RES, V1107, P42, DOI 10.1016/j.brainres.2006.05.092; Lopez-Ferrer D, 2004, ANAL CHEM, V76, P6853, DOI 10.1021/ac049305c; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Maxwell JC, 2005, CURR OPIN PSYCHIATR, V18, P235, DOI 10.1097/01.yco.0000165592.52811.84; Morel J, 2006, MOL CELL PROTEOMICS, V5, P1396, DOI 10.1074/mcp.M600044-MCP200; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Noailles PAH, 2003, DEV BRAIN RES, V147, P153, DOI 10.1016/j.devbrainres.2003.11.003; *NSDUH, 2006, REP METH US AB DEP 2; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; PENG J, 1979, J BIOL CHEM, V279; Perez JA, 1999, J EMERG MED, V17, P469, DOI 10.1016/S0736-4679(99)00009-8; Pu CF, 1996, SYNAPSE, V23, P328, DOI 10.1002/(SICI)1098-2396(199608)23:4<328::AID-SYN11>3.0.CO;2-T; Quinton MS, 2007, PSYCHOPHARMACOLOGY, V193, P341, DOI 10.1007/s00213-007-0796-x; Rakhit R, 2006, BBA-MOL BASIS DIS, V1762, P1025, DOI 10.1016/j.bbadis.2006.05.004; Sadasivan S, 2006, APOPTOSIS, V11, P1573, DOI 10.1007/s10495-006-7690-6; *SAMHSA, 2007, SUBS AB MENT HLTH SE; Semple SJ, 2005, J SUBST ABUSE TREAT, V29, P85, DOI 10.1016/j.jsat.2005.05.001; SHACKA JJ, 2006, NEUROSCI LETT; Soares HD, 2004, INT REV NEUROBIOL, V61, P97; Sokolov BP, 2006, NEUROPSYCHOPHARMACOL, V31, P956, DOI 10.1038/sj.npp.1300891; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Staszewski RD, 2006, J NEUROCHEM, V96, P1267, DOI 10.1111/j.1471-4159.2005.03618.x; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Svetlov SI, 2006, BIOMARKERS, V11, P355, DOI 10.1080/13547500600775110; United Nations Office on Drugs and Crime, 2004, WORLD DRUG REP; Venton BJ, 2006, J NEUROSCI, V26, P3206, DOI 10.1523/JNEUROSCI.4901-04.2006; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Warren MW, 2007, ACTA NEUROPATHOL, V114, P277, DOI 10.1007/s00401-007-0259-9; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; WARREN MW, 2006, INT J NEUROPSYCHOPH, P1; Yuan J, 2001, J NEUROCHEM, V77, P1338, DOI 10.1046/j.1471-4159.2001.00339.x; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	59	34	35	0	3	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	MAY	2008	7	5					1971	1983		10.1021/pr800029h			13	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	296CD	WOS:000255520200018	18452277				2022-02-06	
J	Ling, GSF; Marshall, SA				Ling, Geoffrey S. F.; Marshall, Scott A.			Management of traumatic brain injury in the intensive care unit	NEUROLOGIC CLINICS			English	Article							CLOSED-HEAD INJURY; DECOMPRESSIVE CRANIECTOMY; US ARMY; EXPERIENCE; COMBAT; HYPOTHERMIA; PREVENTION; MODERATE; TRENDS; DEATH	Traumatic brain injury is a common and complex clinical entity that deserves better and continued research on interventions and initial treatment postinjury. Current medical management of traumatic brain injury is articulated on minimizing secondary injury by optimizing cerebral perfusion and oxygenation and preventing or treating nonneurologic morbidity. There are major medical research efforts examining the underlying mechanisms of secondary brain injury, which provides hope for effective therapies in the future. Presently, a number of promising therapeutic modalities are undergoing clinical trials, and as new pharmacologic and medical approaches are introduced, there will be increasing opportunity to treat these patients and improve their neurologic outcomes.	[Ling, Geoffrey S. F.; Marshall, Scott A.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 21042 USA; [Ling, Geoffrey S. F.; Marshall, Scott A.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA		Ling, GSF (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 21042 USA.	gling@usuhs.mil					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BELLAMY RF, 1992, WORLD J SURG, V16, P888, DOI 10.1007/BF02066987; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bledsoe GH, 2005, SOUTH MED J, V98, P436, DOI 10.1097/01.SMJ.0000154309.83339.C0; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Casey KF, 1994, J HEAD TRAUMA REHAB, V9, P82; Chesnut Randall M., 1993, P203; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Chung CY, 2006, PEDIATR NEUROL, V34, P379, DOI 10.1016/j.pediatrneurol.2005.10.012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; GEOCADIN R, 2004, TRAUMATIC BRAIN INJU, P73; GIACINO J, 1994, J HEAD TRAUMA REHAB, V273, P1778; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; JAGGER J, 1992, J NEUROTRAUM, V9, pS313; Jia XF, 2008, RESUSCITATION, V76, P431, DOI 10.1016/j.resuscitation.2007.08.014; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kelly JP, 1997, NEUROLOGY, V48, P581; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LING G, 2007, TXB MED, P2646; Ling G, 2007, J TRAUMA, V62, pS102, DOI 10.1097/TA.0b013e318065b442; LING GS, 1997, NEUROCRITICAL CARE C, P973; Lu J, 2005, ACT NEUR S, V95, P281; Marion D W, 1995, New Horiz, V3, P439; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Morgan T., 1894, J MORPHOL, V9, P1, DOI DOI 10.1002/JMOR.1050090102; *MRC CRASH TRIAL C, 2008, BRIT MED J, P425; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PALTER M, 1994, J HEAD TRAUMA REHAB, V9, P20; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; POVLISHOCK JT, 2007, J NEUROTRAUM, V24, P7; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rosenfeld JV, 2007, J NEUROSURG, V106, P195, DOI 10.3171/jns.2007.106.1.195; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; SALAZAR AM, 1990, CHALLENGES NEUROLOGY; SALAZAR AM, 1990, CURRENT THERAPIES NE, P202; Sariego Jack, 2006, Disaster Manag Response, V4, P114, DOI 10.1016/j.dmr.2006.09.001; Schlifka B, 2007, J TRAUMA, V62, pS103, DOI 10.1097/TA.0b013e318065b4e5; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; Temkin N R, 1995, New Horiz, V3, P518; *US DEP DEF, MAN TECHN PROGR; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Warden DL, 2005, NEW ENGL J MED, V353, P633; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wedmore I, 2006, J TRAUMA, V60, P655, DOI 10.1097/01.ta.0000199392.91772.44; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048; ZOROYA G, KEY IRAQ WOUND BRAIN; Zwahlen RA, 2007, J CRANIO MAXILL SURG, V35, P142, DOI 10.1016/j.jcms.2007.01.006; 2001, J TRAUMA, V5, pS3	68	34	37	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	MAY	2008	26	2					409	+		10.1016/j.ncl.2008.02.001			19	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	320CG	WOS:000257210700005	18514820				2022-02-06	
J	Wang, HC; Chang, WN; Chang, HW; Ho, JT; Yang, TM; Lin, WC; Chuang, YC; Lu, CH				Wang, Hung-Chen; Chang, Wen-Neng; Chang, Hsueh-Wen; Ho, Jih-Tsun; Yang, Tzu-Ming; Lin, Wei-Che; Chuang, Yao-Chung; Lu, Cheng-Hsien			Factors predictive of outcome in posttraumatic seizures	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							EPILEPSY; PHENYTOIN; INJURY; PREVENTION; TRAUMA; AGENTS; DRUGS; RISK	Background: Seizures are important neurologic complications of traumatic brain injury (TBI). There is a need for better delineation of potential prognostic factors and outcomes in patients with posttraumatic seizures (PTS) who could receive treatment when brought to the hospital. Methods: In this 10-year retrospective study, 170 adult patients with PTS were enrolled in this study. The degree of seizure control was analyzed using a Seizure Frequency Scoring System, which classified them into excellent and nonexcellent outcomes. Results: There were 170 patients with acute symptomatic seizure enrolled in this study, 106 of whom had early PTS, whereas 64 had late PTS. Of the 106 early PTS, 58% (61 of 106) occurred within 24 hours of trauma. Risk factors for developing nonexcellent outcome included patients who undergo surgical intervention and presence of late-provoked seizures during the acute phase of TBI. Conclusion: Seizures are an important neurologic complication of TBI. Regarding the potentially side effects of antiepileptic drugs, antiepileptic therapy should be carefully administrated in those nonexcellent outcome patients.	[Chang, Wen-Neng; Chuang, Yao-Chung; Lu, Cheng-Hsien] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Neurol, Kaohsiung, Hsien, Taiwan; [Wang, Hung-Chen; Ho, Jih-Tsun; Yang, Tzu-Ming] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Neurosurg, Kaohsiung, Hsien, Taiwan; [Lin, Wei-Che] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Radiol, Kaohsiung, Hsien, Taiwan; [Chang, Hsueh-Wen] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan		Lu, CH (corresponding author), Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Neurol, 123,Ta Pei Rd,Niao Sung Hsiang, Kaohsiung, Hsien, Taiwan.	chlu99@ms44.url.com.tw		WANG, HUNG-CHEN/0000-0003-3962-1958			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Engel J, 1993, SURG TREATMENT EPILE, P609, DOI DOI 10.1159/000325660; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; RAPP RP, 1983, NEUROSURGERY, V13, P272, DOI 10.1227/00006123-198309000-00010; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; SHINNAR S, 1985, NEW ENGL J MED, V313, P976, DOI 10.1056/NEJM198510173131603; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594	26	34	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4					883	888		10.1097/TA.0b013e31804a7fa4			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	287UN	WOS:000254942100007	18404052				2022-02-06	
J	Rosenthal, G; Morabito, D; Cohen, M; Roeytenberg, A; Derugin, N; Panter, SS; Knudson, MM; Manley, G				Rosenthal, Guy; Morabito, Diane; Cohen, Mitchell; Roeytenberg, Anntna; Derugin, Nikita; Panter, S. Scott; Knudson, M. Margaret; Manley, Geoffrey			Use of hemoglobin-based oxygen-carrying solution-201 to improve resuscitation parameters and prevent secondary brain injury in a swine model of traumatic brain injury and hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						hemoglobin-based oxygen-carrying solution; hemorrhage; resuscitation; secondary brain injury; swine model; traumatic brain injury	CROSS-LINKED HEMOGLOBIN; CEREBRAL PERFUSION-PRESSURE; TENSION; NEUROTOXICITY; CIRCULATION; HYPOTENSION; HBOC-201; VOLUME; DAMAGE; DEATH	Object. Traumatic brain injury (TBI) often occurs as part of a multisystem trauma that may lead to hemorrhagic shock. Effective resuscitation and restoration of oxygen delivery to the brain is important in patients with TBI because hypotension and hypoxia are associated with poor outcome in head injury. We studied the effects of hemoglobin-based oxygen-carrying (HBOC)-201 solution compared with lactated Ringer (LR) solution in a large animal model of brain injury and hemorrhage, in a blinded prospective randomized study. Methods. Swine underwent brain impact injury and hemorrhage to a mean arterial pressure (MAP) of 40 mm Hg. Twenty swine were randomized to undergo resuscitation with HBOC-201 (6 ml/kg) or LR solution (12 ml/kg) and were observed for an average of 6.5 +/- 0.5 hours following resuscitation. At the end of the observation period, magnetic resonance (MR) imaging was performed. Histological studies of swine brains were performed using Fluoro-Jade B, a marker of early neuronal degeneration. Results. Swine resuscitated with HBOC-201 had higher MAP, higher cerebral perfusion pressure (CPP), improved base deficit, and higher brain tissue oxygen tension (PbtO(2)) than animals resuscitated with LR solution. No significant difference in total injury volume on T2-weighted MR imaging was observed between animals resuscitated with HBOC-201 solution (1155 +/- 374 mm(3)) or LR solution (1246 +/- 279 mm(3); p = 0.55). On the side of impact injury, no significant difference in the mean number of Fluoro-Jade B-positive cells/hpf was seen between HBOC-201 solution (61.5 +/- 14.7) and LR solution (48.9 +/- 17.7; p = 0.13). Surprisingly, on the side opposite impact injury, a significant increase in Fluoro-Jade B-positive cells/hpf was seen in animals resuscitated with LR solution (42.8 +/- 28.3) compared with those resuscitated with HBOC-201 solution (5.6 +/- 8.1; p < 0.05), implying greater neuronal injury in LR-treated swine. Conclusions. The improved MAP, CPP, and PbtO(2) observed with HBOC-201 solution in comparison with LR solution indicates that HBOC-201 solution may be a preferable agent for small-volume resuscitation in brain-injured patients with hemorrhage. The use of HBOC-201 solution appears to decrease cellular degeneration in the brain area not directly impacted by the primary injury. Hemoglobin-based oxygen-carrying-201 solution may act by improving cerebral blood flow or increasing the oxygen-carrying capacity of blood, mitigating a second insult to the injured brain.	[Rosenthal, Guy; Roeytenberg, Anntna; Derugin, Nikita; Panter, S. Scott; Manley, Geoffrey] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; [Morabito, Diane; Cohen, Mitchell; Knudson, M. Margaret] Univ Calif San Francisco, Dept Gen Surg, San Francisco, CA 94143 USA		Manley, G (corresponding author), San Francisco Gen Hosp, Dept Neurosurg, Bldg 1,Room 101,1001 Potrero Ave, San Francisco, CA 94117 USA.	manley@itsa.ucsf.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR903697] Funding Source: Medline		Adams J H, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P176; ADAMS JH, 1966, BRAIN, V89, P235, DOI 10.1093/brain/89.2.235; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Barve A, 1997, ARTIF CELL BLOOD SUB, V25, P75, DOI 10.3109/10731199709118899; Bishop GM, 2001, BRAIN RES, V907, P175, DOI 10.1016/S0006-8993(01)02303-4; Boulton M, 1998, AM J PHYSIOL-REG I, V274, pR88, DOI 10.1152/ajpregu.1998.274.1.R88; Boulton M, 1998, AM J PHYSIOL-REG I, V275, pR889, DOI 10.1152/ajpregu.1998.275.3.R889; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FREAS W, 1995, J LAB CLIN MED, V125, P762; Gould SA, 1996, WORLD J SURG, V20, P1200; GRAHAM DI, 1979, STROKE, V10, P724, DOI 10.1161/01.STR.10.6.724; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hattori N, 2003, ACTA NEUROCHIR SUPPL, V86, P49; Heller A, 1998, SHOCK, V10, P401, DOI 10.1097/00024382-199812000-00004; Hess JR, 1996, TRANSFUS MED REV, V10, P276, DOI 10.1016/S0887-7963(96)80003-4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Ketcham EM, 1999, ANN EMERG MED, V33, P326, DOI 10.1016/S0196-0644(99)70370-7; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; Lee SK, 2002, ACAD EMERG MED, V9, P969; Longhi L, 2002, ACT NEUR S, V81, P315; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Mollanji R, 2002, AM J PHYSIOL-REG I, V282, pR1593, DOI 10.1152/ajpregu.00695.2001; Mollanji R, 2001, AM J PHYSIOL-REG I, V280, pR1573, DOI 10.1152/ajpregu.2001.280.5.R1573; Muldoon SM, 1996, J LAB CLIN MED, V128, P579, DOI 10.1016/S0022-2143(96)90130-4; Ortegon DP, 2002, J TRAUMA, V53, P1068, DOI 10.1097/00005373-200212000-00007; PANTER SS, 1994, ARTIF CELL BLOOD SUB, V22, P399, DOI 10.3109/10731199409117870; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; Rieger A, 1999, BRIT J NEUROSURG, V13, P454; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Scott MG, 1997, CLIN CHEM, V43, P1724; SHARMA AC, 1995, AM J PHYSIOL-HEART C, V269, pH1379, DOI 10.1152/ajpheart.1995.269.4.H1379; Stollings JL, 2006, PHARMACOTHERAPY, V26, P1453, DOI 10.1592/phco.26.10.1453; Stowell CP, 2001, TRANSFUSION, V41, P287, DOI 10.1046/j.1537-2995.2001.41020287.x; Tan H, 2001, Chin J Traumatol, V4, P156; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	45	34	35	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2008	108	3					575	587		10.3171/JNS/2008/108/3/0575			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	270PM	WOS:000253732700021	18312106				2022-02-06	
J	Brown, R; Thompson, HJ; Imran, SA; Ur, E; Wilkinson, M				Brown, Russell; Thompson, Hilaire J.; Imran, Syed A.; Ur, Ehud; Wilkinson, Michael			Traumatic brain injury induces adipokine gene expression in rat brain	NEUROSCIENCE LETTERS			English	Article						leptin resistin; fasting-induced adipose factor (FIAF); inflammation; lipopolysaccharide (LPS); hypothalamus; cortex	FLUID-PERCUSSION; IN-VITRO; EXPERIMENTAL-MODELS; LEPTIN; ISCHEMIA; CELLS; ANGIOGENESIS; RESISTIN; MOUSE; VIVO	Traumatic brain injury (TBI) induces cachexia and neuroinflammation which profoundly impact patient recovery. Adipokine genes such as leptin (ob), resistin (rstn) and fasting-induced adipose factor (fiaf) are implicated in energy metabolism and body weight control and are also associated with chronic low grade inflammation. Since central rstn and fiaf expression was increased following hypoxic/ischemic brain injury, we hypothesized that these genes would also be induced in the rat brain following TB1. Realtime RT-PCR detected a 2-2.5-fold increase in ob mRNA in the ipsilateral cortex and thalamus 12h following lateral fluid percussion (FP)-induced brain injury. Fiaf mRNA was elevated 5-7.5-fold in cortex, hippocampus and thalamus, and modest increases were also detectable in the contralateral brain. Remarkably, rstn mRNA was elevated in ipsilateral (150-fold) and in contralateral (50-fold) hippocampus. To test whether these changes were part of an inflammatory response to TBI we also examined the effects of an intracerebral injection of lipopolysaccharide (LPS). We determined that central injection of LPS produced some, but not all, of the changes seen after TBI. For example, in contrast to the stimulatory influence of TBI, LPS had no effect on ob expression in any brain region, though fiaf and rstn mRNA levels were significantly elevated in both ipsi- and contralateral cortex. In conclusion: (a) brain-derived adipokines could be involved in the acute pathology of traumatic brain injury partly through modulation of central inflammatory responses, but also via leptin-mediated neuroprotective effects and (b) TBI-induced brain adipokines may induce the metabolic changes observed following neurotrauma. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Brown, Russell; Imran, Syed A.; Ur, Ehud; Wilkinson, Michael] Dalhousie Univ, Dept Obstet & Gynaecol, IWK Hlth Ctr, Halifax, NS B3K 6R8, Canada; [Brown, Russell; Wilkinson, Michael] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS, Canada; [Imran, Syed A.; Ur, Ehud; Wilkinson, Michael] Dalhousie Univ, Fac Med, Div Endocrinol & Metab, Halifax, NS, Canada; [Thompson, Hilaire J.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA		Wilkinson, M (corresponding author), Dalhousie Univ, Dept Obstet & Gynaecol, IWK Hlth Ctr, Univ Ave,POB 9700, Halifax, NS B3K 6R8, Canada.	mwilk@dal.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR007694, T32NR007106] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [L30 DC008284-01, L30 DC008284] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32-NS043126, T32 NS043126, T32 NS043126-01A1] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32 NR007106, T32-NR007106, T32 NR007106-07, F31 NR007694] Funding Source: Medline		Ahima RS, 2006, PROG BRAIN RES, V153, P155, DOI 10.1016/S0079-6123(06)53009-2; Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Bond BC, 2002, MOL BRAIN RES, V106, P101, DOI 10.1016/S0169-328X(02)00417-5; Brown R, 2005, MOL BRAIN RES, V139, P357, DOI 10.1016/j.molbrainres.2005.05.009; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dicou E, 2001, NEUROREPORT, V12, P3947, DOI 10.1097/00001756-200112210-00019; Emery DL, 2000, J COMP NEUROL, V424, P521; Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Koster A, 2005, ENDOCRINOLOGY, V146, P4943, DOI 10.1210/en.2005-0476; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Lu SC, 2002, FEBS LETT, V530, P158, DOI 10.1016/S0014-5793(02)03450-6; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moinard C, 2005, INTENS CARE MED, V31, P281, DOI 10.1007/s00134-004-2489-9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Paradis E, 2003, J BIOL CHEM, V278, P9698, DOI 10.1074/jbc.M208452200; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Wiesner G, 2006, NEUROREPORT, V17, P1195, DOI 10.1097/01.wnr.0000224776.12647.ba; Wilkinson M, 2007, NEUROENDOCRINOLOGY, V86, P191, DOI 10.1159/000108635; ZHANG F, 2006, NEUR M PLANN ATL GA	29	34	41	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 13	2008	432	1					73	78		10.1016/j.neulet.2007.12.008			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	271RY	WOS:000253807600015	18178314	Green Accepted			2022-02-06	
J	Collins, CL; Fields, SK; Comstock, RD				Collins, C. L.; Fields, S. K.; Comstock, R. D.			When the rules of the game are broken: what proportion of high school sports-related injuries are related to illegal activity?	INJURY PREVENTION			English	Article							RUGBY UNION FOOTBALL; UNITED-STATES; PROFESSIONAL FOOTBALL; ONE SEASON; WORLD CUP; PLAYERS; EPIDEMIOLOGY; SOCCER; INCIDENTS; FREQUENCY	Objectives: To compare sport and gender differences in injury rates and proportions of injuries related to illegal activity and to describe the epidemiology of injuries related to illegal activity. Design: Descriptive epidemiology study. Setting: 100 US high schools. Subjects: Athletes participating in nine sports: boys' football, soccer, basketball, wrestling, and baseball plus girls' soccer, volleyball, basketball, and softball. Main outcome measures: Illegal activity-related injuries were analyzed using data from the 2005-06 and 2006-07 National High School Sports-Related Injury Surveillance Study. Results: Nationally, an estimated 98 066 injuries were directly related to an action that was ruled illegal activity by a referee/official or disciplinary committee, giving an injury rate of 0.24 injuries per 1000 athletic competition-exposures. Boys' and girls' soccer had the highest rates of injuries related to illegal activity, and girls' volleyball, girls' softball, and boys' baseball had the lowest. Overall, 6.4% of all high school sports-related injuries were related to illegal activity, with the highest proportion in girls' basketball (14.0%), girls' soccer (11.9%), and boys' soccer (11.4%). A greater proportion of injuries related to illegal activity were to the head/face (32.3%) and were concussions (25.4%) than injuries not related to illegal activity (13.8% (injury proportion ratio 2.35; 95% CI 1.82 to 3.04; p<0.001) and 10.9% (injury proportion ratio 2.35; 95% CI 1.71 to 3.22; p<0.001), respectively). Conclusions: Illegal activity is an overlooked risk factor for sports-related injury. Reducing illegal activity through enhanced enforcement of sports' rules and targeted education about the dangers of illegal activity for players, coaches, and referees/officials may reduce sports-related injuries.	[Collins, C. L.; Comstock, R. D.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Fields, S. K.] Ohio State Univ, Coll Educ & Human Ecol, Sch Phys Activ & Educ Serv, Columbus, OH 43210 USA; [Comstock, R. D.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. D.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA		Collins, CL (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	christy.collins@nationwidechildrens.org			NCIPC CDC HHS [R49/CE000674-01] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER		Allen W. D., 2002, Journal of Sports Economics, V3, P39, DOI 10.1177/1527002502003001004; Andersen TE, 2004, AM J SPORT MED, V32, p62S, DOI 10.1177/0363546503261412; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; *CDCP, NAT CTR PREV CONTR F; Chalmers DJ, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80046-X; Chomiak J, 2000, AM J SPORT MED, V28, pS58; COLLINS CL, IN PRESS ARCH PEDIAT; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Comstock RD, 2005, J SCI MED SPORT, V8, P101, DOI 10.1016/S1440-2440(05)80030-1; Cromwell F, 2000, BRIT J SPORT MED, V34, P104, DOI 10.1136/bjsm.34.2.104; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; Fauno P, 2006, INT J SPORTS MED, V27, P75, DOI 10.1055/s-2005-837485; Fields SK, 2007, TRAUMA VIOLENCE ABUS, V8, P359, DOI 10.1177/1524838007307293; FINKE RC, 1998, J ORTHOP SPORT PHYS, V10, P54; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Giza E, 2003, AM J SPORT MED, V31, P550, DOI 10.1177/03635465030310041201; Hawkins RD, 1998, BRIT J SPORT MED, V32, P326, DOI 10.1136/bjsm.32.4.326; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; INGLIS GS, 1981, NEW ZEAL MED J, V94, P349; Jakoet I, 1998, S AFR MED J, V88, P45; Junge A, 2000, AM J SPORT MED, V28, pS47; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Junge A, 2004, AM J SPORT MED, V32, p23S, DOI 10.1177/0363546503261246; LEWIS ER, 1996, SPORTS EXERC INJURY, V2, P186; *NAT COLL ATHL ASS, NCAA INJ SURV SYST; Peterson L, 2000, AM J SPORT MED, V28, pS51; ROY SP, 1974, S AFR MED J, V48, P2321; SCHER AT, 1991, S AFR MED J, V79, P614; Schwebel DC, 2006, J SAFETY RES, V37, P507, DOI 10.1016/j.jsr.2006.08.002; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; SMITHERS M, 1985, MED J AUSTRALIA, V142, P457, DOI 10.5694/j.1326-5377.1985.tb113452.x; *US CENS BUR, REG US; WATSON AWS, 1984, AM J SPORT MED, V12, P65, DOI 10.1177/036354658401200110; Watson AWS, 1996, AM J SPORT MED, V24, P323, DOI 10.1177/036354659602400313; Watson AWS, 1996, IRISH J MED SCI, V165, P12, DOI 10.1007/BF02942792; WATTERS DAK, 1984, ARCH EMERG MED, V1, P105; Yard EE, 2006, PEDIATRICS, V118, pE1342, DOI 10.1542/peds.2006-0834	39	34	34	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	FEB	2008	14	1					34	38		10.1136/ip.2007.017277			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	258LB	WOS:000252868300009	18245313				2022-02-06	
J	Lumpkins, K; Bochicchio, GV; Zagol, B; Ulloa, K; Simard, JM; Schaub, S; Meyer, W; Scalea, T				Lumpkins, Kimberly; Bochicchio, Grant V.; Zagol, Bradley; Ulloa, Kristian; Simard, J. Marc; Schaub, Stacey; Meyer, Walter; Scalea, Thomas			Plasma levels of the beta chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) correlate with severe brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	37th Annual Meeting of the Western-Trauma-Association	FEB 25-MAR 02, 2007	Steamboat Springs, CO	Western Trauma Assoc		RANTES; traumatic brain injury; cytokine	INFLAMMATION; INDUCTION	Background: The expression of the beta chemokine RANTES (regulated upon activation, normal T cell expressed, and secreted) has previously been shown to be elevated after traumatic brain injury (TBI) in animal models, but it was unknown whether the plasma level of RANTES was predictive of TBI in critically injured trauma patients. Methods: A prospective study was conducted on 108 critically ill trauma patients. Patients were stratified by radiologic diagnosis of TBI. Severe TBI was classified as the presence of diffuse axonal injury, midline shift, or herniation based on admission head computed tomography findings. Serum levels were evaluated at admission and hospital day 7. RANTES was measured using Luminex multiplex assays. Results: Fifty-four patients with and without TBI were compared. Severe TBI was diagnosed in 23 of the 54 TBI patients (43%) and mild/moderate TBI was found in 31 (57%) patients. The mean age of the study population was 43 +/- 20 years with a mean Injury Severity Score of 29 +/- 14. There was no significant difference between groups in age, sex, and Injury Severity Score. At admission, RANTES was significantly higher in patients with severe brain injury than in non-TBI patients (mean 1,339 pg/mL vs. 708 pg/mL, p=0.046), and there was a trend toward significance when comparing patients with severe versus mild/moderate brain injury (mean 1,339 pg/mL vs. 752 pg/mL, p=0.069). There was no statistically significant difference on day 7. Conclusions: RANTES was a significant early marker of severe TBI in critically injured trauma patients, consistent with animal models. Future research on the role of RANTES in the pathogenesis of human TBI is warranted.	[Lumpkins, Kimberly; Bochicchio, Grant V.; Zagol, Bradley; Ulloa, Kristian; Simard, J. Marc; Meyer, Walter; Scalea, Thomas] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin Outcomes Res, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA		Bochicchio, GV (corresponding author), 22 S Greene St,Rm T3R85B, Baltimore, MD 21201 USA.	gbochicchio@umm.edu		Lumpkins, Kimberly/0000-0002-5236-9411			Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fitch MT, 1999, J NEUROSCI, V19, P8182; Frank S, 2000, BIOCHEM J, V347, P265, DOI 10.1042/0264-6021:3470265; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Lee HP, 2005, J NEUROIMMUNOL, V158, P26, DOI 10.1016/j.jneuroim.2004.08.010; Omari KM, 2004, J NEUROIMMUNOL, V146, P203, DOI 10.1016/j.jneuroim.2003.10.032; Sarto BY, 2004, ANN TROP MED PARASIT, V98, P297, DOI 10.1179/000349804225003271; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Song A, 2000, IMMUNOL REV, V177, P236, DOI 10.1034/j.1600-065X.2000.17610.x	12	34	35	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2					358	361		10.1097/TA.0b013e318160df9b			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	264KV	WOS:000253287100021	18301198				2022-02-06	
J	Whyte, J; Vaccaro, M; Grieb-Neff, P; Hart, T; Polansky, M; Coslett, HB				Whyte, John; Vaccaro, Monica; Grieb-Neff, Patricia; Hart, Tessa; Polansky, Marcia; Coslett, H. Branch			The effects of bromocriptine on attention deficits after traumatic brain injury - A placebo-controlled pilot study	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						bromocriptine; attention deficit; traumatic brain injury	DOPAMINE-RECEPTOR AGONIST; WORKING-MEMORY; INATTENTIVE BEHAVIOR; FAILURES; TASK	Objective: To evaluate the effects of bromocriptine on a variety of aspects of attention, ranging from laboratory-based impairment measures to caregiver ratings and work productivity, in individuals after traumatic brain injury. Design: Twelve adults with moderate to severe traumatic brain injury and attention complaints in the postacute phase of recovery were enrolled in a 6-wk double-blind, placebo-controlled, crossover study of bromocriptine, titrated to a dose of 5 mg twice a day. A wide range of attentional measures was administered weekly, including computerized and paper-and-pencil tests of attention, videotaped records of individual work in a distracting environment, real-time observational scoring of attentiveness in a classroom environment, and caregiver and clinician ratings of attentiveness. Data from these 12 participants were used to identify attentional dimensions suggestive of a treatment effect for independent replication. Results: The effects of bromocriptine on 13 previously identified attentional factors and 13 individual performance scores were assessed via the Wilcoxon signed ranks test, using a relaxed probability cutoff of 0.20 to select those to be studied in a larger replication sample. Only two factor scores and one individual score met the cutoff, and all of these showed trends toward worse performance on bromocriptine than on placebo. A more detailed investigation of bromocriptine's effect on divided attention was also conducted, but the previously reported finding of a beneficial effect on this domain was not replicated. Blood pressure was marginally lower on bromocriptine than on placebo. In view of the lack of cognitive benefit and the fact that several participants experienced possible or probable drug side effects, we did not pursue a larger replication at this drug dose. Conclusions: Bromocriptine in a dose of 5 mg, given twice a day to individuals with attentional complaints after TBI, does not seem to enhance attentional skills, and it may be associated with an excess of adverse events. It is not clear whether intermittent dosing or lower doses might confer benefit.	[Whyte, John; Vaccaro, Monica; Grieb-Neff, Patricia; Hart, Tessa; Coslett, H. Branch] Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; [Whyte, John; Hart, Tessa] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Polansky, Marcia] Drexel Univ, Philadelphia, PA 19104 USA; [Coslett, H. Branch] Univ Penn, Philadelphia, PA 19104 USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brunton L, 2001, PHARMACOL BASIS THER, P215; Deleu D, 2002, CLIN PHARMACOKINET, V41, P261, DOI 10.2165/00003088-200241040-00003; Efron D, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e6; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; Kimberg DY, 2001, HUM BRAIN MAPP, V12, P246, DOI 10.1002/1097-0193(200104)12:4<246::AID-HBM1019>3.0.CO;2-9; Kimberg DY, 2003, NEUROPSYCHOLOGIA, V41, P1020, DOI 10.1016/S0028-3932(02)00317-2; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; MARKEY SP, 1979, J PHARMACOL EXP THER, V211, P31; McAllister Thomas W., 1994, P357; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MELTZER HY, 1982, PHARMACOL BIOCHEM BE, V17, P1, DOI 10.1016/0091-3057(82)90504-4; Muller U, 1998, J NEUROSCI, V18, P2720; PICCIRILLI M, 1985, CLIN NEUROL, P167; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; VOLKOW ND, 2001, J NEUROSCI, V21, P1; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; WHYTE J, 1998, INT PERSPECTIVES TRA, P154	30	34	36	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	2008	87	2					85	99		10.1097/PHM.0b013e3181619609			15	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	330PN	WOS:000257955400001	18209510				2022-02-06	
J	Brosseau-Lachaine, O; Gagnon, I; Forget, R; Faubert, J				Brosseau-Lachaine, Odile; Gagnon, Isabelle; Forget, Robert; Faubert, Jocelyn			Mild traumatic brain injury induces prolonged visual processing deficits in children	BRAIN INJURY			English	Article						visual perception; sensory integration; mild traumatic brain injury; paediatrics; second-order; optic flow	HEAD-INJURY; MOTION PERCEPTION; 2ND-ORDER MOTION; GLAUCOMA PATIENTS; OPTIC FLOW; STIMULI; CONCOMITANTS; PERFORMANCE; POTENTIALS; SYMPTOMS	Primary objective: To compare the sensitivity to simple and complex visual stimuli of children who have sustained a mild traumatic brain injury (mTBI) to that of matched non-injured children and to determine the evolution of visuo-perceptual performance over time. Research design: A prospective design was used to assess 18 children with mTBI and 18 matched healthy controls (8-16 years of age). Methods and procedures: Sensitivity to static and dynamic forms of simple (first-order) and complex (second-order) stimuli were assessed at 1, 4 and 12 weeks post-injury and at equivalent times for controls. Orientation and direction identification thresholds were measured for all participants for static and dynamic conditions, respectively. In addition, sensitivity to radial optic flow (inward vs outward), a complex motion stimulus, was assessed. Main outcomes and results: Thresholds measured from all complex stimuli were significantly affected for the mTBI children over time whereas no difference in threshold between groups across all testing conditions was found for simple, first-order information. Sensitivity to all complex stimuli was still affected 12 weeks after the injury. Conclusion: These findings suggest that injured children present selective processing deficits for higher-order information and that this deficit persists over relatively long periods. Such measures could be useful to assess children who have sustained mTBI and possibly contribute to identifying potential risks of returning these children to demanding physical activities.	[Faubert, Jocelyn] Univ Montreal, Ecole Optometrie, Visual Psychophys & Percept Lab, Montreal, PQ H3T 1P1, Canada; [Brosseau-Lachaine, Odile; Forget, Robert; Faubert, Jocelyn] Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Trauma Programs, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; [Gagnon, Isabelle] McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Forget, Robert] Univ Montreal, Ecole Readaptat, Fac Med, Montreal, PQ H3T 1P1, Canada		Faubert, J (corresponding author), Univ Montreal, Ecole Optometrie, Visual Psychophys & Percept Lab, 3744 Jean Brillant,Room 260-7, Montreal, PQ H3T 1P1, Canada.	jocelyn.faubert@umontreal.ca	Faubert, Jocelyn/E-2207-2011	Gagnon, Isabelle/0000-0003-2043-1644			Bertone A, 2005, BRAIN, V128, P2430, DOI 10.1093/brain/awh561; Bertone A, 2003, J COGNITIVE NEUROSCI, V15, P218, DOI 10.1162/089892903321208150; BERTONE A, 1999, INVEST OPHTHALMOL, V40, P2245; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bosworth CF, 1997, VISION RES, V37, P1989, DOI 10.1016/S0042-6989(96)00326-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Clifford CWG, 1999, VISION RES, V39, P113, DOI 10.1016/S0042-6989(98)00082-0; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gagnon I, 2004, J HEAD TRAUMA REHAB, V19, P391, DOI 10.1097/00001199-200409000-00004; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Giaschi DE, 1996, J OPT SOC AM A, V13, P707, DOI 10.1364/JOSAA.13.000707; Gibson JJ, 1950, PERCEPTION VISUAL WO, P235; GLOVINSKY Y, 1991, INVEST OPHTH VIS SCI, V32, P484; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Habak C, 2002, VISION RES, V42, P2843, DOI 10.1016/S0042-6989(02)00355-3; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Karwatsky P, 2006, OPTOMETRY VISION SCI, V83, P466, DOI 10.1097/01.opx.0000225107.38719.0d; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kogan CS, 2004, NEUROLOGY, V63, P1634, DOI 10.1212/01.WNL.0000142987.44035.3B; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; LACHAPELLE J, 2007, ELECTROPHYSIOL UNPUB; LEDGEWAY T, 1994, VISION RES, V34, P2879, DOI 10.1016/0042-6989(94)90056-6; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Nishida S, 1997, VISION RES, V37, P2685, DOI 10.1016/S0042-6989(97)00092-8; O'Brien HL, 2001, CEREB CORTEX, V11, P1083, DOI 10.1093/cercor/11.11.1083; PADULA WV, 2007, BRAIN INJURY MED; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; QUIGLEY HA, 1988, OPHTHALMOLOGY, V95, P357; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shabana N, 2003, SURV OPHTHALMOL, V48, P92, DOI 10.1016/S0039-6257(02)00401-0; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Smith AT, 1998, J NEUROSCI, V18, P3816; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Tetewsky SJ, 1999, NEUROLOGY, V52, P958, DOI 10.1212/WNL.52.5.958; WEIBULL W, 1951, J APPL MECH-T ASME, V18, P293; WILSON HR, 1992, VISUAL NEUROSCI, V9, P79, DOI 10.1017/S0952523800006386; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Wurtz RH, 1998, CURR BIOL, V8, pR554, DOI 10.1016/S0960-9822(07)00359-4	57	34	34	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	9					657	668		10.1080/02699050802203353			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600003	18698516				2022-02-06	
J	Dooley, JJ; Anderson, V; Hemphill, SA; Ohan, J				Dooley, Julian J.; Anderson, Vicki; Hemphill, Sheryl A.; Ohan, Jeneva			Aggression after paediatric traumatic brain injury: A theoretical approach	BRAIN INJURY			English	Article						Traumatic brain injury; aggression; measurement	PROACTIVE AGGRESSION; REACTIVE AGGRESSION; PHYSICAL AGGRESSION; YOUNG-ADULTS; PRESCHOOL-CHILDREN; SOCIAL COMPETENCE; LATE ADOLESCENCE; HEAD-INJURY; PEER STATUS; BEHAVIOR	Primary objective: To examine aggression in adolescent males with and without traumatic brain injury (TBI). Design: Quasi-experimental, matched-participants design. Methods: Thirty-nine adolescents were examined, including a TBI group (n = 11) and a matched, uninjured comparison group (n = 28). Participants with TBI were injured an average of 8.3 years (SD = 4.2 years) prior. Participants and parents completed the Youth Self Report (YSR) and the Child Behavior Checklist (CBCL), both measures of global psychopathology. In addition, the theoretically-driven Reactive and Proactive Aggression Questionnaire (RPQ) and the Form of Aggression Scale (FAS) were completed. Main outcomes and results: When compared using the YSR and CBCL, no group differences were detected. In contrast, using the self-report RPQ, participants with TBI reported more reactive and proactive aggression than non-injured peers. Using the FAS, participants with TBI reported engaging in aggression out of frustration and not to dominate or acquire objects. Conclusion: Aggressive behaviours are a long-term outcome after paediatric TBI. Measures of global psychopathology do not permit detailed examination of specific behaviour problems such as aggression, which may provide inaccurate data from which to derive incidence rates. In contrast, theoretically-driven measures can provide greater insight into post-TBI aggression with important treatment implications.	[Dooley, Julian J.; Anderson, Vicki; Hemphill, Sheryl A.] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; [Dooley, Julian J.; Anderson, Vicki; Hemphill, Sheryl A.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Anderson, Vicki; Hemphill, Sheryl A.] Royal Childrens Hosp, Parkville, Vic 3052, Australia; [Ohan, Jeneva] Univ British Columbia Okanagan, Irving K Barber Sch Arts & Sci, Psychol & Comp Sci Unit, Kelowna, BC, Canada		Dooley, JJ (corresponding author), Edith Cowan Univ, Dept Psychol & Social Sci, 100 Joondalup Dr, Joondalup, WA 6027, Australia.	j.dooley@ecu.edu.au		Ohan, Jeneva/0000-0002-4801-4239			Achenbach T. M., 1991, MANUAL CHILD BEHAV C, P288; ACHENBACH TM, 1991, MANUAL YOUTH SELF RE, P210; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P886; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BANDURA A, 1978, J COMMUN, V28, P12, DOI 10.1111/j.1460-2466.1978.tb01621.x; BANDURA A, 1973, AGGRESSION SOCIAL LE, P390; BANDURA A, 1983, AGGRESSION THEORETIC, V1, P40; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Brame B, 2001, J CHILD PSYCHOL PSYC, V42, P503, DOI 10.1017/S0021963001007120; Brendgen M, 2001, J ABNORM CHILD PSYCH, V29, P293, DOI 10.1023/A:1010305828208; Brown K, 1996, J ABNORM CHILD PSYCH, V24, P473, DOI 10.1007/BF01441569; Camodeca M, 2002, SOC DEV, V11, P332, DOI 10.1111/1467-9507.00203; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; CATROPPA C, J PEDIAT PS IN PRESS; Connor DF, 2003, CHILD PSYCHIAT HUM D, V33, P279, DOI 10.1023/A:1023084112561; CRICK NR, 1995, CHILD DEV, V66, P710, DOI 10.1111/j.1467-8624.1995.tb00900.x; DANIEL A, 1983, POWER PRIVILEGE PRES, P235; DAY DM, 1992, J CLIN CHILD PSYCHOL, V21, P210, DOI 10.1207/s15374424jccp2103_2; DODGE KA, 1991, DEVELOPMENT AND TREATMENT OF CHILDHOOD AGGRESSION, P201; DODGE KA, 1987, J PERS SOC PSYCHOL, V53, P1146, DOI 10.1037/0022-3514.53.6.1146; Dodge KA, 1997, J ABNORM PSYCHOL, V106, P37, DOI 10.1037/0021-843X.106.1.37; DOLLARD J, 1939, FRUSTRATION AGGRESS, P150; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; FESHBACH S, 1964, PSYCHOL REV, V71, P257, DOI 10.1037/h0043041; Fontaine RG, 2007, PSYCHOL PUBLIC POL L, V13, P143, DOI 10.1037/1076-8971.13.2.143; GAMES PA, 1983, PSYCHOL BULL, V93, P382; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hubbard JA, 2002, CHILD DEV, V73, P1101, DOI 10.1111/1467-8624.00460; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Laird RD, 2005, DEV PSYCHOPATHOL, V17, P127, DOI 10.1017/S0954579405050078; Little TD, 2003, MERRILL PALMER QUART, V49, P343, DOI 10.1353/mpq.2003.0014; Marcus RF, 2001, J GENET PSYCHOL, V162, P260, DOI 10.1080/00221320109597483; Martin JL, 2004, J DEV BEHAV PEDIATR, V25, P150, DOI 10.1097/00004703-200406000-00002; McEvoy MA, 2003, TOP EARLY CHILD SPEC, V23, P53; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; Nagin D, 1999, CHILD DEV, V70, P1181, DOI 10.1111/1467-8624.00086; Polman H, 2007, J ABNORM CHILD PSYCH, V35, P522, DOI 10.1007/s10802-007-9109-4; Poulin F, 2000, DEV PSYCHOL, V36, P233, DOI 10.1037//0012-1649.36.2.233; Poulin F, 2000, PSYCHOL ASSESSMENT, V12, P115, DOI 10.1037/1040-3590.12.2.115; PRICE JM, 1989, J ABNORM CHILD PSYCH, V17, P455, DOI 10.1007/BF00915038; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Prinstein MJ, 2003, MERRILL PALMER QUART, V49, P310, DOI 10.1353/mpq.2003.0015; Pulkkinen L, 1996, AGGRESSIVE BEHAV, V22, P241, DOI 10.1002/(SICI)1098-2337(1996)22:4<241::AID-AB1>3.0.CO;2-O; Raine A, 2006, AGGRESSIVE BEHAV, V32, P159, DOI 10.1002/ab.20115; Saxe R, 2004, ANNU REV PSYCHOL, V55, P87, DOI 10.1146/annurev.psych.55.090902.142044; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Vaughn BE, 2003, MERRILL PALMER QUART, V49, P245, DOI 10.1353/mpq.2003.0017; Vitiello B, 1997, J AM ACAD CHILD PSY, V36, P307, DOI 10.1097/00004583-199703000-00008; Waschbusch DA, 2002, J ABNORM CHILD PSYCH, V30, P641, DOI 10.1023/A:1020867831811; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	62	34	34	3	135	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					836	846		10.1080/02699050802425444			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700003	18850342				2022-02-06	
J	Matsuoka, Y; Nishi, D; Nakajima, S; Kim, Y; Homma, M; Otomo, Y				Matsuoka, Yutaka; Nishi, Daisuke; Nakajima, Satomi; Kim, Yoshiharu; Homma, Masato; Otomo, Yasuhiro			Incidence and prediction of psychiatric morbidity after a motor vehicle accident in Japan: The Tachikawa Cohort of Motor Vehicle Accident Study	CRITICAL CARE MEDICINE			English	Article						accidents; injury; critical care; depression; post-traumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; TRAUMATIC BRAIN-INJURY; HEART-RATE; FOLLOW-UP; EMERGENCY-DEPARTMENT; MAJOR TRAUMA; RISK-FACTORS; VICTIMS; SCALE	Objectives: To assess both the incidence of new-onset psychiatric illness after involvement in a motor vehicle accident in Japan for comparison with Western data and the predictors of psychiatric morbidity and posttraumatic stress disorder (PTSD) evaluated immediately after the accident. Design, Prospective cohort study of injured patients assessed immediately and 4-6 wks after involvement in a motor vehicle accident. Setting. Intensive care unit in a teaching hospital in Tokyo, Japan. Patients. Total of 100 consecutive patients with motor vehicle accident-related injuries (mean Injury Severity Score, 11.2; mean Glasgow Coma Scale, 14.5; age, 18-69 yrs) admitted to the intensive care unit. Patients with traumatic brain injury, suicidality, current psychiatric or neurologic illness, or cognitive impairment were excluded. Measurements. An extensive clinical interview and evaluation of vital signs, sociodemographic variables, previous traumatic events, family history of psychopathology, Impact of Event Scale-Revised, Hospital Anxiety and Depression Scale, Clinician-Administered PTSD Scale, and Mini-International Neuropsychiatric Interview. Results: A total of 31 patients showed some form of new-onset psychiatric illness at the 4- to 1 follow-up. The majority of illnesses consisted of depression (major depression, n = 16; minor depression, n = 7) and PTSD (full PTSD, n = 8; partial PTSD, n 16). Other illnesses included alcohol dependence (n 3), obsessive-compulsive disorder (n = 2), agoraphobia (n = 2), and social phobia (n = 1). Both psychiatric morbidity and PTSD were predicted by a sense of life threat (odds ratio, 4.2 and 6.2, respectively), elevated heart rate (odds ratio, 1.6 and 1.7), and higher Impact of Event Scale-Revised intrusion subscale score (odds ratio, 1.1 and 1.1). Conclusion: This study showed that psychopathology and PTSD after a motor vehicle accident in Japan is common and that the incidence is within the range of that in Western countries. A combination of a sense of life threat, heart rate, and Impact of Event Scale-Revised intrusion subscale allowed for significant prediction of psychiatric morbidity and PTSD.	[Matsuoka, Yutaka; Nishi, Daisuke; Nakajima, Satomi; Kim, Yoshiharu] NIMH, Div Adult Mental Hlth, Natl Ctr Neurol & Psychiat, Tokyo, Japan; [Homma, Masato] Natl Disaster Med Ctr, Dept Crit Care & Traumatol, Tokyo, Japan; [Otomo, Yasuhiro] Tokyo Med & Dent Univ, Dept Acute Crit Care & Disaster Med, Tokyo, Japan		Matsuoka, Y (corresponding author), NIMH, Div Adult Mental Hlth, Natl Ctr Neurol & Psychiat, Tokyo, Japan.	yutaka@ncnp.go.jp	Nishi, Daisuke/AAH-7211-2019; Matsuoka, Yutaka/D-1171-2011; Matsuoka, Yutaka/N-1588-2019	Nishi, Daisuke/0000-0001-9349-3294; Matsuoka, Yutaka/0000-0002-8690-8129			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 2006, ANN NY ACAD SCI, V1071, P19, DOI 10.1196/annals.1364.002; Buckley B, 2004, J TRAUMA STRESS, V17, P317, DOI 10.1023/B:JOTS.0000038480.87290.4a; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Kassam-Adams N, 2005, ARCH GEN PSYCHIAT, V62, P335, DOI 10.1001/archpsyc.62.3.335; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Koren D, 1999, AM J PSYCHIAT, V156, P367; KRAEMER B, 2007, J PSYCHIAT RES; Kugaya A, 1998, JPN J CLIN ONCOL, V28, P333, DOI 10.1093/jjco/28.5.333; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mason S, 2002, EMERG MED J, V19, P400, DOI 10.1136/emj.19.5.400; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231; MAYOU R, 1991, INJURY, V22, P365, DOI 10.1016/0020-1383(91)90095-V; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nishi D, 2006, EMERG MED J, V23, P468, DOI 10.1136/emj.2005.029769; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Otsubo T, 2005, PSYCHIAT CLIN NEUROS, V59, P517, DOI 10.1111/j.1440-1819.2005.01408.x; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Schnyder U, 2000, CRIT CARE MED, V28, P86, DOI 10.1097/00003246-200001000-00014; Schnyder U, 2003, AM J PSYCHIAT, V160, P2025, DOI 10.1176/appi.ajp.160.11.2025; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Schnyder U, 2001, AM J RESP CRIT CARE, V164, P653, DOI 10.1164/ajrccm.164.4.2008087; SCHNYDER U, 2007, IN PRESS PSYCHOTHER; Seekamp A, 1996, INJURY, V27, P133, DOI 10.1016/0020-1383(95)00178-6; Shalev AY, 2005, AM J PSYCHIAT, V162, P1188, DOI 10.1176/appi.ajp.162.6.1188; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simon GE, 2002, PSYCHOL MED, V32, P585, DOI 10.1017/S0033291702005457; STRAIN JJ, 1991, AM J PSYCHIAT, V148, P1044; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Vaiva G, 2004, BIOL PSYCHIAT, V55, P250, DOI 10.1016/j.biopsych.2003.08.009; Vaiva G, 2003, BIOL PSYCHIAT, V54, P947, DOI 10.1016/S0006-3223(03)00412-8; Weiss Daniel S., 1997, P399; Wu KK, 2006, J TRAUMA STRESS, V19, P923, DOI 10.1002/jts.20178; Yamadori A., 1985, SHINKEISHINRIGAKU, V1, P82; Zatzick DF, 2005, BIOL PSYCHIAT, V57, P91, DOI 10.1016/j.biopsych.2004.10.005; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	57	34	36	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2008	36	1					74	80		10.1097/01.CCM.0000291650.70816.D6			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	291YA	WOS:000255232100010	18090377				2022-02-06	
J	Vickery, CD; Sherer, M; Nick, TG; Nakase-Richardson, R; Corrigan, JD; Hammond, F; Macciocchi, S; Ripley, DL; Sander, A				Vickery, Chad D.; Sherer, Mark; Nick, Todd G.; Nakase-Richardson, Risa; Corrigan, John D.; Hammond, Flora; Macciocchi, Stephen; Ripley, David L.; Sander, Angelle			Relationships among premorbid alcohol use, acute intoxication, and early functional status after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcoholic intoxication; brain injuries; rehabilitation; treatment outcome	HEAD-INJURY; SUBSTANCE-ABUSE; LEVEL; INVOLVEMENT; SCALE; COMA	Objective: To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patient's with traumatic brain injury (TBI). Design: Prospective cohort study. Setting: Acute inpatient TBI rehabilitation. Participants: Participants were 1748 persons with TBI. Interventions: Not applicable. Main Outcome Measures: Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview. Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation. Results: Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores. A higher BAL was associated with poorer functional status on the DRS. Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS. Conclusions: The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest. Injury severity had a more significant association with TBI functional status.	[Vickery, Chad D.; Nakase-Richardson, Risa] Methodist Rehabil Ctr, Jackson, MS 39216 USA; [Vickery, Chad D.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Sherer, Mark; Sander, Angelle] Mem Hermann TIRR, Houston, TX USA; [Nick, Todd G.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Ctr Epidemiol & Biostat, Cincinnati, OH USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Macciocchi, Stephen] Shepherd Ctr, Atlanta, GA USA; [Ripley, David L.] Craig Hosp, Englewood, CO USA; [Sander, Angelle] Baylor Coll Med, Harris Cty Hosp Dist, Dept Phys Med & Rehabil, Houston, TX 77030 USA		Vickery, CD (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	cvickery@mmrcrehab.org	Corrigan, John D./E-2921-2011	Ripley, David/0000-0002-5349-1830			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Centers for Disease Control and Prevention (CDC), ALC PUBL HLTH; Corrigan J, PROBLEMATIC SUBSTANC; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; GRANT I, 1987, J CONSULT CLIN PSYCH, V55, P310, DOI 10.1037/0022-006X.55.3.310; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Harel O, 2007, STAT MED, V26, P3057, DOI 10.1002/sim.2787; HARRELL FE, HMISC DESIGN LIB; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEONARD BE, 1995, NEUROCHEM INT, V26, P343, DOI 10.1016/0197-0186(94)00141-G; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; Myers R. H., 1990, CLASSICAL MODERN REG; National Center for Health Statistics, 2006, HLTH US 2006 CHARTB; National Data and Statistical Center, TRAUM BRAIN INJ MOD; NEVO I, 1995, NEUROCHEM INT, V26, P305, DOI 10.1016/0197-0186(94)00139-L; PARSONS OA, 1993, NEUROL CLIN, V11, P205, DOI 10.1016/S0733-8619(18)30178-6; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; STEINBOK P, 1978, NEUROSURGERY, V3, P9, DOI 10.1227/00006123-197807000-00002; Tate PS, 1999, BRAIN INJURY, V13, P767; Turner AP, 2006, REHABIL PSYCHOL, V51, P78, DOI 10.1037/0090-5550.51.1.78; U.S. Department of Health and Human Services, DIET GUID AM; WRIGHT J, 2002, FIM             0302; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	41	34	34	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2008	89	1					48	55		10.1016/j.apmr.2007.07.047			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	249LB	WOS:000252228600009	18164330				2022-02-06	
